PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Szmyd, R; Niska-Blakie, J; Diril, MK; Nunes, PR; Tzelepis, K; Lacroix, A; van Hul, N; Deng, LW; Matos, J; Dreesen, O; Bisteau, X; Kaldis, P				Szmyd, Radoslaw; Niska-Blakie, Joanna; Diril, M. Kasim; Nunes, Patricia Renck; Tzelepis, Konstantinos; Lacroix, Aurelie; van Hul, Noemi; Deng, Lih-Wen; Matos, Joao; Dreesen, Oliver; Bisteau, Xavier; Kaldis, Philipp			Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE; DNA-DAMAGE CHECKPOINT; HOLLIDAY JUNCTION RESOLUTION; INHIBITORY PHOSPHORYLATION; CELL-CYCLE; WEE1 KINASE; NUCLEAR ACCUMULATION; RE-REPLICATION; PROTEIN-KINASE; G2 CHECKPOINT	Cell cycle regulation, especially faithful DNA replication and mitosis, are crucial to maintain genome stability. Cyclin-dependent kinase (CDK)/cyclin complexes drive most processes in cellular proliferation. In response to DNA damage, cell cycle surveillance mechanisms enable normal cells to arrest and undergo repair processes. Perturbations in genomic stability can lead to tumor development and suggest that cell cycle regulators could be effective targets in anticancer therapy. However, many clinical trials ended in failure due to off-target effects of the inhibitors used. Here, we investigate in vivo the importance of WEE1- and MYT1-dependent inhibitory phosphorylation of mammalian CDK1. We generated Cdk1(AF) knockin mice, in which two inhibitory phosphorylation sites are replaced by the non-phosphorylatable amino acids T14A/Y15F. We uncovered that monoallelic expression of CDK1(AF) is early embryonic lethal in mice and induces S phase arrest accompanied by gamma H2AX and DNA damage checkpoint activation in mouse embryonic fibroblasts (MEFs). The chromosomal fragmentation in Cdk1(AF) MEFs does not rely on CDK2 and is partly caused by premature activation of MUS81-SLX4 structure-specific endonuclease complexes, as well as untimely onset of chromosome condensation followed by nuclear lamina disassembly. We provide evidence that tumor development in liver expressing CDK1(AF) is inhibited. Interestingly, the regulatory mechanisms that impede cell proliferation in CDK1(AF) expressing cells differ partially from the actions of the WEE1 inhibitor, MK-1775, with p53 expression determining the sensitivity of cells to the drug response. Thus, our work highlights the importance of improved therapeutic strategies for patients with various cancer types and may explain why some patients respond better to WEE1 inhibitors.	[Szmyd, Radoslaw; Niska-Blakie, Joanna; Diril, M. Kasim; Nunes, Patricia Renck; Tzelepis, Konstantinos; Lacroix, Aurelie; van Hul, Noemi; Bisteau, Xavier; Kaldis, Philipp] ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore; [Szmyd, Radoslaw] NUS, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore; [Niska-Blakie, Joanna] ASTAR, Bioinformat Inst BII, Singapore 138671, Singapore; [Deng, Lih-Wen; Kaldis, Philipp] NUS, Dept Biochem, Singapore 117597, Singapore; [Matos, Joao] Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland; [Dreesen, Oliver] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Diril, M. Kasim] Dokuz Eylul Univ, Izmir Biomed & Genome Inst, TR-35340 Izmir, Turkey; [Nunes, Patricia Renck] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland; [Tzelepis, Konstantinos] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Lacroix, Aurelie] McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada; [Lacroix, Aurelie] McGill Univ, CSACS, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore; Swiss Federal Institutes of Technology Domain; ETH Zurich; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Dokuz Eylul University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Wellcome Trust Sanger Institute; McGill University; McGill University	Kaldis, P (corresponding author), ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore.; Kaldis, P (corresponding author), NUS, Dept Biochem, Singapore 117597, Singapore.	kaldis@imcb.a-star.edu.sg	Nunes, Patricia Renck/W-8183-2019; Kaldis, Philipp/G-2714-2010; Bisteau, Xavier/Q-7239-2018; Dreesen, Oliver/AAJ-2132-2020; Diril, Kasim/GWZ-8547-2022; Diril, Kasim/Y-1632-2018; Van Hul, Noemi/AAB-7985-2020; Bisteau, Xavier/AAH-6744-2021; Matos, Joao/C-1488-2014	Kaldis, Philipp/0000-0002-7247-7591; Bisteau, Xavier/0000-0002-8896-5098; Van Hul, Noemi/0000-0003-1410-8808; Matos, Joao/0000-0002-3754-3709; Tzelepis, Konstantinos/0000-0002-4865-7648; Renck Nunes, Patricia/0000-0002-9680-0779; LACROIX, Aurelie/0000-0003-1801-1608	Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore; National Medical Research Council Singapore, NMRC [NMRC/CBRG/0091/2015]	Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council Singapore, NMRC(National Medical Research Council, Singapore)	We thank Zakiah Talib, June Wang, Vithya Anantaraja and Chloe Sim for animal care; and all past and current members of the Kaldis lab for support and discussions. We thank Jos Jonkers and Anton Berns for providing the Rosa26-CreERT2 mice, Andy McMahon for Esr1-Cre mice, T Jake Liang for Alb-Cre mice and Mark Lewandoski for the beta-actin-Cre/Flpe mice. We acknowledge the technical expertise provided by the Advanced Molecular Pathology Laboratory at IMCB. This work was supported by the Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore and in part by a grant from the National Medical Research Council Singapore, NMRC (NMRC/CBRG/0091/2015) to PK.	Aaltonen K, 2009, BRIT J CANCER, V100, P1055, DOI 10.1038/sj.bjc.6604874; Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Abbas T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012914; Adhikari D, 2016, CELL RES, V26, P1212, DOI 10.1038/cr.2016.119; AJIRO K, 1983, J BIOL CHEM, V258, P4534; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bayart E, 2004, CANCER RES, V64, P8954, DOI 10.1158/0008-5472.CAN-04-1613; Beck H, 2012, MOL CELL BIOL, V32, P4226, DOI 10.1128/MCB.00412-12; Bell JB, 2007, NAT PROTOC, V2, P3153, DOI 10.1038/nprot.2007.471; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bonin A, 2000, METH MOL B, V158, P121; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen T, 2012, DRUG DISCOV TODAY, V17, P194, DOI 10.1016/j.drudis.2011.12.009; Chow JPH, 2013, ONCOGENE, V32, P4778, DOI 10.1038/onc.2012.504; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coulonval K, 2011, MOL BIOL CELL, V22, P3971, DOI 10.1091/mbc.E11-02-0136; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Duda H, 2016, DEV CELL, V39, P740, DOI 10.1016/j.devcel.2016.11.017; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Garcia TB, 2018, LEUKEMIA RES, V64, P30, DOI 10.1016/j.leukres.2017.11.004; Garner E, 2013, CELL REP, V5, P207, DOI 10.1016/j.celrep.2013.08.041; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gupta M, 2007, J BIOL CHEM, V282, P4301, DOI 10.1074/jbc.M607910200; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; HARPER JW, 1993, CELL, V75, P805; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Ho V, 2015, ONCOTARGET, V6, P27252, DOI 10.18632/oncotarget.4583; Hughes BT, 2013, P NATL ACAD SCI USA, V110, P8954, DOI 10.1073/pnas.1302927110; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kao H, 2001, J EXP MED, V194, P1313, DOI 10.1084/jem.194.9.1313; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Klotz-Noack K, 2012, J CELL SCI, V125, P2436, DOI 10.1242/jcs.100883; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lohka MJ, 1998, BIOL CELL, V90, P591, DOI 10.1016/S0248-4900(99)80017-3; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Matos J, 2011, CELL, V147, P158, DOI 10.1016/j.cell.2011.08.032; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Minemoto Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P13, DOI 10.1016/S0003-9861(03)00010-9; Monaco L, 2005, P NATL ACAD SCI USA, V102, P14244, DOI 10.1073/pnas.0506252102; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moser R, 2014, CLIN CANCER RES, V20, P4274, DOI 10.1158/1078-0432.CCR-13-2858; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nakajo N, 2000, GENE DEV, V14, P328; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Pfander B, 2017, FEBS LETT, V591, P2048, DOI 10.1002/1873-3468.12727; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rass U, 2010, GENE DEV, V24, P1559, DOI 10.1101/gad.585310; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sarbajna S, 2014, GENE DEV, V28, P1124, DOI 10.1101/gad.238303.114; Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708; Schuler M, 2004, GENESIS, V39, P167, DOI 10.1002/gene.20039; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka S, 2010, CHROMOSOMA, V119, P565, DOI 10.1007/s00412-010-0291-8; Tominaga Y, 2006, INT J BIOL SCI, V2, P161; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vincent F, 1999, BIOL CELL, V91, P665; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Vriend LEM, 2013, BBA-REV CANCER, V1836, P227, DOI 10.1016/j.bbcan.2013.05.002; WALDMAN T, 1995, CANCER RES, V55, P5187; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wells NJ, 1999, J CELL SCI, V112, P3361; West SC, 2015, COLD SH Q B, V80, P103, DOI 10.1101/sqb.2015.80.027649; Wilkins BJ, 2014, SCIENCE, V343, P77, DOI 10.1126/science.1244508; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wyatt HDM, 2013, MOL CELL, V52, P234, DOI 10.1016/j.molcel.2013.08.035; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yeeles JTP, 2015, NATURE, V519, P431, DOI 10.1038/nature14285; Zhao H, 2012, MOL CELL BIOL, V32, P1421, DOI 10.1128/MCB.06721-11	121	34	34	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					998	1018		10.1038/s41388-018-0464-0	http://dx.doi.org/10.1038/s41388-018-0464-0			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30190546	Green Published, hybrid			2022-12-28	WOS:000458624900006
J	Zhang, MQ; Suarez, E; Vasquez, JL; Nathanson, L; Peterson, LE; Rajapakshe, K; Basil, P; Weigel, NL; Coarfa, C; Agoulnik, IU				Zhang, Manqi; Suarez, Egla; Vasquez, Judy L.; Nathanson, Lubov; Peterson, Leif E.; Rajapakshe, Kimal; Basil, Paul; Weigel, Nancy L.; Coarfa, Cristian; Agoulnik, Irina U.			Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity	ONCOGENE			English	Article							FORKHEAD BOX A1; TUMOR-SUPPRESSOR; SPLICE VARIANT; CANCER DEVELOPMENT; MOUSE PROSTATE; COREPRESSOR 1; PKC-EPSILON; INPP4B; CASTRATION; EXPRESSION	Activation and transcriptional reprogramming of AR in advanced prostate cancer frequently coincides with the loss of two tumor suppressors, INPP4B and PTEN, which are highly expressed in human and mouse prostate epithelium. While regulation of AR signaling by PTEN has been described by multiple groups, it is not known whether the loss of INPP4B affects AR activity. Using prostate cancer cell lines, we showed that INPP4B regulates AR transcriptional activity and the oncogenic signaling pathways Akt and PKC. Analysis of gene expression in prostate cancer patient cohorts showed a positive correlation between INPP4B expression and both AR mRNA levels and AR transcriptional output. Using an Inpp4b(-/-) mouse model, we demonstrated that INPP4B suppresses Akt and PKC signaling pathways and modulates AR transcriptional activity in normal mouse prostate. Remarkably, PTEN protein levels and phosphorylation of S380 were the same in Inpp4b(-/-) and WT males, suggesting that the observed changes were due exclusively to the loss of INPP4B. Our data show that INPP4B modulates AR activity in normal prostate and its loss contributes to the AR-dependent transcriptional profile in prostate cancer.	[Zhang, Manqi] Florida Int Univ, Dept Chem & Biochem, Miami, FL 33199 USA; [Suarez, Egla; Vasquez, Judy L.; Agoulnik, Irina U.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Human & Mol Genet, Miami, FL 33199 USA; [Nathanson, Lubov] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Peterson, Leif E.] Houston Methodist Res Inst, Ctr Biostat, Houston, TX USA; [Rajapakshe, Kimal; Basil, Paul; Weigel, Nancy L.; Coarfa, Cristian; Agoulnik, Irina U.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Agoulnik, Irina U.] Florida Int Univ, Biomol Sci Inst, Sch Integrated Sci & Humanity, Miami, FL 33199 USA	State University System of Florida; Florida International University; State University System of Florida; Florida International University; Nova Southeastern University; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; State University System of Florida; Florida International University	Agoulnik, IU (corresponding author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Human & Mol Genet, Miami, FL 33199 USA.; Agoulnik, IU (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Agoulnik, IU (corresponding author), Florida Int Univ, Biomol Sci Inst, Sch Integrated Sci & Humanity, Miami, FL 33199 USA.	Irina.Agoulnik@fiu.edu	Nathanson, Lubov/ABC-2642-2021; Agoulnik, Irina/AAD-4687-2020	Agoulnik, Irina/0000-0003-4889-0324; Nathanson, Lubov/0000-0003-1038-9083	NCI [P30CA125123, R15 CA17928701A1]; CPRIT grant [RP170005, RP150648]; NATIONAL CANCER INSTITUTE [P30CA125123, R15CA179287] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant R15 CA17928701A1 (IUA), NCI grant P30CA125123 (CC), CPRIT grant RP150648 (NLW, CC), and CPRIT grant RP170005 (CC).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agoulnik IU, 2011, ONCOTARGET, V2, P321; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen M, 2014, CLIN CANCER RES, V20, P3057, DOI 10.1158/1078-0432.CCR-12-3680; Chew CL, 2015, CANCER DISCOV, V5, P740, DOI 10.1158/2159-8290.CD-14-1347; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Creba JA, 1983, BIOCHEM J, V212, P15; Darne C, 1998, EUR J BIOCHEM, V256, P9; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferron M, 2011, CELL METAB, V14, P466, DOI 10.1016/j.cmet.2011.08.013; Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Garabedian MJ, 2008, TRENDS BIOCHEM SCI, V33, P301, DOI 10.1016/j.tibs.2008.04.011; Gavrielides MV, 2006, CANCER RES, V66, P11792, DOI 10.1158/0008-5472.CAN-06-1139; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Guedes LB, 2016, CLIN CANCER RES, V22, P4651, DOI 10.1158/1078-0432.CCR-16-0205; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Henttu P, 1998, BIOCHEM BIOPH RES CO, V224, P5; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hodgson MC, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0061-y; Hodgson MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060455; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hsu IW, 2014, ONCOTARGET, V5, P7917, DOI 10.18632/oncotarget.1421; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jo YS, 2015, HEPATOLOGY, V62, P1606, DOI 10.1002/hep.27907; Karaca M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126270; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kofuji S, 2015, CANCER DISCOV, V5, P730, DOI 10.1158/2159-8290.CD-14-1329; Kooijman EE, 2009, BIOCHEMISTRY-US, V48, P9360, DOI 10.1021/bi9008616; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li Y, 2015, ONCOTARGET, V6, P12; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lokody IB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129470; Lopez SM, 2016, CLIN CANCER RES, V22, P3937, DOI 10.1158/1078-0432.CCR-15-1983; Lopez SM, 2013, BIOCHEM BIOPH RES CO, V440, P277, DOI 10.1016/j.bbrc.2013.09.077; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mediwala SN, 2013, PROSTATE, V73, P267, DOI 10.1002/pros.22566; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nakazawa M, 2014, HORM CANCER-US, V5, P265, DOI 10.1007/s12672-014-0190-1; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Newton AC, 2004, TRENDS PHARMACOL SCI, V25, P175, DOI 10.1016/j.tips.2004.02.010; Newton AC, 2003, BIOCHEM J, V370, P11; Nishizuka Y, 2001, ALCOHOL CLIN EXP RES, V25, p3S, DOI 10.1111/j.1530-0277.2001.tb02367.x; Patek SC, 2017, ONCOTARGET, V8, P4875, DOI 10.18632/oncotarget.13608; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Wu D, 2002, CANCER RES, V62, P7; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yeh S, 2002, PNAS P NATL ACAD SCI, V99, P6; Zhang MQ, 2018, METHODS MOL BIOL, V1786, P219, DOI 10.1007/978-1-4939-7845-8_13	73	7	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1121	1135		10.1038/s41388-018-0498-3	http://dx.doi.org/10.1038/s41388-018-0498-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30228349	Green Accepted			2022-12-28	WOS:000458624900014
J	Zhao, L; Zhang, DJ; Shen, Q; Jin, M; Lin, ZY; Ma, H; Huang, SY; Zhou, PF; Wu, G; Zhang, T				Zhao, Lei; Zhang, Dejun; Shen, Qiong; Jin, Min; Lin, Zhenyu; Ma, Hong; Huang, Shaoyi; Zhou, Pengfei; Wu, Gang; Zhang, Tao			KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; PP2A INHIBITOR; POOR-PROGNOSIS; TUMOR INVASION; STATHMIN; OVEREXPRESSION; EXPRESSION; GROWTH; PHOSPHORYLATION; APOPTOSIS	Tumor metastasis is the main cause of death in advanced colorectal cancer. Our previous research showed that upregulation of KIAA1199 predicted poorer outcomes, and promoted cell motility and tumor metastasis in colorectal cancer, with the mechanisms not being fully elucidated. Here, we demonstrate that silencing of KIAA1199 results in reduced tumor metastasis in the orthotopic transplantation tumor model of colorectal cancer. Importantly, we find that KIAA1199 interacts with protein phosphatase 2A (PP2A) through the C-terminal domain and increases phosphatase activity of PP2A, which is essential for KIAA1199-mediated cell motility. Moreover, we identify stathmin, a microtubule-destabilizing protein, as a downstream of KIAA1199-PP2A complex. KIAA1199-induced dephosphorylation of stathmin results in microtubule destabilization and leads to enhanced cell motility. Furthermore, a microtubule-stabilizing drug paclitaxel could prevent KIAA1199-induced microtubule destabilization, and inhibit cell migration and invasion in vitro and tumor metastasis in vivo in colorectal cancer. Collectively, our study reveals that KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway, and suggests that KIAA1199 may be a promising target for preventing metastasis in colorectal cancer.	[Zhao, Lei; Zhang, Dejun; Jin, Min; Lin, Zhenyu; Ma, Hong; Wu, Gang; Zhang, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China; [Shen, Qiong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China; [Huang, Shaoyi; Zhou, Pengfei] Wuhan YZY Med Sci & Technol Co Ltd, Wuhan 430075, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhang, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China.	taozhangxh@hust.edu.cn			National Natural Science Foundation of China [81702392, 81874061]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China (81702392 to LZ and 81874061 to TZ). The authors acknowledge Liang Zeng, Jingjing Wu, and Yan Xue for technical assistance, and thank Dr. Shuangbing Xu for critical review of the paper. Data deposition The authors agree to submit the author's version of the accepted paper to public repositories.	Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2; Ajay AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-204; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Boudreau RM, 2007, CELL SIGNAL, V19, P139, DOI 10.1016/j.cellsig.2006.05.030; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen J, 2013, ONCOGENE, V32, P1330, DOI 10.1038/onc.2012.141; Cortes J, 2012, BREAST CANCER RES TR, V133, P821, DOI 10.1007/s10549-011-1875-6; Cristobal I, 2012, HAEMATOL-HEMATOL J, V97, P543, DOI 10.3324/haematol.2011.050542; Duong FHT, 2014, CARCINOGENESIS, V35, P114, DOI 10.1093/carcin/bgt258; Etienne-Manneville S, 2013, ANNU REV CELL DEV BI, V29, P471, DOI 10.1146/annurev-cellbio-101011-155711; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Fink SP, 2015, ONCOTARGET, V6, P30500, DOI 10.18632/oncotarget.5921; Jami MS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-194; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jia SQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175058; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kaverina I, 2011, SEMIN CELL DEV BIOL, V22, P968, DOI 10.1016/j.semcdb.2011.09.017; Knight LM, 2015, J VIROL, V89, P35, DOI 10.1128/JVI.02317-14; Koga A, 2017, PANCREATOLOGY, V17, P115, DOI 10.1016/j.pan.2016.12.007; Kuang XY, 2015, ONCOTARGET, V6, P22227, DOI 10.18632/oncotarget.4276; Lee E, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.2; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li W, 2010, CANCER SCI, V101, P1226, DOI 10.1111/j.1349-7006.2010.01523.x; Liu CY, 2016, ONCOTARGET, V7, P9135, DOI 10.18632/oncotarget.7035; Liu P, 2013, ONCOL REP, V29, P419, DOI 10.3892/or.2012.2157; Lu J, 2010, J NEUROSURG, V113, P225, DOI 10.3171/2009.11.JNS091272; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Manna T, 2009, J BIOL CHEM, V284, P15640, DOI 10.1074/jbc.M900343200; Matsuzaki S, 2009, ANN SURG ONCOL, V16, P2042, DOI 10.1245/s10434-009-0469-6; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Nemunaitis J, 2012, EXPERT OPIN THER TAR, V16, P631, DOI 10.1517/14728222.2012.696101; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Rong BX, 2016, ONCOTARGET, V7, P78980, DOI 10.18632/oncotarget.12982; Schweyer S, 2007, J PATHOL, V213, P72, DOI 10.1002/path.2203; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006; Suh HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38273; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Xu J, 2015, INT J CLIN EXP PATHO, V8, P2909; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zimmerman R, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.31	46	22	23	5	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					935	949		10.1038/s41388-018-0493-8	http://dx.doi.org/10.1038/s41388-018-0493-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30202098				2022-12-28	WOS:000458624900002
J	Goto, H; Shimono, Y; Funakoshi, Y; Imamura, Y; Toyoda, M; Kiyota, N; Kono, S; Takao, S; Mukohara, T; Minami, H				Goto, Hideaki; Shimono, Yohei; Funakoshi, Yohei; Imamura, Yoshinori; Toyoda, Masanori; Kiyota, Naomi; Kono, Seishi; Takao, Shintaro; Mukohara, Toru; Minami, Hironobu			Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin	ONCOGENE			English	Article							COMPLEMENT FACTOR-D; MAMMARY-GLAND; IN-VIVO; OBESITY; TISSUE; PURIFICATION; ADIPONECTIN; OVERWEIGHT; RESISTANCE; SYSTEM	Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.	[Goto, Hideaki; Shimono, Yohei; Funakoshi, Yohei; Imamura, Yoshinori; Toyoda, Masanori; Kiyota, Naomi; Mukohara, Toru; Minami, Hironobu] Kobe Univ, Div Med Oncol Hematol, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Shimono, Yohei] Kobe Univ, Div Mol & Cellular Biol, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Kiyota, Naomi; Mukohara, Toru; Minami, Hironobu] Kobe Univ Hosp, Ctr Canc, Kobe, Hyogo 6500017, Japan; [Kono, Seishi; Takao, Shintaro] Kobe Univ, Div Breast & Endocrine Surg, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Mukohara, Toru] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Kashiwa, Chiba 2778577, Japan; [Shimono, Yohei] Fujita Hlth Univ, Dept Biochem, Toyoake, Aichi 4701192, Japan	Kobe University; Kobe University; Kobe University; Kobe University; National Cancer Center - Japan; Fujita Health University	Shimono, Y (corresponding author), Kobe Univ, Div Med Oncol Hematol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.; Shimono, Y (corresponding author), Kobe Univ, Div Mol & Cellular Biol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.; Shimono, Y (corresponding author), Fujita Hlth Univ, Dept Biochem, Toyoake, Aichi 4701192, Japan.	yshimono@med.kobe-u.ac.jp	Imamura, Yoshinori/ABD-4175-2021; Kiyota, Naomi/K-3226-2016	Kiyota, Naomi/0000-0001-8021-6116; Imamura, Yoshinori/0000-0002-5202-531X; Minami, Hironobu/0000-0001-8630-9145	Japan Society for the Promotion of Science (JSPS KAKENHI) [15K14381, 18K07231]; Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science; Japan Foundation for Applied Enzymology; Itoh-Chubei Foundation; Cancer Research Institute, Kanazawa University; Princess Takamatsu Cancer Research Fund	Japan Society for the Promotion of Science (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science; Japan Foundation for Applied Enzymology; Itoh-Chubei Foundation; Cancer Research Institute, Kanazawa University; Princess Takamatsu Cancer Research Fund	This work was supported by: (1) grants-in-aid from the Japan Society for the Promotion of Science (JSPS KAKENHI) 15K14381 and 18K07231 (to YS); (2) Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science (to YS); (3) a grant from the Japan Foundation for Applied Enzymology (to YS); (4) a grant from the Itoh-Chubei Foundation (to YS); (5) an extramural collaborative research grant of Cancer Research Institute, Kanazawa University (to YS); (6) a grant from the Princess Takamatsu Cancer Research Fund (to YS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]; Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Booth A, 2016, HORM MOL BIOL CLIN I, V26, P25, DOI 10.1515/hmbci-2015-0073; Booth A, 2015, HORM MOL BIOL CLIN I, V21, P57, DOI 10.1515/hmbci-2014-0037; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carmona-Fontaine C, 2011, DEV CELL, V21, P1026, DOI 10.1016/j.devcel.2011.10.012; Chedraui P, 2014, MATURITAS, V79, P86, DOI 10.1016/j.maturitas.2014.06.008; Cheng K.-H., 2011, GENOMIC MED BIOMARKE, V3, P53, DOI [10.1016/j.gmbhs.2011.08.003, DOI 10.1016/J.GMBHS.2011.08.003]; Cho MS, 2014, CELL REP, V6, P1085, DOI 10.1016/j.celrep.2014.02.014; Choi J, 2018, PROG LIPID RES, V69, P11, DOI 10.1016/j.plipres.2017.11.002; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; Divella R, 2016, J CANCER, V7, P2346, DOI 10.7150/jca.16884; Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573; Exley MA, 2014, J ENDOCRINOL, V223, pR41, DOI 10.1530/JOE-13-0516; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Goodwin PJ, 2016, J CLIN ONCOL, V34, P4197, DOI 10.1200/JCO.2016.70.5327; Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328; Hoy AJ, 2017, TRENDS MOL MED, V23, P381, DOI 10.1016/j.molmed.2017.02.009; Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767; Isobe T, 2014, ELIFE, V3, DOI 10.7554/eLife.01977; Jiralerspong S, 2016, J CLIN ONCOL, V34, P4203, DOI 10.1200/JCO.2016.68.4480; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Lo JC, 2014, CELL, V158, P41, DOI 10.1016/j.cell.2014.06.005; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Duong MN, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0569-0; Nabizadeh JA, 2016, J IMMUNOL, V196, P4783, DOI 10.4049/jimmunol.1600210; Neuhouser ML, 2015, JAMA ONCOL, V1, P611, DOI 10.1001/jamaoncol.2015.1546; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Park J, 2011, ENDOCR REV, V32, P550, DOI 10.1210/er.2010-0030; Pattrick M, 2009, MOL IMMUNOL, V46, P755, DOI 10.1016/j.molimm.2008.09.013; Pierobon M, 2013, BREAST CANCER RES TR, V137, P307, DOI 10.1007/s10549-012-2339-3; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ratajczak MZ, 2006, EXP HEMATOL, V34, P986, DOI 10.1016/j.exphem.2006.03.015; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rutkowski MJ, 2010, MOL CANCER RES, V8, P1453, DOI 10.1158/1541-7786.MCR-10-0225; Schweizer R, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/120949; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song NJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162228; Sprong T, 2006, BLOOD, V107, P4865, DOI 10.1182/blood-2005-07-2820; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Wang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072962; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Wysoczynski M, 2009, LEUKEMIA, V23, P1455, DOI 10.1038/leu.2009.73; Zimmerlin L, 2011, TISSUE ENG PT A, V17, P93, DOI [10.1089/ten.tea.2010.0248, 10.1089/ten.TEA.2010.0248]	51	66	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					767	779		10.1038/s41388-018-0477-8	http://dx.doi.org/10.1038/s41388-018-0477-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177835				2022-12-28	WOS:000458006300001
J	Kim, IK; McCutcheon, JN; Rao, GH; Liu, SV; Pommier, Y; Skrzypski, M; Zhang, YW; Giaccone, G				Kim, In-Kyu; McCutcheon, Justine N.; Rao, Guanhua; Liu, Stephen V.; Pommier, Yves; Skrzypski, Marcin; Zhang, Yu-Wen; Giaccone, Giuseppe			Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer	ONCOGENE			English	Article							ELEMENT-BINDING-PROTEIN; TUMOR-SUPPRESSOR GENE; MEK INHIBITOR; METHYLTRANSFERASE; IDENTIFICATION; CHEMOTHERAPY; TRANSCRIPTION; EXPRESSION; CARCINOMA; EVOLUTION	Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance to this drug are not fully understood. Here, we report a novel cisplatin-resistance mechanism involving SET Domain Containing 2 (SETD2), a histone H3 lysine 36 (H3K36) trimethyltransferase, and cAMP-responsive element-binding protein 1 (CREB1). A549 cells selected in vivo to give brain metastases exhibited cisplatin resistance and decreased expression of phosphorylated CREB1. Next-generation sequencing (NGS) analysis identified a missense mutation in SETD2 (p.T1171K), and we demonstrated that SETD2-mediated trimethylation of H3K36 (H3K36me3) and CREB1 phosphorylation are critical for cellular sensitivity to cisplatin. Moreover, we showed that suppression of SETD2 or CREB1 and ectopic expression of mutant SETD2 conferred cisplatin resistance through inhibition of H3K36me3 and ERK activation in NSCLC cells. Our results provide evidence that SETD2 and CREB1 contribute to cisplatin cytotoxicity via regulation of the ERK signaling pathway, and their inactivation may lead to cisplatin resistance.	[Kim, In-Kyu; McCutcheon, Justine N.; Rao, Guanhua; Liu, Stephen V.; Zhang, Yu-Wen; Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Pommier, Yves] NCI, Lab Mol Pharmacol, Dev Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Skrzypski, Marcin] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fahrenheit Universities; Medical University Gdansk	Zhang, YW; Giaccone, G (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.	yz457@georgetown.edu; gg496@georgetown.edu	Liu, Stephen/E-5688-2019	Liu, Stephen/0000-0002-4852-3914; Kim, In-Kyu/0000-0002-8427-8311; Skrzypski, Marcin/0000-0002-4391-4318	NATIONAL CANCER INSTITUTE [ZIABC006150] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC006150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abol-Enein H, 2003, LANCET, V361, P1927; Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Choi EB, 2016, ONCOGENE, V35, P4569, DOI 10.1038/onc.2016.3; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Crans-Vargas HN, 2002, BLOOD, V99, P2617, DOI 10.1182/blood.V99.7.2617; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giaccone G, 2018, LANCET ONCOL, V19, P347, DOI 10.1016/S1470-2045(18)30062-7; Hainsworth JD, 2010, J THORAC ONCOL, V5, P1630, DOI 10.1097/JTO.0b013e3181e8b3a3; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Jo SK, 2005, KIDNEY INT, V67, P458, DOI 10.1111/j.1523-1755.2005.67102.x; Kachnic LA, 2010, CANCER LETT, V292, P73, DOI 10.1016/j.canlet.2009.11.009; Kovach SJ, 2006, J CELL PHYSIOL, V206, P411, DOI 10.1002/jcp.20474; Maione P, 2015, THER ADV MED ONCOL, V7, P263, DOI 10.1177/1758834015595048; Mar BG, 2017, BLOOD, V130, P2631, DOI 10.1182/blood-2017-03-775569; Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469; Mizumoto Y, 2007, CANCER SCI, V98, P652, DOI 10.1111/j.1349-7006.2007.00445.x; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; Nagao K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049926; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Ossovskaya V, 2010, GENES CANC, V1, P812, DOI 10.1177/1947601910383418; Park IY, 2016, CELL, V166, P950, DOI 10.1016/j.cell.2016.07.005; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Rao GH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06128-9; ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Seo HS, 2008, CANCER RES, V68, P6065, DOI 10.1158/0008-5472.CAN-07-5376; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun XJ, 2005, J BIOL CHEM, V280, P35261, DOI 10.1074/jbc.M504012200; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316; Xiang W, 2015, ONCOTARGET, V6, P4066, DOI 10.18632/oncotarget.2926; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang R, 2008, CLIN CANCER RES, V14, P6396, DOI 10.1158/1078-0432.CCR-07-5113; Yu ZY, 2010, AM J PHYSIOL-RENAL, V298, pF617, DOI 10.1152/ajprenal.00636.2009; Zhang YL, 2014, CELL REP, V8, P1989, DOI 10.1016/j.celrep.2014.08.031; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	49	23	26	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					180	193		10.1038/s41388-018-0429-3	http://dx.doi.org/10.1038/s41388-018-0429-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093630	Green Accepted			2022-12-28	WOS:000455366700003
J	Bhat, AA; Lu, H; Soutto, M; Capobianco, A; Rai, P; Zaika, A; El-Rifai, W				Bhat, Ajaz A.; Lu, Heng; Soutto, Mohammed; Capobianco, Anthony; Rai, Priyamvada; Zaika, Alexander; El-Rifai, Wael			Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1	ONCOGENE			English	Article							GASTROESOPHAGEAL-REFLUX DISEASE; OXIDATIVE DNA-DAMAGE; KAPPA-B ACTIVATION; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; CONFERS RESISTANCE; NUCLEAR EGFR-STAT3; PROTEIN APE1/REF-1; UNITED-STATES; LOW PH	The development of Barrett's esophagus (BE) and its progression to esophageal adenocarcinoma (EAC) is highly linked to exposure to acidic bile salts due to chronic gastroesophageal reflux disease (GERD). In this study, we investigated the role of Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/REF-1) in STAT3 activation in response to acidic bile salts. Our results indicate that APE1 is constitutively overexpressed in EAC, whereas its expression is transiently induced in response to acidic bile salts in non-neoplastic BE. Using overexpression or shRNA knockdown of APE1, we found that APE1 is required for phosphorylation, nuclear localization, and transcriptional activation of STAT3. By using an APE1 redox-specific mutant (C65A) and APE1 redox inhibitor (E3330), we demonstrate that APE1 activates STAT3 in a redox-dependent manner. By using pharmacologic inhibitors and genetic knockdown systems, we found that EGFR is a required link between APE1 and STAT3. EGFR phosphorylation (Y1068) was directly associated with APE1 levels and redox function. Co-immunoprecipitation and proximity ligation assays indicated that APE1 coexists and interacts with the EGFR-STAT3 protein complex. Consistent with these findings, we demonstrated a significant induction in mRNA expression levels of STAT3 target genes (IL-6, IL-17A, BCL-xL, Survivin, and c-MYC) in BE and EAC cells, following acidic bile salts treatment. ChIP assays indicated that acidic bile salts treatment enhances binding of STAT3 to the promoter of its target genes, Survivin and BCL-xL. Inhibition of APE1/REF-1 redox activity using E3330 abrogated STAT3 DNA binding and transcriptional activity. The induction of APE1-STAT3 axis in acidic bile salts conditions provided a survival advantage and promoted cellular proliferation. In summary, our study provides multiple pieces of evidence supporting a critical role for APE1 induction in activating the EGFR-STAT3 signaling axis in response to acidic bile salts, the main risk factor for Barrett's carcinogenesis.	[Bhat, Ajaz A.; Lu, Heng; Soutto, Mohammed; Capobianco, Anthony; Zaika, Alexander; El-Rifai, Wael] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Bhat, Ajaz A.] Sidra Med, Div Translat Med, Res Branch, Doha, Qatar; [Rai, Priyamvada] Univ Miami, Miller Sch Med, Div Med Oncol, Dept Med, Miami, FL 33136 USA; [Zaika, Alexander; El-Rifai, Wael] Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA	University of Miami; Sidra Medical & Research Center; University of Miami	El-Rifai, W (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.; El-Rifai, W (corresponding author), Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.	welrifai@med.miami.edu	Bhat, Ajaz/V-3642-2019	Bhat, Ajaz/0000-0003-3640-6275; Rai, Priyamvada/0000-0001-7822-7553	U.S. National Institutes of Health [R01CA206563]; U.S. Department of Veterans affairs [1IK6BX003787, I01BX001179]; NATIONAL CANCER INSTITUTE [R01CA206564, R01CA206563] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115, IK6BX003787, I01BX001179] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by grants from the U.S. National Institutes of Health (R01CA206563) and the U.S. Department of Veterans affairs (1IK6BX003787 and I01BX001179). The content of this work is solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, or the University of Miami.	Abdel-Latif MMM, 2004, ANN SURG, V239, P491, DOI 10.1097/01.sla.0000118751.95179.c6; Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; Bernstein H, 2009, WORLD J GASTROENTERO, V15, P3329, DOI 10.3748/wjg.15.3329; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Biswas A, 2015, AM J PHYSIOL-CELL PH, V309, pC296, DOI 10.1152/ajpcell.00022.2015; Bobola MS, 2005, CLIN CANCER RES, V11, P7405, DOI 10.1158/1078-0432.CCR-05-1068; Cardoso AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047462; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Cook MB, 2009, BRIT J CANCER, V101, P855, DOI 10.1038/sj.bjc.6605246; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Di Maso V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143289; Dossa AY, 2016, AM J PHYSIOL-GASTR L, V310, pG81, DOI 10.1152/ajpgi.00065.2015; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Dvorak K, 2007, GUT, V56, P763, DOI 10.1136/gut.2006.103697; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; Eloubeidi MA, 2003, AM J GASTROENTEROL, V98, P1627, DOI 10.1016/S0002-9270(03)00228-4; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fishel ML, 2011, MOL CANCER THER, V10, P1698, DOI 10.1158/1535-7163.MCT-11-0107; Fishel ML, 2010, EXP HEMATOL, V38, P1178, DOI 10.1016/j.exphem.2010.08.011; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; Hong J, 2016, ONCOTARGET, V7, P16688, DOI 10.18632/oncotarget.7696; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; IFTIKHAR SY, 1993, ANN ROY COLL SURG, V75, P411; Inayama M, 2007, HEPATO-GASTROENTEROL, V54, P761; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jenkins GJS, 2008, MUTAGENESIS, V23, P399, DOI 10.1093/mutage/gen029; Jolly AJ, 2004, MUTAGENESIS, V19, P319, DOI 10.1093/mutage/geh035; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kauer WKH, 1997, SURGERY, V122, P874, DOI 10.1016/S0039-6060(97)90327-5; Kelley MR, 2011, ANTIOXID REDOX SIGN, V14, P1387, DOI 10.1089/ars.2010.3410; Kim JS, 2012, INT J RADIAT ONCOL, V82, P130, DOI 10.1016/j.ijrobp.2010.09.037; Lagergren J, 2005, GUT, V54, pI1, DOI 10.1136/gut.2004.041517; Le Bras GF, 2014, LAB INVEST, V94, P1134, DOI 10.1038/labinvest.2014.97; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lechner S, 2002, CARCINOGENESIS, V23, P1281, DOI 10.1093/carcin/23.8.1281; Lee JS, 2001, MUTAT RES-FUND MOL M, V480, P189, DOI 10.1016/S0027-5107(01)00199-3; Li L, 2010, CANCER RES, V70, P8222, DOI 10.1158/0008-5472.CAN-10-0894; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Luo M, 2008, ANTIOXID REDOX SIGN, V10, P1853, DOI 10.1089/ars.2008.2120; Nehra D, 1999, GUT, V44, P598, DOI 10.1136/gut.44.5.598; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Peng DF, 2014, J CANCER, V5, P510, DOI 10.7150/jca.9215; Peng DF, 2012, GUT, V61, P1250, DOI 10.1136/gutjnl-2011-301078; Pera M, 2005, J SURG ONCOL, V92, P151, DOI 10.1002/jso.20357; Picardo SL, 2012, DIGEST SURG, V29, P251, DOI 10.1159/000341498; Poehlmann A, 2012, PATHOL RES PRACT, V208, P269, DOI 10.1016/j.prp.2012.03.007; Reid BJ, 2010, NAT REV CANCER, V10, P87, DOI 10.1038/nrc2773; Shao H, 2003, CANCER RES, V63, P3923; Sital RR, 2006, SCAND J GASTROENTERO, V41, P11, DOI 10.1080/00365520600664219; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sommerfeld A, 2009, J BIOL CHEM, V284, P22173, DOI 10.1074/jbc.M109.005355; Tell G, 2010, CELL MOL LIFE SCI, V67, P3589, DOI 10.1007/s00018-010-0486-4; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Thakur S, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.42; Theisen J, 2000, J GASTROINTEST SURG, V4, P50, DOI 10.1016/S1091-255X(00)80032-3; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vigneron A, 2008, CANCER RES, V68, P815, DOI 10.1158/0008-5472.CAN-07-5115; Yang Z, 2014, INT J ONCOL, V45, P1820, DOI 10.3892/ijo.2014.2589; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu XT, 2007, J CANCER RES CLIN, V133, P145, DOI 10.1007/s00432-006-0139-z; Zhang F, 2015, J TOXICOL PATHOL, V28, P79, DOI 10.1293/tox.2014-0047; Zhang HY, 2009, CANCER RES, V69, P9083, DOI 10.1158/0008-5472.CAN-09-2518; Zhang R, 2005, WORLD J GASTROENTERO, V11, P6466, DOI 10.3748/wjg.v11.i41.6466	75	32	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6011	6024		10.1038/s41388-018-0388-8	http://dx.doi.org/10.1038/s41388-018-0388-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991802	Green Accepted			2022-12-28	WOS:000450175900001
J	Bai, J; Yeh, SY; Qiu, XF; Hu, LY; Zeng, J; Cai, YK; Zuo, L; Li, GH; Yang, GS; Chang, C				Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Zeng, Jun; Cai, Yangke; Zuo, Li; Li, Gonghui; Yang, Guosheng; Chang, Chawnshang			TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; ORPHAN RECEPTORS; GENE-EXPRESSION; VIMENTIN; INVASION; PROLIFERATION; TUMORIGENESIS; SUPERFAMILY; GROWTH; LUNG	While TR4 nuclear receptor plays key roles to promote prostate cancer progression, its roles to alter the progression of clear cell renal cell carcinoma (ccRCC), remains unclear. Here, we demonstrate that TR4 can promote the ccRCC cell vasculogenic mimicry (VM) formation and its associated metastasis via modulating the miR490-3p/vimentin (VIM) signals. Mechanism dissection revealed that TR4 might increase the oncogene VIM expression via decreasing the miR-490-3p expression through direct binding to the TR4-response-elements (TR4REs) on the promoter region of miR-490-3p, which might then directly target the 3' UTR of VIM-mRNA to increase its protein expression. Preclinical studies using the in vivo mouse model with xenografted RCC Caki-1 cells into the sub-renal capsule of nude mice also found that TR4 could promote the ccRCC VM and its associated metastasis via modulating the miR490-3p/VIM signals. Together, results from preclinical studies using multiple RCC cell lines and the in vivo mouse model all conclude that TR4 may play a key role to promote ccRCC VM formation and metastasis and targeting the newly identified TR4/miR-490-3p/VIM signals with small molecules may help us to develop a new therapeutic approach to better suppress the ccRCC metastasis.	[Bai, Jian; Qiu, Xiaofu; Zeng, Jun; Cai, Yangke; Zuo, Li; Yang, Guosheng] Guangdong Second Prov Gen Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Zuo, Li] Nanjing Med Univ, Peoples Affiliated Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Chang, Chawnshang] China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan	University of Rochester; University of Rochester; University of Rochester; Nanjing Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Yang, GS (corresponding author), Guangdong Second Prov Gen Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA.; Chang, C (corresponding author), China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.	2008yangguosheng@sina.com; chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan). We thank Karen Wolf for help preparing the manuscript.	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chen K, 2016, BIOL CELL, V108, P41, DOI 10.1111/boc.201500033; Chen S, 2015, CANCER LETT, V362, P122, DOI 10.1016/j.canlet.2015.03.029; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Chen YT, 2007, BRAIN RES, V1168, P72, DOI 10.1016/j.brainres.2007.06.069; Choi H, 2011, FEBS LETT, V585, P2763, DOI 10.1016/j.febslet.2011.08.002; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Collins LL, 2004, P NATL ACAD SCI USA, V101, P15058, DOI 10.1073/pnas.0405700101; Comperat E, 2012, Diagn Interv Imaging, V93, P221, DOI 10.1016/j.diii.2012.01.015; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ding XF, 2015, INT J CANCER, V136, P955, DOI 10.1002/ijc.29049; Fuyuhiro Y, 2010, ANTICANCER RES, V30, P5239; Gilles C, 2003, CANCER RES, V63, P2658; Gu HH, 2014, BIOCHEM BIOPH RES CO, V444, P104, DOI 10.1016/j.bbrc.2014.01.020; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lee YF, 2002, J STEROID BIOCHEM, V81, P291, DOI 10.1016/S0960-0760(02)00118-8; Li M, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-109; Lin SJ, 2014, CARCINOGENESIS, V35, P1399, DOI 10.1093/carcin/bgu052; Lin SJ, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-43; Liu QQ, 2016, J CELL MOL MED, V20, P1761, DOI 10.1111/jcmm.12851; Liu W, 2015, FEBS LETT, V589, P3148, DOI 10.1016/j.febslet.2015.08.034; Majid S, 2011, CANCER RES, V71, P2611, DOI 10.1158/0008-5472.CAN-10-3666; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mu XM, 2004, MOL CELL BIOL, V24, P5887, DOI 10.1128/MCB.24.13.5887-5899.2004; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Qiao LL, 2015, J CELL MOL MED, V19, P315, DOI 10.1111/jcmm.12496; Qiu XF, 2015, ONCOTARGET, V6, P15397, DOI 10.18632/oncotarget.3778; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Shen J, 2015, CANCER RES, V75, P754, DOI 10.1158/0008-5472.CAN-14-1301; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193; Stadler WM, 2005, CANCER-AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453; Trog D, 2008, AMINO ACIDS, V34, P539, DOI 10.1007/s00726-007-0007-4; UPTON MP, 1986, AM J SURG PATHOL, V10, P560, DOI 10.1097/00000478-198608000-00006; Yamasaki T, 2013, J UROLOGY, V190, P1059, DOI 10.1016/j.juro.2013.02.089; Yang DR, 2013, J BIOL CHEM, V288, P16476, DOI 10.1074/jbc.M112.448142; Zhang LY, 2013, J BIOL CHEM, V288, P4035, DOI 10.1074/jbc.M112.410506; Zhao Y, 2008, CELL BIOCHEM FUNCT, V26, P571, DOI 10.1002/cbf.1478; Zhou L, 2016, J UROLOGY, V196, P335, DOI 10.1016/j.juro.2016.02.2971; Zhu J, 2015, MOL CANCER THER, V14, P1445, DOI 10.1158/1535-7163.MCT-14-0971; Zoni E, 2015, CANCER RES, V75, P2326, DOI 10.1158/0008-5472.CAN-14-2155	46	28	28	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5901	5912		10.1038/s41388-018-0269-1	http://dx.doi.org/10.1038/s41388-018-0269-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973687				2022-12-28	WOS:000448943100007
J	Deng, SJ; Chen, HY; Ye, Z; Deng, SC; Zhu, S; Zeng, Z; He, C; Liu, ML; Huang, K; Zhong, JX; Xu, FY; Li, Q; Liu, Y; Wang, CY; Zhao, G				Deng, Shi-jiang; Chen, Heng-yu; Ye, Zeng; Deng, Shi-chang; Zhu, Shuai; Zeng, Zhu; He, Chi; Liu, Ming-liang; Huang, Kang; Zhong, Jian-xin; Xu, Feng-yu; Li, Qiang; Liu, Yang; Wang, Chun-you; Zhao, Gang			Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LONG NONCODING RNAS; CELLS; PROLIFERATION; HIF-1-ALPHA; INVASION; YB-1; CONTRIBUTES; EXPRESSION; MIGRATION	The contribution of long noncoding RNAs (lncRNAs) to pancreatic cancer progression and the regulatory mechanisms of their expression are attractive areas. In the present study, the overexpression of lncRNA-BX111887 (BX111) in pancreatic cancer tissues was detected by microarray and further validated in a cohort of pancreatic cancer tissues. We further demonstrated that knockdown or overexpression of BX111 dramatically repressed or enhanced proliferation and invasion of pancreatic cancer cells. Mechanically, BX111 activated transcription of ZEB1, a key regulator for epithelia-mesenchymal transition (EMT), via recruiting transcriptional factor Y-box protein (YB1) to its promoter region. Moreover, we revealed that BX111 transcription was induced by hypoxia-inducible factor (HIF-1 alpha) in response to hypoxia. In addition, BX111 contributed to the hypoxia- induced EMT of pancreatic cells by regulating expression of ZEB1 and its downstream proteins E-cadherin and MMP2. Coincidence with in vitro results, BX111 depletion effectively inhibited growth and metastasis of xenograft tumor in vivo. The clinical samples of pancreatic cancer further confirmed a positive association between BX111 and ZEB1. Moreover, high BX111 expression was correlated with late TNM stage, lymphatic invasion and distant metastasis, as well as short overall survival time in patients. Taken together, our findings implicate a hypoxia- induced lncRNA contributes to metastasis and progression of pancreatic cancer, and suggest BX111 might be applied as a potential biomarker and therapeutic target for pancreatic cancer.	[Deng, Shi-jiang; Chen, Heng-yu; Ye, Zeng; Deng, Shi-chang; Zhu, Shuai; Zeng, Zhu; He, Chi; Liu, Ming-liang; Huang, Kang; Zhong, Jian-xin; Xu, Feng-yu; Li, Qiang; Liu, Yang; Wang, Chun-you; Zhao, Gang] Huazhong Univ Sci & Technol, Union Hosp, Dept Pancreat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pancreat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.	gangzhao@hust.edu.cn	fuliyun_new, fuliyun_new/AAZ-4437-2020	Huang, Kang/0000-0003-1169-598X	National Science Foundation Committee (NSFC) of China [81372666, 81672406, 81502076]	National Science Foundation Committee (NSFC) of China(National Natural Science Foundation of China (NSFC))	This study was supported from the National Science Foundation Committee (NSFC) of China (Grant number: 81372666 and 81672406 to Gang Zhao; No. 81502076 to Shi-chang Deng)	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cheng YT, 2015, ONCOTARGET, V6, P10840, DOI 10.18632/oncotarget.3450; Chou CC, 2015, ONCOTARGET, V6, P8271, DOI 10.18632/oncotarget.3186; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Deng SC, 2015, ONCOTARGET, V6, P39661, DOI 10.18632/oncotarget.5350; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gomez-Maldonado L, 2015, ONCOGENE, V34, P2609, DOI 10.1038/onc.2014.200; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jooste V, 2016, INT J CANCER, V139, P1073, DOI 10.1002/ijc.30166; Kang SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112754; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Krzywinski M, 2013, NAT METHODS, V10, P1139, DOI 10.1038/nmeth.2738; Lau E, 2014, NAT REV GENET, V15, DOI 10.1038/nrg3795; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008; Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830; McCarty G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119837; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Salnikov AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046391; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun YW, 2014, BRIT J CANCER, V111, P2131, DOI 10.1038/bjc.2014.520; Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008; Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhan HX, 2016, CANCER LETT, V374, P261, DOI 10.1016/j.canlet.2016.02.018; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhou KR, 2017, NUCLEIC ACIDS RES, V45, pD43, DOI 10.1093/nar/gkw965; Zhu Y, 2016, J CELL MOL MED, V20, P688, DOI 10.1111/jcmm.12769	38	124	133	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5811	5828		10.1038/s41388-018-0382-1	http://dx.doi.org/10.1038/s41388-018-0382-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29970904				2022-12-28	WOS:000448943100001
J	Zhou, W; Sun, W; Yung, MMH; Dai, S; Cai, YH; Chen, CW; Meng, YX; Lee, JB; Braisted, JC; Xu, YH; Southall, NT; Shinn, P; Huang, XF; Song, ZF; Chen, XL; Kai, Y; Cai, X; Li, ZZ; Hao, Q; Cheung, ANY; Ngan, HYS; Liu, SS; Barak, S; Hao, J; Dai, ZJ; Tzatsos, A; Peng, WQ; Pei, HD; Han, ZY; Chan, DW; Zheng, W; Zhu, WG				Zhou, Wei; Sun, Wei; Yung, Mingo M. H.; Dai, Sheng; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Braisted, John C.; Xu, Yinghua; Southall, Noel T.; Shinn, Paul; Huang, Xuefeng; Song, Zhangfa; Chen, Xiulei; Kai, Yan; Cai, Xin; Li, Zongzhu; Hao, Qiang; Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Liu, Stephanie S.; Barak, Stephanie; Hao, Jing; Dai, Zhijun; Tzatsos, Alexandros; Peng, Weiqun; Pei, Huadong; Han, Zhiyong; Chan, David W.; Zheng, Wei; Zhu, Wenge			Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance	ONCOGENE			English	Article							OVARIAN-CANCER; MYELOPROLIFERATIVE NEOPLASMS; POLYCYTHEMIA-VERA; MOLECULAR-MECHANISMS; DNA-DAMAGE; STAGE-III; CISPLATIN; MUTATIONS; PACLITAXEL; INHIBITORS	Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment failure frequently results from platinum drug resistance. Emerging observations suggest a role of reactive oxygen species (ROS) in the resistance of cancer drugs including platinum drugs. However, the molecular link between ROS and cellular survival pathway is poorly understood. Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism. Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo. Significantly, clinic studies also confirm the activated IL-11-JAK2 pathway in platinum-resistant ovarian cancer patients, which highly correlates with poor prognosis. These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	[Zhou, Wei; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Cai, Xin; Li, Zongzhu; Hao, Qiang; Hao, Jing; Pei, Huadong; Han, Zhiyong; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Zhou, Wei; Dai, Sheng; Huang, Xuefeng; Song, Zhangfa] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Colorectal Surg, Hangzhou 310016, Zhejiang, Peoples R China; [Zhou, Wei; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Kai, Yan; Cai, Xin; Li, Zongzhu; Hao, Qiang; Tzatsos, Alexandros; Pei, Huadong; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Sun, Wei; Dai, Sheng; Braisted, John C.; Southall, Noel T.; Shinn, Paul; Zheng, Wei] Natl Ctr Adv Translat Sci, Natl Inst Hlth, Bethesda, MD 20892 USA; [Yung, Mingo M. H.; Chan, David W.] Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Xu, Yinghua] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou 310016, Zhejiang, Peoples R China; [Chen, Xiulei] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Clin Lab, Hangzhou 310016, Zhejiang, Peoples R China; [Kai, Yan; Peng, Weiqun] George Washington Univ, Columbian Coll Arts & Sci, Dept Phys, Washington, DC 20052 USA; [Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Liu, Stephanie S.] Univ Hong Kong, LKS Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Barak, Stephanie] George Washington Univ, Sch Med & Hlth Sci, Dept Pathol, Washington, DC 20037 USA; [Dai, Zhijun] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Shaanxi, Peoples R China; [Tzatsos, Alexandros] George Washington Univ, Sch Med & Hlth Sci, Dept Anat & Regenerat Biol, Washington, DC 20037 USA	George Washington University; Zhejiang University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Hong Kong; Zhejiang University; Zhejiang University; George Washington University; University of Hong Kong; George Washington University; Xi'an Jiaotong University; George Washington University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Zheng, W (corresponding author), Natl Ctr Adv Translat Sci, Natl Inst Hlth, Bethesda, MD 20892 USA.; Chan, DW (corresponding author), Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China.	dwchan@hku.hk; wzheng@mail.nih.gov; wz6812@gwu.edu	Zheng, Wei/GQQ-8951-2022; /AAI-2516-2019; Zheng, Wei/GOE-5990-2022; Kai, Yan/ABH-8469-2020; YUNG, Mingo Ming Ho/AHB-5775-2022; dai, sheng/AGQ-0059-2022; Chan, David/O-9896-2018; Southall, Noel/H-8991-2012; Dai, Zhi-Jun/O-6826-2014; Cheung, Annie Nga Yin/C-4231-2009	Kai, Yan/0000-0003-3262-4160; YUNG, Mingo Ming Ho/0000-0003-0903-1164; Chan, David/0000-0002-6951-3467; Ngan, Hextan Y S/0000-0003-3945-159X; Chen, Chi-Wei/0000-0001-8658-055X; Southall, Noel/0000-0003-4500-880X; Dai, Zhi-Jun/0000-0001-5209-8626; Peng, Weiqun/0000-0001-5521-9091; dai, sheng/0000-0002-5387-8517; Cheung, Annie Nga Yin/0000-0002-1584-7568	National Institutes of Health [CA177898, CA184717]; McCormick Genomic and Proteomic Center; intramural research program at the National Center for Advancing Translational Sciences (NCATS); American Cancer Society [RSG-13-214-01-DMC]; National Natural Science Foundation of China [81402580]; NATIONAL CANCER INSTITUTE [R01CA184717, R01CA177898, R21CA182662, R03CA212068] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000018, ZICTR000242] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Genomic and Proteomic Center; intramural research program at the National Center for Advancing Translational Sciences (NCATS); American Cancer Society(American Cancer Society); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to W. Zhu), the McCormick Genomic and Proteomic Center, and intramural research program at the National Center for Advancing Translational Sciences (NCATS). W Zhu was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society. This work was supported by the National Natural Science Foundation of China grant 81402580 to W Zhou.	Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buchert M, 2016, ONCOGENE, V35, P939, DOI 10.1038/onc.2015.150; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Ernst M, 2014, CLIN CANCER RES, V20, P5579, DOI 10.1158/1078-0432.CCR-13-2492; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Hanker LC, 2012, ANN ONCOL, V23, P2605, DOI 10.1093/annonc/mds203; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jazaeri AA, 2013, MOL CANCER THER, V12, P1958, DOI 10.1158/1535-7163.MCT-12-1028; Kang MA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.134; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; LANGDON SP, 1988, CANCER RES, V48, P6166; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Ma L, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.6; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Onnis B, 2013, J CLIN INVEST, V123, P1615, DOI 10.1172/JCI59623; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park CY, 2015, BIOINFORMATICS, V31, P1093, DOI 10.1093/bioinformatics/btu786; Quintas-Cardama A, 2013, CLIN CANCER RES, V19, P1933, DOI 10.1158/1078-0432.CCR-12-0284; Quintas-Cardama A, 2011, NAT REV DRUG DISCOV, V10, P127, DOI 10.1038/nrd3264; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun W, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.123; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tasdogan A, 2016, CELL STEM CELL, V19, P752, DOI 10.1016/j.stem.2016.08.007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tyner JW, 2010, BLOOD, V115, P5232, DOI 10.1182/blood-2009-05-223727; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wu SC, 2015, CANCER CELL, V28, P29, DOI 10.1016/j.ccell.2015.06.005; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042	40	21	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3981	3997		10.1038/s41388-018-0238-8	http://dx.doi.org/10.1038/s41388-018-0238-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662190	Green Accepted, Green Submitted			2022-12-28	WOS:000439101300006
J	Dorayappan, KDP; Wanner, R; Wallbillich, JJ; Saini, U; Zingarelli, R; Suarez, AA; Cohn, DE; Selvendiran, K				Dorayappan, Kalpana Deepa Priya; Wanner, Ross; Wallbillich, John J.; Saini, Uksha; Zingarelli, Roman; Suarez, Adrian A.; Cohn, David E.; Selvendiran, Karuppaiyah			Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins	ONCOGENE			English	Article							INTERCELLULAR-COMMUNICATION; CARCINOMA CELLS; STEM-CELLS; METASTASIS; TRAFFICKING; PROGRESSION; EXPRESSION; CISPLATIN; PATHWAY; NICHE	Hypoxia-mediated tumor progression, metastasis, and drug resistance are major clinical challenges in ovarian cancer. Exosomes released in the hypoxic tumor microenvironment may contribute to these challenges by transferring signaling proteins between cancer cells and normal cells. We observed that ovarian cancer cells exposed to hypoxia significantly increased their exosome release by upregulating Rab27a, downregulating Rab7, LAMP1/2, NEU-1, and also by promoting a more secretory lysosomal phenotype. STAT3 knockdown in ovarian cancer cells reduced exosome release by altering the Rab family proteins Rab7 and Rab27a under hypoxic conditions. We also found that exosomes from patient-derived ascites ovarian cancer cell lines cultured under hypoxic conditions carried more potent oncogenic proteins-STAT3 and FAS that are capable of significantly increasing cell migration/invasion and chemo-resistance in vitro and tumor progression/metastasis in vivo. Hypoxic ovarian cancer cells derived exosomes (HEx) are proficient in re-programming the immortalized fallopian tube secretory epithelial cells (FT) to become pro-tumorigenic in mouse fallopian tubes. In addition, cisplatin efflux via exosomes was significantly increased in ovarian cancer cells under hypoxic conditions. Co-culture of HEx with tumor cells led to significantly decreased dsDNA damage and increased cell survival in response to cisplatin treatment. Blocking exosome release by known inhibitor Amiloride or STAT3 inhibitor and treating with cisplatin resulted in a significant increase in apoptosis, decreased colony formation, and proliferation. Our results demonstrate that HEx are more potent in augmenting metastasis/chemotherapy resistance in ovarian cancer and may serve as a novel mechanism for tumor metastasis, chemo-resistance, and a point of intervention for improving clinical outcomes.	[Dorayappan, Kalpana Deepa Priya; Wanner, Ross; Saini, Uksha; Zingarelli, Roman; Cohn, David E.; Selvendiran, Karuppaiyah] Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Div Gynecol Oncol, Columbus, OH 43210 USA; [Wallbillich, John J.] Augusta Univ, Div Gynecol Oncol, Dept OB GYN, Georgia Canc Ctr, Augusta, GA USA; [Suarez, Adrian A.] Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Dept Pathol,Gynecol Oncol, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Georgia; Augusta University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Selvendiran, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Div Gynecol Oncol, Columbus, OH 43210 USA.	selvendiran.karuppaiyah@osumc.edu		Wallbillich, John/0000-0001-5913-8088	NIH [S10 OD018056]; National Cancer Institute, Bethesda, MD [P30 CA016058]; Ovarian Cancer Research Fund (OCRF); NCI [RO1-CA176078]; KOH ovarian cancer foundation; NATIONAL CANCER INSTITUTE [R01CA176078, P30CA016058] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD018056] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Bethesda, MD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund (OCRF); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); KOH ovarian cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Zhang Liwen, PhD for proteomic analysis using Fusion Orbitrap instrument at OSU supported by NIH Award Number Grant S10 OD018056; Dr. Xiaokui Mo, Ph.D for analysis of Bioinformatics data; and Dr. Min Gao, Ph.D, Kent University for TEM analysis. Confocal images presented in this manuscript were generated using the services of the Campus Microscopy and Imaging Facility at OSU supported in part by grant P30 CA016058, National Cancer Institute, Bethesda, MD. We also thank Dr. John Olesik, Trace Element Research laboratory at OSU who helped us to quantify the Cisplatin concentration in exosomes by ICP-Mass Spectrometry; Dr. John Hays for his willingness to pre-review this manuscript and provide valuable comments and suggestions; Dr. Matthew Ringel, MD and his laboratory member Dr. Moto Saji for their invaluable help in exosome isolation protocols; and Brentley Smith, GYN/ONC fellow at OSU, Graduate students Dongju Park and Christopher Koivisto, Medical student Rashmi Madhukar, and Undergraduate student Maria Riley, for the IHC, cell culture, and basic assay help. This work was funded by Ovarian Cancer Research Fund (OCRF), NCI RO1-CA176078 grant (to KS and DEC) and KOH ovarian cancer foundation grant to KDPD.	[Anonymous], 2015, SEER STAT FACT SHEET; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Beach A, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-14; Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dorayappan KDP, 2016, GYNECOL ONCOL, V141, P66; ElNaggar AC, 2016, CANCER BIOL THER, V17, P1107, DOI 10.1080/15384047.2016.1210733; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Gao M, 2014, MICROSC RES TECHNIQ, V77, P754, DOI 10.1002/jemt.22397; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; Gupta S, 2007, AM J PHYSIOL-HEART C, V292, pH3052, DOI 10.1152/ajpheart.01355.2006; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kanlikilicer P, 2016, CANCER RES, V76, P7194, DOI 10.1158/0008-5472.CAN-16-0714; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Liang B, 2013, J PROTEOMICS, V80, P171, DOI 10.1016/j.jprot.2012.12.029; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; McCann Georgia A, 2014, Oncoscience, V1, P216; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; Safaei R, 2005, CLIN CANCER RES, V11, P756; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; Savina A, 2002, J CELL SCI, V115, P2505; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shender VO, 2014, MOL CELL PROTEOMICS, V13, P3558, DOI 10.1074/mcp.M114.041194; Su SA, 2017, ONCOTARGET, V8, P25700, DOI 10.18632/oncotarget.14878; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Vaksman O, 2014, CARCINOGENESIS, V35, P2113, DOI 10.1093/carcin/bgu130; Vanlandingham PA, 2009, J BIOL CHEM, V284, P12110, DOI 10.1074/jbc.M809277200; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Zhang HG, 2014, AM J PATHOL, V184, P28, DOI 10.1016/j.ajpath.2013.09.027; Zhang W, 2016, TUMOR BIOL, V37, P4213, DOI 10.1007/s13277-015-4105-8	46	144	152	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3806	3821		10.1038/s41388-018-0189-0	http://dx.doi.org/10.1038/s41388-018-0189-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29636548	Green Accepted			2022-12-28	WOS:000438465600004
J	Jiang, J; Tang, SL; Xia, JH; Wen, JK; Chen, S; Shu, XD; Huen, MSY; Deng, YQ				Jiang, Jun; Tang, Shulin; Xia, Jianhong; Wen, Jikai; Chen, Shuang; Shu, Xiaodong; Huen, Michael S. Y.; Deng, Yiqun			C9orf140, a novel Axin1-interacting protein, mediates the negative feedback loop of Wnt/beta-catenin signaling	ONCOGENE			English	Article							BETA-CATENIN; PHOSPHATASE 2A; UP-REGULATION; P42.3 GENE; IN-VIVO; EXPRESSION; PATHWAY; CANCER; IDENTIFICATION; CELLS	Wnt/beta-catenin signaling activity is maintained in homeostasis by an expanding list of molecular determinants. However, the molecular components and the regulatory mechanisms involved in its fine-tuning remain to be determined. Here, we identified C9orf140, a tumor-specific protein, as a novel Axin1-interacting protein by tandem-affinity purification and mass spectrometry. We further showed that C9orf140 is a negative regulator of Wnt/beta-catenin signaling in cultured cells as well as in zebrafish embryos. It functions upstream of beta-catenin, outcompetes PP2A for binding to Axin1, influences the balance between phosphorylation and de-phosphorylation of beta-catenin, and ultimately compromises Wnt3A-induced beta-catenin accumulation. Interestingly, Wnt-induced C9orf140 expression via beta-catenin. We propose that C9orf140 mediates a negative feedback loop of Wnt/beta-catenin signaling by interacting with Axin1. Our results advance the current understanding of the exquisite control of Wnt/beta-catenin signaling cascade, and provide evidence of the new role of C9orf140.	[Jiang, Jun; Tang, Shulin; Wen, Jikai; Chen, Shuang; Deng, Yiqun] South China Agr Univ, Coll Life Sci, Guangdong Prov Key Lab Prot Funct & Regulat Agr O, Guangzhou 510642, Guangdong, Peoples R China; [Jiang, Jun; Huen, Michael S. Y.] Univ Hong Kong, Sch Biomed Sci, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Xia, Jianhong; Shu, Xiaodong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China	South China Agricultural University; University of Hong Kong; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Deng, YQ (corresponding author), South China Agr Univ, Coll Life Sci, Guangdong Prov Key Lab Prot Funct & Regulat Agr O, Guangzhou 510642, Guangdong, Peoples R China.	yqdeng@scau.edu.cn	wen, jikai/AAV-9818-2021; Deng, Yiqun/K-7709-2013	wen, jikai/0000-0002-4010-4416; Deng, Yiqun/0000-0002-6838-3779	Natural Science Foundation of Guangdong Province [2015A030312005]; Training program for outstanding young teachers in higher education institutions of Guangdong Province [YQ2014027]; National Natural Science Foundation of China [31672611]; Pearl River S&T Nova Program of Guangzhou [201610010063]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Training program for outstanding young teachers in higher education institutions of Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pearl River S&T Nova Program of Guangzhou	We thank Dr. Shengcai Lin for providing the Axin1 and Wnt1 constructs used in this study and Dr. Hans Clevers for providing crucial reagents. This work was supported by the Natural Science Foundation of Guangdong Province [Research Team Project No. 2015A030312005 to YD]; Training program for outstanding young teachers in higher education institutions of Guangdong Province [No. YQ2014027 to JJ]; the National Natural Science Foundation of China [No. 31672611 to YD]; and the Pearl River S&T Nova Program of Guangzhou [No. 201610010063 to JJ].	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Cao WJ, 2015, ANTI-CANCER AGENT ME, V15, P157, DOI 10.2174/1871520614666140818200202; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; Chen P, 2015, J DIGEST DIS, V16, P568, DOI 10.1111/1751-2980.12282; Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cui Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025872; Dong LF, 2015, DRUG METAB DISPOS, V43, P1458, DOI 10.1124/dmd.115.065565; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Hagemann AIH, 2014, J CELL SCI, V127, P3970, DOI 10.1242/jcs.148767; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KELLY GM, 1995, DEVELOPMENT, V121, P1787; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Li S, 2015, FAM CANCER, V14, P325, DOI 10.1007/s10689-014-9775-7; Li ZF, 2011, P NATL ACAD SCI USA, V108, P3116, DOI 10.1073/pnas.1009353108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Weng YR, 2014, CARCINOGENESIS, V35, P1389, DOI 10.1093/carcin/bgu057; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P11312, DOI 10.1073/pnas.1203015109; Xu X, 2007, ONCOGENE, V26, P7371, DOI 10.1038/sj.onc.1210538; Zhang JH, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742-4682-9-53; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	36	10	11	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2992	3005		10.1038/s41388-018-0166-7	http://dx.doi.org/10.1038/s41388-018-0166-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29531269	hybrid, Green Published			2022-12-28	WOS:000433936300007
J	Kim, S; Lee, E; Jung, J; Lee, JW; Kim, HJ; Kim, J; Yoo, HJ; Lee, HJ; Chae, SY; Jeon, SM; Son, BH; Gong, G; Sharan, SK; Chang, S				Kim, Sinae; Lee, Eunji; Jung, Jaeyun; Lee, Jong Won; Kim, Hee Jung; Kim, Jisun; Yoo, Hyun ju; Lee, Hee Jin; Chae, Sun Young; Jeon, Sang Min; Son, Byung Ho; Gong, Gyungyup; Sharan, Shyam K.; Chang, Suhwan			microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; MIR-155; REVEALS; CELLS; TARGETS; GROWTH; FOXO3A; BRCA1; MYC	MicroRNA is an endogenous, small RNA controlling multiple target genes and playing roles in various biological processes including tumorigenesis. Here, we addressed the function of miR-155 using LC-MS/MS-based metabolic profiling of miR-155 deficient breast cancer cells. Our results revealed the loss of miR-155 hampers glucose uptake and glycolysis, via the down-regulation of glucose transporters and metabolic enzymes including HK2, PKM2, and LDHA. We showed this is due to the down-regulation of cMYC, controlled through phosphoinositide-3-kinase regulatory subunit alpha (PIK3R1)-PDK1/AKT-FOXO3a pathway. UTR analysis of the PIK3R1 and FOXO3a indicated miR-155 directly represses these genes. A stable expression of miR-155 in patient-derived cells (PDCs) showed activated glucose metabolism whereas a stable inhibition of miR-155 reduced in vivo tumor growth with retarded glucose metabolism. Furthermore, analysis of 50 triple-negative breast cancer (TNBC) specimens and specific uptake value (SUV) of PET images revealed a positive correlation between miR-155 level and glucose usage in human breast tumors via PIK3R1-PDK/AKT-FOXO3a-cMYC axis. Collectively, these data demonstrate the miR-155 is a key regulator of glucose metabolism in breast cancer.	[Kim, Sinae; Lee, Eunji; Jung, Jaeyun; Chang, Suhwan] Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul 05505, South Korea; [Lee, Jong Won; Kim, Hee Jung; Kim, Jisun; Son, Byung Ho] Asan Med Ctr, Dept Surg, Seoul 05505, South Korea; [Yoo, Hyun ju] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul 05505, South Korea; [Lee, Hee Jin; Gong, Gyungyup] Asan Med Ctr, Dept Pathol, Seoul 05505, South Korea; [Chae, Sun Young] Asan Med Ctr, Dept Nucl Med, Seoul 05505, South Korea; [Jeon, Sang Min] Ajou Univ, Coll Pharm, Suwon 16499, South Korea; [Jeon, Sang Min] Ajou Univ, Inst Pharmaceut Sci & Technol, Suwon 16499, South Korea; [Sharan, Shyam K.] Frederick Natl Lab, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Ulsan; University of Ulsan; Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chang, S (corresponding author), Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul 05505, South Korea.	suhwan.chang@amc.seoul.kr	Jeon, Sang-Min/I-7917-2018	Jeon, Sang-Min/0000-0002-0132-925X; Lee, Hee Jin/0000-0002-4963-6603; Chang, Suhwan/0000-0002-0282-0120; KIM, JISUN/0000-0002-4884-6107	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI13C1538]; National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [1320140]; NATIONAL CANCER INSTITUTE [ZIABC011311] Funding Source: NIH RePORTER	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank to Dr. Ahn, Sung Gwe (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine) for valuable suggestions. The biospecimen and data used in this study was provided by Asan Bio-Resource Center, Korea Biobank Network (2014-3(72)). This work is supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare (Grant number: HI13C1538) and by the National R&D Program for Cancer Control, Ministry of Health & Welfare (No. 1320140), Republic of Korea.	Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chang SW, 2009, J CLIN INVEST, V119, P3160, DOI 10.1172/JCI39836; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dang CV, 2011, COLD SH Q B, V76, P369, DOI 10.1101/sqb.2011.76.011296; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV., 2007, E SCHERING FDN S P, V4, P35; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179; Geltz NR, 1998, BLOOD, V91, P930, DOI 10.1182/blood.V91.3.930.930_930_939; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Huang X, 2012, AM J PATHOL, V181, P26, DOI 10.1016/j.ajpath.2012.03.013; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Kim S, 2016, ONCOTARGET, V7, P11094, DOI 10.18632/oncotarget.7150; Kim S, 2015, CANCER LETT, V357, P488, DOI 10.1016/j.canlet.2014.11.058; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin XL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006308; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Lv X, 2016, MOL MED REP, V14, P1332, DOI 10.3892/mmr.2016.5394; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tili E, 2009, INT REV IMMUNOL, V28, P264, DOI 10.1080/08830180903093796; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang J, 2012, FRONT BIOSCI-LANDMRK, V17, P2350, DOI 10.2741/4056; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	33	71	73	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2982	2991		10.1038/s41388-018-0124-4	http://dx.doi.org/10.1038/s41388-018-0124-4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29527004	Green Published, hybrid			2022-12-28	WOS:000433936300006
J	Wang, H; Bei, L; Shah, CA; Huang, WQ; Platanias, LC; Eklund, EA				Wang, Hao; Bei, Ling; Shah, Chirag A.; Huang, Weiqi; Platanias, Leonidas C.; Eklund, Elizabeth A.			The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; BONE-MARROW-CELLS; GENE-EXPRESSION; ACTIVATES TRANSCRIPTION; ENCODING GP91(PHOX); PROGENITOR CELLS; HOX EXPRESSION; DNA-BINDING; IN-VITRO; DIFFERENTIATION	Chromosomal translocations involving the MLL1 gene characterize a poor prognosis subset of acute myeloid leukemia (AML), referred to as 11q23-AML. Transcription of the HOXA9 and HOXA10 genes is enhanced in hematopoietic stem and progenitor cells in these leukemias. We previously found the ARIH2 gene was repressed by HoxA9 in myeloid progenitors, but activated by HoxA10 during granulopoiesis. ARIH2 encodes the Triad1 protein, an anti-proliferative E3 ubiquitin ligase. In the current study, we investigate the role of Triad1 in leukemogenesis induced by an MLL1 fusion protein (Mll-Ell). We found Mll-Ell increased expression of HoxA9, HoxA10, and Triad1 because HoxA9 represses only one of two ARIH2 cis elements that are activated by HoxA10. Although Triad1 antagonized the generally pro-proliferative effects of the Mll-Ell oncoprotein, we found blocking HoxA9 and HoxA10 phosphorylation shifted the balance to ARIH2 repression in Mll-Ell(+) cells. We investigated the significance of these in vitro results in a murine bone marrow transplant model. We found Triad1 knockdown significantly shortened the latency to development of AML in mice transplanted with Mll-Ell-transduced bone marrow. And, Triad1 expression fell during the prolonged AML latency period in mice transplanted with bone marrow expressing Mll-Ell alone. Our studies identify Triad1 as a leukemia suppressor in 11q23-AML. This suggests defining relevant Triad1 substrates may indicate novel therapeutic targets in this disease.	[Wang, Hao; Bei, Ling; Shah, Chirag A.; Huang, Weiqi; Platanias, Leonidas C.; Eklund, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Bei, Ling; Shah, Chirag A.; Platanias, Leonidas C.; Eklund, Elizabeth A.] Jesse Brown Vet Adm Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.; Eklund, EA (corresponding author), Jesse Brown Vet Adm Med Ctr, Chicago, IL 60612 USA.	e-eklund@northwestern.edu		Wang, Hao/0000-0003-2131-0377	NIH [HL87717]; Robert H. Lurie Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA195642] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087717] Funding Source: NIH RePORTER; Veterans Affairs [I01BX004635] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert H. Lurie Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	NIH grant HL87717, a VA Merit Review, the Mander Foundation, and the Director's Research Fund of the Robert H. Lurie Comprehensive Cancer Center (to EAE).	ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bei L, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.49; Bei L, 2007, J BIOL CHEM, V282, P16846, DOI 10.1074/jbc.M609744200; Bei L, 2011, J BIOL CHEM, V286, P19047, DOI 10.1074/jbc.M110.213983; Bjornsson JM, 2001, BLOOD, V98, P3301, DOI 10.1182/blood.V98.12.3301; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Compendia Biosciences, ONC 4 4; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Eklund E. A., 2011, Critical Reviews in Oncogenesis, V16, P65; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Eklund EA, 2000, J BIOL CHEM, V39, P36878; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Lin AE, 2013, NAT IMMUNOL, V14, P27, DOI 10.1038/ni.2478; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; Lindsey S, 2007, J BIOL CHEM, V282, P2237, DOI 10.1074/jbc.M608642200; Marteijn JAF, 2005, BLOOD, V106, P4114, DOI 10.1182/blood-2005-04-1450; Nabinger SC, 2013, LEUKEMIA, V27, P398, DOI 10.1038/leu.2012.308; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; Roche J, 2004, LEUKEMIA, V18, P1059, DOI 10.1038/sj.leu.2403366; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shah CA, 2013, J BIOL CHEM, V288, P32490, DOI 10.1074/jbc.M113.496109; Shah CA, 2012, J BIOL CHEM, V287, P18230, DOI 10.1074/jbc.M111.328401; Shah CA, 2011, J BIOL CHEM, V286, P3161, DOI 10.1074/jbc.M110.183251; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Van der Reijden BA, 1999, PROTEIN SCI, V8, P1557, DOI 10.1110/ps.8.7.1557; Wang H, 2007, J BIOL CHEM, V282, P16164, DOI 10.1074/jbc.M610556200; Wang H, 2015, J IMMUNOL, V194, P5375, DOI 10.4049/jimmunol.1401909; Wang H, 2011, J BIOL CHEM, V286, P16832, DOI 10.1074/jbc.M110.213975; Wang H, 2009, J BIOL CHEM, V284, P2549, DOI 10.1074/jbc.M804704200; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	38	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2532	2544		10.1038/s41388-018-0131-5	http://dx.doi.org/10.1038/s41388-018-0131-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29459712	Green Published, hybrid			2022-12-28	WOS:000431873400006
J	Hua, SN; Lei, L; Deng, L; Weng, X; Liu, CD; Qi, XL; Wang, S; Zhang, DY; Zou, XJ; Cao, CH; Liu, L; Wu, DH				Hua, Shengni; Lei, Ling; Deng, Ling; Weng, Xie; Liu, Chengdong; Qi, Xiaolong; Wang, Shuang; Zhang, Dongyan; Zou, Xuejing; Cao, Chuanhui; Liu, Li; Wu, Dehua			miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR ETS1; TUMOR-SUPPRESSOR; DIFFERENTIAL EXPRESSION; GASTRIC-CANCER; PROTOONCOGENE; METASTASIS; MICRORNAS; HYPOXIA; NETWORK	Cancer cells have metabolic features that allow them to preferentially metabolize glucose through aerobic glycolysis, providing them with a progression advantage. However, microRNA (miRNA) regulation of aerobic glycolysis in cancer cells has not been extensively investigated. We addressed this in the present study by examining the regulation of miR-139-5p on aerobic glycolysis of hepatocellular carcinoma (HCC) using clinical specimens, HCC cells, and a mouse xenograft model. We found that overexpressing miR-139-5p restrained aerobic glycolysis, suppressing proliferation, migration, and invasion in HCC cells. miR-139-5p regulated hexokinase 1 (HK1) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) expression by directly targeting the transcription factor ETS1, which bound to the promoters of the HK1 and PFKFB3 genes. miR-139-5p-induced aerobic glycolysis, proliferation, migration, and invasion were reversed by ETS1 overexpression, while ETS1 silencing induced the expression of miR-139-5p via a post-transcriptional regulation mode involving Drosha. miR-139-5p expression was reduced in HCC compared to para-carcinoma tissue, which was confirmed in The Cancer Genome Atlas and GSE54751 HCC cohorts. Notably, the lower expression of mir-139 was correlated with worse prognosis. These outcomes indicate that reciprocal regulatory interactions between miR-139-5p and ETS1 modulate aerobic glycolysis, proliferation, and metastasis in HCC cells, suggesting new targets for HCC treatment.	[Hua, Shengni; Lei, Ling; Deng, Ling; Liu, Chengdong; Zhang, Dongyan; Cao, Chuanhui; Wu, Dehua] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Weng, Xie; Zou, Xuejing; Liu, Li] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China; [Weng, Xie; Zou, Xuejing; Liu, Li] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China; [Qi, Xiaolong] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China; [Wang, Shuang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Wu, DH (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China.; Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China.; Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China.	liuli.fimmu@gmail.com; wudehua.gd@gmail.com	hua, shengni/HDN-5084-2022	Liu, Li/0000-0002-5265-4159; Zou, Xuejing/0000-0001-6360-204X; Wu, De-Hua/0000-0003-0560-0016	Nation's Nature Science Foundation of China [81472711, 91540111, 81672756, 81401180, 81372283]; Guangdong Province Nature Science Foundation [2014A030311013]	Nation's Nature Science Foundation of China; Guangdong Province Nature Science Foundation	This work was supported by Nation's Nature Science Foundation of China (Grant nos. 81472711, 91540111, 81672756, 81401180, and 81372283) and the Guangdong Province Nature Science Foundation (Grant no. 2014A030311013).	Adam M, 2003, EUR UROL, V44, P329, DOI 10.1016/S0302-2838(03)00262-8; Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Chabre O, 2013, ENDOCR-RELAT CANCER, V20, P579, DOI 10.1530/ERC-13-0051; Corbetta S, 2010, ENDOCR-RELAT CANCER, V17, P135, DOI 10.1677/ERC-09-0134; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dong Z, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004299; Emmrich S, 2016, ONCOGENE, V35, P1822, DOI 10.1038/onc.2015.247; Endig J, 2016, CANCER CELL, V30, P308, DOI 10.1016/j.ccell.2016.06.009; Findlay VJ, 2013, ADV CANCER RES, V119, P1, DOI 10.1016/B978-0-12-407190-2.00001-0; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Haakensen VD, 2016, INT J CANCER, V139, P1117, DOI 10.1002/ijc.30142; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GF, 2015, NUCLEIC ACIDS RES, V43, P4322, DOI 10.1093/nar/gkv267; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Huang Y, 2012, NUCLEIC ACIDS RES, V40, P10478, DOI 10.1093/nar/gks789; Li L, 2017, CANCER LETT, V400, P89, DOI 10.1016/j.canlet.2017.04.034; Li QG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27157; Liu L, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.20; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Nie HZ, 2015, HEPATOLOGY, V62, P1145, DOI 10.1002/hep.27940; Nucera S, 2016, CANCER CELL, V29, P905, DOI 10.1016/j.ccell.2016.05.007; Pichiorri F, 2016, CANCER CELL, V30, P349, DOI 10.1016/j.ccell.2016.07.007; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Shen J, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0105-1; Shen K, 2014, FEBS J, V281, P3609, DOI 10.1111/febs.12880; Tsoulfas G, 2011, J GASTROENTEROL, V46, P249, DOI 10.1007/s00535-010-0302-9; Wang CD, 2015, J BIOL CHEM, V290, P21925, DOI 10.1074/jbc.M115.644864; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Xu K, 2016, ONCOTARGET, V7, P75118, DOI 10.18632/oncotarget.12611; Zeng S, 2017, CANCER LETT, V390, P67, DOI 10.1016/j.canlet.2016.12.042; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280	42	84	86	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1624	1636		10.1038/s41388-017-0057-3	http://dx.doi.org/10.1038/s41388-017-0057-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335523				2022-12-28	WOS:000428626700006
J	Patrussi, L; Capitani, N; Cattaneo, F; Manganaro, N; Gamberucci, A; Frezzato, F; Martini, V; Visentin, A; Pelicci, PG; D'Elios, MM; Trentin, L; Semenzato, G; Baldari, CT				Patrussi, Laura; Capitani, Nagaja; Cattaneo, Francesca; Manganaro, Noemi; Gamberucci, Alessandra; Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Pelicci, Pier Giuseppe; D'Elios, Mario M.; Trentin, Livio; Semenzato, Gianpietro; Baldari, Cosima T.			p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from beta-arrestin at early endosomes	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CHEMOKINE RECEPTOR; S1P1 EXPRESSION; RAB GTPASES; IN-VIVO; TRAFFICKING; BTK; CHEMOTAXIS; IBRUTINIB; ACTIVATION	Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor- 4 (CXCR4) and chemokine receptor- 7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5(+) endosomes as serine-phosphoproteins bound to beta-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and beta-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.	[Patrussi, Laura; Capitani, Nagaja; Cattaneo, Francesca; Manganaro, Noemi; Baldari, Cosima T.] Univ Siena, Dept Life Sci, Siena, Italy; [Capitani, Nagaja; D'Elios, Mario M.] Univ Florence, Dept Clin & Expt Med, Florence, Italy; [Gamberucci, Alessandra] Univ Siena, Dept Mol & Dev Med, Siena, Italy; [Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Trentin, Livio; Semenzato, Gianpietro] Venetian Inst Mol Med, Padua, Italy; [Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Trentin, Livio; Semenzato, Gianpietro] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy; [Pelicci, Pier Giuseppe] European Inst Oncol, Milan, Italy	University of Siena; University of Florence; University of Siena; Veneto Institute Molecular Medicine; University of Padua; IRCCS European Institute of Oncology (IEO)	Patrussi, L; Baldari, CT (corresponding author), Univ Siena, Dept Life Sci, Siena, Italy.	patrussi2@unisi.it; baldari@unisi.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Visentin, Andrea/M-5872-2019; Martini, Veronica/AAV-6339-2020; FREZZATO, Federica/V-5802-2019; Visentin, Andrea/L-7379-2017; TRENTIN, LIVIO/L-6678-2019; TRENTIN, LIVIO/J-7676-2016; Patrussi, Laura/AAD-4332-2020; D'Elios, Mario Milco/Y-9573-2019	Visentin, Andrea/0000-0003-0271-7200; FREZZATO, Federica/0000-0001-7093-2493; Visentin, Andrea/0000-0001-6830-6717; TRENTIN, LIVIO/0000-0003-1222-6149; TRENTIN, LIVIO/0000-0003-1222-6149; D'Elios, Mario Milco/0000-0001-9160-0930; Baldari, Cosima/0000-0002-4414-6744; MANGANARO, NOEMI/0000-0001-8512-4704; Patrussi, Laura/0000-0003-1542-6955	AIRC [IG-15220, IG-15286, IG-15397]; ITT-Regione Toscana; Cariparo; Cariverona	AIRC(Fondazione AIRC per la ricerca sul cancro); ITT-Regione Toscana; Cariparo(Fondazione Cariparo); Cariverona(Fondazione Cariverona)	This work was carried out with the support of grant AIRC IG-15220 and ITT-Regione Toscana to CTB, AIRC IG-15286, Cariparo and Cariverona to GS and AIRC IG-15397 to LT.	Bamidele AO, 2015, J CELL BIOL, V210, P257, DOI 10.1083/jcb.201411045; Berlin I, 2010, J BIOL CHEM, V285, P37895, DOI 10.1074/jbc.M110.129411; Bolinger MT, 2016, MOL CELL BIOL, V36, P2051, DOI 10.1128/MCB.00053-16; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Bowman SL, 2016, J CELL BIOL, V214, P797, DOI 10.1083/jcb.201512068; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Calebiro D, 2010, TRENDS PHARMACOL SCI, V31, P221, DOI 10.1016/j.tips.2010.02.002; Capitani N, 2012, BLOOD, V120, P4391, DOI 10.1182/blood-2012-04-425959; Capitani N, 2010, BLOOD, V115, P3726, DOI 10.1182/blood-2009-08-239244; Cattaneo F, 2016, ONCOTARGET, V7, P57086, DOI 10.18632/oncotarget.10977; Charest-Morin X, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00122; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Comerford I, 2013, CYTOKINE GROWTH F R, V24, P269, DOI 10.1016/j.cytogfr.2013.03.001; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Finetti F, 2009, NAT CELL BIOL, V11, P1332, DOI 10.1038/ncb1977; Gamberucci A, 2004, CELL CALCIUM, V36, P175, DOI 10.1016/j.ceca.2004.03.002; Gurevich VV, 2015, PROG MOL BIOL TRANSL, V132, P1, DOI 10.1016/bs.pmbts.2015.02.010; Hauser MA, 2016, J LEUKOCYTE BIOL, V99, P869, DOI 10.1189/jlb.2MR0815-380R; Herman SEM, 2015, CLIN CANCER RES, V21, P4642, DOI 10.1158/1078-0432.CCR-15-0781; Hjorto GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00568; Jin L, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0884-7; Kang DS, 2014, CURR OPIN CELL BIOL, V27, P63, DOI 10.1016/j.ceb.2013.11.005; Kehrl JH, 2009, CURR TOP MICROBIOL, V334, P107, DOI 10.1007/978-3-540-93864-4_5; Kennedy JE, 2015, PROG MOL BIOL TRANSL, V132, P15, DOI 10.1016/bs.pmbts.2015.02.005; Kucia M, 2004, J MOL HISTOL, V35, P233; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lagane B, 2008, BLOOD, V112, P34, DOI 10.1182/blood-2007-07-102103; Lee Chung-Shien, 2016, J Oncol Pharm Pract, V22, P92, DOI 10.1177/1078155214561281; Li LS, 2017, J CELL SCI, V130, P1475, DOI 10.1242/jcs.198937; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; MANDERS EMM, 1992, J CELL SCI, V103, P857; Marchese A, 2014, CURR OPIN CELL BIOL, V27, P72, DOI 10.1016/j.ceb.2013.11.011; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murray AJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.122re4; Otero C, 2008, J CELL SCI, V121, P2759, DOI 10.1242/jcs.029074; Otero C, 2006, J IMMUNOL, V177, P2314, DOI 10.4049/jimmunol.177.4.2314; Patrussi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.44; Patrussi L, 2007, BLOOD, V110, P1730, DOI 10.1182/blood-2007-01-068411; Patrussi L, 2017, METHODS MOL BIOL, V1584, P143, DOI 10.1007/978-1-4939-6881-7_10; Patrussi L, 2015, CANCER RES, V75, P4153, DOI 10.1158/0008-5472.CAN-15-0986; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Redondo-Munoz J, 2008, BLOOD, V111, P383, DOI 10.1182/blood-2007-08-107300; Scarfo L, 2016, CRIT REV ONCOL HEMAT, V104, P169, DOI 10.1016/j.critrevonc.2016.06.003; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Swingle Mark, 2007, V365, P23; ten Hacken E, 2016, BBA-MOL CELL RES, V1863, P401, DOI 10.1016/j.bbamcr.2015.07.009; van IJzendoorn SCD, 2002, DEV CELL, V2, P219, DOI 10.1016/S1534-5807(02)00115-6; Vasudevan NT, 2011, CELL CYCLE, V10, P3684, DOI 10.4161/cc.10.21.18042; Visentin A, 2015, CL LYMPH MYELOM LEUK, V15, P612, DOI 10.1016/j.clml.2015.06.001; Wienands J, 2000, CURR TOP MICROBIOL, V245, P53; Wodarz D, 2014, BLOOD, V123, P4132, DOI 10.1182/blood-2014-02-554220; Zhang YY, 2004, STEM CELLS, V22, P1015, DOI 10.1634/stemcells.22-6-1015; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	62	18	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1534	1550		10.1038/s41388-017-0066-2	http://dx.doi.org/10.1038/s41388-017-0066-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29326436	Green Published			2022-12-28	WOS:000427459500010
J	Lubrano, S; Comelli, L; Piccirilli, C; Marranci, A; Dapporto, F; Tantillo, E; Gemignani, F; Gutkind, JS; Salvetti, A; Chiorino, G; Cozza, G; Chiariello, M; Galli, A; Poliseno, L; Cervelli, T				Lubrano, Simone; Comelli, Laura; Piccirilli, Chiara; Marranci, Andrea; Dapporto, Francesca; Tantillo, Elena; Gemignani, Federica; Gutkind, J. Silvio; Salvetti, Alessandra; Chiorino, Giovanna; Cozza, Giorgio; Chiariello, Mario; Galli, Alvaro; Poliseno, Laura; Cervelli, Tiziana			Development of a yeast-based system to identify new hBRAFV600E functional interactors	ONCOGENE			English	Article							B-RAF; MOLECULAR-DYNAMICS; PROTEIN-KINASES; BRAF; PHOSPHORYLATION; PROGRESSION; MUTATIONS; PATHWAY; GROWTH; PTP2	BRAFV600E is a mutant Ser-Thr protein kinase that plays a crucial role in many types of cancer, including melanoma. Despite several aspects of BRAFV600E biology have been already elucidated, the proteins that regulate its expression and activity remain largely unknown, hampering our capacity to control its unrestrained effects. Here, we propose yeast Saccharomyces cerevisiae as a model system that can be used to achieve a better understanding of the regulation of human BRAFV600E. By showing that in osmotic stress conditions hBRAFV600E can rescue the growth of strains carrying a double or triple deletion in MAPKKK belonging to the HOG pathway, we demonstrate that this oncogenic kinase is active in yeast even if it does not have an ortholog. Moreover, we report that, in the yeast ptp3 Delta ptc1 Delta strain that is deleted in the genes encoding for two phosphatases responsible for Hog1 de-phoshorylation, hBRAFV600E mimics the toxicity observed in the presence of constitutive Hog1 activation. Finally, we exploit such a toxicity to perform a functional screening of a human cDNA library, looking for cDNAs able to rescue yeast growth. In this way, we identify SMIM10, a mitochondrial protein that in melanoma cells selectively downregulates BRAFV600E RNA and protein levels, by acting indirectly at the post-transcriptional level. Upon SMIM10 overexpression, BRAFV600E melanoma cells show disrupted mitochondrial structure/function and undergo senescence. They also show decreased ability to proliferate and form colonies, as well as increased sensitivity to the BRAF inhibitor vemurafenib. Interestingly, the analysis of TCGA melanoma samples indicates that patients with higher SMIM10 levels have a better prognosis. Therefore, these data suggest that SMIM10 exerts an oncosuppressive role in melanoma cells. Taken together, our results unveil the potential of S. cerevisiae to study hBRAFV600E, to populate the network of its functional interactors and, in doing so, to uncover new cancer-associated genes with therapeutic potential.	[Lubrano, Simone; Marranci, Andrea; Poliseno, Laura] ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy; [Lubrano, Simone; Comelli, Laura; Piccirilli, Chiara; Marranci, Andrea; Chiariello, Mario; Galli, Alvaro; Poliseno, Laura; Cervelli, Tiziana] IFC CNR, Inst Clin Physiol, Pisa, Italy; [Lubrano, Simone; Gemignani, Federica] Univ Pisa, Dept Biol, Pisa, Italy; [Dapporto, Francesca; Chiariello, Mario] ISPRO, Core Res Lab, Signal Transduct Unit, Siena, Italy; [Tantillo, Elena] Scuola Normale Super Pisa, Pisa, Italy; [Tantillo, Elena] FPS Pisa Sci Fdn, Pisa, Italy; [Gutkind, J. Silvio] UC San Diego Moores Canc Ctr, Dept Pharmacol, La Jolla, CA USA; [Salvetti, Alessandra] Univ Pisa, Dept Clin & Expt Med, Unit Expt Biol & Genet, Pisa, Italy; [Chiorino, Giovanna] Fdn Edo & Elvo Tempia, Lab Canc Genom, Biella, Italy; [Cozza, Giorgio] Univ Padua, Dept Mol Med, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa; Scuola Normale Superiore di Pisa; University of Pisa; University of Padua	Poliseno, L (corresponding author), ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy.; Galli, A; Poliseno, L; Cervelli, T (corresponding author), IFC CNR, Inst Clin Physiol, Pisa, Italy.	alvaro.galli@ifc.cnr.it; laura.poliseno@gmail.com; tizicerv@ifc.cnr.it	Marranci, Andrea/AAA-7874-2019; Gutkind, J. Silvio/J-1201-2016; Galli, Alvaro/K-3146-2018; Chiorino, Giovanna/K-5037-2016; Chiariello, Mario/O-3642-2014; Lubrano, Simone/AAF-1964-2021; Galli, Alvaro/AAL-7247-2020; Poliseno, Laura/B-5711-2012	Marranci, Andrea/0000-0002-8334-8795; Gutkind, J. Silvio/0000-0002-5150-4482; Galli, Alvaro/0000-0002-9091-5639; Chiorino, Giovanna/0000-0002-9502-6400; Chiariello, Mario/0000-0001-8434-5177; Lubrano, Simone/0000-0003-4779-5632; GEMIGNANI, Federica/0000-0003-1297-0701; COZZA, GIORGIO/0000-0002-5155-4682; Poliseno, Laura/0000-0001-6557-955X	Progetto Giovani Ricercatori (University of Padova); ITT; Progetto Giovani Ricercatori (Ministero della Salute) [GR-2011-02348535]; AIRC [MFAG 17095, IG 14477]; Fondazione Pisa grant [127/16]	Progetto Giovani Ricercatori (University of Padova); ITT; Progetto Giovani Ricercatori (Ministero della Salute); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Pisa grant	The authors would like to thank all the Poliseno and Galli lab members, as well as A. Tuccoli, for helpful discussions. They also thank E. O'Shea (Department of Molecular and Cellular Biology, Harvard University, Cambridge, United States, USA) for providing the ECY46 yeast strain. This work was supported by: Progetto Giovani Ricercatori (University of Padova) to GC; Start up funding ITT and Progetto Giovani Ricercatori #GR-2011-02348535 (Ministero della Salute) to LP. It was also partially supported by AIRC grant #MFAG 17095 to LP; Fondazione Pisa grant #127/16 as well as AIRC grant #IG 14477 to AG.	Ascierto PA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1341-2; Atienza JM, 2000, J BIOL CHEM, V275, P20638, DOI 10.1074/jbc.M910024199; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Collavoli A, 2008, FEMS YEAST RES, V8, P351, DOI 10.1111/j.1567-1364.2007.00343.x; Condelli V, 2014, CANCER RES, V74, P6693, DOI 10.1158/0008-5472.CAN-14-1331; Cozza G, 2017, FREE RADICAL BIO MED, V112, P1, DOI 10.1016/j.freeradbiomed.2017.07.010; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Gietz RD, 2007, NAT PROTOC, V2, P38, DOI 10.1038/nprot.2007.15; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Jain A, 2017, ONCOGENE, V36, P4585, DOI 10.1038/onc.2017.76; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Laurent JM, 2016, BRIEF FUNCT GENOMICS, V15, P155, DOI 10.1093/bfgp/elv041; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; Marranci A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0645-4; Marranci A, 2015, J INVEST DERMATOL, V135, P1694, DOI 10.1038/jid.2015.47; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; O'Shaughnessy EC, 2011, CELL, V144, P119, DOI 10.1016/j.cell.2010.12.014; Papin C, 1996, ONCOGENE, V12, P2213; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; PASTOR RW, 1988, MOL PHYS, V65, P1409, DOI 10.1080/00268978800101881; Perkins E, 2001, CANCER RES, V61, P4175; Piper PW, 2006, BIOCHEM SOC T, V34, P783, DOI 10.1042/BST0340783; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Saito H, 2010, CURR OPIN MICROBIOL, V13, P677, DOI 10.1016/j.mib.2010.09.001; Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Stuckey S, 2013, METHOD ENZYMOL, V533, P103, DOI 10.1016/B978-0-12-420067-8.00008-8; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054867	38	3	3	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1355	1366		10.1038/s41388-018-0496-5	http://dx.doi.org/10.1038/s41388-018-0496-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30237439				2022-12-28	WOS:000459249800016
J	Xu, ZY; Wang, YL; Xiao, ZG; Zou, C; Zhang, X; Wang, Z; Wu, DL; Yu, S; Chan, FL				Xu, Zhenyu; Wang, Yuliang; Xiao, Zhan Gang; Zou, Chang; Zhang, Xian; Wang, Zhu; Wu, Dinglan; Yu, Shan; Chan, Franky Leung			Nuclear receptor ERRa and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; INCREASED EXPRESSION; PSA RECURRENCE; CELL-LINE; ALPHA; REARRANGEMENT; ASSOCIATION; HIF-1-ALPHA	The TMPRSS2:ERG (T:E) fusion gene is generally believed to be mainly regulated by the activated androgen receptor (AR) signaling in androgen-dependent prostate cancer. However, its persistent expression in castration-resistant and neuroendocrine prostate cancers implies that other transcription factors might also regulate its expression. Here, we showed that up-regulation of nuclear receptor estrogen-related receptor alpha (ERR alpha) was closely associated with the oncogenic transcription factor ERG expression in prostate cancer, and their increased coexpression patterns were closely associated with high Gleason scores and metastasis in patients. Both ERRa and ERG exhibited a positive expression correlation in a castration-resistant prostate cancer (CRPC) xenograft model VCaP-CRPC. We showed that ERR alpha could directly transactivate T:E fusion gene in both AR-positive and -negative prostate cancer cells via both ERR-binding element- and AR-binding element-dependent manners. Ectopic T:E expression under ERRa regulation could promote both in vitro invasion and in vivo metastasis capacities of AR-negative prostatic cells. Intriguingly, ERG expressed by the T:E fusion could also transactivate the ERR alpha (ESRRA) gene. Hereby, ERR alpha and ERG can synergistically regulate each other and form a reciprocal regulatory loop to promote the advanced growth of prostate cancer. Inhibition of ERR alpha activity by ERR alpha inverse agonist could suppress T:E expression in prostate cancer cells, implicating that targeting ERR alpha could be a potential therapeutic strategy for treating the aggressive T:E-positive prostate cancer.	[Xu, Zhenyu; Zhang, Xian] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China; [Xu, Zhenyu; Wang, Yuliang; Xiao, Zhan Gang; Zou, Chang; Wang, Zhu; Wu, Dinglan; Yu, Shan; Chan, Franky Leung] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Xiao, Zhan Gang] Southwest Med Univ, Dept Pharmacol, Luzhou, Peoples R China; [Zou, Chang] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Clin Med Res Ctr, Shenzhen, Peoples R China	Wannan Medical College; Chinese University of Hong Kong; Southwest Medical University; Jinan University	Yu, S; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.	yushan771@hotmail.com; franky-chan@cuhk.edu.hk	Zou, Chang/AAS-3356-2021; Chan, Franky L./M-1043-2018	Zou, Chang/0000-0002-2003-7834; Chan, Franky L./0000-0003-0567-2052; Wu, Dinglan/0000-0002-5057-9626; Wang, Zhu/0000-0002-5457-3731	General Research Funds [14100914, 14107116]; Research Grants Council of Hong Kong; University Natural Science Research Project of Anhui Province [KJ2016A732]; National Natural Science Foundation of China [81602240, 81402370]	General Research Funds; Research Grants Council of Hong Kong(Hong Kong Research Grants Council); University Natural Science Research Project of Anhui Province(Natural Science Foundation of Anhui Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the General Research Funds (Project numbers 14100914 and 14107116), Research Grants Council of Hong Kong (to F.L.C.), University Natural Science Research Project of Anhui Province (KJ2016A732) (to Z.X.) and National Natural Science Foundation of China (81602240 to Z.X.; 81402370 to C.Z.).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bismar TA, 2012, EUR J CANCER, V48, P538, DOI 10.1016/j.ejca.2012.01.001; Bonaccorsi L, 2009, J ENDOCRINOL INVEST, V32, P590, DOI 10.1007/BF03346514; Boormans JL, 2010, EUR UROL, V57, P830, DOI 10.1016/j.eururo.2009.08.013; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai G, 2017, ONCOGENE, V36, P546, DOI 10.1038/onc.2016.227; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Danila DC, 2011, EUR UROL, V60, P897, DOI 10.1016/j.eururo.2011.07.011; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Esgueva R, 2010, MODERN PATHOL, V23, P539, DOI 10.1038/modpathol.2009.193; Falzarano SM, 2010, MODERN PATHOL, V23, P1499, DOI 10.1038/modpathol.2010.150; Feng FY, 2014, CLIN CANCER RES, V20, P4442, DOI 10.1158/1078-0432.CCR-13-0275; Font-Tello A, 2015, PROSTATE, V75, P1216, DOI 10.1002/pros.23004; Fradet A, 2016, ONCOTARGET, V7, P77071, DOI 10.18632/oncotarget.12787; Fujimura T, 2007, INT J CANCER, V120, P2325, DOI 10.1002/ijc.22363; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Hagglof C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086824; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Lanvin O, 2007, J BIOL CHEM, V282, P28328, DOI 10.1074/jbc.M704295200; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mertz KD, 2007, NEOPLASIA, V9, P200, DOI 10.1593/neo.07103; Minner S, 2011, CLIN CANCER RES, V17, P5878, DOI 10.1158/1078-0432.CCR-11-1251; Mosquera JM, 2009, CLIN CANCER RES, V15, P4706, DOI 10.1158/1078-0432.CCR-08-2927; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Polson ES, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2627; Rubin MA, 2012, ASIAN J ANDROL, V14, P393, DOI 10.1038/aja.2011.145; Scheble VJ, 2012, VIRCHOWS ARCH, V461, P157, DOI 10.1007/s00428-012-1270-7; Schelling LA, 2013, HUM PATHOL, V44, P2227, DOI 10.1016/j.humpath.2013.05.005; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Spencer ES, 2013, PROSTATE, V73, P905, DOI 10.1002/pros.22636; Teyssier C, 2008, NUCLEIC ACIDS RES, V36, P5350, DOI 10.1093/nar/gkn520; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Toubaji A, 2011, MODERN PATHOL, V24, P1511, DOI 10.1038/modpathol.2011.111; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Washington MN, 2010, ENDOCRINOLOGY, V151, P1409, DOI 10.1210/en.2009-0991; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	58	33	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6259	6274		10.1038/s41388-018-0409-7	http://dx.doi.org/10.1038/s41388-018-0409-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30042415	Green Published, hybrid			2022-12-28	WOS:000451622100005
J	Kunz, M; Loffler-Wirth, H; Dannemann, M; Willscher, E; Doose, G; Kelso, J; Kottek, T; Nickel, B; Hopp, L; Landsberg, J; Hoffmann, S; Tuting, T; Zigrino, P; Mauch, C; Utikal, J; Ziemer, M; Schulze, HJ; Holzel, M; Roesch, A; Kneitz, S; Meierjohann, S; Bosserhoff, A; Binder, H; Schartl, M				Kunz, Manfred; Loeffler-Wirth, Henry; Dannemann, Michael; Willscher, Edith; Doose, Gero; Kelso, Janet; Kottek, Tina; Nickel, Birgit; Hopp, Lydia; Landsberg, Jenny; Hoffmann, Steve; Tueting, Thomas; Zigrino, Paola; Mauch, Cornelia; Utikal, Jochen; Ziemer, Mirjana; Schulze, Hans-Joachim; Holzel, Michael; Roesch, Alexander; Kneitz, Susanne; Meierjohann, Svenja; Bosserhoff, Anja; Binder, Hans; Schartl, Manfred			RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; PROGRESSION; VALIDATION; EVOLUTION; THICKNESS; THERAPY	Recent studies revealed trajectories of mutational events in early melanomagenesis, but the accompanying changes in gene expression are far less understood. Therefore, we performed a comprehensive RNA-seq analysis of laser-microdissected melanocytic nevi (n = 23) and primary melanoma samples (n = 57) and characterized the molecular mechanisms of early melanoma development. Using self-organizing maps, unsupervised clustering, and analysis of pseudotime (PT) dynamics to identify evolutionary trajectories, we describe here two transcriptomic types of melanocytic nevi (N1 and N2) and primary melanomas (M1 and M2). N1/M1 lesions are characterized by pigmentation-type and MITF gene signatures, and a high prevalence of NRAS mutations in M1 melanomas. N2/M2 lesions are characterized by inflammatory-type and AXL gene signatures with an equal distribution of wild-type and mutated BRAF and low prevalence of NRAS mutations in M2 melanomas. Interestingly, N1 nevi and M1 melanomas and N2 nevi and M2 melanomas, respectively, cluster together, but there is no clustering in a stage-dependent manner. Transcriptional signatures of M1 melanomas harbor signatures of BRAF/MEK inhibitor resistance and M2 melanomas harbor signatures of anti-PD-1 antibody treatment resistance. Pseudotime dynamics of nevus and melanoma samples are suggestive for a switch-like immune-escape mechanism in melanoma development with downregulation of immune genes paralleled by an increasing expression of a cell cycle signature in late-stage melanomas. Taken together, the transcriptome analysis identifies gene signatures and mechanisms underlying development of melanoma in early and late stages with relevance for diagnostics and therapy.	[Kunz, Manfred; Kottek, Tina; Ziemer, Mirjana] Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal Str 23-25, D-04103 Leipzig, Germany; [Loeffler-Wirth, Henry; Willscher, Edith; Doose, Gero; Hopp, Lydia; Hoffmann, Steve; Binder, Hans] Univ Leipzig, Interdisciplinary Ctr Bioinformat, Hartelstra 16-18, D-04107 Leipzig, Germany; [Dannemann, Michael; Kelso, Janet; Nickel, Birgit] Max Planck Inst Evolutionary Anthropol, Dept Evolutionary Genet, Deutsch Pl 6, D-04103 Leipzig, Germany; [Doose, Gero; Hoffmann, Steve] Univ Leipzig, Bioinformat Grp, Fac Math & Comp Sci, Hartelstr 16-18, D-04107 Leipzig, Germany; [Landsberg, Jenny] Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53127 Bonn, Germany; [Tueting, Thomas] Univ Magdeburg, Dept Dermatol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Zigrino, Paola; Mauch, Cornelia] Univ Cologne, Dept Dermatol Venereol & Allergol, D-50937 Cologne, Germany; [Utikal, Jochen] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany; [Utikal, Jochen] Ruprecht Karl Univ Heidelberg, Dept Dermatol Venereol & Allergol, Univ Med Ctr Mannheim, D-68167 Mannheim, Germany; [Schulze, Hans-Joachim] Fachklin Hornheide, Dept Dermatol, Dorbaumstr 300, D-48157 Munster, Germany; [Holzel, Michael] Univ Bonn, Dept Clin Chem & Clin Pharmacol, Unit RNA Biol, D-53127 Bonn, Germany; [Roesch, Alexander] Univ Duisburg Essen, West German Canc Ctr, Dept Dermatol, Univ Hosp Essen, D-45122 Essen, Germany; [Roesch, Alexander] Univ Duisburg Essen, German Canc Consortium DKTK, D-45122 Essen, Germany; [Kneitz, Susanne; Meierjohann, Svenja; Schartl, Manfred] Univ Wurzburg, Dept Physiol Chem, Biozentrum, D-97074 Wurzburg, Germany; [Kneitz, Susanne; Meierjohann, Svenja; Schartl, Manfred] Univ Clin Wurzburg, Comprehens Canc Ctr Mainfranken, D-97080 Wurzburg, Germany; [Bosserhoff, Anja] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany; [Schartl, Manfred] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA; [Schartl, Manfred] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Leipzig University; Leipzig University; Max Planck Society; Leipzig University; University of Bonn; Otto von Guericke University; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Bonn; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Kunz, M (corresponding author), Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal Str 23-25, D-04103 Leipzig, Germany.	Manfred.kunz@medizin.uni-leipzig.de	Tüting, Thomas/AAJ-3610-2021; Landsberg, Jennifer/AAF-5113-2019; Landsberg, Jenny/AGI-0216-2022; Bosserhoff, Anja/GNH-4801-2022; Hoffmann, Steve/E-1438-2013; Binder, Hans/U-5519-2018	Tüting, Thomas/0000-0001-7146-0934; Landsberg, Jenny/0000-0001-8029-3883; Utikal, Jochen/0000-0001-5316-0241; Binder, Hans/0000-0002-2242-4678; Loeffler-Wirth, Henry/0000-0001-8239-440X; Zigrino, Paola/0000-0002-7470-0064	Deutsche Krebshilfe, Melanomverbund [109716]	Deutsche Krebshilfe, Melanomverbund	MK, MD, AB, SM, and MS were supported by funding of the Deutsche Krebshilfe, Melanomverbund, grant number 109716.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bendall SC, 2014, CELL, V157, P714, DOI 10.1016/j.cell.2014.04.005; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Binder H, 2015, ENCY INFORM SCI TECH, V3rd, P1642, DOI [DOI 10.4018/978-1-4666-5888-2.CH157, 10.4018/978-1-4666-5888-2.ch157]; Binder H., 2013, SYST BIOMED, V1, P99, DOI [10.4161/sysb.25897, DOI 10.4161/SYSB.25897]; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Camp JG, 2017, NATURE, V546, P533, DOI 10.1038/nature22796; Campbell KR, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005212; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; Clarke LE, 2017, CANCER-AM CANCER SOC, V123, P617, DOI 10.1002/cncr.30385; Clarke LE, 2015, J CUTAN PATHOL, V42, P244, DOI 10.1111/cup.12475; Gerber T, 2017, ONCOTARGET, V8, P846, DOI 10.18632/oncotarget.13666; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Harbst K, 2012, CLIN CANCER RES, V18, P4026, DOI 10.1158/1078-0432.CCR-12-0343; Haymaker C, 2012, ONCOIMMUNOLOGY, V1, P735, DOI 10.4161/onci.20823; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Hulstaert E, 2017, ONCOTARGET, V8, P43470, DOI 10.18632/oncotarget.16478; Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; Keenen B, 2010, ONCOGENE, V29, P81, DOI 10.1038/onc.2009.304; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Loffler-Wirth H, 2015, BIOINFORMATICS, V31, P3225, DOI 10.1093/bioinformatics/btv342; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maurus K, 2017, ONCOGENE, V36, P5110, DOI 10.1038/onc.2017.135; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Reid JE, 2016, BIOINFORMATICS, V32, P2973, DOI 10.1093/bioinformatics/btw372; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Solus JF, 2013, ADV ANAT PATHOL, V20, P217, DOI 10.1097/PAP.0b013e3182976c94; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Toronen P, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-307; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wirth H, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-18; Wirth H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-306; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057	51	50	50	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6136	6151		10.1038/s41388-018-0385-y	http://dx.doi.org/10.1038/s41388-018-0385-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29995873				2022-12-28	WOS:000450883000003
J	Kotelevets, L; Walker, F; Mamadou, G; Lehy, T; Jordan, P; Chastre, E				Kotelevets, Larissa; Walker, Francine; Mamadou, Godefroy; Lehy, Therese; Jordan, Peter; Chastre, Eric			The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression	ONCOGENE			English	Article							TUMOR-RELATED RAC1B; COLORECTAL-CANCER; CELL-SURVIVAL; OVEREXPRESSION; ACTIVATION; EXPRESSION; COLITIS; CATENIN; VARIANT; DIFFERENTIATION	We previously have identified the ectopic expression of Rac1b, an activated and novel splice variant of Rac1, in a subset of human colorectal adenocarcinomas, as well as in inflammatory bowel diseases and in colitis mouse model. Rac1b overexpression has been further evidenced in breast, pancreatic, thyroid, ovarian, and lung cancers. In this context, the aim of our study was to investigate the physiopathological implications of Rac1b in intestinal inflammation and carcinogenesis in vivo. The ectopic expression of Rac1b was induced in mouse intestinal epithelial cells after crossing Rosa26-LSL-Rac1b and villin-Cre mice. These animals were let to age or were challenged with dextran sulfate sodium (DSS) to induce experimental colitis, or either received azoxymethane (AOM)/DSS treatment, or were bred with Apc(Min/+) or II10(-/-) mice to trigger intestinal tumors. Rac1b ectopic expression increased the intestinal epithelial cell proliferation and migration, enhanced the production of reactive oxygen species, and promoted the Paneth cell lineage. Although Rac1b overexpression alone was not sufficient to drive intestinal neoplasia, it enhanced Apc-dependent intestinal tumorigenesis. In the context of II10 knockout, the Rac1b transgene strengthened colonic inflammation due to induced intestinal mucosa permeability and promoted cecum and proximal colon carcinogenesis. In contrast, Rac1b alleviated carcinogen/acute inflammation-associated colon carcinogenesis (AOM/DSS). This resulted at least partly from the early mucosal repair after resolution of inflammation. Our data highlight the critical role of Rac1b in driving wound-healing after resolution of intestinal inflammation, and in cooperating with Wnt pathway dysregulation and chronic inflammation to promote intestinal carcinogenesis.	[Kotelevets, Larissa; Chastre, Eric] INSERM, Ctr Rech St Antoine, UMR S 938, Paris, France; [Kotelevets, Larissa; Chastre, Eric] Univ Pierre & Marie Curie Paris 6, Hop St Antoine, Site Batiment Kourilsky, Paris, France; [Walker, Francine; Lehy, Therese] INSERM, U1149, Ctr Rech Inflammat, CNRS,ERL8252, Paris, France; [Walker, Francine] Hop Univ Paris Nord Val de Seine Bichat Claude Be, AP HP, Dept Pathol, Paris, France; [Mamadou, Godefroy] Univ Paris Diderot Paris7, TransCell Lab Lab, Fac Med Xavier Bichat, Paris, France; [Jordan, Peter] Natl Hlth Inst, Dept Human Genet, Lisbon, Portugal	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Kotelevets, L; Chastre, E (corresponding author), INSERM, Ctr Rech St Antoine, UMR S 938, Paris, France.; Kotelevets, L; Chastre, E (corresponding author), Univ Pierre & Marie Curie Paris 6, Hop St Antoine, Site Batiment Kourilsky, Paris, France.	larissa.kotelevets@inserm.fr; eric.chastre@inserm.fr	Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228	University Paris Diderot; INSERM	University Paris Diderot; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	The authors acknowledge Dr. Sylvie Robine (Institut Curie, Paris, France) for her donation of the villin-Cre (B6-Tg (Vil-cre) 20Sy/Nci) mice. The authors greatly thank Valerie Gratio of the CRI cytometry facility. The authors are indebted to Dr. Samira Benadda (INSERM U1149) for her assistance in confocal microscopy, and Olivier Thibaudeau (INSERM U1152) for help in histologic experiments. This work was supported by French minister of higher education and research, INSERM, and University Paris Diderot.	Alonso-Espinaco V, 2014, EUR J CANCER, V50, P1973, DOI 10.1016/j.ejca.2014.04.019; Andreu P, 2008, DEV BIOL, V324, P288, DOI 10.1016/j.ydbio.2008.09.027; Cole AM, 2010, EMBO MOL MED, V2, P472, DOI 10.1002/emmm.201000101; Curtis KM, 2012, MOL CELL NEUROSCI, V49, P138, DOI 10.1016/j.mcn.2011.10.008; Espinha G, 2015, MOL CELL BIOCHEM, V404, P281, DOI 10.1007/s11010-015-2388-0; Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843; Farin HF, 2016, NATURE, V530, P340, DOI 10.1038/nature16937; Goncalves V, 2009, HUM MOL GENET, V18, P3696, DOI 10.1093/hmg/ddp317; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Guo YN, 2015, MOL CANCER THER, V14, P2215, DOI 10.1158/1535-7163.MCT-15-0419; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kang HT, 2017, AGING CELL, V16, P541, DOI 10.1111/acel.12584; Kato M, 2016, EXP ANIM TOKYO, V65, P197, DOI 10.1538/expanim.15-0127; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kotelevets L, 2017, CANCER RES, V77, P2964, DOI 10.1158/0008-5472.CAN-16-1741; Kotelevets L, 2016, INT J PHARMACEUT, V514, P24, DOI 10.1016/j.ijpharm.2016.06.005; Lee K, 2012, MOL BIOL CELL, V23, P4097, DOI 10.1091/mbc.E12-02-0166; Lessel W, 2017, CARCINOGENESIS, V38, P559, DOI 10.1093/carcin/bgx032; Li G, 2016, ONCOTARGET, V7, P17970, DOI 10.18632/oncotarget.7602; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Matos P, 2006, J BIOL CHEM, V281, P13724, DOI 10.1074/jbc.M513243200; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Matos P, 2008, MOL CANCER RES, V6, P1178, DOI 10.1158/1541-7786.MCR-08-0008; Matos P, 2013, NEOPLASIA, V15, P102, DOI 10.1593/neo.121890; Mehner Christine, 2015, Genes Cancer, V6, P480; Mori Yoshifumi, 2013, Small GTPases, V4, P9, DOI 10.4161/sgtp.23311; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Orlichenko L, 2010, J BIOL CHEM, V285, P19153, DOI 10.1074/jbc.M109.099382; Pethe VV, 2011, INT J ONCOL, V39, P805, DOI 10.3892/ijo.2011.1066; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rodriguez-Colman MJ, 2017, NATURE, V543, P424, DOI 10.1038/nature21673; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Silva AL, 2013, EUR J ENDOCRINOL, V168, P795, DOI 10.1530/EJE-12-0960; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; SOBHANI I, 1993, GASTROENTEROLOGY, V105, P22; Stallings-Mann ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004062; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Ungefroren H, 2014, ONCOTARGET, V5, P277, DOI 10.18632/oncotarget.1696; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang F, 2017, CELL RES, V27, P540, DOI 10.1038/cr.2017.7; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	44	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6054	6068		10.1038/s41388-018-0389-7	http://dx.doi.org/10.1038/s41388-018-0389-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29985482	Green Submitted			2022-12-28	WOS:000450175900004
J	Lin, MC; Chien, PH; Wu, HY; Chen, ST; Juan, HF; Lou, PJ; Huang, MC				Lin, Mei-Chun; Chien, Pin-Hui; Wu, Hsin-Yi; Chen, Syue-Ting; Juan, Hsueh-Fen; Lou, Pei-Jen; Huang, Min-Chuan			C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer	ONCOGENE			English	Article							MOLECULAR CHAPERONE COSMC; CELL LUNG-CANCER; O-GLYCOSYLATION; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; EGF RECEPTOR; ITRACONAZOLE; GROWTH; DIMERIZATION; ANGIOGENESIS	Core 1 beta 1,3-galactosyltransferase (C1GALT1) controls the crucial step of GalNAc-type O-glycosylation and is overexpressed in various human malignancies. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. Here we demonstrate that C1GALT1 expression is upregulated in HNSCC tumors and is associated with adverse clinicopathologic features. Moreover, high C1GALT1 expression predicts poor disease-free and overall survivals. C1GALT1 overexpression enhances HNSCC cell viability, migration, and invasion, which can be reversed by erlotinib. Silencing of C1GALT1 suppresses the malignant behavior both in vitro and in vivo. Mass spectrometry and lectin pull-down assays demonstrate that C1GALT1 modifies O-glycans on EGFR. Blocking O-glycan elongation on EGFR by C1GALT1 knockdown decreases EGF-EGFR binding affinity and inhibits EGFR signaling, thereby suppressing malignant phenotypes. Using molecular docking simulations, we identify itraconazole as a C1GALT1 inhibitor that directly binds C1GALT1 and promotes its proteasomal degradation, leading to significant blockade of C1GALT1-mediated effects in HNSCC cells in vitro and in vivo. Collectively, our findings demonstrate a critical role of O-glycosylation in HNSCC progression and highlight the therapeutic potential of targeting C1GALT1 in HNSCC treatment.	[Lin, Mei-Chun; Chien, Pin-Hui] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Otolaryngol, Hsinchu, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Instrumentat Ctr, Taipei, Taiwan; [Chen, Syue-Ting; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Juan, Hsueh-Fen] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Dept Life Sci, Taipei, Taiwan; [Lou, Pei-Jen] Natl Taiwan Univ Hosp & Coll Med, Dept Otolaryngol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Lou, PJ (corresponding author), Natl Taiwan Univ Hosp & Coll Med, Dept Otolaryngol, Taipei, Taiwan.	pjlou@ntu.edu.tw; mchuang@ntu.edu.tw		LOU, PEI-JEN/0000-0002-3383-8593; HUANG, MIN-CHUAN/0000-0002-0704-3447	National Taiwan University Hospital, Hsinchu Branch [HCH104-045, 106-HCH067]; Ministry of Science and Technology, R.O.C. [104-2320-B-002-068-MY3, 103-2314-B-002-082-MY2, 106-2923-B-002-003-MY3, 105-2314-B-002-203-MY2]; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	National Taiwan University Hospital, Hsinchu Branch; Ministry of Science and Technology, R.O.C.; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	We thank Chia-Hsien Lee for help in homology modeling and docking simulation. This study was supported by the National Taiwan University Hospital, Hsinchu Branch, HCH104-045, 106-HCH067 (M.-C.L.) and Ministry of Science and Technology, R.O.C. 104-2320-B-002-068-MY3 (M.-C.H.), 103-2314-B-002-082-MY2, 106-2923-B-002-003-MY3 (P.-J.L.), 105-2314-B-002-203-MY2 (M.-C.L.), and the Academia Sinica, Taiwan Head and Neck Cancer Biosignature (P.-J.L.).	Aftab BT, 2011, CANCER RES, V71, P6764, DOI 10.1158/0008-5472.CAN-11-0691; Antonarakis ES, 2013, ONCOLOGIST, V18, P163, DOI 10.1634/theoncologist.2012-314; Aryal RP, 2014, J BIOL CHEM, V289, P11630, DOI 10.1074/jbc.M114.555870; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Chen BZ, 2016, MOL CANCER THER, V15, P866, DOI 10.1158/1535-7163.MCT-15-0729-T; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Gerken TA, 2011, J BIOL CHEM, V286, P14493, DOI 10.1074/jbc.M111.218701; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Harris KA, 2002, J UROLOGY, V168, P542, DOI 10.1016/S0022-5347(05)64675-7; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kannagi R, 2008, BBA-GEN SUBJECTS, V1780, P525, DOI 10.1016/j.bbagen.2007.10.007; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; King SL, 2017, BLOOD ADV, V1, P429, DOI 10.1182/bloodadvances.2016002121; Kong Y, 2015, GLYCOBIOLOGY, V25, P55, DOI 10.1093/glycob/cwu089; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Liang GZ, 2017, ONCOTARGET, V8, P28510, DOI 10.18632/oncotarget.15324; Lin MC, 2014, ORAL ONCOL, V50, P478, DOI 10.1016/j.oraloncology.2014.02.003; Nguyen-Tan PF, 2014, J CLIN ONCOL, V32, P3858, DOI 10.1200/JCO.2014.55.3925; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Rudin CM, 2013, J THORAC ONCOL, V8, P619, DOI 10.1097/JTO.0b013e31828c3950; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Tarp MA, 2008, BBA-GEN SUBJECTS, V1780, P546, DOI 10.1016/j.bbagen.2007.09.010; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai CH, 2016, CANCER RES, V76, P5756, DOI 10.1158/0008-5472.CAN-16-0641; Tsubamoto H, 2014, ANTICANCER RES, V34, P2481; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Yokota M, 1997, HISTOCHEM J, V29, P555, DOI 10.1023/A:1026475926033	39	31	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5780	5793		10.1038/s41388-018-0375-0	http://dx.doi.org/10.1038/s41388-018-0375-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930379	Green Published, hybrid			2022-12-28	WOS:000448288200006
J	Al Habyan, S; Kalos, C; Szymborski, J; McCaffrey, L				Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke			Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer	ONCOGENE			English	Article							EXPRESSION; ASCITES; CADHERIN; HETEROGENEITY; BEHAVIOR; MODEL	Ovarian cancer is the most lethal gynecological cancer, where survival rates have had modest improvement over the last 30 years. Metastasis of cancer cells is a major clinical problem, and patient mortality occurs when ovarian cancer cells spread beyond the confinement of ovaries. Disseminated ovarian cancer cells typically spread within the abdomen, where ascites accumulation aids in their transit. Metastatic ascites contain multicellular spheroids, which promote chemo-resistance and recurrence. However, little is known about the origin and mechanisms through which spheroids arise. Using live-imaging of 3D culture models and animal models, we report that epithelial ovarian cancer (EOC) cells, the most common type of ovarian cancer, can spontaneously detach as either single cells or clusters. We report that clusters are more resistant to anoikis and have a potent survival advantage over single cells. Using in vivo lineage tracing, we found that multicellular spheroids arise preferentially from collective detachment, rather than aggregation in the abdomen. Finally, we report that multicellular spheroids from collective detachment are capable of seeding intra-abdominal metastases that retain intra-tumoral heterogeneity from the primary tumor.	[Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Al Habyan, Sara; Kalos, Christina; Szymborski, Joseph; McCaffrey, Luke] McGill Univ, Div Expt Med, Montreal, PQ H4A 3J1, Canada; [McCaffrey, Luke] McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ H4A 3T2, Canada	McGill University; McGill University; McGill University	McCaffrey, L (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; McCaffrey, L (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ H4A 3J1, Canada.; McCaffrey, L (corresponding author), McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ H4A 3T2, Canada.	luke.mccaffrey@mcgill.ca		Szymborski, Joseph/0000-0003-1559-6225	CIHR [MOP-119482]	CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr. Didier Trono (Ecole Polytechnique Federale de Lausanne, Switzerland) for lentiviral plasmids acquired through Addgene, and Dr. Patricia Tonin (McGill University) for OV90 cells. This project was supported by funds from CIHR (MOP-119482) to LM. LM is a FRQS Research Scholar - Junior 2.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; ALLEN HJ, 1987, EXP CELL BIOL, V55, P194; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Cody NAL, 2007, ONCOGENE, V26, P618, DOI 10.1038/sj.onc.1209821; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; HAMILTON TC, 1983, CANCER RES, V43, P5379; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Katz E, 2009, CLIN CANCER RES, V15, P70, DOI 10.1158/1078-0432.CCR-08-1233; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Klymenko Y, 2017, NEOPLASIA, V19, P549, DOI 10.1016/j.neo.2017.04.002; Kobel M, 2011, INT J GYNECOL PATHOL, V30, P366, DOI 10.1097/PGP.0b013e31820d20ba; Koensgen D, 2010, ANTICANCER RES, V30, P2525; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Narod S, 2016, NAT REV CLIN ONCOL, V13, P255, DOI 10.1038/nrclinonc.2015.224; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Timmins Nicholas E., 2007, V140, P141; Vankelecom H, 2009, COLD SPRING HARB PRO, V4, P1; Wintzell M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-359; Xu S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05646; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101	32	74	74	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5127	5135		10.1038/s41388-018-0317-x	http://dx.doi.org/10.1038/s41388-018-0317-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789717	Green Published, hybrid			2022-12-28	WOS:000444405300008
J	Horvat, A; Noto, JM; Ramatchandirin, B; Zaika, E; Palrasu, M; Wei, JX; Schneider, BG; El-Rifai, W; Peek, RM; Zaika, AI				Horvat, Andela; Noto, Jennifer M.; Ramatchandirin, Balamurugan; Zaika, Elena; Palrasu, Manikandan; Wei, Jinxiong; Schneider, Barbara G.; El-Rifai, Wael; Peek, Richard M., Jr.; Zaika, Alexander I.			Helicobacter pylori pathogen regulates p14ARF tumor suppressor and autophagy in gastric epithelial cells	ONCOGENE			English	Article							CAGA PROTEIN; ARF; CANCER; P53; ACTIVATION; HYPERMETHYLATION; DEGRADATION; EXPRESSION; RESPONSES; DOMAIN	Infection with Helicobacter pylori is one of the strongest risk factors for development of gastric cancer. Although these bacteria infect approximately half of the world's population, only a small fraction of infected individuals develops gastric malignancies. Interactions between host and bacterial virulence factors are complex and interrelated, making it difficult to elucidate specific processes associated with H. pylori-induced tumorigenesis. In this study, we found that H. pylori inhibits p14ARF tumor suppressor by inducing its degradation. This effect was found to be strain-specific. Downregulation of p14ARF induced by H. pylori leads to inhibition of autophagy in a p53-independent manner in infected cells. We identified TRIP12 protein as E3 ubiquitin ligase that is upregulated by H. pylori, inducing ubiquitination and subsequent degradation of p14ARF protein. Using isogenic H. pylori mutants, we found that induction of TRIP12 is mediated by bacterial virulence factor CagA. Increased expression of TRIP12 protein was found in infected gastric epithelial cells in vitro and human gastric mucosa of H. pylori-infected individuals. In conclusion, our data demonstrate a new mechanism of ARF inhibition that may affect host-bacteria interactions and facilitate tumorigenic transformation in the stomach.	[Horvat, Andela; Ramatchandirin, Balamurugan; Wei, Jinxiong; Zaika, Alexander I.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA; [Horvat, Andela; Ramatchandirin, Balamurugan; Wei, Jinxiong; Zaika, Alexander I.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Noto, Jennifer M.; Schneider, Barbara G.; Peek, Richard M., Jr.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN USA; [Zaika, Elena; Palrasu, Manikandan; El-Rifai, Wael; Zaika, Alexander I.] Univ Miami, Dept Surg, Miami, FL 33136 USA; [Zaika, Alexander I.] Miami VA Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Miami	Zaika, AI (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA.; Zaika, AI (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.; Zaika, AI (corresponding author), Univ Miami, Dept Surg, Miami, FL 33136 USA.; Zaika, AI (corresponding author), Miami VA Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.	axz353@med.miami.edu	Ramatchandirin, Balamurugan/AAB-7958-2020	Ramatchandirin, Balamurugan/0000-0003-0390-1878; Horvat, Andela/0000-0002-5771-2434	National Cancer Institute [CA206564, R01 CA138833]; Department of Veterans Affairs [BX002115]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; NATIONAL CANCER INSTITUTE [R01CA077955, R01CA138833, P01CA116087, P30CA068485, R01CA206564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs. Maria B. Piazuelo and Alberto G. Delgado for help with tissue processing. This work was supported by grants from the National Cancer Institute CA206564, R01 CA138833, the Department of Veterans Affairs BX002115, Vanderbilt Ingram Cancer Center (P30 CA68485), and the Vanderbilt Digestive Disease Research Center (DK058404). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, Vanderbilt University, or University of Miami Health Centers.	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Argent RH, 2008, J MED MICROBIOL, V57, P145, DOI 10.1099/jmm.0.47465-0; Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fox JG, 2003, CANCER RES, V63, P942; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Kuo ML, 2004, CELL CYCLE, V3, P1367, DOI 10.4161/cc.3.11.1244; Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957; N'Diaye EN, 2009, EMBO REP, V10, P173, DOI 10.1038/embor.2008.238; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Peek RM, 1999, CANCER RES, V59, P6124; Pimkina J, 2009, AUTOPHAGY, V5, P397, DOI 10.4161/auto.5.3.7782; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; Sherr CJ, 2012, WIRES DEV BIOL, V1, P731, DOI 10.1002/wdev.40; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2533; Wei JX, 2015, GUT, V64, P1040, DOI 10.1136/gutjnl-2014-307295; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Whitehead RH, 2009, AM J PHYSIOL-GASTR L, V296, pG455, DOI 10.1152/ajpgi.90381.2008; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Zhu YL, 2005, ONCOGENE, V24, P3886, DOI 10.1038/sj.onc.1208551	33	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5054	5065		10.1038/s41388-018-0343-8	http://dx.doi.org/10.1038/s41388-018-0343-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29849123	Green Accepted			2022-12-28	WOS:000444405300002
J	Dai, L; Del Valle, L; Miley, W; Whitby, D; Ochoa, AC; Flemington, EK; Qin, ZQ				Dai, Lu; Del Valle, Luis; Miley, Wendell; Whitby, Denise; Ochoa, Augusto C.; Flemington, Erik K.; Qin, Zhiqiang			Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MELANOMA-CELL LINES; ENDOTHELIAL-CELLS; NUCLEAR ANTIGEN; IN-VIVO; ANTIRETROVIRAL THERAPY; DNA-SEQUENCES; CYCLE ARREST; HTDV/HERV-K; KAPPA-B	Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of several human cancers such as Kaposi's sarcoma (KS), which represents the most common AIDS-associated malignancy that lacks effective treatment options. Despite its clear role in AIDS malignancies, the fact that only a small set of KSHV-infected patients will eventually develop these tumors implies that additional co-factors are required for the development of KSHV-related cancers. In the current study, we demonstrate for the first time that KSHV de novo infection or viral latent proteins are able to transactivate human endogenous retrovirus K (HERV-K) through a variety of cellular signaling pathways and transcriptional factors. Moreover, we found that HERV-K transactivation, particularly activation of its encoded oncogenic NP9 protein, plays an important role in KSHV pathogenesis and tumorigenesis in vitro and in vivo. Our data provide innovative insights into the mechanisms of HERV-K transactivation contributing to viral oncogenesis, which may represent a promising target for KS treatment.	[Dai, Lu; Qin, Zhiqiang] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Dai, Lu; Qin, Zhiqiang] Tongji Univ, Sch Med, East Hosp, Dept Pediat,Res Ctr Translat Med, Shanghai 200120, Peoples R China; [Dai, Lu; Qin, Zhiqiang] Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai 200120, Peoples R China; [Del Valle, Luis] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Pathol, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Miley, Wendell; Whitby, Denise] Frederick Natl Lab Canc Res, Viral Oncol Sect, AIDS & Canc Virus Program, Leidos Biomed Res, POB B, Frederick, MD 21702 USA; [Ochoa, Augusto C.] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Pediat, 1700 Tulane Ave, New Orleans, LA 70112 USA; [Flemington, Erik K.] Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Pathol, 1700 Tulane Ave, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tongji University; Tongji University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tulane University	Qin, ZQ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave, New Orleans, LA 70112 USA.; Qin, ZQ (corresponding author), Tongji Univ, Sch Med, East Hosp, Dept Pediat,Res Ctr Translat Med, Shanghai 200120, Peoples R China.; Qin, ZQ (corresponding author), Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai 200120, Peoples R China.	zqin@lsuhsc.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206	DOD Career Development Award [CA140437]; Louisiana Clinical and Translational Science Center Pilot grant [U54GM104940]; LSU LIFT2 funding; NIH [P20-GM121288-01, RO1-AI101046, R01-AI106676, P01CA214091]; Department of Defense [W81XWH-16-1-0318]; National Cancer Institute, NIH [HHSN261200800001E]; National Natural Science Foundation of China [81472547, 81672924, 81400164, 81772930]; NATIONAL CANCER INSTITUTE [P01CA214091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676, R01AI101046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM121288, U54GM104940, P30GM114732] Funding Source: NIH RePORTER	DOD Career Development Award; Louisiana Clinical and Translational Science Center Pilot grant; LSU LIFT2 funding; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Rolf Renne at the University of Florida for his kind gifts of TIVE-LTC and TIVE cells and Dr. Friedrich A. Grasser from Universitatsklinikum des Saarlandes, Germany for kindly providing HERV-K NP9 plasmids and antibody. This work was supported by grants from a DOD Career Development Award to (CA140437 to ZQ); a Louisiana Clinical and Translational Science Center Pilot grant (U54GM104940 from NIH), a LSU LIFT2 funding, and NIH P20-GM121288-01 (PI: Krzysztof Reiss) subproject to ZQ; NIH RO1-AI101046, R01-AI106676, and P01CA214091 and Department of Defense W81XWH-16-1-0318 to EKF; the federal funds from the National Cancer Institute, NIH, under Contract No. HHSN261200800001E to DW; and the awards from the National Natural Science Foundation of China (81472547, 81672924 to ZQ and 81400164, 81772930 to LD). Funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An FQ, 2006, J VIROL, V80, P4833, DOI 10.1128/JVI.80.10.4833-4846.2006; An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; Angelova M, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0218-8; Ariza-Heredia EJ, 2011, TRANSPLANTATION, V92, P837, DOI 10.1097/TP.0b013e31823104ec; Armbruester V, 2002, CLIN CANCER RES, V8, P1800; Benavente Y, 2011, BRIT J CANCER, V105, P1768, DOI 10.1038/bjc.2011.392; Bonnet F, 2004, CANCER-AM CANCER SOC, V101, P317, DOI 10.1002/cncr.20354; Buscher K, 2006, MELANOMA RES, V16, P223; Buscher K, 2005, CANCER RES, V65, P4172, DOI 10.1158/0008-5472.CAN-04-2983; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen T, 2013, LEUKEMIA, V27, P1469, DOI 10.1038/leu.2013.8; Contreras-Galindo R, 2008, J VIROL, V82, P9329, DOI 10.1128/JVI.00646-08; Dai L, 2016, ONCOTARGET, V7, P10459, DOI 10.18632/oncotarget.7227; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dai L, 2015, CANCER LETT, V362, P158, DOI 10.1016/j.canlet.2015.03.034; Dai L, 2012, INT J CANCER, V131, P834, DOI 10.1002/ijc.26428; Depil S, 2002, LEUKEMIA, V16, P254, DOI 10.1038/sj.leu.2402355; Dewannieux M, 2006, GENOME RES, V16, P1548, DOI 10.1101/gr.5565706; Di Bartolo DL, 2008, BLOOD, V111, P4731, DOI 10.1182/blood-2007-09-110544; Do Kim J, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-85; Downey RF, 2015, INT J CANCER, V137, P1249, DOI 10.1002/ijc.29003; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fuchs NV, 2011, J VIROL, V85, P3436, DOI 10.1128/JVI.02539-10; Gonzalez-Cao M, 2016, CANCER BIOL MED, V13, P483, DOI 10.20892/j.issn.2095-3941.2016.0080; Gonzalez-Hernandez MJ, 2012, J VIROL, V86, P7790, DOI 10.1128/JVI.07215-11; Gross H, 2011, INT J CANCER, V129, P1105, DOI 10.1002/ijc.25760; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; He ML, 2012, CANCER RES, V72, P3582, DOI 10.1158/0008-5472.CAN-11-2876; Hohn O, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00246; Hsiao FC, 2006, J IMMUNOL, V177, P2056, DOI 10.4049/jimmunol.177.4.2056; Hughes JF, 2001, NAT GENET, V29, P487, DOI 10.1038/ng775; Jenkins FJ, 2002, J INFECT DIS, V185, P1238, DOI 10.1086/340237; Kellam P, 1997, J Hum Virol, V1, P19; Kim KY, 2013, J VIROL, V87, P6782, DOI 10.1128/JVI.00011-13; Kraus B, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-21; Labo N, 2015, AIDS, V29, P1217, DOI 10.1097/QAD.0000000000000682; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee YN, 2007, PLOS PATHOG, V3, P119, DOI 10.1371/journal.ppat.0030010; Li SS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005900; Li W, 2016, ONCOTARGET, V7, P32286, DOI 10.18632/oncotarget.8591; Li ZW, 2010, CANCER INVEST, V28, P1031, DOI 10.3109/07357907.2010.512604; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; LOWER R, 1995, J VIROL, V69, P141; Luppi M, 2000, BLOOD, V96, P3279; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Maksakova IA, 2008, CELL MOL LIFE SCI, V65, P3329, DOI 10.1007/s00018-008-8494-3; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Manghera M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-16; Mbisa GL, 2010, J IMMUNOL METHODS, V356, P39, DOI 10.1016/j.jim.2010.02.015; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Qian LW, 2007, J VIROL, V81, P7001, DOI 10.1128/JVI.00016-07; Qin ZQ, 2013, J VIROL, V87, P621, DOI 10.1128/JVI.01441-12; Qin ZQ, 2010, CANCER RES, V70, P3884, DOI 10.1158/0008-5472.CAN-09-4663; Qin ZQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000742; Shamay M, 2006, P NATL ACAD SCI USA, V103, P14554, DOI 10.1073/pnas.0604469103; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sutkowski N, 2001, IMMUNITY, V15, P579, DOI 10.1016/S1074-7613(01)00210-2; Sutkowski N, 2004, J VIROL, V78, P7852, DOI 10.1128/JVI.78.14.7852-7860.2004; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Verma SC, 2004, J VIROL, V78, P10348, DOI 10.1128/JVI.78.19.10348-10359.2004; Wang-Johanning F, 2012, JNCI-J NATL CANCER I, V104, P189, DOI 10.1093/jnci/djr540; Wong JP, 2017, BIOL CHEM, V398, P911, DOI 10.1515/hsz-2017-0101; Ye FC, 2011, ADV VIROL, V2011, DOI 10.1155/2011/193860	67	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4534	4545		10.1038/s41388-018-0282-4	http://dx.doi.org/10.1038/s41388-018-0282-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743595	Green Accepted			2022-12-28	WOS:000441736700004
J	Imamaki, R; Ogawa, K; Kizuka, Y; Komi, Y; Kojima, S; Kotani, N; Honke, K; Honda, T; Taniguchi, N; Kitazume, S				Imamaki, Rie; Ogawa, Kazuko; Kizuka, Yasuhiko; Komi, Yusuke; Kojima, Soichi; Kotani, Norihiro; Honke, Koichi; Honda, Takashi; Taniguchi, Naoyuki; Kitazume, Shinobu			Glycosylation controls cooperative PECAM-VEGFR2-beta 3 integrin functions at the endothelial surface for tumor angiogenesis	ONCOGENE			English	Article							CELL ADHESION MOLECULE; PRECURSOR PROTEIN 770; HOMOPHILIC INTERACTIONS; PLATELET; CANCER; SIALYLATION; RECEPTOR; PECAM-1; GLYCANS; APOPTOSIS	Most of the angiogenesis inhibitors clinically used in cancer treatment target the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway. However, the current strategies for treating angiogenesis have limited efficacy. The issue of how to treat angiogenesis and endothelial dysfunction in cancer remains a matter of substantial debate. Here we demonstrate a glycosylation-dependent regulatory mechanism for tumor angiogenesis. St6gal1(-/-) mice, lacking the alpha 2,6-sialylation enzyme, were shown to exhibit impaired tumor angiogenesis through enhanced endothelial apoptosis. In a previous study, St6gal1(-/-) endothelial cells exhibited a reduction in the cell surface residency of platelet endothelial cell adhesion molecule (PECAM). In this study, we found that cooperative functionality of PECAM-VEGFR2-integrin beta 3 was disturbed in St6gal1(-/-) mice. First, cell surface PECAM-VEGFR2 complexes were lost, and both VEGFR2 internalization and the VEGFR-dependent signaling pathway were enhanced. Second, enhanced anoikis was observed, suggesting that the absence of alpha 2,6-sialic acid leads to dysregulated integrin signaling. Notably, ectopic expression of PECAM increased cell surface integrin-beta 3, indicating that the reduction of cell surface integrin-beta 3 involves loss-of-endothelial PECAM. The results suggest that the cell surface stability of these glycoproteins is significantly reduced by the lack of alpha 2,6-sialic acid, leading to abnormal signal transduction. The present findings highlight that alpha 2,6-sialylation is critically involved in endothelial survival by controlling the cell surface stability and signal transduction of angiogenic molecules, and could be a novel target for anti-angiogenesis therapy.	[Imamaki, Rie; Ogawa, Kazuko; Kizuka, Yasuhiko; Taniguchi, Naoyuki; Kitazume, Shinobu] RIKEN, Dis Glyc Team, Syst Glycobiol Res Grp, Saitama 3510198, Japan; [Komi, Yusuke; Kojima, Soichi] RIKEN, Mol Ligand Biol Res Team, Wako, Saitama 3510198, Japan; [Kotani, Norihiro] Saitama Med Univ, Dept Biochem, Saitama 3500495, Japan; [Honke, Koichi] Kochi Univ, Dept Biochem, Med Sch, Kochi 7838505, Japan; [Honda, Takashi] Fukushima Med Univ, Sch Nursing, Dept Human Life Sci, Fukushima 9601295, Japan; [Kitazume, Shinobu] Fukushima Med Univ, Preparing Sect New Fac Med Sci, Fukushima 9601295, Japan	RIKEN; RIKEN; Saitama Medical University; Kochi University; Fukushima Medical University; Fukushima Medical University	Kitazume, S (corresponding author), RIKEN, Dis Glyc Team, Syst Glycobiol Res Grp, Saitama 3510198, Japan.; Kitazume, S (corresponding author), Fukushima Med Univ, Preparing Sect New Fac Med Sci, Fukushima 9601295, Japan.	shinobuk@fmu.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Kojima, Soichi/N-7104-2015	Taniguchi, Naoyuki/0000-0001-5889-5968; Kotani, Norihiro/0000-0003-3739-6478; Kojima, Soichi/0000-0002-5252-1612; Kizuka, Yasuhiko/0000-0002-3181-9743	Systems Glycobiology Research Project; Strategic Programs for RD of RIKEN; MEXT/JSPS KAKENHI grant [16K08601, 25430122]; Mitsubishi Foundation; Grants-in-Aid for Scientific Research [16K08601] Funding Source: KAKEN	Systems Glycobiology Research Project; Strategic Programs for RD of RIKEN; MEXT/JSPS KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Mitsubishi Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Systems Glycobiology Research Project and the Strategic Programs for R&D of RIKEN (to N.T.), MEXT/JSPS KAKENHI grant numbers 16K08601 and 25430122 (to S.K.), and a grant from the Mitsubishi Foundation (to S.K.). The authors would like to acknowledge Dr. Jamey D. Marth for providing the St6gal1<SUP>-/-</SUP> mice and the RIKEN BSI-Olympus Collaboration Center for technical support.	Abe Y, 1999, J IMMUNOL, V163, P2867; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bird IN, 1999, J CELL SCI, V112, P1989; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Croci DO, 2014, GLYCOBIOLOGY, V24, P1283, DOI 10.1093/glycob/cwu083; Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043; Dennis JW, 2009, CELL, V139, P1229, DOI 10.1016/j.cell.2009.12.008; Domingues I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025668; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gao CJ, 2003, BLOOD, V102, P169, DOI 10.1182/blood-2003-01-0003; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kitazume S, 2014, GLYCOBIOLOGY, V24, P1260, DOI 10.1093/glycob/cwu094; Kitazume S, 2014, J BIOL CHEM, V289, P27604, DOI 10.1074/jbc.M114.563585; Kitazume S, 2012, J BIOL CHEM, V287, P40817, DOI 10.1074/jbc.M112.398578; Kitazume S, 2010, J BIOL CHEM, V285, P40097, DOI 10.1074/jbc.M110.144626; Kitazume S, 2010, J BIOL CHEM, V285, P6515, DOI 10.1074/jbc.M109.073106; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Komi Y, 2007, JPN J CLIN ONCOL, V37, P867, DOI 10.1093/jjco/hym115; Kotani N, 2008, P NATL ACAD SCI USA, V105, P7405, DOI 10.1073/pnas.0710346105; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee C, 2014, J BIOL CHEM, V289, P9121, DOI 10.1074/jbc.M114.555888; Lertkiatmongkol P, 2016, J BIOL CHEM, V291, P26216, DOI 10.1074/jbc.M116.756502; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mahabeleshwar GH, 2006, J EXP MED, V203, P2495, DOI 10.1084/jem.20060807; Markowska AI, 2010, J EXP MED, V207, P1981, DOI 10.1084/jem.20090121; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Nakayama M, 2013, NAT CELL BIOL, V15, P249, DOI 10.1038/ncb2679; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Paddock C, 2016, BLOOD, V127, P1052, DOI 10.1182/blood-2015-07-660092; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sugimoto I, 2007, J BIOL CHEM, V282, P34896, DOI 10.1074/jbc.M704766200; Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Ungewiss C, 2016, SCI REP-UK, V6, DOI 10.1038/srep18652; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456; Xu D, 2011, J BIOL CHEM, V286, P737, DOI 10.1074/jbc.M110.177006; Zhuo Y, 2008, J BIOL CHEM, V283, P22177, DOI 10.1074/jbc.M8000015200	50	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4287	4299		10.1038/s41388-018-0271-7	http://dx.doi.org/10.1038/s41388-018-0271-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717262	Green Published			2022-12-28	WOS:000440566100007
J	Liu, JY; Zeng, QH; Cao, PG; Xie, D; Yang, F; He, LY; Dai, YB; Li, JJ; Liu, XM; Zeng, HL; Fan, XJ; Liu, L; Zhu, YX; Gong, L; Cheng, Y; Zhou, JD; Hu, J; Bo, H; Xu, ZZ; Cao, K				Liu, J. Y.; Zeng, Q. H.; Cao, P. G.; Xie, D.; Yang, F.; He, L. Y.; Dai, Y. B.; Li, J. J.; Liu, X. M.; Zeng, H. L.; Fan, X. J.; Liu, L.; Zhu, Y. X.; Gong, L.; Cheng, Y.; Zhou, J. D.; Hu, J.; Bo, H.; Xu, Z. Z.; Cao, K.			SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival	ONCOGENE			English	Article							RADICAL CYSTECTOMY; SIGNALING PATHWAY; EAU GUIDELINES; CANCER; CHEMOTHERAPY; EXPRESSION; ASTRIN; PROGRESSION; RECURRENCE; PROTEINS	Sperm-associated antigen 5 (SPAG5) is involved in various biological processes. However, the roles of SPAG5 in bladder urothelial carcinoma (BUC) are unknown. This study showed that upregulation of SPAG5 was detected frequently in primary BUC tissues, and was associated with significantly worse survival among the 112 patients that underwent radical cystectomy (RC). Up and downregulating the expression of SPAG5 enhanced or inhibited, respectively, the proliferation of BUC cells in vitro and in vivo, and suppressed or enhanced, respectively, apoptosis in vitro and in vivo. Moreover, SPAG5 increased the resistance of BUC cells to chemotherapy-induced apoptosis. Mechanistic investigations showed that SPAG5 promotes proliferation and suppresses apoptosis in BUC at least partially via upregulating Wnt3 through activating the AKT/mTOR signaling pathway. The importance of the SPAG5/AKT-mTOR/Wnt3 axis identified in BUC cell models was confirmed via immunohistochemical analysis of a cohort of human BUC specimens that underwent RC. Collectively, our data suggested that in patients with BUC who underwent RC, high SPAG5 expression is associated with poor survival. In addition, targeting SPAG5 might represent a novel therapeutic strategy to improve the survival of patients with BUC.	[Liu, J. Y.; He, L. Y.; Dai, Y. B.] Cent South Univ, Xiangya Hosp 3, Dept Urol, Changsha, Hunan, Peoples R China; [Liu, J. Y.; He, L. Y.; Dai, Y. B.] Cent South Univ, Inst Prostate Dis, Changsha, Hunan, Peoples R China; [Zeng, Q. H.] Cent South Univ, Xiangya Hosp 3, Dept Dermatol, Changsha, Hunan, Peoples R China; [Cao, P. G.; Zhu, Y. X.; Gong, L.; Cao, K.] Cent South Univ, Xiangya Hosp 3, Dept Onol, Changsha, Hunan, Peoples R China; [Xie, D.] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Xie, D.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, F.] Cent South Univ, Sch Publ Hlth, Changsha, Hunan, Peoples R China; [Li, J. J.; Zhou, J. D.] Cent South Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha, Hunan, Peoples R China; [Liu, X. M.] Cent South Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha, Hunan, Peoples R China; [Zeng, H. L.] Hunan Key Lab Pharmacodynam & Safety Evaluat New, Changsha, Hunan, Peoples R China; [Fan, X. J.] Cent South Univ, Xiangya Hosp 3, Res Serv Off, Changsha, Hunan, Peoples R China; [Liu, L.] Cent South Univ, Xiangya Hosp 3, Outpatient Serv Off, Changsha, Hunan, Peoples R China; [Cheng, Y.] Cent South Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China; [Hu, J.] Hunan Canc Hosp, Dept Tissue Bank, Changsha, Hunan, Peoples R China; [Bo, H.] Cent South Univ, Inst Reprod & Stem Cell Engn, Changsha, Hunan, Peoples R China; [Xu, Z. Z.] Hunan Canc Hosp, Dept Urol, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Sun Yat Sen University; State Key Lab Oncology South China; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Cao, K (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Onol, Changsha, Hunan, Peoples R China.	CSUcaoke@163.com			Natural Science Foundation of China [81301688, 81572965, 81572689]; Innovation-Driven Project of Central South University [2017CX012]; "125 Talent Project" of the Third Xiangya Hospital of Central South University; "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University [JY201615]; Scientific Projects of Health and Family Planning Commision of Hunan Province [B2017034]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation-Driven Project of Central South University; "125 Talent Project" of the Third Xiangya Hospital of Central South University; "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University; Scientific Projects of Health and Family Planning Commision of Hunan Province	This work was supported by the Natural Science Foundation of China (Grant nos. 81301688, 81572965, and 81572689), the Innovation-Driven Project of Central South University (Grant no. 2017CX012), the "125 Talent Project" and "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University, the New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University (Grant no. JY201615), and the Scientific Projects of Health and Family Planning Commision of Hunan Province (Grant no. B2017034).	Abdel-Fatah TMA, 2016, LANCET ONCOL, V17, P1004, DOI 10.1016/S1470-2045(16)00174-1; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Bengochea A, 2008, BRIT J CANCER, V99, P143, DOI 10.1038/sj.bjc.6604422; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Buechler S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-243; Chang MS, 2001, BIOCHEM BIOPH RES CO, V287, P116, DOI 10.1006/bbrc.2001.5554; Chen WJ, 2017, ONCOTARGET, V8, P61282, DOI 10.18632/oncotarget.18058; Cornen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081843; Diamandis M, 2010, MOL CANCER RES, V8, P1175, DOI 10.1158/1541-7786.MCR-10-0264; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Johansson I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078299; Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8; Kim M, 2008, J HEPATOL, V48, P780, DOI 10.1016/j.jhep.2007.12.020; Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008; Leow JJ, 2014, EUR UROL, V66, P42, DOI 10.1016/j.eururo.2013.08.033; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lotan Y, 2005, J CLIN ONCOL, V23, P6533, DOI 10.1200/JCO.2005.05.516; Lotan Y, 2013, EUR UROL, V64, P465, DOI 10.1016/j.eururo.2013.03.043; Mack GJ, 2001, P NATL ACAD SCI USA, V98, P14434, DOI 10.1073/pnas.261371298; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Peng Y, 2014, CELL SIGNAL, V26, P2782, DOI 10.1016/j.cellsig.2014.08.021; Poppova L, 2016, BRIT J HAEMATOL, V175, P851, DOI 10.1111/bjh.14312; Samarin J, 2016, HEPATOLOGY, V63, P813, DOI 10.1002/hep.28357; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siu MK, 2015, ONCOGENE, V34, P4767, DOI 10.1038/onc.2014.414; Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662; Steele LP, 2006, CELL DEATH DIFFER, V13, P1564, DOI 10.1038/sj.cdd.4401846; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Sternberg CN, 2015, LANCET ONCOL, V16, P76, DOI 10.1016/S1470-2045(14)71160-X; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thedieck K, 2013, CELL, V154, P859, DOI 10.1016/j.cell.2013.07.031; Valk K, 2010, ONCOLOGY-BASEL, V79, P283, DOI 10.1159/000322116; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Yuan LJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.222	38	36	37	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3937	3952		10.1038/s41388-018-0223-2	http://dx.doi.org/10.1038/s41388-018-0223-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662193				2022-12-28	WOS:000439101300003
J	Labgaa, I; Villacorta-Martin, C; D'Avola, D; Craig, AJ; von Felden, J; Martins, SN; Sia, D; Stueck, A; Ward, SC; Fiel, MI; Mahajan, M; Tabrizian, P; Thung, SN; Ang, C; Friedman, SL; Llovet, JM; Schwartz, M; Villanueva, A				Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia; Craig, Amanda J.; von Felden, Johann; Martins-Filho, Sebastiao N.; Sia, Daniela; Stueck, Ashley; Ward, Stephen C.; Fiel, M. Isabel; Mahajan, Milind; Tabrizian, Parissa; Thung, Swan N.; Ang, Celina; Friedman, Scott L.; Llovet, Josep M.; Schwartz, Myron; Villanueva, Augusto			A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULATING TUMOR DNA; CELL-FREE DNA; DROPLET DIGITAL PCR; CLONAL EVOLUTION; LIQUID BIOPSY; LUNG-CANCER; HETEROGENEITY; PROGRESSION; RESISTANCE; LANDSCAPE	Cellular components of solid tumors including DNA are released into the bloodstream, but data on circulating-free DNA (cfDNA) in hepatocellular carcinoma (HCC) are still scarce. This study aimed at analyzing mutations in cfDNA and their correlation with tissue mutations in patients with HCC. We included 8 HCC patients treated with surgical resection for whom we collected paired tissue and plasma/serum samples. We analyzed 45 specimens, including multiregional tumor tissue sampling (n = 24), peripheral blood mononuclear cells (PMBC, n = 8), plasma (n = 8) and serum (n = 5). Ultra-deep sequencing (5500x coverage) of all exons was performed in a targeted panel of 58 genes, including frequent HCC driver genes and druggable mutations. Mutations detected in plasma included known HCC oncogenes and tumor suppressors (e.g., TERT promoter, TP53, and NTRK3) as well as a candidate druggable mutation (JAK1). This approach increased the detection rates previously reported for mutations in plasma of HCC patients. A thorough characterization of cis mutations found in plasma confirmed their tumoral origin, which provides definitive evidence of the release of HCC-derived DNA fragments into the bloodstream. This study demonstrates that ultra-deep sequencing of cfDNA is feasible and can confidently detect somatic mutations found in tissue; these data reinforce the role of plasma DNA as a promising minimally invasive tool to interrogate HCC genetics.	[Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia; Craig, Amanda J.; von Felden, Johann; Martins-Filho, Sebastiao N.; Sia, Daniela; Tabrizian, Parissa; Friedman, Scott L.; Llovet, Josep M.; Schwartz, Myron; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Dept Med, Liver Canc Program, Tisch Canc Inst,Grad Sch Biomed Sci,Div Liver Dis, New York, NY 10029 USA; [Labgaa, Ismail] Lausanne Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland; [D'Avola, Delia] Clin Univ Navarra, Liver Unit, Pamplona, Spain; [D'Avola, Delia] Clin Univ Navarra, CIBEREHD, Pamplona, Spain; [von Felden, Johann] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Martins-Filho, Sebastiao N.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; [Martins-Filho, Sebastiao N.] Univ Toronto, Univ Hlth Network, Dept Pathol & Lab Med, Toronto, ON, Canada; [Stueck, Ashley; Ward, Stephen C.; Fiel, M. Isabel; Mahajan, Milind; Thung, Swan N.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Stueck, Ashley] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Mahajan, Milind] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Tabrizian, Parissa; Schwartz, Myron] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA; [Ang, Celina; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY 10029 USA; [Llovet, Josep M.] Univ Barcelona, Hosp Clin, Liver Canc Translat Res Lab, BCLC Grp,IDIBAPS,CIBEREHD, Catalonia, Spain; [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Icahn School of Medicine at Mount Sinai; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra; University of Hamburg; University Medical Center Hamburg-Eppendorf; Universidade de Sao Paulo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Icahn School of Medicine at Mount Sinai; Dalhousie University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Liver Canc Program, Tisch Canc Inst,Grad Sch Biomed Sci,Div Liver Dis, New York, NY 10029 USA.; Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY 10029 USA.	augusto.villanueva@mssm.edu	D'Avola, Delia/AAD-4289-2020; Llovet, Josep M/D-4340-2014; Llovet, Josep M/ABB-6264-2021	D'Avola, Delia/0000-0002-0907-6648; Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Villanueva, Augusto/0000-0003-3585-3727; Stueck, Ashley/0000-0002-0328-6687; Labgaa, Ismail/0000-0003-4286-2170; Martins Filho, Sebastiao/0000-0002-6123-2601; Craig, Amanda/0000-0001-8987-019X; von Felden, Johann/0000-0003-2839-5174; Sia, Daniela/0000-0002-9000-611X	Swiss National Science Foundation; Foundation Roberto Gianna Gonella; Foundation SICPA; Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Cancer Research Grant from Nuovo Soldati Foundation; Ruth L. Kirschstein NRSA Institutional Research Training Grant [T32 CA078207]; German Research Foundation [FE 1746/1-1]; Brazilian National Council for Scientific and Technological Development; Associacao Piauiense de Combate ao Cancer; European Commission [259744, 667273-2]; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute [SAF-2016-76390]; Asociacion Espanola para el Estudio del Cancer [CA150272P1]; U.S. Department of Defense [CA150272P1, CA150272P3, W81XWH-16-1-0455]; Tisch Cancer Institute (Cancer Center Grant) [P30 CA196521]; NIH [DK56621]; American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award; NATIONAL CANCER INSTITUTE [P30CA196521, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056621] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Foundation Roberto Gianna Gonella; Foundation SICPA; Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Cancer Research Grant from Nuovo Soldati Foundation; Ruth L. Kirschstein NRSA Institutional Research Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); Brazilian National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Associacao Piauiense de Combate ao Cancer; European Commission(European CommissionEuropean Commission Joint Research Centre); Samuel Waxman Cancer Research Foundation; Spanish National Health Institute(Spanish Government); Asociacion Espanola para el Estudio del Cancer; U.S. Department of Defense(United States Department of Defense); Tisch Cancer Institute (Cancer Center Grant); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	IL is supported by a grant from the Swiss National Science Foundation, from Foundation Roberto & Gianna Gonella and Foundation SICPA. DD is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH) and the Cancer Research Grant from Nuovo Soldati Foundation. AJC is supported by a Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32 CA078207). JvF is supported by a grant from the German Research Foundation (FE 1746/1-1). SNM is supported by grants from the Brazilian National Council for Scientific and Technological Development, and "Associacao Piauiense de Combate ao Cancer". JML is supported by grants from the European Commission (Heptromic, proposal number 259744; HEPCAR, proposal number 667273-2), the Samuel Waxman Cancer Research Foundation, the Spanish National Health Institute (J.M.L: SAF-2016-76390), the Asociacion Espanola para el Estudio del Cancer and the U.S. Department of Defense (CA150272P1). AV is supported by the U.S. Department of Defense (CA150272P3) and the Tisch Cancer Institute (Cancer Center Grant P30 CA196521). SLF is supported by NIH grant DK56621 and the U.S. Department of Defense (Contract No. W81XWH-16-1-0455). This study was funded by the American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award to AV.	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; BURKI E, 1948, OPHTHALMOLOGICA, V115, P241; Cai ZX, 2017, INT J CANCER, V141, P977, DOI 10.1002/ijc.30798; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Huang A, 2017, J HEPATOL, V67, P293, DOI 10.1016/j.jhep.2017.03.005; Huang A, 2016, J CANCER, V7, P1907, DOI 10.7150/jca.15823; Izumchenko E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9258; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Labgaa I, 2015, DISCOV MED, V19, P263; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liao WJ, 2016, ONCOTARGET, V7, P40481, DOI 10.18632/oncotarget.9629; Lin XJ, 2015, LANCET ONCOL, V16, P804, DOI 10.1016/S1470-2045(15)00048-0; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349; Ono A, 2015, CELL MOL GASTROENTER, V1, P516, DOI 10.1016/j.jcmgh.2015.06.009; Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; US Food and Drug Administration, FDA APPR 1 BLOOD TES; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhai WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14565; Zill OA, 2015, CANCER DISCOV, V5, P1040, DOI 10.1158/2159-8290.CD-15-0274	40	62	62	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3740	3752		10.1038/s41388-018-0206-3	http://dx.doi.org/10.1038/s41388-018-0206-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628508	Green Accepted			2022-12-28	WOS:000437975200010
J	Abdul-Aziz, AM; Shafat, MS; Sun, Y; Marlein, CR; Piddock, RE; Robinson, SD; Edwards, DR; Zhou, ZG; Collins, A; Bowles, KM; Rushworth, SA				Abdul-Aziz, Amina M.; Shafat, Manar S.; Sun, Yu; Marlein, Christopher R.; Piddock, Rachel E.; Robinson, Stephen D.; Edwards, Dylan R.; Zhou, Zhigang; Collins, Angela; Bowles, Kristian M.; Rushworth, Stuart A.			HIF1 alpha drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia	ONCOGENE			English	Article							MIGRATION INHIBITORY FACTOR; HYPOXIA-INDUCIBLE FACTORS; HEMATOPOIETIC STEM-CELLS; TARGET GENES; HIF-1-ALPHA; EXPRESSION; CANCER; AML; CHEMORESISTANCE; MAINTENANCE	Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as a consequence of failure to eradicate the tumor from the bone marrow microenvironment. We have recently shown that stroma-derived interleukin-8 (IL-8) promotes AML growth and survival in the bone marrow in response to AML-derived macrophage migration inhibitory factor (MIF). In the present study we show that high constitutive expression of MIF in AML blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1 alpha and HIF2 alpha, establish that hypoxia supports AML tumor proliferation through HIF1 alpha signaling. In vivo targeting of leukemic cell HIF1 alpha inhibits AML proliferation in the tumor microenvironment through transcriptional regulation of MIF, but inhibition of HIF2 alpha had no measurable effect on AML blast survival. Functionally, targeted inhibition of MIF in vivo improves survival in models of AML. Here we present a mechanism linking HIF1 alpha to a pro-tumoral chemokine factor signaling pathway and in doing so, we establish a potential strategy to target AML.	[Abdul-Aziz, Amina M.; Shafat, Manar S.; Sun, Yu; Marlein, Christopher R.; Piddock, Rachel E.; Edwards, Dylan R.; Zhou, Zhigang; Bowles, Kristian M.; Rushworth, Stuart A.] Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich NR4 7UQ, Norfolk, England; [Robinson, Stephen D.] Univ East Anglia, Sch Biol Sci, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England; [Collins, Angela; Bowles, Kristian M.] Norfolk & Norwich Univ Hosp NHS Trust, Dept Haematol, Colney Lane, Norwich NR4 7UY, Norfolk, England	University of East Anglia; University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust	Rushworth, SA (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich NR4 7UQ, Norfolk, England.	s.rushworth@uea.ac.uk	Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Bowles, Kristian/0000-0003-1334-4526; Rushworth, Stuart/0000-0002-3711-7558; Shafat, Manar/0000-0002-3493-9089; Robinson, Stephen/0000-0002-6606-7588; Piddock, Rachel E./0000-0002-5831-004X	Ministry of Higher Education and Scientific Research of the State of Libya; Big C cancer charity (Norfolk, UK); National Institute for Health Research (UK); Rosetrees Trust [M499] Funding Source: researchfish	Ministry of Higher Education and Scientific Research of the State of Libya; Big C cancer charity (Norfolk, UK); National Institute for Health Research (UK)(National Institute for Health Research (NIHR)); Rosetrees Trust(Rosetrees Trust)	The authors wish to thank the Ministry of Higher Education and Scientific Research of the State of Libya, The Big C cancer charity (Norfolk, UK) and the National Institute for Health Research (UK) for funding and Professor Richard Ball, Dr Mark Wilkinson and Mr Iain Sheriffs, Norwich Biorepository (UK), for help with sample collection and storage. pCDH-luciferase-T2A-mCherry was kindly gifted from Prof. Dr. med. Irmela Jeremias, (Helmholtz Zentrum Munchen, Munich, Germany).	Abdul-Aziz AM, 2017, CANCER RES, V77, P303, DOI 10.1158/0008-5472.CAN-16-1095; Ammirante M, 2014, P NATL ACAD SCI USA, V111, P14776, DOI 10.1073/pnas.1416498111; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006-3495(01)75733-5; CIPOLLESCHI MG, 1993, BLOOD, V82, P2031; Deeb G, 2011, LEUKEMIA RES, V35, P579, DOI 10.1016/j.leukres.2010.10.020; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Eliasson P, 2010, J CELL PHYSIOL, V222, P17, DOI 10.1002/jcp.21908; Fiegl M, 2009, BLOOD, V113, P1504, DOI 10.1182/blood-2008-06-161539; Forristal CE, 2015, LEUKEMIA, V29, P2075, DOI 10.1038/leu.2015.102; Fu H, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-66; Gaber T, 2011, J IMMUNOL, V186, P764, DOI 10.4049/jimmunol.0903421; Gilkes DM, 2013, FUTURE ONCOL, V9, P1623, DOI [10.2217/FON.13.92, 10.2217/fon.13.92]; GRANT WC, 1947, FED PROC, V6, P114; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu X, 2015, DEV PHASE 1B 2A PROO; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MacRae T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072884; Mahalingam D, 2016, 1 IN HUMAN PHASE 1 S; Miharada K, 2012, ANN NY ACAD SCI, V1266, P55, DOI 10.1111/j.1749-6632.2012.06564.x; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pillinger G, 2015, SCI REP-UK, V5, DOI 10.1038/srep12949; Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263; Rapin N, 2014, BLOOD, V123, P894, DOI 10.1182/blood-2013-02-485771; Rouault-Pierre K, 2013, CELL STEM CELL, V13, P549, DOI 10.1016/j.stem.2013.08.011; Rowe JM, 2010, BLOOD, V116, P3147, DOI 10.1182/blood-2010-05-260117; Rushworth SA, 2012, BLOOD, V120, P5188, DOI 10.1182/blood-2012-04-422121; Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shachar I, 2012, FEBS LETT, V586, P2906, DOI 10.1016/j.febslet.2012.07.016; Shafat MS, 2017, BLOOD, V129, P1320, DOI 10.1182/blood-2016-08-734798; Simons D, 2011, J CELL MOL MED, V15, P668, DOI 10.1111/j.1582-4934.2010.01041.x; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Velasco-Hernandez T, 2015, LEUKEMIA, V29, P2366, DOI 10.1038/leu.2015.156; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Vick B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120925; Vukovic M, 2015, J EXP MED, V212, P2223, DOI 10.1084/jem.20150452; Vyas P, 2014, BLOOD, V124, P3510, DOI 10.1182/blood-2014-10-605055; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wierenga ATJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093494; Yonekura S, 2013, ANTICANCER RES, V33, P3099; Zaitseva L, 2014, ONCOTARGET, V5, P9930, DOI 10.18632/oncotarget.2479	44	14	14	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2676	2686		10.1038/s41388-018-0151-1	http://dx.doi.org/10.1038/s41388-018-0151-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29487418	Green Accepted			2022-12-28	WOS:000432545100005
J	Dubuisson, L; Lormieres, F; Fochi, S; Turpin, J; Pasquier, A; Douceron, E; Oliva, A; Bazarbachi, A; Lallemand-Breitenbach, V; De The, H; Journo, C; Mahieux, R				Dubuisson, Louise; Lormieres, Florence; Fochi, Stefania; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Bazarbachi, Ali; Lallemand-Breitenbach, Valerie; De The, Hugues; Journo, Chloe; Mahieux, Renaud			Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner	ONCOGENE			English	Article							T-CELL LEUKEMIA; KAPPA-B ACTIVATION; VIRUS TYPE-1; IN-VIVO; HBZ; TRANSFORMATION; TRANSCRIPTION; CONJUGATION; PATHWAYS; THERAPY	Since the identification of the antisense protein of HTLV-2 (APH-2) and the demonstration that APH-2 mRNA is expressed in vivo in most HTLV-2 carriers, much effort has been dedicated to the elucidation of similarities and/or differences between APH-2 and HBZ, the antisense protein of HTLV-1. Similar to HBZ, APH-2 negatively regulates HTLV-2 transcription. However, it does not promote cell proliferation. In contrast to HBZ, APH-2 half-life is very short. Here, we show that APH-2 is addressed to PML nuclear bodies in T-cells, as well as in different cell types. Covalent SUMOylation of APH-2 is readily detected, indicating that APH-2 might be addressed to the PML nuclear bodies in a SUMO-dependent manner. We further show that silencing of PML increases expression of APH-2, while expression of HBZ is unaffected. On the other hand, SUMO-1 overexpression leads to a specific loss of APH-2 expression that is restored upon proteasome inhibition. Furthermore, the carboxy-terminal LAGLL motif of APH-2 is responsible for both the targeting of the protein to PML nuclear bodies and its short half-life. Taken together, these observations indicate that natural APH-2 targeting to PML nuclear bodies induces proteasomal degradation of the viral protein in a SUMO-dependent manner. Hence, this study deciphers the molecular and cellular bases of APH-2 short half-life in comparison to HBZ and highlights key differences in the post-translational mechanisms that control the expression of both proteins.	[Dubuisson, Louise; Lormieres, Florence; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Journo, Chloe; Mahieux, Renaud] Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, Int Ctr Res Infectiol,Univ Lyon, Retroviral Oncogenesis Lab,INSERM U1111,CNRS,UMR5, F-69007 Lyon, France; [Dubuisson, Louise; Lormieres, Florence; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Journo, Chloe; Mahieux, Renaud] Equipe Labellisee Ligue Natl Canc, Lyon, France; [Fochi, Stefania] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Bazarbachi, Ali] Amer Univ Beirut, Dept Internal Med, Fac Med, Beirut, Lebanon; [Bazarbachi, Ali] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Lallemand-Breitenbach, Valerie; De The, Hugues] Univ Paris Diderot, Coll France, Paris Sorbonne, Inserm U944,CNRS 7212, Lettre 11 Pl Marcelin Berthelot, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Verona; American University of Beirut; American University of Beirut; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universite Paris Cite	Journo, C; Mahieux, R (corresponding author), Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, Int Ctr Res Infectiol,Univ Lyon, Retroviral Oncogenesis Lab,INSERM U1111,CNRS,UMR5, F-69007 Lyon, France.; Journo, C; Mahieux, R (corresponding author), Equipe Labellisee Ligue Natl Canc, Lyon, France.	chloe.journo@ens-lyon.fr; renaud.mahieux@ens-lyon.fr		Lallemand, Valerie/0000-0001-9852-204X; Bazarbachi, Ali/0000-0002-7171-4997; Journo, Chloe/0000-0002-0973-0777; mahieux, renaud/0000-0002-5129-6804; Turpin, Jocelyn/0000-0001-5177-2471; Lormieres, Florence/0000-0002-7603-1394	ENS Lyon; ANR; Fondation ARC pour la Recherche sur le Cancer; Ministere de la Recherche; ARC; La Ligue Contre le Cancer "programme Equipe Labellisee"; INSERM	ENS Lyon; ANR(French National Research Agency (ANR)); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); ARC(Australian Research Council); La Ligue Contre le Cancer "programme Equipe Labellisee"; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank the microscopy facility team of the Lyon SFR Biosciences. R.M., C.J., and F.L. are supported by ENS Lyon. L.D. is supported by ANR. J.T. was supported by the Fondation ARC pour la Recherche sur le Cancer. E.D. was supported by the Ministere de la Recherche. This work was supported by ARC and La Ligue Contre le Cancer "programme Equipe Labellisee" and INSERM.	Bruhn RMR, 2017, CLIN VIROLOGY, P771; Cachat A, 2013, J VIROL, V87, P13386, DOI 10.1128/JVI.02758-13; Ciminale V, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00398; Currer R, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00406; Dassouki Z, 2015, BLOOD, V125, P474, DOI 10.1182/blood-2014-04-572750; Douceron E, 2012, J INFECT DIS, V205, P82, DOI 10.1093/infdis/jir708; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084/jem.20101095; Everett RD, 2013, NAT REV MICROBIOL, V11, P400, DOI 10.1038/nrmicro3015; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Giam CZ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060161; Halin M, 2009, BLOOD, V114, P2427, DOI 10.1182/blood-2008-09-179879; Hivin P, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-14; Ivanschitz L, 2015, P NATL ACAD SCI USA, V112, P14278, DOI 10.1073/pnas.1507540112; Jean M, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040067; Journo C, 2013, J VIROL, V87, P1123, DOI 10.1128/JVI.01792-12; Journo C, 2009, FUTURE MICROBIOL, V4, P425, DOI 10.2217/FMB.09.13; Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001; Kfoury Y, 2012, ADV CANCER RES, V113, P85, DOI 10.1016/B978-0-12-394280-7.00003-8; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Komatsu T, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100290; Lowrey AJ, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0183-0; Mesnard JM, 2015, VIRUSES-BASEL, V7, P6490, DOI 10.3390/v7122952; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nicot Christophe, 2015, J Cancer Sci, V2, DOI 10.13188/2377-9292.1000009; Panfil AR, 2016, J VIROL, V90, P3760, DOI 10.1128/JVI.03113-15; Pene S, 2014, J VIROL, V88, P10655, DOI 10.1128/JVI.01827-14; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Sahin U, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5187; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Shiio Y, 2006, MOL CELL BIOL, V26, P1386, DOI 10.1128/MCB.26.4.1386-1397.2006; Shirinian M, 2015, J VIROL, V89, P8092, DOI 10.1128/JVI.00918-15; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Watanabe T, 2017, BLOOD, V129, P1071, DOI 10.1182/blood-2016-09-692574; Xie L, 2005, J VIROL, V79, P14536, DOI 10.1128/JVI.79.23.14536-14545.2005; Yamano Y, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00389; Yin H, 2012, J VIROL, V86, P8412, DOI 10.1128/JVI.00717-12; Zhao TJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00247	38	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2806	2816		10.1038/s41388-018-0163-x	http://dx.doi.org/10.1038/s41388-018-0163-x			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29507418				2022-12-28	WOS:000432929800004
J	Ladanyi, A; Mukherjee, A; Kenny, HA; Johnson, A; Mitra, AK; Sundaresan, S; Nieman, KM; Pascual, G; Benitah, SA; Montag, A; Yamada, SD; Abumrad, NA; Lengyel, E				Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Sundaresan, Sinju; Nieman, Kristin M.; Pascual, Gloria; Aznar Benitah, Salvador; Montag, Anthony; Yamada, S. Diane; Abumrad, Nada A.; Lengyel, Ernst			Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis	ONCOGENE			English	Article							FATTY-ACID UPTAKE; MONOCYTE-DERIVED MACROPHAGES; B SCAVENGER RECEPTOR; MESOTHELIAL CELLS; TRANSPORT; MEMBRANE; ACTIVATION; OXIDATION; PROTEINS; ADHESION	Ovarian cancer (OvCa) is characterized by widespread and rapid metastasis in the peritoneal cavity. Visceral adipocytes promote this process by providing fatty acids (FAs) for tumour growth. However, the exact mechanism of FA transfer from adipocytes to cancer cells remains unknown. This study shows that OvCa cells co-cultured with primary human omental adipocytes express high levels of the FA receptor, CD36, in the plasma membrane, thereby facilitating exogenous FA uptake. Depriving OvCa cells of adipocyte-derived FAs using CD36 inhibitors and short hairpin RNA knockdown prevented development of the adipocyte-induced malignant phenotype. Specifically, inhibition of CD36 attenuated adipocyte-induced cholesterol and lipid droplet accumulation and reduced intracellular reactive oxygen species (ROS) content. Metabolic analysis suggested that CD36 plays an essential role in the bioenergetic adaptation of OvCa cells in the adipocyte-rich microenvironment and governs their metabolic plasticity. Furthermore, the absence of CD36 affected cellular processes that play a causal role in peritoneal dissemination, including adhesion, invasion, migration and anchorage independent growth. Intraperitoneal injection of CD36-deficient cells or treatment with an anti-CD36 monoclonal antibody reduced tumour burden in mouse xenografts. Moreover, a matched cohort of primary and metastatic human ovarian tumours showed upregulation of CD36 in the metastatic tissues, a finding confirmed in three public gene expression data sets. These results suggest that omental adipocytes reprogram tumour metabolism through the upregulation of CD36 in OvCa cells. Targeting the stromal-tumour metabolic interface via CD36 inhibition may prove to be an effective treatment strategy against OvCa metastasis.	[Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Nieman, Kristin M.; Yamada, S. Diane; Lengyel, Ernst] Univ Chicago, Dept Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Nieman, Kristin M.; Yamada, S. Diane; Lengyel, Ernst] Univ Chicago, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Ladanyi, Andras] Univ Illinois, Dept Obstet, Gynecol Oncol Sect, Chicago, IL USA; [Ladanyi, Andras] Univ Illinois, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL USA; [Sundaresan, Sinju; Abumrad, Nada A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Sundaresan, Sinju; Abumrad, Nada A.] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; [Pascual, Gloria; Aznar Benitah, Salvador] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Aznar Benitah, Salvador] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain; [Montag, Anthony] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL); Washington University (WUSTL); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Chicago	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA.; Lengyel, E (corresponding author), Univ Chicago, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA.	elengyel@uchicago.edu	Aznar-Benitah, Salvador/F-4761-2016; Angulo, Gloria Pascual/AAA-7668-2019; Lengyel, Ernst/D-9220-2014	Aznar-Benitah, Salvador/0000-0002-9059-5049; Angulo, Gloria Pascual/0000-0003-3810-6647; Lengyel, Ernst/0000-0001-8624-1507; Nieman, Kristin/0000-0001-7529-0872	Bears Care, the charitable beneficiary of the Chicago Bears Football Club; National Cancer Institute [DK033301]; Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant;  [CA 169604]; NATIONAL CANCER INSTITUTE [R01CA169604, R01CA211916, R01CA111882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301, R01DK060022, R01DK111175, P30DK056341] Funding Source: NIH RePORTER	Bears Care, the charitable beneficiary of the Chicago Bears Football Club; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a grant from Bears Care, the charitable beneficiary of the Chicago Bears Football Club (SD Yamada and E Lengyel) by National Cancer Institute grant DK033301 (NA Abumrad) and by CA 169604 (E Lengyel) and the Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant (A Ladanyi). We thank Chunling Zhang and the Center for Research Informatics at the University of Chicago for their bioinformatics support on the microarray data. We are grateful to Gail Isenberg for editing this manuscript.	Abumrad N A, 2000, Curr Opin Clin Nutr Metab Care, V3, P255, DOI 10.1097/00075197-200007000-00003; Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999; Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Agrawal S, 2007, CIRCULATION, V115, P2939, DOI 10.1161/CIRCULATIONAHA.107.696922; Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Baranova IN, 2010, J BIOL CHEM, V285, P8492, DOI 10.1074/jbc.M109.007526; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cheng JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21808; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; Dobrzyn P, 2008, AM J PHYSIOL-ENDOC M, V294, pE357, DOI 10.1152/ajpendo.00471.2007; Eckert MA, 2016, CANCER DISCOV, V6, P1342, DOI 10.1158/2159-8290.CD-16-0607; Ehehalt R, 2006, MOL CELL BIOCHEM, V284, P135, DOI 10.1007/s11010-005-9034-1; Guillaumond F, 2015, P NATL ACAD SCI USA, V112, P2473, DOI 10.1073/pnas.1421601112; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Janabi M, 2001, BIOCHEM BIOPH RES CO, V283, P26, DOI 10.1006/bbrc.2001.4718; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kazantzis M, 2012, BBA-MOL CELL BIOL L, V1821, P852, DOI 10.1016/j.bbalip.2011.09.010; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kenny HA, 2011, CLIN CANCER RES, V17, P459, DOI 10.1158/1078-0432.CCR-10-2258; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee SH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7364; Li W, 2010, J CLIN INVEST, V120, P3996, DOI 10.1172/JCI42823; Liu YY, 2015, CANCER RES, V75, P5046, DOI 10.1158/0008-5472.CAN-15-0706; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Mwaikambo BR, 2009, J BIOL CHEM, V284, P26695, DOI 10.1074/jbc.M109.033480; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Naville D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030686; Nergiz-Unal R., 2011, Cardiovascular & Hematological Agents in Medicinal Chemistry, V9, P42, DOI 10.2174/187152511794182855; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Parrales A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122074; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pepino MY, 2014, ANNU REV NUTR, V34, P281, DOI 10.1146/annurev-nutr-071812-161220; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RANDLE PJ, 1963, LANCET, V1, P785; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rodrigue-Way A, 2014, FASEB J, V28, P1910, DOI 10.1096/fj.13-240168; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Samovski D, 2015, DIABETES, V64, P353, DOI 10.2337/db14-0582; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Sehouli J, 2009, J SURG ONCOL, V99, P424, DOI 10.1002/jso.21288; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Su X, 2009, TRENDS ENDOCRIN MET, V20, P72, DOI 10.1016/j.tem.2008.11.001; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; TANDON NN, 1989, J BIOL CHEM, V264, P7570; Thompson BR, 2010, MOL CELL ENDOCRINOL, V318, P24, DOI 10.1016/j.mce.2009.08.015; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Witz CA, 2001, J SOC GYNECOL INVEST, V8, P299, DOI 10.1016/S1071-5576(01)00122-8	58	215	224	7	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2285	2301		10.1038/s41388-017-0093-z	http://dx.doi.org/10.1038/s41388-017-0093-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29398710	Green Accepted			2022-12-28	WOS:000431100200006
J	Zhang, ML; Huang, NN; Yang, XS; Luo, JY; Yan, S; Xiao, FZ; Chen, WP; Gao, XY; Zhao, K; Zhou, HK; Li, ZQ; Ming, L; Xie, B; Zhang, N				Zhang, Maolei; Huang, Nunu; Yang, Xuesong; Luo, Jingyan; Yan, Sheng; Xiao, Feizhe; Chen, Wenping; Gao, Xinya; Zhao, Kun; Zhou, Huangkai; Li, Ziqiang; Ming, Liu; Xie, Bo; Zhang, Nu			A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; RNAS; TRANSLATION; DATABASE; INITIATION; CIRCRNAS; CANCER	Circular RNAs (circRNAs) are recognized as functional non-coding transcripts in eukaryotic cells. Recent evidence has indicated that even though circRNAs are generally expressed at low levels, they may be involved in many physiological or pathological processes, such as gene regulation, tissue development and carcinogenesis. Although the 'microRNA sponge' function is well characterized, most circRNAs do not contain perfect trapping sites for microRNAs, which suggests the possibility that circRNAs have functions that have not yet been defined. In this study, we show that a circRNA containing an open reading frame (ORF) driven by the internal ribosome entry site (IRES) can translate a functional protein. The circular form of the SNF2 histone linker PHD RING helicase (SHPRH) gene encodes a novel protein that we termed SHPRH-146aa. Circular SHPRH (circ-SHPRH) uses overlapping genetic codes to generate a 'UGA' stop codon, which results in the translation of the 17 kDa SHPRH-146aa. Both circ-SHPRH and SHPRH-146aa are abundantly expressed in normal human brains and are down-regulated in glioblastoma. The overexpression of SHPRH-146aa in U251 and U373 glioblastoma cells reduces their malignant behavior and tumorigenicity in vitro and in vivo. Mechanistically, SHPRH-146aa protects full-length SHPRH from degradation by the ubiquitin proteasome. Stabilized SHPRH sequentially ubiquitinates proliferating cell nuclear antigen (PCNA) as an E3 ligase, leading to inhibited cell proliferation and tumorigenicity. Our findings provide a novel perspective regarding circRNA function in physiological and pathological processes. Specifically, SHPRH-146aa generated from overlapping genetic codes of circ-SHPRH is a tumor suppressor in human glioblastoma.	[Zhang, Maolei; Huang, Nunu; Yang, Xuesong; Yan, Sheng; Chen, Wenping; Gao, Xinya; Zhao, Kun; Zhou, Huangkai; Zhang, Nu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Zhang, Maolei; Huang, Nunu; Yang, Xuesong; Yan, Sheng; Chen, Wenping; Gao, Xinya; Zhao, Kun; Zhou, Huangkai; Zhang, Nu] Guangdong Prov Key Lab Pituitary Tumors, Guangzhou, Guangdong, Peoples R China; [Luo, Jingyan] Forevergen Biosci Ctr, Guangzhou, Guangdong, Peoples R China; [Xiao, Feizhe] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Sci Res Sect, Guangzhou, Guangdong, Peoples R China; [Li, Ziqiang; Ming, Liu] Guangzhou Geneseed Antiaging Res Inst, Guangzhou, Guangdong, Peoples R China; [Xie, Bo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zhang, N (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.; Zhang, N (corresponding author), Guangdong Prov Key Lab Pituitary Tumors, Guangzhou, Guangdong, Peoples R China.	zhangnu2@mail.sysu.edu.cn		Li, Ziqiang/0000-0001-6301-3595	National Key Research and Development Program of China [2016YFA0503000]; National Natural Science Foundation of China [81370072, 81572477]; Science and Technology Project of Guangdong Province [S2013050014535, 2014A030313183, 2016A050502017]; Guangzhou Science and Technology Program [201704020068]; China Postdoctoral Science Foundation [2016M592579]; Innovative Funds for Small and Medium-Sized Enterprises of Guangdong Province [2016A010119103]; Pearl River S&T Nova Program of Guangzhou [201710010178]; U.S. National Cancer Institute [R01CA157933, R01CA172233]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Project of Guangdong Province; Guangzhou Science and Technology Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Innovative Funds for Small and Medium-Sized Enterprises of Guangdong Province; Pearl River S&T Nova Program of Guangzhou; U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Key Research and Development Program of China (2016YFA0503000), the National Natural Science Foundation of China (81370072 and 81572477), the Science and Technology Project of Guangdong Province (S2013050014535, 2014A030313183, 2016A050502017), Guangzhou Science and Technology Program (201704020068), project funded by China Postdoctoral Science Foundation (2016M592579), Innovative Funds for Small and Medium-Sized Enterprises of Guangdong Province (2016A010119103), Pearl River S&T Nova Program of Guangzhou (201710010178) and the U.S. National Cancer Institute (grants R01CA157933 and R01CA172233).	AbouHaidar MG, 2014, P NATL ACAD SCI USA, V111, P14542, DOI 10.1073/pnas.1402814111; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen XP, 2016, SCI REP-UK, V6, DOI 10.1038/srep34985; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lasda E, 2014, RNA, V20, P1829, DOI 10.1261/rna.047126.114; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Lopez-Lastra M, 2005, BIOL RES, V38, P121, DOI 10.4067/S0716-97602005000200003; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mokrejs M, 2006, NUCLEIC ACIDS RES, V34, pD125, DOI 10.1093/nar/gkj081; Motegi A, 2006, J CELL BIOL, V175, P703, DOI 10.1083/jcb.200606145; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552; Song XF, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw075; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Unk I, 2006, P NATL ACAD SCI USA, V103, P18107, DOI 10.1073/pnas.0608595103; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Zeman MK, 2014, J CELL BIOL, V206, P183, DOI 10.1083/jcb.201311063	25	395	423	8	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1805	1814		10.1038/s41388-017-0019-9	http://dx.doi.org/10.1038/s41388-017-0019-9			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29343848				2022-12-28	WOS:000428632600009
J	Stylianou, N; Lehman, ML; Wang, C; Fard, AT; Rockstroh, A; Fazli, L; Jovanovic, L; Ward, M; Sadowski, MC; Kashyap, AS; Buttyan, R; Gleave, ME; Westbrook, TF; Williams, ED; Gunter, JH; Nelson, CC; Hollier, BG				Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Fazli, Ladan; Jovanovic, Lidija; Ward, Micheal; Sadowski, Martin C.; Kashyap, Abhishek S.; Buttyan, Ralph; Gleave, Martin E.; Westbrook, Thomas F.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.			A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; ANDROGEN RECEPTOR; FREE SURVIVAL; CELL-CYCLE; TRANSITION; TUMOR; METASTASIS; PROGRESSION; REVEALS; EMT	The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mirror image of EMT as tumour cells retain a transcriptional "memory" following a reversible EMT. This memory was also enriched in mCRPC samples. Cumulatively, our studies reveal the transcriptional profile of epithelial-mesenchymal plasticity and highlight the unique transcriptional properties of MErT. Furthermore, our findings provide evidence to support the association of epithelial plasticity with poor clinical outcomes in multiple human carcinoma types.	[Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Jovanovic, Lidija; Sadowski, Martin C.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Inst Hlth & Biomed Innovat, Fac Hlth,Sch Biomed Sci,Princess Alexandra Hosp,T, Brisbane, Qld, Australia; [Lehman, Melanie L.; Fazli, Ladan; Buttyan, Ralph; Gleave, Martin E.] Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Ward, Micheal] Univ Queensland, Sch Med, Translat Res Inst, Glycat & Diabet Complicat Grp,Mater Res Inst, Brisbane, Qld, Australia; [Kashyap, Abhishek S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Westbrook, Thomas F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Queensland University of Technology (QUT); University of British Columbia; Mater Research; University of Queensland; Queensland University of Technology (QUT); Baylor College of Medicine	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Inst Hlth & Biomed Innovat, Fac Hlth,Sch Biomed Sci,Princess Alexandra Hosp,T, Brisbane, Qld, Australia.	b.hollier@qut.edu.au	Fard, Ati/AAX-4092-2021; Williams, Elizabeth D/B-1538-2008; Gunter, Jennifer H/B-8960-2016; Stylianou, Nataly/GOP-1782-2022	Williams, Elizabeth D/0000-0002-3364-6655; Gunter, Jennifer H/0000-0003-2447-5732; Gleave, Martin/0000-0003-4235-0167; Sadowski, Martin/0000-0002-5267-1442; Taherian Fard, Atefeh/0000-0002-9126-4540; Stylianou, Nataly/0000-0002-8006-5730; Wang, Chenwei/0000-0002-2097-8634	Australian Government Department of Health; Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; National Health and Medical Research Council of Australia [1100417]	Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by funding from the Australian Government Department of Health, Queensland Government National and International Research Alliance Program funding to the Australian-Canadian Prostate Cancer Research Alliance as well as by the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award. This work was also supported by funding from the National Health and Medical Research Council of Australia (ID 1100417 to CC Nelson, BG Hollier, ML Lehman and ME Gleave).	Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bishop JL, 2015, ENDOCR-RELAT CANCER, V22, pR165, DOI 10.1530/ERC-15-0137; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chikaish Y, 2011, ANTICANCER RES, V31, P4451; Colditz J, 2016, MOL CELL BIOCHEM, V421, P139, DOI 10.1007/s11010-016-2794-y; Cooperberg MR, 2013, J CLIN ONCOL, V31, P1428, DOI 10.1200/JCO.2012.46.4396; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Du LT, 2016, CANCER MED-US, V5, P1962, DOI 10.1002/cam4.719; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hoshino H, 2009, BIOCHEM BIOPH RES CO, V390, P1061, DOI 10.1016/j.bbrc.2009.10.117; HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; LaTulippe E, 2002, CANCER RES, V62, P4499; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Ma ZF, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0042-9; Malek JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028561; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miao L, 2017, CANCER RES, V77, P3101, DOI 10.1158/0008-5472.CAN-16-2169; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pereira L, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00013; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rokavec M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04234-2; Sadowski MC, 2014, ONCOTARGET, V5, P9362, DOI 10.18632/oncotarget.2433; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Sethi S, 2011, AM J TRANSL RES, V3, P90; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; Sieh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040217; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Ware KE, 2016, ONCOTARGET, V7, P50520, DOI 10.18632/oncotarget.10476; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Ye X, 2017, NATURE, V547, pE1, DOI 10.1038/nature22816; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	69	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					913	934		10.1038/s41388-018-0488-5	http://dx.doi.org/10.1038/s41388-018-0488-5			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194451	hybrid, Green Published			2022-12-28	WOS:000458624900001
J	Yuki, R; Tatewaki, T; Yamaguchi, N; Aoyama, K; Honda, T; Kubota, S; Morii, M; Manabe, I; Kuga, T; Tomonaga, T; Yamaguchi, N				Yuki, Ryuzaburo; Tatewaki, Takashi; Yamaguchi, Noritaka; Aoyama, Kazumasa; Honda, Takuya; Kubota, Sho; Morii, Mariko; Manabe, Ichiro; Kuga, Takahisa; Tomonaga, Takeshi; Yamaguchi, Naoto			Desuppression of TGF-beta signaling via nuclear c-Abl-mediated phosphorylation of TIF1 gamma/TRIM33 at Tyr-524,-610, and-1048	ONCOGENE			English	Article							SRC-FAMILY KINASES; TYROSINE PHOSPHORYLATION; PROTEIN; CHROMATIN; ACTIVATION; TGF-BETA-1; MECHANISM; RECEPTOR; CANCER; SMAD4	Protein-tyrosine kinases regulate a broad range of intracellular processes occurring primarily just beneath the plasma membrane. With the greatest care to prevent dephosphorylation, we have shown that nuclear tyrosine phosphorylation regulates global chromatin structural states. However, the roles for tyrosine phosphorylation in the nucleus are poorly understood. Here we identify transcriptional intermediary factor 1-gamma (TIF1 gamma/TRIM33/Ectodermin), which suppresses transforming growth factor-beta (TGF-beta) signaling through the association with Smad2/3 transcription factor, as a new nuclear substrate of c-Abl tyrosine kinase. Replacement of the three tyrosine residues Tyr-524, -610, and -1048 with phenylalanine (3YF) inhibits c-Abl-mediated phosphorylation of TIF1. and enhances TIF1 gamma's association with Smad3. Importantly, knockdown-rescue experiments show that 3YF strengthens TIF1 gamma's ability to suppress TGF-beta signaling. Intriguingly, activation of c-Abl by epidermal growth factor (EGF) induces desuppression of TGF-beta signaling via enhancing the tyrosine phosphorylation level of TIF1 gamma. TGF-beta together with EGF synergistically provokes desuppressive responses of epithelial-tomesenchymal transition through tyrosine phosphorylation of TIF1 gamma. These results suggest that nuclear c-Abl-mediated tyrosine phosphorylation of TIF1 gamma has a desuppressive role in TGF-beta-Smad2/3 signaling.	[Yuki, Ryuzaburo; Tatewaki, Takashi; Yamaguchi, Noritaka; Aoyama, Kazumasa; Honda, Takuya; Kubota, Sho; Morii, Mariko; Yamaguchi, Naoto] Chiba Univ, Grad Sch Pharmaceut Sci, Lab Mol Cell Biol, Chiba 2608675, Japan; [Yuki, Ryuzaburo; Manabe, Ichiro] Chiba Univ, Grad Sch Med, Lab Dis Biol & Mol Med, Chiba 2608670, Japan; [Kuga, Takahisa; Tomonaga, Takeshi] Natl Inst Biomed Innovat Hlth & Nutr, Lab Proteome Res, Osaka 5670085, Japan	Chiba University; Chiba University	Yamaguchi, N (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Lab Mol Cell Biol, Chiba 2608675, Japan.	nyama@faculty.chiba-u.jp	Kuga, Takahisa/AAX-9334-2020; Manabe, Ichiro/AAE-5105-2021	Honda, Takuya/0000-0002-7141-0088; Kubota, Sho/0000-0001-6119-1259	MEXT [15K07922, 16K08227]; Global COE Program from the MEXT; Program for Leading Graduate School (LGS) from the MEXT	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE Program from the MEXT; Program for Leading Graduate School (LGS) from the MEXT	We are grateful to Dr. Eli Canaani (Weizmann Institute of Science), Dr. Hiroyuki Miyoshi (RIKEN BRC, Tsukuba), Dr. Toshiki Tamura (National Institute of Infectious Diseases, Tokyo), and Dr. Masatoshi Tagawa (Chiba Cancer Center Research Institute, Chiba) for their materials. This work was supported in part by grantsin-aid for Scientific Research 15K07922 (to Naoto Y) and 16K08227 (to Noritaka Y), Global COE Program, and Program for Leading Graduate School (LGS) from the MEXT. KA and SK were G-COE Research Assistants. TH and M.M. were LGS Research Assistants. SK, TH, and MM are JSPS Research Fellows.	Agricola E, 2011, MOL CELL, V43, P85, DOI 10.1016/j.molcel.2011.05.020; Aoyama K, 2015, CELL BIOL INT, V39, P446, DOI 10.1002/cbin.10413; Aoyama K, 2013, EXP CELL RES, V319, P3251, DOI 10.1016/j.yexcr.2013.09.003; Aoyama K, 2011, EXP CELL RES, V317, P2874, DOI 10.1016/j.yexcr.2011.09.013; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bergeron JJM, 2016, ANNU REV BIOCHEM, V85, P573, DOI 10.1146/annurev-biochem-060815-014659; Cans C, 2000, BIOCHEM PHARMACOL, V60, P1203, DOI 10.1016/S0006-2952(00)00434-2; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF1202, DOI 10.1152/ajprenal.00406.2005; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Fattet L, 2013, J CELL SCI, V126, P3713, DOI 10.1242/jcs.126748; Fukumoto Y, 2010, CYTOTECHNOLOGY, V62, P73, DOI 10.1007/s10616-010-9259-z; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hasegawa H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116048; He JC, 2008, INVEST OPHTH VIS SCI, V49, P2936, DOI 10.1167/iovs.07-0900; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Herquel B, 2011, TRANSCR-AUSTIN, V2, P231, DOI 10.4161/trns.2.5.17725; Honda T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19599-1; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ishibashi K, 2013, J CELL SCI, V126, P625, DOI 10.1242/jcs.116277; Jia M., 2011, Experimental Oncology, V33, P170; Kasahara K, 2007, J CELL PHYSIOL, V211, P220, DOI 10.1002/jcp.20931; Khatri A, 2016, J CELL SCI, V129, P9, DOI 10.1242/jcs.175521; Krainock M, 2016, J CLIN MED, V19, pE27; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kubota S, 2015, J BIOL CHEM, V290, P10891, DOI 10.1074/jbc.M115.643882; Kubota S, 2013, J BIOL CHEM, V288, P17871, DOI 10.1074/jbc.M112.437756; Kuki K, 2017, BIOCHEM BIOPH RES CO, V490, P1045, DOI 10.1016/j.bbrc.2017.06.163; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; Morabito CJ, 2001, DEV BIOL, V234, P204, DOI 10.1006/dbio.2001.0254; Morii M, 2017, J BIOL CHEM, V292, P1648, DOI 10.1074/jbc.M116.753202; Morii M, 2015, CELL BIOL INT, V39, P923, DOI 10.1002/cbin.10460; Nasrollahi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18831; Obata Y, 2010, J CELL SCI, V123, P2649, DOI 10.1242/jcs.066266; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Quere R, 2014, P NATL ACAD SCI USA, V111, P10592, DOI 10.1073/pnas.1405546111; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Sato I, 2009, J CELL SCI, V122, P965, DOI 10.1242/jcs.034843; Schlessinger Joseph, 2014, Cold Spring Harb Perspect Biol, V6, DOI 10.1101/cshperspect.a008912; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Soeda S, 2013, EXP CELL RES, V319, P1382, DOI 10.1016/j.yexcr.2013.02.023; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takahashi A, 2009, EXP CELL RES, V315, P1117, DOI 10.1016/j.yexcr.2009.02.010; Tamura T, 2000, INT IMMUNOL, V12, P1205, DOI 10.1093/intimm/12.8.1205; Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915; Wang JYJ, 2014, MOL CELL BIOL, V34, P1188, DOI 10.1128/MCB.01454-13; Wang SN, 2010, AM J PHYSIOL-RENAL, V298, pF142, DOI 10.1152/ajprenal.00320.2009; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yamaguchi N, 2001, J CELL SCI, V114, P1631; Yamaguchi N, 2017, J CELL BIOCHEM, V118, P1453, DOI 10.1002/jcb.25804; Yamaguchi N, 2015, BIOCHEM J, V471, P67, DOI 10.1042/BJ20150372; Yuki R, 2015, J CELL BIOCHEM, V116, P954, DOI 10.1002/jcb.25046	64	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					637	655		10.1038/s41388-018-0481-z	http://dx.doi.org/10.1038/s41388-018-0481-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177833				2022-12-28	WOS:000457300300003
J	Lee, E; Ouzounova, M; Piranlioglu, R; Ma, MT; Guzel, M; Marasco, D; Chadli, A; Gestwicki, JE; Cowell, JK; Wicha, MS; Hassan, KA; Korkaya, H				Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Ma, Minh Thu; Guzel, Mustafa; Marasco, Daniela; Chadli, Ahmed; Gestwicki, Jason E.; Cowell, John K.; Wicha, Max S.; Hassan, Khaled A.; Korkaya, Hasan			The pleiotropic effects of TNF alpha in breast cancer subtypes is regulated by TNFAIP3/A20	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; ZINC-FINGER PROTEIN; NF-KAPPA-B; HSP70 PROTECTS; A20; CELLS; EXPRESSION; PROMOTES; BASAL; UBIQUITINATION	TNF alpha is a pleiotropic cytokine which fuels tumor cell growth, invasion, and metastasis in some malignancies, while in others it induces cytotoxic cell death. However, the molecular mechanism by which TNF alpha exerts its diverse effects on breast cancer subtypes remains elusive. Using in vitro assays and mouse xenografts, we show here that TNF alpha contributes to the aggressive properties of triple negative breast cancer (TNBC) cell lines via upregulation of TNFAIP3(A20). In a striking contrast, TNF alpha induces a potent cytotoxic cell death in luminal (ER+) breast cancer cell lines which fail to upregulate A20 expression. Overexpression of A20 not only protects luminal breast cancer cell lines from TNF alpha-induced cell death via inducing HSP70-mediated anti-apoptotic pathway but also promotes a robust EMT/CSC phenotype by activating the pStat3-mediated inflammatory signaling. Furthermore, A20 overexpression in luminal breast cancer cells induces aggressive metastatic properties in mouse xenografts via generating a permissive inflammatory microenvironment constituted by granulocytic-MDSCs. Collectively, our results reveal a mechanism by which A20 mediates pleiotropic effects of TNF alpha playing role in aggressive behaviors of TNBC subtype while its deficiency results in TNF alpha-induced apoptotic cell death in luminal breast cancer subtype.	[Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Ma, Minh Thu; Chadli, Ahmed; Cowell, John K.; Korkaya, Hasan] Augusta Univ, Dept Biochem & Mol Biol, Georgia Canc Ctr, Augusta, GA 30912 USA; [Guzel, Mustafa] Medipol Univ, Regenerat & Restorat Res Ctr REMER, Istanbul, Turkey; [Marasco, Daniela] Univ Naples Federico II, Dept Pharm, I-80134 Naples, Italy; [Gestwicki, Jason E.; Hassan, Khaled A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Wicha, Max S.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Ouzounova, Maria] CRCL, Dept Canc Cell Plast, Lyon, France	University System of Georgia; Augusta University; Istanbul Medipol University; University of Naples Federico II; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL)	Korkaya, H (corresponding author), Augusta Univ, Dept Biochem & Mol Biol, Georgia Canc Ctr, Augusta, GA 30912 USA.	hkorkaya@augusta.edu	Korkaya, Hasan/GRY-1016-2022; Ouzounova, Maria/B-7189-2014; Wicha, Max/AAE-7268-2019; Korkaya, Hasan/ABD-6282-2020	Ouzounova, Maria/0000-0001-8934-3461; Korkaya, Hasan/0000-0002-0719-5862; Piranlioglu, Raziye/0000-0003-2450-3887; Guzel, Prof. Mustafa/0000-0002-1423-0435	NCI NIH HHS [R35 CA197585] Funding Source: Medline; NINDS NIH HHS [R01 NS059690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA197585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bocchini Claire E, 2014, JAKSTAT, V3, pe970459, DOI 10.4161/21623988.2014.970459; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; da Silva CG, 2013, HEPATOLOGY, V57, P2014, DOI 10.1002/hep.26197; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Diao JJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0453-2; Gabai VL, 2016, CANCER RES, V76, P5926, DOI 10.1158/0008-5472.CAN-16-0800; Hadisaputri YE, 2017, INT J ONCOL, V50, P1002, DOI 10.3892/ijo.2017.3869; Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T; Hjelmeland AB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000319; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jia DY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.319; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kim G, 2015, ONCOGENE, V34, P671, DOI 10.1038/onc.2014.4; Komander D, 2008, BIOCHEM J, V409, P77, DOI 10.1042/BJ20071399; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee JH, 2017, NAT CELL BIOL, V19, P1260, DOI 10.1038/ncb3609; Mahat DB, 2016, MOL CELL, V62, P63, DOI 10.1016/j.molcel.2016.02.025; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meng XZ, 2002, SHOCK, V17, P345, DOI 10.1097/00024382-200205000-00001; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132; Reeg S, 2016, FREE RADICAL BIO MED, V99, P153, DOI 10.1016/j.freeradbiomed.2016.08.002; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Wang YF, 2015, MOBILE SOCIAL NETWORKING AND COMPUTING: A MULTIDISCIPLINARY INTEGRATED PERSPECTIVE, P3; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Zhong HH, 2016, CANCER RES, V76, P480, DOI 10.1158/0008-5472.CAN-15-0883	43	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					469	482		10.1038/s41388-018-0472-0	http://dx.doi.org/10.1038/s41388-018-0472-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166590	Green Accepted			2022-12-28	WOS:000456589800002
J	Qin, Y; Vasilatos, SN; Chen, L; Wu, H; Cao, ZS; Fu, YM; Huang, M; Vlad, AM; Lu, BF; Oesterreich, S; Davidson, NE; Huang, Y				Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Cao, Zhishen; Fu, Yumei; Huang, Min; Vlad, Anda M.; Lu, Binfeng; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi			Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade	ONCOGENE			English	Article							INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; CANCER; LSD1; EXPRESSION; CHEMOKINES; MICROENVIRONMENT; PEMBROLIZUMAB; REEXPRESSION; MPDL3280A	Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.	[Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA; [Qin, Ye; Huang, Min; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Cao, Zhishen; Vlad, Anda M.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Fu, Yumei] Allegheny Gen Hosp Pathol, Pittsburgh, PA USA; [Vlad, Anda M.; Lu, Binfeng] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Davidson, Nancy E.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA; [Davidson, Nancy E.] Univ Washington, Seattle, WA 98195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle	Huang, Y (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA.; Huang, Y (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	yih26@pitt.edu	Huang, Yi/AAW-7892-2021	Huang, Yi/0000-0002-9982-117X; Chen, Lin/0000-0002-8126-3333	US Army Breast Cancer Research Program [W81XWH-14-1-0237, W81XWH-14-1-0238]; Breast Cancer Research Foundation; NIH/NCI [P30CA047904]; Natural Science Foundation of China [81502366]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER	US Army Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by US Army Breast Cancer Research Program (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED/SO), Breast Cancer Research Foundation (to NED and SO), NIH/NCI P30CA047904 and Natural Science Foundation of China (81502366 to YQ).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Akahori T, 2006, TRANSPLANT P, V38, P3366, DOI 10.1016/j.transproceed.2006.10.115; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bhatti S, 2017, JCO PRECIS ONCOL, V1, P1; Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186; Cao CY, 2018, INT J CANCER, V143, P1388, DOI 10.1002/ijc.31419; Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014; Cunnick GH, 2002, HISTOL HISTOPATHOL, V17, P863, DOI 10.14670/HH-17.863; Deken MA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238557; Dirix L, 2016, CANC RES S, V76, pS1; Dong HD, 1999, NAT MED, V5, P1365; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Huang Y, 2012, ROYAL SOC CHEM DRUG, V17, P238; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Janzer A, 2012, J BIOL CHEM, V287, P30984, DOI 10.1074/jbc.M112.341040; Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Muthuswamy R, 2012, CANCER RES, V72, P3735, DOI 10.1158/0008-5472.CAN-11-4136; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Pasculli B, 2018, SEMIN CANCER BIOL, V51, P22, DOI 10.1016/j.semcancer.2018.01.007; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rugo HS, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-S5-07; Sandhu R, 2015, AM J PATHOL, V185, P282, DOI 10.1016/j.ajpath.2014.12.003; Shayan G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1261779; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Solinas C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000255; Terranova-Barberio M, 2017, ONCOTARGET, V8; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033; Wang K, 2017, HUM PATHOL, V69, P110, DOI 10.1016/j.humpath.2017.09.012; Wimberly H, 2015, CANCER IMMUNOL RES, V3, P326, DOI 10.1158/2326-6066.CIR-14-0133; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584	55	91	94	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					390	405		10.1038/s41388-018-0451-5	http://dx.doi.org/10.1038/s41388-018-0451-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30111819	Green Accepted			2022-12-28	WOS:000455851200007
J	Zhu, J; Zhao, C; Kharman-Biz, A; Zhuang, T; Jonsson, P; Liang, N; Williams, C; Lin, CY; Qiao, Y; Zendehdel, K; Stromblad, S; Treuter, E; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Jonsson, P.; Liang, N.; Williams, C.; Lin, C. -Y.; Qiao, Y.; Zendehdel, K.; Stromblad, S.; Treuter, E.; Dahlman-Wright, K.			The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation (vol 33, pg 4340, 2018)	ONCOGENE			English	Correction									[Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Liang, N.; Qiao, Y.; Stromblad, S.; Treuter, E.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Kharman-Biz, A.; Zendehdel, K.] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran; [Jonsson, P.; Williams, C.; Lin, C. -Y.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	Karolinska Institutet; Tehran University of Medical Sciences; University of Houston System; University of Houston	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.	karin.dahlman-wright@ki.se		Liang, Ning/0000-0002-7848-2893; Zendehdel, Kazem/0000-0002-0269-4945				Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	1	3	3	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					299	300		10.1038/s41388-018-0502-y	http://dx.doi.org/10.1038/s41388-018-0502-y			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30262864	Bronze, Green Published			2022-12-28	WOS:000455366700011
J	Lee, E; Collazo-Lorduy, A; Castillo-Martin, M; Gong, YX; Wang, L; Oh, WK; Galsky, MD; Cordon-Cardo, C; Zhu, J				Lee, Eunjee; Collazo-Lorduy, Ana; Castillo-Martin, Mireia; Gong, Yixuan; Wang, Li; Oh, William K.; Galsky, Matthew D.; Cordon-Cardo, Carlos; Zhu, Jun			Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; ALKALOID EMETINE; DOWN-REGULATION; MICRORNA; CISPLATIN; TARGETS; CELLS	Bladder cancers can be categorized into subtypes according to gene expression patterns. P53-like muscle-invasive bladder cancers are generally resistant to cisplatin-based chemotherapy, but exhibit heterogeneous clinical outcomes with a prognosis intermediate to that of the luminal and basal subtypes. The optimal approach to p53-like tumors remains poorly defined and better means to risk-stratify such tumors and identification of novel therapeutic targets is urgently needed. MicroRNAs (miRNAs) play a key role in cancer, both in tumorigenesis and tumor progression. In the past few years, miRNA expression signatures have been reported as prognostic biomarkers in different tumor types including bladder cancer. However, miRNA's expression does not always correlate well with its activity. We previously developed ActMiR, a computational method for explicitly inferring miRNA activities. We applied ActMiR to The Cancer Genome Atlas (TCGA) bladder cancer data set and identified the activities of miR-106b-5p and miR-532-3p as potential prognostic markers of the p53-like subtype, and validated them in three independent bladder cancer data sets. Especially, higher miR-106b-5p activity was consistently associated with better survival in these data sets. Furthermore, we experimentally validated causal relationships between miR-106-5p and its predicted target genes in p53-like cell line HT1197. HT1197 cells treated with the miR-106b-5p-specific inhibitor were more invasive while cells treated with the miR-106b-5p-specific mimic were less invasive than corresponding controls. Altogether, our results suggest that miR-106b-5p activity can categorize p53-like bladder tumors into more and less-favorable prognostic groups, which provides critical information for personalizing treatment option for p53-like bladder cancers.	[Lee, Eunjee; Wang, Li; Zhu, Jun] Dept Genet & Genom Sci, New York, NY 10029 USA; [Lee, Eunjee; Wang, Li; Zhu, Jun] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Lee, Eunjee; Wang, Li; Zhu, Jun] Sema4, Stamford, CT 06902 USA; [Collazo-Lorduy, Ana; Castillo-Martin, Mireia; Cordon-Cardo, Carlos] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Castillo-Martin, Mireia] Champalimaud Ctr Unknown, Dept Pathol, Lisbon, Portugal; [Gong, Yixuan; Oh, William K.; Galsky, Matthew D.; Zhu, Jun] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Fundacao Champalimaud; Icahn School of Medicine at Mount Sinai	Zhu, J (corresponding author), Dept Genet & Genom Sci, New York, NY 10029 USA.; Zhu, J (corresponding author), Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA.; Zhu, J (corresponding author), Sema4, Stamford, CT 06902 USA.; Zhu, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.	jun.zhu@mssm.edu	Oh, William/B-9163-2012	Oh, William/0000-0001-5113-8147; Zhu, Jun/0000-0003-0834-8178; Cordon-Cardo, Carlos/0000-0003-0858-5624	National Institutes of Health [R01-AG046170, U01-HG008451]; Spanish Society of Medical Oncology; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG008451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG046170] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Society of Medical Oncology; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank members of Zhu laboratory for discussions. This work was partially supported by National Institutes of Health (grant numbers R01-AG046170, U01-HG008451); and the Spanish Society of Medical Oncology to ACL.	Arvey A, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.24; Aushev VN, 2018, CLIN CANCER RES, V24, P581, DOI 10.1158/1078-0432.CCR-17-0996; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Ching CB, 2010, LAB INVEST, V90, P1406, DOI 10.1038/labinvest.2010.133; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Enokida H, 2016, INVESTIG CLIN UROL, V57, pS60, DOI 10.4111/icu.2016.57.S1.S60; Esposti DD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16226-3; Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1; Foreman KE, 2014, J UROLOGY, V191, P502, DOI 10.1016/j.juro.2013.09.014; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guancial EA, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.04.014; Harrell F, 2013, NON TRADITIONAL REF, V3; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuzaka B, 2015, ARCH MED SCI, V11, P378, DOI 10.5114/aoms.2014.46796; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee E, 2016, BIOINFORMATICS, V32, P96, DOI 10.1093/bioinformatics/btv531; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Lindgren D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038863; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; Moller M, 2007, ONCOL REP, V18, P737; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ochoa AE, 2016, ONCOTARGET, V7, P80164, DOI 10.18632/oncotarget.13284; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Seiler R, 2017, EUR UROL, V72, P142, DOI 10.1016/j.eururo.2017.03.021; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Q, 2015, INT J ONCOL, V46, P389, DOI 10.3892/ijo.2014.2703; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wu LJ, 2015, ONCOL LETT, V9, P213, DOI 10.3892/ol.2014.2706; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhao W, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-419	41	17	17	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5858	5872		10.1038/s41388-018-0367-0	http://dx.doi.org/10.1038/s41388-018-0367-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29970902	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000448943100004
J	Meng, QC; Shi, S; Liang, C; Liang, DK; Hua, J; Zhang, B; Xu, J; Yu, XJ				Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun			Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3 beta/Snail signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; TAMOXIFEN RESISTANCE; CELLS; SNAIL; EXPRESSION; SURVIVAL; RISK; OVEREXPRESSION; POLYMORPHISM; GEMCITABINE	The devastating prognosis of pancreatic ductal adenocarcinoma (PDAC) is partially attributed to chemotherapy resistance. Glutathione peroxidase-1 (GPx1) plays various roles in the development and progression of multiple tumors, with the exception of pancreatic cancer. Here, we tentatively explored the role of GPx1 in the malignant biological behavior and gemcitabine (GEM) resistance of PDAC. GPx1 levels were detected using tissue microarrays and were negatively correlated with the overall survival of patients with PDAC. GPx1 silencing induced a mesenchymal transition phenotype and increased GEM resistance in vitro and in vivo. Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3 beta (GSK3 beta)/Snail signaling was involved in this process, as determined by RNA sequencing. Moreover, low GPx1 expression correlated with a worse survival rate in patients with PDAC who received GEM adjuvant chemotherapy, whereas this correlation was not detected in patients receiving fluoropyrimidine. Based on our results, GPx1 inhibits the epithelial-mesenchymal transition (EMT) and chemoresistance by regulating the Akt/GSK3 beta/Snail signaling axis in PDAC. Furthermore, GPx1 may be a potential predictive biomarker in GEM-treated PDAC patients.	[Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Meng, Qingcai; Shi, Si; Liang, Chen; Liang, Dingkong; Hua, Jie; Zhang, Bo; Xu, Jin; Yu, Xianjun] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Yu, XJ (corresponding author), Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.	yuxianjun@fudanpci.org		Liang, Chen/0000-0003-0578-7589; Shi, Si/0000-0002-6652-0629; yu, xianjun/0000-0002-6697-7143	National Science Foundation for Distinguished Young Scholars of China [81625016]; Shanghai Sailing Program [17YF1402500]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Shanghai Sailing Program	We thank Professor Daming Gao (Institutes for Biological Sciences, Chinese Academy of Sciences) and Professor Yi Qin (Cancer Research Institute, Fudan University) for providing critical comments. This study was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (no. 81625016) and the Shanghai Sailing Program (no. 17YF1402500).	Arsova-Sarafinovska Z, 2009, INT UROL NEPHROL, V41, P63, DOI 10.1007/s11255-008-9407-y; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Chao W, 2017, MOLECULES, V22, DOI 10.3390/molecules22040537; Cullen JJ, 2003, PANCREAS, V26, P23, DOI 10.1097/00006676-200301000-00005; Faucher K, 2005, MOL CELL BIOCHEM, V277, P81, DOI 10.1007/s11010-005-5075-8; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Gao X, 2017, ONCOTARGET, V8, P51888, DOI 10.18632/oncotarget.17128; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d; Hoos WA, 2013, J CLIN ONCOL, V31, P3432, DOI 10.1200/JCO.2013.49.4823; Ichimura Y, 2004, J UROLOGY, V172, P728, DOI 10.1097/01.ju.0000130942.40597.9d; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Kodydkova J, 2013, PANCREAS, V42, P614, DOI 10.1097/MPA.0b013e318288360a; Kourie HR, 2016, WORLD J GASTRO ONCOL, V8, P297, DOI 10.4251/wjgo.v8.i3.297; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li SJ, 2000, CANCER RES, V60, P3927; Liang C, 2015, ONCOTARGET, V6, P14440, DOI 10.18632/oncotarget.3885; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; Ratnasinghe D, 2000, CANCER RES, V60, P6381; Ravn-Haren G, 2006, CARCINOGENESIS, V27, P820, DOI 10.1093/carcin/bgi267; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soltysova A, 2005, NEOPLASMA, V52, P435; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Sun SB, 2017, CELL BIOL INT, V41, P842, DOI 10.1002/cbin.10792; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Xiong GB, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0739-x; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu LF, 2012, LAB INVEST, V92, P744, DOI 10.1038/labinvest.2012.8	50	72	76	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5843	5857		10.1038/s41388-018-0392-z	http://dx.doi.org/10.1038/s41388-018-0392-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29980787				2022-12-28	WOS:000448943100003
J	Bruggeman, JW; Koster, J; Lodder, P; Repping, S; Hamer, G				Bruggeman, Jan Willem; Koster, Jan; Lodder, Paul; Repping, Sjoerd; Hamer, Geert			Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development	ONCOGENE			English	Article							CANCER/TESTIS-ANTIGEN; MESSENGER-RNA; IDENTIFICATION; DATABASE	Cancer cells have been found to frequently express genes that are normally restricted to the testis, often referred to as cancer/testis (CT) antigens or genes. Because germ cell-specific antigens are not recognized as "self" by the innate immune system, CT-genes have previously been suggested as ideal candidate targets for cancer therapy. The use of CT-genes in cancer therapy has thus far been unsuccessful, most likely because their identification has relied on gene expression in whole testis, including the testicular somatic cells, precluding the detection of true germ cell-specific genes. By comparing the transcriptomes of micro-dissected germ cell subtypes, representing the main developmental stages of human spermatogenesis, with the publicly accessible transcriptomes of 2617 samples from 49 different healthy somatic tissues and 9232 samples from 33 tumor types, we here discover hundreds of true germ cell-specific cancer expressed genes. Strikingly, we found these germ cell cancer genes (GC-genes) to be widely expressed in all analyzed tumors. Many GC-genes appeared to be involved in processes that are likely to actively promote tumor viability, proliferation and metastasis. Targeting these true GC-genes thus has the potential to inhibit tumor growth with infertility being the only possible side effect. Moreover, we identified a subset of GC-genes that are not expressed in spermatogonial stem cells. Targeting of this GC-gene subset is predicted to only lead to temporary infertility, as untargeted spermatogonial stem cells can recover spermatogenesis after treatment. Our GC-gene dataset enables improved understanding of tumor biology and provides multiple novel targets for cancer treatment.	[Bruggeman, Jan Willem; Lodder, Paul; Repping, Sjoerd; Hamer, Geert] Univ Amsterdam, Acad Med Ctr, Amsterdam Res Inst Reprod & Dev, Ctr Reprod Med, Amsterdam, Netherlands; [Koster, Jan] Univ Amsterdam, Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hamer, G (corresponding author), Univ Amsterdam, Acad Med Ctr, Amsterdam Res Inst Reprod & Dev, Ctr Reprod Med, Amsterdam, Netherlands.	g.hamer@amc.uva.nl	Koster, Jan/C-5934-2008	Koster, Jan/0000-0002-0890-7585; Bruggeman, Jan Willem/0000-0003-1901-4720; Hamer, Geert/0000-0002-9583-6796	ZonMw VIDI [91796362]; AMC Fellowship; People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme [CIG 293765]	ZonMw VIDI(Netherlands Organization for Health Research and Development); AMC Fellowship; People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme	This work was financed by ZonMw VIDI-grant 91796362 to SR and; an AMC Fellowship and The People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (CIG 293765) to GH.	Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Chen YT, 2005, P NATL ACAD SCI USA, V102, P7940, DOI 10.1073/pnas.0502583102; Dawkins Richard, 1976, SELFISH GENE; Gjerstorff MF, 2015, ONCOTARGET, V6, P15772, DOI 10.18632/oncotarget.4694; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Jan SZ, 2017, DEVELOPMENT, V144, P3659, DOI 10.1242/dev.152413; Jan SZ, 2012, BBA-MOL BASIS DIS, V1822, P1838, DOI 10.1016/j.bbadis.2012.02.008; JANITZ M, 1994, MOL REPROD DEV, V38, P231, DOI 10.1002/mrd.1080380215; Jungbluth Achim A, 2007, Cancer Immun, V7, P15; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; Koster J, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.TRANSCAGEN-A2-45; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Maxfield KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9840; Nielsen AY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060890; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vincent MD, 2011, ADV CANCER RES, V112, P283, DOI 10.1016/B978-0-12-387688-1.00010-7; Wang C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10499; Whitehurst AW, 2014, ANNU REV PHARMACOL, V54, P251, DOI 10.1146/annurev-pharmtox-011112-140326; Yokoe T, 2008, CANCER RES, V68, P1074, DOI 10.1158/0008-5472.CAN-07-0964	25	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5694	5700		10.1038/s41388-018-0357-2	http://dx.doi.org/10.1038/s41388-018-0357-2			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907769	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000447619100008
J	Lee, GW; Park, JB; Park, SY; Seo, J; Shin, SH; Park, JW; Kim, SJ; Watanabe, M; Chun, YS				Lee, Gun-Woo; Park, Jun Bum; Park, Sung Yeon; Seo, Jieun; Shin, Seung-Hyun; Park, Jong-Wan; Kim, Sang Jung; Watanabe, Masatoshi; Chun, Yang-Sook			The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; PROTEIN NEDDYLATION; NEDD8 CONJUGATION; IN-VITRO; MLN4924; EXPRESSION; PATHWAY; TARGET; ACTIVATION; APOPTOSIS	Neddylation is a cellular process that covalently conjugates substrate proteins with the small ubiquitin-like molecule NEDD8. As neddylation is required for fast turnover of proteins in proliferating cancer cells, the neddylation process is currently regarded as a potential target for cancer therapy. However, little is known about the role of neddylation in cancer invasion and metastasis. Unexpectedly, we here found that the neddylation blockade stimulates migration of lung cancer and glioblastoma cells. Mechanistically, C-CBL acts as the E3 ligase for neddylation of the proto-oncogene c-Src. After neddylation, c-Src is poly-ubiquitinated and degraded through the proteasome, which inhibits the PI3K-AKT pathway responsible for cell migration. In human lung cancer tissues, the downregulation of C-CBL was associated with c-Src/AKT, cancer metastasis, and poor survival in patients. Therefore, C-CBL is likely to play a tumor suppressive role by antagonizing a robust oncogenic signaling driven by c-Src. This study provides new insight about the role of neddylation in cancer metastasis. It also implies that the metastasis risk should be carefully evaluated before the clinical application of neddylation inhibitors as anticancer regimens.	[Lee, Gun-Woo; Park, Jun Bum; Park, Sung Yeon; Seo, Jieun; Shin, Seung-Hyun; Park, Jong-Wan; Kim, Sang Jung; Chun, Yang-Sook] Dept Biomed Sci, Seoul 110799, South Korea; [Park, Sung Yeon; Park, Jong-Wan; Kim, Sang Jung; Chun, Yang-Sook] Ischem Hypox Dis Inst, Seoul 110799, South Korea; [Kim, Sang Jung; Chun, Yang-Sook] Seoul Natl Univ, Dept Physiol, Coll Med, Seoul 110799, South Korea; [Watanabe, Masatoshi] Yokohama Natl Univ, Grad Sch Engn, Lab Med Engn, Yokohama, Kanagawa 2408501, Japan	Seoul National University (SNU)	Chun, YS (corresponding author), Dept Biomed Sci, Seoul 110799, South Korea.; Chun, YS (corresponding author), Ischem Hypox Dis Inst, Seoul 110799, South Korea.; Chun, YS (corresponding author), Seoul Natl Univ, Dept Physiol, Coll Med, Seoul 110799, South Korea.	chunys@snu.ac.kr		Seo, Jieun/0000-0003-1319-832X; Park, Jong-Wan/0000-0003-4676-5191; Kim, Sang Jeong/0000-0001-8931-3713	Korean Health Technology RD grant [HI15C2695]; National Research Foundation grants from the Korean government [2016R1AB4013377, 2012R1A5A2A44671346]	Korean Health Technology RD grant; National Research Foundation grants from the Korean government(National Research Foundation of Korea)	This work was supported by a Korean Health Technology R&D grant (HI15C2695), and National Research Foundation grants from the Korean government (2016R1AB4013377, 2012R1A5A2A44671346).	Abidi N, 2015, ENDOCR-RELAT CANCER, V22, pT55, DOI 10.1530/ERC-14-0315; Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Cheng CY, 2010, BRIT J PHARMACOL, V160, P1595, DOI 10.1111/j.1476-5381.2010.00858.x; Duncan K, 2012, FUTURE ONCOL, V8, P1461, DOI [10.2217/FON.12.131, 10.2217/fon.12.131]; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Katzav S, 2015, ONCOTARGET, V6, P10689, DOI 10.18632/oncotarget.3986; Korrodi-Gregorio L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165973; Kuo KL, 2015, CANCER LETT, V363, P127, DOI 10.1016/j.canlet.2015.01.015; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lo FY, 2011, CANCER-AM CANCER SOC, V117, P5344, DOI 10.1002/cncr.26153; Luo ZG, 2012, CANCER RES, V72, P3360, DOI 10.1158/0008-5472.CAN-12-0388; Milhollen MA, 2010, BLOOD, V116, P1515, DOI 10.1182/blood-2010-03-272567; Nawrocki ST, 2013, CLIN CANCER RES, V19, P3577, DOI 10.1158/1078-0432.CCR-12-3212; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Ohh Michael, 2003, Methods Mol Biol, V222, P167; Oved S, 2006, J BIOL CHEM, V281, P21640, DOI 10.1074/jbc.M513034200; Park HS, 2016, CELL DEATH DIFFER, V23, P1296, DOI 10.1038/cdd.2016.6; Ryu JH, 2011, J BIOL CHEM, V286, P6963, DOI 10.1074/jbc.M110.188706; Salon C, 2007, J PATHOL, V213, P303, DOI 10.1002/path.2223; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386; Sarkaria I, 2006, CANCER RES, V66, P9437, DOI 10.1158/0008-5472.CAN-06-2074; Seong MW, 2014, BIOCHEM BIOPH RES CO, V455, P153, DOI 10.1016/j.bbrc.2014.10.129; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Wang XF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/974309; Wu X, 2016, INT J MOL MED, V37, P639, DOI 10.3892/ijmm.2016.2472; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Zhang LY, 2012, ONCOL LETT, V3, P395, DOI 10.3892/ol.2011.487; Zhou XC, 2016, P NATL ACAD SCI USA, V113, pE2935, DOI 10.1073/pnas.1522367113	37	20	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5552	5568		10.1038/s41388-018-0354-5	http://dx.doi.org/10.1038/s41388-018-0354-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29899407				2022-12-28	WOS:000446991200006
J	Cai, H; Cho, EA; Li, Y; Sockler, J; Parish, CR; Chong, BH; Edwards, J; Dodds, TJ; Ferguson, PM; Wilmott, JS; Scolyer, RA; Halliday, GM; Khachigian, LM				Cai, Hong; Cho, Eun-Ae; Li, Yue; Sockler, Jim; Parish, Christopher R.; Chong, Beng H.; Edwards, Jarem; Dodds, Tristan J.; Ferguson, Peter M.; Wilmott, James S.; Scolyer, Richard A.; Halliday, Gary M.; Khachigian, Levon M.			Melanoma protective antitumor immunity activated by catalytic DNA	ONCOGENE			English	Article							CD4 T-CELLS; C-JUN; EXPRESSION; INHIBITION; SURVIVAL; DNAZYME; GROWTH; GENE; CARCINOMA; MUTATION	Melanoma incidence is increasing worldwide, and although drugs such as BRAF/MEK small-molecule inhibitors and immune checkpoint antibodies improve patient outcomes, most patients ultimately fail these therapies and alternative treatment strategies are urgently needed. DNAzymes have recently undergone clinical trials with signs of efficacy and no serious adverse events attributable to the DNAzyme. Here we investigated c-Jun expression in human primary and metastatic melanoma. We also explored the role of T cell immunity in DNAzyme inhibition of primary melanoma growth and the prevention of growth in non-treated tumors after the cessation of treatment in a mouse model. c-Jun was expressed in 80% of melanoma cells in human primary melanomas (n = 17) and in 83% of metastatic melanoma cells (n = 38). In contrast, c-Jun was expressed in only 11% of melanocytes in benign nevi (n = 24). Dz13, a DNAzyme targeting c-Jun/AP-1, suppressed both Dz13-injected and untreated B16F10 melanoma growth in the same mice, an abscopal effect relieved in each case by administration of anti-CD4/anti-CD8 antibodies. Dz13 increased levels of cleaved caspase-3 within the tumors. New, untreated melanomas grew poorly in mice previously treated with Dz13. Administration of anti-CD4/anti-CD8 antibodies ablated this inhibitory effect and the tumors grew rapidly. Dz13 inhibited c-Jun expression, reduced intratumoral vascularity (vascular lumina area defined by CD31 staining), and increased CD4(+) cells within the tumors. This study provides the first demonstration of an abscopal effect of a DNAzyme on tumor growth and shows that Dz13 treatment prevents growth of subsequent new tumors in the same animal. Dz13 may be useful clinically as a therapeutic antitumor agent by preventing tumor relapse through adaptive immunity.	[Cai, Hong; Li, Yue; Khachigian, Levon M.] Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia; [Cai, Hong; Li, Yue; Khachigian, Levon M.] Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia; [Cho, Eun-Ae; Halliday, Gary M.] Univ Sydney, Dermatol Res Labs, Sydney, NSW 2006, Australia; [Cho, Eun-Ae; Halliday, Gary M.] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Sockler, Jim] Datapharm Australia, Stat Operat & Programming, Sydney, NSW 2047, Australia; [Parish, Christopher R.] Australian Natl Univ, John Curtin Sch Med Res, Canc & Vasc Biol Grp, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia; [Chong, Beng H.] Univ New South Wales, St George Clin Sch, Kogarah, NSW 2217, Australia; [Chong, Beng H.] St George Hosp, Dept Haematol, Kogarah, NSW 2217, Australia; [Edwards, Jarem; Dodds, Tristan J.; Ferguson, Peter M.; Wilmott, James S.; Scolyer, Richard A.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2050, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney; Australian National University; John Curtin School of Medical Research; University of New South Wales Sydney; St George Hospital; Melanoma Institute Australia; University of Sydney	Khachigian, LM (corresponding author), Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia.; Khachigian, LM (corresponding author), Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Scolyer, Richard/AAE-8511-2019; Wilmott, James/AGA-8227-2022; Chong, Beng/AAE-2617-2019; Chong, Beng/AAM-9010-2021; Khachigian, Levon/AAZ-7458-2020; Li, Yue/AAB-3024-2019	Scolyer, Richard/0000-0002-8991-0013; Wilmott, James/0000-0002-6750-5244; Ferguson, Peter M./0000-0002-8335-0406; Li, Yue/0000-0002-5304-9188; Parish, Christopher/0000-0001-7740-0430	Translational Program Grant from Cancer Institute of New South Wales; National Health and Medical Research Council of Australia	Translational Program Grant from Cancer Institute of New South Wales; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a Translational Program Grant from Cancer Institute of New South Wales, and Program and Fellowship support from National Health and Medical Research Council of Australia.	Apalla Zoe, 2017, Dermatol Pract Concept, V7, P1, DOI 10.5826/dpc.0702a01; BARTH A, 1995, J AM COLL SURGEONS, V181, pA193; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Bhindi R, 2007, AM J PATHOL, V171, P1079, DOI 10.2353/ajpath.2007.070120; Cai H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003960; Cao Y, 2014, MOL THER, V22, P371, DOI 10.1038/mt.2013.257; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Cho EA, 2013, LANCET, V381, P1835, DOI 10.1016/S0140-6736(12)62166-7; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Hoefer F, 2017, ANAL METHODS-UK, V9, P697, DOI 10.1039/c6ay03061k; Hooijkaas AI, 2012, ONCOIMMUNOLOGY, V1, P609, DOI 10.4161/onci.20226; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Johnson DB, 2015, JAMA ONCOL, V1, P380, DOI 10.1001/jamaoncol.2015.0565; Kahan-Hanum M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01535; Kakavand H, 2015, MODERN PATHOL, V28, P1535, DOI 10.1038/modpathol.2015.110; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Khachigian LM, 2000, J CLIN INVEST, V106, P1189, DOI 10.1172/JCI11620; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lardone RD, 2016, ONCOTARGET, V7, P14415, DOI 10.18632/oncotarget.7361; Li Y, 2013, INT J CARDIOL, V168, P3659, DOI 10.1016/j.ijcard.2013.05.092; Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21319; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Madore J, 2016, CLIN CANCER RES, V22, P3915, DOI 10.1158/1078-0432.CCR-15-1714; Mann GJ, 2013, J INVEST DERMATOL, V133, P509, DOI 10.1038/jid.2012.283; Melanoma-Institute-Australia, 2015, MEL FACTS STAT; Nedergaard BS, 2007, BRIT J CANCER, V97, P1135, DOI 10.1038/sj.bjc.6604001; Perales MA, 2004, ANN SURG ONCOL, V11, P881, DOI 10.1245/ASO.2004.08.911; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shklovskaya E, 2016, IMMUNOL CELL BIOL, V94, P593, DOI 10.1038/icb.2016.14; Tan ML, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-9; Xie JJ, 2014, BBA-MOL BASIS DIS, V1842, P2479, DOI 10.1016/j.bbadis.2014.04.017; Yan SF, 2016, ANTICANCER RES, V36, P6449, DOI 10.21873/anticanres.11243; Zanetti M, 2015, J IMMUNOL, V194, P2049, DOI 10.4049/jimmunol.1402669; Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726; Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120; Zhang ZP, 2017, MICROB PATHOGENESIS, V103, P155, DOI 10.1016/j.micpath.2016.12.024	42	9	10	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5115	5126		10.1038/s41388-018-0306-0	http://dx.doi.org/10.1038/s41388-018-0306-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29844573				2022-12-28	WOS:000444405300007
J	Zhu, B; Tang, LM; Chen, SY; Yin, CQ; Peng, SG; Li, X; Liu, TZ; Liu, W; Han, CP; Stawski, L; Xu, ZX; Zhou, GB; Chen, X; Gao, XM; Goding, CR; Xu, N; Cui, RT; Cao, P				Zhu, Bo; Tang, Liming; Chen, Shuyang; Yin, Chengqian; Peng, Shiguang; Li, Xin; Liu, Tongzheng; Liu, Wei; Han, Changpeng; Stawski, Lukasz; Xu, Zhi-Xiang; Zhou, Guangbiao; Chen, Xiang; Gao, Xiumei; Goding, Colin R.; Xu, Nan; Cui, Rutao; Cao, Peng			Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy	ONCOGENE			English	Article							OXIDATIVE STRESS; MESSENGER-RNA; EXPRESSION; PTEN; STABILIZATION; PEMBROLIZUMAB; MODULATION; MECHANISMS; IPILIMUMAB; NIVOLUMAB	Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (UVR) induction of PD-L1 in skin is directly controlled by nuclear factor E2-related transcription factor 2 (NRF2). Depletion of NRF2 significantly induces tumor infiltration by both CD8(+) and CD4(+) T cells to suppress melanoma progression, and combining NRF2 inhibition with anti-PD-1 treatment enhanced its anti-tumor function. Our studies identify a critical and targetable PD-L1 upstream regulator and provide an alternative strategy to inhibit the PD-1/PD-L1 signaling in melanoma treatment.	[Zhu, Bo; Chen, Shuyang; Yin, Chengqian; Peng, Shiguang; Li, Xin; Liu, Tongzheng; Liu, Wei; Han, Changpeng; Cui, Rutao] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Tang, Liming; Cao, Peng] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing 210028, Jiangsu, Peoples R China; [Tang, Liming] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou, Jiangsu, Peoples R China; [Peng, Shiguang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Dermatol, Beijing 100020, Peoples R China; [Liu, Wei; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China; [Stawski, Lukasz] Boston Univ, Sch Med, Arthrit Ctr, Sect Rheumatol, Boston, MA 02118 USA; [Xu, Zhi-Xiang] Univ Alabama Birmingham, Sch Med, Dept Med, Div Hematol & Oncol, Birmingham, AL 35233 USA; [Zhou, Guangbiao] Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, 1 Beichen West Rd, Beijing 100101, Peoples R China; [Chen, Xiang] Cent Suth Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Chen, Xiang] Cent Suth Univ, Xiangya Hosp, Dept Dermatol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Goding, Colin R.] Univ Oxford, Ludwig Inst Canc Res, Oxford OX3 7DQ, England; [Xu, Nan] Tongji Univ, Shanghai East Hosp, Dermatol Dept, Shanghai 200120, Peoples R China; [Cao, Peng] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Nanjing 211166, Jiangsu, Peoples R China	Boston University; Nanjing University of Chinese Medicine; Nanjing Medical University; Capital Medical University; Tianjin University of Traditional Chinese Medicine; Boston University; University of Alabama System; University of Alabama Birmingham; Chinese Academy of Sciences; Institute of Zoology, CAS; Central South University; Central South University; Ludwig Institute for Cancer Research; University of Oxford; Tongji University; Nanjing Medical University	Cui, RT (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.; Cao, P (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing 210028, Jiangsu, Peoples R China.; Xu, N (corresponding author), Tongji Univ, Shanghai East Hosp, Dermatol Dept, Shanghai 200120, Peoples R China.; Cao, P (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Nanjing 211166, Jiangsu, Peoples R China.	xnhrb@aliyun.com; rutaocui@bu.edu; pcao79@yahoo.com	Yin, Chengqian/AAK-2991-2020; Zhou, Guangbiao/J-6575-2017; Zhou, Guang-Biao/ABG-5795-2021; Liu, Wei/E-8826-2018	Zhou, Guangbiao/0000-0002-6327-2316; , Peng/0000-0002-2044-3074; Li, Xin/0000-0003-2525-9679; Zhou, Guang-Biao/0000-0001-6778-7133; Yin, Chengqian/0000-0003-4247-6245; Liu, Wei/0000-0003-1792-6048	National Institutes of Health [R01CA137098, R01CA193913, R01CA196896]; Melanoma Research Foundation Establish Investigator Award, Hong Kong; National Natural Science Foundation of China [81428025, 81630106, 31771619, 81673977]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Foundation Establish Investigator Award, Hong Kong; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant	We thank Drs. Wenshu Wu and Rui He for carefully reading and suggestions. This work was supported by the National Institutes of Health (RC: R01CA137098, R01CA193913 and R01CA196896), Melanoma Research Foundation Establish Investigator Award (RC), Hong Kong, Macao Young Scientists of the National Natural Science Foundation of China (Grant No. 81428025 for RC) and National Natural Science Foundation of China (81630106), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant (PC). National Natural Science Foundation of China (31771619) for HH. The National Natural Science Foundation of China (Grant No. 81673977 for 2016 for XM). RC is an American Cancer Society Research Scholar.	Beyer TA, 2007, CELL DEATH DIFFER, V14, P1250, DOI 10.1038/sj.cdd.4402133; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Chorley BN, 2012, NUCLEIC ACIDS RES, V40, P7416, DOI 10.1093/nar/gks409; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gogas H, 2015, AM J THER, V22, P54, DOI 10.1097/MJT.0b013e31829e883d; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Heckman CJ, 2013, JOVE-J VIS EXP, V75, P50175, DOI DOI 10.3791/5017523748556; Hintsala HR, 2016, ANTICANCER RES, V36, P1497; Hybertson BM, 2014, CLIN GENET, V86, P447, DOI 10.1111/cge.12474; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim JH, 2016, J ALLERGY CLIN IMMUN, V137, P1466, DOI 10.1016/j.jaci.2015.11.021; Kondo A, 2010, BLOOD, V116, P1124, DOI 10.1182/blood-2009-12-255125; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003; Menter A, 2010, J AM ACAD DERMATOL, V62, P114, DOI 10.1016/j.jaad.2009.08.026; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nishimura H, 1996, INT IMMUNOL, V8, P773, DOI 10.1093/intimm/8.5.773; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Romero Diana, 2016, Nat Rev Clin Oncol, V13, P266, DOI 10.1038/nrclinonc.2016.52; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Sidaway Peter, 2016, Nat Rev Clin Oncol, V13, P652, DOI [10.1038/nrclinonc.2016.158, 10.1038/nrclinonc.2016.156]; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Umansky V, 2014, J DTSCH DERMATOL GES, V12, P1021, DOI 10.1111/ddg.12411; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Westmark CJ, 2005, ONCOGENE, V24, P502, DOI 10.1038/sj.onc.1208224; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhu B, 2016, ONCOGENE, V35, P4212, DOI 10.1038/onc.2015.486	48	45	47	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4941	4954		10.1038/s41388-018-0314-0	http://dx.doi.org/10.1038/s41388-018-0314-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29786078	Green Submitted			2022-12-28	WOS:000443823600003
J	Coant, N; Garcia-Barros, M; Zhang, QF; Obeid, LM; Hannun, YA				Coant, Nicolas; Garcia-Barros, Monica; Zhang, Qifeng; Obeid, Lina M.; Hannun, Yusuf A.			AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells	ONCOGENE			English	Article							ADJUVANT TREATMENT; PATHWAY; SPHINGOLIPIDS; MECHANISM; LINES; GENE; FLUOROURACIL; SPHINGOSINE; OXALIPLATIN; LEUCOVORIN	Despite advances in the field, colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Research into bioactive sphingolipids over the past two decades has played an important role in increasing our understanding of the pathogenesis and therapeutics of CRC. In the complex metabolic network of sphingolipids, ceramidases (CDases) have a key function. These enzymes hydrolyze ceramides into sphingosine (SPH) which in turn is phosphorylated by sphingosine kinases (SK) 1 and 2 to generate sphingosine-1 phosphate (S1P). Importantly, we have recently shown that inhibition of neutral CDase (nCDase) induces an increase of ceramide in colon cancer cells which decreases cellular growth, increases apoptosis and modulates the WNT/beta-catenin pathway. We have also shown that the deletion of nCDase protected mice from the onset and progression of colorectal cancer in the AOM carcinogen model. Here, we demonstrate that AKT is a key target for the growth suppressing functions of ceramide. The results show that inhibition of nCDase activates GSK3 beta through dephosphorylation, and thus is required for the subsequent phosphorylation and degradation of beta-catenin. Our findings show that inhibition of nCDase also inhibits the basal activation status of AKT, and we further establish that a constitutively active AKT (AKT T308D, S473D; AKT(DD)) reverses the effect of nCDase on beta-catenin degradation. Functionally, the AKT(DD) mutant is able to overcome the growth suppressive effects of nCDase inhibition in CRC cells. Moreover, nCDase inhibition induces a growth delay of xenograft tumors from control cells, whereas xenograft tumors from constitutively active AKT cells become resistant to nCDase inhibition. Taken together, these results provide important mechanistic insight into how nCDase regulates cell proliferation. These findings demonstrate a heretofore unappreciated, but critical, role for nCDase in enabling/maintaining basal activation of AKT and also suggest that nCDase is a suitable novel target for colon cancer therapy.	[Coant, Nicolas; Garcia-Barros, Monica; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Zhang, Qifeng] Babraham Inst, Signalling Programme, Babraham Res Campus, Cambridge, England; [Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Obeid, Lina M.] Northport VA Med Ctr, Northport, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hannun, YA (corresponding author), SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.	Yusuf.Hannun@stonybrookmedicine.edu		COANT, Nicolas/0000-0001-9237-2132	NCI [CA172517, CA97132]; Research Histology Core Laboratory, Department of Pathology, Stony Brook University; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA172517] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000156] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Research Histology Core Laboratory, Department of Pathology, Stony Brook University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by NCI grants CA172517 and CA97132. We acknowledge the support from the "Research Histology Core Laboratory, Department of Pathology, Stony Brook University". We would like to thank Ayanna Lewis, MD for proof reading the manuscript.	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Airola MV, 2015, STRUCTURE, V23, P1482, DOI 10.1016/j.str.2015.06.013; Anderson Karen E., 2016, Advances in Biological Regulation, V62, P18, DOI 10.1016/j.jbior.2015.11.002; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Carrato Alfredo, 2008, Gastrointest Cancer Res, V2, pS42; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gandy KAO, 2013, BIOCHEM J, V449, P661, DOI 10.1042/BJ20120213; Garcia-Barros M, 2016, FASEB J, V30, P4159, DOI 10.1096/fj.201600611R; Garcia-Barros M, 2014, BBA-MOL CELL BIOL L, V1841, P773, DOI 10.1016/j.bbalip.2013.09.007; Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312; Halder K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091656; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Holland WL, 2011, J CLIN INVEST, V121, P1858, DOI 10.1172/JCI43378; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang BH, 2008, CURR CANCER DRUG TAR, V8, P19, DOI 10.2174/156800908783497122; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; KIM JH, 1986, CANCER RES, V46, P1120; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Krycer JR, 2010, TRENDS ENDOCRIN MET, V21, P268, DOI 10.1016/j.tem.2010.01.001; Kumar A, 2012, CARCINOGENESIS, V33, P1726, DOI 10.1093/carcin/bgs174; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Nelson VM, 2013, J GASTROINTEST ONCOL, V4, P245, DOI 10.3978/j.issn.2078-6891.2013.035; Nikolova-Karakashian MN, 2010, ADV EXP MED BIOL, V688, P86; Oaks J, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00388; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Rahman A, 2016, FREE RADICAL BIO MED, V96, P273, DOI 10.1016/j.freeradbiomed.2016.05.001; Sasaki AT, 2006, EUR J CELL BIOL, V85, P873, DOI 10.1016/j.ejcb.2006.04.007; Snider AJ, 2012, PROSTAG OTH LIPID M, V99, P124, DOI 10.1016/j.prostaglandins.2012.08.003; Stewart B, 2014, WORLD CANC REPORT 20, P619; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Symolon H, 2011, MOL CANCER THER, V10, P648, DOI 10.1158/1535-7163.MCT-10-0754; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Verdaguer H, 2016, THER ADV MED ONCOL, V8, P230, DOI 10.1177/1758834016635888; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wu BX, 2009, BBA-MOL CELL BIOL L, V1791, P730, DOI 10.1016/j.bbalip.2009.03.012; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	51	15	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3852	3863		10.1038/s41388-018-0236-x	http://dx.doi.org/10.1038/s41388-018-0236-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662189	Green Accepted			2022-12-28	WOS:000438465600007
J	Jiang, YQ; Xu, ES; Zhang, J; Chen, MY; Flores, E; Chen, XB				Jiang, Yuqian; Xu, Enshun; Zhang, Jin; Chen, Mingyi; Flores, Elsa; Chen, Xinbin			The Rbm38-p63 feedback loop is critical for tumor suppression and longevity	ONCOGENE			English	Article							RNA-BINDING PROTEIN; P53 FAMILY; CELLULAR SENESCENCE; TARGET GENES; P63; CELLS; STABILITY; RNPC1; TAP63; MICE	The RNA-binding protein Rbm38 is a target of p63 tumor suppressor and can in-turn repress p63 expression via mRNA stability. Thus, Rbm38 and p63 form a negative feedback loop. To investigate the biological significance of the Rbm38-p63 loop in vivo, a cohort of WT, Rbm38(-/-), TAp63(+/-), and Rbm38(-/-); TAp63(+/-) mice were generated and monitored throughout their lifespan. While mice deficient in Rbm38 or TAp63 alone died mostly from spontaneous tumors, compound Rbm38(-/-); TAp63(+/-) mice had an extended lifespan along with reduced tumor incidence. We also found that loss-of-Rbm38 markedly decreased the percentage of liver steatosis in TAp63(+/)- mice. Moreover, we found that Rbm38 deficiency extends the lifespan of tumor-free TAp63(+/-) mice along with reduced expression of senescence-associated biomarkers. Consistent with this, Rbm38(-/-); TAp63(+/-) MEFs were resistant, whereas Rbm38(-/-) or TAp63(+/-) MEFs were prone, to cellular senescence. Importantly, we showed that the levels of inflammatory cytokines (IL17D and Tnfsf15) were significantly reduced by Rbm38 deficiency in senescence-resistant Rbm38(-/-); TAp63(+/-) mouse livers and MEFs. Together, our data suggest that Rbm38 and p63 function as intergenic suppressors in aging and tumorigenesis and that the Rbm38-p63 loop may be explored for enhancing longevity and cancer management.	[Jiang, Yuqian; Xu, Enshun; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA; [Chen, Mingyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Flores, Elsa] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA	University of California System; University of California Davis; University of Texas System; University of Texas Southwestern Medical Center Dallas; H Lee Moffitt Cancer Center & Research Institute	Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu	jiang, yu/HGU-0029-2022	chen, xinbin/0000-0002-4582-6506	National Institutes of Health [CA195828]; NATIONAL CANCER INSTITUTE [R01CA195828] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by the National Institutes of Health (CA195828 to X.C.).	Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen XB, 2003, CANCER BIOL THER, V2, P55; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003; Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hwang SY, 2004, ARTHRITIS RES THER, V6, pR120, DOI 10.1186/ar1038; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Meylan F, 2011, IMMUNOL REV, V244, P188, DOI 10.1111/j.1600-065X.2011.01068.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x; Porteiro B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15111; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Scoumanne A, 2011, NUCLEIC ACIDS RES, V39, P213, DOI 10.1093/nar/gkq778; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang J, 2006, CELL DEATH DIFFER, V13, P2118, DOI 10.1038/sj.cdd.4401972; Zhang J, 2014, P NATL ACAD SCI USA, V111, P18637, DOI 10.1073/pnas.1415607112; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107	35	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2863	2872		10.1038/s41388-018-0176-5	http://dx.doi.org/10.1038/s41388-018-0176-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520104	Green Accepted, Green Submitted			2022-12-28	WOS:000432929800008
J	Li, X; Ma, HG; Li, L; Chen, YF; Sun, X; Dong, ZZ; Liu, JY; Zhu, WM; Zhang, JT				Li, Xia; Ma, Hongguang; Li, Lin; Chen, Yifan; Sun, Xiao; Dong, Zizheng; Liu, Jing-Yuan; Zhu, Weiming; Zhang, Jian-Ting			Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth	ONCOGENE			English	Article							EPITHELIAL-CELLS; CANCER; PHOSPHORYLATION; PATHOGENESIS; EXPRESSION; PATHWAY	Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and plays important roles in multiple aspects of cancer aggressiveness. Thus, targeting STAT3 promises to be an attractive strategy for the treatment of advanced metastatic tumors. Bisindolylmaleimide alkaloid (BMA) has been shown to have anticancer activities and was thought to suppress tumor cell growth by inhibiting protein kinase C. In this study, we show that a newly synthesized BMA analog, BMA097, is effective in suppressing tumor cell and xenograft growth and in inducing spontaneous apoptosis. We also provide evidence that BMA097 binds directly to the SH2 domain of STAT3 and inhibits STAT3 phosphorylation and activation, leading to reduced expression of STAT3 downstream target genes. Structure activity relationship analysis revealed that the hydroxymethyl group in the 2,5-dihydropyrrole-2,5-dione prohibits STAT3 inhibitory activity of BMA analogs. Altogether, we conclude that the synthetic BMA analogs may be developed as anti-cancer drugs by targeting and binding to the SH2 domain of STAT3 and inhibiting the STAT3 signaling pathway.	[Li, Xia; Chen, Yifan; Dong, Zizheng; Liu, Jing-Yuan; Zhang, Jian-Ting] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Li, Xia; Li, Lin; Sun, Xiao] Shandong Univ, Sch Ocean, Weihai, Peoples R China; [Ma, Hongguang; Zhu, Weiming] Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ China, Qingdao, Peoples R China; [Liu, Jing-Yuan] Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA; [Zhang, Jian-Ting] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Shandong University; Ministry of Education, China; Ocean University of China; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Li, X; Liu, JY; Zhang, JT (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.; Zhu, WM (corresponding author), Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ China, Qingdao, Peoples R China.; Liu, JY (corresponding author), Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA.; Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA.	xiali@sdu.edu.cn; jliu2@iu.edu; weimingzhu@ouc.edu.cn; jianzhan@iu.edu	li, xia/HHZ-7468-2022	Zhang, Jian-Ting/0000-0002-2803-9914	Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT_17R68]; National Natural Science Foundation of China [81273532, U1501221]; National Institute of Health [R01 CA211904]; NATIONAL CANCER INSTITUTE [R01CA211904] Funding Source: NIH RePORTER	Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank IU Big Red supercomputers for the CPU time. This work was supported in part by grants from the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT, No IRT_17R68), the National Natural Science Foundation of China (Nos. 81273532 & U1501221) and by National Institute of Health Grant R01 CA211904.	Bhatnagar I, 2010, MAR DRUGS, V8, P2673, DOI 10.3390/md8102673; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Q, 2006, J BIOL CHEM, V281, P31152, DOI 10.1074/jbc.M603529200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Huang W, 2014, ACS CHEM BIOL, V9, P1188, DOI 10.1021/cb500071v; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Liu JY, 2011, J CHEM INF MODEL, V51, P2612, DOI 10.1021/ci200212y; Liu SS, 2013, ACTA PHARMACOL SIN, V34, P271, DOI 10.1038/aps.2012.137; Ma HG, 2016, CHINESE J ORG CHEM, V36, P1839, DOI 10.6023/cjoc201602035; Mantel C, 2012, BLOOD, V120, P2589, DOI 10.1182/blood-2012-01-404004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Mukohara T, 2003, LUNG CANCER, V41, P123, DOI 10.1016/S0169-5002(03)00225-3; Pajak B, 2008, ADV MED SCI-POLAND, V53, P21, DOI 10.2478/v10039-008-0028-6; Pereira ER, 1996, J MED CHEM, V39, P4471; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pfeiffer M, 2009, BRIT J CANCER, V100, P1949, DOI 10.1038/sj.bjc.6605068; Qian L, 2006, BIOCHEM BIOPH RES CO, V345, P660, DOI 10.1016/j.bbrc.2006.04.153; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	28	17	18	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2469	2480		10.1038/s41388-017-0076-0	http://dx.doi.org/10.1038/s41388-017-0076-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29456240	Green Submitted, Green Accepted			2022-12-28	WOS:000431386000010
J	Meder, L; Konig, K; Dietlein, F; Macheleidt, I; Florin, A; Ercanoglu, MS; Rommerscheidt-Fuss, U; Koker, M; Schon, G; Odenthal, M; Klein, F; Buttner, R; Schulte, JH; Heukamp, LC; Ullrich, RT				Meder, Lydia; Koenig, Katharina; Dietlein, Felix; Macheleidt, Iris; Florin, Alexandra; Ercanoglu, Meryem S.; Rommerscheidt-Fuss, Ursula; Koker, Mirjam; Schoen, Gisela; Odenthal, Margarete; Klein, Florian; Buettner, Reinhard; Schulte, Johannes H.; Heukamp, Lukas C.; Ullrich, Roland T.			LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER PATIENTS; K-RAS; MULTIPLE MECHANISMS; CELL-PROLIFERATION; PANCREATIC-CANCER; DOWN-REGULATION; KRAS MUTATIONS; BREAST-CANCER; SELF-RENEWAL	LIN28B is a RNA-binding protein regulating predominantly let-7 microRNAs with essential functions in inflammation, wound healing, embryonic stem cells, and cancer. LIN28B expression is associated with tumor initiation, progression, resistance, and poor outcome in several solid cancers, including lung cancer. However, the functional role of LIN28B, especially in non-small cell lung adenocarcinomas, remains elusive. Here, we investigated the effects of LIN28B expression on lung tumorigenesis using LIN28B transgenic overexpression in an autochthonous KRAS(G12V)-driven mouse model. We found that LIN28B overexpression significantly increased the number of CD44+/CD326+ tumor cells, upregulated VEGF-A and miR-21 and promoted tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) accompanied by enhanced AKT phosphorylation and nuclear translocation of c-MYC. Moreover, LIN28B accelerated tumor initiation and enhanced proliferation which led to a shortened overall survival. In addition, we analyzed lung adenocarcinomas of the Cancer Genome Atlas (TCGA) and found LIN28B expression in 24% of KRAS-mutated cases, which underscore the relevance of our model.	[Meder, Lydia; Koker, Mirjam; Schoen, Gisela; Ullrich, Roland T.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Meder, Lydia; Koker, Mirjam; Schoen, Gisela; Odenthal, Margarete; Buettner, Reinhard; Ullrich, Roland T.] Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany; [Koenig, Katharina] Lab Dr Quade & Kollegen GmbH, Aachener Str 338, D-50933 Cologne, Germany; [Dietlein, Felix] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Dietlein, Felix] Broad Inst MIT & Havard, Canc Program, Cambridge, MA 02142 USA; [Macheleidt, Iris; Florin, Alexandra; Rommerscheidt-Fuss, Ursula; Odenthal, Margarete; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Ercanoglu, Meryem S.; Klein, Florian] Univ Cologne, Lab Expt Immunol, Inst Virol, Robert Koch Str 21, D-50931 Cologne, Germany; [Buettner, Reinhard] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany; [Schulte, Johannes H.] Charite Univ Med Berlin, Dept Pediat Oncol Hematol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Schulte, Johannes H.] German Canc Consortium DKTK Berlin, Berlin, Germany; [Schulte, Johannes H.] BIH, Berlin, Germany; [Schulte, Johannes H.] Deutsch Krebsforschungszentrum Heidelberg DKFZ, Heidelberg, Germany; [Heukamp, Lukas C.] New Oncol, Gottfried Hagen Str 20, D-51105 Cologne, Germany; [Heukamp, Lukas C.] Inst Hematopathol Hamburg, Fangdieckstr 75a, Hamburg, Germany	University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Cologne; University of Cologne; University of Cologne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Helmholtz Association; German Cancer Research Center (DKFZ)	Meder, L (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.; Meder, L (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany.	lydia.meder@uk-koeln.de	Schulte, Johannes H./V-2474-2018; Heukamp, Lukas/G-9967-2012	Meder, Lydia/0000-0002-9547-5812; Heukamp, Lukas/0000-0002-3388-3482; Schulte, Johannes Hubertus/0000-0003-0671-1201	Deutsche Forschungsgemeinschaft (DFG) [UL379/1-1]; German Research Foundation [SFB832]; Thyssen foundation [10.16.1.028MN]; Nachwuchsforschungsgruppen-NRW [1411ng005]; German ministry of science and education (BMBF) as part of the e:Med initiative [01ZX11307E, 017X1303B]; Center for Molecular Medicine Cologne (CMMC)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Research Foundation(German Research Foundation (DFG)); Thyssen foundation; Nachwuchsforschungsgruppen-NRW; German ministry of science and education (BMBF) as part of the e:Med initiative; Center for Molecular Medicine Cologne (CMMC)	This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (Grant No.: UL379/1-1 to RTU), by the German Research Foundation (SFB832, Z2 and TP6 to RTU; Z1 and TP5 to LCH and RB), by the Thyssen foundation (Grant No.: 10.16.1.028MN to RTU), by the Nachwuchsforschungsgruppen-NRW (Grant No.: 1411ng005 to RTU), by the German ministry of science and education (BMBF) as part of the e:Med initiative (Grant No.: 01ZX11307E and 017X1303B to JHS) and by the Center for Molecular Medicine Cologne (CMMC) (to RB and MO).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alam M, 2015, MOL CANCER RES, V13, P449, DOI 10.1158/1541-7786.MCR-14-0363; Balzeau J, 2017, FRONT GENET, V8, P1, DOI 10.3389/fgene.2017.00031; Bauml J, 2013, CLIN LUNG CANCER, V14, P581, DOI 10.1016/j.cllc.2013.05.002; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cao J, 2016, MOL MED REP, V13, P75, DOI 10.3892/mmr.2015.4568; Chien CS, 2015, CANCER RES, V75, P2553, DOI 10.1158/0008-5472.CAN-14-2215; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cufii S, 2013, SCI REP-UK, V3, P1, DOI 10.1038/srep02459; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Fennell DA, 2016, CANCER TREAT REV, V44, P42, DOI 10.1016/j.ctrv.2016.01.003; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hu HB, 2016, LUNG CANCER, V97, P87, DOI 10.1016/j.lungcan.2016.04.017; Hu Q, 2014, INT J CLIN EXP PATHO, V7, P5083; Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Konig K, 2015, J THORAC ONCOL, V10, P1049, DOI 10.1097/JTO.0000000000000570; Konig K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057996; Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033; Landskroner-Eiger S, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006643; Lee YS, 2016, ONCOGENE, V35, P827, DOI 10.1038/onc.2015.153; Li C, 2016, ONCOTARGET, V7, P66989, DOI 10.18632/oncotarget.11888; Li CG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107276; Li Y, 2014, CANCER LETT, V355, P130, DOI 10.1016/j.canlet.2014.09.007; Liu CH, 2017, INT J ONCOL, V50, P1109, DOI 10.3892/ijo.2017.3876; Manier S, 2017, LEUKEMIA, V31, P853, DOI 10.1038/leu.2016.296; Mellema WW, 2013, J THORAC ONCOL, V8, P1190, DOI 10.1097/JTO.0b013e318298764e; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Morizane R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04578; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495; Powers JT, 2016, NATURE, V535, P246, DOI 10.1038/nature18632; Qiu JL, 2012, CHIN J CANCER, V31, P223, DOI 10.5732/cjc.011.10426; Qu X, 2014, J INVEST DERMATOL, V134, P159, DOI 10.1038/jid.2013.281; Ragusa M, 2014, AM J CLIN ONCOL-CANC, V37, P343, DOI 10.1097/COC.0b013e31827a7e7a; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sato H, 2017, SCI REP-UK, V7, DOI 10.1038/srep40847; Shao YB, 2015, AM J CANCER RES, V5, P2643; Sonobe M, 2012, ANN SURG ONCOL, V19, pS347, DOI 10.1245/s10434-011-1799-8; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang TZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0402-5; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Wefers AK, 2017, CEREBELLUM, V16, P122, DOI 10.1007/s12311-016-0774-0; Wilbert ML, 2012, MOL CELL, V48, P195, DOI 10.1016/j.molcel.2012.08.004; Wu TF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083869; Wu ZH, 2016, TUMOR BIOL, V37, P7245, DOI 10.1007/s13277-015-4604-7; Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7; Zhang J, 2016, CELL STEM CELL, V19, P66, DOI 10.1016/j.stem.2016.05.009; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhang Z, 2017, CANCER GENE THER, V24, P83, DOI 10.1038/cgt.2017.1; Zhou JB, 2017, MOL CANCER RES, V15, P294, DOI 10.1158/1541-7786.MCR-16-0275-T; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	60	14	14	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2746	2756		10.1038/s41388-018-0158-7	http://dx.doi.org/10.1038/s41388-018-0158-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29503447				2022-12-28	WOS:000432545100010
J	Logue, JS; Cartagena-Rivera, AX; Chadwick, RS				Logue, Jeremy S.; Cartagena-Rivera, Alexander X.; Chadwick, Richard S.			c-Src activity is differentially required by cancer cell motility modes	ONCOGENE			English	Article							FOCAL ADHESION KINASE; PHASE-II TRIAL; SARACATINIB AZD0530; INHIBITOR SARACATINIB; BREAST-CANCER; MIGRATION; FAK; PROTEOLYSIS; BMS-354825; DASATINIB	Cancer cell migration requires that cells respond and adapt to their surroundings. In the absence of extracellular matrix cues, cancer cells will undergo a mesenchymal to ameboid transition, whereas a highly confining space will trigger a switch to "leader bleb-based" migration. To identify oncogenic signaling pathways mediating these transitions, we undertook a targeted screen using clinically useful inhibitors. Elevated Src activity was found to change actin and focal adhesion dynamics, whereas inhibiting Src triggered focal adhesion disassembly and blebbing. On non-adherent substrates and in collagen matrices, amoeboid-like, blebbing cells having high Src activity formed protrusions of the plasma membrane. To evaluate the role of Src in confined cells, we use a novel approach that places cells under a slab of polydimethylsiloxane (PDMS), which is held at a defined height. Using this method, we find that leader bleb-based migration is resistant to Src inhibition. High Src activity was found to markedly change the architecture of cortical actomyosin, reduce cell mechanical properties, and the percentage of cells that undergo leader bleb-based migration. Thus, Src is a signal transducer that can potently influence transitions between migration modes with implications for the rational development of metastasis inhibitors.	[Logue, Jeremy S.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Logue, Jeremy S.; Cartagena-Rivera, Alexander X.; Chadwick, Richard S.] NIDCD, NIH, Bethesda, MD 20892 USA; [Logue, Jeremy S.] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Albany Medical College	Logue, JS (corresponding author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.; Logue, JS (corresponding author), NIDCD, NIH, Bethesda, MD 20892 USA.; Logue, JS (corresponding author), Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA.	loguej@mail.amc.edu	Cartagena-Rivera, Alexander X./I-6101-2016	Cartagena-Rivera, Alexander X./0000-0001-6227-2499	intramural research program at the NIH; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000033] Funding Source: NIH RePORTER	intramural research program at the NIH; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Clare Waterman (NHLBI) and members of the Waterman Lab for insightful discussions and for the use of spinning disk confocal microscopes. We thank the NHLBI Light Microscopy Core Facility for use of the Zeiss LSM 880 Airyscan. This work was supported by funds from the intramural research program at the NIH.	Artym Vira V, 2010, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1018s48; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Bergert M, 2015, NAT CELL BIOL, V17, P524, DOI 10.1038/ncb3134; Cartagena-Rivera AX, 2016, BIOPHYS J, V110, P2528, DOI 10.1016/j.bpj.2016.04.034; Case LB, 2015, NAT CELL BIOL, V17, P955, DOI 10.1038/ncb3191; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Charras GT, 2005, NATURE, V435, P365, DOI 10.1038/nature03550; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Ferrando IM, 2012, MOL CELL PROTEOMICS, V11, P355, DOI 10.1074/mcp.M111.015750; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Fury MG, 2011, ANTICANCER RES, V31, P249; Gangadhar TC, 2013, INVEST NEW DRUG, V31, P769, DOI 10.1007/s10637-012-9897-4; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Horton ER, 2016, J CELL BIOL, V212, P349, DOI 10.1083/jcb.201508080; ILLC D, 1995, NATURE, V377, P539; Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Logue JS, 2015, ELIFE, V4, DOI 10.7554/eLife.08314; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Mackay HJ, 2012, INVEST NEW DRUG, V30, P1158, DOI 10.1007/s10637-011-9650-4; Mayer EL, 2011, CLIN CANCER RES, V17, P6897, DOI 10.1158/1078-0432.CCR-11-0070; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Molina JR, 2014, LUNG CANCER, V85, P245, DOI 10.1016/j.lungcan.2014.03.004; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Plotnikov SV, 2012, CELL, V151, P1513, DOI 10.1016/j.cell.2012.11.034; Ruprecht V, 2015, CELL, V160, P673, DOI 10.1016/j.cell.2015.01.008; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schilder RJ, 2012, GYNECOL ONCOL, V127, P70, DOI 10.1016/j.ygyno.2012.06.009; Schmid B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-274; Sharma MR, 2012, INVEST NEW DRUG, V30, P1211, DOI 10.1007/s10637-011-9681-x; Shin W., 2010, LIVE CELL IMAGING LA, P119; Tozluoglu M, 2013, NAT CELL BIOL, V15, P751, DOI 10.1038/ncb2775; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wong SY, 2006, CELL CYCLE, V5, P812, DOI 10.4161/cc.5.8.2646; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	45	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2104	2121		10.1038/s41388-017-0071-5	http://dx.doi.org/10.1038/s41388-017-0071-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379163	hybrid, Green Published			2022-12-28	WOS:000430589000003
J	Warren, AY; Massie, CE; Watt, K; Luko, K; Orafidiya, F; Selth, LA; Mohammed, H; Chohan, BS; Menon, S; Baridi, A; Zhao, WF; Escriu, C; Pungsrinont, T; D'Santos, C; Yang, XP; Taylor, C; Qureshi, A; Zecchini, VR; Shaw, GL; Dehm, SM; Mills, IG; Carroll, JS; Tilley, WD; McEwan, IJ; Baniahmad, A; Neal, DE; Asim, M				Warren, Anne Y.; Massie, Charlie E.; Watt, Kate; Luko, Katarina; Orafidiya, Folake; Selth, Luke A.; Mohammed, Hisham; Chohan, Brinder S.; Menon, Suraj; Baridi, Ajoeb; Zhao, Wanfeng; Escriu, Carles; Pungsrinont, Thanakorn; D'Santos, Clive; Yang, Xiaoping; Taylor, Chris; Qureshi, Arham; Zecchini, Vincent R.; Shaw, Greg L.; Dehm, Scott M.; Mills, Ian G.; Carroll, Jason S.; Tilley, Wayne D.; McEwan, Iain J.; Baniahmad, Aria; Neal, David E.; Asim, Mohammad			A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer	ONCOGENE			English	Article							ORIGINATED PROTEIN-KINASE; MITOTIC KINASE; EXPRESSION; PBK/TOPK; GENE; RESISTANCE; DOMAIN; TOPK; ANTIANDROGEN; ABIRATERONE	Elucidation of mechanisms underlying the increased androgen receptor (AR) activity and subsequent development of aggressive prostate cancer (PrCa) is pivotal in developing new therapies. Using a systems biology approach, we interrogated the AR-regulated proteome and identified PDZ binding kinase (PBK) as a novel AR-regulated protein that regulates full-length AR and AR variants (ARVs) activity in PrCa. PBK overexpression in aggressive PrCa is associated with early biochemical relapse and poor clinical outcome. In addition to its carboxy terminus ligand-binding domain, PBK directly interacts with the amino terminus transactivation domain of the AR to stabilise it thereby leading to increased AR protein expression observed in PrCa. Transcriptome sequencing revealed that PBK is a mediator of global AR signalling with key roles in regulating tumour invasion and metastasis. PBK inhibition decreased growth of PrCa cell lines and clinical specimen cultured ex vivo. We uncovered a novel interplay between AR and PBK that results in increased AR and ARVs expression that executes AR-mediated growth and progression of PrCa, with implications for the development of PBK inhibitors for the treatment of aggressive PrCa.	[Warren, Anne Y.; Chohan, Brinder S.; Zhao, Wanfeng] Addenbrookes Cambridge Univ Hosp, Dept Pathol, Cambridge, England; [Massie, Charlie E.] Univ Cambridge, Canc Res UK Cambridge Ctr, Dept Oncol, Early Detect Programme, Cambridge, England; [Watt, Kate; Orafidiya, Folake; McEwan, Iain J.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland; [Luko, Katarina; Pungsrinont, Thanakorn; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, Jena, Germany; [Selth, Luke A.; Tilley, Wayne D.] Univ Adelaide, Fac Hlth Sci, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Selth, Luke A.; Tilley, Wayne D.] Univ Adelaide, Fac Hlth Sci, Sch Med, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA, Australia; [Mohammed, Hisham] OHSU, Knight Canc Inst, Canc Early Detect Adv Res Ctr, Portland, OR USA; [Menon, Suraj; Baridi, Ajoeb; Escriu, Carles; D'Santos, Clive; Yang, Xiaoping; Taylor, Chris; Qureshi, Arham; Zecchini, Vincent R.; Shaw, Greg L.; Carroll, Jason S.; Neal, David E.; Asim, Mohammad] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Dehm, Scott M.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Mills, Ian G.] Queens Univ, CCRCB, Prostate Canc UK Movember Ctr Excellence, Belfast, Antrim, North Ireland; [Mills, Ian G.; Neal, David E.; Asim, Mohammad] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Asim, Mohammad] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, Surrey, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Aberdeen; Friedrich Schiller University of Jena; University of Adelaide; University of Adelaide; Oregon Health & Science University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Minnesota System; University of Minnesota Twin Cities; Queens University Belfast; University of Oxford; University of Surrey	Asim, M (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.; Asim, M (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Asim, M (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, Surrey, England.	m.asim@surrey.ac.uk	Selth, Luke/AAH-4823-2021; Mills, Ian/AAK-9292-2020	Selth, Luke/0000-0002-4686-1418; Mills, Ian/0000-0001-5347-5083; Carroll, Jason/0000-0003-3643-0080; Massie, Charlie/0000-0003-2314-4843; Shaw, Greg/0000-0003-3480-2100; Escriu, Carles/0000-0003-3638-3202; Pungsrinont, Thanakorn/0000-0002-9974-1903; Tilley, Wayne/0000-0003-1893-2626	National Institute for Health Research; Hutchison Whampoa Limited; Human Research Tissue bank (Addenbrooke's Hospital Cambridge); Cancer Research UK; NATIONAL CANCER INSTITUTE [R01CA174777] Funding Source: NIH RePORTER	National Institute for Health Research(National Institute for Health Research (NIHR)); Hutchison Whampoa Limited; Human Research Tissue bank (Addenbrooke's Hospital Cambridge); Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Uro-Oncology Laboratories of Professor David Neal and Dr. Mohammad Asim for helpful discussions. We also thank research staff of CI core facilities for providing technical support. We thank Drs Curtis Pettaway for LNCaP-LN3 and Zoran Culig for LNCaP-Bic cells. We acknowledge the support of National Institute for Health Research, Hutchison Whampoa Limited, the Human Research Tissue bank (Addenbrooke's Hospital Cambridge) and Cancer Research UK. We thank men with PrCa who donated their time and samples to the Cambridge Biorepository, which were used in this research. We also acknowledge the support of the research staff in S4 for carefully curating all samples and provided the follow-up data (Jo Burge, Marie Corcoran, Anne George and Sara Stern).	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Asim M, 2008, ONCOGENE, V27, P3596, DOI 10.1038/sj.onc.1211016; Asim M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00393-y; Asim M, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1140262; Asim M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv371; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Augello MA, 2013, J CLIN INVEST, V123, P493, DOI 10.1172/JCI64750; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brand LJ, 2015, ONCOTARGET, V6, P3811, DOI 10.18632/oncotarget.2924; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay CW, 2014, HORM CANCER-US, V5, P299, DOI 10.1007/s12672-014-0185-y; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hu F, 2013, LEUKEMIA RES, V37, P447, DOI 10.1016/j.leukres.2012.11.010; Khan N, 2008, CANCER RES, V68, P8555, DOI 10.1158/0008-5472.CAN-08-0240; Kim DJ, 2012, CANCER RES, V72, P3060, DOI 10.1158/0008-5472.CAN-11-3851; Luo Q, 2014, INT J CLIN EXP PATHO, V7, P8059; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Scher HI, 2004, ENDOCR-RELAT CANCER, V11, P459, DOI 10.1677/erc.1.00525; Shaw GL, 2016, EUR UROL, V70, P214, DOI 10.1016/j.eururo.2015.10.042; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Singh PK, 2014, IMMUNOBIOLOGY, V219, P469, DOI 10.1016/j.imbio.2014.02.003; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001	52	13	13	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1136	1150		10.1038/s41388-018-0501-z	http://dx.doi.org/10.1038/s41388-018-0501-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30237440	Green Published, hybrid			2022-12-28	WOS:000458624900015
J	Xu, YF; Liu, ZL; Pan, C; Yang, XQ; Ning, SL; Liu, HD; Guo, S; Yu, JM; Zhang, ZL				Xu, Yun-Fei; Liu, Zeng-Li; Pan, Chang; Yang, Xiao-Qing; Ning, Shang-Lei; Liu, Hong-Da; Guo, Sen; Yu, Jin-Ming; Zhang, Zong-Li			HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium	ONCOGENE			English	Article							EXPRESSION; CONTRIBUTES; PROGRESSION; INJURY	Perihilar cholangiocarcinoma (PHCCA) is the most common type of cholangiocarcinoma with low resection rate and high morbidity. The study of PHCCA biomarkers made progresses slowly compared with intrahepatic cholangiocarcinoma because of surgical complexity and low possibility of radical surgery, which resulted in the difficulty of specimen obtainment. To screen and identify new biomarkers in PHCCA, we constructed a retrospective cohort with 121 PHCCA patients and a prospective cohort consisting of 64 PHCCA patients, and screened the candidate biomarkers by immunohistochemistry and quantified PCR. In our study, expression of high mobility group box 1 (HMGB1) was demonstrated to be significantly associated with microvascular density (MVD) and unfavorable prognosis of PHCCA in both retrospective and prospective study. Moreover, HMGB1 concentrations in bile and serum of PHCCA patients and healthy controls were detected and compared. Postoperative serum HMGB1 and reflux cholangitis indicated recurrence and unfavorable prognosis of PHCCA. With experiments in vitro and in vivo, we demonstrated that intracellular HMGB1 could be released from PHCCA cells and induce invasion and angiogenesis with LPS stimulation. VEGFR2 expression in vessel endothelial cells was upregulated by the released HMGB1 from PHCCA, resulting in the ectopic angiogenesis. In conclusion, intracellular HMGB1 could be released from PHCCA cells and promote angiogenesis via elevating VEGFR2 in vessel endothelial cells. High expression of HMGB1 was associated with MVD and poor prognosis in clinical analyzation. Postoperative serum HMGB1 and cholangitis could predict high recurrence and unfavorable prognosis.	[Xu, Yun-Fei; Liu, Zeng-Li; Ning, Shang-Lei; Guo, Sen; Zhang, Zong-Li] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Shandong, Peoples R China; [Pan, Chang] Shandong Univ, Dept Emergency Med, Qilu Hosp, Jinan, Shandong, Peoples R China; [Pan, Chang] Shandong Univ, Chest Pain Ctr, Qilu Hosp, Jinan, Shandong, Peoples R China; [Yang, Xiao-Qing] Shandong Univ, Dept Pathol, Qianfoshan Hosp, Jinan, Shandong, Peoples R China; [Liu, Hong-Da] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Yu, Jin-Ming] Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; University of Jinan	Zhang, ZL (corresponding author), Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Shandong, Peoples R China.; Yu, JM (corresponding author), Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.	sdyujinming@163.com; zzlzzl1900@163.com	guo, sen/GWQ-3573-2022	Liu, Hongda/0000-0002-5977-9130	National Natural Science Foundation of China [81601668, 31701013]; Shandong Province Major Research and Design Program [2017GSF218059, 2016GSF201132]; Natural Science Foundation of Shandong [ZR2017BC032]; China Postdoctoral Science Foundation [2017M610167, 2017T100163]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Province Major Research and Design Program; Natural Science Foundation of Shandong(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The study was supported by National Natural Science Foundation of China (Grant Nos. 81601668 and 31701013), Shandong Province Major Research and Design Program (Grant Nos. 2017GSF218059 and 2016GSF201132), Natural Science Foundation of Shandong (Grant No. ZR2017BC032), and China Postdoctoral Science Foundation (Grant Nos. 2017M610167 and 2017T100163).	Avgousti DC, 2016, NATURE, V535, P173, DOI 10.1038/nature18317; DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3; Dixelius J, 2006, CANCER RES, V66, P2089, DOI 10.1158/0008-5472.CAN-05-2217; Gnanasekar M, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/157103; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Kang R, 2017, CELL RES, V27, P916, DOI 10.1038/cr.2017.51; Kuniyasu H, 2005, AM J PATHOL, V166, P751, DOI 10.1016/S0002-9440(10)62296-1; Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031; Lillemoe Keith D, 2003, Semin Gastrointest Dis, V14, P208; Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Sia D, 2013, GASTROENTEROLOGY, V144, P829, DOI 10.1053/j.gastro.2013.01.001; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Tang DL, 2011, ANTIOXID REDOX SIGN, V14, P1315, DOI 10.1089/ars.2010.3356; van Beijnum JR, 2013, ONCOGENE, V32, P363, DOI 10.1038/onc.2012.49; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Xu YF, 2015, WORLD J GASTROENTERO, V21, P3256, DOI 10.3748/wjg.v21.i11.3256; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Yang H, 2015, MOL MED, V21, pS6, DOI 10.2119/molmed.2015.00087; Yang RK, 2009, AM J PHYSIOL-REG I, V297, pR362, DOI 10.1152/ajpregu.00184.2009; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Zhang QH, 2013, AUTOPHAGY, V9, P451, DOI 10.4161/auto.23691	24	49	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					868	880		10.1038/s41388-018-0485-8	http://dx.doi.org/10.1038/s41388-018-0485-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177842				2022-12-28	WOS:000458006300008
J	Swaroop, A; Oyer, JA; Will, CM; Huang, XX; Yu, WB; Troche, C; Bulic, M; Durham, BH; Wen, QJ; Crispino, JD; MacKerell, AD; Bennett, RL; Kelleher, NL; Licht, JD				Swaroop, Alok; Oyer, Jon A.; Will, Christine M.; Huang, Xiaoxiao; Yu, Wenbo; Troche, Catalina; Bulic, Marinka; Durham, Benjamin H.; Wen, Qiang Jeremy; Crispino, John D.; MacKerell, Alexander D., Jr.; Bennett, Richard L.; Kelleher, Neil L.; Licht, Jonathan D.			An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia	ONCOGENE			English	Article							MULTIPLE-MYELOMA; GENE-EXPRESSION; LYSINE 36; SOMATIC MUTATIONS; IN-VIVO; METHYLATION; MMSET; H3; EZH2; LANDSCAPE	NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.	[Swaroop, Alok; Huang, Xiaoxiao; Troche, Catalina; Bennett, Richard L.; Licht, Jonathan D.] Univ Florida, Div Hematol Oncol, Hlth Canc Ctr, Gainesville, FL 32611 USA; [Swaroop, Alok; Oyer, Jon A.; Will, Christine M.; Huang, Xiaoxiao; Bulic, Marinka; Wen, Qiang Jeremy; Crispino, John D.; Licht, Jonathan D.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; [Huang, Xiaoxiao; Kelleher, Neil L.] Northwestern Univ, Dept Chem, Chem Life Proc Inst, Evanston, IL USA; [Huang, Xiaoxiao] Northwestern Univ, Dept Mol Biosci, Chem Life Proc Inst, Evanston, IL USA; [Yu, Wenbo; MacKerell, Alexander D., Jr.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Comp Aided Drug Design Ctr, Baltimore, MD 21201 USA; [Durham, Benjamin H.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	State University System of Florida; University of Florida; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Licht, JD (corresponding author), Univ Florida, Div Hematol Oncol, Hlth Canc Ctr, Gainesville, FL 32611 USA.; Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA.	jdlicht@ufl.edu	Bennett, Richard/ABF-9211-2021; Huang, Xiaoxiao/ABG-2564-2020; MacKerell, Alex/AAA-2560-2020; Licht, Jonathan/AAL-9184-2020	Huang, Xiaoxiao/0000-0002-4623-2005; Licht, Jonathan/0000-0002-3942-1369; Oyer, Jon/0000-0002-5479-3400; Bennett, Richard/0000-0002-0243-2443; Durham, Benjamin/0000-0001-8090-5448; Crispino, John/0000-0002-8182-8306; Swaroop, Alok/0000-0003-0317-6688; Yu, Wenbo/0000-0001-6962-5314	Leukemia and Lymphoma Society Specialized Center of Excellence grant; Samuel Waxman Cancer Research Foundation; Celgene [P41 GM108569, R01 GM067193]; Lauri Strauss Leukemia Foundation;  [T32 CA009560];  [F30 CA203292];  [R01 CA195732];  [R01 GM051501]; NATIONAL CANCER INSTITUTE [T32CA009560, R01CA195732, F30CA203292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051501, R01GM067193, T32GM008152, P41GM108569] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society Specialized Center of Excellence grant(Leukemia and Lymphoma Society); Samuel Waxman Cancer Research Foundation; Celgene(Bristol-Myers SquibbCelgene Corporation); Lauri Strauss Leukemia Foundation; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by T32 CA009560 (AS), F30 CA203292 (AS), R01 CA195732 (JDL), R01 GM051501 (ADM), a Leukemia and Lymphoma Society Specialized Center of Excellence grant (JDL), the Samuel Waxman Cancer Research Foundation (ADM and JDL) and Celgene (JDL), P41 GM108569 and R01 GM067193 (NLK) and the Lauri Strauss Leukemia Foundation (JAO, CT).	[Anonymous], 2016, CANC FACTS FIG 2016; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brito JLR, 2009, HAEMATOL-HEMATOL J, V94, P78, DOI 10.3324/haematol.13426; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Campos-Sanchez E, 2017, CELL REP, V19, P1586, DOI 10.1016/j.celrep.2017.04.069; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Damgaard T, 2009, LEUKEMIA LYMPHOMA, V50, P236, DOI 10.1080/10428190802699332; Ding LW, 2017, CANCER RES, V77, P390, DOI 10.1158/0008-5472.CAN-16-1303; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Faderl SH, 2008, HEMATOL MALIG, P1, DOI 10.1007/978-3-540-72304-2; Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106; Golub TR, 2007, NATURE, V446, P739, DOI 10.1038/446739a; Hake SB, 2006, P NATL ACAD SCI USA, V103, P6428, DOI 10.1073/pnas.0600803103; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart K, 2012, J CHEM THEORY COMPUT, V8, P348, DOI 10.1021/ct200723y; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; HOLM S, 1979, SCAND J STAT, V6, P65; Huang Z, 2013, CANCER RES, V73, P6277, DOI 10.1158/0008-5472.CAN-13-1000; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim SM, 2006, BIOCHEM BIOPH RES CO, V345, P318, DOI 10.1016/j.bbrc.2006.04.095; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; LaFave LM, 2013, NAT GENET, V45, P1269, DOI 10.1038/ng.2808; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee MS, 2002, J CHEM PHYS, V116, P10606, DOI 10.1063/1.1480013; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Loh ML, 2013, BLOOD, V122, P824; Lucio-Eterovic AK, 2010, P NATL ACAD SCI USA, V107, P16952, DOI 10.1073/pnas.1002653107; Ma XT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7604; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mueller F, 2012, METHODS MOL BIOL, V833, P153, DOI 10.1007/978-1-61779-477-3_11; Mullighan CG, 2013, BLOOD, V122, P3899, DOI 10.1182/blood-2013-08-460311; Oyer JA, 2014, LEUKEMIA, V28, P198, DOI 10.1038/leu.2013.204; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Qiao Q, 2011, J BIOL CHEM, V286, P8361, DOI 10.1074/jbc.M110.204115; Ravandi F, 2002, LEUKEMIA RES, V26, P643, DOI 10.1016/S0145-2126(01)00188-6; Rotenberg M., 1970, METHODS COMPUTATIONA; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Society AC, 2014, CANC FACTS FIG 2014; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Szenker E, 2011, CELL RES, V21, P421, DOI 10.1038/cr.2011.14; Tisi D, 2016, ACS CHEM BIOL, V11, P3093, DOI 10.1021/acschembio.6b00308; Van Rechem C, 2014, BBA-GENE REGUL MECH, V1839, P1463, DOI 10.1016/j.bbagrm.2014.05.014; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Wynn RF, 2010, ACUTE LYMPHOBLASTIC, P75; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zheng YP, 2014, PROTEOMICS, V14, P2190, DOI 10.1002/pmic.201400060; Zheng YP, 2012, P NATL ACAD SCI USA, V109, P13549, DOI 10.1073/pnas.1205707109; Zhu L, 2016, CANCER DISCOV, V6, P770, DOI 10.1158/2159-8290.CD-16-0058	70	23	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					671	686		10.1038/s41388-018-0474-y	http://dx.doi.org/10.1038/s41388-018-0474-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171259	Green Accepted			2022-12-28	WOS:000457300300005
J	Yu, XH; Liu, YH; Yin, LL; Peng, YB; Peng, YC; Gao, YX; Yuan, BW; Zhu, QL; Cao, TY; Xie, BW; Sun, LQ; Chen, Y; Gong, ZC; Qiu, YZ; Fan, XG; Li, X				Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yongbo; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Chen, Yan; Gong, Zhicheng; Qiu, Yuanzheng; Fan, Xuegong; Li, Xiong			Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; CELL-CYCLE; NASOPHARYNGEAL CARCINOMA; DNA-REPLICATION; MAMMALIAN CDC6; EXPRESSION; TRANSCRIPTION; ACTIVATION; APOPTOSIS; TARGETS	Ionizing radiation (IR) is a conventional cancer therapeutic, to which cancer cells develop radioresistance with exposure. The residual cancer cells after radiation treatment also have increased metastatic potential. The mechanisms by which cancer cells develop radioresistance and gain metastatic potential are still unknown. In this study acute IR exposure induced cancer cell senescence and apoptosis, but after long-term IR exposure, cancer cells exhibited radioresistance. The proliferation of radioresistant cells was retarded, and most cells were arrested in G0/G1 phase. The radioresistant cells simultaneously showed resistance to further IR-induced apoptosis, premature senescence, and epithelial to mesenchymal transformation (EMT). Acute IR exposure steadily elevated CDC6 protein levels due to the attenuation of ubiquitination, while CDC6 overexpression was observed in the radioresistant cells because the insufficiency of CDC6 phosphorylation blocked protein translocation from nucleus to cytoplasm, resulting in subcellular protein accumulation when the cells were arrested in G0/G1 phase. CDC6 ectopic overexpression in CNE2 cells resulted in apoptosis resistance, G0/G1 cell cycle arrest, premature senescence, and EMT, similar to the characteristics of radioresistant CNE2-R cells. Targeting CDC6 with siRNA promoted IR-induced senescence, sensitized cancer cells to IR-induced apoptosis, and reversed EMT. Furthermore, CDC6 depletion synergistically repressed the growth of CNE2-R xenografts when combined with IR. The study describes for the first time cell models for IR-induced senescence, apoptosis resistance, and EMT, three major mechanisms by which radioresistance develops. CDC6 is a novel radioresistance switch regulating senescence, apoptosis, and EMT. These studies suggest that CDC6(high)KI67(low) represents a new diagnostic marker of radiosensitivity, and CDC6 represents a new therapeutic target for cancer radiosensitization.	[Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Li, Xiong] Cent South Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China; [Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Li, Xiong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Changsha, Hunan, Peoples R China; [Peng, Yongbo] Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Changsha, Hunan, Peoples R China; [Chen, Yan] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha, Hunan, Peoples R China; [Gong, Zhicheng] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China; [Qiu, Yuanzheng] Cent South Univ, Xiangya Hosp, Dept Otorhinolaryngol, Changsha, Hunan, Peoples R China; [Fan, Xuegong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China	Central South University; Central South University; Hunan University; Central South University; Central South University; Central South University; Central South University	Li, X (corresponding author), Cent South Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China.; Li, X (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Changsha, Hunan, Peoples R China.	lixiongxiangya@csu.edu.cn	Peng, Yong-bo/ADE-0574-2022	Peng, Yong-bo/0000-0003-4861-7184	National Natural Science Foundation of China (NSFC) [81572542]; Doctoral Fund of Ministry of Education of China (RFDP) [20130162110029]; Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM) [2014-1685]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China (RFDP); Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM)	We thank Pro. Zhiqiang Xiao and the members of the Hunan Key Laboratory of Viral Hepatitis and Center of Molecular Medicine, Xiangya Hospital, Central South University for constructive discussion of this study. This work was supported by grants from the National Natural Science Foundation of China (NSFC, 81572542), the Doctoral Fund of Ministry of Education of China (RFDP, 20130162110029), and Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM, 2014-1685).	Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004766; Chen W, 2015, CANCER BIOL MED, V12, P23, DOI 10.7497/j.issn.2095-3941.2014.0015; Clijsters L, 2013, J CELL BIOL, V201, P1013, DOI 10.1083/jcb.201211019; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Feng DR, 2003, CANCER RES, V63, P7356; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lee M, 2014, BMB REP, V47, P51, DOI 10.5483/BMBRep.2014.47.2.005; Li G, 2013, EUR J CANCER, V49, P2596, DOI 10.1016/j.ejca.2013.03.001; Liu YH, 2014, BBA-GENE REGUL MECH, V1839, P297, DOI 10.1016/j.bbagrm.2014.02.016; Liu YH, 2014, MOL CARCINOGEN, V53, P380, DOI 10.1002/mc.21989; Liu YH, 2010, J CELL BIOCHEM, V111, P1546, DOI 10.1002/jcb.22886; Madani I, 2008, B CANCER, V95, P292, DOI 10.1684/bdc.2008.0598; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Raleigh DR, 2013, FUTURE ONCOL, V9, P219, DOI [10.2217/FON.12.185, 10.2217/fon.12.185]; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sideridou M, 2011, J CELL BIOL, V195, P1123, DOI 10.1083/jcb.201108121; Smit MA, 2010, AGING-US, V2, P735, DOI 10.18632/aging.100209; Su ZW, 2016, ONCOL REP, V36, P72, DOI 10.3892/or.2016.4768; Suarez C, 2010, EUR ARCH OTO-RHINO-L, V267, P1811, DOI 10.1007/s00405-010-1385-x; Walter D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10530; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Young A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-808	34	32	32	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					549	563		10.1038/s41388-018-0460-4	http://dx.doi.org/10.1038/s41388-018-0460-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30158672	Green Published, hybrid			2022-12-28	WOS:000456589800007
J	Willems, E; Dedobbeleer, M; Digregorio, M; Lombard, A; Goffart, N; Lumapat, PN; Lambert, J; Van den Ackerveken, P; Szpakowska, M; Chevigne, A; Scholtes, F; Rogister, B				Willems, Estelle; Dedobbeleer, Matthias; Digregorio, Marina; Lombard, Arnaud; Goffart, Nicolas; Lumapat, Paul Noel; Lambert, Jeremy; Van den Ackerveken, Priscilla; Szpakowska, Martyna; Chevigne, Andy; Scholtes, Felix; Rogister, Bernard			Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; STEM-LIKE CELLS; SUBVENTRICULAR ZONES; INITIATING CELLS; A KINASE; RADIOTHERAPY; INHIBITION; PROLIFERATION; TEMOZOLOMIDE; ACTIVATION	Primary glioblastoma is the most frequent human brain tumor in adults and is generally fatal due to tumor recurrence. We previously demonstrated that glioblastoma-initiating cells invade the subventricular zones and promote their radio-resistance in response to the local release of the CXCL12 chemokine. In this work, we show that the mitotic Aurora A kinase (AurA) is activated through the CXCL12-CXCR4 pathway in an ERK1/2-dependent manner. Moreover, the CXCL12-ERK1/2 signaling induces the expression of Ajuba, the main cofactor of AurA, which allows the auto-phosphorylation of AurA. We show that AurA contributes to glioblastoma cell survival, radio-resistance, self-renewal, and proliferation regardless of the exogenous stimulation with CXCL12. On the other hand, AurA triggers the CXCL12-mediated migration of glioblastoma cells in vitro as well as the invasion of the subventricular zone in xenograft experiments. Moreover, AurA regulates cytoskeletal proteins (i.e., Actin and Vimentin) and favors the pro-migratory activity of the Rho-GTPase CDC42 in response to CXCL12. Altogether, these results show that AurA, a well-known kinase of the mitotic machinery, may play alternative roles in human glioblastoma according to the CXCL12 concentration.	[Willems, Estelle; Dedobbeleer, Matthias; Digregorio, Marina; Lombard, Arnaud; Goffart, Nicolas; Lumapat, Paul Noel; Lambert, Jeremy; Van den Ackerveken, Priscilla; Scholtes, Felix; Rogister, Bernard] Univ Liege, Lab Nervous Syst Dis & Therapy, GIGA Neurosci, Liege, Belgium; [Lombard, Arnaud; Lambert, Jeremy; Scholtes, Felix] CHU Liege, Dept Neurosurg, Liege, Belgium; [Szpakowska, Martyna; Chevigne, Andy] Luxembourg Inst Hlth, Immunopharmacol & Interact, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Rogister, Bernard] CHU Liege, Dept Neurol, Liege, Belgium	University of Liege; University of Liege; Luxembourg Institute of Health; University of Liege	Rogister, B (corresponding author), Univ Liege, Lab Nervous Syst Dis & Therapy, GIGA Neurosci, Liege, Belgium.; Rogister, B (corresponding author), CHU Liege, Dept Neurol, Liege, Belgium.	Bernard.Rogister@uliege.be	Rogister, Bernard/AAJ-9591-2020; Lombard, Arnaud/AAG-1624-2021	Szpakowska, Martyna/0000-0002-5659-8377; Chevigne, Andy/0000-0003-4768-6743; Van Den Ackerveken, Priscilla/0000-0001-5913-6293; Digregorio, Marina/0000-0002-5317-7788; Lombard, Arnaud/0000-0002-7789-0801	National Fund for Scientific Research (F.N.R.S.), Special Funds of the University of Liege; Televie sub-organization, Special Funds of the University of Liege; Anti-Cancer Center near the University of Liege Grant; Leon Fredericq Grant; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR); European Erasmus Mundus; Luxembourg Institute of Health (LIH) MESR; Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR)	National Fund for Scientific Research (F.N.R.S.), Special Funds of the University of Liege; Televie sub-organization, Special Funds of the University of Liege; Anti-Cancer Center near the University of Liege Grant; Leon Fredericq Grant; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR); European Erasmus Mundus; Luxembourg Institute of Health (LIH) MESR; Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR)	The National Fund for Scientific Research (F.N.R.S.) and the Televie sub-organization, the Special Funds of the University of Liege; an Anti-Cancer Center near the University of Liege and Leon Fredericq Grants; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR), European Erasmus Mundus (Paul Noel Lumapat), the Luxembourg Institute of Health (LIH) MESR, the Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR) (Martyna Szpakowska and Andy Chevigne).	Adeberg S, 2014, INT J RADIAT ONCOL, V90, P886, DOI 10.1016/j.ijrobp.2014.07.027; Bai MR, 2014, GENE, V543, P133, DOI 10.1016/j.gene.2014.03.048; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Chevigne A, 2014, BBA-MOL CELL RES, V1843, P1031, DOI 10.1016/j.bbamcr.2014.01.017; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Edalat L, 2016, ONCOTARGET, V7, P14259, DOI 10.18632/oncotarget.7423; Fogh BS, 2014, J HISTOCHEM CYTOCHEM, V62, P172, DOI 10.1369/0022155413517701; Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003; Goffart N, 2017, NEURO-ONCOLOGY, V19, P66, DOI 10.1093/neuonc/now136; Goffart N, 2015, NEURO-ONCOLOGY, V17, P81, DOI 10.1093/neuonc/nou144; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Hong X, 2014, CANCER CHEMOTH PHARM, V73, P983, DOI 10.1007/s00280-014-2430-z; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kroonen J, 2011, INT J CANCER, V129, P574, DOI 10.1002/ijc.25709; Lehman NL, 2012, CELL CYCLE, V11, P489, DOI 10.4161/cc.11.3.18996; Li N, 2015, MOL CANCER THER, V14, P419, DOI 10.1158/1535-7163.MCT-14-0526; Li S, 2015, J BIOL CHEM, V290, P17546, DOI 10.1074/jbc.M115.652453; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059750; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SRA, 2016, BRIT J CANCER, V115, P1445, DOI 10.1038/bjc.2016.354; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Mannino M, 2014, STEM CELL RES, V13, P135, DOI 10.1016/j.scr.2014.05.001; Mistry AM, 2017, J NEURO-ONCOL, V131, P125, DOI 10.1007/s11060-016-2278-7; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Samaras V, 2009, PATHOL RES PRACT, V205, P765, DOI 10.1016/j.prp.2009.06.011; Singh SK, 2003, CANCER RES, V63, P5821; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun HZ, 2014, BBA-MOL CELL RES, V1843, P934, DOI 10.1016/j.bbamcr.2014.01.019; Ullmann U, 2007, MOL HUM REPROD, V13, P21, DOI 10.1093/molehr/gal091; Van Brocklyn JR, 2014, CANCER RES, V74, P5364, DOI 10.1158/0008-5472.CAN-14-0386; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Willems E, 2017, TARGET ONCOL, V12, P11, DOI 10.1007/s11523-016-0457-2; Wu MH, 2008, J CELL BIOCHEM, V103, P245, DOI 10.1002/jcb.21400; Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00144; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044; Zorba A, 2014, ELIFE, V3, DOI 10.7554/eLife.02667	44	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					73	87		10.1038/s41388-018-0437-3	http://dx.doi.org/10.1038/s41388-018-0437-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082913	Green Published, hybrid			2022-12-28	WOS:000454775900006
J	Chen, ST; Kuo, TC; Liao, YY; Lin, MC; Tien, YW; Huang, MC				Chen, Syue-Ting; Kuo, Ting-Chun; Liao, Ying-Yu; Lin, Mei-Chun; Tien, Yu-Wen; Huang, Min-Chuan			Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; PHASE-I; CANCER-CELLS; EXPRESSION; MET; FIBROBLASTS; ACTIVATION; PROGNOSIS; STROMA; PHENOTYPES	Mucins are heavily glycosylated proteins that play critical roles in the pathogenesis of tumour malignancies. Pancreatic ductal adenocarcinoma (PDAC) is characterised by the aberrant expression of mucins. However, the role of mucin (MUC) 20 in PDAC remains unclear. PDAC is usually surrounded by a dense fibrotic stroma consisting of an extracellular matrix and pancreatic stellate cells (PSCs). The stroma creates a nutrient-deprived, hypoxic, and acidic microenvironment, and promotes the malignant behaviours of PDAC cells. In this study, immunohistochemical staining demonstrated that high MUC20 expression correlated with poor progression-free survival and high local recurrence rate of PDAC patients (n = 61). The expression of MUC20 was induced by serum deprivation, hypoxia, and acidic pH in PDAC cells. MUC20 knockdown with siRNA decreased cell viability, as well as migration and invasion induced by PSCs in HPAC and HPAF-II cells. In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice. Phospho-RTK array and western blot analysis indicated that MUC20 knockdown decreased HGF-mediated phosphorylation of MET in PDAC cells. Moreover, HGF-induced malignant phenotypes could be suppressed by MUC20 knockdown. Co-immunoprecipitation revealed the physical association of MUC20 and MET. These findings suggest that MUC20 knockdown suppresses the malignant phenotypes of PDAC cells at least partially through the inhibition of the HGF/MET pathway and that MUC20 could act as a potential therapeutic target.	[Chen, Syue-Ting; Liao, Ying-Yu; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Kuo, Ting-Chun; Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ Hosp, Dept Otolaryngol, Hsinchu, Hsinchu, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Tien, YW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.	ywtien5106@ntu.edu.tw; mchuang@ntu.edu.tw		TIEN, YU-WEN/0000-0002-9126-2705; HUANG, MIN-CHUAN/0000-0002-0704-3447; KUO, TING-CHUN/0000-0003-1960-1423	National Taiwan University Hospital [106-N3608]; Translational Research Program of National Taiwan University Hospital; National Taiwan University College of Medicine [107C101-B2, NSC-83]; Ministry of Science and Technology, Taiwan [104-2320-B-002-068-MY3, 106-2321-B-002-034]	National Taiwan University Hospital(National Taiwan University); Translational Research Program of National Taiwan University Hospital; National Taiwan University College of Medicine(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by National Taiwan University Hospital (106-N3608 to Dr. TCK), Translational Research Program of National Taiwan University Hospital and National Taiwan University College of Medicine (107C101-B2 and NSC-83 to Dr. MCH), and Ministry of Science and Technology, Taiwan (104-2320-B-002-068-MY3 to Dr. MCH and 106-2321-B-002-034 to Dr. YWT). In addition, we are grateful to Dr. WH Lee (Genomics Research Center, Academia Sinica, Taiwan) for providing human PDAC and PSC cell lines. We are grateful to Dr. SH Wang (Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taiwan) for providing reagents and technical assistance during revision process.	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chen CH, 2016, GYNECOL ONCOL, V140, P131, DOI 10.1016/j.ygyno.2015.11.025; Chen CH, 2013, GYNECOL ONCOL, V128, P560, DOI 10.1016/j.ygyno.2012.12.012; Erkan M, 2012, NAT REV GASTRO HEPAT, V9, P454, DOI 10.1038/nrgastro.2012.115; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Goydos JS, 1996, J SURG RES, V63, P298, DOI 10.1006/jsre.1996.0264; Gulec SA, 2011, CLIN CANCER RES, V17, P4091, DOI 10.1158/1078-0432.CCR-10-2579; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Higuchi T, 2004, MOL CELL BIOL, V24, P7456, DOI 10.1128/MCB.24.17.7456-7468.2004; Higuchi T, 2004, J BIOL CHEM, V279, P1968, DOI 10.1074/jbc.M304558200; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mei L, 2016, J GASTROINTEST ONCOL, V7, P487, DOI 10.21037/jgo.2016.03.03; Molina V, 2012, TUMOR BIOL, V33, P799, DOI 10.1007/s13277-011-0297-8; Moniaux N, 2006, J BIOL CHEM, V281, P23676, DOI 10.1074/jbc.M600302200; Nielsen MFB, 2016, WORLD J GASTROENTERO, V22, P2678, DOI 10.3748/wjg.v22.i9.2678; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Patel MB, 2014, CARCINOGENESIS, V35, P1891, DOI 10.1093/carcin/bgu122; Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pothula SP, 2016, BRIT J CANCER, V114, P269, DOI 10.1038/bjc.2015.478; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Ramanathan RK, 2005, CANCER IMMUNOL IMMUN, V54, P254, DOI 10.1007/s00262-004-0581-1; Rizwani W, 2015, CANCERS, V7, P1785, DOI 10.3390/cancers7030861; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Takikita M, 2009, CANCER RES, V69, P2950, DOI 10.1158/0008-5472.CAN-08-3879; Tanaka S, 2016, ANN SURG ONCOL, V23, P197, DOI 10.1245/s10434-015-4463-x; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Yamasaki H, 2004, INT J ONCOL, V24, P107; Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003	38	27	27	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6041	6053		10.1038/s41388-018-0403-0	http://dx.doi.org/10.1038/s41388-018-0403-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29993037	Green Published, hybrid			2022-12-28	WOS:000450175900003
J	Li, A; Chen, P; Leng, Y; Kang, JH				Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong			Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway	ONCOGENE			English	Article							TUMOR-STROMA; HDAC6; MICROENVIRONMENT; CELLS; INFLAMMATION; INHIBITORS; CHEMOTHERAPY; METASTASES; PROMOTION; FIBROSIS	Cancer-associated fibroblasts (CAFs) are important components in breast tumors and essential for tumor progression and metastasis. However, the role of epigenetic modification in driving the function of CAFs within breast tumors is only marginally known. Herein, we reported that histone deacetylase 6 (HDAC6), one of class II histone deacetylases, was frequently upregulated in the CAFs of breast tumor and promotes an immunosuppressive microenvironment. The genetic or pharmacologic disruption of HDAC6 in CAFs delays tumor growth, inhibits the tumor recruitment of myeloid-derived suppressor cells and regulatory T cells, alters the macrophage phenotype switch, and increases the CD8+ and CD4+ T-cell activation in vivo. Mechanistically, we identified prostaglandin E2/cyclooxygenase-2 (COX2) as a major target of HDAC6 in CAFs by regulating STAT3 activation. Overexpressing COX2 in HDAC6-knockdown CAFs can completely restore the immunosuppressive properties of the fibroblasts. Clinically, a positive correlation among the stromal expression levels of HDAC6, p-STAT3, and COX2 in human breast cancer was observed. High-stromal expression of HDAC6 was markedly associated with poor survival outcome. Overall, our findings indicated that fibroblastic HDAC6 was a vital epigenetic mediator involved in programming an immunosuppressive tumor microenvironment that dampens antitumor immunity. Thus, HDAC6 may be a good potential target to improve breast cancer immunotherapy.	[Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong] Tongji Univ, Clin & Translat Res Ctr, Shanghai Matern & Infant Hlth Hosp 1, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China	Tongji University	Kang, JH (corresponding author), Tongji Univ, Clin & Translat Res Ctr, Shanghai Matern & Infant Hlth Hosp 1, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China.	jhkang@tongji.edu.cn			Ministry of Science and Technology of China [2016YFA0101300]; Science and Technology Commission of Shanghai Municipality [16PJ1410200]; Fundamental Research Funds for the Central Universities [1501219171, 22120170068]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants obtained from the Ministry of Science and Technology of China (grant #2016YFA0101300), Science and Technology Commission of Shanghai Municipality (grant #16PJ1410200), and the Fundamental Research Funds for the Central Universities (grant #1501219171, 22120170068).	Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Cheng F, 2014, J IMMUNOL, V193, P2850, DOI 10.4049/jimmunol.1302778; Cheng F, 2014, MOL IMMUNOL, V60, P44, DOI 10.1016/j.molimm.2014.02.019; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Cohen N, 2017, ONCOGENE, V36, P4457, DOI 10.1038/onc.2017.65; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Fanelli A, 2017, THER ADV DRUG SAF, V8, P173, DOI 10.1177/2042098617690485; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Frangogiannis NG, 2017, J CLIN INVEST, V127, P1600, DOI 10.1172/JCI87491; Fulton AM, 2006, CANCER RES, V66, P9794, DOI 10.1158/0008-5472.CAN-06-2067; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karavitis J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23129; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lee HJ, 2017, CELL SIGNAL, V38, P1, DOI 10.1016/j.cellsig.2017.06.012; Li L, 2016, ONCOGENE, V35, P4048, DOI 10.1038/onc.2015.476; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003; Marsh T, 2013, BBA-MOL BASIS DIS, V1832, P1070, DOI 10.1016/j.bbadis.2012.10.013; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Putcha P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0658-0; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reader J, 2011, CANCER METAST REV, V30, P449, DOI 10.1007/s10555-011-9303-2; Regulski M, 2016, DRUG DISCOV TODAY, V21, P598, DOI 10.1016/j.drudis.2015.12.003; Scherz-Shouval R, 2014, CELL, V158, P564, DOI 10.1016/j.cell.2014.05.045; Schoepp M, 2017, CANCERS, V9, DOI 10.3390/cancers9060054; Schuetze KB, 2014, J MOL CELL CARDIOL, V70, P100, DOI 10.1016/j.yjmcc.2014.02.015; Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Smith MP, 2016, CLIN CANCER RES, V22, P5966, DOI 10.1158/1078-0432.CCR-16-0954; Su CW, 2016, CRIT REV ONCOL HEMAT, V107, P33, DOI 10.1016/j.critrevonc.2016.08.010; Terranova-Barberio M, 2016, IMMUNOTHERAPY-UK, V8, P705, DOI 10.2217/imt-2016-0014; Wang HP, 2017, TRENDS CANCER, V3, P583, DOI 10.1016/j.trecan.2017.06.005; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Yan HL, 2012, CELL SIGNAL, V24, P961, DOI 10.1016/j.cellsig.2011.12.019; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Youn GS, 2015, GLIA, V63, P1953, DOI 10.1002/glia.22865; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584	50	44	47	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5952	5966		10.1038/s41388-018-0379-9	http://dx.doi.org/10.1038/s41388-018-0379-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980788				2022-12-28	WOS:000449562500004
J	Hodgkinson, K; Forrest, LA; Vuong, N; Garson, K; Djordjevic, B; Vanderhyden, BC				Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Djordjevic, Bojana; Vanderhyden, Barbara C.			GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; PI3K/AKT PATHWAY; E-CADHERIN; GROWTH; ALPHA; 17-BETA-ESTRADIOL; INVASION; ACTIVATION; TARGETS; CELLS	Estrogenic hormone replacement therapy increases the risk of developing ovarian cancer, and estrogen promotes tumour initiation and growth in mouse models of this disease. GREB1 (Growth regulation by estrogen in breast cancer 1) is an ESR1 (estrogen receptor 1)-upregulated protein which may mediate estrogen action. GREB1 knockdown prevents hormone-driven proliferation of several breast and prostate cancer cell lines and prolongs survival of mice engrafted with ovarian cancer cells, but its mechanism of action remains unclear. In this study, we explored GREB1 function in ovarian cancer. GREB1 overexpression in ovarian cancer cell lines increased cell proliferation and migration and promoted a mesenchymal morphology associated with increased Col1a2, which encodes a collagen I subunit. GREB1 knockdown inhibited proliferation and promoted an epithelial morphology associated with decreased Col1a2. In human tissues, GREB1 was expressed in all ESR1-expressing tissues throughout the normal female reproductive tract, in addition to several tissues that did not show ESR1 expression. In a TMA of ovarian cancer cases, GREB1 was expressed in 75-85% of serous, endometrioid, mucinous, and clear cell carcinomas. Serous, endometrioid, and mucinous ovarian cancers were almost always positive for either ESR1 or GREB1, suggesting a possible reliance on signalling through ESR1 and/or GREB1. Targeting GREB1 may inhibit tumour-promoting pathways both downstream and independent of ESR1 and is therefore a possible treatment strategy worthy of further investigation.	[Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Vanderhyden, Barbara C.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Vanderhyden, Barbara C.] Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Djordjevic, Bojana] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Vanderhyden, BC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Vanderhyden, BC (corresponding author), Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada.	bvanderhyden@ohri.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Dr. Kenneth S. Korach for kindly providing us with his conditional ESR1-deletion mice (30). We also thank the tissue donors and their families, who made this research possible. This work was supported by a grant from the Canadian Institutes of Health Research (BCV), a donation from The Carol Annibale Ovarian Cancer Foundation, Ontario Graduate Scholarships (to K.H., N.V.), and a Queen Elizabeth II Graduate Scholarship in Science and Technology (to K.H.).	Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55; Armaiz-Pena GN, 2009, CLIN CANCER RES, V15, P2971, DOI 10.1158/1078-0432.CCR-08-2525; Brodeur AC, 2017, INT J NEPHROL RENOV, V10, P251, DOI 10.2147/IJNRD.S141393; Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608; Cheng JC, 2011, CANCER LETT, V304, P107, DOI 10.1016/j.canlet.2011.02.008; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Ding JX, 2006, GYNECOL ONCOL, V103, P623, DOI 10.1016/j.ygyno.2006.04.023; Ebell MH, 2016, AM J PREV MED, V50, P384, DOI 10.1016/j.amepre.2015.09.023; Gamwell LF, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100347; Gapstur SM, 2015, LANCET, V385, P1835, DOI 10.1016/S0140-6736(14)61687-1; Gershenson DM, 2017, J CLIN ONCOL, V35, P1103, DOI 10.1200/JCO.2016.71.0632; Ghosh MG, 2000, CANCER RES, V60, P6367; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Haakensen VD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-332; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1043/1543-2165-134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]; Hewitt SC, 2010, FASEB J, V24, P4660, DOI 10.1096/fj.10-163428; Hnatyszyn HJ, 2010, BREAST CANCER RES TR, V122, P371, DOI 10.1007/s10549-009-0584-x; Hua KQ, 2008, INT J ONCOL, V33, P959, DOI 10.3892/ijo_00000083; Laviolette LA, 2014, INT J CANCER, V135, P1072, DOI 10.1002/ijc.28741; Laviolette LA, 2010, ENDOCRINOLOGY, V151, P929, DOI 10.1210/en.2009-0602; Lee Kyu-Sup, 1992, Kurume Medical Journal, V39, P285; Lim D, 2013, PATHOLOGY, V45, P229, DOI 10.1097/PAT.0b013e32835f2264; Lippman Marc E, 2008, Trans Am Clin Climatol Assoc, V119, P77; Lu ZY, 2014, MOL MED REP, V10, P2433, DOI 10.3892/mmr.2014.2561; Mabuchi S, 2015, GYNECOL ONCOL, V137, P173, DOI 10.1016/j.ygyno.2015.02.003; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Mori Y, 2008, EXP CELL RES, V314, P1094, DOI 10.1016/j.yexcr.2007.12.010; Mullany LK, 2014, MOL ENDOCRINOL, V28, P127, DOI 10.1210/me.2013-1308; Okano K, 2012, MOL CELL BIOCHEM, V369, P247, DOI 10.1007/s11010-012-1388-6; Pellegrini C, 2012, FERTIL STERIL, V98, P1200, DOI 10.1016/j.fertnstert.2012.06.056; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Ribeiro JR, 2014, J STEROID BIOCHEM, V143, P160, DOI 10.1016/j.jsbmb.2014.02.010; SAWADA M, 1990, INT J CANCER, V45, P359, DOI 10.1002/ijc.2910450225; Shu DY, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20611; Spillman MA, 2010, CANCER RES, V70, P8927, DOI 10.1158/0008-5472.CAN-10-1238; Sun J, 2007, MOL ENDOCRINOL, V21, P2651, DOI 10.1210/me.2007-0082; Sundar S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4443; Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Yan Y, 2013, MOL CELL BIOCHEM, V378, P1, DOI 10.1007/s11010-013-1579-9	42	35	37	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5873	5886		10.1038/s41388-018-0377-y	http://dx.doi.org/10.1038/s41388-018-0377-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973689	Green Published, hybrid			2022-12-28	WOS:000448943100005
J	Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; Knudsen, E; Pettitt, SJ; Ryan, CJ; Lord, CJ				Brough, Rachel; Gulati, Aditi; Haider, Syed; Kumar, Rahul; Campbell, James; Knudsen, Erik; Pettitt, Stephen J.; Ryan, Coim J.; Lord, Christopher J.			Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer	ONCOGENE			English	Article							COP9 SIGNALOSOME; CELL-CYCLE; NEOADJUVANT CHEMOTHERAPY; PATHWAY DISRUPTION; PROTEIN EXPRESSION; OVARIAN-CANCER; LARGE-SCALE; P53; ASSOCIATION; INHIBITORS	Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating molecular profiling data with data from multiple genetic perturbation screens, we identified candidate synthetic lethal (SL) interactions associated with RB1 defects in TNBC. We refined this analysis by identifying the highly penetrant effects, reasoning that these would be more robust in the face of molecular heterogeneity and would represent more promising therapeutic targets. A significant proportion of the highly penetrant RB1 SL effects involved proteins closely associated with RB1 function, suggesting that this might be a defining characteristic. These included nuclear pore complex components associated with the MAD2 spindle checkpoint protein, the kinase and bromodomain containing transcription factor TAF1, and multiple components of the SCFSKP Cullin F box containing complex. Small-molecule inhibition of SCFSKP elicited an increase in p27Kip levels, providing a mechanistic rationale for RB1 SL. Transcript expression of SKP2, a SCFSKP component, was elevated in RB1-defective TNBCs, suggesting that in these tumours, SKP2 activity might buffer the effects of RB1 dysfunction.	[Brough, Rachel; Gulati, Aditi; Haider, Syed; Kumar, Rahul; Campbell, James; Pettitt, Stephen J.; Lord, Christopher J.] Breast Canc Now Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; [Brough, Rachel; Gulati, Aditi; Kumar, Rahul; Campbell, James; Pettitt, Stephen J.; Lord, Christopher J.] Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England; [Knudsen, Erik] Univ Arizona, Dept Med, Tucson, AZ 85721 USA; [Ryan, Coim J.] Univ Coll Dublin, Syst Biol Ireland, Dublin, Ireland; [Ryan, Coim J.] Univ Coll Dublin, Sch Comp Sci, Dublin, Ireland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Arizona; University College Dublin; University College Dublin	Lord, CJ (corresponding author), Breast Canc Now Toby Robins Breast Canc Res Ctr, London SW3 6JB, England.; Lord, CJ (corresponding author), Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England.; Ryan, CJ (corresponding author), Univ Coll Dublin, Syst Biol Ireland, Dublin, Ireland.; Ryan, CJ (corresponding author), Univ Coll Dublin, Sch Comp Sci, Dublin, Ireland.	Colm.RyanRyan@ucd.ie; Chris.Lord@icr.ac.uk	Lord, Christopher/AAX-7130-2021; kumar, rahul/GZG-2171-2022; Kumar, Rahul/ABB-3530-2020; Lord, Christopher/B-3295-2012	Pettitt, Stephen/0000-0003-3313-3857; Lord, Christopher/0000-0002-3226-0515; Ryan, Colm/0000-0003-2750-9854; Kumar, Rahul/0000-0002-6927-5390	Breast Cancer Now and Cancer Research UK Programme; Science Foundation Ireland; Health Research Board; Wellcome Trust under the SFI-HRB-Wellcome Trust Biomedical Research Partnership [103049/Z/13/Z]; NHS; Cancer Research UK; British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER	Breast Cancer Now and Cancer Research UK Programme; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Wellcome Trust under the SFI-HRB-Wellcome Trust Biomedical Research Partnership(Wellcome Trust); NHS; Cancer Research UK(Cancer Research UK); British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by Breast Cancer Now and Cancer Research UK Programme Grants to CJL. CJR was a Sir Henry Wellcome Fellow jointly funded by Science Foundation Ireland, the Health Research Board and the Wellcome Trust (grant number 103049/Z/13/Z) under the SFI-HRB-Wellcome Trust Biomedical Research Partnership. We acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden Hospital. This study makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium, which was funded by Cancer Research UK and the British Columbia Cancer Agency Branch. The results published here are based, in part, upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/.	Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernad R, 2006, J BIOL CHEM, V281, P19378, DOI 10.1074/jbc.M512585200; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Bouche L, 2017, J MED CHEM, V60, P4002, DOI 10.1021/acs.jmedchem.7b00306; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell J, 2016, CELL REP, V14, P2490, DOI 10.1016/j.celrep.2016.02.023; Ceron J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-30; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen X, 2012, CANCER INFORM, V11, P147, DOI 10.4137/CIN.S9983; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Chung D, 2015, BIOMOLECULES, V5, P2388, DOI 10.3390/biom5042388; Corney DC, 2008, ADV EXP MED BIOL, V622, P99, DOI 10.1007/978-0-387-68969-2_9; Crawford TD, 2016, J MED CHEM, V59, P5391, DOI 10.1021/acs.jmedchem.6b00264; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Goldhoff P, 2012, J NEUROPATH EXP NEUR, V71, P83, DOI 10.1097/NEN.0b013e31823fe8f1; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Haverty PM, 2016, NATURE, V533, P333, DOI 10.1038/nature17987; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; HIGASHIYAMA M, 1994, ONCOLOGY-BASEL, V51, P544; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lawrence RT, 2015, CELL REP, V11, P630, DOI 10.1016/j.celrep.2015.03.050; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li P, 2017, J CELL PHYSIOL, V232, P1246, DOI 10.1002/jcp.25696; Lin CY, 2002, CURR BIOL, V12, P2142, DOI 10.1016/S0960-9822(02)01389-1; Lingaraju GM, 2014, NATURE, V512, P161, DOI 10.1038/nature13566; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-38; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; Orjalo AV, 2006, MOL BIOL CELL, V17, P3806, DOI 10.1091/mbc.E05-11-1061; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson TJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078641; Rodriguez-Bravo V, 2014, CELL, V156, P1017, DOI 10.1016/j.cell.2014.01.010; Russnes HG, 2017, AM J PATHOL, V187, P2152, DOI 10.1016/j.ajpath.2017.04.022; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sdelci S, 2016, NAT CHEM BIOL, V12, P504, DOI 10.1038/nchembio.2080; Searle JS, 2010, ONCOTARGET, V1, P228; Semczuk A, 2000, PATHOL RES PRACT, V196, P41, DOI 10.1016/S0344-0338(00)80020-5; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667; Takada M, 2014, BREAST CANCER RES TR, V145, P143, DOI 10.1007/s10549-014-2907-9; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trere D, 2009, ANN ONCOL, V20, P1818, DOI 10.1093/annonc/mdp209; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Wu ZG, 2016, CELL BIOL INT, V40, P968, DOI 10.1002/cbin.10633; Xu XLL, 2014, NATURE, V514, P385, DOI 10.1038/nature13813; Zhao H, 2017, ONCOGENE, V36, P60, DOI 10.1038/onc.2016.175	68	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5701	5718		10.1038/s41388-018-0368-z	http://dx.doi.org/10.1038/s41388-018-0368-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29915391	Green Published, hybrid			2022-12-28	WOS:000448288200001
J	Golfmann, K; Meder, L; Koker, M; Volz, C; Borchmann, S; Tharun, L; Dietlein, F; Malchers, F; Florin, A; Buttner, R; Rosen, N; Rodrik-Outmezguine, V; Hallek, M; Ullrich, RT				Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Tharun, Lars; Dietlein, Felix; Malchers, Florian; Florin, Alexandra; Buettner, Reinhard; Rosen, Neal; Rodrik-Outmezguine, Vanessa; Hallek, Michael; Ullrich, Roland T.			Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; CARCINOMA-CELLS; GROWTH; RECEPTOR; ACTIVATION; SURVIVAL; BGJ398; TUMORS; AKT	FGFR1 amplification has been found in 15% of patients with breast cancer and has been postulated as a promising marker to predict response against FGFR inhibitors. However, early phase clinical trials of selective FGFR inhibitors demonstrated only limited efficacy in FGFR1-amplified breast cancer patients. We found that BGJ398, an FGFR inhibitor, effectively inhibited phosphorylation of FGFR1 and MEK/ERK signaling in FGFR1-amplified breast cancer without affecting tumor cell proliferation. However, FGFR1 knockout inhibited tumor angiogenesis in vivo. We unraveled that FGFR1 regulates the secretion of the proangiogenic vascular endothelial growth factor (VEGF) in a MAPK-dependent manner. We further found that FGF-FGFR1 signaling induces an autocrine activation of VEGF-VEGFR1 pathway that again amplifies VEGF secretion via VEGF-VEGFR1-AKT signaling. Targeting both VEGFR1 and FGFR1 resulted in synergistic anti-angiogenic treatment effects in vivo. We thus postulate synergistic treatment effects in FGFR1/VEGFR1-positive breast cancer patients by dual targeting of FGFR and VEGFR.	[Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Hallek, Michael; Ullrich, Roland T.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Buettner, Reinhard; Hallek, Michael; Ullrich, Roland T.] Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany; [Borchmann, Sven] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp, Kerpener Str 62, D-50937 Cologne, Germany; [Borchmann, Sven; Dietlein, Felix] Univ Hosp Cologne, Else Kroner Forsch Kolleg Clonal Evolut Canc, D-50931 Cologne, Germany; [Tharun, Lars; Florin, Alexandra; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Dietlein, Felix] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Dietlein, Felix] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02142 USA; [Malchers, Florian] Univ Hosp Cologne, Dept Translat Genom, Weyertal 115b, D-50931 Cologne, Germany; [Malchers, Florian; Hallek, Michael; Ullrich, Roland T.] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany; [Rosen, Neal; Rodrik-Outmezguine, Vanessa] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, 1275 York Ave, New York, NY 10021 USA	University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Cologne; University of Cologne; Memorial Sloan Kettering Cancer Center	Ullrich, RT (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.; Ullrich, RT (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany.; Ullrich, RT (corresponding author), Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany.	roland.ullrich@uk-koeln.de	Hallek, Michael/Y-3191-2019; Borchmann, Sven/ABB-5244-2021; Rosen, Neal/ABF-2677-2020	Hallek, Michael/0000-0002-7425-4455; Borchmann, Sven/0000-0001-6662-6864; Malchers, Florian/0000-0002-3443-4419; Meder, Lydia/0000-0002-9547-5812	Thyssen Foundation [10.16.1.028MN]; Nachwuchsforschungsgruppen-NRW [1411ng005]; Deutsche Forschungsgemeinschaft (DFG) [UL379/1-1]; Deutsche Krebshilfe [70113009]	Thyssen Foundation; Nachwuchsforschungsgruppen-NRW; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the Thyssen Foundation (Grant No.: 10.16.1.028MN to RTU), by the Nachwuchsforschungsgruppen-NRW (Grant No.: 1411ng005 to RTU), by the Deutsche Forschungsgemeinschaft (DFG) (Grant No.: UL379/1-1 to RTU) and by the Deutsche Krebshilfe (Grant No.: 70113009 to RTU).	Andre F, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps1134; Andre F, 2015, BREAST CANCER RES TR, V150, P1, DOI 10.1007/s10549-015-3301-y; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Dales JP, 2003, ANN PATHOL, V23, P297; Datta J, 2017, MOL CANCER THER, V16, P614, DOI 10.1158/1535-7163.MCT-15-1010; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Kut C, 2007, BRIT J CANCER, V97, P978, DOI 10.1038/sj.bjc.6603923; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Malchers F, 2017, CLIN CANCER RES, V23, P5527, DOI 10.1158/1078-0432.CCR-17-0478; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; Musolino A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0807-8; Mylona E, 2007, GYNECOL ONCOL, V104, P557, DOI 10.1016/j.ygyno.2006.09.031; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ocana A, 2017, ONCOTARGET, V8, P22218, DOI 10.18632/oncotarget.14731; Packer LM, 2017, MOL CANCER THER, V16, P637, DOI 10.1158/1535-7163.MCT-16-0415; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Terry S, 2015, ONCOTARGET, V6, P11994, DOI 10.18632/oncotarget.2740; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wu Y, 2006, INT J CANCER, V119, P1519, DOI 10.1002/ijc.21865	25	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5682	5693		10.1038/s41388-018-0380-3	http://dx.doi.org/10.1038/s41388-018-0380-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29970903				2022-12-28	WOS:000447619100007
J	Serandour, AA; Mohammed, H; Miremadi, A; Mulder, KW; Carroll, JS				Serandour, A. A.; Mohammed, H.; Miremadi, A.; Mulder, K. W.; Carroll, J. S.			TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers	ONCOGENE			English	Article							BREAST-CANCER; THERAPY; FOXA1; TRANSCRIPTION; INTEGRATION; INHIBITORS; COMPLEXES; PROTEINS; REVEALS; TARGET	The chromatin state is finely tuned to regulate function and specificity for transcription factors such as oestrogen receptor alpha (ER), which contributes to cell growth in breast cancer. ER transcriptional potential is mediated, in large part, by the specific associated proteins and co-factors that interact with it. Despite the identification and characterisation of several ER coregulators, a complete and systematic view of ER-regulating chromatin modifiers is lacking. By exploiting a focused siRNA screen that investigated the requirement for a library of 330 chromatin regulators in ER-mediated cell growth, we find that the NuRD and coREST histone deacetylation complexes are critical for breast cancer cell proliferation. Further, by proteomic and genomics approaches, we discover the transcription factor TRPS1 to be a key interactor of the NuRD and coREST complexes. Interestingly, TRPS1 gene amplification occurs in 28% of human breast tumours and is associated with poor prognosis. We propose that TRPS1 is required to repress spurious binding of ER, where it contributes to the removal of histone acetylation. Our data suggest that TRPS1 is an important ER-associated transcriptional repressor that regulates cell proliferation, chromatin acetylation and ER binding at the chromatin of cis-regulatory elements.	[Serandour, A. A.; Mohammed, H.; Miremadi, A.; Mulder, K. W.; Carroll, J. S.] Univ Cambridge, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England; [Serandour, A. A.] Univ Nantes, CRCINA, INSERM, CNRS,Univ Angers, Nantes, France; [Serandour, A. A.] Ecole Cent Nantes, Nantes, France; [Mohammed, H.] Oregon Hlth & Sci Univ, Knight Canc Early Detect Adv Res Ctr, Portland, OR 97201 USA; [Mulder, K. W.] Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Dev Biol, Nijmegen, Netherlands	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Nantes Universite; Ecole Centrale de Nantes; Oregon Health & Science University; Radboud University Nijmegen	Mulder, KW; Carroll, JS (corresponding author), Univ Cambridge, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England.; Mulder, KW (corresponding author), Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Dev Biol, Nijmegen, Netherlands.	k.mulder@science.ru.nl; jason.carroll@cruk.cam.ac.uk	Serandour, Aurelien/AAG-7036-2019	Serandour, Aurelien/0000-0001-5253-9567; Carroll, Jason/0000-0003-3643-0080	ERC; Komen Scholar Award; University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited	ERC(European Research Council (ERC)European Commission); Komen Scholar Award; University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited	We would like to thank Clive D'Santos and Chris Taylor from the CRUK CI Proteomics core, James Hadfield and the other members of the Genomics core, and Suraj Menon from the Bioinformatics core. Jason Carroll is supported by an ERC Consolidator grant and a Komen Scholar Award. We would like to acknowledge the support of the University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited.	Alluri PG, 2014, CELL RES, V24, P899, DOI 10.1038/cr.2014.90; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Cerase A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0733-y; Chen Jie Qing, 2011, Hormones & Cancer, V2, P132, DOI 10.1007/s12672-011-0067-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kurihara I, 2007, PLOS GENET, V3, P1053, DOI 10.1371/journal.pgen.0030102; Ladd B, 2016, ONCOTARGET, V7, P54120, DOI 10.18632/oncotarget.10852; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Mulder KW, 2012, NAT CELL BIOL, V14, P753, DOI 10.1038/ncb2520; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Perdomo J, 2002, EUR J BIOCHEM, V269, P5885, DOI 10.1046/j.1432-1033.2002.03313.x; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sanchez-Garcia F, 2014, CELL, V159, P1461, DOI 10.1016/j.cell.2014.10.048; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P453, DOI 10.1016/j.tem.2015.08.002; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Wu LL, 2014, ONCOTARGET, V5, P7677, DOI 10.18632/oncotarget.2291; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	39	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5281	5291		10.1038/s41388-018-0312-2	http://dx.doi.org/10.1038/s41388-018-0312-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29895970	Green Submitted, Green Accepted			2022-12-28	WOS:000445759700003
J	Wang, KX; Ji, WX; Yu, YF; Li, ZM; Niu, XM; Xia, WL; Lu, S				Wang, Kaixuan; Ji, Wenxiang; Yu, Yongfeng; Li, Ziming; Niu, Xiaomin; Xia, Weiliang; Lu, Shun			FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer	ONCOGENE			English	Article							FACTOR RECEPTOR 1; FGFR1 AMPLIFICATION; GROWTH; SOX2; STEM; INHIBITOR; MECHANISMS; SURVIVAL; GENE; EMT	Epithelial-mesenchymal transition (EMT) is an important process for cancer metastasis, drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 (FGFR1) was found to promote EMT and metastasis in prostate and breast cancers, but the effects and mechanisms in lung cancer was unclear. In this study, we aimed to explore whether and how activation of FGFR1 promotes EMT and metastasis in FGFR1-amplified lung cancer. We show that activation of FGFR1 by its ligand fibroblast growth factor 2 (FGF2) promoted proliferation, EMT, migration, and invasion in FGFR1-amplified lung cancer cell lines H1581 and DMS114, whereas inhibition of FGFR1 suppressed these processes. FGFR1 activation upregulated expression of Sry-related HMG box 2 (SOX2) by downstream phosphorylated ERK1/2; moreover, the upregulation of SOX2 by autophosphorylation variant ERK2_R67S plasmid transfection was not suppressed by FGFR1 inhibitor AZD4547 or MEK/ERK inhibitor AZD6244 in vitro. And SOX2 expression was also significantly upregulated in ERK2_R67S lentivirus-transfected stable cell lines in vivo. Overexpression of SOX2 promoted cell proliferation, EMT, migration, and invasion. Importantly, activation of FGFR1 could not promote these processes in SOX2-silenced stable cell lines. In orthotopic and subcutaneous lung cancer xenograft models, inhibition of FGFR1 suppressed tumor growth, SOX2 expression, EMT, and metastasis in vivo; however, these processes caused by SOX2-overexpressing stable cell lines were not suppressed by FGFR1 inhibition. Higher expression of FGFR1 and SOX2 were positively correlated, and both were associated with shorter survival in lung cancer patients. In conclusion, our findings reveal that activation of FGFR1 promotes cell proliferation, EMT, and metastasis by the newly defined FGFR1-ERK1/2-SOX2 axis in FGFR1-amplified lung cancer.	[Wang, Kaixuan; Ji, Wenxiang; Yu, Yongfeng; Li, Ziming; Niu, Xiaomin; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, West Huaihai Rd 241, Shanghai 200030, Peoples R China; [Wang, Kaixuan; Xia, Weiliang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Huashan Rd 1954, Shanghai 200030, Peoples R China; [Wang, Kaixuan; Xia, Weiliang] Shanghai Jiao Tong Univ, MedX Res Inst, Huashan Rd 1954, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Lu, S (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, West Huaihai Rd 241, Shanghai 200030, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Huashan Rd 1954, Shanghai 200030, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, MedX Res Inst, Huashan Rd 1954, Shanghai 200030, Peoples R China.	wlxia@sjtu.edu.cn; shunlu@sjtu.edu.cn	Lu, Shun/ABF-8341-2021; XIA, WEILIANG/AEA-0835-2022	XIA, WEILIANG/0000-0002-0256-4219	National Key R&D Program of China [2016YFC1303300]; National Natural Science Foundation of China [81672272, 81773115]; National Key Grant of China [2016YFC0906400]; Shanghai Health & Family Planning Commission [201540365]; Shanghai Municipal Science & Technology Commission [17431906103]; Shanghai Scientific Research Projects [14140902800]; AstraZeneca	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Grant of China; Shanghai Health & Family Planning Commission; Shanghai Municipal Science & Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Scientific Research Projects; AstraZeneca(AstraZeneca)	This work was funded by the National Key R&D Program of China (2016YFC1303300 to S.L.), the National Natural Science Foundation of China (81672272 to S.L. and 81773115 to W.X.), the National Key Grant of China (2016YFC0906400 to W.X.), the Key Project of Shanghai Health & Family Planning Commission (201540365 to S.L.), Shanghai Municipal Science & Technology Commission Research Project (17431906103 to S.L.), and Shanghai Scientific Research Projects (14140902800 to S.L.) We thank Wangxi Hai and Med-X Ruijin Hospital Micro PET/CT Research Center for the microCT scan and analysis. We thank AstraZeneca Pharmaceutical Company for kindly supply of AZD4547 and AstraZeneca Research Funding.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Adachi Y, 2017, CARCINOGENESIS, V38, P1063, DOI 10.1093/carcin/bgx091; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brady DC, 2014, NATURE, V509, P492, DOI 10.1038/nature13180; Brewer JR, 2016, GENE DEV, V30, P751, DOI 10.1101/gad.277137.115; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Chen YJ, 2014, BIOMATERIALS, V35, P10058, DOI 10.1016/j.biomaterials.2014.09.003; Datta J, 2017, MOL CANCER THER, V16, P614, DOI 10.1158/1535-7163.MCT-15-1010; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Goke F, 2015, CLIN CANCER RES, V21, P4356, DOI 10.1158/1078-0432.CCR-14-3357; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanna N, 2017, J CLIN ONCOL, V35, P3484, DOI 10.1200/JCO.2017.74.6065; Hu YP, 2016, ONCOTARGET, V7, P87124, DOI 10.18632/oncotarget.13547; Jakobsen KR, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.17; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Ji WX, 2016, ONCOTARGET, V7, P15118, DOI 10.18632/oncotarget.7701; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh M, 2016, TRENDS PHARMACOL SCI, V37, P1081, DOI 10.1016/j.tips.2016.10.003; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim HR, 2017, ANN ONCOL, V28, P1250, DOI 10.1093/annonc/mdx098; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kim M, 2017, ONCOGENE, V36, P5199, DOI 10.1038/onc.2017.4; Kotani H, 2016, ONCOGENE, V35, P3587, DOI 10.1038/onc.2015.426; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Lim SH, 2016, CANCER-AM CANCER SOC, V122, P3024, DOI 10.1002/cncr.30135; Maehara O, 2017, CARCINOGENESIS, V38, P1073, DOI 10.1093/carcin/bgx095; Malchers F, 2017, CLIN CANCER RES, V23, P5527, DOI 10.1158/1078-0432.CCR-17-0478; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Mandal R, 2016, ONCOGENE, V35, P2547, DOI 10.1038/onc.2015.329; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Paik PK, 2017, CLIN CANCER RES, V23, P5366, DOI 10.1158/1078-0432.CCR-17-0645; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Peng L, 2014, NANOMED-NANOTECHNOL, V10, P1497, DOI 10.1016/j.nano.2014.03.016; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schultheis AM, 2014, MODERN PATHOL, V27, P214, DOI 10.1038/modpathol.2013.141; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singleton KR, 2015, CANCER RES, V75, P4398, DOI 10.1158/0008-5472.CAN-15-0509; Sousa V, 2016, VIRCHOWS ARCH, V469, P173, DOI 10.1007/s00428-016-1954-5; Tan Q, 2016, ONCOTARGET, V7, P18394, DOI 10.18632/oncotarget.7817; Taniguchi J, 2017, NUCLEIC ACIDS RES, V45, P9219, DOI 10.1093/nar/gkx693; Terry S, 2017, MOL ONCOL, V11, P824, DOI 10.1002/1878-0261.12093; Thomas A, 2014, J THORAC ONCOL, V9, P567, DOI 10.1097/JTO.0000000000000089; Toschi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095303; Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008-5472.CAN-16-2874; Wang L, 2016, ONCOGENE, V35, P867, DOI 10.1038/onc.2015.141; Weina K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-19; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuan H, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0534-0; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694	68	78	81	1	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5340	5354		10.1038/s41388-018-0311-3	http://dx.doi.org/10.1038/s41388-018-0311-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858603				2022-12-28	WOS:000445759700007
J	Chen, J; Li, WJ; Cui, K; Ji, KY; Xu, SX; Xu, Y				Chen, Jian; Li, Wenjuan; Cui, Ke; Ji, Kaiyuan; Xu, Shuxiang; Xu, Yang			Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway	ONCOGENE			English	Article							II-BETA; COLORECTAL-CANCER; STRAND BREAKS; CELLS; ANTICANCER; INHIBITION; DOXORUBICIN; PROTECTS; TARGET	Cancer chemotherapeutic agents such as doxorubicin are DNA damage inducers that also kill normal cells, making them highly toxic to cancer patients. To improve the efficacy and safety of chemotherapy, it is important to develop new chemotherapeutic agents that selectively kill cancer cells. Here we demonstrate that artemisitene (ATT), a natural derivative of the antimalarial drug artemisinin, selectively induces DNA double-stranded breaks (DSBs) and apoptosis in various human cancer cells by suppressing the expression of topoisomerases in human cancer cells. ATT effectively kills human cancer cells without apparent cytotoxicity on normal human cells or mouse liver and kidney. We discovered that c-Myc induces the expression of topoisomerases to prevent accumulation of DNA damage in human cancer cells. ATT selectively destabilizes c-Myc in human cancer cells by promoting the ubiquitination of c-Myc through the specific induction of the c-Myc E3 ligase NEDD4. Therefore, ATT represents a promising new chemotherapeutic drug candidate that can eliminate human cancer cells with minimized cytotoxic effects on normal cells.	[Chen, Jian; Ji, Kaiyuan; Xu, Shuxiang; Xu, Yang] Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Tumor Immunotherapy, Guangzhou 510515, Guangdong, Peoples R China; [Li, Wenjuan; Cui, Ke; Xu, Yang] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat & Translat Med, Guangzhou 510632, Guangdong, Peoples R China; [Xu, Yang] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Southern Medical University - China; Guangzhou University of Chinese Medicine; University of California System; University of California San Diego	Xu, Y (corresponding author), Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Tumor Immunotherapy, Guangzhou 510515, Guangdong, Peoples R China.; Xu, Y (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat & Translat Med, Guangzhou 510632, Guangdong, Peoples R China.; Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Chen, Jian/0000-0001-7535-6499	Postdoctoral Science Foundation of China [2015M582371]; NSFC [81430032, U1601222, 81502595]; Guangdong Provincial Key Laboratory of Cancer Immunotherapy; Guangzhou Key Laboratory of Tumor Immunology Research; Guangdong Provincial Key Special Science and Technology Project [2015B020225004]; Guangdong NSF Major basic research developmental project; California Institute for Regenerative Medicine	Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); NSFC(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Key Laboratory of Cancer Immunotherapy; Guangzhou Key Laboratory of Tumor Immunology Research; Guangdong Provincial Key Special Science and Technology Project; Guangdong NSF Major basic research developmental project; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	Wenjuan Li was supported by a fellowship from Postdoctoral Science Foundation of China (2015M582371). This study was supported by NSFC (nos. 81430032, U1601222, 81502595), Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, Guangdong Provincial Key Special Science and Technology Project (2015B020225004), Guangdong NSF Major basic research developmental project, and grants from California Institute for Regenerative Medicine.	Azarova AM, 2007, P NATL ACAD SCI USA, V104, P11014, DOI 10.1073/pnas.0704002104; Bandi S, 2011, AM J PATHOL, V178, P161, DOI 10.1016/j.ajpath.2010.11.001; Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229; Bollimpelli VS, 2017, ARCH BIOCHEM BIOPHYS, V633, P78, DOI 10.1016/j.abb.2017.06.021; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen WM, 2016, FASEB J, V30, P2500, DOI 10.1096/fj.201500109R; Chen Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11057; Choi WH, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030030; Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002; Chumduri C, 2013, CELL HOST MICROBE, V13, P746, DOI 10.1016/j.chom.2013.05.010; Cowell IG, 2012, P NATL ACAD SCI USA, V109, P8989, DOI 10.1073/pnas.1204406109; Cuya SM, 2017, CANCER CHEMOTH PHARM, V80, P1, DOI 10.1007/s00280-017-3334-5; Damiani RM, 2016, ARCH TOXICOL, V90, P2063, DOI 10.1007/s00204-016-1759-y; Efferth T, 2011, PHYTOMEDICINE, V18, P959, DOI 10.1016/j.phymed.2011.06.008; Ezoe S, 2012, INT J ENV RES PUB HE, V9, P2444, DOI 10.3390/ijerph9072444; Farrell AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014365; Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hsu E, 2006, T ROY SOC TROP MED H, V100, P505, DOI 10.1016/j.trstmh.2005.09.020; Jadaun A, 2017, J PHOTOCH PHOTOBIO B, V167, P299, DOI 10.1016/j.jphotobiol.2017.01.010; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Kim EJ, 2017, TOXICOL APPL PHARM, V330, P84, DOI 10.1016/j.taap.2017.07.007; Kim J, 2017, ONCOGENE, V36, P6472, DOI 10.1038/onc.2017.265; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Lake BB, 2012, STEM CELLS, V30, P888, DOI 10.1002/stem.1054; Li T, 2012, INT IMMUNOPHARMACOL, V12, P144, DOI 10.1016/j.intimp.2011.11.004; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Lyu YL, 2007, CANCER RES, V67, P8839, DOI 10.1158/0008-5472.CAN-07-1649; Matsumoto Y, 2005, J MED INVESTIG, V52, P41, DOI 10.2152/jmi.52.41; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Ooko E, 2015, PHYTOMEDICINE, V22, P1045, DOI 10.1016/j.phymed.2015.08.002; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Posner GH, 2002, BIOORGAN MED CHEM, V10, P227, DOI 10.1016/S0968-0896(01)00270-X; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rubin EH, 2000, HUM PATHOL, V31, P631, DOI 10.1053/hupa.2000.8629; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Singh S, 2012, FREE RADICAL BIO MED, V53, P1782, DOI 10.1016/j.freeradbiomed.2012.07.025; Slezakova S, 2017, ANTICANCER RES, V37, P5995, DOI 10.21873/anticanres.12046; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Xu SM, 2016, PROTEIN CELL, V7, P684, DOI 10.1007/s13238-016-0297-y; Zhang P, 2010, BRIT J CANCER, V102, P862, DOI 10.1038/sj.bjc.6605572	44	18	19	2	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5079	5087		10.1038/s41388-018-0331-z	http://dx.doi.org/10.1038/s41388-018-0331-z			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29795406				2022-12-28	WOS:000444405300004
J	Gabbasov, R; Xiao, F; Howe, CG; Bickel, LE; O'Brien, SW; Benrubi, D; Do, TV; Zhou, Y; Nicolas, E; Cai, KQ; Litwin, S; Seo, S; Golemis, EA; Connolly, DC				Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G.; Bickel, Laura E.; O'Brien, Shane W.; Benrubi, Daniel; Do, Thuy-Vy; Zhou, Yan; Nicolas, Emmanuelle; Cai, Kathy Q.; Litwin, Samuel; Seo, Sachiko; Golemis, Erica A.; Connolly, Denise C.			NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice	ONCOGENE			English	Article							SUBSTRATE LYMPHOCYTE TYPE; EPITHELIAL-CELL; FALLOPIAN-TUBE; T-CELLS; EXPRESSION; CARCINOMA; KINASE; DIFFERENTIATION; MIGRATION; SURVIVAL	Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) supports oncogenic signaling in a number of solid and hematologic tumors. Little is known about the role of NEDD9 in ovarian carcinoma (OC), but available data suggest elevated mRNA and protein expression in advanced stage high-grade cancers. We used a transgenic MISIIR-TAg mouse OC model combined with genetic ablation of Nedd9 to investigate its action in the development and progression of OC. A Nedd9(-/-)genotype delayed tumor growth rate, reduced incidence of ascites, and reduced expression and activation of signaling proteins including SRC, STAT3, E-cadherin, and AURKA. Cell lines established from MISIIR-TAg; Nedd9(-/-) and MISIIR-TAg; Nedd9(+/+) mice exhibited altered migration and invasion. Growth of these cells in a syngeneic allograft model indicated that systemic Nedd9 loss in the microenvironment had little impact on tumor allograft growth, but in a Nedd9 wildtype background Nedd9(-/-) allografts exhibited significantly reduced growth, dissemination, and oncogenic signaling compared to Nedd9(+/+) allografts. Gene expression analysis revealed that Nedd9(+/+) tumors exhibited more mesenchymal "stem-like" transcriptional program, including increased expression of Aldh1a1 and Aldh1a2. Conversely, loss of Nedd9 resulted in increased expression of differentiation genes, including fallopian tube markers Foxj1, Ovgp1, and Pax8. Collectively, these data suggest that tumor cell-intrinsic Nedd9 expression promotes OC development and progression by broad induction of oncogenic protein signaling and stem/mesenchymal gene expression.	[Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G.; Bickel, Laura E.; O'Brien, Shane W.; Do, Thuy-Vy; Golemis, Erica A.; Connolly, Denise C.] Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Gabbasov, Rashid] Kazan Fed Univ, Dept Biochem & Biotechnol, Kazan, Russia; [Benrubi, Daniel] Fox Chase Canc Ctr, Div Gynecol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Zhou, Yan; Litwin, Samuel] Fox Chase Canc Ctr, Biostat & Bioinformat Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Nicolas, Emmanuelle] Fox Chase Canc Ctr, Genom Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Cai, Kathy Q.] Fox Chase Canc Ctr, Histopathol Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Seo, Sachiko] Natl Canc Res Ctr East, Dept Hematol & Oncol, Kashiwa, Chiba, Japan	Fox Chase Cancer Center; Kazan Federal University; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center	Connolly, DC (corresponding author), Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	Denise.Connolly@fccc.edu	Gabbasov, Rashid/D-2482-2019; Howe, Caitlin/ABF-3709-2020	Gabbasov, Rashid/0000-0001-7621-7407; Howe, Caitlin/0000-0002-4935-9298; Golemis, Erica/0000-0003-3618-3673	Ovarian SPORE [P50 CA083638]; FCCC Core Grant [NCI P30 CA006927];  [R01 CA136596];  [R01 CA63366]; NATIONAL CANCER INSTITUTE [R01CA063366, R01CA136596, P50CA083638, P30CA006927] Funding Source: NIH RePORTER	Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FCCC Core Grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 CA136596 (to DCC); R01 CA63366 (to EAG); Ovarian SPORE P50 CA083638, the FCCC Core Grant NCI P30 CA006927, and charitable donations from the Roberta Dubrow Fund, the Teal Tea Foundation, and the Bucks County Board of Associates (to DCC).	Beck TN, 2014, PHYSIOL GENOMICS, V46, P699, DOI 10.1152/physiolgenomics.00062.2014; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Colvin EK, 2014, SEMIN CELL DEV BIOL, V27, P61, DOI 10.1016/j.semcdb.2014.02.004; Connolly DC, 2003, CANCER RES, V63, P1389; Connolly DC, 2009, CURR PROTOC PHARM; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632; Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Fuller ES, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00057; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hensley H, 2007, CANCER BIOL THER, V6, P1717, DOI 10.4161/cbt.6.11.4830; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Liu HQ, 2013, CLIN CANCER RES, V19, P5053, DOI 10.1158/1078-0432.CCR-13-1115; Ma Y, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-85; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; Natraj U, 2002, BIOL REPROD, V67, P1897, DOI 10.1095/biolreprod67.6.1897; Nikonova AS, 2014, IUBMB LIFE, V66, P387, DOI 10.1002/iub.1282; Okada A, 2004, J MOL ENDOCRINOL, V32, P615, DOI 10.1677/jme.0.0320615; Paik DY, 2012, STEM CELLS, V30, P2487, DOI 10.1002/stem.1207; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Quinn BA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-24; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; Schwede M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057799; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Seo S, 2011, CANCER SCI, V102, P2109, DOI 10.1111/j.1349-7006.2011.02066.x; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sivertsen S, 2006, ACTA CYTOL, V50, P603, DOI 10.1159/000326027; Thomas J, 2010, BIOL CELL, V102, P499, DOI 10.1042/BC20100035; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Wang HX, 2014, HUM PATHOL, V45, P401, DOI 10.1016/j.humpath.2013.10.005; Wang Z, 2016, ONCOTARGET, V8, P1714; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Xu S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05646; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhong J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035058	56	15	16	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4854	4870		10.1038/s41388-018-0296-y	http://dx.doi.org/10.1038/s41388-018-0296-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773902	Green Accepted			2022-12-28	WOS:000443146000007
J	White, MC; Schroeder, RD; Zhu, K; Xiong, K; McConkey, DJ				White, Matthew C.; Schroeder, Rebecca D.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.			HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells	ONCOGENE			English	Article							INITIATION-FACTOR 2; REGULATED EIF-2-ALPHA KINASE; PROTEASOME INHIBITION LEADS; UNFOLDED PROTEIN RESPONSE; MULTIPLE-MYELOMA CELLS; HEAT-SHOCK PROTEINS; EIF2-ALPHA KINASE; OXIDATIVE STRESS; PARKINSONS-DISEASE; ACTIVATION LOOP	Human cancer cells display extensive heterogeneity in their sensitivities to the proteasome inhibitor bortezomib (Velcade). The molecular mechanisms underlying this heterogeneity remain unclear, and strategies to overcome resistance are limited. Here, we discover that inherent differences in eIF2 alpha phosphorylation among a panel of ten human pancreatic cancer cell lines significantly impacts bortezomib sensitivity, and implicate the HRI (heme-regulated inhibitor) eIF2 alpha kinase as a novel therapeutic target. Within our panel, we identified a subset of cell lines with defective induction of eIF2 alpha phosphorylation, conferring a high degree of sensitivity to bortezomib. These bortezomib-sensitive cells exhibited impaired translation attenuation followed by toxic accumulation of protein aggregates and reactive oxygen species (ROS), whereas the bortezomib-resistant cell lines displayed increased phosphorylation of eIF2 alpha, decreased translation, few protein aggregates, and minimal ROS production. Importantly, we identified HRI as the primary bortezomib-activated eIF2 alpha kinase, and demonstrated that HRI knockdown promoted cell death in the bortezomib-resistant cells. Overall, our data implicate inducible HRI-mediated phosphorylation of eIF2 alpha as a central cytoprotective mechanism following exposure to bortezomib and provide proof-of-concept for the development of HRI inhibitors to overcome proteasome inhibitor resistance.	[White, Matthew C.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [White, Matthew C.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [White, Matthew C.; Schroeder, Rebecca D.; McConkey, David J.] Univ Texas Grad Sch Biomed Sci, Program Expt Therapeut, Houston, TX 77030 USA; [McConkey, David J.] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21287 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University	McConkey, DJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Univ Texas Grad Sch Biomed Sci, Program Expt Therapeut, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21287 USA.	djmcconkey@jhmi.edu		Xiong, Katherine/0000-0002-1603-2037; White, Matthew/0000-0002-8274-0453; Schroeder, Rebecca/0000-0002-7336-1857	NIH/NCI [R01 CA127494]; M.D. Anderson Cancer Center Support Grant [P30 CA016672-38]; Albert Schweitzer Fellowship; Tzu-Chi Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA127494] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); M.D. Anderson Cancer Center Support Grant; Albert Schweitzer Fellowship; Tzu-Chi Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from NIH/NCI (R01 CA127494), and the M.D. Anderson Cancer Center Support Grant P30 CA016672-38 (D.J.M.). M.C.W. would like to acknowledge awards from The Albert Schweitzer Fellowship and the Tzu-Chi Foundation	Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Burwick N, 2017, LEUKEMIA RES, V55, P23, DOI 10.1016/j.leukres.2017.01.007; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chen SQ, 2010, CANCER RES, V70, P4318, DOI 10.1158/0008-5472.CAN-09-4428; Fournier MJ, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-12; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Goldberg AL, 2000, NAT BIOTECHNOL, V18, P494, DOI 10.1038/75349; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; He Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024855; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Knutsen JHJ, 2015, J CELL SCI, V128, P4420, DOI 10.1242/jcs.176545; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Mittal SPK, 2014, INT J BIOCHEM CELL B, V54, P186, DOI 10.1016/j.biocel.2014.07.016; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Rafie-Kolpin M, 2003, BIOCHEMISTRY-US, V42, P6536, DOI 10.1021/bi034005v; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Vilas-Boas FDS, 2016, J NEURO-ONCOL, V127, P253, DOI 10.1007/s11060-015-2043-3; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Taniuchi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32886; Uma S, 1999, MOL CELL BIOL, V19, P5861; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Wengrod J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0899; Weniger MA, 2011, CLIN CANCER RES, V17, P5101, DOI 10.1158/1078-0432.CCR-10-3367; WU DL, 2011, JOVE J VIS EXP NOV, P14220, DOI DOI 10.3791/3357; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xu WP, 2011, CANCER CELL, V20, P281, DOI 10.1016/j.ccr.2011.08.020; Yefidoff-Freedman R, 2017, J MED CHEM, V60, P5392, DOI 10.1021/acs.jmedchem.7b00059; Yerlikaya A, 2008, BIOCHEM J, V412, P579, DOI 10.1042/BJ20080324; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343; Zhu KY, 2009, CANCER RES, V69, P1836, DOI 10.1158/0008-5472.CAN-08-4103	57	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4413	4427		10.1038/s41388-018-0227-y	http://dx.doi.org/10.1038/s41388-018-0227-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720726	Green Accepted			2022-12-28	WOS:000441144300006
J	Heukers, R; Fan, TS; de Wit, RH; van Senten, JR; De Groof, TWM; Bebelman, MP; Lagerweij, T; Vieira, J; de Munnik, SM; Smits-de Vries, L; van Offenbeek, J; Rahbar, A; van Hoorick, D; Soderberg-Naucler, C; Wurdinger, T; Leurs, R; Siderius, M; Vischer, HF; Smit, MJ				Heukers, Raimond; Fan, Tian Shu; de Wit, Raymond H.; van Senten, Jeffrey R.; De Groof, Timo W. M.; Bebelman, Maarten P.; Lagerweij, Tonny; Vieira, Joao; de Munnik, Sabrina M.; Smits-de Vries, Laura; van Offenbeek, Jody; Rahbar, Afsar; van Hoorick, Diane; Soderberg-Naucler, Cecilia; Wurdinger, Thomas; Leurs, Rob; Siderius, Marco; Vischer, Henry F.; Smit, Martine J.			The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN CYTOMEGALOVIRUS US28; IN-VIVO; NERVOUS-SYSTEM; NECK-CANCER; NANOBODIES; CELLS; PROMOTES; INFECTION; THERAPY	Glioblastoma (GBM) is the most aggressive and an incurable type of brain cancer. Human cytomegalovirus (HCMV) DNA and encoded proteins, including the chemokine receptor US28, have been detected in GBM tumors. US28 displays constitutive activity and is able to bind several human chemokines, leading to the activation of various proliferative and inflammatory signaling pathways. Here we show that HCMV, through the expression of US28, significantly enhanced the growth of 3D spheroids of U251- and neurospheres of primary glioblastoma cells. Moreover, US28 expression accelerated the growth of glioblastoma cells in an orthotopic intracranial GBM-model in mice. We developed highly potent and selective US28-targeting nanobodies, which bind to the extracellular domain of US28 and detect US28 in GBM tissue. The nanobodies inhibited chemokine binding and reduced the constitutive US28-mediated signaling with nanomolar potencies and significantly impaired HCMV/US28-mediated tumor growth in vitro and in vivo. This study emphasizes the oncomodulatory role of HCMV-encoded US28 and provides a potential therapeutic approach for HCMV-positive tumors using the nanobody technology.	[Heukers, Raimond; Fan, Tian Shu; de Wit, Raymond H.; van Senten, Jeffrey R.; De Groof, Timo W. M.; Bebelman, Maarten P.; de Munnik, Sabrina M.; Smits-de Vries, Laura; van Offenbeek, Jody; Leurs, Rob; Siderius, Marco; Vischer, Henry F.; Smit, Martine J.] Vrije Univ, Fac Sci, Div Med Chem, AIMMS, De Boelelaan 1108, NL-1081 HZ Amsterdam, Netherlands; [Lagerweij, Tonny; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Neurooncol Res Grp, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands; [Vieira, Joao; van Hoorick, Diane] Ablynx NV, Technol Pk 21, B-9052 Zwijnaarde, Belgium; [Rahbar, Afsar; Soderberg-Naucler, Cecilia] Karolinska Inst, Dept Med Solna, Ctr Mol Med, Expt Cardiovasc Res Unit, S-17177 Stockholm, Sweden; [Rahbar, Afsar; Soderberg-Naucler, Cecilia] Karolinska Inst, Ctr Mol Med, Dept Med & Neurol, S-17177 Stockholm, Sweden	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Karolinska Institutet; Karolinska Institutet	Smit, MJ (corresponding author), Vrije Univ, Fac Sci, Div Med Chem, AIMMS, De Boelelaan 1108, NL-1081 HZ Amsterdam, Netherlands.	mj.smit@vu.nl	Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022; Wurdinger, Thomas/AAA-5645-2022; van Senten, Jeffrey/AAH-4348-2021; Lagerweij, Tonny/AAY-7128-2020; Heukers, Raimond/H-9403-2013	Leurs, Rob/0000-0003-1354-2848; Rahbar, Afsar/0000-0003-1158-2512; Smit, Martine/0000-0003-2713-0238; van Senten, Jeffrey Roy/0000-0002-1096-6891; Heukers, Raimond/0000-0003-4498-7751; Bebelman, Maarten/0000-0003-4007-5093; De Groof, Timo/0000-0001-6918-2955	Netherlands Organization for Scientific Research (NWO: Vici grant) [016.140.657]; Dutch Technology Foundation (STW) [11462]	Netherlands Organization for Scientific Research (NWO: Vici grant)(Netherlands Organization for Scientific Research (NWO)); Dutch Technology Foundation (STW)(Technologiestichting STW)	This work was supported by the Netherlands Organization for Scientific Research (NWO: Vici grant 016.140.657) and the Dutch Technology Foundation (STW, 11462).	Baryawno N, 2011, J CLIN INVEST, V121, P4043, DOI 10.1172/JCI57147; Bhattacharjee B, 2012, J VIROL, V86, P6815, DOI 10.1128/JVI.00015-12; Bongers G, 2010, J CLIN INVEST, V120, P3969, DOI 10.1172/JCI42563; Bradley ME, 2015, MOL PHARMACOL, V87, P251, DOI 10.1124/mol.114.094821; Burg JS, 2015, SCIENCE, V347, P1113, DOI 10.1126/science.aaa5026; Burger M, 1999, J IMMUNOL, V163, P2017; Bush NAO, 2017, NEUROSURG REV, V40, P1, DOI 10.1007/s10143-016-0709-8; Caretti V, 2014, ACTA NEUROPATHOL, V127, P897, DOI 10.1007/s00401-014-1272-4; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cobbs C, 2014, NEURO-ONCOLOGY, V16, P1435, DOI 10.1093/neuonc/nou295; Cobbs CS, 2002, CANCER RES, V62, P3347; De Tavernier E, 2016, J BIOL CHEM, V291, P15243, DOI 10.1074/jbc.M115.684241; de Wit RH, 2017, J PHARMACOL EXP THER, V363, P35, DOI 10.1124/jpet.117.242735; de Wit RH, 2016, ONCOTARGET, V7, P67966, DOI 10.18632/oncotarget.11817; Dziurzynski K, 2012, NEURO-ONCOLOGY, V14, P246, DOI 10.1093/neuonc/nor227; GAO JL, 1994, J BIOL CHEM, V269, P28539; Hadaczek P, 2013, CLIN CANCER RES, V19, P6473, DOI 10.1158/1078-0432.CCR-13-1121; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Humby MS, 2016, J VIROL, V90, P2959, DOI 10.1128/JVI.02507-15; Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107; Jansen MHA, 2016, MOL CANCER THER, V15, P2166, DOI 10.1158/1535-7163.MCT-15-0558; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Krishna BA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14321; Lamszus K, 2003, CLIN CANCER RES, V9, P1399; Langemeijer EV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048935; Li YM, 2010, TOXINS, V2, P2645, DOI 10.3390/toxins2112645; Lollinga WT, 2017, TRANSPLANTATION, V101, P531, DOI 10.1097/TP.0000000000001289; Manglik A, 2017, ANNU REV PHARMACOL, V57, P19, DOI 10.1146/annurev-pharmtox-010716-104710; Mason GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003635; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; Maussang D, 2013, J BIOL CHEM, V288, P29562, DOI 10.1074/jbc.M113.498436; Maussang D, 2009, CANCER RES, V69, P2861, DOI 10.1158/0008-5472.CAN-08-2487; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Mujic-Delic A, 2014, TRENDS PHARMACOL SCI, V35, P247, DOI 10.1016/j.tips.2014.03.003; Noriega VM, 2014, VIRUSES-BASEL, V6, P1202, DOI 10.3390/v6031202; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Peng CW, 2016, MOL CLIN ONCOL, V4, P154, DOI 10.3892/mco.2015.692; Rahbar Afsar, 2012, Herpesviridae, V3, P3, DOI 10.1186/2042-4280-3-3; Sinclair JH, 2013, VIRUSES-BASEL, V5, P2803, DOI 10.3390/v5112803; Slinger E, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001180; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; Soderberg-Naucler C, 2013, NEW ENGL J MED, V369, P985, DOI 10.1056/NEJMc1302145; Soroceanu L, 2011, CANCER RES, V71, P6643, DOI 10.1158/0008-5472.CAN-11-0744; Stanton RJ, 2010, J CLIN INVEST, V120, P3191, DOI 10.1172/JCI42955; STEENSGAARD J, 1977, IMMUNOLOGY, V32, P445; Stragliotto G, 2013, INT J CANCER, V133, P1204, DOI 10.1002/ijc.28111; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Taha MS, 2016, BRIT J NEUROSURG, V30, P307, DOI 10.3109/02688697.2015.1119241; Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384; van Driel PBAA, 2016, J CONTROL RELEASE, V229, P93, DOI 10.1016/j.jconrel.2016.03.014; Vischer HF, 2014, NAT REV DRUG DISCOV, V13, P123, DOI 10.1038/nrd4189; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177	55	40	41	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4110	4121		10.1038/s41388-018-0255-7	http://dx.doi.org/10.1038/s41388-018-0255-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706656	hybrid, Green Published			2022-12-28	WOS:000439847000005
J	Chu, PC; Lin, PC; Wu, HY; Lin, KT; Wu, C; Bekaii-Saab, T; Lin, YJ; Lee, CT; Lee, JC; Chen, CS				Chu, Po-Chen; Lin, Peng-Chan; Wu, Hsing-Yu; Lin, Kuen-Tyng; Wu, Christina; Bekaii-Saab, Tanios; Lin, Yih-Jyh; Lee, Chung-Ta; Lee, Jeng-Chang; Chen, Ching-Shih			Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STRONG YB-1 EXPRESSION; I RECEPTOR GENE; GROWTH; MIR-137; CELLS; RESECTION; INVASION; MUTATIONS; SURVIVAL	Although the role of insulin-like growth factor-I receptor (IGF-IR) in promoting colorectal liver metastasis is known, the mechanism by which IGF-IR is upregulated in colorectal cancer (CRC) is not defined. In this study, we obtained evidence that mutant KRAS transcriptionally activates IGF-IR gene expression through Y-box-binding protein (YB)-1 upregulation via a novel MEK-Sp1-DNMT1-miR-137 pathway in CRC cells. The mechanistic link between the tumor suppressive miR-137 and the translational regulation of YB-1 is intriguing because epigenetic silencing of miR-137 represents an early event in colorectal carcinogenesis due to promoter hypermethylation. This proposed signaling axis was further verified by the immunohistochemical evaluations of liver metastases from a cohort of 46 KRAS mutant CRC patients, which showed a significant correlation in the expression levels among Sp1, miR-137, YB-1, and IGF-1R. Moreover, suppression of the expression of YB-1 and IGF-IR via genetic knockdown or the pharmacological inhibition of MEK hampers KRAS-driven colorectal liver metastasis in our animal model studies. From a translational perspective, the identification of this KRAS-driven pathway might provide a mechanistic rationale for the use of a MEK inhibitor as an adjuvant, in combination with standard of care, to prevent the recurrence of colorectal liver metastasis in KRAS mutant CRC patients after receiving liver resection, which warrants further investigation.	[Chu, Po-Chen; Wu, Hsing-Yu; Lin, Kuen-Tyng; Chen, Ching-Shih] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; [Chu, Po-Chen; Chen, Ching-Shih] China Med Univ, Coll Biopharmaceut & Food Sci, Inst New Drug Dev, Taichung 40402, Taiwan; [Lin, Peng-Chan] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70403, Taiwan; [Wu, Hsing-Yu; Chen, Ching-Shih] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 10617, Taiwan; [Wu, Christina] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Bekaii-Saab, Tanios] Mayo Clin, Canc Ctr, Coll Med & Sci, Phoenix, AZ 85054 USA; [Lin, Yih-Jyh; Lee, Jeng-Chang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 70403, Taiwan; [Lee, Chung-Ta] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan 70403, Taiwan	Academia Sinica - Taiwan; China Medical University Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Taiwan University; Emory University; Mayo Clinic; Mayo Clinic Phoenix; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Chen, CS (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.; Chen, CS (corresponding author), China Med Univ, Coll Biopharmaceut & Food Sci, Inst New Drug Dev, Taichung 40402, Taiwan.; Chen, CS (corresponding author), Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 10617, Taiwan.	cschenibc@gmail.com		Bekaii-Saab, Tanios/0000-0001-7721-1699	Ministry of Science and Technology [MOST 105-2320-B-001-004]; American Cancer Society Seed grant; Paul Calabresi Scholar K12 Training grant; Academia Sinica; Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); American Cancer Society Seed grant(American Cancer Society); Paul Calabresi Scholar K12 Training grant; Academia Sinica(Academia Sinica - Taiwan); Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine	This work was supported by the Ministry of Science and Technology grant MOST 105-2320-B-001-004 (P-CC), American Cancer Society Seed grant (CW), Paul Calabresi Scholar K12 Training grant (CW), intramural funding from Academia Sinica (C-SC), Bi-Institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine (C-SC).	Adam R, 2009, J CLIN ONCOL, V27, P1829, DOI 10.1200/JCO.2008.19.9273; Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Ardito F, 2014, J GASTROINTEST SURG, V18, P1987, DOI 10.1007/s11605-014-2657-3; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bennouna J, 2011, INVEST NEW DRUG, V29, P1021, DOI 10.1007/s10637-010-9392-8; Brand Toni M, 2012, Small GTPases, V3, P34, DOI 10.4161/sgtp.18751; Brudvik KW, 2015, BRIT J SURG, V102, P1175, DOI 10.1002/bjs.9870; Busch EL, 2014, CANCER EPIDEM BIOMAR, V23, P1164, DOI 10.1158/1055-9965.EPI-14-0017; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Chattopadhyay N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144825; Chen DL, 2013, CARCINOGENESIS, V34, P803, DOI 10.1093/carcin/bgs400; Chibi M, 2008, J MOL BIOL, V384, P908, DOI 10.1016/j.jmb.2008.09.060; Chu PC, 2016, ONCOGENE, V35, P3897, DOI 10.1038/onc.2015.458; Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514; Cui FY, 2016, ONCOL REP, V36, P487, DOI 10.3892/or.2016.4834; de Jong MC, 2009, ANN SURG, V250, P440, DOI 10.1097/SLA.0b013e3181b4539b; Ding CB, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0280-0; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Ewing GP, 2010, CLIN COLORECTAL CANC, V9, P219, DOI 10.3816/CCC.2010.n.032; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Huang CC, 2015, ONCOTARGET, V6, P8698, DOI 10.18632/oncotarget.3537; Ishizu K, 2007, BIOL PHARM BULL, V30, P1779, DOI 10.1248/bpb.30.1779; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kashif M, 2015, SCI REP-UK, V5, DOI 10.1038/srep14118; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Lai MG, 2015, MOL MED REP, V11, P3301, DOI 10.3892/mmr.2015.3182; Lasham A, 2013, BIOCHEM J, V449, P11, DOI 10.1042/BJ20121323; Lee Michael S, 2014, Gastrointest Cancer Res, V7, pS2; Leonard GD, 2005, J CLIN ONCOL, V23, P2038, DOI 10.1200/JCO.2005.00.349; Leporrier J, 2006, BRIT J SURG, V93, P465, DOI 10.1002/bjs.5278; Li CY, 2015, MOL MED REP, V12, P7072, DOI 10.3892/mmr.2015.4263; Li Z, 2012, J INT MED RES, V40, P1589, DOI 10.1177/147323001204000439; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo CL, 2013, J INVEST DERMATOL, V133, P768, DOI 10.1038/jid.2012.357; Lutz M, 2006, FEBS LETT, V580, P3921, DOI 10.1016/j.febslet.2006.06.023; Mahmoudi E, 2017, MOL PSYCHIATR, V22, P44, DOI 10.1038/mp.2016.150; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Mouneimne G, 2009, CANCER CELL, V15, P357, DOI 10.1016/j.ccr.2009.04.006; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Nash GM, 2010, ANN SURG ONCOL, V17, P572, DOI 10.1245/s10434-009-0605-3; Neault M, 2016, CELL REP, V14, P1966, DOI 10.1016/j.celrep.2016.01.068; Okamoto K, 2012, EMBO J, V31, P1752, DOI 10.1038/emboj.2012.25; Passiglia F, 2016, CRIT REV ONCOL HEMAT, V99, P150, DOI 10.1016/j.critrevonc.2015.12.015; Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6; Shibao K, 1999, INT J CANCER, V83, P732; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108; Smith AR, 2015, ONCOTARGET, V6, P12558, DOI 10.18632/oncotarget.3726; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vigneri PG, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00230; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Weng WH, 2016, CLIN CANCER RES, V22, P4947, DOI 10.1158/1078-0432.CCR-16-0360; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2006, TRENDS ENDOCRIN MET, V17, P236, DOI 10.1016/j.tem.2006.06.007; Wu YY, 2014, ANGIOGENESIS, V17, P247, DOI 10.1007/s10456-013-9394-1; Wu Y, 2012, J SURG ONCOL, V105, P724, DOI 10.1002/jso.23030; Yan XB, 2014, INT J CLIN EXP PATHO, V7, P8715; Yang HJ, 2016, ONCOTARGET, V7, P2709, DOI 10.18632/oncotarget.6458; Zhang XM, 2017, ONCOL LETT, V14, P2325, DOI 10.3892/ol.2017.6444; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zhu XL, 2013, ACTA BIOCH BIOPH SIN, V45, P80, DOI 10.1093/abbs/gms099; Zhu YM, 2007, INT J COLORECTAL DIS, V22, P661, DOI 10.1007/s00384-006-0224-4	67	30	30	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3440	3455		10.1038/s41388-018-0222-3	http://dx.doi.org/10.1038/s41388-018-0222-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559746				2022-12-28	WOS:000436411300009
J	Li, L; Liu, TZ; Li, YH; Wu, CM; Luo, KT; Yin, YJ; Chen, YP; Nowsheen, S; Wu, JH; Lou, ZK; Yuan, J				Li, Lei; Liu, Tongzheng; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Nowsheen, Somaira; Wu, Jinhuan; Lou, Zhenkun; Yuan, Jian			The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization	ONCOGENE			English	Article							HIPPO PATHWAY; GROWTH-CONTROL; CANCER-CELLS; DNA-DAMAGE; DIFFERENTIATION; INHIBITION; PHOSPHORYLATION; TUMORIGENESIS; INACTIVATION; APOPTOSIS	The Yes-associated protein 1 (YAP1), a major downstream effector of the Hippo pathway, functions as a transcriptional regulator and has an important role in cellular control of organ size and tumor growth. Elevated oncogenic activity of YAP1 has been clarified in different types of human cancers, which contributes to cancer cell survival and chemoresistance. However, the molecular mechanism of YAP1 overexpression in cancer is still not clear. Here we demonstrate that the deubiquitination enzyme USP9X deubiquitinates and stabilizes YAP1, thereby promoting cancer cell survival. Increased USP9X expression correlates with increased YAP1 protein in human breast cancer cell lines and patient samples. Moreover, depletion of USP9X increases YAP1 polyubiquitination, which in turn elevates YAP1 turnover and cell sensitivity to chemotherapy. Overall, our study establishes the USP9X-YAP1 axis as an important regulatory mechanism of breast cancer and provides a rationale for potential therapeutic interventions in the treatment of breast cancer.	[Li, Lei; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Yuan, Jian] Tongji Univ, East Hosp, Res Ctr Translat Med, Sch Med, Shanghai 200120, Peoples R China; [Li, Lei; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Yuan, Jian] Tongji Univ, East Hosp, Key Lab Arrhythmias, Minist Educ China,Sch Med, Shanghai 200120, Peoples R China; [Liu, Tongzheng] Jinan Univ, Inst Tumor Pharmacol, Guangzhou 510632, Guangdong, Peoples R China; [Luo, Kuntian; Lou, Zhenkun; Yuan, Jian] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Nowsheen, Somaira] Mayo Clin, Grad Sch Biomed Sci, Sch Med, Med Scientist Training Program, Rochester, MN 55905 USA; [Wu, Jinhuan] Tianjin Med Univ, Sch Biomed Engn & Technol, Tianjin, Peoples R China	Tongji University; Ministry of Education, China; Tongji University; Jinan University; Mayo Clinic; Mayo Clinic; Tianjin Medical University	Yuan, J (corresponding author), Tongji Univ, East Hosp, Res Ctr Translat Med, Sch Med, Shanghai 200120, Peoples R China.; Yuan, J (corresponding author), Tongji Univ, East Hosp, Key Lab Arrhythmias, Minist Educ China,Sch Med, Shanghai 200120, Peoples R China.; Liu, TZ (corresponding author), Jinan Univ, Inst Tumor Pharmacol, Guangzhou 510632, Guangdong, Peoples R China.; Lou, ZK; Yuan, J (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.	Liutongzheng@jnu.edu.cn; Lou.zhenkun@mayo.edu; yuanjian229@hotmail.com	Li, Li/AEM-3636-2022; LI, LI/GVS-5344-2022; li, li/HII-4157-2022	Yuan, Jian/0000-0002-2801-8849; Lou, Zhenkun/0000-0003-1938-3091	NSFC [81773758, 81572770, 31371367]; National Institutes of Health [CA203971, CA203561, CA189666, CA130996]; Ovarian Cancer SPORE in Mayo Clinic [P50CA136393]; Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA148940, P50CA136393, R01CA130996, R01CA189666, R01CA203971, R01CA129344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065841] Funding Source: NIH RePORTER	NSFC(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer SPORE in Mayo Clinic; Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs William G. Kaelin, Qing Zhang, Kunliang Guan, and Junjie Chen for kindly providing constructs. This study was supported by NSFC (81773758, 81572770, and 31371367), National Institutes of Health grant (CA203971, CA203561, CA189666, and CA130996), Ovarian Cancer SPORE in Mayo Clinic (P50CA136393), and the Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund.	Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Bora-Singhal N, 2015, STEM CELLS, V33, P1705, DOI 10.1002/stem.1993; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Nguyen HT, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.1; Nguyen HT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169587; Jung KH, 2016, STEM CELLS, V34, P1284, DOI 10.1002/stem.2283; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Liu TZ, 2016, CANCER RES, V76, P572, DOI 10.1158/0008-5472.CAN-15-0671; Luo KT, 2017, EMBO J, V36, P1434, DOI 10.15252/embj.201695669; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagai H, 2009, MOL CELL, V36, P805, DOI 10.1016/j.molcel.2009.10.016; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Pefani DE, 2016, MOL CELL, V63, P156, DOI 10.1016/j.molcel.2016.05.012; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Peterson LF, 2015, BLOOD, V125, P3588, DOI 10.1182/blood-2014-10-605584; Piersma B, 2015, AM J PATHOL, V185, P3326, DOI 10.1016/j.ajpath.2015.08.011; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Savio MG, 2016, CURR BIOL, V26, P173, DOI 10.1016/j.cub.2015.11.050; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Strano S, 2007, MOL CELL, V27, P863, DOI 10.1016/j.molcel.2007.09.004; Svalina MN, 2014, CANCER CELL, V26, P154, DOI 10.1016/j.ccr.2014.07.011; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Tu KS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-110; Vitolol MI, 2007, CANCER BIOL THER, V6, P856, DOI 10.4161/cbt.6.6.4241; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wolfsperger F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.405; Yu FX, 2015, ANNU REV PHYSIOL, V77, P201, DOI 10.1146/annurev-physiol-021014-071733; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng XN, 2014, GENE DEV, V28, P1429, DOI 10.1101/gad.242131.114; Zhi X, 2012, AM J PATHOL, V180, P2452, DOI 10.1016/j.ajpath.2012.02.025; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	42	42	42	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2422	2431		10.1038/s41388-018-0134-2	http://dx.doi.org/10.1038/s41388-018-0134-2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449692	Green Accepted			2022-12-28	WOS:000431386000006
J	Li, XM; Ruan, XH; Zhang, PT; Yu, Y; Gao, M; Yuan, SK; Zhao, ZW; Yang, J; Zhao, L				Li, Xiaomeng; Ruan, Xianhui; Zhang, Peitao; Yu, Yang; Gao, Ming; Yuan, Shukai; Zhao, Zewei; Yang, Jie; Zhao, Li			TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57(KIP2) repression	ONCOGENE			English	Article							BECKWITH-WIEDEMANN-SYNDROME; BOX TRANSCRIPTION FACTORS; ULNAR-MAMMARY SYNDROME; BREAST-CANCER; DOWNSTREAM TARGET; CYCLE REGULATORS; E-CADHERIN; C-MYC; EXPRESSION; GENE	The T-box transcription factor TBX3 has been implicated in the patterning and differentiation of a number of tissues during embryonic development, and is overexpressed in a variety of cancers; however, the precise function of TBX3 in papillary thyroid carcinoma (PTC) development remains to be determined. In the current study, we report downregulation of TBX3 in PTC cells delays the G1/S-phase transition, decreases cell growth in vitro, and inhibits tumor formation in vivo. We identified p57(KIP2) as a novel downstream target that serves as the key mediator of TBX3's control over PTC cell proliferation. Reduced expression of TBX3 resulted in increased p57(KIP2) level, while knockdown of p57(KIP2) rescues the cell-cycle arrest phenotype. In clinical PTC specimens, the expression of TBX3 is markedly upregulated and significantly correlated with advanced tumor grade, but negatively correlated with the expression of p57(KIP2). Mechanism investigation revealed that TBX3 directly binds to the CDKN1C gene promoter region, the coding gene of p57(KIP2), and represses its transcription. Furthermore, recruitment of main components of the PRC2 complex as well as class I histone deacetylases, HDAC1 and HDAC2, is required for TBX3 to fulfill the transcriptional repression function. Our findings illustrate the previously unknown function and mechanism in cell proliferation regulation by the TBX3-p57(KIP2) axis and provide evidence for the contribution of the PRC2 complex and HDAC1/2. Targeting of this pathway may present a novel and molecular defined strategy against PTC development.	[Li, Xiaomeng; Zhang, Peitao; Yuan, Shukai; Zhao, Zewei; Yang, Jie; Zhao, Li] Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China; [Ruan, Xianhui; Yu, Yang; Gao, Ming] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Tumor, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University	Yang, J; Zhao, L (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China.	yangj@tijmu.edu.cn; shzhaoli@tijmu.edu.cn		Yuan, Shukai/0000-0003-0354-5113	National Natural Science Foundation of China [31371329, 81702710, 81472580]; Innovation Team Development Plan of the Ministry of Education [IRT13085]; Tianjin Municipal Science and Technology Commission [13JCYBJC37200, 17JCQNJC11200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Team Development Plan of the Ministry of Education; Tianjin Municipal Science and Technology Commission	This research work was supported by the grants from the National Natural Science Foundation of China (31371329 to L.Z., 81702710 to S.Y., 81472580 to M.G.). Innovation Team Development Plan of the Ministry of Education (IRT13085), The Tianjin Municipal Science and Technology Commission (13JCYBJC37200 to L,Z., 17JCQNJC11200 to S.Y.).	Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Borriello A, 2011, MOL CANCER RES, V9, P1269, DOI 10.1158/1541-7786.MCR-11-0220; Boyd SC, 2013, J INVEST DERMATOL, V133, P1269, DOI 10.1038/jid.2012.421; Burgucu D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-481; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; Douglas NC, 2013, J MAMMARY GLAND BIOL, V18, P143, DOI 10.1007/s10911-013-9282-8; Fagman H, 2011, DEV BIOL, V359, P163, DOI 10.1016/j.ydbio.2011.08.015; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Higashimoto K, 2006, CYTOGENET GENOME RES, V113, P306, DOI 10.1159/000090846; Ito Y, 2004, PATHOBIOLOGY, V71, P164, DOI 10.1159/000076472; Ito Y, 2002, INT J MOL MED, V9, P373; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kobatake T, 2004, ONCOL REP, V12, P1087; Lai SL, 2000, CLIN CANCER RES, V6, P3172; Li J, 2013, MOL BIOL CELL, V24, P3569, DOI 10.1091/mbc.E13-05-0273; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Lloyd RV, 2011, HEAD NECK PATHOL, V5, P51, DOI 10.1007/s12105-010-0236-9; Lomnytska M, 2006, INT J CANCER, V118, P412, DOI 10.1002/ijc.21332; Lyng H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-268; Melck A, 2007, ANN SURG ONCOL, V14, P3403, DOI 10.1245/s10434-007-9572-8; Mesbah K, 2012, HUM MOL GENET, V21, P1217, DOI 10.1093/hmg/ddr553; Perkhofer L, 2016, STEM CELL RES, V17, P367, DOI 10.1016/j.scr.2016.08.007; Platonova N, 2007, CELL TISSUE RES, V328, P301, DOI 10.1007/s00441-006-0364-4; Renard CA, 2007, CANCER RES, V67, P901, DOI 10.1158/0008-5472.CAN-06-2344; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Sato N, 2005, CLIN CANCER RES, V11, P4681, DOI 10.1158/1078-0432.CCR-04-2471; Shan ZZ, 2015, AM J CANCER RES, V5, P344; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.94; Trowe MO, 2013, DEVELOPMENT, V140, P2299, DOI 10.1242/dev.094524; Wansleben S, 2014, BBA-REV CANCER, V1846, P380, DOI 10.1016/j.bbcan.2014.08.004; Willmer T, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0019-0; Willmer T, 2015, CELL CYCLE, V14, P3173, DOI 10.1080/15384101.2015.1080398; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011; Yarosh W, 2008, CANCER RES, V68, P693, DOI 10.1158/0008-5472.CAN-07-5012; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhao L, 2012, DEV CELL, V22, P585, DOI 10.1016/j.devcel.2011.12.023	38	15	15	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2773	2792		10.1038/s41388-017-0090-2	http://dx.doi.org/10.1038/s41388-017-0090-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511350				2022-12-28	WOS:000432929800002
J	Liu, YY; Chen, MB; Cheng, L; Zhang, ZQ; Yu, ZQ; Jiang, Q; Chen, G; Cao, C				Liu, Yuan-yuan; Chen, Min-Bin; Cheng, Long; Zhang, Zhi-qing; Yu, Zheng-quan; Jiang, Qin; Chen, Gang; Cao, Cong			microRNA-200a downregulation in human glioma leads to G alpha i1 over-expression, Akt activation, and cell proliferation	ONCOGENE			English	Article							CANCER STATISTICS; TUMOR-SUPPRESSOR; COMPLEX; GENE; RESISTANCE; SURVIVAL; THERAPY; KINASE	We previously identified a pivotal role for G protein alpha inhibitory subunit 1 (G alpha i1) in mediating PI3K-Akt signaling by receptor tyrosine kinases (RTKs). Here, we examined the expression and biological function of G alpha i1 in human glioma. G alpha i1 mRNA and protein expression were significantly upregulated in human glioma tissues, which correlated with downregulation of an anti-G alpha i1 miRNA: microRNA-200a ("miR-200a"). Forced-expression of miR-200a in established (A172/U251MG lines) and primary (patient-derived) human glioma cells resulted in G alpha i1 downregulation, Akt inactivation and proliferation inhibition. Reduction of G alpha i1 expression by shRNA, dominant negative mutant interference, or complete G alpha i1 depletion inhibited Akt activation and cell proliferation. Notably, miR-200a was unable to inhibit glioma cell proliferation when G alpha i1 was silenced or mutated. Co-immunoprecipitation studies, in human glioma cells and tissues, show that G alpha i1 forms a complex with multiple RTKs (EGFR, PDGFR alpha, and FGFR) and the adapter protein Gab1. In vivo, the growth of subcutaneous and orthotopic glioma xenografts in nude mice was largely inhibited by expression of G alpha i1 shRNA or miRNA-200a. Collectively, miR-200a downregulation in human glioma leads to G alpha i1 over-expression, Akt activation and glioma cell proliferation.	[Liu, Yuan-yuan] Jiangsu Univ, Kunshan Peoples Hosp 1, Clin Res & Lab Ctr, Kunshan, Peoples R China; [Liu, Yuan-yuan; Cheng, Long; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China; [Liu, Yuan-yuan; Cheng, Long; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China; [Chen, Min-Bin] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Radiotherapy & Oncol, Kunshan, Peoples R China; [Cheng, Long] Soochow Univ, Affiliated Hosp 2, Dept Intervent Radiol, Suzhou, Peoples R China; [Yu, Zheng-quan; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China; [Jiang, Qin; Cao, Cong] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Jiangsu, Peoples R China; [Cao, Cong] Municipal Hosp Suzhou, Suzhou, Peoples R China	Jiangsu University; Soochow University - China; Soochow University - China; Jiangsu University; Soochow University - China; Soochow University - China; Nanjing Medical University	Cao, C (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.; Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China.; Jiang, Q; Cao, C (corresponding author), Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Jiangsu, Peoples R China.; Cao, C (corresponding author), Municipal Hosp Suzhou, Suzhou, Peoples R China.	Jqin710@vip.sina.com; nju_neurosurgery@163.com; caocong@suda.edu.cn	liu, yuanyuan/GWZ-5838-2022		National Natural Science Foundation of China [81771457, 81371055, 81570859, 81302195, 31371139, 81502162, 81571282, 81472786, 81773192]; Natural Science Foundation of Jiangsu Province [BK20130301, BK20170060, BK20171248]; Clinical Special Project of Suzhou [LCZX201601]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Clinical Special Project of Suzhou	This study was supported in part by grants from the National Natural Science Foundation of China (81502162, 81771457, 81371055, and 81570859, 81302195, 31371139 and 81502162, 81571282, 81472786, and 81773192); Grants from Natural Science Foundation of Jiangsu Province (BK20130301, BK20170060, and BK20171248), and by Clinical Special Project of Suzhou (LCZX201601). We thank Dr. John Marshall for English edits and proof-reading of the manuscript.	Agnihotri S, 2012, J CLIN INVEST, V122, P253, DOI 10.1172/JCI59334; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Bostrom J, 1998, CANCER RES, V58, P29; Cai S, 2017, ONCOTARGET, V8, P35061, DOI 10.18632/oncotarget.17043; Cao C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001478; Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138; FURMAN MA, 1977, J NEUROSURG, V46, P477, DOI 10.3171/jns.1977.46.4.0477; Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164; He XL, 2014, NAT MED, V20, P1035, DOI 10.1038/nm.3666; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Huang TT, 2009, NEUROTHERAPEUTICS, V6, P500, DOI 10.1016/j.nurt.2009.04.008; Khasraw M, 2009, NAT REV NEUROL, V5, P646, DOI 10.1038/nrneurol.2009.194; Lefranc F, 2009, ADV TECH STAND NEURO, V34, P3, DOI 10.1007/978-3-211-78741-0_1; Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525; Li XJ, 2015, P NATL ACAD SCI USA, V112, P4731, DOI 10.1073/pnas.1503779112; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Li Z, 2016, ONCOTARGET; Liu M, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150092; Lo Hui-Wen, 2010, Curr Mol Pharmacol, V3, P37; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Pollack IF, 2010, NAT REV NEUROL, V6, P533, DOI 10.1038/nrneurol.2010.144; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Shashidhar S, 2005, ONCOGENE, V24, P1673, DOI 10.1038/sj.onc.1208395; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Wang YZ, 2013, CANCER LETT, V331, P139, DOI 10.1016/j.canlet.2012.12.024; Wang ZW, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-10; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Zhang D, 2016, TUMOR BIOL, V37, P1327, DOI 10.1007/s13277-015-3922-0; Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025; Zhang YM, 2015, J INVEST DERMATOL, V135, P181, DOI 10.1038/jid.2014.326	39	62	63	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2890	2902		10.1038/s41388-018-0184-5	http://dx.doi.org/10.1038/s41388-018-0184-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520106				2022-12-28	WOS:000432929800010
J	Aira, LE; Villa, E; Colosetti, P; Gamas, P; Signetti, L; Obba, S; Proics, E; Gautier, F; Bailly-Maitre, B; Lacquel, A; Robert, G; Luciano, F; Juin, PP; Ricci, JE; Auberger, P; Marchetti, S				Aira, Lazaro E.; Villa, Elodie; Colosetti, Pascal; Gamas, Parvati; Signetti, Laurie; Obba, Sandrine; Proics, Emma; Gautier, Fabien; Bailly-Maitre, Beatrice; Lacquel, Arnaud; Robert, Guillaume; Luciano, Frederic; Juin, Philippe P.; Ricci, Jean-Ehrland; Auberger, Patrick; Marchetti, Sandrine			The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim	ONCOGENE			English	Article							FAMILY-MEMBER BIM; BCL-2 FAMILY; CELL-DEATH; B-CELLS; PHOSPHORYLATION; PROTEIN; HOMEOSTASIS; RESISTANCE; IMATINIB; PATHWAY	Phosphorylation of Ser/Thr residues is a well-established modulating mechanism of the pro-apoptotic function of the BH3-only protein Bim. However, nothing is known about the putative tyrosine phosphorylation of this Bcl-2 family member and its potential impact on Bim function and subsequent Bax/Bak-mediated cytochrome c release and apoptosis. As we have previously shown that the tyrosine kinase Lyn could behave as an anti-apoptotic molecule, we investigated whether this Src family member could directly regulate the pro-apoptotic function of Bim. In the present study, we show that Bim is phosphorylated onto tyrosine residues 92 and 161 by Lyn, which results in an inhibition of its pro-apoptotic function. Mechanistically, we show that Lyn-dependent tyrosine phosphorylation of Bim increases its interaction with anti-apoptotic members such as Bcl-xL, therefore limiting mitochondrial outer membrane permeabilization and subsequent apoptosis. Collectively, our data uncover one molecular mechanism through which the oncogenic tyrosine kinase Lyn negatively regulates the mitochondrial apoptotic pathway, which may contribute to the transformation and/or the chemotherapeutic resistance of cancer cells.	[Aira, Lazaro E.; Villa, Elodie; Colosetti, Pascal; Gamas, Parvati; Signetti, Laurie; Obba, Sandrine; Proics, Emma; Bailly-Maitre, Beatrice; Lacquel, Arnaud; Robert, Guillaume; Luciano, Frederic; Ricci, Jean-Ehrland; Auberger, Patrick; Marchetti, Sandrine] Univ Cote dAzur, INSERM, C3M, Nice, France; [Gautier, Fabien; Juin, Philippe P.] Univ Nantes, Univ Angers, Inst Rech Sante, INSERM,CRCINA,UMR 1232, 8 Quai Moncousu,BP 70721, F-44007 Nantes 1, France; [Gautier, Fabien; Juin, Philippe P.] Inst Cancerol Ouest, Bvd J Monod,Site Rene Gauducheau, F-44805 St Herblain, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Marchetti, S (corresponding author), Univ Cote dAzur, INSERM, C3M, Nice, France.	marchett@unice.fr	AUBERGER, Patrick/G-1491-2013; Ricci, Jean Ehrland/I-7117-2016; robert, guillaume/O-1935-2017; Jacquel, Arnaud/O-1928-2017; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; Marchetti, Sandrine/P-6479-2016; luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; JUIN, Philippe/Q-1338-2019; JUIN, Philippe P/H-3636-2014; Carmen, Team2/Y-7383-2019	AUBERGER, Patrick/0000-0002-2481-8275; Ricci, Jean Ehrland/0000-0003-1585-8117; robert, guillaume/0000-0002-6350-2222; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Marchetti, Sandrine/0000-0001-8326-5730; luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; JUIN, Philippe/0000-0002-4997-3888; JUIN, Philippe P/0000-0002-4997-3888; Carmen, Team2/0000-0001-9867-5724; Lab, Carmen/0000-0002-5935-3236; Colosetti, Pascal/0000-0002-5848-6053; Bailly-Maitre, Beatrice/0000-0002-8389-8498	Fondation ARC pour la Recherche sur le Cancer [PJA 20131200392, PGA1RF201702053889]; Fondation pour la Recherche Medicale [DMP20101120387]; INSERM; Ministere de la Recherche; University of Nice-Sophia-Antipolis; French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01]; Conseil general des AM et de la region PACA et Corse	Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); University of Nice-Sophia-Antipolis; French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE(French National Research Agency (ANR)); Conseil general des AM et de la region PACA et Corse	This work was supported by grants from the Fondation ARC pour la Recherche sur le Cancer (#PJA 20131200392 and #PGA1RF201702053889), the Fondation pour la Recherche Medicale (DMP20101120387), the INSERM, the Ministere de la Recherche, and the University of Nice-Sophia-Antipolis. This work and LEA were funded by the French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01. We thank Frederic Larbret for technical support for FACS sorting. We thank Dr. Simon Cook for GST-Bim constructs, Dr. Andreas Villunger for kindly providing the WEHI-231 cell line, Dr. David Rubinsztein for the plasmid encoding human BimEL, and Drs. Doug Green and Stephen Tait for HeLa cells stably expressing Smac-GFP. We thank Drs. Eric Eldering and Fabio Brocco for insights and helpful discussion. We thank the Conseil general des AM et de la region PACA et Corse for its financial support.	Ban T, 2016, IMMUNITY, V45, P319, DOI 10.1016/j.immuni.2016.07.015; Belloc F, 2007, CANCER BIOL THER, V6, P912, DOI 10.4161/cbt.6.6.4101; Bian YY, 2016, NAT CHEM BIOL, V12, P959, DOI [10.1038/NCHEMBIO.2178, 10.1038/nchembio.2178]; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Carpenter RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078836; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Clybouw C, 2012, CELL DEATH DIFFER, V19, P1060, DOI 10.1038/cdd.2011.198; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Fox JL, 2010, EMBO J, V29, P3853, DOI 10.1038/emboj.2010.244; Gamas P, 2009, LEUKEMIA, V23, P1500, DOI 10.1038/leu.2009.60; Gogada R, 2013, J BIOL CHEM, V288, P368, DOI 10.1074/jbc.M112.386102; Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420; GREEN DR, 2015, COLD SPRING HARB PER, V7, DOI DOI 10.1101/CSHPERSPECT.A006080; Gross AJ, 2011, EUR J IMMUNOL, V41, P3645, DOI 10.1002/eji.201141708; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Leonard JT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5309; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21; Luciano F, 2003, FASEB J, V17, P711, DOI 10.1096/fj.02-0716fje; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040; Mahon FX, 2008, CANCER RES, V68, P9809, DOI 10.1158/0008-5472.CAN-08-1008; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pecot J, 2016, CELL REP, V17, P3347, DOI 10.1016/j.celrep.2016.11.064; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Scapini P, 2009, IMMUNOL REV, V228, P23, DOI 10.1111/j.1600-065X.2008.00758.x; Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492; Tait SWG, 2010, DEV CELL, V18, P802, DOI [10.1016/j.devcel.2010.03.014, 10.1016/j.devce1.2010.03.014]; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zonta F, 2014, BLOOD, V123, P875, DOI 10.1182/blood-2013-02-485540	52	5	5	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2122	2136		10.1038/s41388-017-0112-0	http://dx.doi.org/10.1038/s41388-017-0112-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29391601				2022-12-28	WOS:000430589000004
J	Babbar, M; Huang, Y; An, J; Landas, SK; Sheikh, MS				Babbar, Mansi; Huang, Ying; An, Jie; Landas, Steve K.; Sheikh, M. Saeed			CHTM1, a novel metabolic marker deregulated in human malignancies	ONCOGENE			English	Article							CREB; ACTIVATION; COACTIVATOR; OXIDATION; COMPLEX; CELLS	A better understanding of the link between cellular metabolism and tumorigenesis is needed. Here, we report characterization of a novel protein named coiled-coil helix tumor and metabolism 1 (CHTM1). We have found that CHTM1 is associated with cancer and cellular metabolism. CHTM1 localizes to mitochondria and cytosol, and its deficiency in cancer cells results in decreased mitochondrial oxygen consumption and ATP levels as well as oxidative stress indicating mitochondrial dysfunction. CHTM1-deficient cancer cells display poor growth under glucose/glutamine-deprived conditions, whereas cells expressing increased levels of exogenous CHTM1 exhibit enhanced proliferation and survival under similar conditions. CHTM1 deficiency also leads to defects in lipid metabolism resulting in fatty acid accumulation, which explains poor growth of CHTM1-deficient cells under glucose/glutamine deprivation since nutrient deprivation increases dependency on lipids for energy generation. We also demonstrate that CHTM1 mediates its effect via the PKC, CREB, and PGC-1alpha signaling axis, and cytosolic accumulation of CHTM1 during nutrient deprivation appears to be important for its effect on cellular signaling events. Furthermore, analyses of tissue specimens from 71 breast and 97 colon cancer patients show CHTM1 expression to be upregulated in the majority of tumor specimens representing these malignancies. Collectively, our findings are highly significant because CHTM1 is a novel metabolic marker that is important for the growth of tumorigenic cells under limiting nutrient supplies and thus, links cellular metabolism and tumorigenesis.	[Babbar, Mansi; Huang, Ying; An, Jie; Sheikh, M. Saeed] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; [Landas, Steve K.] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA; [An, Jie] Gulfstream Diagnost Genom, Dallas, TX USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@upstate.edu	Babbar, Mansi/AAP-7320-2020; Babbar, Mansi/P-1698-2019	BABBAR, MANSI/0000-0002-9690-8974	Carol M. Baldwin breast cancer fund; NIH [CA150132]; NATIONAL CANCER INSTITUTE [R03CA150132] Funding Source: NIH RePORTER	Carol M. Baldwin breast cancer fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Daniel P. Kelly, Sanford- Burnham Medical Research Institute, FL for providing the anti-PGC-1 alpha anti-body and Dr. Michael Shuen, York University, Ontario, Canada for pGL3-PGC-1 alpha promoter construct. Dr. David M. Markovitz (Department of Internal Medicine, University of Michigan Medical Center) kindly provided UACC-62 melanoma cells (originally from Dr. Maria S. Soengas, Melanoma Laboratory, Spanish National Cancer Research Center). This work was supported in part by Carol M. Baldwin breast cancer fund and NIH grant CA150132.	Agarwal NR, 2016, CELL BIOL INT, V40, P821, DOI 10.1002/cbin.10619; An J, 2012, J BIOL CHEM, V287, P7411, DOI 10.1074/jbc.M111.277103; Babbar Mansi, 2013, Mol Cell Pharmacol, V5, P109; Banci L, 2012, J STRUCT BIOL, V180, P190, DOI 10.1016/j.jsb.2012.07.007; Burri L, 2005, MOL BIOL CELL, V16, P2926, DOI 10.1091/mbc.E04-12-1086; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Fath MA, 2009, CANCER BIOL THER, V8, P1228, DOI 10.4161/cbt.8.13.8631; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11; Landor SKJ, 2011, P NATL ACAD SCI USA, V108, P18814, DOI 10.1073/pnas.1104943108; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Li BL, 2006, BIOCHEM BIOPH RES CO, V350, P179, DOI 10.1016/j.bbrc.2006.09.016; Lucchesi C, 2016, ONCOGENE, V35, P2565, DOI 10.1038/onc.2015.339; Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Yang J, 2012, J CLIN INVEST, V122, P600, DOI 10.1172/JCI58780; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200	29	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2052	2066		10.1038/s41388-017-0051-9	http://dx.doi.org/10.1038/s41388-017-0051-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29371680	Green Accepted			2022-12-28	WOS:000429899400008
J	Jia, WZ; Zhao, XP; Zhao, L; Yan, H; Li, JJ; Yang, H; Huang, G; Liu, JJ				Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Yan, Hui; Li, Jiajin; Yang, Hao; Huang, Gang; Liu, Jianjun			Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4	ONCOGENE			English	Article							ADVANCED BREAST-CANCER; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; DEPENDENT KINASES; DOWN-REGULATION; GLYCOLYSIS; GROWTH; INHIBITORS; ARREST; EXPRESSION; CARCINOMA	There is growing interest in studying the molecular mechanisms of crosstalk between cancer metabolism and the cell cycle. 6-phosphate fructose-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a well-known glycolytic activator that plays an important role in tumorigenesis. We investigated whether PFKFB3 was directly involved in oncogenic signaling networks. Mass Spectrometry showed that PFKFB3 interacts with cyclin-dependent kinase (CDK) 4, which controls the transition from G1 phase to S phase of the cell cycle. Further analysis indicated that lysine 147 was a key site for the binding of PFKBFB3 to CDK4. PFKFB3 binding resulted in the accumulation of CDK4 protein by inhibiting ubiquitin proteasome degradation mediated by the heat shock protein 90-Cdc37-CDK4 complex. The proteasome-dependent degradation of CDK4 was accelerated by disrupting the interaction of PFKFB3 with CDK4 by mutating lysine (147) to alanine. Blocking PFKFB3-CDK4 interaction improved the therapeutic effect of FDA-approved CDK4 inhibitor palbociclib on breast cancer. These findings suggest that PFKFB3 is a hub for coordinating cell cycle and glucose metabolism. Combined targeting of PFKFB3 and CDK4 may be new strategy for breast cancer treatment.	[Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Yan, Hui; Li, Jiajin; Yang, Hao; Huang, Gang; Liu, Jianjun] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai, Peoples R China; [Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai University of Medicine & Health Sciences	Huang, G; Liu, JJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai, Peoples R China.; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China.	huang2802@163.com; ljjsh@133sh.com		Li, Jiajin/0000-0003-1300-6025	National Natural Science Foundation of China [81471687, 81530053, 81372195, 81471685, 81572719, 81601520]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by research grants from National Natural Science Foundation of China (No. 81471687, 81530053, 81372195, 81471685, 81572719, 81601520).	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Atsumi T, 2002, CANCER RES, V62, P5881; Braden WA, 2008, ONCOGENE, V27, P7083, DOI 10.1038/onc.2008.319; Calvo MN, 2006, FEBS LETT, V580, P3308, DOI 10.1016/j.febslet.2006.04.093; Cavalier MC, 2012, PROTEINS, V80, P1143, DOI 10.1002/prot.24015; Cen L, 2012, NEURO-ONCOLOGY, V14, P870, DOI 10.1093/neuonc/nos114; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Cieslar-Pobuda A, 2015, ONCOTARGET, V6, P29753, DOI 10.18632/oncotarget.4995; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Dai MO, 2016, SCI REP-UK, V6, DOI 10.1038/srep35383; Dimco G, 2010, CELL CYCLE, V9, P4638, DOI 10.4161/cc.9.23.13955; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Erez A, 2015, NAT REV CANCER, V15, P440, DOI 10.1038/nrc3949; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Finn RS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0661-5; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Gillam MP, 2015, ONCOGENE, V34, P932, DOI 10.1038/onc.2014.3; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Imbert-Fernandez Y, 2014, J BIOL CHEM, V289, P9440, DOI 10.1074/jbc.M113.529990; Jia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097448; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Katsumi Y, 2011, BIOCHEM BIOPH RES CO, V413, P62, DOI 10.1016/j.bbrc.2011.08.047; Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342; Lu J, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0194-5; Lu YZ, 2014, J CLIN INVEST, V124, P1672, DOI 10.1172/JCI63139; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mao CQ, 2014, MOL THER, V22, P964, DOI 10.1038/mt.2014.18; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Perez M, 2015, ONCOTARGET, V6, P40557, DOI 10.18632/oncotarget.5829; Reid MA, 2016, GENE DEV, V30, P1837, DOI 10.1101/gad.287235.116; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Shi H, 2009, CANCER SCI, V100, P1585, DOI 10.1111/j.1349-7006.2009.01223.x; Smith JR, 2009, ONCOGENE, V28, P157, DOI 10.1038/onc.2008.380; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Verba KA, 2016, SCIENCE, V352, P1542, DOI 10.1126/science.aaf5023; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wu AB, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-38; Yalcin A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.292; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang Y, 2014, ONCOL REP, V31, P2759, DOI 10.3892/or.2014.3127; Young RJ, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12228; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	59	32	32	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1685	1698		10.1038/s41388-017-0072-4	http://dx.doi.org/10.1038/s41388-017-0072-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29335521				2022-12-28	WOS:000428632600001
J	Kotani, H; Adachi, Y; Kitai, H; Tomida, S; Bando, H; Faber, AC; Yoshino, T; Voon, DC; Yano, S; Ebi, H				Kotani, Hiroshi; Adachi, Yuta; Kitai, Hidenori; Tomida, Shuta; Bando, Hideaki; Faber, Anthony C.; Yoshino, Takayuki; Voon, Dominic C.; Yano, Seiji; Ebi, Hiromichi			Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers	ONCOGENE			English	Article							MEK INHIBITION; C-RAF; B-RAF; FEEDBACK ACTIVATION; COLORECTAL CANCERS; PHASE-2 TRIAL; OPEN-LABEL; WILD-TYPE; MUTATIONS; SENSITIVITY	BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.	[Kotani, Hiroshi; Adachi, Yuta; Kitai, Hidenori; Yano, Seiji; Ebi, Hiromichi] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan; [Tomida, Shuta] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biobank, Okayama, Japan; [Bando, Hideaki; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Chiba, Japan; [Faber, Anthony C.] Virginia Commonwealth Univ, Sch Dent, VCU Philips Inst Oral Hlth Res, Richmond, VA USA; [Faber, Anthony C.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA; [Voon, Dominic C.; Ebi, Hiromichi] Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan	Kanazawa University; Okayama University; National Cancer Center - Japan; Virginia Commonwealth University; Virginia Commonwealth University; Kanazawa University	Ebi, H (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan.; Ebi, H (corresponding author), Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan.	hebi@staff.kanazawa-u.ac.jp	Ebi, Hiromichi/AAA-7358-2019; 雄太, 足立/N-6838-2019; Kitai, Hidenori/AAD-4168-2022	Ebi, Hiromichi/0000-0003-3155-7576; Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Kotani, Hiroshi/0000-0002-6001-0636; tomida, shuta/0000-0003-3786-936X; KITAI, HIDENORI/0000-0001-6372-846X	Japan Society for the Promotion of Science [26830105, 16K07164, 21390256]; Japan Agency for Medical Research and Development [16cm0106513h0001]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work is supported by Grants-in-Aid for Scientific Research (H. Ebi, 26830105 and 16K07164; S. Yano, 21390256) from Japan Society for the Promotion of Science, and Grant-in-Aid to Project for Cancer Research and Therapeutics Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (H. Ebi and S. Yano, 16cm0106513h0001). A.C.F. is a George and Lavinia Blick Scholar and a Harrison Endowed Scholar in Cancer Research.	Bates DM, 2012, CLASSES; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Carter J, 2015, AM J CLIN PATHOL, V144, P620, DOI 10.1309/AJCP85ATMJOZOUDJ; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Langen AJ, 2017, THER ADV MED ONCOL, V9, P46, DOI 10.1177/1758834016670555; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Desai J, 2017, AACR ANN M; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Joshi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118210; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Laquerre S, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B88; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Okimoto RA, 2016, P NATL ACAD SCI USA, V113, P13456, DOI 10.1073/pnas.1610456113; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Tang ZY, 2015, MOL CANCER THER, V14, P2187, DOI 10.1158/1535-7163.MCT-15-0262; Team RC, 2016, LANG ENV STAT COMP; Tu NN, 2015, J THORAC ONCOL, V10, P1396, DOI 10.1097/JTO.0000000000000644; Van Cutsem E, 2015, ANN ONCOL, V26, P149, DOI 10.1093/annonc/mdu496; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	45	19	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1775	1787		10.1038/s41388-017-0035-9	http://dx.doi.org/10.1038/s41388-017-0035-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348459				2022-12-28	WOS:000428632600007
J	Coburn, LA; Singh, K; Asim, M; Barry, DP; Allaman, MM; Al-Greene, NT; Hardbower, DM; Polosukhina, D; Williams, CS; Delgado, AG; Piazuelo, MB; Washington, MK; Gobert, AP; Wilson, KT				Coburn, Lori A.; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Al-Greene, Nicole T.; Hardbower, Dana M.; Polosukhina, Dina; Williams, Christopher S.; Delgado, Alberto G.; Piazuelo, M. Blanca; Washington, M. Kay; Gobert, Alain P.; Wilson, Keith T.			Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							M1 MACROPHAGE ACTIVATION; AMINO-ACID TRANSPORTER-2; NITRIC-OXIDE PRODUCTION; L-ARGININE TRANSPORT; HELICOBACTER-PYLORI; BOWEL-DISEASE; PLASMA ARGININE; COLITIS; CHEMOKINES; ARGINASE	Solute carrier family 7 member 2 (SLC7A2, also known as CAT2) is an inducible transporter of the semi-essential amino acid L-arginine (L-Arg), which has been implicated in wound repair. We have reported that both SLC7A2 expression and L-Arg availability are decreased in colonic tissues from inflammatory bowel disease patients and that mice lacking Slc7a2 exhibit a more severe disease course when exposed to dextran sulfate sodium (DSS) compared to wild-type (WT) mice. Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). SLC7A2 was localized predominantly to colonic epithelial cells in WT mice. Utilizing the AOM-DSS model, Slc7a2(-/-) mice had significantly increased tumor number, burden, and risk of high-grade dysplasia vs. WT mice. Tumors from Slc7a2(-/-) mice exhibited significantly increased levels of the proinflammatory cytokines/chemokines IL-1 beta, CXCL1, CXCL5, IL-3, CXCL2, CCL3, and CCL4, but decreased levels of IL-4, CXCL9, and CXCL10 compared to tumors from WT mice. This was accompanied by a shift toward pro-tumorigenic M2 macrophage activation in Slc7a2-deficient mice, as marked by increased colonic CD11b(+)F4/80(+)ARG1(+) cells with no alteration in CD11b(+)F4/80(+)NOS2(+) cells by flow cytometry and immunofluorescence microscopy. The shift toward M2 macrophage activation was confirmed in bone marrow-derived macrophages from Slc7a2(-/-) mice. In bone marrow chimeras between Slc7a2(-/-) and WT mice, the recipient genotype drove the CAC phenotype, suggesting the importance of epithelial SLC7A2 in abrogating neoplastic risk. These data reveal that SLC7A2 has a significant role in the protection from CAC in the setting of chronic colitis, and suggest that the decreased SLC7A2 in inflammatory bowel disease (IBD) may contribute to CAC risk. Strategies to enhance L-Arg availability by supplementing L-Arg and/or increasing L-Arg uptake could represent a therapeutic approach in IBD to reduce the substantial long-term risk of colorectal carcinoma.	[Coburn, Lori A.; Williams, Christopher S.; Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Coburn, Lori A.; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Al-Greene, Nicole T.; Hardbower, Dana M.; Polosukhina, Dina; Williams, Christopher S.; Delgado, Alberto G.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Coburn, Lori A.; Williams, Christopher S.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Hardbower, Dana M.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Williams, Christopher S.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Allaman, Margaret/GNO-9854-2022; Gobert, Alain P/AHB-1368-2022; /B-5647-2008	Allaman, Margaret M./0000-0002-2803-1365; /0000-0002-3972-3914; Coburn, Lori/0000-0003-3249-9806	National Institutes of Health (NIH) [R01AT004821, 3R01AT004821-02S1, R01DK053620, R01CA190612, P01CA116087, P01CA028842]; Veterans Affairs Merit Review [I01BX001453]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH [5T32DK007673, P30DK058404]; Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award [1IK2BX002126];  [T32GM008554];  [F31DK10715]; NATIONAL CANCER INSTITUTE [P01CA116087, R01CA190612, P01CA028842] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, T32DK007673, P30DK058404, T32DK007737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [IK2BX002126, I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review(US Department of Veterans Affairs); Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work was funded by the National Institutes of Health (NIH) grants R01AT004821, 3R01AT004821-02S1, R01DK053620, R01CA190612, P01CA116087, and P01CA028842 (to KTW), Veterans Affairs Merit Review grant I01BX001453 (to KTW), the Thomas F. Frist Sr. Endowment (to KTW), and the Vanderbilt Center for Mucosal Inflammation and Cancer (to KTW). LAC was supported by the NIH training grant 5T32DK007673, a Vanderbilt Physician Scientist Development Award, and a Veterans Affairs Career Development Award 1IK2BX002126. DMH was supported by T32GM008554 and F31DK10715. Additional support was provided by the NIH grant P30DK058404 (Vanderbilt Digestive Disease Research Center). Whole slide imaging and quantification were performed in the Digital Histology Shared Resource at the Vanderbilt University Medical Center (http://www.mc.vanderbilt.edu/dhsr).	ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; Brower V, 2005, J NATL CANCER I, V97, P251, DOI 10.1093/jnci/97.4.251; CASTILLO L, 1994, METABOLISM, V43, P114, DOI 10.1016/0026-0495(94)90166-X; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P7749, DOI 10.1073/pnas.90.16.7749; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Coburn LA, 2016, INFLAMM BOWEL DIS, V22, P1847, DOI 10.1097/MIB.0000000000000790; Coburn LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033546; Coman D, 2008, CLIN NUTR, V27, P489, DOI 10.1016/j.clnu.2008.05.007; Erreni M, 2011, CANCER MICROENVIRON, V4, P141, DOI 10.1007/s12307-010-0052-5; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, AMINO ACIDS, V48, P2375, DOI 10.1007/s00726-016-2231-2; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Herrinton LJ, 2012, GASTROENTEROLOGY, V143, P382, DOI 10.1053/j.gastro.2012.04.054; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Isidro RA, 2016, AM J PHYSIOL-GASTR L, V311, pG59, DOI 10.1152/ajpgi.00123.2016; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Martin L, 2006, AM J PHYSIOL-CELL PH, V290, pC1364, DOI 10.1152/ajpcell.00520.2005; Martinez F.O., 2014, F1000PRIME REP, V6, DOI DOI 10.12703/P6-13; Mori M, 2007, J NUTR, V137, p1616S, DOI 10.1093/jn/137.6.1616S; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Nagy TA, 2011, GASTROENTEROLOGY, V141, P553, DOI 10.1053/j.gastro.2011.05.004; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; ROSE WC, 1949, FED PROC, V8, P546; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Shivashankar R, 2017, CLIN GASTROENTEROL H, V15, P857, DOI 10.1016/j.cgh.2016.10.039; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008-5472.CAN-18-0116; Singh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005984; Singh K, 2013, AM J PHYSIOL-GASTR L, V305, pG225, DOI 10.1152/ajpgi.00091.2013; Singh K, 2012, AM J PHYSIOL-GASTR L, V302, pG1061, DOI 10.1152/ajpgi.00544.2011; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Sun P, 2017, J NUTR BIOCHEM, V47, P35, DOI 10.1016/j.jnutbio.2017.04.016; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Valbuena G, 2003, AM J PATHOL, V163, P1357, DOI 10.1016/S0002-9440(10)63494-3; Zimmerman NP, 2008, INFLAMM BOWEL DIS, V14, P1000, DOI 10.1002/ibd.20480	49	24	24	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1067	1079		10.1038/s41388-018-0492-9	http://dx.doi.org/10.1038/s41388-018-0492-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30202097	Green Accepted			2022-12-28	WOS:000458624900010
J	Liu, ZJ; Wei, YJ; Zhang, L; Yee, PP; Johnson, M; Zhang, XX; Gulley, M; Atkinson, JM; Trebak, M; Wang, HG; Li, W				Liu, Zhijun; Wei, Yiju; Zhang, Lei; Yee, Patricia P.; Johnson, Martin; Zhang, Xuexin; Gulley, Melissa; Atkinson, Jennifer M.; Trebak, Mohamed; Wang, Hong-Gang; Li, Wei			Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ	ONCOGENE			English	Article							PROTEIN-KINASE-C; CELL-PROLIFERATION; 2-AMINOETHYLDIPHENYL BORATE; TAZ; YAP; STIM1; CA2+; ACTIVATION; AMLODIPINE; CHANNELS	Glioblastomas (GBM) are the most aggressive brain cancers without effective therapeutics. The Hippo pathway transcriptional coactivators YAP/TAZ were implicated as drivers in GBM progression and could be therapeutic targets. Here we found in an unbiased screen of 1650 compounds that amlodipine is able to inhibit survival of GBM cells by suppressing YAP/TAZ activities. Instead of its known function as an L-type calcium channel blocker, we found that amlodipine is able to activate Ca2+ entry by enhancing store-operated Ca2+ entry (SOCE). Amlodipine as well as approaches that cause store depletion and activate SOCE trigger phosphorylation and activation of Lats1/2, which in turn phosphorylate YAP/TAZ and prevent their accumulation in the cell nucleus. Furthermore, we identified that protein kinase C (PKC) beta II is a major mediator of Ca2+-induced Lats1/2 activation. Ca2+ induces accumulation of PKC beta II in an actin cytoskeletal compartment. Such translocation depends on inverted formin-2 (INF2). Depletion of INF2 disrupts both PKC beta II translocation and Lats1/2 activation. Functionally, we found that elevation of cytosolic Ca2+ or PKC beta II expression inhibits YAP/TAZ-mediated gene transcription. In vivo PKC beta II expression inhibits GBM tumor growth and prolongs mouse survival through inhibition of YAP/TAZ in an orthotopic mouse xenograft model. Our studies indicate that Ca2+ is a crucial intracellular cue that regulates the Hippo pathway and that triggering SOCE could be a strategy to target YAP/TAZ in GBM.	[Liu, Zhijun; Wei, Yiju; Zhang, Lei; Yee, Patricia P.; Gulley, Melissa; Atkinson, Jennifer M.; Wang, Hong-Gang; Li, Wei] Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China; [Johnson, Martin; Zhang, Xuexin; Trebak, Mohamed] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; [Wang, Hong-Gang] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Pharmacol, Hershey, PA 17033 USA; [Li, Wei] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Li, W (corresponding author), Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.; Li, W (corresponding author), Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	weili@pennstatehealth.psu.edu	Zhang, Lei/AAJ-2148-2020; Atkinson, Jennifer/AAE-5466-2019	Atkinson, Jennifer/0000-0001-5164-5114; ZHANG zhang xue xin, XUEXIN/0000-0001-8276-3885; Zhang, Lei/0000-0002-2227-0613; Li, Wei/0000-0001-5696-4309	National Institutes of Health MSTP [5T32GM118294]; National Institutes of Health [R01HL097111, R01HL123364, K22 5K22CA190440]; AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research [14-20-10-LI]; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE [K22CA190440] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR002016, UL1TR002014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123364, R01HL097111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM118294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG050072] Funding Source: NIH RePORTER	National Institutes of Health MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Thomas Abraham and Wade Edris in the Microscopy Imaging Core Facility, Kang Li in the Molecular and Histopathology Core Facility, and Wesley Raup-Konsavage in the Drug Discovery, Development and Delivery Core Facility of Penn State College of Medicine for technical support and sample analysis. This work was supported by the National Institutes of Health MSTP Grant 5T32GM118294 (to P.P.Y. through PSU), National Institutes of Health Grants R01HL097111 and R01HL123364 (to M.T.), K22 5K22CA190440 (to W.L.), AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research 14-20-10-LI (to W.L.), and the Four Diamonds Fund for Pediatric Cancer Research (to W.L.).	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Asai M, 2008, N-S ARCH PHARMACOL, V377, P423, DOI 10.1007/s00210-007-0243-x; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; DeHaven WI, 2008, J BIOL CHEM, V283, P19265, DOI 10.1074/jbc.M801535200; FAULKNER JK, 1986, BRIT J CLIN PHARMACO, V22, P21, DOI 10.1111/j.1365-2125.1986.tb02874.x; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Gong R, 2015, CELL RES, V25, P985, DOI 10.1038/cr.2015.88; Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Jardin I, 2016, BBA-MOL CELL RES, V1863, P1418, DOI 10.1016/j.bbamcr.2015.10.003; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li WJ, 2016, ONCOTARGET, V7, P82686, DOI 10.18632/oncotarget.12625; Liu HL, 2011, EXP MOL PATHOL, V91, P753, DOI 10.1016/j.yexmp.2011.09.005; Mana-Capelli S, 2014, MOL BIOL CELL, V25, P1676, DOI 10.1091/mbc.E13-11-0701; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; Motiani RK, 2013, PFLUG ARCH EUR J PHY, V465, P1249, DOI 10.1007/s00424-013-1254-8; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Orr BA, 2011, J NEUROPATH EXP NEUR, V70, P568, DOI 10.1097/NEN.0b013e31821ff8d8; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Potier M, 2008, PFLUG ARCH EUR J PHY, V457, P405, DOI 10.1007/s00424-008-0533-2; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shao XW, 2015, P NATL ACAD SCI USA, V112, pE2595, DOI 10.1073/pnas.1504837112; Smyth JT, 2008, J CELL SCI, V121, P762, DOI 10.1242/jcs.023903; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Sun SG, 2016, TRENDS CELL BIOL, V26, P694, DOI 10.1016/j.tcb.2016.05.003; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Tian T, 2015, BIOCHEM BIOPH RES CO, V463, P638, DOI 10.1016/j.bbrc.2015.05.115; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trebak M, 2017, PHYSIOLOGY, V32, P332, DOI 10.1152/physiol.00011.2017; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wales P, 2016, ELIFE, V5, DOI 10.7554/eLife.19850; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014	48	41	41	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					120	139		10.1038/s41388-018-0425-7	http://dx.doi.org/10.1038/s41388-018-0425-7			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082911	Green Accepted			2022-12-28	WOS:000454775900009
J	Chen, WH; Cai, MY; Zhang, JX; Wang, FW; Tang, LQ; Liao, YJ; Jin, XH; Wang, CY; Guo, L; Jiang, YG; Ren, CP; Mai, HQ; Zeng, MS; Kung, HF; Qian, CN; Xie, D				Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Jiang, Yi-Guo; Ren, Cai-Ping; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan			FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1	ONCOGENE			English	Article							LEUKOCYTE FORMIN; CANCER; METASTASIS; REORGANIZATION; CYTOSKELETON; INVADOPODIA; EXPRESSION; MICRORNAS; MECHANISM; CORTACTIN	It has been suggested that formin-like protein 1 (FMNL1) plays an important role in the pathogenic process of several hematopoietic malignancies. In this study, we performed a series of in vivo and in vitro assays to elucidate the biological functions of FMNL1 and underlying mechanisms in human nasopharyngeal carcinoma (NPC) pathogenesis. Herein, we report that high expression of FMNL1 in NPC is positively associated with an aggressive disease and/or poor patient survival. Ectopic overexpression of FMNL1 in NPC cells substantially promoted cell invadopodia formation, epithelial-mesenchymal transition (EMT) and invasiveness, whereas depletion of FMNL1 potently suppressed NPC cells invadopodia formation, EMT, and invasive/metastatic capacities. We further show that FMNL1 could enhance NPC cell aggressiveness by increasing a key downstream target, the metastasis-associated protein 1 (MTA1) gene. Importantly, ectopic overexpression of FMNL1 in NPC cells markedly improved the binding of HDAC1 with Profilin2 in the cytoplasm and suppressed the enrichment of HDAC1 on the promoter of MTA1 and thereby, leading to an increased MTA1 transcription and expression. Furthermore, in addition to the amplification of FMNL1 gene, decreased level of miR-16 in NPCs is another critical mechanism to upregulate FMNL1 expression. These results, collectively, provide first-line of evidences that high expression of FMNL1, resulted from decreased miR-16 and/or MTA1 amplification, has a potent oncogenic role to drive the development and aggressive process of NPC by upregulating MTA1, and FMNL1 might be employed as a new prognostic biomarker and therapeutic target for human NPC.	[Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Chen, Wen-Hui] Jinan Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Cai, Mu-Yan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Tang, Lin-Quan; Guo, Ling; Mai, Hai-Qiang; Qian, Chao-Nan] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Canc, Guangzhou, Guangdong, Peoples R China; [Jiang, Yi-Guo] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Ren, Cai-Ping] Cent South Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha, Hunan, Peoples R China; [Ren, Cai-Ping] Cent South Univ, Sch Basic Med Sci, Chinese Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Kung, Hsiang-Fu] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Jinan University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Central South University; Central South University; Chinese University of Hong Kong; State Key Lab Oncology South China	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China.	xiedan@sysucc.org.cn	LIAO, YIJI/Z-4902-2019	LIAO, YIJI/0000-0002-0849-4573; zeng, musheng/0000-0003-3509-5591; Jiang, Yiguo/0000-0002-9499-2594	National Key R&D Program of China [2017YFC1309001]; Nature Science Foundation of China [81572359, 81572848, 81702681, 81730072]; Open Project of State Key Laboratory of Respiratory Disease of China [SKLRD2016OP004]	National Key R&D Program of China; Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Project of State Key Laboratory of Respiratory Disease of China	This work was supported by grants from the National Key R&D Program of China (No. 2017YFC1309001), the Nature Science Foundation of China (No. 81572359, 81572848, 81702681, and 81730072) and Open Project of State Key Laboratory of Respiratory Disease of China (No. SKLRD2016OP004).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Chesarone MA, 2010, NAT REV MOL CELL BIO, V11, P62, DOI 10.1038/nrm2816; FANDI A, 1994, SEMIN ONCOL, V21, P382; Favaro P, 2013, J LEUKOCYTE BIOL, V94, P503, DOI 10.1189/jlb.0113057; Favaro PMB, 2006, LEUKEMIA RES, V30, P735, DOI 10.1016/j.leukres.2005.10.003; Favaro PMB, 2003, BIOCHEM BIOPH RES CO, V311, P365, DOI 10.1016/j.bbrc.2003.10.012; Gardberg M, 2014, J HISTOCHEM CYTOCHEM, V62, P460, DOI 10.1369/0022155414532293; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; He SH, 2013, J CELL PHYSIOL, V228, P1525, DOI 10.1002/jcp.24311; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Kuhn Sonja, 2014, Small GTPases, V5, pe29513, DOI 10.4161/sgtp.29513; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Li JS, 2013, CHIN J CANCER, V32, P3, DOI 10.5732/cjc.011.10381; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Marzook H, 2014, CANCER METAST REV, V33, P953, DOI 10.1007/s10555-014-9521-5; Mersich AT, 2010, CYTOSKELETON, V67, P573, DOI 10.1002/cm.20468; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Schuster IG, 2007, BLOOD, V110, P2931, DOI 10.1182/blood-2006-11-058750; Song QC, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-54; Song QC, 2013, INT J BIOCHEM CELL B, V45, P1439, DOI 10.1016/j.biocel.2013.04.017; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; Tang YN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9230; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wee Joseph Tien Seng, 2010, Chin J Cancer, V29, P517; Wei William I, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P99, DOI 10.1097/MOO.0b013e3280148a06; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Winter M, 2013, EMBO J, V32, P3176, DOI 10.1038/emboj.2013.243; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017; Zhang LF, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0018-6; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207	43	17	17	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6243	6258		10.1038/s41388-018-0351-8	http://dx.doi.org/10.1038/s41388-018-0351-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30013189				2022-12-28	WOS:000451622100004
J	Park, JW; Chae, YC; Kim, JY; Oh, H; Seo, SB				Park, Jin Woo; Chae, Yun-Cheol; Kim, Ji-Young; Oh, Hyein; Seo, Sang-Beom			Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; LYSINE METHYLATION; INHIBITION; PROTEIN	The histone methyltransferase multiple myeloma SET domain protein (MMSET/WHSC1) is highly expressed in diverse tumor types, and its expression appears to be involved in cell proliferation. In this study, we report that MMSET interacts with and methylates Aurora kinase A (AURKA). We show that MMSET-mediated methylation of AURKA induces interaction with p53 as well as enhanced kinase activity of AURKA, which results in the proteasomal degradation of p53. MMSET-mediated p53 degradation increases cell proliferation and results in oncogenic activity. Furthermore, knockdown of MMSET potently inhibits tumorigenic cells and renders them sensitive to growth inhibition by the therapeutic drug, alisertib (AURKA inhibitor). Taken together, our results suggest that MMSET is a regulator of p53 stability via methylation of AURKA in proliferating cells and might be a potential therapeutic target in solid tumors.	[Park, Jin Woo; Chae, Yun-Cheol; Kim, Ji-Young; Oh, Hyein; Seo, Sang-Beom] Chung Ang Univ, Dept Life Sci, Coll Nat Sci, Seoul 06974, South Korea	Chung Ang University	Seo, SB (corresponding author), Chung Ang Univ, Dept Life Sci, Coll Nat Sci, Seoul 06974, South Korea.	sangbs@cau.ac.kr			National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [NRF-2016R1A4A1008035, NRF-2017R1A2B4004407]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning NRF-2016R1A4A1008035 and NRF-2017R1A2B4004407)	Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811; Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; De Luca M, 2006, CELL CYCLE, V5, P296; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Lee YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106661; Li N, 2017, J CLIN INVEST, V127, P1284, DOI 10.1172/JCI91144; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Marxer M, 2014, ONCOGENE, V33, P3550, DOI 10.1038/onc.2013.325; Maxwell CA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001199; Moll UM, 2003, MOL CANCER RES, V1, P1001; Morishita M, 2014, BMC STRUCT BIOL, V14, DOI 10.1186/s12900-014-0025-x; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; Park JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep12485; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Sammons MA, 2015, GENOME RES, V25, P179, DOI 10.1101/gr.181883.114; Shen C, 2015, MOL CELL, V60, P847, DOI 10.1016/j.molcel.2015.10.033; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Yang XD, 2009, EPIGENETICS-US, V4, P429, DOI 10.4161/epi.4.7.9787; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55	30	20	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6212	6224		10.1038/s41388-018-0393-y	http://dx.doi.org/10.1038/s41388-018-0393-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30013191				2022-12-28	WOS:000451622100002
J	Amin, MKBA; Shimizu, A; Zankov, DP; Sato, A; Kurita, S; Ito, M; Maeda, T; Yoshida, T; Sakaue, T; Higashiyama, S; Kawauchi, A; Ogita, H				Amin, Mohammad Khusni B. Ahmat; Shimizu, Akio; Zankov, Dimitar P.; Sato, Akira; Kurita, Souichi; Ito, Masami; Maeda, Toshinaga; Yoshida, Tetsuya; Sakaue, Tomohisa; Higashiyama, Shigeki; Kawauchi, Akihiro; Ogita, Hisakazu			Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1	ONCOGENE			English	Article							PHOSPHOLIPID-BINDING PROTEINS; PROSTATE-CANCER; THERAPEUTIC TARGET; SUPPRESSOR GENE; GROWTH; EMP1; MICROENVIRONMENT; ANGIOGENESIS; RECEPTOR; CD151	Tumor metastasis is the most common cause of cancer death. Elucidation of the mechanism of tumor metastasis is therefore important in the development of novel, effective anti-cancer therapies to reduce cancer mortality. Interaction between cancer cells and surrounding stromal cells in the tumor microenvironment is a key factor in tumor metastasis. Using a co-culture assay system with human prostate cancer LNCaP cells and primary human prostate stromal cells, we identified epithelial membrane protein 1 (EMP1) as a gene with elevated expression in the cancer cells. The orthotopic injection of LNCaP cells overexpressing EMP1 (EMP1-LNCaP cells) into the prostate of nude mice induced lymph node and lung metastases, while that of control LNCaP cells did not. EMP1-LNCaP cells had higher cell motility and Racl activity than control LNCaP cells. These results were also observed in other lines of cancer cells. We newly identified copine-III as an intracellular binding partner of EMP1. Knockdown of copine-III attenuated the increased cell motility and Rac1 activity in EMP1-LNCaP cells. Reduced cell motility and Rac1 activity following knockdown of copine-III in EMP1-LNCaP cells were recovered by reexpression of wild-type copine-III, but not of a copine-III mutant incapable of interacting with EMP1, suggesting the importance of the EMP1-copine-III interaction. Phosphorylated and activated Src and a Rac guanine nucleotide exchange factor Vav2 were found to be involved in the EMP1-induced enhancement of cell motility and Rac1 activation. Moreover, EMP1 was highly expressed in prostate cancer samples obtained from patients with higher Gleason score. These results demonstrate that upregulation of EMP1 significantly increases cancer cell migration that leads to tumor metastasis, suggesting that EMP1 may play an essential role as a positive regulator of tumor metastasis.	[Amin, Mohammad Khusni B. Ahmat; Shimizu, Akio; Zankov, Dimitar P.; Sato, Akira; Kurita, Souichi; Ito, Masami; Maeda, Toshinaga; Ogita, Hisakazu] Shiga Univ Med Sci, Div Mol Med Biochem, Dept Biochem & Mol Biol, Otsu, Shiga, Japan; [Yoshida, Tetsuya; Kawauchi, Akihiro] Shiga Univ Med Sci, Dept Urol, Otsu, Shiga, Japan; [Sakaue, Tomohisa; Higashiyama, Shigeki] Ehime Univ, Div Cell Growth & Tumor Regulat, Proteosci Ctr PROS, Toon, Japan; [Sakaue, Tomohisa] Ehime Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Toon, Japan; [Higashiyama, Shigeki] Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Japan	Shiga University of Medical Science; Shiga University of Medical Science; Ehime University; Ehime University; Ehime University	Ogita, H (corresponding author), Shiga Univ Med Sci, Div Mol Med Biochem, Dept Biochem & Mol Biol, Otsu, Shiga, Japan.	hogita@belle.shiga-med.ac.jp	Ogita, Hisakazu/AAE-4416-2020; Ahmat Amin, Mohammad Khusni Bin/C-7336-2012	Ahmat Amin, Mohammad Khusni Bin/0000-0002-1948-4071; Ogita, Hisakazu/0000-0001-6750-1668	Japan Society for the Promotion of Science; Uehara Memorial Foundation; Takeda Science Foundation; Naito Foundation; Ichiro Kanehara Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Naito Foundation(Naito Memorial Foundation); Ichiro Kanehara Foundation	We thank Mr. Takefumi Yamamoto, Mr. Akifumi Morinaga, Mr. Akihiro Nishida, Ms. Xiaoling Pang, and Ms. Nor Idayu A. Rahman at Shiga University of Medical Science for their excellent technical assistance in this study. This study was supported by Grants-in-aid for Scientific Research KAKENHI from Japan Society for the Promotion of Science, The Uehara Memorial Foundation, Takeda Science Foundation, The Naito Foundation, and The Ichiro Kanehara Foundation.	Aries IM, 2014, LEUKEMIA, V28, P1828, DOI 10.1038/leu.2014.80; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Caudell EG, 2000, BIOCHEMISTRY-US, V39, P13034, DOI 10.1021/bi001250v; Chen J, 2012, ADV CANCER RES, V114, P1, DOI 10.1016/B978-0-12-386503-8.00001-6; Cifuentes FF, 2015, ONCOL LETT, V10, P2142, DOI 10.3892/ol.2015.3522; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; Detchokul S, 2014, ONCOL REP, V31, P241, DOI 10.3892/or.2013.2823; Fischer M, 2011, CANCER RES, V71, P1520, DOI 10.1158/0008-5472.CAN-10-2817; Fu MY, 2010, CLIN CANCER RES, V16, P3954, DOI 10.1158/1078-0432.CCR-10-0368; Fukumoto Y, 2011, J BIOL CHEM, V286, P43537, DOI 10.1074/jbc.M111.308858; Fumoto S, 2009, CANCER LETT, V274, P25, DOI 10.1016/j.canlet.2008.08.021; Goicoechea SM, 2014, CELL ADHES MIGR, V8, P535, DOI 10.4161/cam.28721; Goubran HA, 2014, CANCER GROWTH METAST, V7, P9, DOI 10.4137/CGM.S11285; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Heinrich C, 2010, ONCOGENE, V29, P1598, DOI 10.1038/onc.2009.456; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Jain A, 2005, P NATL ACAD SCI USA, V102, P11858, DOI 10.1073/pnas.0502113102; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karlou M, 2010, NAT REV UROL, V7, P494, DOI 10.1038/nrurol.2010.134; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Majima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068134; Martin TA, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.26518; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Mitsuhashi Y, 2012, HISTOPATHOLOGY, V60, P826, DOI 10.1111/j.1365-2559.2011.04158.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Pang XL, 2016, HYPERTENSION, V68, P630, DOI 10.1161/HYPERTENSIONAHA.116.07357; Qin Y, 2017, J NEURO-ONCOL, V134, P29, DOI 10.1007/s11060-017-2507-8; Qin Y, 2014, J BIOL CHEM, V289, P13974, DOI 10.1074/jbc.M113.543728; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Scott Andrew M, 2012, Cancer Immun, V12, P14; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; Sun GG, 2014, TUMOR BIOL, V35, P3185, DOI 10.1007/s13277-013-1416-5; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Uemura H, 2005, MOL CANCER THER, V4, P1699, DOI 10.1158/1535-7163.MCT-04-0295; Voss MA, 2011, BRIT J CANCER, V104, P1611, DOI 10.1038/bjc.2011.80; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang YW, 2017, BBA-REV CANCER, V1868, P199, DOI 10.1016/j.bbcan.2017.04.004; Wang YW, 2014, J UROLOGY, V192, P242, DOI 10.1016/j.juro.2013.12.001; Wang YW, 2005, LAB INVEST, V85, P1392, DOI 10.1038/labinvest.3700335; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Xue Q, 2013, EXP MOL PATHOL, V95, P313, DOI 10.1016/j.yexmp.2013.07.001; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yoshida A, 2015, BIOL OPEN, V4, P1063, DOI 10.1242/bio.010918; Zankov DP, 2017, SCI REP-UK, V7, DOI 10.1038/srep39335; Zarzynska JM, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/141747	50	31	31	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5416	5434		10.1038/s41388-018-0286-0	http://dx.doi.org/10.1038/s41388-018-0286-0			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29867202	Green Published, hybrid			2022-12-28	WOS:000446312900004
J	Wei, S; Wang, J; Oyinlade, O; Ma, D; Wang, SY; Kratz, L; Lal, B; Xu, QF; Liu, SQ; Shah, SR; Zhang, H; Li, YQ; Quinones-Hinojosa, A; Zhu, H; Huang, ZY; Cheng, LZ; Qian, J; Xia, SL				Wei, Shuang; Wang, Jie; Oyinlade, Olutobi; Ma, Ding; Wang, Shuyan; Kratz, Lisa; Lal, Bachchu; Xu, Qingfu; Liu, Senquan; Shah, Sagar R.; Zhang, Hao; Li, Yunqing; Quinones-Hinojosa, Alfredo; Zhu, Heng; Huang, Zhi-yong; Cheng, Linzhao; Qian, Jiang; Xia, Shuli			Heterozygous IDH1(R132H/WT) created by "single base editing" inhibits human astroglial cell growth by downregulating YAP	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; IDH1 MUTATION; GLIOMA-CELLS; DNA METHYLATION; GENE-EXPRESSION; ACTIVATION; CANCER; PROLIFERATION; D-2-HYDROXYGLUTARATE; CRISPR-CAS9	Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified in a number of cancer types, including brain cancer. The Cancer Genome Atlas project has revealed that IDH1 mutations occur in 70-80% of grade II and grade III gliomas. Until recently, most of the functional studies of IDH1 mutations in cellular models have been conducted in overexpression systems with the IDH1 wild type background. In this study, we employed a modified CRISPR/Cas9 genome editing technique called "single base editing", and efficiently introduced heterozygous IDH1 R132H mutation (IDH1(R132H/WT)) in human astroglial cells. Global DNA methylation profiling revealed hypermethylation as well as hypomethylation induced by IDH1(R132H/WT). Global gene expression analysis identified molecular targets and pathways altered by IDH1(R132H/WT), including cell proliferation, extracellular matrix (ECM), and cell migration. Our phenotype analysis indicated that compared with IDH1 wild type cells, IDH1(R132H/WT) promoted cell migration by upregulating integrin beta 4 (ITGB4); and significantly inhibited cell proliferation. Using our mutated IDH1 models generated by "single base editing", we identified novel molecular targets of IDH1(R132H/WT), namely Yes-associated protein (YAP) and its downstream signaling pathway Notch, to mediate the cell growth-inhibiting effect of IDH1(R132H/WT). In summary, the "single base editing" strategy has successfully created heterozygous IDH1 R132H mutation that recapitulates the naturally occurring IDH1 mutation. Our isogenic cellular systems that differ in a single nucleotide in one allele of the IDH1 gene provide a valuable model for novel discoveries of IDH1(R132H/WT)-driven biological events.	[Wei, Shuang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan 430030, Hubei, Peoples R China; [Wei, Shuang; Oyinlade, Olutobi; Ma, Ding; Wang, Shuyan; Kratz, Lisa; Lal, Bachchu; Xu, Qingfu; Li, Yunqing; Xia, Shuli] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Wei, Shuang; Ma, Ding; Wang, Shuyan; Lal, Bachchu; Xu, Qingfu; Li, Yunqing; Xia, Shuli] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wang, Jie; Qian, Jiang] Johns Hopkins Sch Med, Dept Wilmer Eye Inst, Baltimore, MD 21205 USA; [Oyinlade, Olutobi; Zhu, Heng] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Liu, Senquan; Cheng, Linzhao] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA; [Shah, Sagar R.; Quinones-Hinojosa, Alfredo] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA; [Shah, Sagar R.] Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Zhang, Hao] Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Zhu, Heng] Johns Hopkins Sch Med, Ctr High Throughput Biol, Baltimore, MD 21205 USA; [Huang, Zhi-yong] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gen Surg, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Huazhong University of Science & Technology	Xia, SL (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.; Xia, SL (corresponding author), Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	xia@kennedykrieger.org	Wei, Shuang/AAA-4031-2019	Wang, Jie/0000-0002-7491-7001; Huang, Zhiyong/0000-0002-2239-0674	NIH [R01NS091165, EY024580, EY023188, GM111514, T32 GM007445]; Ford Foundation predoctoral fellowship program; NATIONAL EYE INSTITUTE [R01EY023188, R01EY024580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445, R01GM111514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS091165] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ford Foundation predoctoral fellowship program; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr. G. Major from NIH/NINDS for SVG cells, and Dr. Mingyao Ying from Kennedy Krieger Institute for YAP constructs. We thank Dr. John Laterra and Dr. Hernando Lopez for comments on this work. This work was supported by grants from NIH R01NS091165 (S.X.), NIH EY024580 (J.Q.), NIH EY023188 (J.Q.), and NIH GM111514 (H.Z. and J.Q.), Ford Foundation predoctoral fellowship program (O.O.) and NIH T32 GM007445 (O.O.).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cui DM, 2016, INT J BIOCHEM CELL B, V73, P72, DOI 10.1016/j.biocel.2016.02.007; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duncan CG, 2012, GENOME RES, V22, P2339, DOI 10.1101/gr.132738.111; Ferenczy MW, 2013, J NEUROIMMUNE PHARM, V8, P1303, DOI 10.1007/s11481-013-9499-8; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fu YJ, 2012, BIOTECHNOL LETT, V34, P441, DOI 10.1007/s10529-011-0800-8; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Konsavage WM, 2012, J BIOL CHEM, V287, P11730, DOI 10.1074/jbc.M111.327767; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Licciardello MP, 2015, ONCOGENE, V34, P3780, DOI 10.1038/onc.2014.319; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luchman HA, 2012, NEURO-ONCOLOGY, V14, P184, DOI 10.1093/neuonc/nor207; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Ma SH, 2015, ONCOTARGET, V6, P8606, DOI 10.18632/oncotarget.3330; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Piaskowski S, 2011, BRIT J CANCER, V104, P968, DOI 10.1038/bjc.2011.27; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Sabit H, 2014, BRAIN TUMOR PATHOL, V31, P242, DOI 10.1007/s10014-013-0172-y; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Shah SR, 2017, CELL REP, V21, P495, DOI 10.1016/j.celrep.2017.09.057; Shi JL, 2014, NEUROL SCI, V35, P839, DOI 10.1007/s10072-013-1607-2; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wan J, 2017, ELIFE, V6, DOI 10.7554/eLife.20068; Wang GL, 2014, MOL MED REP, V9, P1799, DOI 10.3892/mmr.2014.2052; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	44	19	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5160	5174		10.1038/s41388-018-0334-9	http://dx.doi.org/10.1038/s41388-018-0334-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849122	Green Accepted			2022-12-28	WOS:000445093100002
J	Abdoul-Azize, S; Buquet, C; Li, H; Picquenot, JM; Vannier, JP				Abdoul-Azize, Souleymane; Buquet, Catherine; Li, Hong; Picquenot, Jean-Michel; Vannier, Jean-Pierre			Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin	ONCOGENE			English	Article							CANCER-CELLS; INDUCED CARDIOTOXICITY; NEURONAL APOPTOSIS; LEUKEMIA-CELLS; STATINS; STORE; BIM; ACTIVATION; PATHWAY; INDUCE	Recent studies have suggested that the lipid-lowering agent simvastatin holds great promise as a cancer therapeutic; it inhibits the growth of multiple tumors, including triple-negative breast cancer. Doxorubicin-and simvastatin-induced cytotoxicity has been associated with the modulation of Ca2+ signaling, but the underlying mechanisms remain incompletely understood. Here we identify how Ca2+ signaling regulates the breast tumor cell response to doxorubicin and simvastatin. These two drugs inhibit cell survival while increasing apoptosis in two human breast cancer cell lines and five primary breast tumor specimens through the modulation of Ca2+ signaling. Signal transduction and functional studies revealed that both simvastatin and doxorubicin trigger persistent cytosolic Ca2+ release, thereby stimulating the proapoptotic BIM pathway and mitochondrial Ca2+ overload, which are responsible for metabolic dysfunction and apoptosis induction. Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. In addition, reduction of the Ca2+ signal by chelation or pharmacological inhibition significantly prevents drug-mediated anticancer signaling. Unexpectedly, a scratch-wound assay indicated that these two drugs induce rapid cell migration, while inhibiting cell invasion and colony formation in a Ca2+-dependent manner. Further, the in vivo data for MDA-MB-231 xenografts demonstrate that upon chelation of Ca2+, the ability of both drugs to reduce the tumor burden was significantly reduced via caspase-3 deactivation. Our results establish a calcium-based mechanism as crucial for executing the cell death process triggered by simvastatin and doxorubicin, and suggest that combining simvastatin with doxorubicin may be an effective regimen for the treatment of breast cancer.	[Abdoul-Azize, Souleymane; Buquet, Catherine; Li, Hong; Vannier, Jean-Pierre] Univ Rouen, Fac Med & Pharm, IRIB, Unite Inserm,U1234, F-76183 Rouen, France; [Picquenot, Jean-Michel] Ctr Henri Becquerel Lutte Canc CLCC Normandie, Serv Anat & Cytol Pathol, F-76038 Rouen 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Abdoul-Azize, S (corresponding author), Univ Rouen, Fac Med & Pharm, IRIB, Unite Inserm,U1234, F-76183 Rouen, France.	souleymane.abdoul-azize@univ-rouen.fr	Abdoul-Azize, Souleymane/AAB-2181-2021	Abdoul-Azize, Souleymane/0000-0003-2065-9091	French Ministry of Higher Education and Research; Association Vie et Espoir	French Ministry of Higher Education and Research; Association Vie et Espoir	This work was supported by grants from the French Ministry of Higher Education and Research, and the Association Vie et Espoir. We thank members of the LIONS CLUB Les Andelys association for their support with equipment.	Abdoul-Azize S, 2017, ONCOTARGET, V8, P27339, DOI 10.18632/oncotarget.16039; Ansari L, 2017, CANCER GENE THER, V24, P189, DOI 10.1038/cgt.2017.9; Borahay MA, 2014, J BIOL CHEM, V289, P35075, DOI 10.1074/jbc.M114.583575; Buranrat B, 2017, ONCOL LETT, V14, P6243, DOI 10.3892/ol.2017.6783; Burridge PW, 2016, NAT MED, V22, P547, DOI 10.1038/nm.4087; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cheng HY, 2016, ONCOTARGET, V7, P16866, DOI 10.18632/oncotarget.7619; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; David L, 2004, MATRIX BIOL, V23, P183, DOI 10.1016/j.matbio.2004.05.005; David L, 2008, ACTA BIOMATER, V4, P256, DOI 10.1016/j.actbio.2007.08.012; Einbond LS, 2016, FITOTERAPIA, V109, P146, DOI 10.1016/j.fitote.2015.12.005; Gajek Arkadiusz, 2015, Asian Pac J Cancer Prev, V16, P8503; Gao JQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168219; Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994; Giorgi C, 2015, P NATL ACAD SCI USA, V112, P1779, DOI 10.1073/pnas.1410723112; Gogebakan B, 2014, TUMOR BIOL, V35, P8033, DOI 10.1007/s13277-014-1752-0; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Huang XX, 2015, CURR CANCER DRUG TAR, V15, P481, DOI 10.2174/156800961506150805151905; Kato S, 2010, J CELL MOL MED, V14, P1180, DOI 10.1111/j.1582-4934.2009.00771.x; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Lavik AR, 2015, ONCOTARGET, V6, P27388, DOI 10.18632/oncotarget.4489; Leung YM, 1999, JPN J PHARMACOL, V81, P253, DOI 10.1254/jjp.81.253; Li Y, 2013, INT J MOL MED, V31, P1234, DOI 10.3892/ijmm.2013.1292; Liao YY, 2009, P NATL ACAD SCI USA, V106, P3202, DOI 10.1073/pnas.0813346106; Liu CX, 2016, ONCOTARGET, V7, P7534, DOI 10.18632/oncotarget.7183; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marchi S, 2016, CURR OPIN PHARMACOL, V29, P1, DOI 10.1016/j.coph.2016.03.002; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; MORTIMER JE, 2003, P AN M AM SOC CLIN, V22, P93; Motiani RK, 2010, J BIOL CHEM, V285, P19173, DOI 10.1074/jbc.M110.102582; Ouadid-Ahidouch H, 2013, TRENDS MOL MED, V19, P117, DOI 10.1016/j.molmed.2012.11.004; Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rambal AA, 2009, LEUKEMIA, V23, P1744, DOI 10.1038/leu.2009.80; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Safwat S, 2017, J PHARM PHARMACOL, V69, P613, DOI 10.1111/jphp.12707; Shi J, 2017, J PHYSIOL-LONDON, V595, P1039, DOI 10.1113/JP273302; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Szwed M, 2016, CELL ONCOL, V39, P107, DOI 10.1007/s13402-015-0256-2; Tanwar J, 2018, CELL CALCIUM, V69, P19, DOI 10.1016/j.ceca.2017.06.002; Tiwari M, 2017, J CELL PHYSIOL, V232, P976, DOI 10.1002/jcp.25670; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Wu QJ, 2015, ONCOTARGET, V6, P42988, DOI 10.18632/oncotarget.5557; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yao H, 2017, ONCOTARGET, V8, P1913, DOI 10.18632/oncotarget.12284; Zhang HT, 2016, CELL PHYSIOL BIOCHEM, V40, P1079, DOI 10.1159/000453163; Zhang S, 2016, MOL NEUROBIOL, V53, P7078, DOI 10.1007/s12035-015-9573-8; Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919	51	22	23	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4979	4993		10.1038/s41388-018-0329-6	http://dx.doi.org/10.1038/s41388-018-0329-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795329				2022-12-28	WOS:000443823600006
J	Gates, LA; Gu, GW; Chen, Y; Rohira, AD; Lei, JT; Hamilton, RA; Yu, Y; Lonard, DM; Wang, J; Wang, SP; Edwards, DG; Lavere, PF; Shao, JY; Yi, P; Jain, A; Jung, SY; Malovannaya, A; Li, SQ; Shao, JY; Roeder, RG; Ellis, MJ; Qin, J; Fuqua, SAW; O'Malley, BW; Foulds, CE				Gates, Leah A.; Gu, Guowei; Chen, Yue; Rohira, Aarti D.; Lei, Jonathan T.; Hamilton, Ross A.; Yu, Yang; Lonard, David M.; Wang, Jin; Wang, Shu-Ping; Edwards, David G.; Lavere, Philip F.; Shao, Jiangyong; Yi, Ping; Jain, Antrix; Jung, Sung Yun; Malovannaya, Anna; Li, Shunqiang; Shao, Jieya; Roeder, Robert G.; Ellis, Matthew J.; Qin, Jun; Fuqua, Suzanne A. W.; O'Malley, Bert W.; Foulds, Charles E.			Proteomic profiling identifies key coactivators utilized by mutant ER alpha proteins as potential new therapeutic targets	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; ESR1 MUTATIONS; ENDOCRINE RESISTANCE; GENETIC SCREENS; PROTEASOME; RECRUITMENT; INHIBITOR; REVEALS; DNA	Approximately 75% of breast cancers are estrogen receptor alpha (ER alpha)-positive and are treatable with endocrine therapies, but often patients develop lethal resistant disease. Frequent mutations (10-40%) in the ligand-binding domain (LBD) codons in the gene encoding ER alpha (ESR1) have been identified, resulting in ligand-independent, constitutively active receptors. In addition, ESR1 chromosomal translocations can occur, resulting in fusion proteins that lack the LBD and are entirely unresponsive to all endocrine treatments. Thus, identifying coactivators that bind to these mutant ERa proteins may offer new therapeutic targets for endocrine-resistant cancer. To define coactivator candidate targets, a proteomics approach was performed profiling proteins recruited to the two most common ER alpha LBD mutants, Y537S and D538G, and an ESR1-YAP1 fusion protein. These mutants displayed enhanced coactivator interactions as compared to unliganded wild-type ER alpha. Inhibition of these coactivators decreased the ability of ESR1 mutants to activate transcription and promote breast cancer growth in vitro and in vivo. Thus, we have identified specific coactivators that may be useful as targets for endocrine-resistant breast cancers.	[Gates, Leah A.; Gu, Guowei; Rohira, Aarti D.; Hamilton, Ross A.; Yu, Yang; Lonard, David M.; Wang, Jin; Lavere, Philip F.; Shao, Jiangyong; Yi, Ping; Jain, Antrix; Malovannaya, Anna; Qin, Jun; O'Malley, Bert W.; Foulds, Charles E.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gates, Leah A.] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA; [Gu, Guowei; Lei, Jonathan T.; Edwards, David G.; Ellis, Matthew J.; Fuqua, Suzanne A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chen, Yue] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA 70130 USA; [Lei, Jonathan T.; Ellis, Matthew J.] Baylor Coll Med, Interdept Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Wang, Jin] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; [Wang, Jin] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA; [Wang, Shu-Ping; Roeder, Robert G.] Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10065 USA; [Jung, Sung Yun; Malovannaya, Anna; Qin, Jun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Li, Shunqiang; Shao, Jieya] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA; [Ellis, Matthew J.; Fuqua, Suzanne A. W.; O'Malley, Bert W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Foulds, Charles E.] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA	Baylor College of Medicine; Rockefeller University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Rockefeller University; Baylor College of Medicine; Washington University (WUSTL); Baylor College of Medicine; Baylor College of Medicine	Foulds, CE (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Foulds, CE (corresponding author), Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA.	foulds@bcm.edu	Jain, Antrix/AEB-7319-2022; Wang, Jin/AAC-7292-2019; Wang, Shu-Ping/S-4379-2018	Jain, Antrix/0000-0002-2815-3645; Wang, Jin/0000-0003-3625-7919; Wang, Shu-Ping/0000-0002-5895-1269; Lei, Jonathan/0000-0002-0209-8051; Jung, Sung Yun/0000-0003-1521-7977; Malovannaya, Anna/0000-0003-2953-6485	NCI [P30 CA125123]; CPRIT [RP170005, RP150578, RR140033, RP150440, RP120732-P2, RP110784]; NIH [DK56338, CA125123, R01 HD008188, R01 HD007857, R01 CA207270, R01 CA072038, R01 GM115622, R01 CA207701, R21 CA213535, R01 DK071900, R01 CA178765, 1F31CA210385-01, T32 GM088129]; Susan G. Komen Foundation [PG12220321, CCR14300139]; Breast Cancer Research Foundation [17-055]; DOD [W81XWH-13-1-0285, W81XWH-16-1-0539]; Human Frontier Science Program Fellowship [LT000538/2011-L]; McNair Medical Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857, R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F31CA210385, R01CA207701, R21CA213535, R01CA178765, R01CA072038, R01CA207270, P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071900, P30DK056338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM088129, R01GM115622] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; DOD(United States Department of Defense); Human Frontier Science Program Fellowship(Human Frontier Science Program); McNair Medical Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the following BCM cores (Tissue Culture, Monoclonal Antibody/Recombinant Protein and Mass Spectrometry Proteomics (funded by NCI P30 CA125123 and CPRIT RP170005), Gene Vector, Integrated Microscopy (funded by NIH (DK56338 and CA125123) and CPRIT (RP150578))), David Bader, Doug Chan, and Rainer Lanz. We acknowledge the joint participation with the Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with BCM and the Cancer Program. This work was supported by the NIH ((R01 HD008188 and R01 HD007857 to B.W.O.), (R01 CA207270 and R01 CA072038 to S.A.W.F), (R01 GM115622, R01 CA207701, and R21 CA213535 to J.W.), (R01 DK071900 and R01 CA178765 to R.G.R.), (1F31CA210385-01 to L.A.G.), and (T32 GM088129 to J.T.L.)), CPRIT ((RR140033 to M.J.E), (RP150440 and RP120732-P2 to S.A.W.F.), and (RP110784 to J.Q.)), Susan G. Komen Foundation ((PG12220321 to M.J.E.) and (CCR14300139 to Jieya Shao)), Breast Cancer Research Foundation (17-055 to S.A.W.F.), DOD ((W81XWH-13-1-0285 to B.W.O.) and (W81XWH-16-1-0539 to M.J.E.)), the Human Frontier Science Program Fellowship (LT000538/2011-L to S.P.W.), and the McNair Medical Foundation (M.J.E.).	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Alluri PG, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2156; Boney-Montoya J, 2010, MOL ENDOCRINOL, V24, P346, DOI 10.1210/me.2009-0429; Bossi D, 2016, CANCER DISCOV, V6, P650, DOI 10.1158/2159-8290.CD-15-1200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Ciruelos E, 2014, BREAST, V23, P201, DOI 10.1016/j.breast.2014.01.016; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Dawkins JBN, 2016, CANCER RES, V76, P4861, DOI 10.1158/0008-5472.CAN-16-0481; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Foulds CE, 2013, MOL CELL, V51, P185, DOI 10.1016/j.molcel.2013.06.007; Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Gu GW, 2015, BREAST CANCER RES TR, V150, P535, DOI 10.1007/s10549-015-3354-y; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hartmaier RJ, 2018, ANN ONCOL, V29, P872, DOI 10.1093/annonc/mdy025; Jeong KW, 2012, MOL ENDOCRINOL, V26, P955, DOI 10.1210/me.2012-1066; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Joseph JD, 2016, ELIFE, V5, DOI 10.7554/eLife.15828; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kinyamu HK, 2008, MOL CARCINOGEN, V47, P845, DOI 10.1002/mc.20440; Lake MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044160; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Mao CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34753; Massarweh S, 2007, CLIN CANCER RES, V13, P1950, DOI 10.1158/1078-0432.CCR-06-2540; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Powers GL, 2010, ONCOGENE, V29, P1509, DOI 10.1038/onc.2009.434; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Scott GK, 2017, ONCOTARGET, V8, P83432, DOI 10.18632/oncotarget.12735; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Thaler S, 2015, INT J CANCER, V137, P686, DOI 10.1002/ijc.29404; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Van Asten K, 2014, ENDOCR-RELAT CANCER, V21, pR31, DOI 10.1530/ERC-13-0269; Wang SP, 2017, MOL CELL, V67, P308, DOI 10.1016/j.molcel.2017.06.028; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wardell SE, 2015, CLIN CANCER RES, V21, P5121, DOI 10.1158/1078-0432.CCR-15-0360; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; Wierer M, 2013, CELL REP, V3, P2021, DOI 10.1016/j.celrep.2013.05.024; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhang QX, 1997, CANCER RES, V57, P1244; Zhao YC, 2017, CANCER RES, V77, P5602, DOI 10.1158/0008-5472.CAN-17-1265	66	36	36	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4581	4598		10.1038/s41388-018-0284-2	http://dx.doi.org/10.1038/s41388-018-0284-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29748621	Green Published, hybrid			2022-12-28	WOS:000441736700007
J	Yoon, S; Lee, EJ; Choi, JH; Chung, T; Kim, DY; Im, JY; Bae, MH; Kwon, JH; Kim, HH; Kim, HC; Park, YN; Wang, HJ; Woo, HG				Yoon, Sarah; Lee, Eun-Ju; Choi, Ji-Hye; Chung, Taek; Kim, Do Young; Im, Jong-Yeop; Bae, Myung-Ho; Kwon, Jung-Hee; Kim, Hyuk-Hoon; Kim, Hyung Chul; Park, Young Nyun; Wang, Hee-Jung; Woo, Hyun Goo			Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; LIPOCALIN 2; RESISTANCE; PROGRESSION; EXPRESSION; ANGIOGENESIS; SENSITIVITY; INDUCTION; MECHANISM; HUMANS	Gene mutations play critical roles during cancer development and progression, and therefore represent targets for precision medicine. Here we recapitulated the pharmacogenomic data to delineate novel candidates for actionable mutations and therapeutic target drugs. As a proof-of-concept, we demonstrated that the loss-of-function of SULF2 by mutation (N491K) or inhibition enhanced sorafenib sensitivity in liver cancer cells and in vivo mouse models. This effect was mediated by deregulation of EGFR signaling and downstream expression of LCN2. We also report that the liver cancer patients non-responding to sorafenib treatment exhibit higher expression of SULF2 and LCN2. In conclusion, we suggest that SULF2 plays a key role in sorafenib susceptibility and resistance in liver cancer via deregulation of LCN2. Diagnostic or therapeutic targeting of SULF2 (e.g., OKN-007) and/or LCN2 can be a novel precision strategy for sorafenib treatment in cancer patients.	[Yoon, Sarah; Lee, Eun-Ju; Choi, Ji-Hye; Im, Jong-Yeop; Woo, Hyun Goo] Ajou Univ, Sch Med, Dept Physiol, Suwon, South Korea; [Choi, Ji-Hye; Im, Jong-Yeop; Woo, Hyun Goo] Ajou Univ, Dept Biomed Sci, Grad Sch, Suwon, South Korea; [Chung, Taek; Park, Young Nyun] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Chung, Taek; Park, Young Nyun] Yonsei Univ, Coll Med, PLUS Project Med Sci BK21, Seoul, South Korea; [Kim, Do Young] Yonsei Univ, Coll Med, Dept Gastroenterol, Seoul, South Korea; [Bae, Myung-Ho; Kwon, Jung-Hee] CbsBioscience Inc, Daejeon, South Korea; [Kim, Hyuk-Hoon] Ajou Univ, Sch Med, Dept Emergency Med, Suwon, South Korea; [Kim, Hyung Chul] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wang, Hee-Jung] Ajou Univ, Sch Med, Dept Surg, Suwon, South Korea	Ajou University; Ajou University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ajou University	Woo, HG (corresponding author), Ajou Univ, Sch Med, Dept Physiol, Suwon, South Korea.; Woo, HG (corresponding author), Ajou Univ, Dept Biomed Sci, Grad Sch, Suwon, South Korea.	hg@ajou.ac.kr	Woo, Hyun Goo | 우현구/I-8954-2019; Woo, Hyun Goo/AEJ-7372-2022	Woo, Hyun Goo | 우현구/0000-0002-0916-893X; Woo, Hyun Goo/0000-0002-0916-893X	Korea Healthcare Technology R&D Project, Ministry of Health Welfare [HI15C1551, HI14C3392]; National Research Foundation of Korea (NRF) - Korea government (MSIP) [NRF-2017M3A9B6061509, NRF-2017R1E1A1A01074733, NRF-2015R1D1A4A01020022]	Korea Healthcare Technology R&D Project, Ministry of Health Welfare; National Research Foundation of Korea (NRF) - Korea government (MSIP)	This work was supported by grants from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare (HI15C1551 and HI14C3392) and from the National Research Foundation of Korea (NRF) funded by the Korea government (MSIP) (NRF-2017M3A9B6061509, NRF-2017R1E1A1A01074733, and NRF-2015R1D1A4A01020022).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Berasain C, 2013, GUT, V62, P1674, DOI 10.1136/gutjnl-2013-304564; Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019; Chen G, 2017, CANCER RES, V77, P632, DOI 10.1158/0008-5472.CAN-15-2556; Chen HA, 2016, HEPATOLOGY, V64, P1637, DOI 10.1002/hep.28773; Ding GX, 2015, PROSTATE, V75, P957, DOI 10.1002/pros.22978; Frese MA, 2009, J BIOL CHEM, V284, P28033, DOI 10.1074/jbc.M109.035808; Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2010, HEPATOLOGY, V52, P1680, DOI 10.1002/hep.23848; Leung L, 2012, PLOS ONE, V7; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nishida N, 2015, DIGEST DIS, V33, P771, DOI 10.1159/000439102; Park JG, 2015, CLIN MOL HEPATOL, V21, P287, DOI 10.3350/cmh.2015.21.3.287; Peng S, 2014, HEPATOLOGY, V60, P1264, DOI 10.1002/hep.27236; Rosen SD, 2010, EXPERT OPIN THER TAR, V14, P935, DOI 10.1517/14728222.2010.504718; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Shiiba M, 2013, INT J ONCOL, V42, P1197, DOI 10.3892/ijo.2013.1815; Sun XF, 2016, HEPATOLOGY, V64, P488, DOI 10.1002/hep.28574; Tang RH, 2009, J BIOL CHEM, V284, P21505, DOI 10.1074/jbc.M109.028472; Tovar V, 2017, GUT, V66, P530, DOI 10.1136/gutjnl-2015-309501; Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yoo J, 2012, AM J PHYSIOL-GASTR L, V302, pG805, DOI 10.1152/ajpgi.00522.2011; Zhang Y, 2012, CANCER EPIDEMIOL, V36, pE294, DOI 10.1016/j.canep.2012.05.012; Zhao P, 2013, MOL METAB, V2, P161, DOI 10.1016/j.molmet.2013.04.003	31	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4443	4454		10.1038/s41388-018-0291-3	http://dx.doi.org/10.1038/s41388-018-0291-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720727				2022-12-28	WOS:000441144300008
J	Cannataro, VL; Gaffney, SG; Stender, C; Zhao, ZM; Philips, M; Greenstein, AE; Townsend, JP				Cannataro, Vincent L.; Gaffney, Stephen G.; Stender, Carly; Zhao, Zi-Ming; Philips, Mark; Greenstein, Andrew E.; Townsend, Jeffrey P.			Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C	ONCOGENE			English	Article							EGFR T790M MUTATION; ACQUIRED-RESISTANCE; INTRATUMORAL HETEROGENEITY; POPULATION-GENETICS; LUNG CANCERS; RAS; INHIBITORS; THERAPY; MUTANT; GENES	Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant. However, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS G12-positive lung tumors to determine the prevalence of other oncogenic mutations within KRAS or within commonly mutated downstream genes that could confer resistance at the time of treatment. We also passaged patient-derived xenografts to assess the potential for novel KRAS mutation to arise during subsequent tumor evolution. Furthermore, we estimate the de novo mutation rate in KRAS position 12 and in genes downstream of KRAS. Finally, we present an approach for estimation of the selection intensity for these point mutations that explains their high prevalence in tumors. We find no evidence of heterogeneity that may compromise KRAS G12C targeted therapy within sequenced lung tumors or passaged xenografts. We find that mutations that confer resistance are even less likely to occur downstream of KRAS than to occur within KRAS. Our approach predicts that BRAF V600E would provide the highest fitness advantage for de novo-resistant subclones. Overall, our findings suggest that resistance to targeted therapy of KRAS G12C-positive tumors is unlikely to be present at the time of treatment and, among the de novo mutations likely to confer resistance, mutations in BRAF, a gene with targeted inhibitors presently available, result in subclones with the highest fitness advantage.	[Cannataro, Vincent L.; Gaffney, Stephen G.; Stender, Carly; Zhao, Zi-Ming; Townsend, Jeffrey P.] Yale Univ, Dept Biostat, New Haven, CT 06520 USA; [Philips, Mark] NYU, Sch Med, Dept Med, New York, NY USA; [Philips, Mark] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Philips, Mark] NYU, Sch Med, Dept Pharmacol, New York, NY USA; [Greenstein, Andrew E.] Gilead Sci, Foster City, CA USA; [Townsend, Jeffrey P.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Townsend, Jeffrey P.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	Yale University; New York University; New York University; New York University; Gilead Sciences; Yale University; Yale University	Townsend, JP (corresponding author), Yale Univ, Dept Biostat, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	jeffrey.townsend@yale.edu	Townsend, Jeffrey/H-2747-2019	Townsend, Jeffrey/0000-0002-9890-3907; Mark, Philips/0000-0002-1179-8156; Cannataro, Vincent/0000-0002-6364-7747; Gaffney, Stephen/0000-0002-5490-2945; Greenstein, Andrew/0000-0002-1470-1970	Gilead Sciences, Inc.; NATIONAL CANCER INSTITUTE [R01CA116034] Funding Source: NIH RePORTER	Gilead Sciences, Inc.(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially funded by Gilead Sciences, Inc.	Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Alsdorf WH, 2013, EXP MOL PATHOL, V94, P155, DOI 10.1016/j.yexmp.2012.09.016; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Bustamante CD, 2005, STAT BIOL HEALTH, P63, DOI 10.1007/0-387-27733-1_4; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cannataro VL, 2016, EVOL APPL, V9, P565, DOI 10.1111/eva.12361; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Cox Adrienne D, 2010, Small GTPases, V1, P2; Desai MM, 2007, CURR BIOL, V17, P385, DOI 10.1016/j.cub.2007.01.072; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fiala O, 2013, CANCER GENET-NY, V206, P26, DOI 10.1016/j.cancergen.2012.12.003; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Greulich Heidi, 2010, Genes Cancer, V1, P1200, DOI 10.1177/1947601911407324; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto D, 2016, PANCREAS, V45, P1111, DOI 10.1097/MPA.0000000000000624; Hobbs GA, 2016, CANCER CELL, V29, P251, DOI 10.1016/j.ccell.2016.02.015; Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001; Hunter JC, 2014, P NATL ACAD SCI USA, V111, P8895, DOI 10.1073/pnas.1404639111; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Izar B, 2014, J THORAC ONCOL, V9, P1363, DOI 10.1097/JTO.0000000000000266; Kadara H, 2017, ANN ONCOL, V28, P75, DOI 10.1093/annonc/mdw436; Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood-2012-01-405985; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008-5472.CAN-15-2962; Mao CQ, 2014, MOL THER, V22, P964, DOI 10.1038/mt.2014.18; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Montalvo SK, 2017, FUTURE ONCOL, V13, P263, DOI 10.2217/fon-2016-0363; Moran P., 1958, MATH P CAMBRIDGE PHI, V54, P60, DOI DOI 10.1017/S0305004100033193; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nadal E, 2014, J THORAC ONCOL, V9, P1513, DOI 10.1097/JTO.0000000000000305; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Parsons TL, 2007, THEOR POPUL BIOL, V72, P121, DOI 10.1016/j.tpb.2006.11.004; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Porta M, 2009, MUTAT RES-REV MUTAT, V682, P83, DOI 10.1016/j.mrrev.2009.07.003; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Roberts PJ, 2013, J CLIN ONCOL, V31, P1112, DOI 10.1200/JCO.2012.43.0454; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Rozhok AI, 2016, TRENDS CANCER, V2, P552, DOI 10.1016/j.trecan.2016.09.004; SAWYER SA, 1992, GENETICS, V132, P1161; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schildhaus HU, 2015, CLIN CANCER RES, V21, P907, DOI 10.1158/1078-0432.CCR-14-0450; Schmitt MW, 2016, NAT REV CLIN ONCOL, V13, P335, DOI 10.1038/nrclinonc.2015.175; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Singh H, 2015, J CLIN ONCOL, V33, P3650, DOI 10.1200/JCO.2015.62.1052; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suda K, 2009, J THORAC ONCOL, V4, P1, DOI 10.1097/JTO.0b013e3181913c9f; Svaton M, 2016, ANTICANCER RES, V36, P1077; Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620; Vilarinho S, 2014, GASTROENTEROLOGY, V146, pS495; Visscher M, 2016, CURR OPIN CHEM BIOL, V30, P61, DOI 10.1016/j.cbpa.2015.11.004; Westover KD, 2016, CANCER DISCOV, V6, P233, DOI 10.1158/2159-8290.CD-16-0092; Wilson CY, 2016, DRUG DISCOV TODAY, V21, P1915, DOI 10.1016/j.drudis.2016.08.002; Xiong Y, 2017, ACS MED CHEM LETT, V8, P61, DOI 10.1021/acsmedchemlett.6b00373; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yun C- H, 2016, P NATL ACAD SCI USA, V105, P2070; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232; Ziogas DE, 2016, BIOMARK MED, V10, P681, DOI 10.2217/bmm-2016-0044	73	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2444	2455		10.1038/s41388-017-0105-z	http://dx.doi.org/10.1038/s41388-017-0105-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29453361	Green Submitted			2022-12-28	WOS:000431386000008
J	Rajabi, H; Hiraki, M; Kufe, D				Rajabi, Hasan; Hiraki, Masayuki; Kufe, Donald			MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; GROUP PROTEIN EZH2; CARCINOMA-ASSOCIATED ANTIGEN; AGGRESSIVE BREAST-CANCER; LUNG-CANCER; PANCREATIC-CANCER; STEM-CELLS; MULTIPLE-MYELOMA; DNA METHYLATION; DRUG-RESISTANCE	The PRC2 and PRC1 complexes are aberrantly expressed in human cancers and have been linked to decreases in patient survival. MUC1-C is an oncoprotein that is also overexpressed in diverse human cancers and is associated with a poor prognosis. Recent studies have supported a previously unreported function for MUC1-C in activating PRC2 and PRC1 in cancer cells. In the regulation of PRC2, MUC1-C (i) drives transcription of the EZH2 gene, (ii) binds directly to EZH2, and (iii) enhances occupancy of EZH2 on target gene promoters with an increase in H3K27 trimethylation. Regarding PRC1, which is recruited to PRC2 sites in the hierarchical model, MUC1-C induces BMI1 transcription, forms a complex with BMI1, and promotes H2A ubiquitylation. MUC1-C thereby contributes to the integration of PRC2 and PRC1-mediated repression of tumor suppressor genes, such as CDH1, CDKN2A, PTEN and BRCA1. Like PRC2 and PRC1, MUC1-C is associated with the epithelial-mesenchymal transition (EMT) program, cancer stem cell (CSC) state, and acquisition of anticancer drug resistance. In concert with these observations, targeting MUC1-C downregulates EZH2 and BMI1, inhibits EMT and the CSC state, and reverses drug resistance. These findings emphasize the significance of MUC1-C as a therapeutic target for inhibiting aberrant PRC function and reprogramming the epigenome in human cancers.	[Rajabi, Hasan; Hiraki, Masayuki; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Hiraki, Masayuki] Osaka Univ, Grad Sch Med, Dept Gastrointestinal Surg, Suita, Osaka, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Osaka University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			US Department of Defense [BC151648]; National Cancer Institute of the National Institutes of Health [R01CA097098, R01CA166480, R21CA216553]; NATIONAL CANCER INSTITUTE [R01CA097098, R21CA216553, R01CA166480] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This publication was supported by the US Department of Defense under award number BC151648 and the National Cancer Institute of the National Institutes of Health under award numbers R01CA097098, R01CA166480 and R21CA216553.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0608-9; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, 2016, MOL CANCER RES, V14, P1266, DOI 10.1158/1541-7786.MCR-16-0233; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0421-2; Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Bouillez A, 2017, ONCOGENE, V36, P4037, DOI 10.1038/onc.2017.47; Bouillez A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338998; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122577; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; David JM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1117738; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Duraisamy S, 2007, INT J ONCOL, V31, P671; Dyson HJ, 2016, J BIOL CHEM, V291, P6714, DOI 10.1074/jbc.R115.692020; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gong JL, 1998, P NATL ACAD SCI USA, V95, P6279, DOI 10.1073/pnas.95.11.6279; Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179; Goode G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176820; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Inari H, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3154-3; Jang SH, 2016, J BREAST CANCER, V19, P53, DOI 10.4048/jbc.2016.19.1.53; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Lin XZ, 2015, BIOMOLECULES, V5, P3396, DOI 10.3390/biom5043396; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mody HR, 2016, MOL CANCER RES, V14, P1124, DOI 10.1158/1541-7786.MCR-16-0083; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagarsheth N, 2016, CANCER RES, V76, P275, DOI 10.1158/0008-5472.CAN-15-1938; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; Noman MZ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1263412; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Quoix E, 2016, LANCET ONCOL, V17, P212, DOI 10.1016/S1470-2045(15)00483-0; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rosenblatt J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1298; Rosenblatt J, 2013, CLIN CANCER RES, V19, P3640, DOI 10.1158/1078-0432.CCR-13-0282; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stroopinsky D, 2013, CANCER RES, V73, P5569, DOI 10.1158/0008-5472.CAN-13-0677; Tagde A, 2017, ONCOTARGET, V8, P69237, DOI 10.18632/oncotarget.20144; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19239; Wang YY, 2012, WORLD J SURG, V36, P1189, DOI 10.1007/s00268-012-1514-3; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YP, 2017, ONCOTARGET, V8, P37974, DOI 10.18632/oncotarget.16467; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yan KS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061172; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin L, 2012, BLOOD, V119, P810, DOI 10.1182/blood-2011-07-369686; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066	122	32	32	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2079	2088		10.1038/s41388-017-0096-9	http://dx.doi.org/10.1038/s41388-017-0096-9			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379165	Green Accepted			2022-12-28	WOS:000430589000001
J	Grither, WR; Divine, LM; Meller, EH; Wilke, DJ; Desai, RA; Loza, AJ; Zhao, PN; Lohrey, A; Longmore, GD; Fuh, KC				Grither, Whitney R.; Divine, Laura M.; Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Loza, Andrew J.; Zhao, Peinan; Lohrey, Anne; Longmore, Gregory D.; Fuh, Katherine C.			TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL METASTASIS; UP-REGULATION; INVASION; CARCINOMA; COLLAGEN; FIBRONECTIN; MATRIX; FIBROBLASTS; ACTIVATION	The mesenchymal gene program has been shown to promote the metastatic progression of ovarian cancer; however, specific proteins induced by this program that lead to these metastatic behaviors have not been identified. Using patient derived tumor cells and established human ovarian tumor cell lines, we find that the Epithelial-to-Mesenchymal Transition inducing factor TWIST1 drives expression of discoidin domain receptor 2 (DDR2), a receptor tyrosine kinase (RTK) that recognizes fibrillar collagen as ligand. The expression and action of DDR2 was critical for mesothelial cell clearance, invasion and migration in ovarian tumor cells. It does so, in part, by upregulating expression and activity of matrix remodeling enzymes that lead to increased cleavage of fibronectin and spreading of tumor cells. Additionally, DDR2 stabilizes SNAIL1, allowing for sustained mesenchymal phenotype. In patient derived ovarian cancer specimens, DDR2 expression correlated with enhanced invasiveness. DDR2 expression was associated with advanced stage ovarian tumors and metastases. In vivo studies demonstrated that the presence of DDR2 is critical for ovarian cancer metastasis. These findings indicate that the collagen receptor DDR2 is critical for multiple steps of ovarian cancer progression to metastasis, and thus, identifies DDR2 as a potential new target for the treatment of metastatic ovarian cancer.	[Grither, Whitney R.; Loza, Andrew J.; Lohrey, Anne; Longmore, Gregory D.] Washington Univ, ICCE Inst, St Louis, MO USA; [Divine, Laura M.; Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Fuh, Katherine C.] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA; [Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Lohrey, Anne; Fuh, Katherine C.] Washington Univ, Ctr Reprod Hlth Sci CRepHS, St Louis, MO 63130 USA; [Zhao, Peinan] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Clin Res, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Fuh, KC (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA.; Fuh, KC (corresponding author), Washington Univ, Ctr Reprod Hlth Sci CRepHS, St Louis, MO 63130 USA.	kfuh@wudosis.wustl.edu		Fuh, Katherine/0000-0002-7693-2694	Cancer Frontier Fund [8002-88];  [2K12HD000849-28];  [NIHCA196205]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA196205, P30CA091842] Funding Source: NIH RePORTER	Cancer Frontier Fund; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	2K12HD000849-28 (KCF); NIHCA196205 (GDL); Cancer Frontier Fund 8002-88 (KCF and GDL).	Bildsoe H, 2016, DEV BIOL, V418, P189, DOI 10.1016/j.ydbio.2016.08.016; Borza CM, 2014, MATRIX BIOL, V34, P185, DOI 10.1016/j.matbio.2013.12.002; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Chen DY, 2013, INT J GYNECOL CANCER, V23, P1357, DOI 10.1097/IGC.0b013e3182a5e760; Cho A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00245; Chua HH, 2008, HEAD NECK-J SCI SPEC, V30, P427, DOI 10.1002/hed.20724; Coelho NM, 2017, CELL REP, V18, P1774, DOI 10.1016/j.celrep.2017.01.061; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Davidowitz RA, 2012, JOVE, V60; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fan Y, 2016, AM J TRANSL RES, V8, P2845; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Kenny HA, 2009, CANCER TREAT RES, V149, P335, DOI 10.1007/978-0-387-98094-2_16; Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978-0-12-800180-6.00002-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majkowska I, 2017, J BIOL CHEM, V292, P6633, DOI 10.1074/jbc.M116.770057; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; Nadiarnykh O, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-94; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Rauch J, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-23; Ren TT, 2014, J PATHOL, V234, P526, DOI 10.1002/path.4415; Rodrigues R, 2007, ONCOL REP, V18, P917; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Terauchi M, 2007, CLIN EXP METASTAS, V24, P329, DOI 10.1007/s10585-007-9070-1; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555-012-9346-z; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep24606; Wang YL, 2015, INT J CLIN EXP MED, V8, P7388; Xie BH, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0218-6; Xu DB H, 2012, PLOS ONE, V7; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu JK, 2014, CANCER BIOL THER, V15, P612, DOI 10.4161/cbt.28181; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Yang Z, 2007, BIOCHEM BIOPH RES CO, V358, P925, DOI 10.1016/j.bbrc.2007.05.023; Yeh JE, 2013, CURR OPIN ONCOL, V25, P652, DOI 10.1097/01.cco.0000432528.88101.1a; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang K, 2016, J CELL SCI, V129, P1989, DOI 10.1242/jcs.180539; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang XR, 2012, CARTILAGE, V3, P267, DOI 10.1177/1947603511435273; Zhang Y, 2014, BBA-MOL BASIS DIS, V1842, P1350, DOI 10.1016/j.bbadis.2014.04.018	52	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1714	1729		10.1038/s41388-017-0043-9	http://dx.doi.org/10.1038/s41388-017-0043-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348456	Green Accepted			2022-12-28	WOS:000428632600003
J	Long, MD; Singh, PK; Russell, JR; Llimos, G; Rosario, S; Rizvi, A; van den Berg, PR; Kirk, J; Sucheston-Campbell, LE; Smiraglia, DJ; Campbell, MJ				Long, Mark D.; Singh, Prashant K.; Russell, James R.; Llimos, Gerard; Rosario, Spencer; Rizvi, Abbas; van den Berg, Patrick R.; Kirk, Jason; Sucheston-Campbell, Lara E.; Smiraglia, Dominic J.; Campbell, Moray J.			The miR-96 and RAR gamma signaling axis governs androgen signaling and prostate cancer progression	ONCOGENE			English	Article							13-CIS RETINOIC ACID; TUMOR-SUPPRESSOR; RECEPTOR; EXPRESSION; IDENTIFICATION; GENES; CELLS; DIFFERENTIATION; ACTIVATION; CHROMATIN	Expression levels of retinoic acid receptor gamma (NR1B3/RARG, encodes RAR gamma) are commonly reduced in prostate cancer (PCa). Therefore, we sought to establish the cellular and gene regulatory consequences of reduced RAR gamma expression, and determine RAR gamma regulatory mechanisms. RARG shRNA approaches in non-malignant (RWPE-1 and HPr1-AR) and malignant (LNCaP) prostate models revealed that reducing RAR gamma levels, rather than adding exogenous retinoid ligand, had the greatest impact on prostate cell viability and gene expression. ChIP-Seq defined the RAR gamma cistrome, which was significantly enriched at active enhancers associated with AR binding sites. Reflecting a significant genomic role for RAR gamma to regulate androgen signaling, RAR gamma knockdown in HPr1-AR cells significantly regulated the magnitude of the AR transcriptome. RAR gamma downregulation was explained by increased miR-96 in PCa cell and mouse models, and TCGA PCa cohorts. Biochemical approaches confirmed that miR-96 directly regulated RAR gamma expression and function. Capture of the miR-96 targetome by biotin-miR-96 identified that RAR gamma and a number of RAR gamma interacting co-factors including TACC1 were all targeted by miR-96, and expression of these genes were prominently altered, positively and negatively, in the TCGA-PRAD cohort. Differential gene expression analyses between tumors in the TCGA-PRAD cohort with lower quartile expression levels of RARG and TACC1 and upper quartile miR-96, compared to the reverse, identified a gene network including several RAR gamma target genes (e.g., SOX15) that significantly associated with worse disease-free survival (hazard ratio 2.23, 95% CI 1.58 to 2.88, p = 0.015). In summary, miR-96 targets a RAR gamma network to govern AR signaling, PCa progression and disease outcome.	[Long, Mark D.; Russell, James R.; Llimos, Gerard; Rosario, Spencer; van den Berg, Patrick R.; Smiraglia, Dominic J.] RPCCC, Dept Canc Genet & Genom, Buffalo, NY 14263 USA; [Singh, Prashant K.] Roswell Pk Comprehens Canc Ctr, Ctr Personalized Med, Buffalo, NY 14263 USA; [Llimos, Gerard] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Rizvi, Abbas; Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA; [van den Berg, Patrick R.] Leiden Univ, Leiden Inst Phys, NL-2300 RA Leiden, Netherlands; [Kirk, Jason] Roswell Pk Comprehens Canc Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; [Campbell, Moray J.] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University System of Ohio; Ohio State University; Leiden University; Leiden University - Excl LUMC; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Campbell, MJ (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA.	campbell.1933@osu.edu	Rosario, Spencer/AAS-5728-2021; Campbell, Moray/ABF-1264-2021; Smiraglia, Dominic/R-2069-2019	Campbell, Moray/0000-0002-3355-0928; Smiraglia, Dominic/0000-0001-8852-1510; Llimos Aubach, Gerard/0000-0003-3311-6782; Long, Mark/0000-0003-1120-8176	Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health [P50CA159981-01A1]; Molecular Pharmacology and Experimental Therapeutics NRSA T32 program at Roswell Park Comprehensive Cancer Center [T32CA009072]; Prostate program of the Department of Defense Congressionally Directed Medical Research Programs [W81XWH-14-1-0608, W81XWH-11-2-0033]; National Cancer Institute (NCI) [P30CA016056, P30CA016058]; European Union-United States Atlantis Program [P116J090011]; NATIONAL CANCER INSTITUTE [P50CA159981, P30CA016058, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM095459] Funding Source: NIH RePORTER	Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health; Molecular Pharmacology and Experimental Therapeutics NRSA T32 program at Roswell Park Comprehensive Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate program of the Department of Defense Congressionally Directed Medical Research Programs; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Union-United States Atlantis Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	LES-C acknowledges support, in part, of Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health [P50CA159981-01A1]. MDL acknowledges support of Molecular Pharmacology and Experimental Therapeutics NRSA T32 program (T32CA009072) held at Roswell Park Comprehensive Cancer Center. MJC and DJS acknowledge support in part from the Prostate program of the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-14-1-0608, W81XWH-11-2-0033) and the National Cancer Institute (NCI) grant P30CA016056 involving the use of Roswell Park Comprehensive Cancer Center's Genomic Shared Resource. MJC, GL, AR, and PRvdB acknowledge support from the European Union-United States Atlantis Program (P116J090011). MJC and LES-C acknowledge support from the National Cancer Institute (NCI) grant P30CA016056 involving the use of OSUCCC The James, CCSG P30CA016058.	Abe M, 2011, BJU INT, V107, P126, DOI 10.1111/j.1464-410X.2010.09344.x; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Alhasan AH, 2016, P NATL ACAD SCI USA, V113, P10655, DOI 10.1073/pnas.1611596113; Ambrosone CB, 2006, CANCER EPIDEM BIOMAR, V15, P1575, DOI 10.1158/1055-9965.EPI-06-0628; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bao YH, 2017, EUR REV MED PHARMACO, V21, P4548; Beydoun HA, 2011, CANCER CAUSE CONTROL, V22, P1483, DOI 10.1007/s10552-011-9822-8; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Brohee L, 2015, ONCOTARGET, V6, P11264, DOI 10.18632/oncotarget.3595; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 2008, PPAR RES, V2008, DOI 10.1155/2008/314974; Chen CF, 2004, ONCOGENE, V23, P5350, DOI 10.1038/sj.onc.1207682; Dhiman VK, 2015, ONCOTARGET, V6, P42575, DOI 10.18632/oncotarget.6471; Dingwall M, 2011, DIFFERENTIATION, V82, P57, DOI 10.1016/j.diff.2011.05.003; Dong DF, 2012, GENE EXPRESSION, V15, P153, DOI 10.3727/105221612X13372578119571; Dou MM, 2018, CELL PHYSIOL BIOCHEM, V45, P2497, DOI 10.1159/000488268; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Ellis L, 2016, PROSTATE, V76, P1192, DOI 10.1002/pros.23206; Ernst J, 2017, NAT PROTOC, V12, P2478, DOI 10.1038/nprot.2017.124; Ferrari AC, 2002, J CLIN ONCOL, V20, P538, DOI 10.1200/JCO.20.2.538; Foster BA, 1997, CANCER RES, V57, P3325; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guyot R, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-3; Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400; Hindley CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23208; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Huang H, 2014, CURR TOP MED CHEM, V14, P2175, DOI 10.2174/1568026614666141112101840; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Jin FS, 2005, CANCER RES, V65, P6354, DOI 10.1158/0008-5472.CAN-04-4061; Jin M, 2014, CANCER RES, V74, P4183, DOI 10.1158/0008-5472.CAN-14-0404; Johannesson M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004794; Kashyap V, 2013, J CELL SCI, V126, P999, DOI 10.1242/jcs.119701; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kittler R, 2013, CELL REP, V3, P538, DOI 10.1016/j.celrep.2013.01.004; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Leushacke M, 2012, ONCOGENE, V31, P3009, DOI 10.1038/onc.2011.479; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; Long MD, 2015, NUCLEIC ACIDS RES, V43, P7330, DOI 10.1093/nar/gkv642; Long MD, 2015, NUCL RECEPT RES, V2; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu XP, 1999, INT J CANCER, V80, P272, DOI 10.1002/(SICI)1097-0215(19990118)80:2<272::AID-IJC17>3.3.CO;2-O; Lun ATL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1191; Luo ZJ, 2015, MOL CELL, V57, P685, DOI 10.1016/j.molcel.2015.01.007; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; MCBURNEY MW, 1993, CANCER INVEST, V11, P590, DOI 10.3109/07357909309011677; McCormick DL, 1999, CANCER RES, V59, P521; McDonald AC, 2018, PROSTATE, V78, P411, DOI 10.1002/pros.23485; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Mihelich BL, 2011, J BIOL CHEM, V286, P44503, DOI 10.1074/jbc.M111.262915; Mo WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056592; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Nash SH, 2015, CANCER EPIDEM BIOMAR, V24, P1507, DOI 10.1158/1055-9965.EPI-15-0394; Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994; Olokpa E, 2017, PPAR RES, V2017, DOI 10.1155/2017/9456020; Ozpolat B, 2008, APOPTOSIS, V13, P915, DOI 10.1007/s10495-008-0222-9; Pi FM, 2018, NAT NANOTECHNOL, V13, P82, DOI 10.1038/s41565-017-0012-z; Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527; Qiu JHJ, 2010, BLOOD, V115, P643, DOI 10.1182/blood-2009-07-232652; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rivera-Gonzalez GC, 2012, NUCLEIC ACIDS RES, V40, P4825, DOI 10.1093/nar/gks143; Sanda MG, 2017, JAMA ONCOL, V3, P1085, DOI 10.1001/jamaoncol.2017.0177; Simandi Z, 2016, MOL CELL, V63, P647, DOI 10.1016/j.molcel.2016.06.039; Singal R, 2004, ONCOL REP, V12, P631; Singh PK, 2014, ONCOTARGET, V5, P824, DOI 10.18632/oncotarget.1776; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun JK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-168; Tan SM, 2016, METHODS MOL BIOL, V1358, P211, DOI 10.1007/978-1-4939-3067-8_13; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thorne JL, 2011, NUCLEIC ACIDS RES, V39, P2045, DOI 10.1093/nar/gkq875; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Trump DL, 1997, CANCER CHEMOTH PHARM, V39, P349, DOI 10.1007/s002800050582; TRUMP DL, 1994, LEUKEMIA, V8, pS50; Tsai YC, 2017, CANCER LETT, V384, P1, DOI 10.1016/j.canlet.2016.10.014; Ulz P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12008; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Viennois E, 2012, MOL CELL ENDOCRINOL, V351, P129, DOI 10.1016/j.mce.2011.08.036; Wang BD, 2015, CLIN CANCER RES, V21, P4970, DOI 10.1158/1078-0432.CCR-14-1566; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wilde JJ, 2017, J NEUROSCI, V37, P2565, DOI 10.1523/JNEUROSCI.2121-16.2017; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798; Zhang J, 2010, ONCOGENE, V29, P723, DOI 10.1038/onc.2009.373; Zhang K, 2017, GENE, V619, P10, DOI 10.1016/j.gene.2017.03.038; Zhang SS, 2012, CELL BIOCHEM FUNCT, V30, P623, DOI 10.1002/cbf.2922; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	93	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					421	444		10.1038/s41388-018-0450-6	http://dx.doi.org/10.1038/s41388-018-0450-6			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30120411	Green Published, hybrid			2022-12-28	WOS:000455851200009
J	Seo, SU; Woo, SM; Lee, HS; Kim, SH; Min, KJ; Kwon, TK				Seo, Seung Un; Woo, Seon Min; Lee, Hyun-Shik; Kim, Sang Hyun; Min, Kyoung-jin; Kwon, Taeg Kyu			mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; BCL-X-L; DOWN-REGULATION; ENDOPLASMIC-RETICULUM; CYTOCHROME-C; MAMMALIAN TARGET; GLIOMA-CELLS; CANCER-CELLS; MOLECULAR-MECHANISMS; SELECTIVE AUTOPHAGY	mTOR is an important regulator of cell growth and forms two complexes, mTORC1/2. In cancer, mTOR signaling is highly activated, and the regulation of this signaling, as an anti-cancer strategy, has been emphasized. However, PP242 (inhibitor of mTORC1 and mTORC2) alone did not induce human renal carcinoma cell death. In this study, we found that PP242 alone did not alter cell viability, but combined curcumin and PP242 treatment induced cell death. Combined PP242 and curcumin treatment induced Bax activation and decreased expression of Mcl-1 and Bcl-2. Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death. Downregulation of Rictor increased cytosolic Ca2+ release from endoplasmic reticulum, which led to lysosomal damage in PP242 plus curcumin-treated cells. Furthermore, damaged lysosomes induced autophagy. Autophagy inhibitors markedly inhibited cell death. Finally, combined curcumin and PP242 treatment reduced tumor growth and induced cell death in xenograft models. Altogether, our results reveal that combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.	[Seo, Seung Un; Woo, Seon Min; Min, Kyoung-jin; Kwon, Taeg Kyu] Keimyung Univ, Sch Med, Dept Immunol, 2800 Dalgubeoldaero, Daegu 704701, South Korea; [Lee, Hyun-Shik] KNU, Coll Nat Sci, Plus KNU Creat BioRes Grp BK21, Sch Life Sci,Ctr Nonlinear Dynam, Daegu 41566, South Korea; [Kim, Sang Hyun] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Daegu 41944, South Korea	Keimyung University; Kyungpook National University	Min, KJ; Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, 2800 Dalgubeoldaero, Daegu 704701, South Korea.	kyoungjin.min@gmail.com; kwontk@dsmc.or.kr			NRF grant - Korea Government (MSIP) [2014R1A5A2010008, NRF-2016R1A2B2013393, NRF-2016R1D1A1B03933568]	NRF grant - Korea Government (MSIP)	We appreciate critical reading of the manuscript by Jae Man Lee (Kyungpook national university). This work was supported by an NRF grant funded by the Korea Government (MSIP) (2014R1A5A2010008, NRF-2016R1A2B2013393 and NRF-2016R1D1A1B03933568).	Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110; Boulbes DR, 2011, BIOCHEM BIOPH RES CO, V413, P46, DOI 10.1016/j.bbrc.2011.08.034; Chen H, 1999, ANTICANCER RES, V19, P3675; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Deeb D, 2003, MOL CANCER THER, V2, P95; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fei Y, 2016, BRAIN RES, V1646, P580, DOI 10.1016/j.brainres.2016.06.046; Fruman DA, 2009, IMMUNOL REV, V228, P253, DOI 10.1111/j.1600-065X.2008.00750.x; Fu ZP, 2015, ONCOTARGET, V6, P19469, DOI 10.18632/oncotarget.3625; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Gao XH, 2005, J EXP THER ONCOL, V5, P39; Go DH, 2017, ONCOTARGET, V8, P58790, DOI 10.18632/oncotarget.17732; Han MA, 2015, CHEM-BIOL INTERACT, V228, P69, DOI 10.1016/j.cbi.2015.01.020; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3111; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jo Y, 2017, BMB REP, V50, P379, DOI 10.5483/BMBRep.2017.50.7.063; Jung EM, 2005, CARCINOGENESIS, V26, P1905, DOI 10.1093/carcin/bgi167; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maejima I, 2013, EMBO J, V32, P2336, DOI 10.1038/emboj.2013.171; Mochida K, 2015, NATURE, V522, P359, DOI 10.1038/nature14506; Moragoda L, 2001, ANTICANCER RES, V21, P873; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308; OLSSON GM, 1989, VIRCHOWS ARCH B, V56, P263; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Park YS, 2017, TOX RESEARCH, V33, P211, DOI 10.5487/TR.2017.33.3.211; Peyerl FW, 2007, CELL DEATH DIFFER, V14, P447, DOI 10.1038/sj.cdd.4402025; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schuck S, 2014, J CELL SCI, V127, P4078, DOI 10.1242/jcs.154716; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seo SU, 2017, REDOX BIOL, V13, P608, DOI 10.1016/j.redox.2017.07.017; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Sirohi VK, 2017, J NUTR BIOCHEM, V44, P60, DOI 10.1016/j.jnutbio.2016.12.021; Soares HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057289; Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Vinod BS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.26; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073175; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082; Woo SM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.472; Woo SM, 2016, ONCOTARGET, V7, P61520, DOI 10.18632/oncotarget.11137; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005; Zeng XC, 2004, J CELL SCI, V117, P4991, DOI 10.1242/jcs.01373; Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230	60	34	39	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5205	5220		10.1038/s41388-018-0345-6	http://dx.doi.org/10.1038/s41388-018-0345-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849119	Green Published, hybrid			2022-12-28	WOS:000445093100005
J	Lin, J; Xia, J; Zhang, T; Zhang, KY; Yang, Q				Lin, Jian; Xia, Jing; Zhang, Tian; Zhang, Keyun; Yang, Qian			Genome-wide profiling of microRNAs reveals novel insights into the interactions between H9N2 avian influenza virus and avian dendritic cells	ONCOGENE			English	Article							LONG NONCODING RNA; NF-KAPPA-B; IMMUNE-RESPONSES; NUCLEAR IMPORT; INNATE IMMUNITY; A(H7N9) VIRUS; BINDING-SITE; INFECTION; HOST; REPLICATION	The antigen-presenting ability of dendritic cells (DCs) plays an important and irreplaceable role in recognising and clearing viruses. Antiviral responses must rapidly defend against infection while minimising inflammatory damage, but the mechanisms that regulate the magnitude of response within an infected cell are not well understood. MicroRNAs (microRNAs), small non-coding RNAs, can regulate mouse or avian DCs to inhibit the infection and replication of avian influenza virus (AIV). Here, we performed a global analysis to understand how avian DCs respond to H9N2 AIV and provide a potential mechanism to explain how avian microRNAs can defend against H9N2 AIV replication. First, we found that both active and inactive H9N2 AIV enhanced the ability of DCs to present antigens and activate T lymphocytes. Next, total microarray analyses suggested that H9N2 AIV stimulation involved protein localisation, nucleotide binding, leucocyte transendothelial migration and MAPK signalling. Moreover, we constructed 551 transcription factor (TF)-miRNA-mRNA loops based on the above analyses. Furthermore, we found that the haemagglutinin (HA) fragment, neither H5N1-HA or H9N2-HA, could not activate DCs, while truncated HA greatly increased the immune function of DCs by activating ERK and STAT3 signalling pathways. Lastly, our results not only suggested that gga-miR1644 targets muscleblind-like protein 2 (MBNL2) to enhance the ability of avian DCs to inhibit virus replication, but also suggested that gga-miR6675 targets the nuclear localisation sequence of polymerase basic protein 1 (PB1) to trigger the silencing of PB1 genes, resulting in the inhibition of H9N2 AIV replication. Altogether, our innovative study will shed new light on the role of avian microRNAs in evoking avian DCs and inhibiting virus replication.	[Lin, Jian; Xia, Jing; Zhang, Tian; Zhang, Keyun] Nanjing Agr Univ, Coll Life Sci, Weigang 1, Nanjing 210095, Jiangsu, Peoples R China; [Lin, Jian; Yang, Qian] Nanjing Agr Univ, Coll Vet Med, Wei Gang 1, Nanjing 210095, Jiangsu, Peoples R China	Nanjing Agricultural University; Nanjing Agricultural University	Yang, Q (corresponding author), Nanjing Agr Univ, Coll Vet Med, Wei Gang 1, Nanjing 210095, Jiangsu, Peoples R China.	zxbyq@njau.edu.cn		Zhang, Keyun/0000-0001-7208-8572; Lin, Jian/0000-0003-0455-9736	National Key Research and Development Program of China [2017YFD500706]; National Natural Science Grant of P. R. China [31702197, 31172302]; National Science Grant of Jiangsu Province [BK20150666]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Key Research and Development Program of China; National Natural Science Grant of P. R. China(National Natural Science Foundation of China (NSFC)); National Science Grant of Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Key Research and Development Program of China (2017YFD500706), the National Natural Science Grant of P. R. China (No. 31702197), the National Natural Science Grant of P. R. China (No. 31172302), the National Science Grant of Jiangsu Province (No. BK20150666) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bandyopadhyay S, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-163; Barik S, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-104; Bel M, 2011, VIRUSES-BASEL, V3, P312, DOI 10.3390/v3040312; Boivin S, 2010, J BIOL CHEM, V285, P28411, DOI 10.1074/jbc.R110.117531; Cilloniz C, 2010, J VIROL, V84, P7613, DOI 10.1128/JVI.00553-10; Contreras J, 2012, LEUKEMIA, V26, P404, DOI 10.1038/leu.2011.356; den Brouw MLO, 2009, IMMUNOLOGY, V126, P280, DOI 10.1111/j.1365-2567.2008.02896.x; Dev A, 2011, CURR TOP MICROBIOL, V349, P115, DOI 10.1007/82_2010_102; Droebner K, 2011, ANTIVIR RES, V92, P195, DOI 10.1016/j.antiviral.2011.08.002; Fan NN, 2016, BIOMED PHARMACOTHER, V83, P1464, DOI 10.1016/j.biopha.2016.08.049; Hofer CT, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12679; Hofer U, 2013, NAT REV MICROBIOL, V11, P298, DOI 10.1038/nrmicro3012; Hutchinson EC, 2011, J GEN VIROL, V92, P1859, DOI 10.1099/vir.0.032813-0; Imam H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08639; Ingle H, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3183; Jiang M, 2014, J VIRAL HEPATITIS, V21, P99, DOI 10.1111/jvh.12126; Jin Y, 2017, J INFECTION, V75, P179, DOI 10.1016/j.jinf.2017.05.006; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; Ke CW, 2017, EMERG INFECT DIS, V23, P1332, DOI 10.3201/eid2308.170600; Khongnomnan K, 2015, EXP BIOL MED, V240, P1630, DOI 10.1177/1535370215589051; Langlois RA, 2012, P NATL ACAD SCI USA, V109, P12117, DOI 10.1073/pnas.1206039109; Le Negrate G, 2012, CELL MICROBIOL, V14, P168, DOI 10.1111/j.1462-5822.2011.01720.x; Li ZH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00017; Liang JF, 2013, VET IMMUNOL IMMUNOP, V155, P205, DOI 10.1016/j.vetimm.2013.06.014; Lin J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00287; Lin J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3157-5; Lin J, 2016, ONCOTARGET, V7, P48978, DOI 10.18632/oncotarget.9832; Lin TN, 2017, EMERG INFECT DIS, V23, P1041, DOI 10.3201/eid2306.161902; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loucaides EM, 2009, VIROLOGY, V394, P154, DOI 10.1016/j.virol.2009.08.015; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Marjuki H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-134; Metwally A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040766; Moltedo B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002345; Nakada R, 2017, PROTEIN SCI, V26, P1231, DOI 10.1002/pro.3173; Othumpangat S, 2014, VIROLOGY, V468, P256, DOI 10.1016/j.virol.2014.08.007; Ozawa M, 2007, J VIROL, V81, P30, DOI 10.1128/JVI.01434-06; Perrone LA, 2010, J INFECT DIS, V202, P1161, DOI 10.1086/656365; Pichulik T, 2016, EUR J IMMUNOL, V46, P167, DOI 10.1002/eji.201444970; Pizzolla A, 2017, J LEUKOCYTE BIOL, V101, P851, DOI 10.1189/jlb.4MR0716-290R; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Pu J, 2017, J VIROL, V91, DOI [10.1128/jvi.02055-16, 10.1128/JVI.02055-16]; Pu J, 2015, P NATL ACAD SCI USA, V112, P548, DOI 10.1073/pnas.1422456112; Pumroy RA, 2015, STRUCTURE, V23, P374, DOI 10.1016/j.str.2014.11.015; Ramos I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00361; Rivera A, 2016, VIRAL IMMUNOL, V29, P212, DOI 10.1089/vim.2015.0074; Rosenberger CM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006305; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Samir M, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00086; Severin C, 2016, ACTA CRYSTALLOGR D, V72, P245, DOI 10.1107/S2059798316000085; Shen XY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/976575; Sprokholt JK, 2017, J IMMUNOL, V198, P4764, DOI 10.4049/jimmunol.1602121; Tang XY, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.25; Terrier O, 2016, SCI REP-UK, V6, DOI 10.1038/srep29006; Terrier O, 2012, VIROLOGY, V432, P204, DOI 10.1016/j.virol.2012.05.019; Turner JCM, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.142; Tzarum N, 2017, J VIROL, V91, DOI 10.1128/JVI.00046-17; Valadkhan S, 2016, VIRUS RES, V212, P127, DOI 10.1016/j.virusres.2015.09.023; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Westenius V, 2014, VIROLOGY, V471, P38, DOI 10.1016/j.virol.2014.10.002; Xiang B, 2017, J INFECTION, V75, P274, DOI 10.1016/j.jinf.2017.05.002; Xu W, 2014, CELL HOST MICROBE, V16, P187, DOI 10.1016/j.chom.2014.07.008; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; Yin Y, 2015, MUCOSAL IMMUNOL, V8, P799, DOI 10.1038/mi.2014.110; York A, 2014, J VIROL, V88, P13284, DOI 10.1128/JVI.01813-14; Yuan SF, 2016, ANTIVIR RES, V125, P34, DOI 10.1016/j.antiviral.2015.11.005; Zhang Y, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.38; Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91; Zhou A, 2014, VIRUS RES, V184, P1, DOI 10.1016/j.virusres.2014.01.019; Zhou Z, 2015, CELL RES, V25, P39, DOI 10.1038/cr.2014.130; Zhu W, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.19.30533	71	7	7	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4562	4580		10.1038/s41388-018-0279-z	http://dx.doi.org/10.1038/s41388-018-0279-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743596				2022-12-28	WOS:000441736700006
J	Romano, G; Chagani, S; Kwong, LN				Romano, Gabriele; Chagani, Sharmeen; Kwong, Lawrence N.			The path to metastatic mouse models of colorectal cancer	ONCOGENE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER; INTESTINAL TUMORIGENESIS; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; APC MUTATIONS; MUTANT MICE; IN-VIVO; GENES; INACTIVATION	The study and comprehension of the molecular mechanisms underlying cancer biology strongly rely on mouse modeling. An ideal mouse model should have molecular, histopathological, and etiological characteristics as close as possible to those of the corresponding human tumors. Among solid tumors, colorectal cancer (CRC) is one of the malignancies that best suits reproduction in an animal model: it evolves through a progressive set of molecular events and is generally associated with a precise histopathology and a neat cataloging of stages and grades. The development of refined CRC mouse models over several decades has seen them recently evolve toward sophisticated systems that ever more closely approximate the human pathology, with different models addressing different human CRC subtypes. In particular, a metastatic CRC model has been seen as a "holy grail" in this field, and we describe in this review the path taken to achieve metastatic models and discuss the path forward.	[Romano, Gabriele; Chagani, Sharmeen; Kwong, Lawrence N.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kwong, LN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.	lkwong@mdanderson.org		Romano, Gabriele/0000-0001-8023-8657				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Beach R, 2005, AM J PATHOL, V166, P1069, DOI 10.1016/S0002-9440(10)62327-9; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chen HJ, 2016, NAT BIOTECHNOL, V34, P845, DOI 10.1038/nbt.3586; CLARKE AR, 1995, ONCOGENE, V11, P1913; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Halberg RB, 2009, CANCER RES, V69, P5768, DOI 10.1158/0008-5472.CAN-09-0446; Hamamoto T, 2002, CANCER RES, V62, P5955; Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; Kwong LN, 2007, GENETICS, V176, P1237, DOI 10.1534/genetics.107.071217; Kwong LN, 2009, ADV EXP MED BIOL, V656, P85, DOI 10.1007/978-1-4419-1145-2_8; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McIntyre RE, 2015, BIOESSAYS, V37, P909, DOI 10.1002/bies.201500032; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pan QF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00057-3; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Reitmair AH, 1996, CANCER RES, V56, P2922; Robanus-Maandag EC, 2010, CARCINOGENESIS, V31, P946, DOI 10.1093/carcin/bgq046; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Sanchez-Rivera FJ, 2015, NAT REV CANCER, V15, P387, DOI 10.1038/nrc3950; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taketo MM, 2009, GASTROENTEROLOGY, V136, P780, DOI 10.1053/j.gastro.2008.12.049; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Xue YB, 2010, MOL CANCER RES, V8, P1095, DOI 10.1158/1541-7786.MCR-10-0195; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Yu M, 2014, ONCOGENE, V33, P1538, DOI 10.1038/onc.2013.102; Zeineldin M, 2013, BBA-REV CANCER, V1836, P80, DOI 10.1016/j.bbcan.2013.01.001; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	62	19	20	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2481	2489		10.1038/s41388-018-0155-x	http://dx.doi.org/10.1038/s41388-018-0155-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29463860				2022-12-28	WOS:000431873400002
J	Zhang, HL; Song, Y; Yang, HM; Liu, ZY; Gao, LF; Liang, XH; Ma, CH				Zhang, Hualin; Song, Yang; Yang, Huimin; Liu, Zhiyan; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong			Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappa B/IL-6/STAT3 axis	ONCOGENE			English	Article							TRAIL-INDUCED APOPTOSIS; CD8(+) T-CELLS; UP-REGULATION; POOR-PROGNOSIS; EXPRESSION; IMMUNOGLOBULIN; HEPATOCYTES; CHECKPOINTS; DYSFUNCTION; RESISTANCE	T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), mediating immune exhaustion in tumor microenvironment, has become a promising target for tumor therapy. However, the exact mechanisms for tumor cell-intrinsic Tim-3 in tumor development and its potential contribution in Tim-3-targeted therapy strategy have not been elucidated yet. In this study, we showed that human liver cancer tissues contained high ratio of Tim-3-expressing hepatocytes, and cytokines rich in tumor microenvironment and HBV involved in Tim-3 upregulation in malignant hepatocytes. We demonstrated that hepatocyte-specific Tim-3 overexpression enhances tumor cell growth, whereas Tim-3 inhibition on malignant hepatocytes by anti-Tim-3 antibodies or RNAi suppresses tumor growth both in vitro and in Tim-3 knockout mice. Mechanistically, the hepatocyte-Tim-3 receptor activates NF-kappa B phosphorylation, which in turn stimulates IL-6 secretion and STAT3 phosphorylation. Our results identify tumor cell-intrinsic functions of Tim-3 in tumorigenesis and suggest that blocking Tim-3 in tumor cells might contribute to the clinical efficacy of anti-Tim-3 antibody treatment in the future tumor therapy.	[Zhang, Hualin; Song, Yang; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong] Shandong Univ, Key Lab Infect & Immun Shandong Prov, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Zhang, Hualin; Song, Yang; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong] Shandong Univ, Sch Basic Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China; [Yang, Huimin] Shandong Univ, Qilu Hosp, Dept Nephrol, Jinan 250012, Shandong, Peoples R China; [Liu, Zhiyan] Shandong Univ, Dept Pathol & Pathophysiol, Jinan 250012, Shandong, Peoples R China; [Ma, Chunhong] Shandong Univ, State Key Lab Microbial Technol, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Liang, XH; Ma, CH (corresponding author), Shandong Univ, Key Lab Infect & Immun Shandong Prov, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Liang, XH; Ma, CH (corresponding author), Shandong Univ, Sch Basic Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China.; Ma, CH (corresponding author), Shandong Univ, State Key Lab Microbial Technol, Jinan, Shandong, Peoples R China.	liangxiaohong@sdu.edu.cn; machunhong@sdu.edu.cn	Liu, Zhiyan/C-5298-2016; , 刘志艳/AAN-9477-2020; ma, chunhong/C-6043-2008	Liu, Zhiyan/0000-0001-9668-7756; ma, chunhong/0000-0002-8121-4718; Liang, xiaohong/0000-0002-7626-3478	National Key Research and Development Program [2016YFE0127000]; National Natural Science Fund for Outstanding Youth Fund [81425012]; National Science Foundation of China [81425012, 81672425, 81372211, 91529305]; Key Research & Development Plan of Shandong Province [2016ZDJS07A17, 2017GSF18185]	National Key Research and Development Program; National Natural Science Fund for Outstanding Youth Fund; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research & Development Plan of Shandong Province	This work was supported by grants from the National Key Research and Development Program (No. 2016YFE0127000), the National Natural Science Fund for Outstanding Youth Fund (81425012), the National Science Foundation of China (No. 81672425, 81425012, 81372211, 91529305), Key Research & Development Plan of Shandong Province (2016ZDJS07A17, 2017GSF18185).	Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Anderson AC, 2012, CURR OPIN IMMUNOL, V24, P213, DOI 10.1016/j.coi.2011.12.005; Aravalli RN, 2013, ARCH TOXICOL, V87, P227, DOI 10.1007/s00204-012-0931-2; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; Cao Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053834, 10.1371/journal.pone.0055021]; Dolina JS, 2014, HEPATOLOGY, V59, P1351, DOI 10.1002/hep.26938; Du J, 2009, CELL DEATH DIFFER, V16, P219, DOI 10.1038/cdd.2008.144; Du W., 2017, INT J MOL SCI, V18, P645, DOI [10.3390/ijms18030645, DOI 10.3390/IJMS18030645]; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Huang YH, 2015, NATURE, V517, P386, DOI 10.1038/nature13848; Ju Y, 2010, J HEPATOL, V52, P322, DOI 10.1016/j.jhep.2009.12.005; Kikushige Y, 2015, CELL STEM CELL, V17, P341, DOI 10.1016/j.stem.2015.07.011; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Lee J, 2011, MOL CELL BIOL, V31, P3963, DOI 10.1128/MCB.05297-11; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Liang XH, 2007, J IMMUNOL, V178, P503, DOI 10.4049/jimmunol.178.1.503; Luan F, 2009, GUT, V58, P1528, DOI 10.1136/gut.2008.174029; Marraco SAF, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00310; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Ngiow SF, 2011, CANCER RES, V71, P3540, DOI 10.1158/0008-5472.CAN-11-0096; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Piao YR, 2013, ASIAN PAC J CANCER P, V14, P3897, DOI 10.7314/APJCP.2013.14.6.3897; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Tomkowicz B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140694; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Yan WJ, 2015, GUT, V64, P1593, DOI 10.1136/gutjnl-2014-307671; Yi WJ, 2017, IMMUNOLOGY, V150, P301, DOI 10.1111/imm.12686; Yuan J, 2013, NEOPLASMA; Zhou EC, 2015, INT J CLIN EXP PATHO, V8, P8018; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7072; Zhuang XW, 2012, AM J CLIN PATHOL, V137, P978, DOI 10.1309/AJCP9Q6OVLVSHTMY	37	39	52	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2456	2468		10.1038/s41388-018-0140-4	http://dx.doi.org/10.1038/s41388-018-0140-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449693				2022-12-28	WOS:000431386000009
J	Deryugina, EI; Zajac, E; Zilberberg, L; Muramatsu, T; Joshi, G; Dabovic, B; Rifkin, D; Quigley, JP				Deryugina, Elena I.; Zajac, Ewa; Zilberberg, Lior; Muramatsu, Tomoki; Joshi, Grishma; Dabovic, Branka; Rifkin, Daniel; Quigley, James P.			LTBP3 promotes early metastatic events during cancer cell dissemination	ONCOGENE			English	Article							BETA BINDING-PROTEIN; TGF-BETA; VASCULAR INTRAVASATION; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; GROWTH; MECHANISMS; MUTATIONS; DOMAIN; EXPRESSION	Latent transforming growth factor beta(TGF beta)-binding proteins (LTBPs) are important for the secretion, activation, and function of mature TGF beta, especially so in cancer cell physiology. However, specific roles of the LTBPs remain understudied in the context of the primary tumor microenvironment. Herein, we investigated the role of LTBP3 in the distinct processes involved in cancer metastasis. By using three human tumor cell lines of different tissue origin (epidermoid HEp-3 and prostate PC-3 carcinomas and HT-1080 fibrosarcoma) and several metastasis models conducted in both mammalian and avian settings, we show that LTBP3 is involved in the early dissemination of primary cancer cells, namely in the intravasation step of the metastatic cascade. Knockdown of LTBP3 in all tested cell lines led to significant inhibition of tumor cell intravasation, but did not affect primary tumor growth. LTBP3 was dispensable in the late steps of carcinoma cell metastasis that follow tumor cell intravasation, including vascular arrest, extravasation, and tissue colonization. However, LTBP3 depletion diminished the angiogenesis-inducing potential of HEp-3 cells in vivo, which was restorable by exogenous delivery of LTBP3 protein. A similar compensatory approach rescued the dampened intravasation of LTBP3-deficient HEp3 cells, suggesting that LTBP3 regulates the induction of the intravasation-supporting angiogenic vasculature within developing primary tumors. Using our recently developed microtumor model, we confirmed that LTBP3 loss resulted in the development of intratumoral vessels with an abnormal microarchitecture incompatible with efficient intravasation of HEp-3 carcinoma cells. Collectively, these findings demonstrate that LTBP3 represents a novel oncotarget that has distinctive functions in the regulation of angiogenesis-dependent tumor cell intravasation, a critical process during early cancer dissemination. Our experimental data are also consistent with the survival prognostic value of LTBP3 expression in early-stage head and neck squamous cell carcinomas, further indicating a specific role for LTBP3 in cancer progression toward metastatic disease.	[Deryugina, Elena I.; Zajac, Ewa; Muramatsu, Tomoki; Quigley, James P.] Scripps Res Inst, La Jolla, CA 92037 USA; [Zilberberg, Lior; Joshi, Grishma; Dabovic, Branka; Rifkin, Daniel] NYU, Sch Med, New York, NY USA	Scripps Research Institute; New York University	Deryugina, EI (corresponding author), Scripps Res Inst, La Jolla, CA 92037 USA.	deryugin@scripps.edu			National Institutes of Health [R01CA157792, R01CA105412, R01CA034282]; NATIONAL CANCER INSTITUTE [R01CA157792, R01CA105412, R01CA034282] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants R01CA157792 (E.I.D.), R01CA105412 (J.P.Q.), and R01CA034282 (D.R.) from the National Institutes of Health. This is manuscript no. 29589 from TSRI.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chandramouli A, 2011, J MAMMARY GLAND BIOL, V16, P67, DOI 10.1007/s10911-011-9215-3; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Chen Y, 2002, FEBS LETT, V517, P277, DOI 10.1016/S0014-5793(02)02648-0; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Connolly EC, 2012, INT J BIOL SCI, V8, P964, DOI 10.7150/ijbs.4564; Dabovic B, 2015, J CELL PHYSIOL, V230, P226, DOI 10.1002/jcp.24704; Dell Ralph B, 2002, ILAR J, V43, P207; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Deryugina EI, 2008, METHOD ENZYMOL, V444, P21, DOI 10.1016/S0076-6879(08)02802-4; Deryugina EI, 2017, CELL REP, V19, P601, DOI 10.1016/j.celrep.2017.03.064; Deryugina EI, 2016, METHODS MOL BIOL, V1430, P283, DOI 10.1007/978-1-4939-3628-1_19; Deryugina EI, 2015, MATRIX BIOL, V44-46, P94, DOI 10.1016/j.matbio.2015.04.004; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; EKLOV S, 1993, CANCER RES, V53, P3193; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fontana L, 2005, FASEB J, V19, P1798, DOI 10.1096/fj.05-4134com; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HENRIKSEN R, 1995, LAB INVEST, V73, P213; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inoue T, 2014, HUM MOL GENET, V23, P5672, DOI 10.1093/hmg/ddu283; Isogai M, 2003, MOL PLANT MICROBE IN, V16, P188, DOI 10.1094/MPMI.2003.16.3.188; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Juncker-Jensen A, 2013, CANCER RES, V73, P4196, DOI 10.1158/0008-5472.CAN-12-4495; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lack J, 2003, J MOL BIOL, V334, P281, DOI 10.1016/j.jmb.2003.09.053; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lindsay ME, 2012, NAT GENET, V44, P922, DOI 10.1038/ng.2349; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Massague J, 2017, MOL ONCOL, V11, P3, DOI 10.1002/1878-0261.12024; Minder P, 2015, NEOPLASIA, V17, P634, DOI 10.1016/j.neo.2015.08.002; Miyazono Kohei, 1992, Journal of Dermatology (Tokyo), V19, P644; Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004; Naba A, 2014, ELIFE, V3, DOI 10.7554/eLife.01308; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Penttinen C, 2002, J CELL SCI, V115, P3457; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Roth-Eichhorn S, 2001, SCAND J GASTROENTERO, V36, P1204; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Schepers D, 2015, EUR J HUM GENET, V23, P224, DOI 10.1038/ejhg.2014.61; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Tanaka T, 2012, CANCER SCI, V103, P455, DOI 10.1111/j.1349-7006.2011.02174.x; Vehvilainen P, 2011, HUM PATHOL, V42, P269, DOI 10.1016/j.humpath.2010.07.005; Vincent-Chong VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174865; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wan FQ, 2017, ONCOL RES, V25, P503, DOI 10.3727/096504016X14755368915591; Weinberg RA, 2008, CARCINOGENESIS, V29, P1092, DOI 10.1093/carcin/bgn104; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshinaga K, 2008, P NATL ACAD SCI USA, V105, P18758, DOI 10.1073/pnas.0805411105	59	11	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1815	1829		10.1038/s41388-017-0075-1	http://dx.doi.org/10.1038/s41388-017-0075-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29348457	Green Accepted			2022-12-28	WOS:000429303300001
J	Bonetti, P; Climent, M; Panebianco, F; Tordonato, C; Santoro, A; Marzi, MJ; Pelicci, PG; Ventura, A; Nicassio, F				Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Tordonato, Chiara; Santoro, Angela; Marzi, Matteo Jacopo; Pelicci, Pier Giuseppe; Ventura, Andrea; Nicassio, Francesco			Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer	ONCOGENE			English	Article							STEM-CELLS; MOLECULAR PORTRAITS; MICRORNA; METASTASIS; MIRNAS; AXIS	The role of the tumour-suppressor miR-34 family in breast physiology and in mammary stem cells (MaSCs) is largely unknown. Here, we revealed that miR-34 family, and miR-34a in particular, is implicated in mammary epithelium homoeostasis. Expression of miR-34a occurs upon luminal commitment and differentiation and serves to inhibit the expansion of the pool of MaSCs and early progenitor cells, likely in a p53-independent fashion. Mutant mice (miR34-KO) and loss-of-function approaches revealed two separate functions of miR-34a, controlling both proliferation and fate commitment in mammary progenitors by modulating several pathways involved in epithelial cell plasticity and luminal-to-basal conversion. In particular, miR-34a acts as endogenous inhibitor of the Wnt/beta-catenin signalling pathway, targeting up to nine upstream regulators at the same time, thus modulating the expansion of the MaSCs/early progenitor pool. These multiple roles of miR-34a are maintained in a model of human breast cancer, in which chronic expression of miR-34a in triple-negative mesenchymal-like cells (enriched in cancer stem cells-CSCs) could promote a luminal-like differentiation programme, restrict the CSC pool, and inhibit tumour propagation. Hence, activation of miR-34a-dependent programmes could provide a therapeutic opportunity for the subset of breast cancers, which are rich in CSCs and respond poorly to conventional therapies.	[Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Marzi, Matteo Jacopo; Nicassio, Francesco] ITT, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy; [Tordonato, Chiara] IFOM, FIRC Inst Mol Oncol Fdn, I-20139 Milan, Italy; [Santoro, Angela; Pelicci, Pier Giuseppe] European Inst Oncol IE0, Dept Expt Oncol, I-20100 Milan, Italy; [Pelicci, Pier Giuseppe] Univ Milan, Dipartimento Sci Salute, I-20100 Milan, Italy; [Ventura, Andrea] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Istituto Italiano di Tecnologia - IIT; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; Memorial Sloan Kettering Cancer Center	Bonetti, P; Nicassio, F (corresponding author), ITT, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy.	paola.bonetti@iit.it; francesco.nicassio@iit.it	Climent, Montserrat/K-6490-2019; Bonetti, Paola/Y-9182-2019; tordonato, chiara/AAQ-5819-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Marzi, Matteo Jacopo/AAB-9775-2019	Climent, Montserrat/0000-0002-9029-7914; Bonetti, Paola/0000-0002-8805-9837; tordonato, chiara/0000-0001-6556-1747; Marzi, Matteo Jacopo/0000-0002-5068-782X; nicassio, francesco/0000-0002-5954-5318	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG14085, IG18774]; Cariplo [2015-0590]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cariplo(Fondazione Cariplo)	We thank the Genomic Unit and Imaging Unit, Federica Pisati for IHC, Thalia Vlachou for ChIP. Veronica Raker for manuscript editing. This work was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) to FN (IG14085 and IG18774), Cariplo (2015-0590) to FN.	Aranha MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021396; Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brisken C, 2000, GENE DEV, V14, P650; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Jafari N, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701652; Kang L, 2015, CANCER SCI, V106, P700, DOI 10.1111/cas.12656; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Marzi MJ, 2012, J CELL BIOL, V199, P77, DOI 10.1083/jcb.201206033; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rokavec M, 2014, J MOL CELL BIOL, V6, P214, DOI 10.1093/jmcb/mju003; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Song R, 2014, NATURE, V510, P115, DOI 10.1038/nature13413; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Taube JH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02687; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	47	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					360	374		10.1038/s41388-018-0445-3	http://dx.doi.org/10.1038/s41388-018-0445-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093634	Green Published, hybrid			2022-12-28	WOS:000455851200005
J	Zhang, JL; Zhou, YH; Huang, TT; Wu, F; Pan, Y; Dong, YJ; Wang, Y; Chan, AKY; Liu, LP; Kwan, JSH; Cheung, AHK; Wong, CC; Lo, AKF; Cheng, ASL; Yu, J; Lo, KW; Kang, W; To, KF				Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Dong, Yujuan; Wang, Yan; Chan, Aden K. Y.; Liu, Liping; Kwan, Johnny S. H.; Cheung, Alvin H. K.; Wong, Chi Chun; Lo, Angela K. F.; Cheng, Alfred S. L.; Yu, Jun; Lo, Kwok Wai; Kang, Wei; To, Ka Fai			FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p	ONCOGENE			English	Article							MICRORNA TARGET PREDICTION; GENE AMPLIFICATION; CANCER; GROWTH; EXPRESSION; INVASION; INHIBITOR; MIGRATION; MIRDB; CELLS	Fibroblast growth factors (FGFs) and their receptors are significant components during fundamental cellular processes. FGF18 plays a distinctive role in modulating the activity of both tumor cells and tumor microenvironment. This study aims to comprehensively investigate the expression and functional role of FGF18 in gastric cancer (GC) and elucidate its regulatory mechanisms. The upregulation of FGF18 was detected in seven out of eleven (63.6%) GC cell lines. In primary GC samples, FGF18 was overexpressed in genomically stable and chromosomal instability subtypes of GC and its overexpression was associated with poor survival. Knocking down FGF18 inhibited tumor formation abilities, induced G1 phase cell cycle arrest and enhanced anti-cancer drug sensitivity. Expression microarray profiling revealed that silencing of FGF18 activated ATM pathway but quenched TGF-beta pathway. The key factors that altered in the related signaling were validated by western blot and immunofluorescence. Meanwhile, treating GC cells with human recombinant FGF18 or FGF18-conditioned medium accelerated tumor growth through activation of ERK-MAPK signaling. FGF18 was further confirmed to be a direct target of tumor suppressor, miR-590-5p. Their expressions showed a negative correlation in primary GC samples and more importantly, re-overexpression of FGF18 partly abolished the tumor-suppressive effect of miR-590-5p. Our study not only identified that FGF18 serves as a novel prognostic marker and a therapeutic target in GC but also enriched the knowledge of FGF-FGFR signaling during gastric tumorigenesis.	[Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Chan, Aden K. Y.; Kwan, Johnny S. H.; Cheung, Alvin H. K.; Lo, Angela K. F.; Lo, Kwok Wai; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Dong, Yujuan; Wong, Chi Chun; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sir YK Pao Canc Ctr, Hong Kong, Peoples R China; [Huang, Tingting; Cheng, Alfred S. L.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Wang, Yan] Shanxi Med Univ, Key Lab Cardiovasc Med & Clin Pharmacol Shanxi Pr, Taiyuan, Shanxi, Peoples R China; [Liu, Liping] Jinan Univ, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Second Clin Med Coll, Shenzhen, Guangdong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Shanxi Medical University; Jinan University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sir YK Pao Canc Ctr, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	KANG, Wei/C-5451-2016; Yu, Jun/D-8569-2015; Wong, Chi Chun/C-4636-2016; Dong, Yujuan/AAS-3467-2021; Cheng, Alfred SL/C-3327-2014	KANG, Wei/0000-0002-4651-677X; Yu, Jun/0000-0001-5008-2153; Cheng, Alfred SL/0000-0003-2345-6951; PAN, YI/0000-0001-9734-6398; Lo, Kwok Wai/0000-0002-3488-6124	General Research Fund (RGC) from The Research Grants Council of Hong Kong [CUHK14110016]; CUHK Direct Grant for Research [2017.001]	General Research Fund (RGC) from The Research Grants Council of Hong Kong; CUHK Direct Grant for Research	We acknowledge the TCGA Research Network (http://cancergenome.nih.gov/) for providing the gastric cancer dataset and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14110016) from The Research Grants Council of Hong Kong and CUHK Direct Grant for Research (2017.001). We also acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong.	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Belov AA, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015958; Chen G, 2014, INT J CLIN EXP MED, V7, P5947; Chu YX, 2014, J CELL BIOCHEM, V115, P847, DOI 10.1002/jcb.24726; Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Huang TT, 2018, ONCOGENE, V37, P1159, DOI 10.1038/s41388-017-0029-7; Huang TT, 2017, INT J ONCOL, V50, P1501, DOI 10.3892/ijo.2017.3927; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Ishiguro H, 2014, WORLD J GASTROENTERO, V20, P5694, DOI 10.3748/wjg.v20.i19.5694; Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Katoh Y, 2006, INT J MOL MED, V17, P529; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Liu YH, 2017, BIOMED PHARMACOTHER, V86, P466, DOI 10.1016/j.biopha.2016.12.003; Maehara O, 2017, CARCINOGENESIS, V38, P1073, DOI 10.1093/carcin/bgx095; Marechal Alexandre, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a012716; Marek L, 2009, MOL PHARMACOL, V75, P196, DOI 10.1124/mol.108.049544; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Shimokawa T, 2003, CANCER RES, V63, P6116; Shoji H, 2015, ANTICANCER RES, V35, P5055; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1353-3; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Wang FF, 2016, MOL CELL BIOCHEM, V423, P29, DOI 10.1007/s11010-016-2822-y; Wang QX, 2015, CELL PHYSIOL BIOCHEM, V35, P933, DOI 10.1159/000369750; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wei W, 2013, J CLIN INVEST, V123, P4435, DOI 10.1172/JCI70625; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Zhang JL, 2018, MOL CARCINOGEN, V57, P1144, DOI 10.1002/mc.22831; Zhou L, 2017, EUR REV MED PHARMACO, V21, P87; Zhou QX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.306; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2	46	33	35	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					33	46		10.1038/s41388-018-0430-x	http://dx.doi.org/10.1038/s41388-018-0430-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082912	Green Published, hybrid			2022-12-28	WOS:000454775900003
J	Li, WL; Wong, CC; Zhang, XM; Kang, W; Nakatsu, G; Zhao, QF; Chen, HR; Go, MYY; Chiu, PWY; Wang, XH; Ji, JF; Li, XN; Cai, ZW; Ng, EKW; Yu, J				Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Kang, Wei; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Chiu, Philip Wai Yan; Wang, Xiaohong; Ji, Jiafu; Li, Xiaona; Cai, Zongwei; Ng, Enders Kwok Wai; Yu, Jun			CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1 alpha axis to inhibit gastric tumorigenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; CANCER GROWTH; AMPK; METABOLISM; REVEALS; HISTONE; METHYLATION; EPIGENETICS; REGULATOR; INTERPLAY	Metabolic dysfunction is a hallmark of gastric cancer (GC). In this study, we reported the identification of Calcium Binding Protein 39-Like (CAB39L) as a novel regulator of tumor metabolism in GC. CAB39L mRNA was frequently silenced by promoter methylation in GC cell lines and tissues. Functional studies suggested that CAB39L functions as a tumor suppressor, as overexpression of CAB39L elicited suppression of multiple cancer phenotypes both in GC cells and an orthotopic mouse model; whilst its knockdown promoted tumorigenesis. Mechanistically, CAB39L interacted with LKB1-STRAD complex and induced LKB1, leading to the phosphorylation and activation of AMPK alpha/beta. LKB1-AMPK activation in GC cell lines was tumor suppressive, as metformin (an AMPK activator) inhibited GC cell growth in the CAB39L-silenced cells. Moreover, knockdown of LKB1 reversed growth inhibitory effect of CAB39L, indicating that tumor suppression by CAB39L depended on LKB1-AMPK. RNAseq and gene set enrichment analysis revealed that CAB39L was closely correlated with oxidative phosphorylation and mitochondrial biogenesis. Consistently, CAB39L-induced p-AMPK elicited PGC1 alpha phosphorylation and increased the expression of genes involved in mitochondrial respiration complexes. Accordingly, CAB39L reversed the Warburg effect in GC, as evidenced by enhanced oxygen consumption rate and reduced extracellular acidification rate; inversely, CAB39L knockdown promoted a metabolic shift towards the Warburg phenotype. In GC patients, CAB39L promoter hypermethylation was correlated with poor prognosis. Our data demonstrate that CAB39L is a novel tumor suppressor which suppresses tumorigenesis by promoting LKB1-AMPK-PGC1 alpha axis, thereby preventing a metabolic shift that drives carcinogenesis. CAB39L methylation is a potential prognostic biomarker for GC patients.	[Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Li, Weilin; Chiu, Philip Wai Yan; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Kang, Wei] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Li, Xiaona; Cai, Zongwei] Hong Kong Baptist Univ, Dept Chem, State Key Lab Environm & Biol Anal, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University; Hong Kong Baptist University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.; Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.	endersng@surgery.cuhk.edu.hk; junyu@cuhk.edu.hk	Chen, Huarong/ABZ-5810-2022; Li, Weilin/ABG-9032-2021; Chiu, Philip/ABB-1454-2020; KANG, Wei/C-5451-2016; Nakatsu, Geicho/AAU-3089-2021; Cai, Zongwei/ABD-4001-2020; chen, huarong/ABH-8561-2020; Ng, Enders Kwok-wai/E-8276-2016	Chiu, Philip/0000-0001-9292-112X; KANG, Wei/0000-0002-4651-677X; Cai, Zongwei/0000-0002-8724-7684; chen, huarong/0000-0003-2192-1864; Ng, Enders Kwok-wai/0000-0001-7219-5810	RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Faculty of Medicine CUHK direct grant; Shenzhen Virtual University Park Support Scheme; Vice-Chancellor's Discretionary Fund CUHK	RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Faculty of Medicine CUHK direct grant; Shenzhen Virtual University Park Support Scheme; Vice-Chancellor's Discretionary Fund CUHK	This project was supported by research funds from RGC/GRF Hong Kong (14114615, 14101917, 14111216, and 14106145); National Natural Science Foundation of China (NSFC) (81772501, 81502064); HMRF Hong Kong (03140856); Faculty of Medicine CUHK direct grant; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Camacho L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0598-8; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Das M, 2017, LANCET ONCOL, V18, pE307, DOI 10.1016/S1470-2045(17)30321-2; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Filippi BM, 2011, EMBO J, V30, P1730, DOI 10.1038/emboj.2011.78; Garrido N, 2009, FERTIL STERIL, V91, P1307, DOI 10.1016/j.fertnstert.2008.01.078; Gupta V, 2014, CURR PHARM DESIGN, V20, P1706, DOI 10.2174/13816128113199990536; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jacome AA, 2016, WORLD J GASTROENTERO, V22, P1160, DOI 10.3748/wjg.v22.i3.1160; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LeBleu VS, 2014, NAT CELL BIOL, P1001, DOI DOI 10.1038/NCB3039; Li XN, 2017, ONCOTARGET, V8; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Meng FQ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5063239; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Rahmioglu N, 2015, HUM MOL GENET, V24, P1185, DOI 10.1093/hmg/ddu516; Richmond A, 2008, DIS MODEL MECH, V1, P78, DOI 10.1242/dmm.000976; Selaru FM, 2009, AM J GASTROENTEROL, V104, P1910, DOI 10.1038/ajg.2008.145; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Whitburn J, 2017, CURR UROL REP, V18, DOI 10.1007/s11934-017-0693-8; William WN, 2012, ANN ONCOL, V23, P78, DOI 10.1093/annonc/mdr036; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xing F, 2017, CELL REP, V18, P468, DOI 10.1016/j.celrep.2016.12.037; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377	45	29	32	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6383	6398		10.1038/s41388-018-0402-1	http://dx.doi.org/10.1038/s41388-018-0402-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30054562	Green Published, hybrid			2022-12-28	WOS:000452989100001
J	Wang, YN; Zeng, ZL; Lu, JH; Wang, Y; Liu, ZX; He, MM; Zhao, Q; Wang, ZX; Li, T; Lu, YX; Wu, QN; Yu, K; Wang, F; Pu, HY; Li, B; Jia, WH; Shi, M; Xie, D; Kang, TB; Huang, P; Ju, HQ; Xu, RH				Wang, Ying-nan; Zeng, Zhao-lei; Lu, Jiahuan; Wang, Yun; Liu, Ze-xian; He, Ming-ming; Zhao, Qi; Wang, Zi-xian; Li, Ting; Lu, Yun-xin; Wu, Qi-nian; Yu, Kai; Wang, Feng; Pu, Heng-Ying; Li, Bo; Jia, Wei-hua; Shi, Ming; Xie, Dan; Kang, Tie-bang; Huang, Peng; Ju, Huai-qiang; Xu, Rui-hua			CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis	ONCOGENE			English	Article							BETA-OXIDATION; LEUKEMIA-CELLS; SURVIVAL; METABOLISM; ETOMOXIR; ENERGY; AXIS; BIOCHEMISTRY; ANTIOXIDANT; HOMEOSTASIS	Anoikis is a critical obstacle to cancer metastasis. Colorectal cancer (CRC) exhibits a high rate of metastasis, leading to death, and the mechanisms involved in anoikis resistance are still unclear. We identified that the fatty acid oxidation (FAO) pathway was activated in detached CRC cells. Multiple genes in the FAO pathway, specifically the rate-limiting enzyme CPT1A, were upregulated in CRC cells grown in suspension. Reactive oxygen species elimination mediated by CPT1A in CRC cells was vital to anoikis resistance. In vivo experiments showed that CPT1A-suppressed CRC cells colonized the lung at a much lower rate than normal CRC cells, suggesting that CPT1A-mediated FAO activation increased metastatic capacity. In clinical tissue specimens from CRC patients, elevated expression of CPT1A was observed in metastatic sites compared with primary sites. Our results demonstrate that CPT1A-mediated FAO activation induces CRC cells to resist anoikis, suggesting that CPT1A is an attractive target for treating metastatic CRC.	[Wang, Ying-nan; Zeng, Zhao-lei; Lu, Jiahuan; Wang, Yun; Liu, Ze-xian; He, Ming-ming; Zhao, Qi; Wang, Zi-xian; Li, Ting; Lu, Yun-xin; Wu, Qi-nian; Yu, Kai; Wang, Feng; Pu, Heng-Ying; Jia, Wei-hua; Shi, Ming; Xie, Dan; Kang, Tie-bang; Ju, Huai-qiang; Xu, Rui-hua] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Li, Bo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Guangdong, Peoples R China; [Huang, Peng] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center	Ju, HQ; Xu, RH (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	juhq@sysucc.org.cn; xurh@sysucc.org.cn	Liu, Zexian/D-1153-2011; Zhao, Qi/X-7899-2019; xu, rui/GRX-5734-2022; Xu, Rui-Hua/AAW-4766-2021	Liu, Zexian/0000-0001-9698-0610; Zhao, Qi/0000-0002-8683-6145; Xu, Rui-Hua/0000-0001-9771-8534; Ju, Huai-Qiang/0000-0003-1713-5465; Yu, Kai/0000-0003-3343-2902	National Natural Science Foundation of China [81602137, 81572392]; Natural Science Foundation of Guangdong Province [2017A030313485, 2014A030312015]; Science and Technology Program of Guangdong [2015B020232008]; Science and Technology Program of Guangzhou [15570006, 201508020250, 201604020003]; Pearl River S&T Nova Program of Guangzhou [201806010002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Pearl River S&T Nova Program of Guangzhou	This research was supported by the National Natural Science Foundation of China (81602137, 81572392); Natural Science Foundation of Guangdong Province (2017A030313485, 2014A030312015); Science and Technology Program of Guangdong (2015B020232008), Science and Technology Program of Guangzhou (15570006, 201508020250, 201604020003) and by grants from Pearl River S&T Nova Program of Guangzhou (201806010002).	Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cabrero A, 2003, J LIPID RES, V44, P388, DOI 10.1194/jlr.M200294-JLR200; Casals N, 2016, PROG LIPID RES, V61, P134, DOI 10.1016/j.plipres.2015.11.004; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Conti R, 2011, DIABETES, V60, P644, DOI 10.2337/db10-0346; Cook AD, 2005, ANN SURG ONCOL, V12, P637, DOI 10.1245/ASO.2005.06.012; Cully M, 2017, NAT REV DRUG DISCOV, V16, P15, DOI 10.1038/nrd.2016.274; D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harjes U, 2016, CRIT REV ONCOL HEMAT, V97, P15, DOI 10.1016/j.critrevonc.2015.10.011; Hernlund E, 2008, INT J CANCER, V123, P476, DOI 10.1002/ijc.23525; Hinderling VB, 2002, AM J CLIN NUTR, V76, P141, DOI 10.1093/ajcn/76.1.141; Holubarsch CJF, 2007, CLIN SCI, V113, P205, DOI 10.1042/CS20060307; Houten SM, 2016, ANNU REV PHYSIOL, V78, P23, DOI 10.1146/annurev-physiol-021115-105045; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Huang A, 2016, CANCER LETT, V377, P149, DOI 10.1016/j.canlet.2016.04.040; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Ju HQ, 2017, ONCOGENE, V36, P6282, DOI 10.1038/onc.2017.227; Ju HQ, 2016, THERANOSTICS, V6, P1160, DOI 10.7150/thno.14848; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Noguchi T, 2016, ONCOLOGY-BASEL, V90, P221, DOI 10.1159/000444493; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Pacilli A, 2013, JNCI-J NATL CANCER I, V105, P489, DOI 10.1093/jnci/djt030; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Paumen MB, 1997, BIOCHEM BIOPH RES CO, V231, P523, DOI 10.1006/bbrc.1997.6089; Pollack LA, 2006, CANCER CAUSE CONTROL, V17, P449, DOI 10.1007/s10552-005-0505-1; Qu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.132; Ricciardi MR, 2015, BLOOD, V126, P1925, DOI 10.1182/blood-2014-12-617498; Rodrigues MF, 2016, BIOCHEM J, V473, P703, DOI 10.1042/BJ20150645; Rufer AC, 2009, CELL MOL LIFE SCI, V66, P2489, DOI 10.1007/s00018-009-0035-1; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Setoyama D, 2013, GENES CELLS, V18, P1107, DOI 10.1111/gtc.12098; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zammit VA, 2008, IUBMB LIFE, V60, P347, DOI 10.1002/iub.78; Zhu L, 2017, J NUCL MED, V58, P533, DOI 10.2967/jnumed.116.182345; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	58	117	119	0	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6025	6040		10.1038/s41388-018-0384-z	http://dx.doi.org/10.1038/s41388-018-0384-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29995871				2022-12-28	WOS:000450175900002
J	Elias, D; Vever, H; Laenkholm, AV; Gjerstorff, MF; Yde, CW; Lykkesfeldt, AE; Ditzel, HJ				Elias, D.; Vever, H.; Laenkholm, A. -V.; Gjerstorff, M. F.; Yde, C. W.; Lykkesfeldt, A. E.; Ditzel, H. J.			Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (vol 34, pg 1919, 2015)	ONCOGENE			English	Correction									[Elias, D.; Vever, H.; Gjerstorff, M. F.; Ditzel, H. J.] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense C, Denmark; [Laenkholm, A. -V.] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Yde, C. W.; Lykkesfeldt, A. E.] Danish Canc Soc Res Ctr, Breast Canc Grp, Cell Death & Metab, Copenhagen, Denmark; [Ditzel, H. J.] Odense Univ Hosp, Dept Oncol, Odense, Denmark	University of Southern Denmark; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Elias, D; Ditzel, HJ (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense C, Denmark.; Ditzel, HJ (corresponding author), Odense Univ Hosp, Dept Oncol, Odense, Denmark.	delias@health.sdu.dk; hditzel@health.sdu.dk		Laenkholm, Anne-Vibeke/0000-0003-2166-8686				Elias D, 2015, ONCOGENE, V34, P1919, DOI 10.1038/onc.2014.138	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5585	5586		10.1038/s41388-018-0495-6	http://dx.doi.org/10.1038/s41388-018-0495-6			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	30242243	Green Published, hybrid			2022-12-28	WOS:000446991200008
J	Oda, T; Yamazumi, Y; Hiroko, T; Kamiya, A; Kiriya, S; Suyama, S; Shiozaki-Sato, Y; Akiyama, T				Oda, Takeaki; Yamazumi, Yusuke; Hiroko, Takatoshi; Kamiya, Atsushi; Kiriya, Saori; Suyama, Saki; Shiozaki-Sato, Yumi; Akiyama, Tetsu			Mex-3B induces apoptosis by inhibiting miR-92a access to the Bim-3 ' UTR	ONCOGENE			English	Article							RNA-BINDING PROTEIN; COLORECTAL-CANCER CELLS; AU-RICH ELEMENT; MESSENGER-RNA; P53; EXPRESSION; MICRORNAS; GENE; IDENTIFICATION; DISEASE	Cells respond to a variety of cellular stresses, including DNA damage, by regulating genes whose expression modulates cell cycle arrest, DNA repair, senescence, and/or apoptosis. MicroRNAs (miRNAs) play essential roles in both normal development and disease pathogenesis by destabilizing mRNAs and inhibiting translation. In turn, miRNA biogenesis, turnover, and activity can be regulated by specific RNA-binding proteins. Here we show that Mex-3B, an hnRNP K homology (KH) domain-containing RNA-binding protein, critically modulates DNA stress-induced apoptosis by posttranscriptionally upregulating the pro-apoptotic BH3 (Bcl-2 homology region 3)-only family member Bim. Furthermore, our data indicate that binding of Mex-3B to the 3'-untranslated region (3'UTR) of Bim interferes with the interaction of an Argonaute (Ago)-miR-92a complex with a miR-92a target site present in the Bim RNA. Our results provide novel insights into the posttranscriptional mechanisms that are critical for cellular stress responses.	[Oda, Takeaki; Yamazumi, Yusuke; Hiroko, Takatoshi; Kamiya, Atsushi; Kiriya, Saori; Suyama, Saki; Shiozaki-Sato, Yumi; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp			P-CREATE (Project for Cancer Research and Therapeutic Evolution) from the Japan Agency for Medical Research and Development [17cm0106103h0002]; P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics) from the Japan Agency for Medical Research and Development [15cm0106016h0005]; MEXT, Japan [17H06325]	P-CREATE (Project for Cancer Research and Therapeutic Evolution) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Y Nakamura for adenovirus expressing p53. This work was supported by P-CREATE (Project for Cancer Research and Therapeutic Evolution: Grant No. 17cm0106103h0002) and P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics: Grant No. 15cm0106016h0005) grants from the Japan Agency for Medical Research and Development, and Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Analysis and Regulation of Cellular Diversity: Grant No. 17H06325) from MEXT, Japan.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Buchet-Poyau K, 2007, NUCLEIC ACIDS RES, V35, P1289, DOI 10.1093/nar/gkm016; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cano F, 2013, MOL IMMUNOL, V55, P135, DOI 10.1016/j.molimm.2012.10.015; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Le Borgne M, 2014, DEVELOPMENT, V141, P2096, DOI 10.1242/dev.108514; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pereira B, 2013, NUCLEIC ACIDS RES, V41, P3986, DOI 10.1093/nar/gkt087; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamazumi Y, 2016, CELL REP, V16, P2456, DOI 10.1016/j.celrep.2016.07.062; Yang Y, 2016, CELL RES, V26, P288, DOI 10.1038/cr.2016.16; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006	48	8	8	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5233	5247		10.1038/s41388-018-0336-7	http://dx.doi.org/10.1038/s41388-018-0336-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849121				2022-12-28	WOS:000445093100007
J	Li, NN; Zhang, Y; Sidlauskas, K; Ellis, M; Evans, I; Frankel, P; Lau, J; El-Hassan, T; Guglielmi, L; Broni, J; Richard-Loendt, A; Brandner, S				Li, Ningning; Zhang, Ying; Sidlauskas, Kastytis; Ellis, Matthew; Evans, Ian; Frankel, Paul; Lau, Joanne; El-Hassan, Tedani; Guglielmi, Loredana; Broni, Jessica; Richard-Loendt, Angela; Brandner, Sebastian			Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; PROSTATE-CANCER CELLS; STEM-CELL; DOWN-REGULATION; CYCLE ARREST; HUMAN GLIOBLASTOMA; FATE DETERMINATION; TUMOR-SUPPRESSOR; EXPRESSION; MIR-449A	To identify biomarkers for glioma growth, invasion and progression, we used a candidate gene approach in mouse models with two complementary brain tumour phenotypes, developing either slow-growing, diffusely infiltrating gliomas or highly proliferative, non-invasive primitive neural tumours. In a microRNA screen we first identified microRNA-449a as most significantly differentially expressed between these two tumour types. miR-449a has a target dependent effect, inhibiting cell growth and migration by downregulation of CCND1 and suppressing neural phenotypes by inhibition of G protein coupled-receptor (GPR) 158. GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma. The correlation of GPR158 expression with molecular subtypes, patient survival and therapy response suggests a possible role of GPR158 as prognostic biomarker in human gliomas.	[Li, Ningning; Zhang, Ying; Sidlauskas, Kastytis; Ellis, Matthew; Lau, Joanne; Broni, Jessica; Richard-Loendt, Angela; Brandner, Sebastian] UCL, Inst Neurol, Dept Neurodegenerat, Queen Sq, London WC1N 3BG, England; [Li, Ningning] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen 518107, Peoples R China; [Evans, Ian; Frankel, Paul] UCL, Div Med, Univ St, London WC1E 6JF, England; [El-Hassan, Tedani; Brandner, Sebastian] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Guglielmi, Loredana] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England; [Broni, Jessica; Richard-Loendt, Angela] UCL, Inst Neurol, UCL IQPath Lab, Queen Sq, London WC1N 3BG, England	University of London; University College London; Sun Yat Sen University; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; Queen Mary University London; University of London; University College London	Li, NN; Brandner, S (corresponding author), UCL, Inst Neurol, Dept Neurodegenerat, Queen Sq, London WC1N 3BG, England.; Li, NN (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen 518107, Peoples R China.; Brandner, S (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England.	linn29@mail.sysu.edu.cn; s.brandner@ucl.ac.uk	Evans, Ian/C-8533-2009; Brandner, Sebastian/J-4562-2014	Evans, Ian/0000-0002-0468-8274; Brandner, Sebastian/0000-0002-9821-0342; Zhang, Ying/0000-0003-2194-7116; Li, Ningning/0000-0002-0414-5878; Ellis, Matthew/0000-0002-5264-0531	Brain Tumour Charity UK (BTC) [8/128]; Centre grant from BTC [8/197]; Brain Tumour Research UK; Department of Health's NIHR Biomedical Research Centre's funding scheme; CRUK Accelerator Ed-UCL Grant [C416/A23615]; University College London (Overseas research scholarship, UCL ORS); UCLH Charity; Cancer Research UK [C1 15121 A 20256]	Brain Tumour Charity UK (BTC); Centre grant from BTC; Brain Tumour Research UK; Department of Health's NIHR Biomedical Research Centre's funding scheme(National Institute for Health Research (NIHR)); CRUK Accelerator Ed-UCL Grant; University College London (Overseas research scholarship, UCL ORS); UCLH Charity; Cancer Research UK(Cancer Research UK)	Part of this work was supported by a grant from the Brain Tumour Charity UK to NL and SB (BTC, 8/128) and by a Centre grant from BTC (8/197). LG and part of NL were supported by a Centre of Excellence grant to Queen May University London from Brain Tumour Research UK. SB is also supported by the Department of Health's NIHR Biomedical Research Centre's funding scheme. The tissue resource is supported by the CRUK Accelerator Ed-UCL Grant C416/A23615. YZ is supported by a PhD fellowship from University College London (Overseas research scholarship, UCL ORS) and by funds from UCLH Charity. ME is funded by a Cancer Research UK Accelerator grant C1 15121 A 20256. We thank M. Elizabeth Fini, UCSC Los Angeles for the pcDNA3.1 hGPR158 vector.	Al-Mayhani TMF, 2009, J NEUROSCI METH, V176, P192, DOI 10.1016/j.jneumeth.2008.07.022; Barca-Mayo O, 2014, CELL MOL LIFE SCI, V71, P2975, DOI 10.1007/s00018-014-1576-5; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bjarndottir TK, 2005, GENE, V362, P70, DOI 10.1016/j.gene.2005.07.029; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen SH, 2014, ONCOL LETT, V7, P568, DOI 10.3892/ol.2013.1737; Chen SP, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1738-3; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Cimadamore F, 2013, P NATL ACAD SCI USA, V110, pE3017, DOI 10.1073/pnas.1220176110; Dahia PLM, 2014, NAT REV CANCER, V14, P108, DOI 10.1038/nrc3648; Fang YT, 2013, ONCOL REP, V30, P399, DOI 10.3892/or.2013.2465; Fededa JP, 2016, EMBO J, V35, P2386, DOI 10.15252/embj.201694056; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Henriquez NV, 2013, CANCER RES, V73, P5834, DOI 10.1158/0008-5472.CAN-13-1299; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Insel PA, 2007, BBA-BIOMEMBRANES, V1768, P994, DOI 10.1016/j.bbamem.2006.09.029; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; JIANG W, 1992, CANCER RES, V52, P2980; Johnsson P, 2013, NAT STRUCT MOL BIOL, V20, P440, DOI 10.1038/nsmb.2516; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Khrimian L, 2017, J EXP MED, V214, P2859, DOI 10.1084/jem.20171320; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; Lize M, 2010, CELL DEATH DIFFER, V17, P452, DOI 10.1038/cdd.2009.188; Lize M, 2011, CELL CYCLE, V10, P2874, DOI 10.4161/cc.10.17.17181; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lukaszewicz AI, 2011, P NATL ACAD SCI USA, V108, P11632, DOI 10.1073/pnas.1106230108; Ma JF, 2015, NEUROCHEM RES, V40, P1681, DOI 10.1007/s11064-015-1635-9; Mao AH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27346; Marino S, 2000, GENE DEV, V14, P994; Marino S, 2002, DEVELOPMENT, V129, P3513; Martin HC, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r51; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Noonan EJ, 2010, ONCOTARGET, V1, P349, DOI 10.18632/oncotarget.167; Orlandi C, 2012, J CELL BIOL, V197, P711, DOI 10.1083/jcb.201202123; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117758; Patel N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057843; Pham JT, 2012, AM J STEM CELLS, V1, P182; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200; Redshaw N, 2009, BRAIN RES, V1250, P20, DOI 10.1016/j.brainres.2008.11.020; Reuss DE, 2015, ACTA NEUROPATHOL, V130, P407, DOI 10.1007/s00401-015-1454-8; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Saddiki H, 2015, BIOINFORMATICS, V31, P225, DOI 10.1093/bioinformatics/btu618; Shi W, 2016, ONCOTARGET, V7, P18906, DOI 10.18632/oncotarget.7753; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Su WY, 2012, CELL RES, V22, P1374, DOI 10.1038/cr.2012.57; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tan SM, 2014, CELL REP, V8, P1225, DOI 10.1016/j.celrep.2014.07.023; Thompson MD, 2014, METHODS MOL BIOL, V1175, P153, DOI 10.1007/978-1-4939-0956-8_8; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigneswaran K, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.57; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Weller M, 2013, LANCET ONCOL, V14, pE370, DOI 10.1016/S1470-2045(13)70168-2; Wu JW, 2014, P NATL ACAD SCI USA, V111, pE2851, DOI 10.1073/pnas.1407777111; Yang XJ, 2009, GENE DEV, V23, P2388, DOI 10.1101/gad.1819009; Yao MJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-232; Yao YL, 2015, MOL ONCOL, V9, P640, DOI 10.1016/j.molonc.2014.11.003; You JC, 2015, AM J CANCER RES, V5, P2730; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhao ZZ, 2015, RNA BIOL, V12, P538, DOI 10.1080/15476286.2015.1023495; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0556-3	71	19	20	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4313	4333		10.1038/s41388-018-0277-1	http://dx.doi.org/10.1038/s41388-018-0277-1			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29720725	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000440566100009
J	Pinazza, M; Ghisi, M; Minuzzo, S; Agnusdei, V; Fossati, G; Ciminale, V; Pezze, L; Ciribilli, Y; Pilotto, G; Venturoli, C; Amadori, A; Indraccolo, S				Pinazza, Marica; Ghisi, Margherita; Minuzzo, Sonia; Agnusdei, Valentina; Fossati, Gianluca; Ciminale, Vincenzo; Pezze, Laura; Ciribilli, Yari; Pilotto, Giorgia; Venturoli, Carolina; Amadori, Alberto; Indraccolo, Stefano			Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells	ONCOGENE			English	Article							ACTIVATING MUTATIONS; ACETYLATION; ENDOCYTOSIS; RECEPTOR	Several studies have revealed that endosomal sorting controls the steady-state levels of Notch at the cell surface in normal cells and prevents its inappropriate activation in the absence of ligands. However, whether this highly dynamic physiologic process can be exploited to counteract dysregulated Notch signaling in cancer cells remains unknown. T-ALL is a malignancy characterized by aberrant Notch signaling, sustained by activating mutations in Notch1 as well as overexpression of Notch3, a Notch paralog physiologically subjected to lysosome-dependent degradation in human cancer cells. Here we show that treatment with the pan-HDAC inhibitor Trichostatin A (TSA) strongly decreases Notch3 full-length protein levels in T-ALL cell lines and primary human T-ALL cells xenografted in mice without substantially reducing NOTCH3 mRNA levels. Moreover, TSA markedly reduced the levels of Notch target genes, including pT alpha, CR2, and DTX-1, and induced apoptosis of T-ALL cells. We further observed that Notch3 was post-translationally regulated following TSA treatment, with reduced Notch3 surface levels and increased accumulation of Notch3 protein in the lysosomal compartment. Surface Notch3 levels were rescued by inhibition of dynein with ciliobrevin D. Pharmacologic studies with HDAC1, 6, and 8-specific inhibitors disclosed that these effects were largely due to inhibition of HDAC6 in TALL cells. HDAC6 silencing by specific shRNA was followed by reduced Notch3 expression and increased apoptosis of TALL cells. Finally, HDAC6 silencing impaired leukemia outgrowth in mice, associated with reduction of Notch3 full-length protein in vivo. These results connect HDAC6 activity to regulation of total and surface Notch3 levels and suggest HDAC6 as a potential novel therapeutic target to lower Notch signaling in T-ALL and other Notch3-addicted tumors.	[Pinazza, Marica; Agnusdei, Valentina; Ciminale, Vincenzo; Venturoli, Carolina; Amadori, Alberto; Indraccolo, Stefano] Ist Oncol Veneto IOV IRCCS, Padua, Italy; [Ghisi, Margherita; Minuzzo, Sonia; Ciminale, Vincenzo; Pilotto, Giorgia; Amadori, Alberto] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy; [Fossati, Gianluca] Italfarmaco SPA, Milan, Italy; [Pezze, Laura; Ciribilli, Yari] Univ Trento, Lab Mol Canc Genet, CIBIO, Trento, Italy; [Ghisi, Margherita] CRCT, Toulouse, France	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; Italfarmaco; University of Trento; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Indraccolo, S (corresponding author), Ist Oncol Veneto IOV IRCCS, Padua, Italy.	stefano.indraccolo@unipd.it	Ghisi, Margherita/G-2756-2017; Minuzzo, Sonia Anna/AAP-2062-2020; Ciminale, Vincenzo/L-1416-2016; Ciribilli, Yari/K-2751-2018; Indraccolo, Stefano/AAE-6261-2021; Agnusdei, Valentina/I-1137-2018	Minuzzo, Sonia Anna/0000-0003-2588-6058; Ciminale, Vincenzo/0000-0001-6197-1802; Ciribilli, Yari/0000-0001-9231-379X; Indraccolo, Stefano/0000-0002-4810-7136; Agnusdei, Valentina/0000-0002-2617-360X; Pezze, Laura/0000-0001-8924-0083; Ghisi, Margherita/0000-0003-0583-9879	AIRC [IG18803]	AIRC(Fondazione AIRC per la ricerca sul cancro)	AIRC (IG18803 to SI).	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2003, SEMIN IMMUNOL, V15, P107, DOI 10.1016/S1044-5323(03)00007-1; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Conner SD, 2016, INT REV CEL MOL BIO, V323, P107, DOI 10.1016/bs.ircmb.2015.12.002; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302; Gu YS, 2016, ONCOTARGET, V7, P29804, DOI 10.18632/oncotarget.7772; Jia LJ, 2009, INT J BIOCHEM CELL B, V41, P2594, DOI 10.1016/j.biocel.2009.08.019; Kanwar R, 2004, CURR BIOL, V14, pR1043, DOI 10.1016/j.cub.2004.11.041; Liu J, 2016, CRIT REV ONCOL HEMAT, V104, P21, DOI 10.1016/j.critrevonc.2016.05.010; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Masiero M, 2011, LEUKEMIA, V25, P588, DOI 10.1038/leu.2010.323; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Pacheco MTF, 2016, EXP CELL RES, V340, P248, DOI 10.1016/j.yexcr.2015.12.016; Palermo R, 2012, ONCOGENE, V31, P3807, DOI 10.1038/onc.2011.533; Pasto A, 2014, CANCER RES, V74, P2106, DOI 10.1158/0008-5472.CAN-13-2022; Pinazza M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.394; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; Serafin V, 2011, J PATHOL, V224, P448, DOI 10.1002/path.2895; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Singh BN, 2010, EXPERT REV ANTICANC, V10, P935, DOI [10.1586/era.10.62, 10.1586/ERA.10.62]; Sorensen EB, 2010, TRAFFIC, V11, P1234, DOI 10.1111/j.1600-0854.2010.01090.x; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Windler SL, 2010, CURR BIOL, V20, P538, DOI 10.1016/j.cub.2010.01.049	36	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3839	3851		10.1038/s41388-018-0234-z	http://dx.doi.org/10.1038/s41388-018-0234-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643474	Green Published, hybrid			2022-12-28	WOS:000438465600006
J	Duplaquet, L; Kherrouche, Z; Baldacci, S; Jamme, P; Cortot, AB; Copin, MC; Tulasne, D				Duplaquet, Leslie; Kherrouche, Zoulika; Baldacci, Simon; Jamme, Philippe; Cortot, Alexis B.; Copin, Marie-Christine; Tulasne, David			The multiple paths towards MET receptor addiction in cancer	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; SPLICE-SITE MUTATION; DOMAIN BINDING-SITE; GENE COPY NUMBER; C-MET; ACQUIRED-RESISTANCE; JUXTAMEMBRANE DOMAIN	Targeted therapies against receptor tyrosine kinases (RTKs) are currently used with success on a small proportion of patients displaying clear oncogene activation. Lung cancers with a mutated EGFR provide a good illustration. The efficacy of targeted treatments relies on oncogene addiction, a situation in which the growth or survival of the cancer cells depends on a single deregulated oncogene. MET, a member of the RTK family, is a promising target because it displays many deregulations in a broad panel of cancers. Although clinical trials having evaluated MET inhibitors in large populations have yielded disappointing results, many recent case reports suggest that MET inhibition may be effective in a subset of patients with unambiguous MET activation and thus, most probably, oncogene addiction. Interestingly, preclinical studies have revealed a particularity of MET addiction: it can arise through several mechanisms, and the mechanism involved can differ according to the cancer type. The present review describes the different mechanisms of MET addiction and their consequences for diagnosis and therapeutic strategies. Although in each cancer type MET addiction affects a restricted number of patients, pooling of these patients across all cancer types yields a targetable population liable to benefit from addiction-targeting therapies.	[Duplaquet, Leslie; Kherrouche, Zoulika; Baldacci, Simon; Jamme, Philippe; Cortot, Alexis B.; Copin, Marie-Christine; Tulasne, David] Univ Lille, CNRS, Inst Pasteur Lille, UMR Mech Tumorigenesis & Targeted Therapies M3T 8, F-59000 Lille, France; [Cortot, Alexis B.] Univ Lille, CHU Lille, Thorac Oncol Dept, F-59000 Lille, France; [Copin, Marie-Christine] Univ Lille, CHU Lille, Inst Pathol, Ave Oscar Lambret, F-59000 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille, CNRS, Inst Pasteur Lille, UMR Mech Tumorigenesis & Targeted Therapies M3T 8, F-59000 Lille, France.	david.tulasne@ibl.fr	Tulasne, David/A-8705-2008; KHERROUCHE, Zoulika/HHN-0213-2022; Tulasne, David/AAR-5287-2020; Cortot, Alexis B/F-7006-2019; KHERROUCHE, Zoulika/L-6549-2019	Tulasne, David/0000-0002-6764-7242; Cortot, Alexis B/0000-0003-0098-2238; Duplaquet, Leslie/0000-0002-6544-0432; Baldacci, Simon/0000-0003-3610-1316	CNRS; Institut Pasteur de Lille; INSERM; Ligue contre le Cancer, comite Nord; Association pour la Recherche sur le Cancer; Institut National du Cancer; Canceropole Nord-Ouest; Site de Recherche Integree sur le Cancer, SIRIC ONCOLille	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer, comite Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Nord-Ouest; Site de Recherche Integree sur le Cancer, SIRIC ONCOLille	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the 'Ligue contre le Cancer, comite Nord', the 'Association pour la Recherche sur le Cancer', the 'Institut National du Cancer', the 'Canceropole Nord-Ouest' and the 'Site de Recherche Integree sur le Cancer, SIRIC ONCOLille'.	Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Apicella M, 2017, ONCOGENE, V36, P1200, DOI 10.1038/onc.2016.283; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Benderra MA, 2016, J THORAC ONCOL, V11, pE21, DOI 10.1016/j.jtho.2015.08.001; Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boland JM, 2013, J THORAC ONCOL, V8, P574, DOI 10.1097/JTO.0b013e318287c395; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Brockmann MA, 2003, CLIN CANCER RES, V9, P4578; Burel-Vandenbos F, 2017, NEUROPATH APPL NEURO, V43, P252, DOI 10.1111/nan.12320; Calvi C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003228; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Caparica R, 2017, J THORAC ONCOL, V12, P141, DOI 10.1016/j.jtho.2016.09.116; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Catenacci DVT, 2017, CANCER-AM CANCER SOC, V123, P1061, DOI 10.1002/cncr.30437; Chen HM, 2015, FEBS LETT, V589, P1437, DOI 10.1016/j.febslet.2015.04.032; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2013, J CLIN ONCOL, V31, P181, DOI 10.1200/JCO.2012.43.3383; Cloughesy T, 2017, J CLIN ONCOL, V35, P343, DOI 10.1200/JCO.2015.64.7685; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cortot AB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw262; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Davies KD, 2017, JCO PRECISION ONCOLO, V1, P1; Dimou A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107677; Dong HJ, 2016, LUNG CANCER, V102, P118, DOI 10.1016/j.lungcan.2016.11.006; Drilon A.R., 2016, J CLIN ONCOL S, V34, DOI DOI 10.1200/JC0.2016.34.15_SUPPL.108; Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014; Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146; Ellingson BM, 2017, NEURO-ONCOLOGY, V19, P89, DOI 10.1093/neuonc/now187; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan YN, 2017, HEPATOLOGY, V66, P1644, DOI 10.1002/hep.29304; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Funakoshi Y, 2013, INVEST NEW DRUG, V31, P1158, DOI 10.1007/s10637-013-9959-2; Gainor JF, 2016, J THORAC ONCOL, V11, pE83, DOI 10.1016/j.jtho.2016.02.021; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Ghadjar P, 2009, CLIN EXP METASTAS, V26, P809, DOI 10.1007/s10585-009-9280-9; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Heideman DAM, 2001, J PATHOL, V194, P428, DOI 10.1002/path.934; Heist RS, 2016, J THORAC ONCOL, V11, P1242, DOI 10.1016/j.jtho.2016.06.013; Heist RS, 2016, ONCOLOGIST, V21, P481, DOI 10.1634/theoncologist.2015-0510; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Ignatius SH, 2017, J THORAC ONCOL, V12, P137, DOI 10.1016/j.jtho.2016.09.119; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jenkins RW, 2015, CLIN LUNG CANCER, V16, pE101, DOI 10.1016/j.cllc.2015.01.009; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Jorge SE, 2015, LUNG CANCER, V90, P369, DOI 10.1016/j.lungcan.2015.10.028; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; Kondo S, 2013, INT J CLIN ONCOL, V18, P207, DOI 10.1007/s10147-011-0361-9; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Koochekpour S, 1997, CANCER RES, V57, P5391; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Kwak Y, 2015, INT J CLIN EXP PATHO, V8, P14932; Lamszus K, 1998, INT J CANCER, V75, P19, DOI 10.1002/(SICI)1097-0215(19980105)75:1<19::AID-IJC4>3.0.CO;2-4; Lapere C, 2017, AM J SURG PATHOL, V41, P414, DOI 10.1097/PAS.0000000000000810; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Lee J, 2016, CLIN ONCOL-UK, V28, pE35, DOI 10.1016/j.clon.2016.01.009; Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lefebvre J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.377; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Li YQ, 2015, ONCOTARGET, V6, P13309, DOI 10.18632/oncotarget.3751; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; LONGATI P, 1994, ONCOGENE, V9, P49; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Ma PC, 2003, CANCER RES, V63, P6272; Mahjoubi L, 2016, INVEST NEW DRUG, V34, P397, DOI 10.1007/s10637-016-0332-0; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mendenhall MA, 2015, J THORAC ONCOL, V10, pE33, DOI 10.1097/JTO.0000000000000491; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Montagne R, 2017, ONCOTARGET, V8, P11268, DOI 10.18632/oncotarget.14499; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; Nakayama M, 2013, CYTOKINE, V62, P446, DOI 10.1016/j.cyto.2013.04.006; Noonan SA, 2016, J THORAC ONCOL, V11, P1293, DOI 10.1016/j.jtho.2016.04.033; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Park S, 2012, HISTOL HISTOPATHOL, V27, P197, DOI 10.14670/HH-27.197; Park S, 2015, LUNG CANCER, V90, P381, DOI 10.1016/j.lungcan.2015.10.022; Park WS, 1999, CANCER RES, V59, P307; Pelosi G, 2016, J THORAC ONCOL, V11, P718, DOI 10.1016/j.jtho.2016.01.009; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Project, 2016, NAT MED, V22, P1314; Pyo JS, 2016, J GASTRIC CANCER, V16, P141, DOI 10.5230/jgc.2016.16.3.141; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Raghav K, 2016, ONCOTARGET, V7, P54627, DOI 10.18632/oncotarget.10559; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Scagliotti G, 2015, J CLIN ONCOL, V33, P2667, DOI 10.1200/JCO.2014.60.7317; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schildhaus HU, 2015, CLIN CANCER RES, V21, P907, DOI 10.1158/1078-0432.CCR-14-0450; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmitz K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120079; Schuller AG, 2015, CLIN CANCER RES, V21, P2811, DOI 10.1158/1078-0432.CCR-14-2685; Shea M, 2016, J THORAC ONCOL, V11, pE81, DOI 10.1016/j.jtho.2016.01.017; Shieh JM, 2013, INT J MED SCI, V10, P988, DOI 10.7150/ijms.5944; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tanaka A, 2012, LUNG CANCER, V75, P89, DOI 10.1016/j.lungcan.2011.06.004; Tiedt R, 2011, CANCER RES, V71, P5255, DOI 10.1158/0008-5472.CAN-10-4433; Togashi Y, 2015, LUNG CANCER, V90, P590, DOI 10.1016/j.lungcan.2015.10.020; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Tran TN, 2016, CLIN LUNG CANCER, V17, pe31; Trusolino L, 2016, CANCER DISCOV, V6, P1306, DOI 10.1158/2159-8290.CD-16-1181; Tsuta K, 2012, J THORAC ONCOL, V7, P331, DOI 10.1097/JTO.0b013e318241655f; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Tyner JW, 2010, CANCER RES, V70, P6233, DOI 10.1158/0008-5472.CAN-10-0429; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Veenstra C, 2016, ONCOTARGET, V7, P37145, DOI 10.18632/oncotarget.9268; Vieira T, 2014, LUNG CANCER, V85, P276, DOI 10.1016/j.lungcan.2014.06.004; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2013, HEPATOLOGY, V58, P706, DOI 10.1002/hep.26402; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Waqar SN, 2015, J THORAC ONCOL, V10, pE29, DOI 10.1097/JTO.0000000000000478; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wen PY, 2011, NEURO-ONCOLOGY, V13, P437, DOI 10.1093/neuonc/noq198; Xie Q, 2012, P NATL ACAD SCI USA, V109, P570, DOI 10.1073/pnas.1119059109; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Yin XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143468; Zhang Y, 2016, J THORAC ONCOL, V11, pE59, DOI 10.1016/j.jtho.2015.12.102; Zhang Y, 2013, CLIN CANCER RES, V19, P1433, DOI 10.1158/1078-0432.CCR-12-2832; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	150	30	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3200	3215		10.1038/s41388-018-0185-4	http://dx.doi.org/10.1038/s41388-018-0185-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551767				2022-12-28	WOS:000435526600002
J	Wen, JF; Wang, Y; Gao, C; Zhang, GX; You, Q; Zhang, WM; Zhang, ZH; Wang, SL; Peng, GY; Shen, LZ				Wen, Jianfei; Wang, Yao; Gao, Cheng; Zhang, Guoxin; You, Qiang; Zhang, Weiming; Zhang, Zhihong; Wang, Shoulin; Peng, Guangyong; Shen, Lizong			Helicobacter pylori infection promotes Aquaporin 3 expression via the ROS-HIF-1 alpha-AQP3-ROS loop in stomach mucosa: a potential novel mechanism for cancer pathogenesis	ONCOGENE			English	Article							GASTRIC-CANCER; CELLS; INFLAMMATION; HIF-1-ALPHA; MIGRATION; STRESS; ROS	Helicobacter pylori (H. pylori) is the major stomach carcinogen, but the molecular mechanism responsible for the pathogenesis of cancer development mediated by H. pylori infection is still unclear. Aquaporin 3 (AQP3), overexpressed in gastric carcinoma, has a crucial role in gastric carcinogenesis and progression. However, the triggers and precise regulations for AQP3 upregulation during gastric carcinogens also remain unknown. Here we report that H. pylori infection-mediated carcinogenesis may be mechanistically depended on the upregulation of AQP3 expression via reactive oxygen species (ROS) pathway activation in the stomach. The retrospective analyses of clinical samples from patients with gastric carcinoma and other different stages of gastric diseases indicated that AQP3 expression was positively associated with gastric mucosal disease progression and H. pylori infection status as well. Furthermore, H. pylori infection significantly upregulated AQP3 and HIF-1 alpha expression and increased ROS amount in human gastric epithelial AGS and GES-1 cells. Blockage of ROS with inhibitors, NAC and DPI, markedly decreased the expression of AQP3 and HIF-1 alpha in both AGS and GES-1 cells simultaneously. Furthermore, the increased AQP3 in cells was mechanistically due to the transcriptional regulation by HIF-1 alpha. In addition, H. pylori infection exerted production of proinflammatory cytokines IL-6, IL-8, and TNF depending on AQP3 level. Importantly, these in vitro novel findings were further investigated in vivo in a mouse H. pylori infectious model. Our current studies identify the mechanistic link between H. pylori infection and AQP3 upregulation in the pathogenesis of gastric carcinoma, which involves the activation of the ROS-HIF-1 alpha axis and the exacerbated ROS-HIF1 alpha-AQP3-ROS loop.	[Wen, Jianfei; Wang, Yao; Gao, Cheng; Shen, Lizong] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Guoxin] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing 210029, Jiangsu, Peoples R China; [You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Geriatr, Nanjing 210003, Jiangsu, Peoples R China; [Zhang, Weiming; Zhang, Zhihong] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China; [Wang, Shoulin] Nanjing Med Univ, Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Peng, Guangyong] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Saint Louis University	Shen, LZ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Jiangsu, Peoples R China.	shenlz@njmu.edu.cn	CHENG, GAO/AAH-4004-2021	CHENG, GAO/0000-0001-5549-1327	National Natural Science Foundation of China [81272711]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Key Medical Talents Program of Jiangsu Province [ZDRCA2016014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Key Medical Talents Program of Jiangsu Province	This project was partially supported by the National Natural Science Foundation of China (Grant No. 81272711 to LS, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801 to LS), and the Key Medical Talents Program of Jiangsu Province (ZDRCA2016014 to LS).	Alzahrani S, 2014, WORLD J GASTROENTERO, V20, P12767, DOI 10.3748/wjg.v20.i36.12767; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Backert S, 2016, HELICOBACTER, V21, P19, DOI 10.1111/hel.12335; Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012; Bhattacharyya A, 2010, AM J PHYSIOL-GASTR L, V299, pG1177, DOI 10.1152/ajpgi.00372.2010; Bienert GP, 2014, BBA-GEN SUBJECTS, V1840, P1596, DOI 10.1016/j.bbagen.2013.09.017; Chen J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-38; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Dong Xinhong, 2016, Zhonghua Yi Xue Za Zhi, V96, P265, DOI 10.3760/cma.j.issn.0376-2491.2016.04.007; Dong XQ, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.87; Fichtner-Feigl S, 2015, TRENDS IMMUNOL, V36, P451, DOI 10.1016/j.it.2015.06.007; Gajewski A, 2016, ACTA BIOCHIM POL, V63, P145, DOI 10.18388/abp.2015_1122; Gobert AP, 2017, FREE RADICAL BIO MED, V105, P16, DOI 10.1016/j.freeradbiomed.2016.09.024; Gobert AP, 2017, CURR TOP MICROBIOL, V400, P27, DOI 10.1007/978-3-319-50520-6_2; Grandjean G, 2016, CANCER RES, V76, P4259, DOI 10.1158/0008-5472.CAN-16-0401; Handa O, 2010, INFLAMM RES, V59, P997, DOI 10.1007/s00011-010-0245-x; Hartung ML, 2015, CELL REP, V13, P70, DOI 10.1016/j.celrep.2015.08.074; Huang YM, 2010, CANCER BIOL THER, V9, P1000, DOI 10.4161/cbt.9.12.11705; Kang MJ, 2014, HELICOBACTER, V19, P476, DOI 10.1111/hel.12169; Koeppel M, 2015, CELL REP, V11, P1703, DOI 10.1016/j.celrep.2015.05.030; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li X, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu024; Li YN, 2014, TOXICOL LETT, V224, P165, DOI 10.1016/j.toxlet.2013.10.029; Miller EW, 2010, P NATL ACAD SCI USA, V107, P15681, DOI 10.1073/pnas.1005776107; Nakamura J, 2010, INT J CANCER, V127, P1158, DOI 10.1002/ijc.25129; Nam SY, 2011, BRIT J CANCER, V104, P166, DOI 10.1038/sj.bjc.6606020; Nizet V, 2009, NAT REV IMMUNOL, V9, P609, DOI 10.1038/nri2607; Nookaew I, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-41; Park JH, 2003, CLIN CANCER RES, V9, P433; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Satooka H, 2016, MOL CELL BIOL, V36, P1206, DOI 10.1128/MCB.00971-15; Shen LZ, 2010, BIOMED PHARMACOTHER, V64, P313, DOI 10.1016/j.biopha.2009.12.003; Shida M, 2016, INT J ONCOL, V48, P1379, DOI 10.3892/ijo.2016.3359; Shimizu T, 2017, CURR TOP MICROBIOL, V400, P305, DOI 10.1007/978-3-319-50520-6_13; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Thiagarajah JR, 2017, P NATL ACAD SCI USA, V114, P568, DOI 10.1073/pnas.1612921114; Thompson PA, 2015, CARCINOGENESIS, V36, pS232, DOI 10.1093/carcin/bgv038; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wan XK, 2016, HELICOBACTER, V21, P554, DOI 10.1111/hel.12311; Wang G, 2012, PLOS ONE, V7; Wang JP, 2012, CANCER LETT, V319, P109, DOI 10.1016/j.canlet.2011.12.040; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046; Zhao HJ, 2015, ONCOTARGET, V6, P38926, DOI 10.18632/oncotarget.5370; Zhou YC, 2016, ONCOTARGET, V7, P16529, DOI 10.18632/oncotarget.7664	47	34	35	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3549	3561		10.1038/s41388-018-0208-1	http://dx.doi.org/10.1038/s41388-018-0208-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563612				2022-12-28	WOS:000436412500006
J	Bao, LL; You, B; Shi, S; Shan, Y; Zhang, QC; Yue, HJ; Zhang, J; Zhang, W; Shi, YW; Liu, YF; Wang, X; Liu, D; You, YW				Bao, Lili; You, Bo; Shi, Si; Shan, Ying; Zhang, Qicheng; Yue, Huijun; Zhang, Jie; Zhang, Wei; Shi, Yunwei; Liu, Yifei; Wang, Xin; Liu, Dong; You, Yiwen			Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; EXPRESSION; CANCER; MICRORNAS; CHEMOTHERAPY; OVEREXPRESSION; RADIOTHERAPY; METAANALYSIS; VESICLES; GROWTH	Benefiting from more precise imaging and radiotherapy, patients with locoregionally nasopharyngeal carcinoma (NPC) have a significantly higher survival rate. Nonetheless, distant metastasis is still the predominant mode of failure. Advances in cancer research have highlighted that pathological angiogenesis is necessary for tumor metastasis by offering oxygen, nutrients, or cell metastatic conduits. MicroRNAs (miRNAs), a class of small noncoding RNAs, are increasingly implicated in modulation of angiogenesis in physiological and pathological conditions. Currently, we detected that miR-23a was highly enriched in NPC tissues at the metastatic or premetastatic stage, and its levels in NPC were associated with microvessel density. Subsequently, we proved that alteration of miR-23a expression modulated the growth, migration, and tube formation of HUVECs in vitro and affected the blood vessel outgrowth in the zebrafish model. Considering the possibility that extracellular miR-23a was horizontally transferred from CNE2 cells to HUVECs, we analyzed miR-23a encapsulated in exosomes, showing that overexpression of exosomal miR-23a in NPC promoted angiogenesis both in vitro and in vivo. Moreover, we provided evidences that miR-23a regulated angiogenesis by directly targeting testis-specific gene antigen (TSGA10). Taken together, our findings revealed that metastasis-associated miR-23a from NPC-derived exosomes plays an important role in mediating angiogenesis by targeting TSGA10.	[Bao, Lili; You, Bo; Shi, Si; Shan, Ying; Zhang, Qicheng; Yue, Huijun; Zhang, Jie; Zhang, Wei; You, Yiwen] Nantong Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China; [Shi, Yunwei; Wang, Xin; Liu, Dong] Nantong Univ, Coinnovat Ctr Neuroregenerat, Jiangsu Key Lab Neuroregenerat, Qixiu Rd 19, Nantong 226001, Peoples R China; [Liu, Yifei] Nantong Univ, Dept Pathol, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China	Nantong University; Nantong University; Nantong University	You, YW (corresponding author), Nantong Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China.; Liu, D (corresponding author), Nantong Univ, Coinnovat Ctr Neuroregenerat, Jiangsu Key Lab Neuroregenerat, Qixiu Rd 19, Nantong 226001, Peoples R China.	liudongtom@gmail.com; docyouyiwen@163.com	Liu, Dong/O-1271-2013	Liu, Dong/0000-0002-2764-6544	National Natural Science Foundation of China [81672682, 81602385]; Provincial Natural Science Foundation of Jiangsu, China [SBK2015022581]; innovative research project for postgraduate students of Jiangsu province [SJLX15_0645]; innovative research project for Nantong University postgraduate students [YKC15093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Provincial Natural Science Foundation of Jiangsu, China(National Natural Science Foundation of China (NSFC)); innovative research project for postgraduate students of Jiangsu province; innovative research project for Nantong University postgraduate students	This work was supported by grants from the National Natural Science Foundation of China (No. 81672682 to YY, and No. 81602385 to BY), the Provincial Natural Science Foundation of Jiangsu, China (No. SBK2015022581 to YY), the innovative research project for postgraduate students of Jiangsu province (No. SJLX15_0645 to LB), and the innovative research project for Nantong University postgraduate students (No. YKC15093 to LB).	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180; Bao LL, 2016, TUMOR BIOL, V37, P15043, DOI 10.1007/s13277-016-5400-8; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chan ATC, 2010, ANN ONCOL, V21, P308, DOI 10.1093/annonc/mdq277; Demircioglu F, 2016, CURR OPIN CELL BIOL, V42, P121, DOI 10.1016/j.ceb.2016.07.008; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graner MW, 2009, FASEB J, V23, P1541, DOI 10.1096/fj.08-122184; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Hatzl S, 2016, CANCER RES, V76, P3644, DOI 10.1158/0008-5472.CAN-15-3049; Honegger A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004712; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain Rakesh K, 2005, Oncology (Williston Park), V19, P7; Kahlert C, 2014, J BIOL CHEM, V289, P3869, DOI 10.1074/jbc.C113.532267; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li ZL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1044712; Lin JC, 2003, BRIT J CANCER, V88, P187, DOI 10.1038/sj.bjc.6600716; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Mansouri K, 2016, HUM MOL GENET, V25, P233, DOI 10.1093/hmg/ddv461; NIELSEN NH, 1977, ACTA PATH MICRO IM A, V85, P850; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ruan W, 2012, CARDIOVASC RES, V93, P623, DOI 10.1093/cvr/cvr290; Shi S, 2015, J CANCER, V6, P1245, DOI 10.7150/jca.12825; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vickers KC, 2012, CURR OPIN LIPIDOL, V23, P91, DOI 10.1097/MOL.0b013e328350a425; Wang X, 2016, CARDIOVASC RES, V110, P140, DOI 10.1093/cvr/cvw023; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang Z, 2016, BRIT J CANCER, V115, P731, DOI 10.1038/bjc.2016.244; You B, 2016, ONCOTARGET, V7, P12505, DOI 10.18632/oncotarget.7274; Yuan X, 2013, INT J CLIN EXP PATHO, V6, P2651; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuo XL, 2015, INT J CLIN EXP MED, V8, P1265	52	115	122	3	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2873	2889		10.1038/s41388-018-0183-6	http://dx.doi.org/10.1038/s41388-018-0183-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520105	Green Published, hybrid			2022-12-28	WOS:000432929800009
J	Li, ZH; Takenobu, H; Setyawati, AN; Akita, N; Haruta, M; Satoh, S; Shinno, Y; Chikaraishi, K; Mukae, K; Akter, J; Sugino, RP; Nakazawa, A; Nakagawara, A; Aburatani, H; Ohira, M; Kamijo, T				Li, Zhenghao; Takenobu, Hisanori; Setyawati, Amallia Nuggetsiana; Akita, Nobuhiro; Haruta, Masayuki; Satoh, Shunpei; Shinno, Yoshitaka; Chikaraishi, Koji; Mukae, Kyosuke; Akter, Jesmin; Sugino, Ryuichi P.; Nakazawa, Atsuko; Nakagawara, Akira; Aburatani, Hiroyuki; Ohira, Miki; Kamijo, Takehiko			EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; ISLAND METHYLATOR PHENOTYPE; HIGH-RISK NEUROBLASTOMA; PROGNOSTIC-SIGNIFICANCE; FAVORABLE PROGNOSIS; TRK PROTOONCOGENE; H3K27 METHYLATION; PROSTATE-CANCER; FACTOR RECEPTOR; TARGET GENE	The polycomb repressor complex 2 molecule EZH2 is now known to play a role in essential cellular processes, namely, cell fate decisions, cell cycle regulation, senescence, cell differentiation, and cancer development/progression. EZH2 inhibitors have recently been developed; however, their effectiveness and underlying molecular mechanisms in many malignancies have not yet been elucidated in detail. Although the functional role of EZH2 in tumorigenesis in neuroblastoma (NB) has been investigated, mutations of EZH2 have not been reported. A Kaplan-Meier analysis on the event free survival and overall survival of NB patients indicated that the high expression of EZH2 correlated with an unfavorable prognosis. In order to elucidate the functional roles of EZH2 in NB tumorigenesis and its aggressiveness, we knocked down EZH2 in NB cell lines using lentivirus systems. The knockdown of EZH2 significantly induced NB cell differentiation, e.g., neurite extension, and the neuronal differentiation markers, NF68 and GAP43. EZH2 inhibitors also induced NB cell differentiation. We performed a comprehensive transcriptome analysis using Human Gene Expression Microarrays and found that NTRK1 (TrkA) is one of the EZH2-related suppression targets. The depletion of NTRK1 canceled EZH2 knockdown-induced NB cell differentiation. Our integrative methylome, transcriptome, and chromatin immunoprecipitation assays using NB cell lines and clinical samples clarified that the NTRK1 P1 and P2 promoter regions were regulated differently by DNA methylation and EZH2-related histone modifications. The NTRK1 transcript variants 1/2, which were regulated by EZH2-related H3K27me3 modifications at the P1 promoter region, were strongly expressed in favorable, but not unfavorable NB. The depletion and inhibition of EZH2 successfully induced NTRK1 transcripts and functional proteins. Collectively, these results indicate that EZH2 plays important roles in preventing the differentiation of NB cells and also that EZH2-related NTRK1 transcriptional regulation may be the key pathway for NB cell differentiation.	[Li, Zhenghao; Takenobu, Hisanori; Haruta, Masayuki; Satoh, Shunpei; Shinno, Yoshitaka; Chikaraishi, Koji; Mukae, Kyosuke; Akter, Jesmin; Sugino, Ryuichi P.; Ohira, Miki; Kamijo, Takehiko] Saitama Canc Ctr, Res Inst Clin Oncol, Ina, Saitama, Japan; [Li, Zhenghao; Kamijo, Takehiko] Saitama Univ, Lab Tumor Mol Biol, Dept Grad Sch Sci & Engn, Saitama, Saitama, Japan; [Setyawati, Amallia Nuggetsiana; Akita, Nobuhiro] Chiba Canc Ctr, Res Inst, Chiba, Chiba, Japan; [Setyawati, Amallia Nuggetsiana] Diponegoro Univ, Dept Biochem, Fac Med, Kota Semarang, Jawa Tengah, Indonesia; [Akita, Nobuhiro] Nagoya Med Ctr, Dept Pediat, Nagoya, Aichi, Japan; [Chikaraishi, Koji] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Nakazawa, Atsuko] Saitama Childrens Med Ctr, Dept Clin Res, Saitama, Saitama, Japan; [Nakagawara, Akira] Saga Med Ctr KOSEIKAN, Life Sci Res Inst, Saga, Japan; [Aburatani, Hiroyuki] Univ Tokyo, Div Genome Sci, Res Ctr Adv Sci & Technol, Tokyo, Japan	Saitama University; Chiba Cancer Center; Diponegoro University; Nagoya Medical Center; Chiba University; Saitama Children's Medical Center; University of Tokyo	Kamijo, T (corresponding author), Saitama Canc Ctr, Res Inst Clin Oncol, Ina, Saitama, Japan.; Kamijo, T (corresponding author), Saitama Univ, Lab Tumor Mol Biol, Dept Grad Sch Sci & Engn, Saitama, Saitama, Japan.	tkamijo@cancer-c.pref.saitama.jp	Mukae, Kyosuke/K-5181-2019	Mukae, Kyosuke/0000-0001-6411-2990; Akter, Jesmin/0000-0002-4573-1603	Practical Research for Innovative Cancer Control [16ck0106011j0003, 17ck0106332h0001]; Tailor-made Medical Treatment Program from the Japan Agency for Medical Research and Development, AMED [15km0305013h0101]; JSPS KAKENHI [17K19623]; Grants-in-Aid for Scientific Research [17K10131, 16K10051] Funding Source: KAKEN	Practical Research for Innovative Cancer Control; Tailor-made Medical Treatment Program from the Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms. K Sakurai and Ms. N Kawanabe for their technical assistance and Mr. Daniel Mrozek (Medical English Service, Kyoto) for his English editorial assistance. This work was supported in part by Practical Research for Innovative Cancer Control (No. 16ck0106011j0003; No. 17ck0106332h0001) and the Tailor-made Medical Treatment Program (No. 15km0305013h0101) from the Japan Agency for Medical Research and Development, AMED, and JSPS KAKENHI Grant-in-Aid for Challenging Exploratory Research (17K19623).	Abe M, 2005, CANCER RES, V65, P828; Abe M, 2007, CANCER LETT, V247, P253, DOI 10.1016/j.canlet.2006.05.001; Atsuta T, 2001, HYBRIDOMA, V20, P43, DOI 10.1089/027245701300060427; Bate-Eya LT, 2017, EUR J CANCER, V75, P63, DOI 10.1016/j.ejca.2016.12.019; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; Fujimura Y, 2006, DEVELOPMENT, V133, P2371, DOI 10.1242/dev.02405; Haruta M, 2014, CANCER LETT, V348, P167, DOI 10.1016/j.canlet.2014.03.022; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Indo Y, 1997, JPN J HUM GENET, V42, P343, DOI 10.1007/BF02766957; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Kamijo T, 2012, INT J CLIN ONCOL, V17, P190, DOI 10.1007/s10147-012-0415-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; KOGNER P, 1993, CANCER RES, V53, P2044; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Kutmon M, 2016, NUCLEIC ACIDS RES, V44, pD488, DOI 10.1093/nar/gkv1024; Lau DT, 2012, CLIN CANCER RES, V18, P5690, DOI 10.1158/1078-0432.CCR-12-0294; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Niizuma H, 2006, ONCOGENE, V25, P5046, DOI 10.1038/sj.onc.1209515; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Satoh S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32682; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Scaruffi P, 1999, INT J ONCOL, V14, P935; Schramm A, 2015, NAT GENET, V47, P872, DOI 10.1038/ng.3349; Sugawara W, 2007, PEDIATR BLOOD CANCER, V49, P240, DOI 10.1002/pbc.21031; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; de Souza DRV, 2011, PEDIATR BLOOD CANCER, V56, P749, DOI 10.1002/pbc.22823; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604	49	43	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2714	2727		10.1038/s41388-018-0133-3	http://dx.doi.org/10.1038/s41388-018-0133-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29507419	hybrid, Green Published			2022-12-28	WOS:000432545100008
J	Hu, TX; Chong, YT; Qin, HY; Kitamura, E; Chang, CS; Silva, J; Ren, MQ; Cowell, JK				Hu, Tianxiang; Chong, Yating; Qin, Haiyan; Kitamura, Eiko; Chang, Chang-Sheng; Silva, Jeane; Ren, Mingqiang; Cowell, John K.			The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase	ONCOGENE			English	Article							8P11 MYELOPROLIFERATIVE SYNDROME; T-CELL LYMPHOMA; MYELOID-LEUKEMIA; MICRORNAS; CANCER; GENE; ACTIVATION; FGFR1; OVEREXPRESSION; ASSOCIATION	MicroRNAs (miRNAs) have pathogenic roles in the development of a variety of leukemias. Here we identify miRNAs that have important roles in the development of B lymphomas resulting from the expression of the chimeric BCR-FGFR1 kinase. The miR-17/92 cluster was particularly implicated and forced expression resulted in increased cell proliferation, while inhibiting its function using miRNA sponges reduced cell growth and induced apoptosis. Cells treated with the potent BGJ389 FGFR1 inhibitor led to miR-17/92 downregulation, suggesting regulation by FGFR1. Transient luciferase reporter assays and qRT-PCR detection of endogenous miR-17/92 expression in stable transduced cell lines demonstrated that BCR-FGFR1 can regulate miR-17/92 expression. This positive association of miR-17/92 with BCR-FGFR1 was also confirmed in primary mouse SCLL tissues and primary human CLL samples. miR-17/92 promotes cell proliferation and survival by targeting CDKN1A and PTEN in B-lymphoma cell lines and primary tumors. An inverse correlation in expression levels was seen between miR-17/92 and both CDKN1A and PTEN in two cohorts of CLL patients. Finally, in vivo engraftment studies demonstrated that manipulation of miR-17/92 was sufficient to affect BCR-FGFR1-driven leukemogenesis. Overall, our results define miR-17/92 as a downstream effector of FGFR1 in BCR-FGFR1-driven B-cell lymphoblastic leukemia.	[Hu, Tianxiang; Chong, Yating; Qin, Haiyan; Kitamura, Eiko; Chang, Chang-Sheng; Silva, Jeane; Ren, Mingqiang; Cowell, John K.] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA; [Cowell, John K.] Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA	University System of Georgia; Augusta University; Uniformed Services University of the Health Sciences - USA	Cowell, JK (corresponding author), Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA.; Cowell, JK (corresponding author), Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA.	jcowell@augusta.edu	Hu, TianXiang/Q-2099-2019	Hu, TianXiang/0000-0002-5127-9211; Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	National Institutes of Health [CA076167]; NATIONAL CANCER INSTITUTE [R01CA076167] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant CA076167 from the National Institutes of Health.	Agerstam H, 2010, BLOOD, V116, P2103, DOI 10.1182/blood-2009-05-217182; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cowell JK, 2016, BRIT J HAEMATOL, V175, P542, DOI 10.1111/bjh.13877; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Eekels JJM, 2012, GENE THER, V19, P1058, DOI 10.1038/gt.2011.191; Gao J, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/719179; Guasch G, 2004, BLOOD, V103, P309, DOI 10.1182/blood-2003-05-1690; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Jackson CC, 2010, HUM PATHOL, V41, P461, DOI 10.1016/j.humpath.2009.11.003; Jiang X, 2016, CANCER RES, V76, P4470, DOI 10.1158/0008-5472.CAN-15-2949; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kim Kang Ho, 2015, Curr Protoc Mol Biol, V111, DOI 10.1002/0471142727.mb2806s111; Kluiver J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029275; Kumar KR, 2015, AM J CLIN PATHOL, V143, P738, DOI 10.1309/AJCPUD6W1JLQQMNA; Lai NS, 2014, J CLIN NEUROSCI, V21, P755, DOI 10.1016/j.jocn.2013.06.024; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Marcucci G, 2011, BLOOD, V117, P1121, DOI 10.1182/blood-2010-09-191312; Maura F, 2015, LEUKEMIA LYMPHOMA, V56, P3150, DOI 10.3109/10428194.2015.1028051; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mi SL, 2010, P NATL ACAD SCI USA, V107, P3710, DOI 10.1073/pnas.0914900107; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morabito F, 2013, CLIN CANCER RES, V19, P5890, DOI 10.1158/1078-0432.CCR-13-0622; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pan YY, 2014, CURR PHARM DESIGN, V20, P5260, DOI 10.2174/1381612820666140128211724; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Psathas JN, 2013, BLOOD, V122, P4220, DOI 10.1182/blood-2012-12-473090; Qin HY, 2016, HAEMATOLOGICA, V101, pE91, DOI 10.3324/haematol.2015.137695; Ren MQ, 2016, INT J CANCER, V139, P836, DOI 10.1002/ijc.30100; Ren MQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038265; Ren MQ, 2011, CANCER RES, V71, P7312, DOI 10.1158/0008-5472.CAN-11-1109; Ren MQ, 2011, BLOOD, V117, P6837, DOI 10.1182/blood-2010-07-295725; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wu Q, 2016, ONCOTARGET, V7, P49733, DOI 10.18632/oncotarget.10438; Xiao FQ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-195; Xie BY, 2013, BIOINFORMATICS, V29, P638, DOI 10.1093/bioinformatics/btt014; Xu SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7764; Yang ZH, 2013, J BIOL CHEM, V288, P28893, DOI 10.1074/jbc.M113.502682; Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460	50	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1926	1938		10.1038/s41388-017-0091-1	http://dx.doi.org/10.1038/s41388-017-0091-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367757	Green Accepted			2022-12-28	WOS:000429303300009
J	Goreczny, GJ; Forsythe, IJ; Turner, CE				Goreczny, Gregory J.; Forsythe, Ian J.; Turner, Christopher E.			Hic-5 regulates fibrillar adhesion formation to control tumor extracellular matrix remodeling through interaction with tensin1	ONCOGENE			English	Article							FOCAL-ADHESION; BREAST-CANCER; IN-VIVO; PAXILLIN; INTEGRINS; PROTEIN; FIBRONECTIN; BINDING; KINASE; ACTIN	The linearization of the stromal extracellular matrix (ECM) by cancer-associated fibroblasts (CAFs) facilitates tumor cell growth and metastasis. However, the mechanism by which the ECM is remodeled is not fully understood. Hic-5 (TGF beta 1i1), a focal adhesion scaffold protein, has previously been reported to be crucial for stromal ECM deposition and remodeling in vivo. Herein we show that CAFs lacking Hic-5 exhibit a significant reduction in the ability to form fibrillar adhesions, a specialized form of focal adhesion that promote fibronectin fibrillogenesis. Hic-5 was found to promote fibrillar adhesion formation through a newly characterized interaction with tensin1. Furthermore, Src-dependent phosphorylation of Hic-5 facilitated the interaction with tensin1 to prevent beta 1 integrin internalization and trafficking to the lysosome. The interaction between Hic-5 and tensin1 was mechanosensitive, promoting fibrillar adhesion formation and fibronectin fibrillogenesis in a rigidity-dependent fashion. Importantly, this Src-dependent mechanism was conserved in three-dimensional (3D) ECM environments. Immunohistochemistry of tensin1 showed enrichment in CAFs in vivo, which was abrogated upon deletion of Hic-5. Interestingly, elevated Hic-5 expression correlates with reduced distant metastasis-free survival in patients with basal-like, HER2+ and grade 3 tumors. Thus, we have identified Hic-5 as a crucial regulator of ECM remodeling in CAFs by promoting fibrillar adhesion formation through a novel interaction with tensin1.	[Goreczny, Gregory J.; Forsythe, Ian J.; Turner, Christopher E.] SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA.	turnerce@upstate.edu			National Institutes of Health [R01 CA163296, R01 GM047607]; Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE [R01CA163296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank members of the Turner lab for helpful discussions and critical reading of this manuscript and thank Theresa Stowell for performing the qPCR analyses. Financial Support: National Institutes of Health Grant R01 CA163296 and R01 GM047607 to CET and the Carol M Baldwin Breast Cancer Research Fund of CNY awards to CET.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Bottcher RT, 2012, NAT CELL BIOL, V14, P584, DOI 10.1038/ncb2501; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Carraher CL, 2013, J BIOL CHEM, V288, P14805, DOI 10.1074/jbc.M112.435271; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chao WT, 2009, FEBS LETT, V583, P1337, DOI 10.1016/j.febslet.2009.03.037; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; Deakin NO, 2014, J CELL BIOL, V206, P395, DOI 10.1083/jcb.201403039; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Doyle AD, 2016, EXP CELL RES, V343, P60, DOI 10.1016/j.yexcr.2015.10.033; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Georgiadou M, 2017, J CELL BIOL, V216, P1107, DOI 10.1083/jcb.201609066; Goreczny GJ, 2017, ONCOGENE, V36, P2693, DOI 10.1038/onc.2016.422; Hall EH, 2010, MOL CELL PROTEOMICS, V9, P2853, DOI 10.1074/mcp.M110.003665; Kadler KE, 2008, CURR OPIN CELL BIOL, V20, P495, DOI 10.1016/j.ceb.2008.06.008; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kolacna L, 2007, PHYSIOL RES, V56, pS51, DOI 10.33549/physiolres.931302; Legate KR, 2009, J CELL SCI, V122, P187, DOI 10.1242/jcs.041624; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Molkentin JD, 2017, CIRCULATION, V136, P549, DOI 10.1161/CIRCULATIONAHA.116.026238; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pignatelli J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046228; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Provenzano PP, 2011, J CELL SCI, V124, P1195, DOI 10.1242/jcs.067009; Rainero E, 2015, CELL REP, V10, P398, DOI 10.1016/j.celrep.2014.12.037; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Schiller HB, 2013, NAT CELL BIOL, V15, P625, DOI 10.1038/ncb2747; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Stanchi F, 2009, J CELL SCI, V122, P1800, DOI 10.1242/jcs.044602; Stutchbury B, 2017, J CELL SCI, V130, P1612, DOI 10.1242/jcs.195362; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Thomas SM, 1999, J CELL SCI, V112, P181; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Volberg T, 2001, J CELL SCI, V114, P2279; Wormer DB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091815; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhao ZH, 2016, BIOL OPEN, V5, P499, DOI 10.1242/bio.016428	53	25	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1699	1713		10.1038/s41388-017-0074-2	http://dx.doi.org/10.1038/s41388-017-0074-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348458	Green Accepted			2022-12-28	WOS:000428632600002
J	Kato, M; Placencio-Hickok, VR; Madhav, A; Haldar, S; Tripathi, M; Billet, S; Mishra, R; Smith, B; Rohena-Rivera, K; Agarwal, P; Duong, F; Angara, B; Hickok, D; Liu, ZQ; Bhowmick, NA				Kato, Manabu; Placencio-Hickok, Veronica R.; Madhav, Anisha; Haldar, Subhash; Tripathi, Manisha; Billet, Sandrine; Mishra, Rajeev; Smith, Bethany; Rohena-Rivera, Krizia; Agarwal, Priyanka; Duong, Frank; Angara, Bryan; Hickok, David; Liu, Zhenqiu; Bhowmick, Neil A.			Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner	ONCOGENE			English	Article							FRIZZLED-RELATED PROTEIN-1; PROSTATE-CANCER; TGF-BETA; TUMOR PROGRESSION; ENDOGLIN CD105; UP-REGULATION; CELL; INHIBITION; IDENTIFICATION; MORPHOGENESIS	Heterogeneous prostatic carcinoma-associated fibroblasts (CAF) contribute to tumor progression and resistance to androgen signaling deprivation therapy (ADT). CAF subjected to extended passaging, compared to low passage CAF, were found to lose tumor expansion potential and heterogeneity. Cell surface endoglin (CD105), known to be expressed on proliferative endothelia and mesenchymal stem cells, was diminished in high passage CAF. RNA-sequencing revealed SFRP1 to be distinctly expressed by tumor-inductive CAF, which was further demonstrated to occur in a CD105-dependent manner. Moreover, ADT resulted in further expansion of the CD105(+) fibroblastic population and downstream SFRP1 in 3-dimensional cultures and patient-derived xenograft tissues. In patients, CD105(+) fibroblasts were found to circumscribe epithelia with neuroendocrine differentiation. CAF-derived SFRP1, driven by CD105 signaling, was necessary and sufficient to induce prostate cancer neuroendocrine differentiation in a paracrine manner. A partially humanized CD105 neutralizing antibody, TRC105, inhibited fibroblastic SFRP1 expression and epithelial neuroendocrine differentiation. In a novel synthetic lethality paradigm, we found that simultaneously targeting the epithelia and its microenvironment with ADT and TRC105, respectively, reduced castrate-resistant tumor progression, in a model where either ADT or TRC105 alone had little effect.	[Kato, Manabu] Mie Univ Hosp, Nephrourol Surg & Androl, Tsu, Mie, Japan; [Placencio-Hickok, Veronica R.; Madhav, Anisha; Haldar, Subhash; Tripathi, Manisha; Billet, Sandrine; Mishra, Rajeev; Smith, Bethany; Rohena-Rivera, Krizia; Agarwal, Priyanka; Duong, Frank; Angara, Bryan; Hickok, David; Liu, Zhenqiu; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	Mie University; Cedars Sinai Medical Center	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Smith, Bethany/GYT-9168-2022; Bhowmick, Neil/AAA-7302-2019	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; Haldar, Subhash/0000-0002-1230-1770	National Cancer Institute [CA108646]; Veterans Affairs [BX001040]; NATIONAL CANCER INSTITUTE [P01CA098912, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007770] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001040] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Charles Theurer at Tracon Pharmaceuticals, Inc. for the TRC105 and M1043 neutralizing antibodies. The RNA-sequencing and histology slide scanning was performed at the Cedars-Sinai Genomics Core and Microscopy Core, respectively. This work was supported by grants from the National Cancer Institute (CA108646) and Veterans Affairs (BX001040) to NAB.	Aggarwal RR, 2017, ONCOLOGY-NY, V31, P467; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Banerjee J, 2014, ONCOGENE, V33, P4924, DOI 10.1038/onc.2013.431; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Brennen WN, 2013, ONCOTARGET, V4, P106, DOI 10.18632/oncotarget.805; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dayyani F, 2013, PROSTATE, V73, P979, DOI 10.1002/pros.22645; Melo FDE, 2013, EMBO REP, V14, P686, DOI 10.1038/embor.2013.92; DeGraff DJ, 2009, AM J TRANSL RES, V1, P115; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Esteve P, 2011, DEVELOPMENT, V138, P4179, DOI 10.1242/dev.065839; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008-5472.CAN-10-3142; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; GLEAVE M, 1991, CANCER RES, V51, P3753; Hayward SW, 2001, CANCER RES, V61, P8135; Igarashi Atsushi, 2016, Nihon Hinyokika Gakkai Zasshi, V107, P155, DOI 10.5980/jpnjurol.107.155; Joesting MS, 2008, DEV BIOL, V317, P161, DOI 10.1016/j.ydbio.2008.02.021; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; Kanayama M, 2017, PROSTATE, V77, P1489, DOI 10.1002/pros.23425; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Laskaratos FM, 2017, CANCER-AM CANCER SOC, V123, P4770, DOI 10.1002/cncr.31079; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Miyata Y, 2015, PROSTATE, V75, P84, DOI 10.1002/pros.22894; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Olumi AF, 1999, CANCER RES, V59, P5002; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Romero D, 2011, CANCER RES, V71, P3482, DOI 10.1158/0008-5472.CAN-10-2665; Siamakpour-Reihani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020412; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Sun F, 2016, CARCINOGENESIS, V37, P701, DOI 10.1093/carcin/bgw044; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; True LD, 2010, MODERN PATHOL, V23, P1346, DOI 10.1038/modpathol.2010.122; Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901; Zhao HJ, 2009, PROSTATE, V69, P991, DOI 10.1002/pros.20946; Zheng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118276; Zhu YT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv129; Zikusoka MN, 2005, CANCER-AM CANCER SOC, V104, P2292, DOI 10.1002/cncr.21451	50	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					716	730		10.1038/s41388-018-0461-3	http://dx.doi.org/10.1038/s41388-018-0461-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177832	Green Accepted, Green Submitted			2022-12-28	WOS:000457300300008
J	Liu, L; Yang, Y; Liu, SH; Tao, TY; Cai, JC; Wu, JH; Guan, HY; Zhu, X; He, ZJ; Li, J; Song, EW; Zeng, MS; Li, MF				Liu, Lei; Yang, Yi; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Guan, Hongyu; Zhu, Xun; He, Zhenjian; Li, Jun; Song, Erwei; Zeng, Musheng; Li, Mengfeng			EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; CREB-BINDING PROTEIN; STEM-CELLS; DOWN-REGULATION; DRUG-RESISTANT; T790M MUTATION; COLON-CANCER; WNT; INHIBITOR	Aberrant activation of EGFR represents a common event in non-small cell lung carcinoma (NSCLC) and activates various downstream signaling pathways. While EGFR activation of beta-catenin signaling was previously reported, the mediating mechanism remains unclear. Our current study found that EGFR activation in NSCLC cells releases SHC-binging protein 1 (SHCBP1) from SHC adaptor protein 1 (SHC1), which subsequently translocates into the nucleus and directly promotes the transactivating activity of beta-catenin, consequently resulting in development of NSCLC cell stemness and malignant progression. Furthermore, SHCBP1 promotes beta-catenin activity through enhancing the CBP/beta-catenin interaction, and most interestingly, a candidate drug that blocks the CBP/beta-catenin binding effectively abrogates the aforementioned biological effects of SHCBP1. Clinically, SHCBP1 level in NSCLC tumors was found to inversely correlate with patient survival. Together, our study establishes a novel convergence between EGFR and beta-catenin pathways and highlights a potential significance of SHCBP1 as a prognostic biomarker and a therapeutic target.	[Liu, Lei; Yang, Yi; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Zhu, Xun; He, Zhenjian; Li, Jun; Li, Mengfeng] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China; [Liu, Lei; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Yang, Yi] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Diabet Ctr, Guangzhou, Guangdong, Peoples R China; [Zhu, Xun] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China; [He, Zhenjian] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China; [Song, Erwei] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China; [Zeng, Musheng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Yang, Y; Li, MF (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Yang, Y (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China.	yangyi23@mail.sysu.edu.cn; limf@mail.sysu.edu.cn	LIU, LEI/AAL-7491-2021; LIU, LEI/AAY-2012-2020	LIU, LEI/0000-0003-4898-5665; zeng, musheng/0000-0003-3509-5591	National Key Research and Development Project of China [2017YFA0505600, 2017YFA0106300]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621004]; Guangzhou science and technology plan [201803010039, 201804010057]; National Natural Science Foundation of China [81572837, 81330058]; Guangdong Natural Science Foundation [2014A030313036]; Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306023]; Guangdong Te Zhi program youth science and technology talent of project [2015TQ01R281]; Fundamental Research Funds for the Central Universities [17ykpy06]	National Key Research and Development Project of China; Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangdong Natural Science Funds for Distinguished Young Scholar; Guangdong Te Zhi program youth science and technology talent of project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by The National Key Research and Development Project of China (No. 2017YFA0505600,2017YFA0106300); The Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621004); Guangzhou science and technology plan (No. 201803010039, 201804010057); The National Natural Science Foundation of China (No. 81572837, 81330058); Guangdong Natural Science Foundation (No. 2014A030313036); Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2014A030306023); Guangdong Te Zhi program youth science and technology talent of project (No. 2015TQ01R281); the Fundamental Research Funds for the Central Universities (No. 17ykpy06).SS	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Arensman MD, 2014, MOL CANCER THER, V13, P2303, DOI 10.1158/1535-7163.MCT-13-1005; Berns A, 2005, CELL, V121, P811, DOI 10.1016/j.cell.2005.06.004; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Casas-Selves M, 2012, CANCER RES, V72, P4154, DOI 10.1158/0008-5472.CAN-11-2848; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen JF, 2012, GENE DEV, V26, P803, DOI 10.1101/gad.187641.112; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; He KJ, 2014, INT J CANCER, V134, P43, DOI 10.1002/ijc.28341; Hwang KE, 2014, EXP CELL RES, V323, P288, DOI 10.1016/j.yexcr.2014.02.026; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Le Pechoux C, 2011, ONCOLOGIST, V16, P672, DOI 10.1634/theoncologist.2010-0150; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lian CJ, 2016, J PINEAL RES, V61, P317, DOI 10.1111/jpi.12349; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Ma L, 2013, FEBS J, V280, P2027, DOI 10.1111/febs.12226; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Montembault E, 2010, J CELL BIOL, V191, P1351, DOI 10.1083/jcb.201007060; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Park M, 2015, J PROTEOME RES, V14, P3007, DOI 10.1021/acs.jproteome.5b00423; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sato S, 2005, GASTROENTEROLOGY, V129, P1225, DOI 10.1053/j.gastro.2005.07.025; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Sequist LV, 2007, ONCOLOGIST, V12, P90, DOI 10.1634/theoncologist.12-1-90; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209; Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; To KKW, 2017, LUNG CANCER, V103, P58, DOI 10.1016/j.lungcan.2016.11.019; Togashi Y, 2015, J THORAC ONCOL, V10, P93, DOI 10.1097/JTO.0000000000000353; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang Y, BIOCH BIOPHYS RES CO, V450, P899; Yang Y, 2014, INT J CANCER, V135, P1531, DOI 10.1002/ijc.28799; Zhang XR, 2013, J BIOL CHEM, V288, P32229, DOI 10.1074/jbc.M113.463554; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308	60	32	34	4	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					747	764		10.1038/s41388-018-0473-z	http://dx.doi.org/10.1038/s41388-018-0473-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177836	Green Published, hybrid			2022-12-28	WOS:000457300300010
J	Ferro, R; Adamska, A; Lattanzio, R; Mavrommati, I; Edling, CE; Arifin, SA; Fyffe, CA; Sala, G; Sacchetto, L; Chiorino, G; De Laurenzi, V; Piantelli, M; Sansom, OJ; Maffucci, T; Falasca, M				Ferro, R.; Adamska, A.; Lattanzio, R.; Mavrommati, I; Edling, C. E.; Arifin, S. A.; Fyffe, C. A.; Sala, G.; Sacchetto, L.; Chiorino, G.; De Laurenzi, V; Piantelli, M.; Sansom, O. J.; Maffucci, T.; Falasca, M.			GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine	ONCOGENE			English	Article							CANNABINOID RECEPTOR GPR55; LYSOPHOSPHATIDYLINOSITOL; RESISTANCE; PROGRESSION; EXPRESSION; MIGRATION; KRAS	The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRAS(WT/G12D)/TP53(WT/)(R172H)/Pdx1-Cre(+/+) (KPC) mouse model of PDAC significantly prolonged survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), survived nearly three times longer compared to mice treated with vehicle or GEM alone. Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage-dependent and independent growth, cell cycle progression, activation of mitogen-activated protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the tumour suppressor p53 regulates GPR55 protein expression through modulation of the microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD and GEM, both currently approved for medical use, might be tested in clinical trials as a novel promising treatment to improve PDAC patients' outcome.	[Ferro, R.; Mavrommati, I; Edling, C. E.; Arifin, S. A.; Fyffe, C. A.; Maffucci, T.; Falasca, M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cell Biol & Cutaneous Res, 4 Newark St, London E1 2AT, England; [Adamska, A.; De Laurenzi, V; Falasca, M.] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Metab Signalling Grp, Perth, WA 6102, Australia; [Lattanzio, R.; Sala, G.; De Laurenzi, V; Piantelli, M.] Univ G dAnnunzio, Dipartimento Sci Med Orali & Biotecnol, CeSI MeT, Ctr Studi Invecchiamento, I-66100 Chieti, Italy; [Sacchetto, L.; Chiorino, G.] Fdn Edo & Elvo Tempia, Canc Genom Lab, Biella, Italy; [Sansom, O. J.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland	University of London; Queen Mary University London; Curtin University; G d'Annunzio University of Chieti-Pescara; Beatson Institute	Falasca, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cell Biol & Cutaneous Res, 4 Newark St, London E1 2AT, England.; Falasca, M (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Metab Signalling Grp, Perth, WA 6102, Australia.	marco.falasca@curtin.edu.au	Lattanzio, Rossano/K-1927-2018; Sala, Gianluca/C-2056-2017; Chiorino, Giovanna/K-5037-2016; Ferro, Riccardo/AAD-3882-2019; Falasca, Marco/S-4020-2016	Lattanzio, Rossano/0000-0001-9803-4476; Sala, Gianluca/0000-0002-4494-915X; Chiorino, Giovanna/0000-0002-9502-6400; Ferro, Riccardo/0000-0001-6532-4856; SACCHETTO, LIDIA/0000-0001-6590-325X; Sansom, Owen J./0000-0001-9540-3010; Falasca, Marco/0000-0002-9801-7235	Pancreatic Cancer Research Fund; Avner Pancreatic Cancer Foundation; Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS); Ministero Sanita Finalizzata 2011/2012; AIRC [IG 15196.c]	Pancreatic Cancer Research Fund; Avner Pancreatic Cancer Foundation; Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS); Ministero Sanita Finalizzata 2011/2012; AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Pancreatic Cancer Research Fund and Avner Pancreatic Cancer Foundation (grants to MF). RF, CAF, CEE were supported by Pancreatic Cancer Research Fund (grants to MF). AA is supported by Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS). GS was supported by Ministero Sanita Finalizzata 2011/2012. VDL was supported by AIRC IG 15196.c. We thank Prof David A. Tuveson and Prof David Baker for KC/KPC and GPR55<SUP>-/-</SUP> mice respectively; Dr Massimo Broggini for p53 mutants constructs; Prof Hemant Kocher for HPDE cells; GW Pharmaceuticals for providing the cannabidiol used in this study; the Pathology Core facility of the Blizard Institute for helping with IHC. AA, VDL and MF also acknowledge the infrastructure and staff support provided by CHIRI, School of Pharmacy & Biomedical Sciences and by Faculty of Health Sciences, Curtin University.	Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Andradas C, 2016, ONCOTARGET, V7, P47565, DOI 10.18632/oncotarget.10206; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1995, ONCOGENE, V10, P2113; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Falasca M, 2016, BBA-REV CANCER, V1865, P123, DOI 10.1016/j.bbcan.2016.01.001; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hofmann NA, 2015, BRIT J PHARMACOL, V172, P4107, DOI 10.1111/bph.13196; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Kargl J, 2016, BRIT J PHARMACOL, V173, P142, DOI 10.1111/bph.13345; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Paul RK, 2014, BIOCHEM PHARMACOL, V87, P547, DOI 10.1016/j.bcp.2013.11.020; Peixoto RD, 2017, AM J CLIN ONCOL-CANC, V40, P507, DOI 10.1097/COC.0000000000000193; Perez-Gomez E, 2013, ONCOGENE, V32, P2534, DOI 10.1038/onc.2012.278; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Romero-Zerbo SY, 2011, J ENDOCRINOL, V211, P177, DOI 10.1530/JOE-11-0166; Ross RA, 2011, TRENDS PHARMACOL SCI, V32, P265, DOI 10.1016/j.tips.2011.01.005; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; SCARPA A, 1993, AM J PATHOL, V142, P1534; Sisay S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076907; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Vaccaro V, 2011, NEW ENGL J MED, V365, P768, DOI 10.1056/NEJMc1107627; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5; Zheng CN, 2013, J INT MED RES, V41, P300, DOI 10.1177/0300060512474128	36	52	55	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6368	6382		10.1038/s41388-018-0390-1	http://dx.doi.org/10.1038/s41388-018-0390-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30061636	Green Accepted, Green Submitted			2022-12-28	WOS:000452384400007
J	Du, WW; Yang, WN; Li, XM; Awan, FM; Yang, ZG; Fang, L; Lyu, JJ; Li, FY; Peng, C; Krylov, SN; Xie, YZ; Zhang, Y; He, CY; Wu, N; Zhang, C; Sdiri, M; Dong, J; Ma, J; Gao, CQ; Hibberd, S; Yang, BB				Du, William W.; Yang, Weining; Li, Xiangmin; Awan, Faryal Mehwish; Yang, Zhenguo; Fang, Ling; Lyu, Juanjuan; Li, Feiya; Peng, Chun; Krylov, Sergey N.; Xie, Yizhen; Zhang, Yaou; He, Chengyan; Wu, Nan; Zhang, Chao; Sdiri, Mouna; Dong, Jun; Ma, Jian; Gao, Chunqi; Hibberd, Steven; Yang, Burton B.			A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy	ONCOGENE			English	Article							MATURE MIR-17-5P; SEQUENCING DATA; BINDING DOMAIN; NONCODING RNAS; FOXO3 ACTIVITY; GROWTH-FACTOR; TUMOR-GROWTH; HNRNP D0; P53; INHIBITION	Circular RNAs are a large group of noncoding RNAs that are widely expressed in mammalian cells. Genome-wide analyses have revealed abundant and evolutionarily conserved circular RNAs across species, which suggest specific physiological roles of these species. Using a microarray approach, we detected increased expression of a circular RNA circ-Dnmt1 in eight breast cancer cell lines and in patients with breast carcinoma. Silencing circ-Dnmt1 inhibited cell proliferation and survival. Ectopic circ-Dnmt1 increased the proliferative and survival capacities of breast cancer cells by stimulating cellular autophagy. We found that circ-Dnmt1-mediated autophagy was essential in inhibiting cellular senescence and increasing tumor xenograft growth. We further found that ectopically expressed circ-Dnmt1 could interact with both p53 and AUF1, promoting the nuclear translocation of both proteins. Nuclear translocation of p53 induced cellular autophagy while AUF1 nuclear translocation reduced Dnmt1 mRNA instability, resulting in increased Dnmt1 translation. From here, functional Dnmt1 could then translocate into the nucleus, inhibiting p53 transcription. Computational algorithms revealed that both p53 and AUF1 could bind to different regions of circ-Dnmt1 RNA. Our results showed that the highly expressed circular RNA circ-Dnmt1 could bind to and regulate oncogenic proteins in breast cancer cells. Thus circ-Dnmt1 appears to be an oncogenic circular RNA with potential for further preclinical research.	[Du, William W.; Yang, Weining; Li, Xiangmin; Awan, Faryal Mehwish; Yang, Zhenguo; Fang, Ling; Lyu, Juanjuan; Li, Feiya; Wu, Nan; Zhang, Chao; Sdiri, Mouna; Dong, Jun; Ma, Jian; Gao, Chunqi; Hibberd, Steven; Yang, Burton B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Li, Xiangmin; Xie, Yizhen] Guangdong Inst Microbiol, State Key Lab Appl Microbiol Southern China, Guangdong Prov Key Lab Microbial Culture Collect, Guangzhou 510070, Guangdong, Peoples R China; [Awan, Faryal Mehwish] NUST, ASAB, H-12, Islamabad, Pakistan; [Fang, Ling; He, Chengyan] Jilin Univ, China Japan Union Hosp, Jilin, Jilin, Peoples R China; [Peng, Chun] York Univ, Dept Biol, Toronto, ON, Canada; [Krylov, Sergey N.] York Univ, Dept Chem, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Krylov, Sergey N.] York Univ, Ctr Res Biomol Interact, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Xie, Yizhen] Yuewei Edible Fungi Technol Co Ltd, Guangzhou, Guangdong, Peoples R China; [Zhang, Yaou] Tsinghua Univ, Div Life Sci, Key Lab Hlth Sci & Technol, Grad Sch Shenzhen, Shenzhen 518055, Peoples R China; [Yang, Burton B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; National University of Sciences & Technology - Pakistan; Jilin University; York University - Canada; York University - Canada; York University - Canada; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; University of Toronto	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada.; Yang, BB (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	byang@sri.utoronto.ca	Gao, Chun/AAP-2262-2020; ma, jian/AAV-9930-2021	Awan, Faryal Mehwish/0000-0002-8146-8929; Yang, Burton B/0000-0002-2892-7209	Canadian Institutes of Health Research [PJT-153105]; National Natural Science Foundation of Guangdong [2017A030310088]; Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone [2017-L181]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone	This work was supported by grants from Canadian Institutes of Health Research (PJT-153105), National Natural Science Foundation of Guangdong (2017A030310088), and Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone (2017-L181).	Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bai Y, 2018, J NEUROSCI, V38, P32, DOI 10.1523/JNEUROSCI.1348-17.2017; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Chen JM, 2013, PROTEIN SCI, V22, P510, DOI 10.1002/pro.2230; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Du WW, 2015, MOL THER, V23, P1222, DOI 10.1038/mt.2015.64; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Georgia S, 2013, GENE DEV, V27, P372, DOI 10.1101/gad.207001.112; Gratacos FM, 2010, WIRES RNA, V1, P457, DOI 10.1002/wrna.26; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883; Huang RR, 2017, AUTOPHAGY, V13, P1722, DOI 10.1080/15548627.2017.1356975; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kastritis PL, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0835; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; Klein CJ, 2011, NAT GENET, V43, P595, DOI 10.1038/ng.830; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu YC, 2016, NUCLEIC ACIDS RES, V44, pD209, DOI 10.1093/nar/gkv940; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; Panda AC, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx297; Pietal MJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-333; Rutnam ZJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3914; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Shan SW, 2013, J CELL SCI, V126, P1517, DOI 10.1242/jcs.122895; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Torrisani J, 2007, MOL CELL BIOL, V27, P395, DOI 10.1128/MCB.01236-06; Tuszynska I, 2015, NUCLEIC ACIDS RES, V43, pW425, DOI 10.1093/nar/gkv493; Washietl S, 2012, WIRES RNA, V3, P759, DOI 10.1002/wrna.1134; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoshida Y, 2004, ONCOGENE, V23, P4371, DOI 10.1038/sj.onc.1207583; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng LL, 2016, NUCLEIC ACIDS RES, V44, pD196, DOI 10.1093/nar/gkv1273	48	163	171	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5829	5842		10.1038/s41388-018-0369-y	http://dx.doi.org/10.1038/s41388-018-0369-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973691				2022-12-28	WOS:000448943100002
J	Lee, S; Axelsen, TV; Jesse, N; Pedersen, SF; Vahi, P; Boedtkjer, E				Lee, Soojung; Axelsen, Trine, V; Jesse, Nicolai; Pedersen, Stine F.; Vahi, Pernille; Boedtkjer, Ebbe			Na+,HCO3--cotransporter NBCn1 (Slc4a7) accelerates ErbB2-induced breast cancer development and tumor growth in mice	ONCOGENE			English	Article							INTRACELLULAR PH TRANSIENTS; EXPRESSION; CELLS; NHE1; MIGRATION; NA+; EPITHELIUM; EVOLUTION; ARTERIES; HYPOXIA	Metabolic acid production challenges cellular pH homeostasis in solid cancer tissue, and mechanisms of net acid extrusion represent promising new targets for breast cancer therapy. Here, we used genetically engineered mice to investigate the contribution of the Na+,HCO3--cotransporter NBCn1 (Slc4a7) to intracellular acid-base regulation in ErbB2-induced breast cancer tissue and the consequences of NBCn1 knockout for breast tumor development and growth. We demonstrate an approximately 2-fold increase of NBCn1 protein abundance in ErbB2-induced breast cancer tissue compared to normal breast tissue despite a 4-fold decrease in the NBCn1 mRNA level. In congruence, we show that NBCn1 facilitates net acid extrusion and elevates steady-state intracellular pH in breast cancer tissue. Disruption of NBCn1 expression delayed ErbB2-induced breast carcinogenesis from a median tumor-free survival of 9.5 months in wild-type mice to 12 months in NBCn1-knockout mice and decelerated the tumor growth rate by approximately 1/3. Glycolytic metabolism-evaluated based on the interstitial concentrations of lactate and glucose measured in microdialysates-was increased in breast cancer tissue compared to normal breast tissue, but was unaffected by NBCn1 knockout. Disruption of NBCn1 expression inhibited cell proliferation-evaluated by staining for the proliferative marker Ki67-particularly in central tumor areas with predicted increase in acid loading from glycolytic metabolism. In conclusion, NBCn1 regulates intracellular pH in ErbB2-induced breast cancer tissue by providing a pathway for cellular uptake of HCO3-, which can neutralize metabolic acidic waste products. Disrupting NBCn1 expression delays ErbB2-induced breast cancer development, inhibits cancer cell proliferation, and decelerates tumor growth.	[Lee, Soojung; Axelsen, Trine, V; Jesse, Nicolai; Boedtkjer, Ebbe] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Pedersen, Stine F.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Vahi, Pernille] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark	Aarhus University; University of Copenhagen; Aarhus University	Boedtkjer, E (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.	eb@biomed.au.dk	Pedersen, Stine Falsig/O-1133-2019; Boedtkjer, Ebbe/O-8449-2019	Pedersen, Stine Falsig/0000-0002-3044-7714; Boedtkjer, Ebbe/0000-0002-5078-9279	Danish Cancer Society [R42-A4273]; Novo Nordisk Foundation [NNF13OC0007393, NNF15OC0017344, NNF16OC0023194]; Danish Council for Independent Research [7025-00050B]	Danish Cancer Society(Danish Cancer Society); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Council for Independent Research(Det Frie Forskningsrad (DFF))	This work was supported by the Danish Cancer Society (grant no. R42-A4273 to EB), the Novo Nordisk Foundation (grant no. NNF13OC0007393 and NNF15OC0017344 to EB and grant no. NNF16OC0023194 to SFP), and the Danish Council for Independent Research (grant no. 7025-00050B to EB).	Aalkjaer C, 2014, COMPR PHYSIOL, V4, P1605, DOI 10.1002/cphy.c130005; Amith SR, 2017, SEMIN CANCER BIOL, V43, P35, DOI 10.1016/j.semcancer.2017.01.004; Andersen AP, 2018, INT J CANCER, V142, P2529, DOI 10.1002/ijc.31276; Boedtkjer E, 2006, CIRC RES, V98, P515, DOI 10.1161/01.RES.0000204750.04971.76; Boedtkjer E, 2012, CURR PHARM DESIGN, V18, P1345, DOI 10.2174/138161212799504830; Boedtkjer E, 2008, AM J PHYSIOL-CELL PH, V294, pC591, DOI 10.1152/ajpcell.00281.2007; Boedtkjer E, 2016, CARDIOVASC RES, V111, P227, DOI 10.1093/cvr/cvw079; Boedtkjer E, 2013, INT J CANCER, V132, P1288, DOI 10.1002/ijc.27782; Boedtkjer E, 2011, CIRCULATION, V124, P1819, DOI 10.1161/CIRCULATIONAHA.110.015974; Bonde L, 2017, ACTA PHYSIOL, V219, P227, DOI 10.1111/apha.12685; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Bouzinova EV, 2005, AM J PHYSIOL-CELL PH, V289, pC1448, DOI 10.1152/ajpcell.00313.2005; Brockton NT, 2012, ORAL ONCOL, V48, P615, DOI 10.1016/j.oraloncology.2012.01.018; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Counillon L, 2016, BBA-MOL CELL RES, V1863, P2465, DOI 10.1016/j.bbamcr.2016.02.018; Damkier HH, 2006, AM J PHYSIOL-HEART C, V290, pH172, DOI 10.1152/ajpheart.00713.2005; Flinck M, 2018, ACTA PHYSIOL, V223, DOI 10.1111/apha.13068; Froelunde AS, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0952-8; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerweck LE, 1996, CANCER RES, V56, P1194; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gorbatenko A, 2016, BIOCHEM J, V473, P4027, DOI 10.1042/BCJ20160054; Gorbatenko A, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00130; Gorbatenko A, 2014, FASEB J, V28, P350, DOI 10.1096/fj.13-233288; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Larsen AM, 2012, CHEMMEDCHEM, V7, P1808, DOI 10.1002/cmdc.201200335; Lauritzen G, 2010, EXP CELL RES, V316, P2538, DOI 10.1016/j.yexcr.2010.06.005; Lee S, 2016, ONCOGENE, V35, P2112, DOI 10.1038/onc.2015.273; Lee S, 2015, PFLUG ARCH EUR J PHY, V467, P367, DOI 10.1007/s00424-014-1524-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McIntyre A, 2016, CANCER RES, V76, P3744, DOI 10.1158/0008-5472.CAN-15-1862; Morais-Santos F, 2015, ONCOTARGET, V6, P19177, DOI 10.18632/oncotarget.3910; Parakh S, 2017, CANCER TREAT REV, V59, P1, DOI 10.1016/j.ctrv.2017.06.005; Parks SK, 2015, J CELL PHYSIOL, V230, P1954, DOI 10.1002/jcp.24930; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedersen SF, 2006, PFLUG ARCH EUR J PHY, V452, P249, DOI 10.1007/s00424-006-0044-y; Rasmussen JK, 2018, J CEREBR BLOOD F MET, V38, P492, DOI 10.1177/0271678X17699224; Rodriguez-Enriquez S, 2008, J CELL PHYSIOL, V216, P189, DOI 10.1002/jcp.21392; Romero Q, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-341; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Stransky L, 2016, PHYSIOL REV, V96, P1071, DOI 10.1152/physrev.00035.2015; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VAUPEL P, 1989, CANCER RES, V49, P6449	48	22	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5569	5584		10.1038/s41388-018-0353-6	http://dx.doi.org/10.1038/s41388-018-0353-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29907770				2022-12-28	WOS:000446991200007
J	Polycarpou-Schwarz, M; Gross, M; Mestdagh, P; Schott, J; Grund, SE; Hildenbrand, C; Rom, J; Aulmann, S; Sinn, HP; Vandesompele, J; Diederichs, S				Polycarpou-Schwarz, Maria; Gross, Matthias; Mestdagh, Pieter; Schott, Johanna; Grund, Stefanie E.; Hildenbrand, Catherina; Rom, Joachim; Aulmann, Sebastian; Sinn, Hans-Peter; Vandesompele, Jo; Diederichs, Sven			The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation	ONCOGENE			English	Article							RIBOSOME PROFILING REVEALS; MEVALONATE PATHWAY; CHOLESTEROL-SYNTHESIS; MOLECULAR PORTRAITS; RNA; ACTIN; PEPTIDES; TRANSLATION; EXPRESSION; DISCOVERY	Breast cancer is a leading cause of cancer-related death in women. Small open reading frame (sORF)-encoded proteins or microproteins constitute a new class of molecules often transcribed from presumed long non-coding RNA transcripts (lncRNAs). The translation of some of these sORFs has been confirmed, but their cellular function and importance remains largely unknown. Here, we report the identification and characterization of a novel microprotein of 10 kDa, which we named Cancer-Associated Small Integral Membrane Open reading frame 1 (CASIMO1). CASIMO1 RNA is overexpressed predominantly in hormone receptor-positive breast tumors. Its knockdown leads to decreased proliferation in multiple breast cancer cell lines. Its loss disturbs the organization of the actin cytoskeleton, leads to inhibition of cell motility, and causes a G(0)/G(1) cell cycle arrest. The proliferation phenotype upon overexpression is observed only with CASIMO1 protein expression, but not with a non-translatable mutant attributing the effects to the sORF-derived protein rather than a lncRNA function. CASIMO1 microprotein interacts with squalene epoxidase (SQLE), a key enzyme in cholesterol synthesis and a known oncogene in breast cancer. Overexpression of CASIMO1 leads to SQLE protein accumulation without affecting its RNA levels and increased lipid droplet clustering, while knockdown of CASIMO1 decreased SQLE protein abundance and ERK phosphorylation downstream of SQLE. Importantly, SQLE knockdown mimicked the CASIMO1 knockdown phenotype and in turn SQLE overexpression fully rescued the effect of CASIMO1 knockdown. These findings establish CASIMO1 as the first functional microprotein that plays a role in carcinogenesis and is implicated in the cell lipid homeostasis.z	[Polycarpou-Schwarz, Maria; Gross, Matthias; Grund, Stefanie E.; Hildenbrand, Catherina; Diederichs, Sven] German Canc Res Ctr, Div RNA Biol & Canc, Heidelberg, Germany; [Polycarpou-Schwarz, Maria; Gross, Matthias; Aulmann, Sebastian; Sinn, Hans-Peter; Diederichs, Sven] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Mestdagh, Pieter; Vandesompele, Jo] Ghent Univ Belgium, Ctr Med Genet, Ghent, Belgium; [Mestdagh, Pieter; Vandesompele, Jo] Ghent Univ Belgium, CRIG, Ghent, Belgium; [Schott, Johanna] Heidelberg Univ, Div Biochem 1, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, Mannheim, Germany; [Schott, Johanna] Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Mannheim, Germany; [Rom, Joachim] Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany; [Diederichs, Sven] Univ Freiburg, Div Canc Res, Dept Thorac Surg, Med Ctr, Freiburg, Germany; [Diederichs, Sven] Univ Freiburg, Fac Med, Freiburg, Germany; [Diederichs, Sven] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ghent University; Ghent University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Diederichs, S (corresponding author), German Canc Res Ctr, Div RNA Biol & Canc, Heidelberg, Germany.; Diederichs, S (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.; Diederichs, S (corresponding author), Univ Freiburg, Div Canc Res, Dept Thorac Surg, Med Ctr, Freiburg, Germany.; Diederichs, S (corresponding author), Univ Freiburg, Fac Med, Freiburg, Germany.; Diederichs, S (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany.	s.diederichs@dkfz.de	Sinn, Hans-Peter/C-5661-2008; Vandesompele, Jo/W-3411-2018; Diederichs, Sven/J-6237-2012	Sinn, Hans-Peter/0000-0003-2836-6699; Vandesompele, Jo/0000-0001-6274-0184; Gross, Matthias/0000-0003-0449-1591; Diederichs, Sven/0000-0001-7901-4752; Polycarpou-Schwarz, Maria/0000-0002-9125-6460; Mestdagh, Pieter/0000-0001-7821-9684	German Research Foundation [DFG Di 1421/7-1]; RNA@DKFZ Cross Program Topic	German Research Foundation(German Research Foundation (DFG)); RNA@DKFZ Cross Program Topic	We thank Drs. K. Boulay and A. Roth for helpful discussions and suggestions and for critical reading of the manuscript, S. Wiemann for helpful discussions, L. Chatel-Chaix (University of Heidelberg) and R. Pepperkok (EMBL Heidelberg) for antibodies and suggestions, V. Benes, T. Ivacevic, and S. Schmidt (EMBL Heidelberg, Genome Core Facility) for support with microarray performance and the DKFZ Light Microscopy and Flow Cytometry Core Facilities and the ZMBH Flow Cytometry & FACS Core Facility (University of Heidelberg) for technical support. Research in the Diederichs lab is supported by the German Research Foundation (DFG Di 1421/7-1) and the RNA@DKFZ Cross Program Topic. This work is part of the Ph.D. thesis of M.P.-S.	Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009; Andrews SJ, 2014, NAT REV GENET, V15, P193, DOI 10.1038/nrg3520; Aspden JL, 2014, ELIFE, V3, DOI 10.7554/eLife.03528; Basrai MA, 1997, GENOME RES, V7, P768, DOI 10.1101/gr.7.8.768; Bazzini AA, 2014, EMBO J, V33, P981, DOI 10.1002/embj.201488411; Bhattacharyya S, 2009, CLIN EXP METASTAS, V26, P535, DOI 10.1007/s10585-009-9253-z; Bi P, 2017, SCIENCE, V356, P323, DOI 10.1126/science.aam9361; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Brown DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep19435; Cabrera-Quio LE, 2016, RNA BIOL, V13, P1051, DOI 10.1080/15476286.2016.1218589; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Chu Q, 2017, BIOCHEMISTRY-US, V56, P3299, DOI 10.1021/acs.biochem.7b00265; Couso JP, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0765-3; Couso JP, 2017, NAT REV MOL CELL BIO, V18, P575, DOI 10.1038/nrm.2017.58; D'Lima NG, 2017, NAT CHEM BIOL, V13, P174, DOI [10.1038/NCHEMBIO.2249, 10.1038/nchembio.2249]; Dinger ME, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000176; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gill S, 2011, CELL METAB, V13, P260, DOI 10.1016/j.cmet.2011.01.015; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Gutschner T, 2011, GENOME RES, V21, P1944, DOI 10.1101/gr.122358.111; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannus M, 2014, NUCLEIC ACIDS RES, V42, P8049, DOI 10.1093/nar/gku480; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Helms MW, 2008, BRIT J CANCER, V99, P774, DOI 10.1038/sj.bjc.6604556; Housman G, 2016, BBA-GENE REGUL MECH, V1859, P31, DOI 10.1016/j.bbagrm.2015.07.017; Inder KL, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012245; Ingolia NT, 2014, CELL REP, V8, P1365, DOI 10.1016/j.celrep.2014.07.045; Ingolia NT, 2011, CELL, V147, P789, DOI 10.1016/j.cell.2011.10.002; Ji Z, 2015, ELIFE, V4, DOI 10.7554/eLife.08890; Kastenmayer JP, 2006, GENOME RES, V16, P365, DOI 10.1101/gr.4355406; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kondo T, 2010, SCIENCE, V329, P336, DOI 10.1126/science.1188158; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009; Lee KG, 2007, CELL CYCLE, V6, P1487; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Lluch-Senar M, 2015, MOL SYST BIOL, V11; Ma J, 2014, J PROTEOME RES, V13, P1757, DOI 10.1021/pr401280w; Mackowiak SD, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0742-x; Magny EG, 2013, SCIENCE, V341, P1116, DOI 10.1126/science.1238802; Mestdagh P, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr646; Miettinen TP, 2015, CELL REP, V13, P2610, DOI 10.1016/j.celrep.2015.11.045; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Nelson BR, 2016, SCIENCE, V351, P271, DOI 10.1126/science.aad4076; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1985, BIOCHEM J, V230, P765, DOI 10.1042/bj2300765; Saghatelianr A, 2015, NAT CHEM BIOL, V11, P909, DOI 10.1038/nchembio.1964; Schmid I., 2001, CURR PROTOC CYTOM; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030; Simigdala N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0713-5; Skibinski A, 2015, ONCOGENE, V34, P5309, DOI 10.1038/onc.2014.475; Slavoff SA, 2014, J BIOL CHEM, V289, P10950, DOI 10.1074/jbc.C113.533968; Slavoff SA, 2013, NAT CHEM BIOL, V9, P59, DOI [10.1038/NCHEMBIO.1120, 10.1038/nchembio.1120]; Sleator RD, 2010, GENE, V461, P1, DOI 10.1016/j.gene.2010.04.008; Staudt AC, 2011, EMBO REP, V12, P35, DOI 10.1038/embor.2010.196; Stevenson J, 2014, BIOCHEM J, V461, P435, DOI 10.1042/BJ20131404; Sui ZH, 2015, TUMOR BIOL, V36, P6173, DOI 10.1007/s13277-015-3301-x; Ta MT, 2012, FEBS J, V279, P4231, DOI 10.1111/febs.12015; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; Wadler CS, 2007, P NATL ACAD SCI USA, V104, P20454, DOI 10.1073/pnas.0708102104; Zhang HY, 2014, THORAC CANCER, V5, P275, DOI 10.1111/1759-7714.12087; Zhang Q, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15664	69	74	78	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4750	4768		10.1038/s41388-018-0281-5	http://dx.doi.org/10.1038/s41388-018-0281-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765154				2022-12-28	WOS:000442514400009
J	Kota, S; Hou, SR; Guerrant, W; Madoux, F; Troutman, S; Fernandez-Vega, V; Alekseeva, N; Madala, N; Scampavia, L; Kissil, J; Spicer, TP				Kota, Smitha; Hou, Shurong; Guerrant, William; Madoux, Franck; Troutman, Scott; Fernandez-Vega, Virneliz; Alekseeva, Nina; Madala, Neeharika; Scampavia, Louis; Kissil, Joseph; Spicer, Timothy P.			A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype	ONCOGENE			English	Article							HUMAN CANCER-CELLS; SYNTHETIC LETHALITY; K-RAS; DRUG DISCOVERY; SMALL-MOLECULE; IN-VITRO; CULTURE; 3D; 3RD-DIMENSION; SPHEROIDS	The RAS proteins are the most frequently mutated oncogenes in cancer, with highest frequency found in pancreatic, lung, and colon tumors. Moreover, the activity of RAS is required for the proliferation and/or survival of these tumor cells and thus represents a high-value target for therapeutic development. Direct targeting of RAS has proven challenging for multiple reasons stemming from the biology of the protein, the complexity of downstream effector pathways and upstream regulatory networks. Thus, significant efforts have been directed at identifying downstream targets on which RAS is dependent. These efforts have proven challenging, in part due to confounding factors such as reliance on two-dimensional adherent monolayer cell cultures that inadequately recapitulate the physiologic context to which cells are exposed in vivo. To overcome these issues, we implemented a high-throughput screening (HTS) approach using a spheroid-based 3-dimensional culture format, thought to more closely reflect conditions experienced by cells in vivo. Using isogenic cell pairs, differing in the status of KRAS, we identified Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRas(G12v) allele. Significantly, the identification of Proscillaridin A was facilitated by the 3D screening platform and would not have been discovered employing standard 2D culturing methods.	[Kota, Smitha; Hou, Shurong; Guerrant, William; Madoux, Franck; Troutman, Scott; Fernandez-Vega, Virneliz; Alekseeva, Nina; Madala, Neeharika; Scampavia, Louis; Kissil, Joseph; Spicer, Timothy P.] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA; [Madoux, Franck] Amgen Inc, Thousand Oaks, CA 91320 USA	Scripps Research Institute; Amgen	Kissil, J; Spicer, TP (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	jkissil@scripps.edu; spicert@scripps.edu			National Cancer Institute of the National Institutes of Health [R33CA206949, CA124495]; NATIONAL CANCER INSTITUTE [R01CA124495, R33CA206949] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pierre Baillargeon and Lina Deluca at Scripps for their help with compound management. This work was supported in part by the National Cancer Institute of the National Institutes of Health under Award Number R33CA206949 (TPS) and CA124495 (JK).	Alevizopoulos K, 2014, CURR DRUG TARGETS, V15, P988, DOI 10.2174/1389450115666140908125025; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Babij C, 2011, CANCER RES, V71, P5818, DOI 10.1158/0008-5472.CAN-11-0778; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bittker JA., 2010, SCREEN RAS SELECTIVE; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Delebinski CI, 2015, CELL PROLIFERAT, V48, P600, DOI 10.1111/cpr.12208; Denicolai E, 2014, ONCOTARGET, V5, P10934, DOI 10.18632/oncotarget.2541; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Felth J, 2009, J NAT PROD, V72, P1969, DOI 10.1021/np900210m; Fennema E, 2013, TRENDS BIOTECHNOL, V31, P108, DOI 10.1016/j.tibtech.2012.12.003; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Guo W, 2008, CANCER RES, V68, P7403, DOI 10.1158/0008-5472.CAN-08-1449; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Kim N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29721; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Luo TP, 2012, P NATL ACAD SCI USA, V109, P2860, DOI 10.1073/pnas.1120589109; Madoux F, 2017, SLAS DISCOV, V22, P516, DOI 10.1177/2472555216686308; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Powell K, 2017, SCIENCE, V356, P96, DOI 10.1126/science.356.6333.96; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramaiahgari SC, 2014, ARCH TOXICOL, V88, P1083, DOI 10.1007/s00204-014-1215-9; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaw AT, 2011, P NATL ACAD SCI USA, V108, P8773, DOI 10.1073/pnas.1105941108; Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Tung YC, 2011, ANALYST, V136, P473, DOI 10.1039/c0an00609b; Verjans ET, 2018, J CELL PHYSIOL, V233, P2993, DOI 10.1002/jcp.26052; Vicent S, 2010, J CLIN INVEST, V120, P3940, DOI 10.1172/JCI44165; Wang Y, 2010, ONCOGENE, V29, P4658, DOI 10.1038/onc.2010.218; Weiwer M, 2012, ACS MED CHEM LETT, V3, P1034, DOI 10.1021/ml300246r; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zanoni M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19103; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	39	17	17	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4372	4384		10.1038/s41388-018-0257-5	http://dx.doi.org/10.1038/s41388-018-0257-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743592	Green Accepted			2022-12-28	WOS:000441144300003
J	Pure, E; Blomberg, R				Pure, Ellen; Blomberg, Rachel			Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics	ONCOGENE			English	Review							DIPEPTIDYL-PEPTIDASE-IV; PHASE-II TRIAL; FAP-TARGETING IMMUNOLIPOSOMES; MEMBRANE-ASSOCIATED PROTEASES; MESENCHYMAL STEM-CELLS; ALPHA-BASED VACCINES; STROMAL CELLS; TUMOR MICROENVIRONMENT; ANTITUMOR IMMUNITY; SERINE-PROTEASE	Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma. It has also been proposed as a molecular target of cancer therapies, and, especially in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments. Yet despite this growing field of research, our knowledge of FAP's basic biology and functional roles in various cancers has lagged behind its use as a tumor-stromal marker. In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target. We highlight outstanding questions in the field, the answers to which could shape preclinical and clinical studies of FAP.	[Pure, Ellen; Blomberg, Rachel] Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Pure, E (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.	epure@upenn.edu			NCI NIH HHS [R21 CA169741, R01 CA180070, R01 CA141144] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA169741, R01CA180070, R01CA141144] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann AM, 2016, MOL METAB, V5, P233, DOI 10.1016/j.molmet.2016.01.002; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Akinboye ES, 2016, PROSTATE, V76, P703, DOI 10.1002/pros.23162; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Arnold JN, 2014, CANCER IMMUNOL RES, V2, P121, DOI 10.1158/2326-6066.CIR-13-0150; Augoff K, 2014, ONCOL REP, V31, P2820, DOI 10.3892/or.2014.3162; Avery D, 2018, MATRIX BIOL, V67, P90, DOI 10.1016/j.matbio.2017.12.003; Bainbridge TW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12900-8; Baird SK, 2015, APOPTOSIS, V20, P1483, DOI 10.1007/s10495-015-1166-5; Baird SK, 2015, CLIN EXP METASTAS, V32, P507, DOI 10.1007/s10585-015-9723-4; Brennen WN, 2014, PROSTATE, V74, P1308, DOI 10.1002/pros.22847; Brunker P, 2016, MOL CANCER THER, V15, P946, DOI 10.1158/1535-7163.MCT-15-0647; Busek P, 2016, TUMOR BIOL, V37, P13961, DOI 10.1007/s13277-016-5274-9; Busek P, 2016, PANCREATOLOGY, V16, P829, DOI 10.1016/j.pan.2016.06.001; Busek P, 2015, HISTOCHEM CELL BIOL, V143, P497, DOI 10.1007/s00418-014-1292-0; Chen LL, 2017, BIOCHEM BIOPH RES CO, V487, P8, DOI 10.1016/j.bbrc.2017.03.039; Chen MH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14421; Christiansen VJ, 2007, ARCH BIOCHEM BIOPHYS, V457, P177, DOI 10.1016/j.abb.2006.11.006; Chung KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088772; Coppage AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151269; Cui YH, 2016, ONCOL REP, V35, P2952, DOI 10.3892/or.2016.4637; Deng LJ, 2017, J MED CHEM, V60, P5320, DOI 10.1021/acs.jmedchem.6b01755; Ding LX, 2014, ONCOL LETT, V7, P699, DOI 10.3892/ol.2014.1788; Du H, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0147-z; Dunshee DR, 2016, J BIOL CHEM, V291, P5986, DOI 10.1074/jbc.M115.710582; Dvorakova P, 2017, J MED CHEM, V60, P8385, DOI 10.1021/acs.jmedchem.7b00767; Eager RM, 2009, CLIN ONCOL-UK, V21, P464, DOI 10.1016/j.clon.2009.04.007; Eager RM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-263; Errarte P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169105; Fan MH, 2016, J BIOL CHEM, V291, P8070, DOI 10.1074/jbc.M115.701433; Fang JX, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.7; Fang JX, 2016, INT J CANCER, V138, P1013, DOI 10.1002/ijc.29831; Feng XW, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S139039; Ghersi G, 2006, CANCER RES, V66, P4652, DOI 10.1158/0008-5472.CAN-05-1245; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; Gong C, 2014, CANCER RES, V74, P4341, DOI 10.1158/0008-5472.CAN-14-0125; Gong QY, 2016, ANAL CHEM, V88, P8309, DOI 10.1021/acs.analchem.6b02231; Grindel BJ, 2014, MATRIX BIOL, V36, P64, DOI 10.1016/j.matbio.2014.04.005; Guo J, 2015, INT J CLIN EXP PATHO, V8, P10014; Ha Q, 2014, NANOSCALE, V6, P8318, DOI 10.1039/c4nr01415d; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Hamson EJ, 2014, PROTEOM CLIN APPL, V8, P454, DOI 10.1002/prca.201300095; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Hu M, 2017, OMI AJ INTEGR BIOL, V2, P38; Huang T, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.3; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Jackson KW, 2015, NEOPLASIA, V17, P43, DOI 10.1016/j.neo.2014.11.002; Jacob M, 2012, CURR MOL MED, V12, P1220, DOI 10.2174/156652412803833607; Jansen K, 2014, J MED CHEM, V57, P3053, DOI 10.1021/jm500031w; Ji TJ, 2016, ANGEW CHEM INT EDIT, V55, P1050, DOI 10.1002/anie.201506262; Jia BN, 2016, ENDOCRINOLOGY, V157, P3023, DOI 10.1210/en.2016-1035; Jia J, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-16; Jiang GM, 2015, ONCOTARGET, V6, P25932, DOI 10.18632/oncotarget.4577; Jung YY, 2015, TUMOR BIOL, V36, P8685, DOI 10.1007/s13277-015-3594-9; Kahounova Z, 2018, CYTOM PART A, V93A, P941, DOI 10.1002/cyto.a.23101; Kakarla S, 2013, MOL THER, V21, P1611, DOI 10.1038/mt.2013.110; Kawase T, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0340-0; Ke MR, 2017, EUR J MED CHEM, V127, P200, DOI 10.1016/j.ejmech.2016.12.056; Keane FM, 2011, FEBS J, V278, P1316, DOI 10.1111/j.1742-4658.2011.08051.x; Kim GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105094; Kim MG, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw186; Knopf JD, 2015, BBA-MOL CELL RES, V1853, P2515, DOI 10.1016/j.bbamcr.2015.07.013; Koczorowska MM, 2016, MOL ONCOL, V10, P40, DOI 10.1016/j.molonc.2015.08.001; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Krepela E, 2017, BIOCHEM BIOPH RES CO, V491, P126, DOI 10.1016/j.bbrc.2017.07.061; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuo SW, 2012, BIOMATERIALS, V33, P5013, DOI 10.1016/j.biomaterials.2012.03.080; Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805; Lee KN, 2006, BLOOD, V107, P1397, DOI 10.1182/blood-2005-08-3452; Lessard J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122065; Li MM, 2016, MOL MED REP, V13, P2476, DOI 10.3892/mmr.2016.4868; Liao YH, 2017, ONCOTARGET, V8, P30050, DOI 10.18632/oncotarget.16274; Liu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116683; Lo A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92232; Lo A, 2015, CANCER RES, V75, P2800, DOI 10.1158/0008-5472.CAN-14-3041; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lopez JI, 2016, HUM PATHOL, V54, P100, DOI 10.1016/j.humpath.2016.03.009; Luo N, 2014, TRANSL RES, V163, P232, DOI 10.1016/j.trsl.2013.11.008; Luo Y, 2017, CYTOKINE GROWTH FACT; Lv BB, 2016, CANCER GENOM PROTEOM, V13, P201; Mazur A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150287; Meng MY, 2016, TUMOR BIOL, V37, P10317, DOI 10.1007/s13277-016-4825-4; Mhawech-Fauceglia P, 2015, CANCER MICROENVIRON, V8, P23, DOI 10.1007/s12307-014-0153-7; Miao ZF, 2014, TUMOR BIOL, V35, P6105, DOI 10.1007/s13277-014-1808-1; MONSKY WL, 1994, CANCER RES, V54, P5702; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Osborne B, 2014, BBA-PROTEINS PROTEOM, V1844, P1248, DOI 10.1016/j.bbapap.2014.03.015; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Park CK, 2016, BREAST CANCER RES TR, V159, P55, DOI 10.1007/s10549-016-3929-2; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Park JI, 2016, TRANSL ONCOL, V9, P79, DOI 10.1016/j.tranon.2015.12.001; Park SY, 2015, BREAST CANCER RES TR, V149, P727, DOI 10.1007/s10549-015-3291-9; Park YJ, 2016, CANCER LETT, V370, P222, DOI 10.1016/j.canlet.2015.10.021; Patsouras D, 2015, MOL MED REP, V11, P4585, DOI 10.3892/mmr.2015.3259; Pearl ML, 2015, GYNECOL ONCOL, V137, P229, DOI 10.1016/j.ygyno.2015.03.002; Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002; Qi SJ, 2009, ACS APPL MATER INTER, V1, P30, DOI 10.1021/am800027d; Rabenhold M, 2015, J CONTROL RELEASE, V201, P56, DOI 10.1016/j.jconrel.2015.01.022; RETTIG WJ, 1993, CANCER RES, V53, P3327; Rettig WJ, 1986, CANC RES, V46; Roberts EW, 2013, J EXP MED, V210, P1137, DOI 10.1084/jem.20122344; Ruan P, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171027; Ruger R, 2014, J CONTROL RELEASE, V186, P1, DOI 10.1016/j.jconrel.2014.04.050; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Sorrentino C, 2016, ONCOTARGET, V7, P64274, DOI 10.18632/oncotarget.11729; Tansi FL, 2017, ACTA BIOMATER, V54, P281, DOI 10.1016/j.actbio.2017.03.033; Tansi FL, 2016, DATA BRIEF, V9, P143, DOI 10.1016/j.dib.2016.08.058; Tansi FL, 2016, BIOMATERIALS, V88, P70, DOI 10.1016/j.biomaterials.2016.02.028; Tchou J, 2013, HUM PATHOL, V44, P2549, DOI 10.1016/j.humpath.2013.06.016; Teichgraber V, 2015, ADV MED SCI-POLAND, V60, P264, DOI 10.1016/j.advms.2015.04.006; Tulley S, 2014, J BIOL CHEM, V289, P15280, DOI 10.1074/jbc.M114.568501; Tyulkina DV, 2016, DOKL BIOCHEM BIOPHYS, V470, P319, DOI 10.1134/S1607672916050033; Verdelli C, 2015, ENDOCR-RELAT CANCER, V22, P87, DOI 10.1530/ERC-14-0161; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang LL, 2017, ONCOTARGET, V8, P26323, DOI 10.18632/oncotarget.15461; Waster P, 2017, BRIT J CANCER, V117, P535, DOI 10.1038/bjc.2017.182; Wei MT, 2017, ONCOTARGET, V8, P42262, DOI 10.18632/oncotarget.15040; Wen XY, 2017, ONCOL RES, V25, P629, DOI 10.3727/096504016X14768383625385; Werner S, 2016, CLIN CANCER RES, V22, P1725, DOI 10.1158/1078-0432.CCR-15-1268; Wolczyk D, 2016, CELL ONCOL, V39, P353, DOI 10.1007/s13402-016-0280-x; Wong PF, 2016, PEPTIDES, V75, P80, DOI 10.1016/j.peptides.2015.11.004; Wonganu B, 2016, BBA-BIOMEMBRANES, V1858, P1876, DOI 10.1016/j.bbamem.2016.05.001; Wu XF, 2017, ONCOTARGET, V8, P52614, DOI 10.18632/oncotarget.17538; Xia Q, 2017, IMMUNOPHARM IMMUNOT, V39, P37, DOI 10.1080/08923973.2016.1269337; Xia Q, 2016, CELL IMMUNOL, V310, P89, DOI 10.1016/j.cellimm.2016.08.006; Xia Q, 2016, VACCINE, V34, P4526, DOI 10.1016/j.vaccine.2016.07.054; Xia Q, 2016, CANCER IMMUNOL IMMUN, V65, P613, DOI 10.1007/s00262-016-1827-4; Yang J, 2016, AM J TRANSL RES, V8, P3429; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Zhang Jiping, 2010, Front Biosci (Elite Ed), V2, P1154; Zhang MZ, 2015, ONCOL LETT, V10, P34, DOI 10.3892/ol.2015.3151; Zhang Y, 2016, ONCOTARGET, V7, P23282, DOI 10.18632/oncotarget.7818; Zhang YC, 2015, INT J NANOMED, V10, P1625, DOI 10.2147/IJN.S75954; Zhen EY, 2016, BIOCHEM J, V473, P605, DOI 10.1042/BJ20151085; Zhen ZP, 2017, NANO LETT, V17, P862, DOI 10.1021/acs.nanolett.6b04150; Zi FM, 2014, CANCER BIOL THER, V15, P1413, DOI 10.4161/cbt.29924; Zi FM, 2015, MOL MED REP, V11, P3203, DOI 10.3892/mmr.2015.3197	141	127	132	4	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4343	4357		10.1038/s41388-018-0275-3	http://dx.doi.org/10.1038/s41388-018-0275-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720723	Green Accepted			2022-12-28	WOS:000441144300001
J	Handler, J; Cullis, J; Avanzi, A; Vucic, EA; Bar-Sagi, D				Handler, Jesse; Cullis, Jane; Avanzi, Antonina; Vucic, Emily A.; Bar-Sagi, Dafna			Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-beta exposure	ONCOGENE			English	Article							STEM-CELL; EXPRESSION; CANCER; ADENOCARCINOMA; GENERATION; TRANSDIFFERENTIATION; DISSEMINATION; ACTIVATION; PLASTICITY; PROMOTES	Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease and a major health problem in the United States. While the cytokine TGF-beta has been implicated in PDAC development, it can exert both pro-tumorigenic and anti-tumorigenic effects that are highly context dependent and incompletely understood. Using three-dimensional (3D) cultures of Kras(G12D)-expressing mouse pancreatic epithelial cells we demonstrated that while exposure to exogenous TGF-beta induced growth arrest of the Kras(G12D) cells, its subsequent removal allowed the cells to enter a hyper-proliferative, partially mesenchymal (PM), and progenitor-like state. This state was highly stable and was maintained by autocrine TGF-beta signaling. While untreated Kras(G12D) cells formed cystic lesions in vivo, PM cells formed ductal structures resembling human PanINs, suggesting that they had attained increased oncogenic potential. Supporting this hypothesis, we determined that the PM cells share salient molecular and phenotypic features with the quasi-mesenchymal/squamous subtype of human PDAC, which has the worst prognosis of any of the recently identified subtypes. Transient pulses of TGF-beta have been observed during pancreatitis, a major risk factor for PDAC. Our data suggest that transient TGF-beta exposure is sufficient to induce the acquisition of stable PDAC-associated phenotypes in pre-neoplastic Kras(G12D) cells, providing novel molecular insight into the complex role of TGF-beta in tumorigenesis.	[Handler, Jesse; Cullis, Jane; Avanzi, Antonina; Vucic, Emily A.; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA	New York University	Bar-Sagi, D (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.	dafna.bar-sagi@nyumc.org		Bar-Sagi, Dafna/0000-0003-2597-8948; Handler, Jesse/0000-0001-5444-3905	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NIH/NCI grant [CA210263]; NIH [T32GM007308, 5-T32 CA 009161-39, 5-T32AI100853-04]; Canadian Institutes of Health Research postdoctoral fellowship [146792]; NATIONAL CANCER INSTITUTE [R35CA210263, T32CA009161, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI100853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research postdoctoral fellowship(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank L.J. Taylor for discussions and help with article preparation and the members of the Bar-Sagi laboratory for comments. The authors also thank the New York University School of Medicine Genome Technology Center (GTC), especially Adriana Heguy and Igor Dolgalev, for help designing, performing, and analyzing RNA sequencing experiments. The GTC is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. This work was further supported by NIH/NCI grant CA210263 (D. Bar-Sagi). J. Handler was supported by NIH grant T32GM007308. J. Cullis was supported by NIH grants 5-T32 CA 009161-39 and 5-T32AI100853-04. E.A. Vucic is supported by a Canadian Institutes of Health Research postdoctoral fellowship (146792).	American Cancer Society, 2017, CANC FACTS FIG 2017; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Cullis J, 2017, CANCER IMMUNOL RES, V5, P182, DOI 10.1158/2326-6066.CIR-16-0125; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ellenrieder V, 2001, CANCER RES, V61, P4222; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Goonesekere NCW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093046; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Handra-Luca A, 2011, BRIT J CANCER, V104, P1296, DOI 10.1038/bjc.2011.93; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lancaster MA, 2014, NAT PROTOC, V9, P2329, DOI 10.1038/nprot.2014.158; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Malka D, 2002, GUT, V51, P849, DOI 10.1136/gut.51.6.849; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Principe DR, 2016, CANCER RES, V76, P2525, DOI 10.1158/0008-5472.CAN-15-1293; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Riesle E, 1997, GUT, V40, P73, DOI 10.1136/gut.40.1.73; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sadler TW., 2015, LANGMANS MEDICAL EMB, V13; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takadate T, 2013, INT J CANCER, V132, P1368, DOI 10.1002/ijc.27797; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; Wilentz RE, 2000, CANCER RES, V60, P2002; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744	44	12	12	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4334	4342		10.1038/s41388-018-0264-6	http://dx.doi.org/10.1038/s41388-018-0264-6			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713060	Green Accepted			2022-12-28	WOS:000440566100010
J	Klose, R; Adam, MG; Weis, EM; Moll, I; Wustehube-Lausch, J; Tetzlaff, F; Oka, C; Ehrmann, M; Fischer, A				Klose, Ralph; Adam, M. Gordian; Weis, Eva-Maria; Moll, Iris; Wustehube-Lausch, Joycelyn; Tetzlaff, Fabian; Oka, Chio; Ehrmann, Michael; Fischer, Andreas			Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis	ONCOGENE			English	Article							SMALL-VESSEL DISEASE; NOTCH LIGAND; DLL4; SUSCEPTIBILITY; DEFICIENCY; EXPRESSION; REPRESSION; MUTATIONS	The serine protease HTRA1 is involved in several vascular diseases and its expression is often deregulated in cancer. We aimed at identifying how HTRA1 in the vasculature affects tumor growth. Here we report that silencing of HTRA1 in cultured endothelial cells increased migration rate and tube formation, whereas forced HTRA1 expression impaired sprouting angiogenesis. Mechanistically, endothelial HTRA1 expression enhanced Delta/Notch signaling by reducing the amount of the weak Notch ligand JAG1. HTRA1 physically interacted with JAG1 and cleaved it within the intracellular domain, leading to protein degradation. Expression of a constitutive active Notch1 prevented the hypersprouting phenotype upon silencing of HTRA1. In HtrA1-deficient mice, endothelial Notch signaling was diminished and isolated endothelial cells had increased expression of VEGF receptor-2. Growth of syngeneic tumors was strongly impaired in HtrA1(-/-) mice. The tumor vasculature was much denser in HtrA1(-/-) mice and less covered with mural cells. This chaotic and immature vascular network was poorly functional as indicated by large hypoxic tumor areas and low tumor cell proliferation rates. In summary, inhibition of HTRA1 in the tumor stroma impaired tumor progression by deregulating angiogenesis.	[Klose, Ralph; Adam, M. Gordian; Weis, Eva-Maria; Moll, Iris; Wustehube-Lausch, Joycelyn; Tetzlaff, Fabian; Fischer, Andreas] German Canc Res Ctr, Div Vasc Signaling & Canc A270, D-69120 Heidelberg, Germany; [Wustehube-Lausch, Joycelyn; Fischer, Andreas] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci, D-68167 Mannheim, Germany; [Oka, Chio] Nara Inst Sci & Technol, Lab Gene Funct Anim, 8916-5 Takayama, Ikoma, Nara 6300192, Japan; [Ehrmann, Michael] Univ Duisburg Essen, Ctr Med Biotechnol, Fac Biol, D-45117 Essen, Germany; [Fischer, Andreas] Heidelberg Univ Hosp, Med Clin 1, Endocrinol & Clin Chem, D-69120 Heidelberg, Germany; [Adam, M. Gordian] Metan Hlth GmbH, Berlin, Germany; [Wustehube-Lausch, Joycelyn] BioNTech AG, Mainz, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Nara Institute of Science & Technology; University of Duisburg Essen; Ruprecht Karls University Heidelberg; BioNTech SE	Fischer, A (corresponding author), German Canc Res Ctr, Div Vasc Signaling & Canc A270, D-69120 Heidelberg, Germany.; Fischer, A (corresponding author), Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci, D-68167 Mannheim, Germany.; Fischer, A (corresponding author), Heidelberg Univ Hosp, Med Clin 1, Endocrinol & Clin Chem, D-69120 Heidelberg, Germany.	a.fischer@dkfz.de	Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X; Fischer, Andreas/0000-0002-4889-0909	Fritz-Thyssen Foundation [10.13.1.160]; Deutsche Forschungsgemeinschaft [SFB-TR23]; Deutsche Krebshilfe [110638]; Helmholtz Society	Fritz-Thyssen Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Helmholtz Society(Helmholtz Association)	This work was supported by the Fritz-Thyssen Foundation (10.13.1.160), the Deutsche Forschungsgemeinschaft (SFB-TR23, project A7), the Deutsche Krebshilfe (110638), and the Helmholtz Society to AF.	Altobelli E, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4041-2; Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Brutsch R, 2010, CIRC RES, V107, P592, DOI 10.1161/CIRCRESAHA.110.217257; Catrein I, 2005, FEBS J, V272, P2892, DOI 10.1111/j.1742-4658.2005.04710.x; De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004; Fischer A, 2007, NUCLEIC ACIDS RES, V35, P4583, DOI 10.1093/nar/gkm477; Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346; Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200; Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560; Hasan MZ, 2015, DEV BIOL, V397, P89, DOI 10.1016/j.ydbio.2014.10.015; He XP, 2010, CANCER RES, V70, P3109, DOI 10.1158/0008-5472.CAN-09-3557; Jabs M, 2018, CIRCULATION, V137, P2592, DOI 10.1161/CIRCULATIONAHA.117.029733; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Klose R, 2015, CARDIOVASC RES, V107, P153, DOI 10.1093/cvr/cvv151; Kofler NM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16449; Limbourg A, 2007, CIRC RES, V100, P363, DOI 10.1161/01.RES.0000258174.77370.2c; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999; Outtz HH, 2010, J IMMUNOL, V185, P4363, DOI 10.4049/jimmunol.1000720; Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063; Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e; Teoh SSY, 2015, PLACENTA, V36, P990, DOI 10.1016/j.placenta.2015.07.001; Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015; Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155; Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811; Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990	31	17	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4260	4272		10.1038/s41388-018-0258-4	http://dx.doi.org/10.1038/s41388-018-0258-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713059				2022-12-28	WOS:000440566100005
J	Morris, SM; Mhyre, AJ; Carmack, SS; Myers, CH; Burns, C; Ye, WJ; Ferrer, M; Olson, JM; Klinghoffer, RA				Morris, Shelli M.; Mhyre, Andrew J.; Carmack, Savanna S.; Myers, Carrie H.; Burns, Connor; Ye, Wenjuan; Ferrer, Marc; Olson, James M.; Klinghoffer, Richard A.			A modified gene trap approach for improved high-throughput cancer drug discovery	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; EMBRYONIC STEM-CELLS; EXPRESSION SIGNATURE; PROMOTER TRAPS; MELANOMA; BRAF; MUTAGENESIS; LEUKEMIA; TAK-632; DESIGN	While advances in laboratory automation has dramatically increased throughout of compound screening efforts, development of robust cell-based assays in relevant disease models remain resource-intensive and time-consuming, presenting a bottleneck to drug discovery campaigns. To address this issue, we present a modified gene trap approach to efficiently generate pathway-specific reporters that result in a robust "on" signal when the pathway of interest is inhibited. In this proof-of-concept study, we used vemurafenib and trametinib to identify traps that specifically detect inhibition of the mitogen-activated protein kinase (MAPK) pathway in a model of BRAFV600E driven human malignant melanoma. We demonstrate that insertion of our trap into particular loci results in remarkably specific detection of MAPK pathway inhibitors over compounds targeting any other pathway or cellular function. The accuracy of our approach was highlighted in a pilot screen of similar to 6000 compounds where 40 actives were detected, including 18 MEK, 10 RAF, and 3 ERK inhibitors along with a few compounds representing previously under-characterized inhibitors of the MAPK pathway. One such compound, bafetinib, a second generation BCR/ABL inhibitor, reduced phosphorylation of ERK and when combined with trametinib, both in vitro and in vivo, reduced growth of vemurafenib resistant melanoma cells. While piloted in a model of BRAF-driven melanoma, our results set the stage for using this approach to rapidly generate reporters against any transcriptionally active pathway across a wide variety of disease-relevant cell-based models to expedite drug discovery efforts.	[Morris, Shelli M.; Mhyre, Andrew J.; Carmack, Savanna S.; Myers, Carrie H.; Olson, James M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Burns, Connor; Klinghoffer, Richard A.] Presage Biosci, Seattle, WA 98109 USA; [Ye, Wenjuan; Ferrer, Marc] NIH NCATS, Rockville, MD USA; [Olson, James M.] Univ Washington, Sch Med, Div Pediat Hematol Oncol, Seattle, WA 98195 USA; [Olson, James M.] Seattle Childrens Hosp, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.; Klinghoffer, RA (corresponding author), Presage Biosci, Seattle, WA 98109 USA.; Olson, JM (corresponding author), Univ Washington, Sch Med, Div Pediat Hematol Oncol, Seattle, WA 98195 USA.; Olson, JM (corresponding author), Seattle Childrens Hosp, Seattle, WA 98105 USA.	jolson@fredhutch.org; Rich.Klinghoffer@presagebio.com			National Cancer Institute of the National Institutes of Health [R43CA171366, RO1CA193841, RO1CA155360]; Seattle Children's Brain Tumor Research Endowment; NATIONAL CANCER INSTITUTE [R01CA155360, R43CA171366, R01CA114567, R01CA193841] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000363] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Seattle Children's Brain Tumor Research Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We would like to thank Jason Frazier, Robert Finney, Emily J. Girard, Madison W. Nakamoto and the staff of the Genomics Shared Resource and the Comparative Medicine Shared Resource at the Fred Hutchinson Cancer Research Center. This research was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA171366 (R.A.K.), RO1CA193841 (A.J.M. and J.M.O.), RO1CA155360 and the Seattle Children's Brain Tumor Research Endowment (J.M.O.).	Abe H, 2011, ACS MED CHEM LETT, V2, P320, DOI 10.1021/ml200004g; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Friedel RH, 2010, METHOD ENZYMOL, V477, P243, DOI 10.1016/S0076-6879(10)77013-0; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Griner LAM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.360; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Kaelin WG, 2017, NAT REV CANCER, V17, P441, DOI 10.1038/nrc.2017.32; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002; Kimura S, 2005, BLOOD, V106, P3948, DOI 10.1182/blood-2005-06-2209; Li YJ, 2015, INT J CLIN EXP PATHO, V8, P7818; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; Monga M, 2002, LEUKEMIA, V16, P520, DOI 10.1038/sj.leu.2402464; Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825; Okaniwa M, 2013, J MED CHEM, V56, P6478, DOI 10.1021/jm400778d; Okaniwa M, 2012, J MED CHEM, V55, P3452, DOI 10.1021/jm300126x; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Santos FPS, 2010, CURR OPIN INVEST DR, V11, P1450; Southall N. A., 2009, HDB DRUG SCREENING, P442; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang Yuhong, 2010, Curr Chem Genomics, V4, P57, DOI 10.2174/1875397301004010057; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Zhang F, 2014, HUM MOL GENET, V23, pR40, DOI 10.1093/hmg/ddu125	35	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4226	4238		10.1038/s41388-018-0274-4	http://dx.doi.org/10.1038/s41388-018-0274-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717260	hybrid, Green Accepted			2022-12-28	WOS:000440566100003
J	Vaniotis, G; Rayes, RF; Qi, S; Milette, S; Wang, N; Perrino, S; Bourdeau, F; Nystrom, H; He, Y; Lamarche-Vane, N; Brodt, P				Vaniotis, George; Rayes, Roni F.; Qi, Shu; Milette, Simon; Wang, Ni; Perrino, Stephanie; Bourdeau, France; Nystrom, Hanna; He, Yi; Lamarche-Vane, Nathalie; Brodt, Pnina			Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; COLON-CANCER; CARCINOMA-CELLS; PATHWAYS; MICROENVIRONMENT; EXPRESSION; CROSSTALK; INVASION; 3-KINASE/AKT	Liver metastases remain a major cause of death from gastrointestinal tract cancers as well as from other malignancies such as breast and lung carcinomas and melanoma. Understanding the underlying biology is essential for the design of effective targeted therapies. We previously reported that collagen IV alpha 1/alpha 2 overexpression in non-metastatic lung carcinoma (M27(colIV)) cells increased their metastatic ability, specifically to the liver and documented high collagen IV levels in surgical resections of liver metastases from diverse tumor types. Here, we aimed to elucidate the functional relevance of collagen IV to metastatic outgrowth in the liver. Gene expression profiling revealed in M27(colIV) cells significant increases in the expression of chemokines CCL5 (5.7-fold) and CCL7 (2.6-fold) relative to wild-type cells, and this was validated by qPCR and western blotting. Similarly, in human colon carcinoma KM12C and KM12SM cells with divergent liver-colonizing potentials, CCL7 and CCL5 production correlated with type IV collagen expression and the metastatic phenotype. CCL7 silencing by short hairpin RNA (shRNA) reduced experimental liver metastasis in both cell types, whereas CCL5 silencing reduced metastasis of M27(colIV) cells, implicating these cytokines in metastatic expansion in the liver. Subsequent functional analyses implicated both MEK/ERK and PI3K signaling upstream of CCL7 upregulation and identified CCL7 (but not CCL5) as a critical migration/invasion factor, acting via the chemokine receptor CCR3. Chemokine CCL5 was identified as a regulator of the T-cell immune response in the liver. Loss of CCL7 in KM12SM cells was also associated with altered E-cadherin and reduced vimentin and Snail expression, implicating it in epithelial-to-mesenchymal transition in these cells. Moreover, in clinical specimens of colon cancer liver metastases analyzed by immunohistochemistry, CCL5 and CCL7 levels paralleled those of collagen IV. The results identify the chemokines CCL5 and CCL7 as type IV collagen-regulated genes that promote liver metastasis by distinct and complementary mechanisms.	[Vaniotis, George; Rayes, Roni F.; Qi, Shu; Wang, Ni; Perrino, Stephanie; Bourdeau, France; Brodt, Pnina] McGill Univ, Ctr Hlth, Dept Surg, Res Inst, Montreal, PQ, Canada; [Milette, Simon; Brodt, Pnina] McGill Univ, Ctr Hlth, Med & Res Inst, Montreal, PQ, Canada; [Nystrom, Hanna] Umea Univ, Dept Surg, Dept Surg & Perioperat Sci, Umea, Sweden; [He, Yi; Lamarche-Vane, Nathalie] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; [He, Yi; Lamarche-Vane, Nathalie] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [He, Yi; Lamarche-Vane, Nathalie; Brodt, Pnina] McGill Univ, Ctr Hlth, Canc Res Program, Res Inst, Montreal, PQ, Canada; [Brodt, Pnina] McGill Univ, Ctr Hlth, Res Inst, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; Umea University; McGill University; McGill University; McGill University; McGill University	Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Dept Surg, Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Med & Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Canc Res Program, Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Dept Oncol, Montreal, PQ, Canada.	pnina.brodt@mcgill.ca	Nystrom, Hanna/AAK-4743-2021	Rayes, Roni/0000-0001-7508-020X	Canadian Institute for Health Research [MOP 80201]; Quebec Ministere de l'Economie, de l'Innovation et des Exportations [PSR-SIIRI-843]; Swedish Research Council; Vasterbotten County Council; Henry R. Shibata fellowship from the Cedars Cancer Institute; MITACS	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Quebec Ministere de l'Economie, de l'Innovation et des Exportations; Swedish Research Council(Swedish Research CouncilEuropean Commission); Vasterbotten County Council; Henry R. Shibata fellowship from the Cedars Cancer Institute; MITACS	We thank Dr. Julia Burnier for the initial analysis of the microarray data, Ms. Anette Berglund for skillful technical assistance with immunohistochemistry, and the laboratory of Dr. Jean-Jacques Lebrun for help and advice. This work was supported mainly by grants MOP 80201 from the Canadian Institute for Health Research and a PSR-SIIRI-843 grant from the Quebec Ministere de l'Economie, de l'Innovation et des Exportations (to P.B.) and also by grants from the Swedish Research Council and Vasterbotten County Council (to H.N.). R.F.R. was supported by the Henry R. Shibata fellowship from the Cedars Cancer Institute. R.F.R. and G.V. were supported by MITACS internships.	Akram IG, 2016, TUMOR BIOL, V37, P2461, DOI 10.1007/s13277-015-4089-4; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Brunner PM, 2015, EXP DERMATOL, V24, P522, DOI 10.1111/exd.12709; Burnier JV, 2011, ONCOGENE, V30, P3766, DOI 10.1038/onc.2011.89; Cambien B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028842; Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008-5472.CAN-11-2493; Cho YB, 2012, ONCOL REP, V28, P689, DOI 10.3892/or.2012.1815; Eefsen RL, 2012, J ONCOL, V2012, DOI 10.1155/2012/907971; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fidler IJ, 2008, LANCET ONCOL, V9, P808, DOI 10.1016/S1470-2045(08)70201-8; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Goos JACM, 2016, ONCOTARGET, V7, P2123, DOI 10.18632/oncotarget.6188; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178; Hirai H, 2014, CLIN EXP METASTAS, V31, P977, DOI 10.1007/s10585-014-9684-z; Hoyer Morten, 2011, Clin Epidemiol, V3 Suppl 1, P11, DOI 10.2147/CLEP.S20613; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jung DW, 2010, INT J CANCER, V127, P332, DOI 10.1002/ijc.25060; Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377; KITADAI Y, 1995, AM J PATHOL, V147, P1238; Lee YS, 2016, ONCOTARGET, V7, P36842, DOI 10.18632/oncotarget.9209; Li S, 2015, GROWTH HORM IGF RES, V25, P253, DOI 10.1016/j.ghir.2015.07.008; Luo J, 2015, ONCOTARGET, V6, P27555, DOI 10.18632/oncotarget.4515; Yamada M, 2008, CLIN CANCER RES, V14, P2351, DOI 10.1158/1078-0432.CCR-07-4499; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; MORIKAWA K, 1988, CANCER RES, V48, P6863; Mrowietz U, 1999, BRIT J CANCER, V79, P1025, DOI 10.1038/sj.bjc.6690164; Nystrom H, 2015, TUMOR BIOL, V36, P9839, DOI 10.1007/s13277-015-3729-z; PAGET S, 1989, CANCER METAST REV, V8, P98; Proudfoot AEI, 2015, CYTOKINE, V74, P259, DOI 10.1016/j.cyto.2015.02.011; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shen XJ, 2016, ONCOL LETT, V12, P3250, DOI 10.3892/ol.2016.5122; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Stormes KA, 2005, BREAST CANCER RES TR, V89, P209, DOI 10.1007/s10549-004-5328-3; Struyf S, 2001, EUR J IMMUNOL, V31, P2170, DOI 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D; Su BX, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-206; Turdean S, 2012, ACTA MED MARISIENSIS, V58, P254; Van den Eynden GG, 2014, CLIN CANCER RES, V20, P5140, DOI 10.1158/1078-0432.CCR-14-0158; Van den Eynden GG, 2013, CANCER RES, V73, P2031, DOI 10.1158/0008-5472.CAN-12-3931; Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	46	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3790	3805		10.1038/s41388-018-0242-z	http://dx.doi.org/10.1038/s41388-018-0242-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29651051				2022-12-28	WOS:000438465600003
J	Hang, W; Yin, ZX; Liu, G; Zeng, QH; Shen, XF; Sun, QH; Li, DD; Jian, YP; Zhang, YH; Wang, YS; Quan, CS; Zhao, RX; Li, YL; Xu, ZX				Hang, Wei; Yin, Zhi-Xian; Liu, Gang; Zeng, Qinghua; Shen, Xiang-Feng; Sun, Qian-Hui; Li, Dong-Dong; Jian, Yong-Ping; Zhang, Yang-He; Wang, Yi-Shu; Quan, Cheng-Shi; Zhao, Rui-Xun; Li, Yu-Lin; Xu, Zhi-Xiang			Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1	ONCOGENE			English	Article							MUTANT P53 REACTIVATION; CANCER-CELLS; DOWN-REGULATION; STEM-CELLS; HEAD; DRUG; INHIBITION; CARCINOMA; MECHANISM; APOPTOSIS	TP53 mutations frequently occur in head and neck squamous cell carcinoma (HNSCC) patients without human papillomavirus infection. The recurrence rate for these patients is distinctly high. It has been actively explored to identify agents that target TP53 mutations and restore wild-type (WT) TP53 activities in HNSCC. PRIMA-1 (p53-reactivation and induction of massive apoptosis-1) and its methylated analogue PRIMA-1(Met) (also called APR-246) were found to be able to reestablish the DNA-binding activity of p53 mutants and reinstate the functions of WT p53. Herein we report that piperlongumine (PL), an alkaloid isolated from Piper longum L., synergizes with APR-246 to selectively induce apoptosis and autophagic cell death in HNSCC cells, whereas primary and immortalized mouse embryonic fibroblasts and spontaneously immortalized non-tumorigenic human skin keratinocytes (HaCat) are spared from the damage by the co-treatment. Interestingly, PL-sensitized HNSCC cells to APR-246 are TP53 mutation-independent. Instead, we demonstrated that glutathione S-transferase pi 1 (GSTP1), a GST family member that catalyzes the conjugation of GSH with electrophilic compounds to fulfill its detoxification function, is highly expressed in HNSCC tissues. Administration of PL and APR-246 significantly suppresses GSTP1 activity, resulting in the accumulation of ROS, depletion of GSH, elevation of GSSG, and DNA damage. Ectopic expression of GSTP1 or pre-treatment with antioxidant N-acetyl-L-cysteine (NAC) abrogates the ROS elevation and decreases DNA damage, apoptosis, and autophagic cell death prompted by PL/APR-246. In addition, administration of PL and APR-246 impedes UMSCC10A xenograft tumor growth in SCID mice. Taken together, our data suggest that HNSCC cells are selectively sensitive to the combination of PL and APR-246 due to a remarkably synergistic effect of the co-treatment in the induction of ROS by suppression of GSTP1.	[Hang, Wei; Yin, Zhi-Xian; Liu, Gang] Tianjin Huanhu Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tianjin, Peoples R China; [Zeng, Qinghua; Zhao, Rui-Xun; Xu, Zhi-Xiang] Univ Alabama Birmingham, Ctr Comprehens Canc, Div Hematol & Oncol, Birmingham, AL 35294 USA; [Zeng, Qinghua; Shen, Xiang-Feng; Sun, Qian-Hui; Li, Dong-Dong; Jian, Yong-Ping; Zhang, Yang-He; Wang, Yi-Shu; Quan, Cheng-Shi; Li, Yu-Lin; Xu, Zhi-Xiang] Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, Changchun, Jilin, Peoples R China	University of Alabama System; University of Alabama Birmingham; Jilin University	Hang, W (corresponding author), Tianjin Huanhu Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tianjin, Peoples R China.	hangwei2627@126.com			National Natural Science Foundation of China [81573087, 81572139, 81772924]; U.S. National Institutes of Health [R01CA133053]; NATIONAL CANCER INSTITUTE [R01CA133053] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Natural Science Foundation of China (Grant Nos: 81573087, 81572139, and 81772924) and the U.S. National Institutes of Health (Grant No: R01CA133053).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alpay M, 2016, J CANCER RES THER, V12, P556, DOI 10.4103/0973-1482.151936; Basak D, 2016, INT J ONCOL, V48, P1426, DOI 10.3892/ijo.2016.3372; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; Bezerra DP, 2013, EUR J PHARM SCI, V48, P453, DOI 10.1016/j.ejps.2012.12.003; Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Bykov VJN, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00021; Bykov VJN, 2014, FEBS LETT, V588, P2622, DOI 10.1016/j.febslet.2014.04.017; Chou TC, 2007, COMPUSYN SOFTWARE DR, P1; Cosenza M, 2017, APOPTOSIS, V22, P827, DOI 10.1007/s10495-017-1364-4; Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007; Deben C, 2016, CANCER LETT, V375, P313, DOI 10.1016/j.canlet.2016.03.017; Fitzgerald AL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.44; Gersey ZC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3058-2; Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017; Harshbarger W, 2017, J BIOL CHEM, V292, P112, DOI 10.1074/jbc.M116.750299; Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475; Huang BK, 2016, ANTIOXID REDOX SIGN, V24, P924, DOI 10.1089/ars.2015.6482; Huang XM, 2016, CANCER CELL, V30, P940, DOI 10.1016/j.ccell.2016.11.006; Junk DJ, 2008, NEOPLASIA, V10, P450, DOI 10.1593/neo.08120; Jutooru I, 2014, MOL CELL BIOL, V34, P2382, DOI 10.1128/MCB.01602-13; Kim EH, 2011, CANCER PREV RES, V4, P425, DOI 10.1158/1940-6207.CAPR-10-0153; Kim KS, 2006, PIGM CELL RES, V19, P90, DOI 10.1111/j.1600-0749.2005.00281.x; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Meegan MJ, 2017, EUR J MED CHEM, V125, P453, DOI 10.1016/j.ejmech.2016.09.048; Moreira FD, 2016, SCI REP-UK, V6, DOI 10.1038/srep33646; Patel K, 2015, J PHARM SCI-US, V104, P4417, DOI 10.1002/jps.24637; Peng X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.417; Pignanelli C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01230-4; Prasad S, 2016, CURR PHARM DESIGN, V22, P4151, DOI 10.2174/1381612822666160601103027; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Roh JL, 2014, ONCOTARGET, V5, P9227, DOI 10.18632/oncotarget.2402; Satoh T, 2013, FREE RADICAL BIO MED, V65, P645, DOI 10.1016/j.freeradbiomed.2013.07.022; Shalom-Feuerstein R, 2013, P NATL ACAD SCI USA, V110, P2152, DOI 10.1073/pnas.1201753109; Singh M, 2008, MUTAT RES-FUND MOL M, V638, P184, DOI 10.1016/j.mrfmmm.2007.10.003; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tan JK, 2016, NUTR CANCER, V68, P507, DOI 10.1080/01635581.2016.1153671; Tanaka N, 2015, CLIN CANCER RES, V21, P4831, DOI 10.1158/1078-0432.CCR-15-0279; Tessoulin B, 2014, BLOOD, V124, P1626, DOI 10.1182/blood-2014-01-548800; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang HB, 2017, EUR J MED CHEM, V126, P517, DOI 10.1016/j.ejmech.2016.11.034; Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358; Wang YW, 2016, CANCER PREV RES, V9, P234, DOI 10.1158/1940-6207.CAPR-15-0306; Xi Y, 2015, J CANCER, V6, P327, DOI 10.7150/jca.11185; Xu HG, 2015, ONCOGENE, V34, P3848, DOI 10.1038/onc.2014.315; Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zeng Q, 2017, ONCOGENE, V36, P1245, DOI 10.1038/onc.2016.290; Zeng QH, 2016, P NATL ACAD SCI USA, V113, P9333, DOI 10.1073/pnas.1606801113; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024; Zou P, 2016, CANCER LETT, V375, P114, DOI 10.1016/j.canlet.2016.02.058	55	30	30	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3384	3398		10.1038/s41388-017-0110-2	http://dx.doi.org/10.1038/s41388-017-0110-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29348462	Green Accepted			2022-12-28	WOS:000436411300005
J	Liu, XY; Bi, L; Wang, Q; Wen, MX; Li, C; Ren, YD; Jiao, QL; Mao, JH; Wang, CX; Wei, GW; Wang, YS				Liu, Xiaoyan; Bi, Lei; Wang, Qin; Wen, Mingxin; Li, Ce; Ren, Yidan; Jiao, Qinlian; Mao, Jian-Hua; Wang, Chuanxin; Wei, Guangwei; Wang, Yunshan			miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer	ONCOGENE			English	Article							VITAMIN-D-RECEPTOR; PVT1; PROGRESSION; EXPRESSION; PROSTATE; CELLS; EMT; AMPLIFICATION; CONTRIBUTES; CATENIN	Plasmacytoma variant translocation 1 (PVT1) is an lncRNA that plays vital roles in breast cancer (BC) pathogenesis. Increasing evidence suggests that miRNAs that reside in the PVT1 locus are the main driver of the oncogenic roles of PVT1 in cancer. However, the oncogenic role and underlying mechanism of miR-1204, located in the PVT1 locus, in human cancer is still unclear. In this study, we discovered that increased expression of miR-1204 is associated with poor prognosis in BC. Moreover, miR-1204 promotes proliferation, epithelial-mesenchymal transition and invasion of BC cells both in vitro and in vivo. Mechanistic investigations demonstrated that VDR is a novel target gene of miR-1204. Interference of VDR restored miR-1204-mediated BC cell proliferation, tumorigenesis, and metastasis. Collectively, our results demonstrated that the miR-1204-VDR pathway exerts oncogenic effects in BC with potential therapeutic applications in blocking BC development and progression.	[Liu, Xiaoyan; Wen, Mingxin; Wei, Guangwei; Wang, Yunshan] Shandong Univ, Sch Med, Minist Educ, Dept Human Anat, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Xiaoyan; Wen, Mingxin; Wei, Guangwei; Wang, Yunshan] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Bi, Lei; Mao, Jian-Hua; Wang, Yunshan] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA; [Wang, Qin] Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, Ce; Ren, Yidan; Jiao, Qinlian; Wang, Yunshan] Shandong Univ, Sch Ocean, Int Biotechnol R&D Ctr, 180 Wenhua Xi Rd, Weihai 264209, Shandong, Peoples R China; [Bi, Lei] Nanjing Univ Chinese Med, Sch Preclin Med, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China; [Wang, Chuanxin] Shandong Univ, Hosp 2, Dept Clin Lab, Jinan 250033, Shandong, Peoples R China	Shandong University; Shandong University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Shandong University; Shandong University; Nanjing University of Chinese Medicine; Shandong University	Wei, GW; Wang, YS (corresponding author), Shandong Univ, Sch Med, Minist Educ, Dept Human Anat, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wei, GW; Wang, YS (corresponding author), Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, YS (corresponding author), Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.; Wang, YS (corresponding author), Shandong Univ, Sch Ocean, Int Biotechnol R&D Ctr, 180 Wenhua Xi Rd, Weihai 264209, Shandong, Peoples R China.	gwwei@yahoo.com; wangyunshan135@126.com	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021	China Postdoctoral International Exchange Program; National Natural Science Foundation of China [81402193, 31271461, 81472583, 81528017]; Postdoctoral Innovation Project of Shandong Province [147751]; Postdoctoral Science Foundation of China [2015M570597]; National Key R&D Program of China [2017YFC1308600]; Taishan Scholar Program of Shandong Province	China Postdoctoral International Exchange Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Innovation Project of Shandong Province; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); National Key R&D Program of China; Taishan Scholar Program of Shandong Province	This work was supported by the China Postdoctoral International Exchange Program 2015, National Natural Science Foundation of China (no. 81402193), Postdoctoral Innovation Project of Shandong Province (no. 147751), and Postdoctoral Science Foundation of China (no. 2015M570597) to Y.S. Wang; by National Natural Science Foundation of China (nos. 31271461, 81472583, 81528017), National Key R&D Program of China (No. 2017YFC1308600), and the Taishan Scholar Program of Shandong Province to G.W. Wei.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; Bertucci F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037943; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Bronson PG, 2016, NAT GENET, V48, P1425, DOI 10.1038/ng.3675; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Dumont N, 2009, CANCER CELL, V16, P3, DOI 10.1016/j.ccr.2009.06.013; Fabbri M, 2012, CANCER RES, V72, P6333, DOI 10.1158/0008-5472.CAN-12-3229; Fromont G, 2013, HUM PATHOL, V44, P1617, DOI 10.1016/j.humpath.2013.01.012; Gu Y, 2016, J PATHOL, V239, P60, DOI 10.1002/path.4697; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Helms MW, 2008, BRIT J CANCER, V99, P774, DOI 10.1038/sj.bjc.6604556; Hsu CY, 2014, J PATHOL, V232, P330, DOI 10.1002/path.4295; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Johnson AL, 2015, ONCOTARGET, V6, P16304, DOI 10.18632/oncotarget.4059; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li ZW, 2015, CLIN CANCER RES, V21, P844, DOI 10.1158/1078-0432.CCR-14-2437; M'kacher R, 2003, CANCER GENET CYTOGEN, V143, P32, DOI 10.1016/S0165-4608(02)00823-3; Meng LY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13964; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mito JK, 2013, J PATHOL, V229, P132, DOI 10.1002/path.4099; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213; Pradhan AK, 2017, CANCER RES, V77, P949, DOI 10.1158/0008-5472.CAN-16-1731; Raffel S, 2016, CANCER CELL, V29, P133, DOI 10.1016/j.ccell.2016.01.007; Schumacher FR, 2007, CANCER RES, V67, P2951, DOI 10.1158/0008-5472.CAN-06-3591; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Sun Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-137; Thorne J, 2008, P NUTR SOC, V67, P115, DOI 10.1017/S0029665108006964; Torres S, 2017, J PATHOL, V242, P39, DOI 10.1002/path.4874; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182	35	47	52	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3426	3439		10.1038/s41388-018-0215-2	http://dx.doi.org/10.1038/s41388-018-0215-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29555976	Green Published			2022-12-28	WOS:000436411300008
J	Monteonofrio, L; Valente, D; Ferrara, M; Camerini, S; Miscione, R; Crescenzi, M; Rinaldo, C; Soddu, S				Monteonofrio, Laura; Valente, Davide; Ferrara, Manuela; Camerini, Serena; Miscione, Roberta; Crescenzi, Marco; Rinaldo, Cinzia; Soddu, Silvia			HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis	ONCOGENE			English	Article							CHROMOSOMAL PASSENGER COMPLEX; INTERACTING PROTEIN KINASE-2; DNA-DAMAGE RESPONSE; COVALENT MODIFICATION; ACTIVATION-LOOP; SPINDLE; CANCER; ABSCISSION; APOPTOSIS; MIDBODY	Cytokinesis, the final phase of cell division, is necessary to form two distinct daughter cells with correct distribution of genomic and cytoplasmic materials. Its failure provokes genetically unstable states, such as tetraploidization and polyploidization, which can contribute to tumorigenesis. Aurora-B kinase controls multiple cytokinetic events, from chromosome condensation to abscission when the midbody is severed. We have previously shown that HIPK2, a kinase involved in DNA damage response and development, localizes at the midbody and contributes to abscission by phosphorylating extrachromosomal histone H2B at Ser14. Of relevance, HIPK2-defective cells do not phosphorylate H2B and do not successfully complete cytokinesis leading to accumulation of binucleated cells, chromosomal instability, and increased tumorigenicity. However, how HIPK2 and H2B are recruited to the midbody during cytokinesis is still unknown. Here, we show that regardless of their direct (H2B) and indirect (HIPK2) binding of chromosomal DNA, both H2B and HIPK2 localize at the midbody independently of nucleic acids. Instead, by using mitotic kinase-specific inhibitors in a spatio-temporal regulated manner, we found that Aurora-B kinase activity is required to recruit both HIPK2 and H2B to the midbody. Molecular characterization showed that Aurora-B directly binds and phosphorylates H2B at Ser32 while indirectly recruits HIPK2 through the central spindle components MgcRacGAP and PRC1. Thus, among different cytokinetic functions, Aurora-B separately recruits HIPK2 and H2B to the midbody and these activities contribute to faithful cytokinesis.	[Monteonofrio, Laura; Valente, Davide; Rinaldo, Cinzia; Soddu, Silvia] Regina Elena Natl Canc Inst IRCCS, Unit Cellular Networks & Mol Therapeut Targets, I-00144 Rome, Italy; [Ferrara, Manuela; Miscione, Roberta; Rinaldo, Cinzia] Sapienza Univ, Natl Res Council CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy; [Camerini, Serena; Crescenzi, Marco] Italian Natl Inst Hlth, Core Facil, I-00161 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Rinaldo, C; Soddu, S (corresponding author), Regina Elena Natl Canc Inst IRCCS, Unit Cellular Networks & Mol Therapeut Targets, I-00144 Rome, Italy.; Rinaldo, C (corresponding author), Sapienza Univ, Natl Res Council CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy.	cinzia.rinaldo@uniroma1.it; silvia.soddu@ifo.gov.it	Camerini, Serena/A-4637-2017; Soddu, Silvia/ABH-6774-2020; Crescenzi, Marco/J-3603-2018; Soddu, Silvia/K-2467-2018; Valente, Davide/ABA-2484-2021; Rinaldo, Cinzia/A-4252-2015; Monteonofrio, Laura/K-1878-2018	Camerini, Serena/0000-0001-6131-4335; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Valente, Davide/0000-0001-6397-3641; Rinaldo, Cinzia/0000-0001-6124-762X; Monteonofrio, Laura/0000-0003-3981-942X	Italian Association for Cancer Research [14592, 17739]; Italian Foundation for Cancer Research	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Foundation for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	We are grateful to all people cited in the text for their gifts of cells and reagents. We thank G. Di Rocco for critical reading of the manuscript and F. Magi and M.P. Gentileschi for technical assistance. This work was supported by grants from Italian Association for Cancer Research to SS (IG #14592), and to CR (IG #17739). LM and DV were recipients of fellowships from Italian Foundation for Cancer Research.	Afonso O, 2017, CHROMOSOMA, V126, P93, DOI 10.1007/s00412-016-0594-5; Agromayor M, 2013, TRENDS CELL BIOL, V23, P433, DOI 10.1016/j.tcb.2013.04.006; Atilla-Gokcumen GE, 2010, ACS CHEM BIOL, V5, P79, DOI 10.1021/cb900256m; Bastos RN, 2013, J CELL BIOL, V202, P605, DOI 10.1083/jcb.201301094; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blaquiere JA, 2017, CURR TOP DEV BIOL, V123, P73, DOI 10.1016/bs.ctdb.2016.10.002; Borisa AC, 2017, EUR J MED CHEM, V140, P1, DOI 10.1016/j.ejmech.2017.08.045; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carpinelli P, 2008, EXPERT OPIN THER TAR, V12, P69, DOI 10.1517/14728222.12.1.69; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; D'Avino PP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00221; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-63; de la Vega L, 2011, BBA-MOL CELL RES, V1813, P283, DOI 10.1016/j.bbamcr.2010.11.022; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Douglas ME, 2010, SEMIN CELL DEV BIOL, V21, P899, DOI 10.1016/j.semcdb.2010.08.005; Douglas ME, 2010, CURR BIOL, V20, P927, DOI 10.1016/j.cub.2010.03.055; Fededa JP, 2012, NAT CELL BIOL, V14, P440, DOI 10.1038/ncb2482; Feng YY, 2017, ONCOTARGET, V8, P20452, DOI 10.18632/oncotarget.14723; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Hu CK, 2012, MOL BIOL CELL, V23, P1024, DOI 10.1091/mbc.E11-08-0721; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kobiyama K, 2010, J VIROL, V84, P822, DOI 10.1128/JVI.01339-09; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; KURIYAMA R, 1984, J CELL SCI, V66, P265; Kuwano Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101638; Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; Mierzwa B, 2014, DEV CELL, V31, P525, DOI 10.1016/j.devcel.2014.11.006; Mollinari C, 2005, MOL BIOL CELL, V16, P1043, DOI 10.1091/mbc.E04-04-0346; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Normand G, 2010, ADV EXP MED BIOL, V676, P27; Pollard TD, 2017, J CELL BIOL, V216, P3007, DOI 10.1083/jcb.201612068; Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Saul VV, 2013, J MOL MED, V91, P1051, DOI 10.1007/s00109-013-1042-0; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Siepi F, 2013, BBA-MOL CELL RES, V1833, P1443, DOI 10.1016/j.bbamcr.2013.02.018; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Valente D, 2015, ONCOTARGET, V6, P10320, DOI 10.18632/oncotarget.3583; Verdina A, 2017, ONCOTARGET, V8, P16744, DOI 10.18632/oncotarget.14421; Vitale I, 2015, TRENDS CANCER, V1, P124, DOI 10.1016/j.trecan.2015.08.001; Zhao WM, 2005, P NATL ACAD SCI USA, V102, P13158, DOI 10.1073/pnas.0504145102	58	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3562	3574		10.1038/s41388-018-0191-6	http://dx.doi.org/10.1038/s41388-018-0191-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563611	Green Published, hybrid			2022-12-28	WOS:000436412500007
J	Zhang, YQ; Wang, SY; Kang, W; Liu, CX; Dong, YJ; Ren, FL; Wang, YY; Zhang, JL; Wang, GP; To, KF; Zhang, XJ; Sung, JY; Chang, ZJ; Yu, J				Zhang, Yanquan; Wang, Shiyan; Kang, Wei; Liu, Chunxiao; Dong, Yujuan; Ren, Fangli; Wang, Yinyin; Zhang, Jinglin; Wang, Guoping; To, Ka Fai; Zhang, Xueji; Sung, Joseph J. Y.; Chang, Zhijie; Yu, Jun			CREPT facilitates colorectal cancer growth through inducing Wnt/beta-catenin pathway by enhancing p300-mediated beta-catenin acetylation	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; PROMOTES TUMOR-GROWTH; C-TERMINAL DOMAIN; TRANSCRIPTIONAL COACTIVATOR; CHROMOSOMAL GAINS; GENE-EXPRESSION; POOR-PROGNOSIS; CELL-CYCLE; PROGRESSION; P300/CBP	Using whole genome sequencing, we identified gene amplification of CREPT in colorectal cancer (CRC). In this study, we aim to clarify its clinical significance, biological effects, and mechanism in CRC. CREPT was upregulated in CRC cell lines and in 47.37% (72/152) of primary CRC tumors. Amplification of CREPT was detected in 48.28% (56/116) of primary CRC tumors, which was positively correlated with its overexpression (P < 0.001). Multivariate analysis showed that CRC patients with CREPT protein overexpression were significantly associated with poor disease-free survival (P < 0.05). CREPT significantly accelerated CRC cell proliferation and metastasis both in vitro and in vivo. RNA-sequencing (seq) analysis uncovered that the tumor-promoting effect by CREPT was attributed to enhancing Wnt/beta-catenin signaling. Using co-immunoprecipitation coupled with mass spectroscopy, we identified p300 protein was a novel CREPT interacting partner. CREPT greatly increased the interaction between p300 and beta-catenin, thus promoting p300-mediated beta-catenin acetylation and stabilization. Moreover, CREPT cooperated with p300, leading to elevated active histone acetylation markers H3K27ac and H4Ac and decreased repressive histone marker H3K9me3 at the promoters of Wnt downstream targets. In summary, CREPT plays a pivotal oncogenic role in colorectal carcinogenesis through promoting Wnt/beta-catenin pathway via cooperating with p300. CREPT may serve as a prognostic biomarker of patients with CRC.	[Zhang, Yanquan; Wang, Shiyan; Dong, Yujuan; Wang, Guoping; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Sha Tin, Hong Kong, Peoples R China; [Zhang, Yanquan; Wang, Shiyan; Dong, Yujuan; Wang, Guoping; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Sha Tin, Hong Kong, Peoples R China; [Zhang, Yanquan; Liu, Chunxiao; Ren, Fangli; Wang, Yinyin; Chang, Zhijie] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Zhang, Yanquan; Liu, Chunxiao; Ren, Fangli; Wang, Yinyin; Chang, Zhijie] Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China; [Wang, Shiyan; Zhang, Xueji] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Res Ctr Bioengn & Sensing Technol, Beijing, Peoples R China; [Kang, Wei; Zhang, Jinglin; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Sha Tin, Hong Kong, Peoples R China; [Dong, Yujuan] Chinese Univ Hong Kong, Dept Surg, Sha Tin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Tsinghua University; Tsinghua University; University of Science & Technology Beijing; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Sha Tin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Sha Tin, Hong Kong, Peoples R China.; Chang, ZJ (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Chang, ZJ (corresponding author), Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China.	zhijiec@tsinghua.edu.cn; junyu@cuhk.edu.hk	Yu, Jun/D-8569-2015; Dong, Yujuan/AAS-3467-2021; Wang, Yin/HCI-9352-2022; Zhang, Yanquan/D-5615-2017; Chang, Zhijie/AAH-8109-2019; zhang, xueji/ABE-6497-2020; Sung, Joseph J. Y./R-3203-2018; KANG, Wei/C-5451-2016; zhang, xueji/B-1904-2010	Yu, Jun/0000-0001-5008-2153; Zhang, Yanquan/0000-0003-3527-9972; zhang, xueji/0000-0002-0035-3821; Sung, Joseph J. Y./0000-0003-3125-5199; KANG, Wei/0000-0002-4651-677X; ZHANG, Jingwan/0000-0002-0344-3398; Chang, Zhijie/0000-0003-1567-3227	National Natural Science Foundation [81301775, 81230044, 81572728]; RGC-GRF Hong Kong [14106415, 14111216, 14163817]; 135 program project [2016YFC1303200]; National Key Research and Development Program [2016YFA0500301]; Shenzhen Virtual University Park Support Scheme	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); RGC-GRF Hong Kong(Hong Kong Research Grants Council); 135 program project; National Key Research and Development Program; Shenzhen Virtual University Park Support Scheme	This project was supported by the National Natural Science Foundation (81301775, 81230044, 81572728), RGC-GRF Hong Kong (14106415, 14111216, 14163817), 135 program project (2016YFC1303200), National Key Research and Development Program (2016YFA0500301); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chan HM, 2001, J CELL SCI, V114, P2363; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Jung HM, 2009, J CELL BIOCHEM, V106, P703, DOI 10.1002/jcb.22063; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Ma JT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174309; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Ni ZY, 2014, NAT STRUCT MOL BIOL, V21, P686, DOI 10.1038/nsmb.2853; Ni ZY, 2011, TRANSCR-AUSTIN, V2, P237, DOI 10.4161/trns.2.5.17803; Ren Fangli, 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P401, DOI 10.1089/mab.2014.0043; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; She YG, 2014, INT J CLIN EXP PATHO, V7, P6596; Sun W, 2017, HEPATOLOGY, DOI [10.1002/hep.29750, DOI 10.1002/HEP.29750.]; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201; Wang Y, 2014, ONCOL REP, V31, P1389, DOI 10.3892/or.2014.2990; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xie T, 2012, PLOS ONE, V7; Xu LX, 2016, GUT, V65, P635, DOI 10.1136/gutjnl-2014-308257; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JW, 2016, GUT, V65, P1482, DOI 10.1136/gutjnl-2014-308614; Zhang YQ, 2014, J BIOL CHEM, V289, P22589, DOI 10.1074/jbc.M114.560979; Zheng GX, 2016, BIOCHEM BIOPH RES CO, V480, P436, DOI 10.1016/j.bbrc.2016.10.067	41	36	39	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3485	3500		10.1038/s41388-018-0161-z	http://dx.doi.org/10.1038/s41388-018-0161-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563608	Green Published, hybrid			2022-12-28	WOS:000436412500002
J	Rehrauer, H; Wu, LC; Blum, W; Pecze, L; Henzi, T; Serre-Beinier, V; Aquino, C; Vrugt, B; de Perrot, M; Schwaller, B; Felley-Bosco, E				Rehrauer, Hubert; Wu, Licun; Blum, Walter; Pecze, Lazslo; Henzi, Thomas; Serre-Beinier, Veronique; Aquino, Catherine; Vrugt, Bart; de Perrot, Marc; Schwaller, Beat; Felley-Bosco, Emanuela			How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations	ONCOGENE			English	Article							T-CELLS; MOUSE MODEL; GENE; CANCER; MURINE; IDENTIFICATION; EXPRESSION; NF2; REPOPULATION; CHEMOTHERAPY	Chronic exposure to intraperitoneal asbestos triggered a marked response in the mesothelium well before tumor development. Macrophages, mesothelial precursor cells, cytokines, and growth factors accumulated in the peritoneal lavage. Transcriptome profiling revealed YAP/TAZ activation in inflamed mesothelium with further activation in tumors, paralleled by increased levels of cells with nuclear YAP/TAZ. Arg1 was one of the highest upregulated genes in inflamed tissue and tumor. Inflamed tissue showed increased levels of single-nucleotide variations, with an RNA-editing signature, which were even higher in the tumor samples. Subcutaneous injection of asbestos-treated, but tumor-free mice with syngeneic mesothelioma tumor cells resulted in a significantly higher incidence of tumor growth when compared to naive mice supporting the role of the environment in tumor progression.	[Rehrauer, Hubert; Aquino, Catherine] Swiss Fed Inst Technol, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland; [Rehrauer, Hubert; Aquino, Catherine] Univ Zurich, CH-8057 Zurich, Switzerland; [Wu, Licun; de Perrot, Marc] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Latner Thorac Surg Res Labs,Div Thorac Surg, Toronto, ON, Canada; [Blum, Walter; Pecze, Lazslo; Henzi, Thomas; Schwaller, Beat] Univ Fribourg, Dept Med, Unit Anat, Route Albert Gockel 1, CH-1700 Fribourg, Switzerland; [Serre-Beinier, Veronique] Univ Hosp Geneva, Dept Thorac Surg, Geneva, Switzerland; [Vrugt, Bart] Univ Hosp Zurich, Inst Surg Pathol, Zurich, Switzerland; [Felley-Bosco, Emanuela] Univ Hosp Zurich, Lab Mol Oncol, Lungen & Thoraxonkol Zentrum, Sternwartstr 14, CH-8091 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Fribourg; University of Geneva; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Felley-Bosco, E (corresponding author), Univ Hosp Zurich, Lab Mol Oncol, Lungen & Thoraxonkol Zentrum, Sternwartstr 14, CH-8091 Zurich, Switzerland.	emanuela.felley-bosco@usz.ch	Serre-Beinier, Véronique/T-8064-2019; Wu, Licun/AAL-9596-2021; Felley-Bosco, Emanuela/E-7484-2017	Serre-Beinier, Véronique/0000-0002-6016-1645; Wu, Licun/0000-0003-4803-9361; Felley-Bosco, Emanuela/0000-0002-3408-0294; de Perrot, Marc/0000-0003-2000-9427; Schwaller, Beat/0000-0002-8277-7555	Swiss National Science Foundation Sinergia Grant CRSII3 [147697]	Swiss National Science Foundation Sinergia Grant CRSII3(Swiss National Science Foundation (SNSF))	The project is financed by the Swiss National Science Foundation Sinergia Grant CRSII3 #147697.	Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bera TK, 2000, MOL CELL BIOL, V20, P2902, DOI 10.1128/MCB.20.8.2902-2906.2000; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Blum W, 2015, IN VITRO CELL DEV-AN, V51, P714, DOI 10.1007/s11626-015-9885-z; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Broad Institute TCGA Genome Data Analysis Center, 2014, PARADIGM PATHW AN MR; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Carmona R, 2011, J CELL MOL MED, V15, P1200, DOI 10.1111/j.1582-4934.2010.01087.x; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; CHERIE AL, 2016, J THORAC ONCOL, V11, P1765, DOI DOI 10.1016/J.JTHO.2016.06.022; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Chow MT, 2012, IMMUNOL CELL BIOL, V90, P983, DOI 10.1038/icb.2012.46; Cornelissen R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106742; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Dixit R, 2013, DEVELOPMENT, V140, P4398, DOI 10.1242/dev.098079; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Echeverry N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.124; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Foley-Comer AJ, 2002, J CELL SCI, V115, P1383; Frei C, 2011, CARCINOGENESIS, V32, P1324, DOI 10.1093/carcin/bgr127; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; GORMLEY IP, 1980, CARCINOGENESIS, V1, P219, DOI 10.1093/carcin/1.3.219; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; Huaux F, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0158-0; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Jiang QF, 2017, NAT REV CANCER, V17, P381, DOI 10.1038/nrc.2017.23; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jongsma J, 2008, CANCER CELL, V13, P261, DOI 10.1016/j.ccr.2008.01.030; Kadariya Y, 2016, CANCER PREV RES, V9, P406, DOI 10.1158/1940-6207.CAPR-15-0347; Khanna S, 2016, J THORAC ONCOL, V11, P1993, DOI 10.1016/j.jtho.2016.07.033; Kitayama J, 2014, CELL IMMUNOL, V288, P8, DOI 10.1016/j.cellimm.2014.01.008; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lievense LA, 2016, J THORAC ONCOL, V11, P1755, DOI 10.1016/j.jtho.2016.06.021; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; MOALLI PA, 1987, AM J PATHOL, V128, P426; Moore DA, 2013, J MOL DIAGN, V15, P687, DOI 10.1016/j.jmoldx.2013.04.008; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Musah S, 2014, P NATL ACAD SCI USA, V111, P13805, DOI 10.1073/pnas.1415330111; Napolitano A, 2016, ONCOGENE, V35, P1996, DOI 10.1038/onc.2015.243; Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4; Parrotta R, 2017, J THORAC ONCOL, V12, P1309, DOI 10.1016/j.jtho.2017.03.023; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Ren YZR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193458; Rinkevich Y, 2012, NAT CELL BIOL, V14, P1251, DOI 10.1038/ncb2610; Robinson C, 2011, EUR J CANCER, V47, P151, DOI 10.1016/j.ejca.2010.08.015; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shi YD, 2012, CLIN CANCER RES, V18, P4646, DOI 10.1158/1078-0432.CCR-12-0599; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soucie EL, 2016, SCIENCE, V351, DOI 10.1126/science.aad5510; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Suraokar MB, 2014, ANN ONCOL, V25, P1184, DOI 10.1093/annonc/mdu127; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; Tamminen JA, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.29; Tartour E, 2011, CANCER METAST REV, V30, P83, DOI 10.1007/s10555-011-9281-4; Veltman JD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-464; WAGNER JC, 1962, NATURE, V196, P180, DOI 10.1038/196180a0; Wang J, 2016, CELL, V165, P668, DOI 10.1016/j.cell.2016.03.009; Wu LC, 2017, CLIN CANCER RES, V23, P1060, DOI 10.1158/1078-0432.CCR-16-0844; Wu LC, 2012, MOL CANCER THER, V11, P1809, DOI 10.1158/1535-7163.MCT-11-1014; Wu LC, 2011, J THORAC ONCOL, V6, P1578, DOI 10.1097/JTO.0b013e3182208ee0; Zervos E, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0314-2; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	76	35	35	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2645	2659		10.1038/s41388-018-0153-z	http://dx.doi.org/10.1038/s41388-018-0153-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29507420	Green Published, Green Submitted, hybrid, Green Accepted			2022-12-28	WOS:000432545100003
J	Nishida, J; Miyazono, K; Ehata, S				Nishida, Jun; Miyazono, Kohei; Ehata, Shogo			Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-beta-dependent and-independent mechanisms	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ALDEHYDE DEHYDROGENASE; RECEPTOR EXPRESSION; FUNCTIONAL-ANALYSIS; INITIATING CELLS; PROTEIN; TARGET; PROGRESSION; POPULATION; BETAGLYCAN	TGF-beta regulates both the tumor-forming and migratory abilities of various types of cancer cells. However, it is unclear how the loss of TGF-beta signaling components affects these abilities in clear-cell renal cell carcinoma (ccRCC). In this study, we investigated the role of TGFBR3 (TGF-beta type III receptor, also known as betaglycan) in ccRCC. Database analysis revealed decreased expression of TGFBR3 in ccRCC tissues, which correlated with poor prognosis in patients. Orthotopic inoculation experiments using immunocompromised mice indicated that low TGFBR3 expression in ccRCC cells enhanced primary tumor formation and lung metastasis. In the presence of TGFBR3, TGF-beta 2 decreased the aldehyde dehydrogenase (ALDH)-positive ccRCC cell population, in which renal cancer-initiating cells are enriched. Loss of TGFBR3 also enhanced cell migration in cell culture and induced expression of several mesenchymal markers in a TGF-beta-independent manner. Increased lamellipodium formation by FAK-PI3K signaling was observed with TGFBR3 downregulation, and this contributed to TGF-beta-independent cell migration in ccRCC cells. Taken together, our findings reveal that loss of TGFBR3 endows ccRCC cells with multiple metastatic abilities through TGF-beta-dependent and independent pathways.	[Nishida, Jun; Miyazono, Kohei; Ehata, Shogo] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Nishida, Jun/C-4892-2018	Nishida, Jun/0000-0001-5098-9361; Ehata, Shogo/0000-0002-6740-9391	KAKENHI from the Japan Society for the Promotion of Science (JSPS) [15H05774, 15K08393]; Japan Society for the Promotion of Science (JSPS) [16J05993]; Yasuda Medical Foundation; Grants-in-Aid for Scientific Research [16J05993, 15H05774] Funding Source: KAKEN	KAKENHI from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Yasuda Medical Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Yoko Katsuno, Dr. Anna Mizutani, Dr. Yukari Hoshino, Dr. Fumihiko Murai, Dr. Kei Takahashi, and Dr. Luna Taguchi (The University of Tokyo) for technical help; and Dr. Hiroyuki Miyoshi (Keio University) for providing the lentiviral vectors. This work was supported by KAKENHI Grants-in-Aid for Scientific Research (S) (15H05774) (KM) and Scientific Research (C) (15K08393) (SE), and Grant-in-Aid for JSPS Research Fellow (16J05993) (JN) from the Japan Society for the Promotion of Science (JSPS), and the Yasuda Medical Foundation (KM).	Ananth S, 1999, CANCER RES, V59, P2210; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V339, P180, DOI 10.1016/j.mce.2011.04.014; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Katsura A, 2017, MOL ONCOL, V11, P1241, DOI 10.1002/1878-0261.12098; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kubota SI, 2017, CELL REP, V20, P236, DOI 10.1016/j.celrep.2017.06.010; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nagata M, 2006, GENES CELLS, V11, P1267, DOI 10.1111/j.1365-2443.2006.01018.x; NAITO S, 1986, CANCER RES, V46, P4109; Namwanje M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021881; Peired AJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8342625; Riazalhosseini Y, 2016, NAT REV NEPHROL, V12, P655, DOI 10.1038/nrneph.2016.133; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Ueda K., 2013, PLOS ONE, V8, P1; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112	49	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2197	2212		10.1038/s41388-017-0084-0	http://dx.doi.org/10.1038/s41388-017-0084-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29391598	Green Published, hybrid			2022-12-28	WOS:000430589000009
J	Liang, SQ; Buhrer, ED; Berezowska, S; Marti, TM; Xu, D; Froment, L; Yang, HT; Hall, SRR; Vassella, E; Yang, Z; Kocher, GJ; Amrein, MA; Riether, C; Ochsenbein, AF; Schmid, RA; Peng, RW				Liang, Shun-Qing; Buhrer, Elias D.; Berezowska, Sabina; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Vassella, Erik; Yang, Zhang; Kocher, Gregor J.; Amrein, Michael A.; Riether, Carsten; Ochsenbein, Adrian F.; Schmid, Ralph A.; Peng, Ren-Wang			mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; MAMMALIAN TARGET; STEM-CELLS; PHASE-II; EVEROLIMUS; DRUG; PHOSPHORYLATION; PROGRESSION; NSCLC; EMT	Oncogenic KRAS mutations comprise the largest subset of lung cancer defined by genetic alterations, but in the clinic no targeted therapies are available that effectively control mutational KRAS activation. Consequently, patients with KRASdriven tumors are routinely treated with cytotoxic chemotherapy, which is often transiently effective owing to development of drug resistance. In this study, we show that hyperactivated mammalian target of rapamycin (mTOR) pathway is a characteristic hallmark of KRAS-mutant lung adenocarcinoma after chemotherapy treatment, and that KRAS-mutant lung cancer cells rely on persistent mTOR signaling to resist chemotherapeutic drugs. Coherently, mTOR inhibition circumvents the refractory phenotype and restores sensitivity of resistant KRAS-mutant lung cancer cells to chemotherapy. Importantly, drug combinations of clinically approved mTOR inhibitors and chemotherapy drugs synergize in inhibiting cell proliferation of KRAS-mutant cancer cells in vitro and in vivo, and the efficacy of this combination treatment correlates with the magnitude of mTOR activity induced by chemotherapy alone. These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset.	[Liang, Shun-Qing; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Yang, Zhang; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang] Bern Univ Hosp, Inselspital, Div Gen Thorac Surg, Bern, Switzerland; [Liang, Shun-Qing; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Yang, Zhang; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang] Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland; [Buhrer, Elias D.; Amrein, Michael A.; Riether, Carsten; Ochsenbein, Adrian F.] Univ Bern, Dept BioMed Res DBMR, Tumor Immunol, Bern, Switzerland; [Berezowska, Sabina; Vassella, Erik] Univ Bern, Inst Pathol, Bern, Switzerland; [Xu, Duo; Yang, Haitang; Yang, Zhang] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Riether, Carsten; Ochsenbein, Adrian F.] Bern Univ Hosp, Inselspital, Dept Med Oncol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern	Schmid, RA; Peng, RW (corresponding author), Bern Univ Hosp, Inselspital, Div Gen Thorac Surg, Bern, Switzerland.; Schmid, RA; Peng, RW (corresponding author), Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland.	Ralph.Schmid@insel.ch; Renwang.Peng@insel.ch	Liang, Shunqing/AHE-6842-2022; Kocher, Gregor Jan/GQZ-1359-2022; Riether, Carsten/ABC-7699-2021; Liang, Shunqing/GXG-2346-2022; Berezowska, Sabina/AAJ-4557-2021; DUO, XU/AAC-8882-2021; Riether, Carsten/K-8603-2013; Marti, Thomas/AAW-5232-2020; Yang, Haitang/AAS-6986-2020; Yang, Haitang/N-5141-2019; Peng, Ren-Wang/AAM-8542-2021	Liang, Shunqing/0000-0003-4664-6029; Kocher, Gregor Jan/0000-0001-6531-2919; Riether, Carsten/0000-0001-7512-513X; Liang, Shunqing/0000-0003-4664-6029; Berezowska, Sabina/0000-0001-5442-9791; Riether, Carsten/0000-0001-7512-513X; Marti, Thomas/0000-0003-3005-220X; Yang, Haitang/0000-0002-8732-5910; Peng, Ren-Wang/0000-0003-1199-6520; Amrein, Michael Alex/0000-0002-0378-8070; Schmid, Ralph Alexander/0000-0003-0699-079X; Ochsenbein, Adrian/0000-0003-1773-5436; Yang, Zhang/0000-0001-8592-5800	Swiss Cancer League [KFS-3772-08-2015]; Cancer League of the Canton of Bern; China Scholarship Council	Swiss Cancer League; Cancer League of the Canton of Bern; China Scholarship Council(China Scholarship Council)	We gratefully acknowledge Lung Cancer Center (LCC), Bern University Hospital and the Tissue Bank Bern (TBB), Institute of Pathology, University of Bern, in acquiring patient tissues. We thank Silvia Suardi and Jose Galvan (Institute of Pathology) and Colin Tieche and Ming Qiao (Division of General Thoracic Surgery) for technical assistance and help with data acquisition and analysis, Dr. med. Michael von Gunten (Pathologie Langgasse, Bern, Switzerland) and Dr. med. Mathias Gugger (Promed SA Laboratoire medical, Freiburg, Switzerland) for providing pre-chemotherapy biopsies, professor Marianne Geiser (Institute of Anatomy, University of Bern, Bern, Switzerland) and Dr. Yitzhak Zimmer (Department of Radiation Oncology, Bern University Hospital, Bern, Switzerland) for cell lines. This work was supported by Swiss Cancer League (#KFS-3772-08-2015; to R.-W. Peng), Cancer League of the Canton of Bern (to R-W. Peng), a PhD fellowship from China Scholarship Council (to S.-Q. Liang) and a MD-PhD fellowship from Swiss Cancer League (to E.D. Buhrer).	Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Farge T, 2017, CANCER DISCOV, V7, P716, DOI 10.1158/2159-8290.CD-16-0441; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Goffin J, 2010, J THORAC ONCOL, V5, P260, DOI 10.1097/JTO.0b013e3181c6f035; Granville CA, 2007, CLIN CANCER RES, V13, P2281, DOI 10.1158/1078-0432.CCR-06-2570; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hegde GV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045647; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6; Kawabata S, 2014, CELL REP, V7, P1824, DOI 10.1016/j.celrep.2014.05.039; Kawabata S, 2014, ONCOTARGET, V5, P1062, DOI 10.18632/oncotarget.1760; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Langsch S, 2016, CANCER RES, V76, P4160, DOI 10.1158/0008-5472.CAN-15-2580; Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001; Liang SQ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.195; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Papadimitrakopoulou VA, 2012, J THORAC ONCOL, V7, P1594, DOI 10.1097/JTO.0b013e3182614835; Pirazzoli V, 2014, CELL REP, V7, P999, DOI 10.1016/j.celrep.2014.04.014; Price KA, 2010, J THORAC ONCOL, V5, P1623, DOI 10.1097/JTO.0b013e3181ec1531; Ramalingam SS, 2013, J THORAC ONCOL, V8, P369, DOI 10.1097/JTO.0b013e318282709c; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thoma CR, 2014, ADV DRUG DELIVER REV, V69, P29, DOI 10.1016/j.addr.2014.03.001; Vansteenkiste J, 2011, J THORAC ONCOL, V6, P2120, DOI 10.1097/JTO.0b013e3182307ede; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zheng YY, 2013, CANCER CELL, V24, P59, DOI 10.1016/j.ccr.2013.05.021	46	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					622	636		10.1038/s41388-018-0479-6	http://dx.doi.org/10.1038/s41388-018-0479-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171261				2022-12-28	WOS:000457300300002
J	Stratikopoulos, EE; Kiess, N; Szabolcs, M; Pegno, S; Kakit, C; Wu, XW; Poulikakos, PI; Cheung, P; Schmidt, H; Parsons, R				Stratikopoulos, Elias E.; Kiess, Nicole; Szabolcs, Matthias; Pegno, Sarah; Kakit, Cheung; Wu, Xuewei; Poulikakos, Poulikos, I; Cheung, Pamela; Schmidt, Hank; Parsons, Ramon			Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents	ONCOGENE			English	Article							BCL-2 FAMILY; TRANSCRIPTIONAL REGULATION; AROMATASE INHIBITORS; RECEPTOR; RESISTANT; TAMOXIFEN; MUTATIONS; THERAPY; PATHWAY; PIK3CA	Estrogen dependence is major driver of ER + breast cancer, which is associated with PI3K mutation. PI3K inhibition (PI3Ki) can restore dependence on ER signaling for some hormone therapy-resistant ER + breast cancers, but is ineffective in others. Here we show that short-term supplementation with estrogen strongly enhanced Pik3caH1047R-induced mammary tumorigenesis in mice that resulted exclusively in ER + tumors, demonstrating the cooperation of the hormone and the oncogene in tumor development. Similar to human ER + breast cancers that are endocrine-dependent or endocrine-independent at diagnosis, tumor lines from this model retained ER expression but were sensitive or resistant to hormonal therapies. PI3Ki did not induce cell death but did cause upregulation of the pro-apoptotic gene BIM. BH3 mimetics or PI3Ki were unable to restore hormone sensitivity in several resistant mouse and human tumor lines. Importantly however, combination of PI3Ki and BH3 mimetics had a profound, BIM-dependent cytotoxic effect in PIK3CA-mutant cancer cells while sparing normal cells. We propose that addition of BH3 mimetics offers a therapeutic strategy to markedly improve the cytotoxic activity of PI3Ki in hormonal therapy-resistant and ER-independent PIK3CA-mutant breast cancer.	[Stratikopoulos, Elias E.; Kiess, Nicole; Pegno, Sarah; Kakit, Cheung; Wu, Xuewei; Poulikakos, Poulikos, I; Cheung, Pamela; Parsons, Ramon] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Szabolcs, Matthias] Columbia Univ, Dept Pathol, Med Ctr, New York, NY 10032 USA; [Schmidt, Hank] Icahn Sch Med Mt Sinai, Dept Surg, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; Icahn School of Medicine at Mount Sinai	Parsons, R (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA.	ramon.parsons@mssm.edu		Parsons, Ramon/0000-0002-6656-3514	Komen Foundation Scholar Award [SAC110028]; NCI [R01 CA129432]; Department of Defense Breast Cancer Research Program Era of Hope Award [BC087596]; NATIONAL CANCER INSTITUTE [R35CA220491] Funding Source: NIH RePORTER	Komen Foundation Scholar Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Breast Cancer Research Program Era of Hope Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Stuart Aaronson and Jerry Chipuk for providing reagents and helpful discussions, Xi Sun for technical assistance and all members of the Parsons laboratory for critical reading of the manuscript. We also thank the Stand Up To Cancer (SU2C) PI3K Dream Team for providing BYL719. This work was supported by the Komen Foundation Scholar Award SAC110028 and NCI R01 CA129432 to R. Parsons. Additional support was given to E. Stratikopoulos from the Department of Defense Breast Cancer Research Program Era of Hope Award BC087596.	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baird RD, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2520; Baselga J, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-OT1-03-14; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Faber AC, 2015, P NATL ACAD SCI USA, V112, pE1288, DOI 10.1073/pnas.1411848112; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Juric D, 2014, ANN ONCOL         S4, V25, piv150, DOI DOI 10.1093/ANNONC/MDU331.11; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krop IE, 2016, LANCET ONCOL, V17, P811, DOI 10.1016/S1470-2045(16)00106-6; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Mohibi Shakur, 2011, J Carcinog, V10, P35, DOI 10.4103/1477-3163.91116; Mouridsen H, 2003, J CLIN ONCOL, V21, P2101, DOI 10.1200/JCO.2003.04.194; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Ndubaku CO, 2013, J MED CHEM, V56, P4597, DOI 10.1021/jm4003632; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Perez K, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3530; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sabnis G, 2007, CLIN CANCER RES, V13, P2751, DOI 10.1158/1078-0432.CCR-06-2466; Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833; Saura C, 2015, CANCER RES, V75; Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tikoo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036924; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533; Yuan W, 2013, ONCOGENE, V32, P318, DOI 10.1038/onc.2012.53	50	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					47	59		10.1038/s41388-018-0436-4	http://dx.doi.org/10.1038/s41388-018-0436-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076411	Green Accepted			2022-12-28	WOS:000454775900004
J	Ooki, A; Dinalankara, W; Marchionni, L; Tsay, JCJ; Goparaju, C; Maleki, Z; Rom, WN; Pass, HI; Hoque, MO				Ooki, Akira; Dinalankara, Wikum; Marchionni, Luigi; Tsay, Jun-Chieh J.; Goparaju, Chandra; Maleki, Zahra; Rom, William N.; Pass, Harvey, I; Hoque, Mohammad O.			Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma	ONCOGENE			English	Article							SELF-RENEWAL; SERUM DNA; SOX2; GENE; DIFFERENTIATION; METHYLATION; EXPRESSION; PATHWAYS; HEDGEHOG; INITIATION	It remains unclear whether PAX6 acts as a crucial transcription factor for lung cancer stem cell (CSC) traits. We demonstrate that PAX6 acts as an oncogene responsible for induction of cancer stemness properties in lung adenocarcinoma (LUAD). Mechanistically, PAX6 promotes GLI transcription, resulting in SOX2 upregulation directly by the binding of GLI to the proximal promoter region of the SOX2 gene. The overexpressed SOX2 enhances the expression of key pluripotent factors (OCT4 and NANOG) and suppresses differentiation lineage factors (HOPX and NKX2-1), driving cancer cells toward a stem-like state. In contrast, in the differentiated non-CSCs, PAX6 is transcriptionally silenced by its promoter methylation. In human lung cancer tissues, the positive linear correlations of PAX6 expression with GLI and SOX2 expression and its negative correlations with HOPX and NKX2-1 expression were observed. Therapeutically, the blockade of the PAX6-GLISOX2 signaling axis elicits a long-lasting therapeutic efficacy by limiting CSC expansion following chemotherapy. Furthermore, a methylation panel including the PAX6 gene yielded a sensitivity of 79.1% and specificity of 83.3% for cancer detection using serum DNA from stage IA LUAD. Our findings provide a rationale for targeting the PAX6-GLI-SOX2 signaling axis with chemotherapy as an effective therapeutic strategy and support the clinical utility of PAX6 gene promoter methylation as a biomarker for early lung cancer detection.	[Ooki, Akira; Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21231 USA; [Dinalankara, Wikum; Marchionni, Luigi; Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Tsay, Jun-Chieh J.; Rom, William N.] NYU, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10016 USA; [Goparaju, Chandra; Pass, Harvey, I] New York Univ Med, Langone Med Ctr, Dept Cardiothorac Surg, Div Thorac Surg, New York, NY 10016 USA; [Maleki, Zahra] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; New York University; New York University; NYU Langone Medical Center; Johns Hopkins University; Johns Hopkins University	Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21231 USA.; Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.; Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA.	mhoque1@jhmi.edu	Marchionni, Luigi/S-6774-2017	Marchionni, Luigi/0000-0002-7336-8071; Ooki, Akira/0000-0001-7618-5775; Tsay, Jun-Chieh/0000-0002-2282-2510; Rom, William/0000-0002-8793-7028; Pass, Harvey/0000-0003-3222-3471	Flight Attendant Medical Research Institute Clinical Innovative Award [103015]; NCI [R01CA206027]; SPORE in Cervical Cancer [P50 CA098252]; NATIONAL CANCER INSTITUTE [R01CA206027, P50CA098252] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute Clinical Innovative Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); SPORE in Cervical Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Flight Attendant Medical Research Institute Clinical Innovative Award 103015 (M.O. Hoque), NCI R01CA206027 (M.O. Hoque), the Career Development award from SPORE in Cervical Cancer Grants P50 CA098252 (MOH).	Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Asami M, 2011, DEVELOPMENT, V138, P5067, DOI 10.1242/dev.074591; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Begum S, 2011, CLIN CANCER RES, V17, P4494, DOI 10.1158/1078-0432.CCR-10-3436; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Blanchon T, 2007, LUNG CANCER, V58, P50, DOI 10.1016/j.lungcan.2007.05.009; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Coutinho P, 2011, GENOME RES, V21, P1349, DOI 10.1101/gr.124115.111; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Greenberg AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039403; Holland PWH, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-47; Hu B, 2016, CELL DIFFER INVASIVE, V167, pe18; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Lang D, 2008, MOL CARCINOGEN, V47, P148, DOI 10.1002/mc.20375; Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024; Leon G, 2016, PHARMACOL THERAPEUT, V158, P71, DOI 10.1016/j.pharmthera.2015.12.001; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Mascarenhas JB, 2009, J BIOL CHEM, V284, P27524, DOI 10.1074/jbc.M109.047209; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Mayes DA, 2006, CANCER RES, V66, P9809, DOI 10.1158/0008-5472.CAN-05-3877; Nam HS, 2014, TUBERC RESPIR DIS, V76, P211, DOI 10.4046/trd.2014.76.5.211; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Ooki A, 2018, CANCER RES, V78, P168, DOI 10.1158/0008-5472.CAN-17-0836; Ooki A, 2017, CLIN CANCER RES, V23, P7141, DOI 10.1158/1078-0432.CCR-17-1222; Osumi N, 2008, STEM CELLS, V26, P1663, DOI 10.1634/stemcells.2007-0884; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Rauch TA, 2012, TUMOR BIOL, V33, P287, DOI 10.1007/s13277-011-0282-2; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Sansom SN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000511; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Shen Y, 2006, HUM MOL GENET, V15, P2623, DOI 10.1093/hmg/ddl188; Shiraishi M, 2002, ONCOGENE, V21, P3804, DOI 10.1038/sj.onc.1205454; Shyr CR, 2010, PROSTATE, V70, P190, DOI 10.1002/pros.21052; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tammemagi MC, 2013, NEW ENGL J MED, V368, P728, DOI 10.1056/NEJMoa1211776; Watanabe H, 2013, CANCER CELL, V23, P707, DOI 10.1016/j.ccr.2013.05.013; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhao XT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085738	47	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5967	5981		10.1038/s41388-018-0373-2	http://dx.doi.org/10.1038/s41388-018-0373-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980786	Green Accepted			2022-12-28	WOS:000449562500005
J	He, TL; Jin, M; Xu, CX; Ma, ZJ; Wu, FF; Zhang, XB				He, Tianliang; Jin, Min; Xu, Chenxi; Ma, Zhongjun; Wu, Fufang; Zhang, Xiaobo			The homeostasis-maintaining metabolites from bacterial stress response to bacteriophage infection suppress tumor metastasis	ONCOGENE			English	Article							MICROBIAL NATURAL-PRODUCTS; DEEP-SEA FUNGUS; DRUG DISCOVERY; CELL-PROLIFERATION; MARINE-ENVIRONMENT; HYDROTHERMAL VENTS; BREAST-CANCER; DIVERSITY; ORIGIN; GENOME	The antiviral metabolites from bacterial stress response to bacteriophage infection can maintain homeostasis of host cells, while metabolism disorder is a remarkable characteristic of tumorigenesis. In the aspect of metabolic homeostasis, therefore, the antiviral homeostasis-maintaining metabolites of bacteria may possess anti-tumor activity. However, this issue has not been addressed. Here we show that the homeostasis-challenged maintaining metabolites from deep-sea bacteriophage-challenged thermophile can suppress tumor metastasis. The results indicated that the metabolic profiles of the bacteriophage GVE2-infected and virus-free thermophile Geobacillus sp. E263 from a deep-sea hydrothermal vent were remarkably different. Thirteen metabolites were significantly elevated and two metabolites were downregulated in thermophile stress response to GVE2 infection. As an example, the upregulated L-norleucine was characterized. The data showed that L-norleucine had antiviral activity in thermophile. Furthermore, the in vitro and in vivo assays revealed that L-norleucine, as well as its derivative, significantly suppressed metastasis of gastric and breast cancer cells. L-norleucine interacted with hnRNPA2/B1 protein to inhibit the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promote the E-cadherin expression, leading to the inhibition of tumor metastasis. Therefore, our study presented that antiviral homeostasis-maintaining metabolites of microbes might be a promising source for anti-tumor drugs.	[He, Tianliang; Jin, Min; Xu, Chenxi; Zhang, Xiaobo] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Ma, Zhongjun] Zhejiang Univ, Inst Marine Biol & Nat Prod, Dept Ocean Sci & Engn, Hangzhou 310058, Zhejiang, Peoples R China; [Wu, Fufang] Fuyang Normal Univ, Sch Chem & Mat Engn, Fuyang 236037, Peoples R China	Zhejiang University; Zhejiang University; Fuyang Normal University	Zhang, XB (corresponding author), Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.	zxb0812@zju.edu.cn		He, Tianliang/0000-0003-4437-5309; Zhang, Xiaobo/0000-0003-4606-212X	China Ocean Mineral Resources R D Association [DY135-B-04]; National Program on the Key Basic Research Project [2015CB755903]	China Ocean Mineral Resources R D Association; National Program on the Key Basic Research Project	This work was supported by China Ocean Mineral Resources R & D Association (DY135-B-04) and National Program on the Key Basic Research Project (2015CB755903).	Ankrah NYD, 2014, ISME J, V8, P1089, DOI 10.1038/ismej.2013.216; Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1; Brana AF, 2015, MICROB ECOL, V69, P512, DOI 10.1007/s00248-014-0508-0; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; Ferronato MJ, 2015, J STEROID BIOCHEM, V154, P285, DOI 10.1016/j.jsbmb.2015.09.009; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Gulder TAM, 2009, CURR OPIN MICROBIOL, V12, P252, DOI 10.1016/j.mib.2009.05.002; Hanaford AR, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3090; He TL, 2016, MAR BIOTECHNOL, V18, P232, DOI 10.1007/s10126-015-9683-3; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jin M, 2015, APPL MICROBIOL BIOT, V99, P8101, DOI 10.1007/s00253-015-6674-2; Jin M, 2013, MICROBIOL-SGM, V159, P1597, DOI 10.1099/mic.0.067611-0; Katt WP, 2014, DRUG DISCOV TODAY, V19, P450, DOI 10.1016/j.drudis.2013.10.008; Knight V, 2003, APPL MICROBIOL BIOT, V62, P446, DOI 10.1007/s00253-003-1381-9; Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457; Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Li DH, 2007, ARCH PHARM RES, V30, P1051; Li DH, 2007, J ANTIBIOT, V60, P317, DOI 10.1038/ja.2007.40; Li X, 2005, TRENDS BIOTECHNOL, V23, P539, DOI 10.1016/j.tibtech.2005.08.006; Li Y, 2009, J NAT PROD, V72, P912, DOI 10.1021/np900116m; Liu B, 2006, CURR MICROBIOL, V53, P163, DOI 10.1007/s00284-005-0509-9; Loh TJ, 2015, ONCOL REP, V34, P1231, DOI 10.3892/or.2015.4110; Majeed R, 2012, J CANC SCI THER, V4; Martin W, 2008, NAT REV MICROBIOL, V6, P805, DOI 10.1038/nrmicro1991; Nastrucci C, 2012, RECENT PAT ANTI-CANC, V7, P218, DOI 10.2174/157489212799972963; NISHIO M, 1990, J GEN VIROL, V71, P61, DOI 10.1099/0022-1317-71-1-61; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pelaez F, 2006, BIOCHEM PHARMACOL, V71, P981, DOI 10.1016/j.bcp.2005.10.010; Pettit RK, 2011, MICROB BIOTECHNOL, V4, P471, DOI 10.1111/j.1751-7915.2010.00196.x; Qu XH, 2015, ONCOL LETT, V10, P1677, DOI 10.3892/ol.2015.3457; Remes C, 2012, BIOORG CHEM, V41-42, P6, DOI 10.1016/j.bioorg.2011.12.003; Rohwer F, 2009, NATURE, V459, P207, DOI 10.1038/nature08060; Salomon CE, 2004, NAT PROD REP, V21, P105, DOI 10.1039/b301384g; Sana Theodore R, 2008, J Biomol Tech, V19, P258; Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038; Shi F, 2018, ONCOTARGET, V9, P706, DOI 10.18632/oncotarget.23091; Simmons TL, 2008, P NATL ACAD SCI USA, V105, P4587, DOI 10.1073/pnas.0709851105; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tauler J, 2010, CANCER RES, V70, P7137, DOI 10.1158/0008-5472.CAN-10-0860; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wei DH, 2010, J VIROL, V84, P2365, DOI 10.1128/JVI.02182-09; Weitz Joshua S, 2012, F1000 Biol Rep, V4, P17; Xiong ZQ, 2013, MAR DRUGS, V11, P700, DOI 10.3390/md11030700; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	49	4	4	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5766	5779		10.1038/s41388-018-0376-z	http://dx.doi.org/10.1038/s41388-018-0376-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29925861				2022-12-28	WOS:000448288200005
J	Hirata, N; Suizu, F; Matsuda-Lennikov, M; Tanaka, T; Edamura, T; Ishigaki, S; Donia, T; Lithanatudom, P; Obuse, C; Iwanaga, T; Noguchi, M				Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Tanaka, Tsutomu; Edamura, Tatsuma; Ishigaki, Satoko; Donia, Thoria; Lithanatudom, Pathrapol; Obuse, Chikashi; Iwanaga, Toshihiko; Noguchi, Masayuki			Functional characterization of lysosomal interaction of Akt with VRK2	ONCOGENE			English	Article							CELL-DEATH; PROTEIN-KINASE; MAMMALIAN AUTOPHAGY; INHIBITION; CANCER; PHOSPHORYLATION; MTORC1; GROWTH; LINKS; UBIQUITINATION	Serine-threonine kinase Akt (also known as PKB, protein kinase B), a core intracellular mediator of cell survival, is involved in various human cancers and has been suggested to play an important role in the regulation of autophagy in mammalian cells. Nonetheless, the physiological function of Akt in the lysosomes is currently unknown. We have reported previously that PtdIns (3)P-dependent lysosomal accumulation of the Akt-Phafin2 complex is a critical step for autophagy induction. Here, to characterize the molecular function of activated Akt in the lysosomes in the process of autophagy, we searched for the molecules that interact with the Akt complex at the lysosomes after induction of autophagy. By time-of-flight-mass spectrometry (TOF/MS) analysis, kinases of the VRK family, a unique serine-threonine family of kinases in the human kinome, were identified. VRK2 interacts with Akt1 and Akt2, but not with Akt3; the C terminus of Akt and the N terminus of VRK2 facilitate the interaction of Akt and VRK2 in mammalian cells. The kinase-dead form of VRK2A (KD VRK2A) failed to interact with Akt in coimmunoprecipitation assays. Bimolecular fluorescence complementation (BiFC) experiments showed that, in the lysosomes, Akt interacted with VRK2A but not with VRK2B or KD VRK2A. Immunofluorescent assays revealed that VRK2 and phosphorylated Akt accumulated in the lysosomes after autophagy induction. WT VRK2A, but not KD VRK2A or VRK2B, facilitated accumulation of phosphorylated Akt in the lysosomes. Downregulation of VRK2 abrogated the lysosomal accumulation of phosphorylated Akt and impaired nuclear localization of TFEB; these events coincided to inhibition of autophagy induction. The VRK2-Akt complex is required for control of lysosomal size, acidification, bacterial degradation, and for viral replication. Moreover, lysosomal VRK2-Akt controls cellular proliferation and mitochondria) outer-membrane stabilization. Given the roles of autophagy in the pathogenesis of human cancer, the current study provides a novel insight into the oncogenic activity of VRK2-Akt complexes in the lysosomes via modulation of autophagy.	[Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Tanaka, Tsutomu; Edamura, Tatsuma; Ishigaki, Satoko; Donia, Thoria; Lithanatudom, Pathrapol; Noguchi, Masayuki] Hokkaido Univ, Div Canc Biol, Inst Genet Med, Sapporo, Hokkaido, Japan; [Donia, Thoria] Tanta Univ, Chem Dept, Fac Sci, Tanta, Egypt; [Obuse, Chikashi] Hokkaido Univ, Div Mol Life Sci, Grad Sch Life Sci, Sapporo, Hokkaido, Japan; [Iwanaga, Toshihiko] Hokkaido Univ, Lab Histol & Cytol, Grad Sch Med, Sapporo, Hokkaido, Japan; [Lithanatudom, Pathrapol] Chiang Mai Univ, Dept Biol, Fac Sci, Ctr Excellence Bioresources Agr Ind & Med, Chiang Mai 50200, Thailand	Hokkaido University; Egyptian Knowledge Bank (EKB); Tanta University; Hokkaido University; Hokkaido University; Chiang Mai University	Noguchi, M (corresponding author), Hokkaido Univ, Div Canc Biol, Inst Genet Med, Sapporo, Hokkaido, Japan.	m_noguch@igm.hokudai.ac.jp	Suizu, Futoshi/G-3530-2019; Donia, Thoria/I-7715-2019; LITHANATUDOM, PATHRAPOL/AAQ-1131-2021	Suizu, Futoshi/0000-0003-0206-4289; Donia, Thoria/0000-0002-1629-1290; 	Takeda; Naito Foundation; JSPS; Japan Rheumatism Foundation	Takeda(Takeda Pharmaceutical Company Ltd); Naito Foundation(Naito Memorial Foundation); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Rheumatism Foundation(Japan Rheumatism Foundation)	We thank Hiroyuki Miyoshi for the lentivirus and Dr. G. Napolitano and Dr. A. Ballabio for the anti-TFEB antibody. MN is supported by Takeda and Naito Foundation. FS and NH are supported by JSPS and FS by Japan Rheumatism Foundation.	Antal CE, 2013, MOL CELL PROTEOMICS, V12, P3498, DOI 10.1074/mcp.R113.029819; Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556; Blanco S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001660; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chen W, 2005, J BIOL CHEM, V280, P40985, DOI 10.1074/jbc.M502190200; de Duve C, 2005, NAT CELL BIOL, V7, P847, DOI 10.1038/ncb0905-847; Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; Hayakawa A, 2007, BIOCHEM SOC SYMP, V74, P95, DOI 10.1042/BSS2007c09; Hirata N, 2014, BIOCHEM BIOPH RES CO, V450, P891, DOI 10.1016/j.bbrc.2014.06.077; Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kerppola TK, 2008, METHOD CELL BIOL, V85, P431, DOI 10.1016/S0091-679X(08)85019-4; Kim S, 2014, MOL CELL BIOL, V34, P643, DOI 10.1128/MCB.00756-13; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Klerkx EPF, 2009, HISTOL HISTOPATHOL, V24, P749, DOI 10.14670/HH-24.749; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lee E, 2016, SCI REP-UK, V6, DOI 10.1038/srep29097; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li LY, 2006, J GEN VIROL, V87, P2869, DOI 10.1099/vir.0.81953-0; Li Y, 2016, NAT CELL BIOL, V18, P1065, DOI 10.1038/ncb3407; Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Matsuda M, 2010, BIOCHEM BIOPH RES CO, V395, P312, DOI 10.1016/j.bbrc.2010.03.166; Matsuda-Lennikov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079795; Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moffatt MF, 2008, CURR OPIN ALLERGY CL, V8, P411, DOI 10.1097/ACI.0b013e32830f1dc1; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nabar NR, 2017, YALE J BIOL MED, V90, P301; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968; Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Planz O, 2013, ANTIVIR RES, V98, P457, DOI 10.1016/j.antiviral.2013.04.008; Rodriguez-Hernandez I, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-23; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sanz-Garcia M., 2010, EMERGING SIGNALING P, P135; Sanz-Garcia M, 2012, J BIOL CHEM, V287, P23757, DOI 10.1074/jbc.M112.353102; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sha YB, 2017, EMBO J, V36, P2544, DOI 10.15252/embj.201796699; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Singla V, 2010, DEV CELL, V18, P410, DOI 10.1016/j.devcel.2009.12.022; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Suizu F., 2015, AUSTIN J MOL CELL BI, V2, P1004; Suizu F, 2016, EMBO J, V35, P1346, DOI 10.15252/embj.201593003; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zhang B, 2015, CANCER LETT, V356, P704, DOI 10.1016/j.canlet.2014.10.016; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	105	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5367	5386		10.1038/s41388-018-0330-0	http://dx.doi.org/10.1038/s41388-018-0330-0			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29872222	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000446312900001
J	Liao, CP; Lin, TP; Li, PC; Geary, LA; Chen, K; Vaikari, VP; Wu, JB; Lin, CH; Gross, ME; Shih, JC				Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Wu, Jason Boyang; Lin, Chi-Hung; Gross, Mitchell E.; Shih, Jean C.			Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate	ONCOGENE			English	Article							MONOAMINE-OXIDASE-A; PTEN; MICE; IDENTIFICATION; TUMORIGENESIS; MAINTENANCE; PROGRESSION; FIBROBLASTS; HIF-1-ALPHA; GENERATION	Monoamine oxidase A (MAOA) is a mitochondrial enzyme, which degrades monoamine neurotransmitters and dietary amines and produces H2O2. Recent studies have shown increased MAOA expression in prostate cancer (PCa), glioma, and classical Hodgkin lymphoma. However, the biological function of MAOA in cancer development remains unknown. In this study, we investigated the role of MAOA in the development of prostate adenocarcinoma by creating a prostate-specific Pten/MAOA knockout (KO) mouse model, in which MAOA-floxP mouse was crossed with the conditional Pten KO PCa mouse that develops invasive PCa. In contrast to Pten KO mice, age-matched Pten/MAOA KO mice exhibited a significant decrease in both prostate size and the incidence of invasive cancer. We observed a significant decline in AKT phosphorylation and Ki67 expression in Pten/MAOA KO mice, which reduced epithelial cell growth and proliferation. As cancer stem cells (CSCs) are required for tumor initiation and growth, we investigated expression of OCT4 and NANOG in the setting of decreased MAOA expression. We found that both OCT4 and NANOG were significantly attenuated in the prostate epithelia of Pten/MAOA KO mice compared to Pten KO mice, which was confirmed with targeted knockdown of MAOA with a short-hairpin(sh) vector targeting MAOA compared to cells transfected with a control vector. Expression of other markers associated with the a stem cell phenotype, including CD44, alpha 2 beta 1, and CD133 as well as HIF-1 alpha(+)CD44(+) stem cells were all decreased in shMAOA PCa cells compared with empty vector-transfected control cells. We also found spheroid formation ability in PCa cells was decreased when endogenous MAOA was suppressed by siRNA or MAOA inhibitor clorgyline in a colony formation assay. Using the TCGA database, elevatedMAOA expression was associated with reduced Pten levels in high Gleason grade in patient samples. Further, we found that Pten-positive PCa cells were more resistant to clorgyline treatments than Pten-null cells in tumorigenicity and stemness. Taken together, these studies suggest that MAOA expression promotes PCa development by increasing cell proliferation and CSCs and highlights the potential use of MAOA inhibitors for the treatment of PCa.	[Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Shih, Jean C.] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA; [Liao, Chun-Peng; Lin, Tzu-Ping; Li, Pei-Chuan; Geary, Lauren A.; Chen, Kevin; Vaikari, Vijaya Pooja; Shih, Jean C.] USC, Taiwan Ctr Translat Res, Los Angeles, CA 90089 USA; [Liao, Chun-Peng; Gross, Mitchell E.] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90033 USA; [Lin, Tzu-Ping; Lin, Chi-Hung] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 11221, WA, Taiwan; [Wu, Jason Boyang] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Spokane, WA 99210 USA; [Gross, Mitchell E.; Shih, Jean C.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Shih, Jean C.] Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; [Shih, Jean C.] Taipei Med Univ, Coll Pharm, Taipei 11031, Taiwan	University of Southern California; University of Southern California; University of Southern California; National Yang Ming Chiao Tung University; Washington State University; University of Southern California; University of Southern California; Taipei Medical University	Shih, JC (corresponding author), Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), USC, Taiwan Ctr Translat Res, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA.; Shih, JC (corresponding author), Taipei Med Univ, Coll Pharm, Taipei 11031, Taiwan.	jcshih@usc.edu	Vaikari, Vijaya/GRR-4324-2022; Vaikari, Vijaya/ABH-2110-2021; Chen, Kevin/GYU-8963-2022	Vaikari, Vijaya/0000-0001-9175-3558; Liao, Chun-Peng/0000-0001-8920-4322	Department of Defense Prostate Cancer Research Program [W81XWH-12-1-0282]; Daniel Tsai Family Fund; Boyd and Elsie Welin Professorship	Department of Defense Prostate Cancer Research Program(United States Department of Defense); Daniel Tsai Family Fund; Boyd and Elsie Welin Professorship	This work was supported by the Department of Defense Prostate Cancer Research Program grant W81XWH-12-1-0282, the Daniel Tsai Family Fund, and the Boyd and Elsie Welin Professorship (to JCS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense or other funding agency.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adisetiyo H, 2014, J CELL PHYSIOL, V229, P1170, DOI 10.1002/jcp.24546; Adisetiyo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069484; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bortolato M, 2011, NEUROPSYCHOPHARMACOL, V36, P2674, DOI 10.1038/npp.2011.157; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dawood S, 2014, ONCOLOGY-NY, V28, P1101; Dillon LM, 2014, CURR DRUG TARGETS, V15, P65, DOI 10.2174/1389450114666140106100909; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Forristal CE, 2015, LEUKEMIA, V29, P1366, DOI 10.1038/leu.2015.8; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Kushal S, 2016, ONCOTARGET, V7, P13842, DOI 10.18632/oncotarget.7283; Lawson DA, 2005, COLD SH Q B, V70, P187, DOI 10.1101/sqb.2005.70.003; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PC, 2017, J PATHOL, V243, P220, DOI 10.1002/path.4944; Liao CP, 2007, CANCER RES, V67, P7525, DOI 10.1158/0008-5472.CAN-07-0668; Liao Chun-Peng, 2010, Hormones & Cancer, V1, P297, DOI 10.1007/s12672-010-0051-5; Liao CP, 2010, CANCER RES, V70, P7294, DOI 10.1158/0008-5472.CAN-09-3982; Ma JC, 2002, J BIOCHEM, V131, P107, DOI 10.1093/oxfordjournals.jbchem.a003064; Nikitin AY, 2007, HISTOL HISTOPATHOL, V22, P1043, DOI 10.14670/HH-22.1043; Oliveira DSM, 2016, BOSNIAN J BASIC MED, V16, P8, DOI 10.17305/bjbms.2016.917; Peehl DM, 2008, J UROLOGY, V180, P2206, DOI 10.1016/j.juro.2008.07.019; Pfeiffer MJ, 2010, EUR UROL, V57, P246, DOI 10.1016/j.eururo.2009.01.015; Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh C, 2013, P NATL ACAD SCI USA, V110, P12816, DOI 10.1073/pnas.1308037110; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Ting MC, 2012, DIS MODEL MECH, V5, P366, DOI 10.1242/dmm.008458; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu JB, 2015, J AM CHEM SOC, V137, P2366, DOI 10.1021/ja512613j; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xu S, 2015, BRIT J CANCER, V113, P242, DOI 10.1038/bjc.2015.228	50	31	32	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5175	5190		10.1038/s41388-018-0325-x	http://dx.doi.org/10.1038/s41388-018-0325-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29844571	Green Accepted			2022-12-28	WOS:000445093100003
J	Karni-Schmidt, O; Friedler, A; Zupnick, A; McKinney, K; Mattia, M; Beckerman, R; Bouvet, P; Sheetz, M; Fersht, A; Prives, C				Karni-Schmidt, O.; Friedler, A.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Bouvet, P.; Sheetz, M.; Fersht, A.; Prives, C.			Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus (vol 26, pg 3878, 2007)	ONCOGENE			English	Correction									[Karni-Schmidt, O.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Sheetz, M.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Friedler, A.; Fersht, A.] MRC, Dept MRC CPE, Ctr Prot Engn, Cambridge, England; [Friedler, A.] Hebrew Univ Jerusalem, Dept Organ Chem, Jerusalem, Israel; [Bouvet, P.] Ecole Normale Super Lyon, Lab Biol Mol Cellule UMR 5161, 46 Allee Italie, F-69364 Lyon, France	Columbia University; University of Cambridge; Hebrew University of Jerusalem; Ecole Normale Superieure de Lyon (ENS de LYON)	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu	Fersht, Alan R/B-2189-2008; , Bouvet/AAC-8779-2020		Medical Research Council [MC_EX_G0901534] Funding Source: Medline; MRC [MC_EX_G0901534] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4901	4902		10.1038/s41388-018-0321-1	http://dx.doi.org/10.1038/s41388-018-0321-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	30068941	Bronze			2022-12-28	WOS:000443146000010
J	Begum, S; Yiu, A; Stebbing, J; Castellano, L				Begum, S.; Yiu, A.; Stebbing, J.; Castellano, L.			Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas	ONCOGENE			English	Article								The previously unchartered gene expression territory governed by circular RNAs is becoming clearer with the onset of deeper sequencing technologies. The translation of circular RNAs remained a controversial theory until earlier this year, when two studies [1, 2] showed endogenous circular RNA translation in vitro and in vivo, and have further provided mechanistical evidence. In this edition of Oncogene, Zhang et al., provide evidence for the first circular RNA translated with relevance to cancer; a novel tumour suppressor protein, SHPRH-146aa, produced by circ-SHPRH driven by IRES elements. The novel tumour suppressor protein produced by the circular RNA was found to work in synergy with the full-length protein, behaving as a protective decoy molecule to decrease degradation, and thus increasing the tumour suppressive functionality of the gene. An extended patient survival time was seen in glioblastoma patients with elevated levels of SHPRH-146aa. This study also marks the discovery of the first circular RNA with an overlapping initiation and termination codon, resulting in the translation of the full circRNA, exploring a mechanism not previously found or seen.	[Begum, S.] Imperial Coll London, Dept Surg & Canc, Fac Med, Div Computat & Syst Med, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England; [Yiu, A.; Stebbing, J.; Castellano, L.] Imperial Coll London, Fac Med, Div Canc, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England; [Castellano, L.] Univ Sussex, Sch Life Sci, John Maynard Smith Bldg, Brighton BN1 9QG, E Sussex, England	Imperial College London; Imperial College London; University of Sussex	Castellano, L (corresponding author), Imperial Coll London, Fac Med, Div Canc, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.; Castellano, L (corresponding author), Univ Sussex, Sch Life Sci, John Maynard Smith Bldg, Brighton BN1 9QG, E Sussex, England.	l.castellano@imperial.ac.uk	Castellano, Leandro/AAE-1366-2021	Castellano, Leandro/0000-0002-3059-4829; Begum, Sofina/0000-0001-7689-0087; Stebbing, Justin/0000-0002-1117-6947	Department of Health [NIHR-RP-011-053] Funding Source: Medline	Department of Health		CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hou LD, 2017, INT J IMMUNOPATH PH, V30, P1, DOI 10.1177/0394632016686985; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Kumar S, 2017, NATURE, V547, P40, DOI 10.1038/nature23085; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552; Rasool Mahmood, 2016, Noncoding RNA Res, V1, P69, DOI 10.1016/j.ncrna.2016.11.001; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122	14	73	75	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4055	4057		10.1038/s41388-018-0230-3	http://dx.doi.org/10.1038/s41388-018-0230-3			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706655				2022-12-28	WOS:000439847000001
J	Gattelli, A; Sola, MEG; Roloff, TC; Cardiff, RD; Kordon, EC; Chodosh, LA; Hynes, NE				Gattelli, Albana; Garcia Sola, Martin E.; Roloff, Tim C.; Cardiff, Robert D.; Kordon, Edith C.; Chodosh, Lewis A.; Hynes, Nancy E.			Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition	ONCOGENE			English	Article							BREAST-CANCER CELLS; TRANSGENIC MICE; GENE; RESISTANCE; LANDSCAPE; FUSIONS; GROWTH	The receptor tyrosine kinase Ret, a key gain-of-function mutated oncoprotein in thyroid carcinomas, has recently been implicated in other cancer types. While Ret copy number gains and mutations have been reported at low frequencies in breast tumors, we and others have reported that Ret is overexpressed in about 40% of human tumors and this correlates with poor patient prognosis. Ret activation regulates numerous intracellular pathways related to proliferation and inflammation, but it is not known whether abnormal Ret expression is sufficient to induce mammary carcinomas. Using a novel doxycycline-inducible transgenic mouse model with the MMTV promoter controlling Ret expression, we show that overexpression of wild-type Ret in the mammary epithelium produces mammary tumors, displaying a morphology that recapitulates characteristics of human luminal breast tumors. Ret-evoked tumors are estrogen receptor positive and negative for progesterone receptor. Moreover, tumors rapidly regress after doxycycline withdrawal, indicating that Ret is the driving oncoprotein. Using next-generation sequencing, we examined the levels of transcripts in these tumors, confirming a luminal signature. Ret-evoked tumors have been passaged in mice and used to test novel therapeutic approaches. Importantly, we have determined that tumors are resistant to endocrine therapy, but respond successfully to treatment with a Ret kinase inhibitor. Our data provide the first compelling evidence for an oncogenic role of non-mutated Ret in the mammary gland and are an incentive for clinical development of Ret as a cancer biomarker and therapeutic target.	[Gattelli, Albana; Garcia Sola, Martin E.; Kordon, Edith C.] UBA, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Gattelli, Albana; Garcia Sola, Martin E.; Kordon, Edith C.] UBA, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, RA-1428 CABA Buenos Aires, Argentina; [Gattelli, Albana; Roloff, Tim C.; Hynes, Nancy E.] Friedrich Miescher Inst Biomed Res FMI, Maulbeerstr 66, CH-4058 Basel, Switzerland; [Cardiff, Robert D.] UCD, Ctr Genom Pathol, Sch Med, Pathol & Lab Med, Cty Rd 98 & Hutchison Dr, Davis, CA USA; [Chodosh, Lewis A.] Univ Penn Upenn, Perelman Sch Med, Dept Canc Biol, 614 BRB II-III,421 Curie Blvd, Philadelphia, PA USA; [Hynes, Nancy E.] Univ Basel, CH-4002 Basel, Switzerland	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Friedrich Miescher Institute for Biomedical Research; University of Pennsylvania; Pennsylvania Medicine; University of Basel	Gattelli, A (corresponding author), UBA, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina.; Gattelli, A (corresponding author), UBA, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, RA-1428 CABA Buenos Aires, Argentina.; Gattelli, A; Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res FMI, Maulbeerstr 66, CH-4058 Basel, Switzerland.; Hynes, NE (corresponding author), Univ Basel, CH-4002 Basel, Switzerland.	albanaga@fbmc.fcen.uba.ar; Nancy.Hynes@fmi.ch		Gattelli, Albana/0000-0003-1260-5413; Garcia Sola, Martin E/0000-0002-0229-8870	Susan G. Komen for the Cure(R) [KG101234, SAC110041]; Fundacion para el Progreso de la Medicina Cordoba [02]; Krebsliga beider Basel [10-2030]; Novartis Research Foundation	Susan G. Komen for the Cure(R)(Susan G. Komen Breast Cancer Foundation); Fundacion para el Progreso de la Medicina Cordoba; Krebsliga beider Basel; Novartis Research Foundation	AG was supported by grant KG101234 from Susan G. Komen for the Cure (R) and grant GF No 02 from Fundacion para el Progreso de la Medicina Cordoba. NEH was supported by grants from Susan G. Komen for the Cure (R) SAC110041, from Krebsliga beider Basel 10-2030 and by the Novartis Research Foundation.	Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Avalle Lidia, 2012, JAKSTAT, V1, P65, DOI 10.4161/jkst.20045; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Gattelli A, 2013, EMBO MOL MED, V5, P1335, DOI 10.1002/emmm.201302625; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; IWAMOTO T, 1990, ONCOGENE, V5, P535; Kang J, 2012, ONCOGENE, V31, P402, DOI 10.1038/onc.2011.553; Kohno T, 2013, CANCER SCI, V104, P1396, DOI 10.1111/cas.12275; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Plaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209; Rakha EA, 2007, J CLIN ONCOL, V25, P4772, DOI 10.1200/JCO.2007.12.2747; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Spanheimer PM, 2014, CLIN CANCER RES, V20, P2115, DOI 10.1158/1078-0432.CCR-13-2221; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807	25	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4046	4054		10.1038/s41388-018-0235-y	http://dx.doi.org/10.1038/s41388-018-0235-y			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695833				2022-12-28	WOS:000439101300010
J	Sun, LX; Xu, XH; Chen, YJ; Zhou, YX; Tan, R; Qiu, HT; Jin, LT; Zhang, WY; Fan, R; Hong, WJ; Wang, TL				Sun, Lixiang; Xu, Xiaohui; Chen, Yongjun; Zhou, Yuxia; Tan, Ran; Qiu, Hantian; Jin, Liting; Zhang, Wenyi; Fan, Rong; Hong, Wanjin; Wang, Tuanlao			Rab34 regulates adhesion, migration, and invasion of breast cancer cells	ONCOGENE			English	Article							VESICLE TRAFFICKING; ALPHA-5-BETA-1 INTEGRIN; 3D MICROENVIRONMENTS; SRC KINASE; ENDOCYTOSIS; GTPASES; MACROPINOCYTOSIS; PATHWAY; DISEASE; PROTEIN	The small GTPase Rab34 regulates spatial distribution of the lysosomes, secretion, and macropinocytosis. In this study, we found that Rab34 is over-expressed in aggressive breast cancer cells, implying a potential role of Rab34 in breast cancer. Silencing Rab34 by shRNA inhibits cell migration, invasion, and adhesion of breast cancer cells. Rab34 specifically binds to the cytoplasmic tail of integrin beta 3, and depletion of Rab34 promotes the degradation of integrin beta 3. Interestingly, EGF induces the translocation of Rab34 to the membrane ruffle, which is greatly enhanced by the expression of Src kinase. Accordingly, Rab34 is tyrosine phosphorylated by Src at Y247 residue. A mutant mimicking phosphorylated form of Rab34 (Rab34Y247D) promotes cell migration and invasion. Importantly, the tyrosine phosphorylation of Rab34 is inhibited in cells in suspension, and increased with the cells re-adhesion. In addition, Rab34Y247D promotes cell adhesion, and enhances integrin beta 3 endocytosis and recycling. The results uncover a role of Rab34 in migration and invasion of breast cancer cells and its involvement in cancer metastasis, and provide a novel mechanism of tyrosine phosphorylation of Rab34 in regulating cell migration, invasion, and adhesion through modulating the endocytosis, stability, and recycling of integrin beta 3.	[Sun, Lixiang; Xu, Xiaohui; Chen, Yongjun; Zhou, Yuxia; Qiu, Hantian; Jin, Liting; Zhang, Wenyi; Fan, Rong; Hong, Wanjin; Wang, Tuanlao] Xiamen Univ, Sch Pharmaceut Sci, State Key Lab Cellular Stress Biol, Fujian Prov Key Lab Innovat Drug Target Res, Xiamen 361005, Peoples R China; [Tan, Ran] State Ocean Adm, Inst Oceanog 3, Xiamen 361005, Peoples R China; [Hong, Wanjin] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore	Xiamen University; State Oceanic Administration; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ; Wang, TL (corresponding author), Xiamen Univ, Sch Pharmaceut Sci, State Key Lab Cellular Stress Biol, Fujian Prov Key Lab Innovat Drug Target Res, Xiamen 361005, Peoples R China.; Hong, WJ (corresponding author), ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg; xmuibrwtl@xmu.edu.cn		Sun, Lixiang/0000-0002-0287-4831	National Natural Science Foundation of China [31371353, 31671478]; International Science & Technology Cooperation Program of China [2013DFG32730]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Science & Technology Cooperation Program of China	This work was supported by National Natural Science Foundation of China (No. 31371353 and No. 31671478) and International Science & Technology Cooperation Program of China (No. 2013DFG32730). The cDNA of integrin beta 1 and integrin beta 3 were kindly provided by Dr. Jiahuai Han (State Key Laboratory of Cellular Stress Biology, Xiamen University, China).	Agola JO, 2011, CLIN GENET, V80, P305, DOI 10.1111/j.1399-0004.2011.01724.x; Alanko J, 2016, TRENDS CELL BIOL, V26, P391, DOI 10.1016/j.tcb.2016.02.001; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Balzac F, 2005, J CELL SCI, V118, P4765, DOI 10.1242/jcs.02584; Bhuin T, 2014, EXP CELL RES, V328, P1, DOI 10.1016/j.yexcr.2014.07.027; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Coyne CB, 2007, CELL HOST MICROBE, V2, P181, DOI 10.1016/j.chom.2007.07.003; Di Florio A, 2007, ENDOCR-RELAT CANCER, V14, P111, DOI 10.1677/erc.1.01318; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Goldenberg NM, 2007, MOL BIOL CELL, V18, P4762, DOI 10.1091/mbc.E06-11-0991; Gu ZZ, 2011, J CELL BIOL, V193, P61, DOI 10.1083/jcb.201007003; Harris KP, 2011, CURR BIOL, V21, pR841, DOI 10.1016/j.cub.2011.08.061; Hawes CR, 1999, CURR OPIN PLANT BIOL, V2, P454, DOI 10.1016/S1369-5266(99)00023-0; Igarashi T, 2017, ONCOTARGET, V8, P12290, DOI 10.18632/oncotarget.14703; Ihemelandu CU, 2008, AM J SURG, V195, P153, DOI 10.1016/j.amjsurg.2007.09.033; Iwamoto DV, 2015, CURR OPIN CELL BIOL, V36, P41, DOI 10.1016/j.ceb.2015.06.009; Lee U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082125; Lin XS, 2017, CELL SIGNAL, V35, P84, DOI 10.1016/j.cellsig.2017.03.006; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Mettlen M, 2006, TRAFFIC, V7, P589, DOI 10.1111/j.1600-0854.2006.00412.x; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019; Porther N, 2015, Small GTPases, V6, P135, DOI 10.1080/21541248.2015.1050152; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; SALISBURY JL, 1983, INT REV EXP PATHOL, V24, P1; Spang A, 2008, CELL MOL LIFE SCI, V65, P2781, DOI 10.1007/s00018-008-8349-y; Speight P, 2005, TRAFFIC, V6, P858, DOI 10.1111/j.1600-0854.2005.00321.x; Starling GP, 2016, EMBO REP, V17, P823, DOI 10.15252/embr.201541382; Stein MP, 2003, ADV DRUG DELIVER REV, V55, P1421, DOI 10.1016/j.addr.2003.07.009; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Subramani D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-312; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; Tang BL, 2009, CELL MOTIL CYTOSKEL, V66, P365, DOI 10.1002/cm.20376; Valdembri D, 2012, CURR OPIN CELL BIOL, V24, P582, DOI 10.1016/j.ceb.2012.08.004; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang HJ, 2015, TUMOR BIOL, V36, P1573, DOI 10.1007/s13277-014-2732-0; Wang TL, 2004, MOL BIOL CELL, V15, P815, DOI 10.1091/mbc.E03-06-0413; Wang TL, 2002, MOL BIOL CELL, V13, P4317, DOI 10.1091/mbc.E02-05-0280; Wang TL, 2012, J CELL PHYSIOL, V227, P2788, DOI 10.1002/jcp.23023; Wright PK, 2008, RECENT PAT ANTI-CANC, V3, P137, DOI 10.2174/157489208784638730; Xiao R, 2013, BLOOD, V121, P700, DOI 10.1182/blood-2012-07-440644; Zhang B, 2015, GENET TEST MOL BIOMA, V19, P69, DOI 10.1089/gtmb.2014.0210; Zhang JX, 2016, THERANOSTICS, V6, P2099, DOI 10.7150/thno.16587; Zhang XD, 2017, NANOSCALE, V9, P150, DOI 10.1039/c6nr07866d	55	20	20	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3698	3714		10.1038/s41388-018-0202-7	http://dx.doi.org/10.1038/s41388-018-0202-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622794				2022-12-28	WOS:000437975200007
J	Monterisi, S; Lo Riso, P; Russo, K; Bertalot, G; Vecchi, M; Testa, G; Di Fiore, PP; Bianchi, F				Monterisi, Simona; Lo Riso, Pietro; Russo, Karin; Bertalot, Giovanni; Vecchi, Manuela; Testa, Giuseppe; Di Fiore, Pier Paolo; Bianchi, Fabrizio			HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype	ONCOGENE			English	Article							CELL-PROLIFERATION; BREAST-CANCER; MALIGNANT PROGRESSION; SURVIVAL PREDICTION; GROWTH-FACTOR; EXPRESSION; GENE; LET-7; CARCINOMA; OCT4	HOXB7 is a homeodomain (HOX) transcription factor involved in regional body patterning of invertebrates and vertebrates. We previously identified HOXB7 within a ten-gene prognostic signature for lung adenocarcinoma, where increased expression of HOXB7 was associated with poor prognosis. This raises the question of how HOXB7 overexpression can influence the metastatic behavior of lung adenocarcinoma. Here, we analyzed publicly available microarray and RNA-seq lung cancer expression datasets and found that HOXB7-overexpressing tumors are enriched in gene signatures characterizing adult and embryonic stem cells (SC), and induced pluripotent stem cells (iPSC). Experimentally, we found that HOXB7 upregulates several canonical SC/iPSC markers and sustains the expansion of a subpopulation of cells with SC characteristics, through modulation of LIN28B, an emerging cancer gene and pluripotency factor, which we discovered to be a direct target of HOXB7. We validated this new circuit by showing that HOXB7 enhances reprogramming to iPSC with comparable efficiency to LIN28B or its target c-MYC, which is a canonical reprogramming factor.	[Monterisi, Simona; Bertalot, Giovanni; Di Fiore, Pier Paolo; Bianchi, Fabrizio] European Inst Oncol, Mol Med Program, I-20141 Milan, Italy; [Monterisi, Simona; Russo, Karin; Vecchi, Manuela; Di Fiore, Pier Paolo] Mol Oncol Fdn, FIRC Inst, IFOM, I-20139 Milan, Italy; [Lo Riso, Pietro; Testa, Giuseppe] European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; [Testa, Giuseppe; Di Fiore, Pier Paolo] Univ Milan, Dept Oncol & Hematooncol, DIPO, I-20122 Milan, Italy; [Bianchi, Fabrizio] Regenerat Med & Innovat Therapies IRCCS Casa Soll, Inst Stem Cell Biol, ISBREMIT, I-71013 San Giovanni Rotondo, FG, Italy; [Monterisi, Simona] Humanitas Clin & Res Ctr, I-20089 Rozzano, MI, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; IRCCS Humanitas Research Hospital	Bianchi, F (corresponding author), European Inst Oncol, Mol Med Program, I-20141 Milan, Italy.; Bianchi, F (corresponding author), Regenerat Med & Innovat Therapies IRCCS Casa Soll, Inst Stem Cell Biol, ISBREMIT, I-71013 San Giovanni Rotondo, FG, Italy.	f.bianchi@operapadrepio.it	Bertalot, Giovanni/O-8878-2017; Bianchi, Fabrizio/B-5995-2017; Di Fiore, Pier Paolo/K-2130-2012; Bertalot, Giovanni/AAV-8788-2021; Bianchi, Fabrizio/W-7037-2019	Bianchi, Fabrizio/0000-0001-7412-8638; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bianchi, Fabrizio/0000-0001-7412-8638; Bertalot, Giovanni/0000-0002-4862-7705; LO RISO, PIETRO/0000-0003-2542-0637; Testa, Giuseppe/0000-0002-9104-0918	Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG17568, IG 10349, 14040, MCO 10.000]; Monzino Foundation	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Monzino Foundation	We thank Bruno Amati for kindly providing the pBABE-MYC plasmid. We are indebted to Giuseppina Bonizzi, Giovanna Jodice, Elena Belloni, Elena Marino, Francesca De Santis, Stefania Pirroni, Pietro Vella, Valentina Melocchi, Davide Disalvatore and Stefano Freddi for technical support. We thank Ugo Cavallaro for inspiring discussions and comments on the paper. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) (MFAG17568 to FB; IG 10349 and 14040 and MCO 10.000 to PPDF) and from the Monzino Foundation (to PPDF).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Kovochich AN, 2013, CANCER-AM CANCER SOC, V119, P529, DOI 10.1002/cncr.27725; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chien CS, 2015, CANCER RES, V75, P2553, DOI 10.1158/0008-5472.CAN-14-2215; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Dama E, 2017, CLIN CANCER RES, V23, P62, DOI 10.1158/1078-0432.CCR-15-3005; Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Errico MC, 2016, CANCER RES, V76, P2857, DOI 10.1158/0008-5472.CAN-15-3444; Hammachi F, 2012, CELL REPORTS, V1, P99, DOI 10.1016/j.celrep.2011.12.002; He XJ, 2017, ONCOTARGET, V8, P1247, DOI 10.18632/oncotarget.13604; Huan HB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0559-4; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533; Liu S, 2015, CANCER RES, V75, P709, DOI 10.1158/0008-5472.CAN-14-3100; Liu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083083; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morgan R, 2006, TRENDS GENET, V22, P67, DOI 10.1016/j.tig.2005.11.004; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; RIDDIHOUGH G, 1992, NATURE, V357, P643, DOI 10.1038/357643a0; Shao YB, 2015, AM J CANCER RES, V5, P2643; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Stadtfeld M, 2010, NAT METHODS, V7, P53, DOI [10.1038/NMETH.1409, 10.1038/nmeth.1409]; Storti P, 2011, LEUKEMIA, V25, P527, DOI 10.1038/leu.2010.270; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang PH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052088, 10.1371/journal.pone.0057020]; Wang XR, 2012, ONCOL LETT, V3, P955, DOI 10.3892/ol.2012.609; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; Wesselschmidt RL, 2011, METHODS MOL BIOL, V767, P231, DOI 10.1007/978-1-61779-201-4_17; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; Whitfield TW, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r50; Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470; Yamanaka S, 2011, GOOGLE PATENTS; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yan XP, 2013, ONCOL REP, V30, P2733, DOI 10.3892/or.2013.2784; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yuan WW, 2014, MOL CARCINOGEN, V53, P49, DOI 10.1002/mc.21947	57	23	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3575	3588		10.1038/s41388-018-0229-9	http://dx.doi.org/10.1038/s41388-018-0229-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29576613				2022-12-28	WOS:000436412500008
J	Stebbing, J; Shah, K; Lit, LC; Gagliano, T; Ditsiou, A; Wang, TT; Wendler, F; Simon, T; Szabo, KS; O'Hanlon, T; Dean, M; Roslani, AC; Cheah, SH; Lee, SC; Giamas, G				Stebbing, Justin; Shah, Kalpit; Lit, Lei Cheng; Gagliano, Teresa; Ditsiou, Angeliki; Wang, Tingting; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; O'Hanlon, Timothy; Dean, Michael; Roslani, April Camilla; Cheah, Swee Hung; Lee, Soo-Chin; Giamas, Georgios			LMTK3 confers chemo-resistance in breast cancer	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; LEMUR TYROSINE KINASE-3; COMET ASSAY; DNA-DAMAGE; NEOADJUVANT CHEMOTHERAPY; HISTONE H2AX; THERAPEUTIC TARGET; PROGNOSTIC ROLE; ACTIVATES ATM; CELL-DEATH	Lemur tyrosine kinase 3 (LMTK3) is an oncogenic kinase that is involved in different types of cancer (breast, lung, gastric, colorectal) and biological processes including proliferation, invasion, migration, chromatin remodeling as well as innate and acquired endocrine resistance. However, the role of LMTK3 in response to cytotoxic chemotherapy has not been investigated thus far. Using both 2D and 3D tissue culture models, we found that overexpression of LMTK3 decreased the sensitivity of breast cancer cell lines to cytotoxic (doxorubicin) treatment. In a mouse model we showed that ectopic overexpression of LMTK3 decreases the efficacy of doxorubicin in reducing tumor growth. Interestingly, breast cancer cells overexpressing LMTK3 delayed the generation of double strand breaks (DSBs) after exposure to doxorubicin, as measured by the formation of gamma H2AX foci. This effect was at least partly mediated by decreased activity of ataxia-telangiectasia mutated kinase (ATM) as indicated by its reduced phosphorylation levels. In addition, our RNA-seq analyses showed that doxorubicin differentially regulated the expression of over 700 genes depending on LMTK3 protein expression levels. Furthermore, these genes were found to promote DNA repair, cell viability and tumorigenesis processes / pathways in LMTK3-overexpressing MCF7 cells. In human cancers, immunohistochemistry staining of LMTK3 in pre- and postchemotherapy breast tumor pairs from four separate clinical cohorts revealed a significant increase of LMTK3 following both doxorubicin and docetaxel based chemotherapy. In aggregate, our findings show for the first time a contribution of LMTK3 in cytotoxic drug resistance in breast cancer.	[Stebbing, Justin; Lit, Lei Cheng] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England; [Shah, Kalpit; Dean, Michael] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Lit, Lei Cheng; Cheah, Swee Hung] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur 50603, Malaysia; [Gagliano, Teresa; Ditsiou, Angeliki; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Wang, Tingting; Lee, Soo-Chin] Canc Sci Inst Singapore, Ctr Life Sci, 28 Med Dr 02-15, Singapore, Singapore; [O'Hanlon, Timothy] Leidos Biomed Res Inc, NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Roslani, April Camilla] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia	Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universiti Malaya; University of Sussex; National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universiti Malaya	Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	g.giamas@sussex.ac.uk	Dean, Michael C/G-8172-2012; Lee, Soo Chin/S-9111-2016; Giamas, Georgios/AAP-3487-2021; wang, tingting/AAK-2640-2020; Dean, Michael/R-7501-2019; Roslani, April Camilla/B-8245-2010; Lit, Lei Cheng/AAS-9778-2021; Gagliano, Teresa/G-1645-2015	Dean, Michael C/0000-0003-2234-0631; Lee, Soo Chin/0000-0002-5835-6419; Roslani, April Camilla/0000-0003-2458-965X; Lit, Lei Cheng/0000-0002-3210-4491; Gagliano, Teresa/0000-0002-4877-6292; Giamas, Georgios/0000-0002-4417-2707; O'Hanlon, Timothy/0000-0003-2759-733X; Simon, Thomas/0000-0002-3280-2716; Stebbing, Justin/0000-0002-1117-6947	High Impact Research Chancellery Grant [UM.C/625/1/HIR/179]; Action Against Cancer; National Institute for Health Research (NIHR); Colin McDavid Family Trust; Swire Charitable Trust; intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	High Impact Research Chancellery Grant; Action Against Cancer; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Colin McDavid Family Trust; Swire Charitable Trust; intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	This work was supported by grants from: (i) The High Impact Research Chancellery Grant UM.C/625/1/HIR/179 (University of Malaya); (ii) Action Against Cancer; (iii) The National Institute for Health Research (NIHR); (iv) The Colin McDavid Family Trust; (v) The Swire Charitable Trust; (vi) Charles and Diane Herlinger; (vii) Mr Alessandro Dusi and (viii) The intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. Infrastructure support was provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre, the Imperial Biomedical Research Centre (BRC) and the University of Sussex. This work utilized the computational resources of the NIH HPC Biowulf cluster and DCEG CCAD cluster. (http://hpc.nih.gov). We thank Sara Bass for her assistance in library preparation and sequencing.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Azqueta A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00288; Bakkenist Christopher J, 2015, Oncoscience, V2, P542; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brum G, 2013, INT J ONCOL, V42, P211, DOI 10.3892/ijo.2012.1680; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Davies AR, 2014, J CLIN ONCOL, V32, P2983, DOI 10.1200/JCO.2014.55.9070; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Giamas G, 2007, BIOCHEM J, V406, P389, DOI 10.1042/BJ20070091; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gianni L, 2014, LANCET ONCOL, V15, P640, DOI 10.1016/S1470-2045(14)70080-4; Gundry C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14646; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Hatzis C, 2016, CLIN CANCER RES, V22, P26, DOI 10.1158/1078-0432.CCR-14-3304; Jacob J, 2016, CANCER LETT, V372, P137, DOI 10.1016/j.canlet.2015.12.026; Jung EJ, 2008, EXP MOL MED, V40, P276, DOI 10.3858/emm.2008.40.3.276; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee SC, 2009, PHARMACOGENET GENOM, V19, P181, DOI 10.1097/FPC.0b013e32831ebb5d; Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200; Li HP, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-196; Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200; Li ZG, 2014, MOL CLIN ONCOL, V2, P756, DOI 10.3892/mco.2014.301; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lucas X, 2013, NUCLEIC ACIDS RES, V41, pD1130, DOI 10.1093/nar/gks1253; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Nunes J, 2016, ONCOTARGET, V7, P27599, DOI 10.18632/oncotarget.8504; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890; Peng ZH, 2015, J AM CHEM SOC, V137, P6726, DOI 10.1021/jacs.5b00922; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Senavirathna LK, 2013, THERANOSTICS, V3, P687, DOI 10.7150/thno.6381; Shah K, 2015, ONCOTARGET, V6, P14233, DOI 10.18632/oncotarget.3899; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; Shi HB, 2014, INT J CLIN EXP PATHO, V7, P1101; Shi HB, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0754-x; Smart DJ, 2008, MUTAT RES-FUND MOL M, V641, P43, DOI 10.1016/j.mrfmmm.2008.03.005; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stebbing J, 2013, ONCOGENE, V32, P3371, DOI 10.1038/onc.2012.343; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; von Minckwitz G, 2016, EUR J CANCER, V64, P12, DOI 10.1016/j.ejca.2016.05.015; Wakatsuki T, 2013, MOL CANCER THER, V12, P2261, DOI 10.1158/1535-7163.MCT-12-1134; Wang X, 2013, BIOMATERIALS, V34, P4667, DOI 10.1016/j.biomaterials.2013.03.008; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; Xu YC, 2015, CELL REP, V12, P837, DOI 10.1016/j.celrep.2015.06.073; Xu YC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005170; Xu ZG, 2014, TUMOR BIOL, V35, P5007, DOI 10.1007/s13277-014-1660-3; Yamasaki M, 2017, ANN ONCOL, V28, P116, DOI 10.1093/annonc/mdw439; Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002; Yu KD, 2013, CLIN CANCER RES, V19, P2723, DOI 10.1158/1078-0432.CCR-12-2986; Zhang KX, 2015, INT J CLIN EXP PATHO, V8, P629; Zhao GQ, 2013, DNA CELL BIOL, V32, P699, DOI 10.1089/dna.2013.2130; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	70	20	21	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3113	3130		10.1038/s41388-018-0197-0	http://dx.doi.org/10.1038/s41388-018-0197-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540829	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000434641400006
J	Itoh, H; Kadomatsu, T; Tanoue, H; Yugami, M; Miyata, K; Endo, M; Morinaga, J; Kobayashi, E; Miyamoto, T; Kurahashi, R; Terada, K; Mizuta, H; Oike, Y				Itoh, Hitoshi; Kadomatsu, Tsuyoshi; Tanoue, Hironori; Yugami, Masaki; Miyata, Keishi; Endo, Motoyoshi; Morinaga, Jun; Kobayashi, Eisuke; Miyamoto, Takeshi; Kurahashi, Ryoma; Terada, Kazutoyo; Mizuta, Hiroshi; Oike, Yuichi			TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; INTEGRATIVE ANALYSIS; DNA METHYLATION; STROMAL CELLS; C-MYC; CANCER; EXPRESSION; METABOLISM; GROWTH; STAT3	The tumor microenvironment promotes epigenetic changes in tumor cells associated with tumor aggressiveness. Here we report that in primary tumor cells, increased interleukin-6 (IL-6) expression brought on by DNA demethylation of its promoter by ten-eleven translocation 2 (TET2) promotes lung metastasis in osteosarcoma (OS). Xenograft experiments show increased IL-6 expression and decreased methylation of its promoter in OS cells after implantation relative to before implantation. In addition, changes in IL-6 methylation and expression seen in OS cells at the primary site were maintained at the metastatic site. TET2 knockdown in OS cells suppressed upregulation of IL-6 and demethylation of its promoter in xenograft tumors and decreased tumor metastasis. We also present evidence showing that tumor cell-derived IL-6 facilitates glycolytic metabolism in tumor cells by activating the MEK/ERK1/2/hypoxia-inducible transcription factor-1 alpha (HIF-1 alpha) pathway and increases lung colonization by OS cells by upregulating expression of intercellular adhesion molecule-1 (ICAM-1), enhancing tumor metastasis. Blocking IL-6 signaling with a humanized monoclonal antibody against the IL-6 receptor reduced lung metastasis and prolonged survival of xenografted mice. These findings suggest that TET2-dependent IL-6 induction enables acquisition of aggressive phenotypes in OS cells via the tumor microenvironment and that blocking IL-6 signaling could be serve as a potential therapy to antagonize metastasis.	[Itoh, Hitoshi; Kadomatsu, Tsuyoshi; Tanoue, Hironori; Yugami, Masaki; Miyata, Keishi; Endo, Motoyoshi; Morinaga, Jun; Kurahashi, Ryoma; Terada, Kazutoyo; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Itoh, Hitoshi; Tanoue, Hironori; Yugami, Masaki; Mizuta, Hiroshi] Kumamoto Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Morinaga, Jun] Kumamoto Univ, Grad Sch Med Sci, Clin Res Ctr, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Morinaga, Jun] Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Kobayashi, Eisuke; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608525, Japan; [Kobayashi, Eisuke] Natl Canc Ctr, Div Muscloskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Kurahashi, Ryoma] Kumamoto Univ, Grad Sch Med Sci, Dept Urol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Oike, Yuichi] Japan Agcy Med Res & Dev, AMED, CREST, Tokyo, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Keio University; National Cancer Center - Japan; Kumamoto University; Japan Science & Technology Agency (JST)	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Japan Agcy Med Res & Dev, AMED, CREST, Tokyo, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Endo, Motoyoshi/T-5840-2019; Miyata, Keishi/HGF-1876-2022	Miyata, Keishi/0000-0003-0336-1859	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [26116722, 15K06836, 17K08663]; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) [13417915]; CREST program of the Japan Agency for Medical Research and Development (AMED) [17gm0610007h0005]	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); CREST program of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	We thank our colleagues for valuable suggestions and discussion. We also thank K. Tabu, N. Shirai, S. Iwaki, Y. Shogenji, and M. Kamada for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 26116722 to YO, grant 15K06836 to TK, grant 17K08663 to ME), and by the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) (grant 13417915 to YO) and by the CREST program of the Japan Agency for Medical Research and Development (AMED) (grant 17gm0610007h0005 to YO).	Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018-015-1918-y; Avnet S, 2017, INT J CANCER, V140, P1331, DOI 10.1002/ijc.30540; Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078-0432.CCR-16-2726; Bharti R, 2016, CANCER LETT, V375, P51, DOI 10.1016/j.canlet.2016.02.048; Bian ZY, 2010, CANCER SCI, V101, P2554, DOI 10.1111/j.1349-7006.2010.01731.x; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Chen QC, 2015, MOL MED REP, V12, P219, DOI 10.3892/mmr.2015.3375; Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Demaria M, 2012, CELL DEATH DIFFER, V19, P1390, DOI 10.1038/cdd.2012.20; Deng M, 2017, CANCER RES, V77, P6069, DOI 10.1158/0008-5472.CAN-16-2964; Eason K, 2016, CANCER RES, V76, P5195, DOI 10.1158/0008-5472.CAN-16-0141; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Flint TR, 2017, TRENDS MOL MED, V23, P451, DOI 10.1016/j.molmed.2017.03.001; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Goumas FA, 2015, INT J CANCER, V137, P1035, DOI 10.1002/ijc.29445; Guo X, 2011, NEOPLASMA, V58, P153, DOI 10.4149/neo_2011_02_153; Han J, 2016, ONCOL LETT, V12, P4665, DOI 10.3892/ol.2016.5227; Han XG, 2015, CANCER LETT, V369, P405, DOI 10.1016/j.canlet.2015.09.002; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He XD, 2016, CANCER BIOL THER, V17, P188, DOI 10.1080/15384047.2016.1139228; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Isobe A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118080; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kadomatsu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057921; Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956; Lamora A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110096; Lin YM, 2013, CANCER LETT, V328, P135, DOI 10.1016/j.canlet.2012.08.029; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040; Mauer J, 2015, TRENDS IMMUNOL, V36, P92, DOI 10.1016/j.it.2014.12.008; Meyer FRL, 2015, VET J, V206, P67, DOI 10.1016/j.tvjl.2015.06.003; Mylonis I, 2017, J CELL SCI, V130, P466, DOI 10.1242/jcs.195339; Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Ohba T, 2014, MOL CANCER RES, V12, P1100, DOI 10.1158/1541-7786.MCR-14-0037; Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182; Okada S, 2008, INT J HEMATOL, V88, P476, DOI 10.1007/s12185-008-0215-z; Qiu GZ, 2017, TRENDS PHARMACOL SCI, V38, P669, DOI 10.1016/j.tips.2017.05.002; Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115; Reimann E, 2014, HUM GENOMICS, V8, DOI 10.1186/s40246-014-0020-0; Rokavec M, 2016, CELL MOL LIFE SCI, V73, P23, DOI 10.1007/s00018-015-2045-5; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Smida J, 2017, INT J CANCER, V141, P816, DOI 10.1002/ijc.30778; Soga T, 2013, CANCER SCI, V104, P275, DOI 10.1111/cas.12085; Tu B, 2012, CANCER LETT, V325, P80, DOI 10.1016/j.canlet.2012.06.006; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Ueda J, 2014, MOL CELL BIOL, V34, P3702, DOI 10.1128/MCB.00099-14; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233; Wilson C, 2017, ONCOGENE, V36, P2565, DOI 10.1038/onc.2016.412; Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	70	33	33	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2903	2920		10.1038/s41388-018-0160-0	http://dx.doi.org/10.1038/s41388-018-0160-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515232				2022-12-28	WOS:000433936300001
J	Fendrich, V; Jendryschek, F; Beeck, S; Albers, M; Lauth, M; Esni, F; Heeger, K; Dengler, J; Slater, EP; Holler, JPN; Baier, A; Bartsch, DK; Waldmann, J				Fendrich, Volker; Jendryschek, Frederike; Beeck, Saskia; Albers, Max; Lauth, Matthias; Esni, Farzad; Heeger, Kristin; Dengler, Janina; Slater, Emily P.; Holler, Julia P. N.; Baier, Aninja; Bartsch, Detlef K.; Waldmann, Jens			Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; CANCER CELL-LINE; INTRAEPITHELIAL NEOPLASIA; IN-VIVO; METASTASIS; EXPRESSION; MOUSE; CHEMORESISTANCE; GENERATION	Pancreatic cancer (PDAC) is one of the most dismal of human malignancies. Inhibiting or delaying the progression of precursor lesions of PDAC, pancreatic intraepthial neoplasia (PanINs), to invasive cancer, would be a major step. In the present study, we used a transgenic murine model of pancreatic cancer to evaluate the impact of a conditional knockout of the transcription factor Snail1, a major factor in epithelial-to-mesenchymal transition, on acinar-to-ductal formation and on PanIN progression. By interbreeding conditional LsL-Snail(floxf/wt); LsL-Kras(G12D) and Pdx1-Cre strains, we obtained LsL-KrasG12D; Pdx1-Cre(KP) mice, Snail1 heterozygous knockout LsL-KrasG12D; LsL-Snail(flox/-); Pdx1-Cre(KPShet) mice or Snail1 homozygous knockout LsL-Kras(G12D); LsL-Snail(flox/flox); Pdx1-Cre(KPS) mice. Mice were then followed in a longitudinal study for 2, 4, 6, 8, 10, and 12 months. Furthermore, in mice with a genetic or pharmacological inhibition of Snail1, using the Snail1 inhibitor GN25, a model of pancreatic injury by administration of cerulein was introduced to evaluate ADM formation in this setting. A translational approach with a tissue microarray (TMA) of human PanINs and an in vivo nude mouse platform to test GN25 in human pancreatic adenocarcinoma was then adopted. Quantification of PanINs showed delayed initiation and progression of PanIN lesions at all ages in both homozygous and heterozygous Snaildel1; Pdx-1-Cre; LSL-Kras(G12D/+)-Mice. PanINs at TMA revealed snail expression in the majority of cases. GN25 showed growth inhibition in 2/2 human pancreatic adenocarcinomas using a nude mice in vivo platform. Genetic and pharmacologic abrogation of Snail1 signaling in exocrine pancreas impairs development of acinar-to-ductal metaplasia following cerulein-mediated pancreatic injury. The present study suggests a fundamental new approach to delay the progression of PDAC.	[Fendrich, Volker; Jendryschek, Frederike; Beeck, Saskia; Albers, Max; Dengler, Janina; Slater, Emily P.; Baier, Aninja; Bartsch, Detlef K.; Waldmann, Jens] Univ Marburg, Dept Surg, Marburg, Germany; [Lauth, Matthias] IMT, Marburg, Germany; [Esni, Farzad] Univ Pittsburgh, Dept Surg, John G Rangos Res Ctr, Pittsburgh, PA USA; [Heeger, Kristin] Univ Hosp Giessen & Marburg, Dept Internal Med, Div Gastroenterol, Campus Marburg, Marburg, Germany; [Holler, Julia P. N.] Univ Hosp Giessen & Marburg, Dept Surg, Campus Giessen, Giessen, Germany	Philipps University Marburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University Hospital of Giessen & Marburg; University Hospital of Giessen & Marburg	Fendrich, V (corresponding author), Univ Marburg, Dept Surg, Marburg, Germany.	v.fendrich@web.de	Albers, Max/GZA-3575-2022; Esni, Farzad/AAX-1136-2021	Esni, Farzad/0000-0002-0342-6862; Lauth, Matthias/0000-0001-5922-5384	Sander Stiftung	Sander Stiftung	Grant support: VF and ML were supported by a Research Grant from the Sander Stiftung	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Feldmann G, 2007, J HEPATO-BILIARY-PAN, V14, P224, DOI 10.1007/s00534-006-1166-5; Fendrich V, 2008, GASTROENTEROLOGY, V135, P621, DOI 10.1053/j.gastro.2008.04.011; Fendrich V, 2014, NEUROENDOCRINOLOGY, V100, P300, DOI 10.1159/000368610; Fendrich V, 2010, GUT, V59, P630, DOI 10.1136/gut.2009.188961; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Murray SA, 2006, GENESIS, V44, P7, DOI 10.1002/gene.20178; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rhim AD, 2013, PANCREATOLOGY, V13, P114, DOI 10.1016/j.pan.2013.01.004; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; TANIGUCHI S, 1992, CLIN EXP METASTAS, V10, P259; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027; Zhang S, 2015, PANCREAS, V44, P1121, DOI 10.1097/MPA.0000000000000418; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	29	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1845	1856		10.1038/s41388-017-0100-4	http://dx.doi.org/10.1038/s41388-017-0100-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367759				2022-12-28	WOS:000429303300003
J	Liao, YN; Xia, XH; Liu, NN; Cai, JY; Guo, ZQ; Li, YL; Jiang, LL; Dou, QP; Tang, DL; Huang, HB; Liu, JB				Liao, Yuning; Xia, Xiaohong; Liu, Ningning; Cai, Jianyu; Guo, Zhiqiang; Li, Yanling; Jiang, Lili; Dou, Q. Ping; Tang, Daolin; Huang, Hongbiao; Liu, Jinbao			Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; PROSTATE-CANCER; ENZYME USP14; E3 LIGASE; ASSOCIATION; DEGRADATION; ACTIVATION; EXPRESSION; AURANOFIN	It has been well known that androgen receptor (AR) is critical to prostate cancer development and progression. It has also been documented that AR is expressed in more than 60% of breast tumors, which promotes the growth of estrogen receptor-negative (ER-)/AR-positive (AR(+)) breast cancer cells. Thus, AR might be a potential therapeutic target for AR-positive/ER-negative breast cancer patients. Previously we reported that in prostate cancer cells proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14) stabilized AR protein level by removing its ubiquitin chain. In the current study, we studied the USP14-AR protein interaction and cell proliferation status after USP14 reduction or inhibition in breast cancer cells, and our results support the conclusion that targeting USP14 is a novel strategy for treating AR-responsive breast cancer. We found that inhibition of USP14 accelerated the K48-ubiquitination and proteasome-mediated degradation of AR protein. Additionally, both genetic and pharmacological inhibition of USP14 significantly suppressed cell proliferation in AR-responsive breast cancer cells by blocking G(0)/G(1) to S phase transition and inducing apoptosis. Moreover, AR overexpression inhibited USP14 inhibition-induced events, suggesting that AR deubiquitination by USP14 is critical for breast cancer growth and USP14 inhibition is a possible strategy to treat AR-positive breast cancer.	[Liao, Yuning; Xia, Xiaohong; Cai, Jianyu; Guo, Zhiqiang; Li, Yanling; Jiang, Lili; Dou, Q. Ping; Huang, Hongbiao; Liu, Jinbao] Guangzhou Med Univ, Affiliated Canc Hosp, Prot Modificat & Degradat Lab, SKLRD,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Liu, Ningning] Guangzhou Med Univ, Guangzhou Inst Cardiovasc Dis, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China; [Dou, Q. Ping] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Dou, Q. Ping] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Tang, Daolin] Guangzhou Med Univ, Affiliated Hosp 3, Ctr DAMP Biol,Prot Modificat & Degradat Lab, Key Lab Major Obstet Dis Guangdong Prov,Key Lab R, Guangzhou, Guangdong, Peoples R China; [Tang, Daolin] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA	Guangzhou Medical University; Guangzhou Medical University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University; Guangzhou Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huang, HB; Liu, JB (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp, Prot Modificat & Degradat Lab, SKLRD,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.	hhb800616@126.com; jliu@gzhmu.edu.cn	li, yan/GTI-4638-2022; Tang, Daolin/B-2905-2010; Tang, Daolin/ABD-5062-2021	Tang, Daolin/0000-0002-1903-6180; Liu, Ningning/0000-0002-9587-2332; Dou, Qingping/0000-0002-6465-1473	National Natural Science Foundation of China [81472390, 81472762, 31671435]; National Funds for Developing Local Colleges and Universities [B16056001]; Science and Technology Program of Guangzhou [201604020001]; Pearl River S&T Nova Program of Guangzhou [201506010071]; Innovative Academic Team of Guangzhou Education System [1201610014]; Guangzhou Education Commission [1201610098]; Science and Technology Planning Project of Guangdong Province, China [2014A020212691, 2016A030308]; Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions [YQ2015136]; Project of Department of Education of Guangdong Province [2016KTSCX118, 2016KTSCX119]; Research Scholar Grant from the American Cancer Society [RSG-16-014-01-CDD]; National Institutes of Health, USA [R01CA160417, R01GM115366]; Natural Science Foundation of Guangdong Province [2016A030308011]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; NATIONAL CANCER INSTITUTE [R01CA160417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM115366] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Funds for Developing Local Colleges and Universities; Science and Technology Program of Guangzhou; Pearl River S&T Nova Program of Guangzhou; Innovative Academic Team of Guangzhou Education System; Guangzhou Education Commission; Science and Technology Planning Project of Guangdong Province, China; Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions; Project of Department of Education of Guangdong Province; Research Scholar Grant from the American Cancer Society(American Cancer Society); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. The study was supported by the National Natural Science Foundation of China (81472390, 81472762, and 31671435), the National Funds for Developing Local Colleges and Universities (B16056001), the Science and Technology Program of Guangzhou (201604020001), Pearl River S&T Nova Program of Guangzhou (201506010071), Innovative Academic Team of Guangzhou Education System (1201610014), General Project (1201610098) from Guangzhou Education Commission, the Science and Technology Planning Project of Guangdong Province, China (2014A020212691 and 2016A030308), a Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions (YQ2015136), the Project of Department of Education of Guangdong Province(2016KTSCX118, 2016KTSCX119), a Research Scholar Grant from the American Cancer Society (RSG-16-014-01-CDD), the National Institutes of Health, USA (R01CA160417 and R01GM115366), the Natural Science Foundation of Guangdong Province (2016A030308011), and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017). We thank the Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University for flow cytometry analysis.	Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Burska UL, 2013, J BIOL CHEM, V288, P32641, DOI 10.1074/jbc.M113.485912; Chen ST, 2015, J BIOL CHEM, V290, P21713, DOI 10.1074/jbc.M114.628255; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Dirac AMG, 2010, MOL CANCER RES, V8, P844, DOI 10.1158/1541-7786.MCR-09-0424; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Draker R, 2011, NUCLEIC ACIDS RES, V39, P3529, DOI 10.1093/nar/gkq1352; Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf; Faus H, 2005, MOL CELL ENDOCRINOL, V245, P138, DOI 10.1016/j.mce.2005.11.011; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Huang HB, 2016, ONCOTARGET, V7, P2796, DOI 10.18632/oncotarget.6425; Huang HBA, 2014, TOXICOL LETT, V228, P170, DOI 10.1016/j.toxlet.2014.05.012; Huang HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049062; Huang HB, 2011, CANCER LETT, V301, P221, DOI 10.1016/j.canlet.2010.12.015; Huang HB, 2010, CELL RES, V20, P1372, DOI 10.1038/cr.2010.123; Hurvitz SA, 2009, FUTURE ONCOL, V5, P1015, DOI 10.2217/FON.09.68; Lee BH, 2016, NATURE, V532, P398, DOI 10.1038/nature17433; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; Mialki RK, 2013, J BIOL CHEM, V288, P15437, DOI 10.1074/jbc.C112.446682; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Sahtoe DD, 2015, MOL CELL, V57, P887, DOI 10.1016/j.molcel.2014.12.039; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063; Shinji S, 2006, ONCOL REP, V15, P539; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Wang YY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0379-8; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032	40	73	76	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1896	1910		10.1038/s41388-017-0069-z	http://dx.doi.org/10.1038/s41388-017-0069-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353883	hybrid, Green Published			2022-12-28	WOS:000429303300007
J	O'Brien, KP; Khan, S; Gilligan, KE; Zafar, H; Lalor, P; Glynn, C; O'Flatharta, C; Ingoldsby, H; Dockery, P; De Bhulbh, A; Schweber, JR; St John, K; Leahy, M; Murphy, JM; Gallagher, WM; O'Brien, T; Kerin, MJ; Dwyer, RM				O'Brien, K. P.; Khan, S.; Gilligan, K. E.; Zafar, H.; Lalor, P.; Glynn, C.; O'Flatharta, C.; Ingoldsby, H.; Dockery, P.; De Bhulbh, A.; Schweber, J. R.; St John, K.; Leahy, M.; Murphy, J. M.; Gallagher, W. M.; O'Brien, T.; Kerin, M. J.; Dwyer, R. M.			Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379	ONCOGENE			English	Article							BREAST-CANCER; CYCLOOXYGENASE-2 EXPRESSION; STROMAL CELLS; EXOSOMES; METASTASIS; MECHANISM; APOPTOSIS; THERAPY; MIR-379; BRAIN	Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.	[O'Brien, K. P.; Khan, S.; Gilligan, K. E.; Glynn, C.; De Bhulbh, A.; Schweber, J. R.; St John, K.; Kerin, M. J.; Dwyer, R. M.] Natl Univ Ireland Galway, Lambe Inst Translat Res, Sch Med, Discipline Surg, Galway, Ireland; [Zafar, H.] Natl Univ Ireland Galway, Sch Med, Cardiovasc Res Ctr Galway, Galway, Ireland; [Lalor, P.; Dockery, P.] Natl Univ Ireland Galway, Sch Med, Discipline Anat, Galway, Ireland; [O'Flatharta, C.; Murphy, J. M.; O'Brien, T.] Natl Univ Ireland Galway, CURAM, Regenerat Med Inst REMEDI, Galway, Ireland; [Ingoldsby, H.] Univ Hosp Galway, Div Anat Pathol, Galway, Ireland; [Leahy, M.] Natl Univ Ireland Galway, Sch Phys, Tissue Opt & Microcirculat Imaging Grp, Galway, Ireland; [Gallagher, W. M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Canc Biol & Therapeut Lab, Dublin, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; University College Dublin	Dwyer, RM (corresponding author), Natl Univ Ireland Galway, Lambe Inst Translat Res, Sch Med, Discipline Surg, Galway, Ireland.	roisin.dwyer@nuigalway.ie	leahy, martin j/C-8383-2009; Dwyer, Roisin M/C-6654-2013	leahy, martin j/0000-0003-1558-4574; Dwyer, Roisin M/0000-0002-5854-0339; O'Brien, Killian/0000-0002-4340-6858; Gallagher, William/0000-0002-4307-5999; Gilligan, Katie/0000-0001-5669-293X; Dockery, Peter/0000-0001-5103-6589; Kerin, Michael/0000-0003-4164-5561	Irish Cancer Society BREAST-PREDICT collaborative cancer research center [CCRGAL13]; Irish Research Council (IRC) Postgraduate Scholarship [GOIPG/2016/978]; IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship [EPSPD/2016/20]; Wellcome Trust biomedical vacation scholarship; Health Research Board summer scholarship [SS-2015-1365]; Science Foundation Ireland from the European Union's 7th Framework Programme [09/SRC/B1794, 12/RI/2338, HEALTH-2007-B-223298]; charity Breast Cancer Research	Irish Cancer Society BREAST-PREDICT collaborative cancer research center; Irish Research Council (IRC) Postgraduate Scholarship(Irish Research Council for Science, Engineering and Technology); IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship; Wellcome Trust biomedical vacation scholarship(Wellcome Trust); Health Research Board summer scholarship; Science Foundation Ireland from the European Union's 7th Framework Programme(Science Foundation Ireland); charity Breast Cancer Research	KPO'B and SK: Irish Cancer Society BREAST-PREDICT collaborative cancer research center CCRGAL13; KEG: Irish Research Council (IRC) Postgraduate Scholarship GOIPG/2016/978; HZ: IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship EPSPD/2016/20. JRS and KSJ: Wellcome Trust biomedical vacation scholarship; ADB: Health Research Board summer scholarship SS-2015-1365. This research was also supported by Science Foundation Ireland grants 09/SRC/B1794 and 12/RI/2338, funding from the European Union's 7th Framework Programme under grant agreement no. HEALTH-2007-B-223298 (PurStem), and the charity Breast Cancer Research.	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Chen J S, 2016, Zhonghua Yi Xue Za Zhi, V96, P1450, DOI 10.3760/cma.j.issn.0376-2491.2016.18.013; Chen JS, 2016, CANCER LETT, V375, P73, DOI 10.1016/j.canlet.2016.02.043; Chen KH, 2016, ONCOTARGET, V7, P74537, DOI 10.18632/oncotarget.12902; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Clancy C, 2016, CANCER BIOMARK, V17, P427, DOI 10.3233/CBM-160659; Costa C, 2002, J CLIN PATHOL, V55, P429, DOI 10.1136/jcp.55.6.429; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Davoren PA, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-76; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Dwyer RM, 2011, STEM CELLS, V29, P1149, DOI 10.1002/stem.665; Gilligan KE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061122; Gururajan M, 2014, CLIN CANCER RES, V20, P6559, DOI 10.1158/1078-0432.CCR-14-1784; Heijblom M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11778; Hole P, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2101-8; Holmes MD, 2011, BREAST CANCER RES TR, V130, P657, DOI 10.1007/s10549-011-1651-7; Hwang DW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15636; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Katakowski M, 2013, CANCER LETT, V335, P201, DOI 10.1016/j.canlet.2013.02.019; Khan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068753; Laddha SV, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-10; Lai CP, 2014, ACS NANO, V8, P483, DOI 10.1021/nn404945r; Li K, 2017, YONSEI MED J, V58, P234, DOI 10.3349/ymj.2017.58.1.234; Li Z, 2017, J CELL MOL MED, V21, P315, DOI 10.1111/jcmm.12966; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maguire Mark T, 2010, Rehab Manag, V23, P20; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107; Mellin-Olsen J, 2010, EUR J ANAESTH, V27, P592, DOI 10.1097/EJA.0b013e32833b1adf; Momin Eric N., 2010, Current Immunology Reviews, V6, P137; Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Pollari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037361; Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489; Ristimaki A, 2002, CANCER RES, V62, P632; Roggan A, 1999, J BIOMED OPT, V4, P36, DOI 10.1117/1.429919; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh-Ranger G, 2002, EUR J SURG ONCOL, V28, P729, DOI 10.1053/ejso.2002.1329; Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39; Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622; Tian YH, 2014, BIOMATERIALS, V35, P2383, DOI 10.1016/j.biomaterials.2013.11.083; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Xu Z, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3443793; Yamamoto K, 2014, ONCOL REP, V32, P2365, DOI 10.3892/or.2014.3481; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001	51	103	105	2	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2137	2149		10.1038/s41388-017-0116-9	http://dx.doi.org/10.1038/s41388-017-0116-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29367765	Green Submitted			2022-12-28	WOS:000430589000005
J	Ikink, GJ; Boer, M; Bakker, ERM; Vendel-Zwaagstra, A; Klijn, C; ten Hoeve, J; Jonkers, J; Wessels, LF; Hilkens, J				Ikink, Gerjon J.; Boer, Mandy; Bakker, Elvira R. M.; Vendel-Zwaagstra, Annabel; Klijn, Chris; ten Hoeve, Jelle; Jonkers, Jos; Wessels, Lodewyk F.; Hilkens, John			Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance	ONCOGENE			English	Article							TRANSGENIC MAMMARY-TUMORS; EXPRESSED RAS ERAS; TRASTUZUMAB RESISTANCE; GASTRIC-CANCER; PI3K PATHWAY; NEU ONCOGENE; MICE; GENE; ACTIVATION; LAPATINIB	Personalized medicine for cancer patients requires a deep understanding of the underlying genetics that drive cancer and the subsequent identification of predictive biomarkers. To discover new genes and pathways contributing to oncogenesis and therapy resistance in HER2+ breast cancer, we performed Mouse Mammary Tumor Virus (MMTV)-induced insertional mutagenesis screens in ErbB2/cNeu-transgenic mouse models. The screens revealed 34 common integration sites (CIS) in mammary tumors of MMTV-infected mice, highlighting loci with multiple independent MMTV integrations in which potential oncogenes are activated, most of which had never been reported as MMTV CIS. The CIS most strongly associated with the ErbB2-transgenic genotype was the locus containing Eras (ES cell-expressed Ras), a constitutively active RAS-family GTPase. We show that upon expression, Eras acts as a potent oncogenic driver through hyperactivation of the PI3K/AKT pathway, in contrast to other RAS proteins that signal primarily via the MAPK/ERK pathway and require upstream activation or activating mutations to induce signaling. We additionally show that ERAS synergistically enhances HER2-induced tumorigenesis and, in this role, can functionally replace ERBB3/HER3 by acting as a more powerful activator of PI3K/AKT signaling. Although previously reported as pseudogene in humans, we observed ERAS RNA and protein expression in a substantial subset of human primary breast carcinomas. Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	[Ikink, Gerjon J.; Boer, Mandy; Bakker, Elvira R. M.; Vendel-Zwaagstra, Annabel; Hilkens, John] Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands; [Klijn, Chris; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [ten Hoeve, Jelle; Wessels, Lodewyk F.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands.	j.hilkens@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792; Hilkens, John/0000-0002-0932-7793; Ikink, Gerjon/0000-0002-7482-9298				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Aoyama M, 2010, INT J ONCOL, V37, P1011, DOI 10.3892/ijo_00000752; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Callahan R, 2008, J MAMMARY GLAND BIOL, V13, P309, DOI 10.1007/s10911-008-9092-6; Callahan R, 2012, ONCOTARGET, V3, P1320, DOI 10.18632/oncotarget.682; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Engstrom MJ, 2013, BREAST CANC RES TREA, V140, P1; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Gagliato DD, 2016, ONCOTARGET, V7, P64431, DOI 10.18632/oncotarget.7043; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hilkens J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1376; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Ikink GJ, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1279722; Ikink GJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13567; Kaizaki R, 2009, ANTICANCER RES, V29, P2189; Kameda T, 2005, STEM CELLS, V23, P1535, DOI 10.1634/stemcells.2005-0054; Kim HH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027425; Klijn C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062113; Knutson KL, 2004, CANCER RES, V64, P1146, DOI 10.1158/0008-5472.CAN-03-0173; Koudijs MJ, 2011, GENOME RES, V21, P2181, DOI 10.1101/gr.112763.110; Kubota E, 2011, ANTICANCER RES, V31, P3353; Kubota E, 2010, AM J PATHOL, V177, P955, DOI 10.2353/ajpath.2010.091056; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Mah W, 2010, J NEUROSCI, V30, P5559, DOI 10.1523/JNEUROSCI.4839-09.2010; Majewski IJ, 2015, J CLIN ONCOL, V33, P1334, DOI 10.1200/JCO.2014.55.2158; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Vyazunova I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113489; Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248; Wang PY, 2008, MOL CELL NEUROSCI, V39, P83, DOI 10.1016/j.mcn.2008.05.019; Yu Y, 2014, STEM CELLS, V32, P349, DOI 10.1002/stem.1447; Zhao ZA, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150092	50	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1594	1609		10.1038/s41388-017-0031-0	http://dx.doi.org/10.1038/s41388-017-0031-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326437	hybrid, Green Published			2022-12-28	WOS:000428626700004
J	Hsu, PC; Gopinath, RK; Hsueh, YA; Shieh, SY				Hsu, Pei-Ching; Gopinath, Rajaneesh Karimpurath; Hsueh, Yi-An; Shieh, Sheau-Yann			CHK2-mediated regulation of PARP1 in oxidative DNA damage response	ONCOGENE			English	Article							POLY ADP-RIBOSE; POLY(ADP-RIBOSE) POLYMERASE-1; CHK2 ACTIVATION; PROTEIN-KINASE; PHOSPHORYLATION; BINDING; CHECKPOINT; DOMAINS; REPAIR; XRCC1	Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA damage sensor, which upon activation, recruits downstream proteins by poly(ADP-ribosyl)ation (PARylation). However, it remains largely unclear how PARP1 activity is regulated. Interestingly, the data obtained through this study revealed that PARP1 was co-immunoprecipitated with checkpoint kinase 2 (CHK2), and the interaction was increased after oxidative DNA damage. Moreover, CHK2 depletion resulted in a reduction in overall PARylation. To further explore the functional relationship between PARP1 and CHK2, this study employed H2O2 to induce an oxidative DNA damage response in cells. Here, we showed that CHK2 and PARP1 interact in vitro and in vivo through the CHK2 SCD domain and the PARP1 BRCT domain. Furthermore, CHK2 stimulates the PARylation activity of PARP1 through CHK2-dependent phosphorylation. Consequently, the impaired repair associated with PARP1 depletion could be rescued by re-expression of wild-type PARP1 and the phospho-mimic but not the phospho-deficient mutant. Mechanistically, we showed that CHK2-dependent phosphorylation of PARP1 not only regulates its cellular localization but also promotes its catalytic activity and its interaction with XRCC1. These findings indicate that CHK2 exerts a multifaceted impact on PARP1 in response to oxidative stress to facilitate DNA repair and to maintain cell survival.	[Hsu, Pei-Ching; Shieh, Sheau-Yann] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; [Hsu, Pei-Ching; Gopinath, Rajaneesh Karimpurath; Hsueh, Yi-An; Shieh, Sheau-Yann] Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan	Shieh, SY (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.; Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018; Karimpurath Gopinath, Rajaneesh/AHA-8714-2022; KARIMPURATH GOPINATH, RAJANEESH/H-3933-2016	Shieh, Sheau-Yann/0000-0002-5351-4430; KARIMPURATH GOPINATH, RAJANEESH/0000-0003-1554-4310	Academia Sinica, Taiwan	Academia Sinica, Taiwan(Academia Sinica - Taiwan)	We are grateful to the Proteomic Core at Institute of Biomedical Sciences for the assistance with the identification of the PARP1 phosphorylation sites. This work was supported by funding from Academia Sinica, Taiwan to S-YS.	Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Altmeyer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9088; Anderson VE, 2011, CANCER RES, V71, P463, DOI 10.1158/0008-5472.CAN-10-1252; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Barkauskaite E, 2015, MOL CELL, V58, P935, DOI 10.1016/j.molcel.2015.05.007; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Breslin C, 2015, NUCLEIC ACIDS RES, V43, P6934, DOI 10.1093/nar/gkv623; Brunyanszki A, 2014, MOL PHARMACOL, V86, P450, DOI 10.1124/mol.114.094318; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325; Chou WC, 2015, CARCINOGENESIS, V36, P832, DOI 10.1093/carcin/bgv079; Chou WC, 2008, EMBO J, V27, P3140, DOI 10.1038/emboj.2008.229; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Gagne JP, 2009, J PROTEOME RES, V8, P1014, DOI 10.1021/pr800810n; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hegde ML, 2012, PROG MOL BIOL TRANSL, V110, P123, DOI 10.1016/B978-0-12-387665-2.00006-7; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Hong RX, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2754-7; Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Loeffler PA, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-37; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Mansoorabadi SO, 2014, BIOCHEMISTRY-US, V53, P1779, DOI 10.1021/bi401439n; Martin N, 2009, EMBO J, V28, P3534, DOI 10.1038/emboj.2009.279; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meehan Robert S, 2016, Gynecol Oncol Res Pract, V3, P3, DOI 10.1186/s40661-016-0024-7; Messner S, 2009, FASEB J, V23, P3978, DOI 10.1096/fj.09-137695; Muthurajan UM, 2014, P NATL ACAD SCI USA, V111, P12752, DOI 10.1073/pnas.1405005111; Noren Hooten N, 2011, J BIOL CHEM, V286, P44679, DOI 10.1074/jbc.M111.255869; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Pascal JM, 2015, DNA REPAIR, V32, P10, DOI 10.1016/j.dnarep.2015.04.008; Perina D, 2014, DNA REPAIR, V23, P4, DOI 10.1016/j.dnarep.2014.05.003; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ryu H, 2010, J BIOL CHEM, V285, P14415, DOI 10.1074/jbc.M109.074583; Shang FQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151845; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Stolz A, 2011, CLIN CANCER RES, V17, P401, DOI 10.1158/1078-0432.CCR-10-1215; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Vyas S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5426; Vyas S, 2014, NAT REV CANCER, V14, P502, DOI 10.1038/nrc3748; Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yeh YH, 2009, ONCOGENE, V28, P1366, DOI 10.1038/onc.2008.477; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045; Zhang F, 2015, CELL REP, V13, P678, DOI 10.1016/j.celrep.2015.09.040; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088; Zhao H, 2008, CELL CYCLE, V7, P1490, DOI 10.4161/cc.7.10.5963	56	12	12	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1166	1182		10.1038/s41388-018-0506-7	http://dx.doi.org/10.1038/s41388-018-0506-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254210				2022-12-28	WOS:000459249800002
J	Fang, LS; Wu, SS; Zhu, X; Cai, JC; Wu, JH; He, ZJ; Liu, L; Zeng, MS; Song, EW; Li, J; Li, MF; Guan, HY				Fang, Lishan; Wu, Shanshan; Zhu, Xun; Cai, Junchao; Wu, Jueheng; He, Zhenjian; Liu, Lei; Zeng, Musheng; Song, Erwei; Li, Jun; Li, Mengfeng; Guan, Hongyu			MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-beta pathway in NSCLC	ONCOGENE			English	Article							LONG NONCODING RNA; CANCER STATISTICS; CELL; 11Q13; GENE; AMPLIFICATION; PROGRESSION; EXPRESSION; PTEN; INVASION	Non-small cell lung cancer (NSCLC) remains a major cause of death worldwide. As metastatic disease is primarily responsible for the poor clinical outcome of NSCLC, it is important to understand the process, and its underlying molecular mechanism as well, via which NSCLC cells disseminate. In this study, we identified a new competing endogenous RNA (ceRNA), namely, the MYEOV transcript, and found that it is upregulated in NSCLC and associated with a poor prognosis of the disease. We further uncovered that the MYEOV ceRNA plays a critical role in the invasion and metastasis of NSCLC cells. Intriguingly, the MYEOV ceRNA exerted its pro-metastatic function independent of its protein-coding capacity, but in a miR-30c-2-3p binding-dependent manner. Further experiments demonstrated that the MYEOV ceRNA sequestered miR30c-2-3p from binding its targets TGFBR2 and USP15 mRNAs, which in turn leading to constitutive activation of TGF-beta signaling and tumor progression in NSCLC. By identifying a new layer of regulatory modality for TGF-beta signaling, our findings extend the current understanding on the molecular mechanism mediating NSCLC progression and highlight a potential role of MYEOV transcript to serve as the therapeutic target.	[Fang, Lishan; Wu, Shanshan; Zhu, Xun; Cai, Junchao; Wu, Jueheng; Liu, Lei; Li, Mengfeng] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China; [Fang, Lishan] Sun Yat Sen Univ, Cent Lab, Affiliated Hosp 8, Shenzhen, Peoples R China; [Wu, Shanshan; Cai, Junchao; Wu, Jueheng; Liu, Lei; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Zhu, Xun] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China; [He, Zhenjian] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Zeng, Musheng] Sun Yat Sen Univ, Dept Expt Res, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China; [Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, MF (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Guan, HY (corresponding author), Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	limf@mail.sysu.edu.cn; ghongy@mail.sysu.edu.cn	LIU, LEI/AAY-2012-2020; LIU, LEI/AAL-7491-2021	LIU, LEI/0000-0003-4898-5665; Fang, Lishan/0000-0002-0183-861X	Natural Science Foundation of China [81490752]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621004]; Guangzhou science and technology plan [201803010039]; "Guangdong Te Zhi program" youth science and technology talent of project [2015TQ01R281]; Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306023]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; "Guangdong Te Zhi program" youth science and technology talent of project; Guangdong Natural Science Funds for Distinguished Young Scholar	This work was supported by The Natural Science Foundation of China (No. 81490752); The Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621004); Guangzhou science and technology plan (No. 201803010039). "Guangdong Te Zhi program" youth science and technology talent of project (No. 2015TQ01R281); Guangdong Natural Science Funds for Distinguished Young Scholar (2014A030306023).	Anumanthan G, 2005, BRIT J CANCER, V93, P1157, DOI 10.1038/sj.bjc.6602831; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Cai JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15870; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; de Almeida RA, 2006, J BIOL CHEM, V281, P695, DOI 10.1074/jbc.M511467200; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Enright AJ, 2004, GENOME BIOL, V5; Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Hui ABY, 2005, CANCER RES, V65, P8125, DOI 10.1158/0008-5472.CAN-05-0648; Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Leyden J, 2006, BRIT J CANCER, V94, P1204, DOI 10.1038/sj.bjc.6603054; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mathew LK, 2014, CANCER DISCOV, V4, P53, DOI 10.1158/2159-8290.CD-13-0291; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Moreaux J, 2010, EXP HEMATOL, V38, P1189, DOI 10.1016/j.exphem.2010.09.002; Moss AC, 2006, BIOCHEM BIOPH RES CO, V345, P216, DOI 10.1016/j.bbrc.2006.04.094; Pao W, 2012, NAT MED, V18, P349, DOI 10.1038/nm.2697; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rodrigo JP, 2009, J PATHOL, V217, P516, DOI 10.1002/path.2462; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shukla K, 2015, MOL ONCOL, V9, P1106, DOI 10.1016/j.molonc.2015.01.008; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takita J, 2011, CANCER SCI, V102, P1645, DOI 10.1111/j.1349-7006.2011.01995.x; Tan XC, 2018, J CLIN INVEST, V128, P3198, DOI 10.1172/JCI122740; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Yu Q, 2000, GENE DEV, V14, P163; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	47	27	28	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					896	912		10.1038/s41388-018-0484-9	http://dx.doi.org/10.1038/s41388-018-0484-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30181549	Green Published, hybrid			2022-12-28	WOS:000458006300010
J	Lorenzo-Martin, LF; Citterio, C; Menacho-Marquez, M; Conde, J; Larive, RM; Rodriguez-Fdez, S; Garcia-Escudero, R; Robles-Valero, J; Cuadrado, M; Fernandez-Pisonero, I; Dosil, M; Sevilla, MA; Montero, MJ; Fernandez-Salguero, PM; Paramio, JM; Bustelo, XR				Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Garcia-Escudero, Ramon; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Sevilla, Maria A.; Montero, Maria J.; Fernandez-Salguero, Pedro M.; Paramio, Jesus M.; Bustelo, Xose R.			Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms	ONCOGENE			English	Article							EXCHANGE FACTOR VAV1; MESENCHYMAL TRANSITION; GENE-EXPRESSION; TGF-BETA; METASTASIS; EMT; FAMILY; DISSEMINATION; NORMALIZATION; CONTRIBUTES	The bidirectional regulation of epithelial-mesenchymal transitions (EMT) is key in tumorigenesis. Rho GTPases regulate this process via canonical pathways that impinge on the stability of cell-to-cell contacts, cytoskeletal dynamics, and cell invasiveness. Here, we report that the Rho GTPase activators Vav2 and Vav3 utilize a new Rac1-dependent and miR-200cdependent mechanism that maintains the epithelial state by limiting the abundance of the Zeb2 transcriptional repressor in breast cancer cells. In parallel, Vav proteins engage a mir-200c-independent expression prometastatic program that maintains epithelial cell traits only under 3D culture conditions. Consistent with this, the depletion of endogenous Vav proteins triggers mesenchymal features in epithelioid breast cancer cells. Conversely, the ectopic expression of an active version of Vav2 promotes mesenchymal-epithelial transitions using E-cadherin-dependent and independent mechanisms depending on the mesenchymal breast cancer cell line used. In silico analyses suggest that the negative Vav anti-EMT pathway is operative in luminal breast tumors. Gene signatures from the Vav-associated proepithelial and prometastatic programs have prognostic value in breast cancer patients.	[Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Bustelo, Xose R.] Ctr Invest Canc, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Bustelo, Xose R.] Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Garcia-Escudero, Ramon; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Sevilla, Maria A.; Montero, Maria J.; Paramio, Jesus M.; Bustelo, Xose R.] Univ Salamanca, CSIC, Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain; [Garcia-Escudero, Ramon; Paramio, Jesus M.] CIEMAT, Madrid 28040, Spain; [Dosil, Mercedes] Univ Salamanca, Dept Biochem & Mol Biol, Salamanca 37007, Spain; [Montero, Maria J.] Univ Salamanca, Dept Physiol & Pharmacol, Salamanca 37007, Spain; [Fernandez-Salguero, Pedro M.] Univ Extremadura, Dept Biochem Mol Biol & Genet, Badajoz 06071, Spain; [Menacho-Marquez, Mauricio] Lab Max Planck Biol Estruct Quim & Biofis Mol, Rosario, Argentina; [Larive, Romain M.] Inst Biomol Max Mousseron UMR, F-5247 Montpellier, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of Salamanca; University of Salamanca; Universidad de Extremadura; Universite de Montpellier	Bustelo, XR (corresponding author), Ctr Invest Canc, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Inst Biol Mol & Celular Canc, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain.	xbustelo@usal.es	Paramio, Jesus M/M-8482-2014; Rodriguez-Fdez, Sonia/AAD-9317-2021; Dosil, Mercedes/A-9536-2016; Aranda, Javier Conde/P-5537-2015; Garcia-Escudero, Ramon/A-2735-2012; Robles-Valero, Javier/J-4069-2017; Montero, Maria Jose/C-3084-2018	Paramio, Jesus M/0000-0001-7520-3177; Dosil, Mercedes/0000-0001-8119-8263; Aranda, Javier Conde/0000-0002-2187-479X; Garcia-Escudero, Ramon/0000-0001-5640-6542; Rodriguez-Fdez, Sonia/0000-0001-5369-2969; Robles-Valero, Javier/0000-0001-5218-0187; Fernandez-Pisonero, Isabel/0000-0002-5130-2143; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Cuadrado, Myriam/0000-0001-9410-1205; Montero, Maria Jose/0000-0003-2125-0378	Castilla-Leon Government [CSI049U16]; Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2015-64556-R]; Worldwide Cancer Research [14-1248]; Ramon Areces Foundation; Spanish Association against Cancer [GC16173472GARC]; MINECO [BFU2014-52729-P, SAF2015-66015-R, PIE15/00076, SAF2014-51813-R, CD15/00113, BES-2013-063573]; European Regional Development Fund; Spanish Ministry of Education, Culture and Sports [FPU13/02923]	Castilla-Leon Government; Spanish Ministry of Economy and Competitiveness (MINECO)(Spanish Government); Worldwide Cancer Research; Ramon Areces Foundation; Spanish Association against Cancer; MINECO(Spanish Government); European Regional Development Fund(European Commission); Spanish Ministry of Education, Culture and Sports(Spanish Government)	We thank M. Blazquez, A. Abad, and E. Ferminan for lab work, animal work, and microarray analyses, respectively. XRB is supported by grants from the Castilla-Leon Government (CSI049U16), the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R), Worldwide Cancer Research (14-1248), the Ramon Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC). MD (BFU2014-52729-P), JMP (SAF2015-66015-R, PIE15/00076), and PMF-S (SAF2014-51813-R) are supported by MINECO grants. Spanish funding is partially supported by the European Regional Development Fund. LFL-M, JC, and SR-F were supported by funding from the Spanish Ministry of Education, Culture and Sports (LFL-M, FPU13/02923) and the MINECO (JC, CD15/00113; SR-F, BES-2013-063573).	Abate F, 2017, P NATL ACAD SCI USA, V114, P764, DOI 10.1073/pnas.1608839114; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Blenis J, 2017, CELL, V171, P10, DOI 10.1016/j.cell.2017.08.019; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Bustelo X. R., 2014, SMALL GTPASES, V5, P1, DOI DOI 10.4161/21541248.2014.973757; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2012, BIOESSAYS, V34, P748, DOI 10.1002/bies.201200041; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Fabbiano S, 2015, MOL CELL BIOL, V35, P3528, DOI 10.1128/MCB.00518-15; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Itoh M, 2014, BREAST CANCER RES TR, V143, P403, DOI 10.1007/s10549-013-2763-z; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katsura A, 2016, GENES CELLS, V21, P99, DOI 10.1111/gtc.12323; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Larive RM, 2012, MOL BIOL CELL, V23, P2373, DOI 10.1091/mbc.E12-01-0060; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li M, 2016, SCI REP-UK, V6, DOI 10.1038/srep23100; Li XY, 2008, J EXP MED, V205, P2851, DOI 10.1084/jem.20081561; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu M, 2012, TRENDS CELL BIOL, V22, P365, DOI 10.1016/j.tcb.2012.04.004; Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Menacho-Marquez M, 2013, CELL METAB, V18, P199, DOI 10.1016/j.cmet.2013.07.001; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montemayor C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008910; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thaper D, 2017, ONCOGENE, V36, P3964, DOI 10.1038/onc.2017.5; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wakahashi S, 2013, TRANSL RES, V162, P181, DOI 10.1016/j.trsl.2013.06.005; Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481	69	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					209	227		10.1038/s41388-018-0433-7	http://dx.doi.org/10.1038/s41388-018-0433-7			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087437	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000455366700005
J	Yang, XS; Qu, SB; Wang, L; Zhang, HT; Yang, ZX; Wang, JL; Dai, B; Tao, KS; Shang, RZ; Liu, ZC; Li, X; Zhang, ZC; Xia, CC; Ma, B; Liu, W; Li, HM; Dou, KF				Yang, Xisheng; Qu, Shibin; Wang, Lin; Zhang, Hongtao; Yang, Zhaoxu; Wang, Jianlin; Dai, Bin; Tao, Kaishan; Shang, Runze; Liu, Zhengcai; Li, Xiao; Zhang, Zhuochao; Xia, Congcong; Ma, Ben; Liu, Wei; Li, Haimin; Dou, Kefeng			PTBP3 splicing factor promotes hepatocellular carcinoma by destroying the splicing balance of NEAT1 and pre-miR-612	ONCOGENE			English	Article							LONG NONCODING RNA; CELL-PROLIFERATION; BINDING PROTEINS; EXPRESSION; GROWTH; CANCER; ANGIOGENESIS; GENERATION; SFPQ; P53	Nuclear-enriched RNA-binding proteins (RBPs) are mainly involved in transcriptional regulation, which is a critical checkpoint to tune gene diversity and expression levels. We analyzed nuclear RBPs in human HCC tissues and matched normal control tissues. Based on the gene expression levels, PTBP3 was identified as top-ranked in the nuclei of HCC cells. HCC cell lines then were transfected with siRNAs or lentiviral vectors. PTBP3 promoted HCC cell proliferation and metastasis both in vitro and in vivo. RNA immunoprecipitation (RIP), fluorescence in situ hybridization (FISH) and qRT-PCR assays verified that PTBP3 protein recruited abundant lnc-NEAT1 splicing variants (NEAT1_1 and NEAT1_2) and pre-miR-612 (precursor of miR-612) in the nucleus. NEAT1_1, NEAT1_2 and miR-612 expression levels were determined by PTBP3. Correlational analyses revealed that PTBP3 was positively correlated with NEAT1, but it was inversely correlated with miR-612 in HCC. The P53/CCND1 and AKT2/EMT pathways were determined by NEAT1 and miR-612 respectively in HCC. The PTBP3(high) and NEAT1(high)/miR-612(low) patients had a shorter overall survival. Therefore, nuclear-enriched RBP, PTBP3, promotes HCC cell malignant growth and metastasis by regulating the balance of splicing variants (NEAT1_1, NEAT1_2 and miR-612) in HCC.	[Yang, Xisheng; Qu, Shibin; Wang, Lin; Zhang, Hongtao; Yang, Zhaoxu; Wang, Jianlin; Dai, Bin; Tao, Kaishan; Shang, Runze; Liu, Zhengcai; Li, Xiao; Zhang, Zhuochao; Xia, Congcong; Ma, Ben; Liu, Wei; Li, Haimin; Dou, Kefeng] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China; [Qu, Shibin] Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA	Air Force Military Medical University; University of Michigan System; University of Michigan	Li, HM; Dou, KF (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China.	lihaim@fmmu.edu.cn; doukef@fmmu.edu.cn	wang, jian/GVS-0711-2022	Liu, Zhengcai/0000-0001-5046-440X; Li, Haimin/0000-0003-0276-615X; /0000-0002-6624-5532	National Natural Science Foundation of China [81672339]; Project of Scientific Research of Shaanxi [2011KTCL03-15]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Scientific Research of Shaanxi	XY, KD and HL designed the experiments and wrote the paper; SQ, LW, HZ and ZY performed bioinformatics and statistical analyses; JW, KT, ZL, ZZ and BD performed the histopathologic analyses; CX, BM, RS, XL and WL provided expression data and patient sample material. This research was supported by the National Natural Science Foundation of China (No. 81672339) and the Project of Scientific Research of Shaanxi (No. 2011KTCL03-15).	Adriaens C, 2016, NAT MED, V22, P861, DOI 10.1038/nm.4135; Arslan AD, 2013, J BIOMOL SCREEN, V18, P180, DOI 10.1177/1087057112459901; Bhartiya D, 2016, GENOMICS, V107, P59, DOI 10.1016/j.ygeno.2016.01.005; Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270; Castello A, 2016, MOL CELL, V63, P696, DOI 10.1016/j.molcel.2016.06.029; Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Cheung HC, 2009, BRAIN, V132, P2277, DOI 10.1093/brain/awp153; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Fang L, 2017, AM J PHYSIOL-GASTR L, V313, pG150, DOI 10.1152/ajpgi.00426.2016; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Idogawa M, 2017, INT J CANCER, V140, P2785, DOI 10.1002/ijc.30689; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Koster T, 2017, TRENDS PLANT SCI, V22, P512, DOI 10.1016/j.tplants.2017.03.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HC, 2017, NUCLEIC ACIDS RES, V45, P6894, DOI 10.1093/nar/gkx307; Li Q, 2014, ELIFE, V3, DOI 10.7554/eLife.01201; Licatalosi DD, 2012, GENE DEV, V26, P1626, DOI 10.1101/gad.191338.112; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Mang YY, 2017, ONCOTARGETS THER, V10, P1003, DOI 10.2147/OTT.S116319; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547; Pang R, 2006, CANCER LETT, V242, P151, DOI 10.1016/j.canlet.2006.01.008; Peal L, 2011, MOL CELLS, V31, P55, DOI 10.1007/s10059-011-0001-2; Shen W, 2014, NUCLEIC ACIDS RES, V42, P8648, DOI 10.1093/nar/gku579; Shim JS, 2010, JNCI-J NATL CANCER I, V102, P1855, DOI 10.1093/jnci/djq457; Spellman R, 2007, MOL CELL, V27, P420, DOI 10.1016/j.molcel.2007.06.016; Tan HY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081277; Tan LY, 2015, NUCLEIC ACIDS RES, V43, P5586, DOI 10.1093/nar/gkv429; Tao ZH, 2013, J EXP MED, V210, P789, DOI 10.1084/jem.20120153; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zagore LL, 2015, MOL CELL BIOL, V35, P4030, DOI 10.1128/MCB.00676-15; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zerbe LK, 2004, MOL CARCINOGEN, V41, P187, DOI 10.1002/mc.20053; Zhang L, 2017, HEPATOLOGY, V65, P604, DOI 10.1002/hep.28882	39	43	46	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6399	6413		10.1038/s41388-018-0416-8	http://dx.doi.org/10.1038/s41388-018-0416-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30068940				2022-12-28	WOS:000452989100002
J	Al Shareef, Z; Kardooni, H; Murillo-Garzon, V; Domenici, G; Stylianakis, E; Steel, JH; Rabano, M; Gorrono-Etxebarria, I; Zabalza, I; Vivanco, MD; Waxman, J; Kypta, RM				Al Shareef, Zainab; Kardooni, Hoda; Murillo-Garzon, Virginia; Domenici, Giacomo; Stylianakis, Emmanouil; Steel, Jennifer H.; Rabano, Miriam; Gorrono-Etxebarria, Irantzu; Zabalza, Ignacio; Vivanco, Maria dM; Waxman, Jonathan; Kypta, Robert M.			Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN-1; ACINAR MORPHOGENESIS; DKK-3 EXPRESSION; STEM-CELLS; STEM/PROGENITOR; METASTASIS; ACTIVATION; PROMOTER; INTEGRIN; BENIGN	Aberrant transforming growth factor-beta (TGF-beta) signaling is a hallmark of the stromal microenvironment in cancer. Dickkopf-3 (Dkk-3), shown to inhibit TGF-beta signaling, is downregulated in prostate cancer and upregulated in the stroma in benign prostatic hyperplasia, but the function of stromal Dkk-3 is unclear. Here we show that DKK3 silencing in WPMY-1 prostate stromal cells increases TGF-beta signaling activity and that stromal cell-conditioned media inhibit prostate cancer cell invasion in a Dkk-3-dependent manner. DKK3 silencing increased the level of the cell-adhesion regulator TGF-beta-induced protein (TGFBI) in stromal and epithelial cell-conditioned media, and recombinant TGFBI increased prostate cancer cell invasion. Reduced expression of Dkk-3 in patient tumors was associated with increased expression of TGFBI. DKK3 silencing reduced the level of extracellular matrix protein-1 (ECM-1) in prostate stromal cell-conditioned media but increased it in epithelial cell-conditioned media, and recombinant ECM-1 inhibited TGFBI-induced prostate cancer cell invasion. Increased ECM1 and DKK3 mRNA expression in prostate tumors was associated with increased relapse-free survival. These observations are consistent with a model in which the loss of Dkk-3 in prostate cancer leads to increased secretion of TGFBI and ECM-1, which have tumor-promoting and tumor-protective roles, respectively. Determining how the balance between the opposing roles of extracellular factors influences prostate carcinogenesis will be key to developing therapies that target the tumor microenvironment.	[Al Shareef, Zainab; Kardooni, Hoda; Stylianakis, Emmanouil; Steel, Jennifer H.; Waxman, Jonathan; Kypta, Robert M.] Imperial Coll London, Dept Surg & Canc, London, England; [Murillo-Garzon, Virginia; Domenici, Giacomo; Rabano, Miriam; Gorrono-Etxebarria, Irantzu; Vivanco, Maria dM; Kypta, Robert M.] CIC BioGUNE, Ctr Cooperat Res Biosci, Derio, Spain; [Zabalza, Ignacio] Galdakao Usansolo Hosp, Dept Pathol, Galdakao, Spain	Imperial College London; CIC bioGUNE; Galdakao Hospital	Kypta, RM (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.; Kypta, RM (corresponding author), CIC BioGUNE, Ctr Cooperat Res Biosci, Derio, Spain.	r.kypta@imperial.ac.uk	Kypta, Robert/F-7699-2011; Domenici, Giacomo/AAG-6224-2019; Vivanco, Maria/G-2393-2011	Kypta, Robert/0000-0002-2389-310X; Vivanco, Maria/0000-0002-9540-247X; Stylianakis, Emmanouil/0000-0001-5750-0725; Domenici, Giacomo/0000-0002-3947-5930; Gorrono, Irantzu/0000-0003-4160-6781; Mohamed Mohamed Abdoh AL Shareef, Zainab/0000-0003-4213-1052	UAE Ministry of Presidential Affairs; Harris Family Harvey Spack Memorial Fund; Garfield Weston Foundation; Rosetrees Trust; Basque Department of Education [BFI-2010-129]; Spanish Ministry of Science and Innovation [SAF2014-51966-R, SAF2017-84092-R, SAF2017-84934-R]	UAE Ministry of Presidential Affairs; Harris Family Harvey Spack Memorial Fund; Garfield Weston Foundation; Rosetrees Trust(Rosetrees Trust); Basque Department of Education; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We gratefully acknowledge the UAE Ministry of Presidential Affairs, The Harris Family Harvey Spack Memorial Fund, The Garfield Weston Foundation, Rosetrees Trust, Basque Department of Education (BFI-2010-129), and the Spanish Ministry of Science and Innovation (SAF2014-51966-R and SAF2017-84092-R (RMK) and SAF2017-84934-R (MdMV)) for funding, and the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre, the National Institute for Health Research Imperial Biomedical Research Centre, the Department of Industry, Tourism and Trade (Elkartek), the Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country, and the Centre of Excellence Severo Ochoa (2017-2021) for infrastructure support.	Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Ayala G, 2013, J PATHOL, V231, P77, DOI 10.1002/path.4217; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Bauderlique-Le Roy H, 2015, STEM CELLS DEV, V24, P1252, DOI 10.1089/scd.2014.0386; Bekhouche M, 2016, FASEB J, V30, P1741, DOI 10.1096/fj.15-279869; Bello-DeOcampo D, 2001, MUTAT RES-FUND MOL M, V480, P209, DOI 10.1016/S0027-5107(01)00201-9; Buscemi L, 2011, CURR BIOL, V21, P2046, DOI 10.1016/j.cub.2011.11.037; Busceti CL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00111; Chen WY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6826; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dutta A, 2015, BIOCHEM J, V466, P525, DOI 10.1042/BJ20140698; Fong D, 2009, CANCER SCI, V100, P1414, DOI 10.1111/j.1349-7006.2009.01208.x; Fu CY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395012; Fujimoto N, 2006, EXP DERMATOL, V15, P300, DOI 10.1111/j.0906-6705.2006.00409.x; Gao F, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0533-9; Gong YX, 2014, CANCERS, V6, P1298, DOI 10.3390/cancers6031298; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kumon H, 2016, CANCER GENE THER, V23, P400, DOI 10.1038/cgt.2016.53; Kumon H, 2015, CLIN MED INSIGHTS-ON, V9, P31, DOI 10.4137/CMO.S23252; Leonard JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181724; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Montecinos VP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029623; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Prudova A, 2010, MOL CELL PROTEOMICS, V9, P894, DOI 10.1074/mcp.M000050-MCP201; Rohrschneider LR, 2005, DEV BIOL, V283, P503, DOI 10.1016/j.ydbio.2005.04.032; Romero D, 2016, CARCINOGENESIS, V37, P18, DOI 10.1093/carcin/bgv153; Romero Diana, 2013, Bioarchitecture, V3, P42, DOI 10.4161/bioa.25243; Romero D, 2013, J CELL SCI, V126, P1858, DOI 10.1242/jcs.119388; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah JN, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-284; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; St Croix B, 2000, SCIENCE, V289, P1197; Su P, 2016, J IMMUNOL, V197, P1054, DOI 10.4049/jimmunol.1502457; THALMANN GN, 1994, CANCER RES, V54, P2577; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Tu Z, 2001, BLOOD, V98, P2028, DOI 10.1182/blood.V98.7.2028; Untergasser G, 2008, INT J CANCER, V122, P1539, DOI 10.1002/ijc.23255; Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003; Wang XC, 2015, J BIOL CHEM, V290, P19844, DOI 10.1074/jbc.M115.641415; Webber JP, 2016, ONCOTARGET, V7, P20124, DOI 10.18632/oncotarget.7716; Webber MM, 1999, CARCINOGENESIS, V20, P1185, DOI 10.1093/carcin/20.7.1185; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Yu NW, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.061; Zenzmaier C, 2008, PROSTATE, V68, P540, DOI 10.1002/pros.20711; Zenzmaier C, 2013, PROSTATE, V73, P1441, DOI 10.1002/pros.22691; Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902	54	26	27	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5305	5324		10.1038/s41388-018-0294-0	http://dx.doi.org/10.1038/s41388-018-0294-0			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858602	hybrid, Green Published			2022-12-28	WOS:000445759700005
J	Yu, Y; Rahmanto, YS; Lee, MH; Wu, PH; Phillip, JM; Huang, CH; Vitolo, MI; Gaillard, S; Martin, SS; Wirtz, D; Shih, IM; Wang, TL				Yu, Yu; Rahmanto, Yohan Suryo; Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Huang, Chuan-Hsiang; Vitolo, Michele I.; Gaillard, Stephanie; Martin, Stuart S.; Wirtz, Denis; Shih, Ie-Ming; Wang, Tian-Li			Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; BREAST-CANCER CELLS; RHEUMATOID-ARTHRITIS; PHOSPHOINOSITIDE 3-KINASE; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; PROTEIN; PHOSPHORYLATION; METASTASIS	Cell motility and invasiveness are prerequisites for dissemination, and largely account for cancer mortality. We have identified an actionable kinase, spleen tyrosine kinase (SYK), which is keenly tightly associated with tumor progression in ovarian cancer. Here, we report that active recombinant SYK directly phosphorylates cortactin and cofilin, which are critically involved in assembly and dynamics of actin filament through phosphorylation signaling. Enhancing SYK activity by inducing expression of a constitutively active SYK mutant, SYK130E, increased growth factor-stimulated migration and invasion of ovarian cancer cells, which was abrogated by cortactin knockdown. Similarly, SYK inhibitors significantly decreased invasion of ovarian cancer cells across basement membrane in real-time transwell assays and in 3D tumor spheroid models. SYK inactivation by targeted gene knockout or by small molecule inhibition reduced actin polymerization. Collectively, this study reported a new mechanism by which SYK signaling regulates ovarian cancer cell motility and invasiveness, and suggest a target-based strategy to prevent or suppress the advancement of ovarian malignancies.	[Yu, Yu; Rahmanto, Yohan Suryo; Gaillard, Stephanie; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Yu, Yu; Rahmanto, Yohan Suryo; Huang, Chuan-Hsiang; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; [Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Wirtz, Denis] Johns Hopkins Univ, Inst NanoBioTechol, Baltimore, MD 21218 USA; [Vitolo, Michele I.; Martin, Stuart S.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Vitolo, Michele I.; Martin, Stuart S.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst, Ctr Canc, Baltimore, MD 21201 USA; [Gaillard, Stephanie; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.; Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA.; Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21287 USA.	shihie@yahoo.com; tlw@jhmi.edu	Phillip, Jude/AAR-6240-2020; Suryo Rahmanto, Yohan/K-8043-2018; sdsd, shihieih/ABE-6190-2020; Yu, Yu/AAD-7947-2019	Suryo Rahmanto, Yohan/0000-0003-1453-7872; Yu, Yu/0000-0002-0209-0586; Huang, Chuan-Hsiang/0000-0001-9993-8004	NIH/NCI [RO1CA215483, UO1CA200469, RO1CA148826, R21CA187512, K22CA212060, KO1-CA166576]; Richard W. TeLinde Research Program; Ovarian Cancer Research Foundation Alliance (OCRFA) [458972]; Honorable Tina Brozman Foundation; TEAL award; US Department of Defense Ovarian Cancer Consortium [W81XWH-11-2-0230]; NATIONAL CANCER INSTITUTE [R01CA215483, K01CA166576, K22CA212060, R21CA187512, U01CA200469, R01CA174388, R01CA148826] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Richard W. TeLinde Research Program; Ovarian Cancer Research Foundation Alliance (OCRFA); Honorable Tina Brozman Foundation; TEAL award; US Department of Defense Ovarian Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH/NCI grants, RO1CA215483 (I.M.S.), UO1CA200469 (I.M.S.), RO1CA148826 (T.L.W.), R21CA187512 (T.L.W.), K22CA212060 (C.H.H.), KO1-CA166576 (M.I.V.), Richard W. TeLinde Research Program (www.gynecologycancer.org), Ovarian Cancer Research Foundation Alliance (OCRFA) Grant # 458972 (I.M.S.), The Honorable Tina Brozman Foundation (I.M.S. and T.L.W.), TEAL award (T.L.W.), and US Department of Defense Ovarian Cancer Consortium grant W81XWH-11-2-0230 (I.M.S. and T.L.W.).	Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bordeleau F, 2014, AM J PHYSIOL-CELL PH, V306, pC110, DOI 10.1152/ajpcell.00283.2013; Cheng SH, 2011, BLOOD, V118, P6342, DOI 10.1182/blood-2011-02-333773; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gagliardi PA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10206; Ghotra VPS, 2015, CANCER RES, V75, P230, DOI 10.1158/0008-5472.CAN-14-0629; Hastie EL, 2016, EUR J CELL BIOL, V95, P441, DOI 10.1016/j.ejcb.2016.06.006; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Hoon JL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020017; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Inagaki N, 2017, TRENDS CELL BIOL, V27, P515, DOI 10.1016/j.tcb.2017.02.003; Jaumouille V, 2014, DEV CELL, V29, P534, DOI 10.1016/j.devcel.2014.04.031; Kunwar S, 2016, RHEUMATOL INT, V36, P1077, DOI 10.1007/s00296-016-3482-7; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Layton T, 2009, AM J PATHOL, V175, P2625, DOI 10.2353/ajpath.2009.090543; Li Y, 2012, J BIOL CHEM, V287, P31116, DOI 10.1074/jbc.M112.373647; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Luangdilok S, 2007, CANCER RES, V67, P7907, DOI 10.1158/0008-5472.CAN-07-0331; Macdonald-Obermann JL, 2014, J BIOL CHEM, V289, P26178, DOI 10.1074/jbc.M114.586826; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Ocana-Morgner C, 2009, BLOOD, V113, P1474, DOI 10.1182/blood-2008-04-152587; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pearce G, 2011, BLOOD, V117, P1574, DOI 10.1182/blood-2010-07-295659; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Prinos P, 2011, NAT STRUCT MOL BIOL, V18, P673, DOI 10.1038/nsmb.2040; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Ruschel A, 2004, CELL SIGNAL, V16, P1249, DOI 10.1016/j.cellsig.2004.03.007; Sharman J, 2015, BLOOD, V125, P2336, DOI 10.1182/blood-2014-08-595934; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Tsang E, 2008, J BIOL CHEM, V283, P32650, DOI 10.1074/jbc.M806340200; Weinblatt ME, 2008, ARTHRITIS RHEUM-US, V58, P3309, DOI 10.1002/art.23992; Weinblatt ME, 2010, NEW ENGL J MED, V363, P1303, DOI 10.1056/NEJMoa1000500; Wu PH, 2015, SCI REP-UK, V5, DOI 10.1038/srep18437; Xue L, 2012, P NATL ACAD SCI USA, V109, P5615, DOI 10.1073/pnas.1119418109; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yoo Y, 2010, ONCOGENE, V29, P263, DOI 10.1038/onc.2009.319; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618; Yu L, 2014, INT J GYNECOL CANCER, V24, P1158, DOI 10.1097/IGC.0000000000000179; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zhang XY, 2009, MOL CANCER RES, V7, P634, DOI 10.1158/1541-7786.MCR-08-0371	49	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3778	3789		10.1038/s41388-018-0241-0	http://dx.doi.org/10.1038/s41388-018-0241-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643476	Green Accepted			2022-12-28	WOS:000438465600002
J	Crossland, DL; Denning, WL; Ang, S; Olivares, S; Mi, TJ; Switzer, K; Singh, H; Huls, H; Gold, KS; Glisson, BS; Cooper, LJ; Heymach, JV				Crossland, Denise L.; Denning, Warren L.; Ang, Sonny; Olivares, Simon; Mi, Tiejuan; Switzer, Kirsten; Singh, Harjeet; Huls, Helen; Gold, Kate S.; Glisson, Bonnie S.; Cooper, Laurence J.; Heymach, John V.			Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models	ONCOGENE			English	Article							ANTIBODY-DRUG CONJUGATE; LUNG-CANCER; LORVOTUZUMAB MERTANSINE; IMPROVED SURVIVAL; HU ANTIBODIES; PHASE 1/2; EXPRESSION; SYSTEM; TRANSACTIVATOR; PEMBROLIZUMAB	The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed. We hypothesized that CD56-specific chimeric antigen receptor (CAR) T cells could target and eliminate CD56-positive malignancies. Sleeping Beauty transposon-generated CD56R-CAR T cells exhibited a beta T-cell receptors, released antitumor cytokines upon co-culture with CD56(+) tumor targets, demonstrated a lack of fratricide, and expression of cytolytic function in the presence of CD56(+) stimulation. The CD56R-CAR(+) T cells are capable of killing CD56(+) neuroblastoma, glioma, and SCLC tumor cells in in vitro co-cultures and when tested against CD56(+) human xenograft neuroblastoma models and SCLC models, CD56R-CAR(+) T cells were able to inhibit tumor growth in vivo. These results indicate that CD56-CARs merit further investigation as a potential treatment for CD56(+) malignancies.	[Crossland, Denise L.; Olivares, Simon; Mi, Tiejuan; Switzer, Kirsten; Singh, Harjeet; Huls, Helen; Cooper, Laurence J.] UT MD Anderson Canc Ctr, Div Pediat, Houston, TX USA; [Denning, Warren L.; Glisson, Bonnie S.; Heymach, John V.] UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Ang, Sonny] UT MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX USA; [Huls, Helen] Intrexon, Germantown, MD USA; [Gold, Kate S.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Cooper, Laurence J.] ZIOPHARM Oncol Inc, Boston, MA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Heymach, JV (corresponding author), UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.	jheymach@mdanderson.org	Heymach, John/AAG-2361-2019	Heymach, John/0000-0001-9068-8942; Denning, Warren/0000-0003-0781-4288	Cancer Center Core Grant [CA16672]; RO1 [CA124782, CA120956, CA141303]; P01 [CA148600]; SPORES [CA100632, CA136411, CA00632]; Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society; Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; National Foundation for Cancer Research; NIH Cancer Center Support Grant Pediatric Cancer Research Foundation [CA016672]; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund; University of Texas Moon Shot Fund; University of Texas Southwestern Medical Center [5 P50 CA070907]; University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant [5 P50 CA070907]; William Lawrence and Blanche Hughes Children's Foundation	Cancer Center Core Grant; RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); P01; SPORES; Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; National Foundation for Cancer Research; NIH Cancer Center Support Grant Pediatric Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund; University of Texas Moon Shot Fund; University of Texas Southwestern Medical Center; University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant; William Lawrence and Blanche Hughes Children's Foundation	We thank the flow cytometry and cellular imaging core facilities at MD Anderson. This study was funded by Cancer Center Core Grant (CA16672); RO1 (CA124782, CA120956, CA141303, CA141303); P01 (CA148600); SPORES (CA100632, CA136411, CA00632); Albert J Ward Foundation; Alex's Lemonade Stand Foundation; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL Global Research Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg Foundation; Leukemia and Lymphoma Society; Lung Cancer Research Foundation; Lung Cancer Moon Shot; Lymphoma Research Foundation; Miller Foundation; Mr. Herb Simons; Mr. and Mrs. Joe H. Scales; Mr. Thomas Scott; National Foundation for Cancer Research; NIH Cancer Center Support Grant (CA016672) Pediatric Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center Sister Institution Network Fund and Moon Shot Fund; The University of Texas Southwestern Medical Center and The University of Texas MD Anderson Cancer Center NIH Lung SPORE Grant (5 P50 CA070907); William Lawrence and Blanche Hughes Children's Foundation. Publication under the Creative Commons CC-BY license is not required.	Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Bruns M, 2016, ONCOTARGET, V7, P64543, DOI 10.18632/oncotarget.11620; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; DALMAU J, 1995, CANCER, V75, P99, DOI 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I; de Braud F., 2015, J IMMUNOTHER CANCER, V3, pP376, DOI DOI 10.1186/2051-1426-3-S2-P376; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Feng Y, 2016, MABS-AUSTIN, V8, P799, DOI 10.1080/19420862.2016.1155014; FISK B, 1994, LYMPHOKINE CYTOK RES, V13, P125; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Jena B, 2010, BLOOD, V116, P1035, DOI 10.1182/blood-2010-01-043737; Kazarian M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-33; Kelly-Rogers J, 2006, HUM IMMUNOL, V67, P863, DOI 10.1016/j.humimm.2006.08.292; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Michielsen AJ, 2012, MOL CANCER THER, V11, P1829, DOI 10.1158/1535-7163.MCT-12-0162; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; Ohkawa T, 2001, IMMUNOLOGY, V103, P281, DOI 10.1046/j.1365-2567.2001.01248.x; Ott PA, 2017, J CLIN ONCOL, V35, P3823, DOI 10.1200/JCO.2017.72.5069; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Roellecke K, 2016, GENE THER, V23, P615, DOI 10.1038/gt.2016.38; Ryan SO, 2010, CANCER RES, V70, P5788, DOI 10.1158/0008-5472.CAN-09-4519; Sakemura R, 2016, CANCER IMMUNOL RES, V4, P658, DOI 10.1158/2326-6066.CIR-16-0043; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shah MH, 2016, INVEST NEW DRUG, V34, P290, DOI 10.1007/s10637-016-0336-9; Singh H, 2008, CANCER RES, V68, P2961, DOI 10.1158/0008-5472.CAN-07-5600; Singh H, 2011, CANCER RES, V71, P3516, DOI 10.1158/0008-5472.CAN-10-3843; Socinski MA, 2017, CLIN LUNG CANCER, V18, P68, DOI 10.1016/j.cllc.2016.09.002; Whiteman KR, 2014, MABS-AUSTIN, V6, P556, DOI 10.4161/mabs.27756; WINTER SF, 1993, J NATL CANCER I, V85, P2012, DOI 10.1093/jnci/85.24.2012; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	36	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3686	3697		10.1038/s41388-018-0187-2	http://dx.doi.org/10.1038/s41388-018-0187-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622795				2022-12-28	WOS:000437975200006
J	Reebye, V; Huang, KW; Lin, V; Jarvis, S; Cutilas, P; Dorman, S; Ciriello, S; Andrikakou, P; Voutila, J; Saetrom, P; Mintz, PJ; Reccia, I; Rossi, JJ; Huber, H; Habib, R; Kostomitsopoulos, N; Blakey, DC; Habib, NA				Reebye, Vikash; Huang, Kai-Wen; Lin, Vivian; Jarvis, Sheba; Cutilas, Pedro; Dorman, Stephanie; Ciriello, Simona; Andrikakou, Pinelopi; Voutila, Jon; Saetrom, Pal; Mintz, Paul J.; Reccia, Isabella; Rossi, John J.; Huber, Hans; Habib, Robert; Kostomitsopoulos, Nikos; Blakey, David C.; Habib, Nagy A.			Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer	ONCOGENE			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; HUMAN HEPATOCELLULAR-CARCINOMA; C/EBP-ALPHA; TRANSCRIPTION FACTORS; IN-VIVO; PROLIFERATION; EXPRESSION; FIBROSIS; MORTALITY; DISEASE	Liver diseases are a growing epidemic worldwide. If unresolved, liver fibrosis develops and can lead to cirrhosis and clinical decompensation. Around 5% of cirrhotic liver diseased patients develop hepatocellular carcinoma (HCC), which in its advanced stages has limited therapeutic options and negative survival outcomes. CEPBA is a master regulator of hepatic function where its expression is known to be suppressed in many forms of liver disease including HCC. Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression. Here we show how MTL-CEBPA therapy promotes disease reversal in rodent models of cirrhosis, fibrosis, hepatosteatosis, and significantly reduces tumor burden in cirrhotic HCC. Restoration of liver function markers were observed in a carbon-tetrachloride-induced rat model of fibrosis following 2 weeks of MTL-CEBPA therapy. At 14 weeks, animals showed reduction in ascites and enhanced survival rates. MTLCEBPA reversed changes associated with hepatosteatosis in non-alcoholic methionine and cholic-deficient diet-induced steaotic liver disease. In diethylnitrosamine induced cirrhotic HCC rats, MTL-CEBPA treatment led to a significant reduction in tumor burden. The data included here and the rapid adoption of MTL-CEBPA into a Phase 1 study may lead to new therapeutic oligonucleotides for undruggable diseases.	[Reebye, Vikash; Dorman, Stephanie; Andrikakou, Pinelopi; Mintz, Paul J.; Reccia, Isabella; Habib, Nagy A.] Imperial Coll London, Dept Surg, London, England; [Huang, Kai-Wen; Lin, Vivian] Natl Taiwan Univ, Dept Surg & Hepatitis Res, Taipei, Taiwan; [Huang, Kai-Wen; Lin, Vivian] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan; [Jarvis, Sheba] Imperial Coll London, Dept Surg & Canc, London, England; [Cutilas, Pedro] Queen Mary Univ London, Barts Canc Inst, Cell Signalling & Prote Grp, Ctr Haematooncol, London, England; [Ciriello, Simona; Voutila, Jon; Habib, Robert; Blakey, David C.] MiNA Therapeut Ltd, London, England; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Trondheim, Norway; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Comp & Informat Sci, Trondheim, Norway; [Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA USA; [Huber, Hans] BioTD Strategies LLC, Lansdale, PA USA; [Kostomitsopoulos, Nikos] Biomed Res Fdn Acad Athens, Ctr Clin Expt Surg & Translat Res, Athens, Greece	Imperial College London; National Taiwan University; National Taiwan University; Imperial College London; University of London; Queen Mary University London; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); City of Hope; Beckman Research Institute of City of Hope; Academy of Athens	Reebye, V (corresponding author), Imperial Coll London, Dept Surg, London, England.	v.reebye@ic.ac.uk; nagy.habib@ic.ac.uk	Reccia, Isabella/GXZ-6729-2022; Sætrom, Pål/AAH-1216-2019	Sætrom, Pål/0000-0001-8142-7441; Ciriello, Simona/0000-0002-5547-4778; Rodriguez Cutillas, Pedro/0000-0002-3426-2274; Reccia, Isabella/0000-0003-1194-8828; Voutila, Jon/0000-0001-7193-2110; HUANG, KAI-WEN/0000-0001-6375-8714; Andrikakou, Dr Pinelopi/0000-0002-3955-7995	MiNA Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042552] Funding Source: NIH RePORTER	MiNA Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by MiNA Therapeutics.	Allen AM, 2016, HEPATOLOGY, V64, P2165, DOI 10.1002/hep.28812; Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Ee HT, 2005, CANCER RES, V65, P10330; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Ge PS, 2016, NEW ENGL J MED, V375, P767, DOI 10.1056/NEJMra1504367; Hong IH, 2014, J BIOL CHEM, V289, P1106, DOI 10.1074/jbc.M113.526780; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Lu GD, 2010, GASTROENTEROLOGY, V139, P632, DOI 10.1053/j.gastro.2010.03.051; Mei S, 2007, HEPATOL RES, V37, P531, DOI 10.1111/j.1872-034X.2007.00074.x; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22; Portnoy V, 2011, WIRES RNA, V2, P748, DOI 10.1002/wrna.90; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Rodrigueza WV, 2014, CANCER CHEMOTH PHARM, V74, P151, DOI 10.1007/s00280-014-2476-y; Shi YC, 2013, DIGEST LIVER DIS, V45, P844, DOI 10.1016/j.dld.2013.03.013; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Tao LL, 2012, APOPTOSIS, V17, P492, DOI 10.1007/s10495-012-0700-y; Tomizawa M, 2003, ANTICANCER RES, V23, P351; Voutila J, 2017, MOL THER, V25, P2705, DOI 10.1016/j.ymthe.2017.07.018; Watkins PJ, 1996, CANCER RES, V56, P1063; Xu L, 2001, CANCER RES, V61, P3176	21	45	48	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3216	3228		10.1038/s41388-018-0126-2	http://dx.doi.org/10.1038/s41388-018-0126-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29511346	Green Accepted, Green Submitted, hybrid			2022-12-28	WOS:000435526600003
J	Chen, ZZ; Gao, YF; Yao, LT; Liu, YT; Huang, L; Yan, ZY; Zhao, WS; Zhu, PP; Weng, HB				Chen, Zhenzhen; Gao, Yanfeng; Yao, Lintong; Liu, Yating; Huang, Lan; Yan, Zhongyi; Zhao, Wenshan; Zhu, Pingping; Weng, Haibo			LncFZD6 initiates Wnt/beta-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation	ONCOGENE			English	Article							CANCER STEM-CELLS; SIDE POPULATION; WNT; GENE; MECHANISMS	Liver tumor-initiating cells (TICs), the drivers for liver tumorigenesis, accounts for liver tumor initiation, metastasis, drug resistance and relapse. Wnt/beta-catenin signaling pathway emerges as a critical modulator in liver TIC self-renewal. However, the molecular mechanism of Wnt/beta-catenin initiation in liver tumorigenesis and liver TICs is still elusive. Here, we examined the expression pattern of 10 Wnt receptors (FZD1-FZD10), and found only FZD6 is overexpressed along with liver tumorigenesis. What's more, a divergent lncRNA of FZD6, termed lncFZD6, is also highly expressed in liver cancer and liver TICs. LncFZD6 drives liver TIC self-renewal and tumor initiation capacity through FZD6-dependent manner. LncFZD6 interacts with BRG1-embedded SWI/SNF complex and recruits it to FZD6 promoter, and thus drives the transcriptional initiation of FZD6 by chromatin remodeling. WNT5A, a ligand of FZD6, is highly expressed in liver nonTICs and drives the self-renewal of liver TICs through lncFZD6-BRG1-FZD6-dependent manner. Through FZD6 transcriptional regulation in cis, lncFZD6 activates Wnt/beta-catenin signaling in liver TICs. LncFZD6-BRG1-Wnt5A/beta-catenin pathway can serve as a target for liver TIC elimination. Altogether, lncFZD6 promotes Wnt/beta-catenin activation and liver TIC self-renewal through BRG1-dependent FZD6 expression.	[Chen, Zhenzhen; Gao, Yanfeng; Yao, Lintong; Liu, Yating; Yan, Zhongyi; Zhao, Wenshan; Zhu, Pingping; Weng, Haibo] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China; [Gao, Yanfeng] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou 450001, Henan, Peoples R China; [Huang, Lan] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China	Zhengzhou University; Zhengzhou University	Chen, ZZ; Zhu, PP; Weng, HB (corresponding author), Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China.	chenzz2015@zzu.edu.cn; pingpingchustc@hotmail.com; whb@zzu.edu.cn		Zhao, Wenshan/0000-0002-8018-5978; Huang, Lan/0000-0001-9594-4722; Zhu, Pingping/0000-0002-8009-2923; , Chen/0000-0003-2093-4639	National Natural Science Foundation of China [U1704174, U1604286, 81472557, 81601450]; development fund for outstanding young teachers of Zhengzhou University [1521311059]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); development fund for outstanding young teachers of Zhengzhou University	This work was supported by the National Natural Science Foundation of China (U1704174, U1604286, 81472557 and 81601450) and development fund for outstanding young teachers of Zhengzhou University (1521311059).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; De Marco P, 2012, HUM MUTAT, V33, P384, DOI 10.1002/humu.21643; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hidaka S, 2016, J INTEGR NEUROSCI, V15, P571, DOI 10.1142/S021963521650031X; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Naz G, 2012, BRIT J DERMATOL, V166, P1088, DOI 10.1111/j.1365-2133.2011.10800.x; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhu PP, 2017, PROG BIOCHEM BIOPHYS, V44, P697, DOI 10.16476/j.pibb.2017.0242; Zhu PP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13608; Zhu PP, 2016, NAT STRUCT MOL BIOL, V23, P631, DOI 10.1038/nsmb.3235; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979; Zhu PP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8122	42	47	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3098	3112		10.1038/s41388-018-0203-6	http://dx.doi.org/10.1038/s41388-018-0203-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535420	Green Published, hybrid			2022-12-28	WOS:000434641400005
J	Arima, K; Ohmuraya, M; Miyake, K; Koiwa, M; Uchihara, T; Izumi, D; Gao, F; Yonemura, A; Bu, LK; Okabe, H; Imai, K; Hashimoto, D; Baba, Y; Chikamoto, A; Yamashita, Y; Furukawa, T; Araki, K; Baba, H; Ishimoto, T				Arima, Kota; Ohmuraya, Masaki; Miyake, Keisuke; Koiwa, Mayu; Uchihara, Tomoyuki; Izumi, Daisuke; Gao, Feng; Yonemura, Atsuko; Bu, Luke; Okabe, Hirohisa; Imai, Katsunori; Hashimoto, Daisuke; Baba, Yoshifumi; Chikamoto, Akira; Yamashita, Yo-ichi; Furukawa, Toru; Araki, Kimi; Baba, Hideo; Ishimoto, Takatsugu			Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas	ONCOGENE			English	Article							TRANS-RETINOIC ACID; CANCER STEM-CELLS; ENGINEERED MOUSE MODELS; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; DOWN-REGULATION; SUPPRESSOR; INFLAMMATION; TARGET; ROLES	The accumulation of prostaglandin E2 (PGE(2)) during chronic inflammation has been implicated in the progression of several cancers. Cyclooxygenase is the key synthesizing enzyme of PGE(2), although the degradation enzyme 15-ydroxyprostaglandin dehydrogenase (15-PGDH) has received considerable attention recently. We investigated the molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) progression via 15-PGDH downregulation. Here, we found that 15-PGDH expression was inversely correlated with ALDH1, an important cancer stem cell-associated marker indicative of poor prognosis in humans. Moreover, we demonstrated that pharmacological inhibition of 15-PGDH enhanced CYP26A1 expression, leading to depletion of all-trans retinoic acid (ATRA) and expansion of the ALDH1-positive subset in both human PDAC cells and tumor cells of Kras(LSL-G12D/+); Ptfla(Cre/+) (KC) mice. Furthermore, genetic deletion of 15-Pgdh in KC mice showed PGE(2) accumulation and ATRA depletion in the pancreas, resulting in PDAC with high levels of Aldh1 and Ki-67. Finally, ATRA replacement suppressed 15-PGDH inhibition-induced tumor progression in KC mice, and ATRA treatment attenuated Aldh1 activity in tumor cells isolated from the pancreas of 15-Pgdh(-/-) KC mice. These findings provide evidence that 15-PGDH inhibition enhances KRAS-driven tumor progression via ATRA depletion in the pancreas. Therefore, ATRA replacement could be a potential strategy for PDAC treatment.	[Arima, Kota; Miyake, Keisuke; Uchihara, Tomoyuki; Izumi, Daisuke; Gao, Feng; Yonemura, Atsuko; Bu, Luke; Okabe, Hirohisa; Imai, Katsunori; Hashimoto, Daisuke; Baba, Yoshifumi; Chikamoto, Akira; Yamashita, Yo-ichi; Baba, Hideo; Ishimoto, Takatsugu] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan; [Arima, Kota; Miyake, Keisuke; Koiwa, Mayu; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan; [Ohmuraya, Masaki] Hyogo Coll Med, Dept Genet, Nishinomiya, Hyogo, Japan; [Furukawa, Toru] Tohoku Univ, Grad Sch Med, Dept Histopathol, Sendai, Miyagi, Japan; [Araki, Kimi] Kumamoto Univ, Inst Resource Dev & Anal, Kumamoto, Japan	Kumamoto University; Kumamoto University; Hyogo College of Medicine; Tohoku University; Kumamoto University	Baba, H; Ishimoto, T (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan.; Ishimoto, T (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan.	hdobaba@kumamoto-u.ac.jp; taka1516@kumamoto-u.ac.jp	Hashimoto, Daisuke/AAE-7134-2020; Ishimoto, Takatsugu/AAP-1356-2020; Furukawa, Toru/AAF-5596-2021	Ishimoto, Takatsugu/0000-0003-1852-1835; Furukawa, Toru/0000-0002-1083-2324	Japan Society for the Promotion of Science KAKENHI [16H06257, 16K15595, 17K16570, 17K16571]; Pancreas Research Foundation of Japan; Kanae Foundation for the Promotion of Medical Science; Yasuda Medical Foundation; Shinnihon Foundation of Advanced Medical Treatment Research;  [201860083]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Pancreas Research Foundation of Japan(Pancreas Research Foundation of Japan); Kanae Foundation for the Promotion of Medical Science; Yasuda Medical Foundation; Shinnihon Foundation of Advanced Medical Treatment Research; 	We are grateful to Dr. David A. Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing the Kras<SUP>LSL-G12D</SUP> mice and to Dr. Sanford D. Markowitz (Department of Medicine, Case Western Reserve University, Cleveland, OH, USA) for their kind advice about establishing 15-Pgdh<SUP>-/-</SUP>mice. This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (Grant Numbers 16H06257, 16K15595, 17K16570, and 17K16571), Grant-in-Aid for JSPS Research Fellows (Grant Numbers Y201860083), the Pancreas Research Foundation of Japan, the Kanae Foundation for the Promotion of Medical Science, the Yasuda Medical Foundation and the Shinnihon Foundation of Advanced Medical Treatment Research.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Arima K, 2018, CANCER SCI, V109, P462, DOI 10.1111/cas.13467; Baumgart S, 2013, GUT, V62, P310, DOI 10.1136/gutjnl-2011-301008; Chen Z, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1794-8; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Fu ZQ, 2017, CANCER LETT, V410, P68, DOI 10.1016/j.canlet.2017.09.019; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hashimoto M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11315; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Huang GS, 2008, CANCER RES, V68, P5040, DOI 10.1158/0008-5472.CAN-07-6575; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kochel TJ, 2016, BREAST CANCER-BASIC, V10, P61, DOI 10.4137/BCBCR.S38529; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Loo TM, 2017, CANCER DISCOV, V7, P522, DOI 10.1158/2159-8290.CD-16-0932; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mashiko D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03355; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Mehdawi LM, 2016, MOL ONCOL, V10, P1415, DOI 10.1016/j.molonc.2016.07.011; Nelson CH, 2013, CURR TOP MED CHEM, V13, P1402; Nguyen PH, 2016, ONCOGENE, V35, P5619, DOI 10.1038/onc.2016.87; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Rothwell PM, 2011, OBSTET GYNECOL SURV, V66, P222, DOI 10.1097/OGX.0b013e318225cec2; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Taki K, 2016, ONCOGENE, V35, P2407, DOI 10.1038/onc.2015.294; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wei S, 2015, NAT MED, V21, P457, DOI 10.1038/nm.3839; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Young MJ, 2015, CARCINOGENESIS, V36, P498, DOI 10.1093/carcin/bgv018; Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340; Zhao D, 2014, J CLIN INVEST, V124, P5453, DOI 10.1172/JCI76611	45	12	13	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1211	1224		10.1038/s41388-018-0510-y	http://dx.doi.org/10.1038/s41388-018-0510-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250298				2022-12-28	WOS:000459249800005
J	Leclerc, J; Garandeau, D; Pandiani, C; Gaudel, C; Bille, K; Nottet, N; Garcia, V; Colosetti, P; Pagnotta, S; Bahadoran, P; Tondeur, G; Mograbi, B; Dalle, S; Caramel, J; Levade, T; Ballotti, R; Andrieu-Abadie, N; Bertolotto, C				Leclerc, Justine; Garandeau, David; Pandiani, Charlotte; Gaudel, Celine; Bille, Karine; Nottet, Nicolas; Garcia, Virginie; Colosetti, Pascal; Pagnotta, Sophie; Bahadoran, Philippe; Tondeur, Garance; Mograbi, Baharia; Dalle, Stephane; Caramel, Julie; Levade, Thierry; Ballotti, Robert; Andrieu-Abadie, Nathalie; Bertolotto, Corine			Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CONFERS RESISTANCE; GENE-EXPRESSION; HIGH-THROUGHPUT; MITF; PATHWAY; SWITCH; PREDISPOSES; METABOLISM; MUTATION	Phenotypic plasticity and subsequent generation of intratumoral heterogeneity underly key traits in malignant melanoma such as drug resistance and metastasis. Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator. Here, we show that the acid ceramidase ASAH1, which controls sphingolipid metabolism, acted as a rheostat of the phenotypic switch in melanoma cells. Low ASAH1 expression was associated with an invasive behavior mediated by activation of the integrin alphavbeta5-FAK signaling cascade. In line with that, human melanoma biopsies revealed heterogeneous staining of ASAH1 and low ASAH1 expression at the melanoma invasive front. We also identified ASAH1 as a new target of MITF, thereby involving MITF in the regulation of sphingolipid metabolism. Together, our findings provide new cues to the mechanisms underlying the phenotypic plasticity of melanoma cells and identify new anti-metastatic targets.	[Leclerc, Justine; Pandiani, Charlotte; Gaudel, Celine; Bille, Karine; Bahadoran, Philippe; Ballotti, Robert; Bertolotto, Corine] Univ Cote dAzur, Inserm U1065, Biol & Pathol Melanocytes, Equipe Labellisee ARC 2015,Team 1,C3M, Nice, France; [Garandeau, David; Nottet, Nicolas] Univ Cote dAzur, Inserm U1065, C3M, Nice, France; [Garcia, Virginie; Levade, Thierry; Andrieu-Abadie, Nathalie] Univ Toulouse III, Sphingolipids Metab Cell Death & Tumor Progress, Team 4, Inserm,UMR1037,CRCT, Toulouse, France; [Colosetti, Pascal] INSA Lyon, INRA1397, INSERM U1060, CarMeN Lab, Lyon, France; [Pagnotta, Sophie] Univ Cote dAzur, Ctr Commun Microscop Appl, Nice, France; [Bahadoran, Philippe] CHU NICE, Dept Dermatol, Nice, France; [Tondeur, Garance; Dalle, Stephane; Caramel, Julie] Univ Lyon, Inserm, U1052, CNRS 5286,Equipe Labeillsee Ligue Canc, Lyon, France; [Mograbi, Baharia] INSERM ERI21, EA 4319, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bertolotto, C (corresponding author), Univ Cote dAzur, Inserm U1065, Biol & Pathol Melanocytes, Equipe Labellisee ARC 2015,Team 1,C3M, Nice, France.	bertolot@unice.fr	Mograbi, Baharia/N-5531-2018; GARCIA, Virginie/W-8313-2019; BALLOTTI, Robert/F-8825-2013; Andrieu-Abadie, Nathalie/N-6793-2013; Bertolotto, Corine/AAF-6634-2021; Colosetti, Pascal/ABH-4585-2020; Dalle, Stephane/E-4552-2018; Carmen, Team2/Y-7383-2019; Mograbi, Baharia/Q-7953-2019	GARCIA, Virginie/0000-0002-9761-7036; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Bertolotto, Corine/0000-0001-6971-7753; Dalle, Stephane/0000-0002-3423-4548; Carmen, Team2/0000-0001-9867-5724; Leclerc, Justine/0000-0003-3793-458X; BALLOTTI, Robert/0000-0002-7322-4908; Caramel, Julie/0000-0002-8883-918X; Lab, Carmen/0000-0002-5935-3236; Colosetti, Pascal/0000-0002-5848-6053; Nottet, Nicolas/0000-0002-8699-6747	INCA [INCA_10573]; la Ligue Nationale contre le Cancer; Inserm, La Societe Francaise de Dermatologie	INCA(Institut National du Cancer (INCA) France); la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Inserm, La Societe Francaise de Dermatologie	This work was supported by Inserm, La Societe Francaise de Dermatologie, and by a grant from INCA (INCA_10573). CP is a fellowship from la Ligue Nationale contre le Cancer. The authors thank Dr. M Sewer (San Diego, USA) for providing the ASAH1 promoter vector. WM3912, WM8, WM3928 and WM3918 human melanoma cell lines were a kind gift from H Meenhard and G Zhang (Wistar melanoma Institute, Philadelphia, USA).	Bedia C, 2007, CHEMBIOCHEM, V8, P642, DOI 10.1002/cbic.200600533; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bonet C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw340; Bonet C, 2012, J BIOL CHEM, V287, P29887, DOI 10.1074/jbc.M112.371682; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791; Colombino M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-117; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Desch A, 2012, AM J PATHOL, V181, P693, DOI 10.1016/j.ajpath.2012.04.012; Don AS, 2014, BIOMOLECULES, V4, P315, DOI 10.3390/biom4010315; Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fane ME, 2017, EBIOMEDICINE, V16, P63, DOI 10.1016/j.ebiom.2017.01.013; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lai M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07606-w; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Lucki N, 2009, BBA-MOL CELL BIOL L, V1791, P706, DOI 10.1016/j.bbalip.2009.03.005; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Mahdy AEM, 2009, MOL THER, V17, P430, DOI 10.1038/mt.2008.281; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Paillerets BBD, 2014, EUR J CELL BIOL, V93, P71, DOI 10.1016/j.ejcb.2013.10.002; Park JH, 2006, BBA-BIOMEMBRANES, V1758, P2133, DOI 10.1016/j.bbamem.2006.08.019; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Realini N, 2016, J BIOL CHEM, V291, P2422, DOI 10.1074/jbc.M115.666909; Reinhardt J, 2017, CANCER RES, V77, P4697, DOI 10.1158/0008-5472.CAN-17-0395; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Ruckhaberle E, 2009, CLIMACTERIC, V12, P502, DOI 10.3109/13697130902939913; Sanger N, 2015, MOL ONCOL, V9, P58, DOI 10.1016/j.molonc.2014.07.016; Shtraizent N, 2008, J BIOL CHEM, V283, P11253, DOI 10.1074/jbc.M709166200; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Truman JP, 2014, BBA-MOL CELL BIOL L, V1841, P1174, DOI 10.1016/j.bbalip.2013.12.013; Van Allen EM, 2014, PROSTATE CANCER P D, V17, P23, DOI 10.1038/pcan.2013.37; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Walkley SU, 2009, BBA-MOL CELL RES, V1793, P726, DOI 10.1016/j.bbamcr.2008.11.014; Wang F, 1999, CANCER RES, V59, P6185; WARBURG O, 1956, SCIENCE, V124, P269; Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhou J, 2012, AM J HUM GENET, V91, P5, DOI 10.1016/j.ajhg.2012.05.001	64	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1282	1295		10.1038/s41388-018-0500-0	http://dx.doi.org/10.1038/s41388-018-0500-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254208	Green Submitted			2022-12-28	WOS:000459249800010
J	Yu, WW; Ding, J; He, M; Chen, Y; Wang, RH; Han, ZW; Xing, EZ; Zhang, CT; Yeh, SY				Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan			Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer	ONCOGENE			English	Article							LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR PROGRESSION; CERVICAL-CANCER; GROWTH-FACTOR; IN-VITRO; EXPRESSION; METASTASIS; MALAT1; ADENOCARCINOMA	While estrogen receptor beta (ER beta) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alteration of the vasculogenic mimicry (VM) formation to influence the NSCLC cell invasion remains unclear. Here, we analyzed immunohistochemistry data from NSCLC tissues and found that ER beta-positive NSCLC female patients had worse survival outcomes than those of ER beta-negative NSCLC female patients. In vitro studies using multiple NSCLC cell lines also revealed that ER beta could increase the VM formation and cell invasion. Molecular mechanism dissection suggested that ER beta could increase the lncRNA-MALAT1 (MALAT1) expression via directly binding to the estrogen response elements (EREs) located on the promoter of MALAT1, which could then lead to (i) suppressing the miR145-5p and (ii) increasing the NEDD9 protein expression as miR145-5p can directly target the 3'-UTR of NEDD9-mRNA. A preclinical study using the in vivo mouse model further confirmed the in vitro cell lines data. Together, results from the above studies demonstrated that ER beta can promote NSCLC VM formation and cell invasion via altering the ER beta/MALAT1/miR145-5p/NEDD9 signaling. Targeting this newly identified signaling pathway with small molecules may help the development of novel therapies to better suppress the NSCLC metastasis.	[Yu, Weiwei; Chen, Yuan; Zhang, Cuntai] Huazhong Univ Sci & Technol, Gen Dept, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Yu, Weiwei; Ding, Jie; He, Maio; Chen, Yuan; Wang, Ronghao; Han, Zhenwei; Xing, Emily Z.; Zhang, Cuntai; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	Huazhong University of Science & Technology; University of Rochester; University of Rochester	Zhang, CT (corresponding author), Huazhong Univ Sci & Technol, Gen Dept, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Zhang, CT; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Zhang, CT; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	ctzhang0425@163.com; shuyuan_yeh@URMC.Rochester.edu	Wang, Ronghao/AAV-9769-2021		George Whipple Professorship Endowment	George Whipple Professorship Endowment	This work was partially supported by George Whipple Professorship Endowment. We thank Karen Wolf for assistance in manuscript preparation.	Aiello A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38414; [Anonymous], 1996, J Cell Biochem Suppl, V24, P1; Belani CP, 2007, LUNG CANCER, V55, P15, DOI 10.1016/j.lungcan.2006.09.008; CASERO RA, 1986, BIOCHEM BIOPH RES CO, V134, P572, DOI 10.1016/S0006-291X(86)80458-2; Chen Y, 2016, CELL PHYSIOL BIOCHEM, V38, P2194, DOI 10.1159/000445575; Chiang YY, 2014, ONCOL REP, V31, P597, DOI 10.3892/or.2013.2867; Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0; Coelho AL, 2017, ONCOTARGET, V8, P39795, DOI 10.18632/oncotarget.7794; Cui D, 2016, TUMOR BIOL, V37, P4127, DOI 10.1007/s13277-015-4261-x; Ding Y, 2012, ONCOGENE, V31, P2899, DOI 10.1038/onc.2011.467; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hammoud Z, 2008, ENDOCR-RELAT CANCER, V15, P475, DOI 10.1677/ERC-08-0002; Hartman J, 2012, STEROIDS, V77, P1262, DOI 10.1016/j.steroids.2012.07.002; He JB, 2016, SCI REP-UK, V6, DOI 10.1038/srep20586; Hu HB, 2016, LUNG CANCER, V97, P87, DOI 10.1016/j.lungcan.2016.04.017; Huang NS, 2016, ONCOTARGET, V7, P37957, DOI 10.18632/oncotarget.9364; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; Jiang T, 2017, CLIN LUNG CANCER, V18, P421, DOI 10.1016/j.cllc.2016.12.012; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kiyohara C, 2010, GENDER MED, V7, P381, DOI 10.1016/j.genm.2010.10.002; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Li YW, 2016, CANCER BIOL THER, V17, P272, DOI 10.1080/15384047.2016.1139242; Liu JH, 2017, FRONT BIOSCI-LANDMRK, V22, P66, DOI 10.2741/4472; Liu MJ, 2016, ONCOL REP, V36, P1679, DOI 10.3892/or.2016.4909; Liu RL, 2015, INT J BIOL MACROMOL, V81, P491, DOI 10.1016/j.ijbiomac.2015.08.016; Liu SK, 2016, TUMOR BIOL, V37, P633, DOI 10.1007/s13277-015-3732-4; Lother SA, 2013, HORM CANCER-US, V4, P270, DOI 10.1007/s12672-013-0149-7; Lu HZ, 2016, TUMOR BIOL, V37, P1683, DOI 10.1007/s13277-015-3946-5; Lu RJ, 2014, J CANCER RES CLIN, V140, P387, DOI 10.1007/s00432-013-1577-z; Lu Y, 2016, ONCOTARGETS THER, V9, P3077, DOI 10.2147/OTT.S102658; Luo J, 2014, TUMOR BIOL, V35, P11541, DOI 10.1007/s13277-014-2442-7; Luo Z, 2015, INT J CLIN EXP MED, V8, P8686; Ma LH, 2016, TRANSL LUNG CANCER R, V5, P202, DOI 10.21037/tlcr.2016.04.04; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marquez-Garban DC, 2009, ANN NY ACAD SCI, V1155, P194, DOI 10.1111/j.1749-6632.2009.04116.x; Monica V, 2012, CLIN LUNG CANCER, V13, P416, DOI 10.1016/j.cllc.2012.03.006; Morimoto K, 2014, PROSTATE, V74, P901, DOI 10.1002/pros.22809; Nelson AW, 2017, MOL CELL ENDOCRINOL, V440, P138, DOI 10.1016/j.mce.2016.11.016; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Nose N, 2011, LUNG CANCER, V71, P350, DOI 10.1016/j.lungcan.2010.06.009; Onn A, 2003, CLIN CANCER RES, V9, P5532; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Qiu MT, 2014, TUMOR BIOL, V35, P5375, DOI 10.1007/s13277-014-1700-z; Rodriguez-Lara V, 2017, ENDOCR RES, V42, P219, DOI 10.1080/07435800.2017.1292526; Rousseau B, 2015, SCI REP-UK, V5, DOI 10.1038/srep10356; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Shen LQ, 2015, J NEURO-ONCOL, V121, P101, DOI 10.1007/s11060-014-1613-0; Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414; Siegfried JM, 2014, SEMIN ONCOL, V41, P5, DOI 10.1053/j.seminoncol.2013.12.009; Skjefstad K, 2016, STEROIDS, V113, P5, DOI 10.1016/j.steroids.2016.05.008; Slowikowski BK, 2017, MOL BIOL REP, V44, P35, DOI 10.1007/s11033-016-4086-8; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang JZ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3151-6; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866; Weitsman GE, 2006, BREAST CANCER RES TR, V100, P23, DOI 10.1007/s10549-006-9229-5; Wu CT, 2005, HUM PATHOL, V36, P1108, DOI 10.1016/j.humpath.2005.08.003; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416; Wu XL, 2012, J CELL BIOCHEM, V113, P711, DOI 10.1002/jcb.23443; Wu Y, 2015, ONCOTARGET, V6, P9160, DOI 10.18632/oncotarget.3247; Xia WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16901; Yao LL, 2016, J CELL MOL MED, V20, P1673, DOI 10.1111/jcmm.12862; Zhang CG, 2017, EUR REV MED PHARMACO, V21, P115; Zhang GF, 2009, MOL ENDOCRINOL, V23, P146, DOI 10.1210/me.2008-0431; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; Zhu LC, 2015, PATHOL ONCOL RES, V21, P1259, DOI 10.1007/s12253-015-9960-5	67	72	73	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1225	1238		10.1038/s41388-018-0463-1	http://dx.doi.org/10.1038/s41388-018-0463-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250297				2022-12-28	WOS:000459249800006
J	Yuan, XT; Mu, NN; Wang, N; Straat, K; Sofiadis, A; Guo, YX; Stenman, A; Li, KL; Cheng, GH; Zhang, L; Kong, F; Ekblad, L; Wennerberg, J; Nilsson, IL; Juhlin, CC; Larsson, C; Xu, DW				Yuan, Xiaotian; Mu, Ninni; Wang, Na; Straat, Klas; Sofiadis, Anastasios; Guo, Yanxia; Stenman, Adam; Li, Kailin; Cheng, Guanghui; Zhang, Lu; Kong, Feng; Ekblad, Lars; Wennerberg, Johan; Nilsson, Inga-Lena; Juhlin, C. Christofer; Larsson, Catharina; Xu, Dawei			GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression	ONCOGENE			English	Article							TERT PROMOTER MUTATIONS; TRANSCRIPTION FACTOR; ETS FAMILY; CANCER; TELOMERASE; BRAF; COEXISTENCE; GENES	The ETS family transcription factor GABPA is suggested as an oncogenic element, which is further supported by the recent reporting of it as the sole ETS member to activate the mutant TERT promoter in thyroid carcinomas (TC). However, it remains unclear how GABPA contributes to TC pathogenesis. The present study is designed to address this issue. TERT expression was significantly diminished in TERT promoter-mutated TC cells upon GABPA inhibition. Surprisingly, GABPA depletion led to robustly increased cellular invasion independently of TERT promoter mutations and TERT expression. DICER1, a component of the microRNA machinery, was identified as a downstream effector of GABPA. GABPA facilitated Dicer1 transcription while its depletion reduced Dicer1 expression. The mutation of the GABPA binding site in the DICER1 promoter led to diminished basal levels of DICER1 promoter activity and abolishment of GABPA-stimulated promoter activity as well. The forced DICER1 expression abrogated the invasiveness of GABPA-depleted TC cells. Consistently, the analyses of 93 patients with papillary thyroid carcinoma (PTC) revealed a positive correlation between GABPA and DICER1 expression. GABPA expression was negatively associated with TERT expression and promoter mutations, in contrast to published observations in cancer cell lines. Lower GABPA expression was associated with distant metastasis and shorter overall/disease-free survival in PTC patients. Similar results were obtained for PTC cases in the TCGA dataset. In addition, a positive correlation between GABPA and DICER1 expression was seen in multiple types of malignancies. Taken together, despite its stimulatory effect on the mutant TERT promoter and telomerase activation, GABPA may itself act as a tumor suppressor rather than an oncogenic factor to inhibit invasion/metastasis in TCs and be a useful predictor for patient outcomes.	[Yuan, Xiaotian] Shandong Univ, Reprod Ctr, Jinan 250013, Shandong, Peoples R China; [Yuan, Xiaotian; Straat, Klas; Guo, Yanxia; Xu, Dawei] Karolinska Inst, Karolinska Univ Hosp CMM, Dept Med Solna, SE-17176 Stockholm, Sweden; [Mu, Ninni; Wang, Na; Sofiadis, Anastasios; Stenman, Adam; Juhlin, C. Christofer; Larsson, Catharina] Karolinska Inst, Karolinska Univ Hosp CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Guo, Yanxia; Li, Kailin; Cheng, Guanghui; Zhang, Lu; Kong, Feng] Shandong Univ, Hosp 2, Cent Res Lab, Jinan 250033, Shandong, Peoples R China; [Ekblad, Lars] Lund Univ, Fac Med, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden; [Wennerberg, Johan] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Div Otorhinolaryngol Head & Neck Surg, Lund, Sweden; [Nilsson, Inga-Lena] Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, SE-17176 Stockholm, Sweden	Shandong University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Shandong University; Lund University; Lund University; Skane University Hospital; Karolinska Institutet; Karolinska University Hospital	Xu, DW (corresponding author), Karolinska Inst, Karolinska Univ Hosp CMM, Dept Med Solna, SE-17176 Stockholm, Sweden.; Larsson, C (corresponding author), Karolinska Inst, Karolinska Univ Hosp CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	Catharina.Larsson@ki.se; Dawei.Xu@ki.se	Li, Kai/HCI-8860-2022; Stenman, Adam/AAI-3866-2021; yuan, xiaotian/AAN-6330-2020; Juhlin, Carl Christofer/C-1125-2016; Ekblad, Lars/O-8932-2014	Stenman, Adam/0000-0003-3248-7629; yuan, xiaotian/0000-0002-1501-518X; Juhlin, Carl Christofer/0000-0002-5945-9081; Ekblad, Lars/0000-0003-0152-786X; Xu, Dawei/0000-0003-3141-4524; Zhang, Lu/0000-0002-1580-6774; Nilsson, Inga-Lena/0000-0002-8966-3729	Swedish Cancer Society; Cancer Society in Stockholm; Stockholm County Council; Karolinska Institutet; Shandong Provincial Natural Science Foundation, China [2016ZDJS07A09]	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province)	We thank Dr. J.K., Dr. J.F. Costello (University of California, San Francisco) for the TERT promoter reporters, Ms. L. Ahnfalk for excellent assistance in tumor tissue collection, Dr. B. Guan for evaluation of tumor colonies in mouse lung, and E. Berg (Karolinska Institutet) for expert consultations in the statistical analyses. The study was supported by grants from the Swedish Cancer Society, the Cancer Society in Stockholm, Stockholm County Council and Karolinska Institutet, and Shandong Provincial Natural Science Foundation, China (2016ZDJS07A09).	Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; De Lellis R.A., 2004, WHO CLASSIFICATION T, V3rd; Ding DQ, 2013, FASEB J, V27, P4375, DOI 10.1096/fj.13-230904; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafarnejad SM, 2013, ONCOGENE, V32, P2131, DOI 10.1038/onc.2012.239; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Landa I, 2013, J CLIN ENDOCR METAB, V98, pE1562, DOI 10.1210/jc.2013-2383; Lee JJ, 2007, THYROID, V17, P289, DOI 10.1089/thy.2006.0246; Lee SE, 2016, THYROID, V26, P901, DOI 10.1089/thy.2015.0488; Lewis KA, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00083; Liu RY, 2016, ENDOCR-RELAT CANCER, V23, pR143, DOI 10.1530/ERC-15-0533; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Lloyd R., 2017, WHO CLASSIFICATION T, V4th; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Melo M, 2017, J CLIN ENDOCR METAB, V102, P1898, DOI 10.1210/jc.2016-2785; Melo M, 2015, J CLIN ONCOL, V33, P667, DOI 10.1200/JCO.2014.59.4614; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Odrowaz Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049892; Pacini F, 2011, NAT REV ENDOCRINOL, V7, P420, DOI 10.1038/nrendo.2011.52; Pestana A, 2017, J MOL ENDOCRINOL, V58, pR129, DOI 10.1530/JME-16-0195; Prazeres H, 2011, ONCOGENE, V30, P1302, DOI 10.1038/onc.2010.512; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Rupaimoole R, 2016, ONCOGENE, V35, P4312, DOI 10.1038/onc.2015.492; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Schweppe RE, 2013, J CLIN ENDOCR METAB, V98, P956, DOI 10.1210/jc.2012-4182; Sharma NL, 2014, NUCLEIC ACIDS RES, V42, P6256, DOI 10.1093/nar/gku281; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Song YS, 2016, CANCER-AM CANCER SOC, V122, P1370, DOI 10.1002/cncr.29934; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; To SKY, 2017, ONCOGENE, V36, P5927, DOI 10.1038/onc.2017.185; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wang N, 2014, CANCER-AM CANCER SOC, V120, P2965, DOI 10.1002/cncr.28800; Woodward EL, 2017, ENDOCR-RELAT CANCER, V24, P209, DOI 10.1530/ERC-16-0522; Xing MZ, 2014, J CLIN ONCOL, V32, P2718, DOI 10.1200/JCO.2014.55.5094; Yang ZF, 2013, P NATL ACAD SCI USA, V110, P2312, DOI 10.1073/pnas.1212904110; Yu JY, 2018, CANCER LETT, V434, P33, DOI 10.1016/j.canlet.2018.07.013; Zhang K, 2017, CANCER RES, V77, P2534, DOI 10.1158/0008-5472.CAN-16-1887; Zhang L, 2017, J CLIN INVEST, V127, P2159, DOI 10.1172/JCI90077; ZHANG S, 2017, BMC CANCER, V17	48	31	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					965	979		10.1038/s41388-018-0483-x	http://dx.doi.org/10.1038/s41388-018-0483-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30181547				2022-12-28	WOS:000458624900004
J	Yochum, ZA; Cades, J; Wang, HL; Chatterjee, S; Simons, BW; O'Brien, JP; Khetarpal, SK; Lemtiri-Chlieh, G; Myers, KV; Huang, EHB; Rudin, CM; Tran, PT; Burns, TF				Yochum, Zachary A.; Cades, Jessica; Wang, Hailun; Chatterjee, Suman; Simons, Brian W.; O'Brien, James P.; Khetarpal, Susheel K.; Lemtiri-Chlieh, Ghali; Myers, Kayla V.; Huang, Eric H. -B.; Rudin, Charles M.; Tran, Phuoc T.; Burns, Timothy F.			Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer	ONCOGENE			English	Article							BIM DELETION POLYMORPHISM; ACQUIRED-RESISTANCE; MESENCHYMAL TRANSITION; CONFERS RESISTANCE; AZD9291; OSIMERTINIB; ACTIVATION; EXPRESSION; SENSITIVITY; MECHANISMS	Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (similar to 30%) as well as acquired resistance. Epithelial-mesenchymal transition transcription factors (EMT-TFs), have been identified as drivers of EMTmediated resistance to EGFR TKIs, however, strategies to target EMT-TFs are lacking. As the third generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of T790M mutations will significantly decrease in the acquired resistance setting. Previously less common mechanisms of acquired resistance to first generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. Importantly, there are no other FDA approved targeted therapies after progression on osimertinib. Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeting the EMT-TF, TWIST1, in EGFR-mutant NSCLC. We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC. TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells. Conversely, genetic and pharmacological inhibition of TWIST1 in EGFR TKI-resistant EGFR-mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic BH3-only gene, BCL2L11 (BIM), by directly binding to BCL2L11 intronic regions and promoter. As such, pan-BCL2 inhibitor treatment overcame TWIST1mediated EGFR TKI resistance and were more effective in the setting of TWIST1 overexpression. Finally, in a mouse model of autochthonous EGFR-mutant lung cancer, Twist1 overexpression resulted in erlotinib resistance and suppression of erlotinibinduced apoptosis. These studies establish TWIST1 as a driver of resistance to EGFR TKIs and provide rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance to EGFR TKIs.	[Yochum, Zachary A.; Burns, Timothy F.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Yochum, Zachary A.; Chatterjee, Suman; O'Brien, James P.; Khetarpal, Susheel K.; Myers, Kayla V.; Huang, Eric H. -B.; Burns, Timothy F.] UPMC Hillman Canc Ctr, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA; [Cades, Jessica] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Wang, Hailun; Lemtiri-Chlieh, Ghali; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Cades, Jessica; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Simons, Brian W.; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Johns Hopkins University	Burns, TF (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.; Burns, TF (corresponding author), UPMC Hillman Canc Ctr, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA.	tranp@jhmi.edu; burnstf@upmc.edu	Tran, Phuoc/W-2084-2019; Wang, Hailun/T-5696-2019; Rudin, Charles/R-2530-2019; Simons, Brian/G-7352-2015	Tran, Phuoc/0000-0002-0147-0376; Rudin, Charles/0000-0001-5204-3465; Myers, Kayla/0000-0002-0748-1092; Simons, Brian/0000-0003-0644-211X; Wang, Hailun/0000-0001-8651-2856	Uniting Against Lung Cancer Foundation; V Foundation Scholar Award; American Lung Association Award [LCD 257864]; Sidney Kimmel Foundation [SKF-15-099, SKF-13-021]; Doris Duke Charitable Foundation Clinical Scientist Award [2015097]; Pittsburgh LUNG SPORE CDA [P50CA090440]; We Wish Foundation; Howard Hughes Medical Institute Medical Fellowship [T32GM008421-22, 1F30CA213765-01]; Nesbitt Family; Movember-Prostate Cancer Foundation; American Lung Association [LCD-339465]; Commonwealth Foundation; ACS [122688-RSG-12-196-01-TBG]; DoD [W81XWH-13-1-0182]; NIH/NCI [R01CA166348];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA166348, F30CA213765, P30CA008748, P50CA090440, U01CA212007, P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008424] Funding Source: NIH RePORTER	Uniting Against Lung Cancer Foundation; V Foundation Scholar Award; American Lung Association Award; Sidney Kimmel Foundation; Doris Duke Charitable Foundation Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); Pittsburgh LUNG SPORE CDA; We Wish Foundation; Howard Hughes Medical Institute Medical Fellowship; Nesbitt Family; Movember-Prostate Cancer Foundation; American Lung Association; Commonwealth Foundation; ACS(American Cancer Society); DoD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following funding sources: HW has received research funding from the Uniting Against Lung Cancer Foundation. TFB was supported for this project from a V Foundation Scholar Award, American Lung Association Award (LCD 257864), Sidney Kimmel Foundation (SKF-15-099) and a Doris Duke Charitable Foundation Clinical Scientist Award (2015097), a Pittsburgh LUNG SPORE CDA P50CA090440 and generous support from the We Wish Foundation. This project used the Hillman Cancer Center Animal, Flow Cytometry and Biostatistics Facilities that are supported in part by award P30CA047904. ZAY has received research funding for this project from the Howard Hughes Medical Institute Medical Fellowship, T32GM008421-22 and a 1F30CA213765-01. PTT has received research funding for this project from the Nesbitt Family; Movember-Prostate Cancer Foundation; Uniting Against Lung Cancer Foundation; American Lung Association (LCD-339465); Commonwealth Foundation; Sidney Kimmel Foundation (SKF-13-021); ACS (122688-RSG-12-196-01-TBG); DoD (W81XWH-13-1-0182); NIH/NCI (R01CA166348). We Laura Stabile, PhD, James G. Herman, MD, and Frank P. Vendetti PhD at the University of Pittsburgh for the discussion, advice regarding experimental design and supply of reagents when applicable. In addition, we would like to acknowledge the helpful discussion and comments provided by the Burns, Rudin, and Tran laboratory members.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Burns TF, 2013, MOL CANCER RES, V11, P329, DOI 10.1158/1541-7786.MCR-12-0456; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chang AT, 2015, GENE DEV, V29, P603, DOI 10.1101/gad.242842.114; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen YT, 2007, GENESIS, V45, P588, DOI 10.1002/dvg.20332; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Eberlein CA, 2015, CANCER RES, V75, P2489, DOI 10.1158/0008-5472.CAN-14-3167; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hwang W, 2017, CANCER RES, V77, P3013, DOI 10.1158/0008-5472.CAN-16-3168; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Jacqueroud L, 2016, NEOPLASIA, V18, P317, DOI 10.1016/j.neo.2016.03.007; Jakobsen KR, 2016, TRANSL LUNG CANCER R, V5, P172, DOI 10.21037/tlcr.2016.04.07; Jin HO, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.63; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Li L, 2017, ONCOTARGET, V8, P18609, DOI 10.18632/oncotarget.14506; McGowan Marc, 2017, Genes Cancer, V8, P497, DOI 10.18632/genesandcancer.136; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moloudizargari Milad, 2013, Pharmacogn Rev, V7, P199, DOI 10.4103/0973-7847.120524; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ou SHI, 2016, LUNG CANCER, V98, P59, DOI 10.1016/j.lungcan.2016.05.015; Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Planchard D, 2015, ANN ONCOL, V26, P2073, DOI 10.1093/annonc/mdv319; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Ricordel Charles, 2017, J Thorac Oncol, V12, pe184, DOI 10.1016/j.jtho.2017.07.019; Roberts CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37652; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492; Soh SX, 2017, ONCOTARGET, V8, P41474, DOI 10.18632/oncotarget.17102; Song KA, 2018, CLIN CANCER RES, V24, P197, DOI 10.1158/1078-0432.CCR-17-1577; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52; Tanimoto A, 2017, CLIN CANCER RES, V23, P3139, DOI 10.1158/1078-0432.CCR-16-2271; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650; Tran PT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002018; Vazquez-Martin A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02560; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yochum ZA, 2017, MOL CANCER RES, V15, P1764, DOI 10.1158/1541-7786.MCR-17-0298; Yochum ZA, 2016, J THORAC DIS, V8, pE1528, DOI 10.21037/jtd.2016.11.59; Yoshida T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147344; Zhang T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12231; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	60	96	100	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					656	670		10.1038/s41388-018-0482-y	http://dx.doi.org/10.1038/s41388-018-0482-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171258	Green Accepted			2022-12-28	WOS:000457300300004
J	Sbrissa, D; Semaan, L; Govindarajan, B; Li, YF; Caruthers, NJ; Stemmer, PM; Cher, ML; Sethi, S; Vaishampayan, U; Shisheva, A; Chinni, SR				Sbrissa, Diego; Semaan, Louie; Govindarajan, Barani; Li, Yanfeng; Caruthers, Nicholas J.; Stemmer, Paul M.; Cher, Michael L.; Sethi, Seema; Vaishampayan, Ulka; Shisheva, Assia; Chinni, Sreenivasa R.			A novel cross-talk between CXCR4 and PI4KIII alpha in prostate cancer cells	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; PLASMA-MEMBRANE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-PHOSPHATE; SIGNALING PATHWAY; EXPRESSION; PROTEIN; MIGRATION; METASTASIS; DIMERIZATION	Chemokine signaling regulates cell migration and tumor metastasis. CXCL12, a member of the chemokine family, and its receptor, CXCR4, a G protein coupled receptor (GPCR), are key mediators of prostate-cancer (PC) bone metastasis. In PC cells androgens activate CXCR4 gene expression and receptor signaling on lipid rafts, which induces protease expression and cancer cell invasion. To identify novel lipid-raft-associated CXCR4 regulators supporting invasion/metastasis, we performed a SILAC-based quantitative proteomic analysis of lipid-rafts derived from PC3 stable cell lines with overexpression or knockdown of CXCR4. This analysis identified the evolutionarily conserved phosphatidylinositol 4-kinase III alpha (PI4KIII alpha), and SAC1 phosphatase that dephosphorylates phosphatidylinositol-4-phosphate as potential candidate CXCR4 regulators. CXCR4 interacted with PI4KIII alpha membrane targeting machinery recruiting them to the plasma membrane for PI4P production. Consistent with this interaction, PI4KIII alpha was found tightly linked to the CXCR4 induced PC cell invasion. Thus, ablation of PI4KIII alpha in CXCR4-expressing PC3 cells reduced cellular invasion in response to a variety of chemokines. Immunofluorescence microscopy in CXCR4-expressing cells revealed localized production of PI4P on the invasive projections. Human tumor studies documented increased PI4KIII alpha expression in metastatic tumors vs. the primary tumor counterparts, further supporting the PI4KIIIa role in tumor metastasis. Furthermore, we also identified an unexpected function of PI4KIII alpha in GPCR signaling where CXCR4 regulates PI4KIII alpha activity and mediate tumor metastasis. Altogether, our study identifies a novel cross-talk between PI4KIII alpha and CXCR4 in promoting tumor metastasis and suggests that PI4KIII alpha pharmacological targeting may have therapeutic benefit for advanced prostate cancer patients.	[Sbrissa, Diego; Semaan, Louie; Li, Yanfeng; Cher, Michael L.; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Urol, Detroit, MI 48201 USA; [Sbrissa, Diego; Shisheva, Assia] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; [Govindarajan, Barani; Cher, Michael L.; Sethi, Seema; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Caruthers, Nicholas J.; Stemmer, Paul M.] Wayne State Univ, Sch Med, Inst Environm Hlth Sci, Detroit, MI 48201 USA; [Caruthers, Nicholas J.; Stemmer, Paul M.] Wayne State Univ, Sch Med, Prote Core Facil, Detroit, MI 48201 USA; [Cher, Michael L.; Vaishampayan, Ulka; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Urol, Detroit, MI 48201 USA.; Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.; Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.	schinni@med.wayne.edu		Stemmer, Paul/0000-0003-3315-9846; Vaishampayan, Ulka/0000-0001-5800-4571	U.S. Department of Defense [W81XWH-09-1-0250]; NIH-NCI Grant [CA151557]; Fund for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA151557] Funding Source: NIH RePORTER	U.S. Department of Defense(United States Department of Defense); NIH-NCI Grant; Fund for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Special thanks to Dr. Balla for providing PI4KIII alpha and EFR3B expression constructs, Dr. DeCamilli for TTC7B construct and Dr. Mayinger for anti-Sac1 antibodies. We would like to thank Mr. Ussama A. Khan for technical assistance in preparing data. We also thank Astellas/Medivation for supporting clinical protocol for human tumor biopsy material collection. Supported by U.S. Department of Defense, W81XWH-09-1-0250, NIH-NCI Grant CA151557 and Fund for Cancer Research.	Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Bachelder RE, 2002, CANCER RES, V62, P7203; Baird D, 2008, J CELL BIOL, V183, P1061, DOI 10.1083/jcb.200804003; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balla A, 2005, MOL BIOL CELL, V16, P1282, DOI 10.1091/mbc.E04-07-0578; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Balla A, 2008, MOL BIOL CELL, V19, P711, DOI 10.1091/mbc.E07-07-0713; Baskin JM, 2016, NAT CELL BIOL, V18, P132, DOI 10.1038/ncb3271; Bendall SC, 2008, MOL CELL PROTEOMICS, V7, P1587, DOI 10.1074/mcp.M800113-MCP200; Bojjireddy N, 2015, J CELL SCI, V128, P118, DOI 10.1242/jcs.157495; Bojjireddy N, 2014, J BIOL CHEM, V289, P6120, DOI 10.1074/jbc.M113.531426; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Burke JE, 2014, SCIENCE, V344, P1035, DOI 10.1126/science.1253397; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367; Castellone MD, 2004, ONCOGENE, V23, P5958, DOI 10.1038/sj.onc.1207790; Chinni SR, 2006, PROSTATE, V66, P32, DOI 10.1002/pros.20318; Chinni SR, 2008, MOL CANCER RES, V6, P446, DOI 10.1158/1541-7786.MCR-07-0117; Chu KME, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.84; Chung JY, 2015, EMBO REP, V16, P312, DOI 10.15252/embr.201439151; Coke CJ, 2016, J BIOL CHEM, V291, P9991, DOI 10.1074/jbc.M115.712661; Conley-LaComb MK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0552-0; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Dillenburg-Pilla P, 2015, FASEB J, V29, P1056, DOI 10.1096/fj.14-260083; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Ikonomov OC, 2011, J BIOL CHEM, V286, P13404, DOI 10.1074/jbc.M111.222364; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lee BC, 2005, CANCER RES, V65, P2840, DOI 10.1158/0008-5472.CAN-04-3309; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakatsu F, 2012, J CELL BIOL, V199, P1003, DOI 10.1083/jcb.201206095; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2007, J BIOL CHEM, V282, P23878, DOI 10.1074/jbc.M611678200; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Singareddy R, 2013, MOL CANCER RES, V11, P1349, DOI 10.1158/1541-7786.MCR-12-0705; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Wang JH, 2006, MOL CANCER THER, V5, P2474, DOI 10.1158/1535-7163.MCT-05-0261; Wu XD, 2014, DEV CELL, V28, P19, DOI 10.1016/j.devcel.2013.11.012	43	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					332	344		10.1038/s41388-018-0448-0	http://dx.doi.org/10.1038/s41388-018-0448-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30111818	Green Accepted			2022-12-28	WOS:000455851200003
J	Kaverina, NV; Kadagidze, ZG; Borovjagin, AV; Karseladze, AI; Kim, CK; Lesniak, MS; Miska, J; Zhang, P; Baryshnikova, MA; Xiao, T; Ornelles, D; Cobbs, C; Khramtsov, A; Ulasov, IV				Kaverina, Natalya, V; Kadagidze, Zaira G.; Borovjagin, Anton, V; Karseladze, Apollon, I; Kim, Chung Kwon; Lesniak, Maciej S.; Miska, Jason; Zhang, Peng; Baryshnikova, Maria A.; Xiao, Ting; Ornelles, David; Cobbs, Charles; Khramtsov, Andrey; Ulasov, Ilya, V			Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX	ONCOGENE			English	Article							NORMAL HUMAN FIBROBLASTS; MALIGNANT GLIOMA; BECLIN 1; SECRETORY PHENOTYPE; PROTEIN EXPRESSION; HUMAN GLIOBLASTOMA; APOPTOSIS; SENESCENCE; DEATH; P53	Autophagy is an evolutionarily conserved process regulating cellular homeostasis via digestion of dysfunctional proteins and whole cellular organelles by mechanisms, involving their enclosure into double-membrane vacuoles that are subsequently fused to lysosomes. Glioma stem cells utilize autophagy as a main mechanism of cell survival and stress response. Most recently, we and others demonstrated induction of autophagy in gliomas in response to treatment with chemical drugs, such as temozolomide (TMZ) or oncolytic adenoviruses (Ads). As autophagy has been implicated in the mechanism of Ad-mediated cell killing, autophagy deficiency in some glioma tumors could be the reason for their resistance to oncolysis. Despite the observed connection, the exact relationship between autophagy-activating cell signaling and adenoviral infection remains unclear. Here, we report that inhibition of autophagy in target glioma cells induces their resistance to killing by oncolytic agent CRAd-S-5/3. Furthermore, we found that downregulation of autophagy inducer Beclin-1 inhibits replication-competent Ad-induced oncolysis of human glioma by suppressing cell proliferation and inducing premature senescence. To overcome the autophagy-deficient state of such glioma cells and restore their susceptibility to oncolytic Ad-infection, we propose treating glioma tumors with an anticancer drug tamoxifen (TAM) as a means to induce apoptosis in Ad-targeted cancer cells via upregulation of BAX/PUMA genes. In agreement with the above hypothesis, our data suggest that TAM improves susceptibility of Beclin-1-deficient glioma cells to CRAd-S-5/3 oncolysis by means of activating autophagy and pro-apoptotic signaling pathways in the target cancer cells.	[Kaverina, Natalya, V; Kadagidze, Zaira G.; Karseladze, Apollon, I] RAMN, NN Blokhin Natl Med Res Ctr Oncol, Kashirskoe Shosse 23, Moscow 115478, Russia; [Kaverina, Natalya, V; Baryshnikova, Maria A.] RAMN, Inst Expt Diagnost & Biotherapy, NN Blokhin Natl Med Res Ctr Oncol, Kashirskoe Shosse 23, Moscow 115478, Russia; [Borovjagin, Anton, V] Univ Alabama Birmingham, Inst Oral Hlth Res, Birmingham Sch Dent, Birmingham, AL 35205 USA; [Kim, Chung Kwon] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst Suwon, Suwon 440746, South Korea; [Lesniak, Maciej S.; Miska, Jason; Zhang, Peng; Xiao, Ting; Ulasov, Ilya, V] Northwestern Univ, Northwestern Brain Tumor Inst, Chicago, IL 60611 USA; [Ornelles, David] Wake Forest Sch Med, Dept Microbiol & Immunol, Salem, NC 27101 USA; [Cobbs, Charles] Swedish Neurosci Inst, Seattle, WA 98104 USA; [Khramtsov, Andrey] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, Chicago, IL 60611 USA; [Ulasov, Ilya, V] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia	University of Alabama System; University of Alabama Birmingham; Sungkyunkwan University (SKKU); Northwestern University; Swedish Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Sechenov First Moscow State Medical University	Ulasov, IV (corresponding author), Northwestern Univ, Northwestern Brain Tumor Inst, Chicago, IL 60611 USA.; Ulasov, IV (corresponding author), Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia.	ulasov75@yahoo.com	Ulasov, Ilya/A-2352-2014; Khramtsov, Andrey I/H-8701-2018	Ulasov, Ilya/0000-0002-0818-0363; Khramtsov, Andrey I/0000-0001-6301-4619	Russian Fund of Fundamental Research (Russia) [11 411.0008700. 13.082, 13 411. 1008799.13.120]	Russian Fund of Fundamental Research (Russia)	This research was supported by Russian Fund of Fundamental Research (number 11 411.0008700. 13.082 and number 13 411. 1008799.13.120 Russia, MAB) and private donors. We are grateful to Dr. Cobbs for providing patient-derived tumor cells and to Dr. Cobbs's laboratory personnel for their support and technical assistance with experiments.	Abbadie C, 2017, CELL MOL LIFE SCI, V74, P4471, DOI 10.1007/s00018-017-2587-9; Alers S, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-7; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2009, CELL CYCLE, V8, P2319, DOI 10.4161/cc.8.15.9153; Culmsee C, 2003, J NEUROSCI, V23, P8586; Fernandez-Cuesta L, 2011, INT J CANCER, V128, P1813, DOI 10.1002/ijc.25512; Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; Giatromanolaki A, 2014, CANCER BIOL THER, V15, P1468, DOI 10.4161/15384047.2014.955719; GRAHAM FL, 1987, J GEN VIROL, V68, P937, DOI 10.1099/0022-1317-68-3-937; Hothi P, 2012, ONCOTARGET, V3, P1124; Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051; Ito H, 2005, INT J ONCOL, V26, P1401; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Jiang H, 2009, CURR GENE THER, V9, P422, DOI 10.2174/156652309789753356; Joshi A, 2016, CELL DEATH DIFFER, V23, P216, DOI 10.1038/cdd.2015.88; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023367; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kumar M, 2014, AM J RESP CELL MOL, V51, P323, DOI 10.1165/rcmb.2013-0382PS; Lasry A, 2015, TRENDS IMMUNOL, V36, P217, DOI 10.1016/j.it.2015.02.009; Lefranc F, 2009, ADV TECH STAND NEURO, V34, P3, DOI 10.1007/978-3-211-78741-0_1; Lefranc Florence, 2006, Neurosurg Focus, V20, pE7, DOI 10.3171/foc.2006.20.4.4; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059750; Maciel-Baron LA, 2016, AGE, V38, DOI 10.1007/s11357-016-9886-1; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Pei L, 2014, J NEUROSCI, V34, P6546, DOI 10.1523/JNEUROSCI.5119-13.2014; Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227; Piya S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029467; Ro SH, 2013, AUTOPHAGY, V9, P2103, DOI 10.4161/auto.26563; Salminen A, 2013, AGEING RES REV, V12, P520, DOI 10.1016/j.arr.2012.11.004; Sasaki T, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004409; Schilbach K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014760; Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Tepper CG, 2000, EXP CELL RES, V260, P9, DOI 10.1006/excr.2000.4990; Thomas MA, 2009, J VIROL, V83, P2406, DOI 10.1128/JVI.01972-08; Tripathi R, 2014, J CELL MOL MED, V18, P2275, DOI 10.1111/jcmm.12386; Tyler MA, 2009, AUTOPHAGY, V5, P856, DOI 10.4161/auto.8792; Ulasov IV, 2009, BRIT J CANCER, V100, P1154, DOI 10.1038/sj.bjc.6604969; Ulasov IV, 2015, ONCOTARGET, V6, P3977, DOI 10.18632/oncotarget.2897; Vater CA, 1996, ONCOGENE, V13, P739; Villalonga-Planells R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018588; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Zhang M, 2016, EUR REV MED PHARMACO, V20, P3152	49	13	14	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6069	6082		10.1038/s41388-018-0395-9	http://dx.doi.org/10.1038/s41388-018-0395-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991800				2022-12-28	WOS:000450175900005
J	Tan, ZY; Song, LB; Wu, WJ; Zhou, YQ; Zhu, JR; Wu, GY; Cao, LX; Song, JW; Li, J; Zhang, W				Tan, Zhanyao; Song, Libing; Wu, Wenjiao; Zhou, Yanqing; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun; Zhang, Wei			TRIM14 promotes chemoresistance in gliomas by activating Wnt/beta-catenin signaling via stabilizing Dvl2 (vol 37, pg 5403, 2018)	ONCOGENE			English	Correction									[Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China; [Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangdong Prov Key Lab Brain Funct & Dis, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Guangzhou Med Univ, Sch Basic Med Sci, Affiliated Canc Hosp & Inst, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Wu, Wenjiao] Jinan Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Zhou, Yanqing; Zhang, Wei] Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Jinan University; Guangdong Pharmaceutical University	Li, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangdong Prov Key Lab Brain Funct & Dis, Guangzhou, Guangdong, Peoples R China.; Zhang, W (corresponding author), Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; 18666003902@163.com	Cao, Lixue/AAM-9316-2020; wu, ge/ABE-3285-2020	Cao, Lixue/0000-0002-0486-6587; 				Tan ZY, 2018, ONCOGENE, V37, P5403, DOI 10.1038/s41388-018-0344-7	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5476	5476	476	10.1038/s41388-018-0467-x	http://dx.doi.org/10.1038/s41388-018-0467-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	30158671	Bronze			2022-12-28	WOS:000446312900008
J	Sirinian, C; Papanastasiou, AD; Schizas, M; Spella, M; Stathopoulos, GT; Repanti, M; Zarkadis, IK; King, TA; Kalofonos, HP				Sirinian, Chaido; Papanastasiou, Anastasios D.; Schizas, Michail; Spella, Magda; Stathopoulos, Georgios T.; Repanti, Maria; Zarkadis, Ioannis K.; King, Tari A.; Kalofonos, Haralabos P.			RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-kappa B activation and EGFR signaling	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR ACTIVATOR; MAMMARY-CANCER; METASTASIS; TUMORS; EXPRESSION; FAMILY; CELLS; DIFFERENTIATION; PROLIFERATION	The RANK/RANKL axis emerges as a key regulator of breast cancer initiation, progression, and metastasis. RANK-c is a RANK receptor isoform produced through alternative splicing of the TNFRSF11A (RANK) gene and a dominant-negative regulator of RANK-induced nuclear factor-kappa B (NF-kappa B) activation. Here we report that RANK-c transcript is expressed in 3.2% of cases in The Cancer Genome Atlas breast cancer cohort evenly between ER-positive and ER-negative cases. Nevertheless, the ratio of RANK to RANK-c (RANK/RANK-c) is increased in ER-negative breast cancer cell lines compared to ER-positive breast cancer cell lines. In addition, forced expression of RANK-c in ER-negative breast cancer cell lines inhibited stimuli-induced NF-kappa B activation and attenuated migration, invasion, colony formation, and adhesion of cancer cells. Further, RANK-c expression in MDA-MB-231 cells inhibited lung metastasis and colonization in vivo. The RANK-c-mediated inhibition of cancer cell aggressiveness and nuclear factor-kappa B (NF-kappa B) activation in breast cancer cells seems to rely on a RANK-c/TNF receptor-associated factor-2 (TRAF2) protein interaction. This was further confirmed by a mutated RANK-c that is unable to interact with TRAF2 and abolishes the ability to attenuate NF-kappa B activation, migration, and invasion. Additional protein interaction characterization revealed epidermal growth factor receptor (EGFR) as a novel interacting partner for RANK-c in breast cancer cells with a negative effect on EGFR phosphorylation and EGF-dependent downstream signaling pathway activation. Our findings further elucidate the complex molecular biology of the RANKL/RANK system in breast cancer and provide preliminary data for RANK-c as a possible marker for disease progression and aggressiveness.	[Sirinian, Chaido; Papanastasiou, Anastasios D.; Kalofonos, Haralabos P.] Univ Patras, Div Oncol, Dept Med, Clin & Mol Oncol Lab, Patras, Greece; [Schizas, Michail; King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Spella, Magda; Stathopoulos, Georgios T.] Univ Patras, Dept Physiol, Lab Mol Resp Carcinogenesis, Fac Med, Patras, Greece; [Repanti, Maria] Patras Gen Hosp, Dept Pathol, Patras, Greece; [Zarkadis, Ioannis K.] Univ Patras, Sch Med, Dept Biol, Patras, Greece; [King, Tari A.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Surg Oncol, Boston, MA USA	University of Patras; Memorial Sloan Kettering Cancer Center; University of Patras; University of Patras; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Papanastasiou, AD (corresponding author), Univ Patras, Div Oncol, Dept Med, Clin & Mol Oncol Lab, Patras, Greece.	apapanasta@upnet.gr	Stathopoulos, Georgios/AAE-6884-2020; Papanastasiou, Anastasios/AAP-5296-2021; Stathopoulos, Georgios/D-6576-2013	Stathopoulos, Georgios/0000-0002-9215-6461	State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme" [SR 229101]; State Scholarships Foundation [SR 229101]	State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme"; State Scholarships Foundation	CS is funded by the State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme" (SR 229101). The research reported was partially funded by the State Scholarships Foundation (SR 229101). The publicly available dataset from the TCGA breast cancer study was retrieved from the TCGA data portal on 05/2017.	Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Forootan SS, 2016, INT J ONCOL, V48, P130, DOI 10.3892/ijo.2015.3222; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannou AD, 2015, J CLIN INVEST, V125, P2317, DOI 10.1172/JCI79840; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x; Marazioti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071207; Matsuda N, 2017, EXPERT OPIN INV DRUG, V26, P463, DOI 10.1080/13543784.2017.1299707; Melchor L, 2008, ONCOGENE, V27, P3165, DOI 10.1038/sj.onc.1210975; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Papanastasiou Anastasios D, 2014, Curr Mol Pharmacol, V7, P33; Papanastasiou AD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3234; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549-014-2955-1; Rennstam K, 2003, CANCER RES, V63, P8861; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sirinian C, 2013, GENE, V525, P124, DOI 10.1016/j.gene.2013.04.075; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoldi G, 2016, CANCER RES, V76, P5857, DOI 10.1158/0008-5472.CAN-15-2745	48	21	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5101	5114		10.1038/s41388-018-0324-y	http://dx.doi.org/10.1038/s41388-018-0324-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29844572				2022-12-28	WOS:000444405300006
J	Vorhagen, S; Kleefisch, D; Persa, OD; Graband, A; Schwickert, A; Saynisch, M; Leitges, M; Niessen, CM; Iden, S				Vorhagen, Susanne; Kleefisch, Dominik; Persa, Oana-Diana; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Leitges, Michael; Niessen, Carien M.; Iden, Sandra			Shared and independent functions of aPKC lambda and Par3 in skin tumorigenesis	ONCOGENE			English	Article							POLARITY PROTEIN PAR3; NF-KAPPA-B; CELL POLARITY; EPIDERMAL HOMEOSTASIS; BREAST-CANCER; CARCINOGENESIS; STAT3; DIFFERENTIATION; COMPLEX; TUMORS	The polarity proteins Par3 and aPKC are key regulators of processes altered in cancer. Par3/aPKC are thought to dynamically interact with Par6 but increasing evidence suggests that aPKC and Par3 also exert complex-independent functions. Whereas aPKC. serves as tumor promotor, Par3 can either promote or suppress tumorigenesis. Here we asked whether and how Par3 and aPKC lambda genetically interact to control two-stage skin carcinogenesis. Epidermal loss of Par3, aPKC lambda, or both, strongly reduced tumor multiplicity and increased latency but inhibited invasion to similar extents, indicating that Par3 and aPKC lambda function as a complex to promote tumorigenesis. Molecularly, Par3/aPKC lambda cooperate to promote Akt, ERK and NF-kappa B signaling during tumor initiation to sustain growth, whereas aPKC lambda dominates in promoting survival. In the inflammatory tumorigenesis phase Par3/aPKC lambda cooperate to drive Stat3 activation and hyperproliferation. Unexpectedly, the reduced inflammatory signaling did not alter carcinogen-induced immune cell numbers but reduced IL-4 Receptor-positive stromal macrophage numbers in all mutant mice, suggesting that epidermal aPKC lambda and Par3 promote a tumor-permissive environment. Importantly, aPKC lambda also serves a distinct, carcinogen-independent role in controlling skin immune cell homeostasis. Collectively, our data demonstrates that Par3 and aPKC lambda cooperate to promote skin tumor initiation and progression, likely through sustaining growth, survival, and inflammatory signaling.	[Vorhagen, Susanne; Persa, Oana-Diana; Schwickert, Alexandra; Niessen, Carien M.] Univ Cologne, Dept Dermatol, Cologne, Germany; [Vorhagen, Susanne; Kleefisch, Dominik; Persa, Oana-Diana; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Niessen, Carien M.; Iden, Sandra] Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Vorhagen, Susanne; Kleefisch, Dominik; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Niessen, Carien M.; Iden, Sandra] Univ Cologne, CMMC, Cologne, Germany; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway	University of Cologne; University of Cologne; University of Cologne; University of Oslo	Niessen, CM (corresponding author), Univ Cologne, Dept Dermatol, Cologne, Germany.; Niessen, CM; Iden, S (corresponding author), Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.; Niessen, CM; Iden, S (corresponding author), Univ Cologne, CMMC, Cologne, Germany.	carien.niessen@uni-koeln.de; sandra.iden@uk-koeln.de	Leitges, Michael/AAN-1953-2021; Iden, Sandra/ABB-2698-2021	Iden, Sandra/0000-0003-2333-9827; Leitges, Michael/0000-0003-4203-6995; Niessen, Carien M./0000-0002-4892-9391	joint German Research Foundation (DFG) grant [NIE-1234/4-1, ID79/1-1]; Koln Fortune grant [197/2013]; DFG [ID79/2-1, CRC829/A10, CRC829/A01 + A05, NIE-1234/6-1]; German Cancer Society;  [DFG-SFB832]	joint German Research Foundation (DFG) grant(German Research Foundation (DFG)); Koln Fortune grant; DFG(German Research Foundation (DFG)); German Cancer Society; 	We thank Martim Dias Gomes for mouse line maintenance, Julia Stinn, Emmi Wachsmuth, Soriba Letzian, and Annika Schmitz for technical assistance, and the UoC animal facilities and CECAD histology unit for important services. We acknowledge Walter Birchmeier and Shigeo Ohno for sharing mouse lines, and thank the Niessen, Iden, Wickstrom, and Bazzi laboratories for helpful discussions. This project was funded by a joint German Research Foundation (DFG) grant (NIE-1234/4-1 and ID79/1-1 to C.N. and S. I.), a DFG-SFB832 grant to CMN (A3) and a Koln Fortune grant to S. I. (#197/2013). Work in the Iden laboratory is also supported by the DFG (ID79/2-1, CRC829/A10). Work in the Niessen laboratory is supported by the DFG (CRC829/A01 + A05, NIE-1234/6-1) and the German Cancer Society.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Ali NJA, 2016, J INVEST DERMATOL, V136, P2406, DOI 10.1016/j.jid.2016.07.011; Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Campanale JP, 2017, J CELL SCI, V130, P1201, DOI 10.1242/jcs.188599; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Forteza R, 2016, MOL BIOL CELL, V27, P2186, DOI 10.1091/mbc.E16-02-0086; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Godde NJ, 2014, EXP CELL RES, V328, P249, DOI 10.1016/j.yexcr.2014.08.036; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guyer RA, 2015, J BIOL CHEM, V290, P8457, DOI 10.1074/jbc.M114.621011; Hirose T, 2006, DEVELOPMENT, V133, P1389, DOI 10.1242/dev.02294; Hirose T, 2002, J CELL SCI, V115, P2485; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Iden S, 2006, EMBO REP, V7, P1239, DOI 10.1038/sj.embor.7400819; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Ishiuchi T, 2011, NAT CELL BIOL, V13, P860, DOI 10.1038/ncb2274; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Kim C, 2014, EMBO MOL MED, V6, P970, DOI 10.15252/emmm.201303541; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Lechler T, 2007, J CELL BIOL, V176, P147, DOI 10.1083/jcb.200609109; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; Nakamura H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2929-2; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Niessen MT, 2013, J CELL BIOL, V202, P887, DOI 10.1083/jcb.201307001; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Segrelles C, 2007, CANCER RES, V67, P10879, DOI 10.1158/0008-5472.CAN-07-2564; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Tervonen TA, 2011, ADV CANCER RES, V111, P97, DOI 10.1016/B978-0-12-385524-4.00003-9; Tran CS, 2014, CELL HOST MICROBE, V15, P636, DOI 10.1016/j.chom.2014.04.007; Williams SE, 2011, NATURE, V470, P353, DOI 10.1038/nature09793; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012	40	12	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5136	5146		10.1038/s41388-018-0313-1	http://dx.doi.org/10.1038/s41388-018-0313-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789715	hybrid, Green Published			2022-12-28	WOS:000444405300009
J	Xiao, P; Guo, Y; Zhang, H; Zhang, X; Cheng, H; Cao, Q; Ke, Y				Xiao, P.; Guo, Y.; Zhang, H.; Zhang, X.; Cheng, H.; Cao, Q.; Ke, Y.			Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment	ONCOGENE			English	Article							ELECTROPORATION GENE-THERAPY; DENDRITIC CELLS; BREAST-CANCER; ALTERNATIVE ACTIVATION; CXCR3 LIGANDS; LUNG-CANCER; T-CELLS; CHEMOKINE; MACROPHAGES; CARCINOMA	The Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp2) is generally considered to be an oncogene owing to its ability in enhancing the malignancy of multiple types of tumor cells; however, its role in modulating tumor immunity remains largely elusive. Here, we reported that myeloid-restricted ablation of Shp2 suppressed melanoma growth. Mechanistically, loss of Shp2 potentiates macrophage production of CXCL9 in response to IFN-gamma and tumor cell-derived cytokines, thereby facilitating the tumor infiltration of IFN-gamma-producing T cells that could in turn support CXCL9 production within tumor microenvironment. Collectively, our findings highlight a causative role of myeloid Shp2 in dampening T cell-mediated antitumor immunity by restraining the macrophage/CXCL9-T cell/IFN-gamma feedback loop. Thus, targeting macrophage Shp2 may help to create a Th1-dominant tumor immune microenvironment.	[Xiao, P.; Cao, Q.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China; [Xiao, P.; Cao, Q.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310058, Zhejiang, Peoples R China; [Guo, Y.; Zhang, H.; Zhang, X.; Cheng, H.; Ke, Y.] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Cao, Q (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China.; Cao, Q (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310058, Zhejiang, Peoples R China.; Ke, Y (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China.	0000232@zju.edu.cn; yke@zju.edu.cn		Xiao, Peng/0000-0003-0075-581X	National Natural Science Foundation of China [81702807]; Key Project of the National Natural Science Foundation of China [81530001]; Key Research and Development Project of Ministry of Science and Technology of China [2016FYA0501800]; Natural Science Foundation of Zhejiang Province [LY16H030009]; Foundation of Health and Family Planning Commission of Zhejiang Province [2016134143]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Project of Ministry of Science and Technology of China; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Foundation of Health and Family Planning Commission of Zhejiang Province	We thank G. Feng (University of California, San Diego, CA) for providing the Shp2 flox/flox mice. This study was supported by National Natural Science Foundation of China (81702807 to P. Xiao), Key Project of the National Natural Science Foundation of China (81530001 to Y. Ke), Key Research and Development Project of Ministry of Science and Technology of China (2016FYA0501800 to Y. Ke), Natural Science Foundation of Zhejiang Province (LY16H030009 to Q. Cao), and Foundation of Health and Family Planning Commission of Zhejiang Province (2016134143 to Q. Cao).	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Addison CL, 2000, HUM GENE THER, V11, P247, DOI 10.1089/10430340050015996; Andersson A, 2011, CLIN CANCER RES, V17, P3660, DOI 10.1158/1078-0432.CCR-10-3346; Antonelli A, 2010, CYTOKINE, V50, P260, DOI 10.1016/j.cyto.2010.01.009; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Bedognetti D, 2013, BRIT J CANCER, V109, P2412, DOI 10.1038/bjc.2013.557; Bronger H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3115; Caso G, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-7; Cero FT, 2012, EXP LUNG RES, V38, P406, DOI 10.3109/01902148.2012.716903; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Coma G, 2006, CLIN EXP IMMUNOL, V145, P535, DOI 10.1111/j.1365-2249.2006.03145.x; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Ding Q, 2016, CANCER MED-US, V5, P3246, DOI 10.1002/cam4.934; Fang L, 2008, J LEUKOCYTE BIOL, V84, P965, DOI 10.1189/jlb.1107776; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gustafsson K, 2011, SCAND J IMMUNOL, V74, P318, DOI 10.1111/j.1365-3083.2011.02580.x; Hannesdottir L, 2013, EUR J IMMUNOL, V43, P2718, DOI 10.1002/eji.201242505; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Kunz M, 1999, J PATHOL, V189, P552, DOI 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I; Langlais D, 2016, J EXP MED, V213, P585, DOI 10.1084/jem.20151764; Lazzara MJ, 2010, CANCER RES, V70, P3843, DOI 10.1158/0008-5472.CAN-09-3421; Li S, 2002, GENE THER, V9, P390, DOI 10.1038/sj.gt.3301645; Li SM, 2014, J BIOL CHEM, V289, P34152, DOI 10.1074/jbc.M113.546077; Li SL, 2004, MOL THER, V9, P347, DOI 10.1016/j.ymthe.2003.11.022; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Mikucki ME, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8458; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pardee AD, 2010, CANCER RES, V70, P9041, DOI 10.1158/0008-5472.CAN-10-1369; Park JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07316-3; Petro M, 2013, J IMMUNOL, V190, P832, DOI 10.4049/jimmunol.1201906; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ran H, 2016, CANCER CELL, V30, P194, DOI 10.1016/j.ccell.2016.07.010; Reckamp KL, 2007, J IMMUNOTHER, V30, P417, DOI 10.1097/CJI.0b013e31802e089a; Reid-Yu SA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004648; Roccograndi L, 2017, J NEURO-ONCOL, V135, P487, DOI 10.1007/s11060-017-2610-x; Sausgruber N, 2015, ONCOGENE, V34, P2272, DOI 10.1038/onc.2014.170; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; Specht K, 2009, BREAST CANCER RES TR, V118, P45, DOI 10.1007/s10549-008-0207-y; Szabo A, 2012, MELANOMA RES, V22, P351, DOI 10.1097/CMR.0b013e328357076c; Tao B, 2014, J IMMUNOL, V193, P2801, DOI 10.4049/jimmunol.1303463; Thapa M, 2008, J VIROL, V82, P10295, DOI 10.1128/JVI.00931-08; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Wu ZQ, 2016, BIOMED PHARMACOTHER, V78, P8, DOI 10.1016/j.biopha.2015.12.021; Xie M, 2015, J ALLERGY CLIN IMMUN, V135, P386, DOI 10.1016/j.jaci.2014.08.023; Xu JQ, 2017, J IMMUNOL, V199, P2323, DOI 10.4049/jimmunol.1601696; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yun JJ, 2002, AM J PATHOL, V161, P1307, DOI 10.1016/S0002-9440(10)64407-0; Zhang J, 2015, J CELL MOL MED, V19, P2075, DOI 10.1111/jcmm.12618; Zhang R, 2006, GENE THER, V13, P1263, DOI 10.1038/sj.gt.3302756; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54	57	23	25	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5088	5100		10.1038/s41388-018-0337-6	http://dx.doi.org/10.1038/s41388-018-0337-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29795405				2022-12-28	WOS:000444405300005
J	Tan, S; Li, H; Zhang, WJ; Shao, YY; Liu, Y; Guan, HY; Wu, J; Kang, YN; Zhao, JS; Yu, Q; Gu, YZ; Ding, KS; Zhang, M; Qian, WC; Zhu, Y; Cai, HY; Chen, CY; Lobie, PE; Zhao, XD; Sun, JL; Zhu, T				Tan, Sheng; Li, Hua; Zhang, Weijie; Shao, Yunying; Liu, Yuan; Guan, Haiyang; Wu, Jun; Kang, Yani; Zhao, Junsong; Yu, Qing; Gu, Yunzhao; Ding, Keshuo; Zhang, Min; Qian, Wenchang; Zhu, Yong; Cai, Huayong; Chen, Changyu; Lobie, Peter E.; Zhao, Xiaodong; Sun, Jielin; Zhu, Tao			NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression	ONCOGENE			English	Article							CLEAVAGE FACTOR-I; CANCER; REVEALS; CELLS; RECOGNITION; MECHANISM; TUMORS; SITES	Alternative polyadenylation (APA) is an important post-transcriptional regulatory mechanism and involved in many diseases, including cancer. CFIm25, a subunit of the cleavage factor I encoded by NUDT21, is required for 3'RNA cleavage and polyadenylation. Although it has been recently reported to be involved in glioblastoma tumor suppression, its roles and the underlying functional mechanism remain unclear in other types of cancer. In this study, we characterized NUDT21 in hepatocellular carcinoma (HCC). Reduced expression of NUDT21 was observed in HCC tissue compared to adjacent non-tumorous compartment. HCC patients with lower NUDT21 expression have shorter overall and disease-free survival times than those with higher NUDT21 expression after surgery. Knockdown of NUDT21 promotes HCC cell proliferation, metastasis, and tumorigenesis, whereas forced expression of NUDT21 exhibits the opposite effects. We then performed global APA site profiling analysis in HCC cells and identified considerable number of genes with shortened 3'UTRs upon the modulation of NUDT21 expression. In particular, we further characterized the NUDT21-regulated genes PSMB2 and CXXC5. We found NUDT21 knockdown increases usage of the proximal polyadenylation site in the PSMB2 and CXXC5 3'UTRs, resulting in marked increase in the expression of PSMB2 and CXXC5. Moreover, knockdown of PSMB2 or CXXC5 suppresses HCC cell proliferation and invasion. Taken together, our study demonstrated that NUDT21 inhibits HCC proliferation, metastasis and tumorigenesis, at least in part, by suppressing PSMB2 and CXXC5, and thereby provided a new insight into understanding the connection of HCC suppression and APA machinery.	[Tan, Sheng; Zhang, Weijie; Shao, Yunying; Liu, Yuan; Guan, Haiyang; Zhao, Junsong; Yu, Qing; Zhang, Min; Qian, Wenchang; Zhu, Yong; Cai, Huayong; Zhu, Tao] Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Li, Hua; Wu, Jun; Kang, Yani; Gu, Yunzhao] Shanghai Jiao Tong Univ, BioID Ctr, Sch Biomed Engn, Shanghai 200240, Peoples R China; [Ding, Keshuo] Anhui Med Univ, Dept Pathol, Meishan Rd, Hefei 230031, Anhui, Peoples R China; [Chen, Changyu] Anhui Med Univ, Affiliated Hosp 1, Meishan Rd, Hefei 230031, Anhui, Peoples R China; [Lobie, Peter E.] Tsinghua Univ, Precis Med & Healthcare Res Ctr, Tsinghua Berkeley Shenzhen Inst, Shenzhen 518055, Peoples R China; [Zhao, Xiaodong; Sun, Jielin] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, 800 Dongchuan Rd, Shanghai 200240, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Shanghai Jiao Tong University; Anhui Medical University; Anhui Medical University; Tsinghua University; Shanghai Jiao Tong University	Zhu, T (corresponding author), Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.; Zhao, XD; Sun, JL (corresponding author), Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.	xiaodongzhao@sjtu.edu.cn; jlsun@sjtu.edu.cn; zhut@ustc.edu.cn	Kang, Yani/AAQ-1503-2020; tan, sheng/GSN-2599-2022; Wu, Jun/GRS-5039-2022	Kang, Yani/0000-0002-6753-386X; Wu, Jun/0000-0002-3381-2561; LI, HUA/0000-0003-2153-2500; Zhang, Weijie/0000-0002-6462-6067	National Key Scientific Programme of China [2016YFC1302305]; National Natural Science Foundation of China [81672609, 31671299, 81502282, 81472494]; Shenzhen Development and Reform Commission Subject Construction Project [[2017] 1434]	National Key Scientific Programme of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Development and Reform Commission Subject Construction Project	This work was supported by The National Key Scientific Programme of China (2016YFC1302305), The National Natural Science Foundation of China (81672609, 31671299, 81502282, 81472494,) and the Shenzhen Development and Reform Commission Subject Construction Project [2017] 1434. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.	Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Collavoli A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/757960; Coseno M, 2008, NUCLEIC ACIDS RES, V36, P3474, DOI 10.1093/nar/gkn079; Di Giammartino DC, 2011, MOL CELL, V43, P853, DOI 10.1016/j.molcel.2011.08.017; Elkon R, 2013, NAT REV GENET, V14, P496, DOI 10.1038/nrg3482; Erson-Bensan AE, 2016, MOL CANCER RES, V14, P507, DOI 10.1158/1541-7786.MCR-15-0489; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Gennarino VA, 2015, ELIFE, V4, DOI 10.7554/eLife.10782; Knappskog S, 2011, ANN ONCOL, V22, P2208, DOI 10.1093/annonc/mdq737; Lai DP, 2015, HUM MOL GENET, V24, P3410, DOI 10.1093/hmg/ddv089; Lembo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031129; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Llovet JM, 2014, NAT REV CLIN ONCOL, V11, P506, DOI 10.1038/nrclinonc.2014.136; Martin G, 2012, CELL REP, V1, P753, DOI 10.1016/j.celrep.2012.05.003; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Miles WO, 2016, CANCER RES, V76, P7231, DOI 10.1158/0008-5472.CAN-16-0844; Morris AR, 2012, CLIN CANCER RES, V18, P5256, DOI 10.1158/1078-0432.CCR-12-0543; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Venkataraman K, 2005, GENE DEV, V19, P1315, DOI 10.1101/gad.1298605; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107	27	57	59	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4887	4900		10.1038/s41388-018-0280-6	http://dx.doi.org/10.1038/s41388-018-0280-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780166				2022-12-28	WOS:000443146000009
J	Garg, R; Blando, JM; Perez, CJ; Lal, P; Feldman, MD; Smyth, EM; Ricciotti, E; Grosser, T; Benavides, F; Kazanietz, MG				Garg, Rachana; Blando, Jorge M.; Perez, Carlos J.; Lal, Priti; Feldman, Michael D.; Smyth, Emer M.; Ricciotti, Emanuela; Grosser, Tilo; Benavides, Fernando; Kazanietz, Marcelo G.			COX-2 mediates pro-tumorigenic effects of PKC epsilon in prostate cancer	ONCOGENE			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; PROSTAGLANDIN RECEPTOR EP2; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; IN-VIVO; COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITORS; TRANSCRIPTION FACTORS; CELL-PROLIFERATION	The pro-oncogenic kinase PKC epsilon is overexpressed in human prostate cancer and cooperates with loss of the tumor suppressor Pten for the development of prostatic adenocarcinoma. However, the effectors driving PKC epsilon-mediated phenotypes remain poorly defined. Here, using cellular and mouse models, we showed that PKC epsilon overexpression acts synergistically with Pten loss to promote NF-kappa B activation and induce cyclooxygenase-2 (COX-2) expression, phenotypic traits which are also observed in human prostate tumors. Targeted disruption of PKC epsilon from prostate cancer cells impaired COX-2 induction and PGE(2) production. Notably, COX-2 inhibitors selectively killed prostate epithelial cells overexpressing PKC epsilon, and this ability was greatly enhanced by Pten loss. Long-term COX-2 inhibition markedly reduced adenocarcinoma formation, as well as angiogenesis in a mouse model of prostate-specific PKC epsilon expression and Pten loss. Overall, our results provide strong evidence for the involvement of the canonical NF-kappa B pathway and its target gene COX2 as PKC epsilon effectors, and highlight the potential of PKC epsilon as a useful biomarker for the use of COX inhibition for chemopreventive and/or chemotherapeutic purposes in prostate cancer.	[Garg, Rachana; Smyth, Emer M.; Ricciotti, Emanuela; Grosser, Tilo; Kazanietz, Marcelo G.] Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blando, Jorge M.] Univ Texas MD Anderson Canc Ctr, Immunopathol Lab, Dept Immunol, Houston, TX 77030 USA; [Perez, Carlos J.; Benavides, Fernando] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX 78957 USA; [Perez, Carlos J.; Benavides, Fernando] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Lal, Priti; Feldman, Michael D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania; Pennsylvania Medicine	Kazanietz, MG (corresponding author), Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Ricciotti, Emanuela/AAH-2729-2019; Grosser, Tilo/A-1057-2007; Garg, Rachana/AAQ-9518-2020	Grosser, Tilo/0000-0001-8569-8396; Garg, Rachana/0000-0002-7808-1053	DHHS/NCI Cancer Center Support grant [P30 CA016672];  [R01-CA089202];  [R01-CA189765];  [R01-CA196232 (NIH)];  [PC130641 (DOD)];  [W81XWH-12-1-0009 (DOD)]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA189765, R01CA196232, R01CA089202] Funding Source: NIH RePORTER	DHHS/NCI Cancer Center Support grant; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01-CA089202, R01-CA189765, R01-CA196232 (NIH), and PC130641 (DOD) to M.G.K., and W81XWH-12-1-0009 (DOD) to R.G. This study made use of the Research Animal Support Facility at MD Anderson Cancer Center, Smithville, including Laboratory Animal Genetic Services and Mutant Mouse Pathology Services, which are supported by DHHS/NCI Cancer Center Support grant P30 CA016672.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Armstrong AJ, 2012, LANCET ONCOL, V13, P443, DOI 10.1016/S1470-2045(12)70111-0; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Cai Y, 2008, INT J CANCER, V123, P195, DOI 10.1002/ijc.23481; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Claudino RF, 2006, J PHARMACOL EXP THER, V318, P611, DOI 10.1124/jpet.106.102806; Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878; Denkert C, 2007, PROSTATE, V67, P361, DOI 10.1002/pros.20467; Diaz-Meco MT, 2012, IMMUNOL REV, V246, P154, DOI 10.1111/j.1600-065X.2012.01093.x; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; Finetti F, 2015, ENDOCR-RELAT CANCER, V22, P665, DOI 10.1530/ERC-15-0277; Fries S, 2006, GASTROENTEROLOGY, V130, P55, DOI 10.1053/j.gastro.2005.10.002; Garcia M, 2014, BJU INT, V113, pE164, DOI 10.1111/bju.12503; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garg R, 2017, CELL REP, V19, P375, DOI 10.1016/j.celrep.2017.03.042; Garg R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067319; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gowda R, 2012, CANCER BIOL THER, V13, P756, DOI 10.4161/cbt.20558; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gupta S, 2004, CANCER RES, V64, P3334, DOI 10.1158/0008-5472.CAN-03-2422; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Gutierrez-Uzquiza A, 2015, MOL CANCER RES, V13, P1336, DOI 10.1158/1541-7786.MCR-15-0111; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Harris Randall E, 2012, J Exp Pharmacol, V4, P91, DOI 10.2147/JEP.S23826; Henry WS, 2017, CANCER RES, V77, P790, DOI 10.1158/0008-5472.CAN-16-2400; Holden NS, 2008, CELL SIGNAL, V20, P1338, DOI 10.1016/j.cellsig.2008.03.001; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Hu ZX, 2017, ONCOTARGETS THER, V10, P2893, DOI 10.2147/OTT.S134599; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Jain K, 2014, CANCERS, V6, P860, DOI 10.3390/cancers6020860; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jamal MS, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-4204; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Jiang JX, 2013, TRENDS PHARMACOL SCI, V34, P413, DOI 10.1016/j.tips.2013.05.003; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kashiwagi E, 2014, PROSTATE CANCER P D, V17, P10, DOI 10.1038/pcan.2013.53; Kashiwagi E, 2013, ENDOCR-RELAT CANCER, V20, P431, DOI 10.1530/ERC-12-0344; Khor LY, 2007, LANCET ONCOL, V8, P912, DOI 10.1016/S1470-2045(07)70280-2; Kim BH, 2011, KOREAN J UROL, V52, P253, DOI 10.4111/kju.2011.52.4.253; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lu ZG, 2009, CANCER RES, V69, P5927, DOI 10.1158/0008-5472.CAN-08-4786; Masferrer JL, 2000, CANCER RES, V60, P1306; Mesquita RFDS, 2014, MOL CELL BIOL, V34, P574, DOI 10.1128/MCB.01098-13; Narayanan BA, 2006, PROSTATE, V66, P257, DOI 10.1002/pros.20331; Narayanan BA, 2007, CLIN CANCER RES, V13, P5965, DOI 10.1158/1078-0432.CCR-07-0744; Nirodi CS, 2004, P NATL ACAD SCI USA, V101, P1840, DOI 10.1073/pnas.0303950101; O'Callaghan G, 2015, BRIT J PHARMACOL, V172, P5239, DOI 10.1111/bph.13331; Ogino S, 2008, CLIN CANCER RES, V14, P8221, DOI 10.1158/1078-0432.CCR-08-1841; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Richardsen E, 2010, CANCER EPIDEMIOL, V34, P316, DOI 10.1016/j.canep.2010.03.019; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Terry MB, 2004, JAMA-J AM MED ASSOC, V291, P2433, DOI 10.1001/jama.291.20.2433; Tougeron D, 2014, CLIN CANCER RES, V20, P1087, DOI 10.1158/1078-0432.CCR-13-2563; Turturro SB, 2016, BREAST CANCER RES TR, V156, P33, DOI 10.1007/s10549-016-3729-8; Veitonmaki T, 2013, EUR J CANCER, V49, P938, DOI 10.1016/j.ejca.2012.09.030; Walter B, 2010, WORLD J UROL, V28, P745, DOI 10.1007/s00345-010-0567-x; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang HB, 2014, J BIOL CHEM, V289, P19823, DOI 10.1074/jbc.M114.548446; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wu DQ, 2002, CANCER RES, V62, P2423; Xuan YT, 2005, CIRCULATION, V112, P1971, DOI 10.1161/CIRCULATIONAHA.105.561522; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; Zheng X, 2010, CANCER PREV RES, V3, P114, DOI 10.1158/1940-6207.CAPR-09-0059	73	34	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4735	4749		10.1038/s41388-018-0318-9	http://dx.doi.org/10.1038/s41388-018-0318-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765153	Green Accepted			2022-12-28	WOS:000442514400008
J	Grun, D; Adhikary, G; Eckert, RL				Grun, Daniel; Adhikary, Gautam; Eckert, Richard L.			NRP-1 interacts with GIPC1 and alpha 6/beta 4-integrins to increase YAP1/Delta Np63 alpha-dependent epidermal cancer stem cell survival	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SKIN-CANCER; ISOFORM EXPRESSION; HIPPO PATHWAY; TUMOR-CELLS; NEUROPILIN-1; VEGF; CARCINOMA; ANGIOGENESIS; PROMOTE	We have identified an epidermal cancer stem (ECS) cell population that drives formation of rapidly growing and highly invasive and vascularized tumors. VEGF-A and neuropilin-1 (NRP-1) are highly expressed in ECS cell tumors and VEGF-A/NRP-1 interaction is required for ECS cell survival and tumor vascularization. We now identify a novel signaling cascade that is triggered by VEGF-A/NRP-1. We show that NRP-1 forms a complex with GIPC1 and alpha 6/beta 4-integrin to activate FAK/Src signaling, which leads to stabilization of a YAP1/Delta Np63 alpha to enhance ECS cell survival, invasion, and angiogenesis. Loss of NRP-1, GIPC1, alpha 6/beta 4-integrins, YAP1, or Delta Np63 alpha reduces these responses. Moreover, restoration of constituently active YAP1 or Delta Np63 alpha in NRP-1 null cells restores the ECS cell phenotype. Tumor xenograft experiments show that NRP-1 knockout ECS cells form small tumors characterized by reduced vascularization as compared to wild-type cells. The NRP-1 knockout tumors display signaling changes consistent with a role for the proposed signaling cascade. These studies suggest that VEGF-A interacts with NRP-1 and GIPC1 to regulate alpha 6/beta 4-integrin, FAK, Src, PI3K/PDK1, LATS1 signaling to increase YAP1/Delta Np63 alpha accumulation to drive ECS cell survival, angiogenesis, and tumor formation.	[Grun, Daniel; Adhikary, Gautam; Eckert, Richard L.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Dept Dermatol, Sch Med, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Eckert, RL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Dept Dermatol, Sch Med, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	reckert@umaryland.edu			NIH [CA131074, CA184027]; Greenebaum Comprehensive Cancer Center [P30 CA134274]; NATIONAL CANCER INSTITUTE [R01CA184027, R01CA131074, P30CA134274] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greenebaum Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH (CA131074 and CA184027) to RLE and a pilot grant from the Greenebaum Comprehensive Cancer Center (P30 CA134274).	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; American Cancer Society, CANC FACTS FIG; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bowden J, 2002, J CUTAN PATHOL, V29, P585, DOI 10.1034/j.1600-0560.2002.291003.x; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Casanova ML, 2002, CANCER RES, V62, P3402; Chew YC, 2013, J BIOL CHEM, V288, P17759, DOI 10.1074/jbc.M113.477133; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Fisher ML, 2016, MOL CARCINOGEN, V55, P2024, DOI 10.1002/mc.22448; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Johnson KE, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/483439; Katoh M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.49; Kim J, 2017, J CLIN INVEST, V127, P3447, DOI 10.1172/JCI93825; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Kostera MI, 2004, J DERMATOL SCI, V34, P3, DOI 10.1016/j.jdermsci.2003.10.003; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Linde N, 2012, J PATHOL, V227, P17, DOI 10.1002/path.3989; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Man XY, 2006, MOL MED, V12, P127, DOI 10.2119/2006-00024.Man; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Shahrabi-Farahani S, 2016, AM J PATHOL, V186, P1055, DOI 10.1016/j.ajpath.2015.11.021; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tani TT, 2001, J BIOL CHEM, V276, P36535, DOI 10.1074/jbc.M105785200; Thurfjell N, 2004, INT J ONCOL, V25, P27; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Wang XH, 2017, DEV CELL, V42, P462, DOI 10.1016/j.devcel.2017.08.002; Yang XH, 2006, BIOCHEM BIOPH RES CO, V349, P31, DOI 10.1016/j.bbrc.2006.07.213; Yoshida A, 2015, BIOL OPEN, V4, P1063, DOI 10.1242/bio.010918; Zhang GL, 2016, TUMOR BIOL, V37, P13777, DOI 10.1007/s13277-016-5138-3; Zhao Y, 2011, INT J DEV BIOL, V55, P477, DOI 10.1387/ijdb.103225yz; Zhu JW, 2012, INT J BIOCHEM CELL B, V44, P246, DOI 10.1016/j.biocel.2011.10.022	55	20	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4711	4722		10.1038/s41388-018-0290-4	http://dx.doi.org/10.1038/s41388-018-0290-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755126	Green Accepted			2022-12-28	WOS:000442514400006
J	Tang, JM; Li, YX; Sang, YZ; Yu, B; Lv, DG; Zhang, WW; Feng, HZ				Tang, Jianming; Li, Yanxin; Sang, Youzhou; Yu, Bo; Lv, Deguan; Zhang, Weiwei; Feng, Haizhong			LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling	ONCOGENE			English	Article							CELL-PROLIFERATION; POOR-PROGNOSIS; GASTRIC-CANCER; MYC; AMPLIFICATION; METASTASIS; EXPRESSION; INVASION; CATENIN; GENE	Recent molecularly targeted approach gains advance in breast cancer treatment. However, the estimated 5-year survival rate has not met the desired expectation for improvement, especially for patients with triple-negative breast cancer (TNBC). Here we report that the lncRNA PVT1 promotes KLF5/beta-catenin signaling to drive TNBC tumorigenesis. PVT1 is upregulated in clinical TNBC tumors. Using genetic approaches targeting PVT1 in TNBC cells, we found that PVT1 depletion inhibited cell proliferation, colony formation, and orthotopic xenograft tumor growth. Mechanistically, PVT1 binds with KLF5 and increases its stability via BAP1, which upregulates beta-catenin signaling, resulting in enhanced TNBC tumorigenesis. PVT1, KLF5, and beta-catenin were also revealed to be co-expressed in clinical TNBC samples. Our findings uncover a new singaling pathway to mediate TNBC, and provide PVT1 as a new target for improving treatment of TNBC.	[Tang, Jianming; Sang, Youzhou; Yu, Bo; Lv, Deguan; Zhang, Weiwei; Feng, Haizhong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Renji Med Clin Stem Cell Res Ctr 10,State Key Lab, Shanghai 200127, Peoples R China; [Li, Yanxin] Shanghai Jiao Tong Univ, Pediat Translat Med Inst, Key Lab Pediat Hematol & Oncol, Shanghai Childrens Med Ctr,Minist Hlth,Sch Med, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Feng, HZ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Renji Med Clin Stem Cell Res Ctr 10,State Key Lab, Shanghai 200127, Peoples R China.; Li, YX (corresponding author), Shanghai Jiao Tong Univ, Pediat Translat Med Inst, Key Lab Pediat Hematol & Oncol, Shanghai Childrens Med Ctr,Minist Hlth,Sch Med, Shanghai 200127, Peoples R China.	liyanxin@scmc.com.cn; Fenghaizhong@sjtu.edu.cn	Feng, Haizhong/E-5795-2017	Feng, Haizhong/0000-0003-3552-6865; Lv, Deguan/0000-0003-3142-9814; Tang, Jianming/0000-0003-3738-9761	National Natural Science Foundation of China [81372704, 81572467, 81470315, 81772663]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [2014024]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161310]; New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau [2017BR021]; State Key Laboratory of Oncogenes and Related Genes in China [91-17-25]; Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine [ZT201701]; Shanghai Jiao Tong University School of Medicine Hospital Fund [14XJ10069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau; State Key Laboratory of Oncogenes and Related Genes in China; Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine Hospital Fund	This work was supported in part by the National Natural Science Foundation of China (No. 81372704, 81572467 to H.F.; No. 81470315, 81772663 to Y.L.); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 2014024), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161310), New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau (2017BR021), the State Key Laboratory of Oncogenes and Related Genes in China (No. 91-17-25), and Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine (ZT201701) to H.F.; and Shanghai Jiao Tong University School of Medicine Hospital Fund (No. 14XJ10069) to Y.L.	Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Grampp S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13183; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Guo LL, 2015, CELL SIGNAL, V27, P961, DOI 10.1016/j.cellsig.2015.02.005; Iden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156274; Ishikawa ET, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2645; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878; Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Nakaya T, 2014, CANCER RES, V74, P2882, DOI 10.1158/0008-5472.CAN-13-2574; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Shi PG, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.10; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Takahashi Y, 2014, Br J Cancer, V110, P164, DOI 10.1038/bjc.2013.698; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; WEBB E, 1984, NATURE, V312, P777, DOI 10.1038/312777a0; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100; Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012; Zhou W, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9557	33	101	108	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4723	4734		10.1038/s41388-018-0310-4	http://dx.doi.org/10.1038/s41388-018-0310-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29760406				2022-12-28	WOS:000442514400007
J	Knickelbein, K; Tong, JS; Chen, DS; Wang, YJ; Misale, S; Bardelli, A; Yu, J; Zhang, L				Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Misale, Sandra; Bardelli, Alberto; Yu, Jian; Zhang, Lin			Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; ACQUIRED-RESISTANCE; RAS ONCOGENES; APOPTOSIS; THERAPY; INHIBITION; MUTATIONS; CETUXIMAB; MEK; PANITUMUMAB	Intrinsic and acquired resistance to anti-EGFR antibody therapy, frequently mediated by a mutant or amplified KRAS oncogene, is a significant challenge in the treatment of colorectal cancer (CRC). However, the mechanism of KRAS-mediated therapeutic resistance is not well understood. In this study, we demonstrate that clinically used anti-EGFR antibodies, including cetuximab and panitumumab, induce killing of sensitive CRC cells through p73-dependent transcriptional activation of the pro-apoptotic Bcl-2 family protein PUMA. PUMA induction and p73 activation are abrogated in CRC cells with acquired resistance to anti-EGFR antibodies due to KRAS alterations. Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS-mediated resistance to anti-EGFR antibodies in vitro and in vivo by restoring PUMA induction. Our results suggest that PUMA plays a critical role in meditating the sensitivity of CRC cells to anti-EGFR antibodies, and that restoration of PUMA-mediated apoptosis is a promising approach to improve the efficacy of EGFR-targeted therapy.	[Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Yu, Jian; Zhang, Lin] UMPC Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Yu, Jian; Zhang, Lin] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Misale, Sandra] Mem Sloan Kettering Canc, Program Mol Pharmacol, New York, NY 10065 USA; [Bardelli, Alberto] IRCCS, Candiolo Canc Inst FPO, I-10060 Candiolo, TO, Italy; [Bardelli, Alberto] IRCCS, Dept Oncol, I-10060 Candiolo, TO, Italy; [Yu, Jian] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Memorial Sloan Kettering Cancer Center; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), UMPC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009; Wang, Yixuan/GZK-6559-2022; Wang, Yin/HCI-9352-2022; wang, yi/GVT-8516-2022; wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; BARDELLI, Alberto/J-9721-2018	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Tong, Jingshan/0000-0003-1640-5769; BARDELLI, Alberto/0000-0003-1647-5070	U.S. National Institute of Health [R01CA106348, R01CA172136, R01CA203028, R01CA217141, U19AI068021, R01CA215481]; Cotswold Foundation; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine;  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA217141, P30CA047904, R01CA203028, R01CA106348, R01CA215481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cotswold Foundation; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank our lab members for critical reading. This work is supported by U.S. National Institute of Health grants (R01CA106348, R01CA172136, R01CA203028, and R01CA217141 to LZ; U19AI068021 and R01CA215481 to JY). KK was supported by a fellowship from the Cotswold Foundation and the Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine. This project used the UPMC Hillman Cancer Center shared facilities that were supported in part by award P30CA047904.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Banck MS, 2009, CLIN CANCER RES, V15, P7492, DOI 10.1158/1078-0432.CCR-09-0188; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Brown MF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.104; Chen DS, 2014, ONCOTARGET, V5, P8107, DOI 10.18632/oncotarget.2440; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Del Poeta G, 2016, DRUG TODAY, V52, P249, DOI 10.1358/dot.2016.52.4.2470954; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kasper S, 2013, ONCOGENE, V32, P2873, DOI 10.1038/onc.2012.302; Knickelbein K, 2015, GENES DIS, V2, P4, DOI 10.1016/j.gendis.2014.10.002; Lee HJ, 2015, CELL RES, V25, P225, DOI 10.1038/cr.2015.8; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Martini M, 2012, NAT REV CLIN ONCOL, V9, P87, DOI 10.1038/nrclinonc.2011.164; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sun J, 2014, MOL CANCER THER, V13, P1298, DOI 10.1158/1535-7163.MCT-13-0846; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Tsai KKC, 2003, CANCER RES, V63, P3418; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang L, 2013, CURR COLORECT CANC R, V9, P331, DOI 10.1007/s11888-013-0188-z	44	26	26	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4599	4610		10.1038/s41388-018-0289-x	http://dx.doi.org/10.1038/s41388-018-0289-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29755130	Green Accepted			2022-12-28	WOS:000441736700008
J	Rademaker, G; Hennequiere, V; Brohee, L; Nokin, MJ; Lovinfosse, P; Durieux, F; Gofflot, S; Bellier, J; Costanza, B; Herfs, M; Peiffer, R; Bettendorff, L; Deroanne, C; Thiry, M; Delvenne, P; Hustinx, R; Bellahcene, A; Castronovo, V; Peulen, O				Rademaker, Gilles; Hennequiere, Vincent; Brohee, Laura; Nokin, Marie-Julie; Lovinfosse, Pierre; Durieux, Florence; Gofflot, Stephanie; Bellier, Justine; Costanza, Brunella; Herfs, Michael; Peiffer, Raphael; Bettendorff, Lucien; Deroanne, Christophe; Thiry, Marc; Delvenne, Philippe; Hustinx, Roland; Bellahcene, Akeila; Castronovo, Vincent; Peulen, Olivier			Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness	ONCOGENE			English	Article							CANCER-CELLS; DETERMINES; AUTOPHAGY; SURVIVAL; FUSION; PHOSPHORYLATION; HETEROGENEITY; PROGRESSION; METABOLISM; PLASTICITY	Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death. Therapeutic options remain very limited and are based on classical chemotherapies. Energy metabolism reprogramming appears as an emerging hallmark of cancer and is considered a therapeutic target with considerable potential. Myoferlin, a ferlin family member protein overexpressed in PDAC, is involved in plasma membrane biology and has a tumor-promoting function. In the continuity of our previous studies, we investigated the role of myoferlin in the context of energy metabolism in PDAC. We used selected PDAC tumor samples and PDAC cell lines together with small interfering RNA technology to study the role of myoferlin in energetic metabolism. In PDAC patients, we showed that myoferlin expression is negatively correlated with overall survival and with glycolytic activity evaluated by F-18-deoxyglucose positron emission tomography. We found out that myoferlin is more abundant in lipogenic pancreatic cancer cell lines and is required to maintain a branched mitochondrial structure and a high oxidative phosphorylation activity. The observed mitochondrial fission induced by myoferlin depletion led to a decrease of cell proliferation, ATP production, and autophagy induction, thus indicating an essential role of myoferlin for PDAC cell fitness. The metabolic phenotype switch generated by myoferlin silencing could open up a new perspective in the development of therapeutic strategies, especially in the context of energy metabolism.	[Rademaker, Gilles; Hennequiere, Vincent; Nokin, Marie-Julie; Durieux, Florence; Bellier, Justine; Costanza, Brunella; Peiffer, Raphael; Bellahcene, Akeila; Castronovo, Vincent; Peulen, Olivier] Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium; [Brohee, Laura; Deroanne, Christophe] Univ Liege, Lab Connect Tissue Biol, GIGA Canc, Liege, Belgium; [Lovinfosse, Pierre; Hustinx, Roland] Univ Liege, Dept Nucl Med & Oncol Imaging, Univ Hosp Ctr, Liege, Belgium; [Gofflot, Stephanie] Univ Liege, Univ Hosp, Tissue Biobank, Liege, Belgium; [Herfs, Michael; Delvenne, Philippe] Univ Liege, Lab Expt Pathol, GIGA Canc, Liege, Belgium; [Bettendorff, Lucien] Univ Liege, Neurophysiol Lab, GIGA Neurosci, Liege, Belgium; [Thiry, Marc] Univ Liege, Lab Cellular & Tissular Biol, GIGA Neurosci, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Peulen, O (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium.	olivier.peulen@uliege.be	Rademaker, Gilles/X-1386-2019; Costanza, Brunella/AAB-6354-2022; Peulen, Olivier/C-1250-2018	Rademaker, Gilles/0000-0003-0170-781X; Peulen, Olivier/0000-0002-6933-0134; Brohee, Laura/0000-0001-8498-1579; Peiffer, Raphael/0000-0001-5839-8849; Costanza, Brunella/0000-0001-8279-805X	FNRS Televie grant	FNRS Televie grant(Fonds de la Recherche Scientifique - FNRS)	We acknowledge Dr Chantal Humblet and Mrs Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese and Dr Jean-Jacques Goval (GIGA-imaging platform, ULg), Dr Emmanuel Di Valentin (GIGA-viral vector platform, ULg), Mrs Patricia Piscicelli (Laboratory of Cellular and Tissular Biology), Mrs Naima Maloujahmoum, and Selina Nuchtern (Metastasis Research Laboratory) for their respective experimental support. We thank Mrs Caroline Ziane for proofreading and English editing. We are also thankful to the institutional Biobank of the University Hospital Liege for providing patient material. The results shown in this work are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. Akeila Bellahcene and Lucien Bettendorff are Research Directors (FNRS). Christophe Deroanne is a Research Associate (FNRS). Dr Michael Herfs, Dr Marie-Julie Nokin, Dr Brunella Costanza, Mrs Laura Brohee, Mrs Florence Durieux, and Mrs Justine Bellier are supported by an FNRS Televie grant. M. Raphael Peiffer is student-researcher supported by the ULg Medicine Faculty. The sponsor had no other roles in the study.	Alirol E, 2006, ONCOGENE, V25, P4706, DOI 10.1038/sj.onc.1209600; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Blomme A, 2016, ONCOGENE, V4, P1151; Blomme A, 2016, ONCOTARGET, V7, P83669, DOI 10.18632/oncotarget.13276; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Cao YL, 2017, NATURE, V542, P372, DOI 10.1038/nature21077; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; ELSASSER HP, 1992, VIRCHOWS ARCH B, V61, P295, DOI 10.1007/BF02890431; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Higashi T, 1997, J NUCL MED, V38, P1337; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Hyun SH, 2016, EUR J NUCL MED MOL I, V43, P1461, DOI 10.1007/s00259-016-3316-6; Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301; Jahani-Asl A, 2007, EMBO REP, V8, P912, DOI 10.1038/sj.embor.7401077; Jones P, 2017, CLIN CANC RES, V23; Kim SE, 2015, BIOCHEM BIOPH RES CO, V463, P205, DOI 10.1016/j.bbrc.2015.05.022; Kosinski M, 2015, RTCGA CANC GENOME AT; Larson Steven M., 1999, Clin Positron Imaging, V2, P159, DOI 10.1016/S1095-0397(99)00016-3; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee JW, 2014, J NUCL MED, V55, P898, DOI 10.2967/jnumed.113.131847; Mao K, 2013, CELL CYCLE, V12, P3131, DOI 10.4161/cc.26352; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Neuzillet C, 2017, PHARMACOL THERAPEUT, V174, P145, DOI 10.1016/j.pharmthera.2017.02.028; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Protopopova M, 2016, MOL CANCER RES, V14, DOI 10.1158/1557-3125.METCA15-A65; R Development Core Team, 2009, R LANG ENV STAT COMP; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; von der Malsburg K, 2011, DEV CELL, V21, P694, DOI 10.1016/j.devcel.2011.08.026; Yamano K, 2011, NAT CELL BIOL, V13, P1026, DOI 10.1038/ncb2334; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362	51	35	35	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4398	4412		10.1038/s41388-018-0287-z	http://dx.doi.org/10.1038/s41388-018-0287-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720728	Green Published, hybrid			2022-12-28	WOS:000441144300005
J	Guarnieri, AL; Towers, CG; Drasin, DJ; Oliphant, MUJ; Andrysik, Z; Hotz, TJ; Vartuli, RL; Linklater, ES; Pandey, A; Khanal, S; Espinosa, JM; Ford, HL				Guarnieri, A. L.; Towers, C. G.; Drasin, D. J.; Oliphant, M. U. J.; Andrysik, Z.; Hotz, T. J.; Vartuli, R. L.; Linklater, E. S.; Pandey, A.; Khanal, S.; Espinosa, J. M.; Ford, H. L.			The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L	ONCOGENE			English	Article							CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; GASTRIC-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC IMPLICATIONS; SIGNALING PATHWAY; MICRORNA CLUSTER; LUNG-CANCER; IN-VITRO	Tumor-initiating cells (TIC) represent a subset of tumor cells with increased self-renewal capability. TICs display resistance to frontline cancer treatment and retain the ability to repopulate a tumor after therapy, leading to cancer relapse. NOTCH signaling has been identified as an important driver of the TIC population, yet mechanisms governing regulation of this pathway in cancer remain to be fully elucidated. Here we identify a novel mechanism of NOTCH regulation and TIC induction in breast cancer via the miR-106b-25 miRNA cluster. We show that the miR-106b-25 cluster upregulates NOTCH1 in multiple breast cancer cell lines, representing both estrogen receptor (ER+) and triple negative breast cancer (TNBC) through direct repression of the E3 ubiquitin ligase, NEDD4L. We further show that upregulation of NOTCH1 is necessary for TIC induction downstream of miR-106b-25 in both ER + and TNBC breast cancer cells, and that re-expression of NEDD4L is sufficient to reverse miR106b-25-mediated NOTCH1 upregulation and TIC induction. Importantly, we demonstrate a significant positive correlation between miR-106b-25 and NOTCH1 protein, yet a significant inverse correlation between miR-106b-25 and NEDD4L mRNA in human breast cancer, suggesting a critical role for the miR106b-25/NEDD4L/ NOTCH1 axis in the disease. Further, we show for the first time that NEDD4L expression alone is significantly associated with a better relapse-free prognosis for breast cancer patients. These data expand our knowledge of the mechanisms underlying NOTCH activation and TIC induction in breast cancer, and may provide new avenues for the development of therapies targeting this resistant subset of tumor cells.	[Guarnieri, A. L.; Towers, C. G.; Drasin, D. J.; Vartuli, R. L.; Linklater, E. S.; Ford, H. L.] Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Guarnieri, A. L.; Towers, C. G.; Oliphant, M. U. J.; Andrysik, Z.; Hotz, T. J.; Vartuli, R. L.; Pandey, A.; Khanal, S.; Espinosa, J. M.; Ford, H. L.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Oliphant, M. U. J.; Ford, H. L.] Univ Colorado, Integrated Physiol Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Andrysik, Z.; Espinosa, J. M.] Univ Colorado, Linda Crnic Inst Syndrome, Anschutz Med Campus, Aurora, CO 80045 USA; [Espinosa, J. M.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder	Ford, HL (corresponding author), Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Integrated Physiol Program, Anschutz Med Campus, Aurora, CO 80045 USA.	Heide.Ford@ucdenver.edu			METAvivor Foundation; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0296]; Ruth L. Kirschstein National Service Research Award (F32) [1F32CA199716-01]; Ruth L. Kirschstein National Service Research Award (F31) [5F31CA210622-02]; NCI [F99 CA223023]; NIH-RO1 Diversity Supplement [R01-CA157790]; UNCF/MERCK Graduate Fellowship; T32 Cancer Biology training grant [CA190216-1 A1]; UC Denver AMC Molecular Biology Program T32 training grant [T32 GM008730];  [R01CA095277];  [R01CA117907]; NATIONAL CANCER INSTITUTE [F31CA210622, F99CA223023, R01CA157790, R01CA095277, R01CA117907, T32CA190216, F32CA199716, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	METAvivor Foundation; Department of Defense Breast Cancer Research Program(United States Department of Defense); Ruth L. Kirschstein National Service Research Award (F32); Ruth L. Kirschstein National Service Research Award (F31); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH-RO1 Diversity Supplement; UNCF/MERCK Graduate Fellowship; T32 Cancer Biology training grant; UC Denver AMC Molecular Biology Program T32 training grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Paul Jedlicka for the generous gift of mice for limiting dilution experiments. We also want to thank the University of Colorado Cancer center flow cytometry shared resource for performing flow cytometry experiments needed for this work (P30CA046934), the Functional Genomics Facility for shRNA constructs, and The Cancer Genome Atlas (TCGA) for use of their breast cancer patient data set. This work was supported by R01CA095277 (HLF), R01CA117907 (JME), the METAvivor Foundation (HLF), the Department of Defense Breast Cancer Research Program W81XWH-10-1-0296 (ALG), the Ruth L. Kirschstein National Service Research Award (F32) 1F32CA199716-01 (ALG), the Ruth L. Kirschstein National Service Research Award (F31) 5F31CA210622-02 (MUJO), the NCI fellow transition award F99 CA223023 (MUJO), UC Denver AMC Molecular Biology Program T32 training grant T32 GM008730 (CGT), NIH-RO1 Diversity Supplement to R01-CA157790 (CGT), the UNCF/MERCK Graduate Fellowship (CGT), and the T32 Cancer Biology training grant CA190216-1 A1 (CGT).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Pires BRB, 2016, ANTICANCER RES, V36, P5681, DOI 10.21873/anticanres.11151; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chastagner P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002735; Chen S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165776; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Espinoza I, 2013, CANCER LETT, V341, P41, DOI 10.1016/j.canlet.2013.08.027; Espinoza I, 2013, PHARMACOL THERAPEUT, V139, P95, DOI 10.1016/j.pharmthera.2013.02.003; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051; Gong C, 2015, ONCOGENE, V34, P84, DOI 10.1038/onc.2013.525; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Koch U, 2013, DEVELOPMENT, V140, P689, DOI 10.1242/dev.080614; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Li C, 2015, THORAC CANCER, V6, P524, DOI 10.1111/1759-7714.12242; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Liu S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002537; Liu YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep28329; Lo Sardo F, 2017, CARCINOGENESIS, V38, P64, DOI 10.1093/carcin/bgw110; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Ni XJ, 2014, CANCER SCI, V105, P18, DOI 10.1111/cas.12309; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Pursglove SE, 2005, INT J BIOCHEM CELL B, V37, P2472, DOI 10.1016/j.biocel.2005.06.013; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Qu MH, 2016, TUMOR BIOL, V37, P5645, DOI 10.1007/s13277-015-4328-8; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Schrijver WAME, 2017, ONCOTARGET, V8, P3111, DOI 10.18632/oncotarget.13623; Shyamasundar S, 2016, INT J ONCOL, V49, P2629, DOI 10.3892/ijo.2016.3761; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Xu X, 2016, SCI REP-UK, V6, DOI 10.1038/srep31267; Yang F, 2017, CELL MOL LIFE SCI, V74, P951, DOI 10.1007/s00018-016-2334-7; Yau WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057882; Yen CS, 2016, WORLD J GASTROENTERO, V22, P5183, DOI 10.3748/wjg.v22.i22.5183; Yu D, 2014, LAB INVEST, V94, P1370, DOI 10.1038/labinvest.2014.125; Zhang RP, 2016, TUMOR BIOL, V37, P10507, DOI 10.1007/s13277-016-4937-x	53	37	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3879	3893		10.1038/s41388-018-0239-7	http://dx.doi.org/10.1038/s41388-018-0239-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662198	Green Accepted			2022-12-28	WOS:000438465600009
J	Ramirez-Moya, J; Wert-Lamas, L; Santisteban, P				Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar			MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; MOLECULAR PATHOGENESIS; GENETIC ALTERATIONS; EXPRESSION; MIR-146B; PROTEIN; MUTATIONS; STAT3	Recent studies have shown that miR-146b is the most upregulated microRNA in thyroid cancer and has a central role in cancer progression through mechanisms that remain largely unidentified. As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation. Among the predicted target genes of miR-146b, we found the tumor-suppressor phosphatase and tensin homolog (PTEN). Constitutive overexpression of miR-146b in thyroid epithelial cell lines significantly decreased PTEN mRNA and protein levels by direct binding to its 3'-UTR. This was accompanied by PI3K/AKT hyperactivation, leading to the exclusion of FOXO1 and p27 from the nucleus and a corresponding increase in cellular proliferation. Moreover, miR-146b overexpression led to protection from apoptosis and an increased migration and invasion potential, regulating genes involved in epithelial-mesenchymal transition. Notably, with the single exception of E-cadherin expression, all of these outcomes could be reversed by PTEN coexpression. Further analysis showed that miR-146b directly inhibits E-cadherin expression through binding to its 3'-UTR. Interestingly, miR-146b inhibition in human thyroid tumor xenografts, using a synthetic and clinically amenable molecule, blocked tumor growth when delivered intratumorally. Importantly, this inhibition increased PTEN protein levels. In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer. Both events are related to a more aggressive tumoral phenotype. Targeting miR-146b therefore represents a promising therapeutic strategy for the treatment of this disease.	[Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar] Univ Autonoma Madrid, CSIC, Madrid, Spain; [Santisteban, Pilar] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Univ Autonoma Madrid, CSIC, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Wert-Lamas, Leon/ABD-2880-2020; Ramírez-Moya, Julia/B-9104-2018; Santisteban, Pilar/E-7829-2016	Ramírez-Moya, Julia/0000-0002-2458-2186; Santisteban, Pilar/0000-0002-2758-796X	Ministerio de Economia y Competitividad (MINECO) of Spain [SAF2013-44709-R, SAF2016-75531-R]; Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER) [RD12/0036/0030]; Fundacion Espanola contra el Cancer [GCB14142311CRES]; Ministerio de Educacion Cultura y Deporte; MEC; ISCIII (Spain) [PI14/01980]	Ministerio de Economia y Competitividad (MINECO) of Spain(Spanish Government); Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER); Fundacion Espanola contra el Cancer; Ministerio de Educacion Cultura y Deporte(Spanish Government); MEC(European Commission); ISCIII (Spain)(Instituto de Salud Carlos III)	We are grateful to Andrea Martinez-Cano for her technical assistance, Javier Perez for the artwork and Dr Kenneth McCreath for helpful comments on the manuscript. We thank Dr Jeronimo Blanco (Catalonian Institute for Advance Chemistry-CSIC) and Dr Eugenia Mato (Institut de Reserca de l'Hospital de la Santa Creu i Sant Pau) Barcelona (Spain) for gifting the CMV-Firefly luc-IRES-EGFP and Cal62-Luc cells, respectively. We also thank the Histology Facility at CNB-CSIC for the histological preparation of biological samples. This work was supported by grants SAF2013-44709-R and SAF2016-75531-R from the Ministerio de Economia y Competitividad (MINECO) of Spain, RD12/0036/0030 from Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER), and GCB14142311CRES from Fundacion Espanola contra el Cancer. JR-M holds a FPU fellowship from Ministerio de Educacion Cultura y Deporte. LW-L was funded by an FPI fellowship from MEC and is currently an investigator of the project PI14/01980 from ISCIII (Spain).	Acibucu F, 2014, EXP CLIN ENDOCR DIAB, V122, P137, DOI 10.1055/s-0034-1367025; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Burger ML, 2014, BLOOD, V123, P4089, DOI 10.1182/blood-2013-11-539411; Chou CK, 2016, J CLIN ENDOCR METAB, V101, P4357, DOI 10.1210/jc.2016-2276; Chou CK, 2013, J CLIN ENDOCR METAB, V98, pE196, DOI 10.1210/jc.2012-2666; Couto JP, 2012, P NATL ACAD SCI USA, V109, pE2361, DOI 10.1073/pnas.1201232109; Deng XZ, 2015, CELL PHYSIOL BIOCHEM, V35, P71, DOI 10.1159/000369676; Dettmer M, 2013, THYROID, V23, P1383, DOI 10.1089/thy.2012.0632; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fahiminiya S, 2016, NEW ENGL J MED, V375, P2306, DOI 10.1056/NEJMc1613118; Fassina A, 2014, CANCER CYTOPATHOL, V122, P274, DOI 10.1002/cncy.21383; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Fuziwara CS, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/743450; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Geraldo MV, 2012, ONCOGENE, V31, P1910, DOI 10.1038/onc.2011.381; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Lee JC, 2013, CANCER-AM CANCER SOC, V119, P4358, DOI 10.1002/cncr.28254; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lima CR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2146-z; Liu CP, 2016, SCI REP-UK, V6, DOI 10.1038/srep36990; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu RY, 2017, JAMA ONCOL, V3, P202, DOI 10.1001/jamaoncol.2016.3288; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Paes JE, 2008, ENDOCRIN METAB CLIN, V37, P375, DOI 10.1016/j.ecl.2008.01.001; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Riesco-Eizaguirre G, 2016, EUR J ENDOCRINOL, V175, pR203, DOI 10.1530/EJE-16-0202; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Santarpia L, 2008, J CLIN ENDOCR METAB, V93, P278, DOI 10.1210/jc.2007-1076; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sosonkina N, 2014, CANCERS, V6, P526, DOI 10.3390/cancers6010526; Su XY, 2016, ONCOTARGETS THER, V9, P6965, DOI 10.2147/OTT.S116594; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang J, 2010, NUCLEIC ACIDS RES, V38, pD119, DOI 10.1093/nar/gkp803; Wojtas B, 2014, MOL CELL ENDOCRINOL, V388, P1, DOI 10.1016/j.mce.2014.02.011; Xiang M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004497; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xu B, 2017, THYROID, V27, P632, DOI 10.1089/thy.2016.0582; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Zaballos MA, 2013, MOL ENDOCRINOL, V27, P50, DOI 10.1210/me.2012-1032	62	63	64	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3369	3383		10.1038/s41388-017-0088-9	http://dx.doi.org/10.1038/s41388-017-0088-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29353884				2022-12-28	WOS:000436411300004
J	Di Costanzo, A; Del Gaudio, N; Conte, L; Dell'Aversana, C; Vermeulen, M; de The, H; Migliaccio, A; Nebbioso, A; Altucci, L				Di Costanzo, Antonella; Del Gaudio, Nunzio; Conte, Lidio; Dell'Aversana, Carmela; Vermeulen, Michiel; de The, Hugues; Migliaccio, Antimo; Nebbioso, Angela; Altucci, Lucia			The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; POLYCOMB GROUP PROTEINS; HISTONE H3; SUMOYLATION; CANCER; CHROMODOMAIN; REPRESSION; TARGET; CELLS; TUMORIGENESIS	Polycomb group (PcG) proteins regulate transcription, playing a key role in stemness and differentiation. Deregulation of PcG members is known to be involved in cancer pathogenesis. Emerging evidence suggests that CBX2, a member of the PcG protein family, is overexpressed in several human tumors, correlating with lower overall survival. Unraveling the mechanisms regulating CBX2 expression may thus provide a promising new target for anticancer strategies. Here we show that the HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. We identify CBX4 and RNF4 as the E3 SUMO and E3 ubiquitin ligase, respectively, and describe the specific molecular mechanism regulating CBX2 protein stability. Finally, we show that CBX2-depleted leukemic cells display impaired proliferation, underscoring its critical role in regulating leukemia cell tumorogenicity. Our results show that SAHA affects CBX2 stability, revealing a potential SAHA-mediated anti-leukemic activity though SUMO2/3 pathway.	[Di Costanzo, Antonella; Del Gaudio, Nunzio; Conte, Lidio; Dell'Aversana, Carmela; Migliaccio, Antimo; Nebbioso, Angela; Altucci, Lucia] Univ Campania Luigi Vanvitelli, Dept Biochem Biophys & Gen Pathol, Vico L De Crecchio 7, I-80138 Naples, Italy; [Vermeulen, Michiel] Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Radboud Inst Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; [de The, Hugues] Hop St Louis, Inst Univ Hematol, INSERM Unite Mixte Rech 944, Equipe Labellisee Ligue Natl Canc, Paris 10, France	Universita della Campania Vanvitelli; Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Di Costanzo, A; Altucci, L (corresponding author), Univ Campania Luigi Vanvitelli, Dept Biochem Biophys & Gen Pathol, Vico L De Crecchio 7, I-80138 Naples, Italy.	antonella.dicostanzo@unina.it; lucia.altucci@unicampania.it	NEBBIOSO, ANGELA/GVS-1294-2022; Dell'Aversana, Carmela/P-7829-2018; Vermeulen, Michiel/C-8883-2013; Altucci, Lucia/S-8031-2019; Migliaccio, Antimo/AAB-3376-2019	Dell'Aversana, Carmela/0000-0001-6588-698X; Vermeulen, Michiel/0000-0003-0836-6894; Migliaccio, Antimo/0000-0002-4197-2055; Conte, Lidio/0000-0002-9520-1344; altucci, lucia/0000-0002-7312-5387; Del Gaudio, Nunzio/0000-0003-3691-443X	Blueprint [282510]; EPIGEN (MIUR-CNR); MIUR [PRIN2012ZHN9YH, 20152TE5PK]; AIRC [17217]; COST EPICHEMBIO [CM1406]	Blueprint; EPIGEN (MIUR-CNR)(Consiglio Nazionale delle Ricerche (CNR)); MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); COST EPICHEMBIO(European Cooperation in Science and Technology (COST))	Blueprint (282510), EPIGEN (MIUR-CNR); MIUR (PRIN2012ZHN9YH; 20152TE5PK), AIRC (17217); COST EPICHEMBIO CM1406.	Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Clermont PL, 2014, BRIT J CANCER, V111, P1663, DOI 10.1038/bjc.2014.474; Clermont PL, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0182-9; Dell'Aversana C, 2017, LEUKEMIA, V31, P2315, DOI 10.1038/leu.2017.64; Di Costanzo A, 2011, J CELL PHYSIOL, V226, P2189, DOI 10.1002/jcp.22553; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Enserink JM, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0010-1; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; Frank CL, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0065-5; Fujikawa D, 2016, BLOOD, V127, P1790, DOI 10.1182/blood-2015-08-662593; Grau DJ, 2011, GENE DEV, V25, P2210, DOI 10.1101/gad.17288211; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hatano A, 2010, BIOCHEM BIOPH RES CO, V397, P93, DOI 10.1016/j.bbrc.2010.05.074; Ismail IH, 2012, NUCLEIC ACIDS RES, V40, P5497, DOI 10.1093/nar/gks222; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kaustov L, 2011, J BIOL CHEM, V286, P521, DOI 10.1074/jbc.M110.191411; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lee SH, 2013, CANCER LETT, V335, P397, DOI 10.1016/j.canlet.2013.02.051; Li B, 2007, BIOCHEM J, V405, P369, DOI 10.1042/BJ20061873; Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008; Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Niessen HEC, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-10; Portanova P, 2008, INT J ONCOL, V33, P325, DOI 10.3892/ijo_00000012; Ren CY, 2015, CHEM BIOL, V22, P161, DOI 10.1016/j.chembiol.2014.11.021; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002704; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwartz YB, 2013, NAT REV GENET, V14, P853, DOI 10.1038/nrg3603; Simhadri C, 2014, J MED CHEM, V57, P2874, DOI 10.1021/jm401487x; Smits AH, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks941; Stielow C, 2014, NUCLEIC ACIDS RES, V42, P3044, DOI 10.1093/nar/gkt1317; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; van den Boom V, 2013, BLOOD, V121, P2452, DOI 10.1182/blood-2012-08-451666; Wang W, 2015, MED RES REV, V35, P1220, DOI 10.1002/med.21358; Wu Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep09520; Zhang L, 2017, CELL DEATH DIFFER, V24, P1530, DOI 10.1038/cdd.2017.29; Zhao J, 2007, CELL MOL LIFE SCI, V64, P3017, DOI 10.1007/s00018-007-7137-4	47	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2559	2572		10.1038/s41388-018-0143-1	http://dx.doi.org/10.1038/s41388-018-0143-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467492	Green Published, hybrid			2022-12-28	WOS:000431873400008
J	Akhter, MZ; Sharawat, SK; Kumar, V; Kochat, V; Equbal, Z; Ramakrishnan, M; Kumar, U; Mathur, S; Kumar, L; Mukhopadhyay, A				Akhter, Md Zahid; Sharawat, Surender K.; Kumar, Vikash; Kochat, Veena; Equbal, Zaffar; Ramakrishnan, Mallika; Kumar, Umesh; Mathur, Sandeep; Kumar, Lalit; Mukhopadhyay, Asok			Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype	ONCOGENE			English	Article							MARROW-DERIVED CELLS; STEM-CELLS; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; TUMOR PROGRESSION; BREAST-CANCER; THERAPY; CONTRIBUTE; EXOSOMES; CHEMORESISTANCE	Epithelial ovarian carcinoma (EOC) patients often acquire resistance against common chemotherapeutic drugs like paclitaxel and cisplatin. The mechanism responsible for the same is ambiguous. We have identified a putative drug-resistant tumour cell phenotype (EpCAM(+) CD45(+)) in the ascitic fluid of EOC patients, which appears to originate from the primary tumour. These cells represent the major tumour burden and are more drug resistant compared to EpCAM(+) tumour cells due to the over-expression of SIRT1, ABCA1 and BCL2 genes. We have found that the entire EpCAM(+) CD45+ population is highly invasive with signature mesenchymal gene expression and also consists of subpopulations of ovarian cancer stem cells (CD133(+) and CD117(+) CD44(+)). Additionally, we demonstrate that the EpCAM(+) CD45(+) tumour cells over-express major histocompatibility complex class I antigen, which enable them to evade the natural killer cell-mediated immune surveillance. Preliminary evidence obtained in OVCAR-5 cells suggests that exosomes, secreted by non-tumour cells of the ascitic fluid, play an important role in rendering drug resistance and invasive properties to the cancer cells. Identification of such aggressive tumour cells and deciphering their origin is important for designing better drug targets for EOC.	[Akhter, Md Zahid; Sharawat, Surender K.; Kumar, Vikash; Kochat, Veena; Equbal, Zaffar; Ramakrishnan, Mallika; Kumar, Umesh; Mathur, Sandeep; Kumar, Lalit; Mukhopadhyay, Asok] Natl Inst Immunol, Stem Cell Biol Lab, New Delhi, India; [Mathur, Sandeep] All India Inst Med Sci, Dept Pathol, New Delhi, India; [Kumar, Lalit] All India Inst Med Sci, Dept Med Oncol, New Delhi, India; [Akhter, Md Zahid] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; [Sharawat, Surender K.] All India Inst Med Sci, Dept Med Oncol, New Delhi, India; [Kochat, Veena] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Ramakrishnan, Mallika] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany; [Kumar, Umesh] Univ Delhi, Dept Biochem, Genom Facil, South Campus, New Delhi, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Texas System; UTMD Anderson Cancer Center; University of Delhi	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Stem Cell Biol Lab, New Delhi, India.	ashok@nii.ac.in	Kumar, Umesh/AAX-9989-2021; Kochat, Veena/AAX-1915-2021; Kumar, Umesh/AAQ-9159-2021; Akhter, Zahid/AAA-8410-2022	Kumar, Umesh/0000-0002-4715-7967; Akhter, Zahid/0000-0002-1602-3704; SHARAWAT, SURENDER K/0000-0001-6322-0586; Equbal, Zaffar/0000-0001-7791-1804	Department of Biotechnology, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	AM is grateful for the generous support provided by the Department of Biotechnology, Government of India to the Centre of Molecular Medicine, NII. We would like to thank Mr. Nila Ram and Mr. Ajay Sharma for acquiring confocal images. AM would like to thank Dr. Ayub Qadri, Scientist (NII, New Delhi), Prof. NK Mehra (AIIMS, New Delhi) and Dr. Awadhesh Pandit (NCBS, Bangalore) for valuable discussion in some parts of the study. Also, we are thankful to Dr. TR Santhosh Kumar (RGCB, Thiruvananthapuram, Kerala) for providing the OVCAR-5 cell line.	Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Ahmed N, 2013, J CELL BIOCHEM, V114, P21, DOI 10.1002/jcb.24317; Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.14; Avital I, 2007, STEM CELLS, V25, P2903, DOI 10.1634/stemcells.2007-0409; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Baligar P, 2017, HEPATOLOGY, V65, P1319, DOI 10.1002/hep.29027; Baligar P, 2016, STEM CELLS, V34, P135, DOI 10.1002/stem.2210; Bamias A, 2007, GYNECOL ONCOL, V106, P75, DOI 10.1016/j.ygyno.2007.02.029; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barker N, 2001, TRENDS MOL MED, V7, P535, DOI 10.1016/S1471-4914(01)02215-8; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-11; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Kim Yonghyun, 2009, Int J Stem Cells, V2, P109; LARIZZA L, 1984, J EXP MED, V160, P1579, DOI 10.1084/jem.160.5.1579; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Li HX, 2014, ARCH GYNECOL OBSTET, V290, P1067, DOI 10.1007/s00404-014-3377-3; Liu CF, 2006, NEOPLASIA, V8, P716, DOI 10.1593/neo.06253; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matte I, 2012, AM J CANCER RES, V2, P566; Olumi AF, 1999, CANCER RES, V59, P5002; Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231; Ozols RF, 2006, SEMIN ONCOL, V33, pS3, DOI 10.1053/j.seminoncol.2006.03.011; Paley PJ, 2001, CURR OPIN ONCOL, V13, P399, DOI 10.1097/00001622-200109000-00015; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; Qian JL, 2016, ONCOL LETT, V11, P1738, DOI 10.3892/ol.2016.4150; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramakrishnan M, 2013, CANCER RES, V73, P5360, DOI 10.1158/0008-5472.CAN-13-0896; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Rousalova I, 2010, INT J ONCOL, V37, P1361, DOI 10.3892/ijo_00000788; Rubin SC, 1999, OBSTET GYNECOL, V93, P21, DOI 10.1016/S0029-7844(98)00334-2; Runz S, 2007, GYNECOL ONCOL, V107, P563, DOI 10.1016/j.ygyno.2007.08.064; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shain KH, 2015, ONCOGENE, V34, P4673, DOI 10.1038/onc.2014.403; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Sunayama J, 2010, STEM CELLS, V28, P1930, DOI 10.1002/stem.521; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Wang RF, 2001, TRENDS IMMUNOL, V22, P269, DOI 10.1016/S1471-4906(01)01896-8; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	54	35	38	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2089	2103		10.1038/s41388-017-0106-y	http://dx.doi.org/10.1038/s41388-017-0106-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379166				2022-12-28	WOS:000430589000002
J	Chiang, YJ; Liao, WT; Ho, KC; Wang, SH; Chen, YG; Ho, CL; Huang, SF; Shih, LY; Yang-Yen, HF; Yen, JJY				Chiang, Yun-Jung; Liao, Wei-Ting; Ho, Kun-Chin; Wang, Shih-Hao; Chen, Yu-Guang; Ho, Ching-Liang; Huang, Shiu-Feng; Shih, Lee-Yung; Yang-Yen, Hsin-Fang; Yen, Jeffrey Jong-Young			CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							TUBEROUS SCLEROSIS; TSC1-TSC2 COMPLEX; LYSOSOMAL RECRUITMENT; MTOR; TARGET; PTEN; APOPTOSIS; INACTIVATION; INTEGRATION; DOWNSTREAM	High-frequency relapse remains a clinical hurdle for complete remission of T-cell acute lymphoblastic leukemia (T-ALL) patients, with heterogeneous dysregulated signaling profiles-including of Raf-MEK-ERK and Akt-mTORC1-S6K signaling pathways-recently being implicated in disease outcomes. Here we report that GM-CSF/IL-3/IL-5 receptor common beta-chain-associated protein (CBAP) is highly expressed in human T-ALL cell lines and many primary tumor tissues and is required to bolster leukemia cell proliferation in tissue culture and for in vivo leukemogenesis in a xenograft mouse model. Downregulation of CBAP markedly restrains expansion of leukemia cells and alleviates disease aggravation of leukemic mice. Transcriptomic profiling and molecular biological analyses suggest that CBAP acts upstream of Ras and Rac1, and functions as a modulator of both Raf-MEK-ERK and Akt-mTORC1 signaling pathways to control leukemia cell growth. Specifically, CBAP facilitated Akt-dependent TSC2 phosphorylation in cell-based assays and in vitro analysis, decreased lysosomal localization of TSC2, and elevated Rheb-GTP loading and subsequent activation of mTORC1 signaling. Taken together, our findings reveal a novel oncogenic contribution of CBAP in T-ALL leukemic cells, in addition to its original proapoptotic function in cytokine-dependent cell lines and primary hematopoietic cells, by demonstrating its functional role in the regulation of Akt-TSC2-mTORC1 signaling for leukemia cell proliferation. Thus, CBAP represents a novel therapeutic target for many types of cancers and metabolic diseases linked to PI3K-Akt-mTORC1 signaling.	[Chiang, Yun-Jung; Liao, Wei-Ting; Ho, Kun-Chin; Wang, Shih-Hao; Yen, Jeffrey Jong-Young] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chen, Yu-Guang; Ho, Ching-Liang] Natl Def Med Ctr, Div Hematol Oncol, Dept Internal Med, Triserv Gen Hosp, Taipei 11490, Taiwan; [Huang, Shiu-Feng] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli 35053, Taiwan; [Shih, Lee-Yung] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Dept Internal Med,Coll Med, Taoyuan 33305, Taiwan; [Yang-Yen, Hsin-Fang] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Tri-Service General Hospital; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Academia Sinica - Taiwan	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Yang-Yen, Hsin-Fang/ABA-5808-2021; Yen, Jeffrey Jong-Young/Q-5134-2018	Yang-Yen, Hsin-Fang/0000-0001-9048-4800; Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Chiang, Yun-Jung/0000-0001-5024-8977	Ministry of Science and Technology, Taiwan [NSC102-2320-B001-007-MY3, MOST105-2320-B-001-012-MY3]; Tri-Service General Hospital [TSGH-106-01-34, MOST103-2811-B-001-090, MOST105-2811-B-001-044]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Tri-Service General Hospital	We thank Dr. Richard Lin at Stony Brook University Medical Center for his careful reading of the manuscript and his suggestions. We thank the National Center for Genome Medicine, National RNAi Core Facility, and the Molecular and Genetic Imaging Core of the Taiwan Mouse Clinic for their technical support. This work was supported by grants from the Ministry of Science and Technology, Taiwan to JJYY (NSC102-2320-B001-007-MY3 and MOST105-2320-B-001-012-MY3), and was partly supported by Tri-Service General Hospital (TSGH-106-01-34). YJC is supported by postdoctoral fellowships MOST103-2811-B-001-090 and MOST105-2811-B-001-044.	Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Chiang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061761; Chiarini F, 2010, CANCER RES, V70, P8097, DOI 10.1158/0008-5472.CAN-10-1814; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Demetriades C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10662; Demetriades C, 2014, CELL, V156, P786, DOI 10.1016/j.cell.2014.01.024; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Ho KC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.474; Hoshii T, 2014, J BIOCHEM, V156, P73, DOI 10.1093/jb/mvu037; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jotta PY, 2010, LEUKEMIA, V24, P239, DOI 10.1038/leu.2009.209; Kao CJ, 2008, ONCOGENE, V27, P1397, DOI 10.1038/sj.onc.1210778; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kuchta K, 2009, NUCLEIC ACIDS RES, V37, P7701, DOI 10.1093/nar/gkp854; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lin KR, 2007, J BIOL CHEM, V282, P21962, DOI 10.1074/jbc.M701663200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonetti A, 2015, ONCOTARGET, V6, P10399, DOI 10.18632/oncotarget.3295; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049; Nikolaidis N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000204; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Roti G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00170; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silverman LB, 1999, CANCER-AM CANCER SOC, V85, P1395, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2; Stofega Mary, 2006, V332, P269; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Wermuth PJ, 2005, BLOOD, V105, P1222, DOI 10.1182/blood-2004-03-0802; You MJ, 2015, AM J CLIN PATHOL, V144, P411, DOI 10.1309/AJCPMF03LVSBLHPJ; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	44	7	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1432	1447		10.1038/s41388-018-0507-6	http://dx.doi.org/10.1038/s41388-018-0507-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30266989	hybrid, Green Published			2022-12-28	WOS:000459945800005
J	Pai, VC; Hsu, CC; Chan, TS; Liao, WY; Chuu, CP; Chen, WY; Li, CR; Lin, CY; Huang, SP; Chen, LT; Tsai, KK				Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Liao, Wen-Ying; Chuu, Chih-Pin; Chen, Wei-Yu; Li, Chi-Rong; Lin, Ching-Yu; Huang, Shu-Pin; Chen, Li-Tzong; Tsai, Kelvin K.			ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling	ONCOGENE			English	Article							PLANAR CELL POLARITY; TUMOR; MARKER; METASTASIS; EXPRESSION; PATHWAY; SOX9; IDENTIFICATION; ELEVATION; RECEPTOR	Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-beta-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH(+) CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced beta-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.	[Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 11031, Taiwan; [Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Lab Adv Mol Therapeut,Div Gastroenterol, Taipei 11696, Taiwan; [Pai, Vincent C.; Liao, Wen-Ying; Chen, Li-Tzong; Tsai, Kelvin K.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chuu, Chih-Pin; Lin, Ching-Yu] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan 35053, Miaoli County, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Li, Chi-Rong] Minist Hlth & Welf, Dept Teaching & Res, Taichung Hosp, Taichung 40343, Taiwan; [Huang, Shu-Pin] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung 80756, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Tsai, KK (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 11031, Taiwan.; Tsai, KK (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Lab Adv Mol Therapeut,Div Gastroenterol, Taipei 11696, Taiwan.; Tsai, KK (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan.	tsaik@tmu.edu.tw	Lin, Ching Yu/AAN-9581-2020	Lin, Ching Yu/0000-0001-9041-5653; Tsai, Kelvin/0000-0002-1612-2868; Li, Chi-Rong/0000-0002-0314-8284	Ministry of Science and Technology [MOST 104-2314-B-400-022, MOST 105-2314-B-400-018, MOST 105-2314-B-400-003]; Taipei Medical University [DP2-107-21121-C-04]; Ministry of Health and Welfare grant [MOHW107-TDU-B-212-114020]; National Health Research Institutes intramural grant [CA-106-PP-09]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Medical University; Ministry of Health and Welfare grant; National Health Research Institutes intramural grant	Supported in part by Ministry of Science and Technology grants MOST 104-2314-B-400-022, MOST 105-2314-B-400-018 (KKT), MOST 105-2314-B-400-003 (L-TC), Taipei Medical University grant DP2-107-21121-C-04 (KKT), Ministry of Health and Welfare grant MOHW107-TDU-B-212-114020 (KKT) and National Health Research Institutes intramural grant CA-106-PP-09 (KKT).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23; Bikeye SNN, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-1; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bruning-Richardson A, 2011, BRIT J CANCER, V104, P1602, DOI 10.1038/bjc.2011.117; Buchman JJ, 2011, GENE DEV, V25, P1909, DOI 10.1101/gad.16830211; BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419; Capecchi MR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9763; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Fish JL, 2006, P NATL ACAD SCI USA, V103, P10438, DOI 10.1073/pnas.0604066103; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gilligan T, 2002, UROLOGY, V60, P94, DOI 10.1016/S0090-4295(02)01583-2; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gray RS, 2011, DEV CELL, V21, P120, DOI 10.1016/j.devcel.2011.06.011; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Jiang K, 2017, NAT CELL BIOL, V19, P480, DOI 10.1038/ncb3511; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; Kouprina N, 2005, HUM MOL GENET, V14, P2155, DOI 10.1093/hmg/ddi220; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Lin SY, 2008, CLIN CANCER RES, V14, P4814, DOI 10.1158/1078-0432.CCR-07-5262; Liu C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14270; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Schneider JA, 2018, MOL CELL ENDOCRINOL, V462, P3, DOI 10.1016/j.mce.2017.02.008; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Voet M, 2009, NAT CELL BIOL, V11, P269, DOI 10.1038/ncb1834; Vange P, 2015, J PATHOL, V237, P447, DOI 10.1002/path.4591; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang WY, 2013, GASTROENTEROLOGY, V145, P1110, DOI 10.1053/j.gastro.2013.07.040; Xie JJ, 2017, INT UROL NEPHROL, V49, P817, DOI 10.1007/s11255-017-1545-7; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	49	62	65	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1340	1353		10.1038/s41388-018-0497-4	http://dx.doi.org/10.1038/s41388-018-0497-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30266990				2022-12-28	WOS:000459249800014
J	Nakano, M; Kikushige, Y; Miyawaki, K; Kunisaki, Y; Mizuno, S; Takenaka, K; Tamura, S; Okumura, Y; Ito, M; Ariyama, H; Kusaba, H; Nakamura, M; Maeda, T; Baba, E; Akashi, K				Nakano, Michitaka; Kikushige, Yoshikane; Miyawaki, Kohta; Kunisaki, Yuya; Mizuno, Shinichi; Takenaka, Katsuto; Tamura, Shingo; Okumura, Yuta; Ito, Mamoru; Ariyama, Hiroshi; Kusaba, Hitoshi; Nakamura, Masafumi; Maeda, Takahiro; Baba, Eishi; Akashi, Koichi			Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer	ONCOGENE			English	Article							HUMAN COLON; MESENCHYMAL TRANSITION; INITIATING CELLS; TUMOR INITIATION; EMT; IDENTIFICATION; METASTASIS; EXPRESSION; PLASTICITY; SIGNATURE	Cancer stem cells (CSCs) possess the capacity for self-renewal and the potential to differentiate into non-CSCs. The recent discoveries of dynamic equilibrium between CSCs and non-CSCs revealed the significance of acquiring CSC-like properties in non-CSCs as an important process in progression of cancer. The mechanism underlying acquisition of CSC-like properties has mainly been investigated in the context of epithelial-mesenchymal transition. Here, we demonstrate the dedifferentiation process may be an alternative mechanism in acquisition of CSC-like properties in human colorectal cancer cells. By exploring the single-cell gene expression analysis of organoids developed from CD44(+) CSCs, we identified TWIST1 as a key molecule for maintaining the undifferentiated state of cancer cells. Consistent with the finding, we found that TGF-beta signaling pathway, a regulator of TWIST1, was specifically activated in the undifferentiated CD44(+) CSCs in human colorectal cancer using microarray-based gene expression analysis and quantitative pathology imaging system. Furthermore, we showed that external stimulation with TGF-beta and the induction of TWIST1 converted CD44(-) non-CSCs into the undifferentiated CD44(+) CSCs, leading to the significant increment of CSCs in xenograft models. This study strongly suggests dedifferentiation driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer.	[Nakano, Michitaka; Kikushige, Yoshikane; Miyawaki, Kohta; Kunisaki, Yuya; Mizuno, Shinichi; Takenaka, Katsuto; Tamura, Shingo; Okumura, Yuta; Ito, Mamoru; Ariyama, Hiroshi; Kusaba, Hitoshi; Maeda, Takahiro; Baba, Eishi; Akashi, Koichi] Kyushu Univ, Dept Med & Biosyst Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan; [Baba, Eishi] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Fukuoka, Japan; [Nakamura, Masafumi] Kyushu Univ, Dept Surg & Oncol, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan	Kyushu University; Kyushu University; Kyushu University	Baba, E (corresponding author), Kyushu Univ, Dept Med & Biosyst Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan.; Baba, E (corresponding author), Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Fukuoka, Japan.	e-baba@intmed1.med.kyushu-u.ac.jp	Maeda, Takahiro/AAC-4563-2019	Maeda, Takahiro/0000-0003-4530-6460; Nakano, Michitaka/0000-0003-1049-5791; Okumura, Yuta/0000-0002-7825-8373	JSPS [16H06391, 16H02662, 15K08970, 16H06250, 25860542, 15H04859]; MEXT, Japan [25115002]; Japan Agency for Medical Research and development, AMED [18cm0106507h0003, 18ck0106196h0003]; Shinnihon Foundation of Advanced Medical Treatment Research; AstraZeneca KK (AZKK Science Promotion Grant)	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Shinnihon Foundation of Advanced Medical Treatment Research; AstraZeneca KK (AZKK Science Promotion Grant)	We especially thank N Torada, T Ueki, and T Manabe, S Nagai from the Department of Surgery and Oncology, Kyushu University, for providing clinical colorectal cancer tissues. They sincerely thank T. Isobe for development of methods and wonderful lecture. They also thank A. Yurino for providing mice, Yasufumi Uehara for taking confocal microscopy images, T Sugio, T Jiroumaru for performing microarray analysis. Co-workers at our labs, F Hanamura, Yumiko Uehara, K Yamaguchi, K Sagara, K Tsuchihashi, S Arita, supported this work. This study was supported in part by a Grant-in-Aid for Scientific Research (S) (to KA, #16H06391), a Grant-in-Aid for Scientific Research (A) (to KA, #16H02662), a Grant-in-Aid for Scientific Research (C) (to EB, #15K08970), a Grant-in-Aid for Young Scientists (A) (to Y Kikushige #16H06250), a Grant-in-Aid for Young Scientists (B) (to SA, #25860542), a Grant-in-Aid for Scientific Research (B) (to Y Kunisaki, #15H04859), from the JSPS, and a Grant-in-Aid for Scientific Research on Innovative Areas "Stem Cell Aging and Disease" (to TM and Y Kikushige, #25115002) from MEXT, Japan, and the "Project for Cancer Research and Therapeutic Evolution" (to KA, 18cm0106507h0003), and the "Practical Research for Innovative Cancer Control" (to Y Kikushige, 18ck0106196h0003) from Japan Agency for Medical Research and development, AMED, and the Shinnihon Foundation of Advanced Medical Treatment Research (to HA, Y Kikushige, and Y Kunisaki), and a collaborative research grant from AstraZeneca KK (to MN, AZKK Science Promotion Grant).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barriga FM, 2017, CELL STEM CELL, V20, P801, DOI 10.1016/j.stem.2017.02.007; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Foroutan M, 2017, MOL CANCER RES, V15, P619, DOI 10.1158/1541-7786.MCR-16-0313; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Jiang JM, 2008, CELL STEM CELL, V3, P127, DOI 10.1016/j.stem.2008.07.011; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Jung P, 2015, STEM CELL REP, V5, P979, DOI 10.1016/j.stemcr.2015.10.003; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kim J, 2011, GENOME MED, V3, DOI 10.1186/gm291; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001; Ovadya Y, 2015, NAT MED, V21, P975, DOI 10.1038/nm.3938; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pino MS, 2010, GASTROENTEROLOGY, V138, P1406, DOI 10.1053/j.gastro.2009.12.010; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shvab A, 2016, ONCOGENE, V35, P549, DOI 10.1038/onc.2015.127; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang DW, 2018, ONCOL REP, V39, P31, DOI 10.3892/or.2017.6076; Wu Y, 2017, BREAST CANCER RES TR, V163, P449, DOI 10.1007/s10549-017-4211-y; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979	52	52	54	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					780	793		10.1038/s41388-018-0480-0	http://dx.doi.org/10.1038/s41388-018-0480-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30181548	Green Accepted			2022-12-28	WOS:000458006300002
J	Stieglitz, D; Lamm, S; Braig, S; Feuerer, L; Kuphal, S; Dietrich, P; Arndt, S; Echtenacher, B; Hellerbrand, C; Karrer, S; Bosserhoff, AK				Stieglitz, David; Lamm, Susanne; Braig, Simone; Feuerer, Lena; Kuphal, Silke; Dietrich, Peter; Arndt, Stephanie; Echtenacher, Bernd; Hellerbrand, Claus; Karrer, Sigrid; Bosserhoff, Anja-Katrin			BMP6-induced modulation of the tumor micro-milieu	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEINS; NECROSIS-FACTOR-ALPHA; MAST-CELLS; MELANOMA-CELLS; METABOTROPIC GLUTAMATE-RECEPTOR-1; HEPCIDIN EXPRESSION; MALIGNANT-MELANOMA; BMP6; REGULATOR; HISTAMINE	Melanoma is the deadliest form of skin cancer with rising incidence, creating a significant health problem. We discovered increased expression of bone morphogenetic protein 6 (BMP6) in melanoma cells and tissues, and observed that BMP6 deficiency caused significantly delayed tumor onset and decelerated tumor progression in a melanoma mouse model. Moreover, we determined that BMP6 inhibits dermal mast cell recruitment and found that mast cell-derived mediators significantly reduced melanoma growth in vitro. In line with this, mast cell deficiency accelerated tumor onset and progression in a melanoma mouse model. Analysis of human melanoma tissues revealed a strong negative correlation between melanoma proliferation and mast cell infiltration. This study elucidates a novel role of BMP6-induced modulation of the tumor microenvironment.	[Stieglitz, David; Lamm, Susanne; Feuerer, Lena; Kuphal, Silke; Dietrich, Peter; Hellerbrand, Claus; Bosserhoff, Anja-Katrin] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Ctr, Dept Biochem & Mol Med, Erlangen, Germany; [Braig, Simone] Univ Munich, Dept Pharm, Pharmaceut Biol, Munich, Germany; [Arndt, Stephanie; Karrer, Sigrid] Univ Med Ctr Regensburg, Dept Dermatol, Regensburg, Germany; [Echtenacher, Bernd] Regensburg Ctr Intervent Immunol RCI, Regensburg, Germany; [Echtenacher, Bernd] Univ Med Ctr Regensburg, Regensburg, Germany; [Hellerbrand, Claus; Bosserhoff, Anja-Katrin] Erlangen EMN, CCC, Erlangen, Germany	University of Erlangen Nuremberg; University of Munich; University of Regensburg; University of Regensburg; University of Erlangen Nuremberg	Bosserhoff, AK (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Ctr, Dept Biochem & Mol Med, Erlangen, Germany.; Bosserhoff, AK (corresponding author), Erlangen EMN, CCC, Erlangen, Germany.	Anja.Bosserhoff@fau.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020		German Cancer Aid; German research Foundation (DFG) [HE2458/18, BO1573]; German research Foundation (DFG, Research Training Group "RTG 1962/1"); Interdisciplinary Center for Clinical Research (IZKF) Erlangen [D24 (AB)]	German Cancer Aid(Deutsche Krebshilfe); German research Foundation (DFG)(German Research Foundation (DFG)); German research Foundation (DFG, Research Training Group "RTG 1962/1"); Interdisciplinary Center for Clinical Research (IZKF) Erlangen	This work was supported by the German Cancer Aid, the German research Foundation (DFG, HE2458/18; BO1573, Research Training Group "RTG 1962/1") and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (D24 (AB)).	Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Arndt S, 2015, GUT, V64, P973, DOI 10.1136/gutjnl-2014-306968; Arndt S, 2010, GASTROENTEROLOGY, V138, P372, DOI 10.1053/j.gastro.2009.09.048; BENYON RC, 1991, J IMMUNOL, V147, P2253; Biswas A, 2014, INT J DERMATOL, V53, P806, DOI 10.1111/j.1365-4632.2012.05745.x; Bosserhoff AK, 2011, EXP DERMATOL, V20, P435, DOI 10.1111/j.1600-0625.2011.01271.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003; Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7; Ch'ng S, 2006, MODERN PATHOL, V19, P149, DOI 10.1038/modpathol.3800474; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; Dyduch G, 2011, POL J PATHOL, V62, P139; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Forward NA, 2009, J IMMUNOL, V183, P3014, DOI 10.4049/jimmunol.0802509; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hellstrand K, 2002, SEMIN ONCOL, V29, P35, DOI 10.1053/sonc.2002.33081; Hsu MY, 2008, LAB INVEST, V88, P842, DOI 10.1038/labinvest.2008.55; Hu F, 2016, ONCOL REP, V35, P1823, DOI 10.3892/or.2015.4540; Jensen-Jarolim E, 2008, ALLERGY, V63, P1255, DOI 10.1111/j.1398-9995.2008.01768.x; Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899; Keller HR, 2017, ONCOTARGET, V8, P75675, DOI 10.18632/oncotarget.18523; Khazaie K, 2011, CANCER METAST REV, V30, P45, DOI 10.1007/s10555-011-9286-z; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mueller DW, 2011, INT J CANCER, V129, P1064, DOI 10.1002/ijc.25768; Na YR, 2009, CANCER SCI, V100, P2218, DOI 10.1111/j.1349-7006.2009.01301.x; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Ott CA, 2016, ONCOTARGET, V7, P62292, DOI 10.18632/oncotarget.11410; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Ribeiro J, 2014, J ETHNOPHARMACOL, V155, P1118, DOI 10.1016/j.jep.2014.06.041; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Schiffner S, 2014, EXP EYE RES, V127, P59, DOI 10.1016/j.exer.2014.07.009; Schiffner S, 2012, EXP DERMATOL, V21, P786, DOI 10.1111/j.1600-0625.2012.01560.x; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Siiskonen H, 2015, MELANOMA RES, V25, P479, DOI 10.1097/CMR.0000000000000192; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Voller D, 2013, BRIT J CANCER, V109, P3116, DOI 10.1038/bjc.2013.646; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; Weller CL, 2011, CLIN SCI, V120, P473, DOI 10.1042/CS20100459; Yang XD, 2011, NAT MED, V17, P87, DOI 10.1038/nm.2278	49	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					609	621		10.1038/s41388-018-0475-x	http://dx.doi.org/10.1038/s41388-018-0475-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171260				2022-12-28	WOS:000457300300001
J	Zhang, XP; Liu, L; Deng, XZ; Li, D; Cai, HD; Ma, YS; Jia, CY; Wu, B; Fan, YB; Lv, ZW				Zhang, Xiaoping; Liu, Lin; Deng, Xianzhao; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Wu, Bo; Fan, Youben; Lv, Zhongwei			MicroRNA 483-3p targets Pard3 to potentiate TGF-beta 1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; LUNG ADENOCARCINOMA; GENE-EXPRESSION; ONCOGENIC ROLE; TIAM1; CARCINOMA; METASTASIS; MIR-483-3P; PROGNOSIS; MIR-21	Anaplastic thyroid cancer (ATC) is associated with poor prognosis and is often untreatable. MicroRNA 483-3p (miR-483) and partitioning-defective 3 (Pard3), a member of the Pard family, have functions and regulatory mechanisms in ATC. The abnormal regulation of miR-483 may play an important role in tumorigenesis, and Par3 is known to regulate cell polarity, cell migration, and cell division. Tumor proliferation promoted by the regulation of miRNA expression can be regulated in thyroid cancer by upregulating transforming growth factor-beta 1 (TGF-beta 1), which is thought to interact with Pard3. When compared with adjacent non-tumor tissues, we found that miR-483 was upregulated and Pard3 was downregulated in 80 thyroid tumor samples. Disease-free survival was decreased when expression of miR-483 was upregulated and Pard3 expression was downregulated. Cell growth, migration, and invasion were induced by overexpression of miR-483. However, knockdown of miR-483 resulted in a loss of cell invasion and viability, both in vitro and in vivo. The expression of Pard3 was increased by the inhibition of miR-483, but TGF-beta 1-induced cell migration and invasion were decreased by miR-483 inhibition. A dual-luciferase reporter assay determined that Pard3 expression was downregulated when targeted with miR483. The epithelial-mesenchymal transition (EMT), as well as Tiam1-Rac signaling, was induced by TGF-beta 1, which was decreased by the overexpression of Pard3. Pard3 decreased the inhibition of EMT and Tiam-Rac1 signaling, which resulted from transfection of ATC cells with miR-483. Overall, the results showed that downregulation of Pard3 resulted in increased cell invasion and EMT in ATC, which was promoted by treatment with miR-483. These findings suggest novel therapeutic targets and treatment strategies for this disease.	[Zhang, Xiaoping; Liu, Lin; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Lv, Zhongwei] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China; [Zhang, Xiaoping; Liu, Lin; Li, Dan; Cai, Haidong; Ma, Yushui; Jia, Chengyou; Lv, Zhongwei] Shanghai Ctr Thyroid Dis, Shanghai 200072, Peoples R China; [Deng, Xianzhao; Wu, Bo; Fan, Youben] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gen Surg, Ctr Thyroid, Shanghai 200233, Peoples R China	Tongji University; Shanghai Jiao Tong University	Lv, ZW (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China.; Lv, ZW (corresponding author), Shanghai Ctr Thyroid Dis, Shanghai 200072, Peoples R China.; Wu, B; Fan, YB (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gen Surg, Ctr Thyroid, Shanghai 200233, Peoples R China.	wubo7421@sohu.com; fanyouben2006@163.com; heyixue163@163.com	Fu, Da/GXF-2656-2022; ma, yushui/HGC-6206-2022; Jia, Chengyou/AAV-1153-2021		National Natural Science Foundation of China [81572626, 81302332, 81371595, 81501505, 81670718]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China (81572626, 81302332, 81371595, 81501505, and 81670718).	Abue M, 2015, INT J ONCOL, V46, P539, DOI 10.3892/ijo.2014.2743; Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO;2-L; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Archibald A, 2015, ONCOGENE, V34, P3199, DOI 10.1038/onc.2014.242; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Cha BK, 2016, ONCOTARGET, V7, P57213, DOI 10.18632/oncotarget.11127; Chen AY, 2009, CANCER-AM CANCER SOC, V115, P3801, DOI 10.1002/cncr.24416; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cheng Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0290-6; Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069; Cui DM, 2016, INT J BIOCHEM CELL B, V73, P72, DOI 10.1016/j.biocel.2016.02.007; Dong L, 2011, J DENT RES, V90, P804, DOI 10.1177/0022034511401407; Ehtesham Naeim, 2016, Adv Biomed Res, V5, P187, DOI 10.4103/2277-9175.190996; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Guo XJ, 2016, CLIN EXP MED, V16, P357, DOI 10.1007/s10238-015-0365-2; Hardin H, 2014, AM J PATHOL, V184, P2342, DOI 10.1016/j.ajpath.2014.04.011; Hassan N, 2017, MOL CELL ENDOCRINOL, V456, P36, DOI 10.1016/j.mce.2016.12.011; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Huang YH, 2013, CANCER RES, V73, P2505, DOI 10.1158/0008-5472.CAN-12-2218; Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Li FF, 2014, CELL PHYSIOL BIOCHEM, V34, P2169, DOI 10.1159/000369660; Li HL, 2016, ONCOTARGET, V7, P66267, DOI [10.18632/oncotarget.11411, 10.18632/oncotarget.11728]; Liu L, 2005, WORLD J GASTROENTERO, V11, P705, DOI 10.3748/wjg.v11.i5.705; Liu L, 2018, EXP CELL RES, V362, P532, DOI 10.1016/j.yexcr.2017.12.019; Liu N, 2013, CANCER LETT, V329, P181, DOI 10.1016/j.canlet.2012.10.032; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Lupini L, 2016, ONCOTARGET, V7, P31361, DOI 10.18632/oncotarget.8913; Ma JJ, 2016, CELL BIOL INT, V40, P448, DOI 10.1002/cbin.10585; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Neff RL, 2008, ENDOCRIN METAB CLIN, V37, P525, DOI 10.1016/j.ecl.2008.02.003; Otsuki Y, 2003, J BIOL CHEM, V278, P5132, DOI 10.1074/jbc.M206733200; Pino MS, 2010, GASTROENTEROLOGY, V138, P1406, DOI 10.1053/j.gastro.2009.12.010; Puppo M, 2016, CELL REP, V16, P967, DOI 10.1016/j.celrep.2016.06.055; Qu XY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0219-x; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193; Stebel A, 2009, ONCOL REP, V21, P217, DOI 10.3892/or_00000211; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Woodcock SA, 2009, J PROTEOME RES, V8, P5629, DOI 10.1021/pr900716e; Xia X, 2015, ONCOTARGET, V6, P21046, DOI 10.18632/oncotarget.4124; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Z, 2003, CELL RES, V13, P343, DOI 10.1038/sj.cr.7290179; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Zhang J, 2014, TUMOR BIOL, V35, P379, DOI 10.1007/s13277-013-1053-z; Zhang K, 2016, ONCOGENE, V35, P1271, DOI 10.1038/onc.2015.184; Zhang KJ, 2016, AM J TRANSL RES, V8, P2196; Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91; Zhou QY, 2017, CELL SIGNAL, V38, P49, DOI 10.1016/j.cellsig.2017.06.016; Zhou Y, 2013, GENET TEST MOL BIOMA, V17, P470, DOI 10.1089/gtmb.2012.0518; Zhu JH, 2016, TRANSL ONCOL, V9, P592, DOI 10.1016/j.tranon.2016.08.003; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	58	31	36	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					699	715		10.1038/s41388-018-0447-1	http://dx.doi.org/10.1038/s41388-018-0447-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171257	Green Published, hybrid			2022-12-28	WOS:000457300300007
J	Li, QG; Wei, P; Wu, JT; Zhang, M; Li, GC; Li, YQ; Xu, Y; Li, XX; Xie, DC; Cai, SJ; Xie, KP; Li, DW				Li, Qingguo; Wei, Ping; Wu, Jitao; Zhang, Meng; Li, Guichao; Li, Yaqi; Xu, Ye; Li, Xinxiang; Xie, Dacheng; Cai, Sanjun; Xie, Keping; Li, Dawei			The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; INDICATES POOR-PROGNOSIS; HEPATOCELLULAR-CARCINOMA; COLON-CANCER; GLUCOSE-METABOLISM; TUMOR-METASTASIS; FOXM1 PROMOTES; EXPRESSION; GROWTH; PROGRESSION	Aberrant expression of Forkhead box (FOX) transcription factors plays vital roles in carcinogenesis. However, the function of the FOX family member FOXC1 in maintenance of colorectal cancer (CRC) malignancy is unknown. Herein, FOXC1 expression in CRC specimens in The Cancer Genome Atlas (TCGA) cohort was analyzed and validated using immunohistochemistry with a tissue microarray. The effect of FOXC1 expression on proliferation of and glycolysis in CRC cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. Our results showed that FOXC1 expression was higher in CRC specimens than in adjacent benign tissue specimens. Univariate survival analyses of the patients from whom the study specimens were obtained, and validated cohorts indicated that ectopic FOXC1 expression was significantly correlated with shortened survival. Silencing FOXC1 expression in CRC cells inhibited their proliferation and colony formation and decreased their glucose consumption and lactate production. In contrast, FOXC1 overexpression had the opposite effect. Furthermore, increased expression of FOXC1 downregulated that of a key glycolytic enzyme, fructose-1,6-bisphosphatase 1 (FBP1). Mechanistically, FOXC1 bound directly to the promoter regions of the FBP1 gene and negatively regulated its transcriptional activity. Collectively, aberrant FBP1 expression contributed to CRC tumorigenicity, and decreased FBP1 expression coupled with increased FOXC1 expression provided better prognostic information than did FOXC1 expression alone. Therefore, the FOXC1/FBP1 axis induces CRC cell proliferation, reprograms metabolism in CRCs, and constitutes potential prognostic predictors and therapeutic targets for CRC.	[Li, Qingguo; Li, Yaqi; Xu, Ye; Li, Xinxiang; Cai, Sanjun; Li, Dawei] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai, Peoples R China; [Li, Qingguo; Wei, Ping; Zhang, Meng; Li, Guichao; Li, Yaqi; Xu, Ye; Li, Xinxiang; Cai, Sanjun; Li, Dawei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Wei, Ping; Zhang, Meng] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Wei, Ping] Fudan Univ, Shanghai Canc Ctr, Inst Canc, Shanghai, Peoples R China; [Wu, Jitao] Yantai Yuhuangding Hosp, Dept Urol, Yantai, Peoples R China; [Li, Guichao] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Xie, Dacheng; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of Texas System; UTMD Anderson Cancer Center	Li, DW (corresponding author), Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.; Li, DW (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.	kepingxie@gmail.com; li_dawei@fudan.edu.cn	xu, ye/GQO-8972-2022		National Science Foundation of China [81472222, 81702353, 81772583, 81572254, 81372646, 81302097, 81672374]; Shanghai Rising-Star Program [17QA1400900]; Shanghai Municipal Natural Science Foundation [17ZR1406400]; Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai [2017YQ046]; National Key Basic Research Program of China [2014CBA02002]; National Cancer Institute, National Institutes of Health [R01-CA129956, R01-CA148954, R01CA152309, R01CA172233, R01CA195651]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; Shanghai Municipal Natural Science Foundation; Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai; National Key Basic Research Program of China(National Basic Research Program of China); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the National Science Foundation of China (81472222, 81702353, 81772583, 81572254, 81372646, 81302097, and 81672374) and Shanghai Rising-Star Program(17QA1400900), Shanghai Municipal Natural Science Foundation (17ZR1406400), Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ046), National Key Basic Research Program of China (2014CBA02002) and grants R01-CA129956, R01-CA148954, R01CA152309, R01CA172233, and R01CA195651 from the National Cancer Institute, National Institutes of Health.	Aravalli RN, 2015, GASTROENTEROLOGY, V149, P861, DOI 10.1053/j.gastro.2015.08.032; Cekaite L, 2016, ONCOTARGET, V7, P6476, DOI 10.18632/oncotarget.6390; Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dang CV, 2008, ERNST SCHERING FOUND, V4, P35, DOI 10.1007/2789_2008_088; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Guo K, 2017, CLIN CANCER RES, V23, P687, DOI 10.1158/1078-0432.CCR-16-1064; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirata H, 2016, CANCER RES, V76, P3265, DOI 10.1158/0008-5472.CAN-15-2601; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kaneda H, 2010, CANCER RES, V70, P2053, DOI 10.1158/0008-5472.CAN-09-2161; Khan AO, 2013, J AAPOS, V17, P105, DOI 10.1016/j.jaapos.2012.09.011; Kondaveeti Y, 2015, CANCER LETT, V364, P44, DOI 10.1016/j.canlet.2015.04.025; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li DW, 2013, CLIN CANCER RES, V19, P62, DOI 10.1158/1078-0432.CCR-12-1588; Li DW, 2011, CLIN CANCER RES, V17, P3558, DOI 10.1158/1078-0432.CCR-10-2729; Li QG, 2016, INT J CANCER, V139, P2502, DOI 10.1002/ijc.30388; Li QG, 2016, MOL CANCER RES, V14, P830, DOI 10.1158/1541-7786.MCR-16-0032; Li QG, 2015, AM J CANCER RES, V5, P2022; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nagel S, 2014, GENE CHROMOSOME CANC, V53, P917, DOI 10.1002/gcc.22204; Paylakhi SH, 2013, EXP EYE RES, V111, P112, DOI 10.1016/j.exer.2013.03.009; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Quan M, 2015, CANCER RES, V75, P4778, DOI 10.1158/0008-5472.CAN-14-1952; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Shi M, 2014, CLIN CANCER RES, V20, P4370, DOI 10.1158/1078-0432.CCR-14-0186; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Sun J, 2016, ONCOTARGET, V7, P43534, DOI 10.18632/oncotarget.9780; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Walenta S, 2000, CANCER RES, V60, P916; Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635; Wang L, 2013, TUMOR BIOL, V34, P853, DOI 10.1007/s13277-012-0617-7; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weber GF, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00257; Wechatekar K, 2005, CLIN RADIOL, V60, P1143, DOI 10.1016/j.crad.2005.05.018; Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277-012-0629-3; Weng WH, 2016, CLIN CANCER RES, V22, P4947, DOI 10.1158/1078-0432.CCR-16-0360; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang Y, 2013, CANCER BIOL THER, V14, P81, DOI 10.4161/cbt.22958; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396; Zhu Y, 2015, ONCOTARGET, V6, P21443, DOI 10.18632/oncotarget.4167	56	35	37	1	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					483	496		10.1038/s41388-018-0469-8	http://dx.doi.org/10.1038/s41388-018-0469-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30171256				2022-12-28	WOS:000456589800003
J	Dhar, SK; Bakthavatchalu, V; Dhar, B; Chen, J; Tadahide, I; Zhu, HN; Gao, TY; St Clair, DK				Dhar, Sanjit K.; Bakthavatchalu, Vasudevan; Dhar, Bithika; Chen, Jing; Tadahide, Izumi; Zhu, Haining; Gao, Tianyan; St Clair, Daret K.			DNA polymerase gamma (Pol gamma) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; KAPPA-B; SURVIVAL; IDENTIFICATION; TUMORIGENESIS; MECHANISMS; PROTEIN; DAMAGE; CELLS	Autophagy is a highly regulated evolutionarily conserved metabolic process induced by stress and energy deprivation. Here, we show that DNA polymerase gamma (Pol gamma) deficiency activates a selective prosurvival autophagic response via mitochondria-mediated reactive oxygen species (ROS) signaling and the mammalian target of rapamycin complex 2 (mTORC2) activities. In keratinocytes, Pol gamma deficiency causes metabolic adaptation that triggers cytosolic sensing of energy demand for survival. Knockdown of Pol gamma causes mitochondrial stress, decreases mitochondrial energy production, increases glycolysis, increases the expression of autophagy-associated genes, and enhances AKT phosphorylation and cell proliferation. Deficiency of Pol gamma preferentially activates mTORC2 formation to increase autophagy and cell proliferation, and knocking down Rictor abrogates these responses. Overexpression of Rictor, but not Raptor, reactivates autophagy in Pol gamma-deficient cells. Importantly, inhibition of ROS by a mitochondria-selective ROS scavenger abolishes autophagy and cell proliferation. These results identify Rictor as a critical link between mitochondrial stress, ROS, and autophagy. They represent a major shift in our understanding of the prosurvival role of the mTOR complexes and highlight mitochondria-mediated ROS as a prosurvival autophagy regulator during cancer development.	[Dhar, Sanjit K.; Dhar, Bithika; Tadahide, Izumi; St Clair, Daret K.] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [Bakthavatchalu, Vasudevan] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Chen, Jing; Zhu, Haining; Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; Massachusetts Institute of Technology (MIT); University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.	dstcl00@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694	National Institutes of Health [CA 49797, CA 73599]; NCI Cancer Center Support Grant [P30 CA177558]; NATIONAL CANCER INSTITUTE [R01CA214638, P30CA177558, R01CA073599, R01CA049797, R01CA133429] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported, in part, by National Institutes of Health Grants CA 49797 and CA 73599 to Daret K. St. Clair, and the NCI Cancer Center Support Grant P30 CA177558 to B. Mark Evers.	Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Aoki H, 2008, AUTOPHAGY, V4, P467, DOI 10.4161/auto.5668; Bakthavatchalu V, 2012, ONCOGENE, V31, P2129, DOI 10.1038/onc.2011.407; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Copeland William C, 2003, ScientificWorldJournal, V3, P34; Dangi A, 2016, J CELL PHYSIOL, V231, P94, DOI 10.1002/jcp.25055; Dhar SK, 2010, J BIOL CHEM, V285, P9835, DOI 10.1074/jbc.M109.060715; Dhar SK, 2014, ANTIOXID REDOX SIGN, V20, P1550, DOI 10.1089/ars.2012.4984; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Duan HY, 2015, EXP CELL RES, V335, P99, DOI 10.1016/j.yexcr.2015.05.003; Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kovalenko O.A., 2009, CURR PROTOC HUM GENE, V62; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Longley Matthew J, 2002, Methods Mol Biol, V197, P245, DOI 10.1385/1-59259-284-8:245; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; Maglio DHG, 2005, PHOTODERMATOL PHOTO, V21, P311, DOI 10.1111/j.1600-0781.2005.00185.x; Matsuda-Lennikov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079795; Matsuzawa Y, 2015, AUTOPHAGY, V11, P1052, DOI 10.1080/15548627.2015.1055439; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Petersson AS, 2001, J MASS SPECTROM, V36, P616, DOI 10.1002/jms.161; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Szczesny B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075201; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Wang P, 2013, MOL CELL BIOCHEM, V372, P161, DOI 10.1007/s11010-012-1457-x; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wu SY, 2010, PHOTOCHEM PHOTOBIOL, V86, P389, DOI 10.1111/j.1751-1097.2009.00682.x	46	11	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6225	6242		10.1038/s41388-018-0404-z	http://dx.doi.org/10.1038/s41388-018-0404-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30038268	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000451622100003
J	Lee, H; Kim, N; Yoo, YJ; Kim, H; Jeong, E; Choi, S; Moon, SU; Oh, SH; Mills, GB; Yoon, S; Kim, WY				Lee, Hani; Kim, Nayoung; Yoo, Young Ji; Kim, Hyejin; Jeong, Euna; Choi, SeokGyeong; Moon, Sung Un; Oh, Seung Hyun; Mills, Gordon B.; Yoon, Sukjoon; Kim, Woo-Young			beta-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer	ONCOGENE			English	Article							GROWTH-FACTOR-I; RAS SIGNALING PATHWAYS; ADVANCED SOLID TUMORS; COLORECTAL-CANCER; PLASMA-LEVELS; PHASE-I; TRANSCRIPTIONAL ACTIVITY; NUCLEAR-LOCALIZATION; BINDING PROTEIN-3; INSULIN-RECEPTORS	The availability of large-scale drug screening data on cell line panels provides a unique opportunity to identify predictive biomarkers for targeted drug efficacy. Analysis of diverse drug data on similar to 990 cancer cell lines revealed enhanced sensitivity of insulin-like growth factor 1 receptor/Insulin Receptor (IGF-1R/IR) tyrosine kinase inhibitors (TKIs) in colon cancer cells. Interestingly, beta-catenin/TCF(T cell factor)-responsive promoter activity exhibited a significant positive association with IGF-1R/IR TM response, while the mutational status of direct upstream genes, such as CTNNB1 and APC, was not significantly associated with the response. The beta-catenin/TCF activity high cell lines express components of IGF-1R/IR signaling more than the low cell lines explaining their enhanced sensitivity against IGF-1R/IR TKI. Reinforcing beta-catenin/TCF responsive promoter activity by introducing CTNNB1 gain-of-function mutations into IGF-1R/IR TM-resistant cells increased the expression and activity of IGF-1R/IR signaling components and also sensitized the cells to IGF-1R/IR TKIs in vitro and in vivo. Analysis of TCGA data revealed that the stronger beta-catenin/TCF responsive promoter activity was associated with higher IGF-1R and IGF2 transcription in human colon cancer specimens as well. Collectively, compared to the mutational status of upstream genes, beta-catenin/TCF responsive promoter activity has potential to be a stronger predictive positive biomarker for IGF-1R/IR TM responses in colon cancer cells. The present study highlights the potential of transcriptional activity as therapeutic biomarkers for targeted therapies, overcoming the limited ability of upstream genetic mutations to predict responses.	[Lee, Hani; Yoo, Young Ji; Kim, Hyejin; Choi, SeokGyeong; Kim, Woo-Young] Sookmyung Womens Univ, Res Ctr Cell Fate Control, Coll Pharm, Seoul 04310, South Korea; [Lee, Hani; Kim, Nayoung; Yoo, Young Ji; Kim, Hyejin; Jeong, Euna; Choi, SeokGyeong; Moon, Sung Un; Yoon, Sukjoon; Kim, Woo-Young] Sookmyung Womens Univ, Ctr Adv Bioinformat & Syst Med, Seoul 04310, South Korea; [Kim, Nayoung; Yoon, Sukjoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea; [Oh, Seung Hyun] Gachon Univ, Coll Pharm, Incheon 21936, South Korea; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Syst Biol, Houston, TX 77030 USA	Sookmyung Women's University; Sookmyung Women's University; Sookmyung Women's University; Gachon University; University of Texas System; UTMD Anderson Cancer Center	Kim, WY (corresponding author), Sookmyung Womens Univ, Res Ctr Cell Fate Control, Coll Pharm, Seoul 04310, South Korea.; Yoon, S; Kim, WY (corresponding author), Sookmyung Womens Univ, Ctr Adv Bioinformat & Syst Med, Seoul 04310, South Korea.; Yoon, S (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea.	yoonsj@sookmyung.ac.kr; wykim@sookmyung.ac.kr		Mills, Gordon/0000-0002-0144-9614	National Research Foundation of Korea [NRF-2018R1A2B6009313, NRF-2017R1A2B2007745, NRF-2016R1A5A1011974, NRF-2012M3A9B6055466, NRF-2015R1D1A1A01056594, NRF-2011-0030074]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea, [NRF-2018R1A2B6009313 to EJ], [NRF-2017R1A2B2007745, and NRF-2016R1A5A1011974 to SY] and [NRF-2012M3A9B6055466, NRF-2015R1D1A1A01056594, and NRF-2011-0030074 to W-YK].	Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; Beneit N, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0477-3; Bommer GT, 2010, J BIOL CHEM, V285, P1928, DOI 10.1074/jbc.M109.060319; Cai J, 2015, GENE DEV, V29, P1493, DOI 10.1101/gad.264515.115; Califano A, 2017, NAT REV CANCER, V17, P116, DOI 10.1038/nrc.2016.124; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Di Cosimo S, 2015, CLIN CANCER RES, V21, P49, DOI 10.1158/1078-0432.CCR-14-0940; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fassnacht M, 2015, LANCET ONCOL, V16, P426, DOI 10.1016/S1470-2045(15)70081-1; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Greshock J, 2010, CANCER RES, V70, P3677, DOI 10.1158/0008-5472.CAN-09-3788; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hlubek F, 2007, INT J CANCER, V121, P1941, DOI 10.1002/ijc.22916; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Kim N, 2012, INT J CANCER, V131, P2456, DOI 10.1002/ijc.27529; Kubo T, 2009, INT J CANCER, V124, P1778, DOI 10.1002/ijc.24150; Ma J, 1999, JNCI-J NATL CANCER I, V91, P2052, DOI 10.1093/jnci/91.23.2052; Ma J, 2000, GROWTH HORM IGF RES, V10, pS28, DOI 10.1016/S1096-6374(00)90013-3; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Najdi R, 2009, ONCOGENE, V28, P4133, DOI 10.1038/onc.2009.271; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollak M, 2008, BEST PRACT RES CL EN, V22, P625, DOI 10.1016/j.beem.2008.08.004; Pollak MN, 2007, AM J CLIN NUTR, V86, p820S, DOI 10.1093/ajcn/86.3.820S; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; Qu X, 2017, ONCOTARGET, V8, P29501, DOI 10.18632/oncotarget.15704; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sabbatini P, 2009, MOL CANCER THER, V8, P2811, DOI 10.1158/1535-7163.MCT-09-0423; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Sclafani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv258; Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057; Sparks AB, 1998, CANCER RES, V58, P1130; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203; Tap WD, 2012, J CLIN ONCOL, V30, P1849, DOI 10.1200/JCO.2011.37.2359; Tatematsu T, 2014, MOL CLIN ONCOL, V2, P725, DOI 10.3892/mco.2014.318; Tognon CE, 2012, EXPERT OPIN THER TAR, V16, P33, DOI 10.1517/14728222.2011.638626; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Wu YP, 2002, CANCER RES, V62, P1030; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhong H, 2017, ONCOGENE, V36, P797, DOI 10.1038/onc.2016.248	55	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5466	5475		10.1038/s41388-018-0362-5	http://dx.doi.org/10.1038/s41388-018-0362-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29895971				2022-12-28	WOS:000446312900007
J	Yu, M; Li, WJ; Wang, QQ; Wang, Y; Lu, F				Yu, Min; Li, Wenjing; Wang, Qianqian; Wang, Yan; Lu, Fei			Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; REV-ERB-BETA; ORPHAN NUCLEAR RECEPTORS; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT GLIOBLASTOMA; GENE-EXPRESSION; GROWTH-ARREST; CANCER-CELLS; CROSS-TALK; PHASE-II	Nuclear receptor NR1D2 is originally characterized as the repressor of genes involved in circadian rhythm. Recently, it is documented that NR1D2 is overexpressed in various cancers. However, the pathways and biological functions that NR1D2 involved in cancers remain poorly understood. Here, we reported that NR1D2 was abundant in human glioblastoma (GBM) tissue and cell lines but not primary human astrocytes. Silencing of NR1D2 changed the morphology of GBM cells, inhibited cell proliferation and motility, whereas had no effects on apoptosis. Importantly, based on RNA-seq and ChIP assay, we identified receptor tyrosine kinase AXL as a new transcriptional target of NR1D2 in GBM cells. AXL mediated partially the regulatory effects of NR1D2 on PI3K/AKT axis and promoted proliferation, migration, and invasion of GBM cells. Besides, NR1D2 knockdown remarkably impaired the maturation of focal adhesion and assembly of F-actin, along with downregulated p-FAK, and proteins involved in actin nucleation and polymerization (p-Rac1/Cdc42, WAVE and PFN2). Moreover, NR1D2 had more targets other than AXL to regulate epithelial-to-mesenchymal transition and cell motility in GBM cells. Altogether, our findings uncover a GBM-promoting role of NR1D2 and provide the rationale for targeting NR1D2 as a potential therapeutic approach.	[Yu, Min; Li, Wenjing; Wang, Qianqian; Lu, Fei] Peking Univ, Shenzhen Grad Sch, Key Lab Chem Genom, State Key Lab Chem Oncogen, Shenzhen 518055, Peoples R China; [Wang, Yan] Qingdao Univ, Qingdao Municipal Hosp, Dept Cardiol, Qingdao 266011, Peoples R China	Peking University; University Town of Shenzhen; Qingdao Municipal Hospital; Qingdao University	Lu, F (corresponding author), Peking Univ, Shenzhen Grad Sch, Key Lab Chem Genom, State Key Lab Chem Oncogen, Shenzhen 518055, Peoples R China.	lufei@pkusz.edu.cn		Wang, Qianqian/0000-0003-4919-1998; Li, Wenjing/0000-0001-9151-9219	Natural Science Foundation of Guangdong Province [2014A030313779]; Shenzhen basic research program [JCYJ20160527100529884, JCYJ20170818085657917]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen basic research program	This work was supported by grants from Natural Science Foundation of Guangdong Province (grant no. 2014A030313779), Shenzhen basic research program (grant no. JCYJ20160527100529884 and JCYJ20170818085657917). We thank Dr. Hui Zhang for the kind gift of U-373 MG cell line.	Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Axelrod H, 2014, ONCOTARGET, V5, P1, DOI 10.18632/oncotarget.2422; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chamberlain MC, 2017, J NEURO-ONCOL, V133, P561, DOI 10.1007/s11060-017-2466-0; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; De Mei C, 2015, ONCOGENE, V34, P2597, DOI 10.1038/onc.2014.203; Debruyne DN, 2016, ONCOGENE, V35, P3681, DOI 10.1038/onc.2015.434; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Gilbert MR, 2017, J NEURO-ONCOL, V131, P193, DOI 10.1007/s11060-016-2288-5; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Iser IC, 2017, MED RES REV, V37, P271, DOI 10.1002/med.21408; Kubelt C, 2015, INT J ONCOL, V46, P2515, DOI 10.3892/ijo.2015.2944; Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209; Li Stephen Yt, 2013, Spermatogenesis, V3, pe25385; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meng J, 2014, ONCOTARGET, V5, P4683, DOI 10.18632/oncotarget.2088; Ott M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047663; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Qi DD, 2016, CELL CYCLE, V15, P2009, DOI 10.1080/15384101.2016.1192729; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Ramakrishnan SN, 2009, BIOCHEM BIOPH RES CO, V388, P654, DOI 10.1016/j.bbrc.2009.08.045; Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200; Rankin EB, 2016, CANCERS, V8, DOI 10.3390/cancers8110103; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Siripala AD, 2007, CELL, V128, P1014, DOI 10.1016/j.cell.2007.02.021; Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun ZQ, 2016, J CELL BIOL, V215, P445, DOI 10.1083/jcb.201609037; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Weathers SP, 2016, J NEURO-ONCOL, V129, P487, DOI 10.1007/s11060-016-2195-9; Wick W, 2016, CLIN CANCER RES, V22, P4797, DOI 10.1158/1078-0432.CCR-15-3153; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Wong GS, 2013, BRIT J CANCER, V108, P755, DOI 10.1038/bjc.2012.592; Yan YR, 2014, NEUROPATHOLOGY, V34, P128, DOI 10.1111/neup.12062; Yin F, 2014, MOL CELL BIOL, V34, P158, DOI 10.1128/MCB.00631-13; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	47	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4838	4853		10.1038/s41388-018-0319-8	http://dx.doi.org/10.1038/s41388-018-0319-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773903				2022-12-28	WOS:000443146000006
J	Zimmerli, D; Cecconi, V; Valenta, T; Hausmann, G; Cantu, C; Restivo, G; Hafner, J; Basler, K; van den Broek, M				Zimmerli, Dario; Cecconi, Virginia; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Restivo, Gaetana; Hafner, Jurg; Basler, Konrad; van den Broek, Maries			WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma	ONCOGENE			English	Article							STEM-CELLS; TUMOR MICROENVIRONMENT; DRUG-RESISTANCE; SKIN TUMORS; TGF-BETA; CANCER; INHIBITION; PORCUPINE; TUMORIGENESIS; INVASION	Human papillomavirus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the most common cancer in immunosuppressed patients. Despite indications suggesting that HPV promotes genomic instability during cSCC development, the molecular pathways underpinning HPV-driven cSCC development remain unknown. We compared the transcriptome of HPV-driven mouse cSCC with normal skin and observed higher amounts of transcripts for Porcupine and WNT ligands in cSCC, suggesting a role for WNT signaling in cSCC progression. We confirmed increased Porcupine expression in human cSCC samples. Blocking the secretion of WNT ligands by the Porcupine inhibitor LGK974 significantly diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to mice with established cSCC resulted in differentiation of cancer cells and significant reduction of the cancer stem cell compartment. Thus, WNT/beta-catenin signaling is essential for HPV-driven cSCC initiation and progression as well as for maintaining the cancer stem cell niche. Interference with WNT secretion may thus represent a promising approach for therapeutic intervention.	[Zimmerli, Dario; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Basler, Konrad] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland; [Cecconi, Virginia; van den Broek, Maries] Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland; [Restivo, Gaetana; Hafner, Jurg] Univ Hosp Zurich, Dept Dermatol, CH-8091 Zurich, Switzerland; [Cantu, Claudio] Linkoping Univ, WCMM, Fac Hlth Sci, Dept Clin & Expt Med IKE, S-58185 Linkoping, Sweden	University of Zurich; University of Zurich; University of Zurich; University Zurich Hospital; Linkoping University	Basler, K (corresponding author), Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland.; van den Broek, M (corresponding author), Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland.	kb@imls.uzh.ch; vandenbroek@immunology.uzh.ch	van den Broek, Maries/L-6532-2019; Cantù, Claudio/AAB-7771-2019; van den Broek, Maries/G-4128-2016	Cantù, Claudio/0000-0003-1547-5415; Valenta, Tomas/0000-0002-3043-1835; van den Broek, Maries/0000-0002-9489-3692; Basler, Konrad/0000-0003-3534-1529; Restivo, Gaetana/0000-0003-4364-2364; , Dario/0000-0002-4920-0244	Swiss National Science Foundation (SNF); Swiss Cancer League; Promedica Foundation Zurich; University of Zurich Research Priority Program "Translational Cancer Research"; Kanton of Zurich	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Swiss Cancer League; Promedica Foundation Zurich; University of Zurich Research Priority Program "Translational Cancer Research"; Kanton of Zurich	We thank Karina Silina and Michal Beffinger (Institute of Experimental Immunology, UZH) for help with some experiments, Lukas Sommer (Institute of Anatomy, UZH) for reagents and discussions, Sabine Werner (Institute for Molecular Health Sciences, ETHZ) for discussions and sharing reagents, Herbert Pfister (Institute of Virology, University of Koln), for mouse strains (Krt14-HPV8-E6), Alexandra Franz for help with R and Martin Moser and Eliane Escher (Institute of Molecular Life Sciences, UZH) for technical support. We thank the personnel of the Laboratory Animal Service Center from the University of Zurich for expert animal care. This work was supported by the Swiss National Science Foundation (SNF) (K.B., M.v.d.B), Swiss Cancer League (K.B.), the Promedica Foundation Zurich (M.v.d.B.), University of Zurich Research Priority Program "Translational Cancer Research" and the Kanton of Zurich (K.B., M.v.d.B.). V.C and T.V. are fellows in the URPP Translational Cancer Research Program.	Accardi R, 2014, PRESSE MED, V43, pE435, DOI 10.1016/j.lpm.2014.08.008; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Chockalingam R, 2015, J CLIN MED, V4, P1229, DOI 10.3390/jcm4061229; Connolly K, 2014, CANCER TREAT REV, V40, P205, DOI 10.1016/j.ctrv.2013.08.005; Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Herr P, 2012, DEV BIOL, V361, P392, DOI 10.1016/j.ydbio.2011.11.003; Hofbauer GFL, 2010, EXP DERMATOL, V19, P473, DOI 10.1111/j.1600-0625.2010.01086.x; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nichols AJ, 2017, JAMA DERMATOL, V153, P571, DOI 10.1001/jamadermatol.2016.5703; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Pourreyron C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031827; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shiokawa D, 2017, CELL REP, V19, P981, DOI 10.1016/j.celrep.2017.04.017; Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Valenta T, 2016, CELL REP, V15, P911, DOI 10.1016/j.celrep.2016.03.088; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yanofsky Valerie R, 2011, J Skin Cancer, V2011, P210813, DOI 10.1155/2011/210813; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zimmerli D, 2017, BRIT J PHARMACOL, V174, P4600, DOI 10.1111/bph.13864; Zito G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4543	41	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3753	3762		10.1038/s41388-018-0244-x	http://dx.doi.org/10.1038/s41388-018-0244-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29662191	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000437975200011
J	Cao, L; Wang, SY; Zhang, YQ; Wong, KC; Nakatsu, G; Wang, XH; Wong, S; Ji, JF; Yu, J				Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Wong, Ka-Chun; Nakatsu, Geicho; Wang, Xiaohong; Wong, Sunny; Ji, Jiafu; Yu, Jun			Zinc-finger protein 471 suppresses gastric cancer through transcriptionally repressing downstream oncogenic PLS3 and TFAP2A	ONCOGENE			English	Article							FUNCTIONAL DIVERSITY; METHYLATION; EXPRESSION; PROGNOSIS; PROMOTER; SURVIVAL; HYPERMETHYLATION; PROGRESSION; PREDICTION; CARCINOMA	Zinc-finger protein 471 (ZNF471) was preferentially methylated in gastric cancer using promoter methylation array. The role of ZNF471 in human cancer is unclear. Here we elucidated the functional significance, molecular mechanisms and clinical impact of ZNF471 in gastric cancer. ZNF471 mRNA was silenced in 15 out of 16 gastric cancer cell lines due to promoter hypermethylation. Significantly higher ZNF471 promoter methylation was also observed in primary gastric cancers compared to their adjacent normal tissues (P < 0.001). ZNF471 promoter CpG-site hypermethylation correlated with poor survival of gastric cancer patients (n = 120, P = 0.001). Ectopic expression of ZNF471 in gastric cancer cell lines (AGS, BGC823, and MKN74) significantly suppressed cell proliferation, migration, and invasion, while it induced apoptosis in vitro and inhibited xenograft tumorigenesis in nude mice. Transcription factor AP-2 Alpha (TFAP2A) and plastin3 (PLS3) were two crucial downstream targets of ZNF471 demonstrated by bioinformatics modeling and ChIP-PCR assays. ZNF471 directly bound to the promoter of TFAP2A and PLS3 and transcriptionally inhibited their expression. TFAP2A and PLS3 showed oncogenic functions in gastric cancer cell lines. Moreover, ZNF471 recruited KAP1 to the promoter of the target genes, thereby inducing H3K9me3 enrichment for transcriptional repression and inhibition of oncogenic TFAP2A and PLS3. In conclusion, ZNF471 acts as a tumor suppressor in gastric cancer by transcriptionally inhibiting downstream targets TFAP2A and PLS3. KAP1 is a co-repressor of ZNF471 at the promoter of the target genes. The promoter CpG-site methylation is an independent prognostic factor for overall survival of gastric cancer patients.	[Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Nakatsu, Geicho; Wong, Sunny; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Nakatsu, Geicho; Wong, Sunny; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Wong, Ka-Chun] City Univ Hong Kong Kowloon Tong, Dept Comp Sci, Kowloon Tong, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Beijing Canc Hosp & Inst, Dept Gastrointestinal Surg, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Wong, Ka-Chun/L-7160-2019; Wong, Sunny H/N-3754-2015; Nakatsu, Geicho/AAU-3089-2021; Yu, Jun/D-8569-2015; Zhang, Yanquan/D-5615-2017	Wong, Ka-Chun/0000-0001-6062-733X; Wong, Sunny H/0000-0002-3354-9310; Yu, Jun/0000-0001-5008-2153; Zhang, Yanquan/0000-0003-3527-9972	RGC-GRF Hong Kong [766613, 14106415, 14111216]; HMRF Hong Kong [1195728]; 135 program project China [2016YFC1303200]; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; 135 program project China; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by RGC-GRF Hong Kong (766613, 14106415, 14111216), HMRF Hong Kong (1195728), 135 program project China (2016YFC1303200), Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute and CUHK direct grant (J. Yu).	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bennett KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006931; Berlato C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2838; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bhat S, 2017, VIRCHOWS ARCH, V470, P445, DOI 10.1007/s00428-017-2094-2; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Claus R, 2012, J CLIN ONCOL, V30, P2483, DOI 10.1200/JCO.2011.39.3090; Deng JY, 2014, ONCOTARGET, V5, P7420, DOI 10.18632/oncotarget.1973; Deng JY, 2014, AM J CANCER RES, V4, P518; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869; Huang L, 2015, AM J TRANSL RES, V7, P2141; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Jen JY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0269-9; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; Mitchell SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-54; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Najafabadi HS, 2015, NAT BIOTECHNOL, V33, P555, DOI 10.1038/nbt.3128; Peille AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080741; Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002; Schmitges FW, 2016, GENOME RES, V26, P1742, DOI 10.1101/gr.209643.116; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shi DB, 2014, CANCER PREV RES, V7, P266, DOI 10.1158/1940-6207.CAPR-13-0271; Sigova AA, 2015, SCIENCE, V350, P978, DOI 10.1126/science.aad3346; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ueda M, 2014, ANN SURG ONCOL, V21, P3680; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang N, 2016, ARCH MED RES, V47, P285, DOI 10.1016/j.arcmed.2016.07.011; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	39	26	27	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3601	3616		10.1038/s41388-018-0220-5	http://dx.doi.org/10.1038/s41388-018-0220-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29610526	hybrid, Green Published			2022-12-28	WOS:000436412500010
J	Huang, X; Wang, XN; Yuan, XD; Wu, WY; Lobie, PE; Wu, ZS				Huang, Xing; Wang, Xiao-nan; Yuan, Xiao-dong; Wu, Wen-yong; Lobie, Peter E.; Wu, Zhengsheng			XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation	ONCOGENE			English	Article							APOPTOSIS PROTEINS; SIGNALING ADAPTER; AUTOPHAGY; CANCER; INHIBITOR; TUMORIGENESIS; BECLIN-1	X-linked inhibitor of apoptosis protein (XIAP) possesses a critical role in promotion of cell survival and maintenance of cellular homeostasis. In cancer, elevated XIAP expression has been associated with malignancy, poor prognosis, and treatment resistance. However, the underlying mechanisms of these effects remain unclear. XIAP has previously been proposed to promote tumor growth through suppression of autophagy. In this study, we examined the expression of XIAP and p62, two critical mediators of autophagy, in breast and colon cancer. We observed a negative correlation between XIAP and p62 expression in normal and cancer tissues of breast and colon, and that the ratio of XIAP and p62 expression determines the cancer phenotype. In vitro, we observed that XIAP interacted with p62 and also that XIAP depletion resulted in increased expression of p62. XIAP functioned as an ubiquitination E3 ligase towards p62 and suppressed p62 expression through ubiquitin-proteasomal degradation. Furthermore, XIAP enhanced cancer cell proliferation, viability, and colony formation in vitro via suppression of p62. In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo. Herein, we have therefore delineated a novel mechanism by which XIAP contributes to development and progression of breast and colon carcinoma.	[Huang, Xing] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Xiao-nan; Yuan, Xiao-dong; Wu, Zhengsheng] Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China; [Huang, Xing] Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China; [Wu, Wen-yong] Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China; [Lobie, Peter E.] Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen, Guangdong, Peoples R China	Zhejiang University; Anhui Medical University; Southeast University - China; Anhui Medical University; Tsinghua University	Huang, X (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China.; Wu, ZS (corresponding author), Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China.; Huang, X (corresponding author), Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China.	dr.huangxing@foxmail.com; woozson@yahoo.com	黄, 星/AAB-2241-2019	黄, 星/0000-0002-8886-2777; Wu, Zhengsheng/0000-0002-6616-2745	National Natural Science Foundation of China [81502975, 81472493, 81572305]; China Postdoctoral Science Foundation [2016T90413, 2015M581693]; Jiangsu Planned Projects for Postdoctoral Research Funds [1501002A]; Fundamental Research Funds for the Central Universities [2242016R20027, 2242016K41045]; Anhui provincial academic and technical leader reserve candidate [2016H074]; Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui [gxyqZD2016046]; Shenzhen Development and Reform Commission Subject Construction Project [[2017]1434]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Planned Projects for Postdoctoral Research Funds; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Anhui provincial academic and technical leader reserve candidate; Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui; Shenzhen Development and Reform Commission Subject Construction Project	We deeply thank Dr. Bert Vogelstein (Johns Hopkins University) for XIAP<SUP>-/-</SUP> HCT116 and XIAP<SUP>-/-</SUP> DLD1 cell lines, Dr. Noboru Mizushima (The University of Tokyo) for Atg5<SUP>-/-</SUP> MEF cell lines, and Dr. Tao Zhu (University of Science & Technology of China) for breast cell lines. Especially, the author Xing Huang would like to express deepest thanks to Dr. Mian Wu (University of Science & Technology of China) for the technological training and ideological inspiration in his lab. This work was supported by grants from National Natural Science Foundation of China (81502975, 81472493, and 81572305), and China Postdoctoral Science Foundation (2016T90413 and 2015M581693). The research was funded in part by Jiangsu Planned Projects for Postdoctoral Research Funds (1501002A), Fundamental Research Funds for the Central Universities (2242016R20027 and 2242016K41045), Anhui provincial academic and technical leader reserve candidate (#2016H074), Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui (#gxyqZD2016046) and the Shenzhen Development and Reform Commission Subject Construction Project ([2017]1434).	Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014; Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133; Hung TH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012202; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474; Kong DK, 2010, MOL BIOL CELL, V21, P1335, DOI 10.1091/mbc.E09-09-0818; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Lee HM, 2011, J IMMUNOL, V186, P1248, DOI 10.4049/jimmunol.1001954; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Merlo P, 2013, EMBO J, V32, P2187, DOI 10.1038/emboj.2013.152; Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Pandey V, 2010, ENDOCRINOLOGY, V151, P909, DOI 10.1210/en.2009-0979; Puissant A, 2012, AM J CANCER RES, V2, P397; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031; Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Wu WY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0108-3	32	21	22	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1448	1460		10.1038/s41388-018-0513-8	http://dx.doi.org/10.1038/s41388-018-0513-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30275562				2022-12-28	WOS:000459945800006
J	Traboulsi, T; El Ezzy, M; Dumeaux, V; Audemard, E; Mader, S				Traboulsi, Tatiana; El Ezzy, Mohamed; Dumeaux, Vanessa; Audemard, Eric; Mader, Sylvie			Role of SUMOylation in differential ER alpha transcriptional repression by tamoxifen and fulvestrant in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SUMO MODIFICATION; POSTMENOPAUSAL WOMEN; HISTONE SUMOYLATION; TISSUE-SPECIFICITY; ANDROGEN RECEPTOR; ENDOCRINE THERAPY; PURE ANTIESTROGEN; ESR1 MUTATIONS; NUCLEAR	Antiestrogens (AEs) are widely used for treatment of estrogen receptor alpha (ER alpha)-positive breast cancer, but display variable degrees of partial agonism in estrogen target tissues and breast cancer (BC) cells. The fact that BC cells resistant to selective ER modulators (SERMs) like tamoxifen (Tam) can still be sensitive to pure AEs, also called selective ER downregulators, suggests different mechanisms of action, some of which may contribute to the more complete suppression of estrogen target genes by pure AEs. We report herein that pure AEs such as fulvestrant induce transient binding of ER alpha to DNA, followed by rapid release after 30-40 min without loss of nuclear localization. Loss of DNA binding preceded receptor degradation and was not prevented by proteasome inhibition. Chromatin was less accessible in the presence of fulvestrant than with estradiol or Tam as early as 20 min following treatment, suggesting that chromatin remodeling by pure AEs at ER alpha target regions prevents transcription in spite of receptor binding. SUMO2/3 marks were detected on chromatin at the peak of ER alpha binding in cells treated with pure AEs, but not SERMs. Furthermore, decreasing SUMOylation by overexpressing the deSUMOylase SENP1 significantly delayed receptor release from DNA and de-repressed expression of estrogen target genes in the presence of fulvestrant, both in ER alpha-expressing MCF-7 cells and in transiently transfected ER-negative SK-BR-3 cells. Finally, mutation V534E, identified in a breast metastasis resistant to hormonal therapies, prevented ER alpha modification and resulted in increased transcriptional activity of estrogen target genes in the presence of fulvestrant in SK-BR-3 cells. Together, our results establish a role for SUMOylation in achieving a more complete transcriptional shut-off of estrogen target genes by pure AEs vs. SERMs in BC cells.	[Traboulsi, Tatiana; El Ezzy, Mohamed; Dumeaux, Vanessa; Audemard, Eric; Mader, Sylvie] Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Traboulsi, Tatiana; Mader, Sylvie] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada; [Dumeaux, Vanessa] Concordia Univ, PERFORM Ctr, Montreal, PQ H4B 1R6, Canada	Universite de Montreal; Universite de Montreal; Concordia University - Canada	Mader, S (corresponding author), Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada.; Mader, S (corresponding author), Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada.	sylvie.mader@umontreal.ca		Audemard, Eric/0000-0002-1661-896X; Traboulsi, Tatiana/0000-0001-9769-0340	Canadian Institutes of Health Research [125863]; Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal; Fonds de recherche Quebec-sante (FRQS) scholarship; Universite de Montreal	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal; Fonds de recherche Quebec-sante (FRQS) scholarship; Universite de Montreal	This work has been funded by the Canadian Institutes of Health Research (grant 125863 to SM) and from the Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal (to SM). TT was the recipient of a Fonds de recherche Quebec-sante (FRQS) scholarship and both TT and MEE were recipients of several scholarships from the Universite de Montreal.	Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305; Angus L, 2017, CANCER TREAT REV, V52, P33, DOI 10.1016/j.ctrv.2016.11.001; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Flach KD, 2016, J ENDOCRINOL, V229, pR43, DOI 10.1530/JOE-16-0003; Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787; Garcia-Dominguez M, 2009, BBA-GENE REGUL MECH, V1789, P451, DOI 10.1016/j.bbagrm.2009.07.001; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gushima M, 2010, MOL CELL ENDOCRINOL, V319, P14, DOI 10.1016/j.mce.2010.01.006; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Heideker J, 2009, DNA REPAIR, V8, P517, DOI 10.1016/j.dnarep.2009.01.010; Hilmi K, 2012, MOL CELL BIOL, V32, P3823, DOI 10.1128/MCB.00290-12; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; HU XF, 1993, INT J CANCER, V55, P873, DOI 10.1002/ijc.2910550529; Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Lemieux S, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx338; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lupien M, 2007, MOL ENDOCRINOL, V21, P797, DOI 10.1210/me.2006-0074; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Maison C, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1225546; MARTIN L, 1978, J ENDOCRINOL, V78, P125, DOI 10.1677/joe.0.0780125; Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690; McDonnell DP, 2015, J MED CHEM, V58, P4883, DOI 10.1021/acs.jmedchem.5b00760; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Neyret-Kahn H, 2013, GENOME RES, V23, P1563, DOI 10.1101/gr.154872.113; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; Paakinaho V, 2014, NUCLEIC ACIDS RES, V42, P1575, DOI 10.1093/nar/gkt1033; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Pourcet B, 2010, J BIOL CHEM, V285, P5983, DOI 10.1074/jbc.M109.078311; Rahman S, 2017, NUCLEIC ACIDS RES, V45, P3017, DOI 10.1093/nar/gkw1220; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shih HM, 2007, BIOCHEM SOC T, V35, P1397, DOI 10.1042/BST0351397; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shin JA, 2005, MOL CELL, V19, P817, DOI 10.1016/j.molcel.2005.08.021; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stielow B, 2008, EMBO REP, V9, P899, DOI 10.1038/embor.2008.127; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Tiefenbach J, 2006, MOL BIOL CELL, V17, P1643, DOI 10.1091/mbc.E05-07-0610; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Traboulsi T, 2017, J MOL ENDOCRINOL, V58, pR15, DOI 10.1530/JME-16-0024; Uchimura Y, 2006, J BIOL CHEM, V281, P23180, DOI 10.1074/jbc.M602280200; WAKELING AE, 1991, CANCER RES, V51, P3867; WARD RL, 1993, BONE MINER, V22, P87, DOI 10.1016/S0169-6009(08)80220-6; Wardell SE, 2012, MOL ENDOCRINOL, V26, P1235, DOI 10.1210/me.2012-1031; Wardell SE, 2011, BIOCHEM PHARMACOL, V82, P122, DOI 10.1016/j.bcp.2011.03.031; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200	67	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1019	1037		10.1038/s41388-018-0468-9	http://dx.doi.org/10.1038/s41388-018-0468-9			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30190545	Green Published, hybrid			2022-12-28	WOS:000458624900007
J	Hu, YL; Jin, R; Gao, M; Xu, H; Zou, SX; Li, XG; Xing, C; Wang, QY; Wang, HL; Feng, JN; Hu, MR; Song, L				Hu, Yongliang; Jin, Rui; Gao, Ming; Xu, Huan; Zou, Shuxian; Li, Xiaoguang; Xing, Chen; Wang, Qiyu; Wang, Hongli; Feng, Jiannan; Hu, Meiru; Song, Lun			Transcriptional repression of IKK beta by p53 in arsenite-induced GADD45 alpha accumulation and apoptosis	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR; WILD-TYPE; GENE; ACTIVATION; ALPHA; CELLS; UBIQUITINATION; STABILIZATION; MECHANISMS	Our previous studies revealed that GADD45 alpha is a liable protein, which undergoes MDM2-dependent constitutive ubiquitination and degradation in resting HepG2 hepatoma cells. Arsenite exposure induces ribosomal stress responses mediated by the ribosomal protein S7, which can block MDM2 activity and result in GADD45a accumulation and cell apoptosis. In the present study, we found that one of the catalytic subunits of I.B kinase (IKK), IKK beta, exerted a novel IKK alpha -and NF-kappa B-independent function in stabilizing MDM2 and therefore contributed to ubiquitination-dependent degradation of GADD45 alpha in resting HepG2 cells. Arsenite stimulation induced transactivation of p53, which formed a complex with its downstream target, Ets-1, and then synergistically repressed IKK beta transcription, reduced MDM2 stability, and ultimately removed the inhibitory effect of MDM2 on GADD45 alpha induction. In addition, DAPK1 functioned as an upstream protein kinase triggering p53/Ets-1-dependent IKK beta and MDM2 reduction and GADD45 alpha accumulation, thus promoting apoptosis in HepG2 cells. Subsequent studies further revealed that the activation of the DAPK1/p53/Ets-1/IKK beta/MDM2/GADD45 alpha cascade was a common signaling event in mediating apoptosis of diverse cancer cells induced by arsenite and other tumor therapeutic agents. Therefore, we conclude that data in the current study have revealed a novel role for IKK beta in negatively regulating GADD45 alpha protein stability and the contribution of p53-dependent IKK beta reduction to mediating cancer cell apoptosis.	[Hu, Yongliang; Gao, Ming; Xu, Huan; Zou, Shuxian; Li, Xiaoguang; Xing, Chen; Wang, Qiyu; Wang, Hongli; Feng, Jiannan; Hu, Meiru; Song, Lun] Beijing Inst Brain Sci, Dept Neuroimmunol, 27 Taiping Rd, Beijing 100850, Peoples R China; [Jin, Rui] Beijing Inst Biotechnol, Dept Tumor Biol, 27 Taiping Rd, Beijing 100850, Peoples R China; [Gao, Ming] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, 18 Shuangqing Rd, Beijing 100085, Peoples R China; [Zou, Shuxian; Song, Lun] Guangxi Med Univ, 22 Shuangyong Rd, Nanning 530021, Peoples R China; [Song, Lun] Anhui Med Univ, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China; [Hu, Yongliang] 309 Hosp PLA, Dept Dermatol, 17 Heishanhu St, Beijing 100091, Peoples R China; [Li, Xiaoguang] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dongan Rd, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Guangxi Medical University; Anhui Medical University; Fudan University	Song, L (corresponding author), Beijing Inst Brain Sci, Dept Neuroimmunol, 27 Taiping Rd, Beijing 100850, Peoples R China.; Song, L (corresponding author), Guangxi Med Univ, 22 Shuangyong Rd, Nanning 530021, Peoples R China.; Song, L (corresponding author), Anhui Med Univ, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.	lunsong0752@163.com	邢, 陈/GWR-2940-2022	邢, 陈/0000-0003-2784-840X	National Natural Science Foundation of China [31570758, 91743115, 31270797]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr. Guojiang Chen to provide the A549 cells. We thank Dr. Ailing Li and Weihua Li to provide the Hep3B cells. This project is supported by the National Natural Science Foundation of China (No. 31570758, 91743115, 31270797) to Dr. Lun Song.	Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Dong W, 2012, NUCLEIC ACIDS RES, V40, P2940, DOI 10.1093/nar/gkr1216; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Gao M, 2013, NUCLEIC ACIDS RES, V41, P5210, DOI 10.1093/nar/gkt223; Gao M, 2010, J CELL BIOCHEM, V109, P1264, DOI 10.1002/jcb.22509; Gao M, 2009, CURR PROTEIN PEPT SC, V10, P388, DOI 10.2174/138920309788922216; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Ho J, 2013, CELL DEATH DIFFER, V10, P403; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang WC, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-3; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Li Y, 2011, MOL CELL BIOCHEM, V358, P61, DOI 10.1007/s11010-011-0921-3; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331; Moskalev AA, 2012, AGEING RES REV, V11, P51, DOI 10.1016/j.arr.2011.09.003; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Song L, 2008, EXP CELL RES, V314, P2187, DOI 10.1016/j.yexcr.2008.04.002; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Song L, 2010, BBA-MOL CELL RES, V1803, P323, DOI 10.1016/j.bbamcr.2010.01.006; St Clair S, 2004, MOL CELL, V16, P725; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004; Tamura RE, 2012, CURR MOL MED, V12, P634; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Xu XD, 2016, AUTOPHAGY, V12, P1832, DOI 10.1080/15548627.2016.1204496; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200	38	7	7	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					731	746		10.1038/s41388-018-0478-7	http://dx.doi.org/10.1038/s41388-018-0478-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177839	Green Published, hybrid			2022-12-28	WOS:000457300300009
J	Guha, P; Gardell, J; Darpolor, J; Cunetta, M; Lima, M; Miller, G; Espat, NJ; Junghans, RP; Katz, SC				Guha, Prajna; Gardell, Jillian; Darpolor, Josephine; Cunetta, Marissa; Lima, Matthew; Miller, George; Espat, N. Joseph; Junghans, Richard P.; Katz, Steven C.			STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; T-CELLS; IMMUNE-RESPONSE; IN-VIVO; GM-CSF; CANCER; FAS; PROMOTES; INFLAMMATION	Immunosuppressive myeloid-derived suppressor cells (MDSC) subvert antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T). Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC) proliferation and blockade of this axis rescued antitumor immunity. We extended these findings in our murine liver metastasis (LM) model, by treating tumor-bearing mice with STAT3 inhibitors (STATTIC or BBI608) to further our understanding of how STAT3 drives L-MDSC suppressive function. STAT3 inhibition caused significant reduction of tumor burden as well as L-MDSC frequencies due to decrease in pSTAT3 levels. L-MDSC isolated from STATTIC or BBI608-treated mice had significantly reduced suppressive function. STAT3 inhibition of L-MDSC was associated with enhanced antitumor activity of CAR-T. Further investigation demonstrated activation of apoptotic signaling pathways in L-MDSC following STAT3 inhibition as evidenced by an upregulation of the pro-apoptotic proteins Bax, cleaved caspase-3, and downregulation of the anti-apoptotic protein Bcl-2. Accordingly, there was also a decrease of pro-survival markers, pErk and pAkt, and an increase in pro-death marker, Fas, with activation of downstream JNK and p38 MAPK. These findings represent a previously unrecognized link between STAT3 inhibition and Fas-induced apoptosis of MDSCs. Our findings suggest that inhibiting STAT3 has potential clinical application for enhancing the efficacy of CAR-T cells in LM through modulation of L-MDSC.	[Guha, Prajna; Gardell, Jillian; Darpolor, Josephine; Cunetta, Marissa; Lima, Matthew; Espat, N. Joseph; Junghans, Richard P.; Katz, Steven C.] Roger Williams Med Ctr, Dept Surg, Providence, RI 02908 USA; [Miller, George] NYU, Sch Med, New York, NY USA; [Espat, N. Joseph; Katz, Steven C.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA	Roger Williams Medical Center; New York University; Boston University	Katz, SC (corresponding author), Roger Williams Med Ctr, Dept Surg, Providence, RI 02908 USA.; Katz, SC (corresponding author), Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA.	skatz@chartercare.org			National Institutes of Health [1K08CA160662-01A1]; NATIONAL CANCER INSTITUTE [K08CA160662] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Sorrento Therapeutics, Inc. for generously preparing the CEA-Fc for anti-CEA CAR detection and Prometheus, Inc. for providing Proleukin (IL2). We also thank Dr. John Morgan and Roger Williams Medical Center Core Facility for providing us with the flow cytometry core facility. Support for this work was provided by the National Institutes of Health (1K08CA160662-01A1).	Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6; Cahill MA, 1996, ONCOGENE, V13, P2087; Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Connolly MK, 2010, J LEUKOCYTE BIOL, V87, P713, DOI 10.1189/jlb.0909607; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gotthardt D, 2014, BLOOD, V124, P2370, DOI 10.1182/blood-2014-03-564450; Guha P, 2017, CANCER GENE THER, V24, P114, DOI 10.1038/cgt.2016.54; Guha P, 2017, J LEUKOCYTE BIOL, V102, P201, DOI 10.1189/jlb.5HI0716-322RR; Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471-4906(02)02260-3; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hu XL, 2013, J BIOL CHEM, V288, P19103, DOI 10.1074/jbc.M112.434530; Ilkovitch D, 2009, CANCER RES, V69, P5514, DOI 10.1158/0008-5472.CAN-08-4625; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Katz SC, 2005, HEPATOLOGY, V42, P293, DOI 10.1002/hep.20795; Katz SC, 2013, ANN SURG ONCOL, V20, P946, DOI 10.1245/s10434-012-2668-9; Katz SC, 2009, ANN SURG ONCOL, V16, P2524, DOI 10.1245/s10434-009-0585-3; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kujawski M, 2010, CANCER RES, V70, P9599, DOI 10.1158/0008-5472.CAN-10-1293; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lee H, 2011, CURR TOP MICROBIOL, V344, P41, DOI 10.1007/82_2010_51; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Liu K, 2010, WORLD J GASTRO ONCOL, V2, P399, DOI 10.4251/wjgo.v2.i11.399; Low W, 1999, ONCOGENE, V18, P3737, DOI 10.1038/sj.onc.1202702; Ma C, 2012, J LEUKOCYTE BIOL, V92, P1199, DOI 10.1189/jlb.0212059; Ma QZ, 2004, CANCER GENE THER, V11, P297, DOI 10.1038/sj.cgt.7700685; Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostrand-Rosenberg S, 2012, CANCER IMMUNOL IMMUN, V61, P1319, DOI 10.1007/s00262-012-1269-6; Pan PY, 2008, BLOOD, V111, P219, DOI 10.1182/blood-2007-04-086835; Parikh N, 2004, J IMMUNOL, V173, P6220, DOI 10.4049/jimmunol.173.10.6220; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salmon RA, 1997, J IMMUNOL, V159, P5309; Scholz M, 2005, MED RES REV, V25, P331, DOI 10.1002/med.20025; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Sinha P, 2011, BLOOD, V117, P5381, DOI 10.1182/blood-2010-11-321752; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Thorn M, 2016, CANCER GENE THER, V23, P188, DOI 10.1038/cgt.2016.19; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Turcotte S, 2014, CANCER IMMUNOL RES, V2, P530, DOI 10.1158/2326-6066.CIR-13-0180; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wittig Ilka, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P449, DOI 10.2174/156800805774912999; Wu AA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1016700; Yang F, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.21; Ye TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.452; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang YM, 2016, CANCER MED-US, V5, P1251, DOI 10.1002/cam4.675; Zhang YL, 2009, J IMMUNOL, V182, P3801, DOI 10.4049/jimmunol.0801548; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao HF, 2015, INT J ONCOL, V47, P429, DOI 10.3892/ijo.2015.3052	76	71	76	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					533	548		10.1038/s41388-018-0449-z	http://dx.doi.org/10.1038/s41388-018-0449-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30158673				2022-12-28	WOS:000456589800006
J	Wang, LT; Wang, SN; Chiou, SS; Liu, KY; Chai, CY; Chiang, CM; Huang, SK; Yokoyama, KK; Hsu, SH				Wang, Li-Ting; Wang, Shen-Nien; Chiou, Shyh-Shin; Liu, Kwei-Yan; Chai, Chee-Yin; Chiang, Cheng-Ming; Huang, Shau-Ku; Yokoyama, Kazunari K.; Hsu, Shih-Hsien			TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer	ONCOGENE			English	Article							ZIP TRANSCRIPTION FACTOR; TUMOR PROGRESSION; BHLH FACTORS; TWIST GENE; PROTEIN; SPZ1; TRANSFORMATION; TUMORIGENESIS; CELLS; BRD4	Metastasis is the main cause of cancer mortality. However, the triggering mechanisms and regulation of epithelial-mesenchymal transition (EMT) factors in the commitment of metastasis have not been well characterized. Spermatogenic Zip 1 (SPZ1) acts as a proto-oncogene and an upstream regulator of EMT during tumorigenesis. Here we report that the HIV-1 Tat-interacting protein 60 kDa (Tip60) acetyltransferase mediates acetylation at lysine residues of SPZ1 at positions 369 and 374, and of TWIST1 at positions 73 and 76, which are required for SPZ1-TWIST1 complex formation and cancer cell migration in vitro and in vivo. Ectopic SPZ1 and TWIST1 expression, but not that of TWIST1 alone, enhanced vascular endothelial growth factor (VEGF) expression via the recruitment of bromodomain-containing protein 4 (BRD4), thus enhancing RNA-Pol II-dependent transcription and inducing metastasis. Neutralization of VEGF using humanized monoclonal antibodies such as Avastin, effectively abrogated the EMT and oncogenesis induced by the acetylated SPZ1-TWIST1 complex. Our findings highlight the importance of acetylation signaling in the SPZ1-TWIST1-BRD4 axis in the mediation of EMT and its regulation during tumor initiation and metastasis.	[Wang, Li-Ting; Liu, Kwei-Yan; Yokoyama, Kazunari K.; Hsu, Shih-Hsien] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan; [Wang, Shen-Nien] Kaohsiung Med Univ Hosp, Dept Surg, Kaohsiung 807, Taiwan; [Wang, Shen-Nien] Pingtung Hosp, Minist Hlth & Welf, Pingtung 900, Taiwan; [Chiou, Shyh-Shin] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung 807, Taiwan; [Chiou, Shyh-Shin] Kaohsiung Med Univ Hosp, Div Hematol Oncol, Kaohsiung 807, Taiwan; [Chai, Chee-Yin] Kaohsiung Med Univ Hosp, Dept Pathol, Kaohsiung 807, Taiwan; [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Huang, Shau-Ku] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan 115, Taiwan; [Yokoyama, Kazunari K.] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung 807, Taiwan; [Yokoyama, Kazunari K.] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung 807, Taiwan; [Yokoyama, Kazunari K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan; [Hsu, Shih-Hsien] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; University of Tokyo; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Yokoyama, KK; Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung 807, Taiwan.; Yokoyama, KK (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan.; Hsu, SH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.	kazu@kmu.edu.tw; jackhsu@kmu.edu.tw	Yokoyama, Kazunari K./Z-1701-2019; Hsu, Shih-Hsien/D-5139-2009	Yokoyama, Kazunari K./0000-0001-8508-7587; Hsu, Shih Hsien/0000-0003-2102-0505; Chai, Chee-Yin/0000-0003-0486-9742; Wang, Li-Ting/0000-0002-3335-8055	Liver Disease Prevention & Treatment Research Foundation, Taiwan; Kaohsiung Medical University Hospital [KMUH100-0R20, KMUH106-6R33]; Ministry of Science and Technology, Taiwan [MOST-105-2314-B-037-070-MY2, MOST-106-2314-B-037-090-MY2, MOST-106-2314-B-037-017, MOST-106-2314-B-037-028, MOST-107-2314-B-037-063-MY3, MOST-107-2314-B-037-028-MY3]; National Health Research of Education [NHRI-Ex106-10416S1, NHRI-Ex107-10720-S1]; Kaohsiung Medical University grant [KMU-TP105E21, KMU-TP10500 5, KMU-DK108012]; US NIH [CA103867]; CPRIT [RP140367, RP180349]; Welch Foundation [I-1805]; NATIONAL CANCER INSTITUTE [R01CA103867] Funding Source: NIH RePORTER	Liver Disease Prevention & Treatment Research Foundation, Taiwan; Kaohsiung Medical University Hospital; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research of Education; Kaohsiung Medical University grant; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the Liver Disease Prevention & Treatment Research Foundation, Taiwan. This work was supported in part by research grants KMUH100-0R20 and KMUH106-6R33 from the Kaohsiung Medical University Hospital, MOST-105-2314-B-037-070-MY2, MOST-106-2314-B-037-090-MY2, MOST-106-2314-B-037-017, MOST-106-2314-B-037-028, MOST-107-2314-B-037-063-MY3, MOST-107-2314-B-037-028-MY3 from the Ministry of Science and Technology, Taiwan, the National Health Research of Education (NHRI-Ex106-10416S1; NHRI-Ex107-10720-S1), Kaohsiung Medical University grant (KMU-TP105E21, KMU-TP10500 5, KMU-DK108012) and US NIH (CA103867), CPRIT (RP140367; RP180349) and Welch Foundation (I-1805).	Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Carmeliet P, 2013, CELL MOL LIFE SCI, V70, P1763, DOI 10.1007/s00018-013-1283-7; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Judes G, 2015, EPIGENOMICS-UK, V7, P1351, DOI 10.2217/epi.15.76; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Llovet JM, 2014, CANCER CELL, V25, P560, DOI 10.1016/j.ccr.2014.04.019; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marquardt T, 2001, CELL, V106, P651, DOI 10.1016/S0092-8674(01)00499-8; Martin A, 2010, NAT CELL BIOL, V12, P924, DOI 10.1038/ncb1010-924; Mattheyses AL, 2015, METHODS MOL BIOL, V1278, P329, DOI 10.1007/978-1-4939-2425-7_20; Nervi C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0157-2; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldner MJ, 2010, J EXP MED, V207, P2855, DOI 10.1084/jem.20100438; Wang LT, 2017, ONCOGENE, V36, P4405, DOI 10.1038/onc.2017.69; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhu QQ, 2016, TUMOR BIOL, V37, P185, DOI 10.1007/s13277-015-4450-7	31	19	22	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					518	532		10.1038/s41388-018-0457-z	http://dx.doi.org/10.1038/s41388-018-0457-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30154425	Green Published, hybrid			2022-12-28	WOS:000456589800005
J	Lai, CY; Liu, H; Tin, KX; Huang, Y; Yeh, KH; Peng, HW; Chen, HD; He, JY; Chiang, YJ; Liu, CS; Weng, SY; Tao, MH; Yen, JJY; Yang-Yen, HF				Lai, Ching-Yu; Liu, Hsuan; Tin, Kai Xuan; Huang, Yi; Yeh, Kun-Hai; Peng, Hubert W.; Chen, Huan-Da; He, Jun-Yu; Chiang, Yun-Jung; Liu, Chun-Shan; Weng, Shih-Yen; Tao, Mi-Hua; Yen, Jeffrey Jong-Young; Yang-Yen, Hsin-Fang			Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells	ONCOGENE			English	Article							GLCNAC TRANSFERASE; C-MYC; CANCER; GLYCOSYLATION; SITE; METABOLISM; PLATFORM; GLYCANS; COMPLEX; DAMAGE	Aged hepatocyte-specific-Mcl-1 knockout (MKO-hep) mice are prone to develop liver tumors mimicking human hepatocellular carcinoma (HCC). Here we reported that a protein named UDP-N-acetylglucosamine pyrophosphorylase-1-like-1 (Uap1l1) is upregulated in the liver of young MKO-hep mice without any macroscopically detectable tumor nodules and is prominently expressed in the hepatic tumors developed in the aged MKO-hep mice. Intriguingly, human UAP1L1 is also significantly upregulated in a distinct subset of HCC tissues and patients with upregulated expression of UAP1L1 appeared to have poor prognosis. Overexpression of UAP1L1 significantly promoted, whereas UAP1L1 knockdown markedly reduced the proliferation of human hepatoma cells both in vitro and in vivo. UAP1L1 shows similar to 59% sequence identity to UDP-N-acetylglucosamine pyrophosphorylase-1 (UAP1), which is directly involved in the synthesis of the sugar donor (UDP-GlcNac) for N-acetylglucosamine modification (O-GlcNAcylation) of proteins. However, unlike UAP1, UAP1L1 harbors very limited UDP-GlcNAc synthesis activity. Moreover, although both UAP1 and UAP1L1 are required for O-GlcNAc transferase (OGT)-mediated protein O-GlcNAcylation, they appear to function distinctly from each other. UAP1L1 directly interacts with OGT, but does not seem to be an OGT substrate. In addition, UAP1L1 alone is not sufficient to activate OGT activity in vitro, suggesting that UAP1L1 may function together with other proteins to modulate OGT activity in vivo. Lastly, UAP1L1 knockdown attenuated c-MYC O-GlcNAcylation and protein stability, and overexpression of c-MYC significantly rescued the proliferation defect of UAP1L1 knockdown HepG2 cells, suggesting that c-MYC is one downstream target of UAP1L1 that contributes to UAP1L1-mediated cell proliferation, at least in HepG2 cells.	[Lai, Ching-Yu; Tin, Kai Xuan; Yeh, Kun-Hai; Peng, Hubert W.; Chen, Huan-Da; He, Jun-Yu; Weng, Shih-Yen; Yang-Yen, Hsin-Fang] Acad Sinica, Inst Mol Biol, Taipei, Taiwan; [Lai, Ching-Yu; Tao, Mi-Hua; Yen, Jeffrey Jong-Young; Yang-Yen, Hsin-Fang] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Liu, Hsuan; Huang, Yi] Chang Gung Univ, Mol Med Res Ctr, Taoyuan, Taiwan; [Liu, Hsuan] Chang Gung Univ, Dept Mol & Cellular Biol, Taoyuan, Taiwan; [Huang, Yi] ACT Genom Co LTD, Taipei, Taiwan; [Chiang, Yun-Jung; Liu, Chun-Shan; Tao, Mi-Hua; Yen, Jeffrey Jong-Young] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Weng, Shih-Yen] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Chang Gung University; Chang Gung University; Academia Sinica - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital	Yang-Yen, HF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.; Yang-Yen, HF (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.	imbyy@gate.sinica.edu.tw	Yang-Yen, Hsin-Fang/ABA-5808-2021; Yen, Jeffrey Jong-Young/Q-5134-2018; Tao, Mi-Hua/S-7020-2018	Yang-Yen, Hsin-Fang/0000-0001-9048-4800; Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Tao, Mi-Hua/0000-0002-4307-5729; Chiang, Yun-Jung/0000-0001-5024-8977; Liu, Chun-Shan/0000-0003-0887-0484; Peng, Hubert/0000-0003-4881-1331	Academia Sinica; National Science Council of Taiwan [99-2320-B-001-009-MY3, 102-2320-B-001 -024 -MY3]; Chang Gung Memorial Hospital [CMRPG3D1512]; Ministry of Education of Taiwan [EMRPD1E1581]	Academia Sinica(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Ministry of Education of Taiwan(Ministry of Education, Taiwan)	We greatly appreciate the gift of mammalian OGT expression vectors from Dr Xiaochun Yu (Beckman Research Institute), the bacterial OGT expression vector from Dr Hsiu-Ming Shih (Academia Sinica), and various hepatoma cell lines from Dr Yuh-Shan Jou (Academia Sinica). We also thank Yi-Ning Chen at the Bioinformatics core at IMB for I-TASSER modeling and the Metabolomics Facilities of the Scientific Instrument Center at Academia Sinica for the analysis of the cellular levels of UDP-GlcNAc. This study was supported in part by an intramural fund from Academia Sinica and by grants (99-2320-B-001-009-MY3; 102-2320-B-001 -024 -MY3) from the National Science Council of Taiwan to H-FY-Y; funding to HL was provided by Chang Gung Memorial Hospital (CMRPG3D1512) and the Ministry of Education of Taiwan (EMRPD1E1581).	Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Capotosti F, 2011, CELL, V144, P376, DOI 10.1016/j.cell.2010.12.030; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2016, NUCLEIC ACIDS RES, V44, P9266, DOI 10.1093/nar/gkw663; Cheung WD, 2008, J BIOL CHEM, V283, P33935, DOI 10.1074/jbc.M806199200; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387; Cummings RD, 2014, CHEM BIOL, V21, P1, DOI 10.1016/j.chembiol.2013.12.010; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Hanover JA, 2012, NAT REV MOL CELL BIO, V13, P312, DOI 10.1038/nrm3334; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Lau KS, 2008, GLYCOBIOLOGY, V18, P750, DOI 10.1093/glycob/cwn071; Lazarus MB, 2012, NAT CHEM BIOL, V8, P966, DOI [10.1038/nchembio.1109, 10.1038/NCHEMBIO.1109]; Lazarus MB, 2011, NATURE, V469, P564, DOI 10.1038/nature09638; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Nakajima K, 2010, GLYCOBIOLOGY, V20, P865, DOI 10.1093/glycob/cwq044; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Terasaka N, 2011, NAT STRUCT MOL BIOL, V18, P1268, DOI 10.1038/nsmb.2121; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Weber A, 2010, HEPATOLOGY, V51, P1226, DOI 10.1002/hep.23479; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Weng SY, 2011, J HEPATOL, V54, P685, DOI 10.1016/j.jhep.2010.07.035; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22	36	15	15	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					317	331		10.1038/s41388-018-0442-6	http://dx.doi.org/10.1038/s41388-018-0442-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30097606				2022-12-28	WOS:000455851200002
J	Liu, ZX; Zhang, WL; Phillips, JB; Arora, R; McClellan, S; Li, JF; Kim, JH; Sobol, RW; Tan, M				Liu, Zixing; Zhang, Wenling; Phillips, Joshua B.; Arora, Ritu; McClellan, Steven; Li, Jiangfeng; Kim, Jin-Hwan; Sobol, Robert W.; Tan, Ming			Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation	ONCOGENE			English	Article							MAJOR VAULT PROTEIN; RAS-INDEPENDENT ACTIVATION; PROSTATE-CANCER; LIGAND EXPRESSION; BREAST-CANCER; PROLIFERATION; INHIBITION; POLARITY; PATHWAY; GROWTH	B7-H3 is a tumor-promoting glycoprotein that is expressed at low levels in most normal tissues, but is overexpressed in various human cancers which is associated with disease progression and poor patient outcome. Although numerous publications have reported the correlation between B7-H3 and cancer progression in many types of cancers, mechanistic studies on how B7-H3 regulates cancer malignancy are rare, and the mechanisms underlying the role of B7-H3 in drug resistance are almost unknown. Here we report a novel finding that upregulation of B7-H3 increases the breast cancer stem cell population and promotes cancer development. Depletion of B7-H3 in breast cancer significantly inhibits the cancer stem cells. By immunoprecipitation and mass spectrometry, we found that B7-H3 is associated with the major vault protein (MVP) and activates MEK through MVP-enhancing B-RAF and MEK interaction. B7-H3 expression increases stem cell population by binding to MVP which regulates the activation of the MAPK kinase pathway. Depletion of MVP blocks the activation of MEK induced by B7-H3 and dramatically inhibits B7-H3 induced stem cells. This study reports novel functions of B7-H3 in regulating breast cancer stem cell enrichment. The novel mechanism for B7-H3-induced stem cell propagation by regulating MVP/MEK signaling axis independent of the classic Ras pathway may have important implications in the development of strategies for overcoming cancer cell resistance to chemotherapy.	[Liu, Zixing; Phillips, Joshua B.; Arora, Ritu; McClellan, Steven; Li, Jiangfeng; Kim, Jin-Hwan; Sobol, Robert W.; Tan, Ming] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA; [Zhang, Wenling] Cent S Univ, Xiangya Sch Med, Dept Med Lab Sci, Changsha, Hunan, Peoples R China; [Tan, Ming] Univ S Alabama, Dept Biochem & Mol Biol, 307N Univ Blvd, Mobile, AL 36688 USA	University of South Alabama; Central South University; University of South Alabama	Tan, M (corresponding author), Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.; Tan, M (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, 307N Univ Blvd, Mobile, AL 36688 USA.	mtan@health.southalabama.edu	Tan, Ming/ABD-5847-2021; Sobol, Robert W./E-4125-2013	Tan, Ming/0000-0003-2007-9898; Sobol, Robert W./0000-0001-7385-3563	NIH [CA148629, R01CA149646]; Vincent F. Kilborn, Jr. Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA149646, R01CA148629] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vincent F. Kilborn, Jr. Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grants R01CA149646 (to M. Tan), the Vincent F. Kilborn, Jr. Cancer Research Foundation (to MT). NIH CA148629 to RWS. RWS is an Abraham A. Mitchell Distinguished Investigator.	Abubaker K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-317; Henriquez-Hernandez LA, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-147; Arigami T, 2010, ANN SURG, V252, P1044, DOI 10.1097/SLA.0b013e3181f1939d; Bender RHF, 2015, STEM CELLS, V33, P1998, DOI 10.1002/stem.1990; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chavin G, 2009, CLIN CANCER RES, V15, P2174, DOI 10.1158/1078-0432.CCR-08-2262; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Galuppo R, 2014, ANTICANCER RES, V34, P1709; Gandalovicova A, 2016, ONCOTARGET, V7, P25022, DOI 10.18632/oncotarget.7214; Godde NJ, 2010, J MAMMARY GLAND BIOL, V15, P149, DOI 10.1007/s10911-010-9180-2; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Halaoui R, 2015, ONCOGENE, V34, P939, DOI 10.1038/onc.2014.59; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Ingebrigtsen VA, 2012, INT J CANCER, V131, P2528, DOI 10.1002/ijc.27566; Kim E, 2006, FEBS J, V273, P793, DOI 10.1111/j.1742-4658.2006.05112.x; Kolli S, 2004, J BIOL CHEM, V279, P29374, DOI 10.1074/jbc.M313955200; Leitner J, 2009, EUR J IMMUNOL, V39, P1754, DOI 10.1002/eji.200839028; Lemke D, 2012, CLIN CANCER RES, V18, P105, DOI 10.1158/1078-0432.CCR-11-0880; Lim S, 2016, CANCER RES, V76, P2231, DOI 10.1158/0008-5472.CAN-15-1538; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Liu H, 2011, MOL CANCER THER, V10, P960, DOI 10.1158/1535-7163.MCT-11-0072; Luo LQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130126; Luo LQ, 2004, J IMMUNOL, V173, P5445, DOI 10.4049/jimmunol.173.9.5445; Macara IG, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0012; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Parker AS, 2011, INT J RADIAT ONCOL, V79, P1343, DOI 10.1016/j.ijrobp.2010.01.061; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Vigdorovich V, 2013, STRUCTURE, V21, P707, DOI 10.1016/j.str.2013.03.003; Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070689; Wang ZS, 2016, ONCOTARGET, V7, P44266, DOI 10.18632/oncotarget.10023; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Xu H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104; Zang XX, 2010, MODERN PATHOL, V23, P1104, DOI 10.1038/modpathol.2010.95; Zhang GB, 2009, LUNG CANCER, V66, P245, DOI 10.1016/j.lungcan.2009.01.017; Zhang W, 2015, CELL SIGNAL, V27, P436, DOI 10.1016/j.cellsig.2014.12.010; Zhou B, 2014, J SURG RES, V188, P396, DOI 10.1016/j.jss.2014.01.014	47	38	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					88	102		10.1038/s41388-018-0407-9	http://dx.doi.org/10.1038/s41388-018-0407-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082909	Green Accepted			2022-12-28	WOS:000454775900007
J	Lu, CH; Yeh, DW; Lai, CY; Liu, YL; Huang, LR; Lee, AYL; Jin, SLC; Chuang, TH				Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Huang, Li-Rung; Lee, Alan Yueh-Luen; Jin, S-L Catherine; Chuang, Tsung-Hsien			USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation	ONCOGENE			English	Article							NF-KAPPA-B; DEUBIQUITINATING ENZYME USP17; TUMOR-ASSOCIATED MACROPHAGES; ACTIVATION; TRAF2; METASTASIS; MECHANISMS; EXPRESSION; INHIBITORS	Macrophage accumulation and inflammation in the lung owing to stresses and diseases is a cause of lung cancer development. However, molecular mechanisms underlying the interaction between macrophages and cancer cells, which drive inflammation and stemness in cancers, are poorly understood. In this study, we investigated the expression of ubiquitin-specific peptidase 17 (USP17) in lung cancers, and role of elevated USP17 in the interaction between macrophages and lung cancer cells. USP17 expression in lung cancers was associated with poor prognosis, macrophage, and inflammatory marker expressions. Macrophages promoted USP17 expression in cancer cells. TNFR-associated factor (TRAF) 2-binding and TRAF3-binding motifs were identified in USP17, through which it interacted with and disrupted the TRAF2/TRAF3 complex. This stabilized its client proteins, enhanced inflammation and stemness in cancer cells, and promoted macrophage recruitment. In different animal studies, co-injection of macrophages with cancer cells promoted USP17 expression in tumors and tumor growth. Conversely, depletion of macrophages in host animals by clodronate liposomes reduced USP17 expression and tumor growth. In addition, overexpression of USP17 in cancer cells promoted tumor growth and inflammation-associated and stemness-associated gene expressions in tumors. These results suggested that USP17 drives a positive-feedback interaction between macrophages and cancer cells to enhance inflammation and stemness in cancer cells, and promotes lung cancer growth.	[Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Lu, Chih-Hao; Jin, S-L Catherine] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Huang, Li-Rung] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Lee, Alan Yueh-Luen] Natl Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan; [Chuang, Tsung-Hsien] Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; National Central University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Chuang, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan.; Chuang, TH (corresponding author), Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan.	thchuang@nhri.org.tw	Chuang, Tsung-Hsien/F-9679-2010	Lee, Alan Yueh-Luen/0000-0003-0252-0571	National Health Research Institutes, Taiwan [IM-106-PP-02, NHRI-EX106-10630SI]; Ministry of Science and Technology of Taiwan [MOST 105-2314-B-400-006, MOST 105-2320-B-400-013-MY3]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	We thank the Laboratory Animal Center of the National Health Research Institutes, Taiwan, for assistance with animal work. This work was supported by grants from National Health Research Institutes, Taiwan (IM-106-PP-02, NHRI-EX106-10630SI) and Ministry of Science and Technology of Taiwan (MOST 105-2314-B-400-006, and MOST 105-2320-B-400-013-MY3).	Bolli E, 2017, CURR OPIN ONCOL, V29, P55, DOI 10.1097/CCO.0000000000000344; Borbely G, 2015, ONCOTARGET, V6, P33623, DOI 10.18632/oncotarget.5601; Burrows JF, 2009, J BIOL CHEM, V284, P9587, DOI 10.1074/jbc.M807216200; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen R, 2010, CELL RES, V20, P802, DOI 10.1038/cr.2010.41; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; de la Vega M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1243; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Farshi P, 2015, EXPERT OPIN THER PAT, V25, P1191, DOI 10.1517/13543776.2015.1056737; Goswami KK, 2017, CELL IMMUNOL, V316, P1, DOI 10.1016/j.cellimm.2017.04.005; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lim KH, 2013, CYTOKINE GROWTH F R, V24, P427, DOI 10.1016/j.cytogfr.2013.05.007; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; MacDonagh L, 2016, CANCER LETT, V372, P147, DOI [10.1016/j.canlet.2016,01.012, 10.1016/j.canlet.2016.01.012]; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; McFarlane C, 2013, ONCOTARGET, V4, P1836, DOI 10.18632/oncotarget.1282; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Ni YM, 2015, INT J MOL SCI, V16, P27956, DOI 10.3390/ijms161126063; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pal A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0461-3; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Popovic D, 1998, CLIN EXP METASTAS, V16, P623, DOI 10.1023/A:1006508413070; Quatromoni JG, 2012, AM J TRANSL RES, V4, P376; Ramakrishna S, 2015, BBA-REV CANCER, V1855, P83, DOI 10.1016/j.bbcan.2014.11.006; Ramakrishna S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037772; Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Shigdar S, 2014, CANCER LETT, V345, P271, DOI 10.1016/j.canlet.2013.07.031; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Sica A, 2017, CANCER IMMUNOL IMMUN, V66, P1025, DOI 10.1007/s00262-017-1997-8; Suarez-Carmona M, 2017, MOL ONCOL, V11, P805, DOI 10.1002/1878-0261.12095; Suresh R, 2016, ADV EXP MED BIOL, V890, P57, DOI 10.1007/978-3-319-24932-2_4; Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Valavanidis A, 2013, INT J ENV RES PUB HE, V10, P3886, DOI 10.3390/ijerph10093886; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Won M, 2016, ARCH PHARM RES, V39, P1075, DOI 10.1007/s12272-016-0772-2; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Yang XD, 2015, IMMUNOL REV, V266, P56, DOI 10.1111/imr.12311; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh DW, 2016, CELL DEATH DIFFER, V23, P841, DOI 10.1038/cdd.2015.147; Yeh DW, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4368101; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zhang S, 2016, ONCOL RES, V24	57	43	43	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6327	6340		10.1038/s41388-018-0411-0	http://dx.doi.org/10.1038/s41388-018-0411-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038267	hybrid, Green Published			2022-12-28	WOS:000452384400004
J	Stamm, H; Klingler, F; Grossjohann, EM; Muschhammer, J; Vettorazzi, E; Heuser, M; Mock, U; Thol, F; Vohwinkel, G; Latuske, E; Bokemeyer, C; Kischel, R; Dos Santos, C; Stienen, S; Friedrich, M; Lutteropp, M; Nagorsen, D; Wellbrock, J; Fiedler, W				Stamm, Hauke; Klingler, Felix; Grossjohann, Eva-Maria; Muschhammer, Jana; Vettorazzi, Eik; Heuser, Michael; Mock, Ulrike; Thol, Felicitas; Vohwinkel, Gabi; Latuske, Emily; Bokemeyer, Carsten; Kischel, Roman; Dos Santos, Cedric; Stienen, Sabine; Friedrich, Matthias; Lutteropp, Michael; Nagorsen, Dirk; Wellbrock, Jasmin; Fiedler, Walter			Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option	ONCOGENE			English	Article							CELL-ENGAGING ANTIBODY; CD8 T-CELLS; POLIOVIRUS RECEPTOR; NECTIN-2 CD112; TIGIT; CD155; DNAM-1; EXPRESSION; CANCER; IDENTIFICATION	Immune checkpoints are promising targets in cancer therapy. Recently, poliovirus receptor (PVR) and poliovirus receptor-related 2 (PVRL2) have been identified as novel immune checkpoints. In this investigation we show that acute myeloid leukemia (AML) cell lines and AML patient samples highly express the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) ligands PVR and PVRL2. Using two independent patient cohorts, we could demonstrate that high PVR and PVRL2 expression correlates with poor outcome in AML. We show for the first time that antibody blockade of PVR or PVRL2 on AML cell lines or primary AML cells or TIGIT blockade on immune cells increases the anti-leukemic effects mediated by PBMCs or purified CD3(+) cells in vitro. The cytolytic activity of the BiTE (R) antibody construct AMG 330 against leukemic cells could be further enhanced by blockade of the TIGIT-PVR/PVRL2 axis. This increased immune reactivity is paralleled by augmented secretion of Granzyme B by immune cells. Employing CRISPR/Cas9-mediated knockout of PVR and PVRL2 in MV4-11 cells, the cytotoxic effects of antibody blockade could be recapitulated in vitro. In NSG mice reconstituted with human T cells and transplanted with either MV4-11 PVR/PVRL2 knockout or wildtype cells, prolonged survival was observed for the knockout cells. This survival benefit could be further extended by treating the mice with AMG 330. Therefore, targeting the TIGIT-PVR/PVRL2 axis with blocking antibodies might represent a promising future therapeutic option in AML.	[Stamm, Hauke; Klingler, Felix; Grossjohann, Eva-Maria; Muschhammer, Jana; Vohwinkel, Gabi; Latuske, Emily; Bokemeyer, Carsten; Wellbrock, Jasmin; Fiedler, Walter] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hubertus Wald Univ Canc Ctr, Hamburg, Germany; [Vettorazzi, Eik] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Heuser, Michael; Thol, Felicitas] Hannover Med Sch, Hematol Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany; [Mock, Ulrike] Univ Med Ctr Hamburg Eppendorf, Res Dept Cell & Gene Therapy, Clin Stem Cell Transplantat, Hamburg, Germany; [Kischel, Roman; Stienen, Sabine; Friedrich, Matthias; Lutteropp, Michael] Amgen Res Munich GmbH, Munich, Germany; [Dos Santos, Cedric] Amgen Inc, Oncol Biomarkers & Early Clin Dev, San Francisco, CA USA; [Nagorsen, Dirk] Amgen Inc, Global Clin Dev, Thousand Oaks, CA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Amgen; Amgen Research Munich GmbH; Amgen; Amgen	Fiedler, W (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hubertus Wald Univ Canc Ctr, Hamburg, Germany.	fiedler@uke.de	Heuser, Michael/S-2363-2017; Vettorazzi, Eik/B-8130-2019	Heuser, Michael/0000-0001-5318-9044; Vettorazzi, Eik/0000-0002-3737-6402; Fiedler, Walter/0000-0003-0275-8803	Lieselotte Beutel Stiftung; AMGEN Inc.	Lieselotte Beutel Stiftung; AMGEN Inc.(Amgen)	We gratefully thank Dr. Daniela Pende (IRCCS AOU San Martino-IST, Genoa, Italy) for scientific discussion and provision of the anti-PVRL2 L14 antibody. We gratefully acknowledge Prof. E. Tolosa of the Institute of Immunology, University Medical Center Hamburg-Eppendorf, Germany, for fruitful scientific discussions and technical support. We are grateful to Prof. C. Hagel, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Germany, for scientific discussions. We would like to thank Dr. Malte Mohme for the scientific discussions and technical support. We would like to thank the members of the Center for Transfusion Medicine for providing buffy coats from healthy donors, the members of the Flow Cytometry UCCH Core Facility for sorting of the CRISPR/Cas9-generated double-knockout cells and the members of the Animal Facility for technical assistance and managing the mouse colonies, all located at the University Medical Center Hamburg-Eppendorf, Germany. The authors thank Prof. R. Schlenk (University Hospital Ulm, Germany) and all participating study centers for providing clinical data on study patients. This work was funded in part by the Lieselotte Beutel Stiftung and by AMGEN Inc.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Callahan MK, 2013, J LEUKOCYTE BIOL, V94, P41, DOI 10.1189/jlb.1212631; Carlsten M, 2009, J IMMUNOL, V183, P4921, DOI 10.4049/jimmunol.0901226; Cella M, 2010, EUR J IMMUNOL, V40, P949, DOI 10.1002/eji.200940234; Chan CJ, 2014, NAT IMMUNOL, V15, P431, DOI 10.1038/ni.2850; Dao T, 2015, NAT BIOTECHNOL, V33, P1079, DOI 10.1038/nbt.3349; DAVER N, 2017, BLOOD S1, V0130; FREISTADT MS, 1993, VIROLOGY, V195, P798, DOI 10.1006/viro.1993.1433; Friedrich M, 2014, MOL CANCER THER, V13, P1549, DOI 10.1158/1535-7163.MCT-13-0956; Gerhardt T, 2015, CARDIOVASC RES, V107, P321, DOI 10.1093/cvr/cvv147; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Inozume T, 2016, J INVEST DERMATOL, V136, P255, DOI 10.1038/JID.2015.404; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kohnke T, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0213-6; Kong YX, 2016, CLIN CANCER RES, V22, P3057, DOI 10.1158/1078-0432.CCR-15-2626; Krupka C, 2016, LEUKEMIA, V30, P484, DOI 10.1038/leu.2015.214; Krupka C, 2014, BLOOD, V123, P356, DOI 10.1182/blood-2013-08-523548; Kurtulus S., 2014, J IMMUNOTHERAPY C S3, V2, pO13, DOI DOI 10.1186/2051-1426-2-S3-O13; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Laszlo GS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.68; Le Mercier I, 2014, CANCER RES, V74, P1933, DOI 10.1158/0008-5472.CAN-13-1506; Levin SD, 2011, EUR J IMMUNOL, V41, P902, DOI 10.1002/eji.201041136; Li M, 2014, J BIOL CHEM, V289, P17647, DOI 10.1074/jbc.M114.572420; Liu S, 2013, CELL DEATH DIFFER, V20, P456, DOI 10.1038/cdd.2012.141; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; Morse MA, 2015, VACCINE, V33, P7377, DOI 10.1016/j.vaccine.2015.10.057; Nishiwada S, 2015, ANTICANCER RES, V35, P2287; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Pende D, 2005, MOL IMMUNOL, V42, P463, DOI 10.1016/j.molimm.2004.07.028; RAVANDI F, 2017, BLOOD S1, V130; Schlenk RF, 2011, BLOOD, V118, P38, DOI 10.1182/blood.V118.21.80.80; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Stanietsky N, 2009, P NATL ACAD SCI USA, V106, P17858, DOI 10.1073/pnas.0903474106; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425; Zhu YW, 2016, J EXP MED, V213, P167, DOI 10.1084/jem.20150785; Zugmaier G, 2015, MOL IMMUNOL, V67, P58, DOI 10.1016/j.molimm.2015.02.033	47	46	51	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5269	5280		10.1038/s41388-018-0288-y	http://dx.doi.org/10.1038/s41388-018-0288-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855615	Green Published, hybrid			2022-12-28	WOS:000445759700002
J	Chow, M; Gao, LN; MacManiman, JD; Bicocca, VT; Chang, BH; Alumkal, JJ; Tyner, JW				Chow, Marilynn; Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.			Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMI-METHYLATED DNA; CELL RECEPTOR; ANTIGEN ROR1; SRA DOMAIN; CANCER; EXPRESSION; NAPHTHAZARIN	Expression of the transmembrane pseudokinase ROR1 is required for survival of t(1;19)-pre-B-cell acute lymphoblastic leukemia (t(1;19) pre-B-ALL), chronic lymphocytic leukemia, and many solid tumors. However, targeting ROR1 with small-molecules has been challenging due to the absence of ROR1 kinase activity. To identify genes that regulate ROR1 expression and may, therefore, serve as surrogate drug targets, we employed an siRNA screening approach and determined that the epigenetic regulator and E3 ubiquitin ligase, UHRF1, is required for t(1;19) pre-B-ALL cell viability in a ROR1-dependent manner. Upon UHRF1 silencing, ROR1 protein is reduced without altering ROR1 mRNA, and ectopically expressed UHRF1 is sufficient to increase ROR1 levels. Additionally, proteasome inhibition rescues loss of ROR1 protein after UHRF1 silencing, suggesting a role for the proteasome in the UHRF1-ROR1 axis. Finally, we show that ROR1-positive cells are twice as sensitive to the UHRF1-targeting drug, naphthazarin, and undergo increased apoptosis compared to ROR1-negative cells. Naphthazarin elicits reduced expression of UHRF1 and ROR1, and combination of naphthazarin with inhibitors of pre-B cell receptor signaling results in further reduction of cell survival compared with either inhibitor alone. Therefore, our work reveals a mechanism by which UHRF1 stabilizes ROR1, suggesting a potential targeting strategy to inhibit ROR1 in t(1;19) pre-B-ALL and other malignancies.	[Chow, Marilynn; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Gao, Lina; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [MacManiman, Jason D.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Chang, Bill H.] Oregon Hlth & Sci Univ, Div Pediat Hematol & Oncol, Doernbecher Childrens Hosp, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.	tynerj@ohsu.edu		Chow-Castro, Marilynn/0000-0001-8819-4441; Bicocca, Vincent/0000-0002-5702-4586	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) [TL1TR000129]; Hyundai Hope on Wheels; Leukemia and Lymphoma Society; V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]; NATIONAL CANCER INSTITUTE [R00CA151457, K99CA151457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000129] Funding Source: NIH RePORTER	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Hyundai Hope on Wheels; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The pCS2-6XMYC vector was a generous gift from Dr. Monika Davare. The authors would like to thank David K. Edwards V, Samantha L. Savage, Anna M. Reister Schultz, Dr. Haijiao Zhang, and Janet Pittsenbarger for their technical expertise and Dr. Kevin M. Watanabe-Smith for editing the manuscript. MC was supported in part by the Oregon Clinical and Translational Research Institute (OCTRI) (TL1TR000129) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). BHC is supported by the Hyundai Hope on Wheels. JWT is supported by The Leukemia and Lymphoma Society, the V Foundation for Cancer Research, Gabrielle's Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01).	Abu-Alainin W, 2016, J PATHOL, V238, P423, DOI 10.1002/path.4665; Acharya BR, 2011, APOPTOSIS, V16, P924, DOI 10.1007/s10495-011-0613-1; Alhosin M, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0453-5; Alhosin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08996; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Baskar S, 2012, MABS-AUSTIN, V4, P349, DOI 10.4161/mabs.19870; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7; Fernandez NB, 2016, MOL CARCINOGEN, V55, P1772, DOI 10.1002/mc.22426; Broome HE, 2011, LEUKEMIA RES, V35, P1390, DOI 10.1016/j.leukres.2011.06.021; Chen DF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162638; Choi MY, 2015, CL LYMPH MYELOM LEUK, V15, pS167, DOI 10.1016/j.clml.2015.02.010; DaneshManesh AH, 2008, INT J CANCER, V123, P1190, DOI 10.1002/ijc.23587; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Foa R, 2003, BRIT J HAEMATOL, V120, P484, DOI 10.1046/j.1365-2141.2003.04113.x; Fukuda T, 2008, P NATL ACAD SCI USA, V105, P3047, DOI 10.1073/pnas.0712148105; Gentile A, 2011, CANCER RES, V71, P3132, DOI 10.1158/0008-5472.CAN-10-2662; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; Jia YH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.7; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Kaucka M, 2011, ACTA PHYSIOL, V203, P351, DOI 10.1111/j.1748-1716.2011.02306.x; Kim JA, 2012, INT J ONCOL, V40, P157, DOI 10.3892/ijo.2011.1195; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Kim MY, 2015, INT J ONCOL, V46, P1659, DOI 10.3892/ijo.2015.2857; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Li P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011859; Loh ML, 2012, CLIN CANCER RES, V18, P2754, DOI 10.1158/1078-0432.CCR-11-1936; Ma J, 2015, BIOCHEM BIOPH RES CO, V464, P147, DOI 10.1016/j.bbrc.2015.06.104; Mani R, 2015, LEUKEMIA, V29, P346, DOI 10.1038/leu.2014.199; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moorman AV, 2010, BLOOD, V115, P206, DOI 10.1182/blood-2009-07-232124; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Myrianthopoulos V, 2016, EUR J MED CHEM, V114, P390, DOI 10.1016/j.ejmech.2016.02.043; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007; Qu XY, 2015, EPIGENETICS-US, V10, P526, DOI 10.1080/15592294.2015.1048060; Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006; Rau R, 2009, HEMATOL ONCOL, V27, P171, DOI 10.1002/hon.904; Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152; Sanchez-Aguilera A, 2010, LEUKEMIA, V24, P97, DOI 10.1038/leu.2009.217; Sanda T, 2013, CANCER DISCOV, V3, P564, DOI 10.1158/2159-8290.CD-12-0504; Shabani M, 2008, LEUKEMIA LYMPHOMA, V49, P1360, DOI 10.1080/10428190802124000; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Tasian SK, 2017, BRIT J HAEMATOL, V176, P867, DOI 10.1111/bjh.14474; Troeger A, 2012, BLOOD, V119, P4708, DOI 10.1182/blood-2011-12-395939; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Widhopf GF, 2014, P NATL ACAD SCI USA, V111, P793, DOI 10.1073/pnas.1308374111; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Zhang SP, 2012, AM J PATHOL, V181, P1903, DOI 10.1016/j.ajpath.2012.08.024; Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]	60	6	6	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5221	5232		10.1038/s41388-018-0299-8	http://dx.doi.org/10.1038/s41388-018-0299-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849118	Green Accepted			2022-12-28	WOS:000445093100006
J	Parekh, A; Das, S; Parida, S; Das, CK; Dutta, D; Mallick, SK; Wu, PH; Kumar, BNP; Bharti, R; Dey, G; Banerjee, K; Rajput, S; Bharadwaj, D; Pal, I; Dey, KK; Rajesh, Y; Jena, BC; Biswas, A; Banik, P; Pradhan, AK; Das, SK; Das, AK; Dhara, S; Fisher, PB; Wirtz, D; Mills, GB; Mandal, M				Parekh, Aditya; Das, Subhayan; Parida, Sheetal; Das, Chandan Kanta; Dutta, Debabrata; Mallick, Sanjaya K.; Wu, Pei-Hsun; Kumar, B. N. Prashanth; Bharti, Rashmi; Dey, Goutam; Banerjee, Kacoli; Rajput, Shashi; Bharadwaj, Deblina; Pal, Ipsita; Dey, Kaushik Kumar; Rajesh, Yetirajam; Jena, Bikash Chandra; Biswas, Angana; Banik, Payel; Pradhan, Anjan K.; Das, Swadesh K.; Das, Amit Kumar; Dhara, Santanu; Fisher, Paul B.; Wirtz, Denis; Mills, Gordon B.; Mandal, Mahitosh			Multi-nucleated cells use ROS to induce breast cancer chemoresistance in vitro and in vivo	ONCOGENE			English	Article							MULTINUCLEATED GIANT-CELLS; MITOTIC CATASTROPHE; REACTIVE OXYGEN; SECRETORY PHENOTYPE; TUMOR-CELLS; POLYPLOIDY; SENESCENCE; HYPOXIA; APOPTOSIS; DOXORUBICIN	Although there is a strong correlation between multinucleated cells (MNCs) and cancer chemo-resistance in variety of cancers, our understanding of how multinucleated cells modulate the tumor micro-environment is limited. We captured multinucleated cells from triple-negative chemo-resistant breast cancers cells in a time frame, where they do not proliferate but rather significantly regulate their micro-environment. We show that oxidatively stressed MNCs induce chemo-resistance in vitro and in vivo by secreting VEGF and MIF. These factors act through the RAS/MAPK pathway to induce chemoresistance by upregulating anti-apoptotic proteins. In MNCs, elevated reactive oxygen species (ROS) stabilizes HIF-1 alpha contributing to increase production of VEGF and MIF. Together the data indicate, that the ROS-HIF-1 alpha signaling axis is very crucial in regulation of chemo-resistance by MNCs. Targeting ROS-HIF-1 alpha in future may help to abrogate drug resistance in breast cancer.	[Parekh, Aditya; Das, Subhayan; Parida, Sheetal; Das, Chandan Kanta; Kumar, B. N. Prashanth; Bharti, Rashmi; Dey, Goutam; Banerjee, Kacoli; Rajput, Shashi; Bharadwaj, Deblina; Pal, Ipsita; Dey, Kaushik Kumar; Rajesh, Yetirajam; Jena, Bikash Chandra; Biswas, Angana; Banik, Payel; Dhara, Santanu; Mandal, Mahitosh] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India; [Dutta, Debabrata; Das, Amit Kumar] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India; [Mallick, Sanjaya K.] Univ Calcutta, BD Biosci Ctr Res Nanosci & Nanotechnol, Kolkata, W Bengal, India; [Wu, Pei-Hsun; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Pradhan, Anjan K.; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, VCU Inst Mol Med,Dept Human & Mol Genet, Richmond, VA 23298 USA; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Div Canc Med, Houston, TX 77030 USA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; University of Calcutta; Johns Hopkins University; Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center	Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.	mahitosh@smst.iitkgp.ernet.in	jain, shashi/AAF-4706-2020; Mandal, Mahitosh/GMW-6195-2022; Dey, Kaushik Kumar/H-5997-2018; das, subhayan/G-3453-2018; JAIN, SHASHI/N-8877-2017; Dhara, Santanu/AAS-5872-2020; Pradhan, Anjan K/O-2555-2014; Bhusetty Nagesh, Prashanth Kumar/ABH-4999-2020; Pal, Ipsita/AAX-4410-2020	jain, shashi/0000-0001-9428-0135; Mandal, Mahitosh/0000-0003-3861-3323; Dey, Kaushik Kumar/0000-0002-9594-6362; das, subhayan/0000-0002-8628-5128; JAIN, SHASHI/0000-0001-9428-0135; Bhusetty Nagesh, Prashanth Kumar/0000-0003-3518-405X; Rajesh, Yetirajam/0000-0002-0277-3942; Biswas, Angana/0000-0002-0983-0428; Jena, Bikash Chandra/0000-0002-6672-9254; Mills, Gordon/0000-0002-0144-9614; Rajesh, Yetirajam/0000-0001-8882-8854; Dey, Goutam/0000-0002-8210-3219	Department of Biotechnology [BT/PR13996/Med/30/309/2010]; Department of Atomic Energy [35/14/05/2015-BRNS/3053]; Ministry of Human Resource Development [4-23/2014-TS]; University Grants Commission, Department of Biotechnology, and Fulbright; NATIONAL CANCER INSTITUTE [R01CA174388] Funding Source: NIH RePORTER	Department of Biotechnology; Department of Atomic Energy(Department of Atomic Energy (DAE)); Ministry of Human Resource Development; University Grants Commission, Department of Biotechnology, and Fulbright; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Anji Anura, Bodhisatwa Das, Raunak Kumar Das, and Prof. Jyotirmoy Chaterjee from IIT Kharagpur for their help in microscopy. We also thank Hasini Jayatilaka and Michelle Karl from Johns Hopkins University for their support. We also thank Sanat Dey, Purna Patra, and other staffs of central research facility of IIT Kharagpur for technical assistance. The research was supported by Department of Biotechnology (BT/PR13996/Med/30/309/2010), Department of Atomic Energy, (35/14/05/2015-BRNS/3053), and Ministry of Human Resource Development (F. NO. 4-23/2014-TS. I). University Grants Commission, Department of Biotechnology, and Fulbright is also hereby acknowledged for scholarship support.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balsas P, 2012, LEUKEMIA RES, V36, P212, DOI 10.1016/j.leukres.2011.09.011; Bar-Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Dey G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10316; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Erenpreisa J, 2008, CELL BIOL INT, V32, P1044, DOI 10.1016/j.cellbi.2008.06.003; FISHBACK NF, 1994, CANCER-AM CANCER SOC, V73, P2936, DOI 10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U; Holt DJ, 2011, BIOMATERIALS, V32, P3977, DOI 10.1016/j.biomaterials.2011.02.021; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kotchetkov R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; Krajcovic M, 2011, NAT CELL BIOL, V13, P324, DOI 10.1038/ncb2174; Kumar BN, 2013, BMC CANCER, V13, P1; Kuo CH, 2014, BREAST CANCER-TOKYO, V21, P358, DOI 10.1007/s12282-012-0400-z; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600-0714.2003.00126.x; Lu YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158587; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mosieniak G, 2010, CURR PHARM DESIGN, V16, P734, DOI 10.2174/138161210790883714; Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008; Most J, 1997, BLOOD, V89, P662, DOI 10.1182/blood.V89.2.662; Nakayama Y, 2015, CELL STRUCT FUNCT, V40, P51, DOI 10.1247/csf.14005; Ogden A, 2015, CANCER LETT, V367, P89, DOI 10.1016/j.canlet.2015.06.025; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rohnalter V, 2015, ONCOTARGET, V6, P40005, DOI 10.18632/oncotarget.5552; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ryska A, 2001, VIRCHOWS ARCH, V439, P768, DOI 10.1007/s004280100470; Sharma S, 2013, MOL CANCER THER, V12, P725, DOI 10.1158/1535-7163.MCT-12-1079; Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Zhang S, 2014, ONCOGENE, V33, P134, DOI 10.1038/onc.2013.318; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825	55	38	40	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4546	4561		10.1038/s41388-018-0272-6	http://dx.doi.org/10.1038/s41388-018-0272-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743594				2022-12-28	WOS:000441736700005
J	Cui, H; Hu, Y; Guo, DD; Zhang, AF; Gu, YJ; Zhang, SD; Zhao, CC; Gong, PH; Shen, XH; Li, YP; Wu, HZ; Wang, L; Zhao, ZJ; Fan, H				Cui, He; Hu, Ying; Guo, Didi; Zhang, Aifeng; Gu, Yuejun; Zhang, Shaodan; Zhao, Chengcheng; Gong, Pihai; Shen, Xiaohui; Li, Yiping; Wu, Huazhang; Wang, Ling; Zhao, Zhujiang; Fan, Hong			DNA methyltransferase 3A isoform b contributes to repressing Ecadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CLINICAL-SIGNIFICANCE; EXPRESSION; DNMT3A; CELLS; STEM; PROTEINS; SNAIL; GENE	DNA methyltransferase 3A (DNMT3A) has been recognised as a key element of epigenetic regulation in normal development, and the aberrant regulation of DNMT3A is implicated in multiple types of cancers, especially haematological malignancies. However, its clinical significance and detailed functional role in solid tumours remain unknown, although abnormal expression has gained widespread attention in these cancers. Here, we show that DNMT3A isoform b (DNMT3Ab), a member of the DNMT3A isoform family, is critical for directing epithelial-mesenchymal transition (EMT)-associated metastasis in gastric cancer (GC). DNMT3Ab is positively linked to tumour-node-metastasis (TNM) stage, lymph node metastasis and poor prognosis in GC patients. Overexpression of DNMT3Ab promotes GC cell migration and invasion as well as EMT through repression of E-cadherin. Meanwhile, DNMT3Ab promotes lung metastasis of GC in vivo. Mechanistic studies indicate that DNMT3Ab mediates the epigenetic inaction of the E-cadherin gene via DNA hypermethylation and histone modifications of H3K9me2 and H3K27me3. Depletion of DNMT3Ab effectively restores the expression of E-cadherin and reverses TGF-beta-induced EMT by reducing DNA methylation, H3K9me2 and H3K27me3 levels at the E-cadherin promoter. Importantly, DNMT3Ab cooperated with H3K9me2 and H3K27me3 contributes to the transcriptional regulation of E-cadherin in a Snail-dependent manner. Further, gene expression profiling analysis indicates that multiple metastasis-associated genes and oncogenic signalling pathways are regulated in response to DNMT3Ab overexpression. These results identify DNMT3Ab as a crucial regulator of metastasis-related genes in GC. Targeting the DNMT3Ab/Snail/E-cadherin axis may provide a promising therapeutic strategy in the treatment of metastatic GC with high DNMT3Ab expression.	[Cui, He; Hu, Ying; Guo, Didi; Gu, Yuejun; Zhang, Shaodan; Zhao, Chengcheng; Gong, Pihai; Shen, Xiaohui; Wu, Huazhang; Wang, Ling; Zhao, Zhujiang; Fan, Hong] Southeast Univ, Dept Med Genet & Dev Biol, Key Lab Dev Genes & Human Dis, Med Sch,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China; [Cui, He] Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China; [Cui, He] Nanjing Med Univ, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Aifeng; Li, Yiping] Southeast Univ, Sch Med, Dept Pathol, Nanjing 210009, Jiangsu, Peoples R China	Southeast University - China; Nanjing Medical University; Nanjing Medical University; Southeast University - China	Fan, H (corresponding author), Southeast Univ, Dept Med Genet & Dev Biol, Key Lab Dev Genes & Human Dis, Med Sch,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China.	fanh@seu.edu.cn		Wu, Huazhang/0000-0002-5482-3761	National Natural Science Foundation of China [81672414, 81472548, 81171915, 81702789]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the grants from National Natural Science Foundation of China (81672414, 81472548, 81171915 and 81702789). We thank Dr. Gang-Ning Liang at the Norris Cancer Center for generously providing the DNMT3Ab constructs. We also appreciate Dr. Jingfei Chen at Department of Oncology, Nanjing First Hospital, Nanjing Medical University, for providing tissue microarrays of GC patients. We also appreciate Dr. Kun Zhang at Department of Oncology, the Third Affiliated Hospital of Harbin Medical University, for providing the clinical samples of GC patients.	Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao XY, 2014, WORLD J GASTROENTERO, V20, P8201, DOI 10.3748/wjg.v20.i25.8201; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chaudry SF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5473197; Chen BF, 2014, EPIGENETICS-US, V9, P669, DOI 10.4161/epi.28324; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Cui H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13781; Cui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123926; DENG G, 1987, CANCER RES, V47, P3195; Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093; Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2; Fan H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-12; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212; Gaidzik VI, 2018, LEUKEMIA, V32, P30, DOI 10.1038/leu.2017.200; Huang L, 2015, AM J TRANSL RES, V7, P2141; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jung H, 2011, CANCER-AM CANCER SOC, V117, P2371, DOI 10.1002/cncr.25778; Kim BG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.73; Koike N, 1997, J CANCER RES CLIN, V123, P310, DOI 10.1007/s004320050063; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; La Salle S, 2006, DEV BIOL, V296, P71, DOI 10.1016/j.ydbio.2006.04.436; Ma PP, 2015, CELL REP, V13, P1552, DOI 10.1016/j.celrep.2015.10.031; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Oliveira AMM, 2016, MOL PSYCHIATR, V21, P1130, DOI 10.1038/mp.2015.175; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peng Z, 2014, WORLD J GASTROENTERO, V20, P5403, DOI 10.3748/wjg.v20.i18.5403; Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159; Prieto-Garcia E, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0980-8; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Suetake I, 2011, BIOCHEM J, V437, P141, DOI 10.1042/BJ20110241; Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293; Thakur A, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0104-2; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vogiatzi P, 2007, J CELL PHYSIOL, V211, P287, DOI 10.1002/jcp.20982; Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019; Weigt J, 2015, GASTROINTEST TUMORS, V2, P61, DOI 10.1159/000431304; Weis B, 2015, ONCOGENE, V34, P1822, DOI 10.1038/onc.2014.114; Wongtrakoongate P, 2015, WORLD J STEM CELLS, V7, P137, DOI 10.4252/wjsc.v7.i1.137; Yang J, 2011, MOL MED REP, V4, P1139, DOI 10.3892/mmr.2011.578; Yu QM, 2012, J SURG ONCOL, V106, P765, DOI 10.1002/jso.23116; Zhao Zhujiang, 2010, J Biomed Biotechnol, V2010, P737535, DOI 10.1155/2010/737535; Zu LD, 2016, CARCINOGENESIS, V37, P333, DOI 10.1093/carcin/bgw011	45	40	44	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4358	4371		10.1038/s41388-018-0285-1	http://dx.doi.org/10.1038/s41388-018-0285-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29717263	hybrid, Green Published			2022-12-28	WOS:000441144300002
J	Li, ZH; Jiang, P; Li, J; Peng, MJ; Zhao, X; Zhang, X; Chen, K; Zhang, YJ; Liu, H; Gan, L; Bi, HQ; Zhen, P; Zhu, J; Li, XW				Li, Zhonghu; Jiang, Peng; Li, Jie; Peng, Minjie; Zhao, Xin; Zhang, Xi; Chen, Kai; Zhang, Yujun; Liu, Hui; Gan, Lang; Bi, Huaqiang; Zhen, Ping; Zhu, Jin; Li, Xiaowu			Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; RNA; METASTASIS; CELLS; BIOMARKERS; MARKERS; MIRNA; GENE; SOX2	Long noncoding RNAs (lncRNAs) or exosomes have recently been shown to play vital regulatory or communication roles in cancer biology. However, the roles and mechanisms of exosomal lncRNAs in tumor invasion or metastasis of pancreatic ductal adenocarcinoma (PDAC) remain unknown. In this study, we aimed to investigate the detailed roles and mechanisms of tumor-generated exosomes in progression and metastasis of PDAC in vitro and in vivo. We identified a lncRNA-Sox2ot from exosomes of highly invasive PDAC cells, and analyzed the expression of Sox2ot in the plasma samples and found that the plasma exosomal Sox2ot expression was high and correlated with TNM stage and overall survival rate of PDAC patients. Further research showed that Sox2ot promotes epithelial-mesenchymal transition (EMT) and stem cell like properties by regulating Sox2 expression. Sox2ot competitively binds to the miR-200 family to regulate the expression of Sox2, thus promoting invasion and metastasis of PDAC. We also confirmed the transmission of the exosomes from producer cells to recipient PDAC cells, exosomal Sox2ot can promote tumor invasion and metastasis in vitro and in vivo. We further confirmed tumor generated exosomes could excrete to tumor cell or blood circulation in vivo condition. Finally, we observed a decreased exosomal Sox2ot expression in postoperative blood samples of PDAC patients. The exosomal lncRNA Sox2ot plays important roles in tumor progression and may be a useful maker for pancreatic cancer prognosis.	[Li, Zhonghu; Jiang, Peng; Li, Jie; Peng, Minjie; Zhao, Xin; Zhang, Xi; Chen, Kai; Zhang, Yujun; Liu, Hui; Gan, Lang; Bi, Huaqiang; Zhen, Ping; Zhu, Jin; Li, Xiaowu] Third Mil Med Univ, Southwest Hosp, Hepatobiliary Surg Inst, Chongqing, Peoples R China	Army Medical University	Li, XW (corresponding author), Third Mil Med Univ, Southwest Hosp, Hepatobiliary Surg Inst, Chongqing, Peoples R China.	lixw1966@163.com	Li, Xiaowu/AAF-2769-2020; bi, huaqiang/GYJ-5005-2022		National Natural Science Foundation of China [81430063]; Natural Science Foundation of Southwest Hospital [SWH2016JCYB-46]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Southwest Hospital	This work was supported by the National Natural Science Foundation of China under Grant 81430063, and the Natural Science Foundation of Southwest Hospital under Grant SWH2016JCYB-46.	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen IH, 2017, P NATL ACAD SCI USA, V114, P3175, DOI 10.1073/pnas.1618088114; Chen T, 2017, J CELL PHYSIOL, V232, P3261, DOI 10.1002/jcp.25797; Conroy T, 2016, EUR J CANCER, V57, P10, DOI 10.1016/j.ejca.2015.12.026; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Ge QY, 2014, MOLECULES, V19, P1568, DOI 10.3390/molecules19021568; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Henderson MC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00038; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Huang XY, 2015, EUR UROL, V67, P33, DOI 10.1016/j.eururo.2014.07.035; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Joyce DP, 2016, INT J CANCER, V139, P1443, DOI 10.1002/ijc.30179; Lennon AM, 2014, CANCER RES, V74, P3381, DOI 10.1158/0008-5472.CAN-14-0734; Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027; Lugea A, 2017, PANCREAS, V46, P1, DOI 10.1097/MPA.0000000000000686; Madhavan B, 2015, INT J CANCER, V136, P2616, DOI 10.1002/ijc.29324; Matsushita H, 2016, GASTROENTEROLOGY, V150, pS1086, DOI 10.1053/j.gastro.2016.02.051; Momen-Heravi F, 2014, NANOMED-NANOTECHNOL, V10, P1517, DOI 10.1016/j.nano.2014.03.014; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pope SM, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.22484; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosa A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1797692; Schaeffer D, 2010, ADV EXP MED BIOL, V702, P79, DOI 10.1007/978-1-4419-7841-7_7; Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh SK, 2015, EMBO J, V34, P517, DOI 10.15252/embj.201489574; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Syn N, 2016, TRENDS PHARMACOL SCI, V37, P606, DOI 10.1016/j.tips.2016.04.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; van den Boorn JG, 2013, ADV DRUG DELIVER REV, V65, P331, DOI 10.1016/j.addr.2012.06.011; Velpula KK, 2011, ONCOTARGET, V2, P1028; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zou YK, 2015, CARCINOGENESIS, V36, P676, DOI 10.1093/carcin/bgv027	42	158	162	2	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3822	3838		10.1038/s41388-018-0237-9	http://dx.doi.org/10.1038/s41388-018-0237-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643475				2022-12-28	WOS:000438465600005
J	Wang, JX; Dong, MJ; Xu, Z; Song, XH; Zhang, SS; Qiao, Y; Che, L; Gordan, J; Hu, KW; Liu, Y; Calvisi, DF; Chen, X				Wang, Jingxiao; Dong, Mingjie; Xu, Zhong; Song, Xinhua; Zhang, Shanshan; Qiao, Yu; Che, Li; Gordan, John; Hu, Kaiwen; Liu, Yan; Calvisi, Diego F.; Chen, Xin			Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; INTRAHEPATIC CHOLANGIOCARCINOMA; MATURE HEPATOCYTES; ALAGILLE-SYNDROME; LIVER DEVELOPMENT; CELL; RECEPTORS; LIGAND; HEPATOBLASTOMA; PROLIFERATION	Liver cancer comprises a group of malignant tumors, among which hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common. ICC is especially pernicious and associated with poor clinical outcome. Studies have shown that a subset of human ICCs may originate from mature hepatocytes. However, the mechanisms driving the trans-differentiation of hepatocytes into malignant cholangiocytes remain poorly defined. We adopted lineage tracing techniques and an established murine hepatocyte-derived ICC model by hydrodynamic injection of activated forms of AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes. Wild-type, Notch1(flox/flox), and Notch2(flox/flox) mice were used to investigate the role of canonical Notch signaling and Notch receptors in AKT/Yap-driven ICC formation. Human ICC and HCC cell lines were transfected with siRNA against Notch2 to determine whether Notch2 regulates biliary marker expression in liver tumor cells. We found that AKT/Yap-induced ICC formation is hepatocyte derived and this process is strictly dependent on the canonical Notch signaling pathway in vivo. Deletion of Notch2 in AKT/Yap-induced tumors switched the phenotype from ICC to hepatocellular adenoma-like lesions, while inactivation of Notch] in hepatocytes did not result in significant histomorphological changes. Finally, in vitro studies revealed that Notch2 silencing in ICC and HCC cell lines down-regulates the expression of Sox9 and EpCAM biliary markers. Notch2 is the major determinant of hepatocyte-derived ICC formation in mice.	[Wang, Jingxiao; Dong, Mingjie; Xu, Zhong; Song, Xinhua; Zhang, Shanshan; Qiao, Yu; Che, Li; Gordan, John; Chen, Xin] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wang, Jingxiao; Hu, Kaiwen] Beijing Univ Chinese Med, Dongfang Hosp, Beijing, Peoples R China; [Dong, Mingjie; Liu, Yan] 307 Hosp Acad Mil Med Sci, Beijing, Peoples R China; [Xu, Zhong] Guizhou Prov Peoples Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China; [Song, Xinhua] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China; [Qiao, Yu] Beijing Hosp Natl Ctr Gerontol, Dept Oncol, Beijing, Peoples R China; [Calvisi, Diego F.] Univ Med Greifswald, Inst Pathol, Greifswald, Germany	University of California System; University of California San Francisco; Beijing University of Chinese Medicine; Fifth Medical Center of Chinese PLA General Hospital; China Agricultural University; Greifswald Medical School	Chen, X (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.; Liu, Y (corresponding author), 307 Hosp Acad Mil Med Sci, Beijing, Peoples R China.; Calvisi, DF (corresponding author), Univ Med Greifswald, Inst Pathol, Greifswald, Germany.	13911798288@163.com; diego.calvisi@uni-greifswald.de; xin.chen@ucsf.edu	Wang, Jingxiao/GWU-9986-2022; Xu, Zhong/AAA-8476-2022	Wang, Jingxiao/0000-0002-7799-781X; Xu, Zhong/0000-0001-7565-6053; che, li/0000-0001-7971-8725	NIH [R01CA190606, P30DK026743]; China Scholarship Council State Scholarship Fund [201606550015]; NATIONAL CANCER INSTITUTE [R01CA136606, R01CA190606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council State Scholarship Fund(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank Dr. Rong Wang at UCSF for providing Notch1<SUP>flox/flox</SUP> mice and Dr. Gregory J. Gores at Mayo Clinic for providing the HuCC-T1 cell line. This study is supported by NIH grants R01CA190606 to X.C., P30DK026743 for UCSF Liver Center; and China Scholarship Council State Scholarship Fund No. 201606550015 to J.W.	Avila JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052133; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Che L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.73; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chen YX, 2012, HEPATOLOGY, V55, P563, DOI 10.1002/hep.24712; Cigliano A, 2017, EXPERT OPIN THER TAR, V21, P471, DOI 10.1080/14728222.2017.1310842; Croquelois A, 2005, HEPATOLOGY, V41, P487, DOI 10.1002/hep.20571; D'Souza B, 2008, ONCOGENE, V27, P5148, DOI 10.1038/onc.2008.229; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Farshidfar F, 2017, CELL REP, V19, P2878, DOI 10.1016/j.celrep.2017.06.008; Geisler F, 2008, HEPATOLOGY, V48, P607, DOI 10.1002/hep.22381; Gil-Garcia B, 2016, BIOL CELL, V108, P29, DOI 10.1111/boc.201500029; Hu JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20484; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Jeliazkova P, 2013, HEPATOLOGY, V57, P2469, DOI 10.1002/hep.26254; Katsube KI, 2005, INT J DEV BIOL, V49, P369, DOI 10.1387/ijdb.041950kk; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kodama Y, 2004, GASTROENTEROLOGY, V127, P1775, DOI 10.1053/j.gastro.2004.09.004; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lim JS, 2017, NATURE, V545, P360, DOI 10.1038/nature22323; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Merrell AJ, 2016, NAT REV MOL CELL BIO, V17, P413, DOI 10.1038/nrm.2016.24; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Morell CM, 2013, CLIN RES HEPATOL GAS, V37, P447, DOI 10.1016/j.clinre.2013.05.008; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Qi RZ, 2003, CANCER RES, V63, P8323; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Storz P, 2017, NAT REV GASTRO HEPAT, V14, P296, DOI 10.1038/nrgastro.2017.12; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Wang CM, 2009, J BIOL CHEM, V284, P16183, DOI 10.1074/jbc.M109.002105; Wong CH, 2016, WORLD J GASTROENTERO, V22, P7046, DOI 10.3748/wjg.v22.i31.7046; Wu WR, 2014, INT J CLIN EXP PATHO, V7, P3272; Wu WR, 2014, ONCOL REP, V31, P2515, DOI 10.3892/or.2014.3123; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Yuan DT, 2017, CANCER CELL, V31, P771, DOI 10.1016/j.ccell.2017.05.006; Zender S, 2013, CANCER CELL, V23, P784, DOI 10.1016/j.ccr.2013.04.019; Zhang SS, 2017, J HEPATOL, V67, P1194, DOI 10.1016/j.jhep.2017.07.006; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140	47	59	61	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3229	3242		10.1038/s41388-018-0188-1	http://dx.doi.org/10.1038/s41388-018-0188-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29545603	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-28	WOS:000435526600004
J	Caja, L; Tzavlaki, K; Dadras, MS; Tan, EJ; Hatem, G; Maturi, NP; Moren, A; Wik, L; Watanabe, Y; Savary, K; Kamali-Moghaddan, M; Uhrbom, L; Heldin, CH; Moustakas, A				Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Tan, E-Jean; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Wik, Lotta; Watanabe, Yukihide; Savary, Katia; Kamali-Moghaddan, Masood; Uhrbom, Lene; Heldin, Carl-Henrik; Moustakas, Aristidis			Snail regulates BMP and TGF beta pathways to control the differentiation status of glioma-initiating cells	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; STEM-CELLS; MESENCHYMAL TRANSITION; SELF-RENEWAL; GLIOBLASTOMA; BONE; MAINTENANCE; INDUCTION; PROGNOSIS; INTERACTS	Glioblastoma multiforme is a brain malignancy characterized by high heterogeneity, invasiveness, and resistance to current therapies, attributes related to the occurrence of glioma stem cells (GSCs). Transforming growth factor beta (TGF beta) promotes self-renewal and bone morphogenetic protein (BMP) induces differentiation of GSCs. BMP7 induces the transcription factor Snail to promote astrocytic differentiation in GSCs and suppress tumor growth in vivo. We demonstrate that Snail represses stemness in GSCs. Snail interacts with SMAD signaling mediators, generates a positive feedback loop of BMP signaling and transcriptionally represses the TGFB1 gene, decreasing TGF beta 1 signaling activity. Exogenous TGF beta 1 counteracts Snail function in vitro, and in vivo promotes proliferation and re-expression of Nestin, confirming the importance of TGFB1 gene repression by Snail. In conclusion, novel insight highlights mechanisms whereby Snail differentially regulates the activity of the opposing BMP and TGF beta pathways, thus promoting an astrocytic fate switch and repressing stemness in GSCs.	[Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden; [Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Watanabe, Yukihide; Savary, Katia; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Ludwig Canc Res, Sci Life Lab, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden; [Tan, E-Jean; Maturi, Naga P.; Uhrbom, Lene] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, SE-75185 Uppsala, Sweden; [Wik, Lotta; Kamali-Moghaddan, Masood] Uppsala Univ, Biomed Ctr, Dept Immunol Genet & Pathol, Sci Life Lab, Box 815, S-75108 Uppsala, Sweden; [Watanabe, Yukihide] Univ Tsukuba, Dept Expt Pathol, Fac Med, Tsukuba, Ibaraki, Japan; [Savary, Katia] Univ Reims, UMR CNRS MEDyC 7369, Reims, France	Uppsala University; Uppsala University; Uppsala University; Uppsala University; University of Tsukuba; Universite de Reims Champagne-Ardenne	Caja, L; Moustakas, A (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.; Caja, L; Moustakas, A (corresponding author), Uppsala Univ, Ludwig Canc Res, Sci Life Lab, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	laja.caja@imbim.uu.se; aris.moustakas@imbim.uu.se	Tan, E-Jean/J-3425-2019; Caja, Laia/J-4618-2019	Tan, E-Jean/0000-0002-4631-174X; Caja, Laia/0000-0002-8786-8763; Maturi, Nagaprathyusha/0000-0002-7726-8617	Ludwig Cancer Research; Swedish Cancer Society [CAN 2012/438, CAN 2015/438, CAN 2012/1186]; Swedish Research Council [K2013-66X-14936-10-5, 2015-02757]; Lisa Erikssons minnesfond	Ludwig Cancer Research; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Lisa Erikssons minnesfond	This work was supported by: Ludwig Cancer Research; Swedish Cancer Society (CAN 2012/438, CAN 2015/438 to ArM); and Swedish Research Council (K2013-66X-14936-10-5 to ArM, 2015-02757 to C-HH). LC was supported by postdoctoral fellowships from Lisa Erikssons minnesfond (2013) and Swedish Cancer Society (CAN 2012/1186).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Caja L, 2015, FEBS LETT, V589, P1588, DOI 10.1016/j.febslet.2015.04.058; Caja L, 2012, CURR PHARM DESIGN, V18, P4072, DOI 10.2174/138161212802430459; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ferletta M, 2011, INT J CANCER, V129, P45, DOI 10.1002/ijc.25647; Floratos A, 2010, BIOINFORMATICS, V26, P1779, DOI 10.1093/bioinformatics/btq282; Gonzalez-Gomez P, 2015, ONCOTARGET, V6, P10950, DOI 10.18632/oncotarget.3459; Haar CP, 2012, NEUROCHEM RES, V37, P1192, DOI 10.1007/s11064-011-0701-1; Herbertz S, 2015, DRUG DES DEV THER, V9, P4479, DOI 10.2147/DDDT.S86621; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Larssen P, 2017, MOL CELL PROTEOMICS, V16, P502, DOI [10.1074/mcp.M116.064725, 10.1074/mcp.A116.064725]; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Marinescu VD, 2005, NUCLEIC ACIDS RES, V33, pD91, DOI 10.1093/nar/gki103; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Nguyen DH, 2013, CANCERINCYTES, V2, DOI DOI 10.1038/PROTEX.2013.097; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Tchaicha JH, 2011, CANCER RES, V71, P6371, DOI 10.1158/0008-5472.CAN-11-0991; Grande MT, 2015, NAT MED, V21, P989, DOI 10.1038/nm.3901; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Villagrasa P, 2012, ONCOGENE, V31, P4022, DOI 10.1038/onc.2011.562; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Watanabe Y, 2016, J BIOL CHEM, V291, P12706, DOI 10.1074/jbc.M116.729699; Whissell G, 2014, NAT CELL BIOL, V16, P695, DOI 10.1038/ncb2992; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301	45	26	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2515	2531		10.1038/s41388-018-0136-0	http://dx.doi.org/10.1038/s41388-018-0136-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29449696	Green Published, hybrid			2022-12-28	WOS:000431873400005
J	Hanna, JA; Garcia, MR; Lardennois, A; Leavey, PJ; Maglic, D; Fagnan, A; Go, JC; Roach, J; Wang, YD; Finkelstein, D; Hatley, ME				Hanna, Jason A.; Garcia, Matthew R.; Lardennois, Alicia; Leavey, Patrick J.; Maglic, Dino; Fagnan, Alexandre; Go, Jonathan C.; Roach, Jordan; Wang, Yong-Dong; Finkelstein, David; Hatley, Mark E.			PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma	ONCOGENE			English	Article							DOWN-REGULATION; PEDIATRIC RHABDOMYOSARCOMA; MICRORNA THERAPEUTICS; NORMAL ERYTHROPOIESIS; TUMOR PROGRESSION; IN-VIVO; GENE; EXPRESSION; FUSION; CANCER	Rhabdomyosarcoma is the most common soft-tissue sarcoma in childhood and histologically resembles developing skeletal muscle. Alveolar rhabdomyosarcoma (ARMS) is an aggressive subtype with a higher rate of metastasis and poorer prognosis. The majority of ARMS tumors (80%) harbor a PAX3-FOXO1 or less commonly a PAX7-FOXO1 fusion gene. The presence of either the PAX3-FOXO1 or PAX7-FOXO1 fusion gene foretells a poorer prognosis resulting in clinical reclassification as either fusion-positive (FP-RMS) or fusion-negative RMS (FN-RMS). The PAX3/7-FOXO1 fusion genes result in the production of a rogue transcription factors that drive FP-RMS pathogenesis and block myogenic differentiation. Despite knowing the molecular driver of FP-RMS, targeted therapies have yet to make an impact for patients, highlighting the need for a greater understanding of the molecular consequences of PAX3-FOXO1 and its target genes including microRNAs. Here we show FP-RMS patient-derived xenografts and cell lines display a distinct microRNA expression pattern. We utilized both loss-and gain-of function approaches in human cell lines with knockdown of PAX3-FOXO1 in FP-RMS cell lines and expression of PAX3-FOXO1 in human myoblasts and identified microRNAs both positively and negatively regulated by the PAX3-FOXO1 fusion protein. We demonstrate PAX3-FOXO1 represses miR-221/222 that functions as a tumor suppressing microRNA through the negative regulation of CCND2, CDK6, and ERBB3. In contrast, miR-486-5p is transcriptionally activated by PAX3-FOXO1 and promotes FP-RMS proliferation, invasion, and clonogenic growth. Inhibition of miR-486-5p in FP-RMS xenografts decreased tumor growth, illustrating a proof of principle for future therapeutic intervention. Therefore, PAX3-FOXO1 regulates key microRNAs that may represent novel therapeutic vulnerabilities in FP-RMS.	[Hanna, Jason A.; Garcia, Matthew R.; Lardennois, Alicia; Leavey, Patrick J.; Maglic, Dino; Fagnan, Alexandre; Go, Jonathan C.; Roach, Jordan; Hatley, Mark E.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Wang, Yong-Dong; Finkelstein, David] St Jude Childrens Res Hosp, Dept Computat Biol, 332 N Lauderdale St, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Hatley, ME (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	mark.hatley@stjude.org	Hanna, Jason A./N-6157-2018; Hatley, Mark Edward/G-8764-2018; Hanna, Jason/ABH-2969-2021	Hanna, Jason A./0000-0001-7253-7964; Hatley, Mark Edward/0000-0001-7147-3946; Hanna, Jason/0000-0001-7253-7964; Lardennois, Alicia/0000-0002-5054-7448	National Cancer Institute of the National Institutes of Health [R01CA216344, K08CA151649, 5R25CA23944]; V foundation for Cancer Research; Hyundai Hope on Wheels; Alex's Lemonade Stand Foundation; American Lebanese Syrian Associated Charities; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA216344, R25CA023944, K08CA151649] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V foundation for Cancer Research; Hyundai Hope on Wheels; Alex's Lemonade Stand Foundation; American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under award numbers R01CA216344 and K08CA151649 to M.E.H. and 5R25CA23944 to D.M. and J.R. The Hatley lab is also supported by the V foundation for Cancer Research, Hyundai Hope on Wheels, and Alex's Lemonade Stand Foundation and by the American Lebanese Syrian Associated Charities.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alexander MS, 2014, J CLIN INVEST, V124, P2651, DOI 10.1172/JCI73579; Alexander MS, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-27; Ayyanathan K, 2000, CANCER RES, V60, P5803; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709; Brioschi M, 2010, NEOPLASIA, V12, P866, DOI 10.1593/neo.10482; Cardinali B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.10; Cardinali B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007607; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dey BK, 2011, MOL CELL BIOL, V31, P203, DOI 10.1128/MCB.01009-10; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; Duan FH, 2012, GENE CHROMOSOME CANC, V51, P662, DOI 10.1002/gcc.21953; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Hanna JA, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.159; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765; Hitachi K, 2014, INT J BIOCHEM CELL B, V47, P93, DOI 10.1016/j.biocel.2013.12.003; Karakatsanis A, 2013, MOL CARCINOGEN, V52, P297, DOI 10.1002/mc.21864; Kashi VP, 2015, NAT REV CANCER, V15, P426, DOI 10.1038/nrc3961; Kneitz B, 2014, CANCER RES, V74, P2591, DOI 10.1158/0008-5472.CAN-13-1606; Koelz M, 2011, INT J ONCOL, V38, P503, DOI 10.3892/ijo.2010.857; Li L, 2012, LAB INVEST, V92, P571, DOI 10.1038/labinvest.2012.10; Machado E, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500603; Mahajan P, 2015, ONCOGENE, V34, P2681, DOI 10.1038/onc.2014.209; Marshall AD, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-25; Matsuzaki J, 2015, J CLIN MED, V4, P1566, DOI 10.3390/jcm4081566; Missiaglia E, 2017, CANCER LETT, V385, P251, DOI 10.1016/j.canlet.2016.10.011; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Narducci MG, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.32; Nordberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050819; Oh HK, 2011, CLIN CANCER RES, V17, P2657, DOI 10.1158/1078-0432.CCR-10-3152; Omura N, 2016, ONCOTARGET, V7, P34977, DOI 10.18632/oncotarget.9009; Parham DM, 2013, WHO CLASSIFICATION T, P130; Peng Y, 2013, P NATL ACAD SCI USA, V110, P15043, DOI 10.1073/pnas.1307107110; Petak I, 2000, CLIN CANCER RES, V6, P4119; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ricci C, 2000, INT J CANCER, V87, P29, DOI 10.1002/1097-0215(20000701)87:1<29::AID-IJC5>3.3.CO;2-A; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Saab R, 2006, MOL CANCER THER, V5, P1299, DOI 10.1158/1535-7163.MCT-05-0383; Seyyedi SS, 2016, TUMOR BIOL, V37, P4841, DOI 10.1007/s13277-015-4289-y; Shaham L, 2015, BLOOD, V125, P1292, DOI 10.1182/blood-2014-06-581892; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Skapek SX, 2013, PEDIATR BLOOD CANCER, V60, P1411, DOI 10.1002/pbc.24532; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Song LB, 2013, CELL RES, V23, P274, DOI 10.1038/cr.2012.174; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stewart E, 2016, DEV BIOL, V411, P287, DOI 10.1016/j.ydbio.2015.03.001; Subramanian S, 2008, ONCOGENE, V27, P2015, DOI 10.1038/sj.onc.1210836; Sultan I, 2009, J CLIN ONCOL, V27, P3391, DOI 10.1200/JCO.2008.19.7483; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864; Wang LS, 2015, BLOOD, V125, P1302, DOI 10.1182/blood-2014-06-581926; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Xu J, 2012, KIDNEY INT, V82, P401, DOI 10.1038/ki.2012.84; Yang QE, 2013, DEVELOPMENT, V140, P280, DOI 10.1242/dev.087403; Youness RA, 2016, ONCOL LETT, V12, P2567, DOI 10.3892/ol.2016.4914; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x	78	25	27	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1991	2007		10.1038/s41388-017-0081-3	http://dx.doi.org/10.1038/s41388-017-0081-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367756	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000429899400004
J	Lai, Q; Wang, HY; Li, AG; Xu, YH; Tang, L; Chen, Q; Zhang, CF; Gao, Y; Song, JF; Du, ZZ				Lai, Qi; Wang, Haiyong; Li, Angui; Xu, Yinhui; Tang, Liang; Chen, Qiang; Zhang, Chunfang; Gao, Yang; Song, Jianfei; Du, Zhenzong			Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells	ONCOGENE			English	Article							PD-L1 EXPRESSION; GENE-EXPRESSION; IFN-GAMMA; IMMUNOTHERAPY; PATHWAY	IFN-gamma-induced PD-L1 expression represents the existence of tumor-specific T cells, which predicts high-response rate to anti-PD-1/L1 therapy, but loss-of-function of IFN signals (e.g., JAK mutation) induces adaptive immune resistance in patients with low-response rate. Interferon regulatory factors (IRF) are frequently epigenetic silenced in carcinogenesis, while the role of methylation in anti-PD-1/L1 therapy remains unclear. We here investigated the methylation status of IFN-gamma related genes IRF1/8 and IFN-alpha/beta-related genes IRF3/7 in lung cancer tissues and found that only highly methylated IRF1 and 7 negatively correlated to cd274 (coding PD-L1) expression, similar to JAK mutation. Interestingly, decitibine (DAC) as methylation inhibitor could hypomethylate IRF1/7 to restore PD-L1 level. Meanwhile, IRF7 enhanced constitutive PD-L1 expression, which was independent of IFN-gamma though directly promote transcription of PD-L1, leading to abrogating cytotoxic T lymphocytes (CTLs) generation which could be restored by anti-PD-L1 antibody, or siRNA-IRF7. The supplement of DAC to anti-PD-1 therapy in vivo improve the efficiency of anti-tumor with less methylated IRF1/7, more interferon-related genes expression (e.g., CXCL9) and IFN-gamma/CD8+ T-cells infiltrations, suggesting that additional treatment of DAC could rescue the ability to response to IFN in lung cancer patients with anti-PD-1/L1 therapy resistance.	[Lai, Qi; Zhang, Chunfang; Gao, Yang; Du, Zhenzong] Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Lai, Qi] Southwest Med Univ, Dept Thorac Surg, Affiliated Tradit Med Hosp, Luzhou, Sichuan, Peoples R China; [Wang, Haiyong; Li, Angui] Guilin Med Univ, Affiliated Hosp, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China; [Chen, Qiang; Song, Jianfei] Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China	Central South University; Southwest Medical University; Guilin Medical University; Guilin Medical University; Guilin Medical University	Du, ZZ (corresponding author), Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.; Du, ZZ (corresponding author), Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China.; Du, ZZ (corresponding author), Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China.; Song, JF (corresponding author), Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China.	guilinsjf@163.com; duzhenzong@sina.com			Natural Science Foundation of Guangxi [2016GXNSFAA380138]; Science Research and Technology Development Plan of Guangxi [2015BC12007]	Natural Science Foundation of Guangxi(National Natural Science Foundation of Guangxi Province); Science Research and Technology Development Plan of Guangxi	This work was supported by the Natural Science Foundation of Guangxi (2016GXNSFAA380138) and Science Research and Technology Development Plan of Guangxi (2015BC12007).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Breugom AJ, 2015, LANCET ONCOL, V16, P200, DOI 10.1016/S1470-2045(14)71199-4; Ding L, 2017, MOL CANCER THER, V16, P1068, DOI 10.1158/1535-7163.MCT-16-0454; Dunn GP, 2005, CANCER RES, V65, P3447, DOI 10.1158/0008-5472.CAN-04-4316; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Ma D, 2014, SCI REP-UK, V4, DOI 10.1038/srep06331; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mehta A, 2015, CANCER METAST REV, V34, P229, DOI 10.1007/s10555-015-9563-3; Naylor EC, 2016, SURG ONCOL CLIN N AM, V25, P601, DOI 10.1016/j.soc.2016.02.011; Ortmann CA, 2005, NUCLEIC ACIDS RES, V33, P6895, DOI 10.1093/nar/gki1001; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Ribas A, 2016, J EXP MED, V213, P2835, DOI 10.1084/jem.20161462; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Socinski MA, 2016, J THORAC ONCOL, V11, P1411, DOI 10.1016/j.jtho.2016.05.024; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Yamashita M, 2010, CANCER SCI, V101, P1708, DOI 10.1111/j.1349-7006.2010.01581.x; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Zhang Z, 2017, LEUKEMIA LYMPHOMA, V58, P969, DOI 10.1080/10428194.2016.1219903	22	38	40	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2302	2312		10.1038/s41388-018-0125-3	http://dx.doi.org/10.1038/s41388-018-0125-3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29422611				2022-12-28	WOS:000431100200007
J	Park, J; Kim, J; Park, B; Yang, KM; Sun, EJ; Tognon, CE; Sorensen, PH; Kim, SJ				Park, Jinah; Kim, Junil; Park, Bora; Yang, Kyung-Min; Sun, Eun Jin; Tognon, Cristina E.; Sorensen, Poul H.; Kim, Seong-Jin			Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHORYLATION-ACETYLATION SWITCH; GENE FUSION; RNA-SEQ; CONGENITAL FIBROSARCOMA; MYELOGENOUS LEUKEMIA; REGULATORY NETWORK; BREAST-CANCER; TRANSFORMATION; TRANSCRIPTION	Chromosomal rearrangements that facilitate tumor formation and progression through activation of oncogenic tyrosine kinases are frequently observed in cancer. The ETV6-NTRK3 (EN) fusion has been implicated in various cancers, including infantile fibrosarcoma, secretory breast carcinoma, and acute myeloblastic leukemia, and has exhibited in vivo and in vitro transforming ability. In the present study, we analyzed transcriptome alterations using DNA microarray and RNA-Seq in EN-transduced NIH3T3 fibroblasts to identify the mechanisms that are involved in EN-mediated tumorigenesis. Through functional profile assessment of EN-regulated transcriptome alterations, we found that upregulated genes by EN were mainly associated with cell motion, membrane invagination, and cell proliferation, while downregulated genes were involved in cell adhesion, which correlated with the transforming potential and increased proliferation in EN-transduced cells. KEGG pathway analysis identified the JAK-STAT signaling pathway with the highest statistical significance. Moreover, Ingenuity Pathway Analysis and gene regulatory network analysis identified the STAT1 transcription factor and its target genes as top EN-regulated molecules. We further demonstrated that EN enhanced STAT1 phosphorylation but attenuated STAT1 acetylation, eventually inhibiting the interaction between the NF-kappa B p65 subunit and acetylated STAT1. Consequently, nuclear translocation of NF-kappa B p65 and subsequent NF-kappa B activity were increased by EN. Notably, inhibition of STAT1 phosphorylation attenuated tumorigenic ability of EN in vitro and in vivo. Taken together, here we report, for the first time, STAT1 as a significant EN-regulated transcription factor and a crucial mediator of EN-induced tumorigenesis.	[Park, Jinah; Park, Bora; Yang, Kyung-Min; Sun, Eun Jin; Kim, Seong-Jin] Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, Gyeonggi Do, South Korea; [Kim, Junil] Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Kim, Junil] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA; [Tognon, Cristina E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [Sorensen, Poul H.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Kim, Seong-Jin] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Suwon 16229, Gyeonggi Do, South Korea	Seoul National University (SNU); University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University; British Columbia Cancer Agency; Seoul National University (SNU)	Kim, SJ (corresponding author), Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, Gyeonggi Do, South Korea.; Kim, SJ (corresponding author), Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Suwon 16229, Gyeonggi Do, South Korea.	jasonsjkim@snu.ac.kr		kim, junil/0000-0002-1202-1808	National Research Foundation grant of Korea [NRF-2014M3A9B5073918]; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea - Korean government [1520120]; British Columbia Cancer Foundation	National Research Foundation grant of Korea(National Research Foundation of Korea); National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea - Korean government; British Columbia Cancer Foundation	This work was supported by a National Research Foundation grant of Korea (NRF-2014M3A9B5073918), a National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (1520120) funded by the Korean government, and the British Columbia Cancer Foundation through generous donations from Team Finn and the Ride to Conquer Cancer (to PHS).	Adamaki M, 2015, LEUKEMIA RES, V39, P1285, DOI 10.1016/j.leukres.2015.09.004; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Blake J. A., 2008, CURR PROTOC BIOINFOR, DOI DOI 10.1002/0471250953.BI0702S23; Brenca M, 2016, J PATHOL, V238, P543, DOI 10.1002/path.4677; Cetinbas N, 2013, J BIOL CHEM, V288, P27940, DOI 10.1074/jbc.M113.475301; Chen JK, 2013, NAT GENET, V45, P34, DOI 10.1038/ng.2491; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fazekas D, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-7; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gridelli C, 2014, CANCER TREAT REV, V40, P300, DOI 10.1016/j.ctrv.2013.07.002; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Hix LM, 2013, J BIOL CHEM, V288, P11676, DOI 10.1074/jbc.M112.441402; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kim J, 2012, NUCLEIC ACIDS RES, V40, P8849, DOI 10.1093/nar/gks664; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kramer OH, 2010, MOL CELL ENDOCRINOL, V315, P40, DOI 10.1016/j.mce.2009.10.007; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Malone JH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-34; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tymoszuk P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-257; Vlahopoulos SA, 2015, CYTOKINE GROWTH F R, V26, P389, DOI 10.1016/j.cytogfr.2015.06.001; Wada R, 2016, PATHOL INT, V66, P431, DOI 10.1111/pin.12431; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Zaidi MR, 2011, CLIN CANCER RES, V17, P6118, DOI 10.1158/1078-0432.CCR-11-0482	46	6	6	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2270	2284		10.1038/s41388-017-0102-2	http://dx.doi.org/10.1038/s41388-017-0102-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391602				2022-12-28	WOS:000431100200005
J	Boudria, A; Abou Faycal, C; Jia, T; Gout, S; Keramidas, M; Didier, C; Lemaitre, N; Manet, S; Coll, JL; Toffart, AC; Moro-Sibilot, D; Albiges-Rizo, C; Josserand, V; Faurobert, E; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Keramidas, Michelle; Didier, Chloe; Lemaitre, Nicolas; Manet, Sandra; Coll, Jean-Luc; Toffart, Anne-Claire; Moro-Sibilot, Denis; Albiges-Rizo, Corinne; Josserand, Veronique; Faurobert, Eva; Brambilla, Christian; Brambilla, Elisabeth; Gazzeri, Sylvie; Eymin, Beatrice			VEGF(165)b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta 1 integrin/VEGFR autocrine loop	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DOWN-REGULATION; CELL CARCINOMA; CANCER; EXPRESSION; ISOFORMS; APOPTOSIS; INVASION; PROTEIN; E2F1	Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGF(xxx) and VEGF(xxx)b families encode splice variants of VEGF-A that differ only at the level of six amino acids in their C-terminal part. The expression level of VEGF(xxx) splice variants and their function as pro-angiogenic factors during tumor neo-angiogenesis have been well-described. The role of VEGF(xxx)b isoforms is less well known, but they have been shown to inhibit VEGF(xxx)-mediated angiogenesis, while being partial or weak activators of VEGFR receptors in endothelial cells. On the opposite, their role on tumor cells expressing VEGFRs at their surface remains largely unknown. In this study, we find elevated levels of VEGF(165)b, the main VEGF(xxx)b isoform, in 36% of non-small cell lung carcinoma (NSCLC), mainly lung adenocarcinoma (46%), and show that a high VEGF(165)b/VEGF(165) ratio correlates with the presence of lymph node metastases. At the molecular level, we demonstrate that VEGF(165)b stimulates proliferation and invasiveness of two lung tumor cell lines through a VEGFR/beta 1 integrin loop. We further provide evidence that the isoform-specific knockdown of VEGF(165)b reduces tumor growth, demonstrating a tumor-promoting autocrine role for VEGF(165)b in lung cancer cells. Importantly, we show that bevacizumab, an anti-angiogenic compound used for the treatment of lung adenocarcinoma patients, increases the expression of VEGF(165)b and activates the invasive VEGFR/beta 1 integrin loop. Overall, these data highlight an unexpected role of the VEGF(165)b splice variant in the progression of lung tumors and their response to anti-angiogenic therapies.	[Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Gazzeri, Sylvie; Eymin, Beatrice] CNRS, INSERM, Team RNA Splicing Cell Signaling & Response Thera, U1209,UMR 5309, F-38042 Grenoble, France; [Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Keramidas, Michelle; Didier, Chloe; Lemaitre, Nicolas; Manet, Sandra; Coll, Jean-Luc; Toffart, Anne-Claire; Moro-Sibilot, Denis; Albiges-Rizo, Corinne; Josserand, Veronique; Faurobert, Eva; Brambilla, Christian; Brambilla, Elisabeth; Gazzeri, Sylvie; Eymin, Beatrice] Univ Grenoble Alpes, Inst Avancee Biosci, F-38041 Grenoble, France; [Keramidas, Michelle; Didier, Chloe; Coll, Jean-Luc; Josserand, Veronique] CNRS, INSERM, Team Canc Targets & Expt Therapeut, U1209,UMR 5309, F-38042 Grenoble, France; [Lemaitre, Nicolas; Toffart, Anne-Claire; Moro-Sibilot, Denis; Brambilla, Christian; Brambilla, Elisabeth] CNRS, INSERM, Team Tumor Mol Pathol & Biomarkers, U1209,UMR 5309, F-38042 Grenoble, France; [Manet, Sandra; Albiges-Rizo, Corinne; Faurobert, Eva] CNRS, INSERM, Team Cell Adhes Dynam & Differentiat, U1209,UMR 5309, F-38042 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Eymin, B (corresponding author), CNRS, INSERM, Team RNA Splicing Cell Signaling & Response Thera, U1209,UMR 5309, F-38042 Grenoble, France.; Eymin, B (corresponding author), Univ Grenoble Alpes, Inst Avancee Biosci, F-38041 Grenoble, France.	Beatrice.Eymin@ujf-grenoble.fr	josserand, veronique/F-1773-2019; gazzeri, sylvie/U-4669-2019; Eymin, Beatrice/M-1962-2013; eymin, beatrice/U-4670-2019; Coll, Jean-Luc/G-2520-2013; JIA, Tao/AAZ-1963-2020; Albiges-Rizo, Corinne/M-2568-2013; gazzeri, sylvie/M-1961-2013; Toffart, Anne-Claire/N-6820-2013; Faurobert, Eva/M-2735-2013	josserand, veronique/0000-0001-6733-3801; gazzeri, sylvie/0000-0001-5817-1839; Eymin, Beatrice/0000-0002-7311-3810; eymin, beatrice/0000-0002-7311-3810; Coll, Jean-Luc/0000-0002-2453-3552; JIA, Tao/0000-0002-8358-6005; gazzeri, sylvie/0000-0001-5817-1839; Faurobert, Eva/0000-0002-2714-8537; MORO-SIBILOT, Denis/0000-0001-6776-8610; ALBIGES-RIZO, Corinne/0000-0002-6333-4150	Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer; INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010); Fondation de France (Projet Grande Ampleur 2011); ROCHE fellowship (Bourse de Recherche Fondamentale); Fondation ARC pour la Recherche Contre le Cancer; Fonds de dotation AGIR pour les Maladies Chroniques; Ministere de l'Education et de la Recherche Algerien (program PROFAS); Fondation pour La Recherche Medicale; Ligue Nationale Contre Le Cancer; Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014)	Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer; INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010); Fondation de France (Projet Grande Ampleur 2011); ROCHE fellowship (Bourse de Recherche Fondamentale); Fondation ARC pour la Recherche Contre le Cancer; Fonds de dotation AGIR pour les Maladies Chroniques; Ministere de l'Education et de la Recherche Algerien (program PROFAS); Fondation pour La Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale Contre Le Cancer(Ligue nationale contre le cancer); Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014)	Plasmid encoding VEGF<INF>165</INF>b was obtained from David Bates (University of Nottingham, UK). We thank Sophie Michallet, Floriane Albert, Celine Barrial, and Virginie Rouyre for technical assistance. We also thank Laurence David-Boudet and Adrien Mombrun for IHC performance. Thanks to Philippe Lorimier for tumor bank gestion and data retrieving. This work was supported by the Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer, the INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010), by the Fondation de France (Projet Grande Ampleur 2011), ROCHE fellowship (Bourse de Recherche Fondamentale), the Fondation ARC pour la Recherche Contre le Cancer, and the Fonds de dotation AGIR pour les Maladies Chroniques. Stephanie Gout and Tao Jia were supported by a post-doctoral fellowship from the Fondation ARC pour la Recherche Contre le Cancer. Asma Boudria was supported by the Ministere de l'Education et de la Recherche Algerien (program PROFAS) and the Fondation pour La Recherche Medicale. Cherine Abou Faycal was supported by the Ligue Nationale Contre Le Cancer. The CAR team is supported by the Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014).	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2002, CANCER RES, V62, P7203; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bates DO, 2002, CANCER RES, V62, P4123; Beasley MB, 2005, SEMIN ROENTGENOL, V40, P90, DOI 10.1053/j.ro.2005.01.001; Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cascone T, 2015, CLIN CANC RES; Catena R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-320; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635; Franzini A, 2015, GENE EXPRESSION SIGN; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Gout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046539; Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360; Hall DMS, 2014, METHODS MOL BIOL, V1070, P1, DOI 10.1007/978-1-4614-8244-4_1; Harris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035231; Huveldt D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056505; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Larrayoz M, 2014, EMBO MOL MED, V6, P539, DOI 10.1002/emmm.201303214; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Pajares MJ, 2012, J CLIN ONCOL, V30, P1129, DOI 10.1200/JCO.2011.37.4231; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Rennel ES, 2008, EUR J CANCER, V44, P1883, DOI 10.1016/j.ejca.2008.05.027; Robinson CJ, 2001, J CELL SCI, V114, P853; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Rugo HS, 2012, J CLIN ONCOL, V30, P898, DOI 10.1200/JCO.2011.38.5492; Salon C, 2007, ONCOGENE, V26, P6927, DOI 10.1038/sj.onc.1210499; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; Toffart AC, 2014, LUNG CANCER, V83, P182, DOI 10.1016/j.lungcan.2013.12.003; Toth Marta, 2012, Methods Mol Biol, V878, P121, DOI 10.1007/978-1-61779-854-2_8; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Xin H, 2016, CELL, V167, P275, DOI 10.1016/j.cell.2016.08.054; Zhang PF, 2013, ONCOL REP, V30, P341, DOI 10.3892/or.2013.2477	49	29	30	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1050	1066		10.1038/s41388-018-0486-7	http://dx.doi.org/10.1038/s41388-018-0486-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194450	Green Submitted			2022-12-28	WOS:000458624900009
J	Zhang, DD; Li, Y; Xu, Y; Kim, J; Huang, S				Zhang, Dan-Dan; Li, Yue; Xu, Yuan; Kim, Jaejik; Huang, Shuang			Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth	ONCOGENE			English	Article							7B MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASE; MIR-200 FAMILY; ENHANCES RADIOSENSITIVITY; MESENCHYMAL TRANSITION; INCREASED EXPRESSION; DOWN-REGULATION; CYCLIC-AMP; PROTEIN; APOPTOSIS	Members of microRNA-200 (miRNA-200) family have a regulatory role in epithelial to mesenchymal transition (EMT) by suppressing Zeb1 and Zeb2 expression. Consistent with its role in suppressing EMT, Hsa-miR-200c-3p (miR-200c), a member of miR-200 family is poorly expressed in mesenchymal-like triple-negative breast cancer (TNBC) cells and ectopic miR-200c expression suppresses cell migration. In this study, we demonstrated that miR-200c potently inhibited TNBC cell growth and tumor development in a mechanism distinct from its ability to downregulate Zeb1 and Zeb2 expression, because silencing them only marginally affected TNBC cell growth. We identified phosphodiesterase 7B (PDE7B) as a bona fide miR-200c target. Importantly, miR-200c-led inhibition in cell growth and tumor development was prevented by forcing PDE7B transgene expression, while knockdown of PDE7B effectively inhibited cell growth. These results suggest that miR-200c inhibits cell growth by targeting PDE7B mRNA. To elucidate mechanism underlying miR-200c/PDE7B regulation of TNBC cell growth, we showed that cAMP concentration was lower in TNBC cells compared with estrogen receptor-positive (ER +) cells, and that both miR-200c and PDE7B siRNAs were able to increase cAMP concentration in TNBC cells. High level of cellular cAMP has been shown to induce cell cycle arrest and apoptosis in TNBC cells. Our observation that ectopic expression of miR-200c triggered apoptosis indicates that it does so by elevating level of cellular cAMP. Analysis of breast tumor gene expression datasets revealed an inverse association between miR-200c and PDE7B expression. Especially, both low miR-200c and high PDE7B expression were correlated with poor survival of breast cancer patients. Our study supports a critical role of miR-200c/PDE7B relationship in TNBC tumorigenesis.	[Zhang, Dan-Dan; Xu, Yuan; Huang, Shuang] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China; [Li, Yue; Huang, Shuang] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32608 USA; [Kim, Jaejik] Sungkyunkwan Univ, Dept Stat, Seoul 03063, South Korea	Shanghai University of Traditional Chinese Medicine; State University System of Florida; University of Florida; Sungkyunkwan University (SKKU)	Zhang, DD; Huang, S (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China.; Huang, S (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32608 USA.	izhangdd@126.com; shuanghuang@ufl.edu	zhang, dan-dan/AAR-5085-2020	zhang, dan-dan/0000-0003-0591-2167	NSF of China [81773946, 81573673, 81001666]; NIH [CA187152]; Florida Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA187152] Funding Source: NIH RePORTER	NSF of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Breast Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by funding from NSF of China 81773946, 81573673, 81001666 (DZ), NIH CA187152 (SH), and Florida Breast Cancer Foundation (SH).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Brooks MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107397; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Cho-Chung YS, 2005, ANN NY ACAD SCI, V1058, P76, DOI 10.1196/annals.1359.014; CHOCHUNG YS, 1981, SCIENCE, V214, P77, DOI 10.1126/science.6269181; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Damiano V, 2017, GENE CHROMOSOME CANC, V56, P147, DOI 10.1002/gcc.22422; Dicitore A, 2016, ENDOCRINE, V51, P101, DOI 10.1007/s12020-015-0597-7; DREES M, 1993, CANCER RES, V53, P3058; Fang C, 2013, LEUKEMIA RES, V37, P536, DOI 10.1016/j.leukres.2013.02.006; Feng ZM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1655-5; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Hong SG, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003706; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hu Q, 2013, ONCOGENE, V32, P3933, DOI 10.1038/onc.2012.414; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jones R, 2017, ONCOTARGET, V8, P23727, DOI 10.18632/oncotarget.15829; Karagkouni D, 2018, NUCLEIC ACIDS RES, V46, pD239, DOI 10.1093/nar/gkx1141; Kim SN, 2001, INT J CANCER, V93, P33, DOI 10.1002/ijc.1308; Knezevic J, 2015, ONCOGENE, V34, P5997, DOI 10.1038/onc.2015.48; Korner C, 2013, J BIOL CHEM, V288, P8750, DOI 10.1074/jbc.M112.414128; Kopp F, 2014, ONCOTARGET, V5, P185, DOI 10.18632/oncotarget.1427; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Levy I, 2011, CURR OPIN PHARMACOL, V11, P689, DOI 10.1016/j.coph.2011.10.003; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Lin J, 2013, J CELL BIOCHEM, V114, P606, DOI 10.1002/jcb.24398; Liu JW, 2016, INT J NANOMED, V11, P6713, DOI 10.2147/IJN.S111647; Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maurice DH, 2014, NAT REV DRUG DISCOV, V13, P290, DOI 10.1038/nrd4228; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Naviglio S, 2010, J CELL PHYSIOL, V225, P801, DOI 10.1002/jcp.22288; Naviglio S, 2009, CANCER BIOL THER, V8, P1183, DOI 10.4161/cbt.8.12.8562; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680; Radisky DC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2885; Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642; Shimizu K, 2009, ANTICANCER RES, V29, P1119; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song CL, 2015, ONCOTARGET, V6, P34968, DOI 10.18632/oncotarget.5198; Sossey-Alaoui K, 2011, INT J CANCER, V129, P1331, DOI 10.1002/ijc.25793; Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065; Tamura M, 2015, CANCER SCI, V106, P1033, DOI 10.1111/cas.12713; Wang W, 2016, ONCOTARGET, V7, P87232, DOI 10.18632/oncotarget.13601; Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339; Yang L, 2015, ONCOTARGET, V6, P20801, DOI 10.18632/oncotarget.4600; Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052; Zhang LZ, 2011, INT J CANCER, V129, P1162, DOI 10.1002/ijc.25785; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105; Zheng Q, 2017, CELL DEATH DIFFER, V24, P2161, DOI 10.1038/cdd.2017.136	55	17	21	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1106	1120		10.1038/s41388-018-0499-2	http://dx.doi.org/10.1038/s41388-018-0499-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30209363	Green Accepted			2022-12-28	WOS:000458624900013
J	Gilbert, SM; Oliphant, CJ; Hassan, S; Peille, AL; Bronsert, P; Falzoni, S; Di Virgilio, F; McNulty, S; Lara, R				Gilbert, S. M.; Oliphant, C. J.; Hassan, S.; Peille, A. L.; Bronsert, P.; Falzoni, S.; Di Virgilio, F.; McNulty, S.; Lara, R.			ATP in the tumour microenvironment drives expression of nfP2X(7), a key mediator of cancer cell survival	ONCOGENE			English	Article							P2X(7) RECEPTOR; P2X7 RECEPTOR; P-2Z RECEPTOR; ACTIVATION; INCREASES; PHARMACOLOGY; LYMPHOCYTES; RELEASE; MOUSE	The ATP-gated receptor P2X(7) is expressed in multiple malignant tumours including neuroblastoma, melanoma, prostate, lung and breast. P2X(7) has a significant role in mediating diverse cell responses, which upon dysregulation are associated with tumour initiation and development. The rapid, ATP-mediated activation of P2X(7) induces a fast-inward cation current in cells. However, prolonged ATP-mediated activation of P2X(7) leads to formation of a pore that increases membrane permeability and eventually causes cell death. This presents a potential paradox, as the tumour microenvironment contains extracellular ATP at levels sufficient to activate the P2X(7) pore and trigger cell death. However, P2X(7) expression is associated with enhanced cancer cell survival, proliferation and metastatic potential. At least one distinct conformational form of P2X(7), termed non-pore functional P2X(7) (nfP2X(7)), has been described, which is not able to form a functional pore. We demonstrate for the first time in this study that exposure to a high ATP concentration, equivalent to those measured in the tumour microenvironment, drives nfP2X(7) expression and also that nfP2X(7) is essential for tumour cell survival. We show that monoclonal antibodies raised against a P2X(7) amino acid sequence (200-216), whose conformation is distinct from that of wild-type (WT) P2X(7), bind specifically to nfP2X(7) expressed on the surface of tumour cells. We also show that nfP2X(7) is broadly expressed in patient-derived tumour sections from a wide range of cancers. Therefore, antibodies raised against E200 provide tools that can differentiate between forms of the P2X(7) receptor that have a key role in cancer.	[Gilbert, S. M.; Oliphant, C. J.; McNulty, S.; Lara, R.] Queen Mary Univ London, Blizard Inst, Babraham Res Campus, Cambridge, England; [Hassan, S.] Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, London, England; [Peille, A. L.] Charles River Discovery Res Serv Germany GmbH, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Med Ctr, Inst Surg Pathol, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Med Ctr, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Fac Med, Freiburg, Germany; [Falzoni, S.; Di Virgilio, F.] Univ Ferrara, Dept Morphol Surg & Expt Med, Sect Pathol Oncol & Expt Biol, Ferrara, Italy	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of London; Queen Mary University London; University of London; Queen Mary University London; University of Freiburg; University of Freiburg; University of Freiburg; University of Ferrara	Lara, R (corresponding author), Queen Mary Univ London, Blizard Inst, Babraham Res Campus, Cambridge, England.	romain.lara@biosceptre.com	Lara, Romain/AAE-8108-2020; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Falzoni, Simonetta/0000-0002-6594-0357	Innovate UK SMART Proof of Concept award [710832]	Innovate UK SMART Proof of Concept award(UK Research & Innovation (UKRI)Innovate UK)	This work was supported by Innovate UK SMART Proof of Concept award (Grant number 710832). We thank Julian A Barden and Angus Gidley-Baird for their support and critical review of the manuscript.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Amoroso F, 2016, ONCOTARGET, V7, P49664, DOI 10.18632/oncotarget.10430; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Barden J. A., 2014, J CLIN CELL IMMUNOL, V5, P237, DOI [10.4172/2155-9899.1000237, DOI 10.4172/2155-9899.1000237]; Barden JA, 2003, FEBS LETT, V538, P159, DOI 10.1016/S0014-5793(03)00172-8; Barden JA, 2011, Patent No. [WO2011020155 A1, 2011020155A1]; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; Donnelly-Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476-5381.2009.00233.x; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilbert SM, 2017, BRIT J DERMATOL, V177, P117, DOI 10.1111/bjd.15364; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lohman AW, 2012, CARDIOVASC RES, V95, P269, DOI 10.1093/cvr/cvs187; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Qiu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114371; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Robert R, 2008, MOL PHARMACOL, V73, P478, DOI 10.1124/mol.107.040725; Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x; Slater M, 2004, BREAST CANCER RES TR, V83, P1, DOI 10.1023/B:BREA.0000010670.85915.0f; Slater M, 2003, MELANOMA RES, V13, P137, DOI 10.1097/00008390-200304000-00005; Sluyter R, 2017, ADV EXP MED BIOL, V1051, P17, DOI 10.1007/5584_2017_59; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tan C, 2015, EXP THER MED, V10, P1472, DOI 10.3892/etm.2015.2705; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7; Zhang XJ, 2004, LEUKEMIA RES, V28, P1313, DOI 10.1016/j.leukres.2004.04.001	47	83	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					194	208		10.1038/s41388-018-0426-6	http://dx.doi.org/10.1038/s41388-018-0426-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087439	Green Published, hybrid			2022-12-28	WOS:000455366700004
J	Castagnino, A; Castro-Castro, A; Irondelle, M; Guichard, A; Lodillinsky, C; Fuhrmann, L; Vacher, S; Aguera-Gonzalez, S; Zagryazhskaya-Masson, A; Romao, M; El Kesrouani, C; Noegel, AA; Dubois, T; Raposo, G; Bear, JE; Clemen, CS; Vincent-Salomon, A; Bieche, I; Chavrier, P				Castagnino, Alessia; Castro-Castro, Antonio; Irondelle, Marie; Guichard, Alan; Lodillinsky, Catalina; Fuhrmann, Laetitia; Vacher, Sophie; Aguera-Gonzalez, Sonia; Zagryazhskaya-Masson, Anna; Romao, Maryse; El Kesrouani, Carole; Noegel, Angelika A.; Dubois, Thierry; Raposo, Graca; Bear, James E.; Clemen, Christoph S.; Vincent-Salomon, Anne; Bieche, Ivan; Chavrier, Philippe			Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function	ONCOGENE			English	Article							ACTIN-BINDING; ARP2/3 COMPLEX; MATRIX-METALLOPROTEINASE; MOLECULAR-MECHANISMS; CORTACTIN PROMOTES; EXOSOME SECRETION; INVASION; WASH; METASTASIS; EXPRESSION	Membrane type 1-matrix metalloproteinase (MT1-MMP), a membrane-tethered protease, is key for matrix breakdown during cancer invasion and metastasis. Assembly of branched actin networks by the Arp2/3 complex is required for MT1-MMP traffic and formation of matrix-degradative invadopodia. Contrasting with the well-established role of actin filament branching factor cortactin in invadopodia function during cancer cell invasion, the contribution of coronin-family debranching factors to invadopodia-based matrix remodeling is not known. Here, we investigated the contribution of coronin 1C to the invasive potential of breast cancer cells. We report that expression of coronin 1C is elevated in invasive human breast cancers, correlates positively with MT1-MMP expression in relation with increased metastatic risk and is a new independent prognostic factor in breast cancer. We provide evidence that, akin to cortactin, coronin 1C is required for invadopodia formation and matrix degradation by breast cancer cells lines and for 3D collagen invasion by multicellular spheroids. Using intravital imaging of orthotopic human breast tumor xenografts, we find that coronin 1C accumulates in structures forming in association with collagen fibrils in the tumor microenvironment. Moreover, we establish the role of coronin 1C in the regulation of positioning and trafficking of MT1-MMP-positive endolysosomes. These results identify coronin 1C as a novel player of the multi-faceted mechanism responsible for invadopodia formation, MT1-MMP surface exposure and invasiveness in breast cancer cells.	[Castagnino, Alessia; Castro-Castro, Antonio; Irondelle, Marie; Guichard, Alan; Lodillinsky, Catalina; Aguera-Gonzalez, Sonia; Zagryazhskaya-Masson, Anna; Chavrier, Philippe] PSL Res Univ, CNRS, UMR144, Inst Curie,Membrane & Cytoskeleton Dynam Grp, 26 Rue Ulm, F-75005 Paris, France; [Irondelle, Marie] PSL Res Univ, Cell & Tissue Imaging Facil, Inst Curie, PICT,IBiSA, 26 Rue Ulm, F-75005 Paris, France; [Lodillinsky, Catalina] Univ Buenos Aires, Fac Med, Inst Oncol AH Roffo, Area Invest, San Martin 5481,C1417DTB, Buenos Aires, DF, Argentina; [Lodillinsky, Catalina] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Fuhrmann, Laetitia; El Kesrouani, Carole; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Pathol Genet Immunol Dept, 26 Rue Ulm, F-75005 Paris, France; [Vacher, Sophie; Bieche, Ivan] PSL Res Univ, Inst Curie, Dept Genet, Pharmacogenom Unit, 26 Rue Ulm, F-75005 Paris, France; [Romao, Maryse; Raposo, Graca] PSL Res Univ, CNRS, Biogenesis & Funct Lysosome Related Organelles Gr, Inst Curie,UMR144, 26 Rue Ulm, F-75005 Paris, France; [Noegel, Angelika A.; Clemen, Christoph S.] Univ Cologne, Med Fac, Inst Biochem 1, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany; [Dubois, Thierry] PSL Res Univ, Inst Curie, Translat Res Dept, Breast Canc Biol Grp, Paris, France; [Bear, James E.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Bear, James E.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27515 USA; [Clemen, Christoph S.] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Heimer Inst Muscle Res, Dept Neurol, Burkle de la Camp Pl 1, D-44789 Bochum, Germany; [Bieche, Ivan] Paris Descartes Univ, Sorbonne Paris Cite, Fac Pharmaceut & Biol Sci, EA7331, 4 Ave Observ, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Cologne; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Ruhr University Bochum; UDICE-French Research Universities; Universite Paris Cite	Chavrier, P (corresponding author), PSL Res Univ, CNRS, UMR144, Inst Curie,Membrane & Cytoskeleton Dynam Grp, 26 Rue Ulm, F-75005 Paris, France.	philippe.chavrier@curie.fr	CHAVRIER, Philippe/B-4707-2010; CHAVRIER, Philippe/AAG-2645-2020	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Raposo, graca/0000-0001-9590-1298; VACHER, Sophie/0000-0002-0042-6023; Guichard, Alan/0000-0001-8623-9570	French National Research Infrastructure France-BioImaging [ANR10-INBS-04]; Worldwide Cancer Research [16-1235]; EMBO Long Term postdoctoral fellowship; Institut National du Cancer [INCA_6521, INCa PLBIO14-161, INCA_ 6521]; INVADE grant from ITMO Cancer (Call Systems Biology 2012); INCa [INCa PLBIO14-161]; German Research Foundation (DFG) [113/22-2]; Fondation pour la Recherche Medicale (FRM) [DGE20111123020]; Cancerople-IdF [2012-2-EML-04-IC-1]; InCA (Cancer National Institute) [2011-1-LABEL-IC-4]; SiRIC [INCa-DGOS-4654]; 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer'	French National Research Infrastructure France-BioImaging; Worldwide Cancer Research; EMBO Long Term postdoctoral fellowship(European Molecular Biology Organization (EMBO)); Institut National du Cancer(Institut National du Cancer (INCA) France); INVADE grant from ITMO Cancer (Call Systems Biology 2012); INCa(Institut National du Cancer (INCA) France); German Research Foundation (DFG)(German Research Foundation (DFG)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Cancerople-IdF; InCA (Cancer National Institute); SiRIC; 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer'	The authors greatly acknowledge the Breast Cancer Study Group and patients of Institut Curie for breast tumor samples. They thank the Cell and Tissue Imaging facility (PICT-IBiSA) and Nikon Imaging Centre, Institut Curie, member of the French National Research Infrastructure France-BioImaging (ANR10-INBS-04) for help with image acquisition and Dr Jakko van Rheenen for help with the mammary window and intravital imaging. AC was supported by a grant from Worldwide Cancer Research (Grant 16-1235 to PC), ACC by an EMBO Long Term postdoctoral fellowship and a grant from 'Institut National du Cancer' (INCA_6521 to PC), AG by INVADE grant from ITMO Cancer (Call Systems Biology 2012) to PC, SAG by a grant from INCa (INCa PLBIO14-161 to PC). and AAN and CSC by a grant from the German Research Foundation (DFG NO 113/22-2). The intravital imaging was supported by the Fondation pour la Recherche Medicale (FRM No DGE20111123020), the Cancerople-IdF (no 2012-2-EML-04-IC-1), InCA (Cancer National Institute, no 2011-1-LABEL-IC-4) and SiRIC (INCa-DGOS-4654). This work was supported by grants from 'Institut National du Cancer' (INCa PLBIO14-161 and INCA_ 6521), Worldwide Cancer Research (Grant 16-1235) and 'Equipe labellisee 2015' from 'Ligue Nationale contre le Cancer' to PC.	Abella JVG, 2016, NAT CELL BIOL, V18, P76, DOI 10.1038/ncb3286; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Cai L, 2008, CELL, V134, P828, DOI 10.1016/j.cell.2008.06.054; Cai L, 2007, J CELL SCI, V120, P1779, DOI 10.1242/jcs.007641; Cai L, 2007, CELL, V128, P915, DOI 10.1016/j.cell.2007.01.031; Castro-Castro A, 2016, ANNU REV CELL DEV BI, V32, P555, DOI 10.1146/annurev-cellbio-111315-125227; Castro-Castro A, 2012, EUR J CELL BIOL, V91, P950, DOI 10.1016/j.ejcb.2012.07.001; Chan KT, 2012, BIOCHEM J, V444, P89, DOI 10.1042/BJ20120209; Chan KT, 2011, TRENDS CELL BIOL, V21, P481, DOI 10.1016/j.tcb.2011.04.004; Clark ES, 2009, ONCOGENE, V28, P431, DOI 10.1038/onc.2008.389; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gomez TS, 2012, MOL BIOL CELL, V23, P3215, DOI 10.1091/mbc.E12-02-0101; Gomez TS, 2009, DEV CELL, V17, P699, DOI 10.1016/j.devcel.2009.09.009; Holtta-Vuori M, 2012, CIRC RES, V110, P450, DOI 10.1161/CIRCRESAHA.111.256842; Hong NH, 2015, J CELL BIOL, V210, P753, DOI 10.1083/jcb.201412127; Hoshino D, 2013, CELL REP, V5, P1159, DOI 10.1016/j.celrep.2013.10.050; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Hurbain I, 2017, METHODS MOL BIOL, V1594, P43, DOI 10.1007/978-1-4939-6934-0_4; Juin A, 2012, MOL BIOL CELL, V23, P297, DOI 10.1091/mbc.E11-07-0594; Kirkbride KC, 2012, CYTOSKELETON, V69, P625, DOI 10.1002/cm.21051; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Liu CL, 2017, ONCOTARGET, V8, P42043, DOI 10.18632/oncotarget.14927; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Macpherson IR, 2014, J CELL SCI, V127, P3893, DOI 10.1242/jcs.135947; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Marchesin V, 2015, J CELL BIOL, V211, P339, DOI 10.1083/jcb.201506002; Marchesin V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121747; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Molinie N, 2018, PHYSIOL REV, V98, P215, DOI 10.1152/physrev.00006.2017; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Puthenveedu MA, 2010, CELL, V143, P761, DOI 10.1016/j.cell.2010.10.003; Ren G, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-67; Rosentreter A, 2007, EXP CELL RES, V313, P878, DOI 10.1016/j.yexcr.2006.12.015; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Sibarita JB, 2005, ADV BIOCHEM ENG BIOT, V95, P201, DOI 10.1007/b102215; Sinha S, 2016, J CELL BIOL, V214, P197, DOI 10.1083/jcb.201601025; Siton O, 2011, CURR BIOL, V21, P2092, DOI 10.1016/j.cub.2011.11.010; Smith SE, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0855-0; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Thal DR, 2008, J PATHOL, V214, P415, DOI 10.1002/path.2308; Wang J, 2014, MOL ONCOL, V8, P1690, DOI 10.1016/j.molonc.2014.07.006; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Willett R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01871-z; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wu L, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-17; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Ziemann A, 2013, NEURO-ONCOLOGY, V15, P548, DOI 10.1093/neuonc/nos388	62	30	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6425	6441		10.1038/s41388-018-0422-x	http://dx.doi.org/10.1038/s41388-018-0422-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30065298	Green Submitted			2022-12-28	WOS:000452989100004
J	Chow, RD; Chen, SD				Chow, Ryan D.; Chen, Sidi			Sno-derived RNAs are prevalent molecular markers of cancer immunity	ONCOGENE			English	Article							SMALL NUCLEOLAR RNAS; LONG NONCODING RNAS; INTRATUMOR HETEROGENEITY; MICRORNA; SNORNAS; EXPRESSION; RESISTANCE; PATTERNS; ANTIBODY; PLATFORM	Small nucleolar RNAs (snoRNAs) constitute a family of noncoding RNAs that are classically known as guide RNAs for processing and modification of ribosomal RNAs. Recently, it was discovered that snoRNAs can be further processed into sno-derived RNAs (sdRNAs), some of which are known to exhibit microRNA-like properties. SdRNAs have been implicated in human cancer; however, a systems-level sdRNA landscape in human cancers is lacking. Through integrative analysis of similar to 22 nt size-selected smRNA-seq datasets from 10,262 patient samples across 32 cancer types, we mapped a pan-cancer sdRNAome and interrogated its signatures in multiple clinically relevant features, particularly cancer immunity and clinical outcome. Aggregating sdRNA abundances by parental snoRNAs, these expression signatures alone are sufficient to distinguish patients with distinct cancer types. Interestingly, a large panel of sdRNAs are significantly correlated with features of the tumor-immune microenvironment, such as immunosuppressive markers, CD8(+) T cell infiltration, cytolytic T cell activity, and tumor vasculature. A set of individual sdRNAs with tumor-immune signatures can also stratify patient survival. These findings implicate snoRNAs and their derivative sdRNAs as a class of prevalent noncoding molecular markers of human cancer immunity.	[Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Syst Biol Inst, West Haven, CT 06516 USA; [Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Med Scientist Training Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Biol & Biomed Sci Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Immunobiol Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Comprehens Canc Ctr, New Haven, CT 06510 USA; [Chen, Sidi] Yale Univ, Sch Med, Stem Cell Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Chen, SD (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Syst Biol Inst, West Haven, CT 06516 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Med Scientist Training Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Biol & Biomed Sci Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Immunobiol Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Comprehens Canc Ctr, New Haven, CT 06510 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Stem Cell Ctr, New Haven, CT 06520 USA.	sidi.chen@yale.edu	Chow, Ryan/ABF-1119-2021; CHEN, SIDI/D-8284-2016	Chow, Ryan/0000-0002-1872-6307; CHEN, SIDI/0000-0002-3819-5005	Yale SBI/Genetics Startup Fund, Damon Runyon [DRG-2117-12, DFS-13-15]; Melanoma Research Alliance [412806, 16-003524]; St.-Baldrick's Foundation [426685]; Breast Cancer Alliance; Cancer Research Institute (CLIP); AACR [499395, 17-20-01-CHEN]; Mary Kay Foundation [017-81]; V Foundation [V2017-022]; DoD [W81XWH-17-1-0235]; NIH/NCI [1U54CA209992, 5P50CA196530-A10805, 4P50CA121974-A08306]; NIH MSTP training grant [T32GM007205]; Ludwig Family Foundation; NATIONAL CANCER INSTITUTE [U54CA209992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	Yale SBI/Genetics Startup Fund, Damon Runyon; Melanoma Research Alliance; St.-Baldrick's Foundation; Breast Cancer Alliance; Cancer Research Institute (CLIP); AACR; Mary Kay Foundation; V Foundation; DoD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH MSTP training grant; Ludwig Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank all members in Chen laboratory for their support. We thank Yale High Performance Computing staff for assistance. S.C. is supported by Yale SBI/Genetics Startup Fund, Damon Runyon (DRG-2117-12 and DFS-13-15), Melanoma Research Alliance (412806 and 16-003524), St.-Baldrick's Foundation (426685), Breast Cancer Alliance, Cancer Research Institute (CLIP), AACR (499395, 17-20-01-CHEN), The Mary Kay Foundation (017-81), The V Foundation (V2017-022), Ludwig Family Foundation, DoD (W81XWH-17-1-0235) and NIH/NCI (1U54CA209992, 5P50CA196530-A10805, and 4P50CA121974-A08306). R.D.C. is supported by the NIH MSTP training grant (T32GM007205).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chu A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv808; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Falaleeva M, 2013, BIOESSAYS, V35, P46, DOI 10.1002/bies.201200117; Freedman JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11106; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Heneghan HM, 2010, ANN SURG, V251, P499, DOI 10.1097/SLA.0b013e3181cc939f; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jackowiak P, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3891-3; Jacobsen A, 2013, NAT STRUCT MOL BIOL, V20, P1325, DOI 10.1038/nsmb.2678; Jorjani H, 2016, NUCLEIC ACIDS RES, V44, P5068, DOI 10.1093/nar/gkw386; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kishore S, 2010, HUM MOL GENET, V19, P1153, DOI 10.1093/hmg/ddp585; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; Krishnan P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162622; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JQ, 2015, AM J CANCER RES, V5, P472; Li ZH, 2012, NUCLEIC ACIDS RES, V40, P6787, DOI 10.1093/nar/gks307; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mannoor K, 2012, BBA-REV CANCER, V1826, P121, DOI 10.1016/j.bbcan.2012.03.005; Martens-Uzunova ES, 2013, CANCER LETT, V340, P201, DOI 10.1016/j.canlet.2012.11.058; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Michel CI, 2011, CELL METAB, V14, P33, DOI 10.1016/j.cmet.2011.04.009; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Morris GE, 2008, BBA-MOL CELL RES, V1783, P2108, DOI 10.1016/j.bbamcr.2008.07.016; Ono M, 2011, NUCLEIC ACIDS RES, V39, P3879, DOI 10.1093/nar/gkq1355; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Patterson DG, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0032-8; Pundhir S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12062; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Sahoo T, 2008, NAT GENET, V40, P719, DOI 10.1038/ng.158; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schubert T, 2012, MOL CELL, V48, P434, DOI 10.1016/j.molcel.2012.08.021; Scott MS, 2012, NUCLEIC ACIDS RES, V40, P3676, DOI 10.1093/nar/gkr1233; Scott MS, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000507; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Starega-Roslan J, 2011, NUCLEIC ACIDS RES, V39, P257, DOI 10.1093/nar/gkq727; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang QY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10966; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; Xu B, 2017, ONCOTARGET, V8, P43953, DOI 10.18632/oncotarget.16693; Yoshida K, 2017, EBIOMEDICINE, V22, P68, DOI 10.1016/j.ebiom.2017.07.009; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	71	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6442	6462		10.1038/s41388-018-0420-z	http://dx.doi.org/10.1038/s41388-018-0420-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30072739	Green Accepted			2022-12-28	WOS:000452989100005
J	Huang, XJ; Xie, XH; Liu, P; Yang, L; Chen, B; Song, CL; Tang, HL; Xie, XM				Huang, Xiaojia; Xie, Xinhua; Liu, Peng; Yang, Lu; Chen, Bo; Song, Cailu; Tang, Hailin; Xie, Xiaoming			Adam12 and Inc015192 act as ceRNAs in breast cancer by regulating miR-34a	ONCOGENE			English	Article							LONG NONCODING RNA; FEEDBACK LOOP; METASTASIS; EXPRESSION; INVASION; CELLS; MICRORNAS; EMT	Long non-coding RNAs (lncRNAs) are reported to play vital roles in the progress of multiple cancers. However, the functions of lncRNAs in breast cancer remain to be discovered. We performed microarrays to identify the differentially expressed mRNAs and lncRNAs in breast tissues with or without miR-34a knockout. To explore the functions of the differentially expressed mRNA and lncRNA in breast cancer, we conducted a series of experiments. We found that Adam12 and lnc015192 were significantly upregulated in miR-34a knockout breast tissues. Knockdown of Adam12 and lnc015192 inhibited breast cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT). Further experiments revealed that lnc015192 regulated Adam12 expression by functioning as a competing endogenous RNA (ceRNA) for miR-34a. In summary, our study demonstrate that Adam12 and lnc015192 promote breast cancer metastasis partly by sponging miR-34a through the ceRNA mechanism.	[Huang, Xiaojia; Xie, Xinhua; Liu, Peng; Yang, Lu; Chen, Bo; Song, Cailu; Tang, Hailin; Xie, Xiaoming] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Tang, HL; Xie, XM (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	tanghl@sysucc.org.cn; xiexm@sysucc.org.cn	Chen, Bo/GRS-7546-2022		National Natural Science Foundation of China [81672598, 81772961]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by funds from the National Natural Science Foundation of China (81672598 and 81772961).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Dong R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.143; Duffy MJ, 2009, CLIN CANCER RES, V15, P1140, DOI 10.1158/1078-0432.CCR-08-1585; Eckert MA, 2017, J CELL SCI, V130, P2036, DOI 10.1242/jcs.198200; Frohlich C, 2006, CLIN CANCER RES, V12, P7359, DOI 10.1158/1078-0432.CCR-06-1066; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jang E, 2016, BIOMATERIALS, V105, P12, DOI 10.1016/j.biomaterials.2016.07.036; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li LS, 2012, MOL THER, V20, P2326, DOI 10.1038/mt.2012.201; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LF, 2017, ONCOTARGET, V8, P31386, DOI 10.18632/oncotarget.15607; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rao VH, 2012, ONCOGENE, V31, P2888, DOI 10.1038/onc.2011.460; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Wang JW, 2016, INT J CANCER, V139, P1327, DOI 10.1002/ijc.30173; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang LH, 2016, ELIFE, V5, DOI 10.7554/eLife.14620; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xiao XS, 2016, SCI REP-UK, V6, DOI 10.1038/srep21735; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Zhu M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14718	34	36	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6316	6326		10.1038/s41388-018-0410-1	http://dx.doi.org/10.1038/s41388-018-0410-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30042416				2022-12-28	WOS:000452384400003
J	Shi, L; Tang, XL; Qian, MX; Liu, ZJ; Meng, FB; Fu, L; Wang, ZM; Zhu, WG; Huang, JD; Zhou, ZJ; Liu, BH				Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Wang, Zimei; Zhu, Wei-Guo; Huang, Jian-Dong; Zhou, Zhongjun; Liu, Baohua			A SIRT1-centered circuitry regulates breast cancer stemness and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-CELLS; SIRT1; EXPRESSION; PROTEIN; IDENTIFICATION; DEACETYLASE; INDUCTION; HETEROGENEITY; LOCALIZATION	Cancer stem cell (CSC)-dictated intratumor heterogeneity accounts for the majority of drug-resistance and distant metastases of breast cancers. Here, we identify a SIRT1-PRRX1-KLF4-ALDH1 circuitry, which couples CSCs, chemo-resistance, metastasis and aging. Pro-longevity protein SIRT1 deacetylates and stabilizes the epithelial-to-mesenchymal-transition (EMT) inducer PRRX1, which inhibits the transcription of core stemness factor KLF4. Loss of SIRT1 destabilizes PRRX1, disinhibits KLF4, and activates the transcription of ALDH1, which induces and functionally marks CSCs, resulting in chemo-resistance and metastatic relapse. Clinically, the level of PRRX1 is positively linked to SIRT1, whereas KLF4 is reversely correlated. Importantly, KLF4 inhibitor Kenpaullone sensitizes breast cancer cells and xenograft tumors to Paclitaxel and improves therapeutic effects. Our findings delineate a SIRT1-centered circuitry that regulates CSC origination, and targeting this pathway might be a promising therapeutic strategy.	[Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Wang, Zimei; Zhu, Wei-Guo; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Guangdong Key Lab Genome Stabil & Human Dis Preve, Shenzhen 518060, Peoples R China; [Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, MRC, Shenzhen 518060, Peoples R China; [Shi, Lei; Huang, Jian-Dong; Zhou, Zhongjun] Univ Hong Kong, Sch Biomed Sci, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Wang, Zimei; Zhu, Wei-Guo; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China; [Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Carson Int Canc Ctr, Shenzhen 518060, Peoples R China	Shenzhen University; Shenzhen University; University of Hong Kong; Shenzhen University; Shenzhen University	Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Guangdong Key Lab Genome Stabil & Human Dis Preve, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, MRC, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Carson Int Canc Ctr, Shenzhen 518060, Peoples R China.	ppliew@szu.edu.cn	Liu, Baohua/AAH-3685-2020; Fu, Li/F-7182-2010; Liu, Baohua/C-9594-2014; Zhou, Zhongjun/C-4476-2009; /C-4277-2009	Liu, Baohua/0000-0002-1599-8059; Fu, Li/0000-0003-2643-6278; Liu, Baohua/0000-0002-1599-8059; Zhou, Zhongjun/0000-0001-7092-8128; Shi, Lei/0000-0002-6043-8819; /0000-0001-7531-2816; Zhu, Wei-Guo/0000-0001-8385-6581	National Natural Science Foundation of China [81422016, 91439133, 81571374, 81501206, 81702909]; National Key R&D Program of China [2017YFA0503900, 2016YFC0904600]; Research Grant Council of Hong Kong [773313, HKU2/CRF/13G]; Natural Science Foundation of Guangdong Province [2014A030308011, 2015A030308007]; Shenzhen Science and Technology Innovation Commission [CXZZ20140903103747568, JCYJ20160226191451487, JCYJ20130329104732074]; Discipline Construction Funding of Shenzhen (2016); China Postdoctoral Science Foundation [2015M582419]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Research Grant Council of Hong Kong(Hong Kong Research Grants Council); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Innovation Commission; Discipline Construction Funding of Shenzhen (2016); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank Dr Qi-Wei Zhai (Shanghai Institutes for Biological Sciences, China) for EGFP-SIRT1 construct and Dr Zhen-Kun Lou (Mayo Clinic College of Medicine, USA) for FLAG-SIRT1 construct. This project is supported by research grants from National Natural Science Foundation of China (81422016, 91439133, 81571374, 81501206 and 81702909), National Key R&D Program of China (2017YFA0503900 and 2016YFC0904600), Research Grant Council of Hong Kong (773313 and HKU2/CRF/13G), Natural Science Foundation of Guangdong Province (2014A030308011 and 2015A030308007), Shenzhen Science and Technology Innovation Commission (CXZZ20140903103747568, JCYJ20160226191451487 and JCYJ20130329104732074), Discipline Construction Funding of Shenzhen (2016) and China Postdoctoral Science Foundation (2015M582419).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Byles V, 2010, INT J BIOL SCI, V6, P599; Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Ertel A, 2012, CELL CYCLE, V11, P253, DOI 10.4161/cc.11.2.19006; Finicelli M, 2014, ONCOTARGET, V5, P9678, DOI 10.18632/oncotarget.1936; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Giordano SH, 2012, J CLIN ONCOL, V30, P2232, DOI 10.1200/JCO.2011.40.1273; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Islam F, 2015, EXP MOL PATHOL, V98, P184, DOI 10.1016/j.yexmp.2015.02.002; Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li P, 2014, EXP BIOL MED, V239, P813, DOI 10.1177/1535370214538727; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Liu XP, 2013, NAT CELL BIOL, V15, P829, DOI 10.1038/ncb2765; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nishi M, 2014, ONCOGENE, V33, P643, DOI 10.1038/onc.2012.614; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ren RT, 2017, CELL METAB, V26, P460, DOI 10.1016/j.cmet.2017.07.019; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tacutu R, 2013, NUCLEIC ACIDS RES, V41, pD1027, DOI 10.1093/nar/gks1155; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Zhao D, 2014, J CLIN INVEST, V124, P5453, DOI 10.1172/JCI76611	51	41	43	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6299	6315		10.1038/s41388-018-0370-5	http://dx.doi.org/10.1038/s41388-018-0370-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038266	Green Published, hybrid			2022-12-28	WOS:000452384400002
J	Li, TF; Deng, Y; Shi, Y; Tian, RJ; Chen, YL; Zou, L; Kazi, JU; Ronnstrand, L; Feng, B; Chan, SO; Chan, WY; Sun, JM; Zhao, H				Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Ronnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui			Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma	ONCOGENE			English	Article							POSITIVE NSCLC; CELL LYMPHOMA; IBRUTINIB; BTK; INHIBITOR; ACTIVATION; RESISTANCE; IDENTIFICATION; CRIZOTINIB; MUTATIONS	Aberrant activation of anaplastic lymphoma kinase (ALK) can cause sporadic and familial neuroblastoma. Using a proteomics approach, we identified Bruton's tyrosine kinase (BTK) as a novel ALK interaction partner, and the physical interaction was confirmed by co-immunoprecipitation. BTK is expressed in neuroblastoma cell lines and tumor tissues. Its high expression correlates with poor relapse-free survival probability of neuroblastoma patients. Mechanistically, we demonstrated that BTK potentiates ALK-mediated signaling in neuroblastoma, and increases ALK stability by reducing ALK ubiquitination. Both ALKWT and ALKF1174L can induce BTK phosphorylation and higher capacity of ALKF1174L is observed. Furthermore, the BTK inhibitor ibrutinib can effectively inhibit the growth of neuroblastoma xenograft in nude mice, and the combination of ibrutinib and the ALK inhibitor crizotinib further enhances the inhibition. Our study provides strong rationale for clinical trial of ALK-positive neuroblastoma using ibrutinib or the combination of ibrutinib and ALK inhibitors.	[Li, Tianfeng; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Zhao, Hui] Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Minist Educ,Fac Med, Hong Kong, Hong Kong, Peoples R China; [Sun, Jianmin] Ningxia Med Univ, Dept Pathogen Biol & Immunol, Sch Basic Med Sci, 1160 Shengli St, Yinchuan 750004, Peoples R China; [Deng, Yi; Chen, Yonglong] Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen 51805, Guangdong, Peoples R China; [Deng, Yi; Chen, Yonglong] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 51805, Guangdong, Peoples R China; [Shi, Yu] Chongqing Med Univ, Key Lab Child Dev & Disorders, Chongqing Key Lab Translat Med Res Cognit Dev & L, Dept Clin Lab,Minist Educ,Childrens Hosp,Chongqin, Chongqing 400014, Peoples R China; [Tian, Ruijun] South Univ Sci & Technol China, Dept Chem, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Guangdong, Peoples R China; [Tian, Ruijun] South Univ Sci & Technol China, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Guangdong, Peoples R China; [Zou, Lin] Chongqing Med Univ, Chongqing Int Sci & Technol Cooperat Ctr Child De, Key Lab Pediat Chongqing, Ctr Clin Mol Med,Childrens Hosp,Minist Educ,Key L, Chongqing 400014, Peoples R China; [Kazi, Julhash U.; Ronnstrand, Lars; Sun, Jianmin] Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden; [Chan, Wai Yee; Zhao, Hui] Chinese Univ Hong Kong, Kunming Inst Zool, Chinese Acad Sci, Joint Lab Bioresources & Mol Res Common Dis, Hong Kong, Hong Kong, Peoples R China; [Ronnstrand, Lars] Lund Univ, Dept Lab Med, Lund Stem Cell Ctr, Lund, Sweden; [Ronnstrand, Lars] Skane Univ Hosp, Div Oncol, Lund, Sweden	Chinese University of Hong Kong; Ningxia Medical University; Southern University of Science & Technology; Southern University of Science & Technology; Chongqing Medical University; Southern University of Science & Technology; Southern University of Science & Technology; Chongqing Medical University; Lund University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese University of Hong Kong; Lund University; Lund University; Skane University Hospital	Zhao, H (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Minist Educ,Fac Med, Hong Kong, Hong Kong, Peoples R China.; Sun, JM (corresponding author), Ningxia Med Univ, Dept Pathogen Biol & Immunol, Sch Basic Med Sci, 1160 Shengli St, Yinchuan 750004, Peoples R China.; Sun, JM (corresponding author), Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden.; Zhao, H (corresponding author), Chinese Univ Hong Kong, Kunming Inst Zool, Chinese Acad Sci, Joint Lab Bioresources & Mol Res Common Dis, Hong Kong, Hong Kong, Peoples R China.	jianmin.sun@nxmu.edu.cn; zhaohui@cuhk.edu.hk	Zhao, Hui/B-8429-2016; Tian, Ruijun/J-3019-2014; Kazi, Julhash U./D-9190-2011; Feng, Bo/D-7831-2014; Chan, Wai Yee/R-7442-2018; Chan, Sun-On/R-6547-2018	Zhao, Hui/0000-0001-8160-6415; Kazi, Julhash U./0000-0002-0719-5336; Feng, Bo/0000-0002-4018-3257; Chan, Wai Yee/0000-0002-9714-0936; Chan, Sun-On/0000-0002-3221-3786; Sun, Jianmin/0000-0003-2327-4285; Tian, Ruijun/0000-0001-9521-5124; Deng, Yi/0000-0003-1378-015X; Ronnstrand, Lars/0000-0003-1275-5809	Research Grants Council of Hong Kong [CUHK24100414, CUHK14167017]; Guangdong Natural Science of Foundation [2017A030313209]; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research [2017B030301018]; Shenzhen Key Laboratory of Cell Microenvironment [ZDSYS20140509142721429]; West China Top Class Discipline Project in Basic Medical Sciences of Ningxia Medical University [NXYLXK2017B07]; CUHK; National Natural Science Foundation of China [31471367, 31671519, 81660473]	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Guangdong Natural Science of Foundation; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research; Shenzhen Key Laboratory of Cell Microenvironment; West China Top Class Discipline Project in Basic Medical Sciences of Ningxia Medical University; CUHK(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr. Marc Vigny for kindly providing the ALK<SUP>WT</SUP> and ALK<SUP>F1174L</SUP> constructs. This work is supported by the Research Grants Council of Hong Kong (CUHK24100414, CUHK14167017) to HZ, the grants from Guangdong Natural Science of Foundation (2017A030313209) and Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research (2017B030301018) and Shenzhen Key Laboratory of Cell Microenvironment (ZDSYS20140509142721429) to YD, the National Natural Science Foundation of China (81660473) and West China Top Class Discipline Project (NXYLXK2017B07) in Basic Medical Sciences of Ningxia Medical University to JS, One-off Funding for KIZ-CUHK Joint Lab/Research Collaboration from CUHK to WYC, the National Natural Science Foundation of China (31471367, 31671519) to YC, and TL is supported by the Graduate Studentships from CUHK. We thank colleagues in our laboratories for the helpful discussion.	Asati V, 2016, EUR J MED CHEM, V109, P314, DOI 10.1016/j.ejmech.2016.01.012; Braun F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125552; Buggy JJ, 2012, INT REV IMMUNOL, V31, P119, DOI 10.3109/08830185.2012.664797; Chakraborty R, 2015, EXPERT REV HEMATOL, V8, P569, DOI 10.1586/17474086.2015.1061427; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; de Claro RA, 2015, CLIN CANCER RES, V21, P3586, DOI 10.1158/1078-0432.CCR-14-2225; Ding N, 2015, ONCOTARGET, V6, P15122, DOI 10.18632/oncotarget.3824; Geoerger B, 2015, J CLIN ONCOL, V33; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grassilli E, 2016, ONCOGENE, V35, P4368, DOI 10.1038/onc.2015.504; Guo W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.343; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Holla VR, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001115; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Khozin S, 2015, CLIN CANCER RES, V21, P2436, DOI 10.1158/1078-0432.CCR-14-3157; Kodityal S, 2016, LUNG CANCER, V92, P19, DOI 10.1016/j.lungcan.2015.11.023; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Larkins E, 2016, CLIN CANCER RES, V22, P5171, DOI 10.1158/1078-0432.CCR-16-1293; Li Y, 2016, ONCOGENE, V35, P6223, DOI 10.1038/onc.2016.155; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; MacGurn JA, 2012, ANNU REV BIOCHEM, V81, P231, DOI 10.1146/annurev-biochem-060210-093619; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Metro G, 2017, LUNG CANCER, V106, P58, DOI 10.1016/j.lungcan.2017.02.003; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Roskoski R, 2016, PHARMACOL RES, V113, P395, DOI 10.1016/j.phrs.2016.09.011; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Smith CIE, 2017, ONCOGENE, V36, P2045, DOI 10.1038/onc.2016.343; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Sun J, 2014, ONCOGENE, V33, P5360, DOI 10.1038/onc.2013.479; Tabbo F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00041; Tan SL, 2013, PHARMACOL THERAPEUT, V138, P294, DOI 10.1016/j.pharmthera.2013.02.001; Tucker DL, 2016, FUTURE ONCOL, V12, P477, DOI 10.2217/fon.15.342; Vela CM, 2016, AM J HEALTH-SYST PH, V73, P367, DOI 10.2146/ajhp140760; Wang CD, 2015, J BIOL CHEM, V290, P21925, DOI 10.1074/jbc.M115.644864; Wang HQ, 2017, ELIFE, V6, DOI 10.7554/eLife.17137; Yau NKM, 2015, CURR CANCER DRUG TAR, V15, P327	43	14	14	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6180	6194		10.1038/s41388-018-0397-7	http://dx.doi.org/10.1038/s41388-018-0397-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	30013190				2022-12-28	WOS:000450883000006
J	Yang, Y; Wu, XQ; Li, WX; Huang, HM; Li, HD; Pan, XY; Li, XF; Huang, C; Meng, XM; Zhang, L; Lv, XW; Wang, H; Li, J				Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun			PSTPIP2 connects DNA methylation to macrophage polarization in CCL4-induced mouse model of hepatic fibrosis	ONCOGENE			English	Article							CHRONIC MULTIFOCAL OSTEOMYELITIS; CHRONIC ACTIVE HEPATITIS; AUTOINFLAMMATORY DISEASE; AUTOIMMUNE HEPATITIS; IN-VIVO; HEPATOCELLULAR-CARCINOMA; PSTPIP2-DEFICIENT MICE; CORTICOSTEROID-THERAPY; LIVER FIBROSIS; ACTIVATION	Macrophages play a crucial role in the progression of hepatic fibrosis (HF). In macrophages, epigenetic mechanisms are increasingly being recognized as crucial controllers of their phenotype. However, the functions of macrophage DNA methylation in experimental models of hepatic fibrosis have not been fully addressed. Here, we analyzed isolated hepatic macrophages DNA methylation from CCL4-induced (4 weeks) mice using reduced representation bisulfite sequencing (RRBS). We identified and validated the methylation status of 26 gene promoter regions associated with CpG islands. We further investigated the function of PSTPIP2 in HF by hepatic-adeno-associated virus (AAV9)-PSTPIP2 overexpression. The molecular mechanisms underlying PSTPIPS2-regulated HF were further explored in mice and RAW264.7 cell line. RRBS results show hypermethylation of PSTPIP2 (chr18: 77,843,840-77,843,968) in the 5'-UTR region. PSTPIP2 expression was significantly decreased in isolated hepatic macrophages from CCL4-induced mice. PSTPIP2 hypermethylation is mediated by the methyltransferases DNMT3a and DNMT3b in LPS-induced RAW264.7 cell line. Further investigation indicated that specific overexpression of PSTPIP2 in C57BL/6 mice reduced the inflammatory response and ameliorated liver fibrosis. These data indicated that hypermethylation of PSTPIP2 caused a mixed induction of hepatic classical macrophage (M1) and alternative macrophage (M2) biomarkers in CCL4-induced HF mice. Furthermore, overexpression of PSTPIP2 inhibited the expression of M1 markers by suppressing STAT1 activity, and enhanced the expression of M2 markers by promoting STAT6 activity. In contrast, knockdown of PSTPIP2 promoted M1 polarization and suppressed M2 polarization in vitro. Adding PSTPIP2 expression alleviates liver fibrosis and hepatic inflammation in mice by regulating macrophage polarization.	[Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Sch Pharm, Anhui Key Lab Bioact Nat Prod, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Key Lab Antiinflammatory & Immune Med, Minist Educ, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Inst Liver Dis, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Anhui Inst Innovat Drugs, Hefei 230032, Anhui, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Li, J (corresponding author), Anhui Med Univ, Sch Pharm, Anhui Key Lab Bioact Nat Prod, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Key Lab Antiinflammatory & Immune Med, Minist Educ, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Inst Liver Dis, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Anhui Inst Innovat Drugs, Hefei 230032, Anhui, Peoples R China.	lj@ahmu.edu.cn	Yang, Yang/AAB-5926-2021; li, xiaofeng/GXF-9442-2022; lv, xiongwen/ABE-6452-2021; li, xiao/GSN-6181-2022	lv, xiongwen/0000-0003-2354-0168; Meng, Xiao-ming/0000-0002-1166-561X; Yang, Yang/0000-0002-0942-1800	National Natural Science Foundation of China [81770609]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81770609).	Amabile G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8091; Bian EB, 2012, TOXICOL APPL PHARM, V264, P13, DOI 10.1016/j.taap.2012.06.022; Brombacher Frank, 2009, V531, P225, DOI 10.1007/978-1-59745-396-7_15; BYRD L, 1991, GENOMICS, V11, P794, DOI 10.1016/0888-7543(91)90002-V; Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036; Cassel SL, 2014, P NATL ACAD SCI USA, V111, P1072, DOI 10.1073/pnas.1318685111; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Cohen-Naftaly Michal, 2011, Therap Adv Gastroenterol, V4, P391, DOI 10.1177/1756283X11413002; Czaja AJ, 2004, HEPATOLOGY, V39, P1631, DOI 10.1002/hep.20235; Czaja AJ, 2004, J HEPATOL, V40, P646, DOI 10.1016/j.jhep.2004.01.009; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dill MT, 2014, J CLIN INVEST, V124, P1568, DOI 10.1172/JCI70408; Drobek A, 2015, J IMMUNOL, V195, P3416, DOI 10.4049/jimmunol.1401494; Ferguson PJ, 2006, BONE, V38, P41, DOI 10.1016/j.bone.2005.07.009; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Fujisaka S, 2009, DIABETES, V58, P2574, DOI 10.2337/db08-1475; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Ghiassi-Nejad Zahra, 2008, Expert Rev Gastroenterol Hepatol, V2, P803, DOI 10.1586/17474124.2.6.803; Grosse J, 2006, BLOOD, V107, P3350, DOI 10.1182/blood-2005-09-3556; Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414; Hansen B, 2002, MOL CELL BIOCHEM, V240, P1, DOI 10.1023/A:1020660303855; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Holt MP, 2008, J LEUKOCYTE BIOL, V84, P1410, DOI 10.1189/jlb.0308173; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Lee UE, 2011, BEST PRACT RES CL GA, V25, P195, DOI 10.1016/j.bpg.2011.02.005; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Liao HJ, 2015, RHEUMATOLOGY, V54, P1317, DOI 10.1093/rheumatology/keu481; Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T; Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; McCarty DM, 2003, GENE THER, V10, P2112, DOI 10.1038/sj.gt.3302134; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Mouzaki M, 2015, CURR DRUG TARGETS, V16, P1324, DOI 10.2174/1389450116666150416120351; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Ohta M, 2009, GASTROENTEROLOGY, V136, P206, DOI 10.1053/j.gastro.2008.09.063; Ramachandran P, 2012, J HEPATOL, V56, P1417, DOI 10.1016/j.jhep.2011.10.026; Roberts SK, 1996, GASTROENTEROLOGY, V110, P848, DOI 10.1053/gast.1996.v110.pm8608895; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Singal AG, 2010, CLIN GASTROENTEROL H, V8, P280, DOI 10.1016/j.cgh.2009.11.018; Smith ZD, 2009, METHODS, V48, P226, DOI 10.1016/j.ymeth.2009.05.003; Tao H, 2011, TOXICOLOGY, V290, P327, DOI 10.1016/j.tox.2011.10.011; Vento-Tormo R, 2016, J ALLERGY CLIN IMMUN, P202; Villalta SA, 2011, HUM MOL GENET, V20, P790, DOI 10.1093/hmg/ddq523; WANG KK, 1988, HEPATOLOGY, V8, P1679, DOI 10.1002/hep.1840080635; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yang JJ, 2013, CELL SIGNAL, V25, P1202, DOI 10.1016/j.cellsig.2013.01.005; Yoo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062152	54	34	36	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6119	6135		10.1038/s41388-018-0383-0	http://dx.doi.org/10.1038/s41388-018-0383-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29993036				2022-12-28	WOS:000450883000002
J	Kong, FY; Deng, X; Kong, XY; Du, YQ; Li, L; Zhu, HY; Wang, YX; Xie, DC; Guha, S; Li, ZS; Guan, M; Xie, KP				Kong, Fanyang; Deng, Xuan; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Xie, Dacheng; Guha, Shivani; Li, Zhaoshen; Guan, Ming; Xie, Keping			ZFPM2-AS1, a novel IncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF (vol 37 pg 5982, 2018)	ONCOGENE			English	Correction									[Kong, Fanyang; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Li, Zhaoshen] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Kong, Fanyang; Kong, Xiangyu; Xie, Dacheng; Guha, Shivani; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Deng, Xuan; Guan, Ming] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai, Peoples R China	Naval Medical University; University of Texas System; UTMD Anderson Cancer Center; Fudan University	Li, ZS (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.; Guan, M (corresponding author), Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai, Peoples R China.	zhaoshenli5610@hotmail.com; guanminghsyy@hotmail.com; kepxie@mdanderson.org						Kong FY, 2018, ONCOGENE, V37, P5982, DOI 10.1038/s41388-018-0387-9	1	6	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					6010	6010		10.1038/s41388-018-0412-z	http://dx.doi.org/10.1038/s41388-018-0412-z			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	30108331	Bronze			2022-12-28	WOS:000449562500008
J	Rossow, L; Veitl, S; Vorlova, S; Wax, JK; Kuhn, AE; Maltzahn, V; Upcin, B; Karl, F; Hoffmann, H; Gatzner, S; Kallius, M; Nandigama, R; Scheld, D; Irmak, S; Herterich, S; Zernecke, A; Ergun, S; Henke, E				Rossow, Leonie; Veitl, Simona; Vorlova, Sandra; Wax, Jacqueline K.; Kuhn, Anja E.; Maltzahn, Verena; Upcin, Berin; Karl, Franziska; Hoffmann, Helene; Gaetzner, Sabine; Kallius, Matthias; Nandigama, Rajender; Scheld, Daniela; Irmak, Ster; Herterich, Sabine; Zernecke, Alma; Ergun, Sueleyman; Henke, Erik			LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy	ONCOGENE			English	Article							LYSYL OXIDASE; TUMOR ANGIOGENESIS; DRUG-DELIVERY; DOUBLE-BLIND; PHASE-II; DOXORUBICIN; IMPROVES; COMBINATION; SIMTUZUMAB; INHIBITION	The potential of altering the tumor ECM to improve drug response remains fairly unexplored. To identify targets for modification of the ECM aiming to improve drug response and overcome resistance, we analyzed expression data sets from pre-treatment patient cohorts. Cross-evaluation identified a subset of chemoresistant tumors characterized by increased expression of collagens and collagen-stabilizing enzymes. We demonstrate that strong collagen expression and stabilization sets off a vicious circle of self-propagating hypoxia, malignant signaling, and aberrant angiogenesis that can be broken by an appropriate auxiliary intervention: Interfering with collagen stabilization by inhibition of lysyl oxidases significantly enhanced response to chemotherapy in various tumor models, even in metastatic disease. Inhibition of collagen stabilization by itself can reduce or enhance tumor growth depending on the tumor type. The mechanistical basis for this behavior is the dependence of the individual tumor on nutritional supply on one hand and on high tissue stiffness for FAK signaling on the other.	[Rossow, Leonie; Veitl, Simona; Wax, Jacqueline K.; Kuhn, Anja E.; Maltzahn, Verena; Upcin, Berin; Karl, Franziska; Hoffmann, Helene; Kallius, Matthias; Nandigama, Rajender; Ergun, Sueleyman; Henke, Erik] Univ Wurzburg, Inst Anat & Cell Biol 2, Koellikerstr 6, D-97070 Wurzburg, Germany; [Vorlova, Sandra; Karl, Franziska; Hoffmann, Helene; Zernecke, Alma] Univ Klinikum Wurzburg, Inst Expt Biomed, Josef Schneider Str 2, D-97082 Wurzburg, Germany; [Upcin, Berin; Irmak, Ster] Bilgi Univ, Sch Hlth Sci, TR-34440 Beyoglu Istanbul, Turkey; [Gaetzner, Sabine] Univ Wurzburg, Inst Tissue Engn, Roentgenring 11, D-97070 Wurzburg, Germany; [Kallius, Matthias; Henke, Erik] Grad Sch Life Sci, Josef Schneider Str 2, D-97082 Wurzburg, Germany; [Scheld, Daniela; Herterich, Sabine] Univ Klinikum Wurzburg, Zent Lab, Josef Schneider Str 2, D-97082 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; Istanbul Bilgi University; University of Wurzburg; University of Wurzburg	Henke, E (corresponding author), Univ Wurzburg, Inst Anat & Cell Biol 2, Koellikerstr 6, D-97070 Wurzburg, Germany.; Henke, E (corresponding author), Grad Sch Life Sci, Josef Schneider Str 2, D-97082 Wurzburg, Germany.	erik.henke@uni-wuerzburg.de	Henke, Erik/AAG-7053-2020	Henke, Erik/0000-0003-2380-2682; Nandigama, Rajender/0000-0002-7344-4732	DFG [HE3565/2-1, HE3565/3-1]	DFG(German Research Foundation (DFG))	We thank Prof. Almut Schulze (Institute for Biochemistry and Molecular Biology, Universitat Wurzburg) and Afsar Barlas (MCCF, Memorial Sloan-Kettering Cancer Center) for helpful discussion. We especially want to acknowledge the tremendous help of Erna Kleinschroth (Institute for Anatomy and Cell Biology II) with histological procedures. Funding was provided by the DFG (Grant Nos. HE3565/2-1 and HE3565/3-1 to EH).	Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; Baish JW, 1996, MICROVASC RES, V51, P327, DOI 10.1006/mvre.1996.0031; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Benson AB, 2017, ONCOLOGIST, V22, P241, DOI 10.1634/theoncologist.2017-0024; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DiChiara AS, 2016, ACS CHEM BIOL, V11, P1408, DOI 10.1021/acschembio.5b01083; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Escorcia FE, 2010, CANCER RES, V70, P9277, DOI 10.1158/0008-5472.CAN-10-2029; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Guo HF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02859-z; HARRISON K, 1978, J NUCL MED, V19, P84; Hecht JR, 2017, ONCOLOGIST, V22, P243, DOI 10.1634/theoncologist.2016-0479; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343; Lankelma J, 1999, CLIN CANCER RES, V5, P1703; Le Calve B, 2016, ONCOTARGET, V7, P32100, DOI 10.18632/oncotarget.8527; LEE TC, 1994, CVGIP-GRAPH MODEL IM, V56, P462, DOI 10.1006/cgip.1994.1042; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Mammoto T, 2013, AM J PATHOL, V183, P1293, DOI 10.1016/j.ajpath.2013.06.026; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Marturano JE, 2013, P NATL ACAD SCI USA, V110, P6370, DOI 10.1073/pnas.1300135110; Mih JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019929; Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647; Netti PA, 2000, CANCER RES, V60, P2497; Pepin KM, 2014, MAGN RESON MED, V71, P1834, DOI 10.1002/mrm.24825; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rohrig F, 2017, ONCOGENE, V36, P1, DOI 10.1038/onc.2016.182; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Samani A, 2007, PHYS MED BIOL, V52, P1565, DOI 10.1088/0031-9155/52/6/002; Schutze F, 2015, SCI REP-UK, V5, DOI 10.1038/srep17576; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Shah NR, 2014, GYNECOL ONCOL, V134, P104, DOI 10.1016/j.ygyno.2014.04.044; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Simon R, 2007, CANCER INFORM, V3, P11; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Walser R, 2013, EUR CELLS MATER, V26, P222, DOI 10.22203/eCM.v026a16; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xie J, 2012, INT ORTHOP, V36, P207, DOI 10.1007/s00264-011-1261-3; Xu XJ, 2008, BIOINFORMATICS, V24, P137, DOI 10.1093/bioinformatics/btm541; Zaffryar-Eilot S, 2013, CARCINOGENESIS, V34, P2370, DOI 10.1093/carcin/bgt241	54	42	43	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4921	4940		10.1038/s41388-018-0320-2	http://dx.doi.org/10.1038/s41388-018-0320-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29780168	Green Published, hybrid			2022-12-28	WOS:000443823600002
J	Lee, J; Yi, S; Won, M; Song, YS; Yi, HS; Park, YJ; Park, KC; Kim, JT; Chang, JY; Lee, MJ; Sul, HJ; Choi, JE; Kim, KS; Kero, J; Kim, J; Shong, M				Lee, Junguee; Yi, Shinae; Won, Minho; Song, Young Shin; Yi, Hyon-Seung; Park, Young Joo; Park, Ki Cheol; Kim, Jung Tae; Chang, Joon Young; Lee, Min Joung; Sul, Hae Joung; Choi, Ji Eun; Kim, Koon Soon; Kero, Jukka; Kim, Joon; Shong, Minho			Loss-of-function of IFT88 determines metabolic phenotypes in thyroid cancer	ONCOGENE			English	Article							INTRAFLAGELLAR TRANSPORT PROTEINS; CYSTIC KIDNEY-DISEASE; BARDET-BIEDL-SYNDROME; PRIMARY CILIA; TUMOR SUPPRESSORS; GENE TG737; SENESCENCE; COMPLEX; AURORA; CELLS	Primary cilia are microtubule-based, dynamic organelles characterized by continuous assembly and disassembly. The intraflagellar transport (IFT) machinery, including IFT88 in cilia, is involved in the maintenance of bidirectional motility along the axonemes, which is required for ciliogenesis and functional competence. Cancer cells are frequently associated with loss of primary cilia and IFT functions. However, there is little information on the role of IFT88 or primary cilia in the metabolic remodeling of cancer cells. Therefore, we investigated the cellular and metabolic effects of the loss-of-function (LOF) mutations of IFT88/primary cilia in thyroid cancer cells. IFT88-deficient 8505C thyroid cancer cells were generated using the CRISPR/Cas9 system, and RNA-sequencing analysis was performed. LOF of the IFT88 gene resulted in a marked defect in ciliogenesis and mitochondrial oxidative function. Gene expression patterns in IFT88-deficient thyroid cancer cells favored glycolysis and lipid biosynthesis. However, LOF of IFT88/primary cilia did not promote thyroid cancer cell proliferation, migration, and invasion. The results suggest that IFT88/primary mary cilia play a role in metabolic reprogramming in thyroid cancer cells.	[Lee, Junguee; Sul, Hae Joung; Choi, Ji Eun] Catholic Univ Korea, Dept Pathol, Daejeon St Marys Hosp, Coll Med, 64 Daeheung Ro, Daejeon 34943, South Korea; [Yi, Shinae; Yi, Hyon-Seung; Kim, Jung Tae; Chang, Joon Young; Kim, Koon Soon; Shong, Minho] Chungnam Natl Univ, Sch Med, Res Ctr Endocrine & Metab Dis, Div Endocrinol,Dept Internal Med, 266 Munhwa Ro, Daejeon 35015, South Korea; [Won, Minho] Chungnam Natl Univ, Sch Med, Dept Pharmacol, 266 Munhwa Ro, Daejeon 35015, South Korea; [Song, Young Shin; Park, Young Joo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, 101 Daehak Ro, Seoul 03080, South Korea; [Park, Ki Cheol] Catholic Univ Korea, Clin Res Inst, Daejeon St Marys Hosp, Coll Med, 64 Daeheung Ro, Daejeon 34943, South Korea; [Lee, Min Joung] Chungnam Natl Univ, Sch Med, Dept Biochem, 266 Munhwa Ro, Daejeon 35015, South Korea; [Kero, Jukka] Univ Turku, Res Ctr Integrat Physiol & Pharmacol, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland; [Kim, Joon] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, 291 Daehak Ro, Daejeon 34040, South Korea	Catholic University of Korea; Chungnam National University; Chungnam National University; Seoul National University (SNU); Seoul National University Hospital; Catholic University of Korea; Chungnam National University; University of Turku; Korea Advanced Institute of Science & Technology (KAIST)	Shong, M (corresponding author), Chungnam Natl Univ, Sch Med, Res Ctr Endocrine & Metab Dis, Div Endocrinol,Dept Internal Med, 266 Munhwa Ro, Daejeon 35015, South Korea.	minhos@cnu.ac.kr	/H-7803-2012; kero, jukka/G-3448-2014; Yi, Hyon-Seung/ABA-2729-2022; Kim, Joon/C-1833-2011; Choi, Ji Eun/H-4890-2016; Park, Young Joo/J-4161-2012	kero, jukka/0000-0001-8767-7222; Choi, Ji Eun/0000-0001-9132-2029; Yi, Hyon-Seung/0000-0002-3767-1954; Won, Minho/0000-0002-5873-5216; Park, Young Joo/0000-0002-3671-6364; shong, minho/0000-0002-0247-7115	NRF/MISIT, Korea [NRF-2015R1C1A1A02037434]; Catholic Medical Center Research Foundation; Daejeon St. Mary's Hospital; NRF - Ministry of Science and ICT [NRF-2014M3A9D8034464]; NRF/MISIT of Korea [NRF-2015M3A9B3028218]	NRF/MISIT, Korea; Catholic Medical Center Research Foundation; Daejeon St. Mary's Hospital; NRF - Ministry of Science and ICT; NRF/MISIT of Korea	This work was supported by a grant (NRF-2015R1C1A1A02037434) from NRF/MISIT, Korea and a grant from the Catholic Medical Center Research Foundation made in the program year of 2016, and a grant from Daejeon St. Mary's Hospital. M. S. was supported by a grant from the NRF funded by the Ministry of Science and ICT (grant number: NRF-2014M3A9D8034464) and a grant from the NRF/MISIT of Korea (grant number: NRF-2015M3A9B3028218).	Ademowo OS, 2017, BIOGERONTOLOGY, V18, P859, DOI 10.1007/s10522-017-9710-z; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berbari NF, 2008, P NATL ACAD SCI USA, V105, P4242, DOI 10.1073/pnas.0711027105; Bishop CL, 2010, MOL CELL, V40, P533, DOI 10.1016/j.molcel.2010.10.027; Boehlke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140378; Boehlke C, 2010, NAT CELL BIOL, V12, P1115, DOI 10.1038/ncb2117; Boissan M, 2009, MOL CELL BIOCHEM, V329, P51, DOI 10.1007/s11010-009-0120-7; Bonura C, 1999, HEPATOLOGY, V30, P677, DOI 10.1002/hep.510300325; Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34; Chevrollier A, 2011, BBA-BIOENERGETICS, V1807, P562, DOI 10.1016/j.bbabio.2010.10.008; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Degnim AC, 2015, BREAST CANCER RES TR, V152, P687, DOI 10.1007/s10549-015-3513-1; Desvignes T, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-256; Dupont PY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-482; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Ishikawa H, 2011, NAT REV MOL CELL BIO, V12, P222, DOI 10.1038/nrm3085; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Katoh Y, 2016, J BIOL CHEM, V291, P10962, DOI 10.1074/jbc.M116.713883; Kero J, 2007, J CLIN INVEST, V117, P2399, DOI 10.1172/JCI30380; Lai CK, 2011, MOL BIOL CELL, V22, P1104, DOI 10.1091/mbc.E10-07-0596; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Lee J, 2016, ONCOTARGET, V7, P79103, DOI 10.18632/oncotarget.12997; Lee J, 2015, CARCINOGENESIS, V36, P1407, DOI 10.1093/carcin/bgv122; Lee SE, 2017, DIABETES, V66, P2774, DOI 10.2337/db17-0333; Llona-Minguez S, 2015, PROG LIPID RES, V58, P51, DOI 10.1016/j.plipres.2015.01.004; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Mignogna C, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0238-7; Oh EC, 2015, CELL METAB, V21, P21, DOI 10.1016/j.cmet.2014.11.019; Paraskevas KI, 2006, CLIN RHEUMATOL, V25, P687, DOI 10.1007/s10067-005-0122-0; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Plotnikova OV, 2012, MOL BIOL CELL, V23, P2658, DOI 10.1091/mbc.E11-12-1056; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Qin HM, 2004, J CELL BIOL, V164, P255, DOI 10.1083/jcb.200308132; Rahmouni K, 2008, J CLIN INVEST, V118, P1458, DOI 10.1172/JCI32357; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Sanchez I, 2016, NAT CELL BIOL, V18, P711, DOI 10.1038/ncb3370; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Seeger-Nukpezah Tamina, 2013, Drug Discov Today Dis Mech, V10, pe135; Song Z, 2010, MOL BIOL REP, V37, P4091, DOI 10.1007/s11033-010-0069-3; Taschner M, 2016, EMBO J, V35, P773, DOI 10.15252/embj.201593164; TeSlaa T, 2014, METHOD ENZYMOL, V542, P91, DOI 10.1016/B978-0-12-416618-9.00005-4; van Diepen JA, 2013, ATHEROSCLEROSIS, V228, P306, DOI 10.1016/j.atherosclerosis.2013.02.028; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yan S, 2015, WORLD J GASTROENTERO, V21, P3492, DOI 10.3748/wjg.v21.i12.3492; Yaqoob P, 2003, CURR OPIN CLIN NUTR, V6, P133, DOI 10.1097/00075197-200303000-00002; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856	55	19	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4455	4474		10.1038/s41388-018-0211-6	http://dx.doi.org/10.1038/s41388-018-0211-6			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743590				2022-12-28	WOS:000441144300009
J	Zhao, J; Du, PZ; Cui, P; Qin, YY; Hu, CE; Wu, J; Zhou, ZW; Zhang, WH; Qin, LX; Huang, GJ				Zhao, Jing; Du, Peizhun; Cui, Peng; Qin, Yunyun; Hu, Cheng'en; Wu, Jing; Zhou, Zhongwen; Zhang, Wenhong; Qin, Lunxiu; Huang, Guangjian			LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer	ONCOGENE			English	Article							NONCODING RNA PVT1; ENDOTHELIAL GROWTH-FACTOR; PHASE-III; TUMORIGENICITY; PROLIFERATION; BEVACIZUMAB; METASTASIS; EXPRESSION; CISPLATIN; CELLS	Angiogenesis can aggravate gastric cancer progression. LncRNAs exert important roles in regulating various cancer behaviors. However, the functions and mechanisms of lncRNAs in angiogenesis remain largely unknown. Here we demonstrated that lncRNA PVT1 was upregulated and significantly associated with high-microvessel density and poor prognosis in gastric cancer. Through gain-and loss-of PVT1 expression, we found PVT1 could obviously induce angiogenesis within tumors, in addition to promoting tumor growth in vitro and in vivo. Mechanistically, PVT1 directly interacted with the signal transducer activator phospho-STAT3 in the nucleus, and increased its protein stability by protecting it from poly-ubiquitination and proteasome-dependent degradation. The binding of PVT1 activated the STAT3 signalling pathway, and successively elevated VEGFA expression to stimulate angiogenesis. The positive correlation of PVT1 and VEGFA expression was also verified in gastric cancer specimens, and high levels of PVT1 and VEGFA in combination frequently predicted shorter survival time. Moreover, we revealed that PVT1 was a STAT3-responsive lncRNA, as STAT3 could occupy the PVT1 promoter to facilitate its transcription. The positive feed-back loop of PVT1 and STAT3 continuously enhanced the oncogenic effects. Collectively, our study first elucidates the mechanism of PVT1-mediated angiogenesis via evoking the STAT3/VEGFA signalling axis, which provides promising target for developing new therapeutic strategy in gastric cancer.	[Zhao, Jing; Du, Peizhun; Qin, Yunyun; Hu, Cheng'en; Qin, Lunxiu; Huang, Guangjian] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Zhao, Jing; Qin, Lunxiu] Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China; [Du, Peizhun; Wu, Jing; Zhang, Wenhong] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai 200040, Peoples R China; [Zhou, Zhongwen] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200040, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Qin, LX; Huang, GJ (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.; Qin, LX (corresponding author), Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China.; Zhang, WH (corresponding author), Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai 200040, Peoples R China.	zhangwenhong@fudan.edu.cn; qinlx@fudan.edu.cn; gjhuang@fudan.edu.cn	高, 雨莉/HGU-8187-2022; Wu, Jing/GQI-1843-2022	Wu, Jing/0000-0002-1224-0912	Natural Science Foundation of China [81672378, 81201521, 81071994, 81672820, 81400007]; Foundation from Science and Technology Commission of Shanghai [09XD1400800]; National Major Scientific Instruments and Equipment Development Project of China [2013YQ15082909, 2012ZX10002012]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation from Science and Technology Commission of Shanghai; National Major Scientific Instruments and Equipment Development Project of China	This study was supported by the Natural Science Foundation of China (81672378, 81201521, 81071994, 81672820, and 81400007), the Foundation from Science and Technology Commission of Shanghai (09XD1400800), and the National Major Scientific Instruments and Equipment Development Project of China (2013YQ15082909, 2012ZX10002012).	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Guo XB, 2016, ONCOTARGET, V7, P30276, DOI 10.18632/oncotarget.7217; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hegde PS, 2013, CLIN CANCER RES, V19, P929, DOI 10.1158/1078-0432.CCR-12-2535; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jariwala N, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.27; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu YJ, 2015, PROCEEDINGS OF 2015 INTERNATIONAL CONFERENCE ON FLUID POWER AND MECHATRONICS - FPM 2015, P1, DOI 10.1109/FPM.2015.7337074; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Shah MA, 2006, J CLIN ONCOL, V24, P5201, DOI 10.1200/JCO.2006.08.0887; Shen L, 2015, GASTRIC CANCER, V18, P168, DOI 10.1007/s10120-014-0351-5; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Xu Z, 2017, ONCOGENE, V36, P1965, DOI 10.1038/onc.2016.356; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan CL, 2016, NEOPLASMA, V63, P442, DOI 10.4149/314_150825N45; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034; Zhu Y, 2016, ONCOTARGET, V7, P14429, DOI 10.18632/oncotarget.7418	34	225	235	5	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4094	4109		10.1038/s41388-018-0250-z	http://dx.doi.org/10.1038/s41388-018-0250-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706652				2022-12-28	WOS:000439847000004
J	Oh, YT; Qian, GQ; Deng, JS; Sun, SY				Oh, You-Take; Qian, Guoqing; Deng, Jiusheng; Sun, Shi-Yong			Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function	ONCOGENE			English	Article							BREAST-CANCER CELLS; ENDOPLASMIC-RETICULUM STRESS; RECEPTOR 5 EXPRESSION; DEATH RECEPTORS; OXIDATIVE STRESS; TRAIL RESISTANCE; AUTOPHAGY; MCPIP1; ENDOCYTOSIS; COACTIVATION	Monocyte chemotactic protein-induced protein-1 (MCPIP1; also called Regnase-1) encoded by the ZC3H12A gene critically regulates inflammatory responses and immune homeostasis primarily by RNase-dependent and - independent mechanisms. However, the relationship of MCPIP1 with apoptosis and cancer and the underlying mechanisms are largely unclear. The current study has demonstrated a previously uncovered connection between MCPIP1 and the negative regulation of death receptor 5 (DR5; also known as TRAIL-R2 or killer/DR5), a cell surface receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is produced endogenously by various immune cells such as T cells. Our findings have revealed that MCPIP1 decreases both total cellular and cell surface DR5, primarily through modulating DUB-mediated protein autophagic/lysosomal degradation. Suppression of MCPIP1 by gene knockdown induces the formation of death-induced signaling complex (DISC) and enhances TRAIL or DR5 activation-induced apoptosis in cancer cells. Moreover, we demonstrated an inverse correlation between MCPIP1 expression and DR5 expression/cell sensitivity to DR5 activation-induced apoptosis in cancer cells. Our findings warrant future investigation of the roles of negative regulation of DR5 by MCPIP1 in cancer and in T-cell immunity.	[Oh, You-Take; Qian, Guoqing; Deng, Jiusheng; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Qian, Guoqing/ABH-1307-2021	Qian, Guoqing/0000-0003-1804-7993	Halpern Research Scholar award	Halpern Research Scholar award	We are thankful to Drs. M. Fu and J. Liu for generously providing us with MCPIP1 expression plasmids and MCPIP1-inducible cell line. We are also grateful to Dr. A. Hammond for editing the manuscript. This study was supported by Halpern Research Scholar award (to S-YS). S-YS is a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar.	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365; Anel A, 2007, FRONT BIOSCI-LANDMRK, V12, P2074, DOI 10.2741/2212; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Bellail AC, 2009, REV RECENT CLIN TRIA, V4, P34, DOI 10.2174/157488709787047530; Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174; Falschlehner C, 2009, ADV EXP MED BIOL, V647, P195, DOI 10.1007/978-0-387-89520-8_14; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Fu L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-315; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jura J, 2012, BBA-MOL CELL RES, V1823, P1905, DOI 10.1016/j.bbamcr.2012.06.029; Kolattukudy PE, 2012, CIRC RES, V110, P174, DOI 10.1161/CIRCRESAHA.111.243212; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Lim B, 2015, EXPERT OPIN THER TAR, V19, P1171, DOI 10.1517/14728222.2015.1049838; Liu HJ, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0167-z; Lu WB, 2016, CANCER RES, V76, P1429, DOI 10.1158/0008-5472.CAN-15-1115; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Oh YT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08424-w; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Oh YT, 2010, J BIOL CHEM, V285, P41310, DOI 10.1074/jbc.M110.153775; Qi DF, 2011, J BIOL CHEM, V286, P41692, DOI 10.1074/jbc.M111.276006; Shanker A, 2007, ADV EXP MED BIOL, V601, P163; Shin GC, 2016, AUTOPHAGY, V12, P2451, DOI 10.1080/15548627.2016.1239002; Skalniak A, 2014, ONCOL REP, V31, P2385, DOI 10.3892/or.2014.3076; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Song JJ, 2010, CELL SIGNAL, V22, P553, DOI 10.1016/j.cellsig.2009.11.012; Sun SY, 2007, J BIOL CHEM, V282, P18800, DOI 10.1074/jbc.M611438200; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Twomey JD, 2015, DRUG RESIST UPDATE, V19, P13, DOI 10.1016/j.drup.2015.02.001; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021; Xu JW, 2012, PROTEIN CELL, V3, P903, DOI 10.1007/s13238-012-2075-9; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Younce CW, 2010, BIOCHEM J, V426, P43, DOI 10.1042/BJ20090976; Zhang YQ, 2009, CANCER BIOL THER, V8, P917, DOI 10.4161/cbt.8.10.8141; Zhang YQ, 2008, MOL CANCER RES, V6, P1861, DOI 10.1158/1541-7786.MCR-08-0313; Zhou LM, 2006, CIRC RES, V98, P1177, DOI 10.1161/01.RES.0000220106.64661.71	41	11	11	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3415	3425		10.1038/s41388-018-0200-9	http://dx.doi.org/10.1038/s41388-018-0200-9			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29551769				2022-12-28	WOS:000436411300007
J	Shinno, N; Kimura, H; Sada, R; Takiguchi, S; Mori, M; Fumoto, K; Doki, Y; Kikuchi, A				Shinno, Naoki; Kimura, Hirokazu; Sada, Ryota; Takiguchi, Shuji; Mori, Masaki; Fumoto, Katsumi; Doki, Yuichiro; Kikuchi, Akira			Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; MULTIPLE-MYELOMA; ARL4C EXPRESSION; BETA-CATENIN/TCF; MEMBRANE-PROTEIN; WNT; DICKKOPF-1; TARGET; GENE	Aberrant expression of the secretory protein Dickkopf1 (DKK1) is associated with poor prognosis of esophageal squamous cell carcinoma (ESCC), but the underlying mechanism of how DKK1 is involved in aggressiveness of ESCC is not clear. In this study, we show that cytoskeleton-associated protein 4 (CKAP4) functions as a DKK1 receptor in ESCC cells. Immunohistochemical analyses of ESCC revealed that both DKK1 and CKAP4 are minimally expressed in associated normal esophageal squamous mucosa of non-tumor regions, but strongly expressed in tumor lesions. Forty-six of 119 cases (38.7%) were positive for both DKK1 and CKAP4. Those expressing both proteins showed poor prognosis and relapse-free survival. Multivariate analysis demonstrated that expression of both proteins was the poor prognostic factor. The Cancer Genome Atlas data set indicated that the mRNA levels of DKK1 and CKAP4 are significantly elevated in the tumor lesions compared to non-tumor regions. DKK1 bound to CKAP4 at endogenous levels. DKK1 induced the internalization of CKAP4 from and its recycling to the plasma membrane. AKT was activated in ESCC cells in which DKK1 was highly expressed and CKAP4 was localized to the plasma membrane. Knockdown of either DKK1 or CKAP4 inhibited AKT activity and cell proliferation in vitro and xenograft tumor formation. Wild-type CKAP4 or DKK1, but not a DKK1 mutant that was unable to bind to CKAP4, rescued phenotypes induced by CKAP4 or DKK1 knockdown, respectively. The anti-CKAP4 antibody also inhibited AKT activity and suppressed xenograft tumor formation. In contrast, in ESCC cells in which DKK1 was marginally expressed, knockdown of CKAP4 or anti-CKAP4 antibody affected neither AKT activity nor cell proliferation. These findings suggest that the DKK1-CKAP4 pathway promotes ESCC cell proliferation and that CKAP4 might represent a novel therapeutic target for ESCCs expressing both DKK1 and CKAP4.	[Shinno, Naoki; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan; [Kimura, Hirokazu; Sada, Ryota; Fumoto, Katsumi; Kikuchi, Akira] Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [25250018, 16H06374, 23112004, 16H06944, T15K198870]; Project Promoting Support for Drug Discovery; Project for Cancer Research And Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and development, AMED; Yasuda Memorial Foundation	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project Promoting Support for Drug Discovery; Project for Cancer Research And Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Yasuda Memorial Foundation	We thank Drs. Yuri Terao and Yuka Umeki at the Center for Medical Research and Education and Department of Molecular Biology and Biochemistry, respectively, Graduate School of Medicine, Osaka University for the technical assistance for the preparation of MISSION TRC shRNAs and mRNA, and qPCR, and Western blotting. This work was supported by Grants-in-Aid for Scientific Research (2013-2015) (No. 25250018) and to AK (2016-2017) (No. 16H06374) to AK, Grants-in-Aid for Scientific Research on Innovative Areas (2011-2015) (No. 23112004) to AK, Grants-in-Aid for Young Scientists (Start-up) (2016-2017) (No. 16H06944) to HK, and Grant-in-Aid for Young Scientists (B) (2015-2017) (No. T15K198870) to NS from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and also supported by the Project Promoting Support for Drug Discovery to KF and the Project for Cancer Research And Therapeutic Evolution (P-CREATE) to AK from the Japan Agency for Medical Research and development, AMED, and by grants to AK from the Yasuda Memorial Foundation.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bendell JC, 2016, J CLIN ONCOL S4S, V34, DOI [10.1200/jco.2016.34.4_suppl.111., DOI 10.1200/JCO.2016.34.4_SUPPL.111.]; Conrads TP, 2006, J BIOL CHEM, V281, P37836, DOI 10.1074/jbc.M604581200; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fujii S, 2015, ONCOGENE, V34, P4834, DOI 10.1038/onc.2014.402; Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Gao ZH, 2014, ONCOL LETT, V7, P1118, DOI 10.3892/ol.2014.1881; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gupta N, 2006, AM J PHYSIOL-LUNG C, V291, pL436, DOI 10.1152/ajplung.00415.2005; Haniu M, 2011, PROTEIN SCI, V20, P1802, DOI 10.1002/pro.705; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Li MH, 2013, CANCER LETT, V337, P248, DOI 10.1016/j.canlet.2013.05.003; Li SX, 2014, CANCER-AM CANCER SOC, V120, P1520, DOI 10.1002/cncr.28593; Li SJ, 2011, J MOL HISTOL, V42, P491, DOI 10.1007/s10735-011-9347-1; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; Makino T, 2009, ANN SURG ONCOL, V16, P2058, DOI 10.1245/s10434-009-0476-7; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Razzaq TM, 2003, J BIOL CHEM, V278, P42679, DOI 10.1074/jbc.M305695200; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sato A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10536; Sato N, 2010, CANCER RES, V70, P5326, DOI 10.1158/0008-5472.CAN-09-3879; SCHWEIZER A, 1993, J CELL SCI, V104, P671; Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236; Shojima K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08042; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Vedrenne C, 2006, TRAFFIC, V7, P639, DOI 10.1111/j.1600-0854.2006.00419.x; Visser E, 2017, ONCOTARGET, V8, P5566, DOI 10.18632/oncotarget.13328; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Zhang WC, 2014, ANN THORAC SURG, V98, P513, DOI 10.1016/j.athoracsur.2014.03.015	45	26	28	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3471	3484		10.1038/s41388-018-0179-2	http://dx.doi.org/10.1038/s41388-018-0179-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563607				2022-12-28	WOS:000436412500001
J	Tusa, I; Gagliardi, S; Tubita, A; Pandolfi, S; Urso, C; Borgognoni, L; Wang, JH; Deng, XM; Gray, NS; Stecca, B; Rovida, E				Tusa, Ignazia; Gagliardi, Sinforosa; Tubita, Alessandro; Pandolfi, Silvia; Urso, Carmelo; Borgognoni, Lorenzo; Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.; Stecca, Barbara; Rovida, Elisabetta			ERK5 is activated by oncogenic BRAF and promotes melanoma growth	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE-5; CELL-PROLIFERATION; MEK5/ERK5 PATHWAY; IMPROVED SURVIVAL; BREAST-CANCER; TUMOR-GROWTH; PROTEIN; INHIBITORS; MUTATIONS; RESISTANCE	Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide. Targeted therapies and immunotherapy have improved the survival of patients with metastatic melanoma in the last few years; however, available treatments are still unsatisfactory. While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored. Here we investigated the function of ERK5 signaling in melanoma. We show that ERK5 is consistently expressed in human melanoma tissues and is active in melanoma cells. Genetic silencing and pharmacological inhibition of ERK5 pathway drastically reduce the growth of melanoma cells and xenografts harboring wild-type (wt) or mutated BRAF (V600E). We also found that oncogenic BRAF positively regulates expression, phosphorylation, and nuclear localization of ERK5. Importantly, ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF. Nevertheless, combined pharmacological inhibition of BRAFV600E and MEK5 is required to decrease nuclear ERK5, that is critical for the regulation of cell proliferation. Accordingly, combination of MEK5 or ERK5 inhibitors with BRAFV600E inhibitor vemurafenib is more effective than single treatments in reducing colony formation and growth of BRAFV600E melanoma cells and xenografts. Overall, these data support a key role of the ERK5 pathway for melanoma growth in vitro and in vivo and suggest that targeting ERK5, alone or in combination with BRAF-MEK1/2 inhibitors, might represent a novel approach for melanoma treatment.	[Tusa, Ignazia; Tubita, Alessandro; Rovida, Elisabetta] Univ Florence, Dept Clin & Expt Biomed Sci, Florence, Italy; [Gagliardi, Sinforosa; Pandolfi, Silvia; Stecca, Barbara] Ist Toscano Tumori, Core Res Lab, Florence, Italy; [Pandolfi, Silvia] VIB KU Leuven Ctr Canc Biol, Leuven, Belgium; [Urso, Carmelo] SM Annunziata Hosp, Dermatopathol Sect, Anat Pathol Unit, Florence, Italy; [Borgognoni, Lorenzo] SM Annunziata Hosp, Plast Surg Unit, Reg Melanoma Referral Ctr, Florence, Italy; [Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Deng, Xianming] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China	University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Flanders Institute for Biotechnology (VIB); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Xiamen University	Rovida, E (corresponding author), Univ Florence, Dept Clin & Expt Biomed Sci, Florence, Italy.; Stecca, B (corresponding author), Ist Toscano Tumori, Core Res Lab, Florence, Italy.	barbara.stecca@ittumori.it; erovida@unifi.it	Rovida, Elisabetta/F-3565-2015; Borgognoni, Lorenzo/X-1981-2019	Rovida, Elisabetta/0000-0002-5949-3239; Borgognoni, Lorenzo/0000-0002-3571-0366; URSO, CARMELO/0000-0002-3746-2917; Stecca, Barbara/0000-0003-1197-1622; Deng, Xianming/0000-0002-9354-5864	Associazione Italiana per la Ricerca sul Cancro, AIRC [IG-15282, IG-14184]	Associazione Italiana per la Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by a grant from Associazione Italiana per la Ricerca sul Cancro, AIRC, (IG-15282 to ER and IG-14184 to BS). We are grateful to Dr P. Dello Sbarba (University of Florence, Florence, Italy) and to Dr Chiariello (Istituto Toscano Tumori, Siena, Italy) for critical revision of the manuscript. We also thank Dr A. Pandiella for providing antibodies and Dr L. Poliseno (Istituto Toscano Tumori, Pisa, Italy) for providing melanoma cells and plasmids.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Carvajal-Vergara X, 2005, BLOOD, V105, P4492, DOI 10.1182/blood-2004-08-2985; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Jong PR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11551; Diaz-Rodriguez E, 2010, J CELL SCI, V123, P3146, DOI 10.1242/jcs.070516; Drew BA, 2012, BBA-REV CANCER, V1825, P37, DOI 10.1016/j.bbcan.2011.10.002; Erazo T, 2013, MOL CELL BIOL, V33, P1671, DOI 10.1128/MCB.01246-12; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gomez N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00105; Honda T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117914; Inesta-Vaquera FA, 2010, CELL SIGNAL, V22, P1829, DOI 10.1016/j.cellsig.2010.07.010; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lin ECK, 2016, P NATL ACAD SCI USA, V113, P11865, DOI 10.1073/pnas.1609019113; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Lochhead PA, 2016, CELL CYCLE, V15, P506, DOI 10.1080/15384101.2015.1120915; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Morimoto H, 2007, J BIOL CHEM, V282, P35449, DOI 10.1074/jbc.M704079200; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Nithianandarajah-Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007; Paoluzzi L, 2016, CANCER MED-US, V5, P1183, DOI 10.1002/cam4.667; Perez-Madrigal D, 2012, CELL SIGNAL, V24, P2360, DOI 10.1016/j.cellsig.2012.08.001; Raviv Z, 2004, J CELL SCI, V117, P1773, DOI 10.1242/jcs.01040; Rovida E, 2008, J IMMUNOL, V180, P4166, DOI 10.4049/jimmunol.180.6.4166; Rovida E, 2015, GUT, V64, P1454, DOI 10.1136/gutjnl-2014-306761; Rovira-Clave X, 2016, J LEUKOCYTE BIOL, V99, P143, DOI 10.1189/jlb.2A0115-034R; Sala E, 2008, MOL CANCER RES, V6, P751, DOI 10.1158/1541-7786.MCR-07-2001; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Simoes AES, 2016, DRUG DISCOV TODAY, V21, P1654, DOI 10.1016/j.drudis.2016.06.010; Song CL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46244; Tatake RJ, 2008, BIOCHEM BIOPH RES CO, V377, P120, DOI 10.1016/j.bbrc.2008.09.087; Teixido C, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.05.07; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Williams CAC, 2016, CELL REP, V16, P1820, DOI 10.1016/j.celrep.2016.07.033; Xia SY, 2017, CELL METAB, V25, P358, DOI 10.1016/j.cmet.2016.12.010; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yang QK, 2011, CLIN CANCER RES, V17, P3527, DOI 10.1158/1078-0432.CCR-10-2504; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008	50	35	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19								10.1038/s41388-018-0164-9	http://dx.doi.org/10.1038/s41388-018-0164-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29483645	hybrid, Green Published			2022-12-28	WOS:000431873400001
J	Wang, HN; Deng, GX; Ai, ML; Xu, ZJ; Mou, TY; Yu, J; Liu, H; Wang, S; Li, GX				Wang, Huanan; Deng, Guangxu; Ai, Meiling; Xu, Zhijun; Mou, Tingyu; Yu, Jiang; Liu, Hao; Wang, Shuang; Li, Guoxin			Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/beta-catenin signaling pathways in gastric cancer progression	ONCOGENE			English	Article							SHOCK-PROTEIN 90; HIGH-LEVEL EXPRESSION; LUNG-CANCER; PERITONEAL DISSEMINATION; CELL-PROLIFERATION; DOWN-REGULATION; POOR SURVIVAL; BETA-CATENIN; ER STRESS; METASTASIS	Hsp90ab1 is upregulated in numerous solid tumors, which is thought to induce the angiogenesis and promote cancer metastasis. However, it's actions in gastric cancer (GC) has not been exhibited. In this study, Hsp90ab1 was demonstrated to be overexpressed and correlated with the poor prognosis, proliferation and invasion of GC. Ectopic expression of Hsp90ab1 promoted the proliferation and metastasis of GC cells both in vitro in cell line models of GC and in vivo using two different xenograft mouse models, while opposite effects were observed in Hsp90ab1 silenced cells. Moreover, the underlining molecular mechanism was explored by the co-immunoprecipitation, immunofluorescence, GST pull-down and in vitro ubiquitination assay. Namely, Hsp90ab1 exerted these functions via the interaction of LRP5 and inhibited ubiquitin-mediated degradation of LRP5, an indispensable coreceptor of the Wnt/beta-catenin signaling pathway. In addition, the crosstalk between Hsp90ab1 and LRP5 contributed to the upregulation of multiple mesenchymal markers, which are also targets of Wnt/beta-catenin. Collectively, this study uncovers the details of the Hsp90ab1-LRP5 axis, providing novel insights into the role and mechanism of invasion and metastasis in GC.	[Wang, Huanan; Deng, Guangxu; Xu, Zhijun; Mou, Tingyu; Yu, Jiang; Liu, Hao; Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou 510515, Guangdong, Peoples R China; [Ai, Meiling; Wang, Shuang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Ai, Meiling] Guangzhou Med Univ, Dept Radiotherapy, Affiliated Canc Hosp & Inst, Guangzhou 510515, Guangdong, Peoples R China; [Wang, Shuang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China	Li, GX (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou 510515, Guangdong, Peoples R China.; Wang, S (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Wang, S (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.	shuangw@126.com; gzliguoxin@163.com	Liu, Hao/I-9884-2019	Liu, Hao/0000-0003-1227-2954	State's Key Project of Research and Development Plan [2017YFC0108300, 2017YFC0108301]; National Natural Science Foundation of China [81672446]; Guangdong Provincial Science and Technology Key Project [2014A020215014]; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China [201402015]; Southern Medical University Clinical Research Start-Up Project [LC2016ZD003]; Guangzhou Science and Technology Project [201400000004-5]; Key Clinical Specialty Discipline Construction Program [[2011]170]	State's Key Project of Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Key Project; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China; Southern Medical University Clinical Research Start-Up Project; Guangzhou Science and Technology Project; Key Clinical Specialty Discipline Construction Program	This work was supported by the grants from the State's Key Project of Research and Development Plan (2017YFC0108300, 2017YFC0108301), National Natural Science Foundation of China (81672446), Guangdong Provincial Science and Technology Key Project (2014A020215014), Research Fund of Public Welfare in the Health Industry, the National Health and Family Planning Commission of China (201402015), the Southern Medical University Clinical Research Start-Up Project (LC2016ZD003), Guangzhou Science and Technology Project (201400000004-5) and the Key Clinical Specialty Discipline Construction Program ([2011]170).	Cai J, 2015, BRIT J CANCER, V113, P1720, DOI 10.1038/bjc.2015.367; Canella A, 2017, CLIN CANCER RES, V23, P6215, DOI 10.1158/1078-0432.CCR-16-3151; Casagolda D, 2010, J CELL SCI, V123, P2621, DOI 10.1242/jcs.067512; Chen DH, 2017, CELL PHYSIOL BIOCHEM, V42, P1025, DOI 10.1159/000478685; Chen Y, 2017, CLIN CANCER RES, V23, P1552, DOI 10.1158/1078-0432.CCR-16-1333; Cheng Q, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3168; Choi HJ, 2018, JNCI-J NATL CANCER I, V110, P400, DOI 10.1093/jnci/djx207; Correia AL, 2013, GENE DEV, V27, P805, DOI 10.1101/gad.211383.112; de la Mare JA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3190-z; DeBruine ZJ, 2017, GENE DEV, V31, P916, DOI 10.1101/gad.298331.117; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Fu YJ, 2011, INT J CANCER, V129, P1541, DOI 10.1002/ijc.26102; Giessrigl B, 2012, HUM MOL GENET, V21, P4615, DOI 10.1093/hmg/dds303; Gu Y, 2016, J PATHOL, V239, P60, DOI 10.1002/path.4697; Ha GH, 2013, CANCER LETT, V332, P63, DOI 10.1016/j.canlet.2013.01.013; Hamamoto R, 2014, CANCER LETT, V351, P126, DOI 10.1016/j.canlet.2014.05.014; Hu YF, 2016, J CLIN ONCOL, V34, P1350, DOI 10.1200/JCO.2015.63.7215; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Jeon YK, 2007, J PATHOL, V213, P170, DOI 10.1002/path.2219; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kannan A, 2014, EUR J CANCER, V50, P204, DOI 10.1016/j.ejca.2013.08.016; Kim SH, 2015, HISTOPATHOLOGY, V67, P509, DOI 10.1111/his.12675; Knoblich K, 2014, CELL MOL LIFE SCI, V71, P1305, DOI 10.1007/s00018-013-1444-8; Kurashige J, 2015, CARCINOGENESIS, V36, P133, DOI 10.1093/carcin/bgu232; Li CF, 2008, CLIN CANCER RES, V14, P7822, DOI 10.1158/1078-0432.CCR-08-1369; Li S, 2017, ONCOL REP, V37, P849, DOI 10.3892/or.2016.5295; Liang L, 2013, GASTROENTEROLOGY, V144, P624, DOI 10.1053/j.gastro.2012.11.033; Liu SGH, 2015, MOL ONCOL, V9, P834, DOI 10.1016/j.molonc.2014.12.009; Lyou Y, 2017, BRIT J PHARMACOL, V174, P4589, DOI 10.1111/bph.13963; Marzook H, 2017, ONCOGENE, V36, P5263, DOI 10.1038/onc.2017.19; Meng J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0640-9; Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219; Okubo K, 2017, GASTRIC CANCER, V20, P802, DOI 10.1007/s10120-017-0705-x; Park S, 2017, REDOX BIOL, V13, P470, DOI 10.1016/j.redox.2017.07.010; Pavlakis N, 2016, J CLIN ONCOL, V34, P2728, DOI 10.1200/JCO.2015.65.1901; Perotti C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2193; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Qiu SL, 2015, J PATHOL, V237, P330, DOI 10.1002/path.4579; Rong BX, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-70; Saveliev SV, 2013, ANAL CHEM, V85, P907, DOI 10.1021/ac302423t; Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414; Singh A, 2015, J INVEST DERMATOL, V135, P1098, DOI 10.1038/jid.2014.460; Sun Y, 2018, THERANOSTICS, V8, P2044, DOI 10.7150/thno.23304; Tsutsumi S, 2009, FUTURE ONCOL, V5, P679, DOI 10.2217/FON.09.30; Verba KA, 2016, SCIENCE, V352, P1542, DOI 10.1126/science.aaf5023; Vinyoles M, 2017, ONCOGENE, V36, P429, DOI 10.1038/onc.2016.209; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Wang L, 2016, GASTROENTEROLOGY, V150, P1183, DOI 10.1053/j.gastro.2016.01.034; Westekemper H, 2011, BRIT J OPHTHALMOL, V95, P853, DOI 10.1136/bjo.2010.183939; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wu SM, 2016, J PINEAL RES, V60, P142, DOI 10.1111/jpi.12295; Wu YK, 2015, INT J CLIN EXP PATHO, V8, P8252; Xiao HJ, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0221-7; Xiong XY, 2014, EXP CELL RES, V326, P78, DOI 10.1016/j.yexcr.2014.05.018; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang SS, 2017, BRIT J CANCER, V117, P1164, DOI 10.1038/bjc.2017.260; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zhang B, 2015, CANCER LETT, V356, P704, DOI 10.1016/j.canlet.2014.10.016; Zhang P, 2017, BRIT J CANCER, V117, P525, DOI 10.1038/bjc.2017.181; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254; Zhao X, 2014, CELL DEATH DIFFER, V21, P1900, DOI 10.1038/cdd.2014.109; Zheng RS, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0234-3; Zhu XH, 2017, INT J CANCER, V141, P172, DOI 10.1002/ijc.30701	63	49	50	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1489	1507		10.1038/s41388-018-0532-5	http://dx.doi.org/10.1038/s41388-018-0532-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305727	Green Published, hybrid			2022-12-28	WOS:000459945800009
J	Chen, TL; Chen, JS; Zhu, YB; Li, Y; Wang, Y; Chen, HJ; Wang, JH; Li, X; Liu, Y; Li, BS; Sun, XL; Ke, YQ				Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan			CsD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2	ONCOGENE			English	Article							MACROPHAGE SCAVENGER RECEPTOR; PROTEIN-KINASE; HUMAN GLIOBLASTOMA; CANCER; CD163; EXPRESSION; BRAIN; CK2; ANTIGEN; CD133	Glioma is a devastating cancer with a dismal prognosis and there is an urgent need to discover novel glioma-specific antigens for glioma therapy. Previous studies have identified CD163-positive tumour cells in certain solid tumours, but CD163 expression in glioma remains unknown. In this study, via an analysis of public datasets, we demonstrated that CD163 overexpression in glioma specimens correlated with an unfavourable patient prognosis. CD163 expression was increased in glioma cells, especially primary glioma cells. The loss of CD163 expression inhibited both cell cycle progression and the proliferation of glioblastoma multiforme (GBM) cell lines and primary glioma cells. CD163 interacted directly with casein kinase 2 (CK2) and CD163 silencing reduced AKT/GSK3 beta/beta-catenin/cyclin D1 pathway activity via CK2. Moreover, CD163 was upregulated in CD133-positive glioma stem cells (GSCs), and CD163 downregulation decreased the expression of GSC markers, including CD133, ALDH1A1, NANOG and OCT4. The knockdown of CD163 impaired GSC stemness by inhibiting the CK2/AKT/GSK3 beta/beta-catenin pathway. Finally, a CD163 antibody successfully induced complement-dependent cytotoxicity against glioma cells. Our findings indicate that CD163 contributes to gliomagenesis via CK2 and provides preclinical evidence that CD163 and the CD163 pathway might serve as a therapeutic target for glioma.	[Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan] Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China; [Wang, Yun] Xinjiang Med Univ, Hosp 1, Dept Neurosurg, Urumqi 830054, Peoples R China; [Li, Baisheng] Huizhou Cent Peoples Hosp, Dept Neurosurg, Huizhou 516001, Peoples R China	Southern Medical University - China; Xinjiang Medical University	Sun, XL; Ke, YQ (corresponding author), Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China.	zjsunxinlin@163.com; kyquan@smu.edu.cn			Natural Science Foundation of China [81772651, 81772652]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (nos. 81772651 and 81772652).	Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; BIGNER SH, 1985, NEUROL CLIN, V3, P769, DOI 10.1016/S0733-8619(18)31008-9; Binnemars-Postma K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050979; Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jensen TO, 2010, J CLIN ONCOL, V28; Kaminska B, 2009, INT J ONCOL, V35, P1091, DOI 10.3892/ijo_00000424; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lai SS, 2016, J HEPATOL, V64, P352, DOI 10.1016/j.jhep.2015.09.025; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin KY, 2010, ANN SURG ONCOL, V17, P1695, DOI 10.1245/s10434-010-0911-9; Lisi L, 2017, NEUROSCI LETT, V645, P106, DOI 10.1016/j.neulet.2017.02.076; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lu X, 2011, ADV EXP MED BIOL, V714, P129, DOI 10.1007/978-94-007-0782-5_6; Ma CY, 2018, MED MOL MORPHOL, V51, P13, DOI 10.1007/s00795-017-0165-8; Natsume A, 2008, DRUG DES DEV THER, V3, P7; Nitta RT, 2015, ONCOGENE, V34, P3688, DOI 10.1038/onc.2014.299; Noubissi FK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091587; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Rasper M, 2010, NEURO-ONCOLOGY, V12, P1024, DOI 10.1093/neuonc/noq070; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Reardona DA, 2017, NEURO-ONCOLOGY, V19, P21, DOI 10.1093/neuonc/nox036.071; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; Sanchez-Torres C, 2003, ARCH VIROL, V148, P2307, DOI 10.1007/s00705-003-0188-4; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Shabo I, 2011, ADV EXP MED BIOL, V714, P141, DOI 10.1007/978-94-007-0782-5_7; Shabo I, 2009, INT J CANCER, V125, P1826, DOI 10.1002/ijc.24506; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tang YY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0222-5; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xi G, 2016, ONCOGENE, V35, P241, DOI 10.1038/onc.2015.78; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	57	27	28	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1183	1199		10.1038/s41388-018-0515-6	http://dx.doi.org/10.1038/s41388-018-0515-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30258108				2022-12-28	WOS:000459249800003
J	van Gijn, SE; Wierenga, E; van den Tempel, N; Kok, YP; Heijink, AM; Spierings, DCJ; Foijer, F; van Vugt, MATM; Fehrmann, RSN				van Gijn, Stephanie E.; Wierenga, Elles; van den Tempel, Nathalie; Kok, Yannick P.; Heijink, Anne Margriet; Spierings, Diana C. J.; Foijer, Floris; van Vugt, Marcel A. T. M.; Fehrmann, Rudolf S. N.			TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells	ONCOGENE			English	Article							EMBRYONIC CELLULAR PROLIFERATION; POLO-LIKE KINASE-1; AURORA-A KINASE; BREAST-CANCER; INVESTIGATIONAL AURORA; DNA-DAMAGE; PHASE-II; MLN8237 ALISERTIB; MAMMARY-TUMORS; INHIBITOR	Genomic instability is a hallmark feature of cancer cells, and can be caused by defective DNA repair, for instance due to inactivation of BRCA2. Paradoxically, loss of Brca2 in mice results in embryonic lethality, whereas cancer cells can tolerate BRCA2 loss. This holds true for multiple DNA repair genes, and suggests that cancer cells are molecularly "rewired" to cope with defective DNA repair and the resulting high levels of genomic instability. In this study, we aim to identify genes that genomically unstable cancer cells rely on for their survival. Using functional genomic mRNA (FGmRNA) profiling, 16,172 cancer samples were previously ranked based on their degree of genomic instability. We analyzed the top 250 genes that showed a positive correlation between FGmRNA levels and the degree of genomic instability, in a co-functionality network. Within this co-functionality network, a strong cluster of 11 cell cycle-related genes was identified, including TPX2. We then assessed the dependency on these 11 genes in the context of survival of genomically unstable cancer cells, induced by BRCA2 inactivation. Depletion of TPX2 or its associated kinase Aurora-A preferentially reduced cell viability in a panel of BRCA2-deficient cancer cells. In line with these findings, BRCA2-depleted and BRCA2-mutant human cell lines, or tumor cell lines derived from Brca2(-/-); p53(-/-) mice showed increased sensitivity to the Aurora-A kinase inhibitor alisertib, with delayed mitotic progression and frequent mitotic failure. Our findings reveal that BRCA2-deficient cancer cells show enhanced sensitivity to inactivation of TPX2 or its partner Aurora-A, which points at an actionable dependency of genomically unstable cancers.	[van Gijn, Stephanie E.; Wierenga, Elles; van den Tempel, Nathalie; Kok, Yannick P.; Heijink, Anne Margriet; van Vugt, Marcel A. T. M.; Fehrmann, Rudolf S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Heijink, Anne Margriet; Spierings, Diana C. J.; Foijer, Floris] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM; Fehrmann, RSN (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.	m.vugt@umcg.nl; r.s.n.fehrmann@umcg.nl	Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; Foijer, Floris/0000-0003-0989-3127; Spierings, Diana/0000-0001-8403-474X; Kok, Yannick/0000-0001-7041-5496; van Gijn, Stephanie/0000-0003-2172-1731; Heijink, Anne Margriet/0000-0001-9229-0575	Dutch Cancer Society [RUG 2011-5093, RUG 2012-5549, RUG 2013-5960]; Netherlands Organisation for Scientific Research [NWO-VIDI 917-13334, NWO-VENI 916-16025]; European Research Council (ERC-Consolidator grant "TENSION")	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); European Research Council (ERC-Consolidator grant "TENSION")	This work was financially supported by grants from the Dutch Cancer Society (RUG 2011-5093 to MATMvV, RUG 2012-5549 to FF, and RUG 2013-5960 to RSNF), the Netherlands Organisation for Scientific Research (NWO-VIDI 917-13334 to MATMvV and NWO-VENI 916-16025 to RSNF), and the European Research Council (ERC-Consolidator grant "TENSION" to MATMvV).	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Alcaraz-Sanabria A, 2017, MOL CANCER THER, V16, P2552, DOI 10.1158/1535-7163.MCT-17-0223; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Bakker B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0971-7; Barr PM, 2015, J CLIN ONCOL, V33, P2399, DOI 10.1200/JCO.2014.60.6327; Blanco I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120020; Borges DD, 2018, LEUKEMIA RES, V64, P61, DOI 10.1016/j.leukres.2017.11.013; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buccitelli C, 2017, GENOME RES, V27, P501, DOI 10.1101/gr.212225.116; Caceres-Gorriti KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091000; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Coleman RL, 2014, ANN ONCOL, V25, piv305; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Dickson MA, 2016, ANN ONCOL, V27, P1855, DOI 10.1093/annonc/mdw281; Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033; Ertych N, 2016, P NATL ACAD SCI USA, V113, P1817, DOI 10.1073/pnas.1525129113; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Graff JN, 2016, CANCER-AM CANCER SOC, V122, P2524, DOI 10.1002/cncr.30073; Habermann JK, 2009, INT J CANCER, V124, P1552, DOI 10.1002/ijc.24017; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Huck JJ, 2014, MOL CANCER THER, V13, P2170, DOI 10.1158/1535-7163.MCT-14-0027; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jasin M, 2013, COLD SPRING HARB PER, V5; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma N, 2010, MOL BIOL CELL, V21, P979, DOI 10.1091/mbc.E09-07-0601; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mankouri HW, 2013, EMBO J, V32, P2661, DOI 10.1038/emboj.2013.211; Matulonis UA, 2012, GYNECOL ONCOL, V127, P63, DOI 10.1016/j.ygyno.2012.06.040; Melichar B, 2015, LANCET ONCOL, V16, P395, DOI 10.1016/S1470-2045(15)70051-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Niu H, 2015, FRONT ONCOL, V5, P3052; Perez de Castro Ignacio, 2012, Genes Cancer, V3, P721, DOI 10.1177/1947601912473306; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Roy R, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3181-c3; Schoonen PM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15981; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shigeishi H, 2009, INT J ONCOL, V34, P1565, DOI 10.3892/ijo_00000286; Slabicki M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000408; Sloane DA, 2010, ACS CHEM BIOL, V5, P563, DOI 10.1021/cb100053q; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takahashi Y, 2015, ANN ONCOL, V26, P935, DOI 10.1093/annonc/mdv034; Tayyar Y, 2017, CRIT REV ONCOL HEMAT, V119, P59, DOI 10.1016/j.critrevonc.2017.09.006; Tomii C, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1095-y; van den Bos H, 2016, GENOME BIOL, V17, P1758; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; WEI P, 2013, J CLIN ONCOL S, V31; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu J, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-200	63	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					852	867		10.1038/s41388-018-0470-2	http://dx.doi.org/10.1038/s41388-018-0470-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177840	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000458006300007
J	Meng, J; Chen, S; Lei, YY; Han, JX; Zhong, WL; Wang, XR; Liu, YR; Gao, WF; Zhang, Q; Tan, Q; Liu, HJ; Zhou, HG; Sun, T; Yang, C				Meng, Jing; Chen, Shuang; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Wang, Xiao-rui; Liu, Yan-rong; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Liu, Hui-juan; Zhou, Hong-gang; Sun, Tao; Yang, Cheng			Hsp90 beta promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma	ONCOGENE			English	Article							HUMAN-MELANOMA CELLS; FUNCTIONAL-SIGNIFICANCE; VASCULAR MIMICRY; CANCER; TWIST1; EXPRESSION; PATHWAYS; PROTEIN; USP19	Hepatocellular carcinoma (HCC) is a typical hypervascular solid tumor. Vasculogenic mimicry (VM) formed by aggressive tumor cells to mimic vasculogenic networks plays an important role in the tumor malignancy of HCC. Hsp90 beta promotes endothelial cell-dependent angiogenesis in HCC. However, the relationship between Hsp90 beta and VM formation is unclear. In this study, we found that Hsp90 beta is positively correlated with VM and EMT marker proteins in HCC tissues and promotes tube formation, cell migration, and invasion in vitro. Hsp90 beta interacts with Twistl and promotes its deubiquitination and stabilization to nuclear translocation and enhances the VE-cadherin promoter activity. Results of in vitro analysis indicate that Hsp90 beta enhances the tumor VM in tumor-burdened mice, and the Hsp90 inhibitor NVP-BEP800 suppresses VM formation by releasing Hsp90 beta and Twistl interaction. This study provides a potential antitumor therapy for inhibiting VM by targeting Hsp90 beta in HCC.	[Meng, Jing; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Zhou, Hong-gang; Sun, Tao; Yang, Cheng] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Meng, Jing; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Zhou, Hong-gang; Sun, Tao; Yang, Cheng] Nankai Univ, Coll Pharm, Tianjin, Peoples R China; [Chen, Shuang; Liu, Yan-rong; Tan, Qiang; Liu, Hui-juan; Sun, Tao; Yang, Cheng] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin, Peoples R China; [Wang, Xiao-rui; Liu, Hui-juan] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China	Nankai University; Nankai University; Tianjin International Joint Academy of Biomedicine; Nankai University	Sun, T; Yang, C (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China.; Sun, T; Yang, C (corresponding author), Nankai Univ, Coll Pharm, Tianjin, Peoples R China.; Sun, T; Yang, C (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin, Peoples R China.	tao.sun@nankai.edu.cn; cheng.yang@nankai.edu.cn		Chen, Shuang/0000-0001-5254-6353	National Natural Science Foundation of China [81572838, 81402973, 81703581]; Tianjin Natural Science and Technology Fund [15JCYBJC26400]; Tianjin Science and Technology Project [15PTGCCX00140]; National Science and Technology Major Project [2017ZX09306007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Natural Science and Technology Fund; Tianjin Science and Technology Project; National Science and Technology Major Project	This study was supported by the National Natural Science Foundation of China (Grant nos. 81572838, 81402973 and 81703581), Tianjin Natural Science and Technology Fund (Grant no. 15JCYBJC26400), Tianjin Science and Technology Project (grant no. 15PTGCCX00140), and the National Science and Technology Major Project (grant no. 2017ZX09306007).	Cao ZF, 2013, EUR J CANCER, V49, P3914, DOI 10.1016/j.ejca.2013.07.148; Cao Z, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030500; Chang SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065895; Delgado-Bellido D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0631-x; Fan YL, 2013, ONCOL LETT, V6, P1174, DOI 10.3892/ol.2013.1555; He WT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147515; Hendrix MJC, 2016, PHARMACOL THERAPEUT, V159, P83, DOI 10.1016/j.pharmthera.2016.01.006; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2006, CELL CYCLE, V5, P478, DOI 10.4161/cc.5.5.2518; Hess AR, 2003, CANCER RES, V63, P4757; Hess AR, 2001, CANCER RES, V61, P3250; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Lee JG, 2014, J BIOL CHEM, V289, P3510, DOI 10.1074/jbc.M113.538934; Li X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14866; Liu X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113921; Liu ZY, 2012, CANCER SCI, V103, P813, DOI 10.1111/j.1349-7006.2011.02199.x; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Massey AJ, 2010, MOL CANCER THER, V9, P906, DOI 10.1158/1535-7163.MCT-10-0055; Mei Yide, 2011, J Biol Chem, V286, P35380, DOI 10.1074/jbc.M111.282020; Meng J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0640-9; Su M, 2008, INT J GYNECOL CANCER, V18, P476, DOI 10.1111/j.1525-1438.2007.01034.x; Sun BC, 2004, INT J ONCOL, V25, P1609; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Williamson SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13322; Wu JY, 2014, EXP THER MED, V8, P893, DOI 10.3892/etm.2014.1800; Yang ZH, 2015, EXP MOL PATHOL, V98, P352, DOI 10.1016/j.yexmp.2015.03.030; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhong WL, 2017, ONCOTARGET, V8, P16829, DOI 10.18632/oncotarget.15166; Zhou Y, 2015, MED SCI MONITOR, V21, P4039, DOI 10.12659/MSM.896712; Zhu QQ, 2016, TUMOR BIOL, V37, P185, DOI 10.1007/s13277-015-4450-7	36	44	45	1	45	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					228	243		10.1038/s41388-018-0428-4	http://dx.doi.org/10.1038/s41388-018-0428-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087438				2022-12-28	WOS:000455366700006
J	Wong, D; Lounsbury, K; Lum, A; Song, J; Chan, S; LeBlanc, V; Chittaranjan, S; Marra, M; Yip, S				Wong, Derek; Lounsbury, Kohl; Lum, Amy; Song, Jungeun; Chan, Susanna; LeBlanc, Veronique; Chittaranjan, Suganthi; Marra, Marco; Yip, Stephen			Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; DOWN-REGULATION; CAPICUA; ATAXIN-1; MUTATIONS; PROTEIN; REPRESSOR; PATHWAY; COMPLEX; TUMORS	Aberrations in Capicua (CIC) have recently been implicated as a negative prognostic factor in a multitude of cancer types through activation of the MAPK signalling cascade and derepression of oncogenic ETS transcription factors. The Ataxin-family protein ATXN1L has previously been reported to interact with CIC in developmental and disease contexts to facilitate the repression of CIC target genes. To further investigate this relationship, we performed functional in vitro studies utilizing ATX/V/L-KO and CICKO human cell lines and characterized a reciprocal functional relationship between CIC and ATXN1L. Transcriptomic interrogation of the CIC-ATXN1-ATXN1L axis in low-grade glioma, prostate adenocarcinoma and stomach adenocarcinoma TCGA cohorts revealed context-dependent convergence of gene sets and pathways related to mitotic cell cycle and division. This study highlights the CIC-ATXN1-ATXN1L axis as a more potent regulator of the cell cycle than previously appreciated.	[Wong, Derek; Yip, Stephen] Univ British Columbia, Pathol & Lab Med, Vancouver, BC, Canada; [Wong, Derek; Lum, Amy; Yip, Stephen] BC Canc, Mol Oncol, Vancouver, BC, Canada; [Lounsbury, Kohl] Univ British Columbia, Cellular & Physiol Sci, Vancouver, BC, Canada; [Song, Jungeun; Chan, Susanna; LeBlanc, Veronique; Chittaranjan, Suganthi; Marra, Marco] BC Canc, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Marra, Marco] Univ British Columbia, Med Genet, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Yip, S (corresponding author), Univ British Columbia, Pathol & Lab Med, Vancouver, BC, Canada.; Yip, S (corresponding author), BC Canc, Mol Oncol, Vancouver, BC, Canada.	Stephen.Yip@vch.ca	Wong, Derek/AAF-8587-2020; Marra, Marco A/B-5987-2008; Yip, Stephen/E-9994-2012	Wong, Derek/0000-0003-2607-5265; Marra, Marco A/0000-0001-7146-7175; Yip, Stephen/0000-0002-8514-9861	VCHRI mentored scientist award; Canada Research Chairs program; Canadian Institutes of Health Research (CIHR) [FDN-143288]	VCHRI mentored scientist award; Canada Research Chairs program(Canada Research Chairs); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank Dr Gregory Cairncross, Dr Jennifer Chan, Dr Kenneth Aldape, Dr Severa Bunda, and members of the David Huntsman and Marco Marra laboratory for helpful discussions. SY is supported by a VCHRI mentored scientist award. MM acknowledges support from the Canada Research Chairs program and the Canadian Institutes of Health Research (CIHR; FDN-143288). We would also like to acknowledge the ongoing support from BrainCare BC, the BC Cancer Foundation, BC Cancer Agency, and the University of British Columbia. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.	Alonso MM, 2008, CANCER LETT, V263, P157, DOI 10.1016/j.canlet.2008.02.001; Astigarraga S, 2007, EMBO J, V26, P668, DOI 10.1038/sj.emboj.7601532; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Bowman AB, 2007, NAT GENET, V39, P373, DOI 10.1038/ng1977; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan AKY, 2014, MODERN PATHOL, V27, P332, DOI 10.1038/modpathol.2013.165; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chittaranjan S, 2014, ONCOTARGET, V5, P7960, DOI 10.18632/oncotarget.2401; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Dalman MR, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S2-S11; de Chiara C, 2003, FEBS LETT, V551, P107, DOI 10.1016/S0014-5793(03)00818-4; Eisenreich S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076623; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gleize V, 2015, ANN NEUROL, V78, P355, DOI 10.1002/ana.24443; Goukassian D, 2001, BRIT J PHARMACOL, V132, P1597, DOI 10.1038/sj.bjp.0703945; Han FX, 2018, ONCOL LETT, V15, P1459, DOI 10.3892/ol.2017.7460; Huang L, 2017, BIOCHEM BIOPH RES CO, V490, P707, DOI 10.1016/j.bbrc.2017.06.105; Iglesias-Ara A, 2015, CELL DEATH DIFFER, V22, P1577, DOI 10.1038/cdd.2015.4; Jimenez G, 2000, GENE DEV, V14, P224; Jimenez G, 2012, J CELL SCI, V125, P1383, DOI 10.1242/jcs.092965; Jin YH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005634; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Kahle JJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003359; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kim E, 2015, SCI REP-UK, V5, DOI 10.1038/srep08272; Kim E, 2013, GENE DEV, V27, P590, DOI 10.1101/gad.212068.112; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; LeBlanc VG, 2017, J PATHOL, V242, P206, DOI 10.1002/path.4894; Lee CJ, 2002, MOL BRAIN RES, V106, P151, DOI 10.1016/S0169-328X(02)00439-4; Lee Y, 2011, DEV CELL, V21, P746, DOI 10.1016/j.devcel.2011.08.017; Liao SD, 2017, GENE DEV, V31, P184, DOI 10.1101/gad.291948.116; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu HC, 2017, NAT GENET, V49, P527, DOI 10.1038/ng.3808; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Muller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005; Okimoto RA, 2017, NAT GENET, V49, P87, DOI 10.1038/ng.3728; Padul V, 2015, GENE CHROMOSOME CANC, V54, P725, DOI 10.1002/gcc.22283; Pasini D, 2014, CELL CYCLE, V3, P394; POST GR, 1992, MOL CHEM NEUROPATHOL, V16, P303, DOI 10.1007/BF03159976; Roch F, 2002, DEVELOPMENT, V129, P993; Rousseaux MWC, 2018, NEURON, V97, P1235, DOI 10.1016/j.neuron.2018.02.013; Sahm F, 2012, ACTA NEUROPATHOL, V123, P853, DOI 10.1007/s00401-012-0993-5; Seim I, 2017, G3-GENES GENOM GENET, V7, P1731, DOI 10.1534/g3.117.039909; Simon-Carrasco L, 2017, GENE DEV, V31, P1456, DOI 10.1101/gad.300244.117; Sonoda Y, 2001, CANCER RES, V61, P4956; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tong X, 2011, EMBO REP, V12, P428, DOI 10.1038/embor.2011.49; Tseng ASK, 2007, CURR BIOL, V17, P728, DOI 10.1016/j.cub.2007.03.023; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang B, 2017, CELL REP, V18, P1543, DOI 10.1016/j.celrep.2017.01.031; Yang L, 2016, P NATL ACAD SCI USA, V113, P10583, DOI 10.1073/pnas.1609417113; Yip S, 2012, J PATHOL, V226, P7, DOI 10.1002/path.2995	65	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					273	290		10.1038/s41388-018-0427-5	http://dx.doi.org/10.1038/s41388-018-0427-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093628				2022-12-28	WOS:000455366700009
J	Ferrandino, F; Bernardini, G; Tsaouli, G; Grazioli, P; Campese, AF; Noce, C; Ciuffetta, A; Vacca, A; Besharat, ZM; Bellavia, D; Screpanti, I; Felli, MP				Ferrandino, Francesca; Bernardini, Giovanni; Tsaouli, Georgia; Grazioli, Paola; Campese, Antonio Francesco; Noce, Claudia; Ciuffetta, Ambra; Vacca, Alessandra; Besharat, Zein Mersini; Bellavia, Diana; Screpanti, Isabella; Felli, Maria Pia			Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation	ONCOGENE			English	Article							NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-TCR; ACTIVATING MUTATIONS; ADRENERGIC-RECEPTOR; SIGNALING PATHWAYS; BONE; EXPRESSION; PROTEIN; BETA	Notch hyperactivation dominates T-cell acute lymphoblastic leukemia development, but the mechanisms underlying "pre-leukemic" cell dissemination are still unclear. Here we describe how deregulated Notch3 signaling enhances CXCR4 cell-surface expression and migratory ability of CD4(+)CD8(+) thymocytes, possibly contributing to "pre-leukemic" cell propagation, early in disease progression. In transgenic mice overexpressing the constitutively active Notch3 intracellular domain, we detect the progressive increase in circulating blood and bone marrow of CD4(+)CD8(+) cells, characterized by high and combined surface expression of Notch3 and CXCR4. We report for the first time that transplantation of such CD4(+)CD8(+) cells reveals their competence in infiltrating spleen and bone marrow of immunocompromised recipient mice. We also show that CXCR4 surface expression is central to the migratory ability of CD4(+)CD8(+) cells and such an expression is regulated by Notch3 through beta-arrestin in human leukemia cells. De novo, we propose that hyperactive Notch3 signaling by boosting CXCR4-dependent migration promotes anomalous egression of CD4(+)CD8(+) cells from the thymus in early leukemia stages. In fact, in vivo CXCR4 antagonism prevents bone marrow colonization by such CD4(+)CD8(+) cells in young Notch3 transgenic mice. Therefore, our data suggest that combined therapies precociously counteracting intrathymic Notch3/CXCR4 crosstalk may prevent dissemination of "pre-leukemic" CD4(+)CD8(+ )cells, by a "thymus-autonomous" mechanism.	[Ferrandino, Francesca; Grazioli, Paola; Vacca, Alessandra; Besharat, Zein Mersini; Felli, Maria Pia] Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy; [Bernardini, Giovanni; Tsaouli, Georgia; Campese, Antonio Francesco; Noce, Claudia; Ciuffetta, Ambra; Bellavia, Diana; Screpanti, Isabella] Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy; [Bernardini, Giovanni] IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, IS, Italy	Sapienza University Rome; Sapienza University Rome; IRCCS Neuromed	Felli, MP (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.; Screpanti, I (corresponding author), Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it; mariapia.felli@uniroma1.it	BERNARDINI, Giovanni/AAA-8160-2019; Bellavia, Diana/AAO-6348-2021; Ferrandino, Francesca/AAA-4905-2020; Besharat, Zein Mersini/G-5413-2013; Bernardini, Giovanni/GRJ-0070-2022	BERNARDINI, Giovanni/0000-0002-3705-2598; Besharat, Zein Mersini/0000-0003-0317-9854; Bellavia, Diana/0000-0001-5728-2537; FELLI, MARIA PIA/0000-0002-5765-2611	Sapienza University; Ateneo 2015 [C26A15MHEL]; Ateneo 2016 [RP116154CE3A9FA1]	Sapienza University; Ateneo 2015; Ateneo 2016	Dedicated to Alberto Gulino. We thank Maria Pelullo, Giulia Diluvio, and Rebeka Popovic for skillful assistance in experiments, Mr. Alessandro Martini for mouse husbandry and Mr. Fernando Duranti for technical assistance, and Sarah Sturman for help in editing the manuscript. Funding was provided by Sapienza University, Ateneo 2015 (C26A15MHEL), and Ateneo 2016 (RP116154CE3A9FA1) to MPF.	Ara T, 2003, J IMMUNOL, V170, P4649, DOI 10.4049/jimmunol.170.9.4649; Armstrong F, 2009, BLOOD, V113, P1730, DOI 10.1182/blood-2008-02-138172; Barbarulo A, 2011, J IMMUNOL, V186, P6199, DOI 10.4049/jimmunol.1002136; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Ben-Baruch A, 2009, CELL ADHES MIGR, V3, P328, DOI 10.4161/cam.3.4.9211; Bernardini G, 2005, FASEB J, V19, P1305, DOI 10.1096/fj.04-3352fje; Bernardini G, 2008, BLOOD, V111, P3626, DOI 10.1182/blood-2007-08-106203; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Campese AF, 2003, SEMIN CELL DEV BIOL, V14, P151, DOI 10.1016/S1084-9521(02)00184-2; Campese AF, 2006, BLOOD, V108, P305, DOI 10.1182/blood-2006-01-0143; Campese AF, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113803; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Cyster JG, 2002, J CLIN INVEST, V109, P1011, DOI 10.1172/JCI200215511; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Franciosa G, 2016, ONCOGENE, V35, P4741, DOI 10.1038/onc.2016.5; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Goertzen CG, 2016, CELL SIGNAL, V28, P165, DOI 10.1016/j.cellsig.2015.12.010; Halkias J, 2013, J CLIN INVEST, V123, P2131, DOI 10.1172/JCI67175; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hupfeld CJ, 2005, J BIOL CHEM, V280, P1016, DOI 10.1074/jbc.M403674200; Janas ML, 2010, TRENDS IMMUNOL, V31, P370, DOI 10.1016/j.it.2010.07.002; Janas ML, 2010, J EXP MED, V207, P247, DOI 10.1084/jem.20091430; Jost TR, 2016, J LEUKOCYTE BIOL, V99, P1077, DOI 10.1189/jlb.5MA0915-394R; Kuksin CA, 2015, BLOOD, V125, P2087, DOI 10.1182/blood-2014-08-594796; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Liu T, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0050-5; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marchese A, 2013, CELL SIGNAL, V25, P707, DOI 10.1016/j.cellsig.2012.11.024; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Massimi I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/607957; Mirandola L, 2012, J PATHOL, V226, P713, DOI 10.1002/path.3015; Parretta E, 2008, J IMMUNOL, V180, P7230, DOI 10.4049/jimmunol.180.11.7230; Passaro D, 2015, CANCER CELL, V27, P769, DOI 10.1016/j.ccell.2015.05.003; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pelullo M, 2014, NEOPLASIA, V16, P1007, DOI 10.1016/j.neo.2014.10.004; Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Plotkin J, 2003, J IMMUNOL, V171, P4521, DOI 10.4049/jimmunol.171.9.4521; Poznansky MC, 2000, NAT MED, V6, P543, DOI 10.1038/75022; Puca L, 2014, J CELL SCI, V127, P1359, DOI 10.1242/jcs.142539; Quaranta R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.326; Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; Scupoli MT, 2008, HAEMATOLOGICA, V93, P524, DOI 10.3324/haematol.12098; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Trampont PC, 2010, NAT IMMUNOL, V11, P162, DOI 10.1038/ni.1830; Uckun FM, 1998, BLOOD, V91, P735; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160	57	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6285	6298		10.1038/s41388-018-0401-2	http://dx.doi.org/10.1038/s41388-018-0401-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038265	Green Published, hybrid			2022-12-28	WOS:000452384400001
J	Ji, XM; Qian, J; Rahman, SMJ; Siska, PJ; Zou, Y; Harris, BK; Hoeksema, MD; Trenary, IA; Heidi, C; Eisenberg, R; Rathmell, JC; Young, JD; Massion, PP				Ji, Xiangming; Qian, Jun; Rahman, S. M. Jamshedur; Siska, Peter J.; Zou, Yong; Harris, Bradford K.; Hoeksema, Megan D.; Trenary, Irina A.; Heidi, Chen; Eisenberg, Rosana; Rathmell, Jeffrey C.; Young, Jamey D.; Massion, Pierre P.			xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression	ONCOGENE			English	Article							GLUTAMATE TRANSPORTER SLC7A11; CYSTINE/GLUTAMATE ANTIPORTER; GLUTAMINASE EXPRESSION; OXIDATIVE-STRESS; CIGARETTE-SMOKE; GROWTH; APOPTOSIS; INHIBITION; OVEREXPRESSION; SENSITIVITY	Many tumors increase uptake and dependence on glucose, cystine or glutamine. These basic observations on cancer cell metabolism have opened multiple new diagnostic and therapeutic avenues in cancer research. Recent studies demonstrated that smoking could induce the expression of xCT (SLC7A11) in oral cancer cells, suggesting that overexpression of xCT may support lung tumor progression. We hypothesized that overexpression of xCT occurs in lung cancer cells to satisfy the metabolic requirements for growth and survival. Our results demonstrated that 1) xCT was highly expressed at the cytoplasmic membrane in non-small cell lung cancer (NSCLC), 2) the expression of xCT was correlated with advanced stage and predicted a worse 5-year survival, 3) targeting xCT transport activity in xCT overexpressing NSCLC cells with sulfasalazine decreased cell proliferation and invasion in vitro and in vivo and 4) increased dependence on glutamine was observed in xCT overexpressed normal airway epithelial cells. These results suggested that xCT regulate metabolic requirements during lung cancer progression and be a potential therapeutic target in NSCLC.	[Ji, Xiangming; Qian, Jun; Rahman, S. M. Jamshedur; Zou, Yong; Harris, Bradford K.; Hoeksema, Megan D.; Massion, Pierre P.] Vanderbilt Univ, Canc Early Detect & Prevent Initiat, Div Allergy Pulm & Crit Care Med, Vanderbilt Ingram Canc Ctr,Sch Med, Nashville, TN 37232 USA; [Ji, Xiangming] Georgia State Univ, Byrdine F Lewis Sch Nursing & Hlth Profess, Dept Nutr, Atlanta, GA 30302 USA; [Siska, Peter J.; Rathmell, Jeffrey C.] Univ Hosp Regensburg, Dept Internal Med 3, D-93053 Regensburg, Germany; [Trenary, Irina A.; Young, Jamey D.] Vanderbilt Univ, Dept Chem & Biomol Engn, 221 Kirkland Hall, Nashville, TN 37235 USA; [Heidi, Chen] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Eisenberg, Rosana] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Massion, Pierre P.] Tennessee Valley Healthcare Syst, Vet Affairs, Nashville, TN 37212 USA	Vanderbilt University; University System of Georgia; Georgia State University; University of Regensburg; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Massion, PP (corresponding author), Vanderbilt Univ, Canc Early Detect & Prevent Initiat, Div Allergy Pulm & Crit Care Med, Vanderbilt Ingram Canc Ctr,Sch Med, Nashville, TN 37232 USA.; Massion, PP (corresponding author), Tennessee Valley Healthcare Syst, Vet Affairs, Nashville, TN 37212 USA.	pierre.massion@vanderbilt.edu		Siska, Peter/0000-0002-1521-6213	NCI [CA102353]; DoD [W81XWH-11-2-0161]; FAMRI foundation [YFEL141014]; NATIONAL CANCER INSTITUTE [R01CA102353, R01CA217987] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); FAMRI foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant CA102353 and DoD W81XWH-11-2-0161 to PPM. This work was also supported by FAMRI foundation YFEL141014 to XJ.	Baek S, 2012, CLIN CANCER RES, V18, P5427, DOI 10.1158/1078-0432.CCR-12-0214; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Chung WJ, 2009, J NEUROCHEM, V110, P182, DOI 10.1111/j.1471-4159.2009.06129.x; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Dai ZY, 2007, J MED CHEM, V50, P1896, DOI 10.1021/jm060960h; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guan J, 2009, CANCER CHEMOTH PHARM, V64, P463, DOI 10.1007/s00280-008-0894-4; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Kobayashi S, 2012, FREE RADICAL BIO MED, V53, P2197, DOI 10.1016/j.freeradbiomed.2012.09.040; Liu RQ, 2007, MOL PHARMACOL, V72, P1637, DOI 10.1124/mol.107.039644; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Lobo C, 2000, BIOCHEM J, V348, P257, DOI 10.1042/0264-6021:3480257; Lora J, 2004, EUR J BIOCHEM, V271, P4298, DOI 10.1111/j.1432-1033.2004.04370.x; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Murphy TA, 2013, BIOTECHNOL BIOENG, V110, P1748, DOI 10.1002/bit.24836; Murphy TA, 2013, METAB ENG, V15, P206, DOI 10.1016/j.ymben.2012.07.008; Nagaraj NS, 2006, TOXICOL LETT, V165, P182, DOI 10.1016/j.toxlet.2006.03.008; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Qian J, 2015, P NATL ACAD SCI USA, V112, P3469, DOI 10.1073/pnas.1421975112; Qian J, 2009, MOL CANCER THER, V8, P101, DOI 10.1158/1535-7163.MCT-08-0973; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Shih AY, 2001, BIOCHEM BIOPH RES CO, V282, P1132, DOI 10.1006/bbrc.2001.4703; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Singh JA, 2004, ARTHRIT RHEUM-ARTHR, V51, P952, DOI 10.1002/art.20827; Siska PJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93411; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Ye P, 2014, MOL CELL BIOL, V34, P3421, DOI 10.1128/MCB.00221-14; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239	46	138	150	5	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					5007	5019		10.1038/s41388-018-0307-z	http://dx.doi.org/10.1038/s41388-018-0307-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789716	Green Published, hybrid			2022-12-28	WOS:000443823600008
J	Rada, M; Nallanthighal, S; Cha, J; Ryan, K; Sage, J; Eldred, C; Ullo, M; Orsulic, S; Cheon, DJ				Rada, Miran; Nallanthighal, Sameera; Cha, Jennifer; Ryan, Kerry; Sage, Jessica; Eldred, Catherine; Ullo, Maria; Orsulic, Sandra; Cheon, Dong-Joo			Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							NF-KAPPA-B; CELL LUNG-CANCER; EXTRACELLULAR-MATRIX; LINKED INHIBITOR; GENE SIGNATURE; ACTIVATION; PROMOTES; COL11A1; SRC; CHEMORESISTANCE	Although, cisplatin resistance is a major challenge in the treatment of ovarian cancer, the precise mechanisms underlying cisplatin resistance are not fully understood. Collagen type XI alpha 1 (COL11A1), a gene encoding a minor fibrillar collagen of the extracellular matrix, is identified as one of the most upregulated genes in cisplatin-resistant ovarian cancer and recurrent ovarian cancer. However, the exact functions of COL11A1 in cisplatin resistance are unknown. Here we demonstrate that COL11A1 binds to integrin alpha 1 beta 1 and discoidin domain receptor 2 (DDR2) and activates downstream signaling pathways to inhibit cisplatin-induced apoptosis in ovarian cancer cells. Mechanistically, we show that COL11A1 activates Src-PI3K/Akt-NF-kB signaling to induce the expression of three inhibitor apoptosis proteins (IAPs), including XIAP, BIRC2, and BIRC3. Genetic and pharmacological inhibition of XIAP, BIRC2, and BIRC3 is sufficient to restore cisplatin-induced apoptosis in ovarian cancer cells in the presence of COL11A1 in ovarian cancer cells and xenograft mouse models, respectively. We also show that the components of COL11A1-integrin alpha 1 beta 1/DDR2-Src-PI3K/Akt-NF-kB-IAP signaling pathway serve as poor prognosis markers in ovarian cancer patients. Taken together, our results suggest novel mechanisms by which COL11A1 confers cisplatin resistance in ovarian cancer. Our study also uncovers IAPs as promising therapeutic targets to reduce cisplatin resistance in ovarian cancer, particularly in recurrent ovarian cancer expressing high levels of COL11A1.	[Rada, Miran; Nallanthighal, Sameera; Cha, Jennifer; Ryan, Kerry; Sage, Jessica; Eldred, Catherine; Ullo, Maria; Cheon, Dong-Joo] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA; [Cha, Jennifer] Rensselaer Polytech Inst, Sch Sci, Troy, NY 12180 USA; [Orsulic, Sandra] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA	Albany Medical College; Rensselaer Polytechnic Institute; Cedars Sinai Medical Center	Cheon, DJ (corresponding author), Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA.	cheond@mail.amc.edu	Rada, Miran/AFC-7022-2022; Rada, Miran/AAO-8034-2021	Rada, Miran/0000-0002-8220-7982; 	Albany Medical College; Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award; AACR Gertrude B. Elion Cancer Research Award	Albany Medical College; Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award; AACR Gertrude B. Elion Cancer Research Award	We thank Drs. Robert C. Bast, Michael DiPersio, and Paula McKeown-Longo for insightful discussions and critical readings of the manuscript; Dr. Nikki Cheng for CAF cells. D.-J.C. is supported by the startup fund from the Albany Medical College, the Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award, and the AACR Gertrude B. Elion Cancer Research Award.	Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Armstrong T, 2004, CLIN CANCER RES, V10, P7427, DOI 10.1158/1078-0432.CCR-03-0825; Asselin E, 2001, CANCER RES, V61, P1862; Cai Q, 2011, J MED CHEM, V54, P2714, DOI 10.1021/jm101505d; Castells M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.384; Cheon DJ, 2014, BIOMARK MED, V8, P523, DOI 10.2217/bmm.14.16; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; Chien J, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00251; Choi YE, 2009, J BIOL CHEM, V284, P12772, DOI 10.1074/jbc.M807550200; Cohen E, 2013, ANTICANCER RES, V33, P379; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Garcia-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Janzen DM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8956; Jia DY, 2016, CANCER LETT, V382, P203, DOI 10.1016/j.canlet.2016.09.001; Jin H, 2015, ONCOL RES, V22, P167, DOI 10.3727/096504015X14298122915664; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Konecny GE, 2009, BRIT J CANCER, V101, P1699, DOI 10.1038/sj.bjc.6605381; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li WY, 2011, J THORAC ONCOL, V6, P1801, DOI 10.1097/JTO.0b013e318226b4a6; Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pramanik KC, 2013, CARCINOGENESIS, V34, P2061, DOI 10.1093/carcin/bgt154; Raglow Z, 2015, CANCER LETT, V357, P448, DOI 10.1016/j.canlet.2014.12.011; Sasaki H, 2000, CANCER RES, V60, P5659; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Teng P-N, 2013, BRIT J CANCER, V110, P123; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wu WS, 2016, ONCOTARGET, V7, P52281, DOI 10.18632/oncotarget.10739; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Xu HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052209	50	53	53	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4809	4820		10.1038/s41388-018-0297-x	http://dx.doi.org/10.1038/s41388-018-0297-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29769618				2022-12-28	WOS:000443146000004
J	Zerdes, I; Matikas, A; Bergh, J; Rassidakis, GZ; Foukakis, T				Zerdes, Ioannis; Matikas, Alexios; Bergh, Jonas; Rassidakis, George Z.; Foukakis, Theodoros			Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations	ONCOGENE			English	Review							CELL LUNG-CANCER; NF-KAPPA-B; TUMOR-INFILTRATING LYMPHOCYTES; INDUCED B7-H1 EXPRESSION; EBV-DRIVEN LMP1; PD-L1 EXPRESSION; SQUAMOUS-CELL; BREAST-CANCER; POOR-PROGNOSIS; OPEN-LABEL	The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies that are approved for routine clinical use. The regulation of PD-L1 expression is complex, varies between different tumor types and occurs at the genetic, transcriptional and post-transcriptional levels. Copy number alterations of PD-L1 locus have been reported with varying frequency in several tumor types. At the transcriptional level, a number of transcriptional factors seem to regulate PD-L1 expression including HIF-1, STAT3, NF-kappa B, and AP-1. Activation of common oncogenic pathways such as JAK/STAT, RAS/ERK, or PI3K/AKT/MTOR, as well as treatment with cytotoxic agents have also been shown to affect tumoral PD-L1 expression. Correlative studies of clinical trials with PD-1/PD-L1 inhibitors have so far shown markedly discordant results regarding the value of PD-L1 expression as a marker of response to treatment. As the indications for immune checkpoint inhibition broaden, understanding the regulation of PD-L1 in cancer will be of utmost importance for defining its role as predictive marker but also for optimizing strategies for cancer immunotherapy. Here, we review the current knowledge of PD-L1 regulation, and its use as biomarker and as therapeutic target in cancer.	[Zerdes, Ioannis; Matikas, Alexios; Bergh, Jonas; Rassidakis, George Z.; Foukakis, Theodoros] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Matikas, Alexios; Bergh, Jonas; Foukakis, Theodoros] Karolinska Univ Hosp, Dept Oncol, Radiumhemmet, Stockholm, Sweden; [Rassidakis, George Z.] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Foukakis, T (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden.; Foukakis, T (corresponding author), Karolinska Univ Hosp, Dept Oncol, Radiumhemmet, Stockholm, Sweden.	Theodoros.Foukakis@ki.se	Zerdes, Ioannis/AAJ-3258-2020; Rassidakis, George/V-9553-2019	Foukakis, Theodoros/0000-0001-8952-9987; Matikas, Alexios/0000-0002-4122-9624; Zerdes, Ioannis/0000-0002-8304-2462; Bergh, Jonas/0000-0001-5526-1847	Swedish Cancer Society [CAN 2015/713]; Cancer Society in Stockholm [154132]; Swedish Breast Cancer Association; European Society for Medical Oncology Georges Mathe Translational Research Fellowship; Hellenic Society of Medical Oncology	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Swedish Breast Cancer Association; European Society for Medical Oncology Georges Mathe Translational Research Fellowship; Hellenic Society of Medical Oncology	This study was supported by the Swedish Cancer Society (CAN 2015/713 to TF); the Cancer Society in Stockholm (154132 to TF); The Swedish Breast Cancer Association (IZ, TF); European Society for Medical Oncology Georges Mathe Translational Research Fellowship (AM); and Hellenic Society of Medical Oncology (AM).	Abbas M, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0770-8; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Atsaves V, 2017, LEUKEMIA, V31, P1633, DOI 10.1038/leu.2017.103; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689; Barrett MT, 2015, ONCOTARGET, V6, P26483, DOI 10.18632/oncotarget.4494; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Belldegrun AS, 2008, CANCER-AM CANCER SOC, V113, P2457, DOI 10.1002/cncr.23851; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellucci R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008824; Bi XW, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0341-7; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Budczies J, 2016, GENE CHROMOSOME CANC, V55, P626, DOI 10.1002/gcc.22365; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Casadevall D, 2017, CLIN LUNG CANCER, V18, P682, DOI 10.1016/j.cllc.2017.04.014; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang YL, 2017, ONCOTARGET, V8, P18021, DOI 10.18632/oncotarget.14935; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Chen S, 2017, INT J CANCER, V140, P1384, DOI 10.1002/ijc.30552; Cheung JC, 2007, METHODS, V41, P451, DOI 10.1016/j.ymeth.2006.10.002; Chikuma S, 2016, INT J CLIN ONCOL, V21, P448, DOI 10.1007/s10147-016-0958-0; Chong LC, 2016, BLOOD, V128, P1206, DOI 10.1182/blood-2015-11-683003; Choueiri TK, 2014, ANN ONCOL, V25, P2178, DOI 10.1093/annonc/mdu445; Clave S, 2018, HISTOPATHOLOGY, V72, P259, DOI 10.1111/his.13339; Coelho M, 2014, 10 NCRI CANC C LIV U; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Dai C, 2017, ONCOTARGETS THER, V10, P3625, DOI 10.2147/OTT.S138044; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diana A, 2016, ONCOTARGET, V7, P40992, DOI 10.18632/oncotarget.10038; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477; Erlmeier F, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0926-1; Escudier B, 2017, ANN ONCOL, V28; Escudier B, 2017, EUR UROL, V72, P368, DOI 10.1016/j.eururo.2017.03.037; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fan YW, 2016, ONCOTARGETS THER, V9, P6075, DOI 10.2147/OTT.S115054; Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3; Fang WF, 2014, ONCOTARGET, V5, P12189, DOI 10.18632/oncotarget.2608; Fang X, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006398; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Gandara D, 2017, AM SOC CLIN ONC ANN; Gandini S, 2016, CRIT REV ONCOL HEMAT, V100, P88, DOI 10.1016/j.critrevonc.2016.02.001; Gangadhar T, 2016, EUR SOC MED ONC ANN; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; George J, 2017, CLIN CANCER RES, V23, P1220, DOI 10.1158/1078-0432.CCR-16-1069; Georgiou K, 2016, BLOOD, V127, P3026, DOI 10.1182/blood-2015-12-686550; Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goldmann T, 2016, ANN ONCOL, V27, P206, DOI 10.1093/annonc/mdv510; Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325; Gong WR, 2011, J CHEMOTHERAPY, V23, P295, DOI 10.1179/joc.2011.23.5.295; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Gowrishankar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123410; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Grinberg-Bleyer Y, 2016, CANCER CELL, V30, P829, DOI 10.1016/j.ccell.2016.11.013; Gu LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182692; Gu XB, 2016, ONCOTARGETS THER, V9, P4805, DOI 10.2147/OTT.S110713; Guo L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2513-x; Han WL, 2003, GENOMICS, V81, P609, DOI 10.1016/S0888-7543(03)00095-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Horita H, 2017, NEOPLASIA, V19, P346, DOI 10.1016/j.neo.2017.02.006; Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Huang SY, 2016, ONCOTARGET, V7, P62490, DOI 10.18632/oncotarget.11519; Huang YD, 2015, ONCOL REP, V33, P3075, DOI 10.3892/or.2015.3933; Igawa S, 2017, ONCOLOGY-BASEL, V92, P283, DOI 10.1159/000458412; Ikeda S, 2016, J THORAC ONCOL, V11, P62, DOI 10.1016/j.jtho.2015.09.010; Ingram JR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00799-8; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jesinghaus M, 2017, ONCOTARGET, V8, P46756, DOI 10.18632/oncotarget.18606; Jiang XF, 2013, CLIN CANCER RES, V19, P598, DOI 10.1158/1078-0432.CCR-12-2731; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Khunger M, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.16.00030; Kim HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36956; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Kogashiwa Y, 2017, ANTICANCER RES, V37, P1417, DOI 10.21873/anticanres.11465; Koh J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1108514; Koh YW, 2017, ANN HEMATOL, V96, P1883, DOI 10.1007/s00277-017-3115-6; Koromilas Antonis E, 2013, JAKSTAT, V2, pe23353, DOI 10.4161/jkst.23353; La-Beck NM, 2015, PHARMACOTHERAPY, V35, P963, DOI 10.1002/phar.1643; Labiano S, 2015, SEMIN ONCOL, V42, P378, DOI 10.1053/j.seminoncol.2015.02.009; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee KS, 2017, CANCER IMMUNOL IMMUN, V66, P927, DOI 10.1007/s00262-017-1999-6; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Leite KRM, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0414-x; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Li XX, 2016, AM J CLIN PATHOL, V146, P496, DOI [10.1093/AJCP/AQW134, 10.1093/ajcp/aqw134]; Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Lienlaf M, 2016, MOL ONCOL, V10, P735, DOI 10.1016/j.molonc.2015.12.012; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin YK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137890; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu YX, 2016, ONCOTARGETS THER, V9, P2649, DOI 10.2147/OTT.S102616; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Long GV, 2017, JAMA ONCOL, V3, P1511, DOI 10.1001/jamaoncol.2017.1588; Luo M, 2016, ONCOTARGET, V7, P29794, DOI 10.18632/oncotarget.7631; Ma K, 2017, ONCOL LETT, V14, P250, DOI 10.3892/ol.2017.6105; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029; Micke P, 2005, AM SOC CLIN ONC ANN; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Motoshima T, 2017, BMC UROL, V17, DOI 10.1186/s12894-016-0195-x; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Nakanishi J, 2007, CANCER IMMUNOL IMMUN, V56, P1173, DOI 10.1007/s00262-006-0266-z; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Ness N, 2017, ONCOTARGET, V8, P26789, DOI 10.18632/oncotarget.15817; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Obeid JM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1235107; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Okita R, 2017, CANCER IMMUNOL IMMUN, V66, P865, DOI 10.1007/s00262-017-1986-y; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115; Paydas S, 2015, ANN HEMATOL, V94, P1545, DOI 10.1007/s00277-015-2403-2; Perez R, 2017, AM SOC CLIN ONC ANN; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Pyo JS, 2017, INT J BIOL MARKER, V32, pE68, DOI 10.5301/jbm.5000225; Qian YG, 2008, CANCER INVEST, V26, P816, DOI 10.1080/07357900801941852; Qin X., 2010, CELL MOL BIOL, V56; Que Y, 2017, J CANCER, V8, P2018, DOI 10.7150/jca.18683; Rakhra K, 2010, CANCER CELL, V18, P485, DOI 10.1016/j.ccr.2010.10.002; Rech AJ, 2013, CANCER DISCOV, V3, P1330, DOI 10.1158/2159-8290.CD-13-0775; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Ruf M, 2016, INT J CANCER, V139, P396, DOI 10.1002/ijc.30077; Rugo HS, 2017, 2017 SAN ANT BREAST; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schlierf A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13166; Schmidt LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136023; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shin SJ, 2016, ANN SURG ONCOL, V23, P694, DOI 10.1245/s10434-015-4903-7; Spranger S, 2016, CELL RES, V26, P639, DOI 10.1038/cr.2016.50; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Sumimoto H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166626; Takada K, 2017, LUNG CANCER, V104, P7, DOI 10.1016/j.lungcan.2016.12.006; Tartari F, 2016, CANCER TREAT REV, V48, P20, DOI 10.1016/j.ctrv.2016.06.002; Tsang JYS, 2017, BREAST CANCER RES TR, V162, P19, DOI 10.1007/s10549-016-4095-2; Tsao MS, 2017, ANN ONCOL, V28, P882, DOI 10.1093/annonc/mdx003; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Uhercik M, 2017, ANTICANCER RES, V37, P4249, DOI 10.21873/anticanres.11817; Utreras Elias, 2009, Drug Discov Today Ther Strateg, V6, P105, DOI 10.1016/j.ddstr.2009.04.004; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; VISAN I, 2017, NAT IMMUNOL, V18, P1067; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HB, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1327494; Wang L, 2015, ONCOTARGET, V6, P41228, DOI 10.18632/oncotarget.5682; Wang QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006369; Wang WP, 2013, HUM GENET, V132, P641, DOI 10.1007/s00439-013-1275-6; Wang WP, 2012, HUM MUTAT, V33, P480, DOI 10.1002/humu.22014; Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Woan KV, 2015, MOL ONCOL, V9, P1447, DOI 10.1016/j.molonc.2015.04.002; Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96; Xia HF, 2017, CLIN CHIM ACTA, V469, P191, DOI 10.1016/j.cca.2017.02.005; Xia Y, 2016, BBA-REV CANCER, V1865, P58, DOI 10.1016/j.bbcan.2015.09.002; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yoon KW, 2015, SCIENCE, V349, DOI 10.1126/science.1261669; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhang MH, 2017, ONCOTARGET, V8, P31347, DOI 10.18632/oncotarget.15532; Zhang N, 2016, INT J ONCOL, V49, P1360, DOI 10.3892/ijo.2016.3632; Zhang P, 2008, MOL IMMUNOL, V45, P1470, DOI 10.1016/j.molimm.2007.08.013; Zhang YX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000515; Zhao L, 2016, ONCOTARGET, V7, P45370, DOI 10.18632/oncotarget.9659; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zhu JJ, 2014, HUM IMMUNOL, V75, P348, DOI 10.1016/j.humimm.2014.01.006	229	149	158	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4639	4661		10.1038/s41388-018-0303-3	http://dx.doi.org/10.1038/s41388-018-0303-3			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765155	hybrid, Green Published			2022-12-28	WOS:000442514400002
J	Miskolczi, Z; Smith, MP; Rowling, EJ; Ferguson, J; Barriuso, J; Wellbrock, C				Miskolczi, Zsofia; Smith, Michael P.; Rowling, Emily J.; Ferguson, Jennifer; Barriuso, Jorge; Wellbrock, Claudia			Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; HIPPO PATHWAY; TRANSCRIPTIONAL REGULATORS; TARGETED THERAPY; IN-VIVO; YAP; CANCER; RESISTANCE; EXPRESSION; CELLS	Despite the general focus on an invasive and de-differentiated phenotype as main driver of cancer metastasis, in melanoma patients many metastatic lesions display a high degree of pigmentation, indicative for a differentiated phenotype. Indeed, studies in mice and fish show that melanoma cells switch to a differentiated phenotype at secondary sites, possibly because in melanoma differentiation is closely linked to proliferation through the lineage-specific transcriptional master regulator MITF. Importantly, while a lot of effort has gone into identifying factors that induce the de-differentiated/invasive phenotype, it is not well understood how the switch to the differentiated/proliferative phenotype is controlled. We identify collagen as a contributor to this switch. We demonstrate that collagen stiffness induces melanoma differentiation through a YAP/PAX3/MITF axis and show that in melanoma patients increased collagen abundance correlates with nuclear YAP localization. However, the interrogation of large patient datasets revealed that in the context of the tumour microenvironment, YAP function is more complex. In the absence of fibroblasts, YAP/PAX3-mediated transcription prevails, but in the presence of fibroblasts tumour growth factor-beta suppresses YAP/PAX3-mediated MITF expression and induces YAP/TEAD/SMAD-driven transcription and a de-differentiated phenotype. Intriguingly, while high collagen expression is correlated with poorer patient survival, the worst prognosis is seen in patients with high collagen expression, who also express MITF target genes such as the differentiation markers TRPM1, TYR and TYRP1, as well as CDK4. In summary, we reveal a distinct lineage-specific route of YAP signalling that contributes to the regulation of melanoma pigmentation and uncovers a set of potential biomarkers predictive for poor survival.	[Miskolczi, Zsofia; Smith, Michael P.; Rowling, Emily J.; Ferguson, Jennifer; Barriuso, Jorge; Wellbrock, Claudia] Univ Manchester, Fac Biol Med & Hlth, Manchester Canc Res Ctr, Sch Med Sci,Div Canc Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England	University of Manchester	Wellbrock, C (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Manchester Canc Res Ctr, Sch Med Sci,Div Canc Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Claudia.Wellbrock@manchester.ac.uk		Wellbrock, Claudia/0000-0002-3825-6381; Smith, Michael/0000-0002-5980-7840; Barriuso, Jorge/0000-0002-5641-9105	Cancer Research UK [C11591/A16416]; BBSRC; Wellcome; UoM Strategic Fund; MRC [MR/L011840/1] Funding Source: UKRI; Cancer Research UK [16416] Funding Source: researchfish; Medical Research Council [MR/L011840/1] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome; UoM Strategic Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Guillaume Jacquement University of Manchester (UoM) for the fibroblasts, and David Gomez Matallanas (UCD Dublin, Ireland) for advice with YAP signalling and providing reagents. C.W. acknowledges the support by Cancer Research UK (grant number C11591/A16416). We thank Peter Walker (UoM) for help with the histology, Peter March, Roger Meadows and Steven Marsden (UoM) for help with microscopy. The Bioimaging Facility microscopes were purchased with grants from BBSRC, Wellcome and the UoM Strategic Fund that also funded the Histology Facility equipment.	Ahn A, 2017, MOL CANCER THER, V16, P1002, DOI 10.1158/1535-7163.MCT-16-0535; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akhmanova M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/167025; Arozarena I, 2017, FEBS J, V284, P2148, DOI 10.1111/febs.14040; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Brozyna AA, 2016, ONCOTARGET, V7, P17844, DOI 10.18632/oncotarget.7528; Chadwick S, 2012, INDIAN J PLAST SURG, V45, P403, DOI 10.4103/0970-0358.101328; Chapman A, 2014, CELL REP, V8, P688, DOI 10.1016/j.celrep.2014.06.045; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Flach EH, 2011, MOL PHARMACEUT, V8, P2039, DOI 10.1021/mp200421k; Frey K, 2011, EXP DERMATOL, V20, P685, DOI 10.1111/j.1600-0625.2011.01314.x; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kim IS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14343; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Kirkpatrick SJ, 2006, OPT EXPRESS, V14, P9770, DOI 10.1364/OE.14.009770; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee CI, 2017, MED CLIN N AM, V101, P725, DOI 10.1016/j.mcna.2017.03.005; Lee JT, 2007, J CELL BIOCHEM, V101, P862, DOI 10.1002/jcb.21204; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Mahoney JE, 2014, DEV CELL, V30, P137, DOI 10.1016/j.devcel.2014.06.003; Manderfield LJ, 2015, DEVELOPMENT, V142, P2962, DOI 10.1242/dev.125807; Marsol IB, 2013, ACTAS DERMO-SIFILOGR, V104, P654, DOI [10.1016/j.adengl.2012.10.012, 10.1016/j.ad.2012.10.003]; Nagelkerke A, 2015, SEMIN CANCER BIOL, V35, P62, DOI 10.1016/j.semcancer.2015.09.001; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Nsengimana J, 2015, ONCOTARGET, V6, P11683, DOI 10.18632/oncotarget.3549; Paul NR, 2015, J CELL BIOL, V210, P1013, DOI 10.1083/jcb.201502040; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Simmons JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11366-y; Smith MP, 2017, EMBO MOL MED, V9, P1011, DOI 10.15252/emmm.201607156; Smith MP, 2016, CANCER CELL, V29, P270, DOI 10.1016/j.ccell.2016.02.003; Smith MP, 2014, CANCER DISCOV, V4, P1214, DOI 10.1158/2159-8290.CD-13-1007; Smith MP, 2013, JNCI-J NATL CANCER I, V105, P33, DOI 10.1093/jnci/djs471; Taylor KL, 2011, DEVELOPMENT, V138, P3579, DOI 10.1242/dev.064014; Vandamme N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00352; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002; Young HL, 2017, J EXP MED, V214, P1691, DOI 10.1084/jem.20160855; Yu HM, 2011, TRENDS CELL BIOL, V21, P47, DOI 10.1016/j.tcb.2010.08.015; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865	55	54	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3166	3182		10.1038/s41388-018-0209-0	http://dx.doi.org/10.1038/s41388-018-0209-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29545604	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000434641400009
J	Liu, F; Dai, M; Xu, QY; Zhu, XL; Zhou, Y; Jiang, SH; Wang, YH; Ai, ZH; Ma, L; Zhang, YL; Hu, LP; Yang, Q; Li, J; Zhao, SJ; Zhang, ZG; Teng, YC				Liu, Fei; Dai, Miao; Xu, Qinyang; Zhu, Xiaolu; Zhou, Yang; Jiang, Shuheng; Wang, Yahui; Ai, Zhihong; Ma, Li; Zhang, Yanli; Hu, Lipeng; Yang, Qin; Li, Jun; Zhao, Shujie; Zhang, Zhigang; Teng, Yincheng			SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappa B-CD47 axis	ONCOGENE			English	Article							NF-KAPPA-B; GENE-EXPRESSION; INFLAMMATION; IDENTIFICATION; RESISTANCE; PATHWAY; EVENTS	High-risk human papillomavirus oncoproteins E6 and E7 are the major etiological factors of cervical cancer but are insufficient for malignant transformation of cervical cancer. Dysregulated alternative splicing, mainly ascribed to aberrant splicing factor levels and activities, contributes to most cancer hallmarks. However, do E6 and E7 regulate the expression of splicing factors? Does alternative splicing acts as an "accomplice" of E6E7 to promote cervical cancer progression? Here, we identified that the splicing factor SRSF10, which promotes tumorigenesis of cervix, was upregulated by E6E7 via E2F1 transcriptional activation. SRSF10 modulates the alternate terminator of interleukin-1 receptor accessory protein exon 13 to increase production of the membrane form of interleukin-1 receptor accessory protein. SRSF10-mediated mIL1RAP upregulates the expression of the "don't eat me" signal CD47 to inhibit macrophage phagocytosis by promoting nuclear factor-KB activation, which is pivotal in inflammatory, immune, and tumorigenesis processes. Altogether, these data reveal a close relationship among HPV infection, alternative splicing and tumor immune evasion, and also suggests that the SRSF10-mIL1RAP-CD47 axis could be an attractive therapeutic target for the treatment of cervical cancer.	[Liu, Fei; Dai, Miao; Xu, Qinyang; Zhu, Xiaolu; Zhou, Yang; Ai, Zhihong; Ma, Li; Teng, Yincheng] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gynecol & Obstet, Sch Med, Shanghai, Peoples R China; [Dai, Miao] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Xiangya Sch Med,Dept Gynecol Oncol, Changsha, Hunan, Peoples R China; [Jiang, Shuheng; Wang, Yahui; Zhang, Yanli; Hu, Lipeng; Yang, Qin; Li, Jun; Zhang, Zhigang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China; [Zhao, Shujie] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Jiangsu, Peoples R China	Shanghai Jiao Tong University; Central South University; Shanghai Jiao Tong University; Nanjing Medical University	Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.	zzhang@shsci.org; ycteng@sjtu.edu.cn	Jiang, Shuheng/M-6584-2019	Jiang, Shuheng/0000-0001-8516-6234	National Natural Science Foundation of China [81372794, 81672565, 81502382]; Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation [13JC404502]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation	We thank Dr. Xueli Zhang (State Key Laboratory for Oncogenes and Related Genes, Shanghai, China) for critical reading of manuscript; Experimental Animal Center of East China Normal University for animal feeding. This work was supported by grants from the National Natural Science Foundation of China (81372794; 81672565; 81502382), and the Science and Technology Commission of Shanghai Municipality-Key Basic Research Foundation (13JC404502).	Adamia S, 2013, CURR CANCER DRUG TAR, V13, P735, DOI 10.2174/15680096113139990083; Agerstam H, 2015, P NATL ACAD SCI USA, V112, P10786, DOI 10.1073/pnas.1422749112; Biewenga P, 2008, GYNECOL ONCOL, V108, P520, DOI 10.1016/j.ygyno.2007.11.024; Casey SC, 2015, SEMIN CANCER BIOL, V35, pS199, DOI 10.1016/j.semcancer.2015.02.007; Centers for Disease Control and Prevention, GLOB CANC STAT; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dai M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41404; Dunne Aisling, 2003, Sci STKE, V2003, pre3, DOI 10.1126/stke.2003.171.re3; Feng Y, 2008, NAT STRUCT MOL BIOL, V15, P1040, DOI 10.1038/nsmb.1485; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Da Costa RMG, 2016, ANTICANCER RES, V36, P2073; Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985; Iwata T, 2015, INT J CLIN ONCOL, V20, P126, DOI 10.1007/s10147-014-0680-8; Jabonowska- Fudziska D, 2014, PRZEGL LEK, V72, P103; Jensen LE, 2003, CELL SIGNAL, V15, P793, DOI 10.1016/S0898-6568(03)00039-1; Jensen LE, 2000, J IMMUNOL, V164, P5277, DOI 10.4049/jimmunol.164.10.5277; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Kozlovski I, 2017, HUM GENET, V136, P1113, DOI 10.1007/s00439-017-1803-x; Landberg N, 2016, LEUKEMIA, V30, P253, DOI 10.1038/leu.2015.135; Li H, 2014, MOL CELL BIOL, V34, P2198, DOI 10.1128/MCB.01674-13; Liu R, 2017, ONCOTARGET, V8, P39021, DOI 10.18632/oncotarget.16547; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Mehta AM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8913860; Munkley J, 2017, HUM GENET, V136, P1143, DOI 10.1007/s00439-017-1792-9; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Peng ZY, 2011, TUMOR BIOL, V32, P359, DOI 10.1007/s13277-010-0128-3; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Senapati R, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0107-4; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Tsai YS, 2015, ONCOTARGET, V6, P6825, DOI 10.18632/oncotarget.3145; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Waggoner SE, 2004, GYNAECOLOGIC CANC CO, P65; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; WHO World Health Organization, HUM PAP HPV CERV CAN; Zeng DD, 2016, ONCOTARGET, V7, P83040, DOI 10.18632/oncotarget.13349; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056; Zhang R, 2017, SCI REP-UK, V7, DOI 10.1038/srep44744; Zhang Wei, 2011, Zhejiang Da Xue Xue Bao Yi Xue Ban, V40, P540; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhou XX, 2014, NUCLEIC ACIDS RES, V42, P4019, DOI 10.1093/nar/gkt1387	55	60	64	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2394	2409		10.1038/s41388-017-0119-6	http://dx.doi.org/10.1038/s41388-017-0119-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429992	hybrid, Green Published			2022-12-28	WOS:000431386000004
J	Pollan, SG; Huang, FJ; Sperger, JM; Lang, JM; Morrissey, C; Cress, AE; Chu, CY; Bhowmick, NA; You, S; Freeman, MR; Spassov, DS; Moasser, MM; Carter, WG; Satapathy, SR; Shah, K; Knudsen, BS				Pollan, Sara G.; Huang, Fangjin; Sperger, Jamie M.; Lang, Joshua M.; Morrissey, Colm; Cress, Anne E.; Chu, C. Y.; Bhowmick, Neil A.; You, Sungyong; Freeman, Michael R.; Spassov, Danislav S.; Moasser, Mark M.; Carter, William G.; Satapathy, Shakti Ranjan; Shah, Kavita; Knudsen, Beatrice S.			Regulation of inside-out beta 1-integrin activation by CDCP1	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CYCLIN-DEPENDENT KINASE-5; SURFACE GLYCOPROTEIN CDCP1; PROSTATE-CANCER CELLS; PKC-DELTA; C-DELTA; INTEGRIN ACTIVATION; MONOCLONAL-ANTIBODY; ANOIKIS RESISTANCE; ANDROGEN RECEPTOR	Tumor metastasis depends on the dynamic regulation of cell adhesion through beta 1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. Here, we demonstrate reduced CDCP1 expression in high-grade, primary prostate cancers, circulating tumor cells and tumor metastases of patients with castrate-resistant prostate cancer. CDCP1 is expressed in epithelial and not mesenchymal cells, and its cell surface and mRNA expression declines upon stimulation with TGF beta 1 and epithelial-to-mesenchymal transition. Silencing of CDCP1 in DU145 and PC3 cells resulted in 3.4-fold higher proliferation of non-adherent cells and 4.4-fold greater anchorage independent growth. CDCP1-silenced tumors grew in 100% of mice, compared to 30% growth of CDCP1-expressing tumors. After CDCP1 silencing, cell adhesion and migration diminished 2.1-fold, caused by loss of inside-out activation of beta 1-integrin. We determined that the loss of CDCP1 reduces CDK5 kinase activity due to the phosphorylation of its regulatory subunit, CDK5R1/p35, by c-SRC on Y234. This generates a binding site for the C2 domain of PKC delta, which in turn phosphorylates CDK5 on T77. The resulting dissociation of the CDK5R1/CDK5 complex abolishes the activity of CDK5. Mutations of CDK5-T77 and CDK5R1-Y234 phosphorylation sites re-establish the CDK5/CDKR1 complex and the inside-out activity of beta 1-integrin. Altogether, we discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates beta 1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer.	[Pollan, Sara G.; Huang, Fangjin; Chu, C. Y.; Bhowmick, Neil A.; You, Sungyong; Freeman, Michael R.; Knudsen, Beatrice S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Sperger, Jamie M.; Lang, Joshua M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Morrissey, Colm] Univ Washington, Seattle, WA 98195 USA; [Cress, Anne E.] Univ Arizona, Ctr Canc, Tucson, AZ 85704 USA; [Spassov, Danislav S.; Moasser, Mark M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Carter, William G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Satapathy, Shakti Ranjan; Shah, Kavita] Purdue Univ, W Lafayette, IN 47907 USA	Cedars Sinai Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Washington; University of Washington Seattle; University of Arizona; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Knudsen, BS (corresponding author), Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.	Beatrice.Knudsen@cshs.org	Shah, Kavita/Y-9755-2019; Spassov, Danislav S/GQA-4368-2022; Bhowmick, Neil/AAA-7302-2019; Satapathy, Shakti Ranjan/L-3124-2018; Cress, Anne/V-6527-2019; You, Sungyong/AAJ-7372-2020; Satapathy, Shakti Ranjan/AAB-5787-2021	Shah, Kavita/0000-0002-0451-1305; Spassov, Danislav S/0000-0002-6680-877X; Bhowmick, Neil/0000-0001-8747-5989; Satapathy, Shakti Ranjan/0000-0002-3212-8960; Cress, Anne/0000-0001-6194-0061; You, Sungyong/0000-0003-3513-1783; Satapathy, Shakti Ranjan/0000-0002-3212-8960	Pacific Northwest Prostate Cancer SPORE [P50CA97186]; Richard M. LUCAS Foundation; Department of Defense Synergistic Idea Development Award [W81XWH-08-1-0268]; Cedars-Sinai Medical Center; NATIONAL CANCER INSTITUTE [P50CA097186, R01CA159406] Funding Source: NIH RePORTER	Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Richard M. LUCAS Foundation; Department of Defense Synergistic Idea Development Award(United States Department of Defense); Cedars-Sinai Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We heartily acknowledge Wen-Chin Huang for assistance in animal surgery, L. Chung for support in in vivo experiments, and to C. Pospisil for cloning PKCd mutant with inactive kinase into vector. We thank the patients and their families, Robert Vessella, Eva Corey, Celestia Higano, Bruce Montgomery, Peter Nelson, Paul Lange, Martine Roudier, and Lawrence True for their contributions to the University of Washington Medical Center Prostate Cancer Donor Rapid Autopsy Program supported by funding by the Pacific Northwest Prostate Cancer SPORE (P50CA97186) and the Richard M. LUCAS Foundation. We are thankful to Jennifer Kitchel and the Biobank and Translational Research Core at Cedars-Sinai Medical Center for xenograft embedding, tissue processing, and IHC staining. This work was supported by Department of Defense Synergistic Idea Development Award W81XWH-08-1-0268 and start-up funding from Cedars-Sinai Medical Center.	Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Bosutti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075538; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Cantu E, 2013, AM J TRANSPLANT, V13, P1898, DOI 10.1111/ajt.12283; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chang KH, 2011, MOL BIOL CELL, V22, P1452, DOI 10.1091/mbc.E10-07-0654; Das L, 2017, J CELL BIOCHEM, V118, P1038, DOI 10.1002/jcb.25673; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Dickreuter E, 2016, ONCOGENE, V35, P1353, DOI 10.1038/onc.2015.212; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Fukuchi K, 2010, MOL PHARMACEUT, V7, P245, DOI 10.1021/mp900236t; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gao C, 2002, MOL CANCER RES, V1, P12; Ginsberg MH, 2014, BMB REP, V47, P655, DOI 10.5483/BMBRep.2014.47.12.241; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Hoffmann A, 2017, US Patent, Patent No. 9555110; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hsu FN, 2011, J BIOL CHEM, V286, P33141, DOI 10.1074/jbc.M111.252080; Jin J, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/931629; Kato H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046576; Kawauchi T, 2012, INT J MOL SCI, V13, P4564, DOI 10.3390/ijms13044564; Kimura H, 2006, LEUKEMIA, V20, P1551, DOI 10.1038/sj.leu.2404312; Knudsen BS, 2009, APPL IMMUNOHISTO M M, V17, P57, DOI 10.1097/PAI.0b013e3181816ae2; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Li XY, 2016, ONCOTARGET, V7, P12869, DOI 10.18632/oncotarget.7331; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Liu Y, 2006, J BIOL CHEM, V281, P12102, DOI 10.1074/jbc.M600508200; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Minciacchi VR, 2017, PROSTATE CANCER P D, V20, P251, DOI 10.1038/pcan.2017.7; Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865; Nakano N, 2005, BRIT J DERMATOL, V153, P37, DOI 10.1111/j.1365-2133.2005.06583.x; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Ohlsson L, 2012, INT J CANCER, V130, P1833, DOI 10.1002/ijc.26182; Orchard-Webb DJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-754; Parvani JG, 2013, MOL BIOL CELL, V24, P3449, DOI 10.1091/mbc.E12-10-0776; Provasi D, 2014, PROTEINS, V82, P3231, DOI 10.1002/prot.24540; Putzke AP, 2011, AM J PATHOL, V179, P400, DOI 10.1016/j.ajpath.2011.03.028; Rai AC, 2014, BIOMETALS, V27, P1231, DOI 10.1007/s10534-014-9785-9; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sandvig K, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012914; Sato K, 2007, J NEUROSCI RES, V85, P3071, DOI 10.1002/jnr.21438; Sawada G, 2014, ANN SURG ONCOL, V21, pS640, DOI 10.1245/s10434-014-3740-4; Schehr JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159397; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Siva AC, 2008, J IMMUNOL METHODS, V330, P109, DOI 10.1016/j.jim.2007.11.008; Spassov DS, 2012, ONCOGENE, V31, P419, DOI 10.1038/onc.2011.246; Spassov DS, 2013, CANCER RES, V73, P1168, DOI 10.1158/0008-5472.CAN-12-2496; Spassov DS, 2011, CELL CYCLE, V10, P1225, DOI 10.4161/cc.10.8.15343; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; Sperger JM, 2016, CLIN CANCER RES, V23, P746; Stahelin RV, 2012, J BIOL CHEM, V287, P30518, DOI 10.1074/jbc.M112.391557; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696; Twardowski PW, 2013, ANTI-CANCER DRUG, V24, P743, DOI 10.1097/CAD.0b013e328361feb0; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Yang J, 2013, ANAT REC, V296, P1501, DOI 10.1002/ar.22769; Yang LF, 2015, ONCOTARGET, V6, P43743, DOI 10.18632/oncotarget.6193; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zarif JC, 2015, ONCOTARGET, V6, P6862, DOI 10.18632/oncotarget.3119	78	15	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2817	2836		10.1038/s41388-018-0142-2	http://dx.doi.org/10.1038/s41388-018-0142-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511352	Green Accepted			2022-12-28	WOS:000432929800005
J	Esteve-Arenys, A; Valero, JG; Chamorro-Jorganes, A; Gonzalez, D; Rodriguez, V; Dlouhy, I; Salaverria, I; Campo, E; Colomer, D; Martinez, A; Rymkiewicz, G; Perez-Galan, P; Lopez-Guillermo, A; Roue, G				Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Rodriguez, V.; Dlouhy, I.; Salaverria, I.; Campo, E.; Colomer, D.; Martinez, A.; Rymkiewicz, G.; Perez-Galan, P.; Lopez-Guillermo, A.; Roue, G.			The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMAS; ANTITUMOR-ACTIVITY; BCL2 INHIBITION; PHASE-I; MYC; BORTEZOMIB; CHEMOTHERAPY; DISTINCT; MCL-1	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, mostly known as double-hit lymphoma (DHL), is a rare entity characterized by morphologic and molecular features between Burkitt lymphoma and the clinically manageable diffuse large B-cell lymphoma (DLBCL). DHL patients usually undergo a rapidly progressing clinical course associated with resistance to standard chemo-immunotherapy. As a consequence, the prognosis of this entity is particularly poor with a median overall survival inferior to 1 year. ABT-199 (venetoclax) is a potent and selective small-molecule antagonist of BCL-2 recently approved for the treatment of a specific subtype of lymphoid neoplasm. In this study, we demonstrate that single-agent ABT-199 efficiently displaces BAX from BCL-2 complexes but fails to maintain a significant antitumor activity over time in most MYC+/BCL2+ DHL cell lines and primary cultures, as well as in a xenograft mouse model of the disease. We further identify the accumulation of the BCL2-like protein BFL-1 to be a major mechanism involved in acquired resistance to ABT-199. Noteworthy, this phenomenon can be counteracted by the BET bromodomain inhibitor CPI203, since gene expression profiling identifies BCL2A1, the BFL-1 coding gene, as one of the top apoptosis-related gene modulated by this compound. Upon CPI203 treatment, simultaneous downregulation of MYC and BFL-1 further overcomes resistance to ABT-199 both in vitro and in vivo, engaging synergistic caspase-mediated apoptosis in DHL cultures and tumor xenografts. Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL.	[Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Roue, G.] CIBERONC, Aggress B Cell Lymphoma Study Grp, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Rodriguez, V.; Salaverria, I.; Campo, E.; Colomer, D.; Perez-Galan, P.; Lopez-Guillermo, A.; Roue, G.] CIBERONC, Div Hematol & Oncol, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Dlouhy, I.; Lopez-Guillermo, A.] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain; [Campo, E.; Colomer, D.; Martinez, A.] Hosp Clin Barcelona, Dept Pathol, Hematopathol Unit, Barcelona, Spain; [Rymkiewicz, G.] Maria Sklodowska Curie Mem Canc Ctr, Dept Pathol, Warsaw, Poland; [Rymkiewicz, G.] Inst Oncol, Warsaw, Poland; [Roue, G.] Vall dHebron Univ Hosp, Lab Expt Hematol, Dept Hematol, Vall dHebron Inst Oncol, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Roue, G (corresponding author), CIBERONC, Aggress B Cell Lymphoma Study Grp, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.; Roue, G (corresponding author), CIBERONC, Div Hematol & Oncol, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.	groue@clinic.ub.es	Jorganes, Aranzazu Chamorro/N-7774-2019; COLOMER, DOLORS/ABG-6894-2020; Miquel, Josep Maria/AAG-3508-2019; Rymkiewicz, Grzegorz/AAB-7301-2019; Campo, Elias/AAC-5593-2019; Esteve-Arenys, Anna/E-5544-2014; ROUÉ, GAËL/D-4759-2014; Chamorro-Jorganes, Aranzazu/B-1871-2019; Lopez-Guillermo, Armando/Z-5684-2019	Jorganes, Aranzazu Chamorro/0000-0002-3505-7221; Campo, Elias/0000-0001-9850-9793; Esteve-Arenys, Anna/0000-0003-1277-5906; ROUÉ, GAËL/0000-0003-0245-2257; Chamorro-Jorganes, Aranzazu/0000-0002-3505-7221; Valero, Juan Garcia/0000-0003-3193-9099; Rymkiewicz, Grzegorz/0000-0002-3478-8014	Fondo de Investigacion Sanitaria [PI12/01847, PI15/00102, PI12/01536]; European Regional Development Fund (ERDF); Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III [RD12/0036/0004, RD12/0036/0039]; Generalitat de Catalunya [2014SGR346, 2014SGR795]; Ministerio de Ciencia e Innovacion (FPU); Agency for Management of University and Research (AGAUR) [2014 BP-B00177]	Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Regional Development Fund (ERDF)(European Commission); Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III; Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Ciencia e Innovacion (FPU)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Agency for Management of University and Research (AGAUR)	The authors thank Jocabed Roldan, Laura Jimenez, and Sandra Cabezas for expert technical assistance. This work was financially supported by Fondo de Investigacion Sanitaria PI12/01847 and PI15/00102 (to G.R.), PI12/01536 (to A.L.-G.), European Regional Development Fund (ERDF) "Una manera de hacer Europa", Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III RD12/0036/0004 (to D.C.) and RD12/0036/0039 (to E.C.) and Generalitat de Catalunya 2014SGR346 (to D.C.) and 2014SGR795 (to E.C.). A.E.-A. was recipient of a predoctoral fellowship from Ministerio de Ciencia e Innovacion (FPU). A.C.-J. holds a postdoctoral fellowship from The Agency for Management of University and Research (AGAUR, Beatriu de Pinos 2014 BP-B00177). This work was carried out at the Esther Koplowitz Center, Barcelona, under the CERCA Program (Generalitat de Catalunya).	Anderson MA, 2016, THER ADV HEMATOL, V7, P52, DOI 10.1177/2040620715608091; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bose P, 2017, LEUKEMIA LYMPHOMA, V58, P2026, DOI 10.1080/10428194.2017.1283032; Brown Jennifer R, 2014, Am Soc Clin Oncol Educ Book, pe317, DOI 10.14694/EdBook_AM.2014.34.e317; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Devaiah BN, 2016, J LEUKOCYTE BIOL, V100, P679, DOI 10.1189/jlb.2RI0616-250R; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Drexler HG, 2016, LEUKEMIA LYMPHOMA, V57, P1015, DOI 10.3109/10428194.2015.1108414; Fan GF, 2010, BLOOD, V115, P3559, DOI 10.1182/blood-2009-08-236760; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fresquet V, 2014, BLOOD, V123, P4111, DOI 10.1182/blood-2014-03-560284; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Grygorowicz MA, 2017, CLIN EXP MED, V17, P193, DOI 10.1007/s10238-016-0411-8; Johnson-Farley N, 2015, LEUKEMIA LYMPHOMA, V56, P2146, DOI 10.3109/10428194.2014.981172; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Kawano Y, 2003, BLOOD, V101, P532, DOI 10.1182/blood-2002-04-1268; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Li L, 2015, LEUKEMIA, V29, P1702, DOI 10.1038/leu.2015.99; Li SY, 2013, ADV ANAT PATHOL, V20, P315, DOI 10.1097/PAP.0b013e3182a289f2; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Moros A, 2014, LEUKEMIA, V28, P2049, DOI 10.1038/leu.2014.106; Niu XJ, 2016, CLIN CANCER RES, V22, P4440, DOI 10.1158/1078-0432.CCR-15-3057; Oppermann S, 2016, BLOOD, V128, P934, DOI 10.1182/blood-2015-12-687814; Perez-Galan P, 2008, LEUKEMIA, V22, P1712, DOI 10.1038/leu.2008.175; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rodriguez RM, 2012, J MOL MED, V90, P587, DOI 10.1007/s00109-011-0837-0; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Roue G, 2011, BLOOD, V117, P1270, DOI 10.1182/blood-2010-04-278853; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Siegel MB, 2015, ONCOTARGET, V6, P18921, DOI 10.18632/oncotarget.4214; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Turakhia SK, 2014, AM J CLIN PATHOL, V142, P339, DOI 10.1309/AJCPBWVHTF7RRSA4; Vandenberg CJ, 2013, BLOOD, V121, P2285, DOI 10.1182/blood-2013-01-475855; Xu XX, 2013, INT J CLIN EXP PATHO, V6, P788; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	46	56	59	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1830	1844		10.1038/s41388-017-0111-1	http://dx.doi.org/10.1038/s41388-017-0111-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353886				2022-12-28	WOS:000429303300002
J	Cheng, TY; Yang, YC; Wang, HP; Tien, YW; Shun, CT; Huang, HY; Hsiao, M; Hua, KT				Cheng, Tsu-Yao; Yang, Yi-Chieh; Wang, Hsiu-Po; Tien, Yu-Wen; Shun, Chia-Tung; Huang, Hsin-Yi; Hsiao, Michael; Hua, Kuo-Tai			Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein	ONCOGENE			English	Article							TUMOR-CELLS; CANCER-CELLS; GENE-TRANSCRIPTION; PKM2; TUMORIGENESIS; ISOFORM; PROGRESSION; EXPRESSION; PROGNOSIS; STRESS	Pyruvate kinase muscle isozymes (PKMs) have crucial roles in regulating metabolic changes during carcinogenesis. A switch from PKM1 to PKM2 isoform was thought to lead to aerobic glycolysis promoting carcinogenesis, and was considered as one of the cancer signatures. However, recent evidence has argued against the existence of PKM isoform switch and related metabolic effects during cancer progression. We compared the effects of PKM1 and PKM2 in cell invasiveness and metastasis of pancreatic ductal adenocarcinoma (PDAC). Both PKM1 and PKM2 expression affected cell migration and invasion abilities of PDAC cells, but only knockdown of PKM2 suppressed metastasis in a xenograft model. By comparing the established PKM2 mutants in the regulation of cell invasion, we found that PKM2 may control cell mobility through its protein kinase and phopho-peptide binding abilities. Further survey for PKM2-associated proteins identified PAK2 as a possible phosphorylation target in PDAC. In vitro binding and kinase assays revealed that PKM2 directly phosphorylated PAK2 at Ser20, Ser141, and Ser192/197. Knockdown of PKM2 decreased PAK2 protein half-life by increasing ubiquitin-dependent proteasomal degradation. Moreover, we identified PAK2 as an HSP90 client protein and the mutation at Ser192/197 of PAK2 reduced PAK2-HSP90 association. Knockdown of PAK2 diminished in vitro cell mobility and in vivo metastatic ability of PKM2 overexpressed PDAC cells. PKM2 and PAK2 protein expression also positively correlated with each other in PDAC tissues. Our findings indicate that PKM2-PAK2 regulation is critical for developing metastasis in PDAC, and suggest that targeting the PKM2/HSP90/PAK2 complex has a potential therapeutic value in this deadly disease.	[Cheng, Tsu-Yao] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Cheng, Tsu-Yao; Wang, Hsiu-Po] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Yang, Yi-Chieh] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Shun, Chia-Tung; Huang, Hsin-Yi] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung, Taiwan; [Hua, Kuo-Tai] Natl Taiwan Univ, Grad Inst Toxicol, Coll Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; National Taiwan University	Hua, KT (corresponding author), Natl Taiwan Univ, Grad Inst Toxicol, Coll Med, Taipei, Taiwan.	kthua@ntu.edu.tw	Hsiao, Michael/U-6238-2019; Cheng, TY/X-1695-2019; Shun, Chia-Tung/M-1400-2019; Yang, Yi-Chieh/D-6248-2019	Hsiao, Michael/0000-0001-8529-9213; Hua, Kuo-Tai/0000-0002-8468-4977; TIEN, YU-WEN/0000-0002-9126-2705; SHUN, CHIA-TUNG/0000-0002-0468-4468; Huang, Hsin-Yi/0000-0003-0062-3091; CHENG, TSU-YAO/0000-0002-7370-5605	Ministry of Science and Technology of Taiwan [104-0210-01-09-02, 105-0210-01-13-01, 106-0210-01-15-02, 105-2320-B-002-035-MY3, 104-2314-B-002-027]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr. Zhi-Min Lu for the Flag-tagged K367M, K433E, and wild-type PKM2; Dr. Zhi-Ren Liu for HA-tagged R399E and wild-type PKM2. This work was supported by grants from the Ministry of Science and Technology of Taiwan, 104-0210-01-09-02, 105-0210-01-13-01, and 106-0210-01-15-02 (to M. H.); 105-2320-B-002-035-MY3 (to K.-T.H.); and 104-2314-B-002-027 (to T.-Y.C.).	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Bluemlein K, 2011, ONCOTARGET, V2, P393; Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; EHRENFRIED JA, 1995, SURG ONCOL, V4, P197, DOI 10.1016/S0960-7404(10)80036-2; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Goonetilleke KS, 2007, PANCREAS, V34, P318, DOI 10.1097/MPA.0b013e31802ee9c7; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hosios AM, 2015, MOL CELL, V59, P850, DOI 10.1016/j.molcel.2015.07.013; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jiang K, 2016, ONCOTARGET, V7, P23530, DOI 10.18632/oncotarget.8120; Jiang YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6566; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Joergensen MT, 2010, PANCREAS, V39, P243, DOI 10.1097/MPA.0b013e3181bae8ab; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kumar Y, 2007, PANCREAS, V35, P114, DOI 10.1097/mpa.0b013e3180537237; Lang SA, 2007, MOL CANCER THER, V6, P1123, DOI 10.1158/1535-7163.MCT-06-0628; Li CG, 2016, DIGEST DIS SCI, V61, P767, DOI 10.1007/s10620-015-3931-2; Li ZW, 2014, BBA-REV CANCER, V1846, P285, DOI 10.1016/j.bbcan.2014.07.008; Liang J, 2017, CELL RES, V27, P329, DOI 10.1038/cr.2016.159; Lockney Natalie A, 2015, J Gastrointest Cancer, V46, P390, DOI 10.1007/s12029-015-9764-6; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; MELLATI AA, 1992, CANCER BIOCHEM BIOPH, V13, P33; Mohammad GH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151635; Nakatsu D, 2015, P NATL ACAD SCI USA, V112, pE1067, DOI 10.1073/pnas.1417197112; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Ogawa H, 2015, MOL CLIN ONCOL, V3, P563, DOI 10.3892/mco.2015.490; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20; Vargas DA, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005007; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wu JY, 2016, ONCOTARGETS THER, V9, P4277, DOI 10.2147/OTT.S106508; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang YC, 2016, ONCOGENE, V35, P3387, DOI 10.1038/onc.2015.397; Zhan C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118663; Zhu HY, 2017, ONCOTARGET, V8, P1628, DOI 10.18632/oncotarget.13703	44	43	46	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1730	1742		10.1038/s41388-017-0086-y	http://dx.doi.org/10.1038/s41388-017-0086-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29335522				2022-12-28	WOS:000428632600004
J	Herr, R; Halbach, S; Heizmann, M; Busch, H; Boerries, M; Brummer, T				Herr, Ricarda; Halbach, Sebastian; Heizmann, Miriam; Busch, Hauke; Boerries, Melanie; Brummer, Tilman			BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ACQUIRED-RESISTANCE; MOLECULAR LANDSCAPE; FEEDBACK INHIBITION; PROGNOSTIC-FACTOR; GENE-EXPRESSION; MEK INHIBITORS; RAF INHIBITION; TUMOR-GROWTH; COLON-CANCER	BRAF mutations occur in similar to 10% of colorectal cancer (CRC) and are associated with poor prognosis. Inhibitors selective for the BRAF(V600E) oncoprotein, the most common BRAF mutant, elicit only poor response rates in BRAF-mutant CRC as single agents. This unresponsiveness was mechanistically attributed to the loss of negative feedbacks on the epidermal growth factor receptor (EGFR) and initiated clinical trials that combine BRAF (and MEK) inhibitors, either singly or in combination, with the anti-EGFR antibodies cetuximab or panitumumab. First results of these combinatorial studies demonstrated improved efficacy, however, the response rates still were heterogeneous. Here, we show that BRAF inhibition leads to the upregulation of a variety of receptor tyrosine kinases (RTKs) in CRC cell lines, including not only the EGFR, but also human epidermal growth factor receptor (HER) 2 and HER3. Importantly, combination of the BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with inhibitors dually targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells. This re-sensitization was also observed after genetic depletion of HER2 or HER3. Interestingly, BRAF inhibitors did not only upregulate RTKs, but also increased the abundance of the GRB2-associated binders (Gab) 1 and Gab2, two important amplifiers of RTK signaling. An allele-specific shRNA-mediated knockdown of BRAF(V600E) revealed that Gab2 upregulation was directly dependent on the loss of the oncoprotein and was not caused by an "off-target" effect of these kinase inhibitors. Furthermore, Gab2 and Gab2-mediated Shp2 signaling were shown to be functionally important in BRAFi resistance. These findings highlight potential new escape mechanisms to these targeted therapies and indicate that a broad suppression of RTK signaling might be beneficial and should be taken into account in future research addressing targeted therapy in BRAF-mutant CRC.	[Herr, Ricarda; Halbach, Sebastian; Heizmann, Miriam; Brummer, Tilman] Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Signal Transduct Tumour Dev & Drug Resistance Grp, Fac Med, Freiburg, Germany; [Heizmann, Miriam] Univ Freiburg, Fac Biol, Freiburg, Germany; [Busch, Hauke; Boerries, Melanie] Univ Freiburg, Syst Biol Cellular Microenvironm, IMMZ, Fac Med, Freiburg, Germany; [Busch, Hauke] Univ Lubeck, Inst Expt Dermatol, Lubeck, Germany; [Busch, Hauke] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany; [Boerries, Melanie; Brummer, Tilman] German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Partner Site Freiburg, Heidelberg, Germany; [Boerries, Melanie; Brummer, Tilman] Univ Freiburg, CCCF, Freiburg, Germany; [Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Lubeck; University of Lubeck; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Herr, R; Brummer, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Signal Transduct Tumour Dev & Drug Resistance Grp, Fac Med, Freiburg, Germany.; Brummer, T (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Partner Site Freiburg, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, CCCF, Freiburg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.	ricarda.herr@mol-med.uni-freiburg.de; tilman.brummer@zbsa.de	Brummer, Tilman/B-6218-2016; Halbach, Sebastian/G-4021-2012; Boerries, Melanie/AAM-2602-2021; Brummer, Tilman/AAA-9428-2020; Busch, Hauke/R-6452-2016	Brummer, Tilman/0000-0003-4387-7905; Halbach, Sebastian/0000-0002-6827-8178; Brummer, Tilman/0000-0003-4387-7905; Griffin, Ricarda/0000-0003-1368-2832; Busch, Hauke/0000-0003-4763-4521	German Research Foundation (DFG) [SFB 850]; Heisenberg professorship [EXC 294 BIOSS]; BMBF [e:Bio 0316184D]; e:Med research and funding concept, DeCaRe [FKZ 01ZX1409B]	German Research Foundation (DFG)(German Research Foundation (DFG)); Heisenberg professorship(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); e:Med research and funding concept, DeCaRe	We thank Martin Kohler for valuable discussions, Roland Rad for sharing MouseT1 cells, and Silke Kowar for expert technical assistance. This work was supported by the German Research Foundation (DFG) through SFB 850, projects B4 (TB) and Z1 (HB and MB), a Heisenberg professorship to TB, EXC 294 BIOSS and the BMBF through e:Bio 0316184D, and MB within the framework of the e:Med research and funding concept, DeCaRe (FKZ 01ZX1409B).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Bai RP, 2015, INT J CANCER, V137, P2310, DOI 10.1002/ijc.29607; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bier D, 2016, CHEMMEDCHEM, V11, P911, DOI 10.1002/cmdc.201500484; Boerries M, 2015, GENOM DATA, V4, P158, DOI 10.1016/j.gdata.2015.04.015; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Caenepeel S, 2017, ONCOTARGET, V8, P17795, DOI 10.18632/oncotarget.14855; Cagnol S, 2013, ONCOGENE, V32, P564, DOI 10.1038/onc.2012.88; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chaussepied M, 2004, MOL CELL, V16, P831, DOI 10.1016/j.molcel.2004.11.003; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Ding CB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0524-2; Ding CB, 2015, INT J CLIN EXP PATHO, V8, P2779; Duckworth C, 2016, ONCOGENE, V35, P4036, DOI 10.1038/onc.2015.472; Ellebaek S, 2016, INT J CANCER, V139, P2095, DOI 10.1002/ijc.30242; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Halbach S, 2016, LEUKEMIA, V30, P1942, DOI 10.1038/leu.2016.92; Halbach S, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0129-y; Halbach S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-30; Herr R, 2015, CANCER RES, V75, P216, DOI 10.1158/0008-5472.CAN-13-3686; Hoeben A, 2013, INT J CANCER, V132, P1042, DOI 10.1002/ijc.27763; Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jubb AM, 2005, CLIN CANCER RES, V11, P5181, DOI 10.1158/1078-0432.CCR-05-0143; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Kugel CH, 2014, CANCER RES, V74, P4122, DOI 10.1158/0008-5472.CAN-14-0464; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Liu W, 2017, LEUKEMIA, V31, P1415, DOI 10.1038/leu.2016.326; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Matsumura T, 2014, ANN SURG ONCOL, V21, pS743, DOI 10.1245/s10434-014-3889-x; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Norz D, 2015, CELL SIGNAL, V27, P2191, DOI 10.1016/j.cellsig.2015.07.016; Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ortiz-Padilla C, 2013, ONCOGENE, V32, P2696, DOI 10.1038/onc.2012.271; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Radic-Sarikas B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03129-6; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Schwarz LJ, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx065; Smith MP, 2016, CLIN CANCER RES, V22, P5966, DOI 10.1158/1078-0432.CCR-16-0954; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159-8290.CD-17-0087; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Vincent KM, 2017, ONCOTARGET, V8, P10498, DOI 10.18632/oncotarget.14443; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Williams CB, 2015, ONCOTARGETS THER, V8, P3561, DOI 10.2147/OTT.S90766; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wohrle FU, 2013, LEUKEMIA, V27, P118, DOI 10.1038/leu.2012.222; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Wohrle FU, 2009, STRUCTURE, V17, P779, DOI 10.1016/j.str.2009.05.003; Wu XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19000; Xiang SH, 2017, BIOCHEM BIOPH RES CO, V484, P719, DOI 10.1016/j.bbrc.2017.01.095; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729; Yang L, 2015, J BIOL CHEM, V290, P26627, DOI 10.1074/jbc.M115.667717; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	91	26	26	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1576	1593		10.1038/s41388-017-0063-5	http://dx.doi.org/10.1038/s41388-017-0063-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326440				2022-12-28	WOS:000428626700003
J	Pruitt, HC; Metge, BJ; Weeks, SE; Chen, DQ; Wei, S; Kesterson, RA; Shevde, LA; Samant, RS				Pruitt, Hawley C.; Metge, Brandon J.; Weeks, Shannon E.; Chen, Dongquan; Wei, Shi; Kesterson, Robert A.; Shevde, Lalita A.; Samant, Rajeev S.			Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN; STEM-CELLS; BREAST-CANCER; PROTEIN NMI; ACTIVATION; TARGET; GLAND; FATE; BETA-CATENIN/LEF-1	The process of organ development requires a delicate balance between cellular plasticity and differentiation. This balance is disrupted in cancer initiation and progression. N-Myc and STAT interactor (NMI: human or Nmi: murine) has emerged as a relevant player in the etiology of breast cancer. However, a fundamental understanding of its relevance to normal mammary biology is lacking. To gain insight into its normal function in mammary gland, we generated a mammary-specific Nmi knockout mouse model. We observed that Nmi protein expression is induced in mammary epithelium at the onset of pregnancy, in luminal cells and persists throughout lactation. Nmi knockout results in a precocious alveolar phenotype. These alveoli exhibit an extensive presence of nuclear beta-catenin and enhanced Wnt/beta-catenin signaling. The Nmi knockout pubertal ductal tree shows enhanced invasion of the mammary fatpad and increased terminal end bud numbers. Tumors from Nmi null mammary epithelium show a significant enrichment of poorly differentiated cells with elevated stem/progenitor markers, active Wnt/beta-catenin signaling, highly invasive morphology as well as, increased number of distant metastases. Our study demonstrates that Nmi has a distinct role in the differentiation process of mammary luminal epithelial cell compartment and developmental aberrations resulting from Nmi absence contribute to metastasis and demonstrates that aberration in normal developmental program can lead to metastatic disease, highlighting the contribution and importance of luminal progenitor cells in driving metastatic disease.	[Pruitt, Hawley C.; Metge, Brandon J.; Weeks, Shannon E.; Wei, Shi; Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Chen, Dongquan] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Samant, RS (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.; Samant, RS (corresponding author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.	rsamant@uab.edu		Samant, Rajeev/0000-0001-5681-4976	Cancer Center Core grant [CA013148]; UAB CCTS award [UL1TR001417, BX003374]; NCI/NIH [CA194048, CA169202]; NATIONAL CANCER INSTITUTE [R01CA140472, R01CA169202, R01CA194048, P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003374] Funding Source: NIH RePORTER	Cancer Center Core grant; UAB CCTS award; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge Sarah K. Bailey and Ann Hanna for their assistance during experimental procedures. We are grateful to Dr. Jeffrey Rosen and his graduate student Daisy for advice with X-gal staining of mammary tissues. We acknowledge the following grant support: Cancer Center Core grant CA013148, for the Heflin Genomics facility and UAB-Transgenic and knockout facility, to RAK. Support from UAB CCTS award #UL1TR001417 to DC BX003374 (VA) and CA194048 (NCI/NIH) to RSS and CA169202 (NCI/NIH) to LAS. HCP is a HHMI-Med-To-Grad Fellow (UAB).	Alexander C.M., 2012, COLD SPRING HARB PER, P1; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Boras-Granic K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0487-6; Boras-Granic Kata, 2008, Organogenesis, V4, P116; Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Devine DJ, 2014, ONCOGENE, V33, P2620, DOI 10.1038/onc.2013.215; Feng X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.200; Gauger KJ, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-25; Gross K, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4010004; Harper KL, 2016, NATURE; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hosseini H., 2016, NATURE; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Joshi PA, 2012, TRENDS ENDOCRIN MET, V23, P299, DOI 10.1016/j.tem.2012.04.002; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030979; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin VTG, 2017, TRENDS CANCER, V3, P126, DOI 10.1016/j.trecan.2016.12.007; Lo PK, 2013, ONCOGENE, V32, P1338, DOI 10.1038/onc.2012.456; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Perotti C, 2009, DIFFERENTIATION, V78, P269, DOI 10.1016/j.diff.2009.05.003; Pruitt HC, 2016, INT J CANCER, V139, P491, DOI 10.1002/ijc.30043; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Tiede B, 2011, CELL RES, V21, P245, DOI 10.1038/cr.2011.11; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhao J, 2017, ONCOTARGET, V8, P12174, DOI 10.18632/oncotarget.14556; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	39	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1610	1623		10.1038/s41388-017-0037-7	http://dx.doi.org/10.1038/s41388-017-0037-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326438	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000428626700005
J	de Boer, HR; Pool, M; Joosten, E; Everts, M; Samplonius, DF; Helfrich, W; Groen, HJM; van Cooten, S; Fusetti, F; Fehrmann, RSN; de Vries, EGE; van Vugt, MATM				de Boer, H. Rudolf; Pool, Martin; Joosten, Esmee; Everts, Marieke; Samplonius, Douwe F.; Helfrich, Wijnand; Groen, Harry J. M.; van Cooten, Suzanne; Fusetti, Fabrizia; Fehrmann, Rudolf S. N.; de Vries, Elisabeth G. E.; van Vugt, Marcel A. T. M.			Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition	ONCOGENE			English	Article							LUNG-CANCER; UP-REGULATION; MET AMPLIFICATION; STAT3 ACTIVATION; DRUG DEVELOPMENT; EXPRESSION; RESISTANCE; FAMILY; GEFITINIB; PROGNOSIS	Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on changes in tumor size. Dynamic biomarkers that reflect effective engagement of targeted therapeutics to the targeted pathway, so-called "effect sensors", would fulfill a need for non-invasive, drug-specific indicators of early treatment effect. Using a proteomics approach to identify effect sensors, we demonstrated MUC1 upregulation in response to epidermal growth factor receptor (EGFR)targeting treatments in breast and lung cancer models. To achieve this, using semi-quantitative mass spectrometry, we found MUC1 to be significantly and durably upregulated in response to erlotinib, an EGFR-targeting treatment. MUC1 upregulation was regulated transcriptionally, involving PI3K-signaling and STAT3. We validated these results in erlotinib-sensitive human breast and non-small lung cancer cell lines. Importantly, erlotinib treatment of mice bearing SUM149 xenografts resulted in increased MUC1 shedding into plasma. Analysis of MUC1 using serial blood sampling may therefore be a new, relatively non-invasive tool to monitor early and drug-specific effects of EGFR-targeting therapeutics.	[de Boer, H. Rudolf; Pool, Martin; Joosten, Esmee; Everts, Marieke; van Cooten, Suzanne; Fehrmann, Rudolf S. N.; de Vries, Elisabeth G. E.; van Vugt, Marcel A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Samplonius, Douwe F.; Helfrich, Wijnand] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Groen, Harry J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Fusetti, Fabrizia] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Netherlands Prote Ctr, Groningen, Netherlands; [Fusetti, Fabrizia] Univ Groningen, Zernike Inst Adv Mat, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.vugt@umcg.nl	Groen, Harry/AAP-2242-2021; Fehrmann, Rudolf/E-2551-2011; Institute, Zernike/W-7033-2019	Fehrmann, Rudolf/0000-0002-7516-315X; Pool, Martin/0000-0002-4892-3109; Groen, Harry J.M./0000-0002-2978-5265; de Boer, Harmen Rudolf/0000-0002-8386-8184; de Vries, Elisabeth/0000-0002-8949-7425	European Research Council (ERC-Advanced Grant) [ERC-2011-293-445]	European Research Council (ERC-Advanced Grant)(European Research Council (ERC))	We thank members of the Medical Oncology Department and Cancer Research Center Groningen for helpful discussions. This work is financially supported by the European Research Council (ERC-Advanced Grant ERC-2011-293-445 to E.G.E.d.V.). E.G. E.d.V. and M.A.T.M.v.V. conceived the study. H.R.d.B., E.J.,S.v.C., and M.E. designed and performed in vitro experiments. E.J. and F.F. performed MS experiments and analysis. R.S.N.F. and H.R.d.B. performed pathway analysis. M.P., D.F.S., and W.H. designed and manufactured molecular imaging tools. H.R.d.B. and M.P. performed in vivo experiments. H.R.d.B., E.G. E.d.V., and M.A.T.M.v.V. wrote the manuscript and all authors contributed to editing of the manuscript. The mass spectrometry proteomics data have been deposited to the Proteome-Xchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 51 with the dataset identifier PXD005985.	Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bearz A, 2007, INT J BIOL MARKER, V22, P307, DOI 10.1177/172460080702200411; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; D'Alessandro R, 2001, BREAST CANCER RES TR, V68, P9, DOI 10.1023/A:1017903724176; de Vries EGE, 2015, J CLIN ONCOL, V33, P2585, DOI 10.1200/JCO.2015.61.6425; de Vries EGE, 2011, CANCER DISCOV, V1, P25, DOI 10.1158/2159-8274.CD-11-0051; Duffy MJ, 2015, ADV CLIN CHEM, V71, P1, DOI [10.1016/bs.acc.2015.05.001, 10.1016/B978-0-12-801401-1.00001-3]; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Fujiwara Y, 2008, LUNG CANCER, V59, P81, DOI 10.1016/j.lungcan.2007.07.018; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Ishikawa N, 2008, INT J CANCER, V122, P2612, DOI 10.1002/ijc.23411; Kani K, 2012, MOL CANCER THER, V11, P1071, DOI 10.1158/1535-7163.MCT-11-0852; Kearns NA, 2014, DEVELOPMENT, V141, P219, DOI 10.1242/dev.103341; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee SI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r76; Lopez JS, 2017, NAT REV CLIN ONCOL, V14, P57, DOI 10.1038/nrclinonc.2016.96; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Petrylak DP, 2006, J NATL CANCER I, V98, P516, DOI 10.1093/jnci/djj129; Pool M, 2017, EUR J NUCL MED MOL I, V44, P1328, DOI 10.1007/s00259-017-3672-x; Pool M, 2017, THERANOSTICS, V7, P2111, DOI 10.7150/thno.17934; Pool M, 2016, ONCOTARGET, V7, P68111, DOI 10.18632/oncotarget.11827; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Savage P, 2017, CELL REP, V21, P1140, DOI 10.1016/j.celrep.2017.10.015; Sequist LV, 2013, J CLIN ONCOL, V31; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Starsichova A, 2010, CELL SIGNAL, V22, P1734, DOI 10.1016/j.cellsig.2010.06.014; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; Yamasaki F, 2007, MOL CANCER THER, V6, P2168, DOI 10.1158/1535-7163.MCT-06-0514	51	7	7	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1477	1488		10.1038/s41388-018-0522-7	http://dx.doi.org/10.1038/s41388-018-0522-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305724	Green Published			2022-12-28	WOS:000459945800008
J	Shmueli, MD; Levy-Kanfo, L; Haj, E; Schoenfeld, AR; Gazit, E; Segal, D				Shmueli, Merav D.; Levy-Kanfo, Limor; Haj, Esraa; Schoenfeld, Alan R.; Gazit, Ehud; Segal, Daniel			Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HIF-ALPHA; LINDAU; DROSOPHILA; HIF-1-ALPHA; COMPLEX; BINDING; HYDROXYPROLINE; UBIQUITINATION; UBIQUITYLATION	The von Hippel-Lindau (VHL) syndrome is a rare inherited cancer, caused by mutations in the VHL gene, many of which render the VHL protein (pVHL) unstable. pVHL is a tumor-suppressor protein implicated in a variety of cellular processes, most notably in response to changes in oxygen availability, due to its role as part of an E3-ligase complex which targets the hypoxia-inducible factor (HIF) for degradation. Previously we reported, using in silico and in vitro analyses, that common oncogenic VHL mutations render pVHL less stable than the wild-type protein, distort its core domain and as a result reduce the ability of the protein to bind its target HIF-1 alpha. Among various chemical chaperones tested, arginine was the most effective in refolding mutant of pVHL. Here we examined the consequences of administering L- or D-arginine to a Drosophila VHL model and to human renal carcinoma cells, both expressing misfolded versions of human pVHL. Arginine treatment increased pVHL solubility in both models and increased the half-life of the mutant pVHL proteins in the cell culture. In both models, L- as well as D-arginine enhanced the ability of wild-type pVHL and certain misfolded mutant versions of pVHL to bind ODD, the HIF-derived target peptide, reflecting restoration of pVHL function. Moreover, continuous feeding of Drosophila expressing misfolded versions of pVHL either L- or D-arginine rich diet rescued their lethal phenotype. Collectively, these in vivo results suggest that arginine supplementation should be examined as a potential novel treatment for VHL cancer syndrome.	[Shmueli, Merav D.; Levy-Kanfo, Limor; Haj, Esraa; Gazit, Ehud; Segal, Daniel] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; [Schoenfeld, Alan R.] Adelphi Univ, Dept Biol, One South Ave,POB 701, Garden City, NY 11530 USA	Tel Aviv University; Adelphi University	Segal, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	dsegal@post.tau.ac.il	Shmueli, Merav/HDM-9859-2022; Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Shmueli, Merav/0000-0002-9196-7633; Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; Segal, Daniel/0000-0002-6777-505X	Israel Cancer Association; Cancer Biology Research Center in Tel Aviv University; VHL Alliance	Israel Cancer Association; Cancer Biology Research Center in Tel Aviv University; VHL Alliance	This work was supported in part by the Israel Cancer Association, the Cancer Biology Research Center in Tel Aviv University, and the VHL Alliance (to DS).	Arakawa T, 2007, BIOPHYS CHEM, V127, P1, DOI 10.1016/j.bpc.2006.12.007; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bangiyeva V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-229; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Chen CH, 2009, LANGMUIR, V25, P6717, DOI 10.1021/la9002065; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; Duchi S, 2010, DEVELOPMENT, V137, P1493, DOI 10.1242/dev.042804; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hsouna A, 2010, MOL CELL BIOL, V30, P3779, DOI 10.1128/MCB.01578-09; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Khan SH, 2010, IUBMB LIFE, V62, P891, DOI 10.1002/iub.406; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Li JG, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3469790; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeal CJ, 2016, J NUTR, V146, P2587, DOI 10.3945/jn.116.234740; Miller F, 2005, J BIOL CHEM, V280, P7985, DOI 10.1074/jbc.M413160200; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Navarro E, 2005, BASIC CLIN PHARMACOL, V97, P149, DOI 10.1111/j.1742-7843.2005.pto_973110.x; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shmueli MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109864; Shmueli MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066333; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tabaro F, 2016, SCI REP-UK, V6, DOI 10.1038/srep31128; Tarade D, 2018, ONCOGENE, V37, P139, DOI 10.1038/onc.2017.338; Varshney N, 2017, J KIDNEY CANCER VHL, V4, P20, DOI 10.15586/jkcvhl.2017.88; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	43	4	5	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1038	1049		10.1038/s41388-018-0491-x	http://dx.doi.org/10.1038/s41388-018-0491-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194449				2022-12-28	WOS:000458624900008
J	Yuan, JM; Ng, WH; Lam, PYP; Wang, Y; Xia, HP; Yap, JJ; Guan, SP; Lee, ASG; Wang, M; Baccarini, M; Hu, JC				Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Lee, Ann S. G.; Wang, Mei; Baccarini, Manuela; Hu, Jiancheng			The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants	ONCOGENE			English	Article							LANGERHANS CELL HISTIOCYTOSIS; B-RAF; PROTEIN-KINASES; WILD-TYPE; ACTIVATION MECHANISM; INHIBITOR RESISTANCE; METASTATIC MELANOMA; MAPK PATHWAY; GENE FUSIONS; C-RAF	Although extensively studied for three decades, the molecular mechanisms that regulate the RAF/MEK/ERK kinase cascade remain ambiguous. Recent studies identified the dimerization of RAF as a key event in the activation of this cascade. Here, we show that in-frame deletions in the beta 3-alpha C loop activate ARAF as well as BRAF and other oncogenic kinases by enforcing homodimerization. By characterizing these RAF mutants, we find that ARAF has less allosteric and catalytic activity than the other two RAF isoforms, which arises from its non-canonical APE motif. Further, these RAF mutants exhibit a strong oncogenic potential, and a differential inhibitor resistance that correlates with their dimer affinity. Using these unique mutants, we demonstrate that active RAFs, including the BRAF(V600E) mutant, phosphorylate MEK in a dimer-dependent manner. This study characterizes a special category of oncogenic kinase mutations, and elucidates the molecular basis that underlies the differential ability of RAF isoforms to stimulate MEK-ERK pathway. Further, this study reveals a unique catalytic feature of RAF family kinases that can be exploited to control their activities for cancer therapies.	[Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Hu, Jiancheng] Div Cellular & Mol Res, Singapore, Singapore; [Lam, Paula Y. P.; Wang, Mei; Hu, Jiancheng] Duke NUS Med Sch, Canc & Stem Cell Program, 8 Coll Rd, Singapore 169857, Singapore; [Lee, Ann S. G.] Natl Canc Ctr Singapore, Div Med Sci, 11 Hosp Dr, Singapore 169610, Singapore; [Lee, Ann S. G.] Duke NUS Med Sch, Off Clin & Acad Fac Affairs, 8 Coll Rd, Singapore 169857, Singapore; [Lee, Ann S. G.] Natl Univ Singapore, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore; [Baccarini, Manuela] Univ Vienna, Max F Perutz Labs, Doktor Bohr Gasse 9, A-1030 Vienna, Austria	National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Hu, JC (corresponding author), Div Cellular & Mol Res, Singapore, Singapore.; Hu, JC (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Program, 8 Coll Rd, Singapore 169857, Singapore.	hu.jiancheng@nccs.com.sg	Hu, Jiancheng/ABE-8133-2021; XIA, HONGPING/AAK-7100-2020; Baccarini, Manuela/B-6481-2014	Hu, Jiancheng/0000-0003-1615-0030; Baccarini, Manuela/0000-0002-3033-391X; Wang, Mei/0000-0001-6887-6840	NCCRF startup grant (NCCRF-SUG-JH); NCCRF bridging grant [NCCRF-YR2016-JUL-BG1]; NMRC seeding grants [NCCSPG-YR2015-JUL-14, NCCSPG-YR2016-JAN-17]; Duke-NUS Khoo Bridge Funding Award [Duke-NUS-KBrFA/2017/0003]; Asia Fund Cancer Research [AFCR2017/2019-JH]; SHF Research Grant [SHF/FG692S/2016]	NCCRF startup grant (NCCRF-SUG-JH); NCCRF bridging grant; NMRC seeding grants; Duke-NUS Khoo Bridge Funding Award; Asia Fund Cancer Research; SHF Research Grant	We thank the laboratories of Dr. Hui, Dr. Sabapathy, Dr. Virshup, and Dr. Anand for their help in experimental technologies. We also thank Dr. Andrey Shaw and Dr. Susan Taylor for their assistances. This study is supported by NCCRF startup grant (NCCRF-SUG-JH), NCCRF bridging grant (NCCRF-YR2016-JUL-BG1), NMRC seeding grants (NCCSPG-YR2015-JUL-14 and NCCSPG-YR2016-JAN-17), and Duke-NUS Khoo Bridge Funding Award (Duke-NUS-KBrFA/2017/0003), Asia Fund Cancer Research (AFCR2017/2019-JH) and SHF Research Grant (SHF/FG692S/2016).	Baccarini M, 2005, FEBS LETT, V579, P3271, DOI 10.1016/j.febslet.2005.03.024; Beenstock J, 2016, TRENDS BIOCHEM SCI, V41, P938, DOI 10.1016/j.tibs.2016.08.006; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chakraborty R, 2016, BLOOD, V128, P2533, DOI 10.1182/blood-2016-08-733790; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cseh B, 2014, FEBS LETT, V588, P2398, DOI 10.1016/j.febslet.2014.06.025; Desideri E, 2015, CELL, V161, P967, DOI 10.1016/j.cell.2015.04.045; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Estep AL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001279; Fabrini R, 2009, BIOCHEMISTRY-US, V48, P10473, DOI 10.1021/bi901238t; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hibino K, 2009, BIOPHYS J, V97, P1277, DOI 10.1016/j.bpj.2009.05.048; Hu JC, 2008, MOL IMMUNOL, V45, P1825, DOI 10.1016/j.molimm.2007.11.002; Hu J, 2015, MOL CELL BIOL, V35, P264, DOI 10.1128/MCB.00943-14; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Jin T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01274-0; Kornev AP, 2006, P NATL ACAD SCI USA, V103, P17783, DOI 10.1073/pnas.0607656103; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Lavoie H, 2014, TRENDS BIOCHEM SCI, V39, P475, DOI 10.1016/j.tibs.2014.08.004; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Mooz J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005484; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Nelson DS, 2014, BLOOD, V123, P3152, DOI 10.1182/blood-2013-06-511139; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rebocho AP, 2013, ONCOGENE, V32, P3207, DOI 10.1038/onc.2012.330; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shaw AS, 2014, MOL CELL BIOL, V34, P1538, DOI 10.1128/MCB.00057-14; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Taylor SS, 2013, BIOCHEM SOC T, V41, P981, DOI 10.1042/BST20130120; Taylor SS, 2011, TRENDS BIOCHEM SCI, V36, P65, DOI 10.1016/j.tibs.2010.09.006; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Valley CC, 2015, MOL BIOL CELL, V26, P4087, DOI 10.1091/mbc.E15-05-0269; Wan LX, 2017, CANCER DISCOV, V7, P424, DOI 10.1158/2159-8290.CD-16-0647; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang XX, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005147; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Yang J, 2012, J MOL BIOL, V415, P666, DOI 10.1016/j.jmb.2011.11.035	61	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5719	5734		10.1038/s41388-018-0365-2	http://dx.doi.org/10.1038/s41388-018-0365-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930381	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000448288200002
J	Yui, OM; Benitez, JA; Plouffe, SW; Ryback, D; Klein, A; Smith, J; Greenbaum, J; Delatte, B; Rao, A; Guan, KL; Furnari, FB; Chaim, OM; Miyamoto, S; Brown, JH				Yui, Olivia M.; Benitez, Jorge A.; Plouffe, Steven W.; Ryback, Daniel; Klein, Andrea; Smith, Jeff; Greenbaum, Jason; Delatte, Benjamin; Rao, Anjana; Guan, Kun-Liang; Furnari, Frank B.; Chaim, Olga Meiri; Miyamoto, Shigeki; Brown, Joan Heller			YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; YES-ASSOCIATED PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; TISSUE FACTOR EXPRESSION; LEUKEMIA-ASSOCIATED RHO; CELL-PROLIFERATION; THROMBIN RECEPTOR; CAUSES TRANSFORMATION; RAS TRANSFORMATION; ACTIVATES YAP/TAZ	The role of YAP (Yes-associated protein 1) and MRTF-A (myocardin-related transcription factor A), two transcriptional coactivators regulated downstream of GPCRs (G protein-coupled receptors) and RhoA, in the growth of glioblastoma cells and in vivo glioblastoma multiforme (GBM) tumor development was explored using human glioblastoma cell lines and tumor-initiating cells derived from patient-derived xenografts (PDX). Knockdown of these co-activators in GSC-23 PDX cells using short hairpin RNA significantly attenuated in vitro self-renewal capability assessed by limiting dilution, oncogene expression, and neurosphere formation. Orthotopic xenografts of the MRTF-A and YAP knockdown PDX cells formed significantly smaller tumors and were of lower morbidity than wild-type cells. In vitro studies used PDX and 1321N1 glioblastoma cells to examine functional responses to sphingosine 1-phosphate (S1P), a GPCR agonist that activates RhoA signaling, demonstrated that YAP signaling was required for cell migration and invasion, whereas MRTF-A was required for cell adhesion; both YAP and MRTF-A were required for proliferation. Gene expression analysis by RNA-sequencing of S1P-treated MRTF-A or YAP knockout cells identified 44 genes that were induced through RhoA and highly dependent on YAP, MRTF-A, or both. Knockdown of F3 (tissue factor (TF)), a target gene regulated selectively through YAP, blocked cell invasion and migration, whereas knockdown of HBEGF (heparin-binding epidermal growth factor-like growth factor), a gene selectively induced through MRTF-A, prevented cell adhesion in response to S1P. Proliferation was sensitive to knockdown of target genes regulated through either or both YAP and MRTF-A. Expression of TF and HBEGF was also selectively decreased in tumors from PDX cells lacking YAP or MRTF-A, indicating that these transcriptional pathways are regulated in preclinical GBM models and suggesting that their activation through GPCRs and RhoA contributes to growth and maintenance of human GBM.	[Yui, Olivia M.; Plouffe, Steven W.; Ryback, Daniel; Klein, Andrea; Smith, Jeff; Guan, Kun-Liang; Chaim, Olga Meiri; Miyamoto, Shigeki; Brown, Joan Heller] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Yui, Olivia M.; Plouffe, Steven W.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Benitez, Jorge A.; Furnari, Frank B.] Ludwig Inst Canc Res, San Diego Branch, San Diego, CA USA; [Greenbaum, Jason; Delatte, Benjamin; Rao, Anjana] La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA USA; [Rao, Anjana; Guan, Kun-Liang; Furnari, Frank B.; Brown, Joan Heller] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA; [Rao, Anjana; Furnari, Frank B.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; [Chaim, Olga Meiri] Univ Fed Parana, Dept Cell Biol, Curitiba, Parana, Brazil	University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; La Jolla Institute for Immunology; University of California System; University of California San Diego; University of California System; University of California San Diego; Universidade Federal do Parana	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.; Brown, JH (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.	jhbrown@ucsd.edu	Miyamoto, Shigeki/L-4004-2019; Chaim, Olga M/H-5179-2012; Delatte, Benjamin/AAE-9276-2020; Chaim, Olga Meiri/Y-7559-2019; Guan, Kun-Liang/ADK-7088-2022	Chaim, Olga M/0000-0002-3854-3292; Chaim, Olga Meiri/0000-0002-3854-3292; Klein, Andrea/0000-0003-4146-3493; Delatte, Benjamin/0000-0002-6798-0600	NIH [GM036927, HL028143, HL085577, CA170682, HL097037, NS080939, AI40127, AI109842];  [T32 GM007752];  [T32 DK00754]; NATIONAL CANCER INSTITUTE [R35CA196878, R01CA218859] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085577, R37HL028143, R01HL097037, R01HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI109842, R56AI109842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH Grants GM036927, HL028143, HL085577. and CA170682 to JHB; HL097037 to SM; NS080939 to FBF and JAB; AI40127 and AI109842 to AR. OMY and SWP were supported by T32 GM007752; OMY also received support from T32 DK00754; BD is an HHMI postdoctoral fellow from the Jane Coffin Childs Fund; OMC is a PDE fellow from The Brazilian National Council for Scientific and Technological Development.	Anelli V, 2008, J BIOL CHEM, V283, P3365, DOI 10.1074/jbc.M708241200; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Balasubramaniyan V, 2015, ONCOTARGET, V6, P31007, DOI 10.18632/oncotarget.5219; Bien-Moller S, 2016, ONCOTARGET, V7, P13031, DOI 10.18632/oncotarget.7366; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng G, 2015, TUMOR BIOL, V36, P2869, DOI 10.1007/s13277-014-2915-8; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cui YD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7333; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ensign SPF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00241; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Feng X, 2016, J BIOL CHEM, V291, P18947, DOI 10.1074/jbc.M116.739722; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Gaviglio AL, 2017, FASEB J, V31, P1903, DOI 10.1096/fj.201600828R; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Guettler S, 2008, MOL CELL BIOL, V28, P732, DOI 10.1128/MCB.01623-07; Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X; Haseley A, 2012, CANCER RES, V72, P1353, DOI 10.1158/0008-5472.CAN-11-2526; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Hua Y, 2005, J THROMB HAEMOST, V3, P1917, DOI 10.1111/j.1538-7836.2005.01446.x; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Magnus N, 2014, BIOCHEM BIOPH RES CO, V454, P262, DOI 10.1016/j.bbrc.2014.10.041; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Quan TH, 2014, AM J PATHOL, V184, P937, DOI 10.1016/j.ajpath.2013.12.017; Rak J, 2009, BEST PRACT RES CL HA, V22, P71, DOI 10.1016/j.beha.2008.12.008; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Rossol-Allisone J, 2009, CELL SIGNAL, V21, P1559, DOI 10.1016/j.cellsig.2009.05.010; Ruf W, 2011, J THROMB HAEMOST, V9, P306, DOI 10.1111/j.1538-7836.2011.04318.x; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah SR, 2016, NEUROSURGERY, V63, P185, DOI DOI 10.1227/01.NEU.0000489786.22041.2D; Siney EJ, 2017, MOL NEUROBIOL, V54, P3893, DOI 10.1007/s12035-016-0053-6; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; TOKSOZ D, 1994, ONCOGENE, V9, P621; Walsh CT, 2008, FASEB J, V22, P4011, DOI 10.1096/fj.08-113266; Wang J., 2008, PLOS ONE, V3, P3769; Wang SB, 2016, THROMB RES, V141, pS65, DOI 10.1016/S0049-3848(16)30369-3; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yu OM, 2016, MOL CELL BIOL, V36, P39, DOI 10.1128/MCB.00772-15; Yu OM, 2015, MOL PHARMACOL, V88, P171, DOI 10.1124/mol.115.097857; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	78	38	41	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5492	5507		10.1038/s41388-018-0301-5	http://dx.doi.org/10.1038/s41388-018-0301-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29887596	Green Accepted, Green Published			2022-12-28	WOS:000446991200002
J	Li, WL; Ng, JMK; Wong, CC; Ng, EKW; Yu, J				Li, Weilin; Ng, Jennifer Mun-Kar; Wong, Chi Chun; Ng, Enders Kwok Wai; Yu, Jun			Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; LYMPH-NODE METASTASIS; ENDOTHELIAL GROWTH-FACTOR; POOR-PROGNOSIS; STEM-CELLS; PERITONEAL DISSEMINATION; IN-VIVO; MATRIX METALLOPROTEINASES; HELICOBACTER-PYLORI; GENE-EXPRESSION	The term metastasis is widely used to describe the endpoint of the process by which tumour cells spread from the primary location to an anatomically distant site. Achieving successful dissemination is dependent not only on the molecular alterations of the cancer cells themselves, but also on the microenvironment through which they encounter. Here, we reviewed the molecular alterations of metastatic gastric cancer (GC) as it reflects a large proportion of GC patients currently seen in clinic. We hope that further exploration and understanding of the multistep metastatic cascade will yield novel therapeutic targets that will lead to better patient outcomes.	[Li, Weilin; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Li, Weilin; Ng, Jennifer Mun-Kar; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.	endersng@surgery.cuhk.edu.hk; junyu@cuhk.edu.hk	Yu, Jun/D-8569-2015; Wong, Chi Chun/C-4636-2016; Li, Weilin/ABG-9032-2021; Ng, Enders Kwok-wai/E-8276-2016	Yu, Jun/0000-0001-5008-2153; Ng, Enders Kwok-wai/0000-0001-7219-5810	RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by research funds from RGC/GRF Hong Kong (14114615, 14101917, 14111216, 14106145); National Natural Science Foundation of China (NSFC) (81772501, 81502064); HMRF Hong Kong (03140856); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; CUHK direct grant.	Abe A, 2017, GASTRIC CANCER, V20, P92, DOI 10.1007/s10120-015-0584-y; Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Aihara R, 2005, BRIT J SURG, V92, P454, DOI 10.1002/bjs.4868; Al-Batran SE, 2012, ANN ONCOL, V23, P1699, DOI 10.1093/annonc/mdr552; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Arigami T, 2009, INT J ONCOL, V35, P19, DOI 10.3892/ijo_00000308; Arita T, 2016, ONCOTARGET, V7, P56855, DOI 10.18632/oncotarget.10869; Baba K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11769-x; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Berger L, 2016, STEM CELLS, V34, P1011, DOI 10.1002/stem.2269; Bie QL, 2017, ONCOTARGET, V8, P18914, DOI 10.18632/oncotarget.14835; Boulay A, 2001, CANCER RES, V61, P2189; Busuttil RA, 2014, CLIN CANCER RES, V20, P2761, DOI 10.1158/1078-0432.CCR-13-3049; Calcagno DQ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-141; Camerer E, 2004, BLOOD, V104, P397, DOI 10.1182/blood-2004-02-0434; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang Q, 2015, ONCOTARGET, V6, P42838, DOI 10.18632/oncotarget.5814; Chen DH, 2018, J CELL MOL MED, V22, P797, DOI 10.1111/jcmm.13357; Chen FZ, 2013, ONCOL REP, V30, P2705, DOI 10.3892/or.2013.2704; Chen JT, 2015, INT J CLIN EXP PATHO, V8, P10922; Chen YS, 2014, CARCINOGENESIS, V35, P442, DOI 10.1093/carcin/bgt311; Chen Y, 2011, INT J CANCER, V129, P1586, DOI 10.1002/ijc.25831; Cho HJ, 2014, INT J CANCER, V135, P1553, DOI 10.1002/ijc.28801; Cho HJ, 2014, ONCOTARGET, V5, P1554, DOI 10.18632/oncotarget.1733; Cho HJ, 2009, CLIN CANCER RES, V15, P2612, DOI 10.1158/1078-0432.CCR-08-2192; Cho SJ, 2015, INT J CANCER, V136, P810, DOI 10.1002/ijc.29056; Chu DK, 2011, INT J CANCER, V129, P887, DOI 10.1002/ijc.25734; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cui YH, 2016, ONCOTARGET, V7, P34356, DOI 10.18632/oncotarget.8879; Deng G, 2017, FEBS LETT, V591, P2167, DOI 10.1002/1873-3468.12722; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048; Dong WJ, 2016, INT J CANCER, V138, P1680, DOI 10.1002/ijc.29899; Dong YC, 2015, GENE, V563, P29, DOI 10.1016/j.gene.2015.03.003; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Duan JJ, 2016, ONCOTARGET, V7, P44522, DOI 10.18632/oncotarget.9936; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eto K, 2015, INT J CANCER, V136, P1537, DOI 10.1002/ijc.29168; Ferlay J, 2015, INT J CANCER, V136, P86; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukushima M, 2012, NEUROL MED-CHIR, V52, P751, DOI 10.2176/nmc.52.751; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Gan L, 2018, ONCOGENE, V37, P744, DOI 10.1038/onc.2017.363; Ge XX, 2016, ONCOTARGET, V7, P24466, DOI 10.18632/oncotarget.8228; Ghilardi G, 2001, CLIN CANCER RES, V7, P2344; Gong JH, 2015, TUMOR BIOL, V36, P7831, DOI 10.1007/s13277-015-3510-3; Guo B, 2014, MOL CANCER RES, V12, P313, DOI 10.1158/1541-7786.MCR-13-0507; Guo WW, 2016, CARCINOGENESIS, V37, P397, DOI 10.1093/carcin/bgw013; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Han FJ, 2016, ONCOTARGET, V7, P38626, DOI 10.18632/oncotarget.9573; Han JY, 2014, INT J ONCOL, V45, P291, DOI 10.3892/ijo.2014.2401; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; He BY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.253; He CY, 2017, ONCOTARGET, V8, P46818, DOI 10.18632/oncotarget.17473; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Hsu KW, 2014, CARCINOGENESIS, V35, P208, DOI 10.1093/carcin/bgt285; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Huang J, 2015, ONCOTARGET, V6, P1652, DOI 10.18632/oncotarget.2936; Huang N, 2015, ONCOTARGET, V6, P15222, DOI 10.18632/oncotarget.3835; Huang TT, 2015, ONCOTARGET, V6, P18012, DOI 10.18632/oncotarget.4000; Iida T, 2014, ONCOL REP, V31, P605, DOI 10.3892/or.2013.2911; Iwasa S, 2009, ANTICANCER RES, V29, P4751; Jia BQ, 2012, TUMOR BIOL, V33, P919, DOI 10.1007/s13277-012-0317-3; Jiang YX, 2017, ONCOGENE, V36, P1256, DOI 10.1038/onc.2016.291; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; Kabashima A, 2000, CLIN CANCER RES, V6, P3581; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim HP, 2014, ONCOGENE, V33, P3334, DOI 10.1038/onc.2013.285; Kim HK, 2003, EUR J CANCER, V39, P184, DOI 10.1016/S0959-8049(02)00596-8; Koh YJ, 2010, CANCER CELL, V18, P171, DOI 10.1016/j.ccr.2010.07.001; Kou YB, 2013, INT J IMMUNOPATH PH, V26, P361, DOI 10.1177/039463201302600209; Kubben FJGM, 2007, EUR J CANCER, V43, P1869, DOI 10.1016/j.ejca.2007.05.013; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Kurashige J, 2015, CARCINOGENESIS, V36, P133, DOI 10.1093/carcin/bgu232; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee SH, 2015, ONCOTARGET, V6, P33269, DOI 10.18632/oncotarget.5037; Lei C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.493; Li HM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-136; Li H, 2016, CANCER LETT, V370, P39, DOI 10.1016/j.canlet.2015.10.006; Li J, 2015, ONCOTARGET, V6, P8323, DOI 10.18632/oncotarget.3200; Li JH, 2012, J CANCER RES CLIN, V138, P763, DOI 10.1007/s00432-012-1154-x; Li JJ, 2017, FASEB J, V31, P3774, DOI 10.1096/fj.201601140RR; Li MR, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0616-7; Li P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066782; Li RX, 2014, MOL CELL BIOCHEM, V396, P295, DOI 10.1007/s11010-014-2164-6; Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045; Lian DN, 2018, CANCER BIOMARK, V21, P151, DOI 10.3233/CBM-170462; Lian L, 2015, CANCER BIOMARK, V15, P899, DOI 10.3233/CBM-150534; Liang XM, 2015, ONCOTARGET, V6, P17661, DOI 10.18632/oncotarget.3756; Lin BR, 2007, MOL CANCER RES, V5, P1111, DOI 10.1158/1541-7786.MCR-06-0289; Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Liu F, 2018, CANCER SCI, V109, P65, DOI 10.1111/cas.13429; Liu JK, 2017, INT J ONCOL, V50, P356, DOI 10.3892/ijo.2016.3807; Liu XY, 2015, ONCOTARGET, V6, P25418, DOI 10.18632/oncotarget.4456; Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150; Liu ZF, 2014, J CELL MOL MED, V18, P610, DOI 10.1111/jcmm.12209; Lowy AM, 2006, CANCER RES, V66, P4734, DOI 10.1158/0008-5472.CAN-05-4268; Ma HY, 2015, ONCOTARGET, V6, P24348, DOI 10.18632/oncotarget.4484; Maehara Y, 2000, SURGERY, V128, P408, DOI 10.1067/msy.2000.107265; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Marchet A, 2007, ANN SURG, V245, P543, DOI 10.1097/01.sla.0000250423.43436.e1; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Martinho O, 2013, ONCOL REP, V29, P690, DOI 10.3892/or.2012.2179; Mashino K, 2002, CANCER RES, V62, P2937; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mi YS, 2017, CANCER LETT, V389, P11, DOI 10.1016/j.canlet.2016.12.033; Mikami J, 2016, GASTRIC CANCER, V19, P817, DOI 10.1007/s10120-015-0556-2; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Mura G, 2016, J CANC METASTASIS TR, V2, P365, DOI DOI 10.20517/2394-4722.2016.19; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nieswandt B, 1999, CANCER RES, V59, P1295; Nishimura S, 2001, CANCER RES, V61, P7009; Noh HS, 2016, ONCOTARGET, V7, P4632, DOI 10.18632/oncotarget.6728; Ock CY, 2017, GASTRIC CANCER, V20, P254, DOI 10.1007/s10120-016-0613-5; Olmeda D, 2017, NATURE, V546, P676, DOI 10.1038/nature22977; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood-2004-06-2272; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Peng Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.225; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Peruzzi D, 2009, CLIN CANCER RES, V15, P4104, DOI 10.1158/1078-0432.CCR-08-3226; Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Qiao JL, 2016, ONCOTARGET, V7, P46088, DOI 10.18632/oncotarget.10024; Qiao SS, 2015, BIOCHEM J, V469, P469, DOI 10.1042/BJ20150253; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Ren G, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-67; Ren YH, 2014, ONCOTARGET, V5, P7093, DOI 10.18632/oncotarget.2197; Riihimaki M, 2016, ONCOTARGET, V7, P52307, DOI 10.18632/oncotarget.10740; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Sadeghi B, 2000, CANCER-AM CANCER SOC, V88, P358, DOI 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O; Sakimura S, 2015, ANN SURG ONCOL, V22, pS1436, DOI 10.1245/s10434-015-4418-2; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Schumacher D, 2014, PURINERG SIGNAL, V10, P730; Sentani K, 2014, GASTRIC CANCER, V17, P412, DOI 10.1007/s10120-013-0302-6; Sha SM, 2013, DIGEST LIVER DIS, V45, P422, DOI 10.1016/j.dld.2012.12.004; Shi M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-269; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Shibata W, 2013, GUT, V62, P192, DOI 10.1136/gutjnl-2011-301824; Song GY, 2017, ONCOTARGET, V8, P45725, DOI 10.18632/oncotarget.17392; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Speak AO, 2017, NAT PROTOC, V12, P2465, DOI 10.1038/nprot.2017.118; Stanger BZ, 2013, CANCER CELL, V24, P9, DOI 10.1016/j.ccr.2013.06.009; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Sun YT, 2015, TRENDS PHARMACOL SCI, V36, P349, DOI 10.1016/j.tips.2015.04.001; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074527; Tang Y, 2008, CLIN CANCER RES, V14, P2870, DOI 10.1158/1078-0432.CCR-07-4042; Taniguchi S, 2001, CANCER RES, V61, P7627; Tao YM, 2017, ONCOTARGET, V8, P88870, DOI 10.18632/oncotarget.21488; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; van der Weyden L, 2017, NATURE, V541, P233, DOI 10.1038/nature20792; Wang HQ, 2017, ENDOCR-RELAT CANCER, V24, P565, DOI 10.1530/ERC-17-0058; Wang Jian-Jun, 2015, Asian Pac J Cancer Prev, V16, P4203; Wang L, 2015, ONCOTARGET, V6, P11492, DOI 10.18632/oncotarget.3416; Wang YD, 2007, WORLD J GASTROENTERO, V13, P6269, DOI 10.3748/wjg.13.6269; Watanabe M, 2014, J GASTROINTEST SURG, V18, P481, DOI 10.1007/s11605-013-2407-y; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Wu CY, 2007, EUR J CANCER, V43, P799, DOI 10.1016/j.ejca.2006.10.022; Wu CY, 2007, CLIN CANCER RES, V13, P2054, DOI 10.1158/1078-0432.CCR-06-2299; Wu JY, 2006, CANCER RES, V66, P5111, DOI 10.1158/0008-5472.CAN-06-0383; Wu LJ, 2014, INT J CLIN EXP PATHO, V7, P1140; Wu LJ, 2016, TUMOR BIOL, V37, P12169, DOI 10.1007/s13277-016-5071-5; Wu SM, 2016, J PINEAL RES, V60, P142, DOI 10.1111/jpi.12295; Wu WD, 2015, CELL PHYSIOL BIOCHEM, V35, P1764, DOI 10.1159/000373988; Wu XY, 2017, ONCOTARGET, V8, P20741, DOI 10.18632/oncotarget.15119; Xia JL, 2016, CANCER LETT, V381, P31, DOI 10.1016/j.canlet.2016.07.014; Xiang XJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1382, DOI 10.1159/000430304; Xu L, 2017, CANCER LETT, V393, P76, DOI 10.1016/j.canlet.2017.02.014; Xu SH, 2017, ONCOTARGET, V8, P12705, DOI 10.18632/oncotarget.6194; Xu SH, 2015, J PATHOL, V236, P175, DOI 10.1002/path.4515; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Yan L, 2017, TUMOR BIOL, V39; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang B, 2014, CLIN TRANSL ONCOL, V16, P374, DOI 10.1007/s12094-013-1081-6; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yang L, 2017, ONCOTARGET, V8, P68180, DOI 10.18632/oncotarget.19254; Yang SW, 2017, ONCOTARGET, V8, P9535, DOI 10.18632/oncotarget.14484; Yang T, 2016, ONCOTARGET, V7, P18085, DOI 10.18632/oncotarget.7634; Yang Y, 2017, ONCOTARGET, V8, P8057, DOI 10.18632/oncotarget.14074; Yang YH, 2008, CLIN CANCER RES, V14, P74, DOI 10.1158/1078-0432.CCR-07-1179; Ye JX, 2017, MOL ONCOL, V11, P1208, DOI 10.1002/1878-0261.12089; Yi J, 2008, NEOPLASIA, V10, P41, DOI 10.1593/neo.07754; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846; Yonemura Y, 2001, CLIN CANCER RES, V7, P1647; Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338; Yu S, 2016, ONCOTARGET, V7, P34773, DOI 10.18632/oncotarget.8977; Yu WW, 2017, ONCOTARGET, V8, P39280, DOI 10.18632/oncotarget.16849; Yuan WQ, 2016, ONCOTARGET, V7, P29507, DOI 10.18632/oncotarget.8789; Zarrabi K, 2011, J BIOL CHEM, V286, P33167, DOI 10.1074/jbc.M111.256644; Zhang BG, 2014, ONCOTARGET, V5, P10584, DOI 10.18632/oncotarget.2513; Zhang HY, 2018, CANCER SCI, V109, P629, DOI 10.1111/cas.13488; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang H, 2018, ANN SURG, V267, P311, DOI 10.1097/SLA.0000000000002058; Zhang JP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0467-9; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495; Zhang YJ, 2015, ONCOTARGET, V6, P7244, DOI 10.18632/oncotarget.3133; Zhao L, 2018, CELL BIOL INT, V42, P294, DOI 10.1002/cbin.10894; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254; Zhao X, 2014, CELL DEATH DIFFER, V21, P1900, DOI 10.1038/cdd.2014.109; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zhao ZS, 2010, CLIN CANCER RES, V16, P260, DOI 10.1158/1078-0432.CCR-09-1247; Zheng HC, 2006, ANTICANCER RES, V26, P3579; Zhong HJ, 2011, INT J HYPERTHER, V27, P604, DOI 10.3109/02656736.2011.564598; Zhong J, 2016, WORLD J GASTROENTERO, V22, P2434, DOI 10.3748/wjg.v22.i8.2434; Zhou Q, 2017, ONCOGENE, V36, P1873, DOI 10.1038/onc.2016.352; Zhou Q, 2016, CELL PHYSIOL BIOCHEM, V39, P453, DOI 10.1159/000445638; Zhou XY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0145-6; Zhu HY, 2015, INT J MOL MED, V35, P798, DOI 10.3892/ijmm.2015.2069; Zhu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.263; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297	241	38	39	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4903	4920		10.1038/s41388-018-0341-x	http://dx.doi.org/10.1038/s41388-018-0341-x			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795331	hybrid, Green Published			2022-12-28	WOS:000443823600001
J	O'Bryant, D; Wang, ZX				O'Bryant, Deon; Wang, Zhengxin			The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss	ONCOGENE			English	Article							RECEPTOR COFACTOR P44; TGF-BETA; SUPPRESSOR GENE; CANCER; DELETION; PROLIFERATION; COMPLEX; GROWTH; MOUSE; CELLS	Prostate cancer is the most commonly diagnosed malignancy among men, but few genetic factors that drive prostate cancer initiation have been identified. The WD repeat domain 77 (Wdr77) protein is essential for cellular proliferation when localizes in the cytoplasm of epithelial cells at the early stage of prostate development. In the adult prostate, it is transported into the nucleus and functions as a co-regulator of the androgen receptor to promote cellular differentiation and prostate function. This developmental process is reversed during prostate tumorigenesis, i.e.,Wdr77 is translocated from the nucleus into the cytoplasm to drive proliferation of prostate cancer cells. In this study, we used in vivo genetic studies to further investigate the role of Wdr77 in prostate tumorigenesis. We found that prostate-specific deletion of Wdr77 abolished prostate tumor initiation induced by loss of the tumor suppressor Pten. Mechanistically, Wdr77 ablation inhibited E2F3 activation and enhanced TGF beta signaling, leading to attenuated cellular proliferation induced by loss of Pten. These findings establish a critical role of Wdr77 for prostate tumor initiation.	[O'Bryant, Deon; Wang, Zhengxin] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA	Clark Atlanta University	Wang, ZX (corresponding author), Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA.	zwang@cau.edu			NIH NIGMS-RISE [R25GM06414]; NIMHD RCMI [5G12MD007590]; NIMHD [5P20MD002285];  [W81XWH-12-1-0453 PC111461]	NIH NIGMS-RISE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMHD RCMI; NIMHD; 	We thank Ms. Shen Gao for animal work and technique support. DOB is supported by NIH NIGMS-RISE R25GM06414 and ZW is supported by W81XWH-12-1-0453 PC111461, NIMHD RCMI 5G12MD007590, and NIMHD 5P20MD002285. The funding agencies had no role in study design, data collection or analysis, decision to publish or manuscript preparation.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Bilir B, 2016, CANCER RES, V76, P1112, DOI 10.1158/0008-5472.CAN-15-1868; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Gao S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049173; Gao S, 2010, ENDOCRINOLOGY, V151, P3941, DOI 10.1210/en.2009-1080; Gu Z, 2013, ONCOGENE, V32, P1888, DOI 10.1038/onc.2012.207; Gu ZP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022395; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Liu WN, 2016, ASIAN J ANDROL, V18, P533, DOI 10.4103/1008-682X.177120; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024; Peng Y, 2008, P NATL ACAD SCI USA, V105, P5236, DOI 10.1073/pnas.0712262105; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Sheng XM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2632-3; Shtivelman E, 2014, ONCOTARGET, V5, P7217, DOI 10.18632/oncotarget.2406; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sitnicka E, 1996, BLOOD, V88, P82; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tu WH, 2003, NEOPLASIA, V5, P267, DOI 10.1016/S1476-5586(03)80058-1; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Yi PF, 2014, BIOCHEM BIOPH RES CO, V450, P409, DOI 10.1016/j.bbrc.2014.05.125; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; Zhou LR, 2006, J MOL ENDOCRINOL, V37, P283, DOI 10.1677/jme.1.02062	42	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4151	4163		10.1038/s41388-018-0254-8	http://dx.doi.org/10.1038/s41388-018-0254-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706654				2022-12-28	WOS:000439847000008
J	AlQarni, S; Al-Sheikh, Y; Campbell, D; Drotar, M; Hannigan, A; Boyle, S; Herzyk, P; Kossenkov, A; Armfield, K; Jamieson, L; Bailo, M; Lieberman, PM; Tsimbouri, P; Wilson, JB				AlQarni, Sana; Al-Sheikh, Yazeed; Campbell, Donald; Drotar, Mark; Hannigan, Adele; Boyle, Shelagh; Herzyk, Pawel; Kossenkov, Andrew; Armfield, Kate; Jamieson, Lauren; Bailo, Mariarca; Lieberman, Paul M.; Tsimbouri, Penelope; Wilson, Joanna B.			Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; TRANSGENIC MICE; IN-VITRO; P53; EXPRESSION; SURVIVAL; PROTEIN; IMMORTALIZATION; TUMORIGENESIS; TRANSCRIPTION	Epstein-Barr virus (EBV)-associated Burkitt's lymphoma is characterised by the deregulation of c-Myc expression and a restricted viral gene expression pattern in which the EBV nuclear antigen-1 (EBNA1) is the only viral protein to be consistently expressed. EBNA1 is required for viral genome propagation and segregation during latency. However, it has been much debated whether the protein plays a role in viral-associated tumourigenesis. We show that the lymphomas which arise in E mu EBNA1 transgenic mice are unequivocally linked to EBNA1 expression and that both C-Myc and Mdm2 deregulation are central to this process. Tumour cell survival is supported by IL-2 and there is a skew towards CD8-positive T cells in the tumour environment, while the immune check-point protein PD-L1 is upregulated in the tumours. Additionally, several isoforms of Mdm2 are upregulated in the E mu EBNA1 tumours, with increased phosphorylation at ser166, an expression pattern not seen in E mu c-Myc transgenic tumours. Concomitantly, E2F1, Xiap, Mta1, C-Fos and Stat1 are upregulated in the tumours. Using four independent inhibitors of Mdm2 we demonstrate that the E mu EBNA1 tumour cells are dependant upon Mdm2 for survival (as they are upon c-Myc) and that Mdm2 inhibition is not accompanied by upregulation of p53, instead cell death is linked to loss of E2F1 expression, providing new insight into the underlying tumourigenic mechanism. This opens a new path to combat EBV-associated disease.	[AlQarni, Sana; Al-Sheikh, Yazeed; Campbell, Donald; Drotar, Mark; Hannigan, Adele; Herzyk, Pawel; Armfield, Kate; Jamieson, Lauren; Bailo, Mariarca; Tsimbouri, Penelope; Wilson, Joanna B.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [Al-Sheikh, Yazeed] King Saud Univ, Coll Appl Med Sci, Riyadh, Saudi Arabia; [Hannigan, Adele] TCBiopharm, 2 Parklands Way Holtown, Motherwell ML1 4WR, Scotland; [Boyle, Shelagh] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Kossenkov, Andrew; Lieberman, Paul M.] Wistar Inst Anat & Biol, Ctr Chem Biol & Translat Med, 3601 Spruce St, Philadelphia, PA 19104 USA	University of Glasgow; King Saud University; University of Edinburgh; The Wistar Institute	Wilson, JB (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	Joanna.wilson@glasgow.ac.uk			Bloodwise; Wellcome Trust; BBSRC; Saudi Arabian PhD scholarships; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA093606] Funding Source: NIH RePORTER	Bloodwise; Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Saudi Arabian PhD scholarships; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding contribution to the work includes former LRF (now Bloodwise) grants. AH was supported by a Wellcome Trust PhD studentship while at GU, KA is supported by a PhD BBSRC studentship. SA is, and YA was, supported by Saudi Arabian PhD scholarships.	Achilli F, 2005, AMYOTROPH LATERAL SC, V6, P111, DOI 10.1080/14660820510035351; Bill KLJ, 2016, CLIN CANCER RES, V22, P1150, DOI 10.1158/1078-0432.CCR-15-1522; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Canaan A, 2009, P NATL ACAD SCI USA, V106, P22421, DOI 10.1073/pnas.0911676106; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Deschamps T, 2017, J GEN VIROL, V98, P251, DOI 10.1099/jgv.0.000681; Drotar ME, 2003, INT J CANCER, V106, P388, DOI 10.1002/ijc.11224; Gnanasundram SV, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02282-w; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Gu LB, 2016, CANCER CELL, V30, P623, DOI 10.1016/j.ccell.2016.08.015; Hannigan A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-184; Kang MS, 2005, P NATL ACAD SCI USA, V102, P820, DOI 10.1073/pnas.0408774102; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; Kojima K, 2010, MOL CANCER THER, V9, P2545, DOI 10.1158/1535-7163.MCT-10-0337; Li DQ, 2009, J BIOL CHEM, V284, P34545, DOI 10.1074/jbc.M109.056499; Malik-Soni N, 2012, J VIROL, V86, P6999, DOI 10.1128/JVI.00194-12; O'Neil JD, 2008, J GEN VIROL, V89, P2833, DOI 10.1099/vir.0.2008/003392-0; Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323; Owen TJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-241; Renouf B, 2009, LEUKEMIA, V23, P1557, DOI 10.1038/leu.2009.92; Rosso Melissa, 2014, Subcell Biochem, V85, P247, DOI 10.1007/978-94-017-9211-0_14; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Schuster K, 2007, MOL CANCER RES, V5, P403, DOI 10.1158/1541-7786.MCR-06-0146; Sivachandran N, 2011, J VIROL, V85, P10425, DOI 10.1128/JVI.05293-11; Tempera I, 2016, J VIROL, V90, P345, DOI 10.1128/JVI.02318-15; Tian X, 2011, CELL SIGNAL, V23, P193, DOI 10.1016/j.cellsig.2010.09.003; Tsimbouri P, 2002, ONCOGENE, V21, P5182, DOI 10.1038/sj.onc.1205490; Tsimbourri P, 2008, J GEN VIROL, V89, P2821, DOI 10.1099/vir.0.83296-0; Volk EL, 2009, MOL CANCER RES, V7, P863, DOI 10.1158/1541-7786.MCR-08-0418; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson J B, 2001, Methods Mol Biol, V174, P361; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wood VHJ, 2007, ONCOGENE, V26, P4135, DOI 10.1038/sj.onc.1210496; Xie N, 2016, SCI REP-UK, V6, DOI 10.1038/srep36171; Zhang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100960; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315	39	15	16	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3998	4012		10.1038/s41388-018-0147-x	http://dx.doi.org/10.1038/s41388-018-0147-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29691476	Green Accepted			2022-12-28	WOS:000439101300007
J	Saponaro, C; Sergio, S; Coluccia, A; De Luca, M; La Regina, G; Mologni, L; Famiglini, V; Naccarato, V; Bonetti, D; Gautier, C; Gianni, S; Vergara, D; Salzet, M; Fournier, I; Bucci, C; Silvestri, R; Passerini, CG; Maffia, M; Coluccia, AML				Saponaro, Concetta; Sergio, Sara; Coluccia, Antonio; De Luca, Maria; La Regina, Giuseppe; Mologni, Luca; Famiglini, Valeria; Naccarato, Valentina; Bonetti, Daniela; Gautier, Candice; Gianni, Stefano; Vergara, Daniele; Salzet, Michel; Fournier, Isabelle; Bucci, Cecilia; Silvestri, Romano; Passerini, Carlo Gambacorti; Maffia, Michele; Coluccia, Addolorata Maria Luce			beta-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITION; REGULATORY FACTOR-1; NUCLEAR NHERF1; PROTEIN; GROWTH; COLON; PTEN; PHOSPHORYLATION; ASSOCIATION; ACTIVATION	Nuclear activated beta-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring different Wnt/beta-catenin pathway mutations in APC/KRAS or beta-catenin/KRAS genes, and both genetic and pharmacological knockdown approaches, we show that oncogenic beta-catenin signaling negatively regulates the expression of NHERF1 (Na+/H+ exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or downregulated in early dysplastic adenomas to exacerbate nuclear beta-catenin activity. Chromatin immunoprecipitation (ChIP) assays demonstrated that beta-catenin represses NHERF1 via TCF4 directly, while the association between TCF1 and the Nherf1 promoter increased upon beta-catenin knockdown. To note, the occurrence of a cytostatic survival response in settings of single beta-catenin-depleted CRC cells was abrogated by combining NHERF1 inhibition via small hairpin RNA (shRNA) or RS5517, a novel PDZ1-domain ligand of NHERF1 that prevented its ectopic nuclear entry. Mechanistically, dual NHERF1/beta-catenin targeting promoted an autophagy-to-apoptosis switch consistent with the activation of Caspase-3, the cleavage of PARP and reduced levels of phospho-ERK1/2, Beclin-1, and Rab7 autophagic proteins compared with beta-catenin knockdown alone. Collectively, our data unveil novel beta-catenin/TCF-dependent mechanisms of CRC carcinogenesis, also offering preclinical proof of concept for combining beta-catenin and NHERF1 pharmacological inhibitors as a mechanism-based strategy to augment apoptotic death of CRC cells refractory to current Wnt/beta-catenin-targeted therapeutics.	[Saponaro, Concetta; Sergio, Sara; Vergara, Daniele; Maffia, Michele; Coluccia, Addolorata Maria Luce] Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy; [Saponaro, Concetta] IRCCS Ist Tumori Giovanni Paolo II, Funct Biomorphol Lab, Bari, Italy; [Sergio, Sara; De Luca, Maria; Vergara, Daniele; Bucci, Cecilia; Maffia, Michele; Coluccia, Addolorata Maria Luce] Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy; [Coluccia, Antonio; La Regina, Giuseppe; Famiglini, Valeria; Naccarato, Valentina; Silvestri, Romano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Drug Chem & Technol, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Mologni, Luca; Passerini, Carlo Gambacorti] Univ Milano Bicocca, San Gerardo Hosp, Dept Clin Med, I-20052 Monza, Italy; [Bonetti, Daniela; Gautier, Candice; Gianni, Stefano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Biochem, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Salzet, Michel; Fournier, Isabelle] U1192 Lab Prote Reponse Inflammatoire & Spectrome, F-59000 Lille, France	IRCCS Istituto Tumori Bari Giovanni Paolo II; University of Salento; Fondazione Cenci Bolognetti; Sapienza University Rome; San Gerardo Hospital; University of Milano-Bicocca; Fondazione Cenci Bolognetti; Sapienza University Rome; Universite de Lille - ISITE; Universite de Lille	Coluccia, AML (corresponding author), Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy.; Coluccia, AML (corresponding author), Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy.	michele.maffia@unisalento.it; malu.coluccia@unisalento.it	Vergara, Daniele/K-3831-2014; FOURNIER, Isabelle/H-9195-2015; Saponaro, Concetta/K-7886-2018; sergio, sara/AAC-3849-2019; SERGIO, SARA/AAL-4019-2021; La Regina, Giuseppe/I-2161-2012; Mologni, Luca/AAC-1065-2022; Coluccia, Antonio/K-3114-2018; Salzet, Michel/A-7675-2011; MAFFIA, MICHELE/AAC-2943-2020; Bucci, Cecilia/F-6699-2012	Vergara, Daniele/0000-0002-2396-7674; FOURNIER, Isabelle/0000-0003-1096-5044; La Regina, Giuseppe/0000-0003-3252-1161; Mologni, Luca/0000-0002-6365-5149; Coluccia, Antonio/0000-0002-7940-8206; Salzet, Michel/0000-0003-4318-0817; Bucci, Cecilia/0000-0002-6232-6183; Saponaro, Concetta/0000-0002-8196-3583; Sergio, Sara/0000-0002-4490-4189	Italian Association for Cancer Research (AIRC)-Investigator Grant (IG) [14236]; Italian Grant PRIN 2015 [2015FCHJ8E]; European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant [675341]; AIRC IG 2016 [19068]; Apulia Regione Cluster Project SISTEMA [T7WGSJ3]; Veronesi Foundation fellowship	Italian Association for Cancer Research (AIRC)-Investigator Grant (IG); Italian Grant PRIN 2015; European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant; AIRC IG 2016; Apulia Regione Cluster Project SISTEMA; Veronesi Foundation fellowship	We thank Dr. Hans Clevers (Hubrecht Laboratory, Utrecht, The Netherlands) for providing the pcDNA<INF>6</INF>TR and pTER vectors. We gratefully acknowledge funding from Italian Association for Cancer Research (AIRC)-Investigator Grant (IG) 2014 No. 14236 (AMLC). This work was partially supported by Italian Grant PRIN 2015 (2015FCHJ8E) (RS), European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant agreement No. 675341 (SG), AIRC IG 2016 No. 19068 (CB) and Apulia Regione Cluster Project SISTEMA No. T7WGSJ3 (MM). MDL was recipient of a Veronesi Foundation fellowship. We warmly thank Dr. Antonio Danieli for his technical assistance.	Bellizzi A, 2011, HISTOPATHOLOGY, V58, P1086, DOI 10.1111/j.1365-2559.2011.03844.x; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Case DA, 2012, AMBER 12; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; De Luca M, 2014, J CELL SCI, V127, P2697, DOI 10.1242/jcs.142604; Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x; Du GF, 2016, ONCOTARGET, V7, P29440, DOI 10.18632/oncotarget.8751; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fitzpatrick JM, 2014, BIOCHEMISTRY-US, V53, P5916, DOI 10.1021/bi500368k; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Georgescu MM, 2016, NEOPLASIA, V18, P512, DOI 10.1016/j.neo.2016.07.003; Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Ho-Bouldoires THN, 2015, FREE RADICAL BIO MED, V89, P34, DOI 10.1016/j.freeradbiomed.2015.07.011; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ivarsson Y, 2007, J BIOL CHEM, V282, P8568, DOI 10.1074/jbc.M611026200; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Karn T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028403; Korb Oliver, 2007, Swarm Intelligence, V1, P115, DOI 10.1007/s11721-007-0006-9; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Liu H, 2015, AUTOPHAGY, V11, P2323, DOI 10.1080/15548627.2015.1074372; Malfettone A, 2012, EXP MOL PATHOL, V92, P296, DOI 10.1016/j.yexmp.2012.03.004; Mamonova T, 2012, BIOCHEMISTRY-US, V51, P3110, DOI 10.1021/bi201213w; Mangia A, 2012, ONCOL REP, V28, P889, DOI 10.3892/or.2012.1895; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mayasundari A, 2008, BIOORG MED CHEM LETT, V18, P942, DOI 10.1016/j.bmcl.2007.12.038; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Mologni L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051449; Pan Y, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1616; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Saponaro C, 2014, CANCER BIOMARK, V14, P177, DOI 10.3233/CBM-130329; Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-362; Song GJ, 2015, J BIOL CHEM, V290, P2879, DOI 10.1074/jbc.M114.609768; Song LL, 2015, CLIN COLORECTAL CANC, V14, P133, DOI 10.1016/j.clcc.2015.02.001; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vaquero J, 2017, ONCOGENE, V36, P3067, DOI 10.1038/onc.2016.462; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Wheeler DS, 2011, ONCOGENE, V30, P32, DOI 10.1038/onc.2010.389; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102	50	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3301	3316		10.1038/s41388-018-0170-y	http://dx.doi.org/10.1038/s41388-018-0170-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551770	hybrid, Green Published			2022-12-28	WOS:000435526600009
J	Xi, JJ; Huang, Q; Wang, LD; Ma, XD; Deng, QP; Kumar, M; Zhou, ZY; Li, L; Zeng, ZY; Young, KH; Zhang, MZ; Li, Y				Xi, Jiajia; Huang, Qian; Wang, Lei; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Ling; Zeng, Zhaoyang; Young, Ken H.; Zhang, Mingzhi; Li, Yong			miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; INTERFERON-GAMMA; IFN-GAMMA; EXPRESSION; MICRORNAS; CANCER; IDENTIFICATION; CELLS; RNAS; INTERLEUKIN-4	MicroRNA-21 (miR-21) is one of the most abundant microRNAs in mammalian cells. It has been intensively studied for its role in regulating apoptosis and oncogenic transformation. However, the impact of miR-21 on host anti-tumor immunity remains unknown. Tumor-associated macrophages are a major leukocyte type that infiltrates tumors and predominantly develops into immunosuppressive, tumor-promoting M2-like macrophages. In contrast, the pro-inflammatory M1-like macrophages have tumoricidal activity. In this study, we show that genetic deficiency of miR-21 promotes the polarization of macrophages toward an M1-like phenotype in vivo and in vitro in the presence of tumor cells; thus it confers host mice with enhanced anti-tumor immunity. By downregulating JAK2 and STAT1, miR-21 inhibits the IFN-gamma-induced STAT1 signaling pathway, which is required for macrophage M1 polarization. We also show that the expression of miR-21 in macrophages is regulated upon polarization stimuli as well as upon macrophages co-culturing with tumor cells. Thus, tumor cells may stimulate miR-21 expression in tumor-associated macrophages to prevent tumoricidal M1 polarization. However, augmented STAT1 signaling mediated by miR-21 deficiency upregulates PD-L1 expression in macrophages, which is known to inhibit phagocytic anti-tumor activity. This adverse effect can be alleviated by PD-1 blockade; indeed, miR-21 depletion in macrophages and PD-1 antibody treatment offer superior anti-tumor activity than either agent alone. These studies shed lights on potential application of the combination of miR-21 inhibition and immune checkpoint blockade to target the tumor microenvironment.	[Xi, Jiajia; Huang, Qian; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Yong] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Wang, Lei; Ma, Xiaodong] South China Normal Univ, Inst Brain Res & Rehabil, Guangzhou 510631, Guangdong, Peoples R China; [Kumar, Munish] Univ Allahabad, Dept Biochem, UGC, Allahabad, Uttar Pradesh, India; [Zhou, Zhiyuan; Li, Ling; Zhang, Mingzhi] Zhengzhou Univ, Affiliated Hosp 1, Lymphoma Diag & Treatment Ctr Henan Prov, Dept Oncol, Zhengzhou 450000, Henan, Peoples R China; [Zeng, Zhaoyang] Cent South Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Young, Ken H.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Cleveland Clinic Foundation; South China Normal University; University of Allahabad; Zhengzhou University; Central South University; University of Texas System; UTMD Anderson Cancer Center	Li, Y (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.	liy2@ccf.org	li, li/AAT-2097-2020; li, li/HII-4157-2022; LI, LI/GVS-5344-2022; Li, Li/AEM-3636-2022; MA, XIAO/HHN-5611-2022; LI, LI QING/GRR-8855-2022; Kumar, Munish/Z-4106-2019; li, li/GPX-3938-2022	Li, Yong/0000-0001-8838-1714; Deng, Qipan/0000-0002-3803-1676; Wang, Lei/0000-0001-5492-5613	NIH [CA138688, CA177810]; Natural Science Foundation of China [81528019]; NATIONAL CANCER INSTITUTE [R01CA177810, R01CA138688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported by NIH R01 grants (CA138688 and CA177810) and Natural Science Foundation of China (No. 81528019).	Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Anaya J., 2016, PEER J COMPUT SCI, V13, P2; Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Buscaglia Lindsey E Becker, 2011, Chin J Cancer, V30, P371; Caescu CI, 2015, BLOOD, V125, pE1, DOI 10.1182/blood-2014-10-608000; Carissimi C, 2014, BIOCHIMIE, V107, P319, DOI 10.1016/j.biochi.2014.09.021; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Duchaine TF, 2009, CURR ONCOL, V16, P265; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Haverkamp JM, 2014, IMMUNITY, V41, P947, DOI 10.1016/j.immuni.2014.10.020; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Ma XD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8151; Ma XD, 2013, CARCINOGENESIS, V34, P1216, DOI 10.1093/carcin/bgt044; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Pratheeshkumar P, 2016, SCI REP-UK, V6, DOI 10.1038/srep37227; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAUB DD, 1995, J LEUKOCYTE BIOL, V58, P80, DOI 10.1002/jlb.58.1.80; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Venturutti L, 2016, ONCOGENE, V35, P2208, DOI 10.1038/onc.2015.281; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	49	72	74	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3151	3165		10.1038/s41388-018-0178-3	http://dx.doi.org/10.1038/s41388-018-0178-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540832	Green Accepted			2022-12-28	WOS:000434641400008
J	Browne, AL; Charmsaz, S; Vareslija, D; Fagan, A; Cosgrove, N; Cocchiglia, S; Purcell, S; Ward, E; Bane, F; Hudson, L; Hill, AD; Carroll, JS; Redmond, AM; Young, LS				Browne, Alacoque L.; Charmsaz, Sara; Vareslija, Damir; Fagan, Ailis; Cosgrove, Nicola; Cocchiglia, Sinead; Purcell, Siobhan; Ward, Elspeth; Bane, Fiona; Hudson, Lance; Hill, Arnold D.; Carroll, Jason S.; Redmond, Aisling M.; Young, Leonie S.			Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer	ONCOGENE			English	Article							STEROID-RECEPTOR COACTIVATOR-1; PROTEIN METHYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; P160 COACTIVATORS; GENE-EXPRESSION; SOLID TUMORS; STAT FAMILY; FACTOR-I; ER; METASTASIS	Steroid receptor coactivator 1 (SRC-1) interacts with nuclear receptors and other transcription factors (TFs) to initiate transcriptional networks and regulate downstream genes which enable the cancer cell to evade therapy and metastasise. Here we took a top-down discovery approach to map out the SRC-1 transcriptional network in endocrine resistant breast cancer. First, rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) was employed to uncover new SRC-1 TF partners. Next, RNA sequencing (RNAseq) was undertaken to investigate SRC-1 TF target genes. Molecular and patientderived xenograft studies confirmed STAT1 as a new SRC-1 TF partner, important in the regulation of a cadre of four SRC-1 transcription targets, NFIA, SMAD2, E2F7 and ASCL1. Extended network analysis identified a downstream 79 gene network, the clinical relevance of which was investigated in RNAseq studies from matched primary and local-recurrence tumours from endocrine resistant patients. We propose that SRC-1 can partner with STAT1 independently of the estrogen receptor to initiate a transcriptional cascade and control regulation of key endocrine resistant genes.	[Browne, Alacoque L.; Charmsaz, Sara; Vareslija, Damir; Fagan, Ailis; Cosgrove, Nicola; Cocchiglia, Sinead; Purcell, Siobhan; Ward, Elspeth; Bane, Fiona; Hudson, Lance; Hill, Arnold D.; Young, Leonie S.] Royal Coll Surg, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [Carroll, Jason S.; Redmond, Aisling M.] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge, England	Royal College of Surgeons - Ireland; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Young, LS (corresponding author), Royal Coll Surg, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland.	lyoung@rcsi.ie		Ward, Elspeth/0000-0002-7530-2279; Carroll, Jason/0000-0003-3643-0080; Vareslija, Damir/0000-0003-1000-0357; Cosgrove, Nicola/0000-0002-8296-115X	Science Foundation Ireland [08-IN1-B1853, 12/1A/1294]; Health Research Board of Ireland [HRB/POR/2012/101]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL, BREASTPREDICT]; Cancer Research UK [20411] Funding Source: researchfish	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board of Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant; Cancer Research UK(Cancer Research UK)	We kindly acknowledge the funding support from the Science Foundation Ireland (08-IN1-B1853 and 12/1A/1294), the Health Research Board of Ireland (HRB/POR/2012/101). This work was partly supported by the Irish Cancer Society Collaborative Cancer Research Centre grant, BREASTPREDICT, CCRC13GAL.	Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chu JJ, 2015, ONCOTARGET, V6, P31944, DOI 10.18632/oncotarget.5128; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Dammer EB, 2007, MOL ENDOCRINOL, V21, P415, DOI 10.1210/me.2006-0361; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dieci MV, 2013, ANN ONCOL, V24, P101, DOI 10.1093/annonc/mds248; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fleming FJ, 2004, J CLIN PATHOL, V57, P1069, DOI 10.1136/jcp.2004.016733; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Glasgow SM, 2013, J NEUROSCI, V33, P13560, DOI 10.1523/JNEUROSCI.0321-13.2013; Grabowska MM, 2014, MOL ENDOCRINOL, V28, P949, DOI 10.1210/me.2013-1213; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Hoefnagel LDC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2645; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kolde R., 2015, PHEATMAP PRETTY HEAT; Kulakovskiy IV, 2013, NUCLEIC ACIDS RES, V41, pD195, DOI 10.1093/nar/gks1089; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; McBryan J, 2015, CLIN CANCER RES, V21, P5371, DOI 10.1158/1078-0432.CCR-14-2155; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; McIlroy M, 2010, CANCER RES, V70, P1585, DOI 10.1158/0008-5472.CAN-09-3713; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Redmond AM, 2015, ONCOGENE, V34, P3871, DOI 10.1038/onc.2014.323; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Stashi E, 2014, TRENDS ENDOCRIN MET, V25, P337, DOI 10.1016/j.tem.2014.05.004; Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Vareslija D, 2017, METHODS MOL BIOL, V1501, P327, DOI 10.1007/978-1-4939-6475-8_17; Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583; Verfaillie A., 2015, CURR PROTOC BIOINFOR, V52, P1; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125; Wang L, 2016, HORM CANCER-US, V7, P229, DOI 10.1007/s12672-016-0261-6; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Weirauch MT, 2014, CELL, V158, P1431, DOI 10.1016/j.cell.2014.08.009; Wu LL, 2014, ONCOTARGET, V5, P7677, DOI 10.18632/oncotarget.2291; Xu Y, 2014, INT J BIOL SCI, V10, P396, DOI 10.7150/ijbs.8193; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Ye Y, 2009, MOL CANCER RES, V7, P1984, DOI 10.1158/1541-7786.MCR-09-0119	64	20	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2008	2021		10.1038/s41388-017-0042-x	http://dx.doi.org/10.1038/s41388-017-0042-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367763	Green Published, hybrid			2022-12-28	WOS:000429899400005
J	Liu, GH; Feng, S; Jia, L; Wang, CY; Fu, Y; Luo, YZ				Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang			Lung fibroblasts promote metastatic colonization through upregulation of stearoyl-CoA desaturase 1 in tumor cells	ONCOGENE			English	Article							CATHEPSIN-B; CYSTEINE CATHEPSINS; THERAPEUTIC TARGET; CANCER-CELLS; PROGRESSION; PROLIFERATION; SURVIVAL; NETWORK; MTOR; LIPOGENESIS	As a rate-limiting step in metastasis, metastatic colonization requires survival signals from supportive stroma. However, the mechanisms driving this process are incompletely understood. Here, we showed that the proliferation of B16F10 cells was promoted when cocultured with lung fibroblasts. Meanwhile, co-injection of B16F10 tumor cells with mouse lung fibroblasts significantly increased lung metastasis. Based on GEO database, we identified stearoyl-CoA desaturase 1 (SCD1) as a novel factor promoting metastatic colonization. Importantly, we found that fibroblast-secreted cathepsin B (CTSB) induced the upregulation of SCD1 in B16F10 through Annexin A2 (ANXA2) and PI3K/Akt/mTOR pathway. The elevated SCD1 induced a higher ratio of monounsaturated fatty acids to saturated fatty acids in B16F10 cells. The changes in fatty acid composition contributed to tumor cell proliferation and metastatic colonization. Furthermore, targeting SCD1 effectively inhibited lung metastasis and prolonged the overall survival of mice. Meanwhile, the expression of SCD1 was negatively correlated with disease-free survival in five types of cancer patients. Collectively, our study identifies SCD1 as a critical modulator of tumor cell proliferation that is activated by cathepsin B, secreted by lung fibroblasts at the metastatic niche. Our novel findings provide potential therapeutic targets to prevent tumor metastasis.	[Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Natl Engn Lab Antitumor Prot Therapeut, Beijing, Peoples R China; [Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing, Peoples R China; [Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Sch Life Sci, Canc Biol Lab, Beijing, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Natl Engn Lab Antitumor Prot Therapeut, Beijing, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Sch Life Sci, Canc Biol Lab, Beijing, Peoples R China.	yluo@mail.tsinghua.edu.cn			General Programs of the National Natural Science Foundation of China [81672865, 81472667, 81461148021, 81272529]; Major Scientific and Technological Special Project for "significant new drugs creation" [2013ZX09509103]	General Programs of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Scientific and Technological Special Project for "significant new drugs creation"	This work was supported in part by the General Programs of the National Natural Science Foundation of China (Nos. 81672865, 81472667, 81461148021, and 81272529) and the Major Scientific and Technological Special Project for "significant new drugs creation" (No. 2013ZX09509103).	AbuAli G, 2015, ONCOGENE, V34, P1718, DOI 10.1038/onc.2014.93; Aggarwal N, 2014, PROTEOM CLIN APPL, V8, P427, DOI 10.1002/prca.201300105; Atilla-Gokcumen GE, 2014, CELL, V156, P428, DOI 10.1016/j.cell.2013.12.015; Bansal S, 2014, J SURG RES, V186, P29, DOI 10.1016/j.jss.2013.07.001; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chen Y, 2015, INT J CANCER, V136, P182, DOI 10.1002/ijc.28950; Du XN, 2012, CANCER RES, V72, P5843, DOI 10.1158/0008-5472.CAN-12-1329; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Harbeck N, 2001, CLIN CANCER RES, V7, P2757; Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036; Huang J, 2016, ONCOTARGET, V7, P39970, DOI 10.18632/oncotarget.9461; Huang YJ, 2009, CANCER RES, V69, P7529, DOI 10.1158/0008-5472.CAN-08-4382; Igal RA, 2016, BBA-MOL CELL BIOL L, V1861, P1865, DOI 10.1016/j.bbalip.2016.09.009; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Jia L, 2017, J PATHOL, V243, P255, DOI 10.1002/path.4952; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kim M, 2010, ANTIVIR THER, V15, P897, DOI 10.3851/IMP1646; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Liu GH, 2015, J PATHOL, V237, P190, DOI 10.1002/path.4564; Luyimbazi D, 2010, MOL CANCER THER, V9, P2770, DOI 10.1158/1535-7163.MCT-09-0980; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nodomi S, 2016, ONCOGENE, V35, P5317, DOI 10.1038/onc.2016.72; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Qi FF, 2015, CLIN CANCER RES, V21, P3071, DOI 10.1158/1078-0432.CCR-14-2785; Qiang L, 2015, CELL REP, V11, P1797, DOI 10.1016/j.celrep.2015.05.025; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5; Roy D, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-13; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; von Roemeling CA, 2013, CLIN CANCER RES, V19, P2368, DOI 10.1158/1078-0432.CCR-12-3249; Wang H, 2015, DIABETES, V64, P2442, DOI 10.2337/db14-0528; Wang JQ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5692852; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100	53	23	24	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1519	1533		10.1038/s41388-017-0062-6	http://dx.doi.org/10.1038/s41388-017-0062-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29326439				2022-12-28	WOS:000427459500009
J	Lin, SC; Chung, CH; Chung, CH; Kuo, MH; Hsieh, CH; Chiu, YF; Shieh, YS; Chou, YT; Wu, CW				Lin, Sheng-Chieh; Chung, Chi-Hsiu; Chung, Chih-Hung; Kuo, Ming-Han; Hsieh, Cheng-Han; Chiu, Yu-Fan; Shieh, Yi-Shing; Chou, Yu-Ting; Wu, Cheng-Wen			OCT4B mediates hypoxia-induced cancer dissemination	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LUNG ADENOCARCINOMA; INDUCIBLE FACTORS; STEM; PROTEIN; CELLS; OCT-4; GENE; SLUG; TRANSACTIVATION	Hypoxia, the reduction of oxygen levels in cells or tissues, elicits a set of genes to adjust physiological and pathological demands during normal development and cancer progression. OCT4, a homeobox transcription factor, is essential for self-renewal of embryonic stem cells, but little is known about the role of OCT4 in non-germ-cell tumorigenesis. Here, we report that hypoxia stimulates a short isoform of OCT4, called OCT4B, via a HIF2 alpha-dependent pathway to induce the epithelial-mesenchymal transition (EMT) and facilitate cancer dissemination. OCT4B overexpression decreased epithelial barrier properties, which led to an increase in cell migration and invasion in lung cancer cells. OCT4B knockdown attenuated HIF2 alpha-induced EMT and inhibited cancer dissemination in cell-line and animal models. We observed that OCT4B bound the SLUG promoter and enhanced its expression, and SLUG silencing inhibited OCT4B-mediated EMT, accompanied with decreased cell migration and invasion. Correlation analysis revealed that OCT4B expression was significantly associated with the SLUG level in lung tumors. These results provide novel insights into OCT4B-mediated oncogenesis in cancer dissemination.	[Lin, Sheng-Chieh; Kuo, Ming-Han; Chiu, Yu-Fan; Chou, Yu-Ting; Wu, Cheng-Wen] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan; [Lin, Sheng-Chieh] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Chung, Chi-Hsiu; Chung, Chih-Hung; Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Hsieh, Cheng-Han; Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan; [Hsieh, Cheng-Han] Taipei Med Univ, Res Ctr Canc Translat Med, Taipei, Taiwan; [Shieh, Yi-Shing] Triserv Gen Hosp, Dept Oral Diag & Pathol, Taipei, Taiwan; [Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Tsing Hua University; China Medical University Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University; Tri-Service General Hospital; Academia Sinica - Taiwan	Chou, YT; Wu, CW (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan.; Wu, CW (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	ytchou@life.nthu.edu.tw; cwwu@ym.edu.tw		Chou, Yu-Ting/0000-0001-9274-8603	National Tsing Hua University; National Yang-Ming University; Institute of Biomedical Science at Academia Sinica; Ministry of Science and Technology [NSC 102-2320-B-007-010, MOST104-2321-B-010-007, MOST 105-2325-B-010-003, MOST 106-2320-B-007-005-MY3]; Ministry of Health and Welfare, Executive Yuan, Taiwan [MOHW105-TDU-B-211-134003]	National Tsing Hua University; National Yang-Ming University; Institute of Biomedical Science at Academia Sinica; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Health and Welfare, Executive Yuan, Taiwan	This work was supported by National Tsing Hua University, National Yang-Ming University, Institute of Biomedical Science at Academia Sinica, Ministry of Science and Technology (NSC 102-2320-B-007-010, MOST104-2321-B-010-007, MOST 105-2325-B-010-003, MOST 106-2320-B-007-005-MY3), and Ministry of Health and Welfare (MOHW105-TDU-B-211-134003), Executive Yuan, Taiwan.	Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bollineni VR, 2012, CANCER TREAT REV, V38, P1027, DOI 10.1016/j.ctrv.2012.04.003; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Chou YT, 2012, CELL DEATH DIFFER, V19, P2015, DOI 10.1038/cdd.2012.91; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Crino L, 2010, ANN ONCOL, V21, pv103, DOI 10.1093/annonc/mdq207; Gao Y, 2012, STEM CELLS, V30, P665, DOI 10.1002/stem.1034; Gao YA, 2010, J GENET GENOMICS, V37, P461, DOI 10.1016/S1673-8527(09)60065-5; Guo CL, 2012, STEM CELL RES, V9, P69, DOI 10.1016/j.scr.2012.04.004; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jiang JA, 2011, CANCER BIOL THER, V11, P714, DOI 10.4161/cbt.11.8.15274; Karoubi Golnaz, 2009, Interact Cardiovasc Thorac Surg, V8, P393, DOI 10.1510/icvts.2008.193995; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pani G, 2010, CANCER METAST REV, V29, P351, DOI 10.1007/s10555-010-9225-4; Papamichos SI, 2009, GENE CHROMOSOME CANC, V48, P1112, DOI 10.1002/gcc.20707; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Theodorou E, 2009, GENE DEV, V23, P575, DOI 10.1101/gad.1772509; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang X, 2009, STEM CELLS, V27, P1265, DOI 10.1002/stem.58; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje	39	7	8	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1093	1105		10.1038/s41388-018-0487-6	http://dx.doi.org/10.1038/s41388-018-0487-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30209362				2022-12-28	WOS:000458624900012
J	Goroshchuk, O; Kolosenko, I; Vidarsdottir, L; Azimi, A; Palm-Apergi, C				Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline			Polo-like kinases and acute leukemia	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; INHIBITOR BI 2536; BOX DOMAIN; IN-VITRO; ANTITUMOR-ACTIVITY; TARGETING PLK1; RNAI PRODRUGS; AML PATIENTS; CANCER	Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for the development of novel and more specific therapies with fewer side effects. The family of Polo-like kinases (Plks) is a group of five serine/threonine kinases that play an important role in cell cycle regulation and are critical targets for therapeutic invention. Plk1 and Plk4 are novel targets for cancer therapy as leukemic cells often express higher levels than normal cells. In contrast, Plk2 and Plk3 are considered to be tumor suppressors. Several small molecule inhibitors have been developed for targeting Plk1 inhibition. Despite reaching phase III clinical trials, one of the ATP-competitive Plk1 inhibitor, volasertib, did not induce an objective clinical response and even caused lethal side effects in some patients. In order to improve the specificity of the Plk1 inhibitors and reduce off-target side effects, novel RNA interference (RNAi)-based therapies have been developed. In this review, we summarize the mechanisms of action of the Plk family members in acute leukemia, describe preclinical studies and clinical trials involving Plk-targeting drugs and discuss novel approaches in Plk targeting.	[Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline] Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden	Karolinska Institutet	Palm-Apergi, C (corresponding author), Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden.	caroline.palm.apergi@ki.se		Vidarsdottir, Linda/0000-0003-3082-1320; Palm Apergi, Caroline/0000-0003-2236-2099; Goroshchuk, Oksana/0000-0002-1585-1962; Azimi, Alireza/0000-0002-7398-5643	Swedish Foundation for Strategic Research; Swedish Childhood Cancer Foundation	Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Childhood Cancer Foundation(European Commission)	This study was supported by the Swedish Foundation for Strategic Research (C.P.A.) and the Swedish Childhood Cancer Foundation (C.P.A.).	Abbou S, 2016, ANTICANCER RES, V36, P599; [Anonymous], 2008, WHO CLASSIFICATION T, V4th ed; [Anonymous], 2017, EU CLIN TRIALS REGIS, P1; Archambault V, 2017, CELL CYCLE, V16, P1220, DOI 10.1080/15384101.2017.1325043; Armstrong GT, 2014, J CLIN ONCOL, V32, P1218, DOI 10.1200/JCO.2013.51.1055; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bassan R, 2011, J CLIN ONCOL, V29, P532, DOI 10.1200/JCO.2010.30.1382; Benetatos L, 2011, ANN HEMATOL, V90, P1037, DOI 10.1007/s00277-011-1193-4; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Casolaro A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058424; Chang JE, 2010, LEUKEMIA LYMPHOMA, V49, P2298; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Dasmahapatra G, 2013, CLIN CANCER RES, V19, P404, DOI 10.1158/1078-0432.CCR-12-2799; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; de Carcer G, 2011, MOL CELL BIOL, V31, P1225, DOI 10.1128/MCB.00607-10; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; de Viron E, 2009, BRIT J HAEMATOL, V147, P641, DOI 10.1111/j.1365-2141.2009.07900.x; Dinner S, 2016, J CELL BIOCHEM, V117, P1745, DOI 10.1002/jcb.25559; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Ferlay J, 2013, IARC CANCERBASE, P11; Fey MF, 2013, ANN ONCOL, V24, P138, DOI 10.1093/annonc/mdt320; Fournier M, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2016.1270391; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; Gorlick R, 2014, PEDIATR BLOOD CANCER, V61, P158, DOI 10.1002/pbc.24616; Gustafsson G., 2013, CHILD CANC INCID SUR, V1984-2010, P1; Hartsink-Segers SA, 2013, HAEMATOLOGICA, V98, P1539, DOI 10.3324/haematol.2013.084434; Hoelzer D, 2016, ANN ONCOL, V27, pv69, DOI 10.1093/annonc/mdw025; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hu CK, 2012, MOL BIOL CELL, V23, P2702, DOI 10.1091/mbc.E12-01-0058; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Ikezoe T, 2009, LEUKEMIA, V23, P1564, DOI 10.1038/leu.2009.94; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kannan S, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2912.2912; Kantarjian HM, 2000, J CLIN ONCOL, V18, P547, DOI 10.1200/JCO.2000.18.3.547; Kazazian K, 2017, CANCER RES, V77, P434, DOI 10.1158/0008-5472.CAN-16-2060; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; Kim SM, 2014, AMINO ACIDS, V46, P2595, DOI 10.1007/s00726-014-1798-8; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kolosenko I, 2017, J CONTROL RELEASE, V261, P199, DOI 10.1016/j.jconrel.2017.07.002; Lee KS, 2015, TRENDS PHARMACOL SCI, V36, P858, DOI 10.1016/j.tips.2015.08.013; Li L, 2009, ACTA PHARMACOL SIN, V30, P1443, DOI 10.1038/aps.2009.141; Li S, 2018, MEDICINE, V97, P1; Li ZH, 2016, J CANCER, V7, P1125, DOI 10.7150/jca.14307; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu D, 2012, J CELL BIOL, V198, P491, DOI 10.1083/jcb.201205090; Maniswami RR, 2018, EXPERT OPIN THER TAR, V22, P59, DOI 10.1080/14728222.2018.1410140; Marina M, 2014, FRONT BIOSCI-LANDMRK, V19, P352, DOI 10.2741/4212; Mason JM, 2014, CANCER CELL, V26, P163, DOI 10.1016/j.ccr.2014.05.006; McArthur K, 2017, ONCOTARGE; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Metayer C, 2013, CANCER EPIDEMIOL, V37, P336, DOI 10.1016/j.canep.2012.12.011; Mross K, 2012, BRIT J CANCER, V107, P280, DOI 10.1038/bjc.2012.257; Muller-Tidow C, 2013, BRIT J HAEMATOL, V163, P214, DOI 10.1111/bjh.12518; Munch C, 2015, LEUKEMIA RES, V39, P462, DOI 10.1016/j.leukres.2015.01.007; NCNN Clinical Practice Guidelines in Oncology, 2015, NED TIJDSCHR TANDHEE, V109, P463; Nielsen SN, 2017, PEDIAT BLOOD CANC, V64, P1; Normandin K, 2016, SCI REP-UK, V6, DOI 10.1038/srep37581; Oliveira JC, 2014, PEDIATR BLOOD CANCER, V61, P1227, DOI 10.1002/pbc.24978; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Osca-Gelis G, 2013, HAEMATOLOGICA, V98, pE95, DOI 10.3324/haematol.2013.084061; Pritchard-Jones K, 2014, CANCER-AM CANCER SOC, V120, P2388, DOI 10.1002/cncr.28745; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Reaman Gregory H, 2011, PRACTICAL HDB, P336; Reindl W, 2009, CHEMBIOCHEM, V10, P1145, DOI 10.1002/cbic.200900059; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Scharow A, 2016, CHEMBIOCHEM, V17, P759, DOI 10.1002/cbic.201500535; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Sobin L, 2000, INT CLASSIFICATION D; Spaniol K, 2011, ANTI-CANCER DRUG, V22, P531, DOI 10.1097/CAD.0b013e3283454526; Sparta AM, 2014, CELL CYCLE, V13, P2237, DOI 10.4161/cc.29267; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Talati C, 2016, CRIT REV ONCOL HEMAT, V98, P200, DOI 10.1016/j.critrevonc.2015.10.013; Tao YF, 2017, ONCOL REP, V37, P1419, DOI 10.3892/or.2017.5417; Thomas DA, 1999, CANCER-AM CANCER SOC, V86, P1216, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O; Tontsch-Grunt U, 2018, CANCER LETT, V421, P112, DOI 10.1016/j.canlet.2018.02.018; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; Wang NN, 2015, INT J MOL SCI, V16, P1266, DOI 10.3390/ijms16011266; Ward A, 2015, LEUKEMIA LYMPHOMA, V56, P2123, DOI 10.3109/10428194.2014.971407; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819; Zwaan CM, 2015, J CLIN ONCOL, V33, P2949, DOI 10.1200/JCO.2015.62.8289	90	36	37	6	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					1	16		10.1038/s41388-018-0443-5	http://dx.doi.org/10.1038/s41388-018-0443-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30104712				2022-12-28	WOS:000454775900001
J	Luo, LY; Tang, HL; Ling, L; Li, N; Jia, XT; Zhang, ZJ; Wang, XR; Shi, LJ; Yin, J; Qiu, N; Liu, H; Song, Y; Luo, K; Li, HS; He, ZM; Zheng, GP; Xie, XM				Luo, Liyun; Tang, Hailin; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei; Xie, Xiaoming			LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; PROMOTES; METASTASIS; CHEMORESISTANCE; METADHERIN; PROTEIN	Breast cancer is a heterogeneous disease, and triple-negative breast cancer (TNBC) continues to be a serious health problem. The potential involvement of lncRNAs in TNBC progression remains unexplored. Here, we demonstrated that LINC01638 is highly expressed in TNBC tissues and cells. LINC01638 maintains the mesenchymal traits of TNBC cells, including an enriched epithelial-mesenchymal transition (EMT) signature and cancer stem cell-like state. LINC01638 knockdown suppresses tumor proliferation and metastasis both in vitro and in vivo. LINC01638 overexpression predicts a poor outcome of breast cancer patients. Mechanistically, LINC01638 interacts with c-Myc to prevent SPOP-mediated c-Myc ubiquitination and degradation. C-Myc transcriptionally enhances MTDH (metadherin) expression and subsequently activates Twist1 expression to induce EMT. Our findings describe LINC01638-mediated signal transduction and highlight the crucial role of LINC01638 in TNBC progression.	[Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Key Lab Translat Med Malignant Tumor Tr, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Med Univ, Prot Modificat & Degradat Lab, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Tang, Hailin; Xie, Xiaoming] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol,Canc Ctr, Dongfeng Rd 651 E, Guangzhou 510060, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Zheng, GP (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Zheng, GP (corresponding author), Guangzhou Key Lab Translat Med Malignant Tumor Tr, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Zheng, GP (corresponding author), Guangzhou Med Univ, Prot Modificat & Degradat Lab, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Xie, XM (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol,Canc Ctr, Dongfeng Rd 651 E, Guangzhou 510060, Guangdong, Peoples R China.	zhengguopei@126.com; xiexm@sysucc.org.cn	wang, xiao/HGB-7081-2022	wang, xiao/0000-0002-4088-3341	National Natural Science Foundation of China [81672616, 81402196, 81772961, 81401989, 81772825]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306003]; Guangdong Natural Science Funds [2017A030313867]; Science and Technology Program of Guangzhou [201710010100]; Guangzhou Municipal University Scientific Research project [1201610027]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds for Distinguished Young Scholars; Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Guangzhou Municipal University Scientific Research project	This study was supported by grants from the National Natural Science Foundation of China: No. 81672616 (GZ), No. 81402196 (GZ), No. 81772961 (HT), No. 81401989 (NL) and No. 81772825 (HL); supported by grants from Guangdong Natural Science Funds for Distinguished Young Scholars: No. 2016A030306003 (GZ) and Guangdong Natural Science Funds: No. 2017A030313867 (GZ); supported by grants from Science and Technology Program of Guangzhou: No. 201710010100 (GZ) and Guangzhou Municipal University Scientific Research project: 1201610027 (GZ).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Blanco MA, 2011, J BIOL CHEM, V286, P19982, DOI 10.1074/jbc.M111.240077; Booy EP, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0679-7; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Emdad L, 2013, ADV CANCER RES, V120, P75, DOI 10.1016/B978-0-12-401676-7.00003-6; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Geng C, 2017, ONCOGENE, V36, P4767, DOI 10.1038/onc.2017.80; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Jiang ZY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0853-2; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu LP, 2010, CANCER RES, V70, P3750, DOI 10.1158/0008-5472.CAN-09-3838; Luo M, 2015, CELL STEM CELL, V16, P426, DOI 10.1016/j.stem.2015.02.002; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Sarkar D, 2013, ADV CANCER RES, V120, P39, DOI 10.1016/B978-0-12-401676-7.00002-4; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Yin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073268; Yoo BK, 2010, CANCER RES, V70, P3249, DOI 10.1158/0008-5472.CAN-09-4009; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zheng GP, 2018, CLIN CANCER RES, V24, P1163, DOI 10.1158/1078-0432.CCR-17-2619	37	77	81	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6166	6179		10.1038/s41388-018-0396-8	http://dx.doi.org/10.1038/s41388-018-0396-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	30002443				2022-12-28	WOS:000450883000005
J	Zhou, YS; Xu, ZJ; Quan, D; Zhang, F; Zhang, H; Xiao, TQ; Hou, SL; Qiao, H; Harismendy, O; Wang, JYJ; Suo, GL				Zhou, Yuanshuai; Xu, Zhongjuan; Quan, Daniel; Zhang, Fan; Zhang, Hai; Xiao, Tongqian; Hou, Shulan; Qiao, Hong; Harismendy, Olivier; Wang, Jean Y. J.; Suo, Guangli			Nuclear respiratory factor 1 promotes spheroid survival and mesenchymal transition in mammary epithelial cells	ONCOGENE			English	Article							MITOCHONDRIAL CALCIUM UNIPORTER; BREAST-CANCER CELLS; PANCREATIC-CANCER; FACTOR-I; BIOGENESIS; EXPRESSION; TRANSCRIPTION; DETACHMENT; REGULATOR; CCDC90A	Epithelial cells aggregate into spheroids when deprived of matrix, and the proclivity for spheroid formation and survival is a hallmark of normal and tumorigenic mammary stem cells. We show here that Nuclear Respiratory Factor 1 (NRF1) is a spheroid promoter by in silico identification of this transcription factor as highly connected to top shRNA-hits deduced from re-iterative selections for shRNAs enriched in MCF10A spheroids. NRF1-promoted spheroid survival is linked to its stimulation of mitochondrial OXPHOS, cell migration, invasion, and mesenchymal transition. Conversely, NRF1 knockdown in breast cancer MDA-MB-231 cells reduced spheroids, migration, invasion, and mesenchymal marker expression. NRF1 knockdown also reduced tumor burden in mammary fat pads and lungs of orthotopic-or tail vein-transplanted mice. With the Luminal A subtype of breast cancer, higher NRF1 expression is associated with lower survival. These results show that NRF1, an activator of mitochondrial metabolism, supports mammary spheroid survival and tumor development.	[Zhou, Yuanshuai; Xu, Zhongjuan; Zhang, Hai; Xiao, Tongqian; Hou, Shulan; Suo, Guangli] Chinese Acad Sci, CAS Key Lab Nanobio Interface, Suzhou Inst Nanotech & Nanobion, Nanjing 215123, Jiangsu, Peoples R China; [Zhou, Yuanshuai; Xiao, Tongqian] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Quan, Daniel; Harismendy, Olivier; Wang, Jean Y. J.] Univ Calif San Diego, Sch Med, Dept Med, Div Hematol Oncol,Moores Canc Ctr, La Jolla, CA 92093 USA; [Zhang, Fan; Qiao, Hong] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA	Chinese Academy of Sciences; Suzhou Institute of Nano-Tech & Nano-Bionics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of California System; University of California San Diego; University of Texas System; University of Texas Austin	Suo, GL (corresponding author), Chinese Acad Sci, CAS Key Lab Nanobio Interface, Suzhou Inst Nanotech & Nanobion, Nanjing 215123, Jiangsu, Peoples R China.	glsuo2013@sinano.ac.cn	Harismendy, Olivier/AAM-2072-2021	Harismendy, Olivier/0000-0002-8098-9888; Quan, Daniel/0000-0003-1752-0080; Wang, Jean Yin Jen/0000-0002-8217-0868	pilot project in the San Diego Systems Biology Center [NIH P50GM085764]; National Natural Science Foundation of China [31471307]; Ministry of Science and Technology (MOST) [2014CB965003, 2017YFA0104301]; Hundred Talent Program of Chinese Academy of Sciences; CAS/SAFEA International Innovation Teams program; NIH [R01CA043054]; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM085764] Funding Source: NIH RePORTER	pilot project in the San Diego Systems Biology Center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); CAS/SAFEA International Innovation Teams program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Dai, Q. Wang, Z. Zhang, and G. Cheng for insightful comments on the study, and X. He for technical assistance. Nano-Bio-Chem Centre in Suzhou Institute of Nano-Tech and Nano-Bionics (SINANO) is acknowledged for professional assistance of cell imaging and FACS assay. This study was initiated as a pilot project in the San Diego Systems Biology Center (NIH P50GM085764) that supported G.S., D.Q., O.H., and J.Y.J.W.; D.Q. was also supported by a grant to J.Y.J.W. (NIH R01CA043054). The study of NFR1 was supported by National Natural Science Foundation of China (Grant No. 31471307), Ministry of Science and Technology (MOST) (Grant No. 2014CB965003, and 2017YFA0104301) to G.S., who is also supported by Hundred Talent Program of Chinese Academy of Sciences. The study was also supported by the CAS/SAFEA International Innovation Teams program.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Au SH, 2016, P NATL ACAD SCI USA, V113, P4947, DOI 10.1073/pnas.1524448113; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Hindupur SK, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0420-z; Ivanova MM, 2011, FASEB J, V25, P1402, DOI 10.1096/fj.10-169029; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mason JA, 2017, TRENDS CANCER, V3, P475, DOI 10.1016/j.trecan.2017.04.009; Mattingly KA, 2008, MOL ENDOCRINOL, V22, P609, DOI 10.1210/me.2007-0029; Mattingly KA, 2012, ARCH TOXICOL, V86, P633, DOI 10.1007/s00204-011-0778-y; Ng TL, 2012, CELL DEATH DIFFER, V19, P501, DOI 10.1038/cdd.2011.119; Oliver D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43023; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Paupe V, 2015, CELL METAB, V21, P109, DOI 10.1016/j.cmet.2014.12.004; Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285; Rayavarapu RR, 2015, J BIOL CHEM, V290, P8722, DOI 10.1074/jbc.M114.612754; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Vais H, 2015, CELL METAB, V22, P533, DOI 10.1016/j.cmet.2015.09.015; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vlahakis A, 2017, J MOL BIOL, V429, P515, DOI 10.1016/j.jmb.2016.11.027; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	37	16	17	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6152	6165		10.1038/s41388-018-0349-2	http://dx.doi.org/10.1038/s41388-018-0349-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29995872	Green Accepted			2022-12-28	WOS:000450883000004
J	Park, JJ; Park, MH; Oh, EH; Soung, NK; Lee, SJ; Jung, JK; Lee, OJ; Yun, SJ; Kim, WJ; Shin, EY; Kim, EG				Park, Jung-Jin; Park, Mee-Hee; Oh, Eun Hye; Soung, Nak-Kyun; Lee, Soo Jae; Jung, Jae-Kyung; Lee, Ok-Jun; Yun, Seok Joong; Kim, Wun-Jae; Shin, Eun-Young; Kim, Eung-Gook			The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer	ONCOGENE			English	Article							SLUG; SNAIL; INVASION; GROWTH; PHOSPHORYLATION; METASTASIS; EXPRESSION; REPRESSOR; OVARIAN; CELLS	Epithelial-mesenchymal transition (EMT) facilitates cancer invasion and metastasis and thus accelerates cancer progression. p21-activated kinase 4 (PAK4) is a critical regulator of prostate cancer (PC) progression. Here, we report that PAK4 activation promotes PC progression through the EMT regulator Slug. We find that phosphorylated PAK4(S474) (pPAK4) levels, an index of PAK4 activation, were tightly associated with Gleason score (p < 0.001), a clinical indicator of PC progression, but not with prostate serum antigen levels or tumor stage. Stable silencing of PAK4 in PC cells reduced their potential for EMT, cellular invasion, and metastasis in vivo. PAK4 bound and directly phosphorylated Slug at two previously unknown sites, S158 and S254, which resulted in its stabilization. The non-phosphorylatable form Slug(S158A/S254A) upregulated transcription of CDH1, which encodes E-cadherin, and thus suppressed EMT and invasion, to a greater extent than did wild-type Slug. The strong EMT inducer TGF-beta elevated pPAK4 and pSlug(S158) levels; PAK4 knockdown or introduction of a dominant-negative form of PAK4 inhibited both TGF-beta-stimulated EMT and an increase in pSlug(S158) levels. Finally, immunohistochemistry revealed a positive correlation between pPAK4 and pSlug(S158) but an inverse correlation between pSlug(S158) and E-cadherin. The results suggest that the PAK4-Slug axis represents a novel pathway that promotes PC progression.	[Park, Jung-Jin; Park, Mee-Hee; Oh, Eun Hye; Shin, Eun-Young; Kim, Eung-Gook] Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 28644, South Korea; [Park, Mee-Hee] KNIH, Korea Ctr Dis Control & Prevent, Div Med Sci Knowledge Management, Osong Eup 28159, Cheongju, South Korea; [Soung, Nak-Kyun] KRIBB, World Class Inst, Ochang Eup 28116, Cheongju, South Korea; [Lee, Soo Jae; Jung, Jae-Kyung] Chungbuk Natl Univ, Coll Pharm, Osong Eup 28160, Cheongju, South Korea; [Lee, Ok-Jun] Chungbuk Natl Univ, Coll Med, Dept Pathol, Cheongju 28644, South Korea; [Yun, Seok Joong; Kim, Wun-Jae] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 28644, South Korea	Chungbuk National University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungbuk National University; Chungbuk National University; Chungbuk National University	Shin, EY; Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 28644, South Korea.	eyshin@chungbuk.ac.kr; egkim@chungbuk.ac.kr		Jung, Jae-Kyung/0000-0002-0490-9663	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2017R1A2B3005714, 2015R1A2A2A04004251]; International Science and Business Belt Program through the Ministry of Science, ICT [2017K000490]; Chungbuk National University grant (2015)	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); International Science and Business Belt Program through the Ministry of Science, ICT; Chungbuk National University grant (2015)	This work was supported in part by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2017R1A2B3005714 and 2015R1A2A2A04004251), International Science and Business Belt Program through the Ministry of Science, ICT (2017K000490), and Chungbuk National University grant (2015).	Al-Azayzih A, 2015, BBA-MOL CELL RES, V1853, P1229, DOI 10.1016/j.bbamcr.2015.02.023; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Broster SA, 2015, FUTURE ONCOL, V11, P3197, DOI 10.2217/fon.15.253; Chen MQ, 2006, PROSTATE, V66, P911, DOI 10.1002/pros.20325; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Esposito S, 2015, ONCOTARGET, V6, P17121, DOI 10.18632/oncotarget.2736; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goc A, 2013, J BIOL CHEM, V288, P3025, DOI 10.1074/jbc.M112.424770; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039; Kalikin LM, 2003, CANCER BIOL THER, V2, P656; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Ko H, 2007, CELLS TISSUES ORGANS, V185, P66, DOI 10.1159/000101305; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Mladinich M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5285892; Molina-Ortiz P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036132; Naber HPH, 2013, BIOCHEM BIOPH RES CO, V435, P58, DOI 10.1016/j.bbrc.2013.04.037; Nakazawa M, 2017, J STEROID BIOCHEM, V166, P84, DOI 10.1016/j.jsbmb.2016.05.007; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Park MH, 2013, ONCOGENE, V32, P2475, DOI 10.1038/onc.2012.255; Rennefahrt UEE, 2007, J BIOL CHEM, V282, P15667, DOI 10.1074/jbc.M700253200; Risolino M, 2014, P NATL ACAD SCI USA, V111, pE3775, DOI 10.1073/pnas.1407074111; Saitoh M, 2016, ONCOGENE, V35, P1049, DOI 10.1038/onc.2015.161; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Slabakova E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350; Tania M, 2014, TUMOR BIOL, V35, P7335, DOI 10.1007/s13277-014-2163-y; Thakur N, 2014, CELL CYCLE, V13, P2400, DOI 10.4161/cc.29339; Virtakoivu R, 2015, CANCER RES, V75, P2349, DOI 10.1158/0008-5472.CAN-14-2842; Wang C, 2014, ONCOGENE, V33, P3473, DOI 10.1038/onc.2013.300; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang ZY, 2017, ONCOTARGET, V8, P22563, DOI 10.18632/oncotarget.15124; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301; Yang HB, 2013, J BIOL CHEM, V288, P8737, DOI 10.1074/jbc.M113.455675; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Zhang KJ, 2011, LAB INVEST, V91, P426, DOI 10.1038/labinvest.2010.201; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	50	30	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5147	5159		10.1038/s41388-018-0327-8	http://dx.doi.org/10.1038/s41388-018-0327-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849120				2022-12-28	WOS:000445093100001
J	Mendonsa, AM; Na, TY; Gumbiner, BM				Mendonsa, Alisha M.; Na, Tae-Young; Gumbiner, Barry M.			E-cadherin in contact inhibition and cancer	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; CELL-ADHESION MOLECULE; HIPPO PATHWAY; BETA-CATENIN; BREAST-CANCER; SIGNALING ACTIVITY; MEDIATED ADHESION; TUMOR PROGRESSION; ACTIVATION; MIGRATION	E-cadherin is a key component of the adherens junctions that are integral in cell adhesion and maintaining epithelial phenotype of cells. Homophilic E-cadherin binding between cells is important in mediating contact inhibition of proliferation when cells reach confluence. Loss of E-cadherin expression results in loss of contact inhibition and is associated with increased cell motility and advanced stages of cancer. In this review we discuss the role of E-cadherin and its downstream signaling in regulation of contact inhibition and the development and progression of cancer.	[Mendonsa, Alisha M.; Na, Tae-Young; Gumbiner, Barry M.] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA 98101 USA; [Gumbiner, Barry M.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Gumbiner, Barry M.] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Mendonsa, AM (corresponding author), Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA 98101 USA.	alisha.mendonsa@seattlechildrens.org			National Cancer Institute at the National Institutes of Health [R01CA207115-02]; NATIONAL CANCER INSTITUTE [R01CA207115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122467] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work has been supported by the grant R01CA207115-02 awarded to Dr. Barry Gumbiner from the National Cancer Institute at the National Institutes of Health.	ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chen Q, 2015, GENE DEV, V29, P1285, DOI 10.1101/gad.264234.115; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Citi Sandra, 2014, Small GTPases, V5, P1, DOI 10.4161/21541248.2014.973760; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Cox RT, 1999, GENETICS, V153, P319; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Das T, 2015, NAT CELL BIOL, V17, P276, DOI 10.1038/ncb3115; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fedor-Chaiken M, 2003, CELL COMMUN ADHES, V10, P105, DOI 10.1080/714040416; FRIEDL P, 1995, CANCER RES, V55, P4557; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansford S, 2015, JAMA ONCOL, V1, P23, DOI 10.1001/jamaoncol.2014.168; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Hirata H, 2017, SCI REP-UK, V7, DOI 10.1038/srep46326; Hirate Y, 2013, CURR BIOL, V23, P1181, DOI 10.1016/j.cub.2013.05.014; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Kim JH, 2009, P NATL ACAD SCI USA, V106, P11149, DOI 10.1073/pnas.0812651106; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Klezovitch Olga, 2015, F1000Res, V4, P550, DOI 10.12688/f1000research.6445.1; Kourtidis A, 2017, J CELL BIOL, V216, P3073, DOI 10.1083/jcb.201612125; Kourtidis A, 2017, EXP CELL RES, V358, P78, DOI 10.1016/j.yexcr.2017.04.006; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; Li HB, 2016, MAMM GENOME, V27, P556, DOI 10.1007/s00335-016-9662-7; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Liang J, 2017, NATURE, V548, P588, DOI 10.1038/nature23678; LIEBERMAN MA, 1981, J MEMBRANE BIOL, V63, P1, DOI 10.1007/BF01969440; Maiden SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148574; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Mana-Capelli S, 2014, MOL BIOL CELL, V25, P1676, DOI 10.1091/mbc.E13-11-0701; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nabeshima K, 1999, HISTOL HISTOPATHOL, V14, P1183, DOI 10.14670/HH-14.1183; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058; Petrova YI, 2012, MOL BIOL CELL, V23, P2092, DOI 10.1091/mbc.E11-12-1060; Priya R, 2015, CURR TOP DEV BIOL, V112, P65, DOI 10.1016/bs.ctdb.2014.11.016; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035; Ribatti D, 2017, EXP CELL RES, V359, P17, DOI 10.1016/j.yexcr.2017.06.012; Rubsam M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01170-7; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Scarpa E, 2015, DEV CELL, V34, P421, DOI 10.1016/j.devcel.2015.06.012; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schroeder MC, 2012, SEMIN CELL DEV BIOL, V23, P803, DOI 10.1016/j.semcdb.2012.06.001; Shashikanth N, 2015, J BIOL CHEM, V290, P21749, DOI 10.1074/jbc.M115.657098; Shi XL, 2017, DEVELOPMENT, V144, P3957, DOI 10.1242/dev.157917; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Sun SG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9402; Szymaniak AD, 2015, DEV CELL, V34, P283, DOI 10.1016/j.devcel.2015.06.020; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van de Wetering M, 2001, CANCER RES, V61, P278; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; Yang CC, 2015, P NATL ACAD SCI USA, V112, P1785, DOI 10.1073/pnas.1420850112; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yewale C, 2013, BIOMATERIALS, V34, P8690, DOI 10.1016/j.biomaterials.2013.07.100; Yi C, 2013, HIPPO SIGNALING PATH; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	99	186	197	5	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4769	4780		10.1038/s41388-018-0304-2	http://dx.doi.org/10.1038/s41388-018-0304-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780167	Green Accepted			2022-12-28	WOS:000443146000001
J	Zhao, CH; Li, YT; Qiu, W; He, FX; Zhang, WM; Zhao, D; Zhang, ZW; Zhang, EB; Ma, P; Liu, YQ; Ma, L; Yang, FM; Wang, YW; Shu, YQ				Zhao, Chenhui; Li, Yongting; Qiu, Wen; He, Fengxia; Zhang, Weiming; Zhao, Dan; Zhang, Zhiwei; Zhang, Erbao; Ma, Pei; Liu, Yiqian; Ma, Ling; Yang, Fengming; Wang, Yingwei; Shu, Yongqian			C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation	ONCOGENE			English	Article							RAT THY-1 NEPHRITIS; GLOMERULAR MESANGIAL CELLS; PROMOTES PROLIFERATION; COMPLEMENT-SYSTEM; ANAPHYLATOXIN C5A; CARCINOMA-CELLS; COLON-CANCER; EXPRESSION; GROWTH; PROGRESSION	Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and multiple evidence has confirmed that C5a production is elevated in NSCLC microenvironment. Although NSCLC cell proliferation induced by C5a has been reported, the involved mechanism has not been elucidated. In this study, we examined the proliferation-related genes (i.e., KLF5, GCN5, and GDF15) and C5a receptor (C5aR) expression in tumor tissues as well as C5a concentration in plasma of NSCLC patients, and then determined the roles of KLF5, GCN5, and GDF15 in C5a-triggered NSCLC cell proliferation and the related mechanism both in vitro and in vivo. Our results found that the expression of KLF5, GCN5, GDF15, C5aR, and C5a was significantly upregulated in NSCLC patients. Mechanistic exploration in vitro revealed that C5a could facilitate A549 cell proliferation through increasing KLF5, GCN5, and GDF15 expression. Besides, KLF5 and GCN5 could form a complex, binding to GDF15 promoter in a KLF5-dependent manner and leading to GDF15 gene transcription. More importantly, GCN5-mediated KLF5 acetylation contributing to GDF15 gene transcription and cell proliferation upon C5a stimulation, the region (-103 to + 58 nt) of GDF15 promoter which KLF5 could bind to, and two new KLF5 lysine sites (K335 and K391) acetylated by GCN5 were identified for the first time. Furthermore, our experiment in vivo demonstrated that the growth of xenograft tumors in BALB/c nude mice was greatly suppressed by the silence of KLF5, GCN5, or GDF15. Collectively, these findings disclose that C5a-driven KLF5-GCN5-GDF15 axis had a critical role in NSCLC proliferation and might serve as targets for NSCLC therapy.	[Zhao, Chenhui; Ma, Pei; Liu, Yiqian; Ma, Ling; Yang, Fengming; Shu, Yongqian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Li, Yongting; Qiu, Wen; Zhao, Dan; Zhang, Zhiwei; Wang, Yingwei] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China; [He, Fengxia] Nanjing Med Univ, Affiliated Hosp 2, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Zhang, Weiming] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.	shuyqtg@126.com	Ma, Pei/ABD-6343-2021; Shu, Yongqian/ABD-5698-2021	He, Fengxia/0000-0002-1695-3127	National Natural Science Foundations of China [81272532, 81472626, 81672896]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundations of China (Nos. 81272532, 81472626, and 81672896). We thank Fuqiang Wang for technical assistance.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; Cai KM, 2014, ONCOL REP, V32, P2260, DOI 10.3892/or.2014.3420; Carrillo-Garcia C, 2014, DEVELOPMENT, V141, P773, DOI 10.1242/dev.096131; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Du C, 2016, FEBS LETT, V590, P408, DOI 10.1002/1873-3468.12069; Griner SE, 2013, BIOCHEM PHARMACOL, V85, P46, DOI 10.1016/j.bcp.2012.10.007; Guruharsha KG, 2011, CELL, V147, P690, DOI 10.1016/j.cell.2011.08.047; He FX, 2016, J MOL CELL BIOL, V8, P477, DOI 10.1093/jmcb/mjw021; Hou M, 2017, CELL PHYSIOL BIOCHEM, V43, P1767, DOI 10.1159/000484063; Imamura T, 2016, BREAST CANCER-TOKYO, V23, P876, DOI 10.1007/s12282-015-0654-3; Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263; Kadara H, 2006, CANCER BIOL THER, V5, P518, DOI 10.4161/cbt.5.5.2602; Kaypee S, 2016, PHARMACOL THERAPEUT, V162, P98, DOI 10.1016/j.pharmthera.2016.01.011; Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007; Kim JS, 2005, MOL CANCER THER, V4, P487; Li Q, 2014, CELL PHYSIOL BIOCHEM, V33, P1, DOI 10.1159/000356645; Li XC, 2014, INT J ONCOL, V45, P1507, DOI 10.3892/ijo.2014.2544; Liu K, 2015, INT J MOL SCI, V16, P21897, DOI 10.3390/ijms160921897; Liu T, 2003, CANCER RES, V63, P5034; Lu Y, 2014, ONCOL REP, V32, P2817, DOI 10.3892/or.2014.3489; Maeda Y, 2015, ONCOL REP, V33, P1844, DOI 10.3892/or.2015.3800; Majaz S, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0114-6; Mamidi S, 2017, IMMUNOBIOLOGY, V222, P45, DOI 10.1016/j.imbio.2015.11.008; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Markiewski MM, 2009, CANCER RES, V69, P6367, DOI 10.1158/0008-5472.CAN-09-1918; Nitta H, 2014, ONCOL REP, V32, P1715, DOI 10.3892/or.2014.3341; Noritsugu K, 2017, BIOCHEM BIOPH RES CO, V489, P455, DOI 10.1016/j.bbrc.2017.05.170; Pandey MK, 2017, NATURE, V543, P108, DOI 10.1038/nature21368; Piao CM, 2015, J BIOL CHEM, V290, P10667, DOI 10.1074/jbc.M114.612622; Qiu W, 2012, J PATHOL, V226, P619, DOI 10.1002/path.3011; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Sayegh ET, 2014, CANCER MED-US, V3, P747, DOI 10.1002/cam4.241; Takabayashi T, 2004, SURGERY, V135, P544, DOI 10.1016/j.surg.2003.09.010; Tanno T, 2014, BLOOD, V123, P725, DOI 10.1182/blood-2013-08-524025; Towner LD, 2016, J BIOL CHEM, V291, P14927, DOI 10.1074/jbc.M115.708446; Tu M, 2014, MOL MED REP, V10, P663, DOI 10.3892/mmr.2014.2317; Urakawa N, 2015, LAB INVEST, V95, P491, DOI 10.1038/labinvest.2015.36; Vadrevu SK, 2014, CANCER RES, V74, P3454, DOI 10.1158/0008-5472.CAN-14-0157; Wan JH, 2015, NUCLEIC ACIDS RES, V43, P3591, DOI 10.1093/nar/gkv238; Wang JC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003830; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Wang YG, 2017, NATURE, V552, P273, DOI 10.1038/nature25003; Yin YW, 2015, GENE EXPRESSION, V16, P187, DOI 10.3727/105221615X14399878166230; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247; Zhang H, 2017, ONCOGENE, V36, P5609, DOI 10.1038/onc.2017.163; Zhang J, 2014, FASEB J, V28, P1511, DOI 10.1096/fj.13-242693; Zheng X, 2018, ONCOGENE, V37, P502, DOI 10.1038/onc.2017.354	50	39	47	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4821	4837		10.1038/s41388-018-0298-9	http://dx.doi.org/10.1038/s41388-018-0298-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773900	Green Published, hybrid			2022-12-28	WOS:000443146000005
J	Zhou, X; Li, GH; An, SQ; Li, WX; Yang, HH; Guo, YC; Dai, Z; Dai, SX; Zheng, JJ; Huang, JF; Iavarone, A; Zhao, XD				Zhou, Xia; Li, Gonghua; An, Sanqi; Li, Wen-Xing; Yang, Huihui; Guo, Yicheng; Dai, Zhi; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei; Iavarone, Antonio; Zhao, Xudong			A new method of identifying glioblastoma subtypes and creation of corresponding animal models	ONCOGENE			English	Article							ONCOGENE ACTIVATION; CO-DELETION; MUTATIONS; GENE; GLIOMAS; IDH1; CANCER; DEFINE; 1P/19Q	Glioblastoma (GBM) accounts for up to 50% of brain parenchymal tumors. It is the most malignant type of brain cancer with very poor survival and limited remedies. Cancer subtyping is important for cancer research and therapy. Here, we report a new subtyping method for GBM based on the genetic alterations of CDKN2A and TP53 genes. CDKN2A and TP53 are the most frequently mutated genes with mutation rates of 60 and 30%, respectively. We found that patients with deletion of CDKN2A possess worse survival than those with TP53 mutation. Interestingly, survival of patients with both TP53 mutation and CDKN2A deletion is no worse than for those with only one of these genetic alterations, but similar to those with TP53 mutation alone. Next, we investigated differences in the gene expression profile between TP53 and CDKN2A samples. Consistent with the survival data, the samples with both TP53 mutation and CDKN2A deletion showed a gene expression profile similar to those samples with TP53 mutation alone. Finally, we found that activation of RAS pathway plus Cdkn2a/b silencing can induce GBM, in a similar way to tumor induction by RAS activation plus TP53 silencing. In conclusion, we show that the genetic alterations of CDKN2A and TP53 may be used to stratify GBM, and the new animal models matching this stratification method were generated.	[Zhou, Xia; An, Sanqi; Yang, Huihui; Dai, Zhi; Zhao, Xudong] Chinese Acad Sci, Kunming Inst Zool, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China; [Zhou, Xia; An, Sanqi; Yang, Huihui; Guo, Yicheng; Dai, Zhi; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei; Zhao, Xudong] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China; [Li, Gonghua; An, Sanqi; Li, Wen-Xing; Guo, Yicheng; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei] Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China; [Li, Wen-Xing] Anhui Univ, Inst Hlth Sci, Hefei 230601, Anhui, Peoples R China; [Iavarone, Antonio] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Zhao, Xudong] Chinese Acad Sci, Kunming Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China; [Zhao, Xudong] Soochow Univ, Coll Pharmaceut Sci, KIZ SU Joint Lab Anim Model & Drug Dev, Suzhou 215000, Jiangsu, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology; Anhui University; Columbia University; Chinese Academy of Sciences; Soochow University - China	Zhao, XD (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.; Huang, JF; Zhao, XD (corresponding author), Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China.; Huang, JF (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China.; Iavarone, A (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.; Zhao, XD (corresponding author), Chinese Acad Sci, Kunming Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China.; Zhao, XD (corresponding author), Soochow Univ, Coll Pharmaceut Sci, KIZ SU Joint Lab Anim Model & Drug Dev, Suzhou 215000, Jiangsu, Peoples R China.	huangjf@mail.kiz.ac.cn; ai2102@cumc.columbia.edu; zhaoxudong@mail.kiz.ac.cn	Dai, shaoxing/ABA-8699-2020	zhao, zhao xu dong/0000-0001-9126-7365; Li, Wen-Xing/0000-0001-9984-8439; Li, Gong-Hua/0000-0002-9311-6613; Guo, Yicheng/0000-0001-5357-660X; Iavarone, Antonio/0000-0002-0683-4634	Strategic Priority Research Program of the Chinese Academy of Sciences [XDA 01040403]; National Natural Science Foundation of China (NSFC) [81171960]; Top Talents Program of Yunnan Province China [2012HA014]; Yunnan Applied Basic Research Projects [2013FA020]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Top Talents Program of Yunnan Province China; Yunnan Applied Basic Research Projects	We thank Dr. Dong Yang and Qiu Tu for the useful advice. We also thank Yujie Xia for technical assistance with the histological analysis. This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA 01040403), the National Natural Science Foundation of China (NSFC, 81171960), the Top Talents Program of Yunnan Province China (2012HA014) to XZ, and Yunnan Applied Basic Research Projects (2013FA020).	Arvold ND, 2014, CLIN INTERV AGING, V9, P357, DOI 10.2147/CIA.S44259; Bhowmick DA, 2004, CANCER RES, V64, P1220, DOI 10.1158/0008-5472.CAN-03-3137; Boots-Sprenger SHE, 2013, MODERN PATHOL, V26, P922, DOI 10.1038/modpathol.2012.166; Brennan CW, 2014, CELL, V157, P753, DOI 10.1016/j.cell.2014.04.004; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Costa BM, 2010, CANCER RES, V70, P453, DOI 10.1158/0008-5472.CAN-09-2189; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gallardo T, 2007, GENESIS, V45, P413, DOI 10.1002/dvg.20310; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Geraerts M, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-34; Goel Manish Kumar, 2010, Int J Ayurveda Res, V1, P274, DOI 10.4103/0974-7788.76794; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Helseth R, 2010, ACTA NEUROL SCAND, V122, P159, DOI 10.1111/j.1600-0404.2010.01350.x; Huang W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-1; Ichimura K, 1996, ONCOGENE, V13, P1065; Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025; Kato H, 2000, CLIN CANCER RES, V6, P3937; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Lee JC, 2011, J CLIN INVEST, V121, P4170, DOI 10.1172/JCI59255; Liu YC, 2013, IEEE T CYBERNETICS, V43, P982, DOI 10.1109/TSMCB.2012.2220543; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Marusyk Andriy, 2010, Biochim Biophys Acta, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Mischel PS, 2003, J NEUROPATH EXP NEUR, V62, P542; Mistry M, 2015, J CLIN ONCOL, V33, P1015, DOI 10.1200/JCO.2014.58.3922; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357-014-9161-z; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Popova SN, 2014, HISTOPATHOLOGY, V64, P365, DOI 10.1111/his.12252; Qian WF, 2010, TRENDS GENET, V26, P425, DOI 10.1016/j.tig.2010.07.002; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stancheva G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/654727; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Tu Q, 2018, ONCOGENE, V37, P128, DOI 10.1038/onc.2017.316; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vogazianou AP, 2010, NEURO-ONCOLOGY, V12, P664, DOI 10.1093/neuonc/nop075; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010	50	2	2	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4781	4791		10.1038/s41388-018-0305-1	http://dx.doi.org/10.1038/s41388-018-0305-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29769617				2022-12-28	WOS:000443146000002
J	Lu, JQ; Liu, LS; Zheng, MJ; Li, XL; Wu, AL; Wu, QZ; Liao, C; Zou, J; Song, H				Lu, Jinqiu; Liu, Liansheng; Zheng, Mingjie; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Liao, Cheng; Zou, Jian; Song, Hai			MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function	ONCOGENE			English	Article							ACTIVATOR FUNCTION; PROTEINS; CANCER; OVEREXPRESSION; EXPRESSION; SITE	Hedgehog (Hh) pathway plays a pivotal role in diverse aspects of development and postnatal physiology. Perturbation of Hh signaling and activation of GLI1 (glioma-associated oncogene 1), a dedicated transcription factor for Hh pathway, are highly associated with several cancers, such as medulloblastoma and basal cell carcinoma. Dynamic and precise control of GLI1 activity is thus important to ensure proper homeostasis and tumorigenesis. Here we show that MEKK2 (MAP3K2) and MEKK3 (MAP3K3) inhibit GLI1 transcriptional activity and oncogenic function through phosphorylation on multiple Ser/Thr sites of GLI1, which reduces GLI1 protein stability, DNA-binding ability, and increases the association of GLI1 with SUFU. Interestingly, MEKK2 and MEKK3 are responsible for FGF2-mediated inhibition on Hh signaling. Moreover, expression of MEKK2 and MEKK3 inhibits medulloblastoma cell proliferation and negatively correlates with Hh pathway activity in medulloblastoma clinical samples. Together, these findings reveal a novel noncanonical GLI1 regulation and provide a potential therapeutic target for the treatment of cancers with aberrant Hh pathway activation, such as medulloblastoma.	[Lu, Jinqiu; Liu, Liansheng; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Song, Hai] Zhejiang Univ, Inst Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Lu, Jinqiu; Liu, Liansheng; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Song, Hai] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China; [Zheng, Mingjie; Zou, Jian] Zhejiang Univ, Inst Translat Med, Affiliated Hosp 2, Eye Ctr,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China; [Liao, Cheng] Janssen China Res & Dev Ctr, Lung Canc Translat Res, Discovery Ctr, 5F,Bldg 1 North,Jinchuang Mans 4560 Jinke, Shanghai 201210, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Song, H (corresponding author), Zhejiang Univ, Inst Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.; Song, H (corresponding author), Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China.	haisong@zju.edu.cn	Lu, Jinqiu/HIR-7408-2022	Zheng, Mingjie/0000-0003-0735-3995; Li, Xiaoling/0000-0002-1554-1569	National Natural Science Foundation of China [31471368]; Zhejiang Provincial Natural Science Foundation of China [LR16C120001, LZ15H120001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province)	We thank Bin Zhao and Zongping Xia (both Zhejiang University, China) for reagents, members of the Song laboratory for discussion, and Pao-Tien Chuang for critical reading of the manuscript. This work was supported by the National Natural Science Foundation of China (grant number 31471368), the Zhejiang Provincial Natural Science Foundation of China (grant number LR16C120001) to HS, and the Zhejiang Provincial Natural Science Foundation of China (grant number LZ15H120001) to JZ. HS is a scholar in the National 1000 Young Talents Program.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534-5807(03)00394-0; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Barnfield PC, 2005, DIFFERENTIATION, V73, P397, DOI 10.1111/j.1432-0436.2005.00042.x; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Fan YH, 2014, J PATHOL, V232, P75, DOI 10.1002/path.4283; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; Gotschel F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065403; Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113; Hasan R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-2; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jiang L, 2013, ONCOL LETT, V6, P1333, DOI 10.3892/ol.2013.1553; Karlstrom RO, 2003, DEVELOPMENT, V130, P1549, DOI 10.1242/dev.00364; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lewis KE, 1999, DEV BIOL, V216, P469, DOI 10.1006/dbio.1999.9519; Lin CW, 2014, DEV BIOL, V392, P324, DOI 10.1016/j.ydbio.2014.05.014; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Neumann CJ, 1999, DEVELOPMENT, V126, P4817; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Umapathy G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005470; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wilson CW, 2010, DEVELOPMENT, V137, P2079, DOI 10.1242/dev.045021; Zhang DY, 2006, EMBO J, V25, P97, DOI 10.1038/sj.emboj.7600913; Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450	35	22	23	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3864	3878		10.1038/s41388-018-0249-5	http://dx.doi.org/10.1038/s41388-018-0249-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662197	Green Published, hybrid			2022-12-28	WOS:000438465600008
J	Newman, JH; Augeri, DJ; NeMoyer, R; Malhotra, J; Langenfeld, E; Chesson, CB; Dobias, NS; Lee, MJ; Tarabichi, S; Jhawar, SR; Bommareddy, PK; Marshall, S; Sadimin, ET; Kerrigan, JE; Goedken, M; Minerowicz, C; Jabbour, SK; Li, SG; Carayannopolous, MO; Zloza, A; Langenfeld, J				Newman, Jenna H.; Augeri, David J.; NeMoyer, Rachel; Malhotra, Jyoti; Langenfeld, Elaine; Chesson, Charles B.; Dobias, Natalie S.; Lee, Michael J.; Tarabichi, Saeed; Jhawar, Sachin R.; Bommareddy, Praveen K.; Marshall, Sh'Rae; Sadimin, Evita T.; Kerrigan, John E.; Goedken, Michael; Minerowicz, Christine; Jabbour, Salma K.; Li, Shengguo; Carayannopolous, Mary O.; Zloza, Andrew; Langenfeld, John			Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer	ONCOGENE			English	Article							IN-VIVO; APOPTOSIS PROTEIN; BMP; ACTIVATION; DEATH; EXPRESSION; GROWTH; RESPONSES; THERAPY; XIAP	BMP receptor inhibitors induce death of cancer cells through the downregulation of antiapoptotic proteins XIAP, pTAK1, and Id1-Id3. However, the current most potent BMP receptor inhibitor, DMH2, does not downregulate BMP signaling in vivo because of metabolic instability and poor pharmacokinetics. Here we identified the site of metabolic instability of DMH2 and designed a novel BMP receptor inhibitor, JL5. We show that JL5 has a greater volume of distribution and suppresses the expression of Id1 and pTak1 in tumor xenografts. Moreover, we demonstrate JL5-induced tumor cell death and tumor regression in xenograft mouse models without immune cells and humanized with adoptively transferred human immune cells. In humanized mice, JL5 additionally induces the infiltration of immune cells within the tumor microenvironment. Our studies show that the BMP signaling pathway is targetable in vivo and BMP receptor inhibitors can be developed as a therapeutic to treat cancer patients.	[Newman, Jenna H.; Chesson, Charles B.; Dobias, Natalie S.; Bommareddy, Praveen K.; Marshall, Sh'Rae; Li, Shengguo; Zloza, Andrew] Rutgers Canc Inst New Jersey, Sect Surg Oncol Res, Div Surg Oncol, New Brunswick, NJ 08903 USA; [Augeri, David J.] Rutgers State Univ, Off Translat Sci Mol Design & Synth, Piscataway, NJ 08854 USA; [NeMoyer, Rachel; Lee, Michael J.; Tarabichi, Saeed; Zloza, Andrew] Rutgers State Univ, Dept Surg, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA; [Malhotra, Jyoti] Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ 08903 USA; [Langenfeld, Elaine; Langenfeld, John] Rutgers Canc Inst New Jersey, Dept Surg, Div Surg Oncol & Thorac Surg, New Brunswick, NJ 08903 USA; [Jhawar, Sachin R.; Jabbour, Salma K.] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; [Sadimin, Evita T.; Minerowicz, Christine; Carayannopolous, Mary O.] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Sci, New Brunswick, NJ 08903 USA; [Kerrigan, John E.] Rutgers State Univ, Dept Bioinformat, Rutgers Biomed Hlth Sci, Piscataway, NJ 08854 USA; [Goedken, Michael] Rutgers State Univ, Off Translat Sci, Res Pathol Serv, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Zloza, A (corresponding author), Rutgers Canc Inst New Jersey, Sect Surg Oncol Res, Div Surg Oncol, New Brunswick, NJ 08903 USA.; Zloza, A (corresponding author), Rutgers State Univ, Dept Surg, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.; Langenfeld, J (corresponding author), Rutgers Canc Inst New Jersey, Dept Surg, Div Surg Oncol & Thorac Surg, New Brunswick, NJ 08903 USA.	andrew.zloza@rutgers.edu; langenje@cinj.rutgers.edu	Jhawar, Sachin R/M-1587-2017; Bommareddy, Praveen/L-1173-2019	Jhawar, Sachin R/0000-0001-8604-4757; Bommareddy, Praveen/0000-0003-0089-8693; Kerrigan, John/0000-0001-6562-4533; Zloza, Andrew/0000-0001-8844-6493	NCI [P30CA72720]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work utilized shared resources at Rutgers Cancer Institute of New Jersey, which are supported by NCI P30CA72720.	Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bobbio A, 2015, PHARMACOL RES, V99, P217, DOI 10.1016/j.phrs.2015.06.011; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clement JH, 2005, INT J ONCOL, V27, P401; Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052; de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Galban S, 2009, BIOCHEM J, V417, P765, DOI 10.1042/BJ20081677; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hahm E, 2017, NAT MED, V23, P100, DOI 10.1038/nm.4242; Hao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090748; Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kohlhapp FJ, 2016, CELL REP, V17, P957, DOI 10.1016/j.celrep.2016.09.068; Kohlhapp FJ, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0063-3; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kurooka H, 2012, BIOCHEM BIOPH RES CO, V420, P281, DOI 10.1016/j.bbrc.2012.02.150; Lai TH, 2008, PROSTATE, V68, P1341, DOI 10.1002/pros.20799; Langenfeld E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061256; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Langenfeld EM, 2005, MOL CANCER RES, V3, P679, DOI 10.1158/1541-7786.MCR-05-0124; Langenfeld EM, 2005, ANN THORAC SURG, V80, P1028, DOI 10.1016/j.athoracsur.2005.03.094; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Le Page C, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-4; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Lu R, 2014, AIDS RES HUM RETROV, V30, P677, DOI [10.1089/AID.2013.0289, 10.1089/aid.2013.0289]; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Martinez CG, 2011, IMMUNOL CELL BIOL, V89, P610, DOI 10.1038/icb.2010.135; Martinez VG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131453; Martinez VG, 2014, EUR J IMMUNOL, V44, P1031, DOI 10.1002/eji.201343693; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Nguyen A, 2014, INT ORTHOP, V38, P2313, DOI 10.1007/s00264-014-2512-x; Nickel J, 2009, CYTOKINE GROWTH F R, V20, P367, DOI 10.1016/j.cytogfr.2009.10.022; Obexer P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00197; Owens P, 2015, ONCOGENE, V34, P2437, DOI 10.1038/onc.2014.189; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Robson NC, 2014, CANCER RES, V74, P5019, DOI 10.1158/0008-5472.CAN-13-2845; Rothhammer T, 2005, CANCER RES, V65, P448; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sountoulidis A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041460; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Weaver M, 1999, DEVELOPMENT, V126, P4005; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Ye L, 2011, FRONT BIOSCI-LANDMRK, V16, P865, DOI 10.2741/3725; Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang YG, 2015, AIDS RES HUM RETROV, V31, P774, DOI 10.1089/aid.2014.0341; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622; Zloza A, 2012, NAT MED, V18, P422, DOI 10.1038/nm.2683; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	58	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3672	3685		10.1038/s41388-018-0156-9	http://dx.doi.org/10.1038/s41388-018-0156-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622797				2022-12-28	WOS:000437975200005
J	Su, TH; Liao, JB; Dai, ZH; Xu, LX; Chen, SL; Wang, YF; Peng, ZW; Zhang, QY; Peng, S; Kuang, M				Su, Tianhong; Liao, Junbin; Dai, Zihao; Xu, Lixia; Chen, Shuling; Wang, Yifei; Peng, Zhenwei; Zhang, Qiuyang; Peng, Sui; Kuang, Ming			Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PROTEIN 90 HSP90; HEAT-SHOCK; NUCLEAR TRANSLOCATION; SORAFENIB SUPPRESSES; RISK-FACTORS; RECURRENCE; INHIBITORS; MECHANISM; THERAPY	Recent studies indicated that insufficient radiofrequency ablation (RFA) could endow hepatocellular carcinoma (HCC) with higher aggressive potential. Stress-induced phosphoprotein 1 (STIP1), which was found highly expressed in HCC, is a chaperone molecule mediating cell homeostasis under thermal stress. We aimed to explore the role of STIP1 on the metastasis of residual HCC after RFA. Mice model with orthotopic HCC implants or caudal vein injection were employed to assess potential of lung metastasis and/or intrahepatic metastasis (IHM) of HCC cells. Cell culture model was used to determine cell invasion, mesenchymal marker genes expression, and underlying molecular mechanisms. Clinical specimens were collected to analyze the relationship between STIP1 and clinical outcome. We found that insufficient RFA elicited more IHM of HCCLM3 tumors, which could be reduced by silencing STIP1. Knockdown of STIP1 also significantly decreased lung metastatic potential of HCCLM3 cells. In vitro, HCCLM3 and HepG2 displayed a spindle-shaped morphology with upregulation of STIP1 and mesenchymal markers after sublethal heat exposure. Mechanistically, heat exposure induced the formation of STIP1-heat shock protein 90 (HSP90) complex, which could shuttle epithelial transcription repressor Snail1 into nucleus and regulate mesenchymal gene transcription. Blocking the HSP90-STIP1 complex reduced the invasive potential of HCC cells after heat exposure. Using clinical specimen, we found that STIP1 was expressed significantly higher in metastatic tumor tissues and in sera from metastatic HCC patients (p < 0.05). The high expression of STIP1 was significantly linked to shorter recurrence-free survival (p < 0.05). To sum up, our study found that STIP1 is positively associated with the sublethal heat-induced cancer cell metastasis through mediating the mesenchymal gene transcription. Blocking STIP1 activity may suppress HCC cell metastatic potential after RFA.	[Su, Tianhong; Liao, Junbin; Dai, Zihao; Wang, Yifei; Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Guangdong, Peoples R China; [Xu, Lixia; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China; [Chen, Shuling; Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Guangzhou, Guangdong, Peoples R China; [Peng, Zhenwei; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Guangdong, Peoples R China; [Zhang, Qiuyang] Baylor Scott & White Res Inst, Ctr Esophageal Res, Dallas, TX USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Baylor Health Care System; Baylor University Medical Center	Kuang, M (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China.; Kuang, M (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Guangdong, Peoples R China.	pengsui@vip.163.com; kuangminda@hotmail.com			National Natural Science Foundation of China [81470817, 81771958]; Guangdong Science and Technology Plan [2016A020215189, 2014A020212396]; National Natural Science Foundation of Guangdong [2015A030311039]; Guangzhou Science and Technology Plan [201704020099]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Plan; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Plan	This work was supported by the National Natural Science Foundation of China (81470817, 81771958), the Guangdong Science and Technology Plan (2016A020215189, 2014A020212396), the National Natural Science Foundation of Guangdong (2015A030311039) and the Guangzhou Science and Technology Plan (201704020099).	Chang CH, 2014, MOL PHARMACOL, V85, P849, DOI 10.1124/mol.113.090654; Chen ZB, 2017, BIOCHEM BIOPH RES CO, V493, P365, DOI 10.1016/j.bbrc.2017.09.016; Cikos S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-113; Daniel S, 2008, BBA-MOL CELL RES, V1783, P1003, DOI 10.1016/j.bbamcr.2008.01.014; Dong SY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1949-7; Dong SY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-273; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Home T, 2015, CANCER RES, V75, P907, DOI 10.1158/0008-5472.CAN-14-2905; Kang TW, 2017, CLIN MOL HEPATOL, V23, P95, DOI 10.3350/cmh.2017.0006; Kasugai H, 2007, ONCOLOGY-BASEL, V72, P72, DOI 10.1159/000111710; Kim KW, 2011, AM J ROENTGENOL, V196, pW565, DOI 10.2214/AJR.10.5122; Kumalo HM, 2015, CHEM BIOL DRUG DES, V86, P1131, DOI 10.1111/cbdd.12582; Lam VWT, 2008, J AM COLL SURGEONS, V207, P20, DOI 10.1016/j.jamcollsurg.2008.01.020; Lau WY, 2009, ANN SURG, V249, P20, DOI 10.1097/SLA.0b013e31818eec29; Lee HY, 2013, EUR RADIOL, V23, P190, DOI 10.1007/s00330-012-2561-8; Lei W, 2017, J BIOL CHEM, V292, P10414, DOI 10.1074/jbc.M116.769489; Li YY, 2016, METHODS MOL BIOL, V1406, P73, DOI 10.1007/978-1-4939-3444-7_6; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Pimienta G, 2011, MOL PHARMACEUT, V8, P2252, DOI 10.1021/mp200346y; Ruzzenente A, 2004, WORLD J GASTROENTERO, V10, P1137; Sadikot T, 2013, ASSAY DRUG DEV TECHN, V11, P478, DOI 10.1089/adt.2012.498; Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schulz R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.508; Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452; Takada Yasutsugu, 2003, Int J Clin Oncol, V8, P332, DOI 10.1007/s10147-003-0328-6; Thompson SM, 2016, PLOS ONE, V11; Walsh N, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-140; Wang C, 2016, INT J CANCER, V138, P1824, DOI 10.1002/ijc.29723; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Xu M, 2013, ACTA RADIOL, V54, P199, DOI 10.1258/ar.2012.120249; Yoshida S, 2013, HEPATOLOGY, V58, P1667, DOI 10.1002/hep.26526; Zavaglia C, 2008, EUR J GASTROEN HEPAT, V20, P196, DOI 10.1097/MEG.0b013e3282f1cc4a; Zhang WM, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1189-1	34	36	37	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3514	3527		10.1038/s41388-018-0169-4	http://dx.doi.org/10.1038/s41388-018-0169-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29559743				2022-12-28	WOS:000436412500004
J	Gerlach, D; Tontsch-Grunt, U; Baum, A; Popow, J; Scharn, D; Hofmann, MH; Engelhardt, H; Kaya, O; Beck, J; Schweifer, N; Gerstberger, T; Zuber, J; Savarese, F; Kraut, N				Gerlach, Daniel; Tontsch-Grunt, Ulrike; Baum, Anke; Popow, Johannes; Scharn, Dirk; Hofmann, Marco H.; Engelhardt, Harald; Kaya, Onur; Beck, Janina; Schweifer, Norbert; Gerstberger, Thomas; Zuber, Johannes; Savarese, Fabio; Kraut, Norbert			The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; SMALL NUCLEAR RIBONUCLEOPROTEIN; P-TEFB; SELECTIVE-INHIBITION; CELL IDENTITY; PROTEIN BRD4; C-MYC; ELONGATION; CANCER	Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical trials. This work presents a novel potent and selective BET inhibitor (BI 894999), which has recently entered clinical trials (NCT02516553). In preclinical studies, this compound is highly active in AML cell lines, primary patient samples, and xenografts. HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood. Mechanistic studies show that BI 894999 targets super-enhancer-regulated oncogenes and other lineage-specific factors, which are involved in the maintenance of the disease state. BI 894999 is active as monotherapy in AML xenografts, and in addition leads to strongly enhanced antitumor effects in combination with CDK9 inhibitors. This treatment combination results in a marked decrease of global p-Ser2 RNA polymerase II levels and leads to rapid induction of apoptosis in vitro and in vivo. Together, these data provide a strong rationale for the clinical evaluation of BI 894999 in AML.	[Gerlach, Daniel; Tontsch-Grunt, Ulrike; Baum, Anke; Popow, Johannes; Scharn, Dirk; Hofmann, Marco H.; Engelhardt, Harald; Kaya, Onur; Beck, Janina; Schweifer, Norbert; Gerstberger, Thomas; Savarese, Fabio; Kraut, Norbert] Boehringer Ingelheim RCV GmbH & Co KG, A-1120 Vienna, Austria; [Zuber, Johannes] Vienna BioCtr VBC, Res Inst Mol Pathol IMP, A-1030 Vienna, Austria; [Zuber, Johannes] Med Univ Vienna, Vienna BioCtr VBC, A-1030 Vienna, Austria	Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna; Vienna Biocenter (VBC)	Savarese, F; Kraut, N (corresponding author), Boehringer Ingelheim RCV GmbH & Co KG, A-1120 Vienna, Austria.	fabio.savarese@boehringer-ingelheim.com; norbert.kraut@boehringer-ingelheim.com	Zuber, Johannes/E-7517-2011	Zuber, Johannes/0000-0001-8810-6835; Gerlach, Daniel/0000-0001-9338-3765; Hofmann, Marco/0000-0001-7557-1156				Aftimos PG, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2504; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746; Berenguer-Daize C, 2016, INT J CANCER, V139, P2047, DOI 10.1002/ijc.30256; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561; Bres V, 2008, CURR OPIN CELL BIOL, V20, P334, DOI 10.1016/j.ceb.2008.04.008; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Coude MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Devaraj SGT, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3686; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Dukler N, 2017, NAT GENET, V49, P2, DOI 10.1038/ng.3759; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gressel S, 2017, ELIFE, V6, DOI 10.7554/eLife.29736; Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449; Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jonkers I, 2015, NAT REV MOL CELL BIO, V16, P167, DOI 10.1038/nrm3953; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lee YS, 2015, MOL CANCER THER, V14, pC202; Lin XY, 2017, MOL CANCER THER, V16, P388, DOI 10.1158/1535-7163.MCT-16-0475; Liu PY, 2014, J BIOL CHEM, V289, P9918, DOI 10.1074/jbc.M113.539015; Liu W, 2013, CELL, V155, P1581, DOI 10.1016/j.cell.2013.10.056; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Moreno N, 2017, ONCOTARGET, V8, P84986, DOI 10.18632/oncotarget.18583; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Rudolph D, 2015, J PHARMACOL EXP THER, V352, P579, DOI 10.1124/jpet.114.221150; Sarosiek KA, 2013, MOL CELL, V51, P751, DOI 10.1016/j.molcel.2013.08.048; Schuller R, 2016, MOL CELL, V61, P305, DOI 10.1016/j.molcel.2015.12.003; Shahbazi J, 2016, CLIN CANCER RES, V22, P2534, DOI 10.1158/1078-0432.CCR-15-1666; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Siegel MB, 2015, ONCOTARGET, V6, P18921, DOI 10.18632/oncotarget.4214; Simo-Riudalbas L, 2015, BRIT J PHARMACOL, V172, P2716, DOI 10.1111/bph.12844; Waizenegger IC, 2016, MOL CANCER THER, V15, P354, DOI 10.1158/1535-7163.MCT-15-0617; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785; Yeh TC, 2017, CLIN CANCER RES, V23, P1025, DOI 10.1158/1078-0432.CCR-16-1658; Yokoyama Y, 2016, CANCER RES, V76, P6320, DOI 10.1158/0008-5472.CAN-16-0854; Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	63	50	52	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2687	2701		10.1038/s41388-018-0150-2	http://dx.doi.org/10.1038/s41388-018-0150-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29491412	hybrid, Green Published			2022-12-28	WOS:000432545100006
J	Li, K; Zhang, TT; Wang, F; Cui, B; Zhao, CX; Yu, JJ; Lv, XX; Zhang, XW; Yang, ZN; Huang, B; Li, X; Hua, F; Hu, ZW				Li, Ke; zhang, Ting-ting; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Huang, Bo; Li, Xia; Hua, Fang; Hu, Zhuo-wei			Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression	ONCOGENE			English	Article							CELL-MIGRATION; BREAST-CANCER; DOUBLE-BLIND; TIP60; TRB3; PHOSPHORYLATION; PATHWAY; GROWTH; INVASION; KINASE	Metformin has beneficial effects of preventing and treating cancers on type 2 diabetic patients. However, the role of metformin in non-diabetic cancer patients and the precise molecular mechanisms against cancer have not yet been sufficiently elucidated. We recently reported that the pseudokinase protein TRIB3 acts as a stress sensor linking metabolic stressors to cancer promotion by inhibiting autophagy and ubiquitin-proteasomal degradation systems; genetically abrogating of TRIB3 expression reduces tumourigenesis and cancer progression. Thus, TRIB3 is a potential therapeutic target for diverse cancers. In this study, we found that metformin attenuates melanoma growth and metastasis by reducing TRIB3 expression in non-diabetic C57BL/6 mice and diabetic KK-Ay mice; overexpression of TRIB3 protects metformin from the activation of autophagic flux, the clearance of accumulated tumour-promoting factors and the attenuation of tumour progression. We further elucidated that TRIB3 acts as an adaptor to recruit lysine acetyltransferase 5 (KAT5) to SMAD3 and induce a phosphorylation-dependent K333 acetylation of SMAD3, which sustains transcriptional activity of SMAD3 and subsequently enhances TRIB3 transcription. Metformin suppresses SMAD3 phosphorylation and decreases the KAT5/SMAD3 interaction, to attenuate the KAT5-mediated K333 acetylation of SMAD3, reduce the SMAD3 transcriptional activity and subsequent TRIB3 expression, thereby antagonizes melanoma progression. Together, our study not only defines a molecular mechanism by which metformin protects against melanoma progression by disturbing the KAT5/TRIB3/SMAD3 positive feedback loop in diabetes and non-diabetes mice, but also suggests a candidate diverse utility of metformin in tumour prevention and therapy because of suppressing stress protein TRIB3 expression.	[Li, Ke; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Hua, Fang; Hu, Zhuo-wei] Chinese Acad Med Sci, Inst Mat Med, Immunol & Canc Pharmacol Grp, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China; [Li, Ke; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Huang, Bo; Hua, Fang; Hu, Zhuo-wei] Peking Union Med Coll, Beijing 100050, Peoples R China; [Li, Ke] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China; [zhang, Ting-ting; Li, Xia] Shandong Univ, Weihai 264209, Peoples R China; [Huang, Bo] Chinese Acad Med Sci, Inst Basic Med, Beijing 100050, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Biotechnology - CAMS; Shandong University; Chinese Academy of Medical Sciences - Peking Union Medical College	Hua, F; Hu, ZW (corresponding author), Chinese Acad Med Sci, Inst Mat Med, Immunol & Canc Pharmacol Grp, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.; Hua, F; Hu, ZW (corresponding author), Peking Union Med Coll, Beijing 100050, Peoples R China.	huafang@imm.ac.cn; huzhuowei@imm.ac.cn	Cui, Bing/F-3599-2018	Cui, Bing/0000-0001-8374-7801; hu, zhuowei/0000-0001-9569-1016	National Key R&D Program of China [2017YFA0205400]; National Natural Science Foundation of China [81530093, 81773781, 81101595, 81472717, 81400140, 81503128]; Beijing Natural Science Foundation [7162133]; CAMS Innovation Found for Medical Sciences [2016-I2M1-007, 2016-I2M-1-011, 2016-I2M-3-008, 2016-I2M-1-008]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); CAMS Innovation Found for Medical Sciences	This work was supported by grants from National Key R&D Program of China (2017YFA0205400), from National Natural Science Foundation of China (81530093, 81773781 to Z.W.H.; 81101595, 81472717 to F.H.; 81400140 to K.L., 81503128 to X.X.L.), from Beijing Natural Science Foundation (7162133 to F.H.), and from CAMS Innovation Found for Medical Sciences (2016-I2M1-007 to Z.W.H., F.H. and C.X.Z.; 2016-I2M-1-011 to K.L.; 2016-I2M-3-008 to B.C. and J.J.Y.; 2016-I2M-1-008 to X.X.L.).	Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Cerezo M, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12267; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Chen GD, 2012, J INVEST DERMATOL, V132, P2632, DOI 10.1038/jid.2012.193; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Higurashi T, 2016, LANCET ONCOL, V17, P475, DOI 10.1016/S1470-2045(15)00565-3; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hua F, 2015, AUTOPHAGY, V11, P1929, DOI 10.1080/15548627.2015.1084458; Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012; Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004; Jiang ZH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-88; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Li K, 2017, CANCER CELL, V31, P697, DOI 10.1016/j.ccell.2017.04.006; Li K, 2016, CANCER MED-US, V5, P1647, DOI 10.1002/cam4.706; Liang GZ, 2015, ONCOL LETT, V10, P1527, DOI 10.3892/ol.2015.3475; Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159-8290.CD-11-0280; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; Montaudie H, 2017, PIGM CELL MELANOMA R, V30, P378, DOI 10.1111/pcmr.12576; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Parker BL, 2014, J BIOL CHEM, V289, P25890, DOI 10.1074/jbc.M114.556035; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Preston MA, 2014, EUR UROL, V66, P1012, DOI 10.1016/j.eururo.2014.04.027; Quinn BJ, 2013, TRENDS ENDOCRIN MET, V24, P469, DOI 10.1016/j.tem.2013.05.004; Sayed Rana, 2015, Asian Pac J Cancer Prev, V16, P6621; Shiota M, 2010, PROSTATE, V70, P540, DOI 10.1002/pros.21088; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stades AME, 2004, J INTERN MED, V255, P179, DOI 10.1046/j.1365-2796.2003.01271.x; Takino T, 2016, CLIN EXP METASTAS, V33, P45, DOI 10.1007/s10585-015-9756-8; Tang PMK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14677; Tomcik M, 2016, ANN RHEUM DIS, V75, P609, DOI 10.1136/annrheumdis-2014-206234; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Tyteca S, 2006, MOL CELL, V24, P807, DOI 10.1016/j.molcel.2006.12.005; Wahdan-Alaswad R, 2016, CELL CYCLE, V15, P1046, DOI 10.1080/15384101.2016.1152432; Wang LK, 2012, NUCLEIC ACIDS RES, V40, pW376, DOI 10.1093/nar/gks437; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Wu IJ, 2017, ARCH BIOCHEM BIOPHYS, V622, P26, DOI 10.1016/j.abb.2017.04.008; Wu LF, 2016, CELL, V167, P1705, DOI 10.1016/j.cell.2016.11.055; Xiao H, 2016, SCI REP-UK, V6, DOI 10.1038/srep28597; Xiao H, 2010, CARDIOVASC RES, V87, P504, DOI 10.1093/cvr/cvq066; Xu WH, 2017, INT J MACH LEARN CYB, V8, P1, DOI 10.1007/s13042-016-0600-5; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou H, 2013, MOL MED REP, V8, P47, DOI 10.3892/mmr.2013.1453	58	29	32	6	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2967	2981		10.1038/s41388-018-0172-9	http://dx.doi.org/10.1038/s41388-018-0172-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29520103				2022-12-28	WOS:000433936300005
J	Lahusen, TJ; Kim, SJ; Miao, K; Huang, ZB; Xu, XL; Deng, CX				Lahusen, Tyler J.; Kim, Seung-Jin; Miao, Kai; Huang, Zebin; Xu, Xiaoling; Deng, Chu-Xia			BRCA1 function in the intra-S checkpoint is activated by acetylation via a pCAF/SIRT1 axis	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL REGULATION; PHASE CHECKPOINT; TUMOR-SUPPRESSOR; BREAST-CANCER; SIRT1; CHK1; PHOSPHORYLATION	Breast cancer associated gene 1 (BRCA1) function has been shown to be regulated by phosphorylation but the role of acetylation has not been determined. Therefore, we tested whether BRCA1 can be acetylated by the acetyltransferases P300/CBP-associated factor (pCAF), GCN5, and p300. p300 exhibited the highest level of BRCA1 acetylation; however, there was also a decrease in the total level of BRCA1. Therefore, we focused on pCAF and GCN5 because they both acetylated BRCA1 without affecting BRCA1 expression. Further analysis indicated that the acetylated form of BRCA1 is deacetylated by wild-type (WT) SIRT1, but not deacetylase mutant SIRT1, suggesting that SIRT1 is a specific deacetylase of BRCA1. We demonstrated that lysine 830 of BRCA1 is a preferential acetylation site by pCAF and tested its function in embryonic stem (ES) cells by changing lysine 830 to arginine using a transcription activator-like effector nuclease (TALEN) system. After exposure to DNA damage-inducing UV radiation, the viability of BRCA1 K830R mutant cells is greater than the WT ES cells. Further analysis using additional cell lines indicated that the BRCA1 K830R mutation impairs the intra-S checkpoint. Also, checkpoint kinase 1 (CHK1) phosphorylation was less in K830R cells as compared with WT cells after UV exposure. These data suggest that acetylation of BRCA1 on lysine 830 activates BRCA1 function at the intra-S checkpoint after DNA damage.	[Lahusen, Tyler J.; Kim, Seung-Jin; Deng, Chu-Xia] NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA; [Miao, Kai; Huang, Zebin; Xu, Xiaoling; Deng, Chu-Xia] Univ Macau, Fac Hlth Sci, Macau, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Macau	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.; Deng, CX (corresponding author), Univ Macau, Fac Hlth Sci, Macau, Peoples R China.	cxdeng@umac.mo			Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; Chair Professor Grant by University of Macau, Macau SAR, China [CPG2017-00026-FHS]; Macao Science and Technology Development Fund grants [065/2015/A2, 094/2015/A3]	Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; Chair Professor Grant by University of Macau, Macau SAR, China; Macao Science and Technology Development Fund grants	We thank Dr. Zhen Xiao for BRCA1 acetylation analysis and the members of the Deng laboratory for helpful discussion. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA, and by the Chair Professor Grant (CPG2017-00026-FHS), granted to C.D. by University of Macau, Macau SAR, China; Macao Science and Technology Development Fund grants (065/2015/A2 and 094/2015/A3), granted to C.D.	Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; Kim HB, 2015, INT J BIOL SCI, V11, P923, DOI 10.7150/ijbs.10896; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Luo JY, 2016, INT J BIOL SCI, V12, P1500, DOI 10.7150/ijbs.16176; Masuda T, 2016, INT J BIOL SCI, V12, P133, DOI 10.7150/ijbs.14242; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nielsen FC, 2016, NAT REV CANCER, V16, P599, DOI 10.1038/nrc.2016.72; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park EY, 2016, INT J BIOL SCI, V12, P1555, DOI 10.7150/ijbs.13833; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang RH, 2014, INT J BIOL SCI, V10, P1193, DOI 10.7150/ijbs.11066; Warmerdam DO, 2013, J CELL SCI, V126, P1923, DOI 10.1242/jcs.118265; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zheng HP, 2017, SCI REP-UK, V7, DOI 10.1038/srep43517	30	13	13	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2343	2350		10.1038/s41388-018-0127-1	http://dx.doi.org/10.1038/s41388-018-0127-1			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29440709				2022-12-28	WOS:000431100200010
J	Rauf, F; Festa, F; Park, JG; Magee, M; Eaton, S; Rinaldi, C; Betanzos, CM; Gonzalez-Malerva, L; LaBaer, J				Rauf, Femina; Festa, Fernanda; Park, Jin G.; Magee, Mitchell; Eaton, Seron; Rinaldi, Capria; Betanzos, Carlos Morales; Gonzalez-Malerva, Laura; LaBaer, Joshua			Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner	ONCOGENE			English	Article							BREAST-CANCER CELLS; GASTROINTESTINAL STROMAL TUMORS; OVARIAN-CANCER; THERAPEUTIC TARGET; IMATINIB MESYLATE; CATENIN PATHWAY; BTK INHIBITOR; EXPRESSION; MALIGNANCIES; MUTATIONS	Alterations in ERBB family members have been associated with many tumor malignancies. EGFR and ERBB2 have been extensively explored in clinical oncology and several drugs currently target them therapeutically. However, the significance of ERBB4 as a potential therapeutic target remains mostly unexplored, even though ERBB4 is overexpressed or mutated in many solid tumors. Using a unique functional protein microarray platform, we found that ibrutinib inhibits ERBB4 activity in the same nM range as its canonical target, BTK. Cell-based assays revealed that ibrutinib treatment inhibited cell growth and decreased phosphorylation of ERBB4 and downstream targets MEK and ERK in cancer cell lines with high levels of endogenous ERBB4. In vivo, ibrutinib-responsive mouse xenograft tumors showed decreased tumor volumes with ibrutinib treatment. Interestingly, global gene expression comparisons between responsive and non-responsive cells identified a signature featuring the WNT pathway that predicts growth responsiveness to ibrutinib. Non-responsive ERBB4-expressing cell lines featured elevated activity of the WNT pathway, through the overexpression of WNT5A. Moreover, inhibition of WNT5A expression led to an ibrutinib response in non-responsive cell lines. Our data show that inhibiting ERBB4 reduces cell growth in cells that have low WNT5A expression and reveal a link between the ERBB4 and WNT pathways.	[Rauf, Femina; Festa, Fernanda; Park, Jin G.; Magee, Mitchell; Eaton, Seron; Rinaldi, Capria; Betanzos, Carlos Morales; Gonzalez-Malerva, Laura; LaBaer, Joshua] Arizona State Univ, Virginia G Piper Biodesign Ctr Personalized Diagn, Tempe, AZ 85281 USA	Arizona State University; Arizona State University-Tempe	LaBaer, J (corresponding author), Arizona State Univ, Virginia G Piper Biodesign Ctr Personalized Diagn, Tempe, AZ 85281 USA.	jlabaer@asu.edu		Festa, Fernanda/0000-0002-2822-823X				Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anderson KS, 2011, J PROTEOME RES, V10, P85, DOI 10.1021/pr100686b; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Berglof A, 2015, SCAND J IMMUNOL, V82, P208, DOI 10.1111/sji.12333; Bian XF, 2017, J PROTEOME RES, V16, P195, DOI 10.1021/acs.jproteome.6b00354; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Davies S, 2014, INT J GYNECOL PATHOL, V33, P402, DOI 10.1097/PGP.0000000000000081; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Gilmour LMR, 2001, CANCER RES, V61, P2169; Grabinski N, 2014, INVEST NEW DRUG, V32, P1096, DOI 10.1007/s10637-014-0141-2; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kim JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2195-3; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Kurppa KJ, 2016, ONCOGENE, V35, P1283, DOI 10.1038/onc.2015.185; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Masso-Valles D, 2015, CANCER RES, V75, P1675, DOI 10.1158/0008-5472.CAN-14-2852; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Nakata A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13076; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112; Smith MR, 2015, EXPERT OPIN PHARMACO, V16, P1879, DOI 10.1517/14656566.2015.1067302; Wang XH, 2016, MOL CANCER THER, V15, P2198, DOI 10.1158/1535-7163.MCT-15-0813; Williams CS, 2015, CARCINOGENESIS, V36, P710, DOI 10.1093/carcin/bgv049; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Wu H, 2014, ACS CHEM BIOL, V9, P1086, DOI 10.1021/cb4008524	31	26	27	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2237	2250		10.1038/s41388-017-0079-x	http://dx.doi.org/10.1038/s41388-017-0079-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29398709	Green Published, hybrid			2022-12-28	WOS:000431100200003
J	Saatci, O; Borgoni, S; Akbulut, O; Durmus, S; Raza, U; Eyupoglu, E; Alkan, C; Akyol, A; Kutuk, O; Wiemann, S; Sahin, O				Saatci, Ozge; Borgoni, Simone; Akbulut, Ozge; Durmus, Selvi; Raza, Umar; Eyupoglu, Erol; Alkan, Can; Akyol, Aytekin; Kutuk, Ozgur; Wiemann, Stefan; Sahin, Ozgur			Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer	ONCOGENE			English	Article							POLO-LIKE KINASE; SPINDLE-ASSEMBLY CHECKPOINT; ANTIBODY-DRUG CONJUGATE; LOW-DOSE CYTARABINE; TRASTUZUMAB EMTANSINE; TUMOR HETEROGENEITY; GENE-EXPRESSION; MITOTIC ARREST; CELLS; MECHANISMS	Trastuzumab-refractory, HER2 (human epidermal growth factor receptor 2)-positive breast cancer is commonly treated with trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the microtubule-targeting agent, DM1. However, drug response reduces greatly over time due to acquisition of resistance whose molecular mechanisms are mostly unknown. Here, we uncovered a novel mechanism of resistance against T-DM1 by combining whole transcriptome sequencing (RNA-Seq), proteomics and a targeted small interfering RNA (siRNA) sensitization screen for molecular level analysis of acquired and de novo T-DM1-resistant models of HER2-overexpressing breast cancer. We identified Polo-like kinase 1 (PLK1), a mitotic kinase, as a resistance mediator whose genomic as well as pharmacological inhibition restored drug sensitivity. Both acquired and de novo resistant models exhibited synergistic growth inhibition upon combination of T-DM1 with a selective PLK1 inhibitor, volasertib, at a wide concentration range of the two drugs. Mechanistically, T-DM1 sensitization upon PLK1 inhibition with volasertib was initiated by a spindle assembly checkpoint (SAC)-dependent mitotic arrest, leading to caspase activation, followed by DNA damage through CDK1-dependent phosphorylation and inactivation of Bcl-2/xL. Furthermore, we showed that Ser70 phosphorylation of Bcl-2 directly regulates apoptosis by disrupting the binding to and sequestration of the pro-apoptotic protein Bim. Importantly, T-DM1 resistance signature or PLK1 expression correlated with cell cycle progression and DNA repair, and predicted a lower sensitivity to taxane/trastuzumab combination in HER2-positive breast cancer patients. Finally, volasertib in combination with T-DM1 greatly synergized in models of T-DM1 resistance in terms of growth inhibition both in three dimensional (3D) cell culture and in vivo. Altogether, our results provide promising pre-clinical evidence for potential testing of T-DM1/volasertib combination in T-DM1 refractory HER2-positive breast cancer patients for whom there is currently no treatment available.	[Saatci, Ozge; Akbulut, Ozge; Durmus, Selvi; Raza, Umar; Eyupoglu, Erol; Sahin, Ozgur] Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey; [Borgoni, Simone; Wiemann, Stefan] German Canc Res Ctr, Div Mol Genome Anal, INF580, D-69120 Heidelberg, Germany; [Alkan, Can] Bilkent Univ, Dept Comp Engn, TR-06800 Ankara, Turkey; [Akyol, Aytekin] Hacettepe Univ, Dept Pathol, Sch Med, TR-06410 Ankara, Turkey; [Kutuk, Ozgur] Baskent Univ, Dept Med Genet, TR-01250 Adana, Turkey; [Saatci, Ozge; Sahin, Ozgur] Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, TR-06800 Ankara, Turkey	Ihsan Dogramaci Bilkent University; Helmholtz Association; German Cancer Research Center (DKFZ); Ihsan Dogramaci Bilkent University; Hacettepe University; Baskent University; Ihsan Dogramaci Bilkent University	Saatci, O (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey.; Saatci, O (corresponding author), Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, TR-06800 Ankara, Turkey.	sahinozgur@gmail.com	Sahin, Özgür/F-4403-2014; Akbulut Çalışkan, Özge/Q-8134-2018; Akyol, Aytekin/B-6384-2009; Wiemann, Stefan/E-4424-2013; Durmus, Selvi/J-2075-2018; Alkan, Can/D-2982-2009; KUTUK, OZGUR/AAH-1671-2019	Sahin, Özgür/0000-0002-8033-7089; Akbulut Çalışkan, Özge/0000-0002-3647-1969; Akyol, Aytekin/0000-0002-4075-3475; Wiemann, Stefan/0000-0003-4683-3174; Durmus, Selvi/0000-0003-3792-1607; Alkan, Can/0000-0002-5443-0706; KUTUK, OZGUR/0000-0001-9854-7220; Borgoni, Simone/0000-0003-3833-0032; raza, umar/0000-0002-0081-6996	TUBITAK-BMBF Bilateral Grant [214Z130, 01DL16003]; EMBO Installation Grant [2791]; Genentech, USA Inc. [OR-213615]; Baskent University; The Science Academy	TUBITAK-BMBF Bilateral Grant; EMBO Installation Grant; Genentech, USA Inc.(Roche HoldingGenentech); Baskent University(Baskent University); The Science Academy	This project was supported by TUBITAK-BMBF Bilateral Grant numbers: TUBITAK, 214Z130 (to OS) and BMBF WTZ, 01DL16003 (to SW). OS further acknowledges the support from EMBO Installation Grant Number 2791. Special thanks to Genentech, USA Inc. for providing us with T-DM1 under Material Transfer Agreement with MTA number OR-213615. We thank the DKFZ Genomics and Proteomics Core Facility for providing sequencing excellent services. We also thank Deniz Atasoy and Pelin Dilsiz from Istanbul Medipol University for their help with confocal microscopy. OK acknowledges support from Baskent University and The Science Academy.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Barok M, 2007, MOL CANCER THER, V6, P2065, DOI 10.1158/1535-7163.MCT-06-0766; Barok M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3621; Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Cheng L, 2015, CURR PHARM DESIGN, V21, P1347, DOI 10.2174/1381612820999141029162811; Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110; DeAngelo DJ, 2015, CL LYMPH MYELOM LEUK, V15, pS194, DOI 10.1016/j.clml.2015.04.046; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Gagliato DD, 2016, ONCOTARGET, V7, P64431, DOI 10.18632/oncotarget.7043; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Hain KO, 2016, SCI REP-UK, V6, DOI 10.1038/srep26766; Hayashi T, 2015, J UROLOGY, V194, P1120, DOI 10.1016/j.juro.2015.05.087; Henjes F, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.16; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee KS, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-4; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LoRusso PM, 2011, CLIN CANCER RES, V17, P6437, DOI 10.1158/1078-0432.CCR-11-0762; MAGER PP, 1981, PHARMAZIE, V36, P382; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Mutlu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32541; Nicoletti R, 2015, CLIN EXP METASTAS, V32, P29, DOI 10.1007/s10585-014-9688-8; Oroudjev E, 2010, MOL CANCER THER, V9, P2700, DOI 10.1158/1535-7163.MCT-10-0645; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rantanen S, 2001, LEUKEMIA LYMPHOMA, V42, P1089, DOI 10.3109/10428190109097729; Raza U, 2016, ONCOTARGET, V7, P49859, DOI 10.18632/oncotarget.10489; Recondo G, 2016, CANCER MANAG RES, V8, P57, DOI 10.2147/CMAR.S104447; Roden DM, 2011, CIRCULATION, V123, P1661, DOI 10.1161/CIRCULATIONAHA.109.914820; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonntag J, 2014, EXPERT REV PROTEOMIC, V11, P757, DOI 10.1586/14789450.2014.971113; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tanner M, 2004, MOL CANCER THER, V3, P1585; Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062; Trakala M, 2015, BLOOD, V126, P1707, DOI 10.1182/blood-2015-03-634402; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wang QF, 2012, CANCER RES, V72, P4417, DOI 10.1158/0008-5472.CAN-12-1339-T; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wright N, 2017, FRONT BIOSCI-LANDMRK, V22, P1549, DOI 10.2741/4558; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Yamada HY, 2006, MOL CANCER THER, V5, P2963, DOI 10.1158/1535-7163.MCT-06-0319; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yim H, 2013, ANTI-CANCER DRUG, V24, P999, DOI 10.1097/CAD.0000000000000007; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	75	32	35	0	37	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2251	2269		10.1038/s41388-017-0108-9	http://dx.doi.org/10.1038/s41388-017-0108-9			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391599	Green Published			2022-12-28	WOS:000431100200004
J	Balamurugan, K; Mendoza-Villanueva, D; Sharan, S; Summers, GH; Dobrolecki, LE; Lewis, MT; Sterneck, E				Balamurugan, Kuppusamy; Mendoza-Villanueva, Daniel; Sharan, Shikha; Summers, Glenn H.; Dobrolecki, Lacey E.; Lewis, Michael T.; Sterneck, Esta			C/EBP delta links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes	ONCOGENE			English	Article						Hypoxia; IL-6; Breast cancer; Cancer stem cells; C/EBP; CEBPD; Inflammation; FBXW7; NOTCH; MYC	TUMOR-INITIATING CELLS; EXPRESSION; IDENTIFICATION; INFLAMMATION; METASTASIS; CARCINOMA; PATHWAY; MODELS; DRIVER	To improve cancer patient outcome significantly, we must understand the mechanisms regulating stem-like cancer cells, which have been implicated as a cause of metastasis and treatment resistance. The transcription factor C/EBP delta can exhibit pro- and anti-tumorigenic activities, but the mechanisms underlying the complexity of its functions are poorly understood. Here we identify a role for breast cancer cell intrinsic C/EBP delta in promoting phenotypes that have been associated with cancer stem cells (CSCs). While C/EBP delta expression is not abundant in most metastatic breast cancers, our data support a pro-tumorigenic role of C/EBP delta when expressed in subsets of tumor cells and/or through transient activation by the tumor microenvironment or loss of substrate adhesion. Using genetic mouse models and human breast cancer cell lines, we show that deletion or depletion of C/EBP delta reduced expression of stem cell factors and stemnness markers, sphere formation and self-renewal, along with growth of tumors and established experimental metastases in vivo. C/EBP delta is also known as a mediator of the innate immune response, which is enhanced by hypoxia and interleukin-6 (IL-6) signaling, two conditions that also play important roles in cancer progression. Our mechanistic data reveal C/EBP delta as a link that engages two positive feedback loops, in part by directly targeting the IL-6 receptor (IL6RA) gene, and, thus, amplifying IL-6 and HIF-1 signaling. This study provides a molecular mechanism for the synergism of tumor microenvironmental conditions in cancer progression with potential implications for the targeting of CSCs.	[Balamurugan, Kuppusamy; Mendoza-Villanueva, Daniel; Sharan, Shikha; Sterneck, Esta] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA; [Summers, Glenn H.] Leidos Biomed Res Inc, Lab Anim Sci Program, Frederick, MD 21702 USA; [Dobrolecki, Lacey E.; Lewis, Michael T.] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dobrolecki, Lacey E.; Lewis, Michael T.] Baylor Coll Med, Dept Radiol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Mendoza-Villanueva, Daniel] Mission Bio, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; Baylor College of Medicine	Balamurugan, K; Sterneck, E (corresponding author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA.	kuppusamyb@mail.nih.gov; sternecg@mail.nih.gov	Kuppusamy, Balamurugan/AAC-6020-2022; Lewis, Michael T/A-9572-2009	Sterneck, Esta/0000-0001-7716-8766	Intramural Research Program of the NIH, National Cancer Institute; Frederick Cancer Institute (NIH) [HHSN261200800001E]; BCRF Founders Fund Grant [CPRIT DP150069]; V-Foundation grant [T2014-010]; NATIONAL CANCER INSTITUTE [ZIABC010307] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frederick Cancer Institute (NIH); BCRF Founders Fund Grant; V-Foundation grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful for superb support through services provided by Leidos Biomedical Research, Inc., FNLCR (Laboratory Animal Sciences Program, Protein Expression Laboratory, Illustrations, and Graphical Support); and the NCI/CCR cores (Small Animal Imaging, Flow Cytometry, Optical Microscopy, and Analysis Laboratory); and Data Management Services, Inc. for assistance with Statistics. We thank Linda Miller, Suzanne Specht, Rena Mao, and the student interns for their valuable contributions; Heidi Dowst for providing clinical information related to the PDX models; and all the investigators who kindly shared their valuable reagents (see Methods) or provided critical comments on the manuscript. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, in part with Federal Funds from the Frederick Cancer Institute (NIH) under contract no. HHSN261200800001E. LED and MTL were supported by BCRF Founders Fund Grant CPRIT DP150069 and V-Foundation grant T2014-010. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Brower V, 2016, JNCI-J NATL CANCER I, V108, P2; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen JC, 2014, CELL, V159, P402, DOI 10.1016/j.cell.2014.09.021; Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Dobrolecki LE, 2016, CANCER METAST REV, V35, P547, DOI 10.1007/s10555-016-9653-x; Espinoza I, 2013, ONCOTARGETS THER, V6, P1249, DOI 10.2147/OTT.S36162; Fallah Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030053; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Gwak JM, 2017, ONCOTARGET, V8, P36305, DOI 10.18632/oncotarget.16750; Harrison H, 2013, CANCER RES, V73, P1420, DOI 10.1158/0008-5472.CAN-12-2505; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lagadec C, 2014, STEM CELLS, V32, P135, DOI 10.1002/stem.1537; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Mamlouk S, 2013, INT J CANCER, V132, P2721, DOI 10.1002/ijc.27901; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Mendoza-Villanueva D, 2016, ONCOGENE, V35, P6166, DOI 10.1038/onc.2016.156; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Min Y, 2011, ONCOGENE, V30, P4901, DOI 10.1038/onc.2011.187; Min YF, 2017, ONCOTARGET, V8, P50582, DOI 10.18632/oncotarget.16410; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rustighi A, 2014, EMBO MOL MED, V6, P99, DOI 10.1002/emmm.201302909; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Seymour T, 2015, INT J MOL SCI, V16, P27288, DOI 10.3390/ijms161126024; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang YH, 2015, ONCOTARGET, V6, P31069, DOI 10.18632/oncotarget.5209; Watanabe M, 2014, CYTOM PART A, V85, P206, DOI 10.1002/cyto.a.22422; Wei W, 2015, ENDOCR-RELAT CANCER, V22, pR135, DOI 10.1530/ERC-14-0447; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; Yamaguchi J, 2015, KIDNEY INT, V88, P262, DOI 10.1038/ki.2015.21; Yan WX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-62; Yang AM, 2017, CANCER RES, V77, P6641, DOI 10.1158/0008-5472.CAN-16-3452; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3; 2012, ONCOGENE, V31, P2614, DOI DOI 10.1038/ONC.2011.439	49	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3765	3780		10.1038/s41388-018-0516-5	http://dx.doi.org/10.1038/s41388-018-0516-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30262865	Green Accepted			2022-12-28	WOS:000468035600001
J	Klug, LR; Bannon, AE; Javidi-Sharifi, N; Town, A; Fleming, WH; VanSlyke, JK; Musil, LS; Fletcher, JA; Tyner, JW; Heinrich, MC				Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; VanSlyke, Judy K.; Musil, Linda S.; Fletcher, Jonathan A.; Tyner, Jeffrey W.; Heinrich, Michael C.			LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; TYROSINE KINASE; C-KIT; THERAPEUTIC TARGET; MOUSE MODEL; PHASE-II; PROTEIN PHOSPHATASE-1; GENE-MUTATIONS; DOSE IMATINIB	Certain cancers, including gastrointestinal stromal tumor (GIST) and subsets of melanoma, are caused by somatic KIT mutations that result in KIT receptor tyrosine kinase constitutive activity, which drives proliferation. The treatment of KIT-mutant GIST has been revolutionized with the advent of KIT-directed cancer therapies. KIT tyrosine kinase inhibitors (TKI) are superior to conventional chemotherapy in their ability to control advanced KIT-mutant disease. However, these therapies have a limited duration of activity due to drug-resistant secondary KIT mutations that arise (or that are selected for) during KIT TKI treatment. To overcome the problem of KIT TKI resistance, we sought to identify novel therapeutic targets in KIT-mutant GIST and melanoma cells using a human tyrosine kinome siRNA screen. From this screen, we identified lemur tyrosine kinase 3 (LMTK3) and herein describe its role as a novel KIT regulator in KIT-mutant GIST and melanoma cells. We find that LMTK3 regulated the translation rate of KIT, such that loss of LMTK3 reduced total KIT, and thus KIT downstream signaling in cancer cells. Silencing of LMTK3 decreased cell viability and increased cell death in KIT-dependent, but not KIT-independent GIST and melanoma cell lines. Notably, LMTK3 silencing reduced viability of all KIT-mutant cell lines tested, even those with drug-resistant KIT secondary mutations. Furthermore, targeting of LMTK3 with siRNA delayed KIT-dependent GIST growth in a xenograft model. Our data suggest the potential of LMTK3 as a target for treatment of patients with KIT-mutant cancer, particularly after failure of KIT TKIs.	[Klug, Lillian R.; Bannon, Amber E.; Town, Ajia; Heinrich, Michael C.] Portland VA Hlth Care Syst, Portland, OR 97239 USA; [Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; Tyner, Jeffrey W.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; Tyner, Jeffrey W.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Fleming, William H.] Oregon Hlth & Sci Univ, Dept Pediat, Oregon Stem Cell Ctr, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA; [VanSlyke, Judy K.; Musil, Linda S.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; [Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pediat, 75 Francis St, Boston, MA 02115 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Klug, LR (corresponding author), Portland VA Hlth Care Syst, Portland, OR 97239 USA.; Klug, LR (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Klug, LR (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.	klugl@ohsu.edu	Heinrich, Michael/AAC-6745-2019	Heinrich, Michael/0000-0003-3790-0478	VA Merit Review Grants [1I01BX000338-01, 2I01BX000338-05]; GIST Cancer Research Fund; Life Raft Group; V Foundation for Cancer Research; Leukemia & Lymphoma Society; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [TL1 RR024159]; NIH Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R00CA151457, R01CA183974] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024159] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000338] Funding Source: NIH RePORTER	VA Merit Review Grants(US Department of Veterans Affairs); GIST Cancer Research Fund; Life Raft Group; V Foundation for Cancer Research; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Veterans Affairs(US Department of Veterans Affairs)	L.R. Klug, A. Town, A.E. Bannon, and M.C. Heinrich were supported by VA Merit Review Grants 1I01BX000338-01 and 2I01BX000338-05. M.C. Heinrich was also supported by the GIST Cancer Research Fund and the Life Raft Group. L.R. Klug, W.H. Fleming, J.W. Tyner, and M.C. Heinrich were supported by the V Foundation for Cancer Research. J.W. Tyner was supported by the Leukemia & Lymphoma Society, Gabrielle's Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). N. Javidi-Sharifi was supported by the Oregon Clinical and Translational Research Institute (OCTRI), grant number TL1 RR024159 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and NIH Roadmap for Medical Research.	Agarwal A, 2016, METHODS MOL BIOL, V1470, P85, DOI 10.1007/978-1-4939-6337-9_7; An NF, 2016, EXP HEMATOL ONCOL, V5, P1, DOI 10.1186/s40164-016-0060-3; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bannon AE, 2017, EXPERT REV MOL DIAGN, V17, P445, DOI 10.1080/14737159.2017.1308826; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Carvajal RD, 2015, CLIN CANCER RES, V21, P2289, DOI 10.1158/1078-0432.CCR-14-1630; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; DeMatteo RP, 2002, HUM PATHOL, V33, P466, DOI 10.1053/hupa.2002.124122; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Edmonson JH, 2002, CANCER INVEST, V20, P605, DOI 10.1081/CNV-120002485; Gagnon KBE, 2007, AM J PHYSIOL-CELL PH, V292, pC1809, DOI 10.1152/ajpcell.00580.2006; Garner AP, 2014, CLIN CANCER RES, V20, P5745, DOI 10.1158/1078-0432.CCR-14-1397; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gramza AW, 2009, CLIN CANCER RES, V15, P7510, DOI 10.1158/1078-0432.CCR-09-0190; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Jacob J, 2016, CANCER LETT, V372, P137, DOI 10.1016/j.canlet.2015.12.026; Javidi-Sharifi N, 2015, CANCER RES, V75, P880, DOI 10.1158/0008-5472.CAN-14-0573; Kajimoto N, 2015, INT J CLIN EXP PATHO, V8, P11970; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakai N, 2008, J PATHOL, V214, P302, DOI 10.1002/path.2296; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Rossi F, 2010, MOL CANCER RES, V8, P1271, DOI 10.1158/1541-7786.MCR-10-0065; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sakurama K, 2009, MOL CANCER THER, V8, P127, DOI 10.1158/1535-7163.MCT-08-0884; Spencer KR, 2016, CANCER TREAT RES, V167, P295, DOI 10.1007/978-3-319-22539-5_13; Stebbing J, 2013, ONCOGENE, V32, P3371, DOI 10.1038/onc.2012.343; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Takahashi T, 2013, INT J CANCER, V133, P2737, DOI 10.1002/ijc.28282; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tomomura M, 2007, NEUROSCIENCE, V148, P510, DOI 10.1016/j.neuroscience.2007.05.048; Tyner JW, 2008, BLOOD, V111, P2238, DOI 10.1182/blood-2007-06-097253; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Weisberg E, 2003, DRUG RESIST UPDATE, V6, P231, DOI 10.1016/S1368-7646(03)00062-1; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; Xu YC, 2015, CELL REP, V12, P837, DOI 10.1016/j.celrep.2015.06.073; Xu YC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005170	48	8	10	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1200	1210		10.1038/s41388-018-0508-5	http://dx.doi.org/10.1038/s41388-018-0508-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30242244	Green Accepted			2022-12-28	WOS:000459249800004
J	Lau, BW; Huh, K; Madero-Marroquin, R; De Marchi, F; Lim, Y; Wang, QJ; Lobo, F; Marchionni, L; Smith, DB; DeZern, A; Levis, MJ; Aplan, PD; Matsui, W; Gondek, LP				Lau, Bonnie W.; Huh, Kyounghee; Madero-Marroquin, Rafael; De Marchi, Federico; Lim, Yiting; Wang, Qiuju; Lobo, Francisco; Marchionni, Luigi; Smith, Douglas B.; DeZern, Amy; Levis, Mark J.; Aplan, Peter D.; Matsui, William; Gondek, Lukasz P.			Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; STEM-CELLS; TRANSCRIPTION FACTOR; PATHWAY ACTIVATION; SIGNALING PATHWAYS; SCORING SYSTEM; HUMAN HOMOLOG; EARLY DEATH; PREDICTION; EVOLUTION	Myelodysplastic syndromes (MDSs) are stem cell disorders with risk of transformation to acute myeloid leukemia (AML). Gene expression profiling reveals transcriptional expression of GLI1, of Hedgehog (Hh) signaling, in poor-risk MDS/AML. Using a murine model of MDS we demonstrated that constitutive Hh/Gli1 activation accelerated leukemic transformation and decreased overall survival. Hh/Gli1 activation resulted in clonal expansion of phenotypically defined granulocyte macrophage progenitors (GMPs) and acquisition of self-renewal potential in a non-self-renewing progenitor compartment. Transcriptome analysis of GMPs revealed enrichment in gene signatures of self-renewal pathways, operating via direct Gli1 activation. Using human cell lines we demonstrated that in addition to canonical Hh signaling, GLI1 is activated in a Smoothened-independent manner. GLI1 knockdown or inhibition with GANT61 resulted in decreased proliferation and clonogenic potential. Our data suggest that GLI1 activation is frequent in MDS during disease progression and inhibition of GLI1 is an attractive therapeutic target for a subset of patients.	[Lau, Bonnie W.; Huh, Kyounghee; Madero-Marroquin, Rafael; De Marchi, Federico; Lim, Yiting; Wang, Qiuju; Lobo, Francisco; Marchionni, Luigi; Smith, Douglas B.; DeZern, Amy; Levis, Mark J.; Gondek, Lukasz P.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Lim, Yiting] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Lobo, Francisco] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Biol Geral, Belo Horizonte, MG, Brazil; [Aplan, Peter D.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Matsui, William] Univ Texas Austin, Dell Med Sch, LIVESTRONG Canc Inst, Austin, TX 78712 USA	Johns Hopkins University; Johns Hopkins Medicine; Fred Hutchinson Cancer Center; Universidade Federal de Minas Gerais; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Austin	Gondek, LP (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.; Matsui, W (corresponding author), Univ Texas Austin, Dell Med Sch, LIVESTRONG Canc Inst, Austin, TX 78712 USA.	matsuwi@jhmi.edu; lgondek1@jhmi.edu	Lobo, Francisco Pereira/AAG-3118-2021; Marchionni, Luigi/S-6774-2017	Lobo, Francisco Pereira/0000-0002-9671-9313; Marchionni, Luigi/0000-0002-7336-8071	National Institute of Health [K08 HL136894]; Edward P. Evans Foundation; Sidney Kimmel Comprehensive Cancer Center Core Facilities [P30 CA006973]; NATIONAL CANCER INSTITUTE [P30CA006973, ZIABC010983, K24CA198315] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL136894] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward P. Evans Foundation; Sidney Kimmel Comprehensive Cancer Center Core Facilities; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to acknowledge Dr. David Huso, previously an Associate Professor in the Department of Molecular and Comparative Pathobiology at Johns Hopkins, for preparing the histology slides; and Dr. Hao Zhang, Research Associate in the Department of Molecular Microbiology and Immunology at Johns Hopkins, for helping to sort the murine bone marrow for cell subpopulations. This work was supported by grants from the National Institute of Health (K08 HL136894) (LPG) and Edward P. Evans Foundation (LPG). Flow cytometry and microarray analysis was performed with the support of the Sidney Kimmel Comprehensive Cancer Center Core Facilities (P30 CA006973).	Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Brechbiel J, 2014, CANCER TREAT REV, V40, P750, DOI 10.1016/j.ctrv.2014.02.003; Chaudhry P, 2017, BLOOD, V129, P3465, DOI 10.1182/blood-2016-05-718585; CORTES JE, 2016, BLOOD, V128; Dagklis A, 2016, BLOOD, V128, P2642, DOI 10.1182/blood-2016-03-703454; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Fenaux P, 2011, BLOOD, V118, P3765, DOI 10.1182/blood-2011-01-330126; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Gerstung M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6901; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang Y, 2009, BLOOD, V113, P1315, DOI 10.1182/blood-2008-06-163246; Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008-5472.CAN-10-2993; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Joo J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007608; Kang HJ, 2015, KOREAN J RADIOL, V16, P1068, DOI 10.3348/kjr.2015.16.5.1068; Kobune M, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.36; Krug U, 2010, LANCET, V376, P2000, DOI 10.1016/S0140-6736(10)62105-8; LANCET JE, 2016, BLOOD, V128; Lim Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9303; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Liu Z, 2014, ONCOGENE, V33, P65, DOI 10.1038/onc.2012.544; Long B, 2016, CELL PHYSIOL BIOCHEM, V38, P1288, DOI 10.1159/000443075; Makishima H, 2017, NAT GENET, V49, P204, DOI 10.1038/ng.3742; Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Martinelli G, 2015, LANCET HAEMATOL, V2, pE339, DOI 10.1016/S2352-3026(15)00096-4; McMillan R, 2012, CLIN CANCER RES, V18, P4883, DOI 10.1158/1078-0432.CCR-11-2509; Meggendorfer M, 2015, HAEMATOLOGICA, V100, pE487, DOI 10.3324/haematol.2015.127985; Merchant A, 2010, BLOOD, V115, P2391, DOI 10.1182/blood-2009-09-241703; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Ringuette R, 2016, DEV BIOL, V411, P85, DOI 10.1016/j.ydbio.2016.01.006; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Seto M, 2009, MOL CARCINOGEN, V48, P703, DOI 10.1002/mc.20516; Tefferi A, 2015, AM J HEMATOL, V90, P831, DOI 10.1002/ajh.24102; Tefferi A, 2009, NEW ENGL J MED, V361, P1872, DOI 10.1056/NEJMra0902908; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Walter RB, 2011, J CLIN ONCOL, V29, P4417, DOI 10.1200/JCO.2011.35.7525; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wellbrock J, 2015, CLIN CANCER RES, V21, P2388, DOI 10.1158/1078-0432.CCR-14-1059; Xavier-Ferrucio JM, 2015, HAEMATOLOGICA, V100, pE491, DOI 10.3324/haematol.2015.124040; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zou JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136843; Zou JX, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/957502; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	51	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					687	698		10.1038/s41388-018-0431-9	http://dx.doi.org/10.1038/s41388-018-0431-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171262	Green Accepted			2022-12-28	WOS:000457300300006
J	Bao, YH; Guo, YC; Yang, YQ; Wei, XN; Zhang, SS; Zhang, YM; Li, K; Yuan, M; Guo, DL; Macias, V; Zhu, XD; Zhang, W; Yang, WC				Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhang, Shanshan; Zhang, Yongmeng; Li, Kai; Yuan, Ming; Guo, Dongli; Macias, Virgilia; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai			PRSS8 suppresses colorectal carcinogenesis and metastasis	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; BETA-CATENIN; IN-VITRO; CANCER; PROSTASIN; INVASIVENESS; LOCALIZATION; INFLAMMATION; WNT; APC	The serine protease PRSS8 has shown important physiological and pathological functions, but its roles in cancer initiation and progression are unclear. We developed and dynamically characterized a conditional knockout Prss8(fl/fl), p-Villin-Cre(+) mouse model. We found that genetic deficiency of the Prss8 gene caused spontaneous colitis and an inflamed rectum at an early age and caused intestinal tumors at a late age, which were linked to increased intestinal cell proliferation and migration but decreased cell differentiation. Increased PRSS8 expression inhibited cancer cell growth and metastasis in nude mice and inhibited cancer cell migration, invasion, colony formation and tumor sphere formation in vitro, but decreased PRSS8 expression facilitated malignancies in vivo and in vitro. Gene profiling on manipulated cancer cells and intestinal epithelial cells of Prss8 mouse models, gene set enrichment analysis and mechanistic studies revealed that PRSS8 targeted the Wnt/beta-catenin, epithelial-mesenchymal transition, and stem cell signaling pathways, which were further supported by the results from the TCGA data mining and validated by immunohistochemical staining on colorectal cancer tissue microarrays. In conclusion, PRSS8 is a novel tumor suppressor that plays critical roles in the suppression of colorectal carcinogenesis and metastasis.	[Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai] Jining Med Univ, Dept Pathol, Jining 272067, Peoples R China; [Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai] Jining Med Univ, Inst Precis Med, Jining 272067, Peoples R China; [Zhang, Shanshan; Zhang, Yongmeng; Li, Kai; Yuan, Ming] Xinxiang Med Univ, Dept Pathol, Xinxiang 453003, Peoples R China; [Guo, Dongli] Jining Med Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Jining 272067, Peoples R China; [Macias, Virgilia; Yang, Wancai] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; [Zhu, Xiangdong] Univ Illinois, Dept Emergency Med, Chicago, IL 60612 USA; [Zhang, Wei] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA	Jining Medical University; Jining Medical University; Xinxiang Medical University; Jining Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University	Yang, WC (corresponding author), Jining Med Univ, Dept Pathol, Jining 272067, Peoples R China.; Yang, WC (corresponding author), Jining Med Univ, Inst Precis Med, Jining 272067, Peoples R China.; Yang, WC (corresponding author), Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.	wyang06@uic.edu	Yang, Wancai/O-7655-2019	Yang, Wancai/0000-0001-7437-9197; Zhang, Wei/0000-0003-0875-263X	National Nature Science Foundation of China [81672750, 91229115, 81502105]; Key Laboratory of Higher Education Institutes of Shandong Province; Nature Science Foundation of Shandong Province [2016ZRB14436]; Taishan Scholar Program of Shandong Province, China; Innovation Team of Science and Technology, Henan Province, China; Startup Fund from Jining Medical University; Fostering fund from Jining Medical University	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Higher Education Institutes of Shandong Province; Nature Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Taishan Scholar Program of Shandong Province, China; Innovation Team of Science and Technology, Henan Province, China; Startup Fund from Jining Medical University; Fostering fund from Jining Medical University	This work was supported in part by grants from the National Nature Science Foundation of China (grants 81672750 and 91229115 to WY, grant 81502105 to YB), a grant from the Key Laboratory of Higher Education Institutes of Shandong Province, the Nature Science Foundation of Shandong Province (grant 2016ZRB14436 to YG) and Taishan Scholar Program of Shandong Province, China, a grant from the Innovation Team of Science and Technology, Henan Province, China, the Startup Fund from Jining Medical University (to YB and YG) and Fostering fund from Jining Medical University (to YG). We would like to thank Prof. Weixing Zhao (Xinxiang Medical University, Xinxiang, China), Prof. Renya Zhang (Jining Medical University, Jining, China) and Prof. Anjia Han (Sun Yat-sen University, Guangzhou, China) for assistance with the histopathology analysis of the mouse models, Prof. Alan Diamond (University of Illinois at Chicago, Chicago, USA) for critical discussion, and Springer Nature Author Services for editing this manuscript. We would also like to thank the Research Histology and Tissue Imaging Core (RHTIC) facility at the University of Illinois at Chicago (Chicago, IL) for their technical assistance.	Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bao YH, 2016, ONCOTARGET, V7, P28540, DOI 10.18632/oncotarget.8677; Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511; Bao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099132; Baranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bi XL, 2012, CARCINOGENESIS, V33, P326, DOI 10.1093/carcin/bgr293; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Chen LM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-377; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DOKI Y, 1993, CANCER RES, V53, P3421; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hooper JD, 2000, BBA-GENE STRUCT EXPR, V1492, P63, DOI 10.1016/S0167-4781(00)00071-3; Hu D, 2008, CARCINOGENESIS, V29, P2317, DOI 10.1093/carcin/bgn239; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Keppner A, 2016, INFLAMM BOWEL DIS, V22, P2824, DOI 10.1097/MIB.0000000000000940; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Mokry M, 2012, NUCLEIC ACIDS RES, V40, P148, DOI 10.1093/nar/gkr720; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; OKA H, 1993, CANCER RES, V53, P1696; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Paoni NF, 2003, PHYSIOL GENOMICS, V15, P228, DOI 10.1152/physiolgenomics.00078.2003; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Rodriguez-Salas N, 2017, CRIT REV ONCOL HEMAT, V109, P9, DOI 10.1016/j.critrevonc.2016.11.007; Sakashita K, 2008, J SURG ONCOL, V98, P559, DOI 10.1002/jso.21158; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sarojini S, 2012, J ONCOL, V2012, DOI 10.1155/2012/709049; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Uchimura K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4428; UMBAS R, 1994, CANCER RES, V54, P3929; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Yu JX, 1996, GENOMICS, V32, P334, DOI 10.1006/geno.1996.0127; YU JX, 1994, J BIOL CHEM, V269, P18843	50	15	15	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					497	517		10.1038/s41388-018-0453-3	http://dx.doi.org/10.1038/s41388-018-0453-3			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30115975				2022-12-28	WOS:000456589800004
J	Sarwar, M; Khaja, ASS; Aleskandarany, M; Karlsson, R; Althobiti, M; Odum, N; Mongan, NP; Dizeyi, N; Johnson, H; Green, AR; Ellis, IO; Rakha, EA; Persson, JL				Sarwar, Martuza; Khaja, Azharuddin Sajid Syed; Aleskandarany, Mohammed; Karlsson, Richard; Althobiti, Maryam; Odum, Niels; Mongan, Nigel P.; Dizeyi, Nisthman; Johnson, Heather; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.; Persson, Jenny L.			The role of PIP5K1 alpha/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 alpha inhibitor	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; ESTROGEN-RECEPTOR; METASTASIS; EXPRESSION; PREVENTION; RESISTANCE; PATHWAY; PROTEIN; ALPHA; BONE	Despite recent improvement in adjuvant therapies, triple-negative, and ER+ subtypes of breast cancer (BC) with metastatic potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5K alpha), a key upstream factor of PI3K/AKT, and the therapeutic effect of PIP5K alpha inhibitor on subtypes of BC. The clinical importance of PIP5K1 alpha and its association with survivals were analyzed using three BC cohorts from Nottingham (n = 913), KM plotter (n = 112) and TCGA (n = 817). Targeted overexpression or knockdown of PIP5K1 alpha were introduced into BC cell lines. The effects of PIP5K1 alpha and its inhibitor on growth and invasion of BC were confirmed by using in vitro assays including proliferation, migration, apoptosis and luciferase reporter assays and in vivo xenograft mouse models. All statistical tests were two-sided. PIP5K1 alpha was associated with poor patient outcome in triple-negative BC (for PIP5K1 alpha protein, p = 0.011 and for mRNA expression, p = 0.028, log-rank test). 29% of triple-negative BC had PIP5K1A gene amplification. Elevated level of PIP5K1 alpha increased expression of pSer-473 AKT (p < 0.001) and invasiveness of triple-negative MDA-MB-231 cells (p < 0.001). Conversely, inhibition of PIP5K1 alpha using its inhibitor ISA-2011B, or via knockdown suppressed growth and invasiveness of MDA-MB-231 xenografts (mean vehicle-treated controls = 2160 mm(3), and mean ISA-2011B-treated = 600 mm(3), p < 0.001). ISA-2011B-treatment reduced expression of pSer-473 AKT (p < 0.001) and its downstream effectors including cyclin D1, VEGF and its receptors, VEGFR1 and VEGFR2 (p < 0.001) in xenograft tumors. In ER+ cancer cells, PIP5K1 alpha acted on pSer-473 AKT, and was in complexes with VEGFR2, serving as co-factor of ER-alpha to regulate activities of target genes including cyclin D1 and CDK1. Our study suggests that our developed PIP5K1 alpha inhibitor has a great potential on refining targeted therapeutics for treatment of triple-negative and ER+ BC with abnormal PI3K/AKT pathways.	[Sarwar, Martuza; Persson, Jenny L.] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden; [Khaja, Azharuddin Sajid Syed; Karlsson, Richard; Persson, Jenny L.] Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden; [Aleskandarany, Mohammed; Althobiti, Maryam; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Acad Pathol, Sch Med, Div Canc & Stem Cells, Nottingham, England; [Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Mongan, Nigel P.] Univ Nottingham, Fac Med & Hlth Sci, Sch Vet Med & Sci, Nottingham, England; [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, New York, NY 10065 USA; [Dizeyi, Nisthman] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Reprod Res, Malmo, Sweden; [Johnson, Heather] Beijing Inst Basic Med Sci, Dept Biodiag, Beijing, Peoples R China	Lund University; Umea University; University of Nottingham; University of Copenhagen; University of Nottingham; Cornell University; Lund University; Academy of Military Medical Sciences - China	Persson, JL (corresponding author), Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden.; Persson, JL (corresponding author), Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden.	jenny_l.persson@med.lu.se	Syed Khaja, Azharuddin Sajid/AAF-2693-2021; Rakha, Emad/Q-5554-2019; Aleskandarany, Mohammed/X-8585-2019; Green, Andrew/AAF-1991-2020; Aleskandarany, Mohammed/D-9162-2018	Syed Khaja, Azharuddin Sajid/0000-0003-1594-1826; Persson, Jenny/0000-0001-7682-7678; Rakha, Emad/0000-0002-5009-5525; Aleskandarany, Mohammed/0000-0001-5538-5946; Mongan, Nigel/0000-0001-5438-1126; Ellis, Ian/0000-0001-5292-8474; Green, Andrew/0000-0002-0488-5913; Karlsson, Richard Torbjorn Gustav/0000-0003-0448-6135; JOHNSON, HEATHER/0000-0001-7468-0705	Swedish Cancer Society; Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	Swedish Cancer Society(Swedish Cancer Society); Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	This work was supported by grants from the Swedish Cancer Society, The Swedish National Research Council, The Swedish Children Foundation, Malmo Cancer Foundation, Malmo Cancer Foundation, the Government Health Innovation Grant, Kempe STF, Umea University, Medical Faculty Grants to JLP. The Royal Physiographical Foundation to MS. We acknowledge the support of the University of Nottingham and Weill Cornell Medicine (NPM). The authors sincerely thank Teresa Frisan (Umea University, Umea and Karolinska Institute, Stockholm), Pirkko Harkonen (University of Turku, Turku), Yafang Mei (Umea University, Umea) and Yvonne Lundberg Giwercman (Lund University, Lund) for providing reagents for this study. We also thank Per-Anders Bertilsson, Kristina Ekstrom-Holka and Elise Nilsson for technical help, and the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples.	Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Aesoy R, 2008, MOL CANCER RES, V6, P1630, DOI 10.1158/1541-7786.MCR-07-2172; Aleskandarany MA, 2016, BREAST CANCER RES TR, V156, P9, DOI 10.1007/s10549-016-3709-z; Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Andruska N, 2012, J BIOMOL SCREEN, V17, P921, DOI 10.1177/1087057112442960; Applanat MP, 2008, ADV EXP MED BIOL, V617, P437, DOI 10.1007/978-0-387-69080-3_42; Auld DS, 2009, P NATL ACAD SCI USA, V106, P3585, DOI 10.1073/pnas.0813345106; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Coleman RE, 2002, AM J CLIN ONCOL-CANC, V25, pS32, DOI 10.1097/00000421-200212001-00006; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Khaja ASS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072210; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lim E, 2012, ONCOLOGY-NY, V26, P688; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Marino N, 2013, AM J PATHOL, V183, P1084, DOI 10.1016/j.ajpath.2013.06.012; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sarwar M, 2016, ONCOTARGET, V7, P63065, DOI 10.18632/oncotarget.11757; Semenas J, 2014, P NATL ACAD SCI USA, V111, pE3689, DOI 10.1073/pnas.1405801111; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Solzak JP, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0016-8; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Yamaguchi H, 2010, CANCER SCI, V101, P1632, DOI 10.1111/j.1349-7006.2010.01574.x; Yang ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07758; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838	36	18	18	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					375	389		10.1038/s41388-018-0438-2	http://dx.doi.org/10.1038/s41388-018-0438-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30104711	Green Published, hybrid			2022-12-28	WOS:000455851200006
J	van Staalduinen, J; Baker, D; ten Dijke, P; van Dam, H				van Staalduinen, Jente; Baker, David; ten Dijke, Peter; van Dam, Hans			Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?	ONCOGENE			English	Review							E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; REGULATES E-CADHERIN; EMT-ACTIVATOR ZEB1; BREAST-CANCER; DRUG-RESISTANCE; OVARIAN-CANCER; PD-L1 EXPRESSION; CISPLATIN-RESISTANCE; PROMOTES METASTASIS	Chemoresistance remains a major complication of cancer treatments. Recent data provide strong evidence that chemoresistance is linked to epithelial-mesenchymal transition (EMT), a latent developmental process, which is reactivated during cancer progression. EMT involves transcriptional reprogramming and is driven by specific EMT transcription factors (EMT-TFs). In this review, we provide support for the idea that EMT-TFs contribute to the development of resistance against cancer therapy and discuss how EMT-TFs might be targeted to advance novel therapeutic approaches to the treatment of cancer.	[van Staalduinen, Jente; Baker, David; ten Dijke, Peter; van Dam, Hans] Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	ten Dijke, P (corresponding author), Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, Leiden, Netherlands.	p.ten_dijke@lumc.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; van Dam, Hans/0000-0002-8307-4325	Cancer Genomics Centre Netherlands	Cancer Genomics Centre Netherlands	Our studies on epithelial cell plasticity and cancer are supported by Cancer Genomics Centre Netherlands. We are grateful to Jonas Fuxe for critical comments on the manuscript.	Abba ML, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010008; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Aiello NM, 2017, NATURE, V547, pE7, DOI 10.1038/nature22963; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782; Ban YQ, 2016, INT J CLIN EXP MED, V9, P10018; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Baulida J, 2017, MOL ONCOL, V11, P847, DOI 10.1002/1878-0261.12080; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao MX, 2017, ONCOTARGET, V8, P12472, DOI 10.18632/oncotarget.13957; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chen Y, 2013, MOL MED REP, V7, P1579, DOI 10.3892/mmr.2013.1403; Chen YL, 2012, CHEMOTHERAPY, V58, P264, DOI 10.1159/000341860; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chockley PJ, 2016, J IMMUNOL, V197, P691, DOI 10.4049/jimmunol.1600458; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cosset E, 2011, BLOOD, V117, P1673, DOI 10.1182/blood-2009-11-254680; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Deng JJ, 2016, INT J ONCOL, V48, P1117, DOI 10.3892/ijo.2016.3342; Dennis M, 2012, OTOLARYNG HEAD NECK, V147, P726, DOI 10.1177/0194599812446407; Diaz VM, 2016, SEMIN CANCER BIOL, V36, P71, DOI 10.1016/j.semcancer.2015.10.003; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Fang CY, 2017, J GASTROEN HEPATOL, V32, P1204, DOI 10.1111/jgh.13646; Fang ST, 2014, NANOSCALE, V6, P10084, DOI 10.1039/c4nr01518e; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fukagawa A, 2015, CANCER MED-US, V4, P125, DOI 10.1002/cam4.347; Funaki S, 2017, ONCOL REP, V38, P2277, DOI 10.3892/or.2017.5894; Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004; Gao HX, 2016, MOL MED REP, V14, P4135, DOI 10.3892/mmr.2016.5770; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gopal SK, 2017, BIOCHEM J, V474, P21, DOI 10.1042/BCJ20160006; Goswami KK, 2017, CELL IMMUNOL, V316, P1, DOI 10.1016/j.cellimm.2017.04.005; Grassian AR, 2012, J BIOL CHEM, V287, P42180, DOI 10.1074/jbc.M112.417832; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Han H, 2017, MOL CELL, V65, P539, DOI 10.1016/j.molcel.2017.01.011; Hanrahan K, 2017, MOL ONCOL, V11, P251, DOI 10.1002/1878-0261.12030; Hara J, 2014, ONCOL REP, V31, P589, DOI 10.3892/or.2013.2876; Harada K, 2014, INT J ONCOL, V44, P1302, DOI 10.3892/ijo.2014.2270; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; He MJ, 2017, PHARMACOL THERAPEUT, V177, P96, DOI 10.1016/j.pharmthera.2017.03.001; Herhaus L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3519; Hirai M, 2017, INT J ONCOL, V50, P41, DOI 10.3892/ijo.2016.3785; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569; Hsu DSS, 2010, CLIN CANCER RES, V16, P4561, DOI 10.1158/1078-0432.CCR-10-0593; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Inoue Y, 2016, CURR CANCER DRUG TAR, V16, P110, DOI 10.2174/1568009616666151112122126; Jeon YK, 2017, CELL DEATH DIFFER, V24, P469, DOI 10.1038/cdd.2016.143; Ji H, 2015, MOL MED REP, V12, P3841, DOI 10.3892/mmr.2015.3867; Jia DY, 2015, ONCOTARGET, V6, P15436, DOI 10.18632/oncotarget.3623; Jiang Y, 2014, J MOL CELL BIOL, V6, P352, DOI 10.1093/jmcb/mju019; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Jolly MK, 2015, ONCOTARGET, V6, P25161, DOI 10.18632/oncotarget.4629; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Khoo BL, 2015, ONCOTARGET, V6, P15578; Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151; Kim S, 2016, HUM PATHOL, V58, P7, DOI 10.1016/j.humpath.2016.07.007; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Li J, 2016, ONCOL RES, V23, P205, DOI 10.3727/096504016X14549667334007; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Li YQ, 2015, INT J ONCOL, V46, P1461, DOI 10.3892/ijo.2015.2878; Lim S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066558; Lin YW, 2017, ONCOTARGET, V8, P75127, DOI 10.18632/oncotarget.20561; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lindsey S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00358; Liu SF, 2016, ONCOTARGET, V7, P32876, DOI 10.18632/oncotarget.8765; Liu SJ, 2016, INT J BIOCHEM CELL B, V76, P135, DOI 10.1016/j.biocel.2016.05.001; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Liu ZX, 2013, J BIOL CHEM, V288, P4334, DOI 10.1074/jbc.M112.419168; Loriot C, 2012, J CLIN ENDOCR METAB, V97, pE954, DOI 10.1210/jc.2011-3437; Lu M, 2013, P NATL ACAD SCI USA, V110, P18144, DOI 10.1073/pnas.1318192110; Lu SM, 2014, MOL MED REP, V10, P53, DOI 10.3892/mmr.2014.2212; Ma CC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0367-2; Ma JL, 2016, TUMOR BIOL, V37, P6177, DOI 10.1007/s13277-015-4458-z; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334; Mancini M, 2010, CELL SIGNAL, V22, P1247, DOI 10.1016/j.cellsig.2010.04.002; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Masui T, 2014, INT J ONCOL, V44, P693, DOI 10.3892/ijo.2013.2225; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Mirzoeva OK, 2013, MOL CANCER THER, V12, P2213, DOI 10.1158/1535-7163.MCT-13-0104; Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Nishijima N, 2016, INT J ONCOL, V48, P937, DOI 10.3892/ijo.2016.3331; Ock CY, 2016, ONCOTARGET, V7, P15901, DOI 10.18632/oncotarget.7431; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Park SH, 2015, MOL CELLS, V38, P20, DOI 10.14348/molcells.2015.2120; Pattabiraman DR, 2016, COLD SH Q B, V81, P11, DOI 10.1101/sqb.2016.81.030957; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Pitts TM, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00035; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Ren J, 2013, J CELL BIOCHEM, V114, P1395, DOI 10.1002/jcb.24481; Richard G, 2016, EMBO MOL MED, V8, P1143, DOI 10.15252/emmm.201505971; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Roberts CM, 2017, NANOMED-NANOTECHNOL, V13, P965, DOI 10.1016/j.nano.2016.11.010; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sahu SK, 2015, EMBO J, V34, P2162, DOI 10.15252/embj.201490693; Sanchez-Tillo E, 2014, CELL DEATH DIFFER, V21, P247, DOI 10.1038/cdd.2013.123; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Saxena M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.61; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217; Shimbo T, 2016, ADV EXP MED BIOL, V945, P303, DOI 10.1007/978-3-319-43624-1_13; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Strauss R, 2009, CANCER RES, V69, P5115, DOI 10.1158/0008-5472.CAN-09-0645; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Terabe M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1308616; Terabe M, 2009, CLIN CANCER RES, V15, P6560, DOI 10.1158/1078-0432.CCR-09-1066; Tian XJ, 2013, BIOPHYS J, V105, P1079, DOI 10.1016/j.bpj.2013.07.011; Tilghman SL, 2013, MOL CELL PROTEOMICS, V12, P2440, DOI 10.1074/mcp.M112.023861; Tran Hung D, 2014, Cancer Res, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923; Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsukasa K, 2015, HUM CELL, V28, P167, DOI 10.1007/s13577-015-0117-3; Uchibori K, 2012, INT J ONCOL, V40, P1005, DOI 10.3892/ijo.2011.1300; Vannini I, 2007, CELL ONCOL, V29, P279; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Vichalkovski A, 2010, ONCOGENE, V29, P3554, DOI 10.1038/onc.2010.115; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang H, 2014, EUR J PHARMACOL, V723, P156, DOI 10.1016/j.ejphar.2013.12.004; Wang R, 2015, ONCOTARGET, V6, P7000, DOI 10.18632/oncotarget.3193; Wang T, 2014, ONCOL LETT, V7, P1102, DOI 10.3892/ol.2014.1816; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Wu KJ, 2012, MOL ENDOCRINOL, V26, P1496, DOI 10.1210/me.2011-1360; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu Y, 2017, BREAST CANCER RES TR, V163, P449, DOI 10.1007/s10549-017-4211-y; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Xiao HB, 2015, ONCOTARGET, V6, P38005, DOI 10.18632/oncotarget.5357; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825; Xu YX, 2017, P NATL ACAD SCI USA, V114, P11494, DOI 10.1073/pnas.1618091114; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang H, 2015, ONCOTARGET, V6, P6310, DOI 10.18632/oncotarget.3355; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Ye X, 2017, NATURE, V547, pE1, DOI 10.1038/nature22816; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027; Yoshida T, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0147344; Yu Q, 2017, CANC CELL MICROENVIR, V4, P2; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang JY, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040041; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang KJ, 2011, MED ONCOL, V28, pS301, DOI 10.1007/s12032-010-9759-x; Zhang P, 2014, INT J MOL MED, V33, P151, DOI 10.3892/ijmm.2013.1538; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhang T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12231; Zhang WJ, 2012, BIOCHEM BIOPH RES CO, V417, P679, DOI 10.1016/j.bbrc.2011.11.142; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhao Y, 2018, CELL REP, V22, P2442, DOI 10.1016/j.celrep.2018.02.007; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou GH, 2017, BIOMED PHARMACOTHER, V85, P113, DOI 10.1016/j.biopha.2016.11.100; Zhou H, 2016, AGING-US, V8, P2023, DOI 10.18632/aging.101048; Zhu DJ, 2015, AM J CANCER RES, V5, P2000; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	204	100	101	1	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6195	6211		10.1038/s41388-018-0378-x	http://dx.doi.org/10.1038/s41388-018-0378-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30002444				2022-12-28	WOS:000451622100001
J	Li, BZ; Xu, HX; Han, HY; Song, S; Zhang, XJ; Ouyang, L; Qian, CA; Hong, YT; Qiu, YC; Zhou, WQ; Huang, ML; Zhuang, WZ				Li, Bingzong; Xu, Hongxia; Han, Huiying; Song, Sha; Zhang, Xiaojuan; Ouyang, Lu; Qian, Chen'ao; Hong, Yating; Qiu, Yingchun; Zhou, Wenqi; Huang, Moli; Zhuang, Wenzhuo			Exosome-mediated transfer of IncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis	ONCOGENE			English	Article							LONG NONCODING RNA; MESENCHYMAL STEM-CELLS; NATURAL ANTISENSE; SECRETED EXOSOMES; CANCER METASTASIS; BONE-DISEASE; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; INHIBITION	Multiple myeloma (MM) is characterized by the decreased osteogenic potential of mesenchymal stem cells (MSCs). Communication between cancer cells and cancer stromal cells is a driving factor in tumor progression. Understanding the myeloma-stroma interactions is critical to the development of effective strategies that can reverse bone diseases. Here we identified that bioactive lncRNA RUNX2-AS1 in myeloma cells could be packed into exosomes and transmitted to MSCs, thus repressing the osteogenesis of MSCs. RUNX2-AS1, which arises from the antisense strand of RUNX2, was enriched in MSCs derived from MM patients (MM-MSCs). RUNX2-AS1 was capable of forming an RNA duplex with RUNX2 pre-mRNA at overlapping regions and this duplex transcriptionally repressed RUNX2 expression by reducing the splicing efficiency, resulting in decreased osteogenic potential of MSCs. In vivo mouse models, administered an inhibitor of exosome secretion, GW4869, was found to be effective in preventing bone loss, sustained by both bone formation and anticatabolic activities. Therefore, exosomal lncRNA RUNX2-AS1 may serve as a potential therapeutic target for bone lesions in MM. In summary, our results indicated a key role of exosomal lncRUNX2-AS1 in transferring from MM cells to MSCs in osteogenic differentiation, through a unique exosomal lncRUNX2-AS1/RUNX2 pathway.	[Li, Bingzong; Hong, Yating] Soochow Univ, Affiliated Hosp 2, Dept Haematol, Suzhou, Peoples R China; [Xu, Hongxia; Han, Huiying; Song, Sha; Zhang, Xiaojuan; Ouyang, Lu; Qiu, Yingchun; Zhou, Wenqi; Zhuang, Wenzhuo] Soochow Univ, Dept Cell Biol, Sch Biol & Basic Med Sci, Suzhou, Peoples R China; [Qian, Chen'ao; Huang, Moli] Soochow Univ, Dept Bioinformat, Sch Biol & Basic Med Sci, Suzhou, Peoples R China	Soochow University - China	Zhuang, WZ (corresponding author), Soochow Univ, Dept Cell Biol, Sch Biol & Basic Med Sci, Suzhou, Peoples R China.; Huang, ML (corresponding author), Soochow Univ, Dept Bioinformat, Sch Biol & Basic Med Sci, Suzhou, Peoples R China.	huangml@suda.edu.cn; zhuangwenzhuo@suda.edu.cn	li, bz/GVR-7133-2022; li, bing/GWQ-9617-2022	Huang, Moli/0000-0001-5543-9334	National Natural Science Foundation of China [81673448, 81670191]; Natural Science Foundation of Jiangsu Province China [BK 20161218, BK20161223]; Applied Basic Research Programs of Suzhou City [SYS201546]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province China(Natural Science Foundation of Jiangsu Province); Applied Basic Research Programs of Suzhou City; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported in part by National Natural Science Foundation of China (81673448, 81670191), Natural Science Foundation of Jiangsu Province China (BK 20161218, BK20161223), The Applied Basic Research Programs of Suzhou City (SYS201546), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188; Gezer U, 2014, CELL BIOL INT, V38, P1076, DOI 10.1002/cbin.10301; Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood-2006-05-026112; Guo JH, 2009, CELL, V138, P1236, DOI 10.1016/j.cell.2009.06.043; He CS, 2016, MOL CELL, V64, P416, DOI 10.1016/j.molcel.2016.09.034; He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Hudson WH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6395; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074; Li Q, 2015, TUMOR BIOL, V36, P2007, DOI 10.1007/s13277-014-2807-y; Lister N, 2017, P NATL ACAD SCI USA, V114, P9942, DOI 10.1073/pnas.1621490114; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Lokody I, 2014, NAT REV GENET, V15, P362, DOI 10.1038/nrg3741; Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008-5472.CAN-13-1791; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Mohankumar S, 2016, BRIEF FUNCT GENOMICS, V15, P249, DOI 10.1093/bfgp/elv058; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078-0432.CCR-10-1804; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; Scarola M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8631; Shah S, 2014, GENE DEV, V28, P231, DOI 10.1101/gad.230177.113; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Shurtleff MJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19276; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2014, MOL CANCER RES, V12, P1377, DOI 10.1158/1541-7786.MCR-13-0636; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989	45	85	90	5	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5508	5519		10.1038/s41388-018-0359-0	http://dx.doi.org/10.1038/s41388-018-0359-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29895968				2022-12-28	WOS:000446991200003
J	Tan, ZY; Song, LB; Wu, WJ; Zhou, YQ; Zhu, JR; Wu, GY; Cao, LX; Song, JW; Li, J; Zhang, W				Tan, Zhanyao; Song, Libing; Wu, Wenjiao; Zhou, Yanqing; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun; Zhang, Wei			TRIM14 promotes chemoresistance in gliomas by activating Wnt/beta-catenin signaling via stabilizing Dvl2	ONCOGENE			English	Article							MEDIATES CHEMORESISTANCE; MALIGNANT GLIOMA; BREAST-CANCER; CELL; AUTOPHAGY; OVEREXPRESSION; PROLIFERATION; RADIOTHERAPY; PROTEINS; GENETICS	Gliomas are a lethal class of brain cancer, with a median survival below 15 months in spite of therapeutic advances. The poor prognosis of this disease is largely attributed to acquired chemotherapy resistance, and new strategies are urgently needed to target resistant glioma cells. Herein, our study demonstrated that tripartite motif-containing 14 (TRIM14) overexpressed in glioma specimens (including tissues and cell lines), and that high level of TRIM14 predicted poor outcome of glioma patients. Furthermore, we found that upregulation of TRIM14 in glioma cells conferred chemoresistance to temozolomide in vitro and in vivo; conversely, silencing TRIM14 sensitized glioma cells to temozolomide. These findings demonstrated that TRIM14 stabilized dishevelled (Dvl2) and subsequently activated the canonical Wnt signaling and promoted chemoresistance. Moreover, inhibition of Dvl2 reversed the oncogenic effect of TRIM14 on chemoresistance. Importantly, consistent with the abovementioned results, we found that TRIM14 expression was significantly associated with hyperactivation of canonical Wnt pathway in clinical glioma specimens. Collectively, the study reveals a new molecular mechanism driving chemotherapy resistance in gliomas, and suggests an opportunity to develop novel therapeutic interventions against gliomas.	[Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct & Dis, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Key Lab Prot Modificat & Degradat, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Wu, Wenjiao] Jinan Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Zhou, Yanqing; Zhang, Wei] Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Jinan University; Guangdong Pharmaceutical University	Li, J (corresponding author), Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct & Dis, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.; Zhang, W (corresponding author), Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; 18666003902@163.com	wu, ge/ABE-3285-2020; Song, LB/AAL-1968-2020		Natural Science Foundation of China [91740119, 91529301, 91740118, 81530082, 81621004]; Guangzhou Science and Technology Plan Projects [201803010098, 201510010292]; Natural Science Foundation of Guangdong Province [2017A030313799]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by Natural Science Foundation of China (Nos. 91740119, 91529301, 91740118, 81530082 and 81621004); Guangzhou Science and Technology Plan Projects (201803010098, 201510010292); Natural Science Foundation of Guangdong Province (2017A030313799); The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; [Anonymous], 2016, Cancer Discov, V6, pOF2, DOI 10.1158/2159-8290.CD-NB2016-053; Belanich M, 1996, CANCER RES, V56, P783; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009; Hai J, 2017, SCI REP-UK, V7, DOI 10.1038/srep39692; Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1; Harris TM, 2015, ARCH PATHOL LAB MED, V139, P494, DOI 10.5858/arpa.2014-0131-OA; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144; Laperriere N, 2002, RADIOTHER ONCOL, V64, P259, DOI 10.1016/S0167-8140(02)00078-6; Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562; Lei ZJ, 2015, ONCOGENE, V34, P3188, DOI 10.1038/onc.2015.129; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Malbon CC, 2006, CURR TOP DEV BIOL, V72, P153, DOI 10.1016/S0070-2153(05)72002-0; Metcalfe C, 2010, CANCER RES, V70, P6629, DOI 10.1158/0008-5472.CAN-10-1616; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nenasheva VV, 2014, IN VITRO CELL DEV-AN, V50, P121, DOI 10.1007/s11626-013-9683-4; Sardiello M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-225; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song XM, 2015, ONCOL LETT, V10, P2283, DOI 10.3892/ol.2015.3623; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Su X, 2016, ONCOTARGET, V7, P9939, DOI 10.18632/oncotarget.6941; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tao JY, 2016, HEPATOLOGY, V64, P1587, DOI 10.1002/hep.28601; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Wang NX, 2008, DRUG NEWS PERSPECT, V21, P137, DOI 10.1358/dnp.2008.21.3.1203409; Wang Y, 2017, ONCOTARGET, V8, P37511, DOI 10.18632/oncotarget.16400; Wickstrom M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9904; Xing JJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00101-w; Xu GX, 2017, SCI REP-UK, V7, DOI 10.1038/srep42411; Zeng ZL, 2012, CLIN CANCER RES, V18, P4059, DOI 10.1158/1078-0432.CCR-11-3156; Zhang ZM, 2016, ONCOGENE, V35, P4787, DOI 10.1038/onc.2016.10; Zhou Z, 2014, P NATL ACAD SCI USA, V111, pE245, DOI 10.1073/pnas.1316941111	45	41	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5403	5415		10.1038/s41388-018-0344-7	http://dx.doi.org/10.1038/s41388-018-0344-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29867201				2022-12-28	WOS:000446312900003
J	So, D; Shin, HW; Kim, J; Lee, M; Myeong, J; Chun, YS; Park, JW				So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan			Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense	ONCOGENE			English	Article							EXTRACELLULAR VESICLES; CELL-DEATH; MITOCHONDRIAL DAMAGE; LONGEVITY PROTEIN; INFLAMMASOME; PYROPTOSIS; TRANSCRIPTION; DEACETYLASE; PATHWAY; MICROVESICLES	Mammalian cells are equipped with antiviral innate immunity. To survive and grow, human papilloma virus (HPV)-infected cervical cancer cells must overcome this host defense system. However, the precise mechanism whereby cervical cancer cells evade the immunity is not fully understood. We noted that Sirtuin 1 (SIRT1) is overexpressed in HPV-infected cervical cancer cells and hypothesized that SIRT1 counteracts antiviral immunity. Here, we found that cervical cancer cells undergo massive death by SIRT1 knockdown, but this effect is reversed by SIRT1 restoration. SIRT1-knocked-down cells showed representative features of pyroptosis, as well as highly expressed absent in melanoma 2 (AIM2) and its downstream genes related to the inflammasome response. Mechanistically, SIRT1 repressed the NF-kappa B-driven transcription of the AIM2 gene by destabilizing the RELB mRNA. Interestingly, pyroptotic death signaling in SIRT1-knocked-down cells was transmitted to naive cervical cancer cells, which was mediated by extracellular vesicles carrying AIM2 inflammasome proteins. Furthermore, the growth of cervical cancer xenografts was significantly inhibited by either SIRT1-targeting siRNAs or SIRT1-knockdown-derived extracellular vesicles. Immunohistochemical analyses showed that SIRT1 expression correlated with poor clinical outcomes in cervical cancer. In conclusion, SIRT1 enabled HPV-infected cervical cancer cells to continue growing by nullifying AIM2 inflammasome-mediated immunity. Without SIRT1, cervical cancer cells could no longer survive because of the derepression of the AIM2 inflammasome. SIRT1 could therefore be a target for the effective treatment of cervical cancer.	[So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea; [Chun, Yang-Sook] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea.	parkjw@snu.ac.kr		SHIN, HYUN-WOO/0000-0002-4038-9992; Park, Jong-Wan/0000-0003-4676-5191	National Research Foundation of Korea [2016R1A2A1A05005082]	National Research Foundation of Korea(National Research Foundation of Korea)	We thank Dr. Ja Eun Kim (Kyung Hee University) for giving the plasmids for SIRT1 and mutants, and Dr. Woo Ho Kim (Seoul National University) for providing cervical cancer tissue arrays. This work was supported by a grant from the National Research Foundation of Korea (2016R1A2A1A05005082; to JWP).	Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Allison SJ, 2009, AGING-US, V1, P316, DOI 10.18632/aging.100028; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bergsbaken T, 2011, J IMMUNOL, V187, P2748, DOI 10.4049/jimmunol.1100477; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Boyer SN, 1996, CANCER RES, V56, P4620; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Davidson S, 2011, CRIT REV ONCOL HEMAT, V79, P24, DOI 10.1016/j.critrevonc.2010.07.002; Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gadducci A, 2010, ONCOL LETT, V1, P3, DOI 10.3892/ol_00000001; Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; In HY, 2007, P NATL ACAD SCI USA, V105, P3374; Kamura T, 2013, TAIWAN J OBSTET GYNE, V52, P161, DOI 10.1016/j.tjog.2013.04.003; Koh WJ, 2013, J NATL COMPR CANC NE, V11, P320, DOI 10.6004/jnccn.2013.0043; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Man SM, 2016, EUR J IMMUNOL, V46, P269, DOI 10.1002/eji.201545839; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Rathinam VAK, 2011, VIROLOGY, V411, P153, DOI 10.1016/j.virol.2011.02.003; Reinholz M, 2013, ARCH DERMATOL RES, V305, P723, DOI 10.1007/s00403-013-1375-0; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Singh S, 2015, TUMOR BIOL, V36, P6159, DOI 10.1007/s13277-015-3300-y; Small W, 2017, CANCER-AM CANCER SOC, V123, P2404, DOI 10.1002/cncr.30667; Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Velez-Perez A, 2017, HUM PATHOL, V59, P102, DOI 10.1016/j.humpath.2016.09.019; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang J, 2016, INT J SCI, V5, P133; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Zhang DY, 2009, J BIOL CHEM, V284, P20917, DOI 10.1074/jbc.M109.020073; ZIMMERMAN EM, 1969, J CELL PHYSIOL, V74, P67, DOI 10.1002/jcp.1040740110	45	51	56	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5191	5204		10.1038/s41388-018-0339-4	http://dx.doi.org/10.1038/s41388-018-0339-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29844574				2022-12-28	WOS:000445093100004
J	Pavan, S; Meyer-Schaller, N; Diepenbruck, M; Kalathur, RKR; Saxena, M; Christofori, G				Pavan, Simona; Meyer-Schaller, Nathalie; Diepenbruck, Maren; Kalathur, Ravi Kiran Reddy; Saxena, Meera; Christofori, Gerhard			A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; TUMOR PROGRESSION; MASTER REGULATOR; MIR-200 FAMILY; MEK KINASE; PROTEIN; ACTIVATION; ERK5; PATHWAY	An epithelial to mesenchymal transition (EMT) has been correlated to malignant tumor progression and metastasis by promoting cancer cell migration and invasion and chemoresistance. Hence, finding druggable EMT effectors is critical to efficiently interfere with metastasis formation and to overcome therapy resistance. We have employed a high-content microscopy screen in combination with a kinome and phosphatome-wide siRNA library to identify signaling pathways underlying an EMT of murine mammary epithelial cells and breast cancer cells. This screen identified the MEK5-ERK5 axis as a critical player in TGF beta-mediated EMT. Suppression of MEK5-ERK5 signaling completely prevented the morphological and molecular changes occurring during a TGF beta-induced EMT and, conversely, forced highly metastatic breast cancer cells into a differentiated epithelial state. Inhibition of MEK5-ERK5 signaling also repressed breast cancer cell migration and invasion and substantially reduced lung metastasis without affecting primary tumor growth. The results suggest that the MEK5-ERK5 signaling axis via activation of MEF2B and other transcription factors plays an important role in the induction and maintenance of breast cancer cell migration and invasion and thus represents an exploitable target for the pharmacological inhibition of cancer cell metastasis.	[Pavan, Simona; Meyer-Schaller, Nathalie; Diepenbruck, Maren; Kalathur, Ravi Kiran Reddy; Saxena, Meera; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland	University of Basel	Pavan, S; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	simona.pavan@unibas.ch; gerhard.christofori@unibas.ch		Saxena, Meera/0000-0002-4060-4218	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Foundation	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Foundation	This work was supported by the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, the Swiss Cancer League, and Krebsliga Beider Basel. N.M.-S. was supported by a Marie-Heim Vogtlin grant from the Swiss National Foundation.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Badshah II, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00071; Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen RQ, 2012, CANCER RES, V72, P1579, DOI 10.1158/0008-5472.CAN-11-2055; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gui Ting, 2012, J Signal Transduct, V2012, P289243, DOI 10.1155/2012/289243; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Klein AM, 2013, CURR OPIN CELL BIOL, V25, P272, DOI 10.1016/j.ceb.2013.01.002; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kwon AT, 2012, G3-GENES GENOM GENET, V2, P987, DOI 10.1534/g3.112.003202; Laurent J, 2011, CANCER RES, V71, P3781, DOI 10.1158/0008-5472.CAN-10-3684; Lotz-Jenne C, 2016, ONCOTARGET, V7, P25983, DOI 10.18632/oncotarget.8418; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchetti A, 2008, CELL SIGNAL, V20, P2113, DOI 10.1016/j.cellsig.2008.08.002; Milacic Marija, 2012, Cancers (Basel), V4, P1180, DOI 10.3390/cancers4041180; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; von Minckwitz G, 2007, EXPERT OPIN PHARMACO, V8, P485, DOI 10.1517/14656566.8.4.485; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	66	32	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4197	4213		10.1038/s41388-018-0270-8	http://dx.doi.org/10.1038/s41388-018-0270-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713055				2022-12-28	WOS:000440566100001
J	Yue, JN; Lv, DC; Wang, CY; Li, L; Zhao, QN; Chen, HZ; Xu, L				Yue, Jinnan; Lv, Dacheng; Wang, Caiyun; Li, Ling; Zhao, Qingnan; Chen, Hongzhuan; Xu, Lu			Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta 3	ONCOGENE			English	Article							CELL LUNG-CANCER; CONVENTIONAL CARE REGIMENS; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; MICRORNA; EXPRESSION; ERLOTINIB; TKI; PROLIFERATION; DEREGULATION	All lung cancers patients with epidermal growth factor receptor (EGFR) mutation inevitably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases, the mechanism underlying acquired resistance remains unknown. MicroRNAs (miRNAs) is a group of small non-coding RNAs commonly dysregulated in human cancers and have been implicated in therapy resistance. The aim of this study was to understand the roles of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we reported the evidence of miR-483-3p silencing and epithelial-to-mesenchymal transition (EMT) phenotype in both in vitro and in vivo EGFR-mutant NSCLC models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p efficiently increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation and promoting apoptosis. Moreover, miR-483-3p reversed EMT and inhibited migration, invasion, and metastasis of gefitinib-resistant lung cancer cells. Mechanistically, miR-483-3p directly targeted integrin beta 3, and thus repressed downstream FAK/Erk signaling pathway. Furthermore, the silencing of miR-483-3p in gefitinib-resistant lung cancer cells was due to hypermethylation of its own promoter. Taken together, our data identify miR-483-3p as a promising target for combination therapy to overcome acquired EGFR TKI resistance in EGFR-mutant NSCLC.	[Yue, Jinnan; Lv, Dacheng; Wang, Caiyun; Li, Ling; Zhao, Qingnan; Chen, Hongzhuan; Xu, Lu] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, HZ; Xu, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China.	hongzhuan_chen@hotmail.com; luxuluxu@yahoo.com	xu, lu/AAI-6516-2020		National Natural Science Foundation of China [81372522, 81773747]; Science and Technology Commission of Shanghai Municipality [12ZR1416000, 12140901400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Allen KE, 2010, MOL CANCER THER, V9, P3126, DOI 10.1158/1535-7163.MCT-10-0397; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bertero T, 2013, CELL CYCLE, V12, P2183, DOI 10.4161/cc.25330; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chung JH, 2011, LUNG CANCER, V73, P176, DOI 10.1016/j.lungcan.2010.11.011; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Hao J, 2011, FEBS LETT, V585, P207, DOI 10.1016/j.febslet.2010.11.039; Hayakawa H, 2013, CANCER SCI, V104, P1440, DOI 10.1111/cas.12284; Ju LX, 2010, J CELL BIOCHEM, V111, P1565, DOI 10.1002/jcb.22888; Kanda R, 2013, CANCER RES, V73, P6243, DOI 10.1158/0008-5472.CAN-12-4502; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; La Monica S, 2016, J THORAC ONCOL, V11, P1051, DOI 10.1016/j.jtho.2016.03.006; Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001; Li B, 2014, LUNG CANCER, V83, P146, DOI 10.1016/j.lungcan.2013.11.003; Li L, 2017, ONCOTARGET, V8, P92240, DOI 10.18632/oncotarget.21170; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Ozata DM, 2011, ENDOCR-RELAT CANCER, V18, P643, DOI 10.1530/ERC-11-0082; Rupaimoole R, 2016, CANCER DISCOV, V6, P235, DOI 10.1158/2159-8290.CD-15-0893; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shen H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103305; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang CP, 2015, TUMOR BIOL, V36, P9447, DOI 10.1007/s13277-015-3690-x; Wang W, 2012, WORLD J GASTROENTERO, V18, P5442, DOI 10.3748/wjg.v18.i38.5442; Wang W, 2012, CARCINOGENESIS, V33, P1113, DOI 10.1093/carcin/bgs113; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yi C, 2012, ONCOGENE, V31, P4421, DOI 10.1038/onc.2011.629; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou JY, 2014, CANCER LETT, V351, P265, DOI 10.1016/j.canlet.2014.06.010	44	57	60	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4300	4312		10.1038/s41388-018-0276-2	http://dx.doi.org/10.1038/s41388-018-0276-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717264	Green Published, hybrid			2022-12-28	WOS:000440566100008
J	Sirtl, S; Knoll, G; Trinh, DT; Lang, I; Siegmund, D; Gross, S; Schuler-Thurner, B; Neubert, P; Jantsch, J; Wajant, H; Ehrenschwender, M				Sirtl, Simon; Knoll, Gertrud; Dieu Thuy Trinh; Lang, Isabell; Siegmund, Daniela; Gross, Stefanie; Schuler-Thurner, Beatrice; Neubert, Patrick; Jantsch, Jonathan; Wajant, Harald; Ehrenschwender, Martin			Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors	ONCOGENE			English	Article							APOPTOSIS-INDUCING LIGAND; CELL-SURFACE ANTIGEN; MITOCHONDRIAL-MEMBRANE; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; DENDRITIC CELLS; HIGH-SALT; CASPASE 8; TRAIL; BAX	Attempts to exploit the cytotoxic activity of death receptors (DR) for treating cancer have thus far been disappointing. DR activation in most malignant cells fails to trigger cell death and may even promote tumor growth by activating cell death-independent DR-associated signaling pathways. Overcoming apoptosis resistance is consequently a prerequisite for successful clinical exploitation of DR stimulation. Here we show that hyperosmotic stress in the tumor microenvironment unleashes the deadly potential of DRs by enforcing BCL-2 addiction of cancer cells. Hypertonicity robustly enhanced cytotoxicity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and other DR ligands in various cancer entities. Initial events in TRAIL DR signaling remained unaffected, but hypertonic conditions unlocked activation of the mitochondrial death pathway and thus amplified the apoptotic signal. Mechanistically, we demonstrate that hyperosmotic stress imposed a BCL-2-addiction on cancer cells to safeguard the integrity of the outer mitochondrial membrane (OMM), essentially exhausting the protective capacity of BCL-2-like pro-survival proteins. Deprivation of these mitochondrial safeguards licensed DR-generated truncated BH3-interacting domain death agonist (tBID) to activate BCL-2-associated X protein (BAX) and initiated mitochondrial outer membrane permeabilization (MOMP). Our work highlights that hyperosmotic stress in the tumor environment primes mitochondria for death and lowers the threshold for DR-induced apoptosis. Beyond TRAIL-based therapies, our findings could help to strengthen the efficacy of other apoptosis-inducing cancer treatment regimens.	[Sirtl, Simon; Knoll, Gertrud; Dieu Thuy Trinh; Neubert, Patrick; Jantsch, Jonathan; Ehrenschwender, Martin] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany; [Lang, Isabell; Siegmund, Daniela; Wajant, Harald] Univ Hosp Wurzburg, Div Mol Internal Med Med Clin & Polyclin 2, Rontgenring 11, D-97070 Wurzburg, Germany; [Gross, Stefanie; Schuler-Thurner, Beatrice] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Dermatol, Ulmenweg 18, D-91054 Erlangen, Germany	University of Regensburg; University of Wurzburg; University of Erlangen Nuremberg	Ehrenschwender, M (corresponding author), Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	martin.ehrenschwender@ukr.de		Ehrenschwender, Martin/0000-0003-4681-8628; Lang, Isabell/0000-0002-6369-4973; Gross, Stefanie/0000-0002-5406-1736	Deutsche Forschungsgemeinschaft (DFG) [EH 465/2-1, JA 1993/4-1, WA 1025/24-1]; Roggenbuck Stiftung; Universitatsstiftung Angela Schotz-Keilholz; Medical Faculty of the University of Regensburg (ReForM-B-program); Deutsche Krebshilfe [111703]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Roggenbuck Stiftung; Universitatsstiftung Angela Schotz-Keilholz; Medical Faculty of the University of Regensburg (ReForM-B-program); Deutsche Krebshilfe(Deutsche Krebshilfe)	ME is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant EH 465/2-1), the Roggenbuck Stiftung, the Universitatsstiftung Angela Schotz-Keilholz, and the Medical Faculty of the University of Regensburg (ReForM-B-program). JJ is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant JA 1993/4-1). HW is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant WA 1025/24-1) and Deutsche Krebshilfe (Grant 111703).	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Bittner S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.355; Callus BA, 2008, J MOL BIOL, V384, P313, DOI 10.1016/j.jmb.2008.09.041; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P477, DOI 10.1101/pdb.prot086462; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Ehrenschwender M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.534; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fick A, 2012, J BIOL CHEM, V287, P484, DOI 10.1074/jbc.M111.287656; Fischereder M, 2017, AM J PHYSIOL-RENAL, V313, pF319, DOI 10.1152/ajprenal.00703.2016; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Galvez A, 2001, CELL TISSUE RES, V304, P279, DOI 10.1007/s004410100358; Ganesan V, 2012, BIOPHYS J, V103, P483, DOI 10.1016/j.bpj.2012.06.047; Gillissen B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.67; Graves JD, 2014, CANCER CELL, V26, P177, DOI 10.1016/j.ccr.2014.04.028; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang K, 2016, J BIOL CHEM, V291, P11843, DOI 10.1074/jbc.M115.711051; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jantsch J, 2015, CELL METAB, V21, P493, DOI 10.1016/j.cmet.2015.02.003; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Knoll G, 2016, ONCOTARGET, V7, P41488, DOI 10.18632/oncotarget.9206; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kums J, 2017, MABS-AUSTIN, V9, P506, DOI 10.1080/19420862.2016.1274844; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nikpey E, 2017, HYPERTENSION, V69, P660, DOI 10.1161/HYPERTENSIONAHA.116.08539; O'Neill KL, 2016, GENE DEV, V30, P973, DOI 10.1101/gad.276725.115; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pecot J, 2016, CELL REP, V17, P3347, DOI 10.1016/j.celrep.2016.11.064; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schug ZT, 2011, CELL DEATH DIFFER, V18, P538, DOI 10.1038/cdd.2010.135; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Telford W, 2016, CURR PROTOC CYTOM, V77; Thomann S, 2015, IMMUNOLOGY, V146, P327, DOI 10.1111/imm.12509; Todt F, 2015, EMBO J, V34, P67, DOI 10.15252/embj.201488806; Trebing J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.555; Tuthill MH, 2015, ONCOGENE, V34, P2138, DOI 10.1038/onc.2014.156; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Wajant H, 2015, CELL DEATH DIFFER, V22, P1727, DOI 10.1038/cdd.2015.109; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang C, 2012, ONCOGENE, V31, P3177, DOI 10.1038/onc.2011.497; Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yaacoub K, 2016, CANCER LETT, V378, P150, DOI 10.1016/j.canlet.2016.05.012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	60	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4122	4136		10.1038/s41388-018-0265-5	http://dx.doi.org/10.1038/s41388-018-0265-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706657	hybrid, Green Published			2022-12-28	WOS:000439847000006
J	Blanchette-Farra, N; Kita, D; Konstorum, A; Tesfay, L; Lemler, D; Hegde, P; Claffey, KP; Torti, FM; Torti, SV				Blanchette-Farra, Nicole; Kita, Daniel; Konstorum, Anna; Tesfay, Lia; Lemler, David; Hegde, Poornima; Claffey, Kevin P.; Torti, Frank M.; Torti, Suzy V.			Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION PATTERNS; TGF-BETA SUPERFAMILY; TRANSFERRIN RECEPTOR; EPITHELIAL-CELLS; IRON-METABOLISM; MOLECULAR PORTRAITS; ACTIVATION; PROTEIN; GROWTH; STAT3	Hepcidin is a peptide hormone that negatively regulates iron efflux and plays an important role in controlling the growth of breast tumors. In patients with breast cancer, the combined expression of hepcidin and its membrane target, ferroportin, predict disease outcome. However, mechanisms that control hepcidin expression in breast cancer cells remain largely unknown. Here, we use three-dimensional breast cancer spheroids derived from cell lines and breast cancer patients to probe mechanisms of hepcidin regulation in breast cancer. We observe that the extent of hepcidin induction and pathways of its regulation are markedly changed in breast cancer cells grown in three dimensions. In monolayer culture, BMPs, particularly BMP6, regulate hepcidin transcription. When breast cancer cells are grown as spheroids, there is a > 10-fold induction in hepcidin transcripts. Microarray analysis combined with knockdown experiments reveal that GDF-15 is the primary mediator of this change. The increase in hepcidin as breast cells develop a three-dimensional architecture increases intracellular iron, as indicated by an increase in the iron storage protein ferritin. Immunohistochemical staining of human breast tumors confirms that both GDF-15 and hepcidin are expressed in breast cancer specimens. Further, levels of GDF-15 are significantly correlated with levels of hepcidin at both the mRNA and protein level in patient samples, consistent with a role for GDF-15 in control of hepcidin in human breast tumors. Inclusion of tumor-associated fibroblasts in breast cancer spheroids further induces hepcidin. This induction is mediated by fibroblast-dependent secretion of IL-6. Breast cancer cells grown as spheroids are uniquely receptive to IL-6-dependent induction of hepcidin by tumor-associated fibroblasts, since IL6 does not induce hepcidin in cells grown as monolayers. Collectively, our results suggest a new paradigm for tumormediated control of iron through the control of hepcidin by tumor architecture and the breast tumor microenvironment.	[Blanchette-Farra, Nicole; Tesfay, Lia; Lemler, David; Torti, Suzy V.] Univ Connecticut, Hlth Ctr, Dept Mol Biol & Biophys, Farmington, CT 06030 USA; [Kita, Daniel; Claffey, Kevin P.] Univ Connecticut, Hlth Ctr, Dept Cell Biol, Farmington, CT 06030 USA; [Konstorum, Anna] Univ Connecticut, Hlth Ctr, Ctr Quantitat Med, Farmington, CT 06030 USA; [Hegde, Poornima] Univ Connecticut, Hlth Ctr, Dept Pathol, Farmington, CT USA; [Torti, Frank M.] Univ Connecticut, Hlth Ctr, Dept Med, Farmington, CT USA; [Kita, Daniel] Alex Pharmaceut, New Haven, CT USA; [Lemler, David] North Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; University of North Carolina; North Carolina State University	Torti, SV (corresponding author), Univ Connecticut, Hlth Ctr, Dept Mol Biol & Biophys, Farmington, CT 06030 USA.	storti@uchc.edu	Lemler, David/GZG-4253-2022		NCI [R01CA188025, R01CA171101, F32CA214030]; NATIONAL CANCER INSTITUTE [F32CA214030, R01CA188025, R01CA171101] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NCI R01CA188025 (SVT), NCI R01CA171101 (FMT), and NCI F32CA214030 (AK). We thank Li Chen and Drs. Nathaniel Dyment and David Rowe for assistance in image acquisition, Tara L Arvedson (Amgen, Thousand Oaks, CA) for a generous gift of anti-ferroportin antibody and Xiaohong Wang for her assistance in histological sectioning.	Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Arman A, 2003, ADV EXP MED BIOL, V534, P297; Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005; Babitt JL, 2007, J CLIN INVEST, V117, P1933, DOI 10.1172/JCI31342; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Coloff JL, 2016, CELL METAB, V23, P867, DOI 10.1016/j.cmet.2016.03.016; Cooke KS, 2013, BLOOD, V122, P3054, DOI 10.1182/blood-2013-06-505792; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Francia G, 2004, MOL CELL BIOL, V24, P6837, DOI 10.1128/mcb.24.15.6837-6849.2004; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim JB, 2004, BREAST CANCER RES TR, V85, P281, DOI 10.1023/B:BREA.0000025418.88785.2b; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Li C, 2016, ONCOTARGET, V7, P860, DOI 10.18632/oncotarget.6205; Li YL, 2017, ONCOTARGET, V8, P1508, DOI 10.18632/oncotarget.13649; Liu XF, 2017, NAT PROTOC, V12, P439, DOI 10.1038/nprot.2016.174; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Marques O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2228-y; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nguyen DH, QUANTIFYING CHROMOGE, DOI [10.1038/protex.2013.097, DOI 10.1038/PROTEX.2013.097]; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Park YJ, 2010, BMB REP, V43, P91, DOI 10.5483/BMBRep.2010.43.2.091; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Pinnix ZK, 2010, SCI TRANSL MED, V2; Riedl A, 2017, J CELL SCI, V130, P203, DOI 10.1242/jcs.188102; Saias L, 2015, CANCER RES, V75, P2426, DOI 10.1158/0008-5472.CAN-14-3534; Sasahara A, 2017, ONCOTARGET, V8, P24869, DOI 10.18632/oncotarget.15276; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Theil EC, 2016, ACCOUNTS CHEM RES, V49, P784, DOI 10.1021/ar500469e; TONIK SE, 1986, BREAST CANCER RES TR, V7, P71, DOI 10.1007/BF01806791; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Wang W, 2014, CANCER RES, V74, P497, DOI 10.1158/0008-5472.CAN-13-1224; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wilkinson J, 2003, ADV ENZYME REGUL, V43, P135, DOI 10.1016/S0065-2571(02)00037-7; WINAND FJ, 2014, J MOL BIOMARK DIAGN, V5, P199; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; WRBA F, 1986, VIRCHOWS ARCH A, V410, P69, DOI 10.1007/BF00710908; Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631; Yalcin Mehmet Muhittin, 2016, J Diabetes Res, V2016, P1240843, DOI 10.1155/2016/1240843; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yilmaz H, 2016, INDIAN J HEMATOL BLO, V32, P221, DOI 10.1007/s12288-015-0551-0; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zhang SP, 2014, CELL SIGNAL, V26, P2539, DOI 10.1016/j.cellsig.2014.07.029	72	31	31	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4013	4032		10.1038/s41388-018-0243-y	http://dx.doi.org/10.1038/s41388-018-0243-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695834	Green Accepted			2022-12-28	WOS:000439101300008
J	Ji, CD; Yang, L; Yi, WJ; Xiang, DF; Wang, YX; Zhou, ZH; Qian, F; Ren, Y; Cui, W; Zhang, X; Zhang, P; Wang, JM; Cui, YH; Bian, XW				Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Qian, Feng; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Wang, Ji Ming; Cui, Youhong; Bian, Xiuwu			Capillary morphogenesis gene 2 maintains gastric cancer stem-like cell phenotype by activating a Wnt/beta-catenin pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ANTHRAX TOXIN RECEPTOR; GENERATES CELLS; MARKER CD44; WNT; PROGRESSION; DIFFERENTIATION; OVEREXPRESSION; IDENTIFICATION; ANGIOGENESIS	A growing body of evidence shows that the development and progression of gastric cancer (GC) is mainly associated to the presence of gastric cancer stem-like cells (GCSLCs). However, it is unclear how GCSLC population is maintained. This study aimed to explore the role of capillary morphogenesis gene 2 (CMG2) in GCSLC maintenance and the relevance to GC progression. We found that CMG2 was highly expressed in GC tissues and the expression levels were associated with the invasion depth and lymph node metastasis of GC, and inversely correlated with the survival of GC patients. Sorted CMG2(High) GC cells preferentially clustered in CD44(High) stem-like cell population, which expressed high levels of stemness-related genes with increased capabilities of self-renewal and tumorigenicity. Depletion of CMG2 gene resulted in reduction of GCSLC population with attenuated stemness and decrease of invasive and metastatic capabilities with subdued epithelial-mesenchymal transition phenotype in GC cells. Mechanistically, CMG2 interacted with LRP6 in GCSLCs to activate a Wnt/beta-catenin pathway. Thus, our results demonstrate that CMG2 promotes GC progression by maintaining GCSLCs and can serve as a new prognostic indicator and a target for human GC therapy.	[Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China; [Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China; [Zhou, Zhihua] 101 Hosp Peoples Liberat Army, Dept Pathol, Wuxi 214000, Jiangsu, Peoples R China; [Qian, Feng] Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing 400038, Peoples R China; [Wang, Ji Ming] Natl Canc Inst Frederick, Ctr Canc Res, Canc & Inflammat Program, Frederick, MD 21702 USA	Army Medical University; Army Medical University; Army Medical University; Ministry of Education, China; Army Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.; Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.; Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China.	cuiyouhongx@yahoo.com; bianxiuwu@263.net	Bian, Xiu-Wu/D-4736-2017; Zhang, Xia/B-8152-2008; Yang, Lang/AAL-3025-2020; yang, lang/ABA-2517-2021	Bian, Xiu-Wu/0000-0003-4383-0197; Zhang, Xia/0000-0002-9040-1486; Yang, Lang/0000-0002-5234-7394; 	National Natural Science Foundation of China [81372555]; NATIONAL CANCER INSTITUTE [ZIABC010015] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the National Natural Science Foundation of China (81372555) to YC.	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Bekaii-Saab T, 2017, CANCER-AM CANCER SOC, V123, P1303, DOI 10.1002/cncr.30538; Bell SE, 2001, J CELL SCI, V114, P2755; Bessede E, 2014, ONCOGENE, V33, P4123, DOI 10.1038/onc.2013.380; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Burgi J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15861; Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802; Cao SG, 2012, BIOORG MED CHEM LETT, V22, P5885, DOI 10.1016/j.bmcl.2012.07.075; Castanon I, 2013, NAT CELL BIOL, V15, P28, DOI 10.1038/ncb2632; Cervantes A, 2013, CANCER TREAT REV, V39, P60, DOI 10.1016/j.ctrv.2012.09.007; Chen KH, 2016, J BIOL CHEM, V291, P22021, DOI 10.1074/jbc.M116.753301; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cryan LM, 2013, J MED CHEM, V56, P1940, DOI 10.1021/jm301558t; Demitrack ES, 2015, EMBO J, V34, P2522, DOI 10.15252/embj.201490583; Deuquet J, 2012, EMBO J, V31, P3, DOI 10.1038/emboj.2011.442; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao YH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0548-8; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Huang L, 2015, AM J TRANSL RES, V7, P2141; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jiang Y, 2012, GASTRIC CANCER, V15, P440, DOI 10.1007/s10120-012-0140-y; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kodama H, 2017, BRIT J CANCER, V116, P186, DOI 10.1038/bjc.2016.401; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Li LC, 2015, ONCOL LETT, V10, P3293, DOI 10.3892/ol.2015.3727; Li YH, 2001, MOL NEUROBIOL, V23, P53; Liu JJ, 2016, CANCER LETT, V376, P110, DOI 10.1016/j.canlet.2016.03.035; Liu SH, 2016, P NATL ACAD SCI USA, V113, pE4079, DOI 10.1073/pnas.1600982113; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Park JY, 2014, CLIN ENDOSC, V47, P478, DOI 10.5946/ce.2014.47.6.478; Peng Z, 2014, WORLD J GASTROENTERO, V20, P5403, DOI 10.3748/wjg.v20.i18.5403; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rao J, 2015, CANCER LETT, V358, P76, DOI 10.1016/j.canlet.2014.12.040; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Reeves CV, 2010, ONCOGENE, V29, P789, DOI 10.1038/onc.2009.383; Rogers MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039911; Ryu HS, 2012, HUM PATHOL, V43, P520, DOI 10.1016/j.humpath.2011.07.003; Savagner P, 1994, Cancer Treat Res, V71, P229; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Simon E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035486; Singh SR, 2013, CANCER LETT, V338, P110, DOI 10.1016/j.canlet.2013.03.035; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Varga J, 2014, FEBS LETT, V588, P2422, DOI 10.1016/j.febslet.2014.06.019; Wang B, 2013, J GASTROENTEROL, V48, P798, DOI 10.1007/s00535-012-0711-z; Wang T, 2011, BRIT J CANCER, V105, P658, DOI 10.1038/bjc.2011.287; Wang W, 2014, INT J CLIN EXP MED, V7, P5059; Wei W, 2006, CELL, V124, P1141, DOI 10.1016/j.cell.2005.12.045; Xu GH, 2013, J GASTROENTEROL, V48, P781, DOI 10.1007/s00535-012-0712-y; Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003; Ye L, 2014, INT J ONCOL, V45, P1565, DOI 10.3892/ijo.2014.2533; Ye L, 2014, ONCOL LETT, V7, P2149, DOI 10.3892/ol.2014.2038; Ye L, 2014, J CANCER RES CLIN, V140, P957, DOI 10.1007/s00432-014-1650-2; Yu D, 2014, ONCOL REP, V31, P673, DOI 10.3892/or.2013.2893; Zhang CJ, 2011, J CANCER RES CLIN, V137, P1679, DOI 10.1007/s00432-011-1038-5; Zhu L, 2017, ONCOTARGET, V8, P37633, DOI 10.18632/oncotarget.16839; Zou JW, 2014, BIOCHEM BIOPH RES CO, V452, P186, DOI 10.1016/j.bbrc.2014.06.001	67	24	24	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3953	3966		10.1038/s41388-018-0226-z	http://dx.doi.org/10.1038/s41388-018-0226-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662192	Green Published, hybrid			2022-12-28	WOS:000439101300004
J	Zhang, JW; Dulak, AM; Hattersley, MM; Willis, BS; Nikkila, J; Wang, A; Lau, A; Reimer, C; Zinda, M; Fawell, SE; Mills, GB; Chen, HW				Zhang, Jingwen; Dulak, Austin M.; Hattersley, Maureen M.; Willis, Brandon S.; Nikkila, Jenni; Wang, Anderson; Lau, Alan; Reimer, Corinne; Zinda, Michael; Fawell, Stephen E.; Mills, Gordon B.; Chen, Huawei			BRD4 facilitates replication stress-induced DNA damage response	ONCOGENE			English	Article							BROMODOMAIN PROTEIN BRD4; ACUTE MYELOID-LEUKEMIA; DOUBLE-STRAND BREAKS; THERAPEUTIC TARGET; OVARIAN-CARCINOMA; ATR KINASE; IN-VIVO; S-PHASE; INHIBITOR; CANCER	Previous reports have demonstrated that select cancers depend on BRD4 to regulate oncogenic gene transcriptional programs. Here we describe a novel role for BRD4 in DNA damage response (DDR). BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays an indispensable part in DNA replication checkpoint signaling. Inhibition of BRD4 by JQ1 or AZD5153 resulted in a rapid, time-dependent reduction in CHK1 phosphorylation and aberrant DNA replication re-initiation. Furthermore, BRD4 inhibition sensitized cancer cells to various replication stress-inducing agents, and synergized with ATR inhibitor AZD6738 to induce cell killing across a number of cancer cell lines. The synergistic interaction between AZD5153 and AZD6738 is translatable to in vivo ovarian cell-line and patient-derived xenograft models. Taken together, our study uncovers a new biological function of BRD4 and provides mechanistic rationale for combining BET inhibitors with DDR-targeted agents for cancer therapy.	[Zhang, Jingwen; Dulak, Austin M.; Hattersley, Maureen M.; Willis, Brandon S.; Reimer, Corinne; Zinda, Michael; Fawell, Stephen E.; Chen, Huawei] AstraZeneca R&D, IMED Biotech Unit, Oncol, Boston, MA 02298 USA; [Nikkila, Jenni; Wang, Anderson; Lau, Alan] AstraZeneca, IMED Biotech Unit, Oncol, Cambridge, England; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	AstraZeneca; AstraZeneca; University of Texas System; UTMD Anderson Cancer Center	Chen, HW (corresponding author), AstraZeneca R&D, IMED Biotech Unit, Oncol, Boston, MA 02298 USA.	raymond.chen@astrazeneca.com	Zhang, Jing/GWZ-7332-2022; Zhang, Jing/HII-4294-2022	Wang, Anderson/0000-0002-3571-5095; Lau, Alan/0000-0003-1055-9812; Mills, Gordon/0000-0002-0144-9614	NATIONAL CANCER INSTITUTE [U01CA217842] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA217842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Baker A, 2016, CANCER RES, V76, P1158, DOI 10.1158/0008-5472.CAN-15-1070; Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Bradbury RH, 2016, J MED CHEM, V59, P7801, DOI 10.1021/acs.jmedchem.6b00070; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Chen YH, 2009, J BIOL CHEM, V284, P182, DOI 10.1074/jbc.M806530200; Chiang CM, 2009, BIOL REP, V1, P98, DOI DOI 10.3410/B1-98; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; Degorce SL, 2016, J MED CHEM, V59, P6281, DOI 10.1021/acs.jmedchem.6b00519; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; Duursma AM, 2005, CELL CYCLE, V4, P1725, DOI 10.4161/cc.4.12.2193; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Etemadmoghadam D, 2013, CLIN CANCER RES, V19, P5960, DOI 10.1158/1078-0432.CCR-13-1337; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foote KM, 2015, FUTURE MED CHEM, V7, P873, DOI [10.4155/FMC.15.33, 10.4155/fmc.15.33]; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Gong FD, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006272; Goundiam O, 2015, INT J CANCER, V137, P1890, DOI 10.1002/ijc.29568; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Koltun ES, 2012, BIOORG MED CHEM LETT, V22, P3727, DOI 10.1016/j.bmcl.2012.04.024; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005; Nam EA, 2011, J BIOL CHEM, V286, P28707, DOI 10.1074/jbc.M111.248914; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rhyasen GW, 2016, MOL CANCER THER, V15, P2563, DOI 10.1158/1535-7163.MCT-16-0141; Rodriguez-Bravo V, 2006, CANCER RES, V66, P8672, DOI 10.1158/0008-5472.CAN-05-4443; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Vendetti FP, 2015, ONCOTARGET, V6, P44289, DOI 10.18632/oncotarget.6247; Walter D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10530; Waring MJ, 2016, NAT CHEM BIOL, V12, P1097, DOI [10.1038/NCHEMBIO.2210, 10.1038/nchembio.2210]; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	54	48	49	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3763	3777		10.1038/s41388-018-0194-3	http://dx.doi.org/10.1038/s41388-018-0194-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29636547	Green Accepted			2022-12-28	WOS:000438465600001
J	Jung, JH; Jung, DB; Kim, H; Lee, H; Kang, SE; Srivastava, SK; Yun, MY; Kim, SH				Jung, Ji Hoon; Jung, Deok-Beom; Kim, Hyunseok; Lee, Hyemin; Kang, Shi-Eun; Srivastava, Sanjay K.; Yun, Miyong; Kim, Sung-Hoon			Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3 beta and F-box and WD repeat domain-containing 7	ONCOGENE			English	Article							PARKINSONS-DISEASE; CELLS; EXPRESSION; TARGET; APOPTOSIS; ONCOGENE; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION	To elucidate the underlying oncogenic mechanism of zinc finger protein 746 (ZNF746), current study was conducted in colorectal cancers (CRCs). Herein, ZNF746 was overexpressed in HCT116, SW620, and SW480 cells, which was supported by CRC tissue microarray and TCGA analysis. Also, DNA microarray revealed the differentially expressed gene profile particularly related to cell cycle genes and c-Myc in ZNF746 depleted HCT116 cells. Furthermore, ZNF746 enhanced the stability of c-Myc via their direct binding through nuclear colocalization by immunoprecipitation and immunofluorescence, while ZNF746 and c-Myc exist mainly in nucleoplasm. Conversely, ZNF746 depletion attenuated phosphorylation of c-Myc (S62) and glycogen synthase kinase 3 beta (GSK3 beta) (S9) and also activated p-c-Myc (T58), which was reversed by GSK3 inhibitors such as SB-216763 and Enza. Also, c-Myc degradation by ZNF746 depletion was blocked by knockdown of F-box/WD repeat-containing protein 7 (FBW7) ubiquitin ligase or proteosomal inhibitor MG132. Additionally, the growth of ZNF746 depleted HCT116 cancer cells was retarded with decreased expression of ZNF746 and c-Myc. Overall, these findings suggest that ZNF746 promotes CRC progression via c-Myc stability mediated by GSK3 and FBW7.	[Jung, Ji Hoon; Jung, Deok-Beom; Lee, Hyemin; Kim, Sung-Hoon] Kyung Hee Univ, Coll Korean Med, Korean Med Tumor Ecosyst Regulat Res Ctr, Seoul, South Korea; [Kang, Shi-Eun; Yun, Miyong] Kyung Hee Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Seoul, South Korea; [Kim, Hyunseok] NJ Univ Hosp, Univ Hosp Newark, 150 Bergen St, Newark, NJ 07103 USA; [Srivastava, Sanjay K.] Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Amarillo, TX 79106 USA; [Srivastava, Sanjay K.] Texas Tech Univ, Canc Biol Ctr, Hlth Sci Ctr, Amarillo, TX 79106 USA	Kyung Hee University; Kyung Hee University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Kim, SH (corresponding author), Kyung Hee Univ, Coll Korean Med, Korean Med Tumor Ecosyst Regulat Res Ctr, Seoul, South Korea.; Yun, MY (corresponding author), Kyung Hee Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Seoul, South Korea.	myyun91@khu.ac.kr; sungkim7@khu.ac.kr	Srivastava, Sanjay K./AAE-7635-2020; YUN, MIYONG/S-9433-2019	kim, sunghoon/0000-0003-2423-1973	National Research Foundation of Korea (NRF) grant [2017R1A2A1A17069297]	National Research Foundation of Korea (NRF) grant	This work was supported by the National Research Foundation of Korea (NRF) grant (no. 2017R1A2A1A17069297) and also we appreciate Dr. Han YH in KIRMAS for pcDNA3 reporter, 5'-V5-Myc, HA-FBW7, HA-Myc (S62A), and HA-Myc(T58A) and Dr. Lee ES for c-Myc mutant plasmids used in this project.	Aslan JE, 2009, MOL CELL, V34, P497, DOI 10.1016/j.molcel.2009.04.011; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bommer GT, 2007, CANCER CELL, V11, P391, DOI 10.1016/j.ccr.2007.04.015; Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090; Chen BJ, 2014, INT J BIOL SCI, V10, P1084, DOI 10.7150/ijbs.10190; Chen TC, 2016, TOXICOL IN VITRO, V31, P1, DOI 10.1016/j.tiv.2015.11.002; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Conrad T, 2017, METHODS MOL BIOL, V1468, P1, DOI 10.1007/978-1-4939-4035-6_1; de Mello RA, 2013, WORLD J GASTROENTERO, V19, P6315, DOI 10.3748/wjg.v19.i38.6315; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Gao SP, 2016, TUMOR BIOL, V37, P1279, DOI 10.1007/s13277-015-3878-0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Geng JH, 2016, J ALZHEIMERS DIS, V49, P1161, DOI 10.3233/JAD-150423; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang HL, 2014, CURR PHARM DESIGN, V20, P6543, DOI 10.2174/1381612820666140826153203; Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124; Karuppagounder SS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04874; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; Kim B, 2014, ONCOL REP, V31, P73, DOI 10.3892/or.2013.2801; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Koukourakis GV, 2011, CLIN TRANSL ONCOL, V13, P710, DOI 10.1007/s12094-011-0720-z; Kumar Manoj, 2012, Acta Biomed, V83, P220; Li M, 2017, ONCOL REP, V37, P1627, DOI 10.3892/or.2017.5432; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Mansi L, 2011, B CANCER, V98, P1019, DOI 10.1684/bdc.2011.1380; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; MORELLO D, 1989, ONCOGENE, V4, P955; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Robson S, 2006, RECENT PAT ANTI-CANC, V1, P305, DOI 10.2174/157489206778776934; ROTHBERG PG, 1987, SEMIN SURG ONCOL, V3, P152, DOI 10.1002/ssu.2980030305; Roy UKB, 2008, MOL CARCINOGEN, V47, P947, DOI 10.1002/mc.20451; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Schweiger T, 2014, ANN SURG ONCOL, V21, P946, DOI 10.1245/s10434-013-3386-7; Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010; SPENCER CA, 1991, ADV CANCER RES, V56, P1; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang XH, 2016, GASTRIC CANCER, V19, P116, DOI 10.1007/s10120-015-0467-2; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Won SH, 2012, PHYTOTHER RES, V26, P669, DOI 10.1002/ptr.3616; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yuge R, 2015, AM J PATHOL, V185, P399, DOI 10.1016/j.ajpath.2014.10.014	47	27	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3715	3728		10.1038/s41388-018-0225-0	http://dx.doi.org/10.1038/s41388-018-0225-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628506				2022-12-28	WOS:000437975200008
J	Paulitti, A; Andreuzzi, E; Bizzotto, D; Pellicani, R; Tarticchio, G; Marastoni, S; Pastrello, C; Jurisica, I; Ligresti, G; Bucciotti, F; Doliana, R; Colladel, R; Braghetta, P; Poletto, E; Di Silvestre, A; Bressan, G; Colombatti, A; Bonaldo, P; Mongiat, M				Paulitti, Alice; Andreuzzi, Eva; Bizzotto, Dario; Pellicani, Rosanna; Tarticchio, Giulia; Marastoni, Stefano; Pastrello, Chiara; Jurisica, Igor; Ligresti, Giovanni; Bucciotti, Francesco; Doliana, Roberto; Colladel, Roberta; Braghetta, Paola; Poletto, Evelina; Di Silvestre, Alessia; Bressan, Giorgio; Colombatti, Alfonso; Bonaldo, Paolo; Mongiat, Maurizio			The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; VESSEL NORMALIZATION; ANGIOGENESIS; THERAPY; METASTASIS; DEFICIENCY; PATHWAY; BREAST; CANCER; IDENTIFICATION	EMILIN2 is an extracellular matrix constituent playing an important role in angiogenesis; however, the underlying mechanism is unknown. Here we show that EMILIN2 promotes angiogenesis by directly binding epidermal growth factor receptor (EGFR), which enhances interleukin-8 (IL-8) production. In turn, IL-8 stimulates the proliferation and migration of vascular endothelial cells. Emilin2 null mice were generated and exhibited delayed retinal vascular development, which was rescued by the administration of the IL-8 murine ortholog MIP-2. Next, we assessed tumor growth and tumor-associated angiogenesis in these mice. Tumor cell growth in Emilin2 null mice was impaired as well as the expression of MIP-2. The vascular density of the tumors developed in Emilin2 null mice was prejudiced and vessels perfusion, as well as response to chemotherapy, decreased. Accordingly, human tumors expressing high levels of EMILIN2 were more responsive to chemotherapy. These results point at EMILIN2 as a key microenvironmental cue affecting vessel formation and unveil the possibility to develop new prognostic tools to predict chemotherapy efficacy.	[Paulitti, Alice; Andreuzzi, Eva; Pellicani, Rosanna; Tarticchio, Giulia; Bucciotti, Francesco; Doliana, Roberto; Colladel, Roberta; Poletto, Evelina; Di Silvestre, Alessia; Colombatti, Alfonso; Mongiat, Maurizio] CRO, Div Mol Oncol, Dept Translat Res, Aviano, Italy; [Bizzotto, Dario; Braghetta, Paola; Bressan, Giorgio; Bonaldo, Paolo] Univ Padua, Dept Mol Med, Padua, Italy; [Marastoni, Stefano; Pastrello, Chiara; Jurisica, Igor] Princess Margaret Canc Ctr, Dept Comp Sci, Toronto, ON, Canada; [Jurisica, Igor] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Ligresti, Giovanni] Mayo Clin, Dept Tissue Repair & Meccano Biol, Rochester, NY USA	IRCCS Aviano (CRO); University of Padua; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Mayo Clinic	Mongiat, M (corresponding author), CRO, Div Mol Oncol, Dept Translat Res, Aviano, Italy.; Bonaldo, P (corresponding author), Univ Padua, Dept Mol Med, Padua, Italy.	bonaldo@bio.unipd.it; mmongiat@cro.it	Bucciotti, Francesco/AAZ-1255-2020; Doliana, Roberto/AAA-1479-2019; Andreuzzi, Eva/AAX-5692-2020; Mongiat, Maurizio/H-8297-2018; Poletto, Evelina/AAW-3671-2020; Ligresti, Giovanni/AAB-9881-2019; Pellicani, Rosanna/J-1263-2018	Bucciotti, Francesco/0000-0002-4253-855X; Doliana, Roberto/0000-0002-8324-7564; Andreuzzi, Eva/0000-0002-5925-5230; Mongiat, Maurizio/0000-0001-6509-0068; Poletto, Evelina/0000-0001-5675-3026; BIZZOTTO, Dario/0000-0002-9036-5016; Pellicani, Rosanna/0000-0002-0952-0403; DI SILVESTRE, ALESSIA/0000-0003-4878-293X; Bonaldo, Paolo/0000-0002-9571-8140	AIRC [IG-2012-12718, IG-13126 AColombatti]; Italian Ministry of Health [RF-2010-2312580]; Italian Ministry of University and Research (grant PRIN); Italian Ministry of University and Research (Progetto Strategico) [01.00858.ST97]; University of Padova [CDPA075559/07, CPDA148982/14]	AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Research (grant PRIN)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of University and Research (Progetto Strategico); University of Padova	This work was supported by AIRC (grant # IG-2012-12718 to MM, IG-13126 AColombatti), the Italian Ministry of Health (grant#RF-2010-2312580 to MM), the Italian Ministry of University and Research (grants PRIN 2007 and Progetto Strategico 01.00858.ST97 to GB), and the University of Padova (grants CDPA075559/07 to PBraghetta and CPDA148982/14 to PBonaldo).	Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711; Andreuzzi E, 2017, MATRIX BIOL, V64, P40, DOI 10.1016/j.matbio.2017.04.002; Aplin AC, 2008, METHOD ENZYMOL, V443, P119, DOI 10.1016/S0076-6879(08)02007-7; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bot S, 2015, MATRIX BIOL, V41, P44, DOI 10.1016/j.matbio.2014.10.001; Braghetta P, 2004, MATRIX BIOL, V22, P549, DOI 10.1016/j.matbio.2003.10.005; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bryja V, 2006, NAT PROTOC, V1, P2082, DOI 10.1038/nprot.2006.355; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Colladel R, 2016, ONCOTARGET, V7, P2022, DOI 10.18632/oncotarget.6515; COLOMBATTI A, 1989, J HISTOCHEM CYTOCHEM, V37, P757, DOI 10.1177/37.5.2703709; Colombatti A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00093; Danussi C, 2008, MOL CELL BIOL, V28, P4026, DOI 10.1128/MCB.02062-07; Doliana R, 2000, J BIOL CHEM, V275, P785, DOI 10.1074/jbc.275.2.785; Doliana R, 2008, MATRIX BIOL, V27, P96, DOI 10.1016/j.matbio.2007.09.008; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukui A, 2013, MICROBIOL IMMUNOL, V57, P198, DOI 10.1111/1348-0421.12022; Galvagni F, 2017, MATRIX BIOL, V64, P112, DOI 10.1016/j.matbio.2017.08.003; Gharavi NM, 2007, J BIOL CHEM, V282, P31460, DOI 10.1074/jbc.M704267200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Marastoni S, 2014, J PATHOL, V232, P391, DOI 10.1002/path.4316; Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; Mongiat M, 2007, MOL CELL BIOL, V27, P7176, DOI 10.1128/MCB.00696-07; Mongiat M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111822; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Newman AC, 2011, MOL BIOL CELL, V22, P3791, DOI 10.1091/mbc.E11-05-0393; Nguyen-Jackson HT, 2012, J LEUKOCYTE BIOL, V92, P1215, DOI 10.1189/jlb.0312126; Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Schiavinato A, 2016, J INVEST DERMATOL, V136, P1150, DOI 10.1016/j.jid.2016.02.021; Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863; Serini G, 2015, EMBO MOL MED, V7, P1251, DOI 10.15252/emmm.201505551; Veljkovic V, 2007, CURR MED CHEM, V14, P441, DOI 10.2174/092986707779941014; Vincenzi B, 2008, CRIT REV ONCOL HEMAT, V68, P93, DOI 10.1016/j.critrevonc.2008.07.006; Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Zhou J, 2014, CELL SIGNAL, V26, P2896, DOI 10.1016/j.cellsig.2014.08.027	53	29	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3399	3414		10.1038/s41388-017-0107-x	http://dx.doi.org/10.1038/s41388-017-0107-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29483644	Green Published			2022-12-28	WOS:000436411300006
J	Liu, Q; Gheorghiu, L; Drumm, M; Clayman, R; Eidelman, A; Wszolek, MF; Olumi, A; Feldman, A; Wang, M; Marcar, L; Citrin, DE; Wu, CL; Benes, CH; Efstathiou, JA; Willers, H				Liu, Qi; Gheorghiu, Liliana; Drumm, Michael; Clayman, Rebecca; Eidelman, Alec; Wszolek, Matthew F.; Olumi, Aria; Feldman, Adam; Wang, Meng; Marcar, Lynnette; Citrin, Deborah E.; Wu, Chin-Lee; Benes, Cyril H.; Efstathiou, Jason A.; Willers, Henning			PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION REPAIR; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; OXIDATIVE STRESS; SYNTHETIC LETHALITY; BLADDER-CANCER; TUMOR-CELLS; NSCLC CELLS; IN-VIVO; PLATFORM	Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive bladder cancer (MIBC), which has poor therapeutic outcomes. We assessed the DNA damaging and cytotoxic effects of the PARPi olaparib in nine bladder cancer cell lines. Olaparib radiosensitized all cell lines with dose enhancement factors from 1.22 to 2.27. Radiosensitization was correlated with the induction of potentially lethal DNA double-strand breaks (DSB) but not with RAD51 foci formation. The ability of olaparib to radiosensitize MIBC cells was linked to the extent of cell kill achieved with the drug alone. Unexpectedly, increased levels of reactive oxygen species (ROS) resulting from PARPi treatment were the cause of DSB throughout the cell cycle in vitro and in vivo. ROS originated from mitochondria and were required for the radiosensitizing effects of olaparib. Consistent with the role of TP53 in ROS regulation, loss of p53 function enhanced radiosensitization by olaparib in non-isogenic and isogenic cell line models and was associated with increased PARP-1 expression in bladder cancer cell lines and tumors. Impairment of ATM in addition to p53 loss resulted in an even more pronounced radiosensitization. In conclusion, ROS suppression by PARP-1 in MIBC is a potential therapeutic target either for PARPi combined with radiation or drug alone treatment. The TP53 and ATM genes, commonly mutated in MIBC and other cancers, are candidate biomarkers of PARPi-mediated radiosensitization.	[Liu, Qi; Gheorghiu, Liliana; Drumm, Michael; Clayman, Rebecca; Eidelman, Alec; Wang, Meng; Marcar, Lynnette; Efstathiou, Jason A.; Willers, Henning] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; [Liu, Qi] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Wszolek, Matthew F.; Olumi, Aria; Feldman, Adam] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA; [Citrin, Deborah E.] NIH, Radiat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Benes, Cyril H.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Willers, H (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.	hwillers@partners.org	Liu, Qi/AAE-7874-2020	Liu, Qi/0000-0002-3285-7864; Citrin, Deborah/0000-0002-4391-2734	Massachusetts General Hospital [C06 CA059267]; Proton Therapy Research and Treatment Center; UK Wellcome Trust [102696]; NATIONAL CANCER INSTITUTE [C06CA059267, ZIABC010850, ZIABC011552] Funding Source: NIH RePORTER	Massachusetts General Hospital(General Electric); Proton Therapy Research and Treatment Center; UK Wellcome Trust(Wellcome Trust); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Federal Share of program income earned by Massachusetts General Hospital on C06 CA059267, Proton Therapy Research and Treatment Center (J. A. Efstathiou, H. Willers), UK Wellcome Trust 102696 (C.H. Benes).	Ameziane-El-Hassani R, 2013, BIO-PROTOCOL, V3, pe313, DOI [10.21769/bioprotoc.313, DOI 10.21769/BIOPROTOC.313]; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; Birkelbach M, 2013, J THORAC ONCOL, V8, P279, DOI 10.1097/JTO.0b013e31827ecf83; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bridges KA, 2014, ONCOTARGET, V5, P5076, DOI 10.18632/oncotarget.2083; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalmers AJ, 2010, SEMIN RADIAT ONCOL, V20, P274, DOI 10.1016/j.semradonc.2010.06.001; Chan N, 2010, CANCER RES, V70, P8045, DOI 10.1158/0008-5472.CAN-10-2352; Coleman CN, 2016, CLIN CANCER RES, V22, P3138, DOI 10.1158/1078-0432.CCR-16-0069; Deschenes F, 2005, HUM MOL GENET, V14, P3293, DOI 10.1093/hmg/ddi362; Dulaney C, 2017, SEMIN CELL DEV BIOL, V63, P144, DOI 10.1016/j.semcdb.2017.01.007; Engert F, 2015, MOL CANCER THER, V14, P2818, DOI 10.1158/1535-7163.MCT-15-0587; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Gani C, 2015, RADIOTHER ONCOL, V116, P486, DOI 10.1016/j.radonc.2015.08.003; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hempel N, 2009, FREE RADICAL BIO MED, V46, P42, DOI 10.1016/j.freeradbiomed.2008.09.020; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kamsler A, 2001, CANCER RES, V61, P1849; Kotter A, 2014, MOL ONCOL, V8, P1616, DOI 10.1016/j.molonc.2014.06.008; Lamy A, 2006, J UROLOGY, V176, P2686, DOI 10.1016/j.juro.2006.07.132; Lee HJ, 2013, MOL CANCER THER, V12, P2591, DOI 10.1158/1535-7163.MCT-13-0338; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Liu Q, 2015, MOL CANCER RES, V13, P713, DOI 10.1158/1541-7786.MCR-14-0570; Liu Q, 2015, INT J RADIAT ONCOL, V91, P1081, DOI 10.1016/j.ijrobp.2014.12.046; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; Martin-Cordero C, 2012, CURR DRUG TARGETS, V13, P1006, DOI 10.2174/138945012802009044; Michels J, 2014, ONCOGENE, V33, P3894, DOI 10.1038/onc.2013.352; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nisimoto Y, 2014, BIOCHEMISTRY-US, V53, P5111, DOI 10.1021/bi500331y; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Rossi MN, 2009, J BIOL CHEM, V284, P31616, DOI 10.1074/jbc.M109.025882; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Verhagen CVM, 2015, RADIOTHER ONCOL, V116, P358, DOI 10.1016/j.radonc.2015.03.028; Wang M, 2014, CANCER RES, V74, P2825, DOI 10.1158/0008-5472.CAN-13-3157; Wang M, 2011, CANCER RES, V71, P6261, DOI 10.1158/0008-5472.CAN-11-0213; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wurster S, 2016, ONCOTARGET, V7, P9732, DOI 10.18632/oncotarget.6947	53	33	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2793	2805		10.1038/s41388-018-0130-6	http://dx.doi.org/10.1038/s41388-018-0130-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511347	Green Accepted			2022-12-28	WOS:000432929800003
J	McKinnon, T; Venier, R; Yohe, M; Sindiri, S; Gryder, BE; Shern, JF; Kabaroff, L; Dickson, B; Schleicher, K; Chouinard-Pelletier, G; Menezes, S; Gupta, A; Zhang, XH; Guha, R; Ferrer, M; Thomas, CJ; Wei, YH; Davani, D; Guidos, CJ; Khan, J; Gladdy, RA				McKinnon, Timothy; Venier, Rosemarie; Yohe, Marielle; Sindiri, Sivasish; Gryder, Berkley E.; Shern, Jack F.; Kabaroff, Leah; Dickson, Brendan; Schleicher, Krista; Chouinard-Pelletier, Guillaume; Menezes, Serena; Gupta, Abha; Zhang, Xiaohu; Guha, Rajarashi; Ferrer, Marc; Thomas, Craig J.; Wei, Yuhong; Davani, Dariush; Guidos, Cynthia J.; Khan, Javed; Gladdy, Rebecca A.			Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma	ONCOGENE			English	Article							B-CELL LYMPHOMA; ALVEOLAR RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; MUSCLE REGENERATION; FUSION GENE; MUTATIONS; CANCER; FGFR4; DIFFERENTIATION; PATHOGENESIS	Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and outcomes have stagnated, highlighting a need for novel therapies. Genomic analysis of RMS has revealed that alterations in the receptor tyrosine kinase (RTK)/RAS/PI3K axis are common and that FGFR4 is frequently mutated or overexpressed. Although FGFR4 is a potentially druggable receptor tyrosine kinase, its functions in RMS are undefined. This study tested FGFR4-activating mutations and overexpression for the ability to generate RMS in mice. Murine tumor models were subsequently used to discover potential therapeutic targets and to test a dual PI3K/mTOR inhibitor in a preclinical setting. Specifically, we provide the first mechanistic evidence of differential potency in the most common human RMS mutations, V550E or N535K, compared to FGFR4(wt) overexpression as murine myoblasts expressing FGFR4(V550E) undergo higher rates of cellular transformation, engraftment into mice, and rapidly form sarcomas that highly resemble human RMS. Murine tumor cells overexpressing FGFR4(V550E) were tested in an in vitro dose-response drug screen along with human RMS cell lines. Compounds were grouped by target class, and potency was determined using average percentage of area under the dose-response curve (AUC). RMS cells were highly sensitive to PI3K/mTOR inhibitors, in particular, GSK2126458 (omipalisib) was a potent inhibitor of FGFR4V550E tumor-derived cell and human RMS cell viability. FGFR4(V550E)-overexpressing myoblasts and tumor cells had low nanomolar GSK2126458 EC50 values. Mass cytometry using mouse and human RMS cell lines validated GSK2126458 specificity at single-cell resolution, decreasing the abundance of phosphorylated Akt as well as decreasing phosphorylation of the downstream mTOR effectors 4ebp1, Eif4e, and S6. Moreover, PI3K/mTOR inhibition also robustly decreased the growth of RMS tumors in vivo. Thus, by developing a preclinical platform for testing novel therapies, we identified PI3K/mTOR inhibition as a promising new therapy for this devastating pediatric cancer.	[McKinnon, Timothy; Venier, Rosemarie; Kabaroff, Leah; Schleicher, Krista; Chouinard-Pelletier, Guillaume; Menezes, Serena; Gladdy, Rebecca A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Yohe, Marielle; Sindiri, Sivasish; Gryder, Berkley E.; Shern, Jack F.; Khan, Javed] NCI, Genet Branch, Oncogen Sect, Ctr Canc Res, Gaithersburg, MD USA; [Gryder, Berkley E.] Mt Sinai Hosp, Dept Pathol, Toronto, ON, Canada; [Gupta, Abha] Hosp Sick Children, Div Hematol Oncol, Toronto, ON, Canada; [Zhang, Xiaohu; Guha, Rajarashi; Ferrer, Marc; Thomas, Craig J.] Natl Ctr Adv Translat Sci, Div Preclin Innovat, NIH, Bethesda, MD USA; [Wei, Yuhong; Davani, Dariush; Guidos, Cynthia J.] Hosp Sick Children, Dev & Stem Cell Biol, Toronto, ON, Canada; [Gladdy, Rebecca A.] Ontario Inst Canc Res, Toronto, ON, Canada; [Gladdy, Rebecca A.] Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto	Gladdy, RA (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Gladdy, RA (corresponding author), Ontario Inst Canc Res, Toronto, ON, Canada.; Gladdy, RA (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.	gladdy@lunenfeld.ca	Khan, Javed/P-9157-2014; Shern, Jack/V-4002-2019; Gladdy, Rebecca/A-2516-2013; Khan, Javed/AAG-3538-2019	Gladdy, Rebecca/0000-0003-4143-6620; Venier, Rosemarie/0000-0001-6063-7562; Thomas, Craig/0000-0001-9386-9001	Canadian Cancer Society Research Institute; Cancer Stem Cells Program of the Ontario Institute for Cancer Research; Ontario Institute for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011002, ZIABC010806] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000047] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Stem Cells Program of the Ontario Institute for Cancer Research; Ontario Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	CJG was supported by funding from the Canadian Cancer Society Research Institute and the Cancer Stem Cells Program of the Ontario Institute for Cancer Research; RAG was supported by a Clinical Investigator Award from Ontario Institute for Cancer Research.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Barr FG, 1999, CANCER RES, V59, p1711S; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chmielecki J, 2017, CANCER RES, V77, P509, DOI 10.1158/0008-5472.CAN-16-1106; Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kashi VP, 2015, NAT REV CANCER, V15, P426, DOI 10.1038/nrc3961; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kikuchi K, 2011, CURR TOP DEV BIOL, V96, P33, DOI 10.1016/B978-0-12-385940-2.00002-4; Knight SD, 2010, ACS MED CHEM LETT, V1, P39, DOI 10.1021/ml900028r; Lewin J, 2015, J CLIN ONCOL, V33, P3372, DOI 10.1200/JCO.2015.62.7380; Li S, 2013, PLOS ONE, V8; Linardic CM, 2008, CANCER LETT, V270, P10, DOI 10.1016/j.canlet.2008.03.035; Marics I, 2002, DEVELOPMENT, V129, P4559; McKinnon T, 2015, ONCOTARGET, V6, P14220, DOI 10.18632/oncotarget.3856; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Perova T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008661; Poschl J, 2014, ACTA NEUROPATHOL, V128, P123, DOI 10.1007/s00401-014-1297-8; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tenente IM, 2017, ELIFE, V6, DOI 10.7554/eLife.19214; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Weigel BJ, 2016, J CLIN ONCOL, V34, P117, DOI 10.1200/JCO.2015.63.4048; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhao P, 2006, J BIOL CHEM, V281, P429, DOI 10.1074/jbc.M507440200; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457	39	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2630	2644		10.1038/s41388-017-0122-y	http://dx.doi.org/10.1038/s41388-017-0122-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29487419	Green Accepted			2022-12-28	WOS:000432545100002
J	Shen, PY; Jing, Y; Zhang, RY; Cai, MC; Ma, PF; Chen, HG; Zhuang, GL				Shen, Peiye; Jing, Ying; Zhang, Ruiyun; Cai, Mei-Chun; Ma, Pengfei; Chen, Haige; Zhuang, Guanglei			Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; URINARY-BLADDER; ANTIANDROGEN RESISTANCE; LINEAGE PLASTICITY; PROSTATE-CANCER	Neuroendocrine bladder cancer is a relatively rare but often lethal malignancy, with cell of origin, oncogenomic architecture and standard treatment poorly defined. Here we performed comprehensive whole-genome and transcriptome sequencing on a unique cohort of genitourinary neuroendocrine neoplasms, mainly small cell carcinomas of the urinary bladder. The mutational landscape and signatures of neuroendocrine bladder cancer strikingly resembled those in conventional urothelial carcinoma, along with typically mixed histologies, supporting a common cellular origin. We identified pervasive age-related and APOBEC-mediated mutagenesis patterns, and one patient displayed a somatic fingerprint attributable to aristolochic acid exposure, an established etiology of urothelial cell carcinoma. Deep RNA sequencing revealed dysregulated tumorigenic pathways and novel fusion transcripts, including a targetable in-frame PVT1-ERBB2 variant associated with aberrant expression of ERBB2 gene (encoding HER2 receptor). Furthermore, we provided preliminary evidence that combined TP53 and RB1 depletion favored lineage switching from oncogene-addicted urothelial cancer cells to neuroendocrine-like tumor cells, and resulted in decreased response to targeted agents. Together, these data present the first high-resolution genomic portrait of neuroendocrine bladder cancer, which holds important implications for the biological understanding and rational treatment of this deadly disease.	[Shen, Peiye; Jing, Ying; Cai, Mei-Chun; Ma, Pengfei; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China; [Shen, Peiye] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Shen, Peiye] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Chen, Haige] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Urol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China.; Chen, HG (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Urol, Shanghai, Peoples R China.	kirbyhaige@aliyun.com; zhuangguanglei@gmail.com		Jing, Ying/0000-0001-6364-6130; Zhuang, Guanglei/0000-0001-8141-5096	National Natural Science Foundation of China [81672514, 81472537, 81672714, 81502597]; Shanghai Natural Science Foundation [16ZR1420300]; Foundation of Shanghai Hospital Development Center [SHDC12015125]; State Key Laboratory of Oncogenes and Related Genes [91-15-12, SB17-06]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Institutions of Higher Learning; Shanghai Rising-Star Program [16QA1403600]; Shanghai Municipal Commission of Health and Family Planning [20174Y0189, 20174Y0043]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Foundation of Shanghai Hospital Development Center; State Key Laboratory of Oncogenes and Related Genes; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Institutions of Higher Learning; Shanghai Rising-Star Program; Shanghai Municipal Commission of Health and Family Planning	This work was supported by the National Natural Science Foundation of China (81672514 to HC; 81472537 and 81672714 to GZ; 81502597 to YJ), Shanghai Natural Science Foundation (16ZR1420300 to HC), Foundation of Shanghai Hospital Development Center (SHDC12015125 to HC), the Grants from the State Key Laboratory of Oncogenes and Related Genes (no. 91-15-12 to GZ; SB17-06 to M-CC), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), the Shanghai Institutions of Higher Learning (Eastern Scholar to GZ), Shanghai Rising-Star Program (16QA1403600 to GZ), Shanghai Municipal Commission of Health and Family Planning (20174Y0189 to YJ and 20174Y0043 to M-CC).	Chang MT, 2017, CLIN CANC RES; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cheng L, 2005, AM J PATHOL, V166, P1533, DOI 10.1016/S0002-9440(10)62369-3; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hoang ML, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006200; Kouba E, 2016, ENDOCR PATHOL, V27, P188, DOI 10.1007/s12022-016-9444-5; Kouba EJ, 2017, JAMA ONCOL, V3, P1570, DOI 10.1001/jamaoncol.2016.7013; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Priemer D.S., 2017, EUR UROL FOCUS; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965	15	25	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3039	3044		10.1038/s41388-018-0192-5	http://dx.doi.org/10.1038/s41388-018-0192-5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535424				2022-12-28	WOS:000433936300010
J	Takayama, K; Suzuki, T; Tanaka, T; Fujimura, T; Takahashi, S; Urano, T; Ikeda, K; Inoue, S				Takayama, Ken-ichi; Suzuki, Takashi; Tanaka, Tomoaki; Fujimura, Tetsuya; Takahashi, Satoru; Urano, Tomohiko; Ikeda, Kazuhiro; Inoue, Satoshi			TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer	ONCOGENE			English	Article							RESPONSIVE FINGER PROTEIN; ANDROGEN RECEPTOR GENE; E3 UBIQUITIN LIGASE; BREAST-CANCER; MUTANT P53; NUCLEAR EXPORT; NONCODING RNA; TUMOR-GROWTH; EFP; 14-3-3-SIGMA	Prostate cancer growth is promoted by the gene regulatory action of androgen receptor (AR) and its downstream signals. The aberrant dysfunction of tumor suppressor p53 has an important role in the prognosis of cancer. We previously found that androgen treatments translocate p53 to the cytoplasm. The mechanism of this translocation depends on sumoylation of p53 by complex of SUMO E3 ligase RanBP2 with androgen-induced GTPase-activating protein-binding protein 2 (G3BP2). Here, we identified tripartite motif-containing protein 25 (TRIM25)/estrogen-responsive finger protein (Efp) as a novel interacting partner of G3BP2 protein complex. Then, we demonstrated that TRIM25 knockdown resulted in p53 downstream activation for cell cycle inhibition and apoptosis induction in LNCaP and 22Rv1 cells. In contrast, overexpression of TRIM25 promoted prostate cancer cell proliferation and inhibited apoptosis by docetaxel treatment in LNCaP cells. We observed that p53 activity was reduced by mechanism of G3BP2-mediated nuclear export in TRIM25-overexpressing prostate cancer cells. We also found TRIM25 is important for G3BP2/RanBP2-mediated p53 modification. Clinically, we newly demonstrated that TRIM25 is a prognostic factor for prostate cancer patients. Expression of TRIM25 is significantly associated with cytoplasmic p53 expression and G3BP2. Moreover, TRIM25 knockdown results in reduced tumor growth and increased p53 activity in the mouse xenograft model of prostate cancer. Thus, our findings show that overexpression of TRIM25 promoted prostate cancer cell proliferation and cell survival by modulating p53 nuclear export mechanism with G3BP2 interaction.	[Takayama, Ken-ichi; Inoue, Satoshi] Tokyo Metropolitan Inst, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo, Japan; [Suzuki, Takashi] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi, Japan; [Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chuo Ku, Chiba, Japan; [Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Div Endocrinol & Metab, Chuo Ku, Chiba, Japan; [Fujimura, Tetsuya] Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, Tokyo, Japan; [Takahashi, Satoru] Nihon Univ, Sch Med, Dept Urol, Itabashi Ku, Tokyo, Japan; [Urano, Tomohiko] Int Univ Hlth & Welf, Dept Geriatr Med, Chiba, Japan; [Ikeda, Kazuhiro; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan	Tohoku University; Chiba University; Chiba University; University of Tokyo; Nihon University; International University of Health & Welfare; Saitama Medical University	Inoue, S (corresponding author), Tokyo Metropolitan Inst, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo, Japan.; Inoue, S (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.	sinoue@tmig.or.jp	Urano, Tomohiko/AFS-9574-2022; Takayama, Kenichi/AAK-9238-2020	Urano, Tomohiko/0000-0002-1771-024X; Tanaka, Tomoaki/0000-0002-9761-1750	P-DIRECT from the Ministry of Education, Culture, Sports, Science and Technology, Japan; P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science, Japan [15K15581, 15K15353]; Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan; Ministry of Health, Labor and Welfare, Japan; Takeda Science Foundation; Terumo foundation for Life Sciences and Arts; NOVARTIS Foundation for the Promotion of Science, Japan	P-DIRECT from the Ministry of Education, Culture, Sports, Science and Technology, Japan; P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan; Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Terumo foundation for Life Sciences and Arts; NOVARTIS Foundation for the Promotion of Science, Japan	This work was supported by grants of the P-DIRECT and the P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to SI); grants from the Japan Society for the Promotion of Science, Japan (to KT, grant 15K15581; to SI, grant 15K15353); a grant of the Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan (to SI); Grants-in-Aid (to SI) from the Ministry of Health, Labor and Welfare, Japan, and grants from the Takeda Science Foundation (to SI and KT), the Terumo foundation for Life Sciences and Arts (to KT) and the NOVARTIS Foundation for the Promotion of Science (to KT), Japan.	Agell L, 2008, MODERN PATHOL, V21, P1470, DOI 10.1038/modpathol.2008.145; Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cai CM, 2013, TRANSL ANDROL UROL, V2, P148, DOI 10.3978/j.issn.2223-4683.2013.09.02; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Henrique R, 2005, DNA CELL BIOL, V24, P264, DOI 10.1089/dna.2005.24.264; Horie-Inoue K, 2006, SEMIN CANCER BIOL, V16, P235, DOI 10.1016/j.semcancer.2006.03.006; Ikeda K, 1998, GENE, V216, P155, DOI 10.1016/S0378-1119(98)00307-2; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; INOUE S, 1995, GENOMICS, V25, P581, DOI 10.1016/0888-7543(95)80064-S; Jain S, 2016, CELL, V164, P487, DOI 10.1016/j.cell.2015.12.038; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Lee NR, 2015, MOL CELLS, V38, P759, DOI 10.14348/molcells.2015.0047; Linja MJ, 2001, CANCER RES, V61, P3550; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Moreira JMA, 2005, MOL CELL PROTEOMICS, V4, P555, DOI 10.1074/mcp.M400205-MCP200; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nakasato N, 2006, BIOCHEM BIOPH RES CO, V351, P540, DOI 10.1016/j.bbrc.2006.10.061; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Simooka H, 2004, PATHOL INT, V54, P595, DOI 10.1111/j.1440-1827.2004.01668.x; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2016, BRIEF FUNCT GENOMICS, V15, P257, DOI 10.1093/bfgp/elv057; Takayama K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9219; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Ueyama K, 2010, CANCER GENE THER, V17, P624, DOI 10.1038/cgt.2010.19; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Valentino E, 2017, P NATL ACAD SCI USA, V114, P7623, DOI 10.1073/pnas.1700996114; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang S, 2016, ONCOTARGET, V7, P64921, DOI 10.18632/oncotarget.11915; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yue XT, 2017, J MOL BIOL, V429, P1595, DOI 10.1016/j.jmb.2017.03.030; Zhang P, 2015, ONCOGENE, V34, P5729, DOI 10.1038/onc.2015.21; Zhao KW, 2011, BIOCHEM J, V437, P323, DOI 10.1042/BJ20101388; Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217	52	56	57	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2165	2180		10.1038/s41388-017-0095-x	http://dx.doi.org/10.1038/s41388-017-0095-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379164				2022-12-28	WOS:000430589000007
J	Liu, MX; Jin, L; Sun, SJ; Liu, P; Feng, X; Cheng, ZL; Liu, WR; Guan, KL; Shi, YH; Yuan, HX; Xiong, Y				Liu, Meng-Xi; Jin, Lei; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Liu, Wei-Ren; Guan, Kun-Liang; Shi, Ying-Hong; Yuan, Hai-Xin; Xiong, Yue			Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TUMOR-GROWTH; FATTY LIVER; MOUSE-LIVER; MICROENVIRONMENT; GLUCONEOGENESIS; CYCLE; ACID; GLUTATHIONE; WARBURG	Phosphoenolpyruvate carboxykinase (PEPCK or PCK) catalyzes the first rate-limiting step in hepatic gluconeogenesis pathway to maintain blood glucose levels. Mammalian cells express two PCK genes, encoding for a cytoplasmic (PCPEK-C or PCK1) and a mitochondrial (PEPCK-M or PCK2) isoforms, respectively. Increased expressions of both PCK genes are found in cancer of several organs, including colon, lung, and skin, and linked to increased anabolic metabolism and cell proliferation. Here, we report that the expressions of both PCK1 and PCK2 genes are downregulated in primary hepatocellular carcinoma (HCC) and low PCK expression was associated with poor prognosis in patients with HCC. Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. Mechanistically, we show that the pro-apoptotic effect of PCK1 requires its catalytic activity. We demonstrate that forced PCK1 expression in glucose-starved liver cancer cells induced TCA cataplerosis, leading to energy crisis and oxidative stress. Replenishing TCA intermediate a-ketoglutarate or inhibition of reactive oxygen species production blocked the cell death caused by PCK expression. Taken together, our data reveal that PCK1 is detrimental to malignant hepatocytes and suggest activating PCK1 expression as a potential treatment strategy for patients with HCC.	[Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Mol & Cell Biol Res Lab, Shanghai, Peoples R China; [Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Basic Med Sci, Minist Educ, Key Lab Metab & Mol Med, Shanghai, Peoples R China; [Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai, Peoples R China; [Liu, Meng-Xi; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai, Peoples R China; [Jin, Lei; Liu, Wei-Ren; Shi, Ying-Hong] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China; [Jin, Lei; Liu, Wei-Ren; Shi, Ying-Hong] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Yue] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill	Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Mol & Cell Biol Res Lab, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Minist Educ, Key Lab Metab & Mol Med, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai, Peoples R China.; Shi, YH (corresponding author), Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China.; Shi, YH (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China.; Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	shi.yinghong@zs-hospital.sh.cn; yuanhaixin@fudan.edu.cn; yxiong@email.unc.edu	Guan, Kun-Liang/ADK-7088-2022; Liu, Mengxi/N-7308-2019		National Science and Technology Major Project of China [2017ZX10203207-002-004]; 973 Program [2015CB910401]; NSFC [31570784, 81773190]; NIH [CA163834, CA196878, GM51586]; NATIONAL CANCER INSTITUTE [P30CA016086, R01CA163834, R35CA196878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	National Science and Technology Major Project of China; 973 Program(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Bin Zhao (Zhejiang University, Hangzhou, China) for providing plasmids used for inducing liver tumor in mice, including PB[CMV-myc-YAP-5SA] DS, PB[Act-RFP] DS, and Act-PB Transposase. We thank Xiaocan Guo for technical help on hydrodynamic injection. We also thank Dr Jiahuai Han (Xiamen University, Xiamen, China) for generously offering cDNAs for human PCK1 and PCK2 genes. This work was supported by the National Science and Technology Major Project of China (No. 2017ZX10203207-002-004 to HXY), the 973 Program (No. 2015CB910401 to YX), the NSFC grants (No. 31570784 and 81773190 to HXY), and NIH grants (CA163834 to YX; CA196878 and GM51586 to K-LG).	Balan MD, 2015, BIOCHEMISTRY-US, V54, P5878, DOI 10.1021/acs.biochem.5b00822; Beale EG, 2007, CELL BIOCHEM BIOPHYS, V48, P89, DOI 10.1007/s12013-007-0025-6; Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Dunten P, 2002, J MOL BIOL, V316, P257, DOI 10.1006/jmbi.2001.5364; Hakimi Parvin, 2005, Nutr Metab (Lond), V2, P33, DOI 10.1186/1743-7075-2-33; Haslene-Hox H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019217; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Ma SH, 2015, ONCOTARGET, V6, P8606, DOI 10.18632/oncotarget.3330; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mendez-Lucas A, 2013, J HEPATOL, V59, P105, DOI 10.1016/j.jhep.2013.02.020; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Satapati S, 2015, J CLIN INVEST, V125, P4447, DOI 10.1172/JCI82204; Shen SY, 2015, CELL RES, V25, P997, DOI 10.1038/cr.2015.98; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Yang JQ, 2009, J BIOL CHEM, V284, P27025, DOI 10.1074/jbc.R109.040543; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	32	75	81	10	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1637	1653		10.1038/s41388-017-0070-6	http://dx.doi.org/10.1038/s41388-017-0070-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335519	Green Submitted, Green Accepted			2022-12-28	WOS:000428626700007
J	Bao, Y; Wang, ZX; Liu, B; Lu, X; Xiong, Y; Shi, JZ; Li, P; Chen, JM; Zhang, ZQ; Chen, M; Wang, LH; Wu, ZJ				Bao, Yi; Wang, Zhixiang; Liu, Bing; Lu, Xin; Xiong, Ying; Shi, Jiazi; Li, Peng; Chen, Junming; Zhang, Zongqin; Chen, Ming; Wang, Linhui; Wu, Zhenjie			A feed-forward loop between nuclear translocation of CXCR4 and HIF-1 alpha promotes renal cell carcinoma metastasis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER; EXPRESSION; HYPOXIA; SDF-1-ALPHA; BIOLOGY; SDF-1	CXC chemokine receptor 4 (CXCR4) has been suggested to play a critical role in cancer metastasis. Some studies have described CXCR4 nuclear localization in metastatic lesions of renal cell carcinoma (RCC), which has been suggested to be correlated with cancer metastasis. However, the underlying mechanism and clinical significance of CXCR4 nuclear localization remains unknown. Here, we show that CXCR4 nuclear localization is more likely to occur in RCC tissues, especially in metastases, and is associated with poor prognosis. CXCR4 nuclear localization requires its nuclear localization sequence (NLS, residues 146-RPRK-149). After the mutation of NLS in CXCR4, CXCR4 nuclear localization in RCC cells is lost. Nuclear localization of CXCR4 promoted RCC tumorigenicity both in vitro and in vivo. Mechanistically, we found that CXCR4 and hypoxia-inducible factor-1 alpha (HIF-1 alpha) colocalized in RCC cells and interacted with each other. Moreover, CXCR4 nuclear localization promoted nuclear accumulation of HIF-1 alpha, thereby promoting the expression of genes downstream of HIF-1 alpha. Reciprocally, nuclear HIF-1 alpha promoted CXCR4 transcription, thus forming a feed-forward loop. Subcellular CXCR4 and HIF-1 alpha expression levels were independent adverse prognostic factors and could be combined with TNM stage to generate a predictive nomogram of the clinical outcome of patients with RCC. Therefore, our findings indicate that CXCR4 nuclear translocation plays a critical role in RCC metastasis and may serve as a prognostic biomarker and potential therapeutic target.	[Bao, Yi; Liu, Bing; Xiong, Ying; Shi, Jiazi; Li, Peng; Chen, Junming; Zhang, Zongqin; Chen, Ming; Wang, Linhui; Wu, Zhenjie] Second Mil Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China; [Wang, Zhixiang] 458th Hosp PLA, Dept Urol, Guangzhou 510602, Guangdong, Peoples R China; [Lu, Xin] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Li, Peng] 153 Hosp PLA, Dept Urol, Zhengzhou 450042, Henan, Peoples R China; [Chen, Junming] Chinese Peoples Armed Police Forces, Dept Urol, Henan Prov Corps Hosp, Zhengzhou 450052, Henan, Peoples R China	Naval Medical University; Naval Medical University	Wang, LH; Wu, ZJ (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China.	wanglinhui@smmu.edu.cn; wuzhenjie17@smmu.edu.cn	wang, lili/HDL-7210-2022; Wu, Zhenjie/GRJ-0184-2022; wang, lin/HHM-2225-2022; wang, lin/GSE-3040-2022	Wu, Zhenjie/0000-0002-6487-5207; 	National Natural Science Foundation of China [81272817, 81874093, 81572521, 81730073]; Leading Talent Project of Shanghai [2013046]; Translation and Application of Precise Medicine of Second Military Medical University [2017JZ22]; Youth Talent Sailing Programme of Shanghai Science and Technology Committee [16YF1403600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leading Talent Project of Shanghai; Translation and Application of Precise Medicine of Second Military Medical University; Youth Talent Sailing Programme of Shanghai Science and Technology Committee	We thank Dr. Taoyong Chen for valuable comments and expert technical support. This study was supported by the National Natural Science Foundation of China (81272817, 81874093, 81572521 and 81730073), the Leading Talent Project of Shanghai (2013046), the Translation and Application of Precise Medicine of Second Military Medical University (No. 2017JZ22) (to L.W.); the Youth Talent Sailing Programme of Shanghai Science and Technology Committee (16YF1403600) (to Z.W.).	Brocato J, 2014, MOL PHARMACOL, V85, P651, DOI 10.1124/mol.113.089623; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Cabioglu N, 2007, ANN ONCOL, V18, P1021, DOI 10.1093/annonc/mdm060; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Don-Salu-Hewage AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057194; Figlin RA, 1999, J UROLOGY, V161, P381, DOI 10.1016/S0022-5347(01)61897-4; Gong J, 2016, ASIAN J UROL, V3, P286, DOI 10.1016/j.ajur.2016.08.006; Han MZ, 2014, TUMOR BIOL, V35, P4589, DOI 10.1007/s13277-013-1603-4; He X, 2010, PATHOL RES PRACT, V206, P712, DOI 10.1016/j.prp.2010.05.003; Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006; Marechal R, 2009, BRIT J CANCER, V100, P1444, DOI 10.1038/sj.bjc.6605020; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nikkhoo B, 2014, J ONCOL, V2014, DOI 10.1155/2014/808012; Pan JD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-56; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Singh D, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0190-2; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun WD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05685-3; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang LH, 2009, ONCOL REP, V22, P1333, DOI 10.3892/or_00000572; Wang LH, 2009, CLIN EXP METASTAS, V26, P1049, DOI 10.1007/s10585-009-9294-3; Wang SC, 2010, INT J COLORECTAL DIS, V25, P1185, DOI 10.1007/s00384-010-0999-1; Xu ZP, 2016, ONCOL REP, V36, P2681, DOI 10.3892/or.2016.5082; Yoshitake N, 2008, BRIT J CANCER, V98, P1682, DOI 10.1038/sj.bjc.6604363; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482	32	31	31	1	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					881	895		10.1038/s41388-018-0452-4	http://dx.doi.org/10.1038/s41388-018-0452-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177838	Green Published, hybrid			2022-12-28	WOS:000458006300009
J	Li, YS; Zhang, HY; Zhao, Y; Wang, CY; Cheng, ZG; Tang, LN; Gao, YL; Liu, FR; Li, JB; Li, Y; Li, Y; Geng, NX; Rui, X; Teng, YE; Liu, YP; Cao, L; Kumar, R; Jin, F; Li, F				Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Rui, Xue; Teng, Yuee; Liu, Yunpeng; Cao, Liu; Kumar, Rakesh; Jin, Feng; Li, Feng			A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ER alpha-positive breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ANDROGEN RECEPTOR; PAK4; INVASION; PROLIFERATION; MIGRATION; PROMOTES; PROTEIN; EXPRESSION; INHIBITOR	The mechanism of estrogen receptor alpha (ER alpha)-positive breast cancer-associated bone metastasis is poorly understood. In this article, we report that nuclear p21-activated kinase 4 (nPAK4) is a novel repressor of ER alpha-mediated transactivation in a 17 beta-estradiol (E2)-dependent manner and promotes PAK4-ER alpha axis-mediated bone metastasis by targeting leukemia inhibitory factor receptor (LIFR) in ER alpha-positive breast cancer. An evaluation of clinical breast cancer samples revealed that nPAK4 is linked to ERa expression and appears to be associated with a poor prognosis in bone metastatic breast cancer. PAK4 bound and co-translocated with ERa from the cytoplasm to the nucleus upon stimulation with E2. nPAK4 enhanced the invasive potential of ER alpha-positive breast cancer cells in vitro and promoted breast cancer metastasis in vivo. Mechanistically, nPAK4 promoted the metastasis of ER alpha-positive breast cancer cells by targeting LIFR, a bone metastasis suppressor. Strikingly, the nuclear accumulation of PAK4 might promote aggressive phenotypes, highlighting nPAK4 as a novel predictive biomarker for ER alpha-positive breast cancer bone metastasis.	[Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Cao, Liu; Li, Feng] China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China; [Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Cao, Liu; Li, Feng] China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China; [Rui, Xue; Jin, Feng] China Med Univ, Dept Surg Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China; [Teng, Yuee; Liu, Yunpeng] China Med Univ, Dept Med Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China; [Kumar, Rakesh] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India	China Medical University; China Medical University; China Medical University; China Medical University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Li, F (corresponding author), China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China.; Li, F (corresponding author), China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China.; Jin, F (corresponding author), China Med Univ, Dept Surg Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.	jinfeng@cmu.edu.cn; lifeng@cmu.edu.cn	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Li, Feng/0000-0001-5868-7456	MD Anderson cancer center; National Natural Science Foundation of China [31371424, 31571457, 90813038, 81372337]; Ministry of Education of China [IRT13101]; Basic Research Project of Education Department of Liaoning Province [LZ2015071]	MD Anderson cancer center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Basic Research Project of Education Department of Liaoning Province	We thank Raabe T. for the gifts of the Mbt and Mbt<SUP>P1</SUP> mutants fly stocks. We thank Dr. Yu Tong from MD Anderson cancer center for the gifts of the LIFR plasmids. This research was supported by Grants from the National Natural Science Foundation of China No. 31371424 (Feng Li), No. 31571457 (Feng Li), No. 90813038 (Feng Li), No. 81372337 (Yan Li) and Ministry of Education of China IRT13101 (Liu Cao), and Basic Research Project of Education Department of Liaoning Province, No. LZ2015071 (Feng Li).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; BERCHUCK A, 1989, CANCER RES, V49, P2091; Bi YQ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0913-6; Blanco MA, 2012, CELL RES, V22, P1339, DOI 10.1038/cr.2012.89; Cai SW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0165-2; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Choi SW, 2015, J BONE MINER RES, V30, P1494, DOI 10.1002/jbmr.2468; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; Guo Q, 2014, ONCOGENE, V33, P3277, DOI 10.1038/onc.2013.296; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Kobayashi K, 2016, J CLIN PATHOL, V69, P580, DOI 10.1136/jclinpath-2015-203330; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Li YS, 2013, ANAT REC, V296, P1561, DOI 10.1002/ar.22754; Lindberg MK, 2002, J BONE MINER RES, V17, P2183, DOI 10.1359/jbmr.2002.17.12.2183; Liu FA, 2017, MOL THER-NUCL ACIDS, V8, P370, DOI 10.1016/j.omtn.2017.07.005; Liu Y, 2010, ONCOGENE, V29, P5883, DOI 10.1038/onc.2010.329; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu W, 2013, NEOPLASMA, V60, P493, DOI 10.4149/neo_2013_064; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Menzel N, 2008, BIOCHEM J, V416, P231, DOI 10.1042/BJ20080465; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vershinin Z, 2016, J BIOL CHEM, V291, P6786, DOI 10.1074/jbc.M115.697292; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang CY, 2015, NUCLEIC ACIDS RES, V43, P4893, DOI 10.1093/nar/gkv394; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wong LE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.13; Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31; Xu HT, 2016, CANCER RES, V76, P5732, DOI 10.1158/0008-5472.CAN-15-3373; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Zhang HY, 2017, AM J TRANSL RES, V9, P2736; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007; Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011; Zhao Y, 2009, MOL CELL BIOL, V29, P1017, DOI 10.1128/MCB.02123-07; Zhuang T, 2015, ONCOTARGET, V6, P43853, DOI 10.18632/oncotarget.6081	45	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					808	821		10.1038/s41388-018-0456-0	http://dx.doi.org/10.1038/s41388-018-0456-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177834	Green Published, hybrid			2022-12-28	WOS:000458006300004
J	Shao, YW; Wood, GA; Lu, JC; Tang, QL; Liu, J; Molyneux, S; Chen, Y; Fang, H; Adissu, H; McKee, T; Waterhouse, P; Khokha, R				Shao, Yang W.; Wood, Geoffrey A.; Lu, Jinchang; Tang, Qing-Lian; Liu, Jonathan; Molyneux, Sam; Chen, Yan; Fang, Hui; Adissu, Hibret; McKee, Trevor; Waterhouse, Paul; Khokha, Rama			Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma	ONCOGENE			English	Article							GENE-EXPRESSION; COPY NUMBER; G-PROTEINS; HYBRIDIZATION; REARRANGEMENT; POLARITY; GTPASES; CANCER; CANINE; EVENT	Leveraging the conserved cancer genomes across mammals has the potential to transform driver gene discovery in orphan cancers. Here, we combine cross-species genomics with validation across human-dog-mouse systems to uncover a new bone tumor suppressor gene. Comparative genomics of spontaneous human and dog osteosarcomas (OS) expose Disks Large Homolog 2 (DLG2) as a tumor suppressor candidate. DLG2 copy number loss occurs in 42% of human and 56% of canine OS. Functional validation through pertinent human and canine OS DLG2-deficient cell lines identifies a regulatory role of DLG2 in cell division, migration and tumorigenesis. Moreover, osteoblast-specific deletion of Dlg2 in a clinically relevant genetically engineered mouse model leads to acceleration of OS development, establishing DLG2 as a critical determinant of OS. This widely applicable cross-species approach serves as a platform to expedite the search of cancer drivers in rare human malignancies, offering new targets for cancer therapy.	[Shao, Yang W.; Lu, Jinchang; Tang, Qing-Lian; Molyneux, Sam; Chen, Yan; Fang, Hui; McKee, Trevor; Waterhouse, Paul; Khokha, Rama] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada; [Wood, Geoffrey A.; Liu, Jonathan; Adissu, Hibret] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Lu, Jinchang; Tang, Qing-Lian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped Oncol, Guangzhou 510080, Guangdong, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Guelph; Sun Yat Sen University	Khokha, R (corresponding author), Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.	rama.khokha@utoronto.ca	adissu, hibret a/R-3282-2018; Wood, Geoffrey/ABB-2052-2021	adissu, hibret a/0000-0003-3365-7466; Wood, Geoffrey/0000-0003-1756-8607; Waterhouse, Paul/0000-0001-8745-5224	Canadian Institutes of Health Research (CIHR); Ontario Institute for Cancer Research (OICR); Global Leadership Round in Genomics and Life Sciences (GL2); OVC Pet Trust; National Natural Science Foundation of China [81702665]; National Postdoctoral Program for Innovative Talents [BX201600196]; China Postdoctoral Science Foundation [2017M610571]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research (OICR); Global Leadership Round in Genomics and Life Sciences (GL2); OVC Pet Trust; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Postdoctoral Program for Innovative Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study is supported by funding from the Canadian Institutes of Health Research (CIHR), Ontario Institute for Cancer Research (OICR), and Global Leadership Round in Genomics and Life Sciences (GL2) to RK and the OVC Pet Trust to GW. J. Lu is also supported by National Natural Science Foundation of China (81702665), National Postdoctoral Program for Innovative Talents (BX201600196) and China Postdoctoral Science Foundation (2017M610571).	Aguiar SD, 2007, CANCER GENET CYTOGEN, V175, P35, DOI 10.1016/j.cancergencyto.2007.01.007; Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731; Angstadt AY, 2012, CANCER GENET-NY, V205, P572, DOI 10.1016/j.cancergen.2012.09.005; Angstadt AY, 2011, GENE CHROMOSOME CANC, V50, P859, DOI 10.1002/gcc.20908; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen X, 2014, CELL, V158, P1187, DOI 10.1016/j.cell.2014.07.034; Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freeman SS, 2008, CANCER-AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956; Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008-5472.CAN-03-1816; Roberts S, 2012, FEBS J, V279, P3549, DOI 10.1111/j.1742-4658.2012.08729.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stramer B, 2005, J CELL BIOL, V168, P567, DOI 10.1083/jcb.200405120; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; Tsai PC, 2012, AM J VET RES, V73, P1335, DOI 10.2460/ajvr.73.9.1335; van Dam Teunis J P, 2011, Small GTPases, V2, P4; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469	31	41	42	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					291	298		10.1038/s41388-018-0444-4	http://dx.doi.org/10.1038/s41388-018-0444-4			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093633	Green Published, hybrid			2022-12-28	WOS:000455366700010
J	Ohno, Y; Shingyoku, S; Miyake, S; Tanaka, A; Fudesaka, S; Shimizu, Y; Yoshifuji, A; Yamawaki, Y; Yoshida, S; Tanaka, S; Sakura, K; Tanaka, T				Ohno, Yoshiya; Shingyoku, Serina; Miyake, Sakina; Tanaka, Aya; Fudesaka, Sena; Shimizu, Yuta; Yoshifuji, Ai; Yamawaki, Yuki; Yoshida, Sachiyo; Tanaka, Saya; Sakura, Kazuma; Tanaka, Toshiyuki			Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways	ONCOGENE			English	Article							STEM-CELLS; ACTIVIN-A; PLEURAL MESOTHELIOMA; HYALURONAN; RECEPTOR; TUMORIGENICITY; PATHOGENESIS; INSIGHTS; MARKER; GROWTH	Malignant mesothelioma (MM) has a poor prognosis and is largely resistant to standard treatments, so it is important to seek novel therapeutic strategies for this disease. Cancer-initiating cells (CICs) were previously identified in MM using stem cell-associated markers in combination with spheroid cultures. However, the mechanisms underlying the induction and maintenance of CICs in MM remain to be fully explored. Here we showed that the CICs, which had high aldehyde dehydrogenase levels (ALDH(bri)(g)(ht)) and stem cell-associated genes, were expanded in MM cells cultured under sphere-forming conditions. The MM spheroids also initiated tumors in immunodeficient mice more efficiently than did conventional adherent MM cells. In the MM spheroids, the expression of hyaluronan (HA) synthases was upregulated. Inhibiting the HA synthesis or CD44 functions by gene knockdown or neutralizing antibody abolished the formation of large-sized spheroids and the expansion of ALDH(bri)(g)(ht) CICs. The expression of activin-A was also increased in the spheroids, and type I activin-A receptor subunit (ALK4) was upregulated in the ALDH(bright) CICs. The neutralization of activin-A or functional inactivation of ALK4 diminished the ALDH(bri)(g)(ht) CICs without affecting spheroid formation. The knockdown of CD44 or ALK4 strongly suppressed the tumor growth in immunodeficient mice. These results together suggest that the HA-CD44 and activin-A-ALK4 pathways differentially regulate the spheroid formation and maintenance of ALDH(bri)(g)(ht) CICs in MM cells, and that both pathways play critical roles in tumor growth in immunodeficient hosts. Our findings provide a novel therapeutic option for MM that targets signaling pathways that promote the CIC compartment through CD44 and ALK4.	[Ohno, Yoshiya; Shingyoku, Serina; Miyake, Sakina; Tanaka, Aya; Fudesaka, Sena; Shimizu, Yuta; Yoshifuji, Ai; Yamawaki, Yuki; Yoshida, Sachiyo; Tanaka, Saya; Tanaka, Toshiyuki] Hyogo Univ Hlth Sci, Sch Pharm, Lab Immunobiol, Kobe, Hyogo, Japan; [Sakura, Kazuma] Osaka Univ Hosp, Ctr Med Innovat & Translat Res, Osaka, Japan; [Sakura, Kazuma] Osaka Univ, Dept Surg, Grad Sch Med, Osaka, Japan	Osaka University; Osaka University	Tanaka, T (corresponding author), Hyogo Univ Hlth Sci, Sch Pharm, Lab Immunobiol, Kobe, Hyogo, Japan.	tanaka@huhs.ac.jp			JSPS KAKENHI [JP22700889]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by JSPS KAKENHI Grant Number JP22700889.	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Cortes-Dericks L, 2014, BMC CANCER, V14, P2818; Cortes-Dericks L, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0546-5; Ghani FI, 2011, BIOCHEM BIOPH RES CO, V404, P735, DOI 10.1016/j.bbrc.2010.12.054; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hanagiri T, 2012, TUMOR BIOL, V33, P2135, DOI 10.1007/s13277-012-0473-5; Hiraga T, 2013, CANCER RES, V73, P4112, DOI 10.1158/0008-5472.CAN-12-3801; Hoda MA, 2012, BRIT J CANCER, V107, P1978, DOI 10.1038/bjc.2012.519; Hoda MA, 2016, EUR J CANCER, V63, P64, DOI 10.1016/j.ejca.2016.04.018; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Kultti A, 2009, EXP CELL RES, V315, P1914, DOI 10.1016/j.yexcr.2009.03.002; Lin KC, 2017, NAT CELL BIOL, V19, P996, DOI 10.1038/ncb3581; Liu R, 2016, BIOCHEM BIOPH RES CO, V479, P715, DOI 10.1016/j.bbrc.2016.09.146; Liu SL, 2017, CANCER RES, V77, P3791, DOI 10.1158/0008-5472.CAN-16-2545; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2016, AM J CANCER RES, V6, P2431; Loomans HA, 2015, CANCERS, V7, P70, DOI 10.3390/cancers7010070; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mossman BT, 2013, AM J PATHOL, V182, P1065, DOI 10.1016/j.ajpath.2012.12.028; Nasreen N, 2001, ONCOL RES, V13, P71; Pasdar EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119549; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Preca BT, 2017, ONCOTARGET, V8, P11530, DOI 10.18632/oncotarget.14563; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Sekido Y, 2013, CARCINOGENESIS, V34, P1413, DOI 10.1093/carcin/bgt166; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Tajima K, 2010, ONCOGENE, V29, P1941, DOI 10.1038/onc.2009.478; Tamminen JA, 2015, EXP CELL RES, V332, P102, DOI 10.1016/j.yexcr.2014.12.010; Tanaka K, 2017, CANCER LETT, V385, P215, DOI 10.1016/j.canlet.2016.10.020; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Turley EA, 2016, CANCER RES, V76, P2507, DOI 10.1158/0008-5472.CAN-15-3114; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Xiang X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027946; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	38	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6357	6367		10.1038/s41388-018-0405-y	http://dx.doi.org/10.1038/s41388-018-0405-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30061637	hybrid, Green Published			2022-12-28	WOS:000452384400006
J	Zhang, BY; Lyu, JF; Liu, YF; Wu, CJ; Yang, EJ; Pardeshi, L; Tan, KL; Wong, KH; Chen, Q; Xu, XL; Deng, CX; Shim, JS				Zhang, Baoyuan; Lyu, Junfang; Liu, Yifan; Wu, Changjie; Yang, Eun Ju; Pardeshi, Lakhansing; Tan, Kaeling; Wong, Koon Ho; Chen, Qiang; Xu, Xiaoling; Deng, Chu-Xia; Shim, Joong Sup			BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition	ONCOGENE			English	Article							THIOREDOXIN-INTERACTING PROTEIN; UP-REGULATED PROTEIN-1; DNA-DAMAGE; CYCLE; GENE; MYC; SUPPRESSION; EXPRESSION; RESISTANCE; APOPTOSIS	BRCA1 is a tumor suppressor frequently mutated in breast and ovarian cancer, serving it as a target for therapeutic exploitation. Here, we show that BRCA1 has a synthetic lethality interaction with an epigenetics regulator, bromodomain and extra-terminal domain (BET). BET inhibition led to gene expression changes reversing MYC-dependent transcription repression of a redox regulator, thioredoxin-interacting protein (TXNIP), via switching the promoter occupant from MYC to MondoA:MLX complex. Reversing the MYC-TXNIP axis inhibited thioredoxin activity and elevated cellular oxidative stress, causing DNA damages that are detrimental to BRCA1-deficient breast cancer cells. Tumor xenograft models and breast cancer clinical data analyses further demonstrated an in vivo synthetic lethality interaction and clinical association between BET/TXNIP and BRCA1 deficiency in the survival of breast cancer patients.	[Zhang, Baoyuan; Lyu, Junfang; Liu, Yifan; Wu, Changjie; Yang, Eun Ju; Pardeshi, Lakhansing; Tan, Kaeling; Wong, Koon Ho; Chen, Qiang; Xu, Xiaoling; Deng, Chu-Xia; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Ave Univ, Taipa 999078, Macau, Peoples R China	University of Macau	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Ave Univ, Taipa 999078, Macau, Peoples R China.	jsshim@umac.mo	Wong, Koon Ho/P-3685-2018; wong, chris/GSN-0962-2022; Wong, Koon/AAH-3021-2020; LIU, Yifan/AAV-1994-2020	Wong, Koon Ho/0000-0002-9264-5118; Wong, Koon/0000-0002-9264-5118; Pardeshi, Lakhansing/0000-0003-0702-5465; Tan, Kaeling/0000-0002-3347-7628	Multi-Year Research Grant of the University of Macau [MYRG2015-00181-FHS, MYRG2017-00176-FHS]; Science and Technology Development Fund (FDCT) of Macau SAR [FDCT/024/2015/A1]	Multi-Year Research Grant of the University of Macau; Science and Technology Development Fund (FDCT) of Macau SAR	We thank to the members of the Genomics and Bioinformatics Core of FHS at UM for experimental and technical supports for the RNA-sequencing and data analyses and to Jacky Chan and William Pang from ICTO at UM for supporting the High Performance Computing cluster. We are also grateful to the members of FHS Animal Facility at UM for arranging and maintaining experimental animals for this study. This work was supported by the Multi-Year Research Grant of the University of Macau (MYRG2015-00181-FHS and MYRG2017-00176-FHS to J.S.S) and the Science and Technology Development Fund (FDCT) of Macau SAR (FDCT/024/2015/A1 to J.S.S).	Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cadenas C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2599; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2000, BIOESSAYS, V22, P728; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Greenup R, 2013, ANN SURG ONCOL, V20, P3254, DOI 10.1245/s10434-013-3205-1; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kalinin A, 2001, J CELL SCI, V114, P3069; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morrison JA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-62; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nishizawa K, 2011, CARCINOGENESIS, V32, P1459, DOI 10.1093/carcin/bgr137; O'Shea JM, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014258; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Patwari P, 2006, J BIOL CHEM, V281, P21884, DOI 10.1074/jbc.M600427200; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Schafer M, 2011, J INVEST DERMATOL, V131, P1409, DOI 10.1038/jid.2011.119; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shibanuma M, 2011, FREE RADICAL RES, V45, P672, DOI 10.3109/10715762.2011.564169; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Tome ME, 2005, BLOOD, V106, P3594, DOI 10.1182/blood-2005-02-0487; Tomlinson GE, 1998, CANCER RES, V58, P3237; Tonissen KF, 2009, MOL NUTR FOOD RES, V53, P87, DOI 10.1002/mnfr.200700492; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vazquez-Ortiz G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3682; Vermeij WP, 2011, J INVEST DERMATOL, V131, P1435, DOI 10.1038/jid.2010.433; Wilde BR, 2015, BRIT J CANCER, V113, P1529, DOI 10.1038/bjc.2015.360; Woolston CM, 2013, REDOX BIOL, V1, P285, DOI 10.1016/j.redox.2013.04.006; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983	54	11	11	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6341	6356		10.1038/s41388-018-0408-8	http://dx.doi.org/10.1038/s41388-018-0408-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30042414				2022-12-28	WOS:000452384400005
J	Ding, J; Yeh, CR; Sun, Y; Lin, CY; Chou, JS; Ou, ZY; Chang, CS; Qi, J; Yeh, SY				Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Qi, Jun; Yeh, Shuyuan			Estrogen receptor beta promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network	ONCOGENE			English	Article							LONG NONCODING RNA; RESISTANT PROSTATE-CANCER; ANDROGEN-RECEPTOR; ER-BETA; PROGNOSTIC MARKER; TARGETED THERAPY; SIGNALING AXIS; BREAST-CANCER; HOTAIR; EXPRESSION	Recent studies indicated that the estrogen receptor beta (ER beta) could affect the progression of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain to be elucidated. Here, we provide clinical evidence that ER beta expression is correlated in a negative manner with the overall survival/disease-free survival in RCC patients. Mechanism dissection revealed that targeting ER beta with ER beta-shRNA and stimulating the transactivation of ER beta with 17 beta-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression. The ER beta-modulated HOTAIR is able to function via antagonizing several microRNAs, including miR-138, miR-200c, miR-204, or miR-217 to impact various oncogenes, including ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1, and ZEB2, to promote RCC proliferation and invasion. Together, the identification of the ER beta-HOTAIR axis may provide us new biomarkers and/or therapeutic targets to better suppress RCC progression in the future.	[Ding, Jie; Qi, Jun] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai 200092, Peoples R China; [Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	Shanghai Jiao Tong University; University of Rochester; University of Rochester	Qi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai 200092, Peoples R China.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	qijun@xinhuamed.com.cn; shuyuan_yeh@URMC.rochester.edu	Jie, Ding/ABD-8973-2021	Chang, Chawnshang/0000-0001-8510-3516	URMC Urology Department Research fund; George Whipple Professorship Endowment	URMC Urology Department Research fund; George Whipple Professorship Endowment	This work was partially supported by URMC Urology Department Research fund and George Whipple Professorship Endowment.	Batistatou A, 2006, J NEURO-ONCOL, V77, P17, DOI 10.1007/s11060-005-9005-0; Chiyomaru T, 2014, J BIOL CHEM, V289, P12550, DOI 10.1074/jbc.M113.488593; Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070372; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Finley DS, 2011, ONCOLOGIST, V16, P4, DOI 10.1634/theoncologist.2011-S2-04; Fujimura T, 2001, BIOCHEM BIOPH RES CO, V289, P692, DOI 10.1006/bbrc.2001.6038; Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Hall JM, 2013, MOL CARCINOGEN, V52, P715, DOI 10.1002/mc.21913; Hibino S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.17; HOBISCH A, 1995, CANCER RES, V55, P3068; Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Klotz LV, 2012, LANGENBECK ARCH SURG, V397, P569, DOI 10.1007/s00423-012-0946-4; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kontovinis LF, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-82; Lee HW, 2012, PATHOL INT, V62, P735, DOI 10.1111/pin.12001; Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu L, 2016, BJU INT, V117, P351, DOI 10.1111/bju.12702; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Perkel JM, 2013, BIOTECHNIQUES, V54, P301, DOI 10.2144/000114037; Powles T, 2016, EUR UROL, V70, P705, DOI 10.1016/j.eururo.2016.06.009; Powles T, 2016, EUR UROL, V69, P4, DOI 10.1016/j.eururo.2015.10.017; Qin J, 2014, J CLIN INVEST, V124, P5013, DOI 10.1172/JCI76412; Rapisarda A, 2012, ADV CANCER RES, V114, P237, DOI 10.1016/B978-0-12-386503-8.00006-5; Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621; Verkasalo PK, 2001, BRIT J NUTR, V86, P415, DOI 10.1079/BJN2001424; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wang XG, 2015, MOL CANCER RES, V13, P1567, DOI 10.1158/1541-7786.MCR-15-0128; Xu ZQ, 2015, CLIN TRANSL ONCOL, V17, P41, DOI 10.1007/s12094-014-1195-5; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015; Younes M, 2011, ARCH PATHOL LAB MED, V135, P63, DOI 10.1043/2010-0448-RAR.1; Yu CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056667; Zheng JC, 2013, ONCOL LETT, V5, P1583, DOI 10.3892/ol.2013.1236; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	49	80	81	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5037	5053		10.1038/s41388-018-0175-6	http://dx.doi.org/10.1038/s41388-018-0175-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789714				2022-12-28	WOS:000444405300001
J	Berns, K; Caumanns, JJ; Hijmans, EM; Gennissen, AMC; Severson, TM; Evers, B; Wisman, GBA; Meersma, GJ; Lieftink, C; Beijersbergen, RL; Itamochi, H; van der Zee, AGJ; de Jong, S; Bernards, R				Berns, Katrien; Caumanns, Joseph J.; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Wisman, G. Bea A.; Meersma, Gert Jan; Lieftink, Cor; Beijersbergen, Roderick L.; Itamochi, Hiroaki; van der Zee, Ate G. J.; de Jong, Steven; Bernards, Rene			ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors	ONCOGENE			English	Article							COLON-CANCER; RESISTANCE; ACTIVATION; LANDSCAPE; MYC	Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations, we performed kinome-centered lethality screens in a large panel of ovarian clear cell carcinoma cell lines. Using the largest OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated ovarian clear cell cancer cells. Importantly, small molecule inhibitors of the BET (bromodomain and extra terminal domain) family of proteins, to which BRD2 belongs, specifically inhibit proliferation of ARID1A mutated cell lines, both in vitro and in ovarian clear cell cancer xenografts and patient-derived xenograft models. BET inhibitors cause a reduction in the expression of multiple SWI/SNF members including ARID1B, providing a potential explanation for the observed lethal interaction with ARID1A loss. Our data indicate that BET inhibition may represent a novel treatment strategy for a subset of ARID1A mutated ovarian clear cell carcinomas.	[Berns, Katrien; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Lieftink, Cor; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Berns, Katrien; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Lieftink, Cor; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Oncode Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Caumanns, Joseph J.; Wisman, G. Bea A.; Meersma, Gert Jan; van der Zee, Ate G. J.] Univ Groningen, Univ Med Ctr Groningen, Canc Res Ctr Groningen, Gynaecol Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Itamochi, Hiroaki] Iwate Med Univ, Sch Med, Dept Obstet & Gynaecol, Morioka, Iwate 0208505, Japan; [de Jong, Steven] Univ Groningen, Univ Med Ctr Groningen, Canc Res Ctr Groningen, Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Groningen; Iwate Medical University; University of Groningen	Berns, K; Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.; Berns, K; Bernards, R (corresponding author), Netherlands Canc Inst, Oncode Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	k.berns@nki.nl; r.bernards@nki.nl		Beijersbergen, Roderick/0000-0003-0116-4130	Dutch Cancer Society (KWF) [RUG2012-5477]; Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO)	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO)	We thank pathologist E.W. Duiker from UMCG for her contributions on OCCC pathology, H. Maat (Department of Experimental Hematology, UMCG) for her help with ChIP experiments, the people from the Genomics Core Facility of the Netherlands Cancer Institute for their technical support, and members of the Bernards lab for their helpful discussions. This research was supported by grants from the Dutch Cancer Society (KWF, RUG2012-5477) and the Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO).	Alkema NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14495; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Braicu EI, 2011, BRIT J CANCER, V105, P1818, DOI 10.1038/bjc.2011.455; Cheung KL, 2017, MOL CELL, V65, P1068, DOI 10.1016/j.molcel.2016.12.022; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Murakami R, 2017, AM J PATHOL, V187, P2246, DOI 10.1016/j.ajpath.2017.06.012; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prat J, 2012, ANN ONCOL, V23, P111, DOI 10.1093/annonc/mds300; Shao Q, 2014, CANCER RES, V74, P7090, DOI 10.1158/0008-5472.CAN-14-0305; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	29	52	54	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4611	4625		10.1038/s41388-018-0300-6	http://dx.doi.org/10.1038/s41388-018-0300-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29760405	Green Published, hybrid			2022-12-28	WOS:000441736700009
J	Guo, XF; Qiu, W; Liu, QL; Qian, MY; Wang, SB; Zhang, ZP; Gao, X; Chen, ZH; Xue, H; Li, G				Guo, Xiaofan; Qiu, Wei; Liu, Qinglin; Qian, Mingyu; Wang, Shaobo; Zhang, Zongpu; Gao, Xiao; Chen, Zihang; Xue, Hao; Li, Gang			Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways	ONCOGENE			English	Article							NF-KAPPA-B; BLOOD-BRAIN-BARRIER; TUMOR MICROENVIRONMENT; LINKING INFLAMMATION; ROR-ALPHA; GLIOBLASTOMA; ACTIVATION; CANCER; MIGRATION; DIFFERENTIATION	While immunosuppressive environments mediated by myeloid-derived suppressor cells (MDSCs) have been well documented in glioma patients, the mechanisms of MDSC development and activation have not been clearly defined. Here, we elucidated a role for glioma-derived exosomes (GDEs) in potentiating an MDSC pathway. We isolated normoxiastimulated and hypoxia-stimulated GDEs and studied their MDSC induction abilities in vivo and in vitro. Analyses of spleen and bone marrow MDSC proportions (flow cytometry) and reactive oxygen species (ROS), arginase activity, nitric oxide (NO), T-cell proliferation and immunosuppressive cytokine (IL-10 and TGF-beta, ELISA) levels were used to assess MDSC expansion and functional capacity. We also performed microRNA (miRNA) sequencing analysis of two types of GDEs to find miRNAs that potentially mediate the development and activation of MDSCs. GDE miRNA intracellular signaling in MDSCs was also studied. Hypoxia promoted the secretion of GDEs, and mouse MDSCs could uptake GDEs. Hypoxia-stimulated GDEs had a stronger ability to induce MDSCs than N-GDEs. The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN). Mice inoculated with miR-10a or miR-21 knockout glioma cells generated fewer MDSCs than those inoculated with normal glioma cells. These data elucidated a mechanism by which glioma cells influence the differentiation and activation of MDSCs via exosomes and demonstrated how local glioma hypoxia affects the entirety of tumor immune environments.	[Guo, Xiaofan; Qiu, Wei; Qian, Mingyu; Wang, Shaobo; Zhang, Zongpu; Gao, Xiao; Chen, Zihang; Xue, Hao; Li, Gang] Shandong Univ, Brain Sci Res Inst, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Qinglin; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Dept Neurosurg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Xue, H; Li, G (corresponding author), Shandong Univ, Brain Sci Res Inst, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	undeadadams@163.com; ligangqiluhospital@163.com	Xue, Hao/GXV-4717-2022; Liu, Qing/GWC-9222-2022; liu, qingqing/HHD-0360-2022; Wang, Shaobo/AAI-4190-2020	Wang, Shaobo/0000-0001-7759-1687; Li, Gang/0000-0003-3184-1032	National Natural Science Foundation of China [81101594, 81372719, 81172403, 81300510, 81402077, 81571284, 91542115, 81702468]; National Natural Science Foundation of Shandong Province of China [2017CXGC1203]; Taishan Scholars of Shandong Province of China [ts201511093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shandong Province of China; Taishan Scholars of Shandong Province of China	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81101594; 81372719; 81172403; 81300510; 81402077; 81571284; 91542115; 81702468), National Natural Science Foundation of Shandong Province of China (No. 2017CXGC1203) and Taishan Scholars of Shandong Province of China (No. ts201511093).	Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bott A, 2017, ONCOTARGET, V8, P43897, DOI 10.18632/oncotarget.14915; Chen CC, 2016, CELL MOL BIOENG, V9, P509, DOI 10.1007/s12195-016-0458-3; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Dubois LG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00418; Dunn-Pirio AM, 2017, CANCER-AM CANCER SOC, V123, P734, DOI 10.1002/cncr.30371; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garcia JA, 2015, FASEB J, V29, P3863, DOI 10.1096/fj.15-273656; Gieryng A, 2016, WSPOLCZESNA ONKOL, V20, P345, DOI 10.5114/wo.2016.64592; Guo XF, 2016, ONCOTARGET, V7, P80521, DOI 10.18632/oncotarget.11825; Guo X, 2015, ONCOTARGET, V6, P41620, DOI 10.18632/oncotarget.5871; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; Hellwinkel JE, 2016, NEURO-ONCOLOGY, V18, P497, DOI 10.1093/neuonc/nov170; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jeker LT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036684; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Nduom EK, 2015, NEURO-ONCOLOGY, V17, P9, DOI 10.1093/neuonc/nov151; Noman MZ, 2015, CANCER RES, V75, P3771, DOI 10.1158/0008-5472.CAN-15-0405; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Otvos B, 2016, STEM CELLS, V34, P2026, DOI 10.1002/stem.2393; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Whiteside TL, 2013, BIOCHEM SOC T, V41, P245, DOI 10.1042/BST20120265; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wu W, 2015, GUT, V64, P1755, DOI 10.1136/gutjnl-2014-307980; Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Xue H, 2016, ONCOTARGET, V7, P4785, DOI 10.18632/oncotarget.6735; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yu SH, 2007, J IMMUNOL, V178, P6867, DOI 10.4049/jimmunol.178.11.6867; Zaidi AH, 2016, BIOCHEM J, V473, P859, DOI 10.1042/BJ20150624; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489	49	136	143	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4239	4259		10.1038/s41388-018-0261-9	http://dx.doi.org/10.1038/s41388-018-0261-9			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713056				2022-12-28	WOS:000440566100004
J	Seidi, K; Jahanban-Esfahlan, R; Monhemi, H; Zare, P; Minofar, B; Adli, ADF; Farajzadeh, D; Behzadi, R; Abbasi, MM; Neubauer, HA; Moriggl, R; Zarghami, N; Javaheri, T				Seidi, Khaled; Jahanban-Esfahlan, Rana; Monhemi, Hassan; Zare, Peyman; Minofar, Babak; Adli, Amir Daei Farshchi; Farajzadeh, Davoud; Behzadi, Ramezan; Abbasi, Mehran Mesgari; Neubauer, Heidi A.; Moriggl, Richard; Zarghami, Nosratollah; Javaheri, Tahereh			NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth	ONCOGENE			English	Article							ANTI-ANGIOGENIC THERAPY; TISSUE FACTOR; TARGETING AGENTS; MOUSE MODEL; INFARCTION; STAPHYLOCOAGULASE; MICE; VESSELS; METASTASIS; ACTIVATION	Induction of selective thrombosis and infarction in tumor-feeding vessels represents an attractive strategy to combat cancer. Here we took advantage of the unique coagulation properties of staphylocoagulase and genetically engineered it to generate a new fusion protein with novel anti-cancer properties. This novel bi-functional protein consists of truncated coagulase (tCoa) and an NGR (GNGRAHA) motif that recognizes CD13 and alpha(v)beta(3) integrin receptors, targeting it to tumor endothelial cells. Herein, we report that tCoa coupled by its C-terminus to an NGR sequence retained its normal binding activity with prothrombin and alpha(v)beta(3) integrins, as confirmed in silico and in vitro. Moreover, in vivo biodistribution studies demonstrated selective accumulation of FITC-labeled tCoa-NGR fusion proteins at the site of subcutaneously implanted PC3 tumor xenografts in nude mice. Notably, systemic administration of tCoa-NGR to mice bearing 4T1 mouse mammary xenografts or PC3 human prostate tumors resulted in a significant reduction in tumor growth. These anti-tumor effects were accompanied by massive thrombotic occlusion of small and large tumor vessels, tumor infarction and tumor cell death. From these findings, we propose tCoa-NGR mediated tumor infarction as a novel and promising anti-cancer strategy targeting both CD13 and integrin alpha(v)beta(3) positive tumor neovasculature.	[Seidi, Khaled; Jahanban-Esfahlan, Rana; Adli, Amir Daei Farshchi; Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran; [Monhemi, Hassan] Univ Neyshabour, Dept Chem, Khorasan Razavi Prov, Neyshabour, Iran; [Zare, Peyman] Univ Tabriz, Fac Vet Sci, Dept Pathobiol, Tabriz, Iran; [Minofar, Babak] Acad Sci Czech Republ, Ctr Nanobiol & Struct Biol, Inst Microbiol, Zamek 136, Nove Hrady 37333, Czech Republic; [Minofar, Babak] Univ South Bohemia, Fac Sci, Branisovska 1760, Ceske Budejovice 37005, Czech Republic; [Farajzadeh, Davoud] Azarbaijan Shahid Madani Univ, Fac Biol Sci, Dept Cellular & Mol Biol, Tabriz, Iran; [Behzadi, Ramezan] Pasture Inst Iran, North Res Ctr, Amol, Iran; [Abbasi, Mehran Mesgari] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Neubauer, Heidi A.; Moriggl, Richard; Javaheri, Tahereh] Ludwig Boltzmann Inst Canc Res, A-1090 Vienna, Austria; [Neubauer, Heidi A.; Moriggl, Richard; Javaheri, Tahereh] Univ Vet Med Vienna, Inst Anim Breeding & Genet, A-1210 Vienna, Austria; [Moriggl, Richard] Med Univ Vienna, A-1090 Vienna, Austria; [Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem, Tabriz, Iran; [Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Med, Lab Med, Tabriz, Iran; [Zarghami, Nosratollah] Iranian Natl Sci Fdn, Tehran, Iran	Tabriz University of Medical Science; University of Tabriz; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Azarbaijan Shahid Madani University; Tabriz University of Medical Science; Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Medical University of Vienna; Tabriz University of Medical Science; Tabriz University of Medical Science	Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.; Javaheri, T (corresponding author), Ludwig Boltzmann Inst Canc Res, A-1090 Vienna, Austria.; Javaheri, T (corresponding author), Univ Vet Med Vienna, Inst Anim Breeding & Genet, A-1210 Vienna, Austria.; Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem, Tabriz, Iran.; Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Med, Lab Med, Tabriz, Iran.; Zarghami, N (corresponding author), Iranian Natl Sci Fdn, Tehran, Iran.	Zarghami@tbzmed.ac.ir; Tahereh.Javaheri@lbicr.lbg.ac.at	Farajzadeh, Davoud/AAQ-5732-2021; Zare, Peyman/ABE-6329-2020; Moriggl, Richard/H-8118-2019; Neubauer, Heidi A./AAD-8727-2019; Farajzadeh, Davoud/W-2236-2017; Minofar, Babak/I-4326-2012; Minofar, Babak/I-4326-2012	Zare, Peyman/0000-0003-1291-1808; Moriggl, Richard/0000-0003-0918-9463; Minofar, Babak/0000-0002-0188-0471; Farajzadeh, Davoud/0000-0002-9267-4277; Neubauer, Heidi/0000-0001-7372-7786; Minofar, Babak/0000-0001-8096-2194	Drug Applied Research Center, Tabriz University of Medical Sciences; Iran National Science Foundation (INSF) [90007316]	Drug Applied Research Center, Tabriz University of Medical Sciences; Iran National Science Foundation (INSF)(Iran National Science Foundation (INSF))	This study was funded by Drug Applied Research Center, Tabriz University of Medical Sciences (IR) and the Iran National Science Foundation (INSF) (Grant No: 90007316).	Adli ADF, 2018, CHEM BIOL DRUG DES, V91, P996, DOI 10.1111/cbdd.13166; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bieker R, 2009, BLOOD, V113, P5019, DOI 10.1182/blood-2008-04-150318; Brand C, 2016, ONCOTARGET, V7, P6774, DOI 10.18632/oncotarget.6725; Chen J, 2001, THROMB HAEMOSTASIS, V86, P334; Cheng AG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001036; Corti A, 2008, BLOOD, V112, P2628, DOI 10.1182/blood-2008-04-150862; Corti A, 2011, CURR PHARM BIOTECHNO, V12, P1128, DOI 10.2174/138920111796117373; Delano W.L., 2002, PYMOL MOL GRAPHICS S; Dreischaluck J, 2010, INT J ONCOL, V37, P1389, DOI 10.3892/ijo_00000790; Friedrich R, 2006, J BIOL CHEM, V281, P1188, DOI 10.1074/jbc.M507957200; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; Hu PS, 2003, CANCER RES, V63, P5046; Huang FY, 2008, J ZHEJIANG UNIV-SC B, V9, P602, DOI 10.1631/jzus.B0820120; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huang ZJ, 2013, SCI WORLD J, DOI 10.1155/2013/637086; Huang Zheng-jie, 2012, Zhonghua Zhong Liu Za Zhi, V34, P249, DOI 10.3760/cma.j.issn.0253-3766.2012.04.003; Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2982, DOI 10.1002/jcp.26051; Jahanban-Esfahlan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05326-9; Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2019, DOI 10.1002/jcp.25859; Jahanban-Esfahlan R, 2017, INT J HEMATOL, V105, P244, DOI 10.1007/s12185-016-2171-3; Javaheri T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.268; Kastrup CJ, 2008, NAT CHEM BIOL, V4, P742, DOI 10.1038/nchembio.124; Kazemi Z, 2016, MOL PHARMACOL, V89, P630, DOI 10.1124/mol.116.103267; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kessler T, 2005, CLIN CANCER RES, V11, P6317, DOI 10.1158/1078-0432.CCR-05-0389; Kubota Yoshiaki, 2012, Keio Journal of Medicine, V61, P47; Liu C, 2002, CANCER RES, V62, P5470; Liu ZF, 2008, DRUG DEVELOP RES, V69, P329, DOI 10.1002/ddr.20265; McAdow M, 2012, INFECT IMMUN, V80, P3389, DOI 10.1128/IAI.00562-12; Minas TZ, 2017, ONCOTARGET, V8, P34141, DOI 10.18632/oncotarget.9388; Minas TZ, 2015, ONCOTARGET, V6, P37678, DOI 10.18632/oncotarget.5520; MOJOVIC B, 1969, YALE J BIOL MED, V42, P11; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Nilsson F, 2001, CANCER RES, V61, P711; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; Panizzi P, 2004, CELL MOL LIFE SCI, V61, P2793, DOI 10.1007/s00018-004-4285-7; PENCIK J, 2015, NAT COMMUN, V6; Ran S, 1998, CANCER RES, V58, P4646; Seidi K, 2018, J CONTROL RELEASE, V275, P142, DOI 10.1016/j.jconrel.2018.02.020; Seidi K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691001; SMITH DD, 1958, BRIT J EXP PATHOL, V39, P165; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yokota N, 2014, J THROMB HAEMOST, V12, P71, DOI 10.1111/jth.12442	49	29	32	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3967	3980		10.1038/s41388-018-0213-4	http://dx.doi.org/10.1038/s41388-018-0213-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662195	Green Published, hybrid			2022-12-28	WOS:000439101300005
J	Wang, SX; Jia, MM; He, ZK; Liu, XS				Wang, Shixiang; Jia, Mingming; He, Zaoke; Liu, Xue-Song			APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer	ONCOGENE			English	Article							MULTIPLE HUMAN CANCERS; PD-1 BLOCKADE; BREAST-CANCER; EXPRESSION PROFILES; ADVANCED MELANOMA; ADENOCARCINOMA; MUTAGENESIS; TUMORS; HYPERMUTATION; INFILTRATION	Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in NSCLC. However, targeting APOBEC3B high NSCLC is still a big challenge. Here we show that APOBEC3B upregulation is significantly associated with immune gene expression, and APOBEC3B expression positively correlates with known immunotherapy response biomarkers, including: PD-L1 expression and T-cell infiltration in NSCLC. Importantly, APOBEC mutational signature is specifically enriched in NSCLC patients with durable clinical benefit after immunotherapy and APOBEC mutation count can be better than total mutation in predicting immunotherapy response. In together, this work provides evidence that APOBEC3B upregulation and APOBEC mutation count can be used as novel predictive markers in guiding NSCLC checkpoint blockade immunotherapy.	[Wang, Shixiang; Jia, Mingming; He, Zaoke; Liu, Xue-Song] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China; [Wang, Shixiang; Jia, Mingming; He, Zaoke] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Wang, Shixiang; Jia, Mingming; He, Zaoke] Univ Chinese Acad Sci, Beijing, Peoples R China	ShanghaiTech University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Liu, XS (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China.	liuxs@shanghaitech.edu.cn	Liu, Xue-Song/ADF-2183-2022; Wang, Shixiang/ABF-1926-2021	Liu, Xue-Song/0000-0002-7736-0077; Wang, Shixiang/0000-0001-9855-7357; Jia, Mingming/0000-0002-8757-5856; He, Zaoke/0000-0002-5756-3862	Shanghai Pujiang Program [16PJ1407400]; National Natural Science Foundation of China [31771373]; ShanghaiTech University.	Shanghai Pujiang Program(Shanghai Pujiang Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ShanghaiTech University.	We are grateful to the TCGA research network (http://cancergenome.nih.gov/), and the Broad-Novartis Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle/home) for providing the data analyzed in this manuscript. We thank Raymond Shuter for editing the text. We also thank Pengfei Lv of ShanghaiTech for the critical discussions. This work was supported in part by the Shanghai Pujiang Program (16PJ1407400), the National Natural Science Foundation of China (31771373) and startup funding from ShanghaiTech University.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Boichard A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284719; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Cescon DW, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1069-y; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Danaher P, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0215-8; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Dong ZY, 2016, TUMOR BIOL, V37, P4251, DOI 10.1007/s13277-016-4812-9; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Maruyama W, 2016, BIOCHEM BIOPH RES CO, V478, P1466, DOI 10.1016/j.bbrc.2016.08.148; Middlebrooks CD, 2016, NAT GENET, V48, P1330, DOI 10.1038/ng.3670; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Refsland EW, 2013, CURR TOP MICROBIOL, V371, P1, DOI 10.1007/978-3-642-37765-5_1; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Saini N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006385; Sasaki H, 2014, BIOMED REP, V2, P392, DOI 10.3892/br.2014.256; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Shi JX, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002162; Shukuya T, 2016, J THORAC ONCOL, V11, P976, DOI 10.1016/j.jtho.2016.02.015; Smid M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12910; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Starrett GJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12918; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Tang HD, 2016, CANCER CELL, V29, P285, DOI 10.1016/j.ccell.2016.02.004; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762; Wang E, 2013, J CLIN ONCOL, V31, P2369, DOI 10.1200/JCO.2013.49.2157; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yan SM, 2016, J CANCER, V7, P618, DOI 10.7150/jca.14030	51	110	111	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3924	3936		10.1038/s41388-018-0245-9	http://dx.doi.org/10.1038/s41388-018-0245-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695832	Green Published, hybrid			2022-12-28	WOS:000439101300002
J	Jin, P; Shin, SH; Chun, YS; Shin, HW; Shin, YJ; Lee, Y; Kim, D; Nam, DH; Park, JW				Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Shin, Yong Jae; Lee, Yeri; Kim, Donggeon; Nam, Do-Hyun; Park, Jong-Wan			Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-kappa B signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; RECEPTOR CCR6; CHEMOKINE CCL20; CELLS; PROGRESSION; PROGNOSIS; GLIOMAS; CANCER; PROLIFERATION; ANGIOGENESIS	During tumor development, stromal cells are co-opted to the tumor milieu and provide favorable conditions for the tumor. Hypoxia stimulates cancer cells to acquire a more malignant phenotype via activation of hypoxia-inducible factor 1 (HIF-1). Given that cancer cells and astrocytes in glioblastomas coexist in a hypoxic microenvironment, we examined whether astrocytes affect the adaptation of glioblastoma cells to hypoxia. Immunoblotting, reporter assays, quantitative RT-PCR, and chromatin immunoprecipitation were performed to evaluate HIF-1 signaling in glioblastoma cells. Astrocyte-derived chemokine C-C motif ligand 20 (CCL20) was identified using cytokine arrays, and its role in glioblastoma development was evaluated in orthotopic xenografts. Astrocytes augmented HIF-1 alpha expression in glioblastoma cells under hypoxia. The expression of HIF-1 downstream genes, cancer colony formation, and Matrigel invasion of glioblastoma cells were stimulated by conditioned medium from astrocytes pre-exposed to hypoxia. CCL20 was secreted in a hypoxia-dependent manner from astrocytes and busted the hypoxic induction of HIF-1 alpha in glioblastoma cells. Mechanistically, the CCL20/CCR6 signaling pathway upregulates HIF-1 alpha by stimulating nuclear factor kappa B-driven transactivation of the HIF1A gene. Compared with the control tumors, CCR6-deficient glioblastoma xenografts grew more slowly, with poor vascularization, and expressed lower levels of HIF-1 alpha and its downstream proteins. Furthermore, CCR6 expression was correlated with HIF-1 alpha expression in GEO and TCGA datasets from human glioblastoma tissues. These results suggest that glioblastoma cells adapt well to hypoxic stress by virtue of CCL20 derived from neighboring astrocytes.	[Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Plus Educ Program BK21, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Shin, Yong Jae; Lee, Yeri; Kim, Donggeon; Nam, Do-Hyun] Samsung Med Ctr, Res Inst Future Med, Inst Refractory Canc Res, Seoul, South Korea; [Shin, Yong Jae; Nam, Do-Hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Plus Educ Program BK21, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.	parkjw@snu.ac.kr			National Research Foundation of Korea [2017048432]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute [HI14C3418]; Education and Research Encouragement Fund of Seoul National University Hospital	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Education and Research Encouragement Fund of Seoul National University Hospital	This work was supported by a grant of the National Research Foundation of Korea (2017048432) and a grant of Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI14C3418). Park JW was supported by the Education and Research Encouragement Fund of Seoul National University Hospital.	Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Ayrapetov MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026064; Battaglia F, 2008, J LEUKOCYTE BIOL, V83, P648, DOI 10.1189/jlb.0607349; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Ding XJ, 2012, J GASTROINTEST SURG, V16, P828, DOI 10.1007/s11605-011-1775-4; Fischer I, 2005, BRAIN PATHOL, V15, P297; Gagliano N, 2009, ONCOL REP, V22, P1349, DOI 10.3892/or_00000574; Ghadjar P, 2009, INT J CANCER, V125, P741, DOI 10.1002/ijc.24468; Giannopoulou E, 2006, IN VIVO, V20, P421; Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Korkolopoulou P, 2004, NEUROPATH APPL NEURO, V30, P267, DOI 10.1111/j.1365-2990.2003.00535.x; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee YM, 2011, HEPATOLOGY, V53, P171, DOI 10.1002/hep.24010; Li R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094320; Lorger Mihaela, 2012, Cancers (Basel), V4, P218, DOI 10.3390/cancers4010218; Marsigliante S, 2013, J CELL PHYSIOL, V228, P1873, DOI 10.1002/jcp.24349; McColl SR, 2002, IMMUNOL CELL BIOL, V80, P489, DOI 10.1046/j.1440-1711.2002.01113.x; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; O'Brien ER, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00040; Okamoto T, 2007, CURR PHARM DESIGN, V13, P447, DOI 10.2174/138161207780162944; Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282; Placone AL, 2016, TUMOR BIOL, V37, P61, DOI 10.1007/s13277-015-4242-0; Rath BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054752; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Toledo CM, 2015, CELL REP, V13, P2425, DOI 10.1016/j.celrep.2015.11.021; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang L, 2012, MED ONCOL, V29, P3491, DOI 10.1007/s12032-012-0314-9; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Zeng W, 2014, EXP MOL PATHOL, V97, P184, DOI 10.1016/j.yexmp.2014.06.012	34	26	27	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3070	3087		10.1038/s41388-018-0182-7	http://dx.doi.org/10.1038/s41388-018-0182-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535421				2022-12-28	WOS:000434641400003
J	Stanicka, J; Rieger, L; O'Shea, S; Cox, O; Coleman, M; O'Flanagan, C; Addario, B; McCabe, N; Kennedy, R; O'Connor, R				Stanicka, Joanna; Rieger, Leonie; O'Shea, Sandra; Cox, Orla; Coleman, Michael; O'Flanagan, Ciara; Addario, Barbara; McCabe, Nuala; Kennedy, Richard; O'Connor, Rosemary			FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion	ONCOGENE			English	Article							BREAST-CANCER; CORTACTIN PHOSPHORYLATION; CARCINOMA-CELLS; IGF-1 RECEPTOR; RESISTANCE; PROTEIN; SRC; METASTASIS; EXPRESSION; MIGRATION	IGF-1 receptor (IGF-1R) and integrin cooperative signaling promotes cancer cell survival, proliferation, and motility, but whether this influences cancer progression and therapy responses is largely unknown. Here we investigated the non-receptor tyrosine adhesion kinase FES-related (FER), following its identification as a potential mediator of sensitivity to IGF-1R kinase inhibition in a functional siRNA screen. We found that FER and the IGF-1R co-locate in cells and can be coimmunoprecipitated. Ectopic FER expression strongly enhanced IGF-1R expression and phosphorylation on tyrosines 950 and 1131. FER phosphorylated these sites in an IGF-1R kinase-independent manner and also enhanced IGF-1-mediated phosphorylation of SHC, and activation of either AKT or MAPK-signaling pathways in different cells. The IGF-1R, beta 1 Integrin, FER, and its substrate cortactin were all observed to co-locate in cell adhesion complexes, the disruption of which reduced IGF-1R expression and activity. High FER expression correlates with phosphorylation of SHC in breast cancer cell lines and with a poor prognosis in patient cohorts. FER and SHC phosphorylation and IGF-1R expression could be suppressed with a known anaplastic lymphoma kinase inhibitor (AP26113) that shows high specificity for FER kinase. Overall, we conclude that FER enhances IGF-1R expression, phosphorylation, and signaling to promote cooperative growth and adhesion signaling that may facilitate cancer progression.	[Stanicka, Joanna; Rieger, Leonie; O'Shea, Sandra; Cox, Orla; Coleman, Michael; O'Flanagan, Ciara; Addario, Barbara; O'Connor, Rosemary] Univ Coll Cork, Sch Biochem & Cell Biol, Cell Biol Lab, Cork, Ireland; [McCabe, Nuala; Kennedy, Richard] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [McCabe, Nuala; Kennedy, Richard] Queens Univ Belfast, Almac Diagnost, Belfast, Antrim, North Ireland	University College Cork; Queens University Belfast; Queens University Belfast	O'Connor, R (corresponding author), Univ Coll Cork, Sch Biochem & Cell Biol, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	Coleman, Michael/AAM-4725-2021; O'Connor, Rosemary/B-7902-2014	Coleman, Michael/0000-0002-6914-848X; O'Connor, Rosemary/0000-0002-0687-3422; Rieger, Leonie/0000-0003-3263-801X	Science Foundation Ireland [11/PI/1139]; European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program [251480]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program	This work was funded by a Science Foundation Ireland Principal Investigator award 11/PI/1139, and the European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program 251480 BiomarkerIGF.	Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cox OT, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00106; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Deevi RK, 2014, NEOPLASIA, V16, P422, DOI 10.1016/j.neo.2014.04.006; Fan G, 2014, FASEB J, V28; Farabaugh SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00059; Goel HL, 2005, CANCER RES, V65, P6692, DOI 10.1158/0008-5472.CAN-04-4315; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Hellwig S, 2012, CHEM BIOL, V19, P529, DOI 10.1016/j.chembiol.2012.01.020; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Ivaska J, 2011, ANNU REV CELL DEV BI, V27, P291, DOI 10.1146/annurev-cellbio-092910-154017; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; King H, 2014, CANCER TREAT REV, V40, P1096, DOI 10.1016/j.ctrv.2014.07.004; Kostler WJ, 2006, J CANCER RES CLIN, V132, P9, DOI 10.1007/s00432-005-0038-8; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Lennartsson J, 2013, J BIOL CHEM, V288, P15736, DOI 10.1074/jbc.M113.476424; Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5; Liu BA, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-27; Malaguarnera R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00010; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Muellner MK, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145664; Muharram G, 2014, DEV CELL, V29, P421, DOI 10.1016/j.devcel.2014.03.024; Niepel M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004379; O'Flanagan CH, 2016, ONCOTARGET, V7, P56826, DOI 10.18632/oncotarget.10862; Oneyama C, 2016, ONCOGENE, V35, P501, DOI 10.1038/onc.2015.110; Osorio FG, 2016, NAT MED, V22, P91, DOI 10.1038/nm.4013; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sangrar W, 2015, ONCOGENE, V34, P4109, DOI 10.1038/onc.2014.340; Shen MR, 2006, CARCINOGENESIS, V27, P962, DOI 10.1093/carcin/bgi336; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Taliaferro-Smith L, 2015, ONCOTARGET, V6, P4757, DOI 10.18632/oncotarget.3023; van Rossum AGSH, 2005, BREAST CANCER RES, V7, P235, DOI 10.1186/bcr1316; Vistein R, 2014, TRAFFIC, V15, P1195, DOI 10.1111/tra.12202; Voisset E, 2010, LEUKEMIA, V24, P721, DOI 10.1038/leu.2009.301; Wu RF, 2016, MOL CELL BIOL, V36, P2824, DOI 10.1128/MCB.00194-16; Yoneyama T, 2012, MOL BIOL CELL, V23, P771, DOI 10.1091/mbc.E11-06-0517; Zhang S, 2016, CLIN CANCER RES, V22, P5527, DOI 10.1158/1078-0432.CCR-16-0569; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zheng DH, 2010, MOL CARCINOGEN, V49, P200, DOI 10.1002/mc.20590	50	14	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3131	3150		10.1038/s41388-017-0113-z	http://dx.doi.org/10.1038/s41388-017-0113-z			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540831	Green Submitted			2022-12-28	WOS:000434641400007
J	Bolin, S; Borgenvik, A; Persson, CU; Sundstrom, A; Qi, J; Bradner, JE; Weiss, WA; Cho, YJ; Weishaupt, H; Swartling, FJ				Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstrom, Anders; Qi, Jun; Bradner, James E.; Weiss, William A.; Cho, Yoon-Jae; Weishaupt, Holger; Swartling, Fredrik J.			Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma	ONCOGENE			English	Article							SELECTIVE-INHIBITION; KINASE INHIBITOR; BRAIN-TUMORS; PHOSPHORYLATION; STABILIZATION; DISCOVERY; APOPTOSIS; SUBTYPES; POTENT	Medulloblastoma (MB) is the most common malignant brain tumor in children. MYC genes are frequently amplified and correlate with poor prognosis in MB. BET bromodomains recognize acetylated lysine residues and often promote and maintain MYC transcription. Certain cyclin-dependent kinases (CDKs) are further known to support MYC stabilization in tumor cells. In this report, MB cells were suppressed by combined targeting of MYC expression and MYC stabilization using BET bromodomain inhibition and CDK2 inhibition, respectively. Such combination treatment worked synergistically and caused cell cycle arrest as well as massive apoptosis. Immediate transcriptional changes from this combined MYC blockade were found using RNA-Seq profiling and showed remarkable similarities to changes in MYC target gene expression when MYCN was turned off with doxycycline in our MYCN-inducible animal model for Group 3 MB. In addition, the combination treatment significantly prolonged survival as compared to single-agent therapy in orthotopically transplanted human Group 3 MB with MYC amplifications. Our data suggest that dual inhibition of CDK2 and BET bromodomains can be a novel treatment approach for suppressing MYC-driven cancer.	[Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstrom, Anders; Weishaupt, Holger; Swartling, Fredrik J.] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, Uppsala, Sweden; [Qi, Jun; Bradner, James E.] Harvard Med Sch, Dept Med, Boston, MA USA; [Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Cho, Yoon-Jae] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Knight Canc Inst, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA	Uppsala University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University	Swartling, FJ (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, Uppsala, Sweden.	fredrik.swartling@igp.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Borgenvik, Anna/0000-0003-4696-7703; Weiss, William/0000-0003-2230-9132; Persson, Camilla/0000-0002-1312-6177	Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; Ragnar Soderberg Foundation; Swedish Society of Medicine; Swedish Brain Fund; Ake Wiberg Foundation; Worldwide Cancer Research/Association for International Cancer Research; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER	Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Ragnar Soderberg Foundation; Swedish Society of Medicine; Swedish Brain Fund; Ake Wiberg Foundation; Worldwide Cancer Research/Association for International Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Ragnar Soderberg Foundation, the Swedish Society of Medicine, the Swedish Brain Fund, the Ake Wiberg Foundation, and Worldwide Cancer Research/Association for International Cancer Research.	Albanese C, 2013, BRIT J PHARMACOL, V169, P156, DOI 10.1111/bph.12112; Albert TK, 2014, BRIT J PHARMACOL, V171, P55, DOI 10.1111/bph.12408; Baker EK, 2015, SCI REP-UK, V5, DOI 10.1038/srep10120; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Brasca MG, 2009, J MED CHEM, V52, P5152, DOI 10.1021/jm9006559; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Caporali S, 2010, PHARMACOL RES, V61, P437, DOI 10.1016/j.phrs.2009.12.009; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Fiaschetti G, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-39; Filippakopoulos P, 2012, FEBS LETT, V586, P2692, DOI 10.1016/j.febslet.2012.04.045; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Hede SM, 2014, ONCOGENE, V33, P4709, DOI 10.1038/onc.2013.445; Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li MH, 2012, CANCER GENET-NY, V205, P220, DOI 10.1016/j.cancergen.2012.03.002; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Morrissy AS, 2016, NATURE, V529, P351, DOI 10.1038/nature16478; Mulhern RK, 2004, LANCET ONCOL, V5, P399, DOI 10.1016/S1470-2045(04)01507-4; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Painter MW, 2011, J IMMUNOL, V186, P3047, DOI 10.4049/jimmunol.1002695; Pfister S, 2009, J CLIN ONCOL, V27, P1627, DOI 10.1200/JCO.2008.17.9432; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rahmanto AS, 2016, EMBO J, V35, P2192, DOI 10.15252/embj.201693889; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Ryan SL, 2012, ACTA NEUROPATHOL, V123, P501, DOI 10.1007/s00401-011-0923-y; Schmidt AL, 2010, CNS NEUROL DISORD-DR, V9, P335, DOI 10.2174/187152710791292602; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Tailor J, 2013, J NEUROSCI, V33, P12407, DOI 10.1523/JNEUROSCI.0130-13.2013; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Weiss GJ, 2012, INVEST NEW DRUG, V30, P2334, DOI 10.1007/s10637-011-9774-6; Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785	49	42	45	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2850	2862		10.1038/s41388-018-0135-1	http://dx.doi.org/10.1038/s41388-018-0135-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511348	Green Published, hybrid			2022-12-28	WOS:000432929800007
J	Jiao, WJ; Chen, YJ; Song, HJ; Li, D; Mei, H; Yang, F; Fang, E; Wang, XJ; Huang, K; Zheng, LD; Tong, QS				Jiao, Wanju; Chen, Yajun; Song, Huajie; Li, Dan; Mei, Hong; Yang, Feng; Fang, Erhu; Wang, Xiaojing; Huang, Kai; Zheng, Liduan; Tong, Qiangsong			HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis	ONCOGENE			English	Article							INTELECTIN 1 SUPPRESSES; HEPARANASE EXPRESSION; NEUROBLASTOMA-CELLS; GASTRIC-CANCER; GENE-TRANSCRIPTION; GROWTH; INVASION; METASTASIS; ACTIVATION; ANGIOGENESIS	Recent studies reveal the emerging functions of enhancer RNAs (eRNAs) in gene expression. However, the roles of eRNAs in regulating the expression of heparanase (HPSE), an established endo-beta-D-glucuronidase essential for cancer invasion and metastasis, still remain elusive. Herein, through comprehensive analysis of publically available FANTOM5 expression atlas and chromatin interaction dataset, we identified a super enhancer and its derived eRNA facilitating the HPSE expression (HPSE eRNA) in cancers. Gain-of-function and loss-of-function experiments indicated that HPSE eRNA facilitated the in vitro and in vivo tumorigenesis and aggressiveness of cancer cells. Mechanistically, as a p300-regulated nuclear noncoding RNA, HPSE eRNA bond to heterogeneous nuclear ribonucleoprotein U (hnRNPU) to facilitate its interaction with p300 and their enrichment on super enhancer, resulting in chromatin looping between super enhancer and HPSE promoter, p300-mediated transactivation of transcription factor early growth response 1 (EGR1), and subsequent elevation of HPSE expression. In addition, rescue studies in HPSE overexpressing or silencing cancer cells indicated that HPSE eRNA exerted oncogenic properties via driving HPSE expression. In clinical cancer tissues, HPSE eRNA was highly expressed and positively correlated with HPSE levels, and served as an independent prognostic factor for poor outcome of cancer patients. Therefore, these findings indicate that as a novel noncoding RNA, HPSE eRNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis.	[Jiao, Wanju; Chen, Yajun; Zheng, Liduan] Huazhong Univ Sci & Technol, Union Hosp, Dept Pathol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China; [Song, Huajie; Li, Dan; Mei, Hong; Yang, Feng; Fang, Erhu; Wang, Xiaojing; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China; [Huang, Kai; Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pathol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404; Zheng, Liduan/0000-0001-5566-673X	National Natural Science Foundation of China [81272779, 81372667, 81472363, 81402301, 81402408, 81572423, 81672500, 81773094, 81772967]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We appreciate Dr. Tso-Pang Yao for providing vectors. This work was granted by the National Natural Science Foundation of China (81272779, 81372667, 81472363, 81402301, 81402408, 81572423, 81672500, 81773094, and 81772967), and Natural Science Foundation of Hubei Province (2014CFA012).	Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bi HS, 2013, BBA-GEN SUBJECTS, V1830, P4899, DOI 10.1016/j.bbagen.2013.06.026; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fang F, 2014, STEM CELLS, V32, P1805, DOI 10.1002/stem.1705; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; He B, 2014, P NATL ACAD SCI USA, V111, pE2191, DOI 10.1073/pnas.1320308111; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kim YW, 2013, BBA-GENE REGUL MECH, V1829, P963, DOI 10.1016/j.bbagrm.2013.04.006; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; Li D, 2015, ONCOTARGET, V6, P16168, DOI 10.18632/oncotarget.3753; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Masola V, 2014, CURR CANCER DRUG TAR, V14, P286, DOI 10.2174/1568009614666140224155124; Matsuoka Y, 2009, ONCOL REP, V22, P249, DOI 10.3892/or_00000431; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Puvvula PK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6323; Qu HX, 2016, SCI REP-UK, V6, DOI 10.1038/srep32628; Qu HX, 2015, HUM MOL GENET, V24, P2539, DOI 10.1093/hmg/ddv018; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Roshon MJ, 2005, TRANSGENIC RES, V14, P179, DOI 10.1007/s11248-004-8147-8; Shinyo Y, 2003, ANN ONCOL, V14, P1505, DOI 10.1093/annonc/mdg407; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Stadlmann S, 2003, EUR J CANCER, V39, P2229, DOI 10.1016/S0959-8049(03)00457-X; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2003, CANCER RES, V63, P7733; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zheng LD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.293; Zheng LD, 2016, ONCOTARGET, V7, P40314, DOI 10.18632/oncotarget.9739; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	53	51	53	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2728	2745		10.1038/s41388-018-0128-0	http://dx.doi.org/10.1038/s41388-018-0128-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29511351				2022-12-28	WOS:000432545100009
J	Lee, GH; Yoo, KC; An, Y; Lee, HJ; Lee, M; Uddin, N; Kim, MJ; Kim, IG; Suh, Y; Lee, SJ				Lee, Ga-Hang; Yoo, Ki-Chun; An, Yoojeong; Lee, Hae-June; Lee, Minyoung; Uddin, Nizam; Kim, Min-Jung; Kim, In-Gyu; Suh, Yongjoon; Lee, Su-Jae			FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node	ONCOGENE			English	Article							MOLECULAR TARGETS; NOTCH; SRC; STAT5; THERAPY; CHEMOTHERAPY; TRANSDUCER; RECURRENCE; ACTIVATION; EXPRESSION	Basal type breast cancer is the most aggressive and has mesenchymal features with a high metastatic ability. However, the signaling node that determines the basal type features in breast cancer remains obscure. Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype. Importantly, FYN enhanced NOTCH2 activation in basal type breast cancer cells through STAT5-mediated upregulation of Jagged-1 and DLL4 NOTCH ligands, thereby contributed to mesenchymal phenotypes. In addition, we found that high levels of FYN persist in basal type breast cancer cells by a positive feedback loop between FYN and STAT5. FYN interacted directly with STAT5 and increased p-STAT5 that further acts as a transcription factor for FYN. Taken together, our findings demonstrate a pivotal role of FYN and its downstream effectors in maintaining the basal type features in breast cancer.	[Lee, Ga-Hang; Yoo, Ki-Chun; An, Yoojeong; Uddin, Nizam; Suh, Yongjoon; Lee, Su-Jae] Hanyang Univ, Dept Life Sci, Res Inst Nat Sci, Seoul, South Korea; [Lee, Ga-Hang] Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Lee, Hae-June; Lee, Minyoung] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul, South Korea; [Uddin, Nizam] Univ Punjab, CEMB, Lahore, Pakistan; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea; [Kim, In-Gyu] Korea Atom Energy Res Inst, Environm Radiat Res Grp, Dept Radiat Biol, Daejeon, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Samsung Medical Center; Korea Institute of Radiological & Medical Sciences; University of Punjab; Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI)	Suh, Y; Lee, SJ (corresponding author), Hanyang Univ, Dept Life Sci, Res Inst Nat Sci, Seoul, South Korea.	hiswork@hanmail.net; sj0420@hanyang.ac.kr		Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government [NRF-2016R1E1A1A01942075, NRF-2017M2A2A7070460]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (NRF-2016R1E1A1A01942075 and NRF-2017M2A2A7070460).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Barash I, 2012, CARCINOGENESIS, V33, P2320, DOI 10.1093/carcin/bgs362; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Irwin ME, 2011, CANCER BIOL THER, V12, P718, DOI 10.4161/cbt.12.8.16907; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pullen NA, 2012, J BIOL CHEM, V287, P2045, DOI 10.1074/jbc.M111.311142; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Walker SR, 2014, MOL CELL ENDOCRINOL, V382, P616, DOI 10.1016/j.mce.2013.03.010; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	30	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1857	1868		10.1038/s41388-017-0114-y	http://dx.doi.org/10.1038/s41388-017-0114-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29348460				2022-12-28	WOS:000429303300004
J	Liang, HC; Xiao, J; Zhou, ZM; Wu, J; Ge, F; Li, ZC; Zhang, HL; Sun, J; Li, FB; Liu, R; Chen, CS				Liang, Huichun; Xiao, Ji; Zhou, Zhongmei; Wu, Jiao; Ge, Fei; Li, Zongcheng; Zhang, Hailin; Sun, Jian; Li, Fubing; Liu, Rong; Chen, Ceshi			Hypoxia induces miR-153 through the IRE1 alpha-XBP1 pathway to fine tune the HIF1 alpha/VEGFA axis in breast cancer angiogenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM-STRESS; INDUCIBLE FACTOR-1-ALPHA EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; VASCULAR-PERMEABILITY FACTOR; HUMAN ENDOTHELIAL-CELLS; LUNG-CANCER; TUMOR-SUPPRESSOR; TARGETING SNAI1; DOWN-REGULATION; STEM-CELLS	It is well documented that hypoxia activates the hypoxia-inducible factor 1-alpha (HIF1 alpha)/vascular endothelial growth factor A (VEGFA) axis to promote angiogenesis in breast cancer. However, it is unclear how this axis is negatively regulated. In this study, we demonstrated that miR-153 directly inhibits expression of HIF1 alpha by binding to the 3'UTR of HIF1A mRNA, as well as suppresses tube formation of primary human umbilical vein endothelial cells (HUVECs) and breast cancer angiogenesis by decreasing the secretion of VEGFA. Importantly, expression of miR-153 was induced by hypoxiastimulated ER stress, which activates IRE1 alpha and its downstream transcription factor X-box binding protein 1 (XBP1). X-box binding protein 1 directly binds to the promoter of the miR-153 host gene PTPRN and activates transcription. These results indicate that hypoxia induces miR-153 to fine tune the HIF1 alpha/VEGFA axis in breast cancer angiogenesis and miR-153 could be used for breast cancer anti-angiogenesis therapy.	[Liang, Huichun; Zhou, Zhongmei; Zhang, Hailin; Li, Fubing; Liu, Rong; Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming, Yunnan, Peoples R China; [Liang, Huichun; Li, Fubing] Univ Chinese Acad Sci, Beijing, Peoples R China; [Xiao, Ji; Sun, Jian] Kunming Univ Sci & Technol, Med Fac, Kunming, Yunnan, Peoples R China; [Wu, Jiao] Kunming Med Univ, Affiliated Hosp 3, Dept Med Oncol 2, Kunming, Yunnan, Peoples R China; [Ge, Fei] Kunming Med Univ, Affiliated Hosp 1, Dept Breast Surg, Kunming, Yunnan, Peoples R China; [Li, Zongcheng] Acad Mil Med Sci, Affiliated Hosp, Translat Med Ctr Stem Cells,Lab Oncol, State Key Lab Prote,Ivy Translat Med Ctr 307, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Kunming University of Science & Technology; Kunming Medical University; Kunming Medical University; Academy of Military Medical Sciences - China	Liu, R; Chen, CS (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming, Yunnan, Peoples R China.	liurong@mail.kiz.ac.cn; chenc@mail.kiz.ac.cn	Li, Zongcheng/AAN-1952-2021; Li, Zongcheng/AFP-2645-2022	Li, Zongcheng/0000-0002-5189-5268; Chen, Ceshi/0000-0001-6398-3516	Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010303]; National Natural Science Foundation of China [31771516, U1502222, U1602221, 81772847, 81660438]; Yunnan Applied Basic Research Key Projects [2015FA027]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yunnan Applied Basic Research Key Projects	We sincerely thank Professor Lingqiang Zhang from the Academy of Chinese Military Medical Sciences and Professor Wen Liu from Xiamen University for providing reagents. This study was supported by a Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010303), National Natural Science Foundation of China (31771516, U1502222, U1602221, 81772847, and 81660438), and the Yunnan Applied Basic Research Key Projects (2015FA027).	Albini A, 2010, CLIN EXP METASTAS, V27, P419, DOI 10.1007/s10585-010-9312-5; Bao BL, 2012, J NUTR BIOCHEM, V23, P635, DOI 10.1016/j.jnutbio.2011.03.007; Bartoszewska S, 2015, FASEB J, V29, P1467, DOI 10.1096/fj.14-267054; Boelens J, 2007, IN VIVO, V21, P215; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen WJ, 2015, INT J CLIN EXP PATHO, V8, P8671; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chitnis N, 2013, TRENDS BIOCHEM SCI, V38, P447, DOI 10.1016/j.tibs.2013.06.012; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Dai L, 2015, INT J CLIN EXP PATHO, V8, P4735; Dioufa N, 2010, ENDOCRINE, V38, P167, DOI 10.1007/s12020-010-9362-0; FOLKMAN J, 1986, CANCER RES, V46, P467; Ghasemi A, 2016, CLIN LAB, V62, P573, DOI 10.7754/Clin.Lab.2015.150738; He X, 2015, ARTERIOSCL THROM VAS, V35, P1623, DOI 10.1161/ATVBAHA.115.305469; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Janaszak-Jasiecka A, 2016, SCI REP-UK, V6, DOI 10.1038/srep22775; Kang SG, 2012, CARCINOGENESIS, V33, P661, DOI 10.1093/carcin/bgr320; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li Q, 2016, ONCOTARGET, V7, P29749, DOI 10.18632/oncotarget.8831; Li WT, 2015, BREAST CANCER RES TR, V150, P501, DOI 10.1007/s10549-015-3346-y; Liu F, 2017, ACTA BIOCH BIOPH SIN, V49, P520, DOI 10.1093/abbs/gmx039; Liu R, 2016, GROWTH, V17, P18; Liu R, 2016, THERANOSTICS, V6, P533, DOI 10.7150/thno.14315; Mandemakers W, 2013, DIABETOLOGIA, V56, P1547, DOI 10.1007/s00125-013-2901-5; Paridaens A, 2014, LIVER INT, V34, pE10, DOI 10.1111/liv.12457; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shan NX, 2015, BIOCHEM BIOPH RES CO, V456, P385, DOI 10.1016/j.bbrc.2014.11.093; Urra H, 2014, MOL CELL, V54, P542, DOI 10.1016/j.molcel.2014.05.013; Wang Y, 2011, INT J MOL SCI, V12, P7569, DOI 10.3390/ijms12117569; Wang ZL, 2016, TUMOR BIOL, V37, P15509, DOI 10.1007/s13277-015-3846-8; Wu J, 2016, CANCER LETT, V380, P393, DOI 10.1016/j.canlet.2016.06.024; Wu XW, 2016, AM J CANCER RES, V6, P1563; Wu ZH, 2016, ONCOL REP, V35, P1696, DOI 10.3892/or.2015.4529; Wu ZQ, 2013, PROSTATE, V73, P596, DOI 10.1002/pros.22600; Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yang BY, 2016, BIOMED PHARMACOTHER, V84, P845, DOI 10.1016/j.biopha.2016.10.015; Yang W, 2015, ONCOTARGET, V6, P22006, DOI 10.18632/oncotarget.4292; Yuan Y, 2015, INT J CANCER, V136, P1333, DOI 10.1002/ijc.29103; Zeng HF, 2017, BIOCHEM BIOPH RES CO, V487, P140, DOI 10.1016/j.bbrc.2017.04.032; Zhang L, 2013, CANCER RES, V73, P6435, DOI 10.1158/0008-5472.CAN-12-3308; Zou YH, 2016, MOL MED REP, V14, P1033, DOI 10.3892/mmr.2016.5309; Zuo J, 2016, TUMOR BIOL, V37, P16135, DOI 10.1007/s13277-016-5427-x	50	80	85	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1961	1975		10.1038/s41388-017-0089-8	http://dx.doi.org/10.1038/s41388-017-0089-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367761	Green Published, hybrid			2022-12-28	WOS:000429899400002
J	Chong, PSY; Zhou, JB; Chooi, JY; Chan, ZL; Toh, SHM; Tan, TZ; Wee, S; Gunaratne, J; Zeng, Q; Chng, WJ				Chong, Phyllis S. Y.; Zhou, Jianbiao; Chooi, Jing-Yuan; Chan, Zit-Liang; Toh, Sabrina Hui Min; Tan, Tuan Zea; Wee, Sheena; Gunaratne, Jayantha; Zeng, Qi; Chng, Wee-Joo			Non-canonical activation of beta-catenin by PRL-3 phosphatase in acute myeloid leukemia	ONCOGENE			English	Article							SIGNALING PATHWAY; ASSOCIATION	Aberrant activation of Wnt/beta-catenin signaling pathway is essential for the development of AML; however, the mechanistic basis for this dysregulation is unclear. PRL-3 is an oncogenic phosphatase implicated in the development of LSCs. Here, we identified Leo1 as a direct and specific substrate of PRL-3. Serine-dephosphorylated form of Leo1 binds directly to beta-catenin, promoting the nuclear accumulation of beta-catenin and transactivation of TCF/LEF downstream target genes such as cyclin D1 and c-myc. Importantly, overexpression of PRL-3 in AML cells displayed enhanced sensitivity towards beta-catenin inhibition in vitro and in vivo, suggesting that these cells are addicted to beta-catenin signaling. Altogether, our study revealed a novel regulatory role of PRL-3 in the sustenance of aberrant beta-catenin signaling in AML. PRL-3 may serve as a biomarker to select for the subset of AML patients who are likely to benefit from treatment with beta-catenin inhibitors. Our study presents a new avenue of cancer inhibition driven by PRL-3 overexpression or beta-catenin hyperactivation.	[Chong, Phyllis S. Y.; Zhou, Jianbiao; Chan, Zit-Liang; Toh, Sabrina Hui Min; Tan, Tuan Zea; Chng, Wee-Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Zhou, Jianbiao; Chooi, Jing-Yuan; Chng, Wee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Wee, Sheena; Gunaratne, Jayantha; Zeng, Qi] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Gunaratne, Jayantha] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Chng, Wee-Joo] Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst, Singapore, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Chng, WJ (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.; Chng, WJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.; Chng, WJ (corresponding author), Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst, Singapore, Singapore.	mdccwj@nus.edu.sg	Tan, Tuan Zea/I-9227-2019	Tan, Tuan Zea/0000-0001-6624-1593	Singapore National Research Foundation; Ministry of Education under the Research Center of Excellence Program; NMRC Clinician-Scientist IRG [CNIG11nov38]; NMRC Singapore Translational Research (STaR) Investigatorship; National Research Foundation Singapore; Singapore Ministry of Education under the Research Centers of Excellence initiative; RNA Biology Center at the Cancer Science Institute of Singapore, NUS under the Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]	Singapore National Research Foundation(National Research Foundation, Singapore); Ministry of Education under the Research Center of Excellence Program; NMRC Clinician-Scientist IRG(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NMRC Singapore Translational Research (STaR) Investigatorship(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under the Research Centers of Excellence initiative(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore, NUS under the Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore)	This work was supported by the Singapore National Research Foundation and the Ministry of Education under the Research Center of Excellence Program to WJ Chng and NMRC Clinician-Scientist IRG Grant CNIG11nov38 to Zhou J. WJ Chng is supported by NMRC Singapore Translational Research (STaR) Investigatorship. This research is partly supported by the National Research Foundation Singapore and the Singapore Ministry of Education under the Research Centers of Excellence initiative as well as the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006. No potential conflicts of interest were disclosed. We would also like to thank Prof Phil Koeffler, Prof Dan Tenen, Prof Toshio Suda, and Dr Motomi Osato for helpful discussions and critical reading of the manuscript.	Al-Aidaroos AQO, 2010, J CELL BIOCHEM, V111, P1087, DOI 10.1002/jcb.22913; Beekman R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026537; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chaudhary K, 2007, ONCOGENE, V26, P7499, DOI 10.1038/sj.onc.1210582; Chong PSY, 2014, CANCER RES, V74, P3043, DOI 10.1158/0008-5472.CAN-13-2321; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Gandillet A, 2011, LEUKEMIA, V25, P770, DOI 10.1038/leu.2011.17; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709; McParland V, 2011, BIOCHEMISTRY-US, V50, P7579, DOI 10.1021/bi201095z; Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Park JE, 2013, EMBO MOL MED, V5, P1351, DOI 10.1002/emmm.201202183; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Reindl C, 2006, BLOOD, V107, P3700, DOI 10.1182/blood-2005-06-2596; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zhou JX, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0019798, 10.1371/journal.pone.0014752, 10.1371/journal.pone.0024340]	26	14	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1508	1519		10.1038/s41388-018-0526-3	http://dx.doi.org/10.1038/s41388-018-0526-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305722				2022-12-28	WOS:000459945800010
J	Iness, AN; Felthousen, J; Ananthapadmanabhan, V; Sesay, F; Saini, S; Guiley, KZ; Rubin, SM; Dozmorov, M; Litovchick, L				Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Guiley, Keelan Z.; Rubin, Seth M.; Dozmorov, Mikhail; Litovchick, Larisa			The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb	ONCOGENE			English	Article							CARCINOMA IN-SITU; GENE-EXPRESSION; TRANSCRIPTION; TARGET; INTEGRATION; ACTIVATION; MECHANISMS; PHASE; FOXM1; LINE	Overexpression of the oncogene MYBL2 (B-Myb) is associated with increased cell proliferation and serves as a marker of poor prognosis in cancer. However, the mechanism by which B-Myb alters the cell cycle is not fully understood. In proliferating cells, B-Myb interacts with the MuvB core complex including LIN9, LIN37, LIN52, RBBP4, and LIN54, forming the MMB (Myb-MuvB) complex, and promotes transcription of genes required for mitosis. Alternatively, the MuvB core interacts with Rb-like protein p130 and E2F4-DP1 to form the DREAM complex that mediates global repression of cell cycle genes in G0/G1, including a subset of MMB target genes. Here, we show that overexpression of B-Myb disrupts the DREAM complex in human cells, and this activity depends on the intact MuvB-binding domain in B-Myb. Furthermore, we found that B-Myb regulates the protein expression levels of the MuvB core subunit LIN52, a key adapter for assembly of both the DREAM and MMB complexes, by a mechanism that requires S28 phosphorylation site in LIN52. Given that high expression of B-Myb correlates with global loss of repression of DREAM target genes in breast and ovarian cancer, our findings offer mechanistic insights for aggressiveness of cancers with MYBL2 amplification, and establish the rationale for targeting B-Myb to restore cell cycle control.	[Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Litovchick, Larisa] Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Litovchick, Larisa] Virginia Commonwealth Univ, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Guiley, Keelan Z.; Rubin, Seth M.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; [Dozmorov, Mikhail] Virginia Commonwealth Univ, Dept Biostat, Med Coll Virginia Campus, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of California System; University of California Santa Cruz; Virginia Commonwealth University	Litovchick, L (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Litovchick, L (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA.	larisa.litovchick@vcuhealth.org	Iness, Audra Nicole/HDM-4123-2022; Dozmorov, Mikhail/B-1374-2009	Iness, Audra Nicole/0000-0001-5194-1319; Litovchick, Larisa/0000-0002-9540-597X; Ananthapadmanabhan, Varsha/0000-0002-6909-1460; Dozmorov, Mikhail/0000-0002-0086-8358; Rubin, Seth/0000-0002-1670-4147; Sesay, Fatmata/0000-0002-9973-3639	 [R01CA188571];  [R01CA132685];  [R01GM124148];  [F30CA221004]; NATIONAL CANCER INSTITUTE [R01CA132685, R01CA188571, F30CA221004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM090084, R01GM124148] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank James DeCaprio and Iain Morgan for critically reading the manuscript, and Sophia Gruszecki for technical support. This project was supported in part by R01CA188571 (L.L.), R01CA132685 and R01GM124148 (S.M.R.), and F30CA221004 (A.N.I.).	Allegra CJ, 2010, J NATL CANCER I, V102, P161, DOI 10.1093/jnci/djp485; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Becker W, 2011, FEBS J, V278, P246, DOI 10.1111/j.1742-4658.2010.07956.x; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Dedic PN, 2013, MED ONCOL, V30, P523; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Forristal C, 2014, MOL CELL BIOL, V34, P2221, DOI 10.1128/MCB.01523-13; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Iltzsche F, 2017, ONCOGENE, V36, P110, DOI 10.1038/onc.2016.181; Inoue Kazushi, 2016, Biomark Cancer, V8, P25, DOI 10.4137/BIC.S38394; Iwahori S, 2017, VIROLOGY, V512, P95, DOI 10.1016/j.virol.2017.09.009; Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; LUNDIN A, 1986, METHOD ENZYMOL, V133, P27; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Odajima J, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006429; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Ukleja M, 2016, BIOESSAYS, V38, P1048, DOI 10.1002/bies.201600092; Yen HCS, 2008, SCIENCE, V322, P918, DOI 10.1126/science.1160489	44	34	38	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1080	1092		10.1038/s41388-018-0490-y	http://dx.doi.org/10.1038/s41388-018-0490-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30206359	Green Submitted, Green Accepted			2022-12-28	WOS:000458624900011
J	Sun, J; Cai, X; Yung, MMH; Zhou, W; Li, J; Zhang, Y; Li, ZQ; Liu, SS; Cheung, ANY; Ngan, HYS; Li, YL; Dai, ZJ; Kai, Y; Tzatsos, A; Peng, WQ; Chan, DW; Zhu, WG				Sun, Jing; Cai, Xin; Yung, Mingo M. H.; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Liu, Stephanie S.; Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Li, Yiliang; Dai, Zhijun; Kai, Yan; Tzatsos, Alexandros; Peng, Weiqun; Chan, David W.; Zhu, Wenge			miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							MOLECULAR-MECHANISMS; IN-VITRO; ANTISENSE OLIGODEOXYNUCLEOTIDES; INHIBITS PROLIFERATION; CELL CARCINOMA; BREAST-CANCER; TUMOR-CELLS; SENSITIVITY; EXPRESSION; MICRORNA-137	Platinum drugs are used in first-line to treat ovarian cancer, but most of the patients eventually generate resistance after treatment with these drugs. Although both c-Myc and EZH2 have been implicated in regulating cisplatin resistance in ovarian cancer, the interplay between these two regulators is poorly understood. Using RNA sequence analysis (RNA-seq), for the first time we find that miR-137 level is extremely low in cisplatin resistant ovarian cancer cells, correlating with higher levels of c-Myc and EZH2 expression. Further analyses indicate that in resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA, and increased expression of EZH2 activates cellular survival pathways, resulting in the resistance to cisplatin. Inhibition of c-Myc-miR-137-EZH2 pathway re-sensitizes resistant cells to cisplatin. Both in vivo and in vitro analyses indicate that cisplatin treatment activates c-Myc-miR-137-EZH2 pathway. Importantly, elevated c-Myc-miR-137-EZH2 pathway in resistant cells is sustained by dual oxidase maturation factor 1 (DUOXA1)-mediated production of reactive oxygen species (ROS). Significantly, clinical studies further confirm the activated c-Myc-miR-137-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients. Thus, our studies elucidate a novel role of miR-137 in regulating c-Myc-EZH2 axis that is crucial to the regulation of cisplatin resistance in ovarian cancer.	[Sun, Jing; Cai, Xin; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Sun, Jing; Cai, Xin; Zhou, Wei; Li, Jing; Zhang, Yi; Li, Zhuqing; Kai, Yan; Tzatsos, Alexandros; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Yung, Mingo M. H.; Liu, Stephanie S.; Ngan, Hextan Y. S.; Chan, David W.] Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynaecol, Hong Kong, Peoples R China; [Zhou, Wei] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Hangzhou 310016, Zhejiang, Peoples R China; [Cheung, Annie N. Y.] Univ Hong Kong, LKS Fac Med, Dept Pathol, Hong Kong, Peoples R China; [Li, Yiliang] Peking Union Med Coll, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China; [Li, Yiliang] Chinese Acad Med Sci, Tianjin 300192, Peoples R China; [Dai, Zhijun] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Shaanxi, Peoples R China; [Kai, Yan; Peng, Weiqun] George Washington Univ, Dept Phys, Columbian Coll Arts & Sci, Washington, DC 20052 USA; [Tzatsos, Alexandros] George Washington Univ, Sch Med & Hlth Sci, Dept Anat & Regenerat Biol, Washington, DC 20037 USA	George Washington University; George Washington University; University of Hong Kong; Zhejiang University; University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Xi'an Jiaotong University; George Washington University; George Washington University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Chan, DW (corresponding author), Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynaecol, Hong Kong, Peoples R China.	dwchan@hku.hk; wz6812@gwu.edu	Li, Zhuqing/AEW-9886-2022; YUNG, Mingo Ming Ho/AHB-5775-2022; Kai, Yan/ABH-8469-2020; /AAI-2516-2019; Chan, David/O-9896-2018; Dai, Zhi-Jun/O-6826-2014; Cheung, Annie Nga Yin/C-4231-2009	YUNG, Mingo Ming Ho/0000-0003-0903-1164; Kai, Yan/0000-0003-3262-4160; Chan, David/0000-0002-6951-3467; Li, Jing/0000-0002-0079-693X; Dai, Zhi-Jun/0000-0001-5209-8626; Peng, Weiqun/0000-0001-5521-9091; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568	National Institutes of Health [CA177898, CA184717]; McCormick Genomic and Proteomic Center [RSG-13-214-01-DMC]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA184717, R01CA177898] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Genomic and Proteomic Center; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to WZ), the McCormick Genomic and Proteomic Center. W. Zhu was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society.	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Banno K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/232817; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Brennecke J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-228; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Citro G, 1998, CANCER RES, V58, P283; Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3; Cui SC, 2017, MOL MED REP, V16, P9494, DOI 10.3892/mmr.2017.7828; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Dong S, 2016, ONCOL REP, V35, P2151, DOI 10.3892/or.2016.4604; Fabbri M, 2011, CURR OPIN HEMATOL, V18, P266, DOI 10.1097/MOH.0b013e3283476012; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Grasberger H, 2006, J BIOL CHEM, V281, P18269, DOI 10.1074/jbc.C600095200; Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/EPI.12.39, 10.2217/epi.12.39]; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hodzic J, 2011, NUCLEOS NUCLEOT NUCL, V30, P1214, DOI 10.1080/15257770.2011.629271; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Jazaeri AA, 2013, MOL CANCER THER, V12, P1958, DOI 10.1158/1535-7163.MCT-12-1028; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; LANGDON SP, 1988, CANCER RES, V48, P6166; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Liu X, 2017, EUR REV MED PHARMACO, V21, P511; Luo YW, 2016, TUMOR BIOL, V37, P7749, DOI 10.1007/s13277-015-4611-8; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; Meng YX, 2018, CANCER LETT, V428, P104, DOI 10.1016/j.canlet.2018.04.029; MIZUTANI Y, 1994, CANCER, V74, P2546, DOI 10.1002/1097-0142(19941101)74:9<2546::AID-CNCR2820740924>3.0.CO;2-Y; Moitra K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045268; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Norouzi-Barough L, 2018, J CELL PHYSIOL, V233, P4546, DOI 10.1002/jcp.26289; Passetti F, 2009, PHARMACOGENOMICS J, V9, P1, DOI 10.1038/tpj.2008.14; Prathapam T, 2010, J BIOL CHEM, V285, P32529, DOI 10.1074/jbc.M110.151902; Pyndiah S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001556; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Sandiford SDE, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-5; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; SKLAR MD, 1991, CANCER RES, V51, P2118; Smonskey Matthew, 2016, Oncoscience, V3, P21; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stronach EA, 2015, ONCOTARGET, V6, P31593, DOI 10.18632/oncotarget.3415; Sun J, 2016, AM J TRANSL RES, V8, P3077; Sun J, 2016, ONCOTARGETS THER, V9, P21, DOI 10.2147/OTT.S93305; Sun J, 2015, DRUG DES DEV THER, V9, P6327, DOI 10.2147/DDDT.S92777; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van Jaarsveld MTM, 2013, ONCOGENE, V32, P4284, DOI 10.1038/onc.2012.433; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Walker TL, 1996, BRIT J CANCER, V73, P610, DOI 10.1038/bjc.1996.105; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Warburton A, 2015, SCHIZOPHRENIA BULL, V41, P698, DOI 10.1093/schbul/sbu117; Wu YM, 2018, CANCER RES, V78, P671, DOI 10.1158/0008-5472.CAN-17-1327; Xie XK, 2006, CANCER INVEST, V24, P1, DOI 10.1080/07357900500449520; Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94; Zhou W, 2018, ONCOGENE, V37, P3981, DOI 10.1038/s41388-018-0238-8; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	64	73	77	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					564	580		10.1038/s41388-018-0459-x	http://dx.doi.org/10.1038/s41388-018-0459-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166592	Green Accepted			2022-12-28	WOS:000456589800008
J	Fu, QH; Zhang, Q; Lou, Y; Yang, JQ; Nie, G; Chen, Q; Chen, YW; Zhang, JY; Wang, JX; Wei, T; Qin, H; Dang, XW; Bai, XL; Liang, TB				Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Dang, Xiaowei; Bai, Xueli; Liang, Tingbo			Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; COLORECTAL-CANCER; NICHE FORMATION; TGF-BETA; RESECTION; SURVIVAL; GROWTH; PROLIFERATION; DISSEMINATION	Hepatocellular carcinoma (HCC) is a fatal disease and patients with HCC frequently die from metastasis. The mechanisms of HCC metastasis are not completely understood. In the present study, in vitro and in vivo data showed that HCC cells promoted cancer cell proliferation and lung metastases formation in a paracrinal/endocrinal way. We found that HCC-derived exosomes mediated this phenomenon and observed enhanced cell adhesion in the presence of these malignant exosomes. We further identified that reactive oxygen species (ROS) regulated the adhesive molecules. Intriguingly, attached HCC cells released exosomes containing both SMAD Family Member 3 (SMAD3) protein and mRNA, which were delivered to detached HCC cells and facilitated their adhesion. These exosomes induced enhanced SMAD3 signaling in the recipient HCC cells and increased their adhesive ability. In addition, we showed that SMAD3-abundant exosomes existed in the peripheral blood of patients with HCC, and their levels correlated with disease stage and the SMAD3 expression of primary tumors. Our study suggested a possible mechanism by which primary HCC supported metastases formation and revealed the role of SMAD3 in the exosomes-mediated crosstalk between primary and circulating HCC cells.	[Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Dang, Xiaowei] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Zhengzhou, Henan, Peoples R China	Zhejiang University; Zhejiang University; Zhengzhou University	Bai, XL; Liang, TB (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn; shirleybai@zju.edu.cn			National Program on Key Basic Research Project (973 Program) [2014CB542101]; National Natural Science Foundation of China [81401954, 81472212]; Key Program of Medical Scientific Research Foundation of Zhejiang Province, China [WKJ-ZJ-1410]; Medical Science & Technology Program of Zhejiang Province, China [2015KYA114]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China [2014ZZ007]	National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program of Medical Scientific Research Foundation of Zhejiang Province, China; Medical Science & Technology Program of Zhejiang Province, China; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China	This work was financially supported by the National Program on Key Basic Research Project (973 Program, No. 2014CB542101), the National Natural Science Foundation of China (No. 81401954, No. 81472212), Key Program of Medical Scientific Research Foundation of Zhejiang Province, China (No. WKJ-ZJ-1410), the Medical Science & Technology Program of Zhejiang Province, China (No. 2015KYA114), the Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents, and the Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China (No. 2014ZZ007).	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386; Fu QH, 2016, TUMOR BIOL, V37, P7277, DOI 10.1007/s13277-015-4560-2; Garden OJ, 2006, GUT, V55, P1, DOI 10.1136/gut.2006.098053; He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081; Hong YP, 2016, INT J ONCOL, V49, P2206, DOI 10.3892/ijo.2016.3747; Jiang F, 2014, REDOX BIOL, V2, P267, DOI 10.1016/j.redox.2014.01.012; Kim SH, 2012, HEPATOB PANCREAT DIS, V11, P51, DOI 10.1016/S1499-3872(11)60125-2; Li JM, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00029, 10.3389/fonc.2012.00079]; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Mao K, 2017, J CLIN ONCOL S15, V35; Musri FY, 2016, J GASTRIC CANCER, V16, P78, DOI 10.5230/jgc.2016.16.2.78; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Peeters CFJM, 2006, INT J CANCER, V119, P1249, DOI 10.1002/ijc.21928; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rashid OM, 2013, SURGERY, V153, P771, DOI 10.1016/j.surg.2013.02.002; Ren T, 2017, ONCOGENE, V36, P5897, DOI 10.1038/onc.2017.167; Rocken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Singletary SE, 2003, ONCOLOGIST, V8, P241, DOI 10.1634/theoncologist.8-3-241; SLOOTER GD, 1995, BRIT J SURG, V82, P129, DOI 10.1002/bjs.1800820144; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Wen SW, 2016, CANCER RES, V76, P6816, DOI 10.1158/0008-5472.CAN-16-0868; Xu H, 2015, SCI REP-UK, V5, DOI 10.1038/srep16516; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhang ZC, 2017, CANCER LETT, V397, P33, DOI 10.1016/j.canlet.2017.03.004	33	87	90	4	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6105	6118		10.1038/s41388-018-0391-0	http://dx.doi.org/10.1038/s41388-018-0391-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29991801	Green Published, hybrid			2022-12-28	WOS:000450883000001
J	Mutvei, AP; Landor, SKJ; Fox, R; Braune, EB; Tsoi, YL; Phoon, YP; Sahlgren, C; Hartman, J; Bergh, J; Jin, SB; Lendahl, U				Mutvei, Anders P.; Landor, Sebastian K-J; Fox, Rhys; Braune, Eike-Benjamin; Tsoi, Yat Long; Phoon, Yee Peng; Sahlgren, Cecilia; Hartman, Johan; Bergh, Jonas; Jin, Shaobo; Lendahl, Urban			Notch signaling promotes a HIF2 alpha-driven hypoxic response in multiple tumor cell types	ONCOGENE			English	Article							INDUCIBLE FACTOR (HIF)-1-ALPHA; HIF2A MUTATIONS; HIF-2-ALPHA; INHIBITION; FACTOR-2; HIF-2; PHEOCHROMOCYTOMAS; DIFFERENTIATION; PARAGANGLIOMA; EXPRESSION	Hyperactivation of Notch signaling and the cellular hypoxic response are frequently observed in cancers, with increasing reports of connections to tumor initiation and progression. The two signaling mechanisms are known to intersect, but while it is well established that hypoxia regulates Notch signaling, less is known about whether Notch can regulate the cellular hypoxic response. We now report that Notch signaling specifically controls expression of HIF2 alpha, a key mediator of the cellular hypoxic response. Transcriptional upregulation of HIF2 alpha by Notch under normoxic conditions leads to elevated HIF2 alpha protein levels in primary breast cancer cells as well as in human breast cancer, medulloblastoma, and renal cell carcinoma cell lines. The elevated level of HIF2 alpha protein was in certain tumor cell types accompanied by downregulation of HIF1 alpha protein levels, indicating that high Notch signaling may drive a HIF1 alpha-to-HIF2 alpha switch. At the transcriptome level, the presence of HIF2 alpha was required for approximately 21% of all Notch-induced genes: among the 1062 genes that were upregulated by Notch in medulloblastoma cells during normoxia, upregulation was abrogated in 227 genes when HIF2 alpha expression was knocked down by HIF2 alpha siRNA. In conclusion, our data show that Notch signaling affects the hypoxic response via regulation of HIF2 alpha, which may be important for future cancer therapies.	[Mutvei, Anders P.; Landor, Sebastian K-J; Fox, Rhys; Braune, Eike-Benjamin; Tsoi, Yat Long; Phoon, Yee Peng; Jin, Shaobo; Lendahl, Urban] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Landor, Sebastian K-J; Sahlgren, Cecilia] Univ Turku, Turku Ctr Biotechnol, Turku 20520, Finland; [Landor, Sebastian K-J; Sahlgren, Cecilia] Abo Akad Univ, Turku 20520, Finland; [Hartman, Johan] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Bergh, Jonas] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Radiumhemmet,Breast Canc,Canc Theme, Stockholm, Sweden; [Bergh, Jonas] Univ Oxford, Dept Publ Hlth, Oxford OX1 2JD, England	Karolinska Institutet; University of Turku; Abo Akademi University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Oxford	Jin, SB; Lendahl, U (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	Shaobo.Jin@ki.se; Urban.Lendahl@ki.se	Braune, Eike-Benjamin/AAI-5820-2020; Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527; MUTVEI, ANDERS/0000-0002-2498-5225; Fox, Rhys/0000-0002-7433-0331; Bergh, Jonas/0000-0001-5526-1847	Swedish Cancer Society; Swedish Research Council; BRECT Consortium at Karolinska Institutet; ICMC (AstraZeneca); Albin K. Johanssons Foundation; Jane & Aatos Erkko Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); BRECT Consortium at Karolinska Institutet; ICMC (AstraZeneca)(AstraZeneca); Albin K. Johanssons Foundation; Jane & Aatos Erkko Foundation	The financial support from the Swedish Cancer Society, the Swedish Research Council, the BRECT Consortium at Karolinska Institutet, and ICMC (AstraZeneca) (UL) is gratefully acknowledged. SKJL was supported by the Jane & Aatos Erkko and Albin K. Johanssons Foundations. This work is dedicated to the memory of the late friend and colleague Lorenz Poellinger.	Toledo RA, 2017, ENDOCR-RELAT CANCER, V24, pC9, DOI 10.1530/ERC-16-0479; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; Ayaz F, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00345; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Braune EB, 2016, STEM CELL REP, V6, P643, DOI 10.1016/j.stemcr.2016.03.004; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Burroughs SK, 2013, FUTURE MED CHEM, V5, P553, DOI [10.4155/fmc.13.17, 10.4155/FMC.13.17]; Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Danza G, 2012, MOL CANCER RES, V10, P230, DOI 10.1158/1541-7786.MCR-11-0296; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Favier J, 2012, NEW ENGL J MED, V367, P2161, DOI 10.1056/NEJMc1211953; Gao W, 2012, ARTHRITIS RHEUM-US, V64, P2104, DOI 10.1002/art.34397; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jin S, 2013, ONCOGENE, V32, P4892, DOI 10.1038/onc.2012.517; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Koh MY, 2015, CANCER RES, V75, P316, DOI 10.1158/0008-5472.CAN-13-2190; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Landor SKJ', 2017, EXP CELL RES, V356, P146, DOI 10.1016/j.yexcr.2017.04.030; Lanner F, 2013, STEM CELLS DEV, V22, P1360, DOI 10.1089/scd.2012.0259; Lim KJ, 2015, ONCOTARGET, V6, P1666, DOI 10.18632/oncotarget.2762; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Martini S, 2013, STEM CELLS, V31, P741, DOI 10.1002/stem.1320; Meunier A, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00104; O'Reilly SM, 2006, AM J PHYSIOL-CELL PH, V290, pC592, DOI 10.1152/ajpcell.00278.2005; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Pietras A, 2011, MOL CANCER RES, V9, P626, DOI 10.1158/1541-7786.MCR-10-0508; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Pirot P, 2004, BIOCHEM BIOPH RES CO, V322, P526, DOI 10.1016/j.bbrc.2004.07.157; Pistollato F, 2010, STEM CELLS, V28, P1918, DOI 10.1002/stem.518; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185]; Scheuerrnann TH, 2015, J MED CHEM, V58, P5930, DOI 10.1021/acs.jmedchem.5b00529; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017; Toledo RA, 2013, ENDOCR-RELAT CANCER, V20, P349, DOI 10.1530/ERC-13-0101; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Zhao JD, 2015, CANCER TREAT REV, V41, P623, DOI 10.1016/j.ctrv.2015.05.004; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119	62	14	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6083	6095		10.1038/s41388-018-0400-3	http://dx.doi.org/10.1038/s41388-018-0400-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29993038	Green Published, hybrid			2022-12-28	WOS:000450175900006
J	Guo, X; Zhang, Y; Mayakonda, A; Madan, V; Ding, LW; Lin, LH; Zia, S; Gery, S; Tyner, JW; Zhou, W; Yin, D; Lin, DC; Koeffler, HP				Guo, Xiao; Zhang, Yin; Mayakonda, Anand; Madan, Vikas; Ding, Ling-Wen; Lin, Le-Hang; Zia, Saadiya; Gery, Sigal; Tyner, Jeffrey W.; Zhou, Wu; Yin, Dong; Lin, De-Chen; Koeffler, H. Phillip			ARID1A and CEBP alpha cooperatively inhibit UCA1 transcription in breast cancer	ONCOGENE			English	Article							REMODELING GENE ARID1A; CLEAR-CELL CARCINOMA; NONCODING RNA UCA1; TUMOR-SUPPRESSOR; ARID1A/BAF250A EXPRESSION; BLADDER-CANCER; MUTATIONS; PROLIFERATION; ENDOMETRIOSIS; PROGNOSIS	As one of the primary members of SWI/SNF chromatin remodeling complexes, ARID1A contains frequent loss-of-function mutations in many types of cancers. However, the molecular mechanisms underlying ARID1A deficiency in cancer biology remain to be investigated. Using breast cancer as a model, we report that silencing ARID1A significantly increased cellular proliferation and migration. Mechanistically, primarily functioning as a transcriptional repressor, loss of ARID1A profoundly alters histone modifications and the transcriptome. Notably, ARID1A inhibited the expression of a long noncoding RNA, UCA1, by regulating chromatin access of the transcription factor CEBPa. Restoration experiments showed that UCA1 mediates the functions of ARID1A that induces loss of cellular proliferation and migration. Together, our findings characterize ARID1A as a key tumor-suppressor gene in breast cancer through cooperation with CEBPa, and loss-of-function mutations of ARID1A activates UCA1.	[Guo, Xiao; Zhang, Yin; Lin, Le-Hang; Yin, Dong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Res Ctr Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China; [Guo, Xiao; Zia, Saadiya; Gery, Sigal; Lin, De-Chen; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Mayakonda, Anand; Madan, Vikas; Ding, Ling-Wen; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Zhou, Wu] Lishui Univ, Coll Med & Hlth, Dept Med, Lishui, Zhejiang, Peoples R China; [Koeffler, H. Phillip] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore	Sun Yat Sen University; Cedars Sinai Medical Center; National University of Singapore; Oregon Health & Science University; Lishui University; National University of Singapore	Guo, X (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Res Ctr Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China.; Guo, X; Lin, DC (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.	guoxiao152@163.com; De-Chen.Lin@cshs.org	Ding, Ling-Wen/H-6916-2019	Ding, Ling-Wen/0000-0003-0022-1551; Madan, Vikas/0000-0001-7876-624X; zhou, wu/0000-0003-3105-8064	National Research Foundation Singapore under its Singapore Translational Research Investigator Award [NMRC/STaR/0021/2014]; NMRC Centre Grant; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiatives; RNA Biology Center at the Cancer Science Institute of Singapore; NUS, Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]; Tower Cancer Research Foundation; National Natural Science Foundation of China (NSFC) [31401594]; Michele and Ted Kaplan Family Fund; Tower Foundation	National Research Foundation Singapore under its Singapore Translational Research Investigator Award(National Research Foundation, Singapore); NMRC Centre Grant(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centers of Excellence initiatives(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore; NUS, Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore); Tower Cancer Research Foundation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Michele and Ted Kaplan Family Fund; Tower Foundation	ARID1A shRNA and ARID1A CRISPR-Cas9 plasmid are gifts from Vikas Madan, Cancer Science Institute of Singapore; pCDH-CMV-UCA1-EF1-copGFP is a gift from Yin-Yuan Mo, University of Mississippi Medical Center. This research was supported by the National Research Foundation Singapore under its Singapore Translational Research Investigator Award (NMRC/STaR/0021/2014) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute, the National Research Foundation Singapore, and the Singapore Ministry of Education under its Research Centers of Excellence initiatives to H.P.K. This study was additionally funded by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants (MOE2014-T3-1-006). D.-C.L was supported by Tower Cancer Research Foundation. Part research was supported by National Natural Science Foundation of China (NSFC, 31401594, to X.G.) and the generous support of Michele and Ted Kaplan Family Fund and the Tower Foundation.	Alteri R, 2015, BREAST CANC FACTS FI; Baker K, 2013, IMMUNITY, V39, P1095, DOI 10.1016/j.immuni.2013.11.003; Block K, 2010, AM J PATHOL, V176, P2447, DOI 10.2353/ajpath.2010.090606; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339; Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208; Cornen S, 2012, ONCOGENE, V31, P4255, DOI 10.1038/onc.2011.598; Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737; Guan B, 2012, NEOPLASIA, V14, P986, DOI 10.1593/neo.121218; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guo X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.349; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Hughes JM, 2015, ONCOTARGET, V6, P18534, DOI 10.18632/oncotarget.4069; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9; Lin DC, 2018, GUT, V67, P1769, DOI 10.1136/gutjnl-2017-314607; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Priam P, 2017, NAT GENET, V49, P753, DOI 10.1038/ng.3812; Samartzis EP, 2014, ONCOTARGET, V5, P5295, DOI 10.18632/oncotarget.2092; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Sun XX, 2016, CELL STEM CELL, V18, P456, DOI 10.1016/j.stem.2016.03.001; Takao C, 2017, J CANCER, V8, P1, DOI 10.7150/jca.16602; Takeda T, 2016, ONCOL REP, V35, P607, DOI 10.3892/or.2015.4421; Wang HH, 2017, ONCOTARGET, V8, P64638, DOI 10.18632/oncotarget.18344; Wang Z, 2017, TUMOR BIOL, V39, DOI DOI 10.1177/101042831770999028639914; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xiao WB, 2012, INT J CLIN EXP PATHO, V5, P642; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang L, 2016, CANCER CHEMOTH PHARM, V77, P629, DOI 10.1007/s00280-016-2963-4; Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006; Zhao J, 2014, TUMOR BIOL, V35, P4813, DOI 10.1007/s13277-014-1632-7	37	19	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5939	5951		10.1038/s41388-018-0371-4	http://dx.doi.org/10.1038/s41388-018-0371-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980791				2022-12-28	WOS:000449562500003
J	Johnson, CE; Dunlop, EA; Seifan, S; McCann, HD; Hay, T; Parfitt, GJ; Jones, AT; Giles, PJ; Shen, MH; Sampson, JR; Errington, RJ; Davies, DM; Tee, AR				Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Hay, Trevor; Parfitt, Geraint J.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.			Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir - bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article							HIV PROTEASE INHIBITOR; RENAL ANGIOMYOLIPOMA; ER STRESS; AUTOPHAGY; MTOR	Cancer cells lose homeostatic flexibility because of mutations and dysregulated signaling pathways involved in maintaining homeostasis. Tuberous Sclerosis Complex 1 (TSC1) and TSC2 play a fundamental role in cell homeostasis, where signal transduction through TSC1/TSC2 is often compromised in cancer, leading to aberrant activation of mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 hyperactivation increases the basal level of endoplasmic reticulum (ER) stress via an accumulation of unfolded protein, due to heightened de novo protein translation and repression of autophagy. We exploit this intrinsic vulnerability of tumor cells lacking TSC2, by treating with nelvinavir to further enhance ER stress while inhibiting the proteasome with bortezomib to prevent effective protein removal. We show that TSC2-deficient cells are highly dependent on the proteosomal degradation pathway for survival. Combined treatment with nelfinavir and bortezomib at clinically relevant drug concentrations show synergy in selectively killing TSC2-deficient cells with limited toxicity in control cells. This drug combination inhibited tumor formation in xenograft mouse models and patient-derived cell models of TSC and caused tumor spheroid death in 3D culture. Importantly, 3D culture assays differentiated between the cytostatic effects of the mTORC1 inhibitor, rapamycin, and the cytotoxic effects of the nelfinavir/bortezomib combination. Through RNA sequencing, we determined that nelfinavir and bortezomib tip the balance of ER protein homeostasis of the already ER-stressed TSC2-deficient cells in favor of cell death. These findings have clinical relevance in stratified medicine to treat tumors that have compromised signaling through TSC and are inflexible in their capacity to restore ER homeostasis.	[Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.] Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Hay, Trevor; Parfitt, Geraint J.] Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Davies, D. Mark] Singleton Hosp, South West Wales Canc Ctr, Dept Oncol, Swansea SA2 8QA, W Glam, Wales	Cardiff University; Cardiff University; Singleton Hospital	Tee, AR (corresponding author), Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk	/J-6218-2019; Parfitt, Geraint/J-2778-2018	/0000-0002-9209-7561; Parfitt, Geraint/0000-0002-8704-7906; Davies, Mark/0000-0002-0688-3129	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC; Hospital Saturday Fund	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Hospital Saturday Fund	This work was supported by Health and Care Research Wales (the Wales Cancer Research Centre) (to EAD, ART, PJG and TH), the Tuberous Sclerosis Association (to EAD, ART, and MHS), Cancer Research Wales (to CEJ, RJE, and ART), the Tuberous Sclerosis Alliance (to EAD and ART), the Hospital Saturday Fund (to ART) and BBSRC (to RJE). We would like to thank the Wales Gene Park for their contribution to this study.	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Auricchio N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031900; Babcock JT, 2013, J BIOL CHEM, V288, P15687, DOI 10.1074/jbc.M112.431056; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Dabora SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023379; Driessen C, 2016, HAEMATOLOGICA, V101, P346, DOI 10.3324/haematol.2015.135780; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Dunlop EA, 2017, ONCOTARGET, V8, P48711, DOI 10.18632/oncotarget.16232; Dunlop EA, 2011, AUTOPHAGY, V7, P737, DOI 10.4161/auto.7.7.15491; Gandolfi S, 2017, CANCER METAST REV, V36, P561, DOI 10.1007/s10555-017-9707-8; Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161; Johnson CE, 2015, MOL ONCOL, V9, P675, DOI 10.1016/j.molonc.2014.11.005; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kawabata S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.87; Kraus M, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.2; Kraus M, 2014, LEUKEMIA RES, V38, P383, DOI 10.1016/j.leukres.2013.12.017; Lam HC, 2017, J PATHOL, V241, P219, DOI 10.1002/path.4827; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Peng ZF, 2014, J UROLOGY, V192, P1424, DOI 10.1016/j.juro.2014.04.096; Shim JS, 2012, JNCI-J NATL CANCER I, V104, P1576, DOI 10.1093/jnci/djs396; Siroky BJ, 2012, AM J PHYSIOL-RENAL, V303, pF831, DOI 10.1152/ajprenal.00441.2011; Stengel S, 2017, BBA-MOL CELL RES, V1864, P2183, DOI 10.1016/j.bbamcr.2017.07.008; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492	27	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5913	5925		10.1038/s41388-018-0381-2	http://dx.doi.org/10.1038/s41388-018-0381-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980790	Green Accepted, hybrid			2022-12-28	WOS:000449562500001
J	Yang, TT; Ren, C; Qiao, PY; Han, X; Wang, L; Lv, SJ; Sun, YH; Liu, ZJ; Du, Y; Yu, ZH				Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Lv, Shijun; Sun, Yonghong; Liu, Zhijun; Du, Yu; Yu, Zhenhai			PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer	ONCOGENE			English	Article							GLYCOLYSIS; AUTOPHAGY; INCREASES; KINASES; PKM2; PIM2	Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer.	[Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Yu, Zhenhai] Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China; [Lv, Shijun; Sun, Yonghong] Weifang Med Univ, Affiliated Hosp, Dept Pathol, Weifang, Shandong, Peoples R China; [Liu, Zhijun; Du, Yu] Weifang Med Univ, Dept Med Microbiol, Weifang, Shandong, Peoples R China	Weifang Medical University; Weifang Medical University; Weifang Medical University	Yu, ZH (corresponding author), Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China.	tomsyu@163.com	Liu, Zhijun/AAV-9805-2021		Innovation Fund of National Natural Science Foundation of China [81602440, 81602301, 81471048]; Shandong Province College Science and Technology Plan Project [J16LL08, J17KA254]; Projects of Medical and Health Technology Development Program in Shandong province [2016WS0688, 2017WS398]; National Natural Science Foundation of Shangdong Province [ZR2014HM086]	Innovation Fund of National Natural Science Foundation of China; Shandong Province College Science and Technology Plan Project; Projects of Medical and Health Technology Development Program in Shandong province; National Natural Science Foundation of Shangdong Province	The study was supported by research grants from Innovation Fund of National Natural Science Foundation of China (Grant no. 81602440, 81602301, and 81471048), Shandong Province College Science and Technology Plan Project (Grant no. J16LL08 and J17KA254), Projects of Medical and Health Technology Development Program in Shandong province (Grant no. 2016WS0688 and 2017WS398), National Natural Science Foundation of Shangdong Province (Grant no. ZR2014HM086).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Blanco-Aparicio C, 2013, BIOCHEM PHARMACOL, V85, P629, DOI 10.1016/j.bcp.2012.09.018; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Deng GP, 2015, J BIOL CHEM, V290, P20211, DOI 10.1074/jbc.M115.638221; Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Lee JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00906-9; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; McDonald JE, 2017, CLIN CANCER RES, V23, P1981, DOI 10.1158/1078-0432.CCR-16-0235; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Ren CN, 2018, MOL ONCOL, V12, P690, DOI 10.1002/1878-0261.12192; Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019; Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026; Tan VP, 2015, AUTOPHAGY, V11, P963, DOI 10.1080/15548627.2015.1042195; Uddin N, 2015, CANCER SCI, V106, P718, DOI 10.1111/cas.12668; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Xia HG, 2015, J CELL BIOL, V210, P705, DOI 10.1083/jcb.201503044; Xiong XP, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.103; Yu ZH, 2016, BIOCHEM BIOPH RES CO, V473, P953, DOI 10.1016/j.bbrc.2016.03.160; Yu ZH, 2014, CELL SIGNAL, V26, P1560, DOI 10.1016/j.cellsig.2014.03.016; Yu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088301; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Zhang XH, 2015, INT J MED SCI, V12, P487, DOI 10.7150/ijms.10982; Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33	29	61	63	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5997	6009		10.1038/s41388-018-0386-x	http://dx.doi.org/10.1038/s41388-018-0386-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29985480	hybrid, Green Published			2022-12-28	WOS:000449562500007
J	Tao, Y; Liu, ZJ; Hou, YY; Wang, SL; Liu, SH; Jiang, YH; Tan, D; Ge, QL; Li, CF; Hu, YM; Liu, Z; Chen, X; Wang, Q; Wang, ML; Zhang, XR				Tao, Yu; Liu, Zhanjie; Hou, Yingyong; Wang, Shouli; Liu, Sanhong; Jiang, Yuhang; Tan, Dan; Ge, Qiulin; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Wang, Mingliang; Zhang, Xiaoren			Alternative NF-kappa B signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3	ONCOGENE			English	Article							FAMILY-MEMBER BCL-3; C-MYC; CANCER STATISTICS; PROSTATE-CANCER; ACTIVATION; INFLAMMATION; ANGIOGENESIS; EXPRESSION; BINDING; KINASE	Multiple studies have shown that chronic inflammation is closely related to the occurrence and development of colorectal cancer (CRC). Classical NF-kappa B signaling, the key factor in controlling inflammation, has been found to be of great importance to CRC development. However, the role of alternative NF-kappa B signaling in CRC is still elusive. Here, we found aberrant constitutive activation of alternative NF-kappa B signaling both in CRC tissue and CRC cells. Knockdown of RelB downregulates c-Myc and upregulates p27(Kip1) protein level, which inhibits CRC cell proliferation and retards CRC xenograft growth. Conversely, overexpression of RelB increases proliferation of CRC cells. In addition, we revealed a significant correlation between Bcl-3 and RelB in CRC tissues. The expression of RelB was consistent with the expression of Bcl-3 and the phosphorylation of Bcl-3 downstream proteins p-Akt (S473) and p-GSK3 beta (S9). Bcl-3 overexpression can restore the phenotype changes caused by RelB knockdown. Importantly, we demonstrated that alternative NF-kappa B transcriptional factor (p52:RelB) can directly bind to the promoter region of Bcl-3 gene and upregulate its transcription. Moreover, the expression of RelB, NF-kappa B2 p52, and Bcl-3 was associated with poor survival of CRC patients. Taken together, these results represent that alternative NF-kappa B signaling may function as an oncogenic driver in CRC, and also provide new ideas and research directions for the pathogenesis, prevention, and treatment of other inflammatory-related diseases.	[Tao, Yu; Liu, Zhanjie; Liu, Sanhong; Jiang, Yuhang; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Zhang, Xiaoren] Shanghai Jiao Tong Univ, Inst Hlth Sci, Key Lab Stem Cell Biol, Sch Med, Shanghai 200025, Peoples R China; [Tao, Yu; Liu, Zhanjie; Liu, Sanhong; Jiang, Yuhang; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Zhang, Xiaoren] Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China; [Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Dept Pathol, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Wang, Shouli] Soochow Univ, Dept Pathol, Sch Med, Suzhou 215123, Peoples R China; [Liu, Sanhong] Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China; [Tan, Dan; Wang, Mingliang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China; [Ge, Qiulin] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Zhang, Xiaoren] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510000, Guangdong, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; Soochow University - China; ShanghaiTech University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Guangzhou Medical University	Zhang, XR (corresponding author), Shanghai Jiao Tong Univ, Inst Hlth Sci, Key Lab Stem Cell Biol, Sch Med, Shanghai 200025, Peoples R China.; Zhang, XR (corresponding author), Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China.; Wang, ML (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China.; Zhang, XR (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510000, Guangdong, Peoples R China.	mingliang-99@hotmail.com; xrzhang@sibs.ac.cn	wang, mingliang/GXF-2439-2022	Liu, Sanhong/0000-0002-8695-0343; zhang, xiaoren/0000-0003-4080-433X	National Program on Key Research [2016YFC1302400]; National Basic Research Program [2014CB541904, 2014CB943600]; National Natural Science Foundation of China [91742113, 31570902, 31370881]; Natural Science Foundation of Shanghai [14ZR1426300, 18ZR1424400, 18ZR1446400]	National Program on Key Research; National Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This work was supported by the National Program on Key Research (2016YFC1302400), the National Basic Research Program (2014CB541904, 2014CB943600), National Natural Science Foundation of China (91742113, 31570902, 31370881), and Natural Science Foundation of Shanghai (14ZR1426300, 18ZR1424400, 18ZR1446400).	Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Bretones G, 2011, J BIOL CHEM, V286, P9815, DOI 10.1074/jbc.M110.165977; Chandramohan V, 2008, J CELL BIOCHEM, V104, P2091, DOI 10.1002/jcb.21765; Chen C, 2013, BIOCHEM BIOPH RES CO, V430, P505, DOI 10.1016/j.bbrc.2012.12.006; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Ge QL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.309; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jacque E, 2013, ONCOGENE, V32, P2661, DOI 10.1038/onc.2012.282; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Liu ZJ, 2013, J MOL CELL BIOL, V5, P280, DOI 10.1093/jmcb/mjt020; Maldonado V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-152; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Nottingham LK, 2014, ONCOGENE, V33, P1135, DOI 10.1038/onc.2013.49; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Poljak L, 1999, J IMMUNOL, V163, P6581; Saamarthy K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1342-6; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; TANAKA S, 1990, CANCER GENET CYTOGEN, V49, P219, DOI 10.1016/0165-4608(90)90144-Y; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Urban BC, 2016, GUT, V65, P1151, DOI 10.1136/gutjnl-2014-308270; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vallabhapurapu SD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9428; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Wang Y, 2016, ONCOGENE, V35, P4080, DOI 10.1038/onc.2015.470; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Wen DY, 2006, J PHARMACOL EXP THER, V317, P989, DOI 10.1124/jpet.105.097584; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Xu Y, 2009, CANCER RES, V69, P3267, DOI 10.1158/0008-5472.CAN-08-4635; Xue G, 2015, ONCOGENE, V34, P1393, DOI 10.1038/onc.2014.82; Zhang JP, 2007, ENDOCRINOLOGY, V148, P268, DOI 10.1210/en.2006-0500; Zhang XR, 2007, IMMUNITY, V27, P438, DOI 10.1016/j.immuni.2007.07.017	51	8	8	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5887	5900		10.1038/s41388-018-0363-4	http://dx.doi.org/10.1038/s41388-018-0363-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973688				2022-12-28	WOS:000448943100006
J	Bai, MZ; Yang, LL; Liao, H; Liang, XY; Xie, BY; Xiong, J; Tao, X; Chen, X; Cheng, YL; Chen, XJ; Feng, YJ; Zhang, ZB; Zheng, WX				Bai, Mingzhu; Yang, Linlin; Liao, Hong; Liang, Xiaoyan; Xie, Bingying; Xiong, Ji; Tao, Xiang; Chen, Xiong; Cheng, Yali; Chen, Xiaojun; Feng, Youji; Zhang, Zhenbo; Zheng, Wenxin			Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism	ONCOGENE			English	Article							PREDICT LONGER SURVIVAL; GLUTAMINE-METABOLISM; PROGESTIN RESISTANCE; OXIDATIVE STRESS; GASTRIC-CANCER; UP-REGULATION; GENE; P53; IDH1; PROMOTES	Chemoresistance is the major obstacle to cure endometrial cancer, whereas metformin has demonstrated sensitization to chemotherapy in endometrial cancer. A novel finding states that isocitrate dehydrogenase 1 (IDH1) involves in cancer chemoresistance. Recent studies have revealed that epigenetic modifications facilitate chemoresistance. However, whether IDH1 play a role in metformin-induced endometrial cancer chemosensitivity through epigenetic modification is incompletely understood. Immunohistochemistry and Elisa assays were used to evaluate the expression pattern of IDH1 in endometrial tissue and serum, respectively. Western blot was performed to determine changes in expression of key molecules in the IDH1-alpha-KG-TET1-Nrf2 signaling pathway after various treatments. Dot blot assays were used to assess global hydroxymethylation levels after metformin administration or plasmid transfection. Antioxidant response element (ARE) activity in the IDH1 promoter region was monitored by luciferase assay. Cancer cell sensitivity to chemotherapy was detected by SRB assay. We found that activation of the IDH1 signaling pathway in endometrial cancer tissue resulting from aberrant expression of IDH1 and its downstream mediators conferred chemoresistance. We found that this effect was abated by metformin treatment. Dot blot and HMeDIP assays revealed that metformin blocked IDH1-alpha-KG-TET1-mediated enhancement of Nrf2 hydroxymethylation levels, eliminating chemoresistance. Moreover, we observed that chemoresistance was enhanced via a regulatory loop in which Nrf2 activated IDH1-alpha-KG-TET1-Nrf2 signaling via binding to the ARE sites in the IDH1 promoter region. Our findings highlight a critical role of IDH1-alpha-KG-TET1-Nrf2 signaling in chemoresistance and suggest that rational combination therapy with metformin and chemotherapeutics has the potential to suppress chemoresistance. These authors contributed equally: Mingzhu Bai, Linlin Yang, Hong Liao.	[Bai, Mingzhu; Yang, Linlin; Xie, Bingying; Feng, Youji; Zhang, Zhenbo] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Shanghai 200080, Peoples R China; [Yang, Linlin; Liang, Xiaoyan; Chen, Xiong; Zhang, Zhenbo] Shanghai First Peoples Hosp, Baoshan Branch, Dept Obstet & Gynecol, Shanghai 201900, Peoples R China; [Liao, Hong] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Cerv Dis, Shanghai 200040, Peoples R China; [Xiong, Ji] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200040, Peoples R China; [Tao, Xiang] Fudan Univ, Obstet & Gynecol Hosp, Dept Pathol, Shanghai 200011, Peoples R China; [Cheng, Yali; Chen, Xiaojun] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China; [Zheng, Wenxin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Zheng, Wenxin] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA	Shanghai Jiao Tong University; Tongji University; Fudan University; Fudan University; Fudan University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, ZB (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Shanghai 200080, Peoples R China.; Zhang, ZB (corresponding author), Shanghai First Peoples Hosp, Baoshan Branch, Dept Obstet & Gynecol, Shanghai 201900, Peoples R China.; Zheng, WX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.; Zheng, WX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.	zhangzhenbozzb@aliyun.com; Wenxin.Zheng@UTSouthwestern.edu		Bai, Mingzhu/0000-0001-6210-4890; , Linlin/0000-0002-4260-1934	National Natural Science Foundation of China [81672562, 81370074]; Shanghai Municipal Public Health Bureau [XYQ2013119]; "Chenxing Project" from Shanghai Jiao Tong University; Mark and Jane Gibson distinguished professorship endowment fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Public Health Bureau; "Chenxing Project" from Shanghai Jiao Tong University; Mark and Jane Gibson distinguished professorship endowment fund	We thank Prof. Zhao Shimin (Fudan University, Shanghai, China) for providing the plasmids pcDNA3.0-TET1-flag and pRSF-Duet1-IDH1. We also thank Prof. Shi Yujiang (Harvard University, Cambridge, MA) for providing pPB-TET1 plasmid. This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81672562, 81370074), the Shanghai Municipal Public Health Bureau (grant number XYQ2013119) and the "Chenxing Project" from Shanghai Jiao Tong University to ZZ. The work was also partially supported by the Mark and Jane Gibson distinguished professorship endowment fund to WZ. We thank Dr. Yinhua Yu (The University of Texas, M.D. Anderson Cancer Center) for helpful discussions.	Antony S, 2017, MOL CARCINOGEN, V56, P2643, DOI 10.1002/mc.22708; Bajpai R, 2016, ONCOGENE, V35, P3955, DOI 10.1038/onc.2015.464; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Chaudhry P, 2009, ENDOCR-RELAT CANCER, V16, P363, DOI 10.1677/ERC-08-0266; Chen HF, 2016, BIOMEDICINE-TAIWAN, V6, P1, DOI 10.7603/s40681-016-0001-9; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Chen N, 2011, INT J CLIN EXP PATHO, V4, P85; Chin RM, 2014, NATURE, V510, P397, DOI 10.1038/nature13264; Cho JM, 2008, CANCER LETT, V260, P96, DOI 10.1016/j.canlet.2007.10.022; Cuyas E, 2017, CELL CYCLE, V16, P1022, DOI 10.1080/15384101.2017.1310353; Dong LL, 2012, J OBSTET GYNAECOL RE, V38, P1077, DOI 10.1111/j.1447-0756.2011.01839.x; El-Ashmawy NE, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692235; Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Gasparre G, 2011, CANCER RES, V71, P6220, DOI 10.1158/0008-5472.CAN-11-1042; Goodwin PJ, 2009, J CLIN ONCOL, V27, P3271, DOI 10.1200/JCO.2009.22.1630; Hanna RK, 2012, GYNECOL ONCOL, V125, P458, DOI 10.1016/j.ygyno.2012.01.009; Hernandez AV, 2015, EUR J CANCER, V51, P2747, DOI 10.1016/j.ejca.2015.08.031; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Hu X, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-43; Ikeda H, 2004, BIOCHEM J, V380, P515, DOI 10.1042/BJ20031948; Jia L, 2008, CLIN CANCER RES, V14, P2263, DOI 10.1158/1078-0432.CCR-07-4837; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149; Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607; Keenan MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005599; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Kwon OH, 2013, CANCER SCI, V104, P391, DOI 10.1111/cas.12076; Li B, 2016, ONCOTARGET, V7, P59458, DOI 10.18632/oncotarget.10694; Liu Y, 2017, ONCOTARGET, V8, P75206, DOI 10.18632/oncotarget.20663; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Lv QY, 2017, J CANCER, V8, P894, DOI 10.7150/jca.17064; Ma QL, 2015, INT J CANCER, V137, P1058, DOI 10.1002/ijc.29395; MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Meireles CG, 2017, GYNECOL ONCOL, V147, P167, DOI 10.1016/j.ygyno.2017.07.120; Do MT, 2014, FREE RADICAL BIO MED, V74, P21, DOI [10.1016/j.freeradbiomed2014.06.010, 10.1016/j.freeradbiomed.2014.06.010]; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Montgomery RM, 2015, ARQ NEURO-PSIQUIAT, V73, P561, DOI 10.1590/0004-282X20150059; Nanduri J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119762; Ning CC, 2016, CANCER RES, V76, P1354, DOI 10.1158/0008-5472.CAN-15-1260; Ogura R, 2015, NEUROPATHOLOGY, V35, P324, DOI 10.1111/neup.12196; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Qi ST, 2012, CANCER SCI, V103, P269, DOI 10.1111/j.1349-7006.2011.02134.x; Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Saygin C, 2017, J EXP MED, V214, P2715, DOI 10.1084/jem.20170438; Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Sorosky JI, 2012, OBSTET GYNECOL, V120, P383, DOI 10.1097/AOG.0b013e3182605bf1; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Sun N, 2013, CLIN CANCER RES, V19, P5136, DOI 10.1158/1078-0432.CCR-13-0046; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan BK, 2011, J CLIN ENDOCR METAB, V96, P808, DOI 10.1210/jc.2010-1803; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Tao X, 2013, ENDOCR-RELAT CANCER, V20, P415, DOI 10.1530/ERC-12-0005; Tsai YP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0513-0; Valtorta S, 2017, ONCOTARGET, V8, P113090, DOI 10.18632/oncotarget.23028; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Wang JB, 2014, ASIAN PAC J CANCER P, V15, P427, DOI 10.7314/APJCP.2014.15.1.427; Wang LW, 2008, WORLD J GASTROENTERO, V14, P7192, DOI 10.3748/wjg.14.7192; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wang YY, 2016, ONCOTARGET, V7, P10363, DOI 10.18632/oncotarget.7004; Wei KR, 2013, CHINA CANC, V22, P605; Wei Kuang-rong, 2012, Zhonghua Fu Chan Ke Za Zhi, V47, P445; Xiang L, 2012, GYNECOL ONCOL, V127, P595, DOI 10.1016/j.ygyno.2012.08.028; Xu T, 2015, DIABETES CARE, V38, P1858, DOI 10.2337/dc15-0658; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang SH, 2016, ONCOTARGET, V7, P78787, DOI 10.18632/oncotarget.12859; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Yu GZ, 2015, ONCOTARGET, V6, P12748, DOI 10.18632/oncotarget.3327; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974; Zhang HH, 2016, CANCER CHEMOTH PHARM, V78, P13, DOI 10.1007/s00280-016-3037-3; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhang YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081264; Zhang ZB, 2012, CANCER LETT, V319, P89, DOI 10.1016/j.canlet.2011.12.033; Zhang ZB, 2011, INT J GYNECOL CANCER, V21, P213, DOI 10.1097/IGC.0b013e318207dac7; Zhuo ZH, 2016, ARCH GYNECOL OBSTET, V294, P1055, DOI 10.1007/s00404-016-4148-0	85	40	42	3	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5666	5681		10.1038/s41388-018-0360-7	http://dx.doi.org/10.1038/s41388-018-0360-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29921847				2022-12-28	WOS:000447619100006
J	Zeng, KX; Chen, XX; Hu, XX; Liu, XX; Xu, T; Sun, HL; Pan, YQ; He, BS; Wang, SK				Zeng, Kaixuan; Chen, Xiaoxiang; Hu, Xiuxiu; Liu, Xiangxiang; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui			LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NUCLEAR EXPORT; MUTANT P53; IN-VIVO; MDM2; PROTEIN; PATHWAY; PROMOTES; ORIGINS; CELLS	Colorectal cancer (CRC) is one of the most common aggressive malignancies. Like other solid tumors, inactivation of tumor suppressor genes and activation of oncogenes occur during CRC development and progression. Recently, a novel tumor suppressor, LACTB, was proposed to inhibit tumor progression, but the functional and clinical significance of this tumor suppressor in CRC remains unexplored. Herein, we found LACTB was significantly downregulated in CRC due to promoter methylation and histone deacetylation, which was associated with metastasis and advanced clinical stage. CRC patients with low LACTB expression had poorer overall survival and LACTB also determined to be an independent prognostic factor for poorer outcome. Ectopic expression of LACTB suppressed CRC cells proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in vitro and inhibited CRC growth and metastasis in vivo, while knockout of LACTB by CRISPR/Cas9 gene editing technique resulted in an opposite phenotype. Interestingly, LACTB could exert antitumorigenic effect only in HCT116 and HCT8 cells harboring wild-type TP53, but not in HT29 and SW480 cells harboring mutant TP53 or HCT116 p53(-/-) cells. Mechanistic studies demonstrated that LACTB could directly bind to the C terminus of p53 to inhibit p53 degradation by preventing MDM2 from interacting with p53. Moreover, ablation of p53 attenuated the antitumorigenic effects of LACTB overexpression in CRC. Collectively, our findings successfully demonstrate for the first time that LACTB is a novel epigenetic silenced tumor suppressor through modulating the stability of p53, supporting the pursuit of LACTB as a potential therapeutic target for CRC.	[Zeng, Kaixuan; Chen, Xiaoxiang; Wang, Shukui] Southeast Univ, Sch Med, Nanjing 210009, Jiangsu, Peoples R China; [Zeng, Kaixuan; Chen, Xiaoxiang; Hu, Xiuxiu; Liu, Xiangxiang; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China	Southeast University - China; Nanjing Medical University	Wang, SK (corresponding author), Southeast Univ, Sch Med, Nanjing 210009, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China.	sk_wang@njmu.edu.cn			National Nature Science Foundation of China [81472027, 81501820]; Innovation team of Jiangsu provincial health-strengthening engineering by science and education	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation team of Jiangsu provincial health-strengthening engineering by science and education	This project was supported by grants from the National Nature Science Foundation of China (No. 81472027, 81501820) to SKW and YQP; Innovation team of Jiangsu provincial health-strengthening engineering by science and education to SKW.	Bains RK, 2004, ENDOCRINOLOGY, V145, P2666, DOI 10.1210/en.2003-1608; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen YC, 2007, J CELL BIOCHEM, V100, P981, DOI 10.1002/jcb.21079; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirano Y, 2006, CELL, V127, P675, DOI 10.1016/j.cell.2006.11.003; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Keckesova Z, 2017, NATURE, V543, P681, DOI 10.1038/nature21408; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lang V, 2014, MOL ONCOL, V8, P1026, DOI 10.1016/j.molonc.2014.04.002; Leslie PL, 2016, ONCOGENE, V35, P6157, DOI 10.1038/onc.2016.88; Lessel D, 2017, J CLIN INVEST, V127, P3598, DOI 10.1172/JCI92171; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li HT, 2019, ONCOL RES, V27, P423, DOI 10.3727/096504017X15030178624579; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Lu JB, 2016, ARCH BIOCHEM BIOPHYS, V590, P64, DOI 10.1016/j.abb.2015.11.007; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mukhopadhyay S, 2017, BLOOD, V129, P3245, DOI 10.1182/blood-2016-07-727180; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Nomura K, 2017, NAT STRUCT MOL BIOL, V24, P578, DOI 10.1038/nsmb.3414; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Peitsaro N, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-26; Polianskyte Z, 2009, P NATL ACAD SCI USA, V106, P18960, DOI 10.1073/pnas.0906734106; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Russo A, 2013, CELL CYCLE, V12, P76, DOI 10.4161/cc.22963; Sarkar S, 2017, MOL CANCER RES, V15, P1678, DOI 10.1158/1541-7786.MCR-17-0287; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith TS, 2001, GENOMICS, V78, P12, DOI 10.1006/geno.2001.6643; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Willer Cristen J, 2013, Nat Genet, V45, P1274, DOI 10.1038/ng.2797; Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005; Ye J, 2017, ONCOGENE, V36, P6391, DOI 10.1038/onc.2017.241; Yuan XW, 2013, J BIOL CHEM, V288, P31206, DOI 10.1074/jbc.M113.480285; Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582	41	46	48	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5534	5551		10.1038/s41388-018-0352-7	http://dx.doi.org/10.1038/s41388-018-0352-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29899406				2022-12-28	WOS:000446991200005
J	Kanda, M; Tanaka, H; Shimizu, D; Miwa, T; Umeda, S; Tanaka, C; Kobayashi, D; Hattori, N; Suenaga, M; Hayashi, M; Iwata, N; Yamada, S; Fujiwara, M; Kodera, Y				Kanda, Mitsuro; Tanaka, Haruyoshi; Shimizu, Dai; Miwa, Takashi; Umeda, Shinichi; Tanaka, Chie; Kobayashi, Daisuke; Hattori, Norifumi; Suenaga, Masaya; Hayashi, Masamichi; Iwata, Naoki; Yamada, Suguru; Fujiwara, Michitaka; Kodera, Yasuhiro			SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PERITONEAL METASTASIS; MALIGNANT PHENOTYPE; SYNAPTOTAGMIN 7; TRIAL; CHEMOTHERAPY; GUIDELINES; BIOMARKER; SENSOR; EMT	Liver metastasis remains a serious problem in the management of gastric cancer (GC). Our aims were to identify through transcriptome analysis a molecule that mediates hepatic metastasis in GC, and to evaluate its potential as a diagnostic marker and a therapeutic target. The effects of knocking out a relevant molecule using genome editing were evaluated in vitro experiments and in mouse xenograft models. Expression levels of candidate molecule in 300 pairs of gastric tissues were determined to assess whether differentially expressed genes predicted hepatic recurrence, metastasis, or both. Transcriptome data identified the overexpression of synaptotagmin VII (SYT7) in GC tissues with hepatic metastasis. Its expression in the GC cell lines was high, particularly in those that exhibited a differentiated phenotype, and positively correlated with the expression of SNAI1 and TGFB3, and inversely with RGS2. SYT7 knockout inhibited the proliferation of GC cells, indicated by increased apoptosis with activated caspase and loss of mitochondria membrane potential, G2/M cell-cycle arrest and attenuated cell migration, invasion, and adhesion. The tumorigenicity of SYT7-knockout cells was moderately reduced in a mouse model of subcutaneous metastasis in which the levels of BCL2 and HIF1A were decreased and was more strikingly attenuated in a model of hepatic metastasis. The SYT7 levels in the primary GC tissues were significantly associated with hepatic recurrence, metastasis, and adverse prognosis. SYT7 represents a tool for prediction and monitoring of hepatic metastasis from GC as well as being a promising therapeutic target.	[Kanda, Mitsuro; Tanaka, Haruyoshi; Shimizu, Dai; Miwa, Takashi; Umeda, Shinichi; Tanaka, Chie; Kobayashi, Daisuke; Hattori, Norifumi; Suenaga, Masaya; Hayashi, Masamichi; Iwata, Naoki; Yamada, Suguru; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol Surg 2, Nagoya, Aichi, Japan	Nagoya University	Kanda, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol Surg 2, Nagoya, Aichi, Japan.	m-kanda@med.nagoya-u.ac.jp	Kanda, Mitsuro/M-4891-2014; Fujiwara, Michitaka/AAV-9715-2021	Kanda, Mitsuro/0000-0001-5464-3819; Kodera, Yasuhiro/0000-0002-6173-7474	JSS Young Researcher Award 2014;  [16K19889]	JSS Young Researcher Award 2014; 	This work was supported by a Grant-in-Aid for Encouragement of Young Scientists (B, 16K19889, Japan) and JSS Young Researcher Award 2014.	Acikgoz E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141090; Bang YJ, 2010, LANCET, V376, P1302; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Chen XY, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0070-6; Cheng CH, 2016, MOL MED REP, V13, P1495, DOI 10.3892/mmr.2015.4717; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Gao JF, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0072-1; Goodman KA, 2015, J CLIN ONCOL, V33, P3082, DOI 10.1200/JCO.2014.59.1941; Gustavsson N, 2009, J PHYSIOL-LONDON, V587, P1169, DOI 10.1113/jphysiol.2008.168005; Jackman SL, 2016, NATURE, V529, P88, DOI 10.1038/nature16507; Kanda M, 2018, ANN SURG, V267, P495, DOI 10.1097/SLA.0000000000002096; Kanda M, 2016, INT J CANCER, V139, P2290, DOI 10.1002/ijc.30286; Kanda M, 2016, ANN SURG ONCOL, V23, P532, DOI 10.1245/s10434-016-5375-0; Kanda M, 2016, INT J ONCOL, V49, P1195, DOI 10.3892/ijo.2016.3584; Kanda M, 2016, ONCOTARGET, V7, P13667, DOI 10.18632/oncotarget.7269; Kanda M, 2016, INT J CANCER, V138, P721, DOI 10.1002/ijc.29803; Kanda M, 2015, EXPERT REV GASTROENT, V9, P1549, DOI 10.1586/17474124.2015.1094373; Kanda M, 2016, ANN SURG ONCOL, V23, P214, DOI 10.1245/s10434-015-4457-8; Kanda M, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0066-9; Kodera Y, 2014, GASTRIC CANCER, V17, P206, DOI 10.1007/s10120-013-0299-x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Liu H, 2014, TRANSL NEURODEGENER, V3, DOI 10.1186/2047-9158-3-7; Liu XD, 2010, INT J MOL SCI, V11, P2267, DOI 10.3390/ijms11062267; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Miwa T, 2017, ANN SURG ONCOL, V24, P3771, DOI 10.1245/s10434-017-5882-7; Nie Hui, 2017, J Cell Signal, V2; Oki E, 2016, GASTRIC CANCER, V19, P968, DOI 10.1007/s10120-015-0530-z; Okines A, 2010, ANN ONCOL, V21, pv50, DOI 10.1093/annonc/mdq164; Poli G, 2013, ENDOCR-RELAT CANCER, V20, P537, DOI 10.1530/ERC-13-0150; Qi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132743; Razzak M, 2014, NAT REV CLIN ONCOL, V11, P689, DOI [10.1038/nrclinonc.2014.176, 10.1038/nrclinonc.2013.235, 10.1038/nrclinonc.2013.201]; Resende C, 2011, HELICOBACTER, V16, P38, DOI 10.1111/j.1523-5378.2011.00879.x; Samykutty A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/287358; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI 10.1200/JCO.2013.51.7904; Segovia M, 2010, P NATL ACAD SCI USA, V107, P19032, DOI 10.1073/pnas.1014070107; Shih AM, 2016, J CELL BIOCHEM, V117, P1446, DOI 10.1002/jcb.25436; Shimizu D, 2017, SCI REP-UK, V7, DOI 10.1038/srep42089; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Weber JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114033; Wolff DW, 2012, INT J CANCER, V130, P1521, DOI 10.1002/ijc.26138; Wu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088913; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364	47	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5355	5366		10.1038/s41388-018-0335-8	http://dx.doi.org/10.1038/s41388-018-0335-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858600				2022-12-28	WOS:000445759700008
J	Wang, SJ; Li, JJ; Xie, J; Liu, F; Duan, YC; Wu, Y; Huang, SL; He, XH; Wang, ZL; Wu, XH				Wang, Shaojia; Li, Jiajia; Xie, Jie; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua			Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta 4/SNAI1/SIRT3 signaling pathway	ONCOGENE			English	Article							PD-L1 EXPRESSION; OVARIAN-CANCER; CELL; CARCINOMA; SIRT3; MICROENVIRONMENT; PROLIFERATION; TOLERANCE; PROGNOSIS; BREAST	Although PD-L1 has been shown to play a well-characterized role in inhibiting antitumor immunity via engagement of its receptor PD-1 in T lymphocytes, little is known about the tumor cell-intrinsic function of PD-L1 and its association with prognosis. Here, we investigate this issue and dissect the molecular mechanisms underlying the role of PD-L1 in glucose metabolism, proliferation, migration, and invasion in human cervical cancer cells. As a result, we found that PD-L1 overexpression in cervical cancer cells increases glucose metabolism and metastasis-related behaviors. Mechanistically, PDL1 bound directly to integrin beta 4 (ITGB4), activating the AKT/GSK3 beta signaling pathway and consequently inducing the expression of the transcriptional repressor SNAI1. SNAIL in turn influenced the expression of genes involved in the epithelial-to-mesenchymal transition and regulated glucose metabolism by inhibiting SIRT3 promoter activity. High expression of PD-L1 and ITGB4 in human cervical carcinomas was significantly associated with lymph node metastasis and poor prognosis. Finally, F-18-fluorodeoxyglucose microPET/CT and bioluminescence imaging analyses of cervical xenograft tumors in mice revealed that PD-L1 overexpression markedly increases tumor glucose uptake and promotes lymph node metastasis. Together, these results demonstrate that PD-L1 can promote the growth and metastasis of cervical cancer by activating the ITGB4/SNAI1/SIRT3 signaling pathway, and also suggest the possibility of targeting PD-L1 and its downstream effectors as a potential approach for interfering with cervical cancer growth and metastasis.	[Wang, Shaojia; Li, Jiajia; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200032, Peoples R China; [Wang, Shaojia; Li, Jiajia; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China; [Wang, Shaojia; Li, Jiajia; Xie, Jie; Liu, Fei; Duan, Yachen; Wu, Yong; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Xie, Jie] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200032, Peoples R China.; Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.; Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	huf_zlwang@126.com; wu.xh@fudan.edu.cn	Huang, Shenglin/N-9472-2018; He, Xianghuo/I-1497-2014; Wang, Zhiquan/HHS-6768-2022	Huang, Shenglin/0000-0003-1279-0794; He, Xianghuo/0000-0001-8872-668X; 	National Nature Science Foundation of China [81672569]; National Nature Science Young Foundation of China [81502235]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Nature Science Young Foundation of China	We thank RuiBi for the samples for the TMA study, Guangqi Qin for manufacturing the TMAs, and Jun Chen and Jianping Zhang for help with animal imaging. This work was supported in part by grants from the National Nature Science Foundation of China (81672569 to X.W.) and the National Nature Science Young Foundation of China (81502235 to Z.W.).	Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Atahan IL, 2007, INT J GYNECOL CANCER, V17, P833, DOI 10.1111/j.1525-1438.2007.00895.x; Bertsias GK, 2009, ARTHRITIS RHEUM-US, V60, P207, DOI 10.1002/art.24227; Bouvier C, 2016, ONCOTARGET, V7, P64702, DOI 10.18632/oncotarget.11876; Cai GF, 2004, CELL IMMUNOL, V230, P89, DOI 10.1016/j.cellimm.2004.09.004; Cao YJ, 2011, CANCER RES, V71, P1235, DOI 10.1158/0008-5472.CAN-10-2217; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chen MF, 2016, ONCOTARGET, V7, P7913, DOI 10.18632/oncotarget.6861; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chowdhury S, 2016, ONCOTARGET, V7, P32318, DOI 10.18632/oncotarget.8698; Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258; Dai SY, 2014, CELL IMMUNOL, V290, P72, DOI 10.1016/j.cellimm.2014.05.006; Dong HD, 1999, NAT MED, V5, P1365; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Heeren AM, 2015, ONCOTARGET, V6, P32484, DOI 10.18632/oncotarget.5398; Heeren AM, 2015, CANCER IMMUNOL RES, V3, P48, DOI 10.1158/2326-6066.CIR-14-0149; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Kang T, 2017, ACS NANO, V11, P1397, DOI 10.1021/acsnano.6b06477; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Leong SPL, 2014, CA-CANCER J CLIN, V64, P196, DOI 10.3322/caac.21217; Liu EY, 2017, ONCOTARGET, V8, P19467, DOI 10.18632/oncotarget.14444; Liu F, 2016, ONCOTARGET, V7, P8896, DOI 10.18632/oncotarget.6840; Nathanson SD, 2015, SEMIN CELL DEV BIOL, V38, P106, DOI 10.1016/j.semcdb.2014.10.002; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Paul NR, 2015, J CELL BIOL, V210, P1013, DOI 10.1083/jcb.201502040; Qin T, 2015, ONCOTARGET, V6, P33972, DOI 10.18632/oncotarget.5583; Qorraj M, 2017, LEUKEMIA, V31, P470, DOI 10.1038/leu.2016.214; Schreiner B, 2008, EUR J IMMUNOL, V38, P2706, DOI 10.1002/eji.200838137; Schumacker PT, 2011, CANCER CELL, V19, P299, DOI 10.1016/j.ccr.2011.03.001; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Sun ZJ, 2015, CANCER RES, V75, P1635, DOI 10.1158/0008-5472.CAN-14-3016; Udager AM, 2016, ANN ONCOL, V27, P1706, DOI 10.1093/annonc/mdw216; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang SJ, 2016, AM J CANCER RES, V6, P1108; Wang ZL, 2015, ONCOTARGET, V6, P6670, DOI 10.18632/oncotarget.3118; Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403; Wu SF, 2017, ONCOTARGET, V8, P16421, DOI 10.18632/oncotarget.14851; Zhang YH, 2015, AM J REPROD IMMUNOL, V74, P201, DOI 10.1111/aji.12365; ZHOU XL, 2015, MED ONCOL, V32, DOI DOI 10.1007/S12032-015-0655-2; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	46	55	57	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4164	4180		10.1038/s41388-018-0252-x	http://dx.doi.org/10.1038/s41388-018-0252-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706653				2022-12-28	WOS:000439847000009
J	Basu, SK; Gonit, M; Salotti, J; Chen, JJ; Bhat, A; Gorospe, M; Viollet, B; Claffey, KP; Johnson, PF				Basu, Sandip K.; Gonit, Mesfin; Salotti, Jacqueline; Chen, Jiji; Bhat, Atharva; Gorospe, Myriam; Viollet, Benoit; Claffey, Kevin P.; Johnson, Peter F.			A RAS-CaMKK beta-AMPK alpha 2 pathway promotes senescence by licensing post-translational activation of C/EBP beta through a novel 3'UTR mechanism	ONCOGENE			English	Article							PROTEIN-KINASE; SECRETORY PHENOTYPE; UPSTREAM KINASE; CELL-GROWTH; AMPK; PHOSPHORYLATION; PROGRESSION; FIBROBLASTS; METABOLISM; INITIATION	Oncogene-induced senescence (OIS) is an intrinsic tumor suppression mechanism that requires the p53 and RB pathways and post-translational activation of C/EBP beta through the RAS-ERK cascade. We previously reported that in transformed/proliferating cells, C/EBP beta activation is inhibited by G/U-rich elements (GREs) in its 3'UTR. This mechanism, termed "3' UTR regulation of protein activity" (UPA), maintains C/EBP beta in a low-activity state in tumor cells and thus facilitates senescence bypass. Here we show that C/EBP beta UPA is overridden by AMPK signaling. AMPK activators decrease cytoplasmic levels of the GRE binding protein HuR, which is a key UPA component. Reduced cytoplasmic HuR disrupts 3'-UTR-mediated trafficking of Cebpb transcripts to the peripheral cytoplasm-a fundamental feature of UPA-thereby stimulating C/EBP beta activation and growth arrest. In primary cells, oncogenic RAS triggers a Ca++-CaMKK beta-AMPK alpha 2-HuR pathway, independent of AMPK alpha 1, that is essential for C/EBP beta activation and OIS. This axis is disrupted in cancer cells through down-regulation of AMPK alpha 2 and CaMKK beta. Thus, CaMKK beta-AMPK alpha 2 signaling constitutes a key tumor suppressor pathway that activates a novel UPA-cancelling mechanism to unmask the cytostatic and pro-senescence functions of C/EBP beta.	[Basu, Sandip K.; Gonit, Mesfin; Salotti, Jacqueline; Johnson, Peter F.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA; [Chen, Jiji; Bhat, Atharva] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA; [Gorospe, Myriam] NIA, Lab Genet, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Viollet, Benoit] Inst Cochin, INSERM, U1016, F-75014 Paris, France; [Viollet, Benoit] CNRS, UMR8104, F-75014 Paris, France; [Viollet, Benoit] Univ Paris 05, Sorbonne Paris Cite, F-75014 Paris, France; [Claffey, Kevin P.] Univ Connecticut, Hlth Ctr, Dept Cell Biol, Farmington, CT USA; [Gonit, Mesfin] Lentigen Tech Inc, Gaithersburg, MD USA; [Chen, Jiji] NIH, Adv Imaging & Microscopy Resource, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Connecticut; National Institutes of Health (NIH) - USA	Johnson, PF (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA.	johnsope@mail.nih.gov	Viollet, Benoit/N-2397-2019; Salotti, Jacqueline/M-4515-2019; Viollet, Benoit/O-6927-2017; Gorospe, Myriam/Y-3613-2019	Viollet, Benoit/0000-0002-0121-0224; Salotti, Jacqueline/0000-0001-6009-6751; Viollet, Benoit/0000-0002-0121-0224; 	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000511, ZIAAG000393] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank R. Jones for the CA-AMPK vector, N. Bardeesy for Lkb1<SUP>-/-</SUP> MEFs, T. Brown for a pan-AMPK alpha knockdown vector, K. Saylor and N. Martin for animal husbandry and genotyping, and A. Kane (Scientific Publications, Graphics & Media, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research) for preparation of figures. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Basu SK, 2018, CANCER RES, V78, P891, DOI 10.1158/0008-5472.CAN-17-2353; Basu SK, 2011, EMBO J, V30, P3714, DOI 10.1038/emboj.2011.250; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Fox Melissa M, 2013, Genes Cancer, V4, P3, DOI 10.1177/1947601913486346; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Huggins CJ, 2013, MOL CELL BIOL, V33, P3242, DOI 10.1128/MCB.01674-12; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim HH, 2008, CELL CYCLE, V7, P3124, DOI 10.4161/cc.7.20.6884; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lee S, 2010, MOL CELL BIOL, V30, P2621, DOI 10.1128/MCB.00782-09; Lopez de Silanes Isabel, 2005, RNA Biol, V2, P11; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Ovesny M, 2014, BIOINFORMATICS, V30, P2389, DOI 10.1093/bioinformatics/btu202; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Phoenix Kathryn N, 2012, Genes Cancer, V3, P51, DOI 10.1177/1947601912452883; Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rook MS, 2000, J NEUROSCI, V20, P6385, DOI 10.1523/JNEUROSCI.20-17-06385.2000; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Salotti J, 2015, MOL CELL BIOL, V35, P866, DOI 10.1128/MCB.01489-14; Scheffler JM, 2014, METHOD ENZYMOL, V535, P93, DOI 10.1016/B978-0-12-397925-4.00006-7; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Sebastian T, 2009, CANCER RES, V69, P2588, DOI 10.1158/0008-5472.CAN-08-2312; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tangeman Larissa, 2012, J RNAi Gene Silencing, V8, P470; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Wang SB, 2012, J BIOL CHEM, V287, P8001, DOI 10.1074/jbc.M111.315812; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Whelan DR, 2015, SCI REP-UK, V5, DOI 10.1038/srep07924; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yoo PS, 2009, ANN SURG ONCOL, V16, P200, DOI 10.1245/s10434-008-0209-3	62	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3528	3548		10.1038/s41388-018-0190-7	http://dx.doi.org/10.1038/s41388-018-0190-7			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563610	Green Accepted			2022-12-28	WOS:000436412500005
J	Shi, JL; Li, FP; Yao, XX; Mou, TY; Xu, ZJ; Han, Z; Chen, SY; Li, WD; Yu, J; Qi, XL; Liu, H; Li, GX				Shi, Jiaolong; Li, Fengping; Yao, Xingxing; Mou, Tingyu; Xu, Zhijun; Han, Zheng; Chen, Siyu; Li, Wende; Yu, Jiang; Qi, Xiaolong; Liu, Hao; Li, Guoxin			The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition	ONCOGENE			English	Article							BREAST-CANCER; GROWTH-FACTOR; GASTROESOPHAGEAL CANCER; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; TYROSINE KINASE; INHIBITION; HER2; EXPRESSION; DIFFERENTIATION	Trastuzumab is the only target to be approved as the first-line treatment of HER2 positive metastatic gastric cancer, but ubiquitous resistance decreases its therapeutic benefit. In this study, we found HER4, phosphorylation HER4 (p-HER4) and the mesenchymal marker Vimentin increased in trastuzumab-resistant cells (MKN45TR and NCI-N87TR), while epithelial markers expressions in trastuzumab-resistant cell lines and animal models decreased. Additionally, silencing HER4 prevented the epithelial-mesenchymal transition and led to decreased proliferation and migration in vitro and in vivo. The expression of YAP1, a vital downstream interacted target of HER4, decreased when HER4 was knocked down. Interestingly, stimulation of NRG1 could compromise the inhibitory impact and rescue cell survival; whereas, transfection of siYAP1 sensitized trastuzumab-treated cells. Expression analysis of the proteins in patient-derived xenograft model (PDX) mice showed that HER4, p-HER4, YAP1, and Vimentin were clearly upregulated in the trastuzumab-resistant mice compared to mice without trastuzumab resistance. However, HER2 and E-cadherin were downregulated in response to continuous treatment with trastuzumab. These findings elucidated that the central role of the HER4-YAP1 axis in trastuzumab resistance of HER2-positive gastric cancer cells through induction of EMT. Hence, regulating the HER4-YAP1 axis might be a promising strategy for clinical interventions in patients with HER2-positive gastric cancer.	[Shi, Jiaolong; Li, Fengping; Yao, Xingxing; Mou, Tingyu; Xu, Zhijun; Han, Zheng; Yu, Jiang; Qi, Xiaolong; Liu, Hao; Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou, Guangdong, Peoples R China; [Chen, Siyu; Li, Wende] Guangdong Key Lab Lab Anim, Dept Guangdong Lab Anim Monitoring Inst, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Li, GX (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou, Guangdong, Peoples R China.	gzliguoxin@163.com	Liu, Hao/I-9884-2019	Liu, Hao/0000-0003-1227-2954; Qi, Xiaolong/0000-0002-3559-5855	State's Key Project of Research and Development Plan [2017YFC0108300, 2017YFC0108301]; National Natural Science Foundation of China [81672446]; Guangdong Provincial Science and Technology Key Project [2014A020215014, 2016A030313843]; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China [201402015]; Southern Medical University Clinical Research Start-Up Project [LC2016ZD003]; Guangzhou Science and Technology Project [201400000004-5]; Key Clinical Specialty Discipline Construction Program [[2011]170]; Guangzhou Science and Technology Program [201400000004-5]	State's Key Project of Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Key Project; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China; Southern Medical University Clinical Research Start-Up Project; Guangzhou Science and Technology Project; Key Clinical Specialty Discipline Construction Program; Guangzhou Science and Technology Program	This work was supported by the grants from the State's Key Project of Research and Development Plan (2017YFC0108300, 2017YFC0108301), National Natural Science Foundation of China (81672446), Guangdong Provincial Science and Technology Key Project (2014A020215014, 2016A030313843), Research Fund of Public Welfare in the Health Industry, the National Health and Family Planning Commission of China (201402015), the Southern Medical University Clinical Research Start-Up Project (LC2016ZD003), Guangzhou Science and Technology Project (201400000004-5) and the Key Clinical Specialty Discipline Construction Program([2011]170). Guangzhou Science and Technology Program(no. 201400000004-5)	Bang YJ, 2010, LANCET, V376, P1302; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bossi D, 2016, CANCER DISCOV, V6, P650, DOI 10.1158/2159-8290.CD-15-1200; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Canfield K, 2015, CELL CYCLE, V14, P648, DOI 10.4161/15384101.2014.994966; De Mattos-Arruda L, 2015, ONCOTARGET, V6, P37269, DOI 10.18632/oncotarget.5495; Fu CP, 2017, INT J NANOMED, V12, P3365, DOI 10.2147/IJN.S130322; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Haskins JW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005770; He XX, 2015, J CLIN PATHOL, V68, P374, DOI 10.1136/jclinpath-2014-202657; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Janjigian YY, 2012, ANN ONCOL, V23, P2656, DOI 10.1093/annonc/mds104; Jiang YM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.1087; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200; Ling HH, 2017, EXP CELL RES, V350, P218, DOI 10.1016/j.yexcr.2016.11.024; Liu H, 2016, ONCOTARGET, V7, P43894, DOI 10.18632/oncotarget.9707; Lordick F, 2016, NAT REV CLIN ONCOL, V13, P348, DOI 10.1038/nrclinonc.2016.15; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Nafi SNM, 2014, ONCOTARGET, V5, P5934; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5; Okines AFC, 2010, LANCET, V376, P1736, DOI 10.1016/S0140-6736(10)62127-7; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Pasini F, 2011, ANTICANCER RES, V31, P3543; Piro G, 2016, CLIN CANCER RES, V22, P6164, DOI 10.1158/1078-0432.CCR-16-0178; Sassen A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2339; Sato Y, 2013, CANCER SCI, V104, P1618, DOI 10.1111/cas.12290; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Shen ZY, 2015, ONCOTARGET, V6, P20672, DOI 10.18632/oncotarget.3967; Takahashi N, 2016, ONCOTARGET, V7, P4925, DOI 10.18632/oncotarget.6753; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xiong BH, 2016, GROWTH FACTORS, V34, P187, DOI 10.1080/08977194.2016.1251916; Zheng L, 2014, CANCER IMMUNOL IMMUN, V63, P581, DOI 10.1007/s00262-014-1541-z; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep08542; Zuo Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep11634	43	41	41	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3022	3038		10.1038/s41388-018-0204-5	http://dx.doi.org/10.1038/s41388-018-0204-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535422	hybrid, Green Published			2022-12-28	WOS:000433936300009
J	Fantini, D; Glaser, AP; Rimar, KJ; Wang, YD; Schipma, M; Varghese, N; Rademaker, A; Behdad, A; Yellapa, A; Yu, YN; Sze, CCL; Wang, L; Zhao, ZB; Crawford, SE; Hu, DQ; Licht, JD; Collings, CK; Bartom, E; Theodorescu, D; Shilatifard, A; Meeks, JJ				Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Schipma, Matthew; Varghese, Nobish; Rademaker, Alfred; Behdad, Amir; Yellapa, Aparna; Yu, Yanni; Sze, Christie Ching-Lin; Wang, Lu; Zhao, Zibo; Crawford, Susan E.; Hu, Deqing; Licht, Jonathan D.; Collings, Clayton K.; Bartom, Elizabeth; Theodorescu, Dan; Shilatifard, Ali; Meeks, Joshua J.			A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer	ONCOGENE			English	Article							SOMATIC ERCC2 MUTATIONS; ARISTOLOCHIC ACID; CELL-LINES; UROTHELIAL CANCER; CLONAL EVOLUTION; COPY NUMBER; GENOME; SIGNATURE; REPAIR; BASAL	The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model is an attractive model system of muscle-invasive bladder cancer (MIBC) as it recapitulates the histology of human tumors in a background with intact immune system. However, it was unknown whether this carcinogen-induced model also mimicked human MIBC at the molecular and mutational level. In our study, we analyzed gene expression and mutational landscape of the BBN model by next-generation sequencing followed by a bioinformatic comparison to human MIBC using data from The Cancer Genome Atlas and other repositories. BBN tumors showed overexpression of markers of basal cancer subtype, and had a high mutation burden with frequent Trp53 (80%), Kmt2d (70%), and Kmt2c (90%) mutations by exome sequencing, similar to human MIBC. Many variants corresponded to human cancer hotspot mutations, supporting their role as driver mutations. We extracted two novel mutational signatures from the BBN mouse genomes. The integrated analysis of mutation frequencies and signatures highlighted the contribution of aberrations to chromatin regulators and genetic instability in the BBN tumors. Together, our study revealed several similarities between human MIBC and the BBN mouse model, providing a strong rationale for its use in molecular and drug discovery studies.	[Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Yellapa, Aparna; Yu, Yanni; Meeks, Joshua J.] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Fantini, Damiano; Glaser, Alexander P.; Rimar, Kalen J.; Wang, Yiduo; Rademaker, Alfred; Shilatifard, Ali; Meeks, Joshua J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Schipma, Matthew; Varghese, Nobish; Sze, Christie Ching-Lin; Wang, Lu; Zhao, Zibo; Hu, Deqing; Collings, Clayton K.; Bartom, Elizabeth; Shilatifard, Ali] Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA; [Rademaker, Alfred] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Behdad, Amir] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Crawford, Susan E.] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; [Licht, Jonathan D.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA; [Theodorescu, Dan] Univ Colorado, Ctr Comprehens Canc, Dept Surg Urol & Pharmacol, Denver, CO 80202 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Saint Louis University; State University System of Florida; University of Florida; University of Colorado System; University of Colorado Denver	Meeks, JJ (corresponding author), Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA.; Meeks, JJ (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.	joshua.meeks@northwestern.edu	Zhao, Zibo/GWQ-3444-2022; Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020; Bartom, Elizabeth/S-4475-2017; Glaser, Alexander/D-5526-2015	Licht, Jonathan/0000-0002-3942-1369; Bartom, Elizabeth/0000-0002-5618-2582; Glaser, Alexander/0000-0003-1781-9023	John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University;  [BX003692];  [R01 CA180475];  [CA075115];  [R35CA197569]; NATIONAL CANCER INSTITUTE [F31CA228149, T32CA009560, R01CA180475, R35CA197569, R01CA075115, R29CA075115, R50CA221848] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003692] Funding Source: NIH RePORTER	John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Dr. Francesco Favero (Technical University of Denmark) for assistance with the use of the sequenza and copynumber R libraries, Dr. Vania Vidimar (Northwestern University) for insightful discussions and editorial assistance in writing the manuscript, and Dr. Andrea Piunti (Northwestern University) for help with RNA extraction and RNA-seq library preparation. JJM is supported by grant BX003692 and the John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, JDL is supported by R01 CA180475, DT is supported by CA075115. CKC, EB and AS are supported by R35CA197569 awarded to AS.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Calderwood SK, 2013, DISCOV MED, V15, P188; Chen CH, 2012, P NATL ACAD SCI USA, V109, P8241, DOI 10.1073/pnas.1119920109; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Glaser AP, 2017, NAT REV UROL, V14, P215, DOI 10.1038/nrurol.2017.11; Goodspeed A, 2016, MOL CANCER RES, V14, P3, DOI 10.1158/1541-7786.MCR-15-0189; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Horstmann M, 2008, GENDER MED, V5, P385, DOI 10.1016/j.genm.2008.11.002; Kardos J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85902; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Kobayashi T, 2015, NAT REV CANCER, V15, P42, DOI 10.1038/nrc3858; Kramer F, 2017, METHODS MOL BIOL, V1525, P123, DOI 10.1007/978-1-4939-6622-6_6; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li X, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3257-x; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Moriya M, 2011, INT J CANCER, V129, P1532, DOI 10.1002/ijc.26077; NAGAO M, 1977, CANCER RES, V37, P399; Nickerson ML, 2017, ONCOGENE, V36, P35, DOI 10.1038/onc.2016.172; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Peterson LA, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/284935; Pfister NT, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026054; Poon SL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0161-3; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Shin K, 2014, NAT CELL BIOL, V16, P469, DOI 10.1038/ncb2956; Sidorenko VS, 2012, NUCLEIC ACIDS RES, V40, P2494, DOI 10.1093/nar/gkr1095; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; SUMMERHAYES IC, 1979, J NATL CANCER I, V62, P1017; Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Vasconcelos-Nobrega C, 2012, IN VIVO, V26, P727; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Yao RS, 2004, NEOPLASIA, V6, P569, DOI 10.1593/neo.04223; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Zeegers MPA, 2000, CANCER-AM CANCER SOC, V89, P630, DOI 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q; Zhang YW, 2012, BJU INT, V109, P52, DOI 10.1111/j.1464-410X.2011.10283.x	60	60	60	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1911	1925		10.1038/s41388-017-0099-6	http://dx.doi.org/10.1038/s41388-017-0099-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367767	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000429303300008
J	Fielding, AB; Concannon, M; Darling, S; Rusilowicz-Jones, EV; Sacco, JJ; Prior, IA; Clague, MJ; Urbe, S; Coulson, JM				Fielding, Andrew B.; Concannon, Matthew; Darling, Sarah; Rusilowicz-Jones, Emma V.; Sacco, Joseph J.; Prior, Ian A.; Clague, Michael J.; Urbe, Sylvie; Coulson, Judy M.			The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; DEUBIQUITINATING ENZYMES; MAMMALIAN-CELLS; CANCER; STABILITY; LOCALIZATION; DECATENATION; CHECKPOINT; INHIBITORS; MITOSIS	Ubiquitin-specific protease 15 (USP15) is a widely expressed deubiquitylase that has been implicated in diverse cellular processes in cancer. Here we identify topoisomerase II (TOP2A) as a novel protein that is regulated by USP15. TOP2A accumulates during G2 and functions to decatenate intertwined sister chromatids at prophase, ensuring the replicated genome can be accurately divided into daughter cells at anaphase. We show that USP15 is required for TOP2A accumulation, and that USP15 depletion leads to the formation of anaphase chromosome bridges. These bridges fail to decatenate, and at mitotic exit form micronuclei that are indicative of genome instability. We also describe the cell cycle-dependent behaviour for two major isoforms of USP15, which differ by a short serine-rich insertion that is retained in isoform-1 but not in isoform-2. Although USP15 is predominantly cytoplasmic in interphase, we show that both isoforms move into the nucleus at prophase, but that isoform-1 is phosphorylated on its unique S229 residue at mitotic entry. The micronuclei phenotype we observe on USP15 depletion can be rescued by either USP15 isoform and requires USP15 catalytic activity. Importantly, however, an S229D phospho-mimetic mutant of USP15 isoform-1 cannot rescue either the micronuclei phenotype, or accumulation of TOP2A. Thus, S229 phosphorylation selectively abrogates this role of USP15 in maintaining genome integrity in an isoform-specific manner. Finally, we show that USP15 isoform-1 is preferentially upregulated in a panel of non-small cell lung cancer cell lines, and propose that isoform imbalance may contribute to genome instability in cancer. Our data provide the first example of isoform-specific deubiquitylase phospho-regulation and reveal a novel role for USP15 in guarding genome integrity.	[Fielding, Andrew B.; Concannon, Matthew; Darling, Sarah; Rusilowicz-Jones, Emma V.; Sacco, Joseph J.; Prior, Ian A.; Clague, Michael J.; Urbe, Sylvie; Coulson, Judy M.] Univ Liverpool, Inst Translat Med, Cellular & Mol Physiol, Liverpool, Merseyside, England	University of Liverpool	Coulson, JM (corresponding author), Univ Liverpool, Inst Translat Med, Cellular & Mol Physiol, Liverpool, Merseyside, England.	jcoulson@liverpool.ac.uk	Concannon, Matthew/ABG-5026-2021; Urbe, Sylvie/S-1433-2018; Clague, Michael J/A-7199-2008	Concannon, Matthew/0000-0001-8777-4786; Urbe, Sylvie/0000-0003-4735-9814; Clague, Michael J/0000-0003-3355-9479; Coulson, Judy/0000-0003-2191-2001; Prior, Ian/0000-0002-4055-5161; Fielding, Andrew/0000-0002-3170-9966	North West Cancer Research project [CR942]; Wellcome Trust [099793/Z/12/Z, 096567/Z/11/Z]	North West Cancer Research project; Wellcome Trust(Wellcome TrustEuropean Commission)	The authors are supported by a North West Cancer Research project grant CR942 (ABF) and Wellcome Trust PhD studentships 099793/Z/12/Z (MC), and 096567/Z/11/Z (SD). We acknowledge the contribution of Ruth Owen and Bethan Gay towards experiments using the lung cell panel.	Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Bower JJ, 2010, ONCOGENE, V29, P4787, DOI 10.1038/onc.2010.232; Broderick R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7572; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen MC, 2011, HEPATOLOGY, V53, P148, DOI 10.1002/hep.23964; Chen T, 2015, ONCOGENE, V34, P4019, DOI 10.1038/onc.2014.332; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Cornelissen T, 2014, HUM MOL GENET, V23, P5227, DOI 10.1093/hmg/ddu244; Darling S, 2017, BIOCHEM SOC T, V45, P1125, DOI 10.1042/BST20170087; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Faronato M, 2011, ATLAS GENET CYTOGENE, V15, P645; Faronato M, 2013, CELL CYCLE, V12, P1964, DOI 10.4161/cc.25035; Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052; Fournane Sadek, 2012, Genes Cancer, V3, P697, DOI 10.1177/1947601912473477; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gauthier NP, 2008, NUCLEIC ACIDS RES, V36, pD854, DOI 10.1093/nar/gkm729; GORBSKY GJ, 1994, CANCER RES, V54, P1042; Gowher H, 2012, P NATL ACAD SCI USA, V109, P2370, DOI 10.1073/pnas.1121538109; Grabbe C, 2011, NAT REV MOL CELL BIO, V12, P295, DOI 10.1038/nrm3099; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Guturi KKN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12638; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hayes SD, 2012, J BIOL CHEM, V287, P43007, DOI 10.1074/jbc.M112.386938; Heideker J, 2015, BIOCHEM J, V467, P191, DOI 10.1042/bj4670191; Hetfeld BKJ, 2005, CURR BIOL, V15, P1217, DOI 10.1016/j.cub.2005.05.059; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Huang XH, 2009, J MOL BIOL, V391, P691, DOI 10.1016/j.jmb.2009.06.066; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep17873; Kessler BM, 2011, CELL BIOCHEM BIOPHYS, V60, P21, DOI 10.1007/s12013-011-9176-6; Kotani Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep44293; Lim KH, 2016, CELL MOL LIFE SCI, V73, P1439, DOI 10.1007/s00018-015-2129-2; Liu HL, 2015, CELL REP, V13, P93, DOI 10.1016/j.celrep.2015.08.056; Liu WT, 2017, ONCOGENE, V36, P2715, DOI 10.1038/onc.2016.424; Long L, 2014, J BIOL CHEM, V289, P8916, DOI 10.1074/jbc.M114.551754; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Mizuno E, 2007, EXP CELL RES, V313, P3624, DOI 10.1016/j.yexcr.2007.07.028; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Nagasaka K, 2016, NAT CELL BIOL, V18, P692, DOI 10.1038/ncb3353; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nielsen CF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9962; Nishi R, 2014, NAT CELL BIOL, V16, P1016, DOI 10.1038/ncb3028; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Pinto-Fernandez A, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00133; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sahtoe DD, 2015, TRENDS BIOCHEM SCI, V40, P456, DOI 10.1016/j.tibs.2015.05.002; Samejima K, 2012, J CELL BIOL, V199, P755, DOI 10.1083/jcb.201202155; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Shinagawa H, 2008, ANTIOXID REDOX SIGN, V10, P939, DOI 10.1089/ars.2007.1851; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Srihari S, 2013, BIOINFORMATICS, V29, P1553, DOI 10.1093/bioinformatics/btt191; Thorne C, 2011, TRAFFIC, V12, P1563, DOI 10.1111/j.1600-0854.2011.01261.x; Urbe S, 2012, MOL BIOL CELL, V23, P1095, DOI 10.1091/mbc.E11-08-0668; Vlasschaert C, 2016, SCI REP-UK, V6, DOI 10.1038/srep20039; Vos RM, 2009, J VIROL, V83, P8885, DOI 10.1128/JVI.00605-09; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wiltshire TD, 2010, J BIOL CHEM, V285, P14565, DOI 10.1074/jbc.M110.104745; Xu ML, 2009, BIOCHEM BIOPH RES CO, V388, P366, DOI 10.1016/j.bbrc.2009.08.015; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	67	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2326	2342		10.1038/s41388-017-0092-0	http://dx.doi.org/10.1038/s41388-017-0092-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29429988	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000431100200009
J	Zhang, YH; Wester, L; He, JC; Geiger, T; Moerkens, M; Siddappa, R; Helmijr, JA; Timmermans, MM; Look, MP; van Deurzen, CHM; Martens, JWM; Pont, C; de Graauw, M; Danen, EHJ; Berns, EMJJ; Meerman, JHN; Jansen, MPHM; van de Water, B				Zhang, Yinghui; Wester, Lynn; He, Jichao; Geiger, Tamar; Moerkens, Marja; Siddappa, Ram; Helmijr, Jean A.; Timmermans, Mieke M.; Look, Maxime P.; van Deurzen, Caroline H. M.; Martens, John W. M.; Pont, Chantal; de Graauw, Marjo; Danen, Erik H. J.; Berns, Els M. J. J.; Meerman, John H. N.; Jansen, Maurice P. H. M.; van de Water, Bob			IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer	ONCOGENE			English	Article							TAMOXIFEN RESISTANCE; P21-ACTIVATED-KINASE-1 PAK1; ENDOCRINE RESISTANCE; CELL-PROLIFERATION; NEURITE OUTGROWTH; GROWTH-FACTORS; BETA-CATENIN; I RECEPTOR; EXPRESSION; PATHWAY	Antiestrogen resistance in estrogen receptor positive (ER+) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identified 10 regulators of IGF1R-mediated antiestrogen with clinical significance. These include the tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes, particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER+ metastatic breast cancer patients is correlated with unfavorable outcome after first-line tamoxifen monotherapy. Phospho-proteomics has defined PAK2 and the PAK-interacting exchange factors PIX alpha/beta as downstream targets of IGF1R signaling, which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIX alpha/beta modulate IGF1R signaling-driven cell scattering. Targeting PIX alpha/beta entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.	[Zhang, Yinghui; Wester, Lynn; He, Jichao; Moerkens, Marja; Siddappa, Ram; Pont, Chantal; de Graauw, Marjo; Danen, Erik H. J.; Meerman, John H. N.; van de Water, Bob] Leiden Univ, Leiden Acad Ctr Drug Res, Div Toxicol, Leiden, Netherlands; [Geiger, Tamar] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, Tel Aviv, Israel; [Helmijr, Jean A.; Timmermans, Mieke M.; Look, Maxime P.; van Deurzen, Caroline H. M.; Martens, John W. M.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.] Dept Med Oncol & Canc Genom Netherlands, Rotterdam, Netherlands; [van Deurzen, Caroline H. M.] Erasmus Univ, Erasmus MC Canc Inst, Dept Pathol, Med Ctr, Rotterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Tel Aviv University; Sackler Faculty of Medicine; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Zhang, YH; van de Water, B (corresponding author), Leiden Univ, Leiden Acad Ctr Drug Res, Div Toxicol, Leiden, Netherlands.	y.zhang@lacdr.leidenuniv.nl; b.water@lacdr.leidenuniv.nl	jansen, maurice/E-9927-2013	Geiger, Tamar/0000-0002-9526-197X; danen, erik/0000-0002-0491-6345; Zhang, Yinghui/0000-0003-1635-0278	Top Institute Pharma (Leiden, The Netherlands) [T3-107]; Dutch Cancer Society [UL-2011-5124]	Top Institute Pharma (Leiden, The Netherlands)(Netherlands Government); Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by the research project of Top Institute Pharma (Leiden, The Netherlands) "Nuclear Receptors in Targeted Cancer Therapy" (T3-107) and the research project of Dutch Cancer Society "Novel Protein Kinase Targets in Receptor Tyrosine Kinase-mediated Drug Resistant Breast Cancer" (UL-2011-5124).	Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Arnaldez FI, 2012, HEMATOL ONCOL CLIN N, V26, P527, DOI 10.1016/j.hoc.2012.01.004; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Cleator SJ, 2009, CLIN BREAST CANCER, V9, pS6, DOI 10.3816/CBC.2009.s.001; Feng QY, 2010, J BIOL CHEM, V285, P18806, DOI 10.1074/jbc.M109.098079; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frank SR, 2012, CURR BIOL, V22, P1747, DOI 10.1016/j.cub.2012.07.011; Gao CC, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-55; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Heskamp S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117745; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Hsu RM, 2010, MOL BIOL CELL, V21, P287, DOI 10.1091/mbc.E09-03-0232; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Jin K, 2015, CANCER DISCOV, V5, P944, DOI 10.1158/2159-8290.CD-15-0090; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Kok M, 2009, BREAST CANCER RES TR, V113, P275, DOI 10.1007/s10549-008-9939-y; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lacombe J, 2014, CANCER EPIDEM BIOMAR, V23, P1834, DOI 10.1158/1055-9965.EPI-14-0267; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Luey BC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0482-2; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Macek B, 2009, ANNU REV PHARMACOL, V49, P199, DOI 10.1146/annurev.pharmtox.011008.145606; Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067; McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Meng SD, 2004, P NATL ACAD SCI USA, V101, P9393, DOI 10.1073/pnas.0402993101; Menges CW, 2012, MOL CANCER RES, V10, P1178, DOI 10.1158/1541-7786.MCR-12-0082; Moerkens M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-283; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nheu T, 2004, CELL CYCLE, V3, P71; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; Padala RR, 2017, MOL BIOSYST, V13, P830, DOI 10.1039/c6mb00786d; Puigvert JC, 2010, CURRENT PROTOCOLS CE; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sachdev D, 2008, J MAMMARY GLAND BIOL, V13, P431, DOI 10.1007/s10911-008-9105-5; Santiago-Medina M, 2013, J CELL SCI, V126, P1122, DOI 10.1242/jcs.112607; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Tabusa H, 2013, MOL CANCER RES, V11, P109, DOI 10.1158/1541-7786.MCR-12-0466; Vadlakondalf L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00085; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6; Winder T, 2014, PHARMACOGENOMICS J, V14, P28, DOI 10.1038/tpj.2013.8; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Ye P, 2010, GLIA, V58, P1031, DOI 10.1002/glia.20984; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	60	23	27	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1869	1884		10.1038/s41388-017-0027-9	http://dx.doi.org/10.1038/s41388-017-0027-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353882	Green Published			2022-12-28	WOS:000429303300005
J	Shimizu, M; Tanaka, N				Shimizu, Masahiro; Tanaka, Nobuyuki			IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells	ONCOGENE			English	Article							GLUCOSE-METABOLISM; HIGH EXPRESSION; TUMORIGENESIS; INTERLEUKIN-8; GLCNACYLATION; TRANSCRIPTION; MECHANISMS; PATHWAY; SOX2; PHOSPHORYLATION	Interleukin-8 (IL-8) is a pro-inflammatory chemokine that is associated with induction of chemotaxis and degranulation of neutrophils. IL-8 is overexpressed in many tumors, including colon and lung cancer, and recent studies demonstrated essential roles for IL-8 in tumor progression within the tumor microenvironment. However, the molecular mechanism underlying the functions of IL-8 in tumor progression is unclear. In this study, we found that IL-8 is overexpressed in colon and lung cancer cells with cancer stem cell (CSC)-like characteristics and is required for CSC properties, including tumor-initiating abilities. These findings suggest that IL-8 plays an essential role in the development of CSCs. We also showed that IL-8 stimulation of colon and lung cancer cells-induced glucose uptake and expressions of glucose transporter 3 (GLUT3) and glucosamine fructose-6-phosphate aminotransferase (GFAT), a regulator of glucose flux to the hexosamine biosynthetic pathway, resulting in enhancement of protein O-GlcNAcylation. We demonstrated that these events are required for the generation and maintenance CSC-like characteristics of colon and lung cancer cells. Moreover, an O-GlcNAcylation inhibitor, OSMI1, reduced CSC number and tumor development in vivo. Together, these results reveal that IL-8-induced O-GlcNAcylation is required for generation and maintenance of CSCs of colon and lung cancer cells and suggests this regulatory pathway as a candidate therapeutic target of CSCs.	[Shimizu, Masahiro; Tanaka, Nobuyuki] Nippon Med Sch, Inst Adv Med Sci, Dept Mol Oncol, Kawasaki, Kanagawa, Japan	Nippon Medical School	Tanaka, N (corresponding author), Nippon Med Sch, Inst Adv Med Sci, Dept Mol Oncol, Kawasaki, Kanagawa, Japan.	nobuta@nms.ac.jp		Tanaka, Nobuyuki/0000-0002-6373-2220	Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN) [17H04554]	Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN)	We thank Y. Abe. Y. Nakajima, A. Tanimura, and I. Uehara for discussion, and Y. Asano, M. Kawagoe and T. Takatera for technical support. This work was supported by Grants-in-Aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN Grant Number 17H04554). We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alfaro C, 2017, CANCER TREAT REV, V60, P24, DOI 10.1016/j.ctrv.2017.08.004; Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Corbet C, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00958; David JM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030022; Dong TY, 2016, TUMOR BIOL, V37, P8159, DOI 10.1007/s13277-015-4729-8; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Guo HB, 2017, J BIOL CHEM, V292, P4123, DOI 10.1074/jbc.M116.763201; Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625; Hardiville S, 2014, CELL METAB, V20, P208, DOI 10.1016/j.cmet.2014.07.014; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; King JB, 2009, J BIOL CHEM, V284, P9059, DOI 10.1074/jbc.M809608200; Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li LL, 2017, ONCOTARGET, V8, P19205, DOI 10.18632/oncotarget.15164; Liu BQ, 2011, EXP MOL MED, V43, P487, DOI 10.3858/emm.2011.43.9.055; Liu Q, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0597-1; Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mo L, 2016, INT J CLIN EXP PATHO, V9, P9555; Nakajima W, 2016, ONCOTARGET, V7, P36353, DOI 10.18632/oncotarget.9217; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Oikari S, 2016, GLYCOBIOLOGY, V26, P710, DOI 10.1093/glycob/cww019; Ortiz-Meoz RF, 2015, ACS CHEM BIOL, V10, P1392, DOI 10.1021/acschembio.5b00004; Rodrigues-Ferreira C, 2012, J BIOENERG BIOMEMBR, V44, P39, DOI 10.1007/s10863-012-9413-8; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shahzad Aamir, 2010, Int Arch Med, V3, P11, DOI 10.1186/1755-7682-3-11; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-70; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Singh S, 2011, MICROVASC RES, V82, P318, DOI 10.1016/j.mvr.2011.06.011; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang JC, 2015, ONCOTARGET, V6, P42825, DOI 10.18632/oncotarget.5739; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yuzwa SA, 2008, NAT CHEM BIOL, V4, P483, DOI 10.1038/nchembio.96; Zhang YB, 2015, ONCOL LETT, V9, P2809, DOI 10.3892/ol.2015.3075; Zheng JH, 2017, ONCOTARGET, V8, P98635, DOI 10.18632/oncotarget.21709; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	54	41	44	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1520	1533		10.1038/s41388-018-0533-4	http://dx.doi.org/10.1038/s41388-018-0533-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305725				2022-12-28	WOS:000459945800011
J	Neubauer, HA; Tea, MN; Zebol, JR; Gliddon, BL; Stefanidis, C; Moretti, PAB; Pitman, MR; Costabile, M; Kular, J; Stringer, BW; Day, BW; Samuel, MS; Bonder, CS; Powell, JA; Pitson, SM				Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Stringer, Brett W.; Day, Bryan W.; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.			Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma	ONCOGENE			English	Article							INTERMEDIATE CHAIN; CELL-MIGRATION; SPHINGOSINE-1-PHOSPHATE; RECEPTORS; CANCER; EXPRESSION; GROWTH; ROLES; TRANSLOCATION; 1-PHOSPHATE	While the two mammalian sphingosine kinases, SK1 and SK2, both catalyze the generation of pro-survival sphingosine 1-phosphate (S1P), their roles vary dependent on their different subcellular localization. SK1 is generally found in the cytoplasm or at the plasma membrane where it can promote cell proliferation and survival. SK2 can be present at the plasma membrane where it appears to have a similar function to SK1, but can also be localized to the nucleus, endoplasmic reticulum or mitochondria where it mediates cell death. Although SK2 has been implicated in cancer initiation and progression, the mechanisms regulating SK2 subcellular localization are undefined. Here, we report that SK2 interacts with the intermediate chain subunits of the retrograde-directed transport motor complex, cytoplasmic dynein 1 (DYNC1I1 and -2), and we show that this interaction, particularly with DYNC1I1, facilitates the transport of SK2 away from the plasma membrane. DYNC1I1 is dramatically downregulated in patient samples of glioblastoma (GBM), where lower expression of DYNC1I1 correlates with poorer patient survival. Notably, low DYNC1I1 expression in GBM cells coincided with more SK2 localized to the plasma membrane, where it has been recently implicated in oncogenesis. Re-expression of DYNC1I1 reduced plasma membrane-localized SK2 and extracellular S1P formation, and decreased GBM tumor growth and tumor-associated angiogenesis in vivo. Consistent with this, chemical inhibition of SK2 reduced the viability of patient-derived GBM cells in vitro and decreased GBM tumor growth in vivo. Thus, these findings demonstrate a tumor-suppressive function of DYNC1I1, and uncover new mechanistic insights into SK2 regulation which may have implications in targeting this enzyme as a therapeutic strategy in GBM.	[Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia; [Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] SA Pathol, Adelaide, SA, Australia; [Neubauer, Heidi A.; Pitson, Stuart M.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Stefanidis, Cassandra; Costabile, Maurizio] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Stringer, Brett W.; Day, Bryan W.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide; University of South Australia; QIMR Berghofer Medical Research Institute; University of Adelaide	Pitson, SM (corresponding author), Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia.; Pitson, SM (corresponding author), SA Pathol, Adelaide, SA, Australia.; Pitson, SM (corresponding author), Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia.; Pitson, SM (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.	stuart.pitson@unisa.edu.au	Pitson, Stuart/B-9342-2009; Day, Bryan/AAV-6170-2020; costabile, maurizio/AEN-4356-2022; Neubauer, Heidi A./AAD-8727-2019; Stringer, Brett/GZB-1390-2022; Samuel, Michael/D-2706-2011	Pitson, Stuart/0000-0002-9527-2740; costabile, maurizio/0000-0002-2162-6497; Samuel, Michael/0000-0001-7880-6379; Pitman, Melissa/0000-0002-9587-3837; Neubauer, Heidi/0000-0001-7372-7786; Moretti, Paul/0000-0002-3523-1496; Stringer, Brett/0000-0003-4552-9736; Dobbins, Julia/0000-0001-5833-2655; Bonder, Claudine S./0000-0001-9875-967X; Day, Bryan/0000-0002-8948-9089; Tea, Melinda/0000-0001-7045-1198; Powell, jason/0000-0001-8493-9178; Gliddon, Briony/0000-0003-3928-7478	Neurosurgical Research Foundation; Fay Fuller Foundation; National Health and Medical Research Council of Australia (NHMRC) [GNT626936]; NHMRC [508098, 1042589]; Australian Postgraduate Award; Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Fund Early Career Fellowship	Neurosurgical Research Foundation; Fay Fuller Foundation; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Fund Early Career Fellowship	This work was supported by the Neurosurgical Research Foundation, the Fay Fuller Foundation, a National Health and Medical Research Council of Australia (NHMRC) Project Grant (GNT626936), NHMRC Senior Research Fellowships (508098 and 1042589) to SMP, an Australian Postgraduate Award and a Royal Adelaide Hospital (RAH) Dawes Scholarship to HAN, and a RAH Research Fund Early Career Fellowship to MRP.	Abuhusain HJ, 2013, J BIOL CHEM, V288, P37355, DOI 10.1074/jbc.M113.494740; Bien-Moller S, 2016, ONCOTARGET, V7, P13031, DOI 10.18632/oncotarget.7366; Blondeau N, 2007, J NEUROCHEM, V103, P509, DOI 10.1111/j.1471-4159.2007.04755.x; Carpinteiro A, 2008, CANCER LETT, V264, P1, DOI 10.1016/j.canlet.2008.02.020; Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038; French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444; Ha JH, 2008, J CELL BIOL, V181, P1027, DOI 10.1083/jcb.200803150; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Ibbetson SJ, 2013, AM J PATHOL, V183, P930, DOI 10.1016/j.ajpath.2013.05.014; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Kular J, 2015, DEV CELL, V35, P759, DOI 10.1016/j.devcel.2015.11.026; Kuta A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011682; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; LIN SXH, 1992, J CELL SCI, V101, P125; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056471; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Neubauer HA, 2017, F1000 RES, V5, P2825; Neubauer HA, 2016, ONCOTARGET, V7, P64886, DOI 10.18632/oncotarget.11714; Neubauer HA, 2013, FEBS J, V280, P5317, DOI 10.1111/febs.12314; Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Palmer KJ, 2009, MOL BIOL CELL, V20, P2885, DOI 10.1091/mbc.E08-12-1160; Pitman MR, 2015, ONCOTARGET, V6, P7065, DOI 10.18632/oncotarget.3178; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Quint K, 2014, TUMOR BIOL, V35, P8979, DOI 10.1007/s13277-014-2172-x; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Siow D, 2011, CRIT REV BIOCHEM MOL, V46, P365, DOI 10.3109/10409238.2011.580097; Sordillo LA, 2016, ANTICANCER RES, V36, P2085; Stringer BW, 2016, ONCOTARGET, V7, P29306, DOI 10.18632/oncotarget.8720; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun WY, 2016, J IMMUNOL, V196, P3854, DOI 10.4049/jimmunol.1501510; Takabe K, 2014, J LIPID RES, V55, P1839, DOI 10.1194/jlr.R046656; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; Van Brocklyn JR, 2002, CANCER LETT, V181, P195, DOI 10.1016/S0304-3835(02)00050-2; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Young N, 2007, EXP CELL RES, V313, P1615, DOI 10.1016/j.yexcr.2007.02.009; Zebol JR, 2009, INT J BIOCHEM CELL B, V41, P822, DOI 10.1016/j.biocel.2008.08.012; Zhang J, 2002, MOL MICROBIOL, V44, P381, DOI 10.1046/j.1365-2958.2002.02900.x; Zhu W, 2017, ONCOGENE, V36, P2619, DOI 10.1038/onc.2016.428; Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025	52	14	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1151	1165		10.1038/s41388-018-0504-9	http://dx.doi.org/10.1038/s41388-018-0504-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250299	hybrid, Green Published			2022-12-28	WOS:000459249800001
J	Feng, JB; Zhang, Y; She, XL; Sun, YN; Fan, L; Ren, X; Fu, HJ; Liu, CH; Li, PY; Zhao, CH; Liu, Q; Liu, Q; Li, GY; Wu, MH				Feng, Jianbo; Zhang, Yan; She, Xiaoling; Sun, Yingnan; Fan, Li; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Liu, Qiang; Liu, Qing; Li, Guiyuan; Wu, Minghua			Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1 alpha stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment	ONCOGENE			English	Article							MIR-101 REVERSES; ANKYRIN REPEAT; EXPRESSION; CANCER; HIF-1; METHYLATION; HIF-1-ALPHA; PROMOTER; IMPACT; GROWTH	Ectopic epigenetic mechanisms play important roles in facilitating tumorigenesis. Here, we first demonstrated that ANKDD1A is a functional tumor suppressor gene, especially in the hypoxia microenvironment. ANKDD1A directly interacts with FIH1 and inhibits the transcriptional activity of HIF1 alpha by upregulating FIH1. In addition, ANKDD1A decreases the half-life of HIF1 alpha by upregulating FIH1, decreases glucose uptake and lactate production, inhibits glioblastoma multiforme (GBM) autophagy, and induces apoptosis in GBM cells under hypoxia. Moreover, ANKDD1A is highly frequently methylated in GBM. The tumor-specific methylation of ANKDD1A indicates that it could be used as a potential epigenetic biomarker as well as a possible therapeutic target.	[Feng, Jianbo; Zhang, Yan; Sun, Yingnan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Sun, Yingnan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha 410013, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth,Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, Changsha 410008, Hunan, Peoples R China; [She, Xiaoling] Cent S Univ, Second Xiangya Hosp, Changsha 410011, Hunan, Peoples R China; [Fan, Li] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; [Liu, Qiang] Cent S Univ, Third Xiangya Hosp, Changsha 410011, Hunan, Peoples R China; [Liu, Qing] Cent S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; University of California System; University of California Riverside; Central South University; Central South University	Wu, MH (corresponding author), Cent S Univ, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent S Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth,Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, Changsha 410008, Hunan, Peoples R China.	wuminghua554@aliyun.com			National Science Foundation of China [81272297]; National Key Technology Research and Development program of the Ministry of Science and Technology of China [2014BAI04B02]; 111 Project [111-2]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technology Research and Development program of the Ministry of Science and Technology of China(National Key Technology R&D Program); 111 Project(Ministry of Education, China - 111 Project)	This work was supported by grants from the National Science Foundation of China (81272297), National Key Technology Research and Development program of the Ministry of Science and Technology of China under Grant 2014BAI04B02; 111 Project under Grant number 111-2.	Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Beyer AR, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12727; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497; Chung AS, 2005, MOL CELL BIOL, V25, P4716, DOI 10.1128/MCB.25.11.4716-4726.2005; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Du WY, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0180-0; Duyndam MCA, 2003, J BIOL CHEM, V278, P6885, DOI 10.1074/jbc.M206320200; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lei QQ, 2016, ONCOTARGET, V7, P5007, DOI 10.18632/oncotarget.6652; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Liu XP, 2015, ONCOTARGET, V6, P7930, DOI 10.18632/oncotarget.3181; Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221; Madsen CD, 2015, EMBO REP, V16, P1394, DOI 10.15252/embr.201540107; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mehrmohamadi M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13666; Mikeska T, 2014, GENES-BASEL, V5, P821, DOI 10.3390/genes5030821; Nguyen LK, 2015, J CELL SCI, V128, P422, DOI 10.1242/jcs.167304; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pelletier J, 2012, ONCOGENE, V31, P2989, DOI 10.1038/onc.2011.471; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Uhlmann K, 2003, INT J CANCER, V106, P52, DOI 10.1002/ijc.11175; Vakil L, 2016, TUMOR BIOL, V37, P8841, DOI 10.1007/s13277-015-4723-1; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vordermark D, 2002, CANCER, V94, P2317, DOI 10.1002/cncr.10462; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wang EF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086102; Wang ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0355-1; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Wiestler B, 2014, NEURO-ONCOLOGY, V16, P1630, DOI 10.1093/neuonc/nou138; Wilkins SE, 2009, INT J BIOCHEM CELL B, V41, P1563, DOI 10.1016/j.biocel.2009.01.005; Xiaoping L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.197; Xu G, 2015, J NEUROSCI, V35, P7153, DOI 10.1523/JNEUROSCI.4726-14.2015; Yan B, 2011, MOL CELL BIOCHEM, V348, P1, DOI 10.1007/s11010-010-0631-2; Yang M, 2011, J BIOL CHEM, V286, P7648, DOI 10.1074/jbc.M110.193540; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhang ZP, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-99; Zheng X, 2008, P NATL ACAD SCI USA, V105, P3368, DOI 10.1073/pnas.0711591105	53	20	21	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					103	119		10.1038/s41388-018-0423-9	http://dx.doi.org/10.1038/s41388-018-0423-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082910	Green Published, hybrid			2022-12-28	WOS:000454775900008
J	Wang, HJ; Pochampalli, M; Wang, LY; Zou, JX; Li, PS; Hsu, SC; Wang, BJ; Huang, SH; Yang, P; Yang, JC; Chu, CY; Hsieh, CL; Sung, SY; Li, CF; Tepper, CG; Ann, DK; Gao, AC; Evans, CP; Izumiya, Y; Chuu, CP; Wang, WC; Chen, HW; Kung, HJ				Wang, Hung-Jung; Pochampalli, Mamata; Wang, Ling-Yu; Zou, June X.; Li, Pei-Shan; Hsu, Sheng-Chieh; Wang, Bi-Juan; Huang, Shih-Han; Yang, Ping; Yang, Joy C.; Chu, Cheng-Ying; Hsieh, Chia-Ling; Sung, Shian-Ying; Li, Chien-Feng; Tepper, Clifford G.; Ann, David K.; Gao, Allen C.; Evans, Christopher P.; Izumiya, Yoshihiro; Chuu, Chi-Pin; Wang, Wen-Ching; Chen, Hong-Wu; Kung, Hsing-Jien			KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC	ONCOGENE			English	Article							PYRUVATE-KINASE M2; H3K36ME2 HISTONE DEMETHYLASE; GROUP PROTEIN EZH2; PROSTATE-CANCER; ANDROGEN RECEPTOR; ENZALUTAMIDE RESISTANCE; NUCLEAR TRANSLOCATION; CELL PROLIFERATION; JMJD5 PROMOTES; IDENTIFICATION	During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8's oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1 alpha to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8's functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.	[Wang, Hung-Jung; Hsu, Sheng-Chieh; Gao, Allen C.] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan Township 35053, Miaoli County, Taiwan; [Wang, Hung-Jung; Li, Pei-Shan; Kung, Hsing-Jien] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan Township 35053, Miaoli County, Taiwan; [Pochampalli, Mamata; Wang, Ling-Yu; Zou, June X.; Chen, Hong-Wu; Kung, Hsing-Jien] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA; [Hsu, Sheng-Chieh; Kung, Hsing-Jien] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30035, Taiwan; [Wang, Bi-Juan; Huang, Shih-Han; Chuu, Chi-Pin] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan Township 35053, Miaoli County, Taiwan; [Yang, Ping; Yang, Joy C.; Tepper, Clifford G.; Gao, Allen C.; Evans, Christopher P.] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Yang, Ping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Chu, Cheng-Ying; Hsieh, Chia-Ling; Sung, Shian-Ying; Ann, David K.; Kung, Hsing-Jien] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan; [Li, Chien-Feng] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Township 35053, Miaoli County, Taiwan; [Ann, David K.] City Hope Natl Med Ctr, Dept Mol Pharmacol, Beckman Res Inst, Duarte, CA USA; [Evans, Christopher P.; Izumiya, Yoshihiro; Chen, Hong-Wu] Univ Calif Davis, Sch Med, Comprehens Canc Ctr, Sacramento, CA 95817 USA; [Wang, Wen-Ching] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; University of California System; University of California Davis; National Tsing Hua University; National Health Research Institutes - Taiwan; University of California System; University of California Davis; State Key Lab Oncology South China; Sun Yat Sen University; Taipei Medical University; National Health Research Institutes - Taiwan; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Davis; National Tsing Hua University	Wang, HJ (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan Township 35053, Miaoli County, Taiwan.; Wang, HJ; Kung, HJ (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan Township 35053, Miaoli County, Taiwan.; Kung, HJ (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA.; Kung, HJ (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30035, Taiwan.; Kung, HJ (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan.	hjwang@nhri.org.tw; hkung@nhri.org.tw	Wang, Wen-Ching/ABI-2253-2020	Li, Chien-Feng/0000-0002-9527-7576; Wang, Ling-Yu/0000-0002-1413-817X; Wang, Wen-Ching/0000-0002-7422-3667	NIH, USA [CA114575, CA165263, CA206222]; NHRI, Taiwan [NHRI03A1-MGPP18-014, NHRI04A1-MGPP15-014, NHRI05A1-MGPP15-014]; MOHW of Taiwan [MOHW104-TDUM-212-13304]; MOST of Taiwan [MOST102-2320-B-400-018-MY3, MOST104-2321-B-400-009]; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute [NCI P30CA093373]; National Core Facility Program for Biotechnology [MOST 105-2319-B-400-001]; NATIONAL CANCER INSTITUTE [R01CA165263, P30CA093373, R01CA206222] Funding Source: NIH RePORTER	NIH, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHRI, Taiwan(National Health Research Institutes - Taiwan); MOHW of Taiwan; MOST of Taiwan; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute; National Core Facility Program for Biotechnology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants CA114575, CA165263, and CA206222 from NIH, USA; NHRI03A1-MGPP18-014, NHRI04A1-MGPP15-014, and NHRI05A1-MGPP15-014 from NHRI, Taiwan; MOHW104-TDUM-212-13304 from MOHW of Taiwan; MOST102-2320-B-400-018-MY3 and MOST104-2321-B-400-009 from MOST of Taiwan; The UCDCCC Genomics Shared Resource is funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373). We thank Taiwan Bioinformatics Institute Core Facility for assistances on using Oncomine (National Core Facility Program for Biotechnology, MOST 105-2319-B-400-001).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Alumkal JJ, 2012, CANCER DISCOV, V2, P979, DOI 10.1158/2159-8290.CD-12-0392; Amendola PG, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006632; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Chu CH, 2014, J MED CHEM, V57, P5975, DOI 10.1021/jm500249n; Clermont PL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0074-4; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cui YY, 2014, ENDOCR-RELAT CANCER, V21, P435, DOI 10.1530/ERC-14-0107; DePrimo SE, 2002, GENOME BIOL, V3; Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007; Duan ZJ, 2013, PROSTATE, V73, P455, DOI 10.1002/pros.22587; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; He ZM, 2016, J BIOL CHEM, V291, P4684, DOI 10.1074/jbc.M115.672642; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107; Huang XB, 2015, BBA-MOL CELL RES, V1853, P2286, DOI 10.1016/j.bbamcr.2015.05.026; Huang XB, 2013, BIOCHIMIE, V95, P2114, DOI 10.1016/j.biochi.2013.08.002; Ishimura A, 2016, CELL TISSUE RES, V363, P723, DOI 10.1007/s00441-015-2276-7; Ishimura A, 2012, DEVELOPMENT, V139, P749, DOI 10.1242/dev.074138; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Keller KE, 2012, SCIENCE, V338, P1069, DOI 10.1126/science.1224409; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Li HF, 2013, MOL CANCER THER, V12, P2425, DOI 10.1158/1535-7163.MCT-13-0267; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu HL, 2017, P NATL ACAD SCI USA, V114, pE7717, DOI 10.1073/pnas.1706831114; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ma AH, 2006, CANCER RES, V66, P8439, DOI 10.1158/0008-5472.CAN-06-1636; Marcon E, 2014, CELL REP, V8, P297, DOI 10.1016/j.celrep.2014.05.050; Oh S, 2012, BIOCHEM BIOPH RES CO, V420, P61, DOI 10.1016/j.bbrc.2012.02.115; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Shen J, 2017, EMBO REP, V18, P2131, DOI 10.15252/embr.201743892; Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147; Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang L.-Y., 2013, NUCL SIGNALING PATHW; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wong N, 2014, CANCER INVEST, V32, P330, DOI 10.3109/07357907.2014.919306; Wu BH, 2016, ONCOTARGET, V7, P6847, DOI 10.18632/oncotarget.6867; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2; Youn MY, 2012, J BIOL CHEM, V287, P12994, DOI 10.1074/jbc.M111.323105; Zhang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.454; Zhang R, 2015, INT J CLIN EXP PATHO, V8, P6482; Zhao ZH, 2015, INT J CLIN EXP PATHO, V8, P10325; Zhu H, 2014, STEM CELLS, V32, P2098, DOI 10.1002/stem.1724; Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440	63	50	51	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					17	32		10.1038/s41388-018-0414-x	http://dx.doi.org/10.1038/s41388-018-0414-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30072740	hybrid, Green Published			2022-12-28	WOS:000454775900002
J	Kong, FY; Deng, X; Kong, XY; Du, YQ; Li, L; Zhu, HY; Wang, YX; Xie, DC; Guha, S; Li, ZS; Guan, M; Xie, KP				Kong, Fanyang; Deng, Xuan; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Xie, Dacheng; Guha, Shivani; Li, Zhaoshen; Guan, Ming; Xie, Keping			ZFPM2-AS1, a novel IncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF	ONCOGENE			English	Article							MIGRATION-INHIBITORY FACTOR; LONG NONCODING RNAS; MOLECULAR-MECHANISMS; PANCREATIC-CANCER; CELL-PROLIFERATION; ANTISENSE LNCRNA; EXPRESSION; PROGRESSION; GROWTH; ADENOCARCINOMA	Long non-coding RNAs (lncRNAs) are implicated to be involved in the pathogenesis of many cancers. Herein we report on our discovery of a novel lncRNA, ZFPM2 antisense RNA 1 (ZFPM2-AS1), and its critical role in gastric carcinogenesis. ZFPM2-AS1 expression in gastric cancer specimens was analyzed using Gene Expression Omnibus data set and validated in 73 paired gastric tumor and normal adjacent gastric tissue specimens using qRT-PCR. The effect of ZFPM2-AS1 expression on proliferation and apoptosis in gastric cancer cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. ZFPM2-AS1 expression was higher in gastric tumors than in normal gastric tissue. Also, increased ZFPM2-AS1 expression in gastric cancer specimens was associated with tumor size, depth of tumor invasion, differentiation grade, and TNM stage. High ZFPM2-AS1 expression predicted markedly reduced overall and disease-free survival in gastric cancer patients. Functional experiments demonstrated that ZFPM2-AS1 expression promoted proliferation and suppressed apoptosis of gastric cancer cells in vitro and promoted tumor growth in vivo. This effect is associated with attenuated nuclear translocation of p53. Mechanistic experiments demonstrated that tumor-activated ZFPM2-AS1 could bind to and protect the degradation of macrophage migration inhibitory factor (MIF), a potent destabilizer of p53. Knockdown of MIF expression diminished ZFPM2-AS1's impact on p53 expression in gastric cancer cells. Our findings demonstrated that ZFPM2-AS1 regulates gastric cancer progression and revealed a novel ZFPM2-AS1/MIF/p53 signaling axis, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant gastric cells.	[Kong, Fanyang; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Li, Zhaoshen] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Kong, Fanyang; Kong, Xiangyu; Xie, Dacheng; Guha, Shivani; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Deng, Xuan; Guan, Ming] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Lab Med, Shanghai, Peoples R China	Naval Medical University; University of Texas System; UTMD Anderson Cancer Center; Fudan University	Li, ZS (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.; Guan, M (corresponding author), Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Lab Med, Shanghai, Peoples R China.	zhaoshenli5610@hotmail.com; guanminghsyy@hotmail.com; kepxie@mdanderson.org	Zhu, Huiyun/S-8032-2019		National Cancer Institute, National Institutes of Health [R01CA172233, R01CA195651, R01CA198090]; National Natural Science Foundation of China [81772640]; NATIONAL CANCER INSTITUTE [R01CA220236, R01CA195651, R01CA198090, R21CA140999, R01CA172233] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01CA172233, R01CA195651, and R01CA198090 from the National Cancer Institute, National Institutes of Health (to K.X.) and grant 81772640 from the National Natural Science Foundation of China (to X.K.).	Amit-Avraham I, 2015, P NATL ACAD SCI USA, V112, pE982, DOI 10.1073/pnas.1420855112; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Brock SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099795; Conroy H, 2010, QJM-INT J MED, V103, P831, DOI 10.1093/qjmed/hcq148; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Dessein AF, 2010, CANCER RES, V70, P4644, DOI 10.1158/0008-5472.CAN-09-3828; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fu M, 2016, ONCOL REP, V36, P1207, DOI 10.3892/or.2016.4929; Fukaya R, 2016, CANCER RES, V76, P2813, DOI 10.1158/0008-5472.CAN-15-1011; GABBERT HE, 1995, CANCER, V76, P720, DOI 10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E; Guo K, 2017, CLIN CANCER RES, V23, P687, DOI 10.1158/1078-0432.CCR-16-1064; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; Huang B, 2016, ONCOGENE, V35, P4927, DOI 10.1038/onc.2016.25; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; IMAZEKI F, 1992, GASTROENTEROLOGY, V103, P892, DOI 10.1016/0016-5085(92)90022-Q; Jung H, 2008, J BIOL CHEM, V283, P32669, DOI 10.1074/jbc.M806225200; Jung HY, 2008, J BIOL CHEM, V283, P20383, DOI 10.1074/jbc.M800050200; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kong FY, 2017, CANCER RES, V77, P6851, DOI 10.1158/0008-5472.CAN-17-0067; Larsen M, 2008, CANCER LETT, V265, P239, DOI 10.1016/j.canlet.2008.02.012; Li TW, 2016, ONCOTARGET, V7, P8601, DOI 10.18632/oncotarget.6926; Lin YS, 2011, WORLD J GASTROENTERO, V17, P4421, DOI 10.3748/wjg.v17.i39.4421; Lopez-Saez JF, 1998, HISTOL HISTOPATHOL, V13, P1197, DOI 10.14670/HH-13.1197; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Oda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002215; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Salminen A, 2011, CELL SIGNAL, V23, P747, DOI 10.1016/j.cellsig.2010.10.012; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schulz R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.508; Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117; Shi XF, 2015, TUMOR BIOL, V36, P503, DOI 10.1007/s13277-015-3106-y; Shun CT, 2005, WORLD J GASTROENTERO, V11, P3767, DOI 10.3748/wjg.v11.i24.3767; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sugano K, 2015, BEST PRACT RES CL GA, V29, P895, DOI 10.1016/j.bpg.2015.09.013; Sun BL, 2003, INT J MOL MED, V12, P633; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Villegas VE, 2015, INT J MOL SCI, V16, P3251, DOI 10.3390/ijms16023251; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wei N, 2015, ANIM GENET, V46, P133, DOI 10.1111/age.12275; Werner A, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-31; Wight M, 2013, ESSAYS BIOCHEM, V54, P91, DOI [10.1042/BSE0540091, 10.1042/bse0540091]; Winner M, 2007, CANCER RES, V67, P186, DOI 10.1158/0008-5472.CAN-06-3292; Yang SH, 2016, CANCER RES, V76, P3838, DOI 10.1158/0008-5472.CAN-15-2841; Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018	52	65	68	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5982	5996		10.1038/s41388-018-0387-9	http://dx.doi.org/10.1038/s41388-018-0387-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29985481	Green Accepted			2022-12-28	WOS:000449562500006
J	Pennington, KL; Chan, TY; Torres, MP; Andersen, JL				Pennington, K. L.; Chan, T. Y.; Torres, M. P.; Andersen, J. L.			The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CAMKII-MEDIATED PHOSPHORYLATION; SMALL-MOLECULE MODULATORS; DNA-DAMAGE CHECKPOINT; CANCER-CELL-SURVIVAL; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; IN-VIVO; STRUCTURAL-ANALYSIS	14-3-3 proteins are a family of structurally similar phospho-binding proteins that regulate essentially every major cellular function. Decades of research on 14-3-3s have revealed a remarkable network of interacting proteins that demonstrate how 14-3-3s integrate and control multiple signaling pathways. In particular, these interactions place 14-3-3 at the center of the signaling hub that governs critical processes in cancer, including apoptosis, cell cycle progression, autophagy, glucose metabolism, and cell motility. Historically, the majority of 14-3-3 interactions have been identified and studied under nutrient-replete cell culture conditions, which has revealed important nutrient driven interactions. However, this underestimates the reach of 14-3-3s. Indeed, the loss of nutrients, growth factors, or changes in other environmental conditions (e.g., genotoxic stress) will not only lead to the loss of homeostatic 14-3-3 interactions, but also trigger new interactions, many of which are likely stress adaptive. This dynamic nature of the 14-3-3 interactome is beginning to come into focus as advancements in mass spectrometry are helping to probe deeper and identify context-dependent 14-3-3 interactions-providing a window into adaptive phosphorylation-driven cellular mechanisms that orchestrate the tumor cell's response to a variety of environmental conditions including hypoxia and chemotherapy. In this review, we discuss emerging 14-3-3 regulatory mechanisms with a focus on post-translational regulation of 14-3-3 and dynamic protein-protein interactions that illustrate 14-3-3's role as a stress-adaptive signaling hub in cancer.	[Pennington, K. L.; Chan, T. Y.; Andersen, J. L.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [Torres, M. P.] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA	Brigham Young University; University System of Georgia; Georgia Institute of Technology	Andersen, JL (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	jandersen@chem.byu.edu	Chan, Tsz Yin/ABG-4045-2021	Torres, Matthew/0000-0001-7296-4536; Pennington, Katie/0000-0003-2883-0025	National Institutes of Health [R15CA202619, R01GM117400]; Fritz B. Burns Foundation; Elsa U. Pardee Foundation; NATIONAL CANCER INSTITUTE [R15CA202618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM117400] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fritz B. Burns Foundation; Elsa U. Pardee Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants to JLA (R15CA202619) and MPT (R01GM117400), as well as research support from the Fritz B. Burns Foundation and Elsa U. Pardee Foundation to JLA.	Acevedo SF, 2007, GENETICS, V177, P239, DOI 10.1534/genetics.107.072280; Aeluri M, 2014, CHEM REV, V114, P4640, DOI 10.1021/cr4004049; Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Aghazadeh Y, 2014, J BIOL CHEM, V289, P26542, DOI 10.1074/jbc.M114.569079; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Aitken A, 2011, SEMIN CELL DEV BIOL, V22, P673, DOI 10.1016/j.semcdb.2011.08.003; An SS, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-8; Andersen JL, 2011, MOL CELL, V43, P834, DOI 10.1016/j.molcel.2011.07.028; Andersen SD, 2012, DNA REPAIR, V11, P267, DOI 10.1016/j.dnarep.2011.11.007; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Banks CJ, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00354-17; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Cao WD, 2010, APOPTOSIS, V15, P230, DOI 10.1007/s10495-009-0437-4; Chatterjee D, 2004, INT J ONCOL, V25, P503; Chen CM, 2017, METHODS MOL BIOL, V1558, P3, DOI 10.1007/978-1-4939-6783-4_1; Chen QL, 2017, DIABETOLOGIA, V60, P336, DOI 10.1007/s00125-016-4151-9; Chen QL, 2014, CELL SIGNAL, V26, P1636, DOI 10.1016/j.cellsig.2014.04.012; Chen S, 2011, TRENDS ENDOCRIN MET, V22, P429, DOI 10.1016/j.tem.2011.07.005; Chen XQ, 2015, J BIOL CHEM, V290, P12300, DOI 10.1074/jbc.M115.644005; Chen YJ, 2015, NUCLEIC ACIDS RES, V43, pD503, DOI 10.1093/nar/gku1176; Cheruiyot A, 2015, DNA REPAIR, V35, P106, DOI 10.1016/j.dnarep.2015.09.021; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chuthapisith S, 2007, INT J ONCOL, V30, P1545; Cockrell LM, 2010, ONCOGENE, V29, P822, DOI 10.1038/onc.2009.382; Collins BC, 2013, NAT METHODS, V10, P1246, DOI [10.1038/NMETH.2703, 10.1038/nmeth.2703]; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Corradi V, 2011, BIOORG MED CHEM LETT, V21, P6867, DOI 10.1016/j.bmcl.2011.09.011; Corradi V, 2010, BIOORG MED CHEM LETT, V20, P6133, DOI 10.1016/j.bmcl.2010.08.019; Dalal SN, 2004, CELL CYCLE, V3, P672; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dewhurst HM, 2015, MOL CELL PROTEOMICS, V14, P2285, DOI 10.1074/mcp.M115.051177; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dikiy A, 2007, BIOCHEMISTRY-US, V46, P6871, DOI 10.1021/bi602462q; Dong S, 2008, LEUKEMIA, V22, P572, DOI 10.1038/sj.leu.2405064; Du YH, 2006, J BIOMOL SCREEN, V11, P269, DOI 10.1177/1087057105284862; Dubois F, 2009, MOL CELL PROTEOMICS, V8, P2487, DOI 10.1074/mcp.M800544-MCP200; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Ellis JJ, 2003, MOL CELL BIOCHEM, V242, P153, DOI 10.1023/A:1021158216582; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Favier FB, 2010, AM J PHYSIOL-REG I, V298, pR1659, DOI 10.1152/ajpregu.00550.2009; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Gill JG, 2016, COLD SH Q B, V81, P163, DOI 10.1101/sqb.2016.81.030791; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gu Y, 2018, LEUKEMIA, V32, P744, DOI 10.1038/leu.2017.288; Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hartman AM, 2017, EUR J MED CHEM, V136, P573, DOI 10.1016/j.ejmech.2017.04.058; He GF, 2014, MOL CELL BIOL, V34, P148, DOI 10.1128/MCB.00670-13; Holman GD, 2008, CELL METAB, V8, P344, DOI 10.1016/j.cmet.2008.10.006; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jeon YH, 2016, BBA-MOL CELL RES, V1863, P10, DOI 10.1016/j.bbamcr.2015.10.006; Jeon YH, 2013, BBA-MOL CELL RES, V1833, P2135, DOI 10.1016/j.bbamcr.2013.05.005; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Johnson C, 2010, BIOCHEM J, V427, P69, DOI 10.1042/BJ20091834; Joshi S, 2017, AM J CANCER RES, V7, P1654; Kanno T, 2011, J CELL PHYSIOL, V226, P2329, DOI 10.1002/jcp.22571; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Knetsch MLW, 1997, BBA-MOL CELL RES, V1357, P243, DOI 10.1016/S0167-4889(97)00060-8; Kobayashi H, 2011, J BIOL CHEM, V286, P39259, DOI 10.1074/jbc.M111.255489; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lalle M, 2006, J BIOL CHEM, V281, P5137, DOI 10.1074/jbc.M509673200; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Lee JH, 2012, J BIOL CHEM, V287, P20898, DOI 10.1074/jbc.M111.336875; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li C, 2017, J BIOL CHEM, V292, P16746, DOI 10.1074/jbc.M117.803338; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lienhard GE, 2008, TRENDS BIOCHEM SCI, V33, P351, DOI 10.1016/j.tibs.2008.05.004; Lin MT, 2009, INT J CANCER, V125, P603, DOI 10.1002/ijc.24346; Liou JY, 2007, CANCER RES, V67, P3185, DOI 10.1158/0008-5472.CAN-06-3431; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Logsdon CD, 2003, CANCER RES, V63, P2649; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Ma YF, 2005, J BIOL CHEM, V280, P26011, DOI 10.1074/jbc.M409081200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Margolis SS, 2006, MOL BIOL CELL, V17, P1779, DOI 10.1091/mbc.E05-08-0751; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Matta A, 2012, EXPERT OPIN THER TAR, V16, P515, DOI 10.1517/14728222.2012.668185; Maxwell SA, 2009, J BIOL CHEM, V284, P22379, DOI 10.1074/jbc.M109.022418; Merkel O, 2017, MUTAT RES-REV MUTAT, V773, P1, DOI 10.1016/j.mrrev.2017.02.003; Milton AH, 2006, EMBO J, V25, P1046, DOI 10.1038/sj.emboj.7600999; Molzan M, 2012, J MOL BIOL, V423, P486, DOI 10.1016/j.jmb.2012.08.009; Mori M, 2014, CHEMMEDCHEM, V9, P973, DOI 10.1002/cmdc.201400044; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Mortenson JB, 2015, J BIOL CHEM, V290, P12487, DOI 10.1074/jbc.M114.607580; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Neal CL, 2012, ONCOGENE, V31, P897, DOI 10.1038/onc.2011.284; Neal CL, 2010, EXPERT OPIN THER TAR, V14, P1343, DOI 10.1517/14728222.2010.531011; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Neukamm SS, 2013, J BIOL CHEM, V288, P16403, DOI 10.1074/jbc.M113.474593; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Nutt LK, 2009, DEV CELL, V16, P856, DOI 10.1016/j.devcel.2009.04.005; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Ottmann C, 2007, MOL CELL, V25, P427, DOI 10.1016/j.molcel.2006.12.017; Ottmann C, 2007, EMBO J, V26, P902, DOI 10.1038/sj.emboj.7601530; Ottmann C, 2013, BIOORGAN MED CHEM, V21, P4058, DOI 10.1016/j.bmc.2012.11.028; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Paul AL, 2005, MOL BIOL CELL, V16, P1735, DOI 10.1091/mbc.E04-09-0839; Pehmoller C, 2009, AM J PHYSIOL-ENDOC M, V297, pE665, DOI 10.1152/ajpendo.00115.2009; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Petrvalska O, 2016, J BIOL CHEM, V291, P20753, DOI 10.1074/jbc.M116.724310; Pieri BLS, 2014, HORM METAB RES, V46, P621, DOI 10.1055/s-0034-1371824; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Puckett MC, 2013, MOL CELL BIOL, V33, P2252, DOI 10.1128/MCB.00047-13; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Rehman SK, 2014, CANCER RES, V74, P363, DOI 10.1158/0008-5472.CAN-13-2016; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schoenwaelder SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12862; Seong HA, 2010, J BIOL CHEM, V285, P2397, DOI 10.1074/jbc.M109.064295; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Slone SR, 2015, NEUROBIOL DIS, V79, P1, DOI 10.1016/j.nbd.2015.02.032; Sluchanko NN, 2008, ARCH BIOCHEM BIOPHYS, V477, P305, DOI 10.1016/j.abb.2008.05.020; Sluchanko NN, 2017, STRUCTURE, V25, P305, DOI 10.1016/j.str.2016.12.005; Sluchanko NN, 2012, BIOCHEMISTRY-US, V51, P6127, DOI 10.1021/bi300674e; Sluchanko NN, 2011, ARCH BIOCHEM BIOPHYS, V506, P24, DOI 10.1016/j.abb.2010.11.003; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Suzuki H, 2000, CANCER RES, V60, P4353; Takeda K, 2013, GENES CELLS, V18, P369, DOI 10.1111/gtc.12043; Tang SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055268; Tang YF, 2016, ONCOTARGET, V7, P15854, DOI 10.18632/oncotarget.7493; Tang YF, 2015, INT J CLIN EXP PATHO, V8, P15845; Tarrado-Castellarnau M, 2016, ONCOTARGET, V7, P62726, DOI 10.18632/oncotarget.10911; Teo Z, 2017, ONCOGENE, V36, P6408, DOI 10.1038/onc.2017.244; Testerink C, 1999, PLANT PHYSIOL, V121, P81, DOI 10.1104/pp.121.1.81; Thiel P, 2013, CHEM COMMUN, V49, P8468, DOI 10.1039/c3cc44612c; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torres MP, 2016, MOL CELL PROTEOMICS, V15, P3513, DOI 10.1074/mcp.M116.062331; Truong AB, 2002, PROTEINS, V49, P321, DOI 10.1002/prot.10210; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; Vega-Rubin-de-Celis S, 2010, BIOCHEMISTRY-US, V49, P2491, DOI 10.1021/bi902135e; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weerasekara VK, 2014, MOL CELL BIOL, V34, P4379, DOI 10.1128/MCB.00740-14; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Woodcock JM, 2010, CELL SIGNAL, V22, P1291, DOI 10.1016/j.cellsig.2010.04.004; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yan YM, 2012, BIOORG MED CHEM LETT, V22, P4179, DOI 10.1016/j.bmcl.2012.04.027; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang X, 2012, CANCER GENE THER, V19, P153, DOI 10.1038/cgt.2011.85; Yang XL, 2011, NEUROSURGERY, V68, P932, DOI 10.1227/NEU.0b013e3182098c30; Yip MF, 2008, CELL METAB, V8, P384, DOI 10.1016/j.cmet.2008.09.011; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012; Zhao J, 2011, P NATL ACAD SCI USA, V108, P16212, DOI 10.1073/pnas.1100012108; Zhao T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03793; Zhou JB, 2009, MOL CELL BIOL, V29, P4167, DOI 10.1128/MCB.01067-08; Zhou X, 2017, J MOL CELL BIOL, V9, P62, DOI 10.1093/jmcb/mjx001; Zuo SA, 2010, J PROTEOME RES, V9, P3465, DOI 10.1021/pr9011377	197	150	151	5	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5587	5604		10.1038/s41388-018-0348-3	http://dx.doi.org/10.1038/s41388-018-0348-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29915393	Green Published, hybrid			2022-12-28	WOS:000447619100001
J	Su, WJ; Hong, LX; Xu, X; Huang, S; Herpai, D; Li, LS; Xu, YX; Truong, L; Hu, WY; Wu, XH; Xiao, CC; Zhang, W; Han, JH; Debinski, W; Xiang, R; Sun, PQ				Su, Weijun; Hong, Lixin; Xu, Xin; Huang, Shan; Herpai, Denise; Li, Lisheng; Xu, Yingxi; Lan Truong; Hu, Wen-Yuan; Wu, Xiaohua; Xiao, Changchun; Zhang, Wei; Han, Jiahuai; Debinski, Waldemar; Xiang, Rong; Sun, Peiqing			miR-30 disrupts senescence and promotes cancer by targeting both p16(INK4A) and DNA damage pathways	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAK; RAS-INDUCED SENESCENCE; SMALL RNAS; CHROMATIN IMMUNOPRECIPITATION; MESSENGER-RNAS; CHD7; MICRORNAS; REPAIR; TUMORIGENESIS	miR-30 is a microRNA frequently overexpressed in human cancers. However, the biological consequence of miR-30 overexpression in cancer has been unclear. In a genetic screen, miR-30 was found to abrogate oncogenic-induced senescence, a key tumor-suppressing mechanism that involves DNA damage responses, activation of p53 and induction of p16(INK4A). In cells and mouse models, miR-30 disrupts senescence and promotes cancer by suppressing 2 targets, CHD7 and TNRC6A. We show that while CHD7 is a transcriptional coactivator essential for induction of p16(INK4A) in senescent cells, TNRC6A, a miRNA machinery component, is required for expression and functionality of DNA damage response RNAs (DDRNAs) that mediate DNA damage responses and p53 activation by orchestrating histone modifications, chromatin remodeling and recruitment of DNA damage factors at damaged sites. Thus, miR-30 inhibits both p16(INK4A) and p53, 2 key senescence effectors, leading to efficient senescence disruption. These findings have identified novel signaling pathways mediating oncogene-induced senescence and tumor-suppression, and revealed the molecular and cellular mechanisms underlying the oncogenic activity of miR-30. Thus, the miR-30/CHD7/TNRC6A pathway is potentially a novel diagnostic biomarker and therapeutic target for cancer.	[Su, Weijun; Huang, Shan; Herpai, Denise; Zhang, Wei; Debinski, Waldemar; Sun, Peiqing] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Dept Canc Biol, Winston Salem, NC 27101 USA; [Su, Weijun; Xu, Yingxi; Xiang, Rong] Nankai Univ, Sch Med, Tianjin, Peoples R China; [Hong, Lixin; Xu, Yingxi; Lan Truong; Wu, Xiaohua; Sun, Peiqing] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA; [Hong, Lixin; Li, Lisheng; Han, Jiahuai] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Xu, Xin] 2 Peoples Hosp Wuxi City, Wuxi, Peoples R China; [Herpai, Denise; Debinski, Waldemar] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Brain Tumor Ctr Excellence, Winston Salem, NC USA; [Hu, Wen-Yuan] Biosettia Inc, San Diego, CA USA; [Xiao, Changchun] Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Xiao, Changchun] Scripps Res Inst, Dept Microbial Sci, La Jolla, CA 92037 USA; [Zhang, Wei] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Ctr Canc Genom & Precis Oncol, Winston Salem, NC USA	Wake Forest University; Nankai University; Scripps Research Institute; Xiamen University; Wake Forest University; Scripps Research Institute; Scripps Research Institute; Wake Forest University	Sun, PQ (corresponding author), Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Dept Canc Biol, Winston Salem, NC 27101 USA.; Sun, PQ (corresponding author), Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.	psun@wakehealth.edu	Xu, Yingxi/HGA-1792-2022	Li, Lisheng/0000-0002-0793-272X	Overseas Collaboration Fund from National NSF of China [31428013]; NIH/NCI [CA106768, CA131231, CA172115, P30CA012197]; Thomas K. Hearn Brain Tumor Center; International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council [20140027]; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA131231, R01CA106768, R01CA172115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080677] Funding Source: NIH RePORTER	Overseas Collaboration Fund from National NSF of China; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Thomas K. Hearn Brain Tumor Center; International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Joanna Wysocka for CHD7 cDNA, and Tumor Tissue and Pathology, Biostatistics and Bioinformatics, Cell & Viral Vector Laboratory and Cellular Imaging Shared Resources of WFBCCC. This study was supported by Overseas Collaboration Fund from National NSF of China 31428013 (PS, RX), NIH/NCI grants CA106768, CA131231, CA172115 (PS), P30CA012197, and Thomas K. Hearn Brain Tumor Center. WS is supported by International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council (20140027).	Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; di Fagagna FD, 2014, TRENDS CELL BIOL, V24, P171, DOI 10.1016/j.tcb.2013.09.008; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DiGiovanni J, 1991, MODIFICATION TUMOR D, V33, P192; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Eystathioy T, 2002, MOL BIOL CELL, V13, P1338, DOI 10.1091/mbc.01-11-0544; Fabbri M, 2008, CANCER J, V14, P1, DOI 10.1097/PPO.0b013e318164145e; Faraonio R, 2012, CELL DEATH DIFFER, V19, P713, DOI 10.1038/cdd.2011.143; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Gertsenstein M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011260; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hurd EA, 2007, MAMM GENOME, V18, P94, DOI 10.1007/s00335-006-0107-6; Jongmans MCJ, 2006, J MED GENET, V43, P306, DOI 10.1136/jmg.2005.036061; Kim MS, 2010, J PATHOL, V221, P139, DOI 10.1002/path.2683; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Kwong J, 2013, MOL CELL BIOL, V33, P3780, DOI 10.1128/MCB.00784-13; Kwong J, 2009, J BIOL CHEM, V284, P11237, DOI 10.1074/jbc.M808327200; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Mukhopadhyay A, 2008, NAT PROTOC, V3, P698, DOI 10.1038/nprot.2008.38; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Schnetz MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001023; Schnetz MP, 2009, GENOME RES, V19, P590, DOI 10.1101/gr.086983.108; Srikantan S, 2011, CELL CYCLE, V10, P3211, DOI 10.4161/cc.10.19.17050; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang HL, 2012, J BIOL CHEM, V287, P21471, DOI 10.1074/jbc.M112.355354; Wang QH, 2016, CANCER RES, V76, P1904, DOI 10.1158/0008-5472.CAN-15-2334; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xu Y, 2012, MOL CELL, V48, P723, DOI 10.1016/j.molcel.2012.09.026; Yoshizuka N, 2012, MOL CELL BIOL, V32, P606, DOI 10.1128/MCB.06301-11; Zamudio JR, 2014, CELL, V156, P920, DOI 10.1016/j.cell.2014.01.041; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zhao T, 2010, AM J PHYSIOL-ENDOC M, V299, pE110, DOI 10.1152/ajpendo.00192.2010	49	27	29	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5618	5632		10.1038/s41388-018-0358-1	http://dx.doi.org/10.1038/s41388-018-0358-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907771	Green Accepted			2022-12-28	WOS:000447619100003
J	Zhang, Y; Zhou, XX; Li, Y; Xu, YY; Lu, K; Li, PP; Wang, X				Zhang, Ya; Zhou, Xiangxiang; Li, Ying; Xu, Yangyang; Lu, Kang; Li, Peipei; Wang, Xin			Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia	ONCOGENE			English	Article							GLIOMA STEM-CELLS; LARGE GENE LISTS; CANCER CELLS; JNK/MITOCHONDRIAL PATHWAY; HEPATOCELLULAR-CARCINOMA; IBRUTINIB RESISTANCE; EXPRESSION SIGNATURE; DISEASE PROGRESSION; MELK EXPRESSION; LUNG-CANCER	TP53 pathway defects contributed to therapy resistance and adverse clinical outcome in chronic lymphocytic leukemia (CLL), which represents an unmet clinical need with few therapeutic options. Maternal embryonic leucine zipper kinase (MELK) is a novel oncogene, which plays crucial roles in mitotic progression and stem cell maintenance. OTSSP167, an orally administrated inhibitor targeting MELK, is currently in a phase I/II clinical trial in patients with advanced breast cancer and acute myeloid leukemia. Yet, no investigation has been elucidated to date regarding the oncogenic role of MELK and effects of OTSSP167 in chronic lymphocytic leukemia (CLL). Previous studies confirmed MELK inhibition abrogated cancer cell survival via p53 signaling pathway. Thus, we aimed to determine the biological function of MELK and therapeutic potential of OTSSP167 in CLL. Herein, MELK over-expression was observed in CLL cells, and correlated with higher WBC count, advanced stage, elevated LDH, increased beta 2-MG level, unmutated IGHV, positive ZAP-70, deletion of 17p13 and inferior prognosis of CLL patients. In accordance with functional enrichment analyses in gene expression profiling, CLL cells with depletion or inhibition of MELK exhibited impaired cell proliferation, enhanced fast-onset apoptosis, induced G2/M arrest, attenuated cell chemotaxis and promoted sensitivity to fludarabine and ibrutinib. However, gain-of-function assay showed increased cell proliferation and cell chemotaxis. In addition, OTSSP167 treatment reduced phosphorylation of AKT and ERK1/2. It decreased FoxM1 phosphorylation, expression of FoxM1, cyclin B1 and CDK1, while up-regulating p53 and p21 expression. Taken together, MELK served as a candidate of therapeutic target in CLL. OTSSP167 exhibits potent anti-tumor activities in CLL cells, highlighting a novel molecule-based strategy for leukemic interventions.	[Zhang, Ya; Zhou, Xiangxiang; Li, Ying; Xu, Yangyang; Lu, Kang; Li, Peipei; Wang, Xin] Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Wang, Xin] Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University	Wang, X (corresponding author), Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.; Wang, X (corresponding author), Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China.	xinw@sdu.edu.cn			National Natural Science Foundation [81270598, 81473486, 81770210]; Key Research and Development Program of Shandong Province [2018CXGC1213, 2016GSF201029]; Natural Science Foundation of Shandong Province [ZR2012HZ003]; Technology Development Projects of Shandong Province [2014GSF118021]; Program of Shandong Medical Leading Talent; Taishan Scholar Foundation of Shandong Province	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Technology Development Projects of Shandong Province; Program of Shandong Medical Leading Talent; Taishan Scholar Foundation of Shandong Province	This study was partly supported by: National Natural Science Foundation (No. 81270598, No. 81473486, No. 81770210), Key Research and Development Program of Shandong Province (No. 2018CXGC1213, No. 2016GSF201029), Natural Science Foundation of Shandong Province (No. ZR2012HZ003), Technology Development Projects of Shandong Province (No. 2014GSF118021), Program of Shandong Medical Leading Talent, and Taishan Scholar Foundation of Shandong Province.	Alachkar H, 2014, ONCOTARGET, V5, P12371, DOI 10.18632/oncotarget.2642; Beke L, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150194; Bolomsky A, 2018, HAEMATOLOGICA, V103, P325, DOI 10.3324/haematol.2017.172973; Buchner M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7471; Choi S, 2011, BIOCHEM BIOPH RES CO, V412, P207, DOI 10.1016/j.bbrc.2011.07.060; Chuang HY, 2012, BLOOD, V120, P2639, DOI 10.1182/blood-2012-03-416461; Chung S, 2016, ONCOTARGET, V7, P18171, DOI 10.18632/oncotarget.7685; Chung SY, 2012, ONCOTARGET, V3, P1629; Ciccone M, 2014, CANCER CELL, V26, P770, DOI 10.1016/j.ccell.2014.10.020; Cui J, 2016, ONCOGENE, V35, P4708, DOI 10.1038/onc.2016.14; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; Du T, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-100; Ghia P, 2016, LANCET ONCOL, V17, P1342, DOI 10.1016/S1470-2045(16)30442-9; Giuliano CJ, 2018, ELIFE, V7, DOI 10.7554/eLife.32838; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hasegawa K, 2018, J IMMUNOTHER, V41, P201, DOI 10.1097/CJI.0000000000000214; Herold T, 2011, LEUKEMIA, V25, P1639, DOI 10.1038/leu.2011.125; Herold T, 2013, LEUKEMIA LYMPHOMA, V54, P1652, DOI 10.3109/10428194.2012.753445; Hiwatashi K, 2016, ANTICANCER RES, V36, P5183, DOI 10.21873/anticanres.11088; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang HT, 2017, ELIFE, V6, DOI 10.7554/eLife.26693; Inoue H, 2016, ONCOTARGET, V7, P13621, DOI 10.18632/oncotarget.7297; Janostiak R, 2017, CELL REP, V21, P2829, DOI 10.1016/j.celrep.2017.11.033; Ji WB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153518; Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358; Jurmeister S, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708274; Kaur V, 2017, ANN HEMATOL, V96, P1175, DOI 10.1007/s00277-017-2973-2; Khan I, 2017, LEUKEMIA, V31, P251, DOI 10.1038/leu.2016.270; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Kohler RS, 2017, GYNECOL ONCOL, V145, P159, DOI 10.1016/j.ygyno.2017.02.016; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Komarova NL, 2014, P NATL ACAD SCI USA, V111, P13906, DOI 10.1073/pnas.1409362111; Krishnan A, 2017, J CELL BIOCHEM, V118, P797, DOI 10.1002/jcb.25754; Kwok CTD, 2016, STEM CELL RES, V16, P651, DOI 10.1016/j.scr.2016.03.007; Lenz G, 2017, J CLIN ONCOL, V35, P1451, DOI 10.1200/JCO.2016.72.0102; Li PP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0479-5; Li S, 2016, ONCOTARGET, V7, P6266, DOI 10.18632/oncotarget.6673; Lin A, 2017, ELIFE, V6, DOI 10.7554/eLife.24179; Liu Y, 2015, NEOPLASMA, V62, P61, DOI 10.4149/neo_2015_008; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Lu K, 2015, CANCER LETT, V359, P250, DOI 10.1016/j.canlet.2015.01.021; Lu K, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-55; Matsuda T, 2017, ONCOTARGET, V8, P57938, DOI 10.18632/oncotarget.18488; Mertens D, 2017, BLOOD, V129, P1407, DOI 10.1182/blood-2017-01-761536; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motiwala T, 2015, LEUKEMIA, V29, P1350, DOI 10.1038/leu.2014.341; Mraz M, 2014, BLOOD, V124, P84, DOI 10.1182/blood-2013-09-527234; Nilsson D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001037; Parikh SA, 2016, SEMIN ONCOL, V43, P233, DOI 10.1053/j.seminoncol.2016.02.009; Pickard MR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2350; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Simon M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172832; Speers C, 2016, CLIN CANCER RES, V22, P5864, DOI 10.1158/1078-0432.CCR-15-2711; Stefka AT, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.71; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051277; Svirnovski A. I., 2010, Experimental Oncology, V32, P258; Trojani A, 2012, CANCER BIOMARK, V11, P15, DOI 10.3233/CBM-2012-0259; Wang K, 2016, ACTA BIOCH BIOPH SIN, V48, P804, DOI 10.1093/abbs/gmw072; Wang YB, 2014, ELIFE, V3, DOI 10.7554/eLife.01763; Wiestner A, 2015, HAEMATOLOGICA, V100, P1495, DOI 10.3324/haematol.2014.119123; Xia HP, 2016, CANCER LETT, V383, P85, DOI 10.1016/j.canlet.2016.09.017; Zhou XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0391-5	69	31	31	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5520	5533		10.1038/s41388-018-0333-x	http://dx.doi.org/10.1038/s41388-018-0333-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29895969				2022-12-28	WOS:000446991200004
J	Dong, PX; Xiong, Y; Yu, JH; Chen, L; Tao, T; Yi, S; Hanley, SJB; Yue, JM; Watari, H; Sakuragi, N				Dong, Peixin; Xiong, Ying; Yu, Jiehai; Chen, Lin; Tao, Tang; Yi, Song; Hanley, Sharon J. B.; Yue, Junming; Watari, Hidemichi; Sakuragi, Noriaki			Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; MESENCHYMAL TRANSITION; BETA-CATENIN; IFN-GAMMA; INVASION; B7-H1; PROGRESSION; METASTASIS; REVERSES; TARGET	PD-L1, a key inhibitory immune receptor, has crucial functions in cancer immune evasion, but whether PD-L1 promotes the malignant properties of cervical cancer (CC) cells and the mechanism by which PD-L1 is regulated in CC remains unclear. We report that PD-L1 is overexpressed in CC, and shRNA-mediated PD-L1 depletion suppresses the proliferation, invasion, and tumorigenesis of CC cells. Loss of miR-140/142/340/383 contributes to PD-L1 upregulation. miR-18a enhances PD-L1 levels by targeting PTEN, WNK2 (ERK1/2 pathway inhibitor), and SOX6 (Wnt/beta-catenin pathway inhibitor and p53 pathway activator) to activate the PI3K/AKT, MEK/ERK, and Wnt/beta-catenin pathways and inhibit the p53 pathway, and miR-18a also directly suppresses the expression of the tumor suppressors BTG3 and RBSP3 (CTDSPL). miR-18a overexpression in CC cells is triggered by OCT4 overexpression. Our data implicate PD-L1 as a novel oncoprotein and indicate that miR-140/142/340/383 and miR-18a are key upstream regulators of PD-L1 and potential targets for CC treatment.	[Dong, Peixin; Hanley, Sharon J. B.; Sakuragi, Noriaki] Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan; [Dong, Peixin; Watari, Hidemichi] Hokkaido Univ, Dept Obstet & Gynecol, Sch Med, Sapporo, Hokkaido 0608638, Japan; [Xiong, Ying; Yu, Jiehai; Chen, Lin] Sun Yat Sen Univ, Dept Gynecol, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Tao, Tang; Yi, Song] Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; [Yue, Junming] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Yue, Junming] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA	Hokkaido University; Hokkaido University; State Key Lab Oncology South China; Sun Yat Sen University; Chinese University of Hong Kong; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Dong, PX (corresponding author), Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan.; Dong, PX; Watari, H (corresponding author), Hokkaido Univ, Dept Obstet & Gynecol, Sch Med, Sapporo, Hokkaido 0608638, Japan.; Yue, JM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA.; Yue, JM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA.	dpx1cn@gmail.com; jyue@uthsc.edu; watarih@med.hokudai.ac.jp	Dong, Peixin/M-5592-2015	Dong, Peixin/0000-0002-2335-1394	Department of Women's Health Educational System; JSPS [15K10697, 16K11123]; Science and Technology Planning Project of Guangdong Province, China [2014A020212124]	Department of Women's Health Educational System; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Science and Technology Planning Project of Guangdong Province, China	This research was supported by a grant from the Department of Women's Health Educational System, JSPS Grant-in-Aid for Scientific Research (C) (15K10697 and 16K11123) and the Science and Technology Planning Project of Guangdong Province, China (2014A020212124). We thank Dr. Zhujie Xu for experimental assistance.	Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Anand M, 2011, HAEMATOL-HEMATOL J, V96, P253, DOI 10.3324/haematol.2010.027086; Cai YH, 2014, CELL SIGNAL, V26, P1204, DOI 10.1016/j.cellsig.2014.02.013; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen LJ, 2017, CELL PHYSIOL BIOCHEM, V42, P2267, DOI 10.1159/000480000; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Deng JH, 2017, MOL MED REP, V15, P1654, DOI 10.3892/mmr.2017.6180; Dong PX, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0415-y; Dong PX, 2016, ONCOTARGET, V7, P20260, DOI 10.18632/oncotarget.7754; Fang F, 2014, INT J CLIN EXP PATHO, V7, P6447; Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10; Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325; Guo W, 2015, TUMOR BIOL, V36, P9049, DOI 10.1007/s13277-015-3644-3; He J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10019; Heong V, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e20; Huo WY, 2017, J CANCER, V8, P57, DOI 10.7150/jca.16723; Ihira K, 2017, ONCOTARGET, V8, P13509, DOI 10.18632/oncotarget.14586; Jiang DQ, 2017, ONCOTARGET, V8, P4001, DOI 10.18632/oncotarget.13136; Konno Y, 2014, ONCOTARGET, V5, P6049, DOI 10.18632/oncotarget.2157; Kramer HB, 2016, NUCLEIC ACIDS RES, V44, P582, DOI 10.1093/nar/gkv948; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Li J, 2017, CELL PHYSIOL BIOCHEM, V41, P907, DOI [10.1159/00460504, 10.1159/000460504]; Liang XJ, 2014, J LEUKOCYTE BIOL, V95, P179, DOI 10.1189/jlb.0613330; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mezache L, 2015, MODERN PATHOL, V28, P1594, DOI 10.1038/modpathol.2015.108; Mitra S, 2010, GENE CHROMOSOME CANC, V49, P155, DOI 10.1002/gcc.20726; Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Noh KH, 2009, MOL THER, V17, P439, DOI 10.1038/mt.2008.255; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Ribeiro J, 2014, MOL BIOL REP, V41, P1525, DOI 10.1007/s11033-013-2998-0; Ryan BC, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1057-y; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song X, 2014, ONCOL REP, V31, P1191, DOI 10.3892/or.2013.2955; Su S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20070; Su YL, 2016, ONCOTARGET, V7, P68397, DOI 10.18632/oncotarget.11722; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wang YH, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/687535; Wilting SM, 2013, ONCOGENE, V32, P106, DOI 10.1038/onc.2012.20; Xiong Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0520-6; Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Zheng Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.211	49	77	81	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5257	5268		10.1038/s41388-018-0347-4	http://dx.doi.org/10.1038/s41388-018-0347-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855617	hybrid, Green Published			2022-12-28	WOS:000445759700001
J	Bechard, ME; Word, AE; Tran, AV; Liu, XJ; Locasale, JW; McDonald, OG				Bechard, Matthew E.; Word, Anna E.; Tran, Amanda V.; Liu, Xiaojing; Locasale, Jason W.; McDonald, Oliver G.			Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases	ONCOGENE			English	Article							ANABOLIC GLUCOSE-METABOLISM; RAS-TRANSFORMED CELLS; PROMOTE TUMOR-GROWTH; 6-PHOSPHOGLUCONATE DEHYDROGENASE; DUCTAL ADENOCARCINOMA; PHOSPHATE PATHWAY; KRAS; PATTERNS; PROTEIN; BIOSYNTHESIS	Pancreatic ductal adenocarcinoma (PDAC) adopts several unique metabolic strategies to support primary tumor growth. Whether additional metabolic strategies are adopted to support metastatic tumorigenesis is less clear. This could be particularly relevant for distant metastasis, which often follows a rapidly progressive clinical course. Here we report that PDAC distant metastases evolve a unique series of metabolic reactions to maintain activation of the anabolic glucose enzyme phosphogluconate dehydrogenase (PGD). PGD catalytic activity was recurrently elevated across distant metastases, and modulating PGD activity levels dictated tumorigenic capacity. Metabolomics data raised the possibility that distant metastases evolved a core pentose conversion pathway (PCP) that converted glucose-derived metabolites into PGD substrate, thereby hyperactivating the enzyme. Consistent with this, each individual metabolite in the PCP stimulated PGD catalysis in distant metastases, and knockdown of each individual PCP enzyme selectively impaired tumorigenesis. We propose that the PCP manufactures PGD substrate outside of the rate-limiting oxidative pentose phosphate pathway (oxPPP). This enables PGD-dependent tumorigenesis by providing adequate substrate to fuel high catalytic activity, and raises the possibility that PDAC distant metastases adopt their own unique metabolic strategies to support tumor growth.	[Bechard, Matthew E.; Word, Anna E.; Tran, Amanda V.; McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Word, Anna E.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Duke Mol Physiol Inst, Durham, NC USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Epithelial Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Duke University; Duke University; Duke University; Vanderbilt University; Vanderbilt University	McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.; McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Epithelial Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.; McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.	oliver.g.mcdonald@vanderbilt.edu	Locasale, Jason W/ABE-6505-2020	Locasale, Jason W/0000-0002-7766-3502; Word, Anna/0000-0002-6088-1781; Liu, Xiaojing/0000-0002-4231-6017	AACR Pancreatic Cancer Action Network Pathway to Leadership grant; Vanderbilt GI SPORE; Vanderbilt Digestive Diseases Research Center; NATIONAL CANCER INSTITUTE [R01CA222594] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021630, S10OD018164] Funding Source: NIH RePORTER	AACR Pancreatic Cancer Action Network Pathway to Leadership grant; Vanderbilt GI SPORE; Vanderbilt Digestive Diseases Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the AACR Pancreatic Cancer Action Network Pathway to Leadership grant (OGM), the Vanderbilt GI SPORE (OGM), and the Vanderbilt Digestive Diseases Research Center (OGM).	Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Carter H, 2010, CANCER BIOL THER, V10, P582, DOI 10.4161/cbt.10.6.12537; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Davidson SM, 2017, NAT MED, V23, P235, DOI 10.1038/nm.4256; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DYSON JED, 1971, BIOCHEM BIOPH RES CO, V43, P183, DOI 10.1016/S0006-291X(71)80104-3; Egger S, 2010, BIOCHEM SOC T, V38, P1378, DOI 10.1042/BST0381378; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hanau S, 2013, BBA-PROTEINS PROTEOM, V1834, P2647, DOI 10.1016/j.bbapap.2013.09.018; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Qiu WL, 2011, ONCOTARGET, V2, P862; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Rippa M, 1998, BBA-PROTEIN STRUCT M, V1429, P83, DOI 10.1016/S0167-4838(98)00222-2; Rohatgi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098760; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shan CL, 2014, MOL CELL, V55, P552, DOI 10.1016/j.molcel.2014.06.020; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yao PB, 2017, J BIOL CHEM, V292, P17113, DOI 10.1074/jbc.M117.810309; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhong Y, 2017, CLIN CANCER RES, V23, P1607, DOI 10.1158/1078-0432.CCR-15-1615	54	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5248	5256		10.1038/s41388-018-0346-5	http://dx.doi.org/10.1038/s41388-018-0346-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849117	Green Accepted			2022-12-28	WOS:000445093100008
J	Baker, A; Wyatt, D; Bocchetta, M; Li, J; Filipovic, A; Green, A; Peiffer, DS; Fuqua, S; Miele, L; Albain, KS; Osipo, C				Baker, Andrew; Wyatt, Debra; Bocchetta, Maurizio; Li, Jun; Filipovic, Aleksandra; Green, Andrew; Peiffer, Daniel S.; Fuqua, Suzanne; Miele, Lucio; Albain, Kathy S.; Osipo, Clodia			Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+breast cancer cell proliferation and stem cell survival	ONCOGENE			English	Article							BREAST-CANCER; TRASTUZUMAB RESISTANCE; TENSIN HOMOLOG; CHROMOSOME-10 PTEN; GENE-EXPRESSION; PI3K PATHWAY; CYCLIN D1; NOTCH; ACTIVATION; RECEPTOR	Trastuzumab targets the HER2 receptor on breast cancer cells to attenuate HER2-driven tumor growth. However, resistance to trastuzumab-based therapy remains a major clinical problem for women with HER2+ breast cancer. Breast cancer stem cells (BCSCs) are suggested to be responsible for drug resistance and tumor recurrence. Notch signaling has been shown to promote BCSC survival and self-renewal. Trastuzumab-resistant cells have increased Notch-1 expression. Notch signaling drives cell proliferation in vitro and is required for tumor recurrence in vivo. We demonstrate herein a mechanism by which Notch-1 is required for trastuzumab resistance by repressing PTEN expression to contribute to activation of ERK1/2 signaling. Furthermore, Notch-1-mediated inhibition of PTEN is necessary for BCSC survival in vitro and in vivo. Inhibition of MEK1/2-ERK1/2 signaling in trastuzumab-resistant breast cancer cells mimics effects of Notch-1 knockdown on bulk cell proliferation and BCSC survival. These findings suggest that Notch-1 contributes to trastuzumab resistance by repressing PTEN and this may lead to hyperactivation of ERK1/2 signaling. Furthermore, high Notch-1 and low PTEN mRNA expression may predict poorer overall survival in women with breast cancer. Notch-1 protein expression predicts poorer survival in women with HER2+ breast cancer. These results support a potential future clinical trial combining anti-Notch-1 and anti-MEK/ERK therapy for trastuzumab-resistant breast cancer.	[Baker, Andrew; Peiffer, Daniel S.] Loyola Univ Chicago, Stritch Sch Med, Integrated Cell Biol Program, Maywood, IL 60153 USA; [Wyatt, Debra; Bocchetta, Maurizio; Osipo, Clodia] Loyola Univ Chicago, Stritch Sch Med, Oncol Res Inst, Maywood, IL 60153 USA; [Bocchetta, Maurizio] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA; [Li, Jun] Univ Notre Dame, Dept Appl & Computat Math & Stat, Notre Dame, IN 46556 USA; [Filipovic, Aleksandra] Imperial Coll London, London, England; [Green, Andrew] Univ Nottingham, Nottingham, England; [Peiffer, Daniel S.] Loyola Univ Chicago, Stritch Sch Med, MD PhD Program, Maywood, IL 60153 USA; [Fuqua, Suzanne] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Miele, Lucio] Louisiana State Univ, Dept Genet, New Orleans, LA 70112 USA; [Miele, Lucio] Louisiana State Univ, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL 60153 USA; [Osipo, Clodia] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; University of Notre Dame; Imperial College London; University of Nottingham; Loyola University Chicago; Baylor College of Medicine; Louisiana State University System; Louisiana State University System; Loyola University Chicago; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Oncol Res Inst, Maywood, IL 60153 USA.; Osipo, C (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.	cosipo@luc.edu	Li, Jun/C-3269-2015; Green, Andrew/AAF-1991-2020	Li, Jun/0000-0003-4353-5761; Green, Andrew/0000-0002-0488-5913; Miele, Lucio/0000-0002-5853-7287; Osipo, Clodia/0000-0003-1979-8465	American Cancer Society; Breast Cancer Research Foundation	American Cancer Society(American Cancer Society); Breast Cancer Research Foundation	This work was supported by the American Cancer Society (RSG-11-181-01-TBE) awarded to Dr. Clodia Osipo, the Arthur J. Schmitt Fellowship to Dr. Andrew Baker, and in part by the Breast Cancer Research Foundation to Drs. Kathy Albain and Clodia Osipo. We thank Ianina Bognini for assistance during animal studies.	Adachi R, 2011, BIOCHEM BIOPH RES CO, V411, P804, DOI 10.1016/j.bbrc.2011.07.033; Baker AT, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00360; Baldacchino S, 2014, EPMA J, V5, DOI 10.1186/1878-5085-5-3; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2; Chetram MA, 2012, J RECEPT SIG TRANSD, V32, P190, DOI 10.3109/10799893.2012.695798; Chu D, 2011, ANN ONCOL, V22, P2440, DOI 10.1093/annonc/mdq776; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Cohen B, 2010, BREAST CANCER RES TR, V123, P113, DOI 10.1007/s10549-009-0621-9; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Angelo RC, 2015, MOL CANCER THER, V14, P779, DOI 10.1158/1535-7163.MCT-14-0228; Das S, 2015, J BIOL CHEM, V290, P21705, DOI 10.1074/jbc.M115.655563; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Du C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-869; Ebbesen SH, 2016, P NATL ACAD SCI USA, V113, P3030, DOI 10.1073/pnas.1523693113; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Katoh M, 2007, INT J ONCOL, V31, P461; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Kopan R., 2012, COLD SPRING HARB PER, V4, P1; Loibl S, 2016, CLIN CANCER RES, V22, P2675, DOI 10.1158/1078-0432.CCR-15-0965; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218; Mao J, 2013, INT J BIOCHEM CELL B, V45, P1064, DOI 10.1016/j.biocel.2013.02.022; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Mittal S, 2014, MOL CANCER THER, V13, P3198, DOI 10.1158/1535-7163.MCT-14-0280; Mittal S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-128; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nunes J, 2016, ONCOTARGET, V7, P27599, DOI 10.18632/oncotarget.8504; O'Regan RM, 1998, JNCI-J NATL CANCER I, V90, P1552, DOI 10.1093/jnci/90.20.1552; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pandya K, 2011, BRIT J CANCER, V105, P796, DOI 10.1038/bjc.2011.321; Pandya K, 2016, CLIN CANCER RES, V22, P175, DOI 10.1158/1078-0432.CCR-15-0179; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Persson LM, 2010, J VIROL, V84, P1334, DOI 10.1128/JVI.01301-09; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stern HM, 2015, CLIN CANCER RES, V21, P2065, DOI 10.1158/1078-0432.CCR-14-2993; Thery JC, 2014, EUR J CANCER, V50, P892, DOI 10.1016/j.ejca.2014.01.003; Untch M, 2011, J CLIN ONCOL, V29, P3351, DOI 10.1200/JCO.2010.31.4930; Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475; WACHSMAN W, 1987, SCIENCE, V235, P674, DOI 10.1126/science.3027894; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Yakes FM, 2002, CANCER RES, V62, P4132; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yun J, 2015, J CELL PHYSIOL, V230, P3115, DOI 10.1002/jcp.25052	73	60	66	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4489	4504		10.1038/s41388-018-0251-y	http://dx.doi.org/10.1038/s41388-018-0251-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743588	Green Submitted, Green Accepted			2022-12-28	WOS:000441736700001
J	Guo, H; Zhao, LM; Shi, BH; Bao, JY; Zheng, DX; Zhou, BG; Shi, J				Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Zhou, Baoguo; Shi, Juan			GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90	ONCOGENE			English	Article							LONG NONCODING RNAS; 3' UNTRANSLATED REGIONS; HEAT-SHOCK PROTEINS; B-KINASE IKK; HISTONE METHYLTRANSFERASE; TRANSLATIONAL CONTROL; EXPRESSION; CELLS; HEAT-SHOCK-PROTEIN-90; PROLIFERATION	Recently, long noncoding RNAs (lncRNAs) have been reported to play a pivotal role in the occurrence and progression of cancer because of their unique characteristics and have therefore become an active area of cancer research. The object of this study was to screen lncRNAs that are dysregulated in gastric cancer and to investigate their potential functions. Global expression of lncRNAs in gastric cancer and adjacent normal tissues of patients was profiled using a microarray assay. We identified an lncRNA (GALNT5 uaRNA, UTR-associated RNA) that is derived from the 3'-UTR of GALNT5. This lncRNA was transcribed independently of the coding region of GALNT5 and was determined to be markedly upregulated in human gastric carcinoma relative to their corresponding normal gastric tissues by quantitative RT-PCR (qRT-PCR) analysis of tissues from 122 gastric carcinoma patients. The expression of GALNT5 uaRNA was significantly correlated with the TNM stage and with lymph node metastasis. Further results demonstrated that GALNT5 uaRNA facilitated the proliferation and migration of gastric cancer cells in vitro and promoted tumor growth in a mouse model of human gastric cancer. Our results also indicated that GALNT5 uaRNA might function in gastric cancer by binding with HSP90. Further studies indicated that the 5'-end stem-loop motifs of GALNT5 uaRNA promoted the binding of HSP90 and its client proteins, and thus inhibited ubiquitination of the clients. These results expanded our understanding of GALNT5 uaRNA as a new avenue for therapeutic intervention against gastric cancer progression.	[Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Shi, Juan] Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; [Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Shi, Juan] Peking Union Med Coll, Beijing 100005, Peoples R China; [Zhao, Lianmei] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang 050011, Hebei, Peoples R China; [Zhou, Baoguo] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Hebei Medical University; Harbin Medical University	Shi, J (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.; Shi, J (corresponding author), Peking Union Med Coll, Beijing 100005, Peoples R China.; Zhou, BG (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China.	zhoubaoguo@msn.com; shijuantt@163.com		Zheng, Dexian/0000-0003-3966-1212; bao, jiayu/0000-0001-9476-3225; Guo, Hui/0000-0003-3901-6336	Natural Science Foundation of China [81572755, 81372200]; CAMS Initiative for Innovative Medicine (CAMS-I2M) [2016-I2M-1-001]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine (CAMS-I2M)	This work was partially supported by the Natural Science Foundation of China (Grant No. 81572755, 81372200 to J. Shi), CAMS Initiative for Innovative Medicine (CAMS-I2M Grant No. 2016-I2M-1-001to J. Shi).	Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Bishop SC, 2007, CURR CANCER DRUG TAR, V7, P369, DOI 10.2174/156800907780809778; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Cao JN, 2014, BIOL PROCED ONLINE, V16, DOI 10.1186/1480-9222-16-11; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Frith MC, 2005, EUR J HUM GENET, V13, P894, DOI 10.1038/sj.ejhg.5201459; Furuno M, 2006, PLOS GENET, V2, P537, DOI 10.1371/journal.pgen.0020037; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamm CA, 2015, PHARMACOL THERAPEUT, V151, P72, DOI 10.1016/j.pharmthera.2015.03.003; He H, 2014, BRIT J CANCER, V110, P2021, DOI 10.1038/bjc.2014.93; Khurana N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00100; Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Mayer MP, 2015, MOL CELL, V58, P8, DOI 10.1016/j.molcel.2015.02.022; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Mercer TR, 2010, GENOME RES, V20, P1639, DOI 10.1101/gr.112128.110; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109; Rodrigues TC, 2014, FUTURE ONCOL, V10, P2449, DOI 10.2217/fon.14.149; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Tsutsumi S, 2007, CANCER SCI, V98, P1536, DOI 10.1111/j.1349-7006.2007.00561.x; Vahid S, 2017, RECENT PAT ANTI-CANC, V12, P35, DOI 10.2174/1574892811666161102125252; Zhao L, 2016, ONCOGENE, V35, P5770, DOI 10.1038/onc.2016.110; Zhou CC, 2016, HEPATOLOGY, V63, P850, DOI 10.1002/hep.28393	40	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4505	4517		10.1038/s41388-018-0266-4	http://dx.doi.org/10.1038/s41388-018-0266-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743591				2022-12-28	WOS:000441736700002
J	Ahirwar, DK; Nasser, MW; Ouseph, MM; Elbaz, M; Cuitino, MC; Kladney, RD; Varikuti, S; Kaul, K; Satoskar, AR; Ramaswamy, B; Zhang, XL; Ostrowski, MC; Leone, G; Ganju, RK				Ahirwar, Dinesh K.; Nasser, Mohd W.; Ouseph, Madhu M.; Elbaz, Mohamad; Cuitino, Maria C.; Kladney, Raleigh D.; Varikuti, Sanjay; Kaul, Kirti; Satoskar, Abhay R.; Ramaswamy, Bhuvaneswari; Zhang, Xiaoli; Ostrowski, Michael C.; Leone, Gustavo; Ganju, Ramesh K.			Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation	ONCOGENE			English	Article							ENDOTHELIAL PROGENITOR CELLS; TIGHT JUNCTIONS; UP-REGULATION; ANGIOGENESIS; GROWTH; EXPRESSION; ADHERENS	The chemokine CXCL12 has been shown to regulate breast tumor growth, however, its mechanism in initiating distant metastasis is not well understood. Here, we generated a novel conditional allele of Cxcl12 in mice and used a fibroblast-specific Cre transgene along with various mammary tumor models to evaluate CXCL12 function in the breast cancer metastasis. Ablation of CXCL12 in stromal fibroblasts of mice significantly delayed the time to tumor onset and inhibited distant metastasis in different mouse models. Elucidation of mechanisms using in vitro and in vivo model systems revealed that CXCL12 enhances tumor cell intravasation by increasing vascular permeability and expansion of a leaky tumor vasculature. Furthermore, our studies revealed CXCL12 enhances permeability by recruiting endothelial precursor cells and decreasing endothelial tight junction and adherence junction proteins. High expression of stromal CXCL12 in large cohort of breast cancer patients was directly correlated to blood vessel density and inversely correlated to recurrence and overall patient survival. In addition, our analysis revealed that stromal CXCL12 levels in combination with number of CD31+ blood vessels confers poorer patient survival compared to individual protein level. However, no correlation was observed between epithelial CXCL12 and patient survival or blood vessel density. Our findings describe the novel interactions between fibroblasts-derived CXCL12 and endothelial cells in facilitating tumor cell intrvasation, leading to distant metastasis. Overall, our studies indicate that cross-talk between fibroblast-derived CXCL12 and endothelial cells could be used as novel biomarker and strategy for developing tumor microenvironment based therapies against aggressive and metastatic breast cancer.	[Ahirwar, Dinesh K.; Nasser, Mohd W.; Elbaz, Mohamad; Varikuti, Sanjay; Kaul, Kirti; Satoskar, Abhay R.; Ganju, Ramesh K.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Ouseph, Madhu M.; Cuitino, Maria C.; Kladney, Raleigh D.; Ostrowski, Michael C.; Leone, Gustavo] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Kladney, Raleigh D.; Ramaswamy, Bhuvaneswari; Ostrowski, Michael C.; Leone, Gustavo; Ganju, Ramesh K.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Ramaswamy, Bhuvaneswari] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Zhang, Xiaoli] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ganju, RK (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.; Leone, G (corresponding author), Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA.; Leone, G; Ganju, RK (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.	gustavo.leone@osumc.edu; ramesh.ganju@osumc.edu	Nasser, Mohd/Y-3355-2019; Satoskar, Abhay/AAB-7748-2019; Ahirwar, Dinesh Kumar/CAG-3809-2022; Ostrowski, Michael C/H-3108-2011; Ouseph, Madhu/B-8940-2009	Ouseph, Madhu/0000-0002-3422-1675; Ahirwar, Dinesh/0000-0002-0518-7156	Pelotonia Idea award; Department of Defense level II breakthrough awards; NIH R01 grants [CA109527, CA153490]; Pelotonia Postdoctoral award; NATIONAL CANCER INSTITUTE [R01CA153490, R01CA109527, P01CA097189] Funding Source: NIH RePORTER	Pelotonia Idea award; Department of Defense level II breakthrough awards; NIH R01 grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pelotonia Postdoctoral award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to Reham S. Shehab, Sanjit Roy, Chan Fu, Mohamed Adel, and Nitika Agarwal for technical assistance. This work is supported in part by Pelotonia Idea award, Department of Defense level II breakthrough awards, and NIH R01 grants (CA109527 and CA153490) to RKG. DKA was recipient of Pelotonia Postdoctoral award.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Egeblad M, 2008, DIS MODEL MECH, V1, P155, DOI 10.1242/dmm.000596; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hillmer RE, 2015, INT J DEV BIOL, V59, P205, DOI 10.1387/ijdb.140348mj; Ivins S, 2015, DEV CELL, V33, P455, DOI 10.1016/j.devcel.2015.03.026; Li BY, 2015, J INTERF CYTOK RES, V35, P23, DOI 10.1089/jir.2014.0004; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Martins-Green M, 2008, METHOD ENZYMOL, V443, P137, DOI 10.1016/S0076-6879(08)02008-9; McLean AC, 2012, JOVE-J VIS EXP, DOI 10.3791/4389; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Punglia RS, 2007, NEW ENGL J MED, V356, P2399, DOI 10.1056/NEJMra065241; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Smolkova B, 2016, TRANSL ONCOL, V9, P184, DOI 10.1016/j.tranon.2016.03.004; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tan J, 2014, ONCOGENE, V33, P4050, DOI 10.1038/onc.2013.434; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016; Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xu X, 2013, CELLS TISSUES ORGANS, V197, P103, DOI 10.1159/000342921; Yu PF, 2017, ONCOGENE, V36, P840, DOI 10.1038/onc.2016.252	36	68	76	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4428	4442		10.1038/s41388-018-0263-7	http://dx.doi.org/10.1038/s41388-018-0263-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720724	Green Accepted			2022-12-28	WOS:000441144300007
J	Reyes-Uribe, P; Adrianzen-Ruesta, MP; Deng, Z; Echevarria-Vargas, I; Mender, I; Saheb, S; Liu, Q; Altieri, DC; Murphy, ME; Shay, JW; Lieberman, PM; Villanueva, J				Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong; Echevarria-Vargas, Ileabett; Mender, Ilgen; Saheb, Steven; Liu, Qin; Altieri, Dario C.; Murphy, Maureen E.; Shay, Jerry W.; Lieberman, Paul M.; Villanueva, Jessie			Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma	ONCOGENE			English	Article							TELOMERASE REVERSE-TRANSCRIPTASE; INHIBITOR IMETELSTAT; DNA-DAMAGE; PROMOTER MUTATIONS; RESISTANCE; CANCER; CELLS; INDUCTION; ACTIVATION; PATHWAYS	Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there are no clinical agents available to effectively target NRAS or any other RAS oncogene. An alternative approach is to identify and target critical tumor vulnerabilities or non-oncogene addictions that are essential for tumor survival. We investigated the consequences of NRAS blockade in NRAS-mutant melanoma and show that decreased expression of the telomerase catalytic subunit, TERT, is a major consequence. TERT silencing or treatment of NRAS-mutant melanoma with the telomerase-dependent telomere uncapping agent, 6-thio-2'-deoxyguanosine (6-thio-dG), led to rapid cell death, along with evidence of both telomeric and non-telomeric DNA damage, increased ROS levels, and upregulation of a mitochondrial antioxidant adaptive response. Combining 6-thio-dG with the mitochondrial inhibitor Gamitrinib attenuated this adaptive response and more effectively suppressed NRAS-mutant melanoma. Our study uncovers a robust dependency of NRAS-mutant melanoma on TERT, and provides proof-of-principle for a new combination strategy to combat this class of tumors, which could be expanded to other tumor types.	[Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Echevarria-Vargas, Ileabett; Saheb, Steven; Liu, Qin; Murphy, Maureen E.; Villanueva, Jessie] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Deng, Zhong; Lieberman, Paul M.] Wistar Inst Anat & Biol, Gene Express & Regulat Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Mender, Ilgen; Shay, Jerry W.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Villanueva, Jessie] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; The Wistar Institute; The Wistar Institute	Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.; Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	jvillanueva@wistar.org		MENDER, ILGEN/0000-0002-7552-2618; Liu, Qin/0000-0001-9964-580X	NIH [R01CA215733, K01CA175269, P01CA114046, P50CA174523]; American Cancer Society; V Foundation for Cancer Research; Melanoma Research Alliance; Melanoma Research Foundation; Martha Rogers Trust; NCI NRSA Cancer Biology Training Grant [T32 CA009171]; Worldwide Cancer Research [15-0338]; Pennsylvania Department of Health; Cancer Center Support Grant (CCSG) [P30CA010815]; NATIONAL CANCER INSTITUTE [R01CA139319, R35CA220446, T32CA009171, P01CA025874, P30CA010815, K01CA175269, R01CA140652, P50CA174523, P01CA140043, P01CA114046, R01CA215733] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); V Foundation for Cancer Research; Melanoma Research Alliance; Melanoma Research Foundation; Martha Rogers Trust; NCI NRSA Cancer Biology Training Grant; Worldwide Cancer Research; Pennsylvania Department of Health; Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in our laboratory is supported by NIH grants R01CA215733, K01CA175269, P01CA114046, P50CA174523, the American Cancer Society, the V Foundation for Cancer Research, the Melanoma Research Alliance, the Melanoma Research Foundation, and the Martha Rogers Trust. IEV was supported by NCI NRSA T32 CA009171 Cancer Biology Training Grant to the Wistar Institute, and Z.D. is supported by Worldwide Cancer Research (15-0338). This project was funded, in part, under a grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. Support for shared resources utilized in this study was provided by Cancer Center Support Grant (CCSG) P30CA010815 to the Wistar Institute.	Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479; Bagheri S, 2006, P NATL ACAD SCI USA, V103, P11306, DOI 10.1073/pnas.0510085103; Bryan C, 2015, STRUCTURE, V23, P1934, DOI 10.1016/j.str.2015.08.006; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755-148X.2011.00836.x; Fleisig HB, 2016, ONCOGENE, V35, P218, DOI 10.1038/onc.2015.75; Garcia-Beccaria M, 2015, EMBO MOL MED, V7, P930, DOI 10.15252/emmm.201404497; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Gupta R, 2014, P NATL ACAD SCI USA, V111, pE3062, DOI 10.1073/pnas.1411370111; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Santos JH, 2006, HUM MOL GENET, V15, P1757, DOI 10.1093/hmg/ddl098; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Hrdlickova R, 2012, MOL CELL BIOL, V32, P4283, DOI 10.1128/MCB.00550-12; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Johnson DB, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0330-z; Johnson DB, 2014, CLIN CANCER RES, V20, P4186, DOI 10.1158/1078-0432.CCR-13-3270; Joseph I, 2010, CANCER RES, V70, P9494, DOI 10.1158/0008-5472.CAN-10-0233; Kang BH, 2010, CLIN CANCER RES, V16, P4779, DOI 10.1158/1078-0432.CCR-10-1818; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kovalenko OA, 2010, AGING CELL, V9, P203, DOI 10.1111/j.1474-9726.2010.00551.x; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Li YH, 2014, CANCER RES, V74, P1639, DOI 10.1158/0008-5472.CAN-13-3568; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mender I, 2015, BIO PROTOC, V5; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625; Nosrati M, 2004, CLIN CANCER RES, V10, P4983, DOI 10.1158/1078-0432.CCR-04-0134; Olmos Y, 2009, J BIOL CHEM, V284, P14476, DOI 10.1074/jbc.M807397200; Postow MA, 2017, LANCET ONCOL, V18, P414, DOI 10.1016/S1470-2045(17)30172-9; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Queisser A, 2013, CANCER GENET-NY, V206, P374, DOI 10.1016/j.cancergen.2013.10.001; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Sharma NK, 2012, NUCLEIC ACIDS RES, V40, P712, DOI 10.1093/nar/gkr758; Shay JW, 2016, CANCER DISCOV, V6, P584, DOI 10.1158/2159-8290.CD-16-0062; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Viceconte N, 2017, CELL REP, V19, P2529, DOI 10.1016/j.celrep.2017.05.046; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wong DJL, 2016, CANCER TREAT RES, V167, P251, DOI 10.1007/978-3-319-22539-5_10; Zhang G, 2016, J CLIN INVEST, V126, P1834, DOI 10.1172/JCI82661	62	31	32	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4058	4072		10.1038/s41388-018-0247-7	http://dx.doi.org/10.1038/s41388-018-0247-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29695835	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000439847000002
J	Castejon-Grinan, M; Herraiz, C; Olivares, C; Jimenez-Cervantes, C; Garcia-Borron, JC				Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose			cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage	ONCOGENE			English	Article							DOUBLE-STRAND BREAK; NUCLEOTIDE EXCISION-REPAIR; RED HAIR; HUMAN MELANOCYTES; ULTRAVIOLET-RADIATION; FUNCTIONAL-ANALYSIS; CUTANEOUS MELANOMA; FUNCTION MUTATIONS; SIGNALING PATHWAY; CANCER-THERAPY	The melanocortin 1 receptor gene (MC1R), a well-established melanoma susceptibility gene, regulates the amount and type of melanin pigments formed within epidermal melanocytes. MC1R variants associated with increased melanoma risk promote the production of photosensitizing pheomelanins as opposed to photoprotective eumelanins. Wild-type (WT) MC1R activates DNA repair and antioxidant defenses in a cAMP-dependent fashion. Since melanoma-associated MC1R variants are hypomorphic in cAMP signaling, these non-pigmentary actions are thought to be defective in MC1R-variant human melanoma cells and epidermal melanocytes, consistent with a higher mutation load in MC1R-variant melanomas. We compared induction of antioxidant enzymes and DNA damage responses in melanocytic cells of defined MC1R genotype. Increased expression of catalase (CAT) and superoxide dismutase (SOD) genes following MC1R activation was cAMP-dependent and required a WT MC1R genotype. Conversely, pretreatment of melanocytic cells with an MC1R agonist before an oxidative challenge with Luperox decreased (i) accumulation of 8-oxo-7,8-dihydro-2'-deoxyguanine, a major product of oxidative DNA damage, (ii) phosphorylation of histone H2AX, a marker of DNA double-strand breaks, and (iii) formation of DNA breaks. These responses were comparable in cells WT for MC1R or harboring hypomorphic MC1R variants without detectable cAMP signaling. In MC1R-variant melanocytic cells, the DNA-protective responses were mediated by AKT. Conversely, in MC1R-WT melanocytic cells, high cAMP production downstream of MC1R blocked AKT activation and was responsible for inducing DNA repair. Accordingly, MC1R activation could promote repair of oxidative DNA damage by a cAMP-dependent pathway downstream of WT receptor, or via AKT in cells of variant MC1R genotype.	[Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose] Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain; [Castejon-Grinan, Maria; Herraiz, Cecilia; Olivares, Conchi; Jimenez-Cervantes, Celia; Carlos Garcia-Borron, Jose] IMIB, Murcia, Spain	University of Murcia	Herraiz, C (corresponding author), Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain.; Herraiz, C (corresponding author), IMIB, Murcia, Spain.	ceciliahs@um.es	Garcia-Borron, Jose Carlos/H-2247-2015; Castejón Griñán, María/AAC-8557-2022; Serrano, Cecilia Herraiz/H-2550-2015; Jimenez-Cervantes, Celia/H-1953-2015; Olivares, Conchi/H-2794-2015	Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Castejón Griñán, María/0000-0003-4494-3986; Serrano, Cecilia Herraiz/0000-0001-6912-0738; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Olivares, Conchi/0000-0001-7518-3858	MINECO (Spain) [SAF2015-67092-R]; FEDER (European Community); Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM) [19875/GERM/15]; Fundacion Seneca	MINECO (Spain); FEDER (European Community)(European Commission); Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM); Fundacion Seneca(Fundacion Seneca)	Supported by grants SAF2015-67092-R from MINECO (Spain) and FEDER (European Community) and 19875/GERM/15 from Fundacion Seneca, Comunidad Autonoma de la Region de Murcia (CARM). M Castejon holds a pre-doctoral fellowship from the Fundacion Seneca. Cecilia Herraiz was a Juan de la Cierva-Incorporacion fellow of MINECO. We thank Prof. G Ghanem, from the Free University of Brussels for gift of human melanoma cell lines and Prof. Neptuno Rodriguez (University of Murcia) for Hermes melanocytes. We also thank Prof. JL Castejon for help with the statistical analysis of data, Dr. M Abrisqueta for assistance in cell cycle analysis and Dr. A Lopez-Contreras for suggestions and critical reading of the manuscript.	Abdel-Malek ZA, 2014, ARCH BIOCHEM BIOPHYS, V563, P4, DOI 10.1016/j.abb.2014.07.002; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Altieri F, 2008, ANTIOXID REDOX SIGN, V10, P891, DOI 10.1089/ars.2007.1830; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Beaumont KA, 2007, HUM MOL GENET, V16, P2249, DOI 10.1093/hmg/ddm177; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cadet J, 2015, PHOTOCHEM PHOTOBIOL, V91, P140, DOI 10.1111/php.12368; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Garcia-Borron JC, 2014, EXP DERMATOL, V23, P387, DOI 10.1111/exd.12310; CHEDEKEL MR, 1978, P NATL ACAD SCI USA, V75, P5395, DOI 10.1073/pnas.75.11.5395; Cho EA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-36; Cohen-Armon M, 2007, TRENDS PHARMACOL SCI, V28, P556, DOI 10.1016/j.tips.2007.08.005; d'Ischia M, 2015, PIGM CELL MELANOMA R, V28, P520, DOI 10.1111/pcmr.12393; Robles-Espinoza CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12064; Davies JR, 2012, PIGM CELL MELANOMA R, V25, P384, DOI 10.1111/j.1755-148X.2012.00982.x; Dessinioti C, 2011, PHOTOCHEM PHOTOBIOL, V87, P978, DOI 10.1111/j.1751-1097.2011.00970.x; Fajuyigbe D, 2016, PIGM CELL MELANOMA R, V29, P607, DOI 10.1111/pcmr.12511; FELIX CC, 1978, BIOCHEM BIOPH RES CO, V84, P335, DOI 10.1016/0006-291X(78)90175-4; Frandberg PA, 1998, BIOCHEM BIOPH RES CO, V245, P490, DOI 10.1006/bbrc.1998.8459; Garcia-Borron JC, 2014, PIGM CELL MELANOMA R, V27, P699, DOI 10.1111/pcmr.12257; Gerstenblith MR, 2007, HUM MUTAT, V28, P495, DOI 10.1002/humu.20476; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Habib SL, 2016, CELL CYCLE, V15, P3048, DOI 10.1080/15384101.2016.1231259; Hawkins AJ, 2011, RADIOTHER ONCOL, V101, P13, DOI 10.1016/j.radonc.2011.05.074; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Herraiz C, 2017, BBA-MOL BASIS DIS, V1863, P2448, DOI 10.1016/j.bbadis.2017.02.027; Herraiz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144757; Herraiz C, 2012, INT J BIOCHEM CELL B, V44, P2244, DOI 10.1016/j.biocel.2012.09.008; Herraiz C, 2011, MOL ENDOCRINOL, V25, P138, DOI 10.1210/me.2010-0217; Herraiz C, 2009, FEBS LETT, V583, P3269, DOI 10.1016/j.febslet.2009.09.023; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horrell EMW, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00095; Hustedt N, 2017, NAT CELL BIOL, V19, P1, DOI 10.1038/ncb3452; Ito S, 2003, PIGM CELL RES, V16, P523, DOI 10.1034/j.1600-0749.2003.00072.x; Janjetovic Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01305-2; Jarrett SG, 2016, NUCLEIC ACIDS RES, V44, P10711, DOI 10.1093/nar/gkw871; Jarrett SG, 2017, PIGM CELL MELANOMA R, V30, P284, DOI 10.1111/pcmr.12582; Jo H, 2012, P NATL ACAD SCI USA, V109, P10581, DOI 10.1073/pnas.1202810109; Johansson PA, 2017, PIGM CELL MELANOMA R, V30, P255, DOI 10.1111/pcmr.12571; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kadekaro AL, 2012, MOL CANCER RES, V10, P778, DOI 10.1158/1541-7786.MCR-11-0436; Kadekaro AL, 2010, FASEB J, V24, P3850, DOI 10.1096/fj.10-158485; Khaled M, 2002, J BIOL CHEM, V277, P33690, DOI 10.1074/jbc.M202939200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Liu Q, 2014, NEURO-ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Luo Z, 2009, BRIT J PHARMACOL, V157, P935, DOI 10.1111/j.1476-5381.2009.00259.x; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maresca V, 2010, PIGM CELL MELANOMA R, V23, P263, DOI 10.1111/j.1755-148X.2010.00673.x; MEDRANO EE, 1995, CANCER RES, V55, P4047; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Monaghan RM, 2015, NAT CELL BIOL, V17, P782, DOI 10.1038/ncb3170; Musante V, 2017, ELIFE, V6, DOI 10.7554/eLife.24998; Nakayama K, 2006, HUM GENET, V119, P322, DOI 10.1007/s00439-006-0141-1; Napolitano A, 2014, PIGM CELL MELANOMA R, V27, P721, DOI 10.1111/pcmr.12262; Newton RA, 2005, PEPTIDES, V26, P1818, DOI 10.1016/j.peptides.2004.11.031; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Pan YD, 2018, EXP NEUROL, V300, P149, DOI 10.1016/j.expneurol.2017.10.030; Panzella L, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12199; Oliva ABP, 2009, HUM MUTAT, V30, P811, DOI 10.1002/humu.20971; Piao MJ, 2011, TOXICOL LETT, V207, P143, DOI 10.1016/j.toxlet.2011.09.002; Podhorecka M., 2010, J NUCL ACIDS, V2010, P1, DOI DOI 10.4061/2010/920161; Ringholm A, 2004, J INVEST DERMATOL, V123, P917, DOI 10.1111/j.0022-202X.2004.23444.x; Roberts DW, 2008, J CELL PHYSIOL, V215, P344, DOI 10.1002/jcp.21318; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Scherer D, 2010, MUTAT RES-REV MUTAT, V705, P141, DOI 10.1016/j.mrrev.2010.06.002; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Scott MC, 2002, J CELL SCI, V115, P2349; Shahzad M, 2015, PIGM CELL MELANOMA R, V28, P730, DOI 10.1111/pcmr.12400; Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y; Singh P, 2016, FEBS LETT, V590, P3071, DOI 10.1002/1873-3468.12377; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Song XZ, 2009, PIGM CELL MELANOMA R, V22, P809, DOI 10.1111/j.1755-148X.2009.00615.x; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Wei F, 2011, CURR MED CHEM, V18, P5476, DOI 10.2174/092986711798194388; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yang JL, 2016, THERANOSTICS, V6, P2015, DOI 10.7150/thno.15993; Zanna PT, 2008, BIOCHEM BIOPH RES CO, V368, P211, DOI 10.1016/j.bbrc.2008.01.060; Zhang TW, 2016, PIGM CELL MELANOMA R, V29, P266, DOI 10.1111/pcmr.12459	87	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3631	3646		10.1038/s41388-018-0216-1	http://dx.doi.org/10.1038/s41388-018-0216-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622793				2022-12-28	WOS:000437975200002
J	Debernardi, J; Hollville, E; Lipinski, M; Wiels, J; Robert, A				Debernardi, Justine; Hollville, Emilie; Lipinski, Marc; Wiels, Joelle; Robert, Aude			Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt's lymphoma cells	ONCOGENE			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CYTOCHROME-C; SHIGA TOXINS; HELA-CELLS; IN-VITRO; BAX; ACTIVATION; CRISTAE; GLOBOTRIAOSYLCERAMIDE; IDENTIFICATION	The globotriaosylceramide Gb3 is a glycosphingolipid expressed on a subpopulation of germinal center B lymphocytes which has been recognized as the B cell differentiation antigen CD77. Among tumoral cell types, Gb3/CD77 is strongly expressed in Burkitt's lymphoma (BL) cells as well as other solid tumors including breast, testicular and ovarian carcinomas. One known ligand of Gb3/CD77 is Verotoxin-1 (VT-1), a Shiga toxin produced in specific E. coli strains. Previously, we have reported that in BL cells, VT-1 induces apoptosis via a caspase-dependent and mitochondria-dependent pathway. Yet, the respective roles of various apoptogenic factors remained to be deciphered. Here, this apoptotic pathway was found to require cleavage of the BID protein by caspase-8 as well as activation of two other apoptogenic proteins, BAK and BAX. Surprisingly however, t-BID, the truncated form of BID resulting from caspase-8 cleavage, played no role in the conformational changes of BAK and BAX. Rather, their activation occurred under the control of full length BID (FL-BID). Indeed, introducing a non-cleavable form of BID (BID-D59A) into BID-deficient BL cells restored BAK and BAX activation following VT-1 treatment. Still, t-BID was involved along with FL-BID in the BAK-dependent and BAX-dependent cytosolic release of CYT C and SMAC/DIABLO from the mitochondrial intermembrane space: FL-BID was found to control the homo-oligomerization of both BAK and BAX, likely contributing to the initial release of CYT C and SMAC/DIABLO, while t-BID was needed for their hetero-oligomerization and ensuing release amplification. Together, our results reveal a functional cooperation between BAK and BAX during VT-1-induced apoptosis and, unexpectedly, that activation of caspase-8 and production of t-BID were not mandatory for initiation of the cell death process.	[Debernardi, Justine; Hollville, Emilie; Lipinski, Marc; Wiels, Joelle; Robert, Aude] Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Gustave Roussy,UMR 8126, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Wiels, J (corresponding author), Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Gustave Roussy,UMR 8126, F-94805 Villejuif, France.	joelle.wiels@gustaveroussy.fr	robert, aude/F-9584-2015; Hollville, Emilie/ABD-4798-2021; Hollville, Emilie/AAA-3597-2022; Hollville, Emilie/GQZ-8301-2022; Wiels, Joëlle/AGL-2319-2022	robert, aude/0000-0003-3095-4190; Hollville, Emilie/0000-0001-5711-8542; Wiels, Joëlle/0000-0002-3313-2937	Fondation de France [2014 00047509]; Ligue National Contre le Cancer; Fondation ARC	Fondation de France(Fondation de France); Ligue National Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC	We thank Yann Lecluse (Imaging and Cytometry Platform, Institut Gustave Roussy) for expert technical assistance in performing flow cytometry analyses. We are very grateful to Hana Raslova and Julie Riviere (INSERM UMR 1170, Institut Gustave-Roussy) for their help in producing lentivirus and to Evelyne May and Martine Raphael (UMR 8126 CNRS) for helpful discussions and suggestions. This work was supported by grants from the Fondation de France 2014 00047509 (JW), the Ligue National Contre le Cancer (doctoral fellowship to JD) and the Fondation ARC (doctoral fellowship to EH).	Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Arab S, 1997, ONCOL RES, V9, P553; Bergan J, 2012, TOXICON, V60, P1085, DOI 10.1016/j.toxicon.2012.07.016; Cabon L, 2012, CELL DEATH DIFFER, V19, P245, DOI 10.1038/cdd.2011.91; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Ching JCY, 2002, INFECT IMMUN, V70, P4669, DOI 10.1128/IAI.70.8.4669-4677.2002; Cullen SP, 2007, J CELL BIOL, V176, P435, DOI 10.1083/jcb.200612025; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Fujii J, 2003, INFECT IMMUN, V71, P2724, DOI 10.1128/IAI.71.5.2724-2735.2003; Garibal J, 2010, CELL SIGNAL, V22, P467, DOI 10.1016/j.cellsig.2009.10.018; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Grosse L, 2016, EMBO J, V35, P402, DOI 10.15252/embj.201592789; Gupta V, 2012, J BIOL CHEM, V287, P37195, DOI 10.1074/jbc.M112.396390; Iyer S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11734; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Johannes L, 2010, NAT REV MICROBIOL, V8, P105, DOI 10.1038/nrmicro2279; Karch J, 2013, ELIFE, V2, DOI 10.7554/eLife.00772; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Konig HG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-7; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee SY, 2005, INFECT IMMUN, V73, P5115, DOI 10.1128/IAI.73.8.5115-5126.2005; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OHYAMA C, 1990, INT J CANCER, V45, P1040, DOI 10.1002/ijc.2910450610; Pei YH, 2007, APOPTOSIS, V12, P1681, DOI 10.1007/s10495-007-0091-7; Raemy E, 2016, CELL DEATH DIFFER, V23, P1165, DOI 10.1038/cdd.2015.166; Renault TT, 2014, CHEM BIOL, V21, P114, DOI 10.1016/j.chembiol.2013.10.009; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Salvador-Gallego R, 2016, EMBO J, V35, P389, DOI 10.15252/embj.201593384; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706; Tesh VL, 2012, CELL MICROBIOL, V14, P1, DOI 10.1111/j.1462-5822.2011.01684.x; Tesh VL, 2010, FUTURE MICROBIOL, V5, P431, DOI 10.2217/FMB.10.4; Tetaud C, 2003, J BIOL CHEM, V278, P45200, DOI 10.1074/jbc.M303868200; Todt F, 2015, EMBO J, V34, P67, DOI 10.15252/embj.201488806; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Zheng JH, 2016, FEBS J, V283, P2690, DOI 10.1111/febs.13527	42	10	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2410	2421		10.1038/s41388-018-0123-5	http://dx.doi.org/10.1038/s41388-018-0123-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29440708	Green Published, hybrid			2022-12-28	WOS:000431386000005
J	von Muhlinen, N; Horikawa, I; Alam, F; Isogaya, K; Lissa, D; Vojtesek, B; Lane, DP; Harris, CC				von Muhlinen, Natalia; Horikawa, Izumi; Alam, Fatima; Isogaya, Kazunobu; Lissa, Delphine; Vojtesek, Borek; Lane, David P.; Harris, Curtis C.			p53 isoforms regulate premature aging in human cells	ONCOGENE			English	Article							DNA-DAMAGE RESPONSES; DEFECTIVE MATURATION; GENOMIC INSTABILITY; PROGERIA SYNDROMES; DOWN-REGULATION; SENESCENCE; RAD51; PROMOTES; PRELAMIN; ACCUMULATION	Cellular senescence is a hallmark of normal aging and aging-related syndromes, including the premature aging disorder Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder caused by a single mutation in the LMNA gene that results in the constitutive expression of a truncated splicing mutant of lamin A known as progerin. Progerin accumulation leads to increased cellular stresses including unrepaired DNA damage, activation of the p53 signaling pathway and accelerated senescence. We previously established that the p53 isoforms Delta 133p53 and p53 beta regulate senescence in normal human cells. However, their role in premature aging is unknown. Here we report that p53 isoforms are expressed in primary fibroblasts derived from HGPS patients, are associated with their accelerated senescence and that their manipulation can restore the replication capacity of HGPS fibroblasts. We found that in near-senescent HGPS fibroblasts, which exhibit low levels of Delta 133p53 and high levels of p53 beta, restoration of Delta 133p53 expression was sufficient to extend replicative lifespan and delay senescence, despite progerin levels and abnormal nuclear morphology remaining unchanged. Conversely, Delta 133p53 depletion or p53 beta overexpression accelerated the onset of senescence in otherwise proliferative HGPS fibroblasts. Our data indicate that Delta 133p53 exerts its role by modulating full-length p53 (FLp53) signaling to extend the replicative lifespan and promotes the repair of spontaneous progerin-induced DNA double-strand breaks (DSBs). We showed that Delta 133p53 dominant-negative inhibition of FLp53 occurs directly at the p21/CDKN1A and miR-34a promoters, two p53 senescence-associated genes. In addition, Delta 133p53 expression increased the expression of DNA repair RAD51, likely through upregulation of E2F1, a transcription factor that activates RAD51, to promote repair of DSBs. In summary, our data indicate that Delta 133p53 modulates p53 signaling to repress progerin-induced early onset of senescence in HGPS cells. Therefore, restoration of Delta 133p53 expression may be a novel therapeutic strategy to treat aging-associated phenotypes of HGPS in vivo.	[von Muhlinen, Natalia; Horikawa, Izumi; Alam, Fatima; Isogaya, Kazunobu; Lissa, Delphine; Harris, Curtis C.] NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA; [Vojtesek, Borek] Masaryk Mem Canc Inst, Reg Ctr Appl & Mol Oncol, Brno, Czech Republic; [Lane, David P.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Masaryk Memorial Cancer Institute; Karolinska Institutet	Harris, CC (corresponding author), NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA.	harrisc@mail.nih.gov	Ponce, Richard/A-3109-2017	Ponce, Richard/0000-0001-5077-8417; Lane, David/0000-0003-0551-3545	National Cancer Institute, National Institutes of Health; Czech Science Foundation [P206/12/G151];  [MEYS - NPS I - LO1413]; NATIONAL CANCER INSTITUTE [ZIABC011496] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Czech Science Foundation(Grant Agency of the Czech Republic); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Cancer Institute, National Institutes of Health. B.V. was supported with project from Czech Science Foundation P206/12/G151 and project MEYS - NPS I - LO1413.	ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Burtner CR, 2010, NAT REV MOL CELL BIO, V11, P567, DOI 10.1038/nrm2944; Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gong L, 2015, CELL RES, V25, P351, DOI 10.1038/cr.2015.22; Gonzalo S, 2015, CURR OPIN CELL BIOL, V34, P75, DOI 10.1016/j.ceb.2015.05.007; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hennekam RCM, 2006, AM J MED GENET A, V140A, P2603, DOI 10.1002/ajmg.a.31346; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Horikawa I, 2017, CELL DEATH DIFFER, V24, P1017, DOI 10.1038/cdd.2017.48; Horikawa I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5706; Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kubben N, 2016, CELL, V165, P1361, DOI 10.1016/j.cell.2016.05.017; Kudlow BA, 2007, NAT REV MOL CELL BIO, V8, P394, DOI 10.1038/nrm2161; Linke SP, 2003, CANCER RES, V63, P2596; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Liu Y, 2008, FASEB J, V22, P603, DOI 10.1096/fj.07-8598com; Liu YY, 2006, J CELL SCI, V119, P4644, DOI 10.1242/jcs.03263; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Maki CG, 1996, CANCER RES, V56, P2649; Malhas AN, 2009, J CELL BIOL, V184, P45, DOI 10.1083/jcb.200804155; McCord RP, 2013, GENOME RES, V23, P260, DOI 10.1101/gr.138032.112; Merideth MA, 2008, NEW ENGL J MED, V358, P592, DOI 10.1056/NEJMoa0706898; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mondal AM, 2013, J CLIN INVEST, V123, P5247, DOI 10.1172/JCI70355; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Musich PR, 2011, BIOCHEM SOC T, V39, P1764, DOI 10.1042/BST20110687; Musich PR, 2009, AGING-US, V1, P28, DOI 10.18632/aging.100012; Olive M, 2010, ARTERIOSCL THROM VAS, V30, P2301, DOI 10.1161/ATVBAHA.110.209460; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Pereira S, 2008, MECH AGEING DEV, V129, P449, DOI 10.1016/j.mad.2008.04.003; Ragnauth CD, 2010, CIRCULATION, V121, P2200, DOI 10.1161/CIRCULATIONAHA.109.902056; Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103; Soria-Valles C, 2015, NAT CELL BIOL, V17, P1004, DOI 10.1038/ncb3207; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288; Turnquist C, 2016, CELL DEATH DIFFER, V23, P1515, DOI 10.1038/cdd.2016.37; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Vidak S, 2015, GENE DEV, V29, P2022, DOI 10.1101/gad.263939.115; Wei JX, 2012, P NATL ACAD SCI USA, V109, pE2543, DOI 10.1073/pnas.1205664109; Wu MH, 2014, MOL PHARMACOL, V85, P866, DOI 10.1124/mol.113.090688; Yanez RJ, 1999, GENE THER, V6, P1282, DOI 10.1038/sj.gt.3300945; Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE2261, DOI 10.1073/pnas.1320843111	60	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2379	2393		10.1038/s41388-017-0101-3	http://dx.doi.org/10.1038/s41388-017-0101-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429991	Green Accepted			2022-12-28	WOS:000431386000003
J	Solomon, H; Dinowitz, N; Pateras, IS; Cooks, T; Shetzer, Y; Molchadsky, A; Charni, M; Rabani, S; Koifman, G; Tarcic, O; Porat, Z; Kogan-Sakin, I; Goldfinger, N; Oren, M; Harris, CC; Gorgoulis, VG; Rotter, V				Solomon, Hilla; Dinowitz, Nathan; Pateras, Ioannis S.; Cooks, Tomer; Shetzer, Yoav; Molchadsky, Alina; Charni, Meital; Rabani, Stav; Koifman, Gabriela; Tarcic, Ohad; Porat, Ziv; Kogan-Sakin, Ira; Goldfinger, Naomi; Oren, Moshe; Harris, Curtis C.; Gorgoulis, Vassilis G.; Rotter, Varda			Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers	ONCOGENE			English	Article							INFLAMMATION; ACTIVATION; HALLMARKS; PARADIGM; CULTURE; CRYPT	Emerging notion in carcinogenesis ascribes tumor initiation and aggressiveness to cancer stem cells (CSCs). Specifically, colorectal cancer (CRC) development was shown to be compatible with CSCs hypothesis. Mutations in p53 are highly frequent in CRC, and are known to facilitate tumor development and aggressiveness. Yet, the link between mutant p53 and colorectal CSCs is not well-established. In the present study, we set to examine whether oncogenic mutant p53 proteins may augment colorectal CSCs phenotype. By genetic manipulation of mutant p53 in several cellular systems, we demonstrated that mutant p53 enhances colorectal tumorigenesis. Moreover, mutant p53-expressing cell lines harbor larger sub-populations of cells highly expressing the known colorectal CSCs markers: CD44, Lgr5, and ALDH. This elevated expression is mediated by mutant p53 binding to CD44, Lgr5, and ALDH1A1 promoter sequences. Furthermore, ALDH1 was found to be involved in mutant p53-dependent chemotherapy resistance. Finally, analysis of ALDH1 and CD44 in human CRC biopsies indicated a positive correlation between their expression and the presence of oncogenic p53 missense mutations. These findings suggest novel insights pertaining the mechanism by which mutant p53 enhances CRC development, which involves the expansion of CSCs sub-populations within CRC tumors, and underscore the importance of targeting these sub-populations for CRC therapy.	[Solomon, Hilla; Dinowitz, Nathan; Shetzer, Yoav; Molchadsky, Alina; Charni, Meital; Rabani, Stav; Koifman, Gabriela; Tarcic, Ohad; Kogan-Sakin, Ira; Goldfinger, Naomi; Oren, Moshe; Rotter, Varda] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Pateras, Ioannis S.; Gorgoulis, Vassilis G.] Univ Athens, Sch Med, Dept Histol Embryol, Mol Carcinogenesis Grp, Athens, Greece; [Cooks, Tomer; Harris, Curtis C.] NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA; [Porat, Ziv] Weizmann Inst Sci, Life Sci Fac, Flow Cytometry Unit, Rehovot, Israel	Weizmann Institute of Science; Athens Medical School; National & Kapodistrian University of Athens; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.	varda.rotter@weizmann.ac.il	Porat, Ziv/K-1672-2012; Ponce, Richard/A-3109-2017; Gorgoulis, Vassilis/AAD-3630-2019	Porat, Ziv/0000-0003-3059-181X; Ponce, Richard/0000-0001-5077-8417; Gorgoulis, Vassilis/0000-0001-9001-4112; koifman, gabriela/0000-0002-7728-5214; Cooks, Tomer/0000-0003-0853-3437; Charni-Natan, Meital/0000-0003-0221-1664; Oren, Moshe/0000-0003-4311-7172	Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI); Israel Science Foundation ISF-MOKED; Philip Garoon grant; NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC011496] Funding Source: NIH RePORTER	Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI); Israel Science Foundation ISF-MOKED; Philip Garoon grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Dr. Ori Brenner for tumor histology analysis, to Dr. Ayala Sharp and Eitan Ariel for their help with the FACS experiments and to Dr. Tamar Unger for cloning consultation. This research was supported by a Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI), Israel Science Foundation ISF-MOKED and Philip Garoon grant. V.R. is the incumbent of the Norman and Helen Asher Professorial Chair for Cancer Research at the Weizmann Institute.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Aloni-Grinstein R, 2014, FEBS LETT, V588, P2580, DOI 10.1016/j.febslet.2014.02.011; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cammareri P, 2008, METHOD CELL BIOL, V86, P311, DOI 10.1016/S0091-679X(08)00014-9; Charni M, 2016, CELL DEATH DIFFER, V23, P509, DOI 10.1038/cdd.2015.119; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767; Di Fiore R, 2014, BONE, V60, P198, DOI 10.1016/j.bone.2013.12.021; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Milyavsky M, 2003, CANCER RES, V63, P7147; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Molchadsky A, 2017, CARCINOGENESIS, V38, P347, DOI 10.1093/carcin/bgw092; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sarig R, 2010, J EXP MED, V207, P2127, DOI 10.1084/jem.20100797; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shetzer Y, 2014, CELL DEATH DIFFER, V21, P1419, DOI 10.1038/cdd.2014.57; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Solomon H, 2012, J CELL SCI, V125, P3144, DOI 10.1242/jcs.099663; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Zeilstra J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072849; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	45	57	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1669	1684		10.1038/s41388-017-0060-8	http://dx.doi.org/10.1038/s41388-017-0060-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29343849	hybrid, Green Accepted			2022-12-28	WOS:000428626700009
J	Xiang, SS; Wang, Z; Ye, YY; Zhang, F; Li, HF; Yang, Y; Miao, HJ; Liang, HB; Zhang, YJ; Jiang, L; Hu, YP; Zheng, L; Liu, XY; Liu, YB				Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Zheng, Lei; Liu, Xiyong; Liu, Yingbin			E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; KARYOPHERIN ALPHA-2; CELL-PROLIFERATION; PROGNOSTIC MARKER; FAMILY-MEMBERS; DNA-DAMAGE; PROTEIN; DP-1; IDENTIFICATION; LOCALIZATION	Karyopherin alpha 2 (KPNA2) is a nuclear import factor that is elevated in multiple cancers. However, its molecular regulation at the transcriptional levels is poorly understood. Here we found that KPNA2 was significantly upregulated in gallbladder cancer (GBC), and the increased levels were correlated with short survival of patients. Gene knocking down of KPNA2 inhibited tumor cell proliferation and migration in vitro as well as xenografted tumor development in vivo. A typical transcription factor E2F1 associated with its DNA-binding partner DP1 bond to the promoter region of KPNA2 and induced KPNA2 expression. In contrast, an atypical transcription factor E2F7 competed against DP1 and blocked E2F1-induced KPNA2 gene activation. Mutation of the dimerization residues of E2F7 or DNA-binding domain of E2F1 abolished the suppressive effects of E2F7 on KPNA2 gene expression. In addition, KPNA2 mediated nuclear localization of E2F1 and E2F7, where they in turn controlled KPNA2 expression. Taken together, our data provided mechanistic insights into divergently transcriptional regulation of KPNA2, thus pointing to KPNA2 as a potential target for cancer therapy.	[Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Key Lab Biliary Tract Dis Res, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Xiang, Shanshan; Wang, Zheng; Ye, Yuanyuan; Zhang, Fei; Li, Huaifeng; Yang, Yang; Miao, Huijie; Liang, Haibin; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Liu, Yingbin] Shanghai Res Ctr Biliary Tract Dis, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Zheng, Lei] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Liu, Xiyong] City Hope Comprehens Canc Ctr, Dept Mol Pharmacol, Duarte, CA USA	Shanghai Jiao Tong University; Johns Hopkins University; City of Hope	Liu, YB (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.; Liu, YB (corresponding author), Shanghai Key Lab Biliary Tract Dis Res, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.; Liu, YB (corresponding author), Shanghai Res Ctr Biliary Tract Dis, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	liuyingbin@xinhuamed.com.cn	LIU, YING/GZL-7252-2022; Liu, Yingbin/AAI-1919-2020	Liu, Yingbin/0000-0001-6110-0185	Shanghai Key Laboratory of Biliary Tract Disease Research Foundation [17DZ2260200]; National Natural Science Foundation of China [91440203, 31620103910, 31601021, 81773043]; Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine [15ZH4003, DKY201507]; development fund for Shanghai talents [201608]	Shanghai Key Laboratory of Biliary Tract Disease Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine; development fund for Shanghai talents	This study was supported by Shanghai Key Laboratory of Biliary Tract Disease Research Foundation (17DZ2260200), the National Natural Science Foundation of China (No. 91440203, 31620103910, 31601021, 81773043), the development fund for Shanghai talents (No. 201608), and the Precision Medicine Research Program of Shanghai Jiao Tong University School of Medicine (No. 15ZH4003, DKY201507). We sincerely thank Professor Shao Rong from Shanghai Jiao Tong University School of Medicine for substantially editing the manuscript and offering constructive suggestions; and A.M. Sieuwerts from Erasmus MC, Dong Qiongzhu from Fudan University for the help.	Alshareeda AT, 2015, BRIT J CANCER, V112, P1929, DOI 10.1038/bjc.2015.165; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Chen CX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000912; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Endo-Munoz L, 2009, CANCER RES, V69, P1800, DOI 10.1158/0008-5472.CAN-08-2725; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hu ZY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0061-1; Huang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.256; Ishida H, 2005, J BIOL CHEM, V280, P24642, DOI 10.1074/jbc.M500189200; Kanthan R, 2015, J ONCOL, V2015, DOI 10.1155/2015/967472; Korah J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.146; Lammens T, 2009, TRENDS CELL BIOL, V19, P111, DOI 10.1016/j.tcb.2009.01.002; Lee BK, 2011, NUCLEIC ACIDS RES, V39, P3558, DOI 10.1093/nar/gkq1313; Lee EK, 2010, NAT STRUCT MOL BIOL, V17, P732, DOI 10.1038/nsmb.1815; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Li ML, 2017, CANCER LETT, V391, P20, DOI 10.1016/j.canlet.2016.12.027; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Liang HB, 2017, CELL PHYSIOL BIOCHEM, V41, P2117, DOI 10.1159/000475454; Lin WC, 2001, GENE DEV, V15, P1833; Liu BY, 2013, J BIOL CHEM, V288, P24581, DOI 10.1074/jbc.M113.467506; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Moon NS, 2005, DEV CELL, V9, P463, DOI 10.1016/j.devcel.2005.08.015; Sakai M, 2010, ANTICANCER RES, V30, P851; Shu YJ, 2017, CELL DEATH DIFFER, V24, P445, DOI 10.1038/cdd.2016.146; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tseng SF, 2005, J BIOL CHEM, V280, P39594, DOI 10.1074/jbc.M508425200; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang CI, 2012, MOL CELL PROTEOMICS, V11, P1105, DOI 10.1074/mcp.M111.016592; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wu XS, 2017, EMBO REP, V18, P1837, DOI 10.15252/embr.201744147; Ye YY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0444-x; Zannini L, 2003, J BIOL CHEM, V278, P42346, DOI 10.1074/jbc.M303304200; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X	44	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1269	1281		10.1038/s41388-018-0494-7	http://dx.doi.org/10.1038/s41388-018-0494-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254209				2022-12-28	WOS:000459249800009
J	Zhou, CF; Ma, J; Huang, L; Yi, HY; Zhang, YM; Wu, XG; Yan, RM; Liang, L; Zhong, M; Yu, YH; Wu, S; Wang, W				Zhou, Chen-Fei; Ma, Jing; Huang, Lei; Yi, Hong-Yan; Zhang, Yan-Mei; Wu, Xiang-Guang; Yan, Rui-Ming; Liang, Li; Zhong, Mei; Yu, Yan-Hong; Wu, Sha; Wang, Wei			Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1	ONCOGENE			English	Article							TUMOR LYMPHANGIOGENESIS; MESENCHYMAL TRANSITION; CANCER METASTASIS; EXPRESSION; INVASION; PROLIFERATION; GROWTH; ANGIOGENESIS; ENDOTHELIUM; RECURRENCE	Cancer-secreted exosomal miRNAs are emerging mediators of cancer-stromal cross-talk in the tumor environment. Our previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identified upregulation of miR-221-3p. Here, we show that miR-221-3p is closely correlated with peritumoral lymphangiogenesis and lymph node (LN) metastasis in CSCC. More importantly, miR-221-3p is characteristically enriched in and transferred by CSCC-secreted exosomes into human lymphatic endothelial cells (HLECs) to promote HLECs migration and tube formation in vitro, and facilitate lymphangiogenesis and LN metastasis in vivo according to both gain-of-function and loss-of-function experiments. Furthermore, we identify vasohibin-1 (VASH1) as a novel direct target of miR-221-3p through bioinformatic target prediction and luciferase reporter assay. Re-expression and knockdown of VASH1 could respectively rescue and simulate the effects induced by exosomal miR-221-3p. Importantly, the miR-221-3p-VASH1 axis activates the ERK/AKT pathway in HLECs independent of VEGF-C. Finally, circulating exosomal miR-221-3p levels also have biological function in promoting HLECs sprouting in vitro and are closely associated with tumor miR-221-3p expression, lymphatic VASH1 expression, lymphangiogenesis, and LN metastasis in CSCC patients. In conclusion, CSCC-secreted exosomal miR-221-3p transfers into HLECs to promote lymphangiogenesis and lymphatic metastasis via downregulation of VASH1 and may represent a novel diagnostic biomarker and therapeutic target for metastatic CSCC patients in early stages.	[Zhou, Chen-Fei; Ma, Jing; Wu, Xiang-Guang; Wang, Wei] Guangzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China; [Zhou, Chen-Fei; Ma, Jing; Yi, Hong-Yan; Yan, Rui-Ming; Zhong, Mei; Yu, Yan-Hong; Wang, Wei] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Sch Clin Med 1, Guangzhou 510515, Guangdong, Peoples R China; [Huang, Lei] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Zhang, Yan-Mei; Wu, Sha] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangdong Prov Key Lab Prote, Guangzhou 510515, Guangdong, Peoples R China; [Liang, Li] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China	Guangzhou Medical University; Southern Medical University - China; Newcastle University - UK; Southern Medical University - China; Southern Medical University - China	Wang, W (corresponding author), Guangzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China.; Wang, W (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Sch Clin Med 1, Guangzhou 510515, Guangdong, Peoples R China.; Wu, S (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangdong Prov Key Lab Prote, Guangzhou 510515, Guangdong, Peoples R China.	shawu99@outlook.com; smugowwang@126.com	Yu, Yan/GYV-4514-2022; Wu, Xiang-Guang/AAC-1937-2020; liang, li/AAB-9126-2022; wu, xiangguang/AAC-6193-2020	wu, xiangguang/0000-0001-8276-4810; huang, lei/0000-0002-1996-944X	National Natural Science Foundation of China [81672589, 81372781]; National Natural Science foundation of Guangdong province [2017A030313872]; Shenzhen Science and Technology Program [JCYJ20160429161218745]; National Key Research and Development Program of China [2016YFC1302901]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science foundation of Guangdong province(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Program; National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (grant numbers: 81672589, 81372781), the National Natural Science foundation of Guangdong province (grant number: 2017A030313872), the Shenzhen Science and Technology Program (grant number: JCYJ20160429161218745), and the National Key Research and Development Program of China (grant number: 2016YFC1302901).	Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Beavis AL, 2016, GYNECOL ONCOL, V143, P302, DOI 10.1016/j.ygyno.2016.08.236; Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; Felicetti F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0811-2; Fu B, 2015, INT J ONCOL, V46, P1169, DOI 10.3892/ijo.2015.2837; Gombos Z, 2005, CLIN CANCER RES, V11, P8364, DOI 10.1158/1078-0432.CCR-05-1238; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115; Heishi T, 2010, AM J PATHOL, V176, P1950, DOI 10.2353/ajpath.2010.090829; Hosaka T, 2009, AM J PATHOL, V175, P430, DOI 10.2353/ajpath.2009.080788; Ito S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073931; Jafri MA, 2017, SEMIN CANCER BIOL, V44, P117, DOI 10.1016/j.semcancer.2017.02.004; Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212; Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408; Kim YJ, 2015, RADIAT ONCOL J, V33, P109, DOI 10.3857/roj.2015.33.2.109; Kneitz B, 2014, CANCER RES, V74, P2591, DOI 10.1158/0008-5472.CAN-13-1606; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lee YJ, 2017, GYNECOL ONCOL, V144, P536, DOI 10.1016/j.ygyno.2017.01.001; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu D, 2014, INT J ONCOL, V45, P1232, DOI 10.3892/ijo.2014.2510; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Maeng YS, 2016, ONCOGENE, V35, P196, DOI 10.1038/onc.2015.73; Manier S, 2017, BLOOD, V129, P2429, DOI 10.1182/blood-2016-09-742296; Mao SY, 2016, J OBSTET GYNAECOL RE, V42, P1317, DOI 10.1111/jog.13058; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Nedaeinia R, 2017, CANCER GENE THER, V24, P48, DOI 10.1038/cgt.2016.77; Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419; Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003; Sato Y, 2013, J BIOCHEM, V153, P5, DOI 10.1093/jb/mvs128; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Takahashi RU, 2017, CLIN CHEM LAB MED, V55, P648, DOI 10.1515/cclm-2016-0708; Takanami I, 2006, ONCOL REP, V15, P437; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Wang J, 2015, MOL CLIN ONCOL, V3, P363, DOI 10.3892/mco.2014.465; Wang T, 2014, HUM PATHOL, V45, P1839, DOI 10.1016/j.humpath.2014.05.001; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Wei WF, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0077-5; Wu LF, 2017, FEBS J, V284, P3000, DOI 10.1111/febs.14162; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183	49	107	116	1	46	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1256	1268		10.1038/s41388-018-0511-x	http://dx.doi.org/10.1038/s41388-018-0511-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254211	hybrid, Green Published			2022-12-28	WOS:000459249800008
J	Weng, CH; Chen, LY; Lin, YC; Shih, JY; Lin, YC; Tseng, RY; Chiu, AC; Yeh, YH; Liu, C; Lin, YT; Fang, JM; Chen, CC				Weng, Chien-Hui; Chen, Li-Yu; Lin, Yu-Chin; Shih, Jin-Yuan; Lin, Yun-Chieh; Tseng, Ruo-Yu; Chiu, An-Chieh; Yeh, Yu-Hsuan; Liu, Chi; Lin, Yi-Ting; Fang, Jim-Min; Chen, Ching-Chow			Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI	ONCOGENE			English	Article							COENZYME-A REDUCTASE; STEM-CELLS; HISTONE DEACETYLASE; VIMENTIN EXPRESSION; DRUG-RESISTANCE; TYROSINE KINASE; CANCER; INHIBITORS; THERAPY; ROLES	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a major advance in treating NSCLC with EGFR-activating mutations. However, acquired resistance, due partially to secondary mutations limits their use. Here we report that NSCLC cells with acquired resistance to gefitinib or osimertinib (AZD9291) exhibit EMT features, with a decrease in E-cadherin, and increases in vimentin and stemness, without possessing any EGFR secondary mutations. Knockdown of E-cadherin in parental cells increased gefitinib resistance and stemness, while knockdown of vimentin in resistant cells resulted in opposite effects. Src activation and Hakai upregulation were found in gefitinib-resistant cells. Knockdown of Hakai elevated E-cadherin expression, attenuated stemness, and resensitized the cells to gefitinib. Clinical cancer specimens with acquired gefitinib resistance also showed a decrease in E-cadherin and an increase in Hakai expression. The dual HDAC and HMGR inhibitor JMF3086 inhibited the Src/Hakai and Hakai/E-cadherin interaction to reverse E-cadherin expression, and attenuated vimentin and stemness to restore gefitinib sensitivity. The EMT features of AZD9291-resistant H1975 cells were related to the upregulation of Zeb1. Both gefitinib and AZD9291 sensitivity was restored by JMF3086 through reversing EMT. Our study not only revealed a common mechanism of EMT in both gefitinib and AZD9291 resistance beyond EGFR mutations per se, but also provides a new strategy to overcome it.	[Weng, Chien-Hui; Chen, Li-Yu; Lin, Yu-Chin; Lin, Yun-Chieh; Tseng, Ruo-Yu; Chiu, An-Chieh; Yeh, Yu-Hsuan; Liu, Chi; Lin, Yi-Ting; Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan; [Lin, Yu-Chin] Mennonite Christian Hosp, Dept Internal Med, Hualien, Taiwan; [Shih, Jin-Yuan] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Fang, Jim-Min] Natl Taiwan Univ, Dept Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan.	chingchowchen@ntu.edu.tw	LIN, YU-CHIN/T-9092-2019	SHIH, JIN-YUAN/0000-0002-2854-5067	Ministry of Science and Technology [MOST-106-2320-B002-003]; Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine; National Taiwan University Hospital [106R39012]; National Health Research Institute of Taiwan [NHRI-EX107-10707BI]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine; National Taiwan University Hospital(National Taiwan University); National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan)	This work was supported by grants from the Ministry of Science and Technology (MOST-106-2320-B002-003), Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine and National Taiwan University Hospital (106R39012), and the National Health Research Institute of Taiwan (NHRI-EX107-10707BI). We thank the technical assistance of the First Core Labs in the National Taiwan University College of Medicine.	Cao ZW, 2011, CANCER RES, V71, P2286, DOI 10.1158/0008-5472.CAN-10-3367; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Chen JB, 2013, J MED CHEM, V56, P3645, DOI 10.1021/jm400179b; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dou J, 2014, CELL BIOL INT, V38, P452, DOI 10.1002/cbin.10223; Figueroa A, 2009, MOL BIOL CELL, V20, P3533, DOI 10.1091/mbc.E08-08-0845; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Honke K, 1997, JPN J CANCER RES, V88, P484, DOI 10.1111/j.1349-7006.1997.tb00407.x; Ishiguro T, 2017, CANCER SCI, V108, P283, DOI 10.1111/cas.13155; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janne PA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.10.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807; Lin YC, 2015, CLIN CANCER RES, V21, P428, DOI 10.1158/1078-0432.CCR-14-1150; Liu YN, 2015, ONCOTARGET, V6, P10415, DOI 10.18632/oncotarget.3389; Locke I, 2002, NEW ENGL J MED, V346, P1498; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Pao W, 2009, CLIN CANCER RES, V15, P5317, DOI 10.1158/1078-0432.CCR-09-0913; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246	48	112	119	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					455	468		10.1038/s41388-018-0454-2	http://dx.doi.org/10.1038/s41388-018-0454-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30111817				2022-12-28	WOS:000456589800001
J	Chen-Wichmann, L; Shvartsman, M; Preiss, C; Hockings, C; Windisch, R; Monte, ER; Leubolt, G; Spiekermann, K; Lausen, J; Brendel, C; Grez, M; Greif, PA; Wichmann, C				Chen-Wichmann, Linping; Shvartsman, Marina; Preiss, Caro; Hockings, Colin; Windisch, Roland; Monte, Enric Redondo; Leubolt, Georg; Spiekermann, Karsten; Lausen, Jorn; Brendel, Christian; Grez, Manuel; Greif, Philipp A.; Wichmann, Christian			Compatibility of RUNX1/ETO fusion protein modules driving CD34+human progenitor cell expansion	ONCOGENE			English	Article							ETO HOMOLOGS; AML1-ETO; DOMAIN; LEUKEMIA; PROMOTES; COMPLEX; GENE; TRANSCRIPTION; REPRESSION; PARTNER	Chromosomal translocations represent frequent events in leukemia. In t(8;21)+ acute myeloid leukemia, RUNX1 is fused to nearly the entire ETO protein, which contains four conserved nervy homology regions, NHR1-4. Furthermore RUNX1/ETO interacts with ETO-homologous proteins via NHR2, thereby multiplying NHR domain contacts. As shown recently, RUNX1/ETO retains oncogenic activity upon either deletion of the NHR3 + 4 N-CoR/SMRT interaction domain or substitution of the NHR2 tetramer domain. Thus, we aimed to clarify the specificities of the NHR domains. A C-terminally NHR3 + 4 truncated RUNX1/ETO containing a heterologous, structurally highly related non-NHR2 tetramer interface translocated into the nucleus and bound to RUNX1 consensus motifs. However, it failed to interact with ETO-homologues, repress RUNX1 targets, and transform progenitors. Surprisingly, transforming capacity was fully restored by C-terminal fusion with ETO's NHR4 zinc-finger or the repressor domain 3 of N-CoR, while other repression domains failed. With an inducible protein assembly system, we further demonstrated that NHR4 domain activity is critically required early in the establishment of progenitor cultures expressing the NHR2 exchanged truncated RUNX1/ETO. Together, we can show that NHR2 and NHR4 domains can be replaced by heterologous protein domains conferring tetramerization and repressor functions, thus showing that the NHR2 and NHR4 domain structures do not have irreplaceable functions concerning RUNX1/ETO activity for the establishment of human CD34+ cell expansion. We could resemble the function of RUNX1/ETO through modular recomposition with protein domains from RUNX1, ETO, BCR and N-CoR without any NHR2 and NHR4 sequences. As most transcriptional repressor proteins do not comprise tetramerization domains, our results provide a possible explanation as to the reason that RUNX1 is recurrently found translocated to ETO family members, which all contain tetramer together with transcriptional repressor moieties.	[Chen-Wichmann, Linping; Shvartsman, Marina; Preiss, Caro; Windisch, Roland; Wichmann, Christian] Ludwig Maximilians Univ Munchen, Hosp Munich, Dept Transfus Med Cell Therapeut & Hemostaseol, Munich, Germany; [Hockings, Colin] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge, England; [Monte, Enric Redondo; Leubolt, Georg; Spiekermann, Karsten; Greif, Philipp A.] Ludwig Maximilians Univ Hosp Munich, Dept Internal Med 3, Munich, Germany; [Spiekermann, Karsten; Greif, Philipp A.] German Canc Consortium DKTK, Heidelberg, Germany; [Spiekermann, Karsten; Greif, Philipp A.] German Canc Res Ctr, Heidelberg, Germany; [Lausen, Jorn] Goethe Univ Frankfurt, Inst Transfus Med & Immunohematol, Frankfurt, Germany; [Lausen, Jorn] German Red Cross Blood Serv, Frankfurt, Germany; [Brendel, Christian] Harvard Med Sch, Dana Farber Canc Inst, Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA; [Grez, Manuel] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany	University of Munich; University of Cambridge; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Wichmann, C (corresponding author), Ludwig Maximilians Univ Munchen, Hosp Munich, Dept Transfus Med Cell Therapeut & Hemostaseol, Munich, Germany.	christian.wichmann@med.uni-muenchen.de	Wichmann, Christian/H-2491-2017; Brendel, Christian/HDN-6077-2022	Greif, Philipp/0000-0002-3744-7936; Redondo Monte, Enric/0000-0002-3588-223X; Brendel, Christian/0000-0003-4081-4351; Hockings, Colin/0000-0002-0248-0517	Jose Carreras Leukemia Foundation [DJCLS R 12/28]; Wilhelm Sander-Foundation [2014.162.2]; Friedrich-Baur Foundation; Deutsche Forschungsgemeinschaft [DFG LA 1389/6-1]	Jose Carreras Leukemia Foundation; Wilhelm Sander-Foundation; Friedrich-Baur Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Simone Schwarz for expert technical assistance and Sandra Moore for critical comments on the manuscript. We are supported by research grants from the Jose Carreras Leukemia Foundation (DJCLS R 12/28, CW), the Wilhelm Sander-Foundation (2014.162.2, PG & CW) the Friedrich-Baur Foundation (CW) and the Deutsche Forschungsgemeinschaft (DFG LA 1389/6-1, JL).	Ahn EY, 2008, P NATL ACAD SCI USA, V105, P17103, DOI 10.1073/pnas.0802696105; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; DeKelver RC, 2013, BLOOD, V121, P3714, DOI 10.1182/blood-2012-11-465641; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; Guastadisegni MC, 2010, LEUKEMIA, V24, P1516, DOI 10.1038/leu.2010.106; Huang EY, 2000, GENE DEV, V14, P45; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kohrs N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005946; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kwok C, 2009, P NATL ACAD SCI USA, V106, P2853, DOI 10.1073/pnas.0810558106; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Lindberg SR, 2003, EUR J HAEMATOL, V71, P439, DOI 10.1046/j.0902-4441.2003.00166.x; Lindberg SR, 2005, EXP HEMATOL, V33, P189, DOI 10.1016/j.exphem.2004.10.011; Link KA, 2016, P NATL ACAD SCI USA, V113, P9075, DOI 10.1073/pnas.1524225113; Liu YZ, 2007, CANCER CELL, V11, P483, DOI 10.1016/j.ccr.2007.04.010; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okumura AJ, 2008, BLOOD, V112, P1392, DOI 10.1182/blood-2007-11-124735; Okumura AJ, 2007, EXP HEMATOL, V35, P978, DOI 10.1016/j.exphem.2007.03.002; Park S, 2009, BLOOD, V113, P3558, DOI 10.1182/blood-2008-06-161307; Ponnusamy K, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.6; Pownall ME, 2003, DEV BIOL, V256, P89, DOI 10.1016/S0012-1606(02)00120-3; Salomon-Nguyen F, 2000, LEUKEMIA, V14, P1704, DOI 10.1038/sj.leu.2401885; Sun XJ, 2013, NATURE, V500, P93, DOI 10.1038/nature12287; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Wichmann C, 2010, BLOOD, V116, P603, DOI 10.1182/blood-2009-10-248047; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Zhao X, 2002, NAT STRUCT BIOL, V9, P117	31	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					261	272		10.1038/s41388-018-0441-7	http://dx.doi.org/10.1038/s41388-018-0441-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093631				2022-12-28	WOS:000455366700008
J	Toshiyama, R; Konno, M; Eguchi, H; Takemoto, H; Noda, T; Asai, A; Koseki, J; Haraguchi, N; Ueda, Y; Matsushita, K; Asukai, K; Ohashi, T; Iwagami, Y; Yamada, D; Sakai, D; Asaoka, T; Kudo, T; Kawamoto, K; Gotoh, K; Kobayashi, S; Satoh, T; Doki, Y; Nishiyama, N; Mori, M; Ishii, H				Toshiyama, Reishi; Konno, Masamitsu; Eguchi, Hidetoshi; Takemoto, Hiroyasu; Noda, Takehiro; Asai, Ayumu; Koseki, Jun; Haraguchi, Naotsugu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Iwagami, Yoshifumi; Yamada, Daisaku; Sakai, Daisuke; Asaoka, Tadafumi; Kudo, Toshihiro; Kawamoto, Koichi; Gotoh, Kunihito; Kobayashi, Shogo; Satoh, Taroh; Doki, Yuichiro; Nishiyama, Nobuhiro; Mori, Masaki; Ishii, Hideshi			Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells	ONCOGENE			English	Article							CANCER; BESTATIN; THERAPY; DRUG; CD13; INHIBITOR; APOPTOSIS; BIOLOGY	Previous studies highlighted that aminopeptidase N (APN)/CD13 acts as a scavenger in the survival of hepatocellular carcinoma (HCC) stem cells by reducing reactive oxygen species (ROS) levels. Hence, it has been proposed that APN/CD13 inhibition can increase cellular ROS levels and sensitize cells to chemotherapeutic agents. Although ubenimex, also known as bestatin, competitively inhibits proteases such as APN/CD13 on the cellular membrane and it is clinically used for patients with acute myeloid leukemia and lymphedema, research has demonstrated that higher concentrations of the agent induce the death of APN/CD13(+) HCC stem cells. In this study, we developed a poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate (PEG-b-PLys(Ube)) to increase the efficacy of reagents in APN/CD13(+) cancer stem cells. Exposure to PEG-b-PLys(Ube) increased the intracellular ROS concentration by inhibiting APN enzyme activity, permitting the induction of apoptosis and attenuation of HCC cell proliferation. In addition, PEG-b-PLys(Ube) exhibited a relatively stronger antitumor effect in mice than PEG-b-PLys alone or phosphate-buffered saline. Moreover, an isobologram analysis revealed that combinations of fluorouracil, cisplatin, or doxorubicin with PEG-b-PLys(Ube) exhibited synergistic effects. This study demonstrated that PEG-b-PLys(Ube) does not impair the properties of ubenimex and exerts a potent antitumor effect.	[Toshiyama, Reishi; Eguchi, Hidetoshi; Noda, Takehiro; Haraguchi, Naotsugu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Iwagami, Yoshifumi; Yamada, Daisaku; Asaoka, Tadafumi; Kawamoto, Koichi; Gotoh, Kunihito; Kobayashi, Shogo; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Konno, Masamitsu; Asai, Ayumu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Sakai, Daisuke; Kudo, Toshihiro; Kawamoto, Koichi; Satoh, Taroh] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Konno, Masamitsu; Asai, Ayumu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Sakai, Daisuke; Kudo, Toshihiro; Kawamoto, Koichi; Satoh, Taroh] Osaka Univ, Grad Sch Med, Dept Chemotherapy, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Asai, Ayumu; Koseki, Jun; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka 5650871, Japan; [Takemoto, Hiroyasu; Nishiyama, Nobuhiro] Tokyo Inst Technol, Lab Chem & Life Sci, Inst Innovat Res, Midori Ku, Nagatsuta Cho, Yokohama, Kanagawa, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Tokyo Institute of Technology	Mori, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan.; Ishii, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka 5650871, Japan.	mmori@gesurg.med.osaka-u.ac.jp; hishii@cfs.med.osaka-u.ac.jp	Satoh, Taroh/AAF-7913-2020; Satoh, Taroh/AAF-5193-2021; Koseki, Jun/ABH-7420-2020; Ishii, Hideshi/AAV-5317-2020; Takemoto, Hiroyasu/F-1886-2014; Iwagami, Yoshifumi/AAJ-3184-2021	Satoh, Taroh/0000-0002-4615-2638; Takemoto, Hiroyasu/0000-0002-0264-8746; Noda, Takehiro/0000-0002-6768-5783	Ministry of Education, Culture, Sports, Science, and Technology [17H04282, 17K19698, 16K15615, 15H05791]; Ministry of Education, Culture, Sports, Science, and Technology (P-DIRECT); Ministry of Education, Culture, Sports, Science, and Technology (P-CREATE); Ministry of Education, Culture, Sports, Science, and Technology (AMED-Japan Cancer Research Project)	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science, and Technology (P-DIRECT); Ministry of Education, Culture, Sports, Science, and Technology (P-CREATE); Ministry of Education, Culture, Sports, Science, and Technology (AMED-Japan Cancer Research Project)	This work received financial support from grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (grant no. 17H04282; 17K19698; 16K15615; 15H05791; P-DIRECT; P-CREATE; AMED-Japan Cancer Research Project).	Abou-Alfa GK, 2006, SEMIN ONCOL, V33, pS79, DOI 10.1053/j.seminoncol.2006.10.015; [Anonymous], 1980, RECENT RESULTS CANC, V75, P126; Bao Bin, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1425s61; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; BRULEYROSSET M, 1979, IMMUNOLOGY, V38, P75; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Colvin H, 2017, ANN GASTROENT SURG, V1, P5, DOI 10.1002/ags3.12008; Dando I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/425708; Ding M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035153; Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Hitzerd SM, 2014, AMINO ACIDS, V46, P793, DOI 10.1007/s00726-013-1648-0; Hu YP, 2012, AM J CANCER RES, V2, P340; Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x; Jhaveri AM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00077; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Karsten U, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-301; Kumamoto Y, 1985, Hinyokika Kiyo, V31, P1861; Lee H, 2002, J CONTROL RELEASE, V79, P283, DOI 10.1016/S0168-3659(02)00002-0; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Luan YP, 2007, CURR MED CHEM, V14, P639, DOI 10.2174/092986707780059571; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Mi P, 2017, J CONTROL RELEASE, V254, P1, DOI 10.1016/j.jconrel.2017.03.036; Mishra P, 2016, ASIAN J PHARM SCI, V11, P337, DOI 10.1016/j.ajps.2015.08.011; NIIMOTO M, 1990, JPN J SURG, V20, P186, DOI 10.1007/BF02470767; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Osada K, 2009, J R SOC INTERFACE, V6, pS325, DOI 10.1098/rsif.2008.0547.focus; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rusznyak LFM, 1967, PHYSL PATHOLOGY, P475; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Sekine K, 1999, LEUKEMIA, V13, P729, DOI 10.1038/sj.leu.2401388; Stange T, 1996, ACTA HISTOCHEM, V98, P323, DOI 10.1016/S0065-1281(96)80025-0; Sun JH, 2016, WORLD J GASTROENTERO, V22, P3547, DOI 10.3748/wjg.v22.i13.3547; Takada M, 2009, ACTA ONCOL MADR, V29, P821; TALMADGE JE, 1986, CANCER RES, V46, P4505; Tanjaya J, 2016, BIORESEARCH OPEN ACC, V5, P159, DOI 10.1089/biores.2016.0018; Terauchi M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-140; Tomimaru Y, 2015, SURG TODAY, V45, P1112, DOI 10.1007/s00595-014-1028-8; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]; Wada H, 2018, SURG TODAY, V48, P73, DOI 10.1007/s00595-017-1553-3; Webster R, 2007, DRUG METAB DISPOS, V35, P9, DOI 10.1124/dmd.106.012419; Wickstrom M, 2011, CANCER SCI, V102, P501, DOI 10.1111/j.1349-7006.2010.01826.x; Yamada N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06438-y; Yamamoto T, 2004, CLIN CANCER RES, V10, P7884, DOI 10.1158/1078-0432.CCR-04-0794; Yamashita M, 2016, INT J ONCOL, V49, P89, DOI 10.3892/ijo.2016.3496; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yasunaga M, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0374-1; Zhao W, 2013, CANCER CELL, V23, P541, DOI 10.1016/j.ccr.2013.02.025; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868	53	17	17	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					244	260		10.1038/s41388-018-0406-x	http://dx.doi.org/10.1038/s41388-018-0406-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30089817				2022-12-28	WOS:000455366700007
J	Cui, YH; Kim, H; Lee, M; Yi, JM; Kim, RK; Uddin, N; Yoo, KC; Kang, JH; Choi, MY; Cha, HJ; Kwon, OS; Bae, IH; Kim, MJ; Kaushik, N; Lee, SJ				Cui, Yan-Hong; Kim, Hyeonmi; Lee, Minyoung; Yi, Joo Mi; Kim, Rae-Kwon; Uddin, Nizam; Yoo, Ki-Chun; Kang, Jae Hyeok; Choi, Mi-Young; Cha, Hyuk-Jin; Kwon, Ok-Seon; Bae, In-Hwa; Kim, Min-Jung; Kaushik, Neha; Lee, Su-Jae			FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; F-BOX PROTEINS; GENE FAMILY; CELL; EXPRESSION; SURVIVAL; PHOSPHORYLATION; METASTASIS; MICRORNAS; MIGRATION	Understanding the molecular mechanisms that underlie the aggressive behavior and relapse of breast cancer may help in the development of novel therapeutic interventions. CUB-domain-containing protein 1 (CDCP1), a transmembrane adaptor protein, is highly maintained and required in the context of cellular metastatic potential in triple-negative breast cancer (TNBC). For this reason, gene expression levels of CDCP1 have been considered as a prognostic marker in TNBC. However, not rarely, transcript levels of genes do not reflect always the levels of proteins, due to the post-transcriptional regulation. Here we show that miR-17/20a control the FBXL14 E3 ligase, establishing FBXL14 as an upstream regulator of the CDCP1 pathway. FBXL14 acts as an novel interaction partner of CDCP1, and facilitates its ubiquitination and proteasomal degradation with an enhanced capacity to suppress CDCP1 protein stability that eventually prevents CDCP1 target genes involved in breast cancer metastasis. Our findings first time uncovers the regulatory mechanism of CDCP-1 protein stabilization, more predictable criteria than gene expression levels for prognosis of breast cancer patients.	[Cui, Yan-Hong; Kim, Hyeonmi; Kim, Rae-Kwon; Uddin, Nizam; Yoo, Ki-Chun; Kang, Jae Hyeok; Choi, Mi-Young; Kaushik, Neha; Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Lee, Minyoung] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 01812, South Korea; [Yi, Joo Mi] Dongnam Inst Radiol & Med Sci, Res Inst, Busan, South Korea; [Cha, Hyuk-Jin; Kwon, Ok-Seon] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Bae, In-Hwa] Korea Inst Radiol & Med Sci, Div Basic Radiat Biosci, Seoul, South Korea; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Seoul National University (SNU); Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Kaushik, N; Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea.	neha.bioplasma@gmail.com; sj0420@hanyang.ac.kr	Cui, Yanhong/ABB-1148-2021; Cha, Hyuk-Jin/AAB-8508-2020; Kaushik, Neha/AAL-8177-2020; Kaushik, Neha/AAY-5982-2020	Cui, Yanhong/0000-0002-4169-6521; Cha, Hyuk-Jin/0000-0001-9277-2662; Kaushik, Neha/0000-0001-8671-6779; Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [NRF-2016R1E1A1A01942075, NRF-2015M2A2A7A01044998]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program NRF-2016R1E1A1A01942075 and NRF-2015M2A2A7A01044998.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brock M, 2011, J BIOL CHEM, V286, P40142, DOI 10.1074/jbc.M111.251793; Brock M, 2009, CIRC RES, V104, P1184, DOI 10.1161/CIRCRESAHA.109.197491; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Cao MQ, 2016, TUMOR BIOL, V37, P1651, DOI 10.1007/s13277-015-3527-7; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Chen CL, 2010, J CELL SCI, V123, P2901, DOI 10.1242/jcs.069765; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Cui YH, 2015, ONCOGENE, V34, P5372, DOI 10.1038/onc.2014.466; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diaz VM, 2016, SEMIN CANCER BIOL, V36, P71, DOI 10.1016/j.semcancer.2015.10.003; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Heo JH, 2016, SEMIN CANCER BIOL, V36, P33, DOI 10.1016/j.semcancer.2015.09.015; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Labidi-Galy SI, 2015, ONCOGENE, V34, P299, DOI 10.1038/onc.2013.562; Law ME, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0741-1; Liu R, 2009, J BIOL CHEM, V284, P16791, DOI 10.1074/jbc.M808919200; Mazzucotelli E, 2006, CURR GENOMICS, V7, P509, DOI 10.2174/138920206779315728; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Shostak K, 2014, NAT COMMUN, V287, P9792; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Turdo F, 2016, ONCOTARGET, V7, P69649, DOI 10.18632/oncotarget.11935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Yi JM, 2013, CLIN CANCER RES, V19, P6544, DOI 10.1158/1078-0432.CCR-12-3224; Zhu HQ, 2014, AM J PATHOL, V184, P2828, DOI 10.1016/j.ajpath.2014.06.024	43	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5794	5809		10.1038/s41388-018-0372-3	http://dx.doi.org/10.1038/s41388-018-0372-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29973690				2022-12-28	WOS:000448288200007
J	Heinicke, U; Haydn, T; Kehr, S; Vogler, M; Fulda, S				Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone			BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis	ONCOGENE			English	Article							MITOCHONDRIAL PATHWAY; ANTITUMOR-ACTIVITY; CANCER-THERAPY; MCL-1; JNJ-26481585; DISCOVERIES; RESISTANCE; CHILDREN; LEUKEMIA; OVERCOME	BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities. Previously, we demonstrated that JNJ-26481585 (JNJ), a second-generation histone deacetylase inhibitor (HDACI), engages mitochondrial apoptosis via upregulation of several BH3-only proteins. In the present study, we describe synergistic interactions of JNJ with BH3 mimetics (i.e. ABT-737, ABT-199) in rhabdomyosarcoma (RMS) cells. Importantly, JNJ synergizes with ABT-199 to trigger apoptosis in primary-derived RMS cells isolated from tumor samples, underlining the translational importance of combining these compounds and their potential to improve cancer therapy. Importantly, JNJ/ABT-199 cotreatment also significantly inhibits long-term survival of RMS cells. Mechanistically, JNJ increases expression levels of the BH3-only protein BIM, while exposure to ABT-199 displaces BIM from BCL-2 and shuttles BIM to MCL-1, which also constitutively sequesters NOXA. Both BIM and NOXA contribute to JNJ/ABT-199-mediated cell death, as individual knockdown of NOXA or BIM significantly prevents cell death. Further, JNJ and ABT-199 act in concert to activate BAK and BAX, resulting in loss of the mitochondrial membrane potential (MMP) and caspase activation. These events are required for JNJ/ABT-199-mediated apoptosis, since BAK or BAX silencing or inhibition of caspases significantly protects from JNJ/ABT-199-induced cell death. Rescue experiments demonstrate that overexpression of MCL-1, but not overexpression of BCL-2, blocks JNJ/ABT-199-induced apoptosis. In conclusion, this study provides the first demonstration of ABT-199-induced priming, which sensitizes RMS cells to HDACI, such as JNJ, by engaging mitochondrial apoptosis, highlighting that BH3 mimetics show great promise for the treatment of RMS.	[Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Consortium DKTK Partner Site, Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Consortium DKTK Partner Site, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	simone.fulda@kgu.de		Vogler, Meike/0000-0003-2650-586X; Fulda, Simone/0000-0002-0459-6417	BMBF; Deutsche Krebshilfe; Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	We thank D. Bruecher for expert technical assistance and C. Hugenberg for excellent secretarial assistance. This work has been partially supported by grants from the BMBF, the Deutsche Krebshilfe and the Deutsche Kinderkrebsstiftung (to SF) and a grant from the Medical Faculty, Goethe-University Frankfurt (to MV).	Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724; Carter BZ, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.512.512; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Choudhary GS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.525; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P481, DOI 10.1101/pdb.prot086470; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2016, ONCOGENE, V35, P3729, DOI 10.1038/onc.2015.440; Heinicke U, 2015, ONCOTARGET, V6, P37836, DOI 10.18632/oncotarget.6097; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Khaw SL, 2014, LEUKEMIA, V28, P1207, DOI 10.1038/leu.2014.1; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7; Michels J, 2014, BIOCHEM PHARMACOL, V92, P55, DOI 10.1016/j.bcp.2014.07.029; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; Niu XJ, 2016, CLIN CANCER RES, V22, P4440, DOI 10.1158/1078-0432.CCR-15-3057; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pazzaglia L, 2009, HISTOL HISTOPATHOL, V24, P61, DOI 10.14670/HH-24.61; Peirs S, 2014, BLOOD, V124, P3738, DOI 10.1182/blood-2014-05-574566; Phillips DC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.88; Portell CA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.509.509; Preuss E, 2013, J BIOL CHEM, V288, P35287, DOI 10.1074/jbc.M113.495986; Sarosiek KA, 2016, FEBS J, V283, P3523, DOI 10.1111/febs.13714; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242	39	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5325	5339		10.1038/s41388-018-0212-5	http://dx.doi.org/10.1038/s41388-018-0212-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858601				2022-12-28	WOS:000445759700006
J	Liu, H; Chen, W; Zhi, X; Chen, EJ; Wei, T; Zhang, J; Shen, J; Hu, LQ; Zhao, B; Feng, XH; Bai, XL; Liang, TB				Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Zhao, Bin; Feng, Xin-Hua; Bai, Xue-Li; Liang, Ting-Bo			Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility	ONCOGENE			English	Article							CANCER-CELLS; METASTASIS; RESISTANCE; MIGRATION; PROTEINS; VESICLES; INVASION; DENSIN-180; MICRORNAS; APOPTOSIS	Tumor self-seeding occurs when circulating malignant cells reinfiltrate the original tumor. The process may breed more aggressive tumor cells, which may contribute to cancer progression. In this study, we observed tumor self-seeding in mouse xenograft models of hepatocellular carcinoma (HCC) for the first time. We confirmed that circulating tumor cell uptake of tumor-derived exosomes, which are increasingly recognized as key instigators of cancer progression by facilitating cell-cell communication, promoted tumor self-seeding by enhancing the invasive and migration capability of recipient HCC cells. Horizontal transfer of exosomal microRNA-25-5p to anoikis-resistant HCC cells significantly enhanced their migratory and invasive abilities, whereas inhibiting microRNA-25-5p alleviated these effects. Our experiments delineate an exosome-based novel pathway employed by functional microRNA from the original tumor cells that can influence the biological fate of circulating tumor cells.	[Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Bai, Xue-Li; Liang, Ting-Bo] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China; [Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Bai, Xue-Li; Liang, Ting-Bo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China; [Zhao, Bin; Feng, Xin-Hua] Zhejiang Univ, Life Sci Inst, Hangzhou, Zhejiang, Peoples R China; [Zhao, Bin; Feng, Xin-Hua] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Liang, TB (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China.; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn	Chen, Wei/X-6211-2019		National Natural Science Foundation of China [81472212]; 973 Program of China [2014CB542101]; Key Program of Medical Scientific Research Foundation of Zhejiang Province, China [WKJ-ZJ-1410]; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China [2014ZZ007]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Program of China(National Basic Research Program of China); Key Program of Medical Scientific Research Foundation of Zhejiang Province, China; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	This work was supported by the National Natural Science Foundation of China (No. 81472212), 973 Program of China (No. 2014CB542101), Key Program of Medical Scientific Research Foundation of Zhejiang Province, China (No. WKJ-ZJ-1410), Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China (No. 2014ZZ007) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Atay S, 2014, P NATL ACAD SCI USA, V111, P711, DOI 10.1073/pnas.1310501111; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Dondossola E, 2012, CANCER RES, V72, P449, DOI 10.1158/0008-5472.CAN-11-2944; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Harris DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117495; Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899; Heikkila E, 2007, MOL CELL BIOCHEM, V305, P9, DOI 10.1007/s11010-007-9522-6; Hendrix A, 2010, CANCER RES, V70, P9533, DOI 10.1158/0008-5472.CAN-10-3248; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Janikashvili N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/430394; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Li BS, 2015, ONCOGENE, V34, P2556, DOI 10.1038/onc.2014.214; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; McKenzie AJ, 2016, CELL REP, V15, P978, DOI 10.1016/j.celrep.2016.03.085; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; PAGET S, 1989, CANCER METAST REV, V8, P98; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Wang CR, 2015, ONCOTARGET, V6, P36231, DOI 10.18632/oncotarget.4740; Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530; Zhang Y, 2013, J CANCER RES CLIN, V140, P329; Zhang YN, 2006, J BIOL CHEM, V281, P22299, DOI 10.1074/jbc.M602902200; Zhang ZY, 2008, CANCER LETT, V267, P106, DOI 10.1016/j.canlet.2008.03.010; Zhou HL, 2014, RNA, V20, P1431, DOI 10.1261/rna.045757.114; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	37	36	38	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4964	4978		10.1038/s41388-018-0309-x	http://dx.doi.org/10.1038/s41388-018-0309-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29786077				2022-12-28	WOS:000443823600005
J	Cong, B; Ohsawa, S; Igaki, T				Cong, Bojie; Ohsawa, Shizue; Igaki, Tatsushi			JNK and Yorkie drive tumor progression by generating polyploid giant cells in Drosophila	ONCOGENE			English	Article							SIGNALING PATHWAY; SUPPRESSOR GENES; APOPTOSIS; PROLIFERATION; OVERGROWTH; BREAST; CANCER; RAS; DEGRADATION; AUTOPHAGY	Epithelial cancer tissues often possess polyploid giant cells, which are thought to be highly oncogenic. However, the mechanisms by which polyploid giant cells are generated in tumor tissues and how such cells contribute to tumor progression remain elusive. We previously noticed in Drosophila imaginal epithelium that cells mutant for the endocytic gene rab5 exhibit enlarged nuclei. Here we find that mutations in endocytic 'neoplastic tumor-suppressor' genes, such as rab5, vps25, erupted, or avalanche result in generation of polyploid giant cells. Genetic analyses on rab5-defective cells reveal that cooperative activation of JNK and Yorkie generates polyploid giant cells via endoreplication. Mechanistically, Yorkie-mediated upregulation of Diap1 cooperates with JNK to downregulate the G2/M cyclin CycB, thereby inducing endoreplication. Interestingly, malignant tumors induced by Ras activation and cell polarity defect also consist of polyploid giant cells, which are generated by JNK and Yorkie-mediated downregulation of CycB. Strikingly, elimination of polyploid giant cells from such malignant tumors by blocking endoreplication strongly suppressed tumor growth and metastatic behavior. Our observations suggest that JNK and Yorkie, two oncogenic proteins activated in many types of human cancers, cooperatively drive tumor progression by generating oncogenic polyploid giant cells.	[Cong, Bojie; Ohsawa, Shizue; Igaki, Tatsushi] Kyoto Univ, Grad Sch Biostudies, Lab Genet, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan	Kyoto University	Igaki, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Genet, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	igaki@lif.kyoto-u.ac.jp		Igaki, Tatsushi/0000-0001-5839-9526	MEXT/JSPS KAKENHI [26114002, 16K14606, 16H02505, 15H05862, 26711013, 17H03673]; Naito Foundation; Takeda Science Foundation; Japan Foundation for Applied Enzymology; Japan Agency for Medical Research and Development; Ichikawa International Scholarship Foundation	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Naito Foundation(Naito Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Japan Foundation for Applied Enzymology; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Ichikawa International Scholarship Foundation	We thank Masato Enomoto, Yukari Sando, Yuya Sanaki, Kiichiro Taniguchi, and Masatoshi Yamamoto for discussions, and K. Sawada, K. Baba and Y. Senda for technical assistance. We also thank Leonie Quinn, Masayuki Miura, Takashi Adachi-Yamada, the Bloomington Stock Center, the Drosophila Genomics and Genetic Resources (DGGR), and the FlyORF for fly stocks. This work was supported in part by grants from the MEXT/JSPS KAKENHI (Grant Number 26114002, 16K14606, 16H02505, 15H05862, 26711013, and 17H03673) to S.O. and T.I., the Naito Foundation to T.I., the Takeda Science Foundation to S.O. and T.I., the Japan Foundation for Applied Enzymology to S.O., and Japan Agency for Medical Research and Development (Project for Elucidating and Controlling Mechanisms of Aging and Longevity) to T.I. B.C. was supported in part by Ichikawa International Scholarship Foundation. This work was supported in part by grants from the MEXT/JSPS KAKENHI (Grant Numbers 26114002, 16K14606, 16H02505, 15H05862, 26711013, and 17H03673), the Naito Foundation, the Takeda Science Foundation, the Japan Foundation for Applied Enzymology, and Japan Agency for Medical Research and Development (Project for Elucidating and Controlling Mechanisms of Aging and Longevity) to T.I. B.C. was supported in part by Ichikawa International Scholarship Foundation.	Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; FRIERSON HF, 1991, AM J SURG PATHOL, V15, P358, DOI 10.1097/00000478-199104000-00004; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Gong FR, 2015, ONCOTARGET, V6, P18469, DOI 10.18632/oncotarget.4063; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gutierrez GJ, 2010, J BIOL CHEM, V285, P14217, DOI 10.1074/jbc.M110.121848; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lindqvist A, 2010, J CELL BIOL, V189, P197, DOI 10.1083/jcb.201003032; Maugeri-Sacca M, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.12; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Mohd-Sarip A, 2012, SCIENCE, V336, P744, DOI 10.1126/science.1215927; Nakamura M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6264; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Robinson BS, 2011, CELL CYCLE, V10, P4110, DOI 10.4161/cc.10.23.18243; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Takino K, 2014, DEV BIOL, V395, P19, DOI 10.1016/j.ydbio.2014.09.003; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Wang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.138; Xu DB, 2009, FLY, V3, P78, DOI 10.4161/fly.3.1.7800; XU T, 1993, DEVELOPMENT, V117, P1223; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang SH, 2017, CANCER CELL, V31, P669, DOI 10.1016/j.ccell.2017.04.004	35	13	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3088	3097		10.1038/s41388-018-0201-8	http://dx.doi.org/10.1038/s41388-018-0201-8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535423				2022-12-28	WOS:000434641400004
J	Ehedego, H; Mohs, A; Jansen, B; Hiththetiya, K; Sicinski, P; Liedtke, C; Trautwein, C				Ehedego, Haksier; Mohs, Antje; Jansen, Bettina; Hiththetiya, Kanishka; Sicinski, Piotr; Liedtke, Christian; Trautwein, Christian			Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; RNA INTERFERENCE; CELL-CYCLE; MICE; PROLIFERATION; EXPRESSION; DELETION; CANCER; PHOSPHORYLATION; ENDOREPLICATION	Chronic liver injury triggers liver fibrosis and hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality. Cyclin E1 (CcnE1, formerly designated Cyclin E) is a regulatory subunit of the Cyclin-dependent kinase 2 (CDK2). It is overexpressed in approximately 70% of human HCCs correlating with poor prognosis, while the relevance of its orthologue Cyclin E2 (CcnE2) is unclear. Hepatocyte-specific deletion of NF-kappa-B essential modulator (NEMO Delta hepa) leads to chronic hepatitis, liver fibrosis, and HCC as well as CcnE upregulation. To this end, we generated NEMO Delta hepa/CcnE1(-/-) and NEMO Delta hepa/CcnE2(-/-) double knockout mice and investigated age-dependent liver disease progression in these animals. Deletion of CcnE1 in NEMO Delta hepa mice decreased basal liver damage and reduced spontaneous liver inflammation in young mice. In contrast, loss of CcnE2 did not affect liver injury in NEMO Delta hepa livers pointing to a unique, non-redundant function of CcnE1 in chronic hepatitis. Accordingly, basal compensatory hepatocyte proliferation in NEMO Delta hepa mice was reduced by concomitant ablation of CcnE1, but not after loss of CcnE2. In aged NEMO.hepa mice, loss of CcnE1 resulted in significant reduction of liver tumorigenesis, while deletion of CcnE2 had no effect on HCC formation. CcnE1, but not its orthologue CcnE2, substantially contributes to hepatic inflammatory response, liver disease progression, and hepatocarcinogenesis in NEMO Delta hepa mice.	[Ehedego, Haksier; Mohs, Antje; Jansen, Bettina; Liedtke, Christian; Trautwein, Christian] Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany; [Hiththetiya, Kanishka] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Sicinski, Piotr] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA USA; [Sicinski, Piotr] Harvard Med Sch, Dept Genet, Boston, MA USA	RWTH Aachen University; RWTH Aachen University Hospital; University of Bonn; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Trautwein, C (corresponding author), Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany.	ctrautwein@ukaachen.de	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887; Mohs, Antje/0000-0001-5937-0696	German Cancer Foundation (Deutsche Krebshilfe) [107682, SFB TRR/57]; Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen; NATIONAL CANCER INSTITUTE [R01CA202634] Funding Source: NIH RePORTER	German Cancer Foundation (Deutsche Krebshilfe)(Deutsche Krebshilfe); Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant of the German Cancer Foundation (Deutsche Krebshilfe) Grant Nr. 107682, the SFB TRR/57 and the Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen.	Aigelsreiter A, 2012, HUM PATHOL, V43, P1012, DOI 10.1016/j.humpath.2011.08.009; Bangen JM, 2017, HEPATOLOGY, V66, P1242, DOI 10.1002/hep.29275; Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152; Bisteau X, 2014, CANCERS, V6, P79, DOI 10.3390/cancers6010079; Chuma M, 2003, HEPATOLOGY, V37, P198, DOI 10.1053/jhep.2003.50022; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hu W, 2014, HEPATOLOGY, V59, P651, DOI 10.1002/hep.26584; Jung YJ, 2001, CANCER LETT, V168, P57, DOI 10.1016/S0304-3835(01)00403-7; Li KY, 2003, CANCER RES, V63, P3593; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Malato Y, 2012, GASTROENTEROLOGY, V143, P1597, DOI 10.1053/j.gastro.2012.08.030; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nevzorova YA, 2012, HEPATOLOGY, V56, P1140, DOI 10.1002/hep.25736; Nevzorova YA, 2009, GASTROENTEROLOGY, V137, P691, DOI 10.1053/j.gastro.2009.05.003; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pok S, 2013, J GASTROEN HEPATOL, V28, P1545, DOI 10.1111/jgh.12216	23	14	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3329	3339		10.1038/s41388-018-0181-8	http://dx.doi.org/10.1038/s41388-018-0181-8			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29551768	Green Accepted			2022-12-28	WOS:000436411300001
J	He, H; Sinha, I; Fan, RR; Haldosen, LA; Yan, FF; Zhao, CY; Dahlman-Wright, K				He, Huan; Sinha, Indranil; Fan, Rongrong; Haldosen, Lars-Arne; Yan, Feifei; Zhao, Chunyan; Dahlman-Wright, Karin			c-Jun/AP-1 overexpression reprograms ER alpha signaling related to tamoxifen response in ER alpha-positive breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE RESISTANCE; MATRIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PHOSPHOLIPASE-D; DNA-BINDING; TGF-BETA; CELLS; FOXA1	A critical mechanism that has been proposed for transcription regulation by estrogen receptor a (ER) is the tethering of ER to DNA via other transcription factors, such as AP-1. However, genome-wide assessment of the overlap in chromatin binding repertoires of these two transcription factors has not been reported. Here, we show that the AP-1 transcription factor c-Jun interacts with ER and that c-Jun chromatin binding shows extensive overlap with ER binding at the global level. Further, we show that c-Jun overexpression reprograms ER chromatin binding and modulates ER-mediated gene regulation. Our data are consistent with a mechanism where estrogen/ER-dependent crosstalk with AP-1 at the transcriptional level is mediated through the tethering of ER to DNA bound AP-1. Additionally, in our system c-Jun overexpression causes reduced sensitivity to tamoxifen in ER+ breast cancer cells. Integrated cistrome, transcriptome, and clinical data reveal TGFBI as a candidate gene which may confer tamoxifen resistance by ER and AP-1 crosstalk. Further, we show that TGFBI expression is elevated in breast cancer compared to normal breast. Together, our data provide a novel genome-wide footprint of ER and AP-1 crosstalk and suggest AP-1 and TGFBI signaling as potential therapeutic targets in AP-1-overexpressing ER-positive breast tumors.	[He, Huan; Sinha, Indranil; Fan, Rongrong; Haldosen, Lars-Arne; Yan, Feifei; Zhao, Chunyan; Dahlman-Wright, Karin] Karolinska Inst, Dept Biosci & Nutr, Novum, SE-14183 Huddinge, Sweden	Karolinska Institutet	Zhao, CY (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum, SE-14183 Huddinge, Sweden.	chunyan.zhao@ki.se	He, Huan/AAF-9644-2019; Fan, Rongrong/N-3446-2017; Fan, Rongrong/AAG-2200-2019	Fan, Rongrong/0000-0002-5707-1497; Fan, Rongrong/0000-0002-5707-1497; Sinha, Indranil/0000-0002-2513-5927; He, Huan/0000-0001-8123-5765	China Scholarship Council; Karolinska Institutet; Swedish Cancer Society (Cancerfonden)	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society)	The authors thank the Bioinformatic and Expression Analysis core facility at the Karolinska Institute (http://www.bea.ki.se/) for performing the Affymetrix and ChIP-seq assays and Hui Gao for critically reading the manuscript. This work was supported by scholarship from the China Scholarship Council, a PhD student grant (KID) from the Karolinska Institutet and grants from the Swedish Cancer Society (Cancerfonden).	Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ali S, 2016, BIOINFORMATION, V12, P135, DOI 10.6026/97320630012135; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Brown HA, 2017, NAT REV DRUG DISCOV, V16, P351, DOI 10.1038/nrd.2016.252; Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahlman-Wright K, 2012, CARCINOGENESIS, V33, P1684, DOI 10.1093/carcin/bgs223; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; den Hollander P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00250; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu XY, 2016, P NATL ACAD SCI USA, V113, pE6600, DOI 10.1073/pnas.1612835113; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heldring N, 2011, MOL ENDOCRINOL, V25, P564, DOI 10.1210/me.2010-0425; Hung MS, 2015, ONCOL REP, V34, P3187, DOI 10.3892/or.2015.4324; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ji ZL, 2012, MOL CELL BIOL, V32, P385, DOI 10.1128/MCB.05504-11; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kharman-Biz A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-441; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Luo M, 2005, MOL CELL BIOL, V25, P7386, DOI 10.1128/MCB.25.16.7386-7398.2005; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Robinson JLL, 2014, ONCOGENE, V33, P5666, DOI 10.1038/onc.2013.508; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schneider D, 2002, BBA-MOL BASIS DIS, V1588, P1, DOI 10.1016/S0925-4439(02)00052-2; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shen Q, 2011, J BIOL CHEM, V286, P14554, DOI 10.1074/jbc.M110.165704; Stender JD, 2017, MOL CELL, V65, P1122, DOI 10.1016/j.molcel.2017.02.008; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Sun M, 2012, MOL ENDOCRINOL, V26, P736, DOI 10.1210/me.2011-1158; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Wright TM, 2014, MOL CANCER RES, V12, P1829, DOI 10.1158/1541-7786.MCR-14-0195; Zhang Y, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-145; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zhao CY, 2010, J BIOL CHEM, V285, P39575, DOI 10.1074/jbc.R110.180109; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	52	24	27	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2586	2600		10.1038/s41388-018-0165-8	http://dx.doi.org/10.1038/s41388-018-0165-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467493				2022-12-28	WOS:000431873400010
J	Tang, JT; Chen, HR; Wong, CC; Liu, DB; Li, T; Wang, XH; Ji, JF; Sung, JJY; Fang, JY; Yu, J				Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Wang, Xiaohong; Ji, Jiafu; Sung, Joseph J. Y.; Fang, Jing-Yuan; Yu, Jun			DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; COPY NUMBER ALTERATIONS; CARCINOMA PROGRESSION; COLON-CANCER; ACTIVATION; GENE; TRANSCRIPTION; ADENOMA; DDX1	Copy number alterations (CNAs) are crucial for colorectal cancer (CRC) development. In this study, DEAD box polypeptide 27 (DDX27) was identified to be highly amplified in both TCGA CRC (474/615) and primary CRC (47/103), which was positively correlated with its mRNA overexpression. High DDX27 mRNA (N = 199) and protein expression (N = 260) predicted poor survival in CRC patients. Ectopic expression of DDX27 increased CRC cells proliferation, migration and invasion, but suppressed apoptosis. Conversely, silencing of DDX27 exerted opposite effects in vitro and significantly inhibited murine xenograft tumor growth and lung metastasis in vivo. Up-regulation of DDX27 enhanced and prolonged TNF-alpha-mediated NF-kappa B signaling. Nucleophosmin (NPM1) was identified as a binding partner of DDX27. DDX27 increased nuclear NPM1 and NF-kappa B-p65 interaction to enhance DNA binding activity of NF-kappa B. Silencing NPM1 abrogated DDX27-activating NF-kappa B signaling and its tumor-promoting function. Together, DDX27 is overexpressed and plays a pivotal oncogenic role in CRC.	[Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut,CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Hong Kong, Peoples R China; [Tang, Jieting; Fang, Jing-Yuan; Yu, Jun] Shanghai Jiao Tong Univ, Shanghai Canc Inst,Minist Hlth,Div Gastroenterol, Shanghai Inst Digest Dis,Ren Ji Hosp,Sch Med, State Key Lab Oncogenes & Related Genes,Key Lab G, Shanghai 200001, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Surg, Beijing 100142, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut,CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Hong Kong, Peoples R China.; Fang, JY; Yu, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst,Minist Hlth,Div Gastroenterol, Shanghai Inst Digest Dis,Ren Ji Hosp,Sch Med, State Key Lab Oncogenes & Related Genes,Key Lab G, Shanghai 200001, Peoples R China.	jingyuanfang@sjtu.edu.cn; junyu@cuhk.edu.hk	chen, huarong/ABH-8561-2020; Liu, Dabin/GNH-2648-2022; Chen, Huarong/ABZ-5810-2022; Yu, Jun/D-8569-2015; Wong, Chi Chun/C-4636-2016; Sung, Joseph J. Y./R-3203-2018	chen, huarong/0000-0003-2192-1864; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Liu, Dabin/0000-0002-3811-8317	CUHK-SJTU Joint Research Collaboration Fund; RGC-GRF Hong Kong [766613, 14106145]; 973 Program China [2013CB531401]; Natural Science Foundation of China (NSFC) [81201963, 81372600]; Shenzhen Municipal Science and Technology R D fund [JCYJ20120619152326450]; Shenzhen Virtual University Park Support Scheme; CUHK	CUHK-SJTU Joint Research Collaboration Fund; RGC-GRF Hong Kong(Hong Kong Research Grants Council); 973 Program China(National Basic Research Program of China); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme; CUHK(Chinese University of Hong Kong)	This project was supported by CUHK-SJTU Joint Research Collaboration Fund (Jun Yu and Jing-Yuan Fang), RGC-GRF Hong Kong (766613, 14106145), 973 Program China (2013CB531401), Natural Science Foundation of China (NSFC) (81201963, 81372600), Shenzhen Municipal Science and Technology R & D fund (JCYJ20120619152326450) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. CUHK direct grant to FKL Chan.	Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Camps J, 2009, GENE CHROMOSOME CANC, V48, P1002, DOI 10.1002/gcc.20699; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Cheng XS, 2014, CANCER LETT, V348, P77, DOI 10.1016/j.canlet.2014.03.008; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Fiume G, 2012, NUCLEIC ACIDS RES, V40, P3548, DOI 10.1093/nar/gkr1224; Flora M, 2012, CANCER GENET-NY, V205, P630, DOI 10.1016/j.cancergen.2012.10.005; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gui SL, 2016, INT UROL NEPHROL, V48, P701, DOI 10.1007/s11255-016-1222-2; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Ishaq M, 2009, J CELL BIOCHEM, V106, P296, DOI 10.1002/jcb.22004; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kumar A, 2011, DIABETES OBES METAB, V13, P750, DOI 10.1111/j.1463-1326.2011.01402.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008; Lin JH, 2017, NUCLEIC ACIDS RES, V45, P3707, DOI 10.1093/nar/gkw1285; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mallam AL, 2012, NATURE, V490, P121, DOI 10.1038/nature11402; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Sillars-Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983; Tanaka K, 2009, ONCOGENE, V28, P2142, DOI 10.1038/onc.2009.89; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Wang R, 2012, NEURO-ONCOLOGY, V14, P1116, DOI 10.1093/neuonc/nos131	41	33	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3006	3021		10.1038/s41388-018-0196-1	http://dx.doi.org/10.1038/s41388-018-0196-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535419	Green Published, hybrid			2022-12-28	WOS:000433936300008
J	Zhang, HY; Wang, QY; Gu, JZ; Yin, Y; Liang, SH; Wu, LD; Xu, H; Zhao, C; Gu, YC				Zhang, Huiyuan; Wang, Qinyi; Gu, Junzhong; Yin, Le; Liang, Shenghui; Wu, Lida; Xu, Hao; Zhao, Chao; Gu, Yuchun			Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived nitric oxide	ONCOGENE			English	Article							TRANSPORTER FAMILY SLC25; SYNTHASE; RESPIRATION; IDENTIFICATION; GLYCOLYSIS; PATHWAY; KINASE; OXYGEN	Warburg effect has been recognized as a hallmark of cancer cells for many years, but its modulation mechanism remains a great focus. Our current study found a member of solute carrier family 25 (SLC25A29), the main arginine transporter on mitochondria, significantly elevated in various cancer cells. Knockout of SLC25A29 by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo. SLC25A29-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis. All of above impacts could be reversed after rescuing SLC25A29 expression in SLC25A29-knockout cells. Arginine is transported into mitochondria partly for nitric oxide (NO) synthesis. Deletion of SLC25A29 resulted in severe decrease of NO production, indicating that the mitochondria is a significant source of NO. SLC25A29-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by SLC25A29. In conclusion, aberrant elevated SLC25A29 in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased cancer progression.	[Zhang, Huiyuan; Wang, Qinyi; Gu, Junzhong; Yin, Le; Liang, Shenghui; Wu, Lida; Xu, Hao; Gu, Yuchun] Peking Univ, Inst Mol Med, Lab Mol Pharmacol, Beijing, Peoples R China; [Zhao, Chao] Univ Cambridge, WT MRC Cambridge Stem Cell Inst, Dept Clin Neurosci, Cambridge, England; [Gu, Yuchun] Aston Univ, Translat & Regenerat Med Ctr, Aston Med Res Inst, Birmingham, W Midlands, England	Peking University; University of Cambridge; Aston University	Gu, YC (corresponding author), Peking Univ, Inst Mol Med, Lab Mol Pharmacol, Beijing, Peoples R China.; Gu, YC (corresponding author), Aston Univ, Translat & Regenerat Med Ctr, Aston Med Res Inst, Birmingham, W Midlands, England.	ycgu@pku.edu.cn	wu, lida/ABD-8498-2020	wu, lida/0000-0001-7059-0788; gu, yuchun/0000-0002-7558-0447	973 Project [2013CB531206, 2012CB517803]; NSF [81170236, 31127001]	973 Project(National Basic Research Program of China); NSF(National Science Foundation (NSF))	This work is supported by the research grants held by Yuchun Gu (973 Project Number 2013CB531206, 973 Project Number 2012CB517803, and NSF Number 81170236 and Number 31127001).	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Brix B, 2012, J NEUROSCI, V32, P9727, DOI 10.1523/JNEUROSCI.0879-12.2012; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Brown GC, 2007, CARDIOVASC RES, V75, P283, DOI 10.1016/j.cardiores.2007.03.022; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Camacho JA, 2009, PEDIATR RES, V66, P35, DOI 10.1203/PDR.0b013e3181a283c1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chang CF, 2015, FREE RADICAL BIO MED, V79, P324, DOI 10.1016/j.freeradbiomed.2014.11.012; Cidad P, 2004, BIOCHEM J, V384, P629, DOI 10.1042/BJ20040886; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dedkova EN, 2009, J PHYSIOL-LONDON, V587, P851, DOI 10.1113/jphysiol.2008.165423; Finocchietto PV, 2009, EXP BIOL MED, V234, P1020, DOI 10.3181/0902-MR-81; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghafourifar P, 2005, METHOD ENZYMOL, V396, P424, DOI 10.1016/S0076-6879(05)96036-9; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hill BG, 2012, BIOL CHEM, V393, P1485, DOI 10.1515/hsz-2012-0198; Jobgen WS, 2006, J NUTR BIOCHEM, V17, P571, DOI 10.1016/j.jnutbio.2005.12.001; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lacza Z, 2009, FRONT BIOSCI, V14, P4436, DOI 10.2741/3539; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Monne M, 2015, AMINO ACIDS, V47, P1763, DOI 10.1007/s00726-015-1990-5; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005; Persichini T, 2005, NEUROSCI LETT, V384, P254, DOI 10.1016/j.neulet.2005.04.085; Porcelli V, 2014, J BIOL CHEM, V289, P13374, DOI 10.1074/jbc.M114.547448; Quintero M, 2006, CANCER RES, V66, P770, DOI 10.1158/0008-5472.CAN-05-0333; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Sekoguchi E, 2003, J BIOL CHEM, V278, P38796, DOI 10.1074/jbc.M306372200; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhong H, 1999, CANCER RES, V59, P5830	48	11	11	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2545	2558		10.1038/s41388-018-0139-x	http://dx.doi.org/10.1038/s41388-018-0139-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29459713				2022-12-28	WOS:000431873400007
J	Gong, L; Pan, X; Lim, CB; de Polo, A; Little, JB; Yuan, ZM				Gong, Lu; Pan, Xiao; Lim, Chuan-Bian; de Polo, Anna; Little, John B.; Yuan, Zhi-Min			A functional interplay between Delta 133p53 and Delta Np63 in promoting glycolytic metabolism to fuel cancer cell proliferation	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; P53 ISOFORM; RESPONSE ELEMENTS; BREAST-CANCER; DNA-DAMAGE; SENESCENCE; EXPRESSION; DEATH; APOPTOSIS; P53-BETA	Although Delta Np63 is known to promote cancer cell proliferation, the underlying mechanism behind its oncogenic function remains elusive. We report here a functional interplay between Delta Np63 and Delta 133p53. These two proteins are co-overexpressed in a subset of human cancers and cooperate to promote cell proliferation. Mechanistically, Delta 133p53 binds to Delta Np63 and utilizes its transactivation domain to upregulate GLUT1, GLUT4, and PGM expression driving glycolysis. While increased glycolysis provides cancer cells with anabolic metabolism critical for proliferation and survival, it can be harnessed for selective cancer cell killing. Indeed, we show that tumors overexpressing both Delta Np63 and Delta 133p53 exhibit heightened sensitivity to vitamin C that accumulate to a lethal level due to accelerated uptake via overexpressed GLUT1. These observations offer a new therapeutic avenue that could be exploited for clinical applications.	[Gong, Lu; Lim, Chuan-Bian; de Polo, Anna; Yuan, Zhi-Min] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Gong, Lu; Lim, Chuan-Bian; de Polo, Anna; Little, John B.; Yuan, Zhi-Min] John B Little Ctr Radiat Sci, Boston, MA 02115 USA; [Pan, Xiao] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China; [Pan, Xiao] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou, Zhejiang, Peoples R China	Harvard University; Harvard T.H. Chan School of Public Health; Zhejiang University; Zhejiang University	Yuan, ZM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.; Yuan, ZM (corresponding author), John B Little Ctr Radiat Sci, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Gong, Lu/X-2715-2019; Gong, Lu/AAM-3697-2021	Gong, Lu/0000-0001-9151-0767; de Polo, Anna/0000-0002-5607-8048	Morningside Foundation; National Cancer Institute at the National Institute of Health [R01CA85679, R01CA167814, R01CA125144]; Zhu Fund	Morningside Foundation; National Cancer Institute at the National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Zhu Fund	This work was supported in part by the Morningside Foundation, the Zhu Fund and grants from the National Cancer Institute at the National Institute of Health (R01CA85679, R01CA167814, and R01CA125144).	Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Arsic N, 2015, STEM CELL REP, V4, P531, DOI 10.1016/j.stemcr.2015.02.001; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gong L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37281; Gong L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1033587; Gong L, 2016, J MOL CELL BIOL, V8, P88, DOI 10.1093/jmcb/mjv069; Gong L, 2015, CELL RES, V25, P351, DOI 10.1038/cr.2015.22; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Hofstetter G, 2011, BRIT J CANCER, V105, P1593, DOI 10.1038/bjc.2011.433; Horikawa I, 2017, CELL DEATH DIFFER, V24, P1017, DOI 10.1038/cdd.2017.48; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ji WS, 2015, INT J CLIN EXP PATHO, V8, P10468; Joruiz SM, 2016, COLD SPRING HARBOR P, V6, DOI [10.1101/cshperspect.a02, DOI 10.1101/CSHPERSPECT.A02]; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Liu J, 2015, CANCER LETT, V356, P197, DOI 10.1016/j.canlet.2013.12.025; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mondal AM, 2013, J CLIN INVEST, V123, P5247, DOI 10.1172/JCI70355; Moore HC, 2010, ONCOGENE, V29, P6475, DOI 10.1038/onc.2010.381; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roth I, 2016, ONCOGENE, V35, P4981, DOI 10.1038/onc.2016.45; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Shen L, 2012, CLIN CANCER RES, V18, P1561, DOI 10.1158/1078-0432.CCR-11-3040; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Turnquist C, 2016, CELL DEATH DIFFER, V23, P1515, DOI 10.1038/cdd.2016.37; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004	36	11	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2150	2164		10.1038/s41388-017-0117-8	http://dx.doi.org/10.1038/s41388-017-0117-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29371679				2022-12-28	WOS:000430589000006
J	Molenaar, RJ; Maciejewski, JP; Wilmink, JW; van Noorden, CJF				Molenaar, Remco J.; Maciejewski, Jaroslaw P.; Wilmink, Johanna W.; van Noorden, Cornelis J. F.			Wild-type and mutated IDH1/2 enzymes and therapy responses	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; PREDICT LONGER SURVIVAL; DNA-REPAIR ENZYMES; LOW-GRADE GLIOMAS; MUTANT IDH1; INTRAHEPATIC CHOLANGIOCARCINOMA; OXIDATIVE STRESS; TUMOR-CELLS; IN-VIVO	Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.	[Molenaar, Remco J.; van Noorden, Cornelis J. F.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands; [Molenaar, Remco J.; Wilmink, Johanna W.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Molenaar, Remco J.; Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Cleveland Clinic Foundation	Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA.	r.j.molenaar@amc.nl		Molenaar, Remco/0000-0001-5651-3997	AMC PhD Scholarship; Dutch Cancer Society (KWF) [UVA 2014-6839, AMC2016.1-10460]; National Institutes of Health (Bethesda, MD; NIH) [R01HL118281, R01HL123904, R01HL132071, R35HL135795]; AA & MDS International Foundation (Rockville, MD); Robert Duggan Charitable Fund (Cleveland, OH); NATIONAL CANCER INSTITUTE [K12CA120780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123904, R01HL118281, R01HL132071, R35HL135795] Funding Source: NIH RePORTER	AMC PhD Scholarship; Dutch Cancer Society (KWF)(KWF Kankerbestrijding); National Institutes of Health (Bethesda, MD; NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AA & MDS International Foundation (Rockville, MD); Robert Duggan Charitable Fund (Cleveland, OH); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by AMC PhD Scholarship (to R.J.M), the Dutch Cancer Society (KWF; UVA 2014-6839, to R.J.M. and C.J.F.v.N and AMC2016.1-10460, to R.J.M., J.W.W. and C.J.F.v.N.), the National Institutes of Health (Bethesda, MD; NIH) grants R01HL118281, R01HL123904, R01HL132071, R35HL135795, a grant from the AA & MDS International Foundation (Rockville, MD), and the Robert Duggan Charitable Fund (Cleveland, OH, all to J.P.M.).	Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Atai NA, 2011, J HISTOCHEM CYTOCHEM, V59, P489, DOI 10.1369/0022155411400606; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Boutzen H, 2016, J EXP MED, V213, P483, DOI 10.1084/jem.20150736; Buckner JC, 2016, NEW ENGL J MED, V374, P1344, DOI 10.1056/NEJMoa1500925; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Charitou P, 2015, EMBO REP, V16, P456, DOI 10.15252/embr.201439096; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Chen FY, 2017, CHEM RES TOXICOL, V30, P1102, DOI 10.1021/acs.chemrestox.7b00009; Cimmino L, 2017, CELL, V170, P1079, DOI 10.1016/j.cell.2017.07.032; Cuyas E, 2015, ONCOTARGET, V6, P12279, DOI 10.18632/oncotarget.3733; Dang L, 2017, ANNU REV BIOCHEM, V86, P305, DOI 10.1146/annurev-biochem-061516-044732; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Emadi A, 2014, EXP HEMATOL, V42, P247, DOI 10.1016/j.exphem.2013.12.001; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fu YJ, 2012, INT J BIOCHEM CELL B, V44, P770, DOI 10.1016/j.biocel.2012.01.017; Gagne LM, 2017, TRENDS CELL BIOL, V27, P738, DOI 10.1016/j.tcb.2017.06.002; Gentile M, 2017, EXPERT OPIN INV DRUG, V26, P1307, DOI 10.1080/13543784.2017.1386173; Gilbert MR, 2014, ACTA NEUROPATHOL, V127, P221, DOI 10.1007/s00401-013-1194-6; Goyal L, 2015, ONCOLOGIST, V20, P1019, DOI 10.1634/theoncologist.2015-0210; Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T; Hartmann C, 2011, CLIN CANCER RES, V17, P4588, DOI 10.1158/1078-0432.CCR-10-3194; Holmgren A, 2010, BIOCHEM BIOPH RES CO, V396, P120, DOI 10.1016/j.bbrc.2010.03.083; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813; Karpel-Massler G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00984-9; Kernytsky A, 2015, BLOOD, V125, P296, DOI 10.1182/blood-2013-10-533604; Khurshed M, 2017, ONCOTARGET, V8, P49165, DOI 10.18632/oncotarget.17106; Kim SY, 2013, BIOCHEM BIOPH RES CO, V433, P260, DOI 10.1016/j.bbrc.2013.02.093; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Koehler A, 2003, ENVIRON TOXICOL CHEM, V22, P2703, DOI 10.1897/02-364; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x; Konopleva M, 2016, CANCER DISCOV, V6, P1106, DOI 10.1158/2159-8290.CD-16-0313; Latini A, 2003, EUR J NEUROSCI, V17, P2017, DOI 10.1046/j.1460-9568.2003.02639.x; Lee JH, 2007, FREE RADICAL BIO MED, V42, P44, DOI 10.1016/j.freeradbiomed.2006.09.016; Li KS, 2017, ONCOTARGET, V8, P28865, DOI 10.18632/oncotarget.15868; Li SC, 2013, NEURO-ONCOLOGY, V15, P57, DOI 10.1093/neuonc/nos261; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Losman JA, 2013, GENE DEV, V27, P836, DOI 10.1101/gad.217406.113; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mohrenz IV, 2013, APOPTOSIS, V18, P1416, DOI 10.1007/s10495-013-0877-8; Molenaar RJ, 2015, LEUKEMIA, V29, P2134, DOI 10.1038/leu.2015.91; Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Molenaar RJ, 2014, BBA-REV CANCER, V1846, P326, DOI 10.1016/j.bbcan.2014.05.004; Molenaar RJ, 2014, NEURO-ONCOLOGY, V16, P1263, DOI 10.1093/neuonc/nou005; Molenaar RJ, 2018, CLIN CANC R IN PRESS; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Navis AC, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-18; Okita Y, 2012, INT J ONCOL, V41, P1325, DOI 10.3892/ijo.2012.1564; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Qi ST, 2012, CANCER SCI, V103, P269, DOI 10.1111/j.1349-7006.2011.02134.x; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Shi JL, 2015, TUMOR BIOL, V36, P655, DOI 10.1007/s13277-014-2644-z; Shi JL, 2014, NEUROL SCI, V35, P839, DOI 10.1007/s10072-013-1607-2; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tateishi K, 2017, CANCER RES, V77, P4102, DOI 10.1158/0008-5472.CAN-16-2263; Tateishi K, 2015, CANCER CELL, V28, P773, DOI 10.1016/j.ccell.2015.11.006; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Tran AN, 2014, NEURO-ONCOLOGY, V16, P414, DOI 10.1093/neuonc/not198; van Lith SAM, 2014, NEURO-ONCOLOGY, V16, P1669, DOI 10.1093/neuonc/nou152; van Lith SAM, 2014, BBA-REV CANCER, V1846, P66, DOI 10.1016/j.bbcan.2014.04.004; VANNOORDEN CJF, 1986, HISTOCHEM J, V18, P364, DOI 10.1007/BF01675217; Wahl DR, 2017, CANCER RES, V77, P960, DOI 10.1158/0008-5472.CAN-16-2008; Wang JB, 2014, ASIAN PAC J CANCER P, V15, P427, DOI 10.7314/APJCP.2014.15.1.427; Wang P, 2013, ONCOGENE, V32, P3091, DOI 10.1038/onc.2012.315; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xu QY, 2017, CLIN CANCER RES, V23, P4511, DOI 10.1158/1078-0432.CCR-16-2628; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zhu AX, 2014, ANN SURG ONCOL, V21, P3827, DOI 10.1245/s10434-014-3828-x; Zhu HX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169038	98	135	141	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1949	1960		10.1038/s41388-017-0077-z	http://dx.doi.org/10.1038/s41388-017-0077-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367755	hybrid, Green Published			2022-12-28	WOS:000429899400001
J	Yu, YL; Dai, M; Lu, A; Yu, E; Merlino, G				Yu, Yanlin; Dai, Meng; Lu, Andrew; Yu, Ellen; Merlino, Glenn			PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation	ONCOGENE			English	Article							PROTEIN-KINASE-B; CANCER CELL MOTILITY; TUMOR-SUPPRESSOR; TYROSINE PHOSPHATASES; PROMOTES DEVELOPMENT; PROSTATE-CANCER; PTEN; PROGRESSION; EXPRESSION; SURVIVAL	PI3K/AKT pathway activation is thought to be a driving force in metastatic melanomas. Members of the pleckstrin homology (PH) domain leucine-rich repeat protein Ser/Thr specific phosphatase family (PHLPP1 and PHLPP2) can regulate AKT activation. By dephosphorylating specific serine residues in the hydrophobic motif, PHLPP1 and PHLPP2 restrain AKT signalings, thereby regulating cell proliferation and survival. We here show that PHLPP1 expression was significantly downregulated or lost and correlated with metastatic potential in melanoma. Forcing expression of either PHLPP1 or PHLPP2 in melanoma cells inhibited cell proliferation, migration, and colony formation in soft agar; but PHLPP1 had the most profound inhibitory effect on metastasis. Moreover, expression of PH mutant forms of PHLPP1 continued to inhibit metastasis, whereas a phosphatase-dead C-terminal mutant did not. The introduction of activated PHLPP1-specific targets AKT2 or AKT3 also promoted melanoma metastasis, while the non-PHLPP1 target AKT1 did not. AKT2 and AKT3 could even rescue the PHLPP1-mediated inhibition of metastasis. An AKT inhibitor blocked the activity of AKT2 and inhibited AKT2-mediated tumor growth and metastasis in a preclinical mouse model. Our data demonstrate that PHLPP1 functions as a metastasis suppressor through its phosphatase activity, and suggest that PHLPP1 represents a novel diagnostic and therapeutic marker for metastatic melanoma.	[Yu, Yanlin; Lu, Andrew; Yu, Ellen; Merlino, Glenn] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Dai, Meng] Southern Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Southern Medical University - China	Yu, YL (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	YuY@mail.nih.gov			NIH intramural research program; NATIONAL CANCER INSTITUTE [ZIABC008756] Funding Source: NIH RePORTER	NIH intramural research program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the funding from the NIH intramural research program. We thank Drs. Miriam Anver, Julia Zhang and Hong Sheng for assistance with tissue microarray and immunohistochemistry.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arboleda MJ, 2003, CANCER RES, V63, P196; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cao J, 2016, ONCOTARGET, V7, P82170, DOI 10.18632/oncotarget.10320; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong L, 2014, ONCOGENE, V33, P4756, DOI 10.1038/onc.2013.420; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Mann MB, 2015, NAT GENET, V47, P486, DOI 10.1038/ng.3275; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; O'Hayre M, 2012, LEUKEMIA, V26, P1689, DOI 10.1038/leu.2012.6; O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Qiao JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056382; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Silva JM, 2014, MOL CANCER RES, V12, P447, DOI 10.1158/1541-7786.MCR-13-0224-T; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Wang ZX, 2013, J SURG ONCOL, V108, P427, DOI 10.1002/jso.23419; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yu YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009072; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yu YL, 2002, CANCER RES, V62, P2951	50	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2225	2236		10.1038/s41388-017-0061-7	http://dx.doi.org/10.1038/s41388-017-0061-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391600	Green Accepted			2022-12-28	WOS:000431100200002
J	Shen, LL; Qu, X; Li, HC; Xu, CS; Wei, MY; Wang, QH; Ru, Y; Liu, B; Xu, YQ; Li, K; Hu, JB; Wang, LF; Ma, YZ; Li, MY; Lai, XF; Gao, L; Wu, KC; Yao, LB; Zheng, JY; Zhang, J				Shen, Liangliang; Qu, Xuan; Li, Huichen; Xu, Chunsheng; Wei, Mengying; Wang, Qinhao; Ru, Yi; Liu, Bei; Xu, Yuqiao; Li, Kai; Hu, Junbi; Wang, Lifeng; Ma, Yongzheng; Li, Mengyang; Lai, Xiaofeng; Gao, Lei; Wu, Kaichun; Yao, Libo; Zheng, Jianyong; Zhang, Jian			NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis	ONCOGENE			English	Article							BETA-CATENIN; CELL-CYCLE; TUMOR-SUPPRESSOR; COLON-CARCINOMA; C-MYC; UBIQUITIN LIGASES; BREAST-CANCER; EXPRESSION; SKP2; PATHWAY	Poorly differentiated colorectal cancers (CRCs) are more aggressive and lack targeted therapies. We and others previously reported the predominant role of tumor-suppressor NDRG2 in promoting CRC differentiation, but the underlying mechanism is largely unknown. Herein, we demonstrate that NDRG2 induction of CRC cell differentiation is dependent on the repression of E3 ligase Skp2 activity. In patients and Ndrg2 knockout mice, NDRG2 and Skp2 are negatively correlated and associated with cell differentiation stage. Further, NDRG2 suppression of Skp2 contributes to the inductions and stabilizations of p21 and p27, which are Skp2 target proteins for degradation. The reduction of either p21 or p27 levels by shRNA can decrease NDRG2-induced AKP activity and resume cell growth inhibition, thus both p21 and p27 are required for NDRG2 effect on the promotion of cell differentiation in CRCs. The mechanistic study shows that NDRG2 suppresses beta-catenin nuclear translocation and decreases the occupancy of beta-catenin/TCF complex on Skp2 promoter, potentially through dephosphorylating GSK-3 beta. By subjecting a series of NDRG2 deletion mutants to Skp2 expression, the loss of NH2-terminal domain can completely abolish NDRG2-dependent differentiation induction. Supporting the biological significance of the reciprocal relationship between NDRG2 and Skp2, an NDRG2(low)/Skp2(high) gene expression signature correlates with poor CRC patient outcome and could be considered as a diagnostic marker of CRCs.	[Shen, Liangliang; Li, Huichen; Wei, Mengying; Wang, Qinhao; Ru, Yi; Wang, Lifeng; Ma, Yongzheng; Li, Mengyang; Lai, Xiaofeng; Yao, Libo; Zhang, Jian] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Qu, Xuan] Shaanxi Univ Chinese Med, Xianyang, Peoples R China; [Xu, Chunsheng] 537 Hosp PLA, Dept Gen Surg, Baoji, Peoples R China; [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Shaanxi, Peoples R China; [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian, Shaanxi, Peoples R China; [Xu, Yuqiao] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Xu, Yuqiao] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian, Shaanxi, Peoples R China; [Li, Kai] Gen Hosp Xinjiang Mil Command, Dept Clin Lab, Xinjiang, Peoples R China; [Hu, Junbi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Xian, Shaanxi, Peoples R China; [Gao, Lei] Wuhan Gen Hosp Guangzhou Mil Reg, Dept Urol, Wuhan, Hubei, Peoples R China; [Wu, Kaichun] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Wu, Kaichun] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Zheng, Jianyong] Fourth Mil Med Univ, Xijing Hosp, Dept Gastrointestinal Surg, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China	Air Force Military Medical University; Shaanxi University of Chinese Medicine; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Shen, LL; Zhang, J (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Zheng, JY (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Gastrointestinal Surg, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.	bioliangshen@fmmu.edu.cn; zhjy68@163.com; biozhangj@fmmu.edu.cn		Li, Mengyang/0000-0001-8973-0445	National Natural Science Foundation of China [31401161, 81230043, 31571437, 81502370, 81401069, 81770523, 81502210]; Founds for Creative Research Groups of China [81421003]; State Key Laboratory of Cancer Biology Project [CBSKL2017Z11]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Founds for Creative Research Groups of China; State Key Laboratory of Cancer Biology Project	This work was financially sponsored by grants from the National Natural Science Foundation of China (no. 31401161; no. 81230043; no. 31571437; no. 81502370; no. 81401069; no. 81770523; and no. 81502210), the Founds for Creative Research Groups of China (no. 81421003), and the State Key Laboratory of Cancer Biology Project (CBSKL2017Z11).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chen J, 1996, ONCOGENE, V13, P1395; Chu D, 2011, MOL CANCER THER, V10, P47, DOI 10.1158/1535-7163.MCT-10-0614; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Derwinger K, 2010, ACTA ONCOL, V49, P57, DOI 10.3109/02841860903334411; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Guo YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077305; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Kang K, 2015, BIOCHEM BIOPH RES CO, V468, P611, DOI 10.1016/j.bbrc.2015.10.167; Kim SJ, 2014, CELL DEATH DIFFER, V21, P1769, DOI 10.1038/cdd.2014.88; Kim YJ, 2013, ONCOL REP, V30, P1890, DOI 10.3892/or.2013.2642; Kim YJ, 2009, CARCINOGENESIS, V30, P598, DOI 10.1093/carcin/bgp047; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li X, 2007, CANCER RES, V67, P8716, DOI 10.1158/0008-5472.CAN-06-3731; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lorentzen A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-192; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakahata S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4393; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Ng RCL, 2014, CELL DEATH DIFFER, V21, P978, DOI 10.1038/cdd.2014.20; Pfeuty B, 2008, CELL CYCLE, V7, P3246, DOI 10.4161/cc.7.20.6853; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Qu X, 2014, J INVEST DERMATOL, V134, P159, DOI 10.1038/jid.2013.281; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shen L, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.48; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian YF, 2013, TUMOR BIOL, V34, P1107, DOI 10.1007/s13277-013-0652-z; Xu XY, 2015, ONCOTARGET, V6, P26161, DOI 10.18632/oncotarget.4544; Yao LB, 2008, ACTA BIOCH BIOPH SIN, V40, P625, DOI 10.1111/j.1745-7270.2008.00434.x; Zhang J, 2006, J BIOL CHEM, V281, P39159, DOI 10.1074/jbc.M605820200	41	36	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1759	1774		10.1038/s41388-017-0118-7	http://dx.doi.org/10.1038/s41388-017-0118-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29343851	Green Published, hybrid			2022-12-28	WOS:000428632600006
J	Wang, E; Sorolla, A; Cunningham, PT; Bogdawa, HM; Beck, S; Golden, E; Dewhurst, RE; Florez, L; Cruickshank, MN; Hoffmann, K; Hopkins, RM; Kim, J; Woo, AJ; Watt, PM; Blancafort, P				Wang, Edina; Sorolla, Anabel; Cunningham, Paula T.; Bogdawa, Heique M.; Beck, Samuel; Golden, Emily; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Hopkins, Richard M.; Kim, Jonghwan; Woo, Andrew J.; Watt, Paul M.; Blancafort, Pilar			Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers	ONCOGENE			English	Article							BET BROMODOMAIN INHIBITORS; C-MYC; TRANSCRIPTION FACTOR; RESISTANCE; OMOMYC; MAX; CHEMOTHERAPY; ACTIVATION; EFFICACY; PROTEIN	Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic strategy to inhibit MYC in TNBC. We found FPPa-OmoMYC to be a potent inducer of apoptosis (with IC50 from 1-2 mu M) in TNBC cells with negligible effects in non-tumorigenic cells. Transcriptome analysis of FPPa-OmoMYC-treated cells indicated that the fusion protein inhibited MYC-dependent networks, inducing dynamic changes in transcriptional, metabolic, and apoptotic processes. We demonstrated the efficacy of FPPa-OmoMYC in inhibiting breast cancer growth when injected orthotopically in TNBC allografts. Lastly, we identified strong pharmacological synergisms between FPPa-OmoMYC and chemotherapeutic agents. This study highlights a novel therapeutic approach to target highly aggressive and chemoresistant MYC-activated cancers.	[Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Blancafort, Pilar] Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Hoffmann, Katrin; Hopkins, Richard M.; Watt, Paul M.] Phylog Pty Ltd, Subiaco, WA 6008, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Watt, Paul M.] Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia; [Beck, Samuel; Kim, Jonghwan] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Beck, Samuel] Kathryn W Davis Ctr Regenerat Biol & Med, MDI Biol Lab, Salsbury Cove, ME 04672 USA	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Texas System; University of Texas Austin	Blancafort, P (corresponding author), QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia.; Watt, PM (corresponding author), Phylog Pty Ltd, Subiaco, WA 6008, Australia.; Watt, PM (corresponding author), Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia.	paul.watt@telethonkids.org.au; pilar.blancafort@uwa.edu.au	Kim, Jonghwan/AAR-2815-2021; Wang, Edina/AAC-5455-2019; Sorolla, Anabel/E-2546-2012	Sorolla, Anabel/0000-0001-8238-8763; Cruickshank, Mark/0000-0002-1869-1175; Woo, Andrew/0000-0003-1198-6373; Beck, Samuel/0000-0002-0184-8367; Dewhurst, Robert/0000-0001-8441-4427; Golden, Emily/0000-0001-6386-201X; Blancafort, Pilar/0000-0002-3881-7396; Wang, Edina/0000-0002-9652-3513; Kim, Jonghwan/0000-0002-9919-9843	ARC Future Fellowship [FT130101767]; CCWA Research Fellowship; NHMRC [APP1069308]; NIH [R01CA170370, R01DA036906]; NCBF [NC-14-024]; RPHMRF; CCWA;  [R01GM112722]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104318, R01GM112722] Funding Source: NIH RePORTER	ARC Future Fellowship(Australian Research Council); CCWA Research Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCBF; RPHMRF; CCWA(Cancer Council Western Australia); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants awarded to PB: the ARC Future Fellowship FT130101767, the CCWA Research Fellowship, NHMRC grant APP1069308, NIH grants R01CA170370, R01DA036906, and the NCBF NC-14-024. JK is supported by R01GM112722. AJW is supported by the RPHMRF and the CCWA. AS is supported by NCBF. We would like to acknowledge the Centre for Microscopy, Characterisation & Analysis, the FACS facility and the AGFR at Harry Perkins Institute.	Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bid HK, 2016, MOL CANCER THER, V15, P1018, DOI 10.1158/1535-7163.MCT-15-0567; Bidwell GL, 2006, BIOCHEM PHARMACOL, V71, P248, DOI 10.1016/j.bcp.2005.10.041; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cinar M, 2015, LEUKEMIA RES, V39, P730, DOI 10.1016/j.leukres.2015.04.003; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2016, CELL, V146, P904; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005; Galardi S, 2016, EMBO REP, V17, P1872, DOI 10.15252/embr.201541489; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Giorello L, 1998, CANCER RES, V58, P3654; Green AR, 2016, BRIT J CANCER, V114, P917, DOI 10.1038/bjc.2016.46; Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Hart JR, 2014, P NATL ACAD SCI USA, V111, P12556, DOI 10.1073/pnas.1319488111; HENDERSON IC, 1989, J CLIN ONCOL, V7, P560, DOI 10.1200/JCO.1989.7.5.560; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; HSU B, 1995, ONCOGENE, V11, P175; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jung LA, 2017, ONCOGENE, V36, P1911, DOI 10.1038/onc.2016.354; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Pereira CBL, 2017, CLIN BREAST CANCER, V17, P188, DOI 10.1016/j.clbc.2016.12.005; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Milech N, 2015, SCI REP-UK, V5, DOI 10.1038/srep18329; Milech Nadia, 2012, Methods Mol Biol, V899, P43, DOI 10.1007/978-1-61779-921-1_3; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Sharma P, 2017, CLIN CANCER RES, V23, P649, DOI 10.1158/1078-0432.CCR-16-0162; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shi XR, 2016, P NATL ACAD SCI USA, V113, pE4558, DOI 10.1073/pnas.1608319113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stellas D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju320; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Watt PM, 2017, CURR OPIN CHEM BIOL, V38, P127, DOI 10.1016/j.cbpa.2017.03.016; Watt PM, 2009, FUTURE MED CHEM, V1, P257, DOI [10.4155/fmc.09.28, 10.4155/FMC.09.28]; Watt PM, 2006, NAT BIOTECHNOL, V24, P177, DOI 10.1038/nbt1190; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	74	37	38	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					140	150		10.1038/s41388-018-0421-y	http://dx.doi.org/10.1038/s41388-018-0421-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076412	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000454775900010
J	Molenaar, RJ; Maciejewski, JP; Wilmink, JW; van Noorden, CJF				Molenaar, Remco J.; Maciejewski, Jaroslaw P.; Wilmink, Johanna W.; van Noorden, Cornelis J. F.			Wild-type and mutated IDH1/2 enzymes and therapy responses (vol 37, pg 1949, 2018)	ONCOGENE			English	Correction									[Molenaar, Remco J.; van Noorden, Cornelis J. F.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands; [Molenaar, Remco J.; Wilmink, Johanna W.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Molenaar, Remco J.; Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Cleveland Clinic Foundation	Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA.	r.j.molenaar@amc.nl						Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z	1	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5810	5810		10.1038/s41388-018-0455-1	http://dx.doi.org/10.1038/s41388-018-0455-1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	30140044	hybrid, Green Published			2022-12-28	WOS:000448288200008
J	Peng, MG; Wang, JJ; Zhang, DY; Jin, HL; Li, JX; Wu, XR; Huang, CS				Peng, Minggang; Wang, Jingjing; Zhang, Dongyun; Jin, Honglei; Li, Jingxia; Wu, Xue-Ru; Huang, Chuanshu			PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein	ONCOGENE			English	Article							DOWN-REGULATION CONTRIBUTES; MATRIX METALLOPROTEINASES; PROGNOSTIC-SIGNIFICANCE; UP-REGULATION; IN-VITRO; CELL; EXPRESSION; P27(KIP1); AKT; ISORHAPONTIGENIN	Pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) is a tumor suppressor that catalyzes the dephosphorylation of the AGC kinases, while p27 acts as a tumor suppressor that regulates cell cycle, apoptosis, and cell motility. Our previous studies have identified that PHLPP2 participates in inhibition of transformation of human bronchial epithelial cells following lung carcinogen B[a] P/B[a] PDE exposure. However, nothing was known about the association of p27 with regulation of PHLPP2 expression and the role of PHLPP2 in bladder cancer (BC) invasion. In our current studies, we demonstrated that PHLPP2 inhibited BC invasion through promoting MMP2 degradation via p62-mediated autophagy; and p27 expression was able to stabilize PHLPP2 protein by inhibiting protein degradation of Hsp90, which could directly bind to PHLPP2 and protect it from degradation. More in-depth studies discovered that stabilization of Hsp90 by p27 was mediated by calpain1 proteolysis system, whereas p27 inhibited calpain1 gene transcription by attenuating Jak1/Stat1 cascade in human invasive BC cells. Collectively, we for the first time revealed PHLPP2 downregulation in BCs and its participating in promotion of BC invasion, as well as novel role of p27 and mechanisms underlying its regulation of PHLPP2 protein degradation through Hsp90-dependent manner. Our findings improve our understanding of p27 and PHLPP2 roles and their crosstalk in regulation of BC invasion, which further contributes to improve the current strategy for invasive bladder cancer therapy.	[Peng, Minggang; Wang, Jingjing; Zhang, Dongyun; Li, Jingxia; Huang, Chuanshu] NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA; [Peng, Minggang] Huazhong Univ Sci & Technol, Union Hosp, Dept Obstet & Gynecol, Tongji Med Coll, 1277 JieFang Ave, Wuhan 430022, Hubei, Peoples R China; [Jin, Honglei] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Wu, Xue-Ru] NYU, Sch Med, Dept Urol, New York, NY 10016 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; Huazhong University of Science & Technology; Wenzhou Medical University; New York University; New York University	Huang, CS (corresponding author), NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA.	Chuanshu.huang@nyumc.org		Huang, Chuanshu/0000-0003-4133-5096; Wu, Xue-Ru/0000-0001-6058-6291	NIH/NCI [CA165980, CA177665, CA217923]; NIH/NIEHS [ES000260]; Natural Science Foundation of China [NSFC91773391]; Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China); NATIONAL CANCER INSTITUTE [P01CA165980, R01CA177665, R01CA217923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was partially supported by the grants of NIH/NCI CA165980, CA177665, and CA217923, and NIH/NIEHS ES000260, and by grants of the Natural Science Foundation of China NSFC91773391 and the Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China).	Au-Yeung Nancy, 2013, JAKSTAT, V2, pe23931, DOI 10.4161/jkst.23931; Averna M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116738; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chou R, 2016, CANCER-AM CANCER SOC, V122, P842, DOI 10.1002/cncr.29843; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Dong GJ, 2015, EUR J IMMUNOL, V45, P2377, DOI 10.1002/eji.201445349; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Esposito V, 1997, CANCER RES, V57, P3381; Fang Y, 2013, MOL CANCER THER, V12, P1492, DOI 10.1158/1535-7163.MCT-12-0922; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Huang HS, 2015, CLIN CANCER RES, V21, P3783, DOI 10.1158/1078-0432.CCR-14-2829; Huang HS, 2014, ONCOTARGET, V5, P493, DOI 10.18632/oncotarget.1643; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Jin HL, 2015, ONCOTARGET, V6, P522, DOI 10.18632/oncotarget.2680; Kamai T, 2000, BJU INT, V86, P14, DOI 10.1046/j.1464-410x.2000.00726.x; Kamai T, 2001, BRIT J CANCER, V84, P1242, DOI 10.1054/bjoc.2000.1736; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; LEVI F, 1993, INT J CANCER, V55, P419, DOI 10.1002/ijc.2910550316; Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704; Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Liu T, 2015, GENET TEST MOL BIOMA, V19, P548, DOI 10.1089/gtmb.2015.0123; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lovaas JD, 2013, PROSTATE, V73, P522, DOI 10.1002/pros.22592; Masciullo V, 1999, CANCER RES, V59, P3790; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Park SL, 2015, ONCOL REP, V34, P1605, DOI 10.3892/or.2015.4119; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Primdahl H, 2002, J CANCER RES CLIN, V128, P295, DOI 10.1007/s00432-002-0344-3; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rabbani F, 2007, BJU INT, V100, P259, DOI 10.1111/j.1464-410X.2007.06927.x; Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0; Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Storr SJ, 2011, NAT REV CANCER, V11, P364, DOI 10.1038/nrc3050; VANDERBURG MEL, 1988, GYNECOL ONCOL, V30, P307, DOI 10.1016/0090-8258(88)90244-2; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Wang Y, 2016, ONCOGENE, V35, P4080, DOI 10.1038/onc.2015.470; Wang Y, 2014, CELL REP, V6, P278, DOI 10.1016/j.celrep.2013.12.031; Xu JW, 2016, ONCOTARGET, V7, P34112, DOI 10.18632/oncotarget.8746; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754; Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.496; Zhang DY, 2014, J CELL SCI, V127, P2920, DOI 10.1242/jcs.148130; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhou L, 2013, ACTA PHARMACOL SIN, V34, P651, DOI 10.1038/aps.2013.12	57	26	28	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5735	5748		10.1038/s41388-018-0374-1	http://dx.doi.org/10.1038/s41388-018-0374-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930380	Green Published, hybrid			2022-12-28	WOS:000448288200003
J	Kim, Y; Shiba-Ishii, A; Nakagawa, T; Iemura, S; Natsume, T; Nakano, N; Matsuoka, R; Sakashita, S; Lee, S; Kawaguchi, A; Sato, Y; Noguchi, M				Kim, Yunjung; Shiba-Ishii, Aya; Nakagawa, Tomoki; Iemura, Shun-Ichiro; Natsume, Tohru; Nakano, Noriyuki; Matsuoka, Ryota; Sakashita, Shingo; Lee, SangJoon; Kawaguchi, Atsushi; Sato, Yukio; Noguchi, Masayuki			Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma	ONCOGENE			English	Article							STRUCTURAL BASIS; UBPY; USP8; 14-3-3-SIGMA; STABILITY; CANCER; ENZYME; DEUBIQUITINATION; CLASSIFICATION; TRAFFICKING	Previously we have reported that stratifin (SFN, 14-3-3 sigma) acts as a novel oncogene, accelerating the tumor initiation and progression of lung adenocarcinoma. Here, pull-down assay and LC-MS/MS analysis revealed that ubiquitin-specific protease 8 (USP8) specifically bound to SFN in lung adenocarcinoma cells. Both USP8 and SFN showed higher expression in human lung adenocarcinoma than in normal lung tissue, and USP8 expression was significantly correlated with SFN expression. Expression of SFN, but not of USP8, was associated with histological subtype, pathological stage, and poor prognosis. USP8 stabilizes receptor tyrosine kinases (RTKs) such as EGFR and MET by deubiquitination, contributing to the proliferative activity of many human cancers including non-small cell lung cancer. In vitro, USP8 binds to SFN and they co-localize at the early endosomes in lung adenocarcinoma cells. Moreover, USP8 or SFN knockdown leads to downregulation of tumor cellular proliferation and upregulation of apoptosis, p-EGFR or p-MET, which are related to the degradation pathway, and accumulation of ubiquitinated RTKs, leading to lysosomal degradation. Additionally, mutant USP8, which is unable to bind to SFN, reduces the expression of RTKs and p-STAT3. We also found that interaction with SFN is critical for USP8 to exert its auto-deubiquitination function and avoid dephosphorylation by PP1. Our findings demonstrate that SFN enhances RTK stabilization through abnormal USP8 regulation in lung adenocarcinoma, suggesting that SFN could be a more suitable therapeutic target for lung adenocarcinoma than USP8.	[Kim, Yunjung; Shiba-Ishii, Aya; Nakano, Noriyuki; Matsuoka, Ryota; Sakashita, Shingo; Noguchi, Masayuki] Univ Tsukuba, Dept Pathol, Fac Med, Ibaraki, Japan; [Nakagawa, Tomoki] Univ Tsukuba, Doctoral Program Biomed Sci, Grad Sch Comprehens Human Sci, Ibaraki, Japan; [Iemura, Shun-Ichiro] Fukushima Med Univ, Translat Res Ctr, Fukushima, Japan; [Natsume, Tohru] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan; [Lee, SangJoon] Univ Tsukuba, PhD Program Human Biol, Sch Integrat & Global Majors, Ibaraki, Japan; [Kawaguchi, Atsushi] Univ Tsukuba, Dept Infect Biol, Fac Med, Ibaraki, Japan; [Sato, Yukio] Univ Tsukuba, Dept Thorac Surg, Fac Med, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; Fukushima Medical University; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; University of Tsukuba; University of Tsukuba	Shiba-Ishii, A; Noguchi, M (corresponding author), Univ Tsukuba, Dept Pathol, Fac Med, Ibaraki, Japan.	aya_shiba@md.tsukuba.ac.jp; nmasayuk@md.tsukuba.ac.jp	Lee, SangJoon/AAL-3341-2021; Kim, Yunjung/AAF-9373-2020	Lee, SangJoon/0000-0001-7500-782X; KIM, Yunjung/0000-0003-3922-3642				Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Ballif BA, 2006, J PROTEOME RES, V5, P2372, DOI 10.1021/pr060206k; Bansal P, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00112; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; Byun S, 2013, CLIN CANCER RES, V19, P3894, DOI 10.1158/1078-0432.CCR-12-3696; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Dufner A, 2015, NAT IMMUNOL, V16, P950, DOI 10.1038/ni.3230; Fraile JM, 2012, ONCOGENE, V31, P2373, DOI 10.1038/onc.2011.443; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Huang WG, 2010, INT J BIOCHEM CELL B, V42, P137, DOI 10.1016/j.biocel.2009.10.001; Kakinuma R, 2016, J THORAC ONCOL, V11, P1012, DOI 10.1016/j.jtho.2016.04.006; Kim JO, 2015, ONCOTARGET, V6, P36551, DOI 10.18632/oncotarget.5336; Kim Y, 2017, PATHOL INT, V67, P292, DOI 10.1111/pin.12546; Komada Masayuki, 2008, Curr Drug Discov Technol, V5, P78, DOI 10.2174/157016308783769469; Ledda F, 2007, BIOMARK INSIGHTS, V2, P45; Li ZM, 2009, AM J TRANSL RES, V1, P326; Ma ZY, 2015, CELL RES, V25, P306, DOI 10.1038/cr.2015.20; Mei Yide, 2011, J Biol Chem, V286, P35380, DOI 10.1074/jbc.M111.282020; Meijer IMJ, 2013, CELL SIGNAL, V25, P919, DOI 10.1016/j.cellsig.2013.01.003; Meijer IMJ, 2011, CELL SIGNAL, V23, P458, DOI 10.1016/j.cellsig.2010.10.023; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2007, EXP CELL RES, V313, P3624, DOI 10.1016/j.yexcr.2007.07.028; Mukai A, 2010, EMBO J, V29, P2114, DOI 10.1038/emboj.2010.100; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Panner A, 2010, CANCER RES, V70, P5046, DOI 10.1158/0008-5472.CAN-09-3979; Pareja F, 2012, ONCOGENE, V31, P4599, DOI 10.1038/onc.2011.587; Perez-Rivas LG, 2015, J CLIN ENDOCR METAB, V100, pE997, DOI 10.1210/jc.2015-1453; Reincke M, 2015, NAT GENET, V47, P31, DOI 10.1038/ng.3166; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Sato T, 2017, CANCER SCI, V108, P536, DOI 10.1111/cas.13148; Savio MG, 2016, CURR BIOL, V26, P173, DOI 10.1016/j.cub.2015.11.050; Sbiera S, 2015, TRENDS ENDOCRIN MET, V26, P573, DOI 10.1016/j.tem.2015.08.003; Shiba-Ishii A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0414-1; Shiba-Ishii A, 2012, AM J PATHOL, V180, P1653, DOI 10.1016/j.ajpath.2011.12.014; Shiba-Ishii A, 2011, INT J CANCER, V129, P2445, DOI 10.1002/ijc.25907; Shimada A, 2005, CANCER SCI, V96, P668, DOI 10.1111/j.1349-7006.2005.00100.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith AJ, 2011, PHYSIOLOGY, V26, P181, DOI 10.1152/physiol.00042.2010; Smith GA, 2016, TRAFFIC, V17, P53, DOI 10.1111/tra.12341; Takeuchi K, 2011, BIOL PHARM BULL, V34, P1774, DOI 10.1248/bpb.34.1774; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Xia RH, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001238; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	52	23	23	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5387	5402		10.1038/s41388-018-0342-9	http://dx.doi.org/10.1038/s41388-018-0342-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29880877				2022-12-28	WOS:000446312900002
J	Li, D; Chen, YJ; Mei, H; Jiao, WJ; Song, HJ; Ye, L; Fang, EH; Wang, XJ; Yang, F; Huang, K; Zheng, LD; Tong, QS				Li, Dan; Chen, Yajun; Mei, Hong; Jiao, Wanju; Song, Huajie; Ye, Lin; Fang, Erhu; Wang, Xiaojing; Yang, Feng; Huang, Kai; Zheng, Liduan; Tong, Qiangsong			Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; TUMOR-SUPPRESSOR; MESSENGER-RNA; PROTEIN NONO; METASTASIS; EXPRESSION; ANGIOGENESIS; INVASION; GENE	Emerging studies have indicated the essential functions of long noncoding RNAs (lncRNAs) during cancer progression. However, whether lncRNAs contribute to the upregulation of v-ets erythroblastosis virus E26 oncogene homolog 1 (Ets-1), an established oncogenic protein facilitating tumor invasion and metastasis, in gastric cancer remains elusive. Herein, we identified Ets-1 promoter-associated noncoding RNA (pancEts-1) as a novel lncRNA associated with the gastric cancer progression via mining of publicly available datasets and rapid amplification of cDNA ends. RNA pull-down, RNA immunoprecipitation, in vitro binding, and RNA electrophoretic mobility shift assays indicated the binding of pancEts-1 to non-POU domain containing octamer binding (NONO) protein. Mechanistically, pancEts-1 facilitated the physical interaction between NONO and Ets related gene (ERG), resulting in increased ERG transactivation and transcription of Ets-1 associated with gastric cancer progression. In addition, pancEts-1 facilitated the growth and aggressiveness of gastric cancer cells via interacting with NONO. In gastric cancer tissues, pancEts-1, NONO, and ERG were upregulated and significantly correlated with Ets-1 levels. High levels of pancEts-1, NONO, ERG, or Ets-1 were respectively associated with poor survival of gastric cancer patients, whereas simultaneous expression of all of them (HR = 3.012, P = 0.105) was not an independent prognostic factor for predicting clinical outcome. Overall, these results demonstrate that lncRNA pancEts-1 exhibits oncogenic properties that drive the progression of gastric cancer via regulating the NONO/ERG/Ets-1 axis.	[Li, Dan; Mei, Hong; Song, Huajie; Ye, Lin; Fang, Erhu; Wang, Xiaojing; Yang, Feng; Tong, Qiangsong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Chen, Yajun; Jiao, Wanju; Zheng, Liduan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Huang, Kai; Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404; Zheng, Liduan/0000-0001-5566-673X	National Natural Science Foundation of China [81772967, 81773094, 81672500, 81572423, 81402408, 81402301, 81472363, 81372667, 81272779]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We appreciate Dr. Jean-Yves Masson for construct gifts. This work was granted by National Natural Science Foundation of China (81772967, 81773094, 81672500, 81572423, 81402408, 81402301, 81472363, 81372667, 81272779), and Natural Science Foundation of Hubei Province (2014CFA012).	Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; CHEN JH, 1993, ONCOGENE, V8, P133; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; Davidson B, 2001, CLIN CANCER RES, V7, P551; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Dong XS, 2009, MOL ENDOCRINOL, V23, P1147, DOI 10.1210/me.2008-0357; Duraes C, 2014, VIRCHOWS ARCH, V464, P367, DOI 10.1007/s00428-013-1533-y; Fujimoto J, 2002, ANN ONCOL, V13, P1598, DOI 10.1093/annonc/mdf248; Gu CH, 2010, GENOMICS, V95, P278, DOI 10.1016/j.ygeno.2010.02.005; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HART AH, 1995, ONCOGENE, V10, P1423; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; Kabbout M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100693; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Liu YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02254-6; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Meadows SM, 2011, SEMIN CELL DEV BIOL, V22, P976, DOI 10.1016/j.semcdb.2011.09.009; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Naito S, 2002, BIOCHEM BIOPH RES CO, V291, P130, DOI 10.1006/bbrc.2002.6418; Pham DH, 2017, HUM MOL GENET, V26, P2042, DOI 10.1093/hmg/ddx094; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Singh AK, 2011, J BIOL CHEM, V286, P21961, DOI 10.1074/jbc.M111.238238; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Takai N, 2002, INT J MOL MED, V9, P287; Terry MB, 2002, SEMIN RADIAT ONCOL, V12, P111, DOI 10.1053/srao.30814; Tokuhara K, 2003, INT SURG, V88, P25; Tsofack SP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-145; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Wei JR, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-22; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yadav SP, 2014, HUM MOL GENET, V23, P2132, DOI 10.1093/hmg/ddt609; Yamaguchi E, 2007, TOHOKU J EXP MED, V213, P41, DOI 10.1620/tjem.213.41; Yamauchi T, 2012, BIOCHEM BIOPH RES CO, V425, P711, DOI 10.1016/j.bbrc.2012.07.103; Yang P, 2016, ONCOTARGET, V7, P42183, DOI 10.18632/oncotarget.9741; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhang HY, 2012, MOL CANCER THER, V11, P1454, DOI 10.1158/1535-7163.MCT-12-0001; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zheng LD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.293; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	58	31	33	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4871	4886		10.1038/s41388-018-0302-4	http://dx.doi.org/10.1038/s41388-018-0302-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773901	Green Published, hybrid			2022-12-28	WOS:000443146000008
J	McClurg, UL; Chit, NCTH; Azizyan, M; Edwards, J; Nabbi, A; Riabowol, KT; Nakjang, S; McCracken, SR; Robson, CN				McClurg, Urszula L.; Chit, Nay C. T. H.; Azizyan, Mahsa; Edwards, Joanne; Nabbi, Arash; Riabowol, Karl T.; Nakjang, Sirintra; McCracken, Stuart R.; Robson, Craig N.			Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12	ONCOGENE			English	Article							DEUBIQUITINATING ENZYME USP12; ANDROGEN RECEPTOR; RESISTANCE; INHIBITORS; MDM2; PHOSPHORYLATION; IDENTIFICATION; UBIQUITINATION; CHEMOTHERAPY; DEGRADATION	The TP53-MDM2-AR-AKT signalling network plays a critical role in the development and progression of prostate cancer. However, the molecular mechanisms regulating this signalling network are not completely defined. By conducting transcriptome analysis, denaturing immunoprecipitations and immunopathology, we demonstrate that the TP53-MDM2-AR-AKT cross-talk is regulated by the deubiquitinating enzyme USP12 in prostate cancer. Our findings explain why USP12 is one of the 12 most commonly overexpressed cancer-associated genes located near an amplified super-enhancer. We find that USP12 deubiquitinates MDM2 and AR, which in turn controls the levels of the TP53 tumour suppressor and AR oncogene in prostate cancer. Consequently, USP12 levels are predictive not only of cancer development but also of patient's therapy resistance, relapse and survival. Therefore, our findings suggest that USP12 could serve as a promising therapeutic target in currently incurable castrate-resistant prostate cancer.	[McClurg, Urszula L.; Chit, Nay C. T. H.; Azizyan, Mahsa; Nakjang, Sirintra; McCracken, Stuart R.; Robson, Craig N.] Newcastle Univ, Northern Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [McClurg, Urszula L.] Newcastle Univ, Inst Cell & Mol Biosci, Med Sch, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Edwards, Joanne] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Wolfson Wohl Canc Res Ctr, Glasgow G61 1QH, Lanark, Scotland; [Nabbi, Arash; Riabowol, Karl T.] Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; [Nakjang, Sirintra] Newcastle Univ, Bioinformat Support Unit, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; University of Glasgow; University of Calgary; Newcastle University - UK	McClurg, UL; Robson, CN (corresponding author), Newcastle Univ, Northern Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; McClurg, UL (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Med Sch, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Urszula.McClurg@ncl.ac.uk; Craig.Robson@ncl.ac.uk	Edwards, Joanne/J-1903-2015	Edwards, Joanne/0000-0002-7192-6906; McClurg, Urszula/0000-0003-2631-4174; Nabbi, Arash/0000-0002-3195-7361	PC UK [PG09-23]; JGWP Foundation [BH142412]; JRE Scientific Committee Charity; Newcastle Healthcare Charity [JG/ML/0414]; Cancer Research UK [C27826/A15994]; Newcastle University	PC UK; JGWP Foundation; JRE Scientific Committee Charity; Newcastle Healthcare Charity; Cancer Research UK(Cancer Research UK); Newcastle University	ULM, SRM and CNR were funded by PC UK (PG09-23), JGWP Foundation (BH142412) and JRE Scientific Committee Charity, Newcastle Healthcare Charity (JG/ML/0414). CNR is supported by Cancer Research UK (C27826/A15994). NCTHC was funded by Newcastle University.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2016, NAT REV UROL, V13, P697, DOI 10.1038/nrurol.2016.212; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Binda O, 2013, EPIGENETICS-US, V8, P177, DOI 10.4161/epi.23416; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Burska UL, 2013, J BIOL CHEM, V288, P32641, DOI 10.1074/jbc.M113.485912; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Dexheimer TS, 2014, J MED CHEM, V57, P8099, DOI 10.1021/jm5010495; Dexheimer TS, 2010, PROBE REPORTS NIH MO; Dharadhar S, 2016, J STRUCT BIOL, V196, P437, DOI 10.1016/j.jsb.2016.09.011; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Joshi S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1531-3; Kee Y, 2010, J BIOL CHEM, V285, P11252, DOI 10.1074/jbc.M109.095141; Kirkegaard T, 2006, HISTOPATHOLOGY, V48, P787, DOI 10.1111/j.1365-2559.2006.02412.x; Lee JK, 2016, NEURO-ONCOLOGY, V18, P37, DOI 10.1093/neuonc/nov091; Li H, 2016, MOL CELL, V63, P249, DOI 10.1016/j.molcel.2016.05.031; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu JB, 2016, INT J ONCOL, V49, P2549, DOI 10.3892/ijo.2016.3752; Lohiya V, 2016, CLIN MED INSIGHTS-ON, V10, P57, DOI 10.4137/CMO.S34535; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Marques RB, 2015, EUR UROL, V67, P1177, DOI 10.1016/j.eururo.2014.08.053; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McClurg UL, 2017, NUCLEIC ACIDS RES, V45, P1793, DOI 10.1093/nar/gkw1162; McClurg UL, 2015, ONCOTARGET, V6, P37724, DOI 10.18632/oncotarget.6075; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; McClurg UL, 2014, ONCOTARGET, V5, P7081, DOI 10.18632/oncotarget.2162; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Poletto M, 2016, NUCLEIC ACIDS RES, V44, P3165, DOI 10.1093/nar/gkw015; Rigas AC, 2007, ONCOGENE, V26, P7611, DOI 10.1038/sj.onc.1210586; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sourisseau T, 2016, CELL CYCLE, V15, P295, DOI 10.1080/15384101.2015.1120918; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Wahi Divya, 2015, Syst Synth Biol, V9, P33, DOI 10.1007/s11693-015-9162-1; Willder JM, 2013, BRIT J CANCER, V108, P139, DOI 10.1038/bjc.2012.480; Xiong XP, 2016, J BIOL CHEM, V291, P25167, DOI 10.1074/jbc.M116.740639; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhang ZQ, 2012, J CANCER RES CLIN, V138, P1231, DOI 10.1007/s00432-012-1193-3	51	21	21	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4679	4691		10.1038/s41388-018-0283-3	http://dx.doi.org/10.1038/s41388-018-0283-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755129	Green Accepted, Green Submitted			2022-12-28	WOS:000442514400004
J	Maurizi, G; Verma, N; Gadi, A; Mansukhani, A; Basilico, C				Maurizi, Giulia; Verma, Narendra; Gadi, Abhilash; Mansukhani, Alka; Basilico, Claudio			Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma	ONCOGENE			English	Article							HIPPO PATHWAY; SELF-RENEWAL; MAINTAIN STEMNESS; ADULT; YAP; P53; RB	The stem cell transcription factor Sox2 is highly expressed in many cancers where it is thought to mark cancer stem cells (CSCs). In osteosarcomas, the most common bone malignancy, high Sox2 expression marks and maintains a fraction of tumor-initiating cells that show all the properties of CSC. Knockdown of Sox2 expression abolishes tumorigenicity and suppresses the CSC phenotype. Here we show that, in a mouse model of osteosarcoma, osteoblast-specific Sox2 conditional knockout (CKO) causes a drastic reduction in the frequency and onset of tumors. The rare tumors detected in the Sox2 CKO animals were all Sox2 positive, indicating that they arose from cells that had escaped Sox2 deletion. Furthermore, Sox2 inactivation in cultured osteosarcoma cells by CRISPR/CAS technology leads to a loss of viability and proliferation of the entire cell population. Inactivation of the YAP gene, a major Hippo pathway effector which is a direct Sox2 target, causes similar results and YAP overexpression rescues cells from the lethality caused by Sox2 inactivation. These effects were osteosarcoma-specific, suggesting a mechanism of cell "addiction" to Sox2-initiated pathways. The requirement of Sox2 for osteosarcoma formation as well as for the survival of the tumor cells suggests that disruption of Sox2-initiated pathways could be an effective strategy for the treatment of osteosarcoma.	[Maurizi, Giulia; Verma, Narendra; Gadi, Abhilash; Mansukhani, Alka; Basilico, Claudio] NYU Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Mansukhani, A; Basilico, C (corresponding author), NYU Sch Med, Dept Microbiol, New York, NY 10016 USA.	Alka.Mansukhani@med.nyu.edu; Claudio.Basilico@med.nyu.edu		Mansukhani, Alka/0000-0003-1020-3242; Maurizi, Giulia/0000-0003-0373-1370	NYSTEM [CO29560];  [NIH/NCI-R21CA186031]; NATIONAL CANCER INSTITUTE [R21CA186031] Funding Source: NIH RePORTER	NYSTEM; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This investigation was supported by NYSTEM contract CO29560 and NIH/NCI-R21CA186031. We thank Dr. Stuart Orkin for providing us with the Tp53, Rb mutant mice; Matthew Murtha for his contribution to some of the initial experiments; and Upal BasuRoy for helpful discussions. We also wish to acknowledge the Histopathology core services at NYU Langone Medical Center.	Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; BASILICO C, 1969, J VIROL, V3, P140, DOI 10.1128/JVI.3.2.140-145.1969; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Driessens G, 2011, CELL STEM CELL, V9, P283, DOI 10.1016/j.stem.2011.09.007; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Guernet A, 2017, METHODS, V121, P130, DOI 10.1016/j.ymeth.2017.03.007; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Liao SR, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv675; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Palumbo P, 2017, ONCOTARGET, V8, P25582, DOI 10.18632/oncotarget.16106; Rainusso N, 2013, CURR ONCOL REP, V15, P296, DOI 10.1007/s11912-013-0321-9; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029; Shahriyari L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076195; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Song WS, 2016, J CHIN MED ASSOC, V79, P538, DOI 10.1016/j.jcma.2016.03.010; Tafani M, 2014, CURR MED CHEM, V21, P1146, DOI 10.2174/0929867321666131129125624; Tan YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5619; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Weina K, 2016, PIGM CELL MELANOMA R, V29, P453, DOI 10.1111/pcmr.12483; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112	31	53	56	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4626	4632		10.1038/s41388-018-0292-2	http://dx.doi.org/10.1038/s41388-018-0292-2			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743593	Green Accepted			2022-12-28	WOS:000441736700010
J	Gluck, AA; Orlando, E; Leiser, D; Poliakova, M; Nisa, L; Quintin, A; Gavini, J; Stroka, DM; Berezowska, S; Bubendorf, L; Blaukat, A; Aebersold, DM; Medova, M; Zimmer, Y				Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Gavini, Jacopo; Stroka, Deborah M.; Berezowska, Sabina; Bubendorf, Lukas; Blaukat, Andree; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak			Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1 alpha levels under hypoxia	ONCOGENE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; INDUCIBLE FACTOR-I; TYROSINE KINASE; MESSENGER-RNA; CANCER-CELLS; C-MET; TRANSCRIPTIONAL ACTIVATION; INVASIVE GROWTH; DNA-DAMAGE; EXPRESSION	Poor oxygenation is a common hallmark of solid cancers that strongly associates with aggressive tumor progression and treatment resistance. While a hypoxia-inducible factor 1 alpha (HIF-1 alpha)-associated transcriptional overexpression of the hepatocyte growth factor (HGF) receptor tyrosine kinase (RTK) MET has been previously documented, any regulation of the HIF-1a system through MET downstream signaling in hypoxic tumors has not been yet described. By using MET-driven in vitro as well as ex vivo tumor organotypic fresh tissue models we report that MET targeting results in depletion of HIF-1 alpha and its various downstream targets. Mechanistically, we provide evidence that MET regulates HIF-1 alpha levels through a protein translation mechanism that relies on phosphorylation modulation of the eukaryotic initiation factor 4G1 (eIF4G1) on serine 1232 (Ser-1232). Targeted phosphoproteomics data demonstrate a significant drop in eIF4G1 Ser-1232 phosphorylation following MET targeting, which is linked to an increased affinity between eIF4G1 and eIF4E. Since phosphorylation of eIF4G1 on Ser-1232 is largely mediated through mitogen-activated protein kinase (MAPK), we show that expression of a constitutively active K-RAS variant is sufficient to abrogate the inhibitory effect of MET targeting on the HIF-1 alpha pathway with subsequent resistance of tumor cells to MET targeting under hypoxic conditions. Analysis of The Cancer Genome Atlas data demonstrates frequent co-expression of MET, HIF-1 alpha and eIF4G1 in various solid tumors and its impact on disease-free survival of non-small cell lung cancer patients. Clinical relevance of the MET-eIF4G1-HIF-1 alpha pathway is further supported by a co-occurrence of their expression in common tumor regions of individual lung cancer patients.	[Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Univ Bern, CH-3010 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Bern Univ Hosp, Radiat Oncol, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Gavini, Jacopo; Stroka, Deborah M.; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Univ Bern, CH-3008 Bern, Switzerland; [Gavini, Jacopo; Stroka, Deborah M.] Bern Univ Hosp, Inselspital, Dept BioMed Res Visceral & Transplantat Surg, CH-3008 Bern, Switzerland; [Berezowska, Sabina] Univ Bern, Inst Pathol, CH-3008 Bern, Switzerland; [Bubendorf, Lukas] Basel Univ Hosp, Inst Pathol, CH-4031 Basel, Switzerland; [Blaukat, Andree] Merck KGaA, Global Res & Dev, D-64293 Darmstadt, Germany	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Basel; Merck KGaA	Zimmer, Y (corresponding author), Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland.; Zimmer, Y (corresponding author), Univ Bern, CH-3010 Bern, Switzerland.; Zimmer, Y (corresponding author), Bern Univ Hosp, Radiat Oncol, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland.; Zimmer, Y (corresponding author), Univ Bern, CH-3008 Bern, Switzerland.	yitzhak.zimmer@insel.ch	Berezowska, Sabina/AAJ-4557-2021; Aebersold, Daniel Matthias/C-2946-2013; Bubendorf, Lukas/G-5299-2015	Berezowska, Sabina/0000-0001-5442-9791; Aebersold, Daniel Matthias/0000-0002-9493-3834; Bubendorf, Lukas/0000-0001-5970-1803; Medova, Michaela/0000-0003-0649-469X; Stroka, Deborah/0000-0002-3517-3871	Stiftung fur klinischexperimentelle Tumorforschung; Stiftung zur Krebsbekampfung [374/2016]	Stiftung fur klinischexperimentelle Tumorforschung; Stiftung zur Krebsbekampfung	This work has been supported by Stiftung fur klinischexperimentelle Tumorforschung (grant to YZ) and by Stiftung zur Krebsbekampfung (grant Nr. 374/2016 to MM). YZ received a drug donation from Merck / EMD Serono. Merck / EMD Serono has reviewed the publication, and the views and opinions described in the publication do not necessarily reflect those of Merck.	Badura M, 2012, P NATL ACAD SCI USA, V109, P18767, DOI 10.1073/pnas.1203853109; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berezowska S, 2017, VIRCHOWS ARCH, V470, P323, DOI 10.1007/s00428-016-2057-z; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boeckx Carolien, 2015, BMC Res Notes, V8, P203, DOI 10.1186/s13104-015-1197-6; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cheng JC, 2013, CANCER LETT, V329, P197, DOI 10.1016/j.canlet.2012.10.029; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; Dobrikov MI, 2013, MOL CELL BIOL, V33, P937, DOI 10.1128/MCB.01441-12; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Francica P, 2016, CLIN CANCER RES, V22, P5322, DOI 10.1158/1078-0432.CCR-15-2987; Fuhrer T, 2011, ANAL CHEM, V83, P7074, DOI 10.1021/ac201267k; Gariboldi MB, 2010, BIOCHEM PHARMACOL, V80, P455, DOI 10.1016/j.bcp.2010.05.011; Gluck AA, 2015, INT J BIOCHEM CELL B, V62, P101, DOI 10.1016/j.biocel.2015.02.018; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Ide T, 2006, INT J CANCER, V119, P2750, DOI 10.1002/ijc.22178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Leiser D, 2015, MOL ONCOL, V9, P1434, DOI 10.1016/j.molonc.2015.04.001; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Medova M, 2013, MOL CANCER THER, V12, P2415, DOI 10.1158/1535-7163.MCT-13-0151; Michieli P, 2009, CELL CYCLE, V8, P3291, DOI 10.4161/cc.8.20.9741; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko OH, 2014, WORLD J GASTROENTERO, V20, P13705, DOI 10.3748/wjg.v20.i38.13705; Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499; Obach M, 2004, J BIOL CHEM, V279, P53562, DOI 10.1074/jbc.M406096200; Okuda K, 2008, CANCER SCI, V99, P2280, DOI 10.1111/j.1349-7006.2008.00916.x; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Paatero I, 2012, J BIOL CHEM, V287, P9659, DOI 10.1074/jbc.M111.299537; Pelletier J, 2015, CANCER RES, V75, P250, DOI 10.1158/0008-5472.CAN-14-2789; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Skuli N, 2006, CANCER RES, V66, P482, DOI 10.1158/0008-5472.CAN-05-2299; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Takacova M, 2014, AM J PATHOL, V184, P953, DOI 10.1016/j.ajpath.2014.01.002; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Thangasamy A, 2009, J BIOL CHEM, V284, P14001, DOI 10.1074/jbc.M809320200; Villa N, 2013, J BIOL CHEM, V288, P32932, DOI 10.1074/jbc.M113.517011; Vordermark D, 2016, CANCER RES, V198, P123; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049	50	12	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4181	4196		10.1038/s41388-018-0256-6	http://dx.doi.org/10.1038/s41388-018-0256-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29717265				2022-12-28	WOS:000439847000010
J	Shi, C; Pan, BQ; Shi, F; Xie, ZH; Jiang, YY; Shang, L; Zhang, Y; Xu, X; Cai, Y; Hao, JJ; Wang, MR				Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong			Sequestosome 1 protects esophageal squamous carcinoma cells from apoptosis via stabilizing SKP2 under serum starvation condition	ONCOGENE			English	Article							CANCER-CELLS; LUNG-CANCER; PB1 DOMAIN; PROSTATE-CANCER; AUTOPHAGY; P62; KINASE; DEGRADATION; P62/SQSTM1; ACTIVATION	Esophageal squamous cell carcinoma (ESCC) is one of the malignancies in digestive system, with a low 5-year survival rate. We previously revealed that Sequestosome 1 (SQSTM1/p62) protein levels were upregulated in ESCC tissues. However, it is unclear about the function of p62 and the underlying mechanism. Here, we used immunofluorescence and immunohistochemistry to investigate the expression of p62 in ESCC. Western blotting, quantitative RT-PCR, colony formation assay, flow cytometry, immunoprecipitation and xenograft tumor assay were used to analyze the role of p62 in vitro and vivo. Here, we showed that p62 serves as a regulator of cell apoptosis under serum starvation condition in ESCC cells. Through activating the protein kinase C iota (PKCiota)-S-phase kinase-associated protein 2 (SKP2) signaling pathway, p62 enhances cell apoptosis resistance and colony formation in vitro and tumor growth in mouse models. Through interaction with the domains PB1, p62 upregulated the expression of PKCiota and then depressed the ubiquitin-mediated proteasomal degradation of SKP2. p62-silencing combined with a PKCiota inhibitor ATM significantly enhanced cell apoptosis and inhibited cell survival. Immunohistochemical analysis revealed a positive association between the expression of p62 and SKP2 in primary ESCC tissues. And importantly, p62 presented a markedly cytoplasmic translocation in cancerous cells, including in 16 (30.76%) tumors at stage T1, as compared with its nuclear location in normal esophageal epithelial cells. In summary, p62 plays an anti-apoptotic role in ESCC cells via stabilizing SKP2 under serum starvation condition. These data suggest that p62 might be an early biomarker and a candidate therapeutic target of ESCC.	[Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong] Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong] Chinese Acad Med Sci, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Hao, JJ; Wang, MR (corresponding author), Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Hao, JJ; Wang, MR (corresponding author), Chinese Acad Med Sci, Beijing 100021, Peoples R China.	hjj8173@126.com; wangmr2015@126.com	Zhang, Yu/G-2453-2011	Zhang, Yu/0000-0003-1375-1594; WANG, Ming-Rong/0000-0002-8767-9356	National Natural Science Foundation of China [31571420, 81520108023]; Beijing Natural Science Foundation [7151008]; CAMS Innovation Fund for Medical Sciences [CIFMS2016-I2M-1-001/3-007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); CAMS Innovation Fund for Medical Sciences	This work was supported by National Natural Science Foundation of China (31571420 and 81520108023). Beijing Natural Science Foundation (7151008) and CAMS Innovation Fund for Medical Sciences (CIFMS2016-I2M-1-001/3-007).	Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620; Burke RM, 2015, ANTIOXID REDOX SIGN, V22, P1243, DOI 10.1089/ars.2014.6182; Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226; Duran A, 2016, CANCER CELL, V30, P595, DOI 10.1016/j.ccell.2016.09.004; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; He PX, 2014, ACTA PHARMACOL SIN, V35, P1055, DOI 10.1038/aps.2014.47; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Inui T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074398; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kopsiaftis S, 2016, MOL CANCER RES, V14, P1182, DOI 10.1158/1541-7786.MCR-16-0111; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lu SH, 2000, MUTAT RES-REV MUTAT, V462, P343, DOI 10.1016/S1383-5742(00)00023-5; Lu W, 2017, ONCOGENE, V36, P1364, DOI 10.1038/onc.2016.300; Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222; Ma CQ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.91; Mansfield AS, 2013, ANTI-CANCER DRUG, V24, P1079, DOI 10.1097/CAD.0000000000000009; Marjuki H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-134; Mohamed A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00070; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nakamura K, 2010, J BIOL CHEM, V285, P2077, DOI 10.1074/jbc.M109.065102; Nakano T, 2004, ACTA NEUROPATHOL, V107, P359, DOI 10.1007/s00401-004-0821-7; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Ren J, 2014, SCI CHINA LIFE SCI, V57, P69, DOI 10.1007/s11427-013-4592-z; Scharf VF, 2014, ANTI-CANCER DRUG, V25, P332, DOI 10.1097/CAD.0000000000000061; Wang BS, 2014, MOL CARCINOGEN, V53, P514, DOI 10.1002/mc.22003; Wang XC, 2009, MOL CANCER RES, V7, P12, DOI 10.1158/1541-7786.MCR-08-0092; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Xie WY, 2015, EXP CELL RES, V339, P270, DOI 10.1016/j.yexcr.2015.11.005; Xu DZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7641; Yamada SI, 2016, PATHOL ONCOL RES, V22, P625, DOI 10.1007/s12253-016-0049-6; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang MZ, 2014, DIABETES, V63, P2063, DOI 10.2337/db13-1279; Zhao ZM, 2017, ANTI-CANCER DRUG, V28, P187, DOI 10.1097/CAD.0000000000000451	36	13	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3260	3274		10.1038/s41388-018-0217-0	http://dx.doi.org/10.1038/s41388-018-0217-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551772				2022-12-28	WOS:000435526600006
J	Yoo, KC; Suh, Y; An, Y; Lee, HJ; Jeong, YJ; Uddin, N; Cui, YH; Roh, TH; Shim, JK; Chang, JH; Park, JB; Kim, MJ; Kim, IG; Kang, SG; Lee, SJ				Yoo, Ki-Chun; Suh, Yongjoon; An, Yoojeong; Lee, Hae-June; Jeong, Ye Ji; Uddin, Nizam; Cui, Yan-Hong; Roh, Tae-Hoon; Shim, Jin-Kyoung; Chang, Jong Hee; Park, Jong Bae; Kim, Min-Jung; Kim, In-Gyu; Kang, Seok-Gu; Lee, Su-Jae			Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation	ONCOGENE			English	Article							FACTOR-KAPPA-B; GLIOMA STEM-CELLS; HYALURONAN SYNTHESIS; BRAIN-TUMOR; GLIOBLASTOMA; ACTIVATION; CANCER; MIGRATION; INVASION; STABILIZATION	Ionizing radiation is widely used for patient with glioblastoma (GBM). However, the effect of radiation on patient survival is marginal and upon recurrence tumors frequently shift toward mesenchymal subtype adopting invasiveness. Here, we show that ionizing radiation affects biomechanical tension in GBM microenvironment and provides proinvasive extracellular signaling cue, hyaluronic acid (HA)-rich condition. In response to radiation, HA production was increased in GBM cells by HA synthase-2 (HAS2) that was transcriptionally upregulated by NF-kappa B. Notably, NF-kappa B was persistently activated by IL-1 alpha-feedback loop, making HA abundance in tumor microenvironment after radiation. Radiation-induced HA abundance causally has been linked to invasiveness of GBM cells by generating movement track as an extracellular matrix, and by acting as a signaling ligand for CD44 receptor, leading to SRC activation, which is sufficient for mesenchymal shift of GBM cells. Collectively, our findings provide an explanation for the frequent brain tumor relapse after radiotherapy, and potential therapeutic targets to block mesenchymal shift upon relapse.	[Yoo, Ki-Chun; Suh, Yongjoon; An, Yoojeong; Uddin, Nizam; Cui, Yan-Hong; Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Lee, Hae-June; Jeong, Ye Ji] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 01812, South Korea; [Roh, Tae-Hoon; Shim, Jin-Kyoung; Chang, Jong Hee; Kang, Seok-Gu] Yonsei Univ, Severance Hosp, Brain Tumor Ctr, Dept Neurosurg,Coll Med, Seoul 03722, South Korea; [Park, Jong Bae] Natl Canc Ctr, Res Inst & Hosp, Specif Organs Canc Branch, Goyang 10408, South Korea; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Lab Radiat Exposure & Therapeut, Seoul 01812, South Korea; [Kim, In-Gyu] Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Daejeon 34057, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Yonsei University; Yonsei University Health System; National Cancer Center - Korea (NCC); Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI)	Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea.; Kang, SG (corresponding author), Yonsei Univ, Severance Hosp, Brain Tumor Ctr, Dept Neurosurg,Coll Med, Seoul 03722, South Korea.	seokgu9@gmail.com; sj0420@hanyang.ac.kr	Cui, Yanhong/ABB-1148-2021	Cui, Yanhong/0000-0002-4169-6521; Chang, Jong Hee/0000-0003-1509-9800; Roh, Tae Hoon/0000-0002-1004-9364; Kang, Seok-Gu/0000-0001-5676-2037; Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [NRF-2015M2A2A7A01044998, NRF-2016R1E1A1A01942075]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (NRF-2015M2A2A7A01044998 and NRF-2016R1E1A1A01942075).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bohrer LR, 2014, CANCER RES, V74, P374, DOI 10.1158/0008-5472.CAN-13-2469; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Catton C, 2003, UROL CLIN N AM, V30, P751, DOI 10.1016/S0094-0143(03)00051-X; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; de Groot J, 2009, J NEURO-ONCOL, V95, P151, DOI 10.1007/s11060-009-9916-2; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; Hartupee J, 2008, J BIOL CHEM, V283, P15689, DOI 10.1074/jbc.M801346200; Hwang E, 2016, ONCOTARGET, V7, P4890, DOI 10.18632/oncotarget.6640; Hyc A, 2009, INT J MOL MED, V24, P579, DOI 10.3892/ijmm_00000268; Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010; Kim MJ, 2011, J CELL SCI, V124, P3084, DOI 10.1242/jcs.080119; Kim YG, 2013, CHILD NERV SYST, V29, P549, DOI 10.1007/s00381-012-1988-1; Kim YH, 2014, CANCER LETT, V354, P132, DOI 10.1016/j.canlet.2014.07.048; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Saavalainen K, 2007, J BIOL CHEM, V282, P11530, DOI 10.1074/jbc.M607871200; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shankar A, 2014, CHIN J CANCER, V33, P148, DOI 10.5732/cjc.013.10095; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; Tammi RH, 2011, FEBS J, V278, P1419, DOI 10.1111/j.1742-4658.2011.08070.x; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigetti D, 2010, J BIOL CHEM, V285, P24639, DOI 10.1074/jbc.M110.134536; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200	36	26	27	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3317	3328		10.1038/s41388-018-0199-y	http://dx.doi.org/10.1038/s41388-018-0199-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29559744				2022-12-28	WOS:000435526600010
J	Zuo, Q; Liu, J; Huang, LP; Qin, YF; Hawley, T; Seo, C; Merlino, G; Yu, YL				Zuo, Qiang; Liu, Jing; Huang, Liping; Qin, Yifei; Hawley, Teresa; Seo, Claire; Merlino, Glenn; Yu, Yanlin			AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; THERAPEUTIC IMPLICATIONS; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SIGNALING PATHWAYS; TARGETED THERAPY; MEK INHIBITION; RAF INHIBITION	Multiple genetic mutations within melanoma not only cause lesion-specific responses to targeted therapy but also alter the molecular route of resistance to that therapy. Inactivation of PTEN occurs in up to 30% of melanomas, frequently with a concurrent activating BRAF mutation. PTEN loss regulates both acquired and intrinsic drug resistance. Here we show that AXL/AKT axis mediated-resistance to BRAF inhibitor (BRAFi) depends upon PTEN status in melanoma. Hyperactivation of both ERK and AKT pathways was associated with BRAFi resistance in melanoma with wildtype PTEN. The PTEN-impaired melanoma cells required only the ERK resistance mechanism. Moreover, we identified AXL as a key upstream effector of AKT pathway-associated resistance to BRAFi in melanoma with wildtype PTEN, but not in melanoma with impaired PTEN. Notably, we confirmed that blocking AXL by shRNA and a small molecular inhibitor could rescue the sensitivity of resistant melanoma cells with wildtype PTEN to BRAFi and inhibit their growth in vitro and in vivo. Our study has uncovered a mechanism by which PTEN status contributes to acquired resistance to BRAFi and offers a rational strategy to guide clinical testing in pre-identified subsets of patients who relapse during treatment with BRAFi. The identified protein AXL represents a promising therapeutic target for BRAF mutant melanoma patients with wildtype PTEN.	[Zuo, Qiang; Huang, Liping; Qin, Yifei; Seo, Claire; Merlino, Glenn; Yu, Yanlin] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zuo, Qiang; Liu, Jing; Huang, Liping] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Hawley, Teresa] NCI, Lab Genome Integr, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Southern Medical University - China; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yu, YL (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	YuY@mail.nih.gov			NIH; NATIONAL CANCER INSTITUTE [ZIABC008756] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from the NIH intramural research program. Thanks, are due to Dr. Miriam Anver for assistance with immunohistochemistry.	Brand TM, 2014, CANCER RES, V74, P5152, DOI 10.1158/0008-5472.CAN-14-0294; Bucheit AD, 2014, CLIN CANCER RES, V20, P5527, DOI 10.1158/1078-0432.CCR-14-1027; Byron SA, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-75; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen G, 2014, HEMATOL ONCOL CLIN N, V28, P523, DOI 10.1016/j.hoc.2014.03.001; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hather G, 2014, CANCER INFORM, V13, P65, DOI 10.4137/CIN.S13974; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HERBST RA, 1994, CANCER RES, V54, P3111; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Meyer AS, 2015, CELL SYST, V1, P25, DOI 10.1016/j.cels.2015.06.002; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Miller MA, 2016, CANCER DISCOV, V6, P382, DOI 10.1158/2159-8290.CD-15-0933; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Sheskin D., 2011, HDB PARAMETRIC NONPA, Vfifth, DOI [DOI 10.1201/9781420036268, 10.2307/2685909]; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stahl JM, 2003, CANCER RES, V63, P2881; Sullivan Ryan, 2015, Am Soc Clin Oncol Educ Book, P177, DOI 10.14694/EdBook_AM.2015.35.177; Sullivan RJ, 2014, HEMATOL ONCOL CLIN N, V28, P437, DOI 10.1016/j.hoc.2014.02.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yao TW, 2017, ONCOTARGET, V8, P583, DOI 10.18632/oncotarget.11882; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	50	47	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3275	3289		10.1038/s41388-018-0205-4	http://dx.doi.org/10.1038/s41388-018-0205-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551771	Green Accepted			2022-12-28	WOS:000435526600007
J	Acosta, J; Wang, W; Feldser, DM				Acosta, Jonuelle; Wang, Walter; Feldser, David M.			Off and back-on again: a tumor suppressor's tale	ONCOGENE			English	Review							CONDITIONAL RNA INTERFERENCE; CRE RECOMBINASE ACTIVITY; IN-VIVO; P53 RESTORATION; TRANSGENIC MICE; GENE-EXPRESSION; CANCER; MOUSE; CRISPR; CELLS	Tumor suppressor genes play critical roles orchestrating anti-cancer programs that are both context dependent and mechanistically diverse. Beyond canonical tumor suppressive programs that control cell division, cell death, and genome stability, unexpected tumor suppressor gene activities that regulate metabolism, immune surveillance, the epigenetic landscape, and others have recently emerged. This diversity underscores the important roles these genes play in maintaining cellular homeostasis to suppress cancer initiation and progression, but also highlights a tremendous challenge in discerning precise context-specific programs of tumor suppression controlled by a given tumor suppressor. Fortunately, the rapid sophistication of genetically engineered mouse models of cancer has begun to shed light on these context-dependent tumor suppressor activities. By using techniques that not only toggle "off" tumor suppressor genes in nascent tumors, but also facilitate the timely restoration of gene function "back-on again" in disease specific contexts, precise mechanisms of tumor suppression can be revealed in an unbiased manner. This review discusses the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back-on again and their potential to uncover the tumor suppressor's tale.	[Acosta, Jonuelle; Feldser, David M.] Univ Penn, Perelman Sch Med, Biomed Grad Studies Program Cellular & Mol Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Wang, Walter] Univ Penn, Sch Arts & Sci, Vagelos Scholars Program, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Feldser, David M.] Univ Penn, Dept Canc Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Feldser, David M.] Univ Penn, Abramson Family Canc Res Inst, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Feldser, DM (corresponding author), Univ Penn, Perelman Sch Med, Biomed Grad Studies Program Cellular & Mol Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.; Feldser, DM (corresponding author), Univ Penn, Dept Canc Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.; Feldser, DM (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.	dfeldser@upenn.edu		Wang, Walter/0000-0003-1054-4688; Feldser, David/0000-0001-5975-864X	American Lung Association [LCD-400095]; NIH [CA193602, CA205340]; Penn Medicine's Abramson Cancer Center [P30-CA016520]; NATIONAL CANCER INSTITUTE [R21CA205340, R01CA193602, P30CA016520, R00CA158581] Funding Source: NIH RePORTER	American Lung Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Penn Medicine's Abramson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Junwei Shi, Donita Brady, and the entire Feldser Laboratory for critical review of this manuscript. D.F. is the Alan Steinberg Scholar in Cancer Research, and a Richard A. "Buz" Cooper Scholar of the Abramson Cancer Center. Work in the Feldser Laboratory is supported by grants from the American Lung Association LCD-400095, NIH CA193602, CA205340, and also by Penn Medicine's Abramson Cancer Center core grant P30-CA016520.	Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Birling Marie-Christine, 2009, Methods Mol Biol, V561, P245, DOI 10.1007/978-1-60327-019-9_16; Buskirk AR, 2004, P NATL ACAD SCI USA, V101, P10505, DOI 10.1073/pnas.0402762101; Cao J, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw660; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180; Davis KM, 2015, NAT CHEM BIOL, V11, P316, DOI [10.1038/NCHEMBIO.1793, 10.1038/nchembio.1793]; Direnzo D, 2012, GASTROENTEROLOGY, V143, P469, DOI 10.1053/j.gastro.2012.04.011; Dominguez AA, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2015.2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155; Dow LE, 2012, NAT PROTOC, V7, P374, DOI 10.1038/nprot.2011.446; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fuhrmann-Benzakein E, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e99; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kaelin WG, 2012, SCIENCE, V337, P421, DOI 10.1126/science.1225787; Katoh Y, 2017, MOL BIOL CELL, V28, P898, DOI 10.1091/mbc.E17-01-0051; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Lao ZM, 2012, CELL REP, V2, P386, DOI 10.1016/j.celrep.2012.07.004; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lu J, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gkx1222; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Murugan K, 2017, MOL CELL, V68, P15, DOI 10.1016/j.molcel.2017.09.007; Nguyen DP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12009; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Premsrirut Prem K, 2013, Cold Spring Harb Protoc, V2013, P835, DOI 10.1101/pdb.prot077057; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Robles-Oteiza C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9783; Sakuma T, 2016, NAT PROTOC, V11, P118, DOI 10.1038/nprot.2015.140; Selivanova G, 2010, SEMIN CANCER BIOL, V20, P46, DOI 10.1016/j.semcancer.2010.02.006; Shchors K, 2013, P NATL ACAD SCI USA, V110, pE1480, DOI 10.1073/pnas.1219142110; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Swisher SG, 2003, CLIN CANCER RES, V9, P93; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Weinmann L, 2008, CELL DEATH DIFFER, V15, P718, DOI 10.1038/sj.cdd.4402301; Whitfield Jonathan, 2015, Cold Spring Harb Protoc, V2015, P227, DOI 10.1101/pdb.top069815; Wiznerowicz M, 2006, NAT METHODS, V3, P682, DOI 10.1038/NMETH914; Wunderlich FT, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e47; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshimi K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10431; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	64	5	5	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3058	3069		10.1038/s41388-018-0186-3	http://dx.doi.org/10.1038/s41388-018-0186-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540833	Green Accepted			2022-12-28	WOS:000434641400002
J	Zhang, ZY; Lin, GH; Yan, YJ; Li, X; Hu, YB; Wang, J; Yin, BJ; Wu, YQ; Li, ZY; Yang, XP				Zhang, Zunyue; Lin, Guohong; Yan, Yujing; Li, Xiang; Hu, Yibing; Wang, Jing; Yin, Bingjiao; Wu, Yaqun; Li, Zhuoya; Yang, Xiang-Ping			Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; GLUTATHIONE-S-TRANSFERASE; NF-KAPPA-B; DRUG-RESISTANCE; DOXORUBICIN; EXPRESSION; DEATH; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; ACTIVATION	Chemoresistance remains a major obstacle to successful treatment of breast cancer. Although soluble tumor necrosis factor-alpha (sTNF-alpha) has been implicated in mediating drug-resistance in human cancers, whether transmembrane tumor necrosis factor-alpha (tmTNF-alpha) plays a role in chemoresistance remains unclear. Here we found that over 50% of studied patients expressed tmTNF-alpha at high levels in breast cancer tissues and tmTNF-alpha expression positively correlated with resistance to anthracycline chemotherapy. Alteration of tmTNF-alpha expression changed the sensitivity of primary human breast cancer cells and breast cancer cell lines to doxorubicin (DOX). Overexpression of N-terminal fragment (NTF) of tmTNF-alpha, a mutant form with intact intracellular domain of tmTNF-alpha to transmit reverse signals, induced DOX-resistance. Mechanistically, the tmTNF-alpha/NTF-ERK-GST-p axis and tmTNF-alpha/NTF-NF-kappa B-mediated anti-apoptotic functions were required for tmTNF-alpha-induced DOX-resistance. In a xenograft mouse model, the combination of tmTNF-alpha suppression with chemotherapy significantly enhanced the efficacy of DOX. Our data indicate that tmTNF-alpha mediates DOX-resistance through reverse signaling and targeting tmTNF-a may be beneficial for the treatment of DOX-resistant breast cancer.	[Zhang, Zunyue; Lin, Guohong; Wang, Jing; Yin, Bingjiao; Li, Zhuoya; Yang, Xiang-Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan 430030, Hubei, Peoples R China; [Yan, Yujing; Li, Xiang; Hu, Yibing; Wu, Yaqun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thyroid & Breast Surg, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Li, ZY; Yang, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan 430030, Hubei, Peoples R China.	zhuoyali@mails.tjmu.edu.cn; yangxp@hust.edu.cn			National Scientific Foundation of China [30872376, 31671470, 81471899]; Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST	This work was supported by the National Scientific Foundation of China (30872376, 31671470, and 81471899), and Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST. We thank Doctor Arian Laurence for corrections of our manuscript and constructive suggestions.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Arcamone F, 2000, BIOTECHNOL BIOENG, V67, P704, DOI 10.1002/(SICI)1097-0290(20000320)67:6<704::AID-BIT8>3.0.CO;2-L; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brantley-Finley C, 2003, BIOCHEM PHARMACOL, V66, P459, DOI 10.1016/S0006-2952(03)00255-7; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Dalpiaz Orietta, 2003, Arch Esp Urol, V56, P197; Daniel D, 2008, CURR CANCER DRUG TAR, V8, P124, DOI 10.2174/156800908783769346; Filipits M, 2003, CLIN CANCER RES, V9, P820; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gahl RF, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.593897; Garner TP, 2016, MOL CELL, V64, P431, DOI 10.1016/j.molcel.2016.10.005; Gordon GJ, 2007, J PATHOL, V211, P439, DOI 10.1002/path.2120; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Huang GX, 2007, MOL CANCER THER, V6, P1610, DOI 10.1158/1535-7163.MCT-06-0580; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kalinina EV, 2007, B EXP BIOL MED+, V143, P328, DOI 10.1007/s10517-007-0102-2; Kirchner S, 2004, J LEUKOCYTE BIOL, V75, P324, DOI 10.1189/jlb.0703343; Kresse M, 2005, J IMMUNOL, V175, P4076, DOI 10.4049/jimmunol.175.6.4076; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Li F, 2015, ARCH TOXICOL, V89, P711, DOI 10.1007/s00204-015-1470-4; Lin AH, 2012, J AGR FOOD CHEM, V60, P6537, DOI 10.1021/jf301567m; Louie SM, 2016, CELL CHEM BIOL, V23, P567, DOI 10.1016/j.chembiol.2016.03.017; Mackey JR, 2013, LANCET ONCOL, V14, P72, DOI 10.1016/S1470-2045(12)70525-9; Martin M, 2013, J CLIN ONCOL, V31, P2593, DOI 10.1200/JCO.2012.46.9841; Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Pang BX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2921; Pendleton M, 2014, ANN NY ACAD SCI, V1310, P98, DOI 10.1111/nyas.12358; Sharifi S, 2015, ADV PHARM BULL, V5, P351, DOI 10.15171/apb.2015.049; Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416.9.1.105; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Sweeney C, 2000, CANCER RES, V60, P5621; Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Verma S, 2008, CANCER TREAT REV, V34, P339, DOI 10.1016/j.ctrv.2008.01.005; Wang LC, 2005, J BIOL CHEM, V280, P7634, DOI 10.1074/jbc.M413384200; Yan D, 2009, BREAST CANCER RES TR, V116, P91, DOI 10.1007/s10549-008-0111-5; Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946; Yu MX, 2009, EUR J CELL BIOL, V88, P181, DOI 10.1016/j.ejcb.2008.09.001; Zajchowski DA, 2012, MOL CANCER THER, V11, P492, DOI 10.1158/1535-7163.MCT-11-0746; Zhang H, 2008, J LEUKOCYTE BIOL, V84, P789, DOI 10.1189/jlb.0208078; Zhou XX, 2015, BLOOD, V126, P1433, DOI 10.1182/blood-2015-01-624833	49	43	44	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3456	3470		10.1038/s41388-018-0221-4	http://dx.doi.org/10.1038/s41388-018-0221-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559745	Green Published, hybrid			2022-12-28	WOS:000436411300010
J	Dong, L; Yu, L; Bai, CR; Liu, L; Long, H; Shi, L; Lin, ZH				Dong, Ling; Yu, Le; Bai, Chunrong; Liu, Liu; Long, Hua; Shi, Lei; Lin, Zhenghong			USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis	ONCOGENE			English	Article							BREAST-CANCER; E OVEREXPRESSION; PROGNOSTIC-SIGNIFICANCE; S-PHASE; TRANSCRIPTIONAL ACTIVATION; LUNG-CANCER; PROTEIN; EXPRESSION; PHOSPHORYLATION; AMPLIFICATION	Overexpression of Cyclin E has been seen in many types of cancers. However, the underlying mechanism remains enigmatic. Herein, we identified ubiquitin-specific peptidase 27 (USP27) as a Cyclin E interactor. We found that USP27 promoted Cyclin E stability by negatively regulating its ubiquitination. In addition, suppression of USP27 expression resulted in the inhibition of the growth, migration, and invasion of hepatocellular carcinoma. Furthermore, we detected a positive correlation between USP27 and Cyclin E expression in hepatocellular carcinoma tissues. Finally, we found that USP27 expression is inhibited by 5-fluorouracil (5-FU) treatment and USP27 depletion sensitizes Hep3B cells to 5-FU-induced apoptosis. USP27-mediated Cyclin E stabilization is involved in tumorigenesis, suggesting that targeting USP27 may represent a new therapeutic strategy to treat cancers with aberrant overexpression of Cyclin E protein.	[Dong, Ling; Yu, Le; Bai, Chunrong; Liu, Liu; Long, Hua; Shi, Lei; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Lab Pathol, Chongqing 401331, Peoples R China	Chongqing University	Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Lab Pathol, Chongqing 401331, Peoples R China.	zhenghonglin@cqu.edu.cn		Lin, Zhenghong/0000-0002-6354-0042	National Natural Science Foundation of China [31571454]; Fundamental Research Funds for the Central Universities [106112017CDJQJ298833]; starting funds of '100 talent scholar program' from Chongqing University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); starting funds of '100 talent scholar program' from Chongqing University	This study was supported by the National Natural Science Foundation of China (Grant Number 31571454 to Z. Lin), the Fundamental Research Funds for the Central Universities (Project Number 106112017CDJQJ298833 to Z. Lin), and the starting funds of '100 talent scholar program' from Chongqing University.	Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Berglund P, 2005, CANCER RES, V65, P9727, DOI 10.1158/0008-5472.CAN-04-3984; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Das T, 2017, NUCLEIC ACIDS RES, V45, P5010, DOI 10.1093/nar/gkx062; Dong YY, 2000, CLIN CANCER RES, V6, P4253; Ear PH, 2013, P NATL ACAD SCI USA, V110, P15716, DOI 10.1073/pnas.1305420110; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Fukuse T, 2000, CANCER RES, V60, P242; Geng Y, 1996, ONCOGENE, V12, P1173; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lin ZH, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.28; Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Luhtala S, 2016, TUMOR BIOL, V37, P9813, DOI 10.1007/s13277-016-4870-z; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Molendini L, 1998, INT J ONCOL, V12, P1007; Muller-Tidow C, 2001, CANCER RES, V61, P647; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Siu KT, 2012, CELL CYCLE, V11, P57, DOI 10.4161/cc.11.1.18775; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Swaffer MP, 2016, CELL, V167, P1750, DOI 10.1016/j.cell.2016.11.034; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Wickliffe K, 2009, CHEM REV, V109, P1537, DOI 10.1021/cr800414e; Wolowiec D, 1996, BRIT J HAEMATOL, V95, P518, DOI 10.1046/j.1365-2141.1996.d01-1930.x; Yasui W, 1996, J Exp Ther Oncol, V1, P88; Yasui W, 1996, VIRCHOWS ARCH, V429, P13	42	30	36	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2702	2713		10.1038/s41388-018-0137-z	http://dx.doi.org/10.1038/s41388-018-0137-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29497124	Green Published, hybrid			2022-12-28	WOS:000432545100007
J	Oyinlade, O; Wei, S; Lal, B; Laterra, J; Zhu, H; Goodwin, CR; Wang, SY; Ma, D; Wan, J; Xia, SL				Oyinlade, Olutobi; Wei, Shuang; Lal, Bachchu; Laterra, John; Zhu, Heng; Goodwin, C. Rory; Wang, Shuyan; Ma, Ding; Wan, Jun; Xia, Shuli			Targeting UDP-alpha-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration	ONCOGENE			English	Article							STEM-LIKE CELLS; CANCER PROGRESSION; HYALURONAN; INVASION; DEHYDROGENASE; MULTIFORME	UDP-glucose 6-dehydrogenase (UGDH) produces UDP-alpha-D-glucuronic acid, the precursors for glycosaminoglycans (GAGs) and proteoglycans of the extracellular matrix. Elevated GAG formation has been implicated in a variety of human diseases, including glioblastoma (GBM). In our previous study, we found that Kruppel-like factor 4 (KLF4) promotes GBM cell migration by binding to methylated DNA, mainly methylated CpGs (mCpG) and transactivating gene expression. We identified UDGH as one of the downstream targets of KLF4-mCpG binding activity. In this study, we show that KLF4 upregulates UGDH expression in a mCpG-dependent manner, and UGDH is required for KLF4-induced cell migration in vitro. UGDH knockdown decreases GAG abundance in GBM cells, as well as cell proliferation and migration in vitro. In intracranial xenografts, reduced UGDH inhibits tumor growth and migration, accompanied by a decrease in the expression of extracellular matrix proteins such as tenascin C, brevican. Our studies demonstrate a novel DNA methylation-dependent UGDH upregulation by KLF4. Developing UGDH antagonists to decrease the synthesis of extracellular matrix components will be a useful strategy for GBM therapy.	[Oyinlade, Olutobi; Wei, Shuang; Lal, Bachchu; Laterra, John; Wang, Shuyan; Ma, Ding; Xia, Shuli] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Oyinlade, Olutobi; Zhu, Heng] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Wei, Shuang; Lal, Bachchu; Laterra, John; Wang, Shuyan; Ma, Ding; Xia, Shuli] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wei, Shuang] Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China; [Laterra, John] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Laterra, John] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Zhu, Heng] Johns Hopkins Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; [Goodwin, C. Rory] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA; [Wan, Jun] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Indiana University System; Indiana University Bloomington	Xia, SL (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.; Xia, SL (corresponding author), Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	xia@kennedykrieger.org	Wei, Shuang/AAA-4031-2019; Wan, Jun/AAN-1337-2020	Wan, Jun/0000-0001-9286-6562	NIH [R01NS091165, R01 NS096754, NS076759, GM111514, R01 GM111514, R33CA186790, U54 HG006434, U24 CA160036, T32 GM007445]; Ford Foundation pre-doctoral fellowship program; Duke SPORE CEP Award; NIH/NINDS; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS096754, R01NS091165, R01NS073611] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ford Foundation pre-doctoral fellowship program; Duke SPORE CEP Award; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from NIH R01NS091165 (to SX), NIH R01 NS096754 (to JL), NS076759 (to JL), NIH GM111514 (to HZ), NIH R01 GM111514 (to HZ), NIH R33CA186790 (to HZ), NIH U54 HG006434 (to HZ), NIH U24 CA160036 (to HZ), Ford Foundation pre-doctoral fellowship program (to OO) and NIH T32 GM007445 (to OO), NIH/NINDS K12 Physician Scientist Award, Burroughs Wellcome Fund, and Duke SPORE CEP Award (to CRG).	Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764; Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x; Barbosa I, 2003, GLYCOBIOLOGY, V13, P647, DOI 10.1093/glycob/cwg082; Batash R., 2017, RECENT LIT REV CURR, V24, P3002, DOI DOI 10.2174/0929867324666170516123206; Clarkin CE, 2011, J CELL PHYSIOL, V226, P749, DOI 10.1002/jcp.22393; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Egger S, 2010, BIOCHEM SOC T, V38, P1378, DOI 10.1042/BST0381378; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Medvedeva YA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-119; Nutt CL, 2001, CANCER RES, V61, P7056; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Venning FA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00224; Wade A, 2013, FEBS J, V280, P2399, DOI 10.1111/febs.12109; Wan J, 2017, ELIFE, V6, DOI 10.7554/eLife.20068; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Wen YX, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0484-2; Wiranowska MR, 2011, GLIOMA EXPLORING ITS, P257; Wu YJ, 2012, CANCER SCI, V103, P1028, DOI 10.1111/j.1349-7006.2012.02260.x; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Ying MY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588988; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	28	25	26	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2615	2629		10.1038/s41388-018-0138-y	http://dx.doi.org/10.1038/s41388-018-0138-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29479058	Green Accepted, Green Submitted			2022-12-28	WOS:000432545100001
J	Ireland, L; Santos, A; Campbell, F; Figueiredo, C; Hammond, D; Ellies, LG; Weyer-Czernilofsky, U; Bogenrieder, T; Schmid, M; Mielgo, A				Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Hammond, Dean; Ellies, Lesley G.; Weyer-Czernilofsky, Ulrike; Bogenrieder, Thomas; Schmid, Michael; Mielgo, Ainhoa			Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer	ONCOGENE			English	Article							MOUSE MAMMARY-TUMOR; PANCREATIC-CANCER; ANTICANCER THERAPIES; FACTOR-I; PHASE-I; RESISTANCE; PROGRESSION; MICROENVIRONMENT; MACROPHAGES; DISEASE	Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and support cancer progression. Thus, gaining a better understanding of how macrophages support cancer could lead to the development of more effective therapies. In this study, we find that breast cancer-associated macrophages express high levels of insulin-like growth factors 1 and 2 (IGFs) and are the main source of IGFs within both primary and metastatic tumors. In total, 75% of breast cancer patients show activation of insulin/IGF-1 receptor signaling and this correlates with increased macrophage infiltration and advanced tumor stage. In patients with invasive breast cancer, activation of Insulin/IGF-1 receptors increased to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent commonly used to treat breast cancer, showed a significant reduction in tumor cell proliferation and lung metastasis in pre-clinical breast cancer models compared to paclitaxel monotherapy. Our findings provide the rationale for further developing the combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer, and Insulin/IGF1R activation and IGF+ stroma cells as potential biomarker candidates for further evaluation.	[Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Schmid, Michael; Mielgo, Ainhoa] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England; [Hammond, Dean] Univ Liverpool, Dept Physiol, Liverpool, Merseyside, England; [Ellies, Lesley G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Weyer-Czernilofsky, Ulrike] Boehringer Ingelheim RCV GmbH & Co KG, Pharmacol & Translat Res, Vienna, Austria; [Bogenrieder, Thomas] Boehringer Ingelheim RCV GmbH & Co KG Med & Trans, Vienna, Austria; [Bogenrieder, Thomas] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadem, Dept Urol, Munich, Germany	University of Liverpool; University of Liverpool; University of California System; University of California San Diego; Boehringer Ingelheim; University of Munich	Mielgo, A (corresponding author), Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England.	amielgo@liverpool.ac.uk	Figueiredo, Carlos Rogerio de/H-1236-2014	Figueiredo, Carlos Rogerio de/0000-0003-3680-4070; Schmid, Michael/0000-0002-3445-0013	Sir Henry Dale research fellowship - Wellcome Trust [102521/Z/13/Z]; Sir Henry Dale research fellowship - Royal Society [102521/Z/13/Z]; Medical Research Council [MR/L000512/1]; North West Cancer Research fund;  [K22CA118182]; MRC [MR/P018920/1, MR/L000512/1] Funding Source: UKRI; Medical Research Council [MR/P018920/1] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [K22CA118182] Funding Source: NIH RePORTER	Sir Henry Dale research fellowship - Wellcome Trust; Sir Henry Dale research fellowship - Royal Society; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Cancer Research fund; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by a Sir Henry Dale research fellowship to Dr. Ainhoa Mielgo, jointly funded by the Wellcome Trust and the Royal Society (grant number 102521/Z/13/Z), a New Investigator research grant from the Medical Research Council to Dr. Michael Schmid (grant number MR/L000512/1) and North West Cancer Research funding. Generation of primary breast cancer cells was supported by funding provided to Dr. Lesley Ellies (K22CA118182).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bronte V, 2015, NAT MED, V21, P117, DOI 10.1038/nm.3794; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004; DEXTER DL, 1978, CANCER RES, V38, P3174; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Farabaugh SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00059; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Gibby K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3174; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gradishar WJ, 2016, CLIN CANCER RES, V22, P301, DOI 10.1158/1078-0432.CCR-15-0588; Guha M, 2013, NAT REV DRUG DISCOV, V12, P250, DOI 10.1038/nrd3992; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Leek RD, 1996, CANCER RES, V56, P4625; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lodhia KA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00142; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma CX, 2013, BREAST CANCER RES TR, V139, P145, DOI 10.1007/s10549-013-2528-8; Maglione JE, 2001, CANCER RES, V61, P8298; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Marquette C, 2012, CURR TREAT OPTION ON, V13, P263, DOI 10.1007/s11864-012-0184-6; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Mills CD, 2016, CANCER RES, V76, P513, DOI 10.1158/0008-5472.CAN-15-1737; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olson OC, 2013, CELL RES, V23, P179, DOI 10.1038/cr.2012.123; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pulaski BA, 1998, CANCER RES, V58, P1486; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Robertson JFR, 2013, LANCET ONCOL, V14, P228, DOI 10.1016/S1470-2045(13)70026-3; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Schmid MC, 2011, CANCER CELL, V19, P715, DOI 10.1016/j.ccr.2011.04.016; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wan YW, 2016, BIOINFORMATICS, V32, P952, DOI 10.1093/bioinformatics/btv677; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883	59	38	38	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2022	2036		10.1038/s41388-017-0115-x	http://dx.doi.org/10.1038/s41388-017-0115-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367764	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000429899400006
J	Niu, Y; Jin, Y; Deng, SC; Deng, SJ; Zhu, S; Liu, Y; Li, X; He, C; Liu, ML; Zeng, Z; Chen, HY; Zhong, JX; Ye, Z; Wang, CY; Zhao, G				Niu, Yi; Jin, Yan; Deng, Shi-Chang; Deng, Shi-Jiang; Zhu, Shuai; Liu, Yang; Li, Xiang; He, Chi; Liu, Ming-Liang; Zeng, Zhu; Chen, Heng-Yu; Zhong, Jian-Xin; Ye, Zeng; Wang, Chun-You; Zhao, Gang			MiRNA-646-mediated reciprocal repression between HIF-1 alpha and MIIP contributes to tumorigenesis of pancreatic cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELLULAR-RESPONSE; BREAST-CANCER; HYPOXIA; EXPRESSION; CELLS; MIGRATION; INVASION; TARGETS; GENE	Migration and invasion inhibitory protein (MIIP) is recently identified as an inhibitor in tumor development. However, the regulatory mechanism and biological contributions of MIIP in pancreatic cancer (PC) have been not elucidated. In this study, we demonstrated a negative feedback of MIIP and hypoxia-induced factor-1 alpha (HIF-1 alpha), which was mediated by a hypoxia-induced microRNA. Compared with paracarcinoma tissues, MIIP was downregulated in PC tissues. Overexpression of MIIP significantly impeded the proliferation and invasion of PC cells both in vitro and in mouse xenograft models. We further verified MIIP was downregulated under hypoxia in a HIF-1 alpha-mediated manner. Interestingly, although MIIP promoter containing two putative hypoxia response elements (HREs), the chromatin immunoprecipitation (ChIP) and luciferase reporter assays did not support an active interaction between HIF-1a and MIIP promoter. Meanwhile, microRNA array revealed a hypoxia-induced microRNA, miR-646, impaired stability of MIIP mRNA and consequently inhibited its expression by targeting the coding sequence (CDS). Coincidently, knockdown of miR-646 significantly repressed proliferation and invasion ability of PC cells both in vitro and in vivo by upregulating MIIP expression. Besides, ChIP and luciferase reporter assays further validated that HIF-1 alpha activated transcription of miR-646 in hypoxia condition. Therefore, these results suggested HIF-1 alpha indirectly regulated MIIP expression in post-transcriptional level through upregulating miR-646 transcription. Conversely, our results further revealed that MIIP suppressed deacetylase ability of histone deacetylase 6 (HDAC6) to promote the acetylation and degradation of HIF-1 alpha, by which impairing HIF-1 alpha accumulation. What is more, a specific relationship between downregulated MIIP and upregulated miR-646 expression was validated in PC samples. Moreover, the dysregulated miR-646 and MIIP expression was correlated with advanced tumor stage, lymphatic invasion, metastasis and shorter overall survival in PC patients. Together, our results highlight that the reciprocal loop of HIF-1 alpha/miR-646/MIIP might be implemented as an applicable target for pancreatic cancer therapy.	[Niu, Yi; Jin, Yan; Deng, Shi-Chang; Deng, Shi-Jiang; Zhu, Shuai; Liu, Yang; Li, Xiang; He, Chi; Liu, Ming-Liang; Zeng, Zhu; Chen, Heng-Yu; Zhong, Jian-Xin; Ye, Zeng; Wang, Chun-You; Zhao, Gang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Pancreat Dis Inst,Dept Pancreat Surg, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Pancreat Dis Inst,Dept Pancreat Surg, Wuhan, Hubei, Peoples R China.	gangzhao@aliyun.com	fuliyun_new, fuliyun_new/AAZ-4437-2020	Jin, Yan/0000-0001-5957-7443; Li, Xiang/0000-0002-5942-7282	National Natural Science Foundation of China [81672406, 81372666, 30972900, 81502076]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (no. 81672406, no. 81372666, no. 30972900, and no. 81502076).	Azam AT, 2016, TUMOR BIOL, V37, P5769, DOI 10.1007/s13277-015-3821-4; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193; Deng SC, 2015, ONCOTARGET, V6, P39661, DOI 10.18632/oncotarget.5350; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Feldser D, 1999, CANCER RES, V59, P3915; Gomez-Roman N, 2016, ONCOTARGET, V7, P22650, DOI 10.18632/oncotarget.7998; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12; Ji P, 2010, ONCOGENE, V29, P3501, DOI 10.1038/onc.2010.114; Jing W, 2011, ONCOTARGET, V7, P9118; Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Krzywinski M, 2013, NAT METHODS, V10, P1139, DOI 10.1038/nmeth.2738; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lee KJ, 2010, BBA-MOL CELL RES, V1803, P608, DOI 10.1016/j.bbamcr.2010.01.004; Li W., 2011, J NUCL ACIDS, V2011, P1, DOI DOI 10.4061/2011/870726; Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830; Liu GJ, 2015, MOL BIOL EVOL, V32, P623, DOI 10.1093/molbev/msu323; Liu Y, 2015, GENE THER, V22, P729, DOI 10.1038/gt.2015.39; Loscalzo J, 2010, J CLIN INVEST, V120, P3815, DOI 10.1172/JCI45105; Mace TA, 2013, J SURG RES, V184, P855, DOI 10.1016/j.jss.2013.04.061; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Pothula SP, 2015, CANC LETT, V24, P232; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Song FF, 2015, ONCOL REP, V33, P2771, DOI 10.3892/or.2015.3905; Sun Y, 2017, J PATHOL, V241, P67, DOI 10.1002/path.4823; Vaiman D, 2017, PLACENTA, V52, P127, DOI 10.1016/j.placenta.2016.12.026; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang R, 2014, SCI WORLD J, DOI 10.1155/2014/312704; Wang XC, 2016, ONCOTARGET, V7, P13717, DOI 10.18632/oncotarget.7263; Wang Y, 2011, CANCER RES, V70, P423; Wang YM, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0342-6; Wang YM, 2011, CURR PROTEIN PEPT SC, V12, P68; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; Wu C, 2011, MOL CELL BIOL, V31, P4760, DOI 10.1128/MCB.05776-11; Wu Q, 2015, J BIOL CHEM, V290, P1170, DOI 10.1074/jbc.M114.601203; Wu Y, 2010, J BIOL CHEM, V285, P3554, DOI 10.1074/jbc.M109.063354; Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614; Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.240; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou HL, 2014, RNA, V20, P1431, DOI 10.1261/rna.045757.114; Zhu S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.189	49	33	35	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1743	1758		10.1038/s41388-017-0082-2	http://dx.doi.org/10.1038/s41388-017-0082-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29343850				2022-12-28	WOS:000428632600005
J	Kuhlen, M; Taeubner, J; Brozou, T; Wieczorek, D; Siebert, R; Borkhardt, A				Kuhlen, Michaela; Taeubner, Julia; Brozou, Triantafyllia; Wieczorek, Dagmar; Siebert, Reiner; Borkhardt, Arndt			Family-based germline sequencing in children with cancer	ONCOGENE			English	Review							DE-NOVO MUTATIONS; LI-FRAUMENI SYNDROME; UNIPARENTAL DISOMY; PARENTAL AGE; PREDISPOSITION GENES; RISK; RATES; ASSOCIATION; DISEASES; VARIANTS	The discovery of cancer-predisposing syndromes (CPSs) using next-generation sequencing (NGS) technologies is of increasing importance in pediatric oncology with regard to diagnosis, treatment, surveillance, family counselling and research. Recent studies indicate that a considerable percentage of childhood cancers are associated with CPSs. However, the ratio of CPSs that are caused by inherited vs. de novo mutations (DNMs), the risk of recurrence, and even the total number of genes, which should be considered as a true cancer-predisposing gene, are still unknown. In contrast to sequencing only single index patients, family-based NGS of the germline is a very powerful tool for providing unique insights into inheritance patterns (e.g., DNMs, parental mosaicism) and types of aberrations (e.g., SNV, CNV, indels, SV). Furthermore, functional perturbations of key cancer pathways (e.g., TP53, FA/BRCA) by at least two co-inherited heterozygous digenic mutations from each parent and currently unrecognized rare variants and unmeasured genetic interactions between common and rare variants may be a widespread genetic phenomenon in the germline of affected children. Therefore, family-based trio sequencing has the potential to reveal a striking new landscape of inheritance in childhood cancer and to facilitate the integration and efforts of individualized treatment strategies, including personalized and preventive medicine and cancer surveillance programs. Consequently, cancer genetics is becoming an increasingly common approach in modern oncology, so trio-sequencing should also be routinely integrated into pediatric oncology.	[Kuhlen, Michaela; Taeubner, Julia; Brozou, Triantafyllia; Borkhardt, Arndt] Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Wieczorek, Dagmar] Heinrich Heine Univ, Inst Human Genet, Med Fac, Dusseldorf, Germany; [Siebert, Reiner] Ulm Univ, Inst Human Genet, Ulm, Germany; [Siebert, Reiner] Ulm Univ, Med Ctr, Ulm, Germany	Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; Ulm University; Ulm University	Kuhlen, M (corresponding author), Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany.	Michaela.Kuhlen@med.uni-duesseldorf.de	Wieczorek, Dagmar/AAU-6008-2021; Siebert, Reiner/A-8049-2010	Wieczorek, Dagmar/0000-0003-2812-6492; Borkhardt, Arndt/0000-0002-6121-4737	German Research Consortium of Translational Cancer Research, DKTK; BMBF [01KU1505G]; KinderKrebsInitiative Buchholz/Holm-Seppensen	German Research Consortium of Translational Cancer Research, DKTK; BMBF(Federal Ministry of Education & Research (BMBF)); KinderKrebsInitiative Buchholz/Holm-Seppensen	The authors thank Stewart Boden for providing English editing. AB is supported by the German Research Consortium of Translational Cancer Research, DKTK. The research of RS on germline alterations in pediatric cancer is supported by the BMBF in the framework of the ICGC-DE-Mining consortium (01KU1505G) and the KinderKrebsInitiative Buchholz/Holm-Seppensen. AB is supported by the German Research Consortium of Translational Cancer Research, DKTK. The research of RS on germline alterations in pediatric cancer is supported by the BMBF in the framework of the ICGC-DE-Mining consortium (01KU1505G) and the KinderKrebsInitiative Buchholz/Holm-Seppensen.	Acuna-Hidalgo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1110-1; Acuna-Hidalgo R, 2015, AM J HUM GENET, V97, P67, DOI 10.1016/j.ajhg.2015.05.008; Ariffin H, 2014, P NATL ACAD SCI USA, V111, P15497, DOI 10.1073/pnas.1417322111; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Ballinger ML, 2016, LANCET ONCOL, V17, P1261, DOI 10.1016/S1470-2045(16)30147-4; Bardai A, 2016, NEW ENGL J MED, V374, P1390, DOI 10.1056/NEJMc1600338; Bell RJA, 2016, MOL CANCER RES, V14, P315, DOI 10.1158/1541-7786.MCR-16-0003; Besenbacher S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6969; Betts MJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1094; Brozou T, 2018, EUR J PEDIATR, V177, P53, DOI 10.1007/s00431-017-2997-6; Campbell CD, 2013, TRENDS GENET, V29, P575, DOI 10.1016/j.tig.2013.04.005; Campbell IM, 2014, AM J HUM GENET, V95, P173, DOI 10.1016/j.ajhg.2014.07.003; Cerrato F, 2008, HUM MOL GENET, V17, P1427, DOI 10.1093/hmg/ddn031; Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862; Conti SL, 2016, ASIAN J ANDROL, V18, P420, DOI 10.4103/1008-682X.175097; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; de Kock L, 2018, GENE CHROMOSOME CANC, V57, P223, DOI 10.1002/gcc.22523; Diets IJ, 2018, CLIN CANCER RES, V24, P1594, DOI 10.1158/1078-0432.CCR-17-1725; Dorairaj JJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-421; Eyre-Walker A, 2007, NAT REV GENET, V8, P610, DOI 10.1038/nrg2146; Farwell KD, 2015, GENET MED, V17, P578, DOI 10.1038/gim.2014.154; Franceschi S, 2017, CARCINOGENESIS, V38, P938, DOI 10.1093/carcin/bgx069; Francioli LC, 2015, NAT GENET, V47, P822, DOI 10.1038/ng.3292; Fremerey J, 2017, FAM CANCER, V16, P401, DOI 10.1007/s10689-016-9958-5; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Goldmann JM, 2016, NAT GENET, V48, P935, DOI 10.1038/ng.3597; Goriely A, 2012, AM J HUM GENET, V90, P175, DOI 10.1016/j.ajhg.2011.12.017; Hadizadeh H, 2017, PEDIAT ALLERG IMM-UK, V28, P280, DOI 10.1111/pai.12685; Heidemann S, 2012, BREAST CANCER RES TR, V134, P1229, DOI 10.1007/s10549-012-2050-4; Hemminki K, 1999, EPIDEMIOLOGY, V10, P271, DOI 10.1097/00001648-199905000-00014; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Johnson KJ, 2009, EPIDEMIOLOGY, V20, P475, DOI 10.1097/EDE.0b013e3181a5a332; King DA, 2014, GENOME RES, V24, P673, DOI 10.1101/gr.160465.113; Kloosterman WP, 2015, GENOME RES, V25, P792, DOI 10.1101/gr.185041.114; Knapke Sara, 2012, Am Soc Clin Oncol Educ Book, P576, DOI 10.14694/EdBook_AM.2012.32.576; Kong A, 2012, NATURE, V488, P471, DOI 10.1038/nature11396; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; Kotzot D, 2008, J MED GENET, V45, P545, DOI 10.1136/jmg.2008.058016; Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408; Kresak JL, 2016, J PEDIATR GENET, V5, P98, DOI 10.1055/s-0036-1579766; Kuhlen M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708641; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Lelieveld SH, 2016, NAT NEUROSCI, V19, P1194, DOI 10.1038/nn.4352; Martin-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892; McBride KA, 2014, NAT REV CLIN ONCOL, V11, P260, DOI 10.1038/nrclinonc.2014.41; Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062; Mestek-Boukhibar L, 2018, J MED GENET, V55, P721, DOI 10.1136/jmedgenet-2018-105396; Mussa A, 2016, J PEDIATR-US, V176, P142, DOI 10.1016/j.jpeds.2016.05.038; Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714; Natacci F, 2008, AM J MED GENET A, V146A, P784, DOI 10.1002/ajmg.a.32228; Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835; Papenhausen P, 2011, AM J MED GENET A, V155A, P757, DOI 10.1002/ajmg.a.33939; Rahbari R, 2016, NAT GENET, V48, P126, DOI 10.1038/ng.3469; Rauch A, 2012, LANCET, V380, P1674, DOI 10.1016/S0140-6736(12)61480-9; Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523; Renaux-Petel M, 2018, J MED GENET, V55, P173, DOI 10.1136/jmedgenet-2017-104976; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rivera B, 2016, ACTA NEUROPATHOL, V131, P847, DOI 10.1007/s00401-016-1549-x; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rotunno M, 2016, HAEMATOLOGICA, V101, P853, DOI 10.3324/haematol.2015.135475; Salem B, 2016, J PEDIAT HEMATOL ONC, V38, pE278, DOI 10.1097/MPH.0000000000000566; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Schwaederle M, 2017, CANCER, V124, P1288; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105; Speedy HE, 2016, BLOOD, V128, P2319, DOI 10.1182/blood-2016-01-695692; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Taeubner J, 2018, TRENDS CANCER, V4, P718, DOI 10.1016/j.trecan.2018.09.002; Taeubner J, 2018, EUR J HUM GENET, V26, P137, DOI 10.1038/s41431-017-0048-4; Veltman JA, 2012, NAT REV GENET, V13, P565, DOI 10.1038/nrg3241; Villani A, 2011, LANCET ONCOL, V12, P559, DOI 10.1016/S1470-2045(11)70119-X; Vislovukh Andrii, 2014, World J Biol Chem, V5, P40, DOI 10.4331/wjbc.v5.i1.40; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Wang R, 2017, AM J EPIDEMIOL, V186, P843, DOI 10.1093/aje/kwx160; Waszak SM, 2017, BIORXIV, DOI [10.1101/208330, DOI 10.1101/208330]; Yamazawa K, 2010, AM J MED GENET C, V154C, P329, DOI 10.1002/ajmg.c.30270; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80; Zhu XL, 2015, GENET MED, V17, P774, DOI 10.1038/gim.2014.191; Zlotogora J, 2004, HUM GENET, V114, P521, DOI 10.1007/s00439-004-1105-y	85	20	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1367	1380		10.1038/s41388-018-0520-9	http://dx.doi.org/10.1038/s41388-018-0520-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305723	Green Published, hybrid			2022-12-28	WOS:000459945800001
J	Yonesaka, K; Takegawa, N; Watanabe, S; Haratani, K; Kawakami, H; Sakai, K; Chiba, Y; Maeda, N; Kagari, T; Hirotani, K; Nishio, K; Nakagawa, K				Yonesaka, Kimio; Takegawa, Naoki; Watanabe, Satomi; Haratani, Koji; Kawakami, Hisato; Sakai, Kazuko; Chiba, Yasutaka; Maeda, Naoyuki; Kagari, Takashi; Hirotani, Kenji; Nishio, Kazuto; Nakagawa, Kazuhiko			An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; HER3; GEFITINIB; AMPLIFICATION; EGFR(T790M); PATRITUMAB; SURVIVAL; C-ERBB-3; PROTEIN	EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I inhibitor, DXd. In the current study, we evaluated the anticancer efficacy of U3-1402 in EGFR-mutant NSCLC cells with acquired resistance to EGFR-TKIs. HCC827GR5 and PC9AZDR7 are EGFR-TKI-resistant clones for gefitinib and osimertinib, respectively. U3-1402 alone or in combination with the EGFR-TKI erlotinib demonstrated potent anticancer efficacy in HCC827GR5 cells using an in vitro growth inhibition assay and in vivo xenograft mouse model. U3-1402 induced apoptosis in HCC827GR5 cells accompanying phosphorylation of histone H2A.X, a marker of DNA damage, but did not block HER3/PI3K/AKT signalling. Further, we found using flow cytometry that the cell surface HER3 expression level in HCC827GR5 cells was twice that found in HCC827 cells, indicating internalization of U3-1402 was increased in resistant cells. In addition, administration of U3-1402 notably repressed growth of EGFR-TKI osimertinib-resistant PC9AZDR7 xenograft tumours, and that PC9AZDR7 cells expressed five times greater cell surface HER3 than PC9 cells. Furthermore, using immunofluorescent microscopy, HER3 was observed predominantly in the nucleus of PC9 cells, but was localized in the cytoplasm of PC9AZDR7 cells. This finding indicates that altered trafficking of the HER3-U3-1402 complex may accelerate linker payload cleavage by cytoplasmic lysosomal enzymes, resulting in DNA damage. Our results indicate that administration of U3-1402 alone or in combination with an EGFR-TKI may have potential as a novel therapy for EGFR-TKI-resistant EGFR-mutant NSCLC.	[Yonesaka, Kimio; Takegawa, Naoki; Watanabe, Satomi; Haratani, Koji; Kawakami, Hisato; Nakagawa, Kazuhiko] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan; [Sakai, Kazuko; Nishio, Kazuto] Kindai Univ, Dept Genome Biol, Fac Med, Osaka, Japan; [Chiba, Yasutaka] Kindai Univ Hosp, Clin Res Ctr, Osaka, Japan; [Maeda, Naoyuki] Daiichi Sankyo Co Ltd, Biomarker Dept, Shinagawa Ku, Tokyo, Japan; [Kagari, Takashi] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Shinagawa Ku, Tokyo, Japan; [Hirotani, Kenji] Daiichi Sankyo Co Ltd, Oncol Clin Dev Dept, Shinagawa Ku, Tokyo, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Yonesaka, K (corresponding author), Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan.	yonesaka@med.kindai.ac.jp	Kawakami, Hisato/L-6845-2019; Watanabe, Satomi/HCI-6317-2022	Kawakami, Hisato/0000-0002-3280-4850; 	Daiichi Sankyo Co., Ltd. [U3-1402]	Daiichi Sankyo Co., Ltd.(Daiichi Sankyo Company Limited)	This study was financially supported by Daiichi Sankyo Co., Ltd. U3-1402 and patritumab were provided by Daiichi Sankyo Co., Ltd.	Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Cappuzzo F, 2005, BRIT J CANCER, V93, P1334, DOI 10.1038/sj.bjc.6602865; Chen R, 2015, MOL CANCER THER, V14, P1376, DOI 10.1158/1535-7163.MCT-15-0036; Doi T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.108; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Juric D, 2015, CLIN CANCER RES, V21, P2462, DOI 10.1158/1078-0432.CCR-14-2412; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Loganzo F, 2016, MOL CANCER THER, V15, P2825, DOI 10.1158/1535-7163.MCT-16-0408; Loganzo F, 2015, MOL CANCER THER, V14, P952, DOI 10.1158/1535-7163.MCT-14-0862; Mendell J, 2015, EBIOMEDICINE, V2, P264, DOI 10.1016/j.ebiom.2015.02.005; Meulendijks D, 2017, CLIN CANCER RES, V23, P5406, DOI 10.1158/1078-0432.CCR-17-0812; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822; Reif R, 2016, J BIOL CHEM, V291, P3837, DOI 10.1074/jbc.M115.686782; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shimizu T, 2017, CANCER CHEMOTH PHARM, V79, P489, DOI 10.1007/s00280-016-3231-3; Takegawa N, 2017, INT J CANCER, V141, P1682, DOI 10.1002/ijc.30870; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Trocme E, 2012, INT J CANCER, V130, P1120, DOI 10.1002/ijc.26118; Ueno S, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3092; Yi ES, 1997, MODERN PATHOL, V10, P142; Yonesaka K, 2016, ONCOGENE, V35, P878, DOI 10.1038/onc.2015.142; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhou CC, 2016, J THORAC ONCOL, V11, P174, DOI 10.1016/j.jtho.2015.10.002	30	40	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1398	1409		10.1038/s41388-018-0517-4	http://dx.doi.org/10.1038/s41388-018-0517-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30302022				2022-12-28	WOS:000459945800003
J	Liu, Y; Long, YH; Wang, SQ; Zhang, YY; Li, YF; Mi, JS; Yu, CH; Li, DY; Zhang, JH; Zhang, XJ				Liu, Yan; Long, Yue-Hong; Wang, Shu-Qing; Zhang, Yuan-Yue; Li, Yu-Feng; Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Jing-Hua; Zhang, Xiao-Jun			JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity	ONCOGENE			English	Article							IN-VIVO; PROTEIN; INHIBITOR; TRANSCRIPTION; COMPLEXES; ACTIVATOR; RECEPTOR; BINDING; DAMAGE	Overexpression of Jumonji domain-containing 6 (JMJD6) has been reported to be associated with more aggressive breast cancer characteristics. However, the precise role of JMJD6 in breast cancer development remains unclear. Here, we demonstrate that JMJD6 has intrinsic tyrosine kinase activity and can utilize ATP and GTP as phosphate donors to phosphorylate Y39 of histone H2A.X (H2A.X-Y39ph). High JMJD6 levels promoted autophagy in triple negative breast cancer (TNBC) cells by regulating the expression of autophagy-related genes. The JMJD6-H2A.X-Y39ph axis promoted TNBC cell growth via the autophagy pathway. We show that combined inhibition of JMJD6 kinase activity and autophagy efficiently decreases TNBC growth. Together, these findings suggest an effective strategy for TNBC treatment.	[Liu, Yan; Long, Yue-Hong; Zhang, Yuan-Yue] North China Univ Sci & Technol, Coll Life Sci, Tangshan, Peoples R China; [Liu, Yan; Zhang, Yuan-Yue; Li, Yu-Feng; Zhang, Jing-Hua] Tangshan Peoples Hosp, Inst Canc, Tangshan, Peoples R China; [Wang, Shu-Qing] Hosp North China Univ Sci & Technol, Tangshan, Peoples R China; [Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Xiao-Jun] Peoples Hosp Zunhua, Zunhua, Peoples R China	North China University of Science & Technology	Zhang, JH (corresponding author), Tangshan Peoples Hosp, Inst Canc, Tangshan, Peoples R China.; Wang, SQ (corresponding author), Hosp North China Univ Sci & Technol, Tangshan, Peoples R China.; Zhang, XJ (corresponding author), Peoples Hosp Zunhua, Zunhua, Peoples R China.	044a141211@ncst.edu.cn; jhzhang_te@163.com; tech_ol@foxmail.com	Li, yu/HHZ-5236-2022; zhang, jin/GXV-9154-2022		National Natural Science Foundation of China [81772834, 81302324, 81301779]; Science Fund for Distinguished Young Scholars of North China University of Science and Technology [JQ201704]; Scientific Research Matching Funds of North China University of Science and Technology; scientific research funds of Tangshan People's Hospital; Doctoral Research Project of North China University of Science and Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Fund for Distinguished Young Scholars of North China University of Science and Technology; Scientific Research Matching Funds of North China University of Science and Technology; scientific research funds of Tangshan People's Hospital; Doctoral Research Project of North China University of Science and Technology	This work was primarily supported by the National Natural Science Foundation of China (grant numbers 81772834, 81302324, 81301779). Other support include: Science Fund for Distinguished Young Scholars of North China University of Science and Technology (JQ201704); Doctoral Research Project of North China University of Science and Technology. This work was also supported by the Scientific Research Matching Funds of North China University of Science and Technology and scientific research funds of Tangshan People's Hospital.	Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Aprelikova O, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0205-6; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801; Cheng AW, 2013, CELL RES, V23, P1163, DOI 10.1038/cr.2013.122; Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060; Cikala M, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-26; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503; Druzinec D, 2013, ADV BIOCHEM ENG BIOT, V136, P65, DOI 10.1007/10_2013_205; Hahn P, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-293; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee YF, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3200; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Liu X, 2010, J BIOL CHEM, V285, P9729, DOI 10.1074/jbc.M109.073452; Liu Y, 2016, FEBS J, V283, P4462, DOI 10.1111/febs.13951; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1999, METHOD ENZYMOL, V304, P3; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Pattingre S, 2004, METHOD ENZYMOL, V390, P17; Poulard C, 2016, ONCOTARGET, V7, P67532, DOI 10.18632/oncotarget.11376; Poulard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126181; Quack I, 2006, P NATL ACAD SCI USA, V103, P14110, DOI 10.1073/pnas.0602587103; Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979; Rio DC., 2013, COLD SPRING HARB PRO, V2013; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Thomas S, 2012, CANCER LETT, V325, P63, DOI 10.1016/j.canlet.2012.05.030; Tsai A, 2006, NAT PROTOC, V1, P2820, DOI 10.1038/nprot.2006.371; Vangimalla SS, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7020041; Wang F, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001819; Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865; Wolf A, 2013, BIOCHEM J, V453, P357, DOI 10.1042/BJ20130529; Wu T, 2014, CELL STEM CELL, V15, P281, DOI 10.1016/j.stem.2014.06.004; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	46	36	37	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					980	997		10.1038/s41388-018-0466-y	http://dx.doi.org/10.1038/s41388-018-0466-y			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30185813				2022-12-28	WOS:000458624900005
J	Han, JH; Wang, FY; Lan, YL; Wang, JB; Nie, CL; Liang, YJ; Song, RP; Zheng, TS; Pan, SH; Pei, TM; Xie, CM; Yang, GC; Liu, XR; Zhu, MX; Wang, Y; Liu, Y; Meng, FZ; Cui, YF; Zhang, B; Liu, YF; Meng, XZ; Zhang, JW; Liu, LX				Han, Jihua; Wang, Fengyue; Lan, Yaliang; Wang, Jiabei; Nie, Chunlei; Liang, Yingjian; Song, Ruipeng; Zheng, Tongsen; Pan, Shangha; Pei, Tiemin; Xie, Changming; Yang, Guangchao; Liu, Xirui; Zhu, Mingxi; Wang, Yan; Liu, Yao; Meng, Fanzheng; Cui, Yifeng; Zhang, Bo; Liu, Yufeng; Meng, Xianzhi; Zhang, Jiewu; Liu, Lianxin			KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling	ONCOGENE			English	Article							CANCER; PROLIFERATION; PROGRESSION; EXPRESSION; IL-6/STAT3; MICRORNA; MIRNA; TWIST	Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. The poor survival may be due to a high proportions of tumor recurrence and metastasis. Kinesin family member C1 (KIFC1) is highly expressed in a variety of neoplasms and is a potential marker for non-small cell lung cancer or ovarian adenocarcinoma metastasis. Nevertheless, the role of KIFC1 in HCC metastasis remains obscure. We investigated this in the present study using HCC cell lines and clinical specimens. Our results indicated that increased levels of KIFC1 were associated with poor prognosis and metastasis in HCC. In addition, KIFC1 induced epithelial-to-mesenchymal transition (EMT) and HCC metastasis both in vitro and in vivo. This tumorigenic effect depended on gankyrin; inhibiting gankyrin activity reversed EMT via activation of protein kinase B (AKT)/Twist family BHLH transcription factor 1 (AKT/TWIST1). We also found that KIFC1 was directly regulated by the microRNA miR-532-3p, whose downregulation was associated with metastatic progression in HCC. These results denote that a decrease in miR-532-3p levels results in increased KIFC1 expression in HCC, leading to metastasis via activation of the gankyrin/AKT/TWIST1 signaling pathway.	[Han, Jihua; Wang, Fengyue; Lan, Yaliang; Wang, Jiabei; Liang, Yingjian; Song, Ruipeng; Pan, Shangha; Pei, Tiemin; Xie, Changming; Yang, Guangchao; Liu, Xirui; Zhu, Mingxi; Wang, Yan; Liu, Yao; Meng, Fanzheng; Cui, Yifeng; Zhang, Bo; Liu, Yufeng; Meng, Xianzhi; Liu, Lianxin] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Key Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China; [Han, Jihua; Nie, Chunlei; Zhang, Jiewu] Harbin Med Univ, Affiliated Hosp 3, Dept Head & Neck Surg, Harbin, Heilongjiang, Peoples R China; [Zheng, Tongsen] Harbin Med Univ, Affiliated Hosp 3, Dept Gastrointestinal Med Oncol, Harbin, Heilongjiang, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University	Meng, XZ; Liu, LX (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Key Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China.; Zhang, JW (corresponding author), Harbin Med Univ, Affiliated Hosp 3, Dept Head & Neck Surg, Harbin, Heilongjiang, Peoples R China.	mengxianzhi@sina.com; drzhangjiewu@sohu.com; liulx@ems.hrbmu.edu.cn	zheng, tongsen/ABB-9572-2021	zheng, tongsen/0000-0002-7539-3924	National Key Program for Science and Technology Research and Development [2016YFC0106503, 2016YFC0106500, 2016YFC0905902]; Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province [2009td06]; Changjiang Scholars and Innovative Research Team in University [IRT1122]; National Natural Scientific Foundation of China [81602058, 81772588, 81773194]; Hei Longjiang Postdoctoral Foundation; China Postdoctoral Science Foundation [2018M630368]; Science and Technology Research Projects of Hei Longjiang Province [GC12C304-5]; Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University [JJZD2017-03, JJQN2018-14]; Fundamental Research Funds for the Provincial Universities [2017LCZX24]; Foundation of the First Affiliated Hospital of Harbin Medical University [2018B017]; Innovative Research Program for Graduate of Harbin Medical University [YJSCX2015-17HYD]	National Key Program for Science and Technology Research and Development; Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province; Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Hei Longjiang Postdoctoral Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Science and Technology Research Projects of Hei Longjiang Province; Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University; Fundamental Research Funds for the Provincial Universities; Foundation of the First Affiliated Hospital of Harbin Medical University; Innovative Research Program for Graduate of Harbin Medical University	This study was supported by National Key Program for Science and Technology Research and Development (grant no. 2016YFC0106503, no. 2016YFC0106500 and no. 2016YFC0905902), Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province (grant no. 2009td06), Changjiang Scholars and Innovative Research Team in University (grant no. IRT1122), the National Natural Scientific Foundation of China (grant no. 81602058, no. 81772588, no. 81773194), Hei Longjiang Postdoctoral Foundation, China Postdoctoral Science Foundation Grant (grant no. 2018M630368), the Science and Technology Research Projects of Hei Longjiang Province (grant no. GC12C304-5), Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University (grant no. JJZD2017-03, no. JJQN2018-14), the Fundamental Research Funds for the Provincial Universities (grant no. 2017LCZX24), the Foundation of the First Affiliated Hospital of Harbin Medical University (grant no. 2018B017), Innovative Research Program for Graduate of Harbin Medical University (grant no. YJSCX2015-17HYD). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bai ZF, 2013, CANCER RES, V73, P4548, DOI 10.1158/0008-5472.CAN-12-4586; Benson EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141279; Chang RM, 2017, CLIN CANCER RES, V23, P2593, DOI 10.1158/1078-0432.CCR-16-0851; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Fu J, 2011, HEPATOLOGY, V53, P181, DOI 10.1002/hep.24015; Goh GBB, 2015, BEST PRACT RES CL GA, V29, P919, DOI 10.1016/j.bpg.2015.09.007; Grinberg-Rashi H, 2009, CLIN CANCER RES, V15, P1755, DOI 10.1158/1078-0432.CCR-08-2124; Han J., 2017, IEEE J SOLID-ST CIRC, V1, P1; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Kanaan Z, 2013, ANN SURG, V258, P400, DOI 10.1097/SLA.0b013e3182a15bcc; Li YH, 2015, CANCER BIOL THER, V16, P1316, DOI 10.1080/15384047.2015.1070980; Liu YF, 2016, J THORAC DIS, V8, P2911, DOI 10.21037/jtd.2016.10.67; Liu Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095043, 10.1371/journal.pone.0086026]; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Nath S, 2007, MOL BIOL CELL, V18, P1839, DOI 10.1091/mbc.E06-06-0524; Oue N, 2016, ONCOL REP, V36, P349, DOI 10.3892/or.2016.4781; Pawar S, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-53; Pei TM, 2015, ONCOTARGET, V6, P17206, DOI 10.18632/oncotarget.4043; Pospisilova S, 2016, NEOPLASMA, V63, P799, DOI 10.4149/neo_2016_518; Riahi MM, 2017, NEOPLASMA, V63, P1560; Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang JB, 2016, HEPATOLOGY, V64, P1606, DOI 10.1002/hep.28781; Wang WP, 2017, ONCOTARGET, V8, P5909, DOI 10.18632/oncotarget.13947; Wang WP, 2015, PATHOL RES PRACT, V211, P939, DOI 10.1016/j.prp.2015.09.010; Xiao YX, 2016, ONCOTARGET, V7, P48656, DOI 10.18632/oncotarget.8799; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu KM, 2009, CELL TISSUE RES, V337, P113, DOI 10.1007/s00441-009-0800-3; Zhao BS, 2013, ASIAN PAC J CANCER P, V14, P139, DOI 10.7314/APJCP.2013.14.1.139; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zhou SL, 2016, HEPATOLOGY, V63, P1560, DOI 10.1002/hep.28445; Zou H, 2015, HEPATOL INT, V9, P399, DOI 10.1007/s12072-015-9634-0	35	50	55	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					406	420		10.1038/s41388-018-0440-8	http://dx.doi.org/10.1038/s41388-018-0440-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30115976	Green Published, hybrid			2022-12-28	WOS:000455851200008
J	Jiang, MZ; Xu, B; Li, XW; Shang, YL; Chu, Y; Wang, WJ; Chen, D; Wu, N; Hu, SJ; Zhang, S; Li, MB; Wu, KC; Yang, XY; Liang, J; Nie, YZ; Fan, DM				Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Yang, Xiaoyong; Liang, Jie; Nie, Yongzhan; Fan, Daiming			O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BETA-N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; E-CADHERIN; C-MYC; EZH2; COLON; PROTEIN; EXPRESSION; MIGRATION	Advanced colorectal cancer (CRC) is one of the deadliest cancers, and the 5-year survival rate of patients with metastasis is extremely low. The epithelial-mesenchymal transition (EMT) is considered essential for metastatic CRC, but the fundamental molecular basis underlying this effect remains unknown. Here, we identified that O-GlcNAcylation, a unique posttranslational modification (PTM) involved in cancer metabolic reprogramming, increased the metastatic capability of CRC. The levels of O-GlcNAcylation were increased in the metastatic CRC tissues and cell lines, which likely promoted the EMT by enhancing EZH2 protein stability and function. The CRC patients with higher levels of O-GlcNAcylation exhibited greater lymph node metastasis potential and lower overall survival. Bioinformatic analysis and luciferase reporter assays revealed that both O-GlcNAcylation transferase (OGT) and EZH2 are posttranscriptionally inhibited by microRNA-101. In addition, O-GlcNAcylation and H3K27me3 modification in the miR-101 promoter region further inhibited the transcription of miR-101, resulting in the upregulation of OGT and EZH2 in metastatic CRC, thus forming a vicious cycle. In this study, we demonstrated that O-GlcNAcylation, which is negatively regulated by microRNA-101, likely promotes CRC metastasis by enhancing EZH2 protein stability and function. Reducing O-GlcNAcylation may be a potential therapeutic strategy for metastatic CRC.	[Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Xu, Bing] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gastroenterol, Xian 710004, Shaanxi, Peoples R China; [Wu, Nan] Northwest Univ, Fac Life Sci, Lab Tissue Engn, Xian, Shaanxi, Peoples R China; [Yang, Xiaoyong] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University; Northwest University Xi'an; Yale University	Nie, YZ; Fan, DM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Nie, YZ; Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn		nan, wu/0000-0002-9939-9810	National Natural Science Foundation of China [81430072, 81730016, 81421003, 81572302, 81772650, 2015BAI13B07, CBSKL2015Z12]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by the National Natural Science Foundation of China (Nos. 81430072, 81730016, 81421003, 81572302, 81772650, 2015BAI13B07, and CBSKL2015Z12). We acknowledge Xiang-Yuan Zhang, Miao-Miao Tian, Zu-Hong Tian, Ying Zhang, and Hai-Bin Ruan for their technical assistance.	Babae N, 2014, ONCOTARGET, V5, P6687, DOI 10.18632/oncotarget.2235; Ben Harosh-Davidovich S, 2018, EXP CELL RES, V364, P42, DOI 10.1016/j.yexcr.2018.01.024; Benton G, 2014, ADV DRUG DELIVER REV, V79-80, P3, DOI 10.1016/j.addr.2014.06.005; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Buren S, 2016, CANCER CELL, V30, P290, DOI 10.1016/j.ccell.2016.06.023; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chaiyawat P, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00193; Cheng SM, 2016, BIOCHEM BIOPH RES CO, V478, P1497, DOI 10.1016/j.bbrc.2016.08.074; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Duranton B, 2003, AMINO ACIDS, V24, P63, DOI 10.1007/s00726-002-0333-5; Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Geng F, 2012, J CELL SCI, V125, P2615, DOI 10.1242/jcs.096735; Gollner S, 2017, NAT MED, V23, P69, DOI 10.1038/nm.4247; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Guo HB, 2017, J BIOL CHEM, V292, P4123, DOI 10.1074/jbc.M116.763201; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hart GW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00183; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Jiang MZ, 2016, ONCOTARGET, V7, P61390, DOI 10.18632/oncotarget.11359; Jin FZ, 2013, EXP CELL RES, V319, P1482, DOI 10.1016/j.yexcr.2013.03.013; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim Sang Wook, 2017, Korean J Gastroenterol, V69, P206, DOI 10.4166/kjg.2017.69.4.206; Love Dona C, 2005, Sci STKE, V2005, pre13, DOI 10.1126/stke.3122005re13; Luo P, 2015, MOL MED REP, V12, P1163, DOI 10.3892/mmr.2015.3491; Ma ZY, 2013, AMINO ACIDS, V45, P719, DOI 10.1007/s00726-013-1543-8; Mangalhara KC, 2017, CANCER LETT, V391, P59, DOI 10.1016/j.canlet.2017.01.016; Meyerhardt Jeffrey A, 2013, Clin Adv Hematol Oncol, V11, P93; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mohammadi A, 2016, BIOMED PHARMACOTHER, V84, P705, DOI 10.1016/j.biopha.2016.09.099; O'Dwyer PJ, 2007, J CLIN ONCOL, V25, P2313, DOI 10.1200/JCO.2006.08.6900; Ozcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Ruan HB, 2013, MOL CELL PROTEOMICS, V12, P3489, DOI 10.1074/mcp.R113.029751; Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Shimomoto T, 2012, CLIN EXP METASTAS, V29, P915, DOI 10.1007/s10585-012-9480-6; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Soumyanarayanan U, 2016, FUTURE MED CHEM, V8, P1635, DOI 10.4155/fmc-2016-0096; Steenackers A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00046; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Vaiana CA, 2016, J BIOL CHEM, V291, P1529, DOI 10.1074/jbc.M115.672220; Vasconcelos-dos-Santos A, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.2; Very N, 2018, J BIOENERG BIOMEMBR, V50, P213, DOI 10.1007/s10863-018-9747-y; Wang J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/823620; Wang L, 2014, HEPATOLOGY, V59, P1850, DOI 10.1002/hep.26720; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515; Xu WQ, 2017, J HEPATOL, V67, P310, DOI 10.1016/j.jhep.2017.03.017; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang YR, 2015, ONCOTARGET, V6, P12529, DOI 10.18632/oncotarget.3725; Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	60	68	73	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					301	316		10.1038/s41388-018-0435-5	http://dx.doi.org/10.1038/s41388-018-0435-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093632	hybrid, Green Published			2022-12-28	WOS:000455851200001
J	He, F; Song, Z; Chen, HC; Chen, ZP; Yang, P; Li, WL; Yang, Z; Zhang, T; Wang, F; Wei, JC; Wei, F; Wang, Q; Cao, J				He, Feng; Song, Zhi; Chen, Huacui; Chen, Zhuanpeng; Yang, Ping; Li, Wanglin; Yang, Zhi; Zhang, Tong; Wang, Fei; Wei, Jianchang; Wei, Fang; Wang, Qiang; Cao, Jie			Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128	ONCOGENE			English	Article							CELL-PROLIFERATION; POOR-PROGNOSIS; GASTRIC-CANCER; UP-REGULATION; PROGRESSION; MECHANISMS; APOPTOSIS; GROWTH; LOOP	Long noncoding RNAs (lncRNAs) are implicated in human cancer, but their mechanisms of action are largely unknown. In this study, we investigated lncRNA alterations that contribute to colorectal cancer (CRC) through microarray expression profiling in CRC patient samples. Here, we report that the CRC-associated lncRNA PVT1-214 is a key regulator of CRC development and progression; patients with high PVT1-214 expression had a shorter survival and poorer prognosis. In vitro and in vivo investigation of the role of PVT1-214 revealed a complex integrated phenotype affecting cell growth, stem-like properties, migration, and invasion. Furthermore, using RNA pull-down and mass spectrometry, we found that Lin28 (also known as Lin28A), a highly conserved RNA-binding protein, is associated with PVT1-214. Strikingly, we found that PVT1-214 not only upregulated Lin28 protein expression in CRC cells by stabilizing Lin28, but also participated in crosstalk with Lin28 mRNA through competition for miR-128 binding, imposing an additional level of post-transcriptional regulation. In addition, we further show that PVT1-214 repressed expression of let-7 family miRNAs, which was abrogated by Lin28 knockdown. Taken together, our findings support a model in which the PVT1-214/Lin28/let-7 axis serves as a critical regulator of CRC pathogenesis, which may simulate a new direction for CRC therapeutic development.	[He, Feng; Chen, Huacui; Chen, Zhuanpeng; Yang, Ping; Li, Wanglin; Yang, Zhi; Zhang, Tong; Wang, Fei; Wei, Jianchang; Wei, Fang; Wang, Qiang; Cao, Jie] South China Univ Technol, Affiliated Hosp 2, Dept Gen Surg, Guangzhou Digest Dis Ct,Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China; [He, Feng] South China Univ Technol, Affiliated Hosp 2, Guangzhou Peoples Hosp 1, Dept Nephrol, Guangzhou 510180, Guangdong, Peoples R China; [He, Feng; Song, Zhi; Chen, Huacui] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Song, Zhi] Sun Yat Sen Univ, Dept Operat Dent & Endodont, Guanghua Sch Stomatol, Hosp Stomatol, Guangzhou 510055, Guangdong, Peoples R China; [Song, Zhi] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China; [Chen, Huacui; Cao, Jie] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou 510180, Guangdong, Peoples R China	South China University of Technology; South China University of Technology; Yale University; Sun Yat Sen University; Guangzhou Medical University	Cao, J (corresponding author), South China Univ Technol, Affiliated Hosp 2, Dept Gen Surg, Guangzhou Digest Dis Ct,Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China.; Cao, J (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou 510180, Guangdong, Peoples R China.	czhongt@126.com			National Natural Science Foundation of China [8187101464, 81600654, 81600862]; Guangdong Natural Science Foundation [2017A030311035, 2016A030313490, 2016A030310227]; Fundamental Research Funds for the Central Universities [XZYXD2175080]; Guangdong Provincial Department of Science and Technology [2017A020215146]; Guangzhou Science Technology and Innovation Commission [201805010003]; US National Institutes of Health (NIH) [R01 HL136507]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL136507] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Provincial Department of Science and Technology; Guangzhou Science Technology and Innovation Commission; US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the National Natural Science Foundation of China (Grant no. 8187101464, 81600654 and 81600862); the Guangdong Natural Science Foundation (Grant no. 2017A030311035, 2016A030313490 and 2016A030310227); the Fundamental Research Funds for the Central Universities (Grant no. XZYXD2175080); and the Guangdong Provincial Department of Science and Technology (Grant no. 2017A020215146); Guangzhou Science Technology and Innovation Commission (Grant no. 201805010003); and US National Institutes of Health (NIH) grant R01 HL136507.	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278; Cao DF, 2011, HUM PATHOL, V42, P710, DOI 10.1016/j.humpath.2010.09.007; Chen FC, 2014, EVOL BIOINFORM, V10, P219, DOI 10.4137/EBO.S20772; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gokbuget D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9584; Guo K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699122; He F, 2016, ONCOTARGET, V7, P81156, DOI 10.18632/oncotarget.13215; He F, 2014, DIABETOLOGIA, V57, P1726, DOI 10.1007/s00125-014-3282-0; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Izaurralde E, 2012, EMBO REP, V13, P662, DOI 10.1038/embor.2012.91; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878; Lu WQ, 2017, ONCOTARGET, V8, P15242, DOI 10.18632/oncotarget.14839; Ma MZ, 2016, CANCER RES, V76, P5361, DOI 10.1158/0008-5472.CAN-15-3047; Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Powers JT, 2016, NATURE, V535, P246, DOI 10.1038/nature18632; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang Y, 2017, BIOCHEM BIOPH RES CO, V493, P429, DOI 10.1016/j.bbrc.2017.09.005; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Zang WQ, 2016, ONCOTARGET, V7, P19960, DOI 10.18632/oncotarget.6963; Zheng JJ, 2016, ONCOTARGET, V7, P62886, DOI 10.18632/oncotarget.11709; Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012	38	74	76	0	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					164	179		10.1038/s41388-018-0432-8	http://dx.doi.org/10.1038/s41388-018-0432-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30076414	Green Accepted			2022-12-28	WOS:000455366700002
J	Han, H; Yang, B; Nakaoka, HJ; Yang, JD; Zhao, YF; Le Nguyen, K; Bishara, AT; Mandalia, TK; Wang, WQ				Han, Han; Yang, Bing; Nakaoka, Hiroki J.; Yang, Jiadong; Zhao, Yifan; Le Nguyen, Kathern; Bishara, Amell Taffy; Mandalia, Tejas Krishen; Wang, Wenqi			Hippo signaling dysfunction induces cancer cell addiction to YAP	ONCOGENE			English	Article							ONCOGENE ADDICTION; TISSUE HOMEOSTASIS; PATHWAY; KINASES; INACTIVATION; ONCOPROTEIN; ACTIVATION; INHIBITORS; YAP/TAZ; LATS1/2	Over the past decades, the Hippo has been established as a crucial pathway involved in organ size control and cancer suppression. Dysregulation of Hippo signaling and hyperactivation of its downstream effector YAP are frequently associated with various human cancers. However, the underlying significance of such YAP activation in cancer development and therapy has not been fully characterized. In this study, we reported that the Hippo signaling deficiency can lead to a YAP-dependent oncogene addiction for cancer cells. Through a clinical compound library screen, we identified histone deacetylase (HDAC) inhibitors as putative inhibitors to suppress YAP expression. Importantly, HDAC inhibitors specifically targeted the viability and xenograft tumor growth for the cancer cells in which YAP is constitutively active. Taken together, our results not only establish an active YAP-induced oncogene addiction in cancer cells, but also lay the foundation to develop targeted therapies for the cancers with Hippo dysfunction and YAP activation.	[Han, Han; Yang, Bing; Nakaoka, Hiroki J.; Yang, Jiadong; Zhao, Yifan; Le Nguyen, Kathern; Bishara, Amell Taffy; Mandalia, Tejas Krishen; Wang, Wenqi] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Wang, WQ (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	wenqiw6@uci.edu	HAN, HAN/AAC-5464-2022; han, han/HDL-7807-2022	HAN, HAN/0000-0003-2222-5270; Wang, Wenqi/0000-0003-4053-5088	American Association for Cancer Research Career Development Award for Translational Breast Cancer Research - Breast Cancer Research Foundation [16-20-26-WANG]; University of California, Irvine Chao Family Comprehensive Cancer Center; NIH [R01 GM126048]; American Cancer Society [RSG-18-009-01-CCG]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM126048] Funding Source: NIH RePORTER	American Association for Cancer Research Career Development Award for Translational Breast Cancer Research - Breast Cancer Research Foundation; University of California, Irvine Chao Family Comprehensive Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs. Steven H Lin and Junjie Chen (MD Anderson Cancer Center) for the clinical compound library. WW is a recipient of an American Association for Cancer Research Career Development Award for Translational Breast Cancer Research supported by the Breast Cancer Research Foundation (16-20-26-WANG). This work was supported by University of California, Irvine Chao Family Comprehensive Cancer Center (Pilot Project 2018) and in part by a NIH grant (R01 GM126048) and a Research Scholar Grant (RSG-18-009-01-CCG) from the American Cancer Society to WW.	Bonilla X, 2016, NAT GENET, V48, P398, DOI 10.1038/ng.3525; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Jung DE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11094-3; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Li Q, 2014, DEV CELL, V31, P291, DOI 10.1016/j.devcel.2014.09.012; Li SX, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.38; Li Y., 2016, COLD SPRING HARB PER, V6; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Plouffe SW, 2018, J BIOL CHEM, V293, P11230, DOI 10.1074/jbc.RA118.002715; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wang WQ, 2008, J CELL SCI, V121, P1334, DOI 10.1242/jcs.018176; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang WQ, 2017, J CELL MOL MED, V21, P2663, DOI 10.1111/jcmm.13182; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	34	22	22	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6414	6424		10.1038/s41388-018-0419-5	http://dx.doi.org/10.1038/s41388-018-0419-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30068939	Green Submitted, Green Accepted			2022-12-28	WOS:000452989100003
J	Loria, R; Laquintana, V; Bon, G; Trisciuoglio, D; Frapolli, R; Covello, R; Amoreo, CA; Ferraresi, V; Zoccali, C; Novello, M; Del Bufalo, D; Milella, M; Biagini, R; D'Incalci, M; Falcioni, R				Loria, Rossella; Laquintana, Valentina; Bon, Giulia; Trisciuoglio, Daniela; Frapolli, Roberta; Covello, Renato; Amoreo, Carla Azzurra; Ferraresi, Virginia; Zoccali, Carmine; Novello, Mariangela; Del Bufalo, Donatella; Milella, Michele; Biagini, Roberto; D'Incalci, Maurizio; Falcioni, Rita			HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance	ONCOGENE			English	Article							SOFT-TISSUE SARCOMA; NUCLEOTIDE-EXCISION-REPAIR; MESENCHYMAL TRANSITION; MYXOID LIPOSARCOMAS; COLON-CANCER; DNA-BINDING; KAPPA-B; ECTEINASCIDIN-743; EXPRESSION; GENE	Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones. Loss-and gain-of-function experiments by HMGA1-specific depletion and overexpression in dedifferentiated and myxoid liposarcoma cells showed the contribution of this oncogenic factor in cell proliferation, motility, invasion, and drug resistance. The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis. These data were also confirmed in patients' tumor biopsies being HMGA1, E2F1, and vimentin expression significantly reduced upon trabectedin therapy, administered as neo-adjuvant chemotherapy. Furthermore, trabectedin treatment inhibits in vitro NFkB pathway in mixoyd liposarcoma sensitive but not in resistant counterparts, and the inhibition of NFkB pathway re-sensitizes the resistant cells to trabectedin treatment. These data support the rational for combining NFkB inhibitors with trabectedin in liposarcoma patients, who have become resistant to the drug.	[Loria, Rossella; Laquintana, Valentina; Bon, Giulia; Falcioni, Rita] IRCCS Regina Elena Natl Canc Inst, Cellular Network & Mol Therapeut Target Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Trisciuoglio, Daniela; Del Bufalo, Donatella] IRCCS Regina Elena Natl Canc Inst, Preclin Models & New Therapeut Agents Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Trisciuoglio, Daniela] Sapienza Univ Rome, Inst Mol Biol & Pathol, CNR Natl Res Council, I-00185 Rome, Italy; [Frapolli, Roberta; D'Incalci, Maurizio] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Via La Masa 19, Milan, Italy; [Covello, Renato; Amoreo, Carla Azzurra; Novello, Mariangela] IRCCS Regina Elena Natl Canc Inst, Pathol Unit, Dept Res Adv Diagnost & Technol Innovat, Via Elio Chianesi 53, I-00144 Rome, Italy; [Ferraresi, Virginia; Milella, Michele] IRCCS Regina Elena Natl Canc Inst, Med Oncol A, Via Elio Chianesi 53, I-00144 Rome, Italy; [Zoccali, Carmine; Biagini, Roberto] IRCCS Regina Elena Natl Canc Inst, Dept Expt Clin Oncol, Orthoped Surg, Via Elio Chianesi 53, I-00144 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Falcioni, R (corresponding author), IRCCS Regina Elena Natl Canc Inst, Cellular Network & Mol Therapeut Target Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	rita.falcioni@ifo.gov.it	ferraresi, virginia/ABH-7898-2020; Zoccali, Carmine/AAR-4473-2020; Frapolli, Roberta/AAA-6729-2020; Falcioni, Rita/H-8869-2017; trisciuoglio, daniela/AAL-4002-2021; Loria, Rossella/ABH-7374-2020; Del Bufalo, Donatella/AAC-1594-2021; Bon, Giulia/ABH-6498-2020; Del Bufalo, Donatella/K-8673-2016; Milella, Michele/ABH-8606-2020; Laquintana, Valentina/U-7577-2017; D'Incalci, Maurizio/AAA-9021-2020; Loria, Rossella/A-6139-2015; Trisciuoglio, Daniela/H-2131-2016	ferraresi, virginia/0000-0001-6419-1668; Zoccali, Carmine/0000-0002-6616-1996; Frapolli, Roberta/0000-0003-2907-273X; Falcioni, Rita/0000-0002-3745-4327; Loria, Rossella/0000-0002-1305-2825; Del Bufalo, Donatella/0000-0002-3148-6096; Bon, Giulia/0000-0002-5409-5864; Del Bufalo, Donatella/0000-0002-3148-6096; Laquintana, Valentina/0000-0002-7374-5279; D'Incalci, Maurizio/0000-0001-8784-1360; Trisciuoglio, Daniela/0000-0002-7007-7914	Ministero della Salute (DMT Sarcoma Group IRE); Italian Association for Cancer Research (AIRC) [IG 18622, IG 19189]; PharmaMar	Ministero della Salute (DMT Sarcoma Group IRE); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); PharmaMar	We thank PharmaMar for providing us trabectedin, Dr. Alessandra Verdina for her support, and Dr. Silvia Soddu for discussion. This work was supported by Ministero della Salute (DMT Sarcoma Group IRE) and PharmaMar to RF, and Italian Association for Cancer Research (AIRC) with a IG 18622 to M.M., and IG 19189 to MD	Allavena P, 2005, CANCER RES, V65, P2964, DOI 10.1158/0008-5472.CAN-04-4037; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; ASHAR HR, 1995, CELL, V82, P57; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Bon G, 2017, ONCOTARGET, V8, P108463, DOI 10.18632/oncotarget.11400; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; Carter NJ, 2010, DRUGS, V70, P355, DOI 10.2165/11202860-000000000-00000; Casali PG, 2010, CURR OPIN ONCOL, V22, P342, DOI 10.1097/CCO.0b013e32833aaac1; Chiappetta G, 1996, ONCOGENE, V13, P2439; Crago AM, 2011, CURR OPIN ONCOL, V23, P373, DOI 10.1097/CCO.0b013e32834796e6; D'Angelo D, 2013, EUR J CANCER, V49, P1142, DOI 10.1016/j.ejca.2012.10.014; D'Incalci M, 2010, MOL CANCER THER, V9, P2157, DOI 10.1158/1535-7163.MCT-10-0263; Damia G, 2001, INT J CANCER, V92, P583, DOI 10.1002/ijc.1221; Di Giandomenico S, 2014, ONCOGENE, V33, P5201, DOI 10.1038/onc.2013.462; Doyle LA, 2014, CANCER-AM CANCER SOC, V120, P1763, DOI 10.1002/cncr.28657; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fletcher C., 2013, IARC WHO CLASSIFICAT, V5; FLETCHER JA, 1992, CANCER RES, V52, P6224; Folgiero V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001592; Frapolli R, 2010, CLIN CANCER RES, V16, P4958, DOI 10.1158/1078-0432.CCR-10-0317; Frensing T, 2008, BBA-GENE REGUL MECH, V1779, P139, DOI 10.1016/j.bbagrm.2007.11.007; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Gordon EM, 2016, ADV THER, V33, P1055, DOI 10.1007/s12325-016-0344-3; Gronchi A, 2017, LANCET ONCOL, V18, P812, DOI 10.1016/S1470-2045(17)30334-0; Guirouilh-Barbat J, 2008, MOL BIOL CELL, V19, P3969, DOI 10.1091/mbc.E08-02-0215; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Loria R, 2015, ONCOTARGET, V6, P2779, DOI 10.18632/oncotarget.2995; Luo WR, 2012, INT J CANCER, V131, P1863, DOI 10.1002/ijc.27467; Massimi I, 2013, MOL CARCINOGEN, V52, P526, DOI 10.1002/mc.21887; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; MORTON DL, 1978, AUST NZ J SURG, V48, P56, DOI 10.1111/j.1445-2197.1978.tb05806.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136; Pentimalli F, 2008, EUR J CANCER, V44, P2668, DOI 10.1016/j.ejca.2008.07.033; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Schuldenfrei A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-549; Singer S, 2003, ANN SURG, V238, P358, DOI 10.1097/01.sla.0000086542.11899.38; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takebayashi Y, 2001, NAT MED, V7, P961, DOI 10.1038/91008; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Uboldi S, 2012, INT J CANCER, V131, P59, DOI 10.1002/ijc.26340; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Zoi I, 2016, TRENDS MOL MED, V22, P839, DOI 10.1016/j.molmed.2016.07.009	50	20	20	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5926	5938		10.1038/s41388-018-0394-x	http://dx.doi.org/10.1038/s41388-018-0394-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980789	hybrid, Green Published			2022-12-28	WOS:000449562500002
J	Lai, SC; Phelps, CA; Short, AM; Dutta, SM; Mu, D				Lai, Shao-Chiang; Phelps, Cody A.; Short, Aleena M.; Dutta, Sucharita M.; Mu, David			Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism	ONCOGENE			English	Article							HUMAN PROSTATE-CANCER; LUNG ADENOCARCINOMA; MEVALONATE PATHWAY; BINDING PROTEIN; NKX2-1; ABCA1; GENE; EXPRESSION; TTF-1/NKX2-1; PROGRESSION	We have discovered an unexpected connection between a critical lung development and cancer gene termed thyroid transcription factor 1 (TTF-1 also known as NKX2-1) and cholesterol metabolism. Our published work implicates that TTF-1 positively regulates miR-33a which is known to repress ATP-binding cassette transporter 1 (ABCA1) and thus its cholesterol efflux activity. We set out to demonstrate that a higher TTF-1 expression would presumably inhibit cholesterol efflux and consequently raise intracellular cholesterol level. Surprisingly, raising TTF-1 expression actually lowers intracellular cholesterol level, which, we believe, is attributed to a direct transactivation of ABCA1 by TTF-1. Subsequently, we show that lung cancer cells primed with a TTF-1-driven decrease of cholesterol were more vulnerable to simvastatin, a frequently prescribed cholesterol biosynthesis inhibitor. In view of the fact that pathologists routinely interrogate human lung cancers for TTF-1 immunopositivity to guide diagnosis and the prevalent use of statins, TTF-1 should be further investigated as a putative biomarker of lung cancer vulnerability to statins.	[Lai, Shao-Chiang; Phelps, Cody A.; Dutta, Sucharita M.; Mu, David] Eastern Virginia Med Sch, Leroy T Canoles Jr Canc Res Ctr, Norfolk, VA 23501 USA; [Lai, Shao-Chiang; Phelps, Cody A.; Mu, David] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; [Short, Aleena M.] Eastern Virginia Med Sch, Biotechnol Masters Program, Norfolk, VA 23501 USA; [Lai, Shao-Chiang] bioAffin Technol Inc, San Antonio, TX USA; [Dutta, Sucharita M.] Beth Israel Deaconess Med Sch, Boston, MA USA	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School; Harvard University; Beth Israel Deaconess Medical Center	Mu, D (corresponding author), Eastern Virginia Med Sch, Leroy T Canoles Jr Canc Res Ctr, Norfolk, VA 23501 USA.; Mu, D (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA.	mud@evms.edu	Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182; Qu, Yi/0000-0002-9993-8810	National Cancer Institute of the National Institutes of Health [R21CA198327]; Fraternal Order of Eagles Aerie, Colonial Beach, Virginia [4315]; NATIONAL CANCER INSTITUTE [R21CA198327] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fraternal Order of Eagles Aerie, Colonial Beach, Virginia; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Arjun Poddar and Sohail Khan for assistance with bioinformatics and statistical analyses. This study was supported by the National Cancer Institute of the National Institutes of Health under Award Number R21CA198327. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Mu laboratory also acknowledges funding from the Fraternal Order of Eagles Aerie #4315, Colonial Beach, Virginia.	Allen RM, 2012, EMBO MOL MED, V4, P882, DOI 10.1002/emmm.201201228; Besnard V, 2007, AM J PHYSIOL-LUNG C, V293, pL1395, DOI 10.1152/ajplung.00275.2007; CHEN HW, 1974, NATURE, V251, P419, DOI 10.1038/251419a0; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; Costet P, 2000, J BIOL CHEM, V275, P28240; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Fernandez C, 2005, J LIPID RES, V46, P920, DOI 10.1194/jlr.M400407-JLR200; Fernandez-Hernando C, 2011, CURR OPIN LIPIDOL, V22, P86, DOI 10.1097/MOL.0b013e3283428d9d; Flaveny CA, 2015, CANCER CELL, V28, P42, DOI 10.1016/j.ccell.2015.05.007; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Hafiane A, 2017, ATHEROSCLEROSIS, V257, P90, DOI 10.1016/j.atherosclerosis.2017.01.013; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee BH, 2013, CANCER RES, V73, P1211, DOI 10.1158/0008-5472.CAN-12-3128; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Li X, 2009, CELL, V137, P273, DOI 10.1016/j.cell.2009.01.058; Lin CY, 2015, NAT REV CANCER, V15, P216, DOI 10.1038/nrc3912; Liu Z, 2017, ONCOGENE, V36, P3740, DOI 10.1038/onc.2016.524; Long J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01086; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Mu D, 2013, J BIOL CHEM, V288, P24992, DOI 10.1074/jbc.R113.491647; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Pandyra A, 2014, CANCER RES, V74, P4772, DOI 10.1158/0008-5472.CAN-14-0130; Peca D, 2015, BIOCHEM SOC T, V43, P913, DOI 10.1042/BST20150100; Phelps CA, 2017, VITAM HORM, V106, P517; Phillips MC, 2014, J BIOL CHEM, V289, P24020, DOI 10.1074/jbc.R114.583658; Qi J, 2012, CELL CYCLE, V11, P177, DOI 10.4161/cc.11.1.18576; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rice SJ, 2013, J BIOL CHEM, V288, P16348, DOI 10.1074/jbc.M113.474643; Runkle EA, 2012, J BIOL CHEM, V287, P28790, DOI 10.1074/jbc.M112.367987; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sharpe LJ, 2013, J BIOL CHEM, V288, P18707, DOI 10.1074/jbc.R113.479808; Smith B, 2012, CELL REP, V2, P580, DOI 10.1016/j.celrep.2012.08.011; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wood LW, 2016, SCI REP-UK, V6, DOI 10.1038/srep19857; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	55	7	7	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3290	3300		10.1038/s41388-018-0174-7	http://dx.doi.org/10.1038/s41388-018-0174-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551766	Green Accepted			2022-12-28	WOS:000435526600008
J	Lindstrom, MS; Jurada, D; Bursac, S; Orsolic, I; Bartek, J; Volarevic, S				Lindstrom, Mikael S.; Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Bartek, Jiri; Volarevic, Sinisa			Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis	ONCOGENE			English	Review							DNA-DAMAGE-RESPONSE; RIBOSOMAL-RNA GENES; DOUBLE-STRAND BREAKS; TRANSCRIPTION-ASSOCIATED RECOMBINATION; REPLICATION FORK PROGRESSION; POLYMERASE-I TRANSCRIPTION; TUMOR-SUPPRESSOR PROTEIN; R-LOOP FORMATION; HUMAN-CELLS; TOPOISOMERASE-I	The nucleolus is the major site for synthesis of ribosomes, complex molecular machines that are responsible for protein synthesis. A wealth of research over the past 20 years has clearly indicated that both quantitative and qualitative alterations in ribosome biogenesis can drive the malignant phenotype via dysregulation of protein synthesis. However, numerous recent proteomic, genomic, and functional studies have implicated the nucleolus in the regulation of processes that are unrelated to ribosome biogenesis, including DNA-damage response, maintenance of genome stability and its spatial organization, epigenetic regulation, cell-cycle control, stress responses, senescence, global gene expression, as well as assembly or maturation of various ribonucleoprotein particles. In this review, the focus will be on features of rDNA genes, which make them highly vulnerable to DNA damage and intra- and interchromosomal recombination as well as built-in mechanisms that prevent and repair rDNA damage, and how dysregulation of this interplay affects genome-wide DNA stability, gene expression and the balance between euchromatin and heterochromatin. We will also present the most recent insights into how malfunction of these cellular processes may be a central driving force of human malignancies, and propose a promising new therapeutic approach for the treatment of cancer.	[Lindstrom, Mikael S.; Bartek, Jiri] Karolinska Inst, Div Genome Biol, Dept Med Biochem & Biophys, Stockholm, Sweden; [Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Volarevic, Sinisa] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia; [Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Volarevic, Sinisa] Univ Rijeka, Sci Ctr Excellence Reprod & Regenerat Med, Rijeka, Croatia; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark	Karolinska Institutet; University of Rijeka; University of Rijeka; Danish Cancer Society	Bartek, J (corresponding author), Karolinska Inst, Div Genome Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.; Volarevic, S (corresponding author), Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia.; Volarevic, S (corresponding author), Univ Rijeka, Sci Ctr Excellence Reprod & Regenerat Med, Rijeka, Croatia.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Copenhagen, Denmark.	jb@cancer.dk; sinisa.volarevic@medri.uniri.hr	Jurada, Deana/R-6012-2018; Bursać, Slađana/Q-7894-2018; Volarevic, Sinisa/O-4349-2018; Oršolić, Ines/AGE-5929-2022; Lindström, Mikael S/AAA-1451-2019; Orsolic, Ines/R-5814-2018	Jurada, Deana/0000-0001-9581-6165; Bursać, Slađana/0000-0002-6478-3409; Volarevic, Sinisa/0000-0003-4893-389X; Oršolić, Ines/0000-0003-4517-7187; Lindström, Mikael S/0000-0003-1148-8497; Orsolic, Ines/0000-0003-4517-7187	Croatian Science Foundation (CSF) [2079]; Karolinska Institutet; Swedish Cancer Society [170176]; Swedish Research Council [VR-MH 2014-46602-117891-30]; King Gustaf V's Jubilee Foundation [134082]	Croatian Science Foundation (CSF); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); King Gustaf V's Jubilee Foundation	We thank Dr. R. Loewith for critical reading of the manuscript. S.V's laboratory is funded by the Croatian Science Foundation (CSF) (grant number: 2079), J.B. laboratory in Stockholm is funded by grants from Karolinska Institutet; the Swedish Cancer Society (grant number: 170176); and the Swedish Research Council (VR-MH 2014-46602-117891-30). M.L. is supported by King Gustaf V's Jubilee Foundation (grant number: 134082).	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Ahmad Y, 2009, NUCLEIC ACIDS RES, V37, pD181, DOI 10.1093/nar/gkn804; Akamatsu Y, 2015, MOL CELL BIOL, V35, P1871, DOI 10.1128/MCB.01521-14; Akhmanova A, 2000, J CELL SCI, V113, P4463; Aldrich JC, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005148; Anger AM, 2013, NATURE, V497, P80, DOI 10.1038/nature12104; Antoniali G, 2014, ANTIOXID REDOX SIGN, V20, P621, DOI 10.1089/ars.2013.5491; Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Azvolinsky A, 2009, MOL CELL, V34, P722, DOI 10.1016/j.molcel.2009.05.022; Badertscher L, 2015, CELL REP, V13, P2879, DOI 10.1016/j.celrep.2015.11.061; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Berger C, 1997, CHROMOSOMA, V106, P479; Bermejo R, 2012, MOL CELL, V45, P710, DOI 10.1016/j.molcel.2012.03.001; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Budkevich TV, 2008, NUCLEIC ACIDS RES, V36, P4736, DOI 10.1093/nar/gkn424; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns KH, 2003, SCIENCE, V300, P633, DOI 10.1126/science.1081813; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Calkins AS, 2013, NUCLEIC ACIDS RES, V41, P7378, DOI 10.1093/nar/gkt502; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen HB, 2016, ONCOTARGET, V7, P83241, DOI 10.18632/oncotarget.13082; Ciccia A, 2014, P NATL ACAD SCI USA, V111, P18631, DOI 10.1073/pnas.1422488112; Coffman FD, 2005, CELL CYCLE, V4, P1223, DOI 10.4161/cc.4.9.1961; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Daniel JA, 2013, MOL CELL, V50, P309, DOI 10.1016/j.molcel.2013.04.017; Danilova N, 2014, DIS MODEL MECH, V7, P895, DOI 10.1242/dmm.015495; Diesch J, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-43; Dimitrova DS, 2011, J CELL SCI, V124, P2743, DOI 10.1242/jcs.082230; Dominguez-Sola D, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014423; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Feng JW, 2015, CELL REP, V13, P1295, DOI 10.1016/j.celrep.2015.10.016; Flach J, 2014, NATURE, V512, P198, DOI 10.1038/nature13619; Floutsakou I, 2013, GENOME RES, V23, P2003, DOI 10.1101/gr.157941.113; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; French SL, 2003, MOL CELL BIOL, V23, P1558, DOI 10.1128/MCB.23.5.1558-1568.2003; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Muse T, 2016, NAT REV MOL CELL BIO, V17, P553, DOI 10.1038/nrm.2016.88; Gentilella A, 2017, MOL CELL, V67, P55, DOI 10.1016/j.molcel.2017.06.005; Gibbons JG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5850; Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017; Goodfellow Sarah J, 2013, Subcell Biochem, V61, P211, DOI 10.1007/978-94-007-4525-4_10; Gottipati P, 2008, MOL CELL BIOL, V28, P154, DOI 10.1128/MCB.00816-07; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grob A, 2014, GENE DEV, V28, P220, DOI 10.1101/gad.234591.113; Grummt I, 2010, FEBS J, V277, P4626, DOI 10.1111/j.1742-4658.2010.07892.x; Guerrero PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016401; Guetg C, 2010, EMBO J, V29, P2135, DOI 10.1038/emboj.2010.17; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamperl S, 2014, DNA REPAIR, V19, P84, DOI 10.1016/j.dnarep.2014.03.023; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Harding SM, 2015, CELL REP, V13, P251, DOI 10.1016/j.celrep.2015.08.085; Hatchi E, 2015, MOL CELL, V57, P636, DOI 10.1016/j.molcel.2015.01.011; Helmrich A, 2013, NAT STRUCT MOL BIOL, V20, P412, DOI 10.1038/nsmb.2543; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4; Hernandez-Hernandez A, 2012, CYTOGENET GENOME RES, V136, P89, DOI 10.1159/000335752; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Hutten S, 2011, CHROMOSOMA, V120, P481, DOI 10.1007/s00412-011-0327-8; Ide S, 2010, SCIENCE, V327, P693, DOI 10.1126/science.1179044; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Killen MW, 2009, HUM MOL GENET, V18, P3417, DOI 10.1093/hmg/ddp282; Kim N, 2012, NAT REV GENET, V13, P204, DOI 10.1038/nrg3152; Kobayashi J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049245; Kobayashi T, 2006, GENES GENET SYST, V81, P155, DOI 10.1266/ggs.81.155; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lamm N, 2015, EMBO MOL MED, V7, P1138, DOI 10.15252/emmm.201404824; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Larsen DH, 2014, NAT CELL BIOL, V16, P792, DOI 10.1038/ncb3007; Larsen DH, 2016, NUCLEIC ACIDS RES, V44, P538, DOI 10.1093/nar/gkv1312; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Li XL, 2006, GENE DEV, V20, P1838, DOI 10.1101/gad.1438306; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Ma HH, 2013, MOL BIOL CELL, V24, P1334, DOI 10.1091/mbc.E12-12-0881; MacLeod RAF, 2000, LEUKEMIA, V14, P1803, DOI 10.1038/sj.leu.2401894; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; McStay B, 2016, GENE DEV, V30, P1598, DOI 10.1101/gad.283838.116; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nemeth A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000889; Nishimura K, 2015, CELL REP, V10, P1310, DOI 10.1016/j.celrep.2015.01.055; O'Donohue MF, 2010, J CELL BIOL, V190, P853, DOI 10.1083/jcb.201005117; Ogawa LM, 2017, MOL BIOSYST, V13, P443, DOI 10.1039/c6mb00740f; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Ogushi S, 2008, SCIENCE, V319, P613, DOI 10.1126/science.1151276; Ogushi S, 2017, J CELL SCI, V130, P2416, DOI 10.1242/jcs.195875; Olausson KH, 2014, J BIOL CHEM, V289, P34601, DOI 10.1074/jbc.M114.569244; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Padeken J, 2013, MOL CELL, V50, P236, DOI 10.1016/j.molcel.2013.03.002; Paredes S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001376; Paredes S, 2009, P NATL ACAD SCI USA, V106, P17829, DOI 10.1073/pnas.0906811106; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pederson T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000521; Peng JC, 2007, NAT CELL BIOL, V9, P25, DOI 10.1038/ncb1514; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Prado F, 2005, EMBO J, V24, P1267, DOI 10.1038/sj.emboj.7600602; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saka K, 2016, NUCLEIC ACIDS RES, V44, P4211, DOI 10.1093/nar/gkw110; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Saxena A, 2006, ONCOGENE, V25, P7274, DOI 10.1038/sj.onc.1209714; Schwab RA, 2015, MOL CELL, V60, P351, DOI 10.1016/j.molcel.2015.09.012; Scott DD, 2016, BIOCHEM CELL BIOL, V94, P419, DOI 10.1139/bcb-2016-0068; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Sloan KE, 2013, CELL REP, V5, P237, DOI 10.1016/j.celrep.2013.08.049; Smirnov E, 2014, J STRUCT BIOL, V188, P259, DOI 10.1016/j.jsb.2014.10.001; Sokka M, 2015, NUCLEIC ACIDS RES, V43, P4975, DOI 10.1093/nar/gkv371; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Stults DM, 2008, GENOME RES, V18, P13, DOI 10.1101/gr.6858507; Stults DM, 2009, CANCER RES, V69, P9096, DOI 10.1158/0008-5472.CAN-09-2680; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; Tchurikov NA, 2015, J MOL CELL BIOL, V7, P366, DOI 10.1093/jmcb/mju038; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Urban V, 2016, J CELL BIOL, V214, P401, DOI 10.1083/jcb.201507099; van Koningsbruggen S, 2010, MOL BIOL CELL, V21, P3735, DOI 10.1091/mbc.E10-06-0508; van Sluis M, 2015, GENE DEV, V29, P1151, DOI 10.1101/gad.260703.115; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Visootsak J, 2004, J PEDIATR-US, V145, P819, DOI 10.1016/j.jpeds.2004.07.041; Wang JD, 2013, J BIOL CHEM, V288, P3174, DOI 10.1074/jbc.M112.414839; Wang M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006994; Warmerdam DO, 2016, CELL REP, V14, P2519, DOI 10.1016/j.celrep.2016.02.048; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wild T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000522; Wimberly H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3115; Xie Q, 2017, NUCLEIC ACIDS RES, V45, P2472, DOI 10.1093/nar/gkw1208; Xie WB, 2012, P NATL ACAD SCI USA, V109, P8161, DOI 10.1073/pnas.1201262109; Xu BS, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006771; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; Yoo NJ, 2012, ACTA ONCOL, V51, P107, DOI 10.3109/0284186X.2011.592148; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yuce O, 2013, MOL CELL BIOL, V33, P406, DOI 10.1128/MCB.01195-12; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	160	107	110	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2351	2366		10.1038/s41388-017-0121-z	http://dx.doi.org/10.1038/s41388-017-0121-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429989	Green Published, hybrid			2022-12-28	WOS:000431386000001
J	Zhang, JX; Chen, ZH; Chen, DL; Tian, XP; Wang, CY; Zhou, ZW; Gao, Y; Xu, Y; Chen, C; Zheng, ZS; Weng, HW; Ye, S; Kuang, M; Xie, D; Peng, S				Zhang, Jia-Xing; Chen, Zhen-Hua; Chen, Dong-Liang; Tian, Xiao-Peng; Wang, Chen-Yuan; Zhou, Zhi-Wei; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Kuang, Ming; Xie, Dan; Peng, Sui			LINC01410-miR-532-NCF2-NF-kappa B feedback loop promotes gastric cancer angiogenesis and metastasis	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; NONCODING RNA; EXPRESSION; CERNA; IDENTIFICATION; PROLIFERATION; BIOMARKERS; NETWORKS; INVASION; GENE	Dysregulation of non-coding RNAs, including miRNAs and lncRNAs has been reported to play vital roles in gastric cancer (GC) carcinogenesis, but the mechanism involved is largely unknown. Using the cancer genome atlas (TCGA) data set and bioinformatics analyses, we identified miR-532-5p as a potential tumor suppressor in GC, and found that lncRNA LINC01410 might be a negative regulator of miR-532-5p. We then conducted a series of in vivo and in vitro assays to explore the effect of LINC01410 on miR-532-5p-mediated GC malignancy and the underlying mechanism involved. MiR-532-5p overexpression inhibited GC metastasis and angiogenesis in vitro and in vivo, whereas miR-532-5p silencing had the opposite effect. Further study showed that miR-532-5p attenuated NF-kappa B signaling by directly inhibiting NCF2 expression, while miR-532-5p silencing in GC enhanced NF-kappa B activity. Furthermore, we demonstrated miR-532-5p down-regulation was caused by aberrantly high expression of LINC01410 in GC. Mechanistically, overexpression of LINC01410 promoted GC angiogenesis and metastasis by binding to and suppressing miR-532-5p, which resulted in up-regulation of NCF2 and sustained NF-kappa B pathway activation. Interestingly, NCF2 could in turn increase the promoter activity and expression of LINC01410 via NF-kappa B, thus forming a positive feedback loop that drives the malignant behavior of GC. Finally, high expression of LINC01410, along with low expression of miR-532-5p, was associated with poor survival outcome in GC patients. Our studies uncover a mechanism for constitutive LINC1410-miR-532-5p-NCF2-NF-kappa B feedback loop activation in GC, and consequently, as a potential therapeutic target in GC treatment.	[Zhang, Jia-Xing; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing; Chen, Dong-Liang; Wang, Chen-Yuan; Xie, Dan] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Chen, Zhen-Hua] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Tian, Xiao-Peng] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Zhou, Zhi-Wei] Sun Yat Sen Univ, Dept Gastr & Pancreat Surg, Canc Ctr, Guangzhou, Peoples R China; [Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Dept Med Ultrasound, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China.	xiedan@sysucc.org.cn; pengsui@vip.163.com			National Key R&D Program of China [2017YFC1309001, 2016YFC1302305]; Natural Science Foundation of China [81772514, 81772513, 81401991, 81572359]; Pearl River S&T Nova Program of Guangzhou [201806010005]	National Key R&D Program of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pearl River S&T Nova Program of Guangzhou	This work was supported by National Key R&D Program of China (2017YFC1309001, 2016YFC1302305), the Natural Science Foundation of China (Nos. 81772514, 81772513, 81401991, and 81572359), and Pearl River S&T Nova Program of Guangzhou (201806010005).	Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Chen DL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0420-1; Guo LL, 2015, WORLD J GASTROENTERO, V21, P11680, DOI 10.3748/wjg.v21.i41.11680; Gupta SC, 2017, INT J CANCER, V140, P1955, DOI 10.1002/ijc.30546; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; Hunt RH, 2015, GUT, V64, P1650, DOI 10.1136/gutjnl-2014-307595; Italiano D, 2012, CELL CYCLE, V11, P4589, DOI 10.4161/cc.22853; Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009; Kong PF, 2017, MOL THER, V25, P1027, DOI 10.1016/j.ymthe.2017.01.013; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050702; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Muise AM, 2012, GUT, V61, P1028, DOI 10.1136/gutjnl-2011-300078; Nakanishi K, 2016, WIRES RNA, V7, P637, DOI 10.1002/wrna.1356; Osama A, 2016, CANCER BIOMARK, V17, P155, DOI 10.3233/CBM-160626; Roviello G, 2016, GASTRIC CANCER, V19, P31, DOI 10.1007/s10120-015-0537-5; Rudolph TK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290re7; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seok H, 2018, CELL MOL LIFE SCI, V75, P797, DOI 10.1007/s00018-017-2656-0; Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tan WQ, 2011, J UROLOGY, V186, P2071, DOI 10.1016/j.juro.2011.06.049; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Teng H, 2016, MOL THER, V24, P1806, DOI 10.1038/mt.2016.103; Veneziano D, 2016, HUM MUTAT, V37, P1283, DOI 10.1002/humu.23066; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Yang JS, 2011, MOL CELL, V43, P892, DOI 10.1016/j.molcel.2011.07.024; Yang S, 2016, ONCOTARGET, V7, P85728, DOI 10.18632/oncotarget.13828; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhang JX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0586-y; Zhang JX, 2017, CLIN CANCER RES, V23, P298, DOI 10.1158/1078-0432.CCR-16-0414	34	98	103	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2660	2675		10.1038/s41388-018-0162-y	http://dx.doi.org/10.1038/s41388-018-0162-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29483646	hybrid, Green Published			2022-12-28	WOS:000432545100004
J	Szczepny, A; Carey, K; McKenzie, L; Jayasekara, WSN; Rossello, F; Gonzalez-Rajal, A; Mccaw, AS; Popovski, D; Wang, D; Sadler, AJ; Mahar, A; Russell, PA; Wright, G; McCloy, RA; Garama, DJ; Gough, DJ; Baylin, SB; Burgess, A; Cain, JE; Watkins, DN				Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Jayasekara, W. Samantha N.; Rossello, Fernando; Gonzalez-Rajal, Alvaro; Mccaw, Andrew S.; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Mahar, Annabelle; Russell, Prudence A.; Wright, Gavin; McCloy, Rachael A.; Garama, Daniel J.; Gough, Daniel J.; Baylin, Stephen B.; Burgess, Andrew; Cain, Jason E.; Watkins, D. Neil			The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DIRECT TARGET GENE; CANCER 1 HIC1; DNA-DAMAGE; BREAST-CANCER; LUNG ADENOCARCINOMA; DRIVES PROGRESSION; MI-2/NURD COMPLEX; P53; INSTABILITY	Hypermethylated-in-Cancer 1 (Hic1) is a tumor suppressor gene frequently inactivated by epigenetic silencing and loss-of-heterozygosity in a broad range of cancers. Loss of HIC1, a sequence-specific zinc finger transcriptional repressor, results in deregulation of genes that promote a malignant phenotype in a lineage-specific manner. In particular, upregulation of the HIC1 target gene SIRT1, a histone deacetylase, can promote tumor growth by inactivating TP53. An alternate line of evidence suggests that HIC1 can promote the repair of DNA double strand breaks through an interaction with MTA1, a component of the nucleosome remodeling and deacetylase (NuRD) complex. Using a conditional knockout mouse model of tumor initiation, we now show that inactivation of Hic1 results in cell cycle arrest, premature senescence, chromosomal instability and spontaneous transformation in vitro. This phenocopies the effects of deleting Brca1, a component of the homologous recombination DNA repair pathway, in mouse embryonic fibroblasts. These effects did not appear to be mediated by deregulation of Hic1 target gene expression or loss of Tp53 function, and rather support a role for Hic1 in maintaining genome integrity during sustained replicative stress. Loss of Hic1 function also cooperated with activation of oncogenic KRas in the adult airway epithelium of mice, resulting in the formation of highly pleomorphic adenocarcinomas with a micropapillary phenotype in vivo. These results suggest that loss of Hic1 expression in the early stages of tumor formation may contribute to malignant transformation through the acquisition of chromosomal instability.	[Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Jayasekara, W. Samantha N.; Mccaw, Andrew S.; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.; Cain, Jason E.] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol & Translat Sci, Clayton, Vic, Australia; [Rossello, Fernando] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Rossello, Fernando] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic, Australia; [Gonzalez-Rajal, Alvaro; Burgess, Andrew; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Mahar, Annabelle] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Russell, Prudence A.] St Vincents Hosp Melbourne, Dept Pathol, Fitzroy, Vic, Australia; [Wright, Gavin] St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic, Australia; [Baylin, Stephen B.] Johns Hopkins, Sidney Kimmel Canc Ctr, Baltimore, MD USA; [Watkins, D. Neil] UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia	Hudson Institute of Medical Research; Monash University; Monash University; Australian Regenerative Medicine Institute; Monash University; Garvan Institute of Medical Research; University of Sydney; St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; Johns Hopkins University; University of New South Wales Sydney; St Vincents Hospital Sydney	Cain, JE (corresponding author), Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia.; Watkins, DN (corresponding author), UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia.	jason.cain@hudson.org.au; n.watkins@garvan.org.au	Gonzalez-Rajal, Alvaro/ABA-6874-2020; sadler, anthony/ABA-5572-2020; Rossello, Fernando/B-1208-2015; Burgess, Andrew/H-3339-2019; Wang, Die/H-8860-2017	Gonzalez-Rajal, Alvaro/0000-0002-9230-0339; sadler, anthony/0000-0002-7970-8030; Rossello, Fernando/0000-0003-3885-8777; Burgess, Andrew/0000-0003-4536-9226; Wang, Die/0000-0001-7628-7309; Gough, Daniel/0000-0001-5725-8668; McCloy, Rachael/0000-0001-7791-4044; Carey, Kirstyn/0000-0003-4743-2700; McKenzie, Lisa/0000-0002-1432-6496; Gough, Daniel/0000-0001-6479-1735	National Health and Medical Research Council (NHMRC) of Australia [GNT10838550]; Victorian Cancer Agency [TS10-01]; National Institutes of Health [NCI-RO1 NS054085]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC [GNT1063914]; Cancer Institute NSW Fellowship [10/FRL/3-02]; Patricia Helen Guest Fellowship; National Health and Medical Research Council of Australia [GNT1063914, GNT1083855]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054085] Funding Source: NIH RePORTER; National Breast Cancer Foundation [IIRS-18-103] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Petre Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW Fellowship; Patricia Helen Guest Fellowship; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Breast Cancer Foundation	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (Project Grant GNT10838550, The Victorian Cancer Agency (TS10-01), The National Institutes of Health (NCI-RO1 NS054085), The Petre Foundation, and the Victorian Government's Operational Infrastructure Support Program. Dr Gough is supported by an NHMRC Career Development Fellowship (GNT1063914). Dr Burgess is supported by Cancer Institute NSW Fellowship (10/FRL/3-02) and a Patricia Helen Guest Fellowship. The contents of this manuscript are solely the responsibility of the participating institutions and individual authors, and do not reflect the views of these funding agencies. We thank Dr Dominique LePrince for the gift of the Hic1-FLAG expression vector. National Health and Medical Research Council of Australia (GNT1083855): J.E.C., D.N.W.; (GNT1063914): D.J.G. National Institutes of Health (NINDS RO1 NS054085): D.N.W., S.B.B. The Petre Foundation: D.N.W. Cancer Institute of NSW Fellowship (10/FRL/3-02) and the Patricia Helen Guest Fellowship: A.B.	Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Badea TC, 2003, J NEUROSCI, V23, P2314; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Briggs KJ, 2008, CANCER RES, V68, P8654, DOI 10.1158/0008-5472.CAN-08-1904; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Britschgi C, 2008, BRIT J HAEMATOL, V141, P179, DOI 10.1111/j.1365-2141.2008.06992.x; Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964; Caldon CE, 2013, CELL CYCLE, V12, P606, DOI 10.4161/cc.23512; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Cheng GC, 2014, CANCER RES, V74, P862, DOI 10.1158/0008-5472.CAN-13-2420; Cohen SM, 2010, NUCLEIC ACIDS RES, V38, P6906, DOI 10.1093/nar/gkq559; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dehennaut V, 2013, J BIOL CHEM, V288, P10254, DOI 10.1074/jbc.M112.421610; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Foveau B, 2012, J BIOL CHEM, V287, P5366, DOI 10.1074/jbc.M111.329466; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Ganem NJ, 2012, J CELL BIOL, V199, P871, DOI 10.1083/jcb.201210040; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Guarente L, 2011, COLD SH Q B, V76, P81, DOI 10.1101/sqb.2011.76.010629; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janeckova L, 2015, MOL CANCER RES, V13, P1139, DOI 10.1158/1541-7786.MCR-15-0033; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Leibiger C, 2013, J HISTOCHEM CYTOCHEM, V61, P306, DOI 10.1369/0022155413476868; Li DQ, 2010, CELL CYCLE, V9, P2071, DOI 10.4161/cc.9.11.11735; Li P, 2015, ONCOTARGET, V6, P38151, DOI 10.18632/oncotarget.5832; Lin YM, 2013, CELL CYCLE, V12, P2266, DOI 10.4161/cc.25365; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Melki JR, 1999, CANCER RES, V59, P3730; Mermoud JE, 2011, CELL CYCLE, V10, P4017, DOI 10.4161/cc.10.23.18558; Mohammad HP, 2011, ONCOGENE, V30, P2659, DOI 10.1038/onc.2010.633; Nagy A, 2008, CSH PROTOC, P2014; Paget S, 2017, ONCOTARGET, V8, P2916, DOI 10.18632/oncotarget.13807; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Prakash R, 2015, COLD SPRING HARB PER, V7; Rood BR, 2002, CANCER RES, V62, P3794; Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8; Sims JK, 2011, MOL BIOL CELL, V22, P3094, DOI 10.1091/mbc.E11-03-0258; Stephen JK, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0005-3; Stevens JB, 2013, CANCER METAST REV, V32, P391, DOI 10.1007/s10555-013-9428-6; Sun Hong, 2007, V383, P303, DOI 10.1007/978-1-59745-335-6_19; Szczepny A, 2017, ONCOGENE, V23, P2314; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thomas A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6282; Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470; Ung M, 2016, CLIN LUNG CANCER, V17, P391, DOI 10.1016/j.cllc.2016.03.001; Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wallace MD, 2014, ONCOGENE, V33, P3688, DOI 10.1038/onc.2013.339; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12	71	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1939	1948		10.1038/s41388-017-0022-1	http://dx.doi.org/10.1038/s41388-017-0022-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367758	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000429303300010
J	Dou, CW; Zhou, ZY; Xu, QR; Liu, ZK; Zeng, YQ; Wang, YF; Li, Q; Wang, L; Yang, W; Liu, QG; Tu, KS				Dou, Changwei; Zhou, Zhenyu; Xu, Qiuran; Liu, Zhikui; Zeng, Yuqun; Wang, Yufeng; Li, Qing; Wang, Liang; Yang, Wei; Liu, Qingguang; Tu, Kangsheng			Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR HYPOXIA; CANCER CELLS; EXPRESSION; TUFTELIN; INDUCTION; PROTEIN; GENE; RESISTANCE; HALLMARKS	Tuftelin1 (TUFT1), an acidic protein constituent of developing and mineralizing tooth tissues, is regulated by hypoxia and the Hedgehog signaling pathway. We investigated the role of TUFT1 in hepatocellular carcinoma (HCC). qRT-PCR, immunohistochemistry and western blot were employed to evaluate TUFT1 level in HCC. MTT, BrdU, 3D culture and Transwell assays were used to assess cell viability, proliferation, in vitro growth, migration, and invasion. Subcutaneous and tail vein injection models were established to investigate in vivo growth and metastasis. Chromatin immunoprecipitation was performed to assess binding of hypoxia-inducible factor 1 alpha (HIF-1 alpha) to TUFT1 promoter. A microRNA array was used to identify hypoxia-related microRNAs. TUFT1 was elevated in HCC, and correlated with unfavorable clinicopathologic characteristics and poor survival. TUFT1 promoted HCC cell growth, metastasis and epithelial-mesenchymal transition in vitro and in vivo via activation of Ca2+/PI3K/AKT pathway. Hypoxia induced TUFT1 expression in an HIF-1 alpha dependent manner, and TUFT1 expression was positively correlated with HIF-1a level in HCC tissues. Hypoxiaenhanced TUFT1 expression by downregulating miR-671-5p rather than by directly promoting the binding of HIF-1 alpha to TUFT1 promoter. MiR-671-5p interacted with the 3'-UTR of TUFT1 mRNA and subsequently inhibited TUFT1 expression. Consequently, knockdown of TUFT1 blocked the effects of hypoxia in promoting HCC progression. TUFT1 promoted the growth, metastasis and EMT of HCC cells through activating Ca2+/PI3K/AKT pathway. The hypoxic microenvironment increased the expression of TUFT1 via downregulation of miR-671-5p. TUFT1 may function as a potential therapeutic target for the intervention and treatment of HCC.	[Dou, Changwei; Liu, Zhikui; Wang, Yufeng; Li, Qing; Wang, Liang; Yang, Wei; Liu, Qingguang; Tu, Kangsheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China; [Dou, Changwei] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Hepatopancreatobiliary Surg & Minimally Inva, Hangzhou, Zhejiang, Peoples R China; [Zhou, Zhenyu] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China; [Xu, Qiuran] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Hangzhou 310014, Zhejiang, Peoples R China; [Zeng, Yuqun] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Nephrol, Hangzhou 310014, Zhejiang, Peoples R China	Xi'an Jiaotong University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Sun Yat Sen University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Hangzhou Medical College; Zhejiang Provincial People's Hospital	Liu, QG; Tu, KS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China.	liuqingguang@vip.sina.com; tks0912@foxmail.com	dou, dou/ABB-4731-2020	Zhou, Zhenyu/0000-0002-7934-4425; Xu, Qiuran/0000-0003-2171-9279; Tu, Kangsheng/0000-0002-0032-1459	National Natural Science Foundation of China [81874049, 81773123, 81572847, 81502092]; Innovation Capacity Support Plan in Shaanxi Province of China [2018KJXX-045]; Fundamental Research Funds for the Central Universities [7N010011015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capacity Support Plan in Shaanxi Province of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This study was supported by grants from the National Natural Science Foundation of China (81874049, 81773123, 81572847, 81502092); Innovation Capacity Support Plan in Shaanxi Province of China (2018KJXX-045); the Fundamental Research Funds for the Central Universities (7N010011015).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; Davis FM, 2014, ONCOGENE, V33, P2307, DOI 10.1038/onc.2013.187; Deutsch D, 1998, EUR J ORAL SCI, V106, P315, DOI 10.1111/j.1600-0722.1998.tb02192.x; DEUTSCH D, 1995, INT J DEV BIOL, V39, P135; Dou CW, 2016, CANCER LETT, V381, P380, DOI 10.1016/j.canlet.2016.08.011; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Gwak GY, 2005, J HEPATOL, V42, P358, DOI 10.1016/j.jhep.2004.11.020; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Jubb A, 2005, J CLIN PATHOL, V58, P1344; Kawasaki N, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-017-0001-2; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Leiser Y, 2007, ANAT REC, V290, P449, DOI 10.1002/ar.20512; Leiser Y, 2011, J CELL PHYSIOL, V226, P165, DOI 10.1002/jcp.22318; Li XH, 2012, ONCOL REP, V28, P77, DOI 10.3892/or.2012.1769; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Mao ZK, 2001, GENE, V279, P181, DOI 10.1016/S0378-1119(01)00749-1; Meng H, 2015, AM J CANCER RES, V5, P1062; Oliveira FS, 2012, J CELL BIOCHEM, V113, P204, DOI 10.1002/jcb.23345; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Sliz E, 2017, TUFT1 NOVEL CANDIDAT, V12; Sliz E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175474; Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680; Tan XH, 2016, ONCOTARGET, V7, P293, DOI 10.18632/oncotarget.6344; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23269; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Xu S, 2016, CELL CYCLE, V15, P2920, DOI 10.1080/15384101.2016.1224043; Zhang YH, 2017, LAB INVEST, V97, P53, DOI 10.1038/labinvest.2016.127; Zheng X, 2013, ONCOL REP, V30, P2020, DOI 10.3892/or.2013.2690; Zheng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049581; Zhou B, 2016, CANCER LETT, V382, P11, DOI 10.1016/j.canlet.2016.08.017	45	77	83	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1239	1255		10.1038/s41388-018-0505-8	http://dx.doi.org/10.1038/s41388-018-0505-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250300				2022-12-28	WOS:000459249800007
J	Birnbaum, MD; Zhao, N; Moorthy, BT; Patel, DM; Kryvenko, ON; Heidman, L; Kumar, A; Morgan, WM; Ban, YG; Reis, IM; Chen, X; Gonzalgo, ML; Jorda, M; Burnstein, KL; Zhang, FL				Birnbaum, Michael D.; Zhao, Ning; Moorthy, Balaji T.; Patel, Devang M.; Kryvenko, Oleksandr N.; Heidman, Laine; Kumar, Akhilesh; Morgan, William M.; Ban, Yuguang; Reis, Isildinha M.; Chen, Xi; Gonzalgo, Mark L.; Jorda, Merce; Burnstein, Kerry L.; Zhang, Fangliang			Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis	ONCOGENE			English	Article							RNA-PROTEIN TRANSFERASE; END RULE PATHWAY; ARGINYLATION; TUMOR; INVASION; ASSAY; BETA	Most prostate cancer cases remain indolent for long periods of time, but metastatic progression quickly worsens the prognosis and leads to mortality. However, little is known about what promotes the metastasis of prostate cancer and there is a lack of effective prognostic indicators, making it immensely difficult to manage options for treatment or surveillance. Arginyltransferase 1 (Ate1) is the enzyme mediating post-translational protein arginylation, which has recently been identified as a master regulator affecting many cancer-relevant pathways including stress response, cell cycle checkpoints, and cell migration/adhesion. However, the precise role of Ate1 in cancer remains unknown. In this study, we found the occurrence of metastasis of prostate cancer is inversely correlated with the levels of Ate1 protein and mRNA in the primary tumor. We also found that metastatic prostate cancer cell lines have a reduced level of Ate1 protein compared to non-metastatic cell lines, and that a depletion of Ate1 drives prostate cancer cells towards more aggressive pro-metastatic phenotypes without affecting proliferation rates. Furthermore, we demonstrated that a reduction of Ate1 can result from chronic stress, and that shRNA-reduced Ate1 increases cellular resistance to stress, and drives spontaneous and stress-induced genomic mutations. Finally, by using a prostate orthotropic xenograft mouse model, we found that a reduction of Ate1 was sufficient to enhance the metastatic phenotypes of prostate cancer cell line PC-3 in vivo. Our study revealed a novel role of Ate1 in suppressing prostate cancer metastasis, which has a profound significance for establishing metastatic indicators for prostate cancer, and for finding potential treatments to prevent its metastasis.	[Birnbaum, Michael D.; Zhao, Ning; Moorthy, Balaji T.; Patel, Devang M.; Heidman, Laine; Kumar, Akhilesh; Morgan, William M.; Burnstein, Kerry L.; Zhang, Fangliang] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Reis, Isildinha M.; Chen, Xi; Gonzalgo, Mark L.; Jorda, Merce; Burnstein, Kerry L.; Zhang, Fangliang] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Jorda, Merce] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Gonzalgo, Mark L.] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA; [Ban, Yuguang; Reis, Isildinha M.; Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Kumar, Akhilesh] Banaras Hindu Univ, Dept Bot, Varanasi 221005, Uttar Pradesh, India	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; Banaras Hindu University (BHU)	Zhang, FL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.; Zhang, FL (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	fzhang2@miami.edu	Patel, Devang/P-9537-2017; Moorthy, Balaji Thas/I-9254-2019	Patel, Devang/0000-0002-0375-2318; Moorthy, Balaji Thas/0000-0002-2196-0209; Zhao, Ning/0000-0001-6514-234X	DoD (CDMRP), Idea Award [PC140622]; DoD (CDMRP), Exploratory grant [PC141013]; NIGMS (NIH) [R01GM107333]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM107333] Funding Source: NIH RePORTER	DoD (CDMRP), Idea Award; DoD (CDMRP), Exploratory grant; NIGMS (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Cell sorting was performed in the core facility of Sylvester Comprehensive Cancer Center. Ex vivo imaging was performed in the small animal imaging facility at the University of Miami Miller School of medicine. Gamma irradiation was performed in the Radiation Control core facility at the University of Miami Miller School of medicine. Immunostaining of tumor array samples was performed in the histology core facility in the Hussman Institute for Human Genomics at the University of Miami Miller School of medicine. Dr. Priyamvada Rai (University of Miami) provided critical reading for the manuscript. Dr. Yuanfang Guan (University of Michigan) provided technical consultations for the analysis related to Ate1 mRNA levels. The research presented in this article is funded in part by these grants: DoD (CDMRP), Idea Award, PC140622; DoD (CDMRP), Exploratory grant, PC141013; and NIGMS (NIH), R01GM107333.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; BALZI E, 1990, J BIOL CHEM, V265, P7464; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Decca MB, 2006, NEUROCHEM RES, V31, P401, DOI 10.1007/s11064-005-9037-z; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eisenach PA, 2014, J BIOL CHEM, V289, P35376, DOI 10.1074/jbc.M114.578674; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FIDLER IJ, 1978, CANCER RES, V38, P2651; Hu RG, 2006, J BIOL CHEM, V281, P32559, DOI 10.1074/jbc.M604355200; Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Kumar A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.284; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Kuroiwa K, 2009, J CLIN PATHOL, V62, P260, DOI 10.1136/jcp.2008.060632; Kurosaka S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000878; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Piatkov KI, 2012, P NATL ACAD SCI USA, V109, pE1839, DOI 10.1073/pnas.1207786109; Rai R, 2016, ONCOGENE, V35, P4058, DOI 10.1038/onc.2015.473; Rai R, 2006, EMBO REP, V7, P800, DOI 10.1038/sj.embor.7400747; Rice MA, 2016, ONCOGENE, V35, P4752, DOI 10.1038/onc.2016.6; Rusthoven CG, 2014, UROL ONCOL-SEMIN ORI, V32, P707, DOI 10.1016/j.urolonc.2014.01.004; Sherman MY, 2015, ONCOGENE, V34, P4153, DOI 10.1038/onc.2014.349; Suzuki F, 1983, METHODS CELL SCI, V8, P109, DOI DOI 10.1007/BF01842703; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Varshavsky A, 2011, PROTEIN SCI, V20, P1298, DOI 10.1002/pro.666; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Zhang FL, 2012, J CELL BIOL, V197, P819, DOI 10.1083/jcb.201112129; Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701; Zhang N, 1998, NEUROCHEM RES, V23, P1411, DOI 10.1023/A:1020706924509	39	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					838	851		10.1038/s41388-018-0462-2	http://dx.doi.org/10.1038/s41388-018-0462-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177837	Green Accepted			2022-12-28	WOS:000458006300006
J	Guntuku, L; Gangasani, JK; Thummuri, D; Borkar, RM; Manavathi, B; Ragampeta, S; Vaidya, JR; Sistla, R; Vegi, NGM				Guntuku, Lalita; Gangasani, Jagadeesh Kumar; Thummuri, Dinesh; Borkar, Roshan M.; Manavathi, Bramanandam; Ragampeta, Srinivas; Vaidya, Jayathirtha Rao; Sistla, Ramakrishna; Vegi, Naidu G. M.			IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; APOPTOSIS; DERIVATIVES; LYSOSOMES; PATHWAY; TARGETS; CELLS	Autophagy is a homeostatic process that recycles damaged organelles and long-lived proteins by delivering them in double-membrane vesicles to lysosomes for degradation. Autophagy has a prominent role in survival, proliferation, and resistance of tumors in metabolic and chemotherapeutic stress conditions. Clinical trials with chloroquine-a known autophagy inhibitor -were unable to achieve complete autophagy inhibition in vivo, warranting the search for more potent autophagy inhibitors. In a process of exploring the mechanism of action of previously identified cytotoxic s-triazine analogs, we discovered that both IITZ-01 and IITZ-02 act as potent autophagy inhibitors. Treatment with these compounds resulted in the vacuolated appearance of cells due to their specific accumulation in lysosomes. In addition, these basic compounds also deacidify lysosomes as evidenced by the decrease in lysotracker red staining and inhibit maturation of lysosomal enzymes leading to lysosomal dysfunction. IITZ-01 and IITZ-02 enhance autophagosome accumulation but inhibit autophagosomal degradation by impairing lysosomal function, finally resulting in the inhibition of autophagy. Interestingly, compound IITZ-01 exhibited more than 10-fold potent autophagy inhibition along with 12- to 20-fold better cytotoxic action than CQ. IITZ-01 and IITZ-02 also abolished mitochondrial membrane potential and triggered apoptosis through the mitochondria-mediated pathway. Furthermore, IITZ-01 and IITZ-02 displayed potent antitumor action in vivo through autophagy inhibition and apoptosis induction in MDA-MB-231 breast cancer xenograft model with IITZ-01 exhibiting superior anticancer efficacy. Overall, these data demonstrate that IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity and awaits further preclinical development as potential anticancer therapeutic.	[Guntuku, Lalita; Thummuri, Dinesh; Vegi, Naidu G. M.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Hyderabad, TS, India; [Gangasani, Jagadeesh Kumar; Vaidya, Jayathirtha Rao] CSIR Indian Inst Chem Technol, Crop Protect Chem Div, Hyderabad, TS, India; [Gangasani, Jagadeesh Kumar; Vaidya, Jayathirtha Rao] AcSIR, Training & Dev Complex,CSIR Campus,CSIR Rd, Chennai, TN, India; [Borkar, Roshan M.; Ragampeta, Srinivas] CSIR Indian Inst Chem Technol, Natl Ctr Mass Spectrometry, Hyderabad, TS, India; [Manavathi, Bramanandam] Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad, TS, India; [Sistla, Ramakrishna] CSIR Indian Inst Chem Technol IICT, Med Chem & Pharmacol Div, Hyderabad, TS, India; [Vegi, Naidu G. M.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati, Assam, India	National Institute of Pharmaceutical Education & Research, Hyderabad; National Institute of Pharmaceutical Education & Research (NIPER); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Academy of Scientific & Innovative Research (AcSIR); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); University of Hyderabad; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); National Institute of Pharmaceutical Education & Research (NIPER)	Vegi, NGM (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Hyderabad, TS, India.; Vegi, NGM (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati, Assam, India.	vgmnaidu@gmail.com	Thummuri, Dinesh/Q-2252-2019; BORKAR, ROSHAN M/J-6995-2019; VAIDYA, JAYATHIRTHA RAO/AET-5302-2022	BORKAR, ROSHAN M/0000-0003-1963-7688; VAIDYA, JAYATHIRTHA RAO/0000-0002-6173-3617; Manavathi, Bramanandam/0000-0002-1797-398X	NIPER-Hyderabad; NIPER-Guwahati; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India	NIPER-Hyderabad; NIPER-Guwahati; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India	GL and DT are thankful to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and Director of NIPER-Hyderabad and NIPER-Guwahati, for providing fellowship and research activity to the authors. We also acknowledge Dr M Lakshman, Sri Venkateshwara University College of Veterinary Sciences, for his help in processing and acquisition of transmission electron microscopy images. We thank Jaya Lakshmi, Veera Bhadra Swami, and Vasu Penugurti for their technical guidance and support.	Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481; Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Cascioferro S, 2017, EUR J MED CHEM, V142, P523, DOI 10.1016/j.ejmech.2017.09.035; Chen C, 2017, MOLECULES, V22, DOI 10.3390/molecules22060891; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279; Collignon J, 2016, BREAST CANCER-TARGET, V8, P93, DOI 10.2147/BCTT.S69488; de Castro MAG, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.12; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Endo S, 2017, GASTROENTEROLOGY, V152, P1492, DOI 10.1053/j.gastro.2017.01.010; Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196; Fu D, 2014, NAT CHEM, V6, P615, DOI [10.1038/nchem.1961, 10.1038/NCHEM.1961]; Guggilapu SD, 2017, EUR J MED CHEM, V128, P1, DOI 10.1016/j.ejmech.2017.01.026; Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491; Hardwick JM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008722; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Jain K, 2013, AM J CANCER RES, V3, P251; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171; Kumar GJ, 2017, MED CHEM RES, V26, P3072, DOI 10.1007/s00044-017-1978-7; Kumar GJ, 2015, MED CHEM RES, V24, P3991, DOI 10.1007/s00044-015-1430-9; Kumar GJ, 2013, MED CHEM RES, V22, P5973, DOI 10.1007/s00044-013-0584-6; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Linder S, 2005, DRUG RESIST UPDATE, V8, P199, DOI 10.1016/j.drup.2005.06.004; Liu B., 2015, MED CHEM LOS ANGELES, V5, P255, DOI [DOI 10.4172/2161-0444.1000255, 10.4172/2161-0444.1000255]; Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Morissette G, 2004, J PHARMACOL EXP THER, V310, P395, DOI 10.1124/jpet.104.066084; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Pal S, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-553; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Peterson EA, 2011, BIOORG MED CHEM LETT, V21, P2064, DOI 10.1016/j.bmcl.2011.02.007; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Ramya PVS, 2018, EUR J MED CHEM, V143, P216, DOI 10.1016/j.ejmech.2017.11.010; Repnik U, 2010, MITOCHONDRION, V10, P662, DOI 10.1016/j.mito.2010.07.008; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Shrivastava S, 2015, EXP MOL PATHOL, V98, P313, DOI 10.1016/j.yexmp.2015.03.031; Shrivastava S, 2014, APOPTOSIS, V19, P1148, DOI 10.1007/s10495-014-0991-2; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Thorburn AM, 2014, MOL PHARM, V114; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Welker ME, 2013, BIOORGAN MED CHEM, V21, P4063, DOI 10.1016/j.bmc.2013.04.083; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185	61	24	24	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					581	595		10.1038/s41388-018-0446-2	http://dx.doi.org/10.1038/s41388-018-0446-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166591				2022-12-28	WOS:000456589800009
J	Wustenhagen, E; Boukhallouk, F; Negwer, I; Rajalingam, K; Stubenrauch, F; Florin, L				Wuestenhagen, Elena; Boukhallouk, Fatima; Negwer, Inka; Rajalingam, Krishnaraj; Stubenrauch, Frank; Florin, Luise			The Myb-related protein MYPOP is a novel intrinsic host restriction factor of oncogenic human papillomaviruses	ONCOGENE			English	Article							MINOR CAPSID PROTEIN; TRANSCRIPTION FACTORS; HPV INFECTION; REPLICATION; L2; EXPRESSION; BINDING; E6; EPIDEMIOLOGY; ONCOPROTEINS	The skin represents a physical and chemical barrier against invading pathogens, which is additionally supported by restriction factors that provide intrinsic cellular immunity. These factors detect viruses to block their replication cycle. Here, we uncover the Myb-related transcription factor, partner of profilin (MYPOP) as a novel antiviral protein. It is highly expressed in the epithelium and binds to the minor capsid protein L2 and the DNA of human papillomaviruses (HPV), which are the primary causative agents of cervical cancer and other tumors. The early promoter activity and early gene expression of the oncogenic HPV types 16 and 18 is potently silenced by MYPOP. Cellular MYPOP-depletion relieves the restriction of HPV16 infection, demonstrating that MYPOP acts as a restriction factor. Interestingly, we found that MYPOP protein levels are significantly reduced in diverse HPV-transformed cell lines and in HPV-induced cervical cancer. Decades ago it became clear that the early oncoproteins E6 and E7 cooperate to immortalize keratinocytes by promoting degradation of tumor suppressor proteins. Our findings suggest that E7 stimulates MYPOP degradation. Moreover, overexpression of MYPOP blocks colony formation of HPV and non-virally transformed keratinocytes, suggesting that MYPOP exhibits tumor suppressor properties.	[Wuestenhagen, Elena; Boukhallouk, Fatima; Florin, Luise] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55131 Mainz, Germany; [Negwer, Inka] Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany; [Rajalingam, Krishnaraj] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mol Signaling Unit, Mainz, Germany; [Stubenrauch, Frank] Univ Hosp, Inst Med Virol & Epidemiol Viral Dis, Div Expt Virol, Tubingen, Germany	Johannes Gutenberg University of Mainz; Max Planck Society; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Florin, L (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	lflorin@uni-mainz.de		Florin, Luise/0000-0003-4310-7329	Max Planck Graduate Center; Johannes Gutenberg-University Mainz (MPGC); Deutsche Forschungsgemeinschaft (DFG) [FL 696/2-1]	Max Planck Graduate Center(Max Planck Society); Johannes Gutenberg-University Mainz (MPGC); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Dr. Hans-Jurgen Butt, Dr. Kaloian Koynov, and Dr. Ulrike Wieland for helpful discussion. We are grateful to Marc A. Schneider and Gilles Spoden for initial experiments (Y2H screening), Karl Sotlar for CIS sections, Claudia Simon for providing the E6 plasmid, Caroline Manicam and Monika Wied-mann for proofreading this manuscript. The skillful technical assistance in lentiviral RNAi system of Aleksandra Dimitrijevic is gratefully acknowledged. This work, including the efforts of Elena Wustenhagen and Inka Negwer, was funded by the Max Planck Graduate Center together with the Johannes Gutenberg-University Mainz (MPGC). Luise Florin receives research support from the Deutsche Forschungsgemeinschaft (DFG; FL 696/2-1).	Akgul B, 2003, VIROLOGY, V308, P279, DOI 10.1016/S0042-6822(02)00133-2; Baldwin Amy, 2007, Open Virol J, V1, P33, DOI 10.2174/1874357900701010033; Bernard HU, 2013, VIROLOGY, V445, P197, DOI 10.1016/j.virol.2013.04.035; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bund T, 2014, CELL MICROBIOL, V16, P1179, DOI 10.1111/cmi.12271; Calton CM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006200; Campos SK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120370; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Digiuseppe S, 2017, VIRUS RES, V231, P1, DOI 10.1016/j.virusres.2016.10.015; DiGiuseppe S, 2015, J VIROL, V89, P10442, DOI 10.1128/JVI.01588-15; DOLLARD SC, 1993, J VIROL, V67, P1721, DOI 10.1128/JVI.67.3.1721-1726.1993; Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Dreer M, 2017, VIRUS RES, V231, P96, DOI 10.1016/j.virusres.2016.11.005; Duggal NK, 2012, NAT REV IMMUNOL, V12, P687, DOI 10.1038/nri3295; Fast LA, 2017, BIOCHEM SOC T, V45, P489, DOI 10.1042/BST20160295; Florin L, 2012, MED MICROBIOL IMMUN, V201, P437, DOI 10.1007/s00430-012-0270-1; Grassel L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32337; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; Jackson J, 2001, BLOOD CELL MOL DIS, V27, P446, DOI 10.1006/bcmd.2001.0403; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kawamura T, 2014, J DERMATOL SCI, V75, P159, DOI 10.1016/j.jdermsci.2014.05.004; Lederer M, 2005, J CELL SCI, V118, P331, DOI 10.1242/jcs.01618; Leitz J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003957; Maglennon Gareth Adam, 2012, Open Virol J, V6, P190, DOI 10.2174/1874357901206010190; McBride AA, 2017, BIOL CHEM, V398, P919, DOI 10.1515/hsz-2017-0113; McBride AA, 2013, VIROLOGY, V445, P57, DOI 10.1016/j.virol.2013.06.006; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; MUNGER K, 1992, CANCER SURV, V12, P197; NURNBERG W, 1995, CANCER RES, V55, P4432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Organista Nava J., 2016, J MOL GENET MED, V10, P1; Porter SS, 2017, VIRUS RES, V231, P10, DOI 10.1016/j.virusres.2016.11.014; Prouse MB, 2012, BBA-GENE REGUL MECH, V1819, P67, DOI 10.1016/j.bbagrm.2011.10.010; Raff AB, 2013, J VIROL, V87, P6062, DOI 10.1128/JVI.00330-13; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Scheffer KD, 2014, VIRUSES-BASEL, V6, P893, DOI 10.3390/v6020893; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(13)60022-7; Schneider MA, 2011, IDENTIFIZIERUNG CHAR, V16, P1; Schneider MA, 2013, J VIROL, V87, P4461, DOI 10.1128/JVI.01803-12; Schneider MA, 2011, CELL MICROBIOL, V13, P32, DOI 10.1111/j.1462-5822.2010.01515.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Soeda E, 2006, VIROLOGY, V351, P29, DOI 10.1016/j.virol.2006.03.016; Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.01.024, 10.1016/j.ygyno.2010.04.002]; Stepp WH, 2013, MBIO, V4, DOI 10.1128/mBio.00845-13; Straub E, 2014, J VIROL, V88, P937, DOI 10.1128/JVI.02296-13; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; Tomaic V, 2016, CANCERS, V8, DOI 10.3390/cancers8100095; Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017; Van Doorslaer K, 2017, MBIO, V8, DOI 10.1128/mBio.01758-17; Wang JW, 2013, VIROLOGY, V445, P175, DOI 10.1016/j.virol.2013.04.017; White EA, 2016, MBIO, V7, DOI 10.1128/mBio.01530-16; Wustenhagen E, 2016, J VIROL, V90, P10629, DOI 10.1128/JVI.01222-16; YEE C, 1985, AM J PATHOL, V119, P361; Yim Eun-Kyoung, 2005, Cancer Res Treat, V37, P319, DOI 10.4143/crt.2005.37.6.319; Zhou Y, 2011, FRONT BIOSCI-LANDMRK, V16, P1109, DOI 10.2741/3738	58	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6275	6284		10.1038/s41388-018-0398-6	http://dx.doi.org/10.1038/s41388-018-0398-6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30018400	Green Published, hybrid			2022-12-28	WOS:000451622100006
J	Kim, JM; Shin, Y; Lee, S; Kim, MY; Punj, V; Shin, HI; Kim, K; Koh, JM; Jeong, D; An, W				Kim, Jin-Man; Shin, Yonghwan; Lee, Sunyoung; Kim, Mi Yeong; Punj, Vasu; Shin, Hong-In; Kim, Kyunghwan; Koh, Jung-Min; Jeong, Daewon; An, Woojin			MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1 alpha and H1.2	ONCOGENE			English	Article							NF-KAPPA-B; LYMPHOTOXIN-ALPHA; HISTONE VARIANTS; EXPRESSION; METASTASIS; CELLS; TUMOR; PHOSPHORYLATION; DIFFERENTIATION; TRANSCRIPTION	Osteoclasts are multinuclear bone-resorbing cells that differentiate from hematopoietic precursor cells. Prostate cancer cells frequently spread to bone and secrete soluble signaling factors to accelerate osteoclast differentiation and bone resorption. However, processes and mechanisms that govern the expression of osteoclastogenic soluble factors secreted by prostate cancer cells are largely unknown. MacroH2A (mH2A) is a histone variant that replaces canonical H2A at designated genomic loci and establishes functionally distinct chromatin regions. Here, we report that mH2A1.2, one of the mH2A isoforms, attenuates prostate cancer-induced osteoclastogenesis by maintaining the inactive state of genes encoding soluble factors in prostate cancer cells. Our functional analyses of soluble factors identify lymphotoxin beta (LT beta) as a major stimulator of osteoclastogenesis and an essential mH2A1.2 target for its anti-osteoclastogenic activity. Mechanistically, mH2A1.2 directly interacts with HP1 alpha and H1.2 and requires them to inactivate LT beta gene in prostate cancer cells. Consistently, HP1 alpha and H1.2 have an intrinsic ability to inhibit osteoclast differentiation in a mH2A1.2-dependent manner. Together, our data uncover a new and specific role for mH2A1.2 in modulating osteoclastogenic potential of prostate cancer cells and demonstrate how this signaling pathway can be exploited to treat osteolytic bone metastases at the molecular level.	[Kim, Jin-Man; Shin, Yonghwan; Lee, Sunyoung; Kim, Kyunghwan; An, Woojin] Univ Southern Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Kim, Mi Yeong; Jeong, Daewon] Yeungnam Univ, Dept Microbiol, Coll Med, Daegu 705717, South Korea; [Punj, Vasu] Univ Southern Calif, Dept Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Shin, Hong-In] Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, Daegu 700412, South Korea; [Kim, Kyunghwan] Chungbuk Natl Univ, Dept Biol, Coll Nat Sci, Cheongju 361763, Chungbuk, South Korea; [Koh, Jung-Min] Univ Ulsan, Div Endocrinol & Metab, Asan Med Ctr, Coll Med, Seoul 138736, South Korea	University of Southern California; Yeungnam University; University of Southern California; Kyungpook National University; Chungbuk National University; University of Ulsan; Asan Medical Center	An, W (corresponding author), Univ Southern Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.	woojinan@usc.edu			NIH [CA201561]; Keck School of Medicine of USC; NATIONAL CANCER INSTITUTE [R01CA201561] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keck School of Medicine of USC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant CA201561 awarded to W.A. The study was also funded in part by pilot project grants from Keck School of Medicine of USC.	Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504-458; Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749-6632.2009.05315.x; Chen HS, 2014, NAT STRUCT MOL BIOL, V21, P981, DOI 10.1038/nsmb.2903; Dell'Orso S, 2016, CELL REP, V14, P1156, DOI 10.1016/j.celrep.2015.12.103; Edwards Claire M, 2008, Int J Med Sci, V5, P263; Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Hideshima T, 2001, CANCER RES, V61, P3071; Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105-2896.2005.00329.x; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115; Kim K, 2013, CELL REP, V5, P1690, DOI 10.1016/j.celrep.2013.11.038; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liepinsh DJ, 2006, MOL CELL BIOL, V26, P4214, DOI 10.1128/MCB.01751-05; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027; Maze I, 2014, NAT REV GENET, V15, P259, DOI 10.1038/nrg3673; Melters DP, 2015, GENES-BASEL, V6, P751, DOI 10.3390/genes6030751; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006; Novack DV, 2008, ANNU REV PATHOL-MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Punj V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037498; Rasmussen TP, 1999, NUCLEIC ACIDS RES, V27, P3685, DOI 10.1093/nar/27.18.3685; Richart AN, 2012, J BIOL CHEM, V287, P18730, DOI 10.1074/jbc.M111.337204; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Timinszky G, 2009, NAT STRUCT MOL BIOL, V16, P923, DOI 10.1038/nsmb.1664; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	46	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5749	5765		10.1038/s41388-018-0356-3	http://dx.doi.org/10.1038/s41388-018-0356-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29925860	Green Accepted			2022-12-28	WOS:000448288200004
J	Roh, E; Lee, MH; Zykova, TA; Zhu, F; Nadas, J; Kim, HG; Bae, KB; Li, Y; Cho, YY; Curiel-Lewandrowski, C; Einspahr, J; Dickinson, SE; Bode, AM; Dong, ZG				Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A.; Zhu, Feng; Nadas, Janos; Kim, Hong-Gyum; Bae, Ki Beom; Li, Yan; Cho, Yong Yeon; Curiel-Lewandrowski, Clara; Einspahr, Janine; Dickinson, Sally E.; Bode, Ann M.; Dong, Zigang			Targeting PRPK and TOPK for skin cancer prevention and therapy	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; CYCLIN D1 EXPRESSION; BETAMETHASONE VALERATE; GROWTH-FACTOR; RISK-FACTORS; PROTEIN; KINASE; CARCINOGENESIS; METASTASIS; PHOSPHORYLATION	Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar-simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (Zemuron (R)) or betamethasone 17-valerate (Betaderm (R)) that could attenuate TOPK-dependent PRPK signaling. Importantly, topical application of either rocuronium bromide or betamethasone decreased SSL-induced epidermal hyperplasia, neovascularization, and cutaneous squamous cell carcinoma (cSCC) development in SKH1 (Crl: SKH1-Hr(hr)) hairless mice by inhibiting PRPK activation, and also reduced expression of the proliferation and oncogenesis markers, COX-2, cyclin D1, and MMP-9. This study is the first to demonstrate that targeting PRPK could be useful against sUV-induced cSCC development.	[Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A.; Zhu, Feng; Nadas, Janos; Kim, Hong-Gyum; Bae, Ki Beom; Li, Yan; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Lee, Mee-Hyun] China US Hormel Canc Inst, Zhengzhou 45008, Henan, Peoples R China; [Zhu, Feng] Huazhong Univ Sci & Technol, Sch Basic Med, Wuhan 430030, Hubei, Peoples R China; [Cho, Yong Yeon] Catholic Univ Korea, Coll Pharm, Bucheon 420743, South Korea; [Curiel-Lewandrowski, Clara; Einspahr, Janine; Dickinson, Sally E.] Univ Arizona, Ctr Canc, Tucson, AZ USA	University of Minnesota System; Huazhong University of Science & Technology; Catholic University of Korea; University of Arizona	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	ZHU, Feng/C-1303-2010; Cho, Yong-Yeon/AAD-4263-2020	Cho, Yong-Yeon/0000-0003-1107-2651; Zhu, Feng/0000-0003-1172-0102	Hormel Foundation; National of Institutes of Health [CA027502, CA166011, CA187027, CA196639]; NATIONAL CANCER INSTITUTE [P01CA027502, R01CA166011, P30CA023074, R01CA196639, R01CA187027] Funding Source: NIH RePORTER	Hormel Foundation; National of Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National of Institutes of Health grants CA027502, CA166011, CA187027, and CA196639 (ZD). We thank Dr. Lorenzo A. Pinna (Universita di Padova, Italy) for the pQE-81L-PRPK plasmid, Alyssa Langfald for confocal microscopy analysis, and Dr. Tia Rai and Nicki Brickman for assistance with manuscript submission.	Abe Y, 2006, BIOCHEM BIOPH RES CO, V344, P377, DOI 10.1016/j.bbrc.2006.03.071; Abe Y, 2001, J BIOL CHEM, V276, P44003, DOI 10.1074/jbc.M105669200; Allanson M, 2007, CANCER IMMUNOL IMMUN, V56, P1807, DOI 10.1007/s00262-007-0324-1; Atzmony L, 2016, AM J CLIN DERMATOL, V17, P11, DOI 10.1007/s40257-015-0160-6; Bode AM, 2006, MOL CARCINOGEN, V45, P422, DOI 10.1002/mc.20222; BOYLE JO, 1993, CANCER RES, V53, P4477; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; Chang CF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071007; Cherpelis BS, 2002, DERMATOL SURG, V28, P268, DOI 10.1046/j.1524-4725.2002.01169.x; Dobrev H, 2001, PHOTODERMATOL PHOTO, V17, P184, DOI 10.1034/j.1600-0781.2001.170408.x; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Facchin S, 2007, CELL MOL LIFE SCI, V64, P2680, DOI 10.1007/s00018-007-7179-7; Fan XM, 2016, ONCOTARGET, V7, P24633, DOI 10.18632/oncotarget.8260; Farasat S, 2011, J AM ACAD DERMATOL, V64, P1051, DOI 10.1016/j.jaad.2010.08.033; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gao G, 2017, MOL CANCER THER, V16, P1843, DOI 10.1158/1535-7163.MCT-17-0212; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guy GP, 2014, AM J PUBLIC HEALTH, V104, pE69, DOI [10.2105/AJPH.2013.301850, 10.1016/j.amepre.2014.08.036]; Hensler S, 2013, CANCER J, V19, P517, DOI 10.1097/PPO.0000000000000010; Huang K, 2012, CLIN EXP DERMATOL, V37, P411, DOI 10.1111/j.1365-2230.2011.04275.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x; Katiyar SK, 2007, TOXICOL APPL PHARM, V224, P220, DOI 10.1016/j.taap.2006.11.017; Katiyar SK, 2015, PHOTOCHEM PHOTOBIOL, V91, P156, DOI 10.1111/php.12330; Kim JE, 2016, ONCOGENE, V35, P4091, DOI 10.1038/onc.2015.471; Kim JE, 2016, ONCOTARGET, V7, P14616, DOI 10.18632/oncotarget.7524; Kwon JY, 2009, CARCINOGENESIS, V30, P1932, DOI 10.1093/carcin/bgp216; Li Y, 2016, ONCOTARGET, V7, P6748, DOI 10.18632/oncotarget.6826; Lohmann CM, 2001, ADV ANAT PATHOL, V8, P27, DOI 10.1097/00125480-200101000-00005; Loyo M, 2013, HEAD NECK-J SCI SPEC, V35, P454, DOI 10.1002/hed.23100; Marcil I, 2000, ARCH DERMATOL, V136, P1524, DOI 10.1001/archderm.136.12.1524; Matsuo Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010277; Missero C, 2014, EXP DERMATOL, V23, P143, DOI 10.1111/exd.12320; Muller-Decker K, 2011, CANCER METAST REV, V30, P343, DOI 10.1007/s10555-011-9306-z; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Panelos J, 2008, MODERN PATHOL, V21, P316, DOI 10.1038/modpathol.3801007; Park JH, 2014, CELL SIGNAL, V26, P849, DOI 10.1016/j.cellsig.2014.01.004; Peterson D, 2010, CANCER RES, V70, P6325, DOI 10.1158/0008-5472.CAN-10-0015; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Ridley AJ, 2009, INT J RADIAT BIOL, V85, P177, DOI 10.1080/09553000902740150; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Runger TM, 2007, J INVEST DERMATOL, V127, P2103, DOI 10.1038/sj.jid.5700988; Saraceno R, 2010, J DERMATOL TREAT, V21, P363, DOI 10.3109/09546630903386606; Schwarz A, 2005, J EXP MED, V201, P173, DOI 10.1084/jem.20041212; Shen YY, 2014, MOL CLIN ONCOL, V2, P545, DOI 10.3892/mco.2014.273; Shih MC, 2012, ONCOGENE, V31, P2389, DOI 10.1038/onc.2011.419; Thompson AK, 2016, JAMA DERMATOL, V152, P419, DOI 10.1001/jamadermatol.2015.4994; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Yano K, 2004, J INVEST DERMATOL, V122, P201, DOI 10.1046/j.0022-202X.2003.22101.x; Yokogawa M, 2013, MOL CARCINOGEN, V52, P760, DOI 10.1002/mc.21901; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048	54	21	22	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5633	5647		10.1038/s41388-018-0350-9	http://dx.doi.org/10.1038/s41388-018-0350-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29904102	Green Accepted			2022-12-28	WOS:000447619100004
J	Boetto, J; Apra, C; Bielle, F; Peyre, M; Kalamarides, M				Boetto, Julien; Apra, Caroline; Bielle, Franck; Peyre, Matthieu; Kalamarides, Michel			Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation	ONCOGENE			English	Article							CRANIOFACIAL DEVELOPMENT; SHH MEDULLOBLASTOMA; CELL CARCINOMA; MUTATIONS; HEDGEHOG; NF2; MOUSE; IDENTIFICATION; LOCALIZATION; INACTIVATION	Somatic activating mutations of smoothened (SMO), a component of the embryonic sonic hedgehog (SHH) signaling pathway, are found in 3-5% of grade I meningiomas, most of them corresponding to meningothelial meningiomas located at the anterior skull base. By generating different developmental stage-specific conditional activations in mice, we define a restricted developmental window during which conditional activation of Smo in Prostaglandin D2-synthase-positive mesoderm-derived meningeal layer of the skull base results in meningothelial meningioma formation. We show a selective vulnerability of the arachnoid from the skull base to Smo activation to initiate tumor development. This prenatal period and specific topography are correlated to the timing and location of SHH signaling involvement in the formation of craniofacial and meninges patterning, strongly corroborating the hypothesis of a developmental origin for Smo-activated meningiomas. Finally, we provide preclinical in vitro evidence of the efficacy of the SMO-inhibitor Sonidegib, supporting further preclinical and clinical evaluation of targeted treatment for refractory SMO-mutant meningiomas.	[Boetto, Julien; Apra, Caroline; Bielle, Franck; Peyre, Matthieu; Kalamarides, Michel] Sorbonne Univ, Inst Cerveau & Moelle Epiniere, INSERM, U1127,CNRS,UMR 7225,CRICM, F-75013 Paris, France; [Bielle, Franck] Hop La Pitie Salpetriere, AP HP, Dept Pathol, F-75013 Paris, France; [Peyre, Matthieu; Kalamarides, Michel] Hop La Pitie Salpetriere, AP HP, Dept Neurosurg, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Kalamarides, M (corresponding author), Sorbonne Univ, Inst Cerveau & Moelle Epiniere, INSERM, U1127,CNRS,UMR 7225,CRICM, F-75013 Paris, France.	michel.kalamarides@aphp.fr	Boetto, Julien/AAG-5777-2021	Boetto, Julien/0000-0003-2572-8594; Apra, Caroline/0000-0003-0944-9544; Peyre, Matthieu/0000-0001-8470-9516; Bielle, Franck/0000-0001-6564-6388	foundation ARC, France. [PJA 20131200431]; UM1 University, Montpellier, France	foundation ARC, France.; UM1 University, Montpellier, France	This work was supported by a grant from the foundation ARC (PJA 20131200431), France. J.B. was funded by a grant from UM1 University, Montpellier, France.	Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316; Boetto J, 2017, NEURO-ONCOLOGY, V19, P345, DOI 10.1093/neuonc/now276; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651; Eberhart JK, 2006, DEVELOPMENT, V133, P1069, DOI 10.1242/dev.02281; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Giovannini M, 2000, GENE DEV, V14, P1617; Huttner HB, 2018, EBIOMEDICINE, V27, P176, DOI 10.1016/j.ebiom.2017.12.020; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Le Roux I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9528; Louis, 2016, WHO CLASSIFICATION G; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marshall GM, 2014, NAT REV CANCER, V14, P277, DOI 10.1038/nrc3679; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; Migden MR, 2015, LANCET ONCOL, V16, P716, DOI 10.1016/S1470-2045(15)70100-2; Ohli J, 2015, ACTA NEUROPATHOL, V130, P307, DOI 10.1007/s00401-015-1453-9; Peyre M, 2013, ONCOGENE, V32, P4264, DOI 10.1038/onc.2012.436; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644; Samkari A, 2015, EXPERT REV NEUROTHER, V15, P763, DOI 10.1586/14737175.2015.1052796; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Vitte J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00346-5; Xavier GM, 2016, DEV BIOL, V415, P198, DOI 10.1016/j.ydbio.2016.02.009; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007; Yuzawa S, 2016, MODERN PATHOL, V29, P708, DOI 10.1038/modpathol.2016.81	31	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4955	4963		10.1038/s41388-018-0328-7	http://dx.doi.org/10.1038/s41388-018-0328-7			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789719	Green Published			2022-12-28	WOS:000443823600004
J	Serrao, A; Jenkins, LM; Chumanevich, AA; Horst, B; Liang, JX; Gatza, ML; Lee, NY; Roninson, IB; Broude, EV; Mythreye, K				Serrao, Anne; Jenkins, Laura M.; Chumanevich, Alexander A.; Horst, Ben; Liang, Jiaxin; Gatza, Michael L.; Lee, Nam Y.; Roninson, Igor B.; Broude, Eugenia V.; Mythreye, Karthikeyan			Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; TGF-BETA RECEPTOR; BREAST-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; CDK8; ACTIVATION; BMP; CELLS; EXPRESSION	CDK8 is a transcription-regulating kinase that controls TGF-beta/BMP-responsive SMAD transcriptional activation and turnover through YAP1 recruitment. However, how the CDK8/YAP1 pathway influences SMAD1 response in cancer remains unclear. Here we report that SMAD1-driven epithelial-to-mesenchymal transition (EMT) is critically dependent on matrix rigidity and YAP1 in a wide spectrum of cancer models. We find that both genetic and pharmacological inhibition of CDK8 and its homologous twin kinase CDK19 leads to abrogation of BMP-induced EMT. Notably, selectively blocking CDK8/19 specifically abrogates tumor cell invasion, changes in EMT-associated transcription factors, E-cadherin expression and YAP nuclear localization both in vitro and in vivo in a murine syngeneic EMT model. Furthermore, RNA-seq meta-analysis reveals a direct correlation between CDK8 and EMT-associated transcription factors in patients. Our findings demonstrate that CDK8, an emerging therapeutic target, coordinates growth factor and mechanical cues during EMT and invasion.	[Serrao, Anne; Jenkins, Laura M.; Horst, Ben; Mythreye, Karthikeyan] Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; [Chumanevich, Alexander A.; Liang, Jiaxin; Roninson, Igor B.; Broude, Eugenia V.; Mythreye, Karthikeyan] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA; [Gatza, Michael L.] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA; [Gatza, Michael L.] Univ Med & Dent New Jersey, New Brunswick, NJ USA; [Lee, Nam Y.] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University	Mythreye, K (corresponding author), Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.; Mythreye, K (corresponding author), Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.	mythreye@sc.edu	liang, jiaxin/AAC-3469-2021; Karthikeyan, Mythreye/ABC-7345-2020	liang, jiaxin/0000-0003-2129-3626; Karthikeyan, Mythreye/0000-0001-5478-0098; Gatza, Michael/0000-0001-6796-7791	NIH [P20GM109091, GM122379-01]; Marsha Rivkin Foundation; Ovarian Cancer Research Fund; University of South Carolina startup funds; University of South Carolina SPARC Graduate Student Research; NATIONAL CANCER INSTITUTE [R01CA230628, R01CA219495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM122379, P20GM109091] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Marsha Rivkin Foundation; Ovarian Cancer Research Fund; University of South Carolina startup funds; University of South Carolina SPARC Graduate Student Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the COBRE Functional Genomics Core (USC Center for Targeted Therapeutics) for lentiviral preparations, COBRE Microscopy and Flow cytometry Core (USC Center for Targeted Therapeutics) for assistance with imaging, Qi Zhang, Zach Mack, Nick Lenze, Priyanka Singh, and Pratik Patel for technical assistance. Grant Support: NIH P20GM109091 (E.V.B., K.M., I.B.R.), Marsha Rivkin Foundation (K.M.), Ovarian Cancer Research Fund (K.M.), University of South Carolina startup funds (K.M.), University of South Carolina SPARC Graduate Student Research, and Predoctoral NIH GM122379-01 (L.M.J.).	Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Ampuja M, 2016, CANCER LETT, V375, P238, DOI 10.1016/j.canlet.2016.03.008; Calvo MB, 2009, CLIN TRANSL ONCOL, V11, P126, DOI 10.1007/S12094-009-0328-8; Broude EV, 2015, CURR CANCER DRUG TAR, V15, P739, DOI 10.2174/156800961508151001105814; Chen HB, 2005, J BIOL CHEM, V280, P21329, DOI 10.1074/jbc.M500362200; Chen MQ, 2017, P NATL ACAD SCI USA, V114, P10208, DOI 10.1073/pnas.1710467114; Chumanevich AA, 2017, ONCOTARGET, V8, P228, DOI 10.18632/oncotarget.13894; Crown J, 2017, ONCOTARGET, V8, P14269, DOI 10.18632/oncotarget.15354; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Galbraith MD, 2010, TRANSCR-AUSTIN, V1, P4, DOI 10.4161/trns.1.1.12373; Gordon KJ, 2009, CARCINOGENESIS, V30, P238, DOI 10.1093/carcin/bgn274; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holtzhausen A, 2014, FASEB J, V28, P1248, DOI 10.1096/fj.13-239178; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Huang ZH, 2016, DEVELOPMENT, V143, P2398, DOI 10.1242/dev.130658; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Le Page C, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-4; Leight JL, 2012, MOL BIOL CELL, V23, P781, DOI 10.1091/mbc.E11-06-0537; Liu YL, 2017, BIOMEDICINE-TAIWAN, V7, P1, DOI 10.1051/bmdcn/2017070101; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; McDermott MSJ, 2017, ONCOTARGET, V8, P12558, DOI 10.18632/oncotarget.14894; Nallet-Staub F, 2015, DEV CELL, V32, P640, DOI 10.1016/j.devcel.2015.01.011; Osborne LD, 2014, MOL BIOL CELL, V25, P3528, DOI 10.1091/mbc.E14-05-1015; Owens P, 2015, ONCOGENE, V34, P2437, DOI 10.1038/onc.2014.189; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; Pickup MW, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022285; Richter A, 2014, STEM CELLS, V32, P636, DOI 10.1002/stem.1592; Rzymski T, 2015, BBA-PROTEINS PROTEOM, V1854, P1617, DOI 10.1016/j.bbapap.2015.05.011; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Swaminathan V, 2011, CANCER RES, V71, P5075, DOI 10.1158/0008-5472.CAN-11-0247; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Varadaraj A, 2015, NEOPLASIA, V17, P826, DOI 10.1016/j.neo.2015.11.003; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Wentland, 2016, U.S. Patent, Patent No. 09321737; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrighton Katharine H, 2011, Nat Rev Mol Cell Biol, V12, P404, DOI 10.1038/nrm3136; Xu W, 2015, CANCER LETT, V356, P613, DOI 10.1016/j.canlet.2014.10.008; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54	54	33	34	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4792	4808		10.1038/s41388-018-0316-y	http://dx.doi.org/10.1038/s41388-018-0316-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780169	Green Accepted			2022-12-28	WOS:000443146000003
J	Wang, PS; Chou, CH; Lin, CH; Yao, YC; Cheng, HC; Li, HY; Chuang, YC; Yang, CN; Ger, LP; Chen, YC; Lin, FC; Shen, TL; Hsiao, M; Lu, PJ				Wang, Po-Shun; Chou, Cheng-Han; Lin, Cheng-Han; Yao, Yun-Chin; Cheng, Hui-Chuan; Li, Hao-Yi; Chuang, Yu-Chung; Yang, Chia-Ning; Ger, Luo-Ping; Chen, Yu-Chia; Lin, Forn-Chia; Shen, Tang-Long; Hsiao, Michael; Lu, Pei-Jung			A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; REVEALS; ADENOCARCINOMA; INHIBITORS; PREDICTION; BIOMARKER; PATHWAY; GENES; BONE	Triple-negative breast cancer (TNBC) patients usually lead to poor prognosis and survival because of metastasis. The major sites for TNBC metastasis include the lungs, brain, liver, and bone. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts longer than 200 nucleotides and have been reported as important regulators in BC metastasis. However, the underlying mechanisms for lncRNAs regulating TNBC metastasis are not fully understood. Here we found that linc-ZNF469-3 was highly expressed in lung-metastatic LM2-4175 TNBC cells and overexpression of linc-ZNF469-3 enhanced invasion ability and stemness properties in vitro and lung metastasis in vivo. Furthermore, we found linc-ZNF469-3 physically interacted with miR-574-5p and overexpression of miR-574-5p attenuated ZEB1 expression. Importantly, endogenous high expressions of linc-ZNF469-3 and ZEB1 were correlated with tumor recurrence in TNBC patients with lung metastasis. Taken together, our findings suggested that linc-ZNF469-3 promotes lung metastasis of TNBC through miR-574-5p-ZEB1 signaling axis and may be used as potential prognostic marker for TNBC patients.	[Wang, Po-Shun; Chou, Cheng-Han; Lin, Cheng-Han; Yao, Yun-Chin; Cheng, Hui-Chuan; Li, Hao-Yi; Lu, Pei-Jung] Natl Cheng Kung Univ, Inst Clin Med, Med Coll, Tainan 70403, Taiwan; [Chuang, Yu-Chung; Yang, Chia-Ning] Natl Univ Kaohsiung, Dept Life Sci, Kaohsiung 81148, Taiwan; [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 81362, Taiwan; [Chen, Yu-Chia] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 81362, Taiwan; [Lin, Forn-Chia] Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 70403, Taiwan; [Shen, Tang-Long] Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei 10617, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan; [Lu, Pei-Jung] Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan 70403, Taiwan	National Cheng Kung University; National University Kaohsiung; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Taiwan University; Academia Sinica - Taiwan; Kaohsiung Medical University; National Cheng Kung University; National Cheng Kung University Hospital	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Med Coll, Tainan 70403, Taiwan.; Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan.; Hsiao, M (corresponding author), Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan.; Lu, PJ (corresponding author), Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan 70403, Taiwan.	mhsiao@gate.sinica.edu.tw; pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019; Shen, Tang-Long/C-7460-2011	Hsiao, Michael/0000-0001-8529-9213; Chou, Cheng-Han/0000-0003-0534-0373; Shen, Tang-Long/0000-0001-6264-3608; Lin, Cheng-Han/0000-0001-5444-3999; Wang, Po-Shun/0000-0002-2344-980X	Ministry of Science and Technology [MOST 103-2320-B-006-048, MOST 105-2320-B-006-054]; National Cheng Kung University Hospital [NCKUH-10605012, NCKUH-10601003]; Academia Sinica and Ministry of Science and Technology [MOST106-0210-01-15-02, MOST 107-0210-01-19-01]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Cheng Kung University Hospital; Academia Sinica and Ministry of Science and Technology	This work was supported by the Ministry of Science and Technology [MOST 103-2320-B-006-048 and MOST 105-2320-B-006-054 to PJL] and National Cheng Kung University Hospital [NCKUH-10605012 and NCKUH-10601003 to FCL and PJL]. Academia Sinica and Ministry of Science and Technology [MOST106-0210-01-15-02, MOST 107-0210-01-19-01 to Michael Hsiao]. Funding for open access charge: Ministry of Science and Technology [MOST 103-2320-B-006-048 and MOST 105-2320-B-006-054]. We thank the National Center for Genome Medicine for assisting with RNA sequencing and the Center for Genome Medicine, National Cheng Kung University for the support of lncRNA annotation and bioinformatic analyses. We also thank Dr. Myriam Gorospe (National Institutes of Health, Baltimore, MD, USA) for the plasmid pMS2 (24 x), pMS2-lincRNA-p21, and pMS2-GST, and Dr. Tang-Long Shen (National Taiwan University, Taipei, Taiwan) for MDA-MB-231 cell lines including parental, LM2-4175, BrM-831, and BoM-1833.	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Biesiada M, 2016, METHODS, V103, P120, DOI 10.1016/j.ymeth.2016.03.010; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Chuang YC, 2015, MOL BIOSYST, V11, P723, DOI 10.1039/c4mb00620h; Cui Z, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-47; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Hsu CY, 2016, AM J RESP CRIT CARE, V193, P869, DOI 10.1164/rccm.201412-2226OC; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jiang YZ, 2016, CANCER RES, V76, P2105, DOI 10.1158/0008-5472.CAN-15-3284; Jin CJ, 2016, ONCOTARGET, V7, P51763, DOI 10.18632/oncotarget.10107; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee CC, 2017, RSC ADV, V7, P29871, DOI 10.1039/c7ra04099g; Lee S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6374504; Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Merola R, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0127-8; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Popenda M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks339; Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4; Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; van Kampen JGM, 2017, CANCER RES, V77, P2008, DOI 10.1158/0008-5472.CAN-16-2609; Velasco-Velazquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005; Vennin C, 2015, ONCOTARGET, V6, P29209, DOI 10.18632/oncotarget.4976; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Xu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.149; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou R, 2016, SCI REP-UK, V6, DOI 10.1038/srep35714; Zhou R, 2015, ONCOTARGET, V6, P44609, DOI 10.18632/oncotarget.6338	57	49	55	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4662	4678		10.1038/s41388-018-0293-1	http://dx.doi.org/10.1038/s41388-018-0293-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755127				2022-12-28	WOS:000442514400003
J	Rogers, S; McCloy, RA; Parker, BL; Gallego-Ortega, D; Law, AMK; Chin, VT; Conway, JRW; Fey, D; Millar, EKA; O'Toole, S; Deng, NT; Swarbrick, A; Chastain, PD; Cesare, AJ; Timpson, P; Caldon, CE; Croucher, DR; James, DE; Watkins, DN; Burgess, A				Rogers, Samuel; McCloy, Rachael A.; Parker, Benjamin L.; Gallego-Ortega, David; Law, Andrew M. K.; Chin, Venessa T.; Conway, James R. W.; Fey, Dirk; Millar, Ewan K. A.; O'Toole, Sandra; Deng, Niantao; Swarbrick, Alexander; Chastain, Paul D.; Cesare, Anthony J.; Timpson, Paul; Caldon, C. Elizabeth; Croucher, David R.; James, David E.; Watkins, D. Neil; Burgess, Andrew			MASTL overexpression promotes chromosome instability and metastasis in breast cancer	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; MITOTIC EXIT; GREATWALL KINASE; HUMAN-CELLS; DNA-DAMAGE; EPITHELIAL-CELLS; DEPHOSPHORYLATION; PHOSPHORYLATION; PHENOTYPE; SUBSTRATE	MASTL kinase is essential for correct progression through mitosis, with loss of MASTL causing chromosome segregation errors, mitotic collapse and failure of cytokinesis. However, in cancer MASTL is most commonly amplified and overexpressed. This correlates with increased chromosome instability in breast cancer and poor patient survival in breast, ovarian and lung cancer. Global phosphoproteomic analysis of immortalised breast MCF10A cells engineered to overexpressed MASTL revealed disruption to desmosomes, actin cytoskeleton, PI3K/AKT/mTOR and p38 stress kinase signalling pathways. Notably, these pathways were also disrupted in patient samples that overexpress MASTL. In MCF10A cells, these alterations corresponded with a loss of contact inhibition and partial epithelial-mesenchymal transition, which disrupted migration and allowed cells to proliferate uncontrollably in 3D culture. Furthermore, MASTL overexpression increased aberrant mitotic divisions resulting in increased micronuclei formation. Mathematical modelling indicated that this delay was due to continued inhibition of PP2A-B55, which delayed timely mitotic exit. This corresponded with an increase in DNA damage and delayed transit through interphase. There were no significant alterations to replication kinetics upon MASTL overexpression, however, inhibition of p38 kinase rescued the interphase delay, suggesting the delay was a G2 DNA damage checkpoint response. Importantly, knockdown of MASTL, reduced cell proliferation, prevented invasion and metastasis of MDA-MB-231 breast cancer cells both in vitro and in vivo, indicating the potential of future therapies that target MASTL. Taken together, these results suggest that MASTL overexpression contributes to chromosome instability and metastasis, thereby decreasing breast cancer patient survival.	[Rogers, Samuel; McCloy, Rachael A.; Gallego-Ortega, David; Law, Andrew M. K.; Chin, Venessa T.; Conway, James R. W.; Deng, Niantao; Swarbrick, Alexander; Timpson, Paul; Caldon, C. Elizabeth; Croucher, David R.; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Rogers, Samuel; Cesare, Anthony J.] Univ Sydney, Childrens Med Res Inst, Westmead, NSW, Australia; [Parker, Benjamin L.; James, David E.] Univ Sydney, Sch Life & Environm Sci, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Gallego-Ortega, David; Fey, Dirk] Univ Coll Dublin, Syst Biol Ireland, Dublin 4, Ireland; [Millar, Ewan K. A.] St George Hosp, Dept Anat Pathol, NSW Hlth Pathol, Sydney, NSW 2217, Australia; [Millar, Ewan K. A.] UNSW Sydney, Sch Med Sci, Kensington, NSW 2033, Australia; [Millar, Ewan K. A.] Sydney Western Univ, Sch Med & Hlth Sci, Campbelltown, NSW 2560, Australia; [O'Toole, Sandra] Univ Sydney, Sydney Med Sch, Fisher Rd, Camperdown, NSW 2006, Australia; [O'Toole, Sandra] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Missenden Rd, Camperdown, NSW 2050, Australia; [Deng, Niantao; Swarbrick, Alexander; Caldon, C. Elizabeth; Croucher, David R.; Watkins, D. Neil] UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Chastain, Paul D.] Univ Illinois, Coll Med Rockford, Dept Hlth Sci Educ, Rockford, IL 61107 USA; [Croucher, David R.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; [James, David E.] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia; [Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia; [Burgess, Andrew] Univ Sydney, ANZAC Res Inst, Sydney, NSW 2139, Australia	Garvan Institute of Medical Research; Children's Medical Research Institute - Australia; University of Sydney; University of Sydney; University College Dublin; St George Hospital; University of New South Wales Sydney; University of Sydney; University of Sydney; University of New South Wales Sydney; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; University College Dublin; University of Sydney; St Vincents Hospital Sydney; University of Sydney; ANZAC Research Institute	Burgess, A (corresponding author), Univ Sydney, ANZAC Res Inst, Sydney, NSW 2139, Australia.	andrew.burgess@anzac.edu.au	Cesare, Anthony J/F-4691-2010; Gallego-Ortega, David/AAK-9067-2020; Timpson, Paul/A-9429-2016; Swarbrick, Alexander/E-6107-2010; Research Institute, ANZAC/CAE-9030-2022; Burgess, Andrew/H-3339-2019; Cesare, Anthony/N-7415-2019; Chastain, Paul/AAN-2692-2020; Millar, Ewan/ABE-9127-2020	Cesare, Anthony J/0000-0002-0864-1254; Gallego-Ortega, David/0000-0002-2347-7835; Swarbrick, Alexander/0000-0002-3051-5676; Burgess, Andrew/0000-0003-4536-9226; Cesare, Anthony/0000-0002-0864-1254; Chastain, Paul/0000-0001-6782-6788; Millar, Ewan/0000-0002-9778-3253; James, David/0000-0001-5946-5257; McCloy, Rachael/0000-0001-7791-4044; Timpson, Paul/0000-0002-5514-7080; Fey, Dirk/0000-0002-5558-0167; Watkins, Neil/0000-0001-8218-4920; Chin, Venessa/0000-0002-4630-4451; Conway, James/0000-0003-3787-277X; Rogers, Samuel/0000-0002-5345-5741; Deng, Niantao/0000-0001-9717-2236; Croucher, David/0000-0003-4965-8674	NBCF [IIRS-18-103]; CINSW FRL [10/FRL/3-02]; Patricia Helen Guest Fellowship	NBCF; CINSW FRL; Patricia Helen Guest Fellowship	We thank Marcos Malumbres for his insightful comments, Medina Krcic for her assistance, A. Cippioni and C. Ormandy for their generous gifts of the AKT/mTOR MagPix and SILAC reagents. This work was supported by NBCF (IIRS-18-103), CINSW FRL (ID#10/FRL/3-02) and a Patricia Helen Guest Fellowship.	Alvarez-Fernandez, 2017, CELL DEATH DIFFER, P1; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Burgess A, 2017, CELL, V169, DOI 10.1016/j.cell.2017.06.003; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chin VT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8504; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Duffy S, 2016, P NATL ACAD SCI USA, V113, P9967, DOI 10.1073/pnas.1611839113; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108; Hinchcliffe EH, 2016, NAT CELL BIOL, V18, P668, DOI 10.1038/ncb3348; Kim ES, 2004, INT J ONCOL, V25, P1375; Kim MS, 2003, CANCER RES, V63, P5454; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Llopis A, 2012, CELL CYCLE, V11, P3627, DOI 10.4161/cc.21917; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Nagel R, 2015, MOL CANCER THER, V14, P1434, DOI 10.1158/1535-7163.MCT-14-0846; Ocasio CA, 2016, ONCOTARGET, V7, P71182, DOI 10.18632/oncotarget.11511; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Pereira B, 2016, NAT COMMUN, V7, P1; Piscitello D, 2017, ONCOGENE, V15, P356; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; Sansregret L, 2018, NAT REV CLIN ONCOL, V85, P14; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Tian JJ, 2017, BIOMED PHARMACOTHER, V92, P919, DOI 10.1016/j.biopha.2017.05.118; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang L, 2014, ONCOTARGET, V5, P11479, DOI 10.18632/oncotarget.2565; Williams BC, 2014, ELIFE, V3, DOI 10.7554/eLife.01695; Wong PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22230; Xue Y, 2008, MOL CELL PROTEOMICS, V7, P1598, DOI 10.1074/mcp.M700574-MCP200; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493; Zhuge BZ, 2017, EUR REV MED PHARMACO, V21, P2413	46	30	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4518	4533		10.1038/s41388-018-0295-z	http://dx.doi.org/10.1038/s41388-018-0295-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743597	Green Published, hybrid			2022-12-28	WOS:000441736700003
J	Yang, H; Xu, M; Lu, F; Zhang, QN; Feng, YQ; Yang, CS; Li, N; Jia, XD				Yang, Hui; Xu, Miao; Lu, Fang; Zhang, Qiannan; Feng, Yongquan; Yang, Chung S.; Li, Ning; Jia, Xudong			Tocopherols inhibit esophageal carcinogenesis through attenuating NF-kappa B activation and CXCR3-mediated inflammation	ONCOGENE			English	Article							NUTRITION INTERVENTION TRIALS; VITAMIN-E; GAMMA-TOCOPHEROL; CANCER PREVENTION; PROSTATE-CANCER; COLON CARCINOGENESIS; ALPHA-TOCOPHEROL; DELTA-TOCOPHEROL; SELENIUM; PROMOTES	Esophageal cancer is one of the common causes of cancer mortality in the world. The predominant histological subtype, esophageal squamous cell carcinoma (ESCC), often results in poor prognosis due to the lack of effective approaches for the early diagnosis and treatment, highlighting the need for preventive intervention against this disease. Here we report that dietary tocopherols significantly prevents esophageal carcinogenesis by inhibiting the activation of NF-kappa B and the subsequent interaction of chemokine CXCL9/10/11 with their receptor CXCR3 in ESCC induced by N-nitrosomethylbenzylamine (NMBA) in murine models. Dietary supplementation with 0.15% alpha-tocopherol (alpha-T), d-tocopherol (delta-T), or gamma-tocopherol rich mixture (gamma-TmT) markedly suppressed the production of pro-inflammatory cytokines, as well as the induction of CXCR3+ effector T cells (CD4+ Th1 and CD8+ CTLs) infiltration, especially at the early stage of carcinogenesis. In experiments in vivo and in vitro, these events were tightly correlated with the blockade of NF-kappa B activation. Our results show that tocopherols decrease carcinogenesis through inhibiting NF-kappa B and CXCR3 signaling, as well as related inflammation in early premalignant lesions. This pathway may offer a novel target for chemoprevention of esophageal cancer.	[Yang, Hui; Zhang, Qiannan; Feng, Yongquan; Li, Ning; Jia, Xudong] Natl Ctr Food Safety Risk Assessment, Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing, Peoples R China; [Xu, Miao] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Sichuan, Peoples R China; [Lu, Fang] Beijing Agr Univ, Beijing, Peoples R China; [Yang, Chung S.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ USA	Sichuan University; Beijing University of Agriculture; Rutgers State University New Brunswick	Yang, H; Jia, XD (corresponding author), Natl Ctr Food Safety Risk Assessment, Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing, Peoples R China.	yanghui@cfsa.net.cn; jiaxudong@cfsa.net.cn	Yang, Hui/AAK-8492-2020	Yang, Hui/0000-0002-6025-338X	National Natural Science Foundation of China [81402679]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the National Natural Science Foundation of China (no. 81402679).	Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124; Bak MJ, 2017, CANCER PREV RES, V10, P188, DOI [10.1158/1940-6207.capr-16-0223, 10.1158/1940-6207.CAPR-16-0223]; Billottet C, 2013, BBA-REV CANCER, V1836, P287, DOI 10.1016/j.bbcan.2013.08.002; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen JX, 2017, MOL CARCINOGEN, V56, P172, DOI 10.1002/mc.22481; Chen JX, 2016, CANCER LETT, V371, P71, DOI 10.1016/j.canlet.2015.11.010; Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200; Das Gupta S, 2015, CANCER PREV RES, V8, P807, DOI 10.1158/1940-6207.CAPR-15-0154; Dietrich M, 2006, J AM COLL NUTR, V25, P292, DOI 10.1080/07315724.2006.10719538; Eitenmiller T, 2004, VITAMIN E FOOD CHEM; Fong LYY, 1999, CANCER LETT, V143, P63, DOI 10.1016/S0304-3835(99)00191-3; Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guan F, 2012, CANCER PREV RES, V5, P644, DOI 10.1158/1940-6207.CAPR-11-0521; Hannelien V, 2012, BBA-REV CANCER, V1825, P117, DOI 10.1016/j.bbcan.2011.10.008; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IARC, 2012, SECT CANC INF; Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Lee JH, 2012, CANCER RES, V72, P3175, DOI 10.1158/0008-5472.CAN-12-0481; Li GX, 2011, CANCER PREV RES, V4, P404, DOI 10.1158/1940-6207.CAPR-10-0130; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; Lunardi S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027473; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Malyak M, 1998, J IMMUNOL, V161, P1997; Malyak M, 1998, J IMMUNOL, V161, P2004; Maresso KC, 2015, CA-CANCER J CLIN, V65, P345, DOI 10.3322/caac.21287; Mark SD, 2000, J NATL CANCER I, V92, P1753, DOI 10.1093/jnci/92.21.1753; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mulligan AM, 2013, CLIN CANCER RES, V19, P336, DOI 10.1158/1078-0432.CCR-11-3314; Patterson TA, 2006, NAT BIOTECHNOL, V24, P1140, DOI 10.1038/nbt1242; Perez S, 2017, FREE RADICAL BIO MED, V104, P75, DOI 10.1016/j.freeradbiomed.2016.12.048; Qiao YL, 2009, JNCI-J NATL CANCER I, V101, P507, DOI 10.1093/jnci/djp037; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Smolarek AK, 2012, CANCER PREV RES, V5, P1310, DOI 10.1158/1940-6207.CAPR-12-0263; Stoner GD, 2006, NUTR CANCER, V54, P33, DOI 10.1207/s15327914nc5401_5; Taylor PR, 2003, J NATL CANCER I, V95, P1414, DOI 10.1093/jnci/djg044; TAYLOR PR, 1994, CANCER RES, V54, pS2029; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Wang H, 2016, MOL CARCINOGEN, V55, P1728, DOI 10.1002/mc.22422; Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016; Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483; Yang CS, 2016, MOL NUTR FOOD RES, V60, P1239, DOI 10.1002/mnfr.201500766; Yang CS, 2012, CANCER PREV RES, V5, P701, DOI 10.1158/1940-6207.CAPR-12-0045; Yang H, 2012, INT J CANCER, V131, P1517, DOI 10.1002/ijc.27423; Yang H, 2011, CARCINOGENESIS, V32, P381, DOI 10.1093/carcin/bgq279; Zhou HF, 2016, BIOMED PHARMACOTHER, V82, P479, DOI 10.1016/j.biopha.2016.04.069; Zipin-Roitman A, 2007, CANCER RES, V67, P3396, DOI 10.1158/0008-5472.CAN-06-3087	53	13	13	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3909	3923		10.1038/s41388-018-0246-8	http://dx.doi.org/10.1038/s41388-018-0246-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662196				2022-12-28	WOS:000439101300001
J	Stantic, M; Wolfsberger, J; Sakil, HAM; Wilhelm, MT				Stantic, Marina; Wolfsberger, Johanna; Sakil, Habib A. M.; Wilhelm, Margareta T.			Delta Np73 enhances HIF-1 alpha protein stability through repression of the ECV complex	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BREAST-CANCER; TUMOR ANGIOGENESIS; UNFAVORABLE PROGNOSIS; FACTOR 1-ALPHA; UBIQUITIN LIGASES; POOR-PROGNOSIS; LUNG-CANCER; FACTOR-I; EXPRESSION	Cellular responses to low oxygen conditions are mainly regulated by the Hypoxia-inducible factors (HIFs). Induction of HIF-1 beta in tumor cells activates the angiogenic switch and allows for metabolic adaptations. HIF-1 alpha protein levels are tightly regulated through ubiquitin-mediated proteosomal degradation; however, high levels of HIF-1 alpha is a common feature in many solid tumors and is thought to enhance cancer cell proliferation, migration, and survival. Here, we report that the oncogenic p73 isoform, Delta Np73, increases HIF-1 alpha protein stability. We found that Delta Np73 represses expression of genes encoding subunits of the ECV complex, in particular Elongin C, Elongin B, Cullin 2, and Rbx1. The ECV complex is an E3 ligase complex responsible for polyubiquitinating HIF-1 alpha. Loss of Delta Np73 increases ubiquitination of HIF-1 alpha, leading to its degradation via the proteosomal pathway, and subsequent decrease of HIF-1 alpha target genes. Taken together, our data demonstrates that high levels of Delta Np73 stabilize HIF-1 alpha protein, allowing for it to accumulate and further potentiating its transcriptional activity and supporting tumor progression.	[Stantic, Marina; Wolfsberger, Johanna; Sakil, Habib A. M.; Wilhelm, Margareta T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden	Karolinska Institutet	Wilhelm, MT (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden.	margareta.wilhelm@ki.se		Stantic, Marina/0000-0002-2800-5538; Wilhelm, Margareta/0000-0002-0516-9724	Swedish Cancer Society; Swedish Research Council; Swedish Childhood Cancer Society; Karolinska Institutet doctoral grants (KID); Young Investigator Award from the Swedish Cancer Society	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Society; Karolinska Institutet doctoral grants (KID); Young Investigator Award from the Swedish Cancer Society	This work was supported by grants from the Swedish Cancer Society and the Swedish Research Council. MS is supported by a postdoctoral fellowship from the Swedish Childhood Cancer Society. JW and HAMS are funded by Karolinska Institutet doctoral grants (KID). MW is supported by a Young Investigator Award from the Swedish Cancer Society.	Amelio I, 2015, P NATL ACAD SCI USA, V112, P226, DOI 10.1073/pnas.1410609111; Birner P, 2000, CANCER RES, V60, P4693; Cardote TAF, 2017, STRUCTURE, V25, P901, DOI 10.1016/j.str.2017.04.009; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dulloo I, 2015, CELL CYCLE, V14, P3533, DOI 10.1080/15384101.2015.1078038; Fernandez-Alonso R, 2015, CELL DEATH DIFFER, V22, P1287, DOI 10.1038/cdd.2014.214; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Koeppel M, 2011, NUCLEIC ACIDS RES, V39, P6069, DOI 10.1093/nar/gkr028; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kuschel A, 2012, J CELL PHYSIOL, V227, P514, DOI 10.1002/jcp.22798; Leung THY, 2013, BRIT J CANCER, V109, P965, DOI 10.1038/bjc.2013.397; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Madden SL, 1996, CANCER RES, V56, P5384; Mahrour N, 2008, J BIOL CHEM, V283, P8005, DOI 10.1074/jbc.M706987200; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Mohlin S, 2017, EXP CELL RES, V356, P192, DOI 10.1016/j.yexcr.2017.03.007; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010; Sakil HAM, 2017, CELL ONCOL, V40, P631, DOI 10.1007/s13402-017-0340-x; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Shibaji T, 2003, ANTICANCER RES, V23, P4721; Soldevilla B, 2014, HUM MOL GENET, V23, P467, DOI 10.1093/hmg/ddt437; Stantic M, 2015, P NATL ACAD SCI USA, V112, P220, DOI 10.1073/pnas.1421697112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theodoropoulos VE, 2004, EUR UROL, V46, P200, DOI 10.1016/j.eururo.2004.04.008; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; Uramoto H, 2006, ANTICANCER RES, V26, P1785; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang RH, 2016, BIOCHEM BIOPH RES CO, V470, P117, DOI 10.1016/j.bbrc.2016.01.005; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464; Zhong H, 1999, CANCER RES, V59, P5830; Zhou WH, 2013, CELL RES, V23, P599, DOI 10.1038/cr.2013.44; Zitterbart K, 2007, ACTA NEUROPATHOL, V114, P641, DOI 10.1007/s00401-007-0298-2	47	3	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3729	3739		10.1038/s41388-018-0195-2	http://dx.doi.org/10.1038/s41388-018-0195-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628507	hybrid, Green Published			2022-12-28	WOS:000437975200009
J	Wang, S; Zou, Z; Luo, X; Mi, Y; Chang, H; Xing, D				Wang, S.; Zou, Z.; Luo, X.; Mi, Y.; Chang, H.; Xing, D.			LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer	ONCOGENE			English	Article							LIVER RECEPTOR HOMOLOG-1; DEPENDENT DIMERIZATION; MOLECULAR-BASIS; HISTONE H2AX; TUMOR CELLS; CDKN1A GENE; PHOSPHORYLATION; RECOGNITION; ASSOCIATION; SENSITIVITY	Liver receptor homolog-1 (LRH1) has been shown to promote tumor proliferation and development. However, the functions of LRH1 in mediating cancer cells chemoresistance are still not clear. Here, we found LRH1 levels were significantly elevated in primary breast cancer tissues in patients who developed early recurrence. Similarly, adriamycin (ADR)-resistant breast cancer cell lines also exerted high LRH1 expression. Indeed, overexpression of LRH1 attenuated cytotoxicity of chemotherapeutic drugs ADR and cisplatin (DDP) in breast cancer cells in vitro and in nude mice tumor model. Comet and BrdU assays showed overexpression of LRH1 blocked breast cancer cells DNA damage by chemotherapeutic drug, whereas depletion of LRH1 enhanced DNA damage. Remarkably, knockdown of LRH1 decreased the levels and foci of DNA damage marker gamma H2AX induced by ADR and DDP. Furthermore, plasmid end joining assay indicated that knockdown of LRH1 significantly decreased non-homologous end joining (NHEJ)-mediated double-strand break (DSB) repair efficiencies. Afterwards, we provided evidences that LRH1 promoted MDC1 transcription by directly activating MDC1 promoter and therefore increased gamma H2AX levels. Importantly, a LRH1-binding site mapped between -1812 and -1804 bp of the proximal MDC1 promoter was identified. Moreover, LRH1 and MDC1 mRNA levels were positively correlated in recurrent breast cancer samples. These results implied LRH1 enhanced breast cancer cell chemoresistance by upregulating MDC1 and attenuating DNA damage. Additionally, we elucidated the coactivator NCOA3 acted synergistically with LRH1 to promote MDC1 expression and chemoresistance. Altogether, LRH1-MDC1 signaling might be considered as a novel molecular target for designing novel therapeutic regimen in chemotherapy resistance breast cancer.	[Wang, S.; Zou, Z.; Chang, H.; Xing, D.] South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China; [Wang, S.; Zou, Z.; Chang, H.; Xing, D.] South China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou, Guangdong, Peoples R China; [Luo, X.] Zhengzhou Univ, Affiliated Luoyang Cent Hosp, Dept Oncol, Luoyang, Peoples R China; [Mi, Y.] Xiamen Univ, Affiliated Hosp 1, Dept Thorac Surg, Xiamen, Peoples R China	South China Normal University; South China Normal University; Zhengzhou University; Xiamen University	Zou, Z; Xing, D (corresponding author), South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China.; Zou, Z; Xing, D (corresponding author), South China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou, Guangdong, Peoples R China.	zouzhengzhi@scnu.edu.cn; xingda@scnu.edu.cn			National Natural Science Foundation of China [81772803, 81630046, 81402187]; Natural Science Foundation of Guangdong Province [2014A030310505]; Foundation for Distinguished Young Talents in Higher Education of Guangdong [C1085229]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Foundation for Distinguished Young Talents in Higher Education of Guangdong	We are grateful to Dr. Simak Ali (Imperial College London, London) for providing pCI-HA3-LRH1 plasmid, to Dr. Michal Goldberg (Hebrew University of Jerusalem, Jerusalem) for providing HA-MDC1 plasmid, to Dr. Vera Gorbunova for providing the pEGFP-Pem1-Ad2 plasmid, to Prof. B-A Li (Xiamen University) for providing the MDA-MB-231/ADR and T47D/ADR cells. This study was supported by grants from the National Natural Science Foundation of China (No. 81772803, 81630046, 81402187); Ph.D. Start-Up Fund of Natural Science Foundation of Guangdong Province (No. 2014A030310505 to ZZ); Foundation for Distinguished Young Talents in Higher Education of Guangdong (No. C1085229 to ZZ).	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Ao X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.367; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Audet-Walsh E, 2016, CELL REP, V14, P920, DOI 10.1016/j.celrep.2015.12.086; Baldock RA, 2015, CELL REP, V13, P2081, DOI 10.1016/j.celrep.2015.10.074; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bianco S, 2015, ONCOGENE, V34, P4509, DOI 10.1038/onc.2014.382; Bianco S, 2014, CANCER RES, V74, P2015, DOI 10.1158/0008-5472.CAN-13-2351; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Burgess RC, 2014, CELL REP, V9, P1703, DOI 10.1016/j.celrep.2014.10.060; Burwinkel B, 2005, CLIN CANCER RES, V11, P2169, DOI 10.1158/1078-0432.CCR-04-1621; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179; Coster G, 2007, J BIOL CHEM, V282, P32053, DOI 10.1074/jbc.M705890200; Coster G, 2010, NUCLEUS-PHILA, V1, P166, DOI 10.4161/nucl.1.2.11176; Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2999-1; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gong C, 2015, J BIOL CHEM, V290, P14811, DOI 10.1074/jbc.M115.652628; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gruosso T, 2016, EMBO MOL MED, V8, P527, DOI 10.15252/emmm.201505891; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009; Holmstrom SR, 2011, GENE DEV, V25, P1674, DOI 10.1101/gad.16860911; Jungmichel S, 2012, NUCLEIC ACIDS RES, V40, P3913, DOI 10.1093/nar/gkr1300; Klammer H, 2010, CANCER RES, V70, P8498, DOI 10.1158/0008-5472.CAN-10-1181; Kramer HB, 2016, NUCLEIC ACIDS RES, V44, P582, DOI 10.1093/nar/gkv948; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Lazarus KA, 2012, J STEROID BIOCHEM, V130, P138, DOI 10.1016/j.jsbmb.2011.12.017; Liu JP, 2012, NUCLEIC ACIDS RES, V40, P3898, DOI 10.1093/nar/gkr1296; Liu XL, 2015, TUMOR BIOL, V36, P4261, DOI 10.1007/s13277-015-3063-5; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Luo XY, 2016, ONCOTARGET, V7, P26480, DOI 10.18632/oncotarget.8419; Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Sidler D, 2011, ONCOGENE, V30, P2411, DOI 10.1038/onc.2010.629; Sirianni R, 2002, J ENDOCRINOL, V174, pR13, DOI 10.1677/joe.0.174R013; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549-010-0994-9; Zhang Z, 2016, J EARTHQ ENG, V25, P1, DOI DOI 10.1089/ARS.2016.6634; Zhang ZZ, 2016, FASEB J, V30, P466, DOI 10.1096/fj.15-274258; Zhu J., 2016, ADV ENERGY MATER, V7, P1; Zou ZZ, 2016, BIOCHEM BIOPH RES CO, V478, P227, DOI 10.1016/j.bbrc.2016.07.063; Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110	51	40	41	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3243	3259		10.1038/s41388-018-0193-4	http://dx.doi.org/10.1038/s41388-018-0193-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29545602				2022-12-28	WOS:000435526600005
J	Lin, J; Ma, JC; Yang, J; Yin, JY; Chen, XX; Guo, H; Wen, XM; Zhang, TJ; Qian, W; Qian, J; Deng, ZQ				Lin, J.; Ma, J. -C.; Yang, J.; Yin, J. -Y.; Chen, X. -X.; Guo, H.; Wen, X. -M.; Zhang, T. -J.; Qian, W.; Qian, J.; Deng, Z. -Q.			Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; LONG NONCODING RNA; CANCER-CELLS; DOWN-REGULATION; STEM-CELLS; POOR SURVIVAL; GENOME-WIDE; EXPRESSION; METASTASIS; MICRORNAS	Cancer-testis (CT) antigens, rarely in normal tissues except testis, are expressed in many tumor types. In recent years, DDX43 has been shown to be expressed in several malignancies. However, the role of DDX43 during tumorigenesis is not well established. In the present study, we explored the function of DDX43 in chronic myeloid leukemia (CML). We found that DDX43 overexpression in CML cell lines enhanced survival and colony formation, inhibited cell apoptosis, promoted tumorigenesis, and CML progression. In contrast, silencing of DDX43 inhibited cell survival and tumorigenesis. Upregulated H19 and downregulated miR-186 were identified in DDX43-transfected cells. Furthermore, we demonstrated that miR-186 targeted DDX43, and overexpressed miR-186 increased apoptosis and decreased cell survival. We also showed that DDX43 regulated the expression of H19 through demethylation and silencing H19 inhibited cell survival. Taken together, these results indicate that DDX43 provides critical support to the progression of CML by enhancing cell survival, colony formation, and inhibiting cell apoptosis, thereby implicating DDX43 as a potential therapeutic target in CML.	[Lin, J.; Ma, J. -C.; Yin, J. -Y.; Guo, H.; Wen, X. -M.; Deng, Z. -Q.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Cent Lab, Zhenjiang, Jiangsu, Peoples R China; [Lin, J.; Ma, J. -C.; Guo, H.; Wen, X. -M.; Zhang, T. -J.; Qian, J.; Deng, Z. -Q.] Key Lab Precis Diag & Treatment Hematol Malignanc, Zhenjiang, Jiangsu, Peoples R China; [Yang, J.; Chen, X. -X.; Zhang, T. -J.; Qian, J.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang, Jiangsu, Peoples R China; [Qian, W.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Otolaryngol, Zhenjiang, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University	Deng, ZQ (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Cent Lab, Zhenjiang, Jiangsu, Peoples R China.; Qian, J; Deng, ZQ (corresponding author), Key Lab Precis Diag & Treatment Hematol Malignanc, Zhenjiang, Jiangsu, Peoples R China.; Qian, J (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang, Jiangsu, Peoples R China.	qianjun0007@hotmail.com; zqdeng2002@163.com		Qian, Jun/0000-0001-7697-2875	National Natural Science Foundation of China [81172592, 81270630]; Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province [CXTDB2017002]; six talent peaks project in Jiangsu Province [2015-WSN-115]; China Postdoctoral Science Foundation [2016M601747]; Jiangsu Provincial "Innovative & entrepreneurial talent team" Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province; six talent peaks project in Jiangsu Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Provincial "Innovative & entrepreneurial talent team" Program	This study was supported by National Natural Science Foundation of China (81172592, 81270630), Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province (CXTDB2017002), six talent peaks project in Jiangsu Province (2015-WSN-115), China Postdoctoral Science Foundation (2016M601747), and Jiangsu Provincial "Innovative & entrepreneurial talent team" Program.	Adams SP, 2002, LEUKEMIA, V16, P2238, DOI 10.1038/sj.leu.2402732; Bernaudo S, 2016, ONCOGENE, V35, P4816, DOI 10.1038/onc.2016.15; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chen Q, 2013, GENET TEST MOL BIOMA, V17, P508, DOI 10.1089/gtmb.2012.0530; Chen Q, 2012, BRIT J HAEMATOL, V158, P293, DOI 10.1111/j.1365-2141.2012.09138.x; Chen Qin, 2011, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V19, P1171; Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x; Cui GH, 2014, TUMOR BIOL, V35, P8933, DOI 10.1007/s13277-014-2168-6; Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113; Erdmann K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-82; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; Ferrer G, 2013, LEUKEMIA LYMPHOMA, V54, P2016, DOI 10.3109/10428194.2012.763123; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Lee DF, 2015, CELL, V161, P240, DOI 10.1016/j.cell.2015.02.045; Li HL, 2013, CARCINOGENESIS, V34, P2145, DOI 10.1093/carcin/bgt158; Liggins Amanda P, 2010, Cancer Immun, V10, P8; Lin J, 2014, LEUKEMIA RES, V38, P601, DOI 10.1016/j.leukres.2014.02.012; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Ma JC, 2014, CELL PHYSIOL BIOCHEM, V34, P2266, DOI 10.1159/000369669; Martelange V, 2000, CANCER RES, V60, P3848; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263; Sidaway Peter, 2016, Nat Rev Clin Oncol, V13, P135, DOI 10.1038/nrclinonc.2016.13; Song YF, 2017, HEPATOLOGY, V66, P1183, DOI 10.1002/hep.29209; Vennin C, 2015, ONCOTARGET, V6, P29209, DOI 10.18632/oncotarget.4976; Wang Q, 2017, ONCOTARGET, V8, P2558, DOI 10.18632/oncotarget.13708; Wang W, 2015, BLOOD, V126, P1699, DOI 10.1182/blood-2015-05-646489; Zhang TJ, 2016, CLIN LAB, V62, P113, DOI 10.7754/Clin.Lab.2015.150606; Zheng J, 2015, ONCOTARGET, V6, P25339, DOI 10.18632/oncotarget.4509; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zhou JD, 2018, J CELL PHYSIOL, V233, P2444, DOI 10.1002/jcp.26119; Zhou W, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9557; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	42	21	21	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2432	2443		10.1038/s41388-018-0146-y	http://dx.doi.org/10.1038/s41388-018-0146-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449695	Green Published, hybrid			2022-12-28	WOS:000431386000007
J	Sirkisoon, SR; Carpenter, RL; Rimkus, T; Anderson, A; Harrison, A; Lange, AM; Jin, GX; Watabe, K; Lo, HW				Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Anderson, Ashley; Harrison, Alexandria; Lange, Allison M.; Jin, Guangxu; Watabe, Kounosuke; Lo, Hui-Wen			Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR; SONIC-HEDGEHOG; SPLICE VARIANT; SELF-RENEWAL; STEM-CELLS; GLI GENE; EXPRESSION; PROTEIN; ACTIVATION	Signal transducer and activator of transcription 3 (STAT3), glioma oncogene homolog 1 (GLI1), and truncated GLI1 (tGLI1) are oncogenic transcription factors playing important roles in breast cancer. tGLI1 is a gain-of-function GLI1 isoform. Whether STAT3 physically and/or functionally interacts with GLI1/tGLI1 has not been explored. To address this knowledge gap, we analyzed 47 node-positive breast cancer specimens using immunohistochemical staining and found that phosphorylated-STAT3 (Y705), GLI1, and tGLI1 are co-overexpressed in the majority of triple-negative breast carcinomas (64%) and HER2-enriched (68%) breast carcinomas, and in lymph node metastases (65%). Using gene set enrichment analysis, we analyzed 710 breast tumors and found that STAT3 activation and GLI1/tGLI1 activation signatures are co-enriched in triple-negative subtypes of breast cancers and HER2-enriched subtypes of breast cancers, but not in luminal subtypes of breast cancers. Patients with high levels of STAT3 and GLI1/tGLI1 co-activation in their breast tumors had worse metastasis-free survival compared to those with low levels. Since these proteins co-overexpress in breast tumors, we examined whether they form complexes and observed that STAT3 interacted with both GLI1 and tGLI1. We further found that the STAT3-GLI1 and STAT3-tGLI1 complexes bind to both consensus GLI1-binding and STAT3-binding sites using chromatin immunoprecipitation (ChIP) assay, and that the co-overexpression markedly activated a promoter controlled by GLI1-binding sites. To identify genes that can be directly co-activated by STAT3 and GLI1/tGLI1, we analyzed three ChIP-seq datasets and identified 34 potential target genes. Following validations using reverse transcription polymerase chain reaction and survival analysis, we identified three genes as novel transcriptional targets of STAT3 and GLI1/tGLI1, R-Ras2, Cep70, and UPF3A. Finally, we observed that co-overexpression of STAT3 with GLI1/tGLI1 promoted the ability of breast cancer cells to form mammospheres and that STAT3 only cooperates with tGLI1 in immortalized mammary epithelial cells. In summary, our study identified novel physical and functional cooperation between two families of oncogenic transcription factors, and the interaction contributes to aggressiveness of breast cancer cells and poor prognosis of triple-negative breast cancers and HER2-enriched breast cancers.	[Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Anderson, Ashley; Harrison, Alexandria; Lange, Allison M.; Watabe, Kounosuke; Lo, Hui-Wen] Dept Canc Biol, Winston Salem, NC 27104 USA; [Jin, Guangxu] Dept Radiol, Winston Salem, NC USA; [Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center	Lo, HW (corresponding author), Dept Canc Biol, Winston Salem, NC 27104 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27109 USA.	hlo@wakehealth.edu		Carpenter, Richard/0000-0001-9986-6493	NIH [R01NS087169, T32CA079448, R01NS087169-3S1, P30CA012197]; DoD grant [W81XWH17-1-0044]; NATIONAL CANCER INSTITUTE [T32CA079448, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to acknowledge our colleagues Dr. Shadi Qasem for providing pathology support, and funding support for this project from NIH grants R01NS087169 (to H-WL), T32CA079448 (to SK, RLC), R01NS087169-3S1 (to H-WL and SRS), P30CA012197 (to BP; core facility), and DoD grant W81XWH17-1-0044 (to H-WL).	Abou-Bakr AA, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.317; Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Brouckaert O, 2012, INT J WOMENS HEALTH, V4, P511, DOI 10.2147/IJWH.S18541; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Clark GJ, 1996, ONCOGENE, V12, P169; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dahmane N, 2001, DEVELOPMENT, V128, P5201; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Brot M, 2009, REV ASSOC MED BRAS, V55, P529, DOI 10.1590/S0104-42302009000500014; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; Han W, 2013, MOL CARCINOGEN, V52, P959, DOI 10.1002/mc.21936; Kameda C, 2009, ANTICANCER RES, V29, P871; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuba S, 2014, JPN J CLIN ONCOL, V44, P1025, DOI 10.1093/jjco/hyu126; Langlois B, 2014, ONCOTARGET, V5, P10529, DOI 10.18632/oncotarget.2470; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Milla LA, 2012, BIOL RES, V45, P223, DOI 10.4067/S0716-97602012000300004; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Peterson KA, 2012, GENE DEV, V26, P2802, DOI 10.1101/gad.207142.112; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013054; Shi XJ, 2017, AM J PATHOL, V187, P679, DOI 10.1016/j.ajpath.2016.11.005; Shi XJ, 2015, FEBS LETT, V589, P1771, DOI 10.1016/j.febslet.2015.06.017; Shi XJ, 2012, CELL CYCLE, V11, P1554, DOI 10.4161/cc.19954; Shi XJ, 2011, J BIOL CHEM, V286, P33401, DOI 10.1074/jbc.M111.252262; Shum EY, 2016, CELL, V165, P382, DOI 10.1016/j.cell.2016.02.046; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Xu LS, 2010, BREAST CANCER RES TR, V123, P59, DOI 10.1007/s10549-009-0617-5; Yang Q, 2012, EXP MOL PATHOL, V93, P227, DOI 10.1016/j.yexmp.2012.04.009; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014; Zhu H, 2010, CURR GENOMICS, V11, P238, DOI 10.2174/138920210791233108	66	57	59	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2502	2514		10.1038/s41388-018-0132-4	http://dx.doi.org/10.1038/s41388-018-0132-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29449694	Green Accepted			2022-12-28	WOS:000431873400004
J	Li, N; Truong, S; Nouri, M; Moore, J; Al Nakouzi, N; Lubik, AA; Buttyan, R				Li, Na; Truong, Sarah; Nouri, Mannan; Moore, Jackson; Al Nakouzi, Nader; Lubik, Amy Anne; Buttyan, Ralph			Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3	ONCOGENE			English	Article							SIGNALING PATHWAY; PROLIFERATION; TARGET; STEROIDOGENESIS; INTERFERENCE; DEGRADATION; MECHANISMS; PROTEASOME; RESISTANCE; PROMOTER	Hedgehog (Hh) is an oncogenic signaling pathway that regulates the activity of Gli transcription factors. Canonical Hh is a Smoothened-(Smo-) driven process that alters the post-translational processing of Gli2/Gli3 proteins. Though evidence supports a role for Gli action in prostate cancer (PCa) cell growth and progression, there is little indication that Smo is involved. Here we describe a non-canonical means for activation of Gli transcription in PCa cells mediated by the binding of transcriptionally-active androgen receptors (ARs) to Gli3. Androgens stimulated reporter expression from a Gli-dependent promoter in a variety of AR + PCa cells and this activity was suppressed by an anti-androgen, Enz, or by AR knockdown. Androgens also upregulated expression of endogenous Gli-dependent genes. This activity was associated with increased intranuclear binding of Gli3 to AR that was antagonized by Enz. Fine mapping of the AR binding domain on Gli2 showed that AR recognizes the Gli protein processing domain (PPD) in the C-terminus. Mutations in the arginine-/serine repeat elements of the Gli2 PPD involved in phosphorylation and ubiquitinylation blocked the binding to AR. beta-TrCP, a ubiquitin ligase that recognizes the Gli PPD, competed with AR for binding to this site. AR binding to Gli3 suppressed its proteolytic processing to the Gli3 repressor form (Gli3R) whereas AR knockdown increased Gli3R. Both full-length and truncated ARs were able to activate Gli transcription. Finally, we found that an ARbinding decoy polypeptide derived from the Gli2 Cterminus can compete with Gli3 for binding to AR. Exogenous overexpression of this decoy suppressed Gli transcriptional activity in PCa cells. Collectively, this work identifies a novel pathway for non-canonical activation of Hh signaling in PCa cells and identifies a means for interference that may have clinical relevance for PCa patients.	[Li, Na; Truong, Sarah; Moore, Jackson; Al Nakouzi, Nader; Lubik, Amy Anne] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Truong, Sarah; Nouri, Mannan; Buttyan, Ralph] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC, Canada; [Buttyan, Ralph] Univ British Columbia, Urol Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia	Buttyan, R (corresponding author), Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC, Canada.; Buttyan, R (corresponding author), Univ British Columbia, Urol Sci, Vancouver, BC, Canada.	rbuttyan@prostatecentre.com		Nouri, Mannan/0000-0002-7442-9251	Canadian Institutes of Health Research [CIHR258931]; Prostate Cancer Canada-Movember Team [T2103]; US Department of Defense [PCRP W81XWH-10-1-0493]; Terry Fox Research Institute New Frontiers [PPG 1062]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Prostate Cancer Canada-Movember Team; US Department of Defense(United States Department of Defense); Terry Fox Research Institute New Frontiers	The authors acknowledge the helpful assistance of Dr Mengqian Chen of the South Carolina School of Pharmacy in the generation of the human Gli3 expression vector. Sources of Support: Canadian Institutes of Health Research (CIHR258931); Prostate Cancer Canada-Movember Team T2103; US Department of Defense PCRP W81XWH-10-1-0493; Terry Fox Research Institute New Frontiers PPG 1062.	Agathocleous M, 2007, CELL CYCLE, V6, P156, DOI 10.4161/cc.6.2.3745; Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Chen MQ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-89; Chen M, 2009, CELL CYCLE, V8, P149, DOI 10.4161/cc.8.1.7532; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Finco I, 2015, ANNU REV PHYSIOL, V77, P105, DOI 10.1146/annurev-physiol-061214-111754; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Koebernick K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/j.1432-0436.2002.700201.x; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Levina E, 2012, PROSTATE, V72, P817, DOI 10.1002/pros.21500; Li N, 2014, PROSTATE, V74, P1400, DOI 10.1002/pros.22855; Lubik AA, 2017, INT J CANCER, V140, P358, DOI 10.1002/ijc.30450; Pan Y, 2007, J BIOL CHEM, V282, P10846, DOI 10.1074/jbc.M608599200; Penning TM, 2015, J STEROID BIOCHEM, V153, P105, DOI 10.1016/j.jsbmb.2015.05.010; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Schrader EK, 2011, J BIOL CHEM, V286, P39051, DOI 10.1074/jbc.M111.274993; Sirab N, 2012, INT J CANCER, V131, P1297, DOI 10.1002/ijc.27384; Stecca B, 2005, TRENDS MOL MED, V11, P199, DOI 10.1016/j.molmed.2005.03.004; Tickle C, 2013, WIRES DEV BIOL, V2, P275, DOI 10.1002/wdev.70; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Ware KE, 2014, ENDOCR-RELAT CANCER, V21, pT87, DOI 10.1530/ERC-13-0470; Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702; Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-2; Xavier GM, 2016, DEV BIOL, V415, P198, DOI 10.1016/j.ydbio.2016.02.009; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhou JC, 2016, CANCER LETT, V370, P313, DOI 10.1016/j.canlet.2015.11.006; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	42	20	21	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2313	2325		10.1038/s41388-017-0098-7	http://dx.doi.org/10.1038/s41388-017-0098-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29429990	hybrid, Green Published			2022-12-28	WOS:000431100200008
J	Russo, A; Czarnecki, AA; Dean, M; Modi, DA; Lantvit, DD; Hardy, L; Baligod, S; Davis, DA; Wei, JJ; Burdette, JE				Russo, Angela; Czarnecki, Austin A.; Dean, Matthew; Modi, Dimple A.; Lantvit, Daniel D.; Hardy, Laura; Baligod, Seth; Davis, David A.; Wei, Jian-Jun; Burdette, Joanna E.			PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; FOCAL ADHESION KINASE; INTRAEPITHELIAL CARCINOMA; SURFACE EPITHELIUM; BORDERLINE TUMORS; MOUSE MODEL; CANCER; EXPRESSION; ORIGIN; TRANSFORMATION	The signaling events involved in the onset of ovarian cancer from the fallopian tube epithelium (FTE) are crucial for early detection and treatment of the disease, but they remain poorly defined. Conditional homozygous knockout of PTEN mediated by PAX8-cre recombinase was sufficient to drive endometrioid and serous borderline ovarian carcinoma, providing the first model of FTE-derived borderline tumors. In addition, heterozygous PTEN deletion in the FTE resulted in hyperplasia, providing a model to study early events of human ovarian pathogenesis. To uncover the mechanism underlying the invasion of cancerous oviductal cells to the ovary, PTEN-deficient murine oviductal cells were developed and tagged with green fluorescent protein. Loss of PTEN increased cell migration, invasion, and upregulated WNT4, a key regulator of Mullerian duct development during embryogenesis. Further investigation revealed that WNT4 was required for increased migration and colonization of the ovary by PTEN-deficient oviductal cells in a a-catenin independent manner. Human tumor microarrays and ovarian cancer cells lines confirmed WNT4 expression in cancer and its role in migration. Together, these findings provide a novel model to study the mechanism of fallopian tube tumor initiation and invasion to the ovary mediated by loss of PTEN, which may help to define early events of human ovarian carcinogenesis.	[Russo, Angela; Czarnecki, Austin A.; Dean, Matthew; Modi, Dimple A.; Lantvit, Daniel D.; Hardy, Laura; Baligod, Seth; Davis, David A.; Burdette, Joanna E.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; [Davis, David A.] J Hopkins Med Inst, Reference Histol Lab, Dept Pathol, Baltimore, MD USA; [Wei, Jian-Jun] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Northwestern University	Burdette, JE (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA.	joannab@uic.edu	WEI, JJ/AAN-2638-2020	Dean, Matthew/0000-0001-5014-9311	Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation; American Cancer Society [ACS RSG-12-230-01-TBG]; NIH [UG3 ES029073-01, T32 AT007533]; NATIONAL CANCER INSTITUTE [R21CA208610] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT007533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [UG3ES029073] Funding Source: NIH RePORTER	Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by Tell Every Amazing Lady (T.E.A.L.) About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation, The American Cancer Society ACS RSG-12-230-01-TBG, the NIH UG3 ES029073-01 and the NIH T32 AT007533. We would also like to thank the Northwestern NUseq Core Facility and Dr. Matthew Schipma.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boone JD, 2016, LAB INVEST, V96, P249, DOI 10.1038/labinvest.2015.150; Bouchard M, 2004, GENESIS, V38, P105, DOI 10.1002/gene.20008; Cho KR, 2009, ARCH PATHOL LAB MED, V133, P1775, DOI 10.1043/1543-2165-133.11.1775; Coffman LG, 2016, TRANSL RES, V175, P92, DOI 10.1016/j.trsl.2016.03.016; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Fathalla MF, 2013, FACTS VIEWS VIS OBGY, V5, P292; Filippone MG, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-21; Haley J, 2016, ONCOTARGET, V7, P32810, DOI 10.18632/oncotarget.9053; Hanrahan AJ, 2014, CANCER DISCOV, V2, P56; Hilliard TS, 2013, INT J MOL SCI, V14, P4762, DOI 10.3390/ijms14034762; Karthikeyan S, 2016, ONCOTARGET, V7, P69871, DOI 10.18632/oncotarget.11499; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kurman RJ, 2011, AM J SURG PATHOL, V35, P1605, DOI 10.1097/PAS.0b013e318229449f; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laury AR, 2011, AM J SURG PATHOL, V35, P1759, DOI 10.1097/PAS.0b013e318233b0f7; Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106; Martins FC, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0526-8; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Modi DA, 2017, ONCOGENE, V36, P3015, DOI 10.1038/onc.2016.455; Mullany LK, 2012, ENDOCRINOLOGY, V153, P1585, DOI 10.1210/en.2011-2121; Ng A, 2015, NAT REV MOL CELL BIO, V16, P625, DOI 10.1038/nrm4056; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Prunskaite-Hyyrylainen R, 2016, HUM MOL GENET, V25, P1059, DOI 10.1093/hmg/ddv621; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Quartuccio SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065067; ROBEY SS, 1989, INT J GYNECOL PATHOL, V8, P214, DOI 10.1097/00004347-198909000-00004; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16; Seidman JD, 2011, GYNECOL ONCOL, V120, P470, DOI 10.1016/j.ygyno.2010.11.020; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Shield-Artin KL, 2012, PROTEOM CLIN APPL, V6, P170, DOI 10.1002/prca.201100008; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sukerkar PA, 2011, BIOCONJUGATE CHEM, V22, P2304, DOI 10.1021/bc2003555; Tada M, 2000, DEVELOPMENT, V127, P2227; Torban E, 2006, J BIOL CHEM, V281, P12705, DOI 10.1074/jbc.M513181200; Vang R, 2013, HISTOPATHOLOGY, V62, P44, DOI 10.1111/his.12046; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Yang-Hartwich Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06116; Zhai YL, 2017, J PATHOL, V243, P16, DOI 10.1002/path.4927; Zhang L, 2016, ONCOGENE, V35, P5010, DOI 10.1038/onc.2016.53	54	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1976	1990		10.1038/s41388-017-0097-8	http://dx.doi.org/10.1038/s41388-017-0097-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367766	Green Accepted			2022-12-28	WOS:000429899400003
J	Tan, EHP; Sng, MK; How, ISB; Chan, JSK; Chen, JP; Tan, CK; Wahli, W; Tan, NS				Tan, Eddie Han Pin; Sng, Ming Keat; How, Ivan Shun Bo; Chan, Jeremy Soon Kiat; Chen, Jiapeng; Tan, Chek Kun; Wahli, Walter; Tan, Nguan Soon			ROS release by PPAR beta/delta-null fibroblasts reduces tumor load through epithelial antioxidant response	ONCOGENE			English	Article							ACTIVATED-RECEPTOR-DELTA; COLORECTAL-CANCER; COLON CARCINOGENESIS; MEDIATED INHIBITION; OXIDATIVE STRESS; IMMUNE CELLS; LUNG INJURY; INFLAMMATION; MICE; GAMMA	Tumor stroma has an active role in the initiation, growth, and propagation of many tumor types by secreting growth factors and modulating redox status of the microenvironment. Although PPAR beta/delta in fibroblasts was shown to modulate oxidative stress in the wound microenvironment, there has been no evidence of a similar effect in the tumor stroma. Here, we present evidence of oxidative stress modulation by intestinal stromal PPAR beta/delta, using a FSPCre-Pparb/d(-/-) mouse model and validated it with immortalized cell lines. The FSPCre-Pparb/d(-/-) mice developed fewer intestinal polyps and survived longer when compared with Pparb/d(fl/fl) mice. The pre-treatment of FSPCre-Pparb/d(-/-) and Pparb/d(fl/fl) with antioxidant N-acetyl-cysteine prior DSS-induced tumorigenesis resulted in lower tumor load. Gene expression analyses implicated an altered oxidative stress processes. Indeed, the FSPCre-Pparb/d(-/-) intestinal tumors have reduced oxidative stress than Pparb/d(fl/fl) tumors. Similarly, the colorectal cancer cells and human colon epithelial cells also experienced lower oxidative stress when co-cultured with fibroblasts depleted of PPAR beta/delta expression. Therefore, our results establish a role for fibroblast PPAR beta/delta in epithelial-mesenchymal communication for ROS homeostasis.	[Tan, Eddie Han Pin; Sng, Ming Keat; How, Ivan Shun Bo; Chan, Jeremy Soon Kiat; Tan, Nguan Soon] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore; [Sng, Ming Keat; Chen, Jiapeng; Tan, Chek Kun; Wahli, Walter; Tan, Nguan Soon] Nanyang Technol Univ, Lee Kong Chian Sch Med, Novena Campus, Singapore, Singapore; [Wahli, Walter] INRA ToxAlim, UMR1331, Chemin Tournefeuille, Toulouse 3, France; [Wahli, Walter] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland; [Tan, Nguan Soon] Inst Mol & Cell Biol, Proteos, Agcy Sci Technol & Res, Singapore, Singapore; [Tan, Nguan Soon] KK Womens & Children Hosp, KK Res Ctr, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; INRAE; University of Lausanne; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Tan, EHP; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore.; Tan, NS (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Novena Campus, Singapore, Singapore.; Tan, NS (corresponding author), Inst Mol & Cell Biol, Proteos, Agcy Sci Technol & Res, Singapore, Singapore.; Tan, NS (corresponding author), KK Womens & Children Hosp, KK Res Ctr, Singapore, Singapore.	HTAN024@e.ntu.edu.sg; nstan@ntu.edu.sg	Wahli, Walter/I-3194-2019; Tan, Nguan Soon/A-2220-2011; Wahli, Walter/B-1398-2009; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Wahli, Walter/0000-0002-5966-9089; Tan, Eddie Han Pin/0000-0002-4475-0255; Sng, Ming Keat/0000-0002-5529-4371	Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2 [MOE2014-T2-1-012]; Academic Research Fund Tier 1 [RG134/15]; Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant	Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2(Ministry of Education, Singapore); Academic Research Fund Tier 1; Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant(Nanyang Technological University)	This work was supported by Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2014-T2-1-012) and Academic Research Fund Tier 1 (RG134/15) to NST, and by the Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant to WW.	Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Borland MG, 2017, TOXICOL SCI, V159, P436, DOI 10.1093/toxsci/kfx147; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chaiswing L, 2010, ANTIOXID REDOX SIGN, V13, P449, DOI 10.1089/ars.2009.3020; Chan JSK, 2018, ONCOGENE, V37, P160, DOI 10.1038/onc.2017.319; Chan JSK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.492; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Iglesias J, 2012, J CLIN INVEST, V122, P4105, DOI 10.1172/JCI42127; Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010; Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371; Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028; Kilgore KS, 2008, CURR OPIN INVEST DR, V9, P463; Kim ER, 2014, WORLD J GASTROENTERO, V20, P9872, DOI 10.3748/wjg.v20.i29.9872; Kim HJ, 2011, J BIOL CHEM, V286, P44585, DOI 10.1074/jbc.M111.222562; Kim MY, 2012, BIOCHEM PHARMACOL, V84, P1627, DOI 10.1016/j.bcp.2012.09.008; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu J, 2011, PPAR RES, V2011, DOI 10.1155/2011/372854; Liu X, 2016, GENE DEV, V30, P1943, DOI 10.1101/gad.283499.116; Manda G, 2015, REDOX BIOL, V5, P347, DOI 10.1016/j.redox.2015.06.014; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Osterreicher CH, 2011, P NATL ACAD SCI USA, V108, P308, DOI 10.1073/pnas.1017547108; Okada H, 2003, KIDNEY INT, V64, P1722, DOI 10.1046/j.1523-1755.2003.00290.x; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Park EY, 2004, CANCER RES, V64, P3701, DOI 10.1158/0008-5472.CAN-03-3924; Peters JM, 2015, TRENDS ENDOCRIN MET, V26, P595, DOI 10.1016/j.tem.2015.09.004; Pickup MW, 2015, MOL ONCOL, V9, P179, DOI 10.1016/j.molonc.2014.08.004; Pinchuk I V, 2010, Curr Gastroenterol Rep, V12, P310, DOI 10.1007/s11894-010-0135-y; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramsey MR, 2006, NAT CELL BIOL, V8, P1213, DOI 10.1038/ncb1106-1213; Reddy RC, 2010, AM J RESP CRIT CARE, V182, P134, DOI 10.1164/rccm.201004-0457ED; Roncoroni L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-40; Saw CLL, 2011, EXPERT OPIN THER TAR, V15, P281, DOI 10.1517/14728222.2011.553602; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tan NS, 2016, PROG LIPID RES, V64, P98, DOI 10.1016/j.plipres.2016.09.001; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Udagawa T, 2010, CURR OPIN PHARMACOL, V10, P369, DOI 10.1016/j.coph.2010.06.010; Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103; Wang DZ, 2014, P NATL ACAD SCI USA, V111, P7084, DOI 10.1073/pnas.1324233111; Wang XL, 2015, J CONTROL RELEASE, V197, P138, DOI 10.1016/j.jconrel.2014.11.001; Yu SQ, 2012, PROSTATE, V72, P437, DOI 10.1002/pros.21445; Zhang WB, 2017, CARCINOGENESIS, V38, P748, DOI 10.1093/carcin/bgx035; ZUO X, 2014, JNCI-J NATL CANCER I, V106, P52, DOI DOI 10.1093/JNCI/DJU052; Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078	54	10	10	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2067	2078		10.1038/s41388-017-0109-8	http://dx.doi.org/10.1038/s41388-017-0109-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367760	Green Published, hybrid			2022-12-28	WOS:000429899400009
J	Peta, E; Sinigaglia, A; Masi, G; Di Camillo, B; Grassi, A; Trevisan, M; Messa, L; Loregian, A; Manfrin, E; Brunelli, M; Martignoni, G; Palu, G; Barzon, L				Peta, Elektra; Sinigaglia, Alessandro; Masi, Giulia; Di Camillo, Barbara; Grassi, Angela; Trevisan, Marta; Messa, Lorenzo; Loregian, Arianna; Manfrin, Erminia; Brunelli, Matteo; Martignoni, Guido; Palu, Giorgio; Barzon, Luisa			HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; EXPRESSION; MIR-146A; CELLS; CONTRIBUTES; APOPTOSIS; MIR-34A; MICE; DYSREGULATION	Persistent infection by high-risk human papillomaviruses (HPVs) is associated with the development of cervical cancer and a subset of anogenital and head and neck squamous cell carcinomas. Abnormal expression of cellular microRNAs (miRNAs) plays an important role in the development of cancer, including HPV-related tumors. In this study, we demonstrated that miR-146a-5p was down-regulated by E6 and, less efficiently, by E7 of high-risk HPV16 in keratinocytes and the presence of low levels of this miRNA in cervical carcinoma cell lines and in high-risk HPV-positive cervical specimens. Downregulation of miR-146a-5p was mediated at least in part by the transcription repressor c-MYC, through binding sites in the miR-146a promoter. Overexpression of miR-146a-5p significantly inhibited proliferation and migration of keratinocytes and cervical cancer cells. The histone demethylase KDM2B was validated as a new direct target of miR-146a-5p and two putative binding sites for miR-146a-5p were identified in its 3'UTR sequence. Western blot analysis and immunohistochemistry showed that KDM2B was overexpressed in HPV16 E6/E7-positive keratinocytes, in cervical cancer cell lines, and in a subset of invasive cervical carcinomas and HPV-positive laryngeal squamous cell carcinomas. In these tumors, KDM2B overexpression was associated with c-MYC copy number gain. In vitro, silencing of KDM2B inhibited proliferation of cervical cancer cells. In conclusion, this study identified a novel player, the hystone demethylase KDM2B, in HPV-mediated tumorigenesis. E6 and, less efficiently, E7 of high-risk HPV16 up-regulated KDM2B expression in human keratinocytes through a pathway involving overexpression of c-MYC, which in turn downregulated miR-146a-5p.	[Peta, Elektra; Sinigaglia, Alessandro; Masi, Giulia; Trevisan, Marta; Messa, Lorenzo; Loregian, Arianna; Palu, Giorgio; Barzon, Luisa] Univ Padua, Dept Mol Med, Padua, Italy; [Di Camillo, Barbara] Univ Padua, Dept Informat Engn, Padua, Italy; [Grassi, Angela] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Manfrin, Erminia; Brunelli, Matteo; Martignoni, Guido] AOUI Hosp Trust Verona, Dept Diagnost & Publ Hlth, Anat Pathol, Verona, Italy	University of Padua; University of Padua; University of Padua; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Barzon, L (corresponding author), Univ Padua, Dept Mol Med, Padua, Italy.	luisa.barzon@unipd.it	Brunelli, Matteo/AAA-7679-2019; Barzon, Luisa/K-7961-2016; Masi, Giulia/K-1577-2016; Grassi, Angela/N-3085-2013; TREVISAN, MARTA/K-6591-2016	Barzon, Luisa/0000-0003-0720-8456; Masi, Giulia/0000-0001-9138-9186; Grassi, Angela/0000-0002-8313-8384; sinigaglia, alessandro/0000-0002-2386-1757; LOREGIAN, ARIANNA/0000-0002-8900-861X; Messa, Lorenzo/0000-0001-6850-0034; BRUNELLI, Matteo/0000-0002-3832-2676; TREVISAN, MARTA/0000-0002-3148-7240	Italian Ministry for Education, University, and Research [2010Z9FLM8]; University of Padova [60A07-3380/10, 60A07-1431/11, 60A07-0183/12, CPDA101217]	Italian Ministry for Education, University, and Research(Ministry of Education, Universities and Research (MIUR)); University of Padova	The authors thank Dr. A Remo (Pathology Unit, Hospital "Mater Salutis" Legnago, Verona, Italy) for providing histological tissue samples. This work was supported by the Italian Ministry for Education, University, and Research (grant 2010Z9FLM8 to G Martignoni and GP); the University of Padova (grants 60A07-3380/10, 1431/11, and 0183/12 to LB; grant CPDA101217 to BD and LB).	Barzon L, 2014, AM J PATHOL, V184, P3376, DOI 10.1016/j.ajpath.2014.08.004; Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gunasekharan V, 2013, J VIROL, V87, P6037, DOI 10.1128/JVI.00153-13; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Honegger A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004712; Hong XH, 2016, ONCOTARGET, V7, P22092, DOI 10.18632/oncotarget.8020; Hu XX, 2010, CANCER RES, V70, P1441, DOI 10.1158/0008-5472.CAN-09-3289; Kottakis F, 2014, CANCER RES, V74, P3935, DOI 10.1158/0008-5472.CAN-13-2733; Labbaye C, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-13; Lajer CB, 2012, BRIT J CANCER, V106, P1526, DOI 10.1038/bjc.2012.109; Li SH, 2017, NEUROCHEM INT, V107, P156, DOI 10.1016/j.neuint.2017.01.011; Liang GY, 2012, NAT CELL BIOL, V14, P457, DOI 10.1038/ncb2483; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Peta E, 2017, HUM PATHOL, V61, P33, DOI 10.1016/j.humpath.2016.10.019; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Punj V, 2010, ONCOGENE, V29, P1835, DOI 10.1038/onc.2009.460; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Tzatsos A, 2011, J BIOL CHEM, V286, P33061, DOI 10.1074/jbc.M111.257667; Tzatsos A, 2009, P NATL ACAD SCI USA, V106, P2641, DOI 10.1073/pnas.0813139106; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Wang T, 2011, CELL STEM CELL, V9, P575, DOI 10.1016/j.stem.2011.10.005; WANG XH, 2008, PLOS ONE, V3, DOI DOI 10.1371/JOURNAL.PONE.0002557; Wang XH, 2011, INT J CANCER, V129, P1362, DOI 10.1002/ijc.25800; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Zandberg DP, 2013, CA-CANCER J CLIN, V63, P57, DOI 10.3322/caac.21167; Zhang RY, 2016, INT J CANCER, V138, P1163, DOI 10.1002/ijc.29872; Zhao JL, 2013, ELIFE, V2, DOI 10.7554/eLife.00537; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108	50	34	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1654	1668		10.1038/s41388-017-0083-1	http://dx.doi.org/10.1038/s41388-017-0083-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335520				2022-12-28	WOS:000428626700008
J	Zhong, YC; Yang, S; Wang, W; Wei, PP; He, SW; Ma, HT; Yang, J; Wang, Q; Cao, LQ; Xiong, W; Zhou, M; Li, GY; Shuai, CJ; Peng, SP				Zhong, Yancheng; Yang, Sheng; Wang, Wei; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Wang, Qian; Cao, Lanqin; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Shuai, Cijun; Peng, Shuping			The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; STEM-CELLS; RHO-KINASE; ROCK2; RNA; EXPRESSION; REGULATOR; PROMOTES; PROLIFERATION	Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignant diseases, however, the molecular mechanism of ovarian cancer is not well defined. Previous studies have found that RNA binding protein Lin28A is a key factor of maintain the pluripotency of stem cells, and it is positively correlated with the degree of several cancers (breast, prostate, liver cancer, etc). Our previous study shows that Lin28A is highly expressed in OC tissues and is involved in the regulation of OC cell biological behavior. In this study, we confirmed that high expression of Lin28A promoted the survival, invasion, metastasis, and inhibited the apoptosis of OC cells. Lin28A interacts with Rho associated coiled-coil containing protein kinase2 (ROCK2) but not ROCK1 and upregulates the expression of ROCK2 in OC cells. The binding sites of each other were identified by truncated mutations and Immuno-precipitaion (IP) assay. After knock down of ROCK2 in cells with high expression of Lin28A, the survival, invasion, metastasis was significantly inhibited and early apoptosis was increased in OC cells and OC xenograft in nude mice. Our experimental data also showed that knock down of ROCK2 but not ROCK1 inhibited the invasion by decreasing the expression of N-cadherin, Slug, beta-catenin and increasing ZO-1 expression. Simultaneously, knock down of ROCK2 induced cell apoptosis by increasing cleaved Caspase-9, cleaved Caspase-7, and cleaved Caspase-3. Taken together, Lin28A regulated the biological behaviors in OC cells through ROCK2 and the interaction of Lin28A/ROCK2 may be a new target for diagnosis and gene therapy of OC.	[Zhong, Yancheng; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Peng, Shuping] Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Zhong, Yancheng; Wei, Pingpin; He, Shiwei; Ma, Haotian; Yang, Juan; Xiong, Wei; Zhou, Ming; Li, Guiyuan; Peng, Shuping] Cent South Univ, Affiliated Tumor Hosp, Xiangya Sch Med, Sch Basic Med Sci, Changsha, Hunan, Peoples R China; [Yang, Sheng] Hongkong Univ, Human Reprod Ctr, Shenzhen Hosp, Haiyuan 1 Rd, Shenzhen, Peoples R China; [Wang, Wei] Jining Med Univ, Pathol Dept, Jining, Shandong, Peoples R China; [Wang, Qian; Cao, Lanqin] Cent South Univ, Dept Gynecol, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Shuai, Cijun] Jiangxi Univ Sci & Technol, Ganzhou 341000, Peoples R China	Central South University; Central South University; Jining Medical University; Central South University; Jiangxi University of Science & Technology	Peng, SP (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China.; Peng, SP (corresponding author), Cent South Univ, Affiliated Tumor Hosp, Xiangya Sch Med, Sch Basic Med Sci, Changsha, Hunan, Peoples R China.	shuping@csu.edu.cn	Shuai, Cijun/AAC-9740-2019	Shuai, Cijun/0000-0002-2029-5112	Natural Science Foundation of China [81572577]; Program of Introducing Talents of Discipline to Universities [111-2-12]; Project of Innovation-driven Plan of Central South University [2016CX023]; Hunan Province Natural Science Foundation of China [2016JJ1027]; Fundamental Research Funds for the Central Universities of Central South University [2017zzts371]; Open-End Fund for the Valuable and Precision Instruments of Central South University; High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Introducing Talents of Discipline to Universities(Ministry of Education, China - 111 Project); Project of Innovation-driven Plan of Central South University; Hunan Province Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central Universities of Central South University; Open-End Fund for the Valuable and Precision Instruments of Central South University; High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University	This work was supported by Natural Science Foundation of China (81572577), Program of Introducing Talents of Discipline to Universities (111-2-12), the Project of Innovation-driven Plan of Central South University (2016CX023), the Hunan Province Natural Science Foundation of China (2016JJ1027), the Fundamental Research Funds for the Central Universities of Central South University (2017zzts371), the Open-End Fund for the Valuable and Precision Instruments of Central South University. We thank the Professor Li zheng and Dr. Ge Xiaolu for their help in Mass Spectrometry identification. We also want to gratitude the High Resolution Mass Spectrometry Laboratory of Advanced Research Center in Central South University for the technological assistance in proteomic examinations.	Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Bhuiyan MIH, 2013, NEUROSCIENCE, V248, P448, DOI 10.1016/j.neuroscience.2013.06.023; Boku S, 2013, BRAIN RES, V1492, P7, DOI 10.1016/j.brainres.2012.11.034; Cheng K, 2013, J CLIN ONCOL, V31; Grieco A, 2013, MOL CELL ENDOCRINOL, V365, P241, DOI 10.1016/j.mce.2012.10.025; Hsu KF, 2015, BRIT J CANCER, V113, P414, DOI 10.1038/bjc.2015.254; Huang YQ, 2012, WIRES RNA, V3, P483, DOI 10.1002/wrna.1112; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Iizuka M, 2012, CELL STRUCT FUNCT, V37, P155, DOI 10.1247/csf.12018; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Kalender ME, 2009, CANCER RES, V69, p658S; Kalender ME, 2010, ONCOL RES, V18, P583, DOI 10.3727/096504010X12767359113767; Liu TD, 2012, EXP CELL RES, V318, P1994, DOI 10.1016/j.yexcr.2012.04.017; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nam Y, 2011, CELL, V147, P1080, DOI 10.1016/j.cell.2011.10.020; Olson MF, 2008, CURR OPIN CELL BIOL, V20, P242, DOI 10.1016/j.ceb.2008.01.002; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200; Pisu M, 2017, GYNECOL ONCOL, V147, P433, DOI 10.1016/j.ygyno.2017.08.028; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Rauh-Hain JA, 2013, GYNECOL ONCOL, V129, P63, DOI 10.1016/j.ygyno.2013.01.009; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Song GL, 2016, INT J ONCOL, V49, P646, DOI 10.3892/ijo.2016.3539; Vigil D, 2012, CANCER RES, V72, P5338, DOI 10.1158/0008-5472.CAN-11-2373; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang QM, 2012, EXPERT OPIN THER TAR, V16, P1013, DOI 10.1517/14728222.2012.715149; Wertel Iwona, 2017, Wiad Lek, V70, P74; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Xue DB, 2011, HISTOPATHOLOGY, V59, P452, DOI 10.1111/j.1365-2559.2011.03949.x; Yap TA, 2012, CLIN CANCER RES, V18, P3912, DOI 10.1158/1078-0432.CCR-11-3313; Yuan RF, 2014, CANCER RES, V74, P5287, DOI 10.1158/0008-5472.CAN-14-0284; Yugaw T, 2013, MOL CELL BIOL, V33, P4434, DOI 10.1128/MCB.00577-13; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607; Zhong YC, 2016, INT J GYNECOL CANCER, V26, P1564, DOI 10.1097/IGC.0000000000000828; Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199	44	18	18	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1381	1397		10.1038/s41388-018-0512-9	http://dx.doi.org/10.1038/s41388-018-0512-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30266988	Green Published, hybrid			2022-12-28	WOS:000459945800002
J	Rubinstein, TA; Shahmoon, S; Zigmond, E; Etan, T; Merenbakh-Lamin, K; Pasmanik-Chor, M; Har-Zahav, G; Barshack, I; Vainer, GW; Skalka, N; Rosin-Arbesfeld, R; Varol, C; Rubinek, T; Wolf, I				Rubinstein, Tammi Arbel; Shahmoon, Shiri; Zigmond, Ehud; Etan, Tal; Merenbakh-Lamin, Keren; Pasmanik-Chor, Metsada; Har-Zahav, Gil; Barshack, Iris; Vainer, Gilad W.; Skalka, Nir; Rosin-Arbesfeld, Rina; Varol, Chen; Rubinek, Tami; Wolf, Ido			Klotho suppresses colorectal cancer through modulation of the unfolded protein response	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTS ENCODING MEMBRANE; TUMOR-SUPPRESSOR; COLON-CANCER; BREAST-CANCER; BETA-CATENIN; GENE; EXPRESSION; METHYLATION; GROWTH	Klotho is an anti-aging transmembrane protein, which can be shed and function as a hormone. Accumulating data indicate klotho as a tumor suppressor in a wide array of malignancies and indicate the subdomain KL1 as the active region of the protein. We aimed to study the role of klotho as a tumor suppressor in colorectal cancer. Bioinformatics analyses of TCGA datasets indicated reduced klotho mRNA levels in human colorectal cancer, along with negative regulation of klotho expression by hypermethylation of the promoter and 1st exon, and hypomethylation of an area within the gene. Overexpression or treatment with klotho or KL1 inhibited proliferation of colorectal cancer cells in vitro. The in vivo activity of klotho and KL1 was examined using two models recapitulating development of tumors in the normal colonic environment of immune-competent mice. Treatment with klotho inhibited formation of colon polyps induced by the carcinogen azoxymethane, and KL1 treatment slowed growth of orthotopically-implanted colorectal tumors. Gene expression array revealed that klotho and KL1 expression enhanced the unfolded protein response (UPR) and this was further established by increased levels of spliced XBP1, GRP78 and phosphorylated-eIF2 alpha. Furthermore, attenuation of the UPR partially abrogated klotho tumor suppressor activity. In conclusion, this study indicates klotho as a tumor suppressor in colorectal cancer and identifies, for the first time, the UPR as a pathway mediating klotho activities in cancer. These data suggest that administration of exogenous klotho or KL1 may serve as a novel strategy for prevention and treatment of colorectal cancer.	[Rubinstein, Tammi Arbel; Shahmoon, Shiri; Etan, Tal; Merenbakh-Lamin, Keren; Rubinek, Tami; Wolf, Ido] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Rubinstein, Tammi Arbel; Shahmoon, Shiri; Zigmond, Ehud; Etan, Tal; Har-Zahav, Gil; Barshack, Iris; Skalka, Nir; Rosin-Arbesfeld, Rina; Rubinek, Tami; Wolf, Ido] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Zigmond, Ehud; Varol, Chen] Tel Aviv Sourasky Med Ctr, Res Ctr Digest Tract & Liver Dis, Tel Aviv, Israel; [Pasmanik-Chor, Metsada] Tel Aviv Univ, Fac Life Sci, Bioinformat Unit, Tel Aviv, Israel; [Har-Zahav, Gil] Safra Childrens Hosp, Dept Pediat Surg, Sheba Med Ctr, Tel Hashomer, Israel; [Barshack, Iris] Sheba Med Ctr, Inst Pathol, Tel Hashomer, Israel; [Vainer, Gilad W.] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel; [Varol, Chen] Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Wolf, I (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Wolf, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	wolf-i@inter.net.il	Varol, Chen/AAW-4202-2021; Vainer, Gilad W./ABH-8314-2020; Varol, Chen/ABH-6487-2020	Vainer, Gilad W./0000-0002-8828-8138; 				Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Banerjee S, 2013, CELL PHYSIOL BIOCHEM, V31, P659, DOI 10.1159/000350085; Berger E, 2011, BIOCHEM BIOPH RES CO, V409, P610, DOI 10.1016/j.bbrc.2011.05.043; Camilli TC, 2011, PIGM CELL MELANOMA R, V24, P175, DOI 10.1111/j.1755-148X.2010.00792.x; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Guda K, 2007, CYTOTECHNOLOGY, V54, P85, DOI 10.1007/s10616-007-9083-2; Hanaoka M, 2018, J GASTROENTEROL, V53, P631, DOI 10.1007/s00535-017-1387-1; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Landgraf M, 2018, TRENDS BIOTECHNOL, V36, P242, DOI 10.1016/j.tibtech.2017.12.001; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Li XX, 2017, ONCOGENE, V36, P6738, DOI 10.1038/onc.2017.284; Li XX, 2014, INT J ONCOL, V45, P611, DOI 10.3892/ijo.2014.2430; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Liu QF, 2015, IRAN J KIDNEY DIS, V9, P291; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; Maas NL, 2015, CLIN CANCER RES, V21, P675, DOI 10.1158/1078-0432.CCR-13-3239; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5; Peleg S, 2010, AM J PHYSIOL-GASTR L, V299, pG593, DOI 10.1152/ajpgi.00193.2010; Piton N, 2016, VIRCHOWS ARCH, V469, P145, DOI 10.1007/s00428-016-1961-6; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; Skalka N, 2013, ONCOGENE, V32, P2836, DOI 10.1038/onc.2012.308; Snaebjornsson P, 2017, INT J CANCER, V141, P531, DOI 10.1002/ijc.30766; Song S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082968; Sun HD, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0717-0; Tang X, 2016, DIS ESOPHAGUS, V29, P207, DOI 10.1111/dote.12289; Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wang LJ, 2011, AM J CANCER RES, V1, P111; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wilhelm-Benartzi CS, 2013, BRIT J CANCER, V109, P1394, DOI 10.1038/bjc.2013.496; Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yang WJ, 2014, TUMOR BIOL, V35, P8267, DOI 10.1007/s13277-014-2100-0; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Zigmond E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028858; Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291	50	25	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					794	807		10.1038/s41388-018-0489-4	http://dx.doi.org/10.1038/s41388-018-0489-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30232408				2022-12-28	WOS:000458006300003
J	Merilahti, JAM; Elenius, K				Merilahti, Johannes A. M.; Elenius, Klaus			Gamma-secretase-dependent signaling of receptor tyrosine kinases	ONCOGENE			English	Review							REGULATED INTRAMEMBRANE PROTEOLYSIS; ALPHA-CONVERTING-ENZYME; GROWTH-FACTOR RECEPTOR; INTRACELLULAR DOMAIN; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; DOWN-REGULATION; ERBB4 ISOFORM; CLEAVAGE	Human genome harbors 55 receptor tyrosine kinases (RTK). At least half of the RTKs have been reported to be cleaved by gamma-secretase-mediated regulated intramembrane proteolysis. The two-step process involves releasing the RTK ectodomain to the extracellular space by proteolytic cleavage called shedding, followed by cleavage in the RTK transmembrane domain by the gamma-secretase complex resulting in release of a soluble RTK intracellular domain. This intracellular domain, including the tyrosine kinase domain, can in turn translocate to various cellular compartments, such as the nucleus or proteasome. The soluble intracellular domain may interact with transcriptional regulators and other proteins to induce specific effects on cell survival, proliferation, and differentiation, establishing an additional signaling mode for the cleavable RTKs. On the other hand, the same process can facilitate RTK turnover and proteasomal degradation. In this review we focus on the regulation of RTK shedding and gamma-secretase cleavage, as well as signaling promoted by the soluble RTK ICDs. In addition, therapeutic implications of increased knowledge on RTK cleavage on cancer drug development are discussed.	[Merilahti, Johannes A. M.; Elenius, Klaus] Univ Turku, Inst Biomed, Turku 20520, Finland; [Merilahti, Johannes A. M.; Elenius, Klaus] Univ Turku, Med Res Lab, Turku 20520, Finland; [Merilahti, Johannes A. M.] Univ Turku, Turku Doctoral Programme Mol Med, Turku 20520, Finland; [Elenius, Klaus] Turku Univ Hosp, Dept Oncol, Turku 20520, Finland	University of Turku; University of Turku; University of Turku; University of Turku	Elenius, K (corresponding author), Univ Turku, Inst Biomed, Turku 20520, Finland.; Elenius, K (corresponding author), Univ Turku, Med Res Lab, Turku 20520, Finland.; Elenius, K (corresponding author), Turku Univ Hosp, Dept Oncol, Turku 20520, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021	Elenius, Klaus/0000-0001-5700-0827; Merilahti, Johannes/0000-0002-9113-5175	Academy of Finland; Cancer Foundation Finland; Sigrid Juselius Foundation; Turku University Central Hospital; Orion Research Foundation; K. Albin Johansson foundation; Jenny and Antti Wihuri Foundation; Finnish Cultural Foundation	Academy of Finland(Academy of Finland); Cancer Foundation Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Orion Research Foundation; K. Albin Johansson foundation; Jenny and Antti Wihuri Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science)	This work was supported by the Academy of Finland, Cancer Foundation Finland, Sigrid Juselius Foundation, Turku University Central Hospital, Orion Research Foundation, K. Albin Johansson foundation, Jenny and Antti Wihuri Foundation, and Finnish Cultural Foundation.	Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391; Adrain C, 2012, SCIENCE, V335, P225, DOI 10.1126/science.1214400; Ancot F, 2009, ONCOGENE, V28, P2185, DOI 10.1038/onc.2009.88; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bae SY, 2015, ONCOTARGET, V6, P10146, DOI 10.18632/oncotarget.3380; Bax DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200; Bernhofer M, 2016, PROTEINS, V84, P1706, DOI 10.1002/prot.25155; Bolduc DM, 2016, P NATL ACAD SCI USA, V113, pE509, DOI 10.1073/pnas.1512952113; Bonacchi A, 2008, HISTOL HISTOPATHOL, V23, P327, DOI 10.14670/HH-23.327; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200; Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164; Carpenter G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008979; Chang W-H, 2017, P NATL ACAD SCI USA, V2017, P15772; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Chen AC, 2015, J CELL BIOL, V211, P1157, DOI 10.1083/jcb.201502001; Chen MK, 2015, FEBS J, V282, P3693, DOI 10.1111/febs.13342; Christova Y, 2013, EMBO REP, V14, P884, DOI 10.1038/embor.2013.128; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Degnin CR, 2011, MOL BIOL CELL, V22, P3861, DOI 10.1091/mbc.E11-01-0080; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; Dombernowsky SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8518; Du Z, 2018, MOL CANCER, V17, P1; Dusterhoft S, 2015, BIOCHEMISTRY-US, V54, P5791, DOI 10.1021/acs.biochem.5b00497; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; Fauvel B, 2014, MABS-AUSTIN, V6, P838, DOI 10.4161/mabs.29089; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Fukumori A, 2016, EMBO J, V35, P1628, DOI 10.15252/embj.201694151; Funamoto S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3529; Gilmore-Hebert M, 2010, MOL CANCER RES, V8, P1388, DOI 10.1158/1541-7786.MCR-10-0042; Glenn G, 2008, FEBS LETT, V582, P911, DOI 10.1016/j.febslet.2008.02.029; Glenn G, 2007, FEBS LETT, V581, P5377, DOI 10.1016/j.febslet.2007.10.031; Golde TE, 2013, BBA-BIOMEMBRANES, V1828, P2898, DOI 10.1016/j.bbamem.2013.06.005; Gooz P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033350; Goth CK, 2015, P NATL ACAD SCI USA, V112, P14623, DOI 10.1073/pnas.1511175112; Grieve AG, 2017, ELIFE, V6, DOI 10.7554/eLife.23968; Grotzinger J, 2017, BBA-MOL CELL RES, V1864, P2088, DOI 10.1016/j.bbamcr.2017.05.024; Guaiquil VH, 2010, J MOL MED, V88, P497, DOI 10.1007/s00109-010-0591-8; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Halford MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075447; Hemming ML, 2008, PLOS BIOL, V6, P2314, DOI 10.1371/journal.pbio.0060257; Hoeing K, 2011, BBA-MOL CELL RES, V1813, P480, DOI 10.1016/j.bbamcr.2010.12.017; Hollmen M, 2009, ONCOGENE, V28, P1309, DOI 10.1038/onc.2008.481; Hollmen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039413; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Inoue E, 2009, J CELL BIOL, V185, P551, DOI 10.1083/jcb.200809151; Iwamoto R, 2017, J CELL SCI, V130, P1321, DOI 10.1242/jcs.196618; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kamp F, 2015, BIOPHYS J, V108, P1229, DOI 10.1016/j.bpj.2014.12.045; Kasuga K, 2007, BIOCHEM BIOPH RES CO, V360, P90, DOI 10.1016/j.bbrc.2007.06.022; Knittle AM, 2017, J BIOL CHEM, V292, P19890, DOI 10.1074/jbc.M117.794271; Kreitman M, 2018, FEBS LETT, V592, P2199, DOI 10.1002/1873-3468.13095; Lai C, 2004, BIOCHEM BIOPH RES CO, V314, P535, DOI 10.1016/j.bbrc.2003.12.131; Langosch D, 2015, TRENDS BIOCHEM SCI, V40, P318, DOI 10.1016/j.tibs.2015.04.001; Laurent SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8333; Li X, 2015, P NATL ACAD SCI USA, V112, P6080, DOI 10.1073/pnas.1505649112; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Lomize AL, 2017, NUCLEIC ACIDS RES, V45, pD250, DOI 10.1093/nar/gkw712; Lorenzen I, 2016, SCI REP-UK, V6, DOI 10.1038/srep35067; Lu YZ, 2017, FASEB J, V31, P1382, DOI 10.1096/fj.201600702R; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Maretzky T, 2013, P NATL ACAD SCI USA, V110, P11433, DOI 10.1073/pnas.1302553110; Marron MB, 2007, J BIOL CHEM, V282, P30509, DOI 10.1074/jbc.M702535200; McElroy B, 2007, BIOCHEM BIOPH RES CO, V358, P1136, DOI 10.1016/j.bbrc.2007.05.062; McIlwain DR, 2012, SCIENCE, V335, P229, DOI 10.1126/science.1214448; Meckler X, 2016, J BIOL CHEM, V291, P12821, DOI 10.1074/jbc.M115.708297; Merilahti JAM, 2017, MOL BIOL CELL, V28, P3123, DOI 10.1091/mbc.E17-04-0261; Miller MA, 2017, CLIN CANCER RES, V23, P623, DOI 10.1158/1078-0432.CCR-16-0869; Miller MA, 2016, CANCER DISCOV, V6, P382, DOI 10.1158/2159-8290.CD-15-0933; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233; Murphy G, 2009, SEMIN CELL DEV BIOL, V20, P138, DOI 10.1016/j.semcdb.2008.09.004; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Na HW, 2012, J BIOL CHEM, V287, P25001, DOI 10.1074/jbc.M112.348904; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Orme JJ, 2016, CLIN IMMUNOL, V169, P58, DOI 10.1016/j.clim.2016.05.011; Osenkowski P, 2008, J BIOL CHEM, V283, P22529, DOI 10.1074/jbc.M801925200; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Paatero I, 2012, J BIOL CHEM, V287, P9659, DOI 10.1074/jbc.M111.299537; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Raikwar NS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112794; Reusch Petra, 2001, Angiogenesis, V4, P123, DOI 10.1023/A:1012226627813; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sannerud R, 2016, CELL, V166, P193, DOI 10.1016/j.cell.2016.05.020; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schauenburg L, 2018, SCI REP, V8, P1; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Sommer A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11523; Srinivasan R, 2000, CANCER RES, V60, P1483; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Sundvall M, 2012, J BIOL CHEM, V287, P23216, DOI 10.1074/jbc.M111.335927; Sundvall M, 2010, MOL BIOL CELL, V21, P4275, DOI 10.1091/mbc.E10-04-0332; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tejeda GS, 2016, J PATHOL, V238, P627, DOI 10.1002/path.4684; Thor AD, 2009, AM J PATHOL, V175, P1802, DOI 10.2353/ajpath.2009.090204; Thorp E, 2011, J BIOL CHEM, V286, P33335, DOI 10.1074/jbc.M111.263020; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urban S, 2014, CELL REP, V8, P1241, DOI 10.1016/j.celrep.2014.07.039; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wakabayashi T, 2009, NAT CELL BIOL, V11, P1340, DOI 10.1038/ncb1978; Wali VB, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0501-z; Wheeler D. L., 2015, RECEPTOR TYROSINE KI; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Xu JD, 2009, J BIOL CHEM, V284, P27220, DOI 10.1074/jbc.M109.048728; Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689; Yumoto N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003322; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397; Zscheppang K, 2011, BBA-MOL CELL RES, V1813, P1717, DOI 10.1016/j.bbamcr.2011.06.020; Zscheppang K, 2011, AM J RESP CELL MOL, V45, P761, DOI 10.1165/rcmb.2010-0179OC; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	122	25	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					151	163		10.1038/s41388-018-0465-z	http://dx.doi.org/10.1038/s41388-018-0465-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30166589	Green Published, hybrid			2022-12-28	WOS:000455366700001
J	Lu, L; Dong, JL; Wang, LL; Xia, Q; Zhang, D; Kim, HJ; Yin, T; Fan, SJ; Shen, Q				Lu, Lu; Dong, Jiali; Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Fan, Saijun; Shen, Qiang			Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide	ONCOGENE			English	Article							HUMAN TUMOR-CELLS; ACQUIRED RADIORESISTANCE; LUNG-CANCER; STEM-CELLS; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; CARCINOMA-CELLS; PATHWAY; GENERATION; MICE	Radiotherapy significantly improves the therapeutic outcomes and survival of breast cancer patients. However, the acquired resistance to this therapeutic modality is a major clinical challenge. Here we show that ionizing irradiation (IR)-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at the Tyr705 residue and the induction of reactive oxygen species (ROS) in wild-type and radioresistant MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) cell lines. Comparing with radiosensitive parental TNBC cells, significantly low levels of ROS and higher protein levels of phospho-STAT3 and Bcl-2 were observed in TNBC cells with acquired radioresistance. Moreover, knockdown of STAT3 by shRNA sensitized the TNBC cells to IR. Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS. In combination with radiation, niclosamide treatment resulted in significant increase of ROS generation and induction of apoptosis in parental and radioresistant TNBC cells in vitro and TNBC xenograft tumors in vivo. These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors. Our findings suggest that niclosamide in combination with irradiation may offer an effective alternative approach for restoring the sensitivity of radioresistant TNBC cells to IR for improved therapeutic efficacy and outcomes.	[Lu, Lu; Dong, Jiali; Fan, Saijun] Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China; [Lu, Lu; Dong, Jiali; Fan, Saijun] Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China; [Wang, Lili] Soochow Univ, Dept Radiat Oncol, Affiliated Hosp 1, Suzhou 215006, Jiangshu, Peoples R China; [Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Shen, Qiang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA; [Xia, Qing] Shanghai Jiao Tong Univ, Dept Oncol, Affiliated Renji Hosp, Sch Med,Pancreat Canc Ctr, Shanghai 200127, Peoples R China; [Zhang, Dan] Shandong Univ Tradit Chinese Med, Coll Basic Med Sci, Jinan 250355, Shandong, Peoples R China; [Yin, Tao] Huazhong Univ Sci & Technol, Pancreat Dis Inst, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Soochow University - China; University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Shandong University of Traditional Chinese Medicine; Huazhong University of Science & Technology	Fan, SJ (corresponding author), Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China.; Fan, SJ (corresponding author), Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China.; Shen, Q (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA.	fansaijun@irm-cams.ac.cn; qshen@mdanderson.org	wang, lili/HDL-7210-2022	Shen, Qiang/0000-0002-1491-5434	National Natural Science Foundation of China [81472495, 81572969, 81172127, 81703169, 81730086]; Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology [2014EG150134]; Tianjin Science and Technology Support Plan Project [14ZCZDSY00001]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-017]; University of Texas M. D. Anderson Cancer Center; Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention; Duncan Family Institute	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology; Tianjin Science and Technology Support Plan Project; CAMS Innovation Fund for Medical Sciences (CIFMS); University of Texas M. D. Anderson Cancer Center; Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention; Duncan Family Institute	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81472495, 81572969, 81172127, 81703169, and 81730086); the Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology (2014EG150134); the Tianjin Science and Technology Support Plan Project (14ZCZDSY00001); the CAMS Innovation Fund for Medical Sciences (CIFMS, No. 2016-I2M-1-017); in part by startup funds from The University of Texas M. D. Anderson Cancer Center (to QS); Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention (to QS); and Seed Funding Research Program of Duncan Family Institute (to QS). We also thank Amy Ninetto, PhD, ELS, Department of Scientific Publications, The University of Texas MD Anderson Cancer Center, for her editing of the manuscript.	Al-Hadiya Badraddin M H, 2005, Profiles Drug Subst Excip Relat Methodol, V32, P67, DOI 10.1016/S0099-5428(05)32002-8; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Arend RC, 2016, ONCOTARGET, V7, P86803, DOI 10.18632/oncotarget.13466; Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Desai S, 2018, BBA-MOL CELL RES, V1865, P196, DOI 10.1016/j.bbamcr.2017.10.006; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dumont FJ, 2012, CURR CANCER DRUG TAR, V12, P899; Fan SJ, 2013, P NATL ACAD SCI USA, V110, P18650, DOI 10.1073/pnas.1308206110; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Han TJ, 2016, J NEURO-ONCOL, V130, P89, DOI 10.1007/s11060-016-2231-9; Hernandez-Aya LF, 2011, J CLIN ONCOL, V29, P2628, DOI 10.1200/JCO.2010.32.1877; Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950; Jin YY, 2018, EXP CELL RES, V362, P362, DOI 10.1016/j.yexcr.2017.11.037; Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465; Kim JS, 2016, ONCOTARGET, V7, P7055, DOI 10.18632/oncotarget.6855; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Li HZ, 2005, CLIN CANCER RES, V11, P5863, DOI 10.1158/1078-0432.CCR-05-0562; Li XX, 2017, BIOMED PHARMACOTHER, V96, P434, DOI 10.1016/j.biopha.2017.09.149; Liu H, 2015, ONCOTARGETS THER, V8, P509, DOI 10.2147/OTT.S76958; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Liu XY, 2012, BIOCHEM PHARMACOL, V83, P1456, DOI 10.1016/j.bcp.2012.02.010; Londono-Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535-7163.MCT-13-0555; Lu L, 2016, FREE RADICAL BIO MED, V99, P463, DOI 10.1016/j.freeradbiomed.2016.09.007; Marmol I, 2017, J INORG BIOCHEM, V176, P123, DOI 10.1016/j.jinorgbio.2017.08.020; Pan JX, 2012, CHIN J CANCER, V31, P178, DOI 10.5732/cjc.011.10290; Peter B, 2018, LEUKEMIA, V32, P1016, DOI 10.1038/leu.2017.338; Ren XM, 2010, ACS MED CHEM LETT, V1, P454, DOI 10.1021/ml100146z; Sato K, 2017, CANCER SCI, V108, P2004, DOI 10.1111/cas.13323; Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238; Shimura T, 2014, RADIOTHER ONCOL, V112, P302, DOI 10.1016/j.radonc.2014.07.015; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tinoco G, 2013, J CANCER, V4, P117, DOI 10.7150/jca.4925; Turaga K, 2010, CANCER CONTROL, V17, P177, DOI 10.1177/107327481001700306; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang LL, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.SABCS14-P6-12-04; Wang TL, 2005, CANCER RES, V65, P10338, DOI 10.1158/0008-5472.CAN-04-4614; Wang X, 2018, CLIN CANCER RES, V24, P858, DOI 10.1158/1078-0432.CCR-17-0345; Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003; Wang Y, 2017, MOL CANCER THER, V16, P578, DOI 10.1158/1535-7163.MCT-16-0606; Wang YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074538; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Ye TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085887; Yeh Jennifer E, 2013, JAKSTAT, V2, pe24635, DOI 10.4161/jkst.24635; You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535-7163.MCT-13-0608; Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329	55	90	91	5	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5292	5304		10.1038/s41388-018-0340-y	http://dx.doi.org/10.1038/s41388-018-0340-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855616				2022-12-28	WOS:000445759700004
J	Xu, TP; Wang, WY; Ma, P; Shuai, Y; Zhao, K; Wang, YF; Li, W; Xia, R; Chen, WM; Zhang, EB; Shu, YQ				Xu, Tong-peng; Wang, Wen-yu; Ma, Pei; Shuai, You; Zhao, Kun; Wang, Yan-fen; Li, Wei; Xia, Rui; Chen, Wen-ming; Zhang, Er-bao; Shu, Yong-qian			Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; EXPRESSION; PROGRESSION; ENHANCER; GENE; INVASIVENESS	Accumulating data indicate that long noncoding RNAs (lncRNAs) serve as important modulators in biological processes and are dysregulated in diverse tumors. The function of FOXD2-AS1 in gastric cancer (GC) progression and related biological mechanisms remain undefined. A comprehensive analysis identified that FOXD2-AS1 enrichment was upregulated markedly in GC and positively correlated with a large tumor size, a later pathologic stage, and a poor prognosis. Gene-set enrichment analysis (GSEA) in GEO datasets uncovered that cell cycle and DNA replication associated genes were enriched in patients with high FOXD2-AS1 expression. Loss of FOXD2-AS1 function inhibited cell growth via inhibiting the cell cycle in GC, whereas upregulation of FOXD2-AS1 expression promoted cancer progression. The enhancer of zeste homolog 2 (EZH2) and lysine (K)-specific demethylase 1A (LSD1) proteins were found to serve as binding partners of FOXD2-AS1 and mediators of FOXD2-AS1 function. Mechanically, FOXD2-AS1 promoted GC tumorigenesis partly through EZH2 and LSD1 mediated EphB3 downregulation. The present results revealed that FOXD2-AS1 acted as a tumor inducer in GC partly through EphB3 inhibition by direct interaction with EZH2 and LSD1, and may prove to be a potential biomarker of carcinogenesis.	[Xu, Tong-peng; Wang, Wen-yu; Ma, Pei; Shuai, You; Zhao, Kun; Shu, Yong-qian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Wang, Yan-fen] Yangzhou Univ, Affiliated Hosp, Dept Pathol, Yangzhou, Jiangsu, Peoples R China; [Li, Wei] CloudSeq Biotech Inc, Shanghai, Peoples R China; [Xia, Rui] Nanjing Chest Hosp, Dept Med Lab, 215 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Wen-ming] Jining 1 Peoples Hosp, Dept Oncol, Jining City 272011, Shandong, Peoples R China; [Zhang, Er-bao] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Yangzhou University; Nanjing Medical University	Xu, TP; Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	tongpeng_xu_njmu@163.com; yongqian_shu@163.com	Shu, Yongqian/ABD-5698-2021; Ma, Pei/ABD-6343-2021	Shu, Yongqian/0000-0002-3034-685X; Wang, Wenyu/0000-0002-7374-4567; zhang, erbao/0000-0002-5752-7976	National Natural Science Foundation of China [81602071, 81672896]; Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center) [BL2012008]; Natural Science Foundation of Jiangsu Province for Youth [BK20161066]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine) [JX10231801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center); Natural Science Foundation of Jiangsu Province for Youth(Natural Science Foundation of Jiangsu Province); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine)	This study was supported by the National Natural Science Foundation of China (81602071 and 81672896); Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center, BL2012008); the Natural Science Foundation of Jiangsu Province for Youth (BK20161066); and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine, JX10231801). We thank CloudSeq Biotech, Inc. (Shanghai, China) for help with bioinformatics analyses.	Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen JS, 2016, NEOPLASMA, V63, P223, DOI 10.4149/207_150821N454; Cheng ASL, 2013, GASTROENTEROLOGY, V144, P122, DOI 10.1053/j.gastro.2012.10.002; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Sarma Kavitha, 2010, Proc Natl Acad Sci U S A, V107, P22196, DOI 10.1073/pnas.1009785107; Shang C, 2016, CANCER CHEMOTH PHARM, V77, P1061, DOI 10.1007/s00280-016-3029-3; Shen L, 2013, LANCET ONCOL, V14, pE535, DOI 10.1016/S1470-2045(13)70436-4; Shin J, 2015, MOL CELL, V57, P949, DOI 10.1016/j.molcel.2015.03.007; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18; Xu TP, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.205; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	41	92	96	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					5020	5036		10.1038/s41388-018-0308-y	http://dx.doi.org/10.1038/s41388-018-0308-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789713				2022-12-28	WOS:000443823600009
J	Jia, L; Wu, DL; Wang, YL; You, WX; Wang, Z; Xiao, LJ; Cai, GH; Xu, ZY; Zou, C; Wang, F; Teoh, JYC; Ng, CF; Yu, S; Chan, FL				Jia, Lin; Wu, Dinglan; Wang, Yuliang; You, Wenxing; Wang, Zhu; Xiao, Lijia; Cai, Ganhui; Xu, Zhenyu; Zou, Chang; Wang, Fei; Teoh, Jeremy Yuen-Chun; Ng, Chi-Fai; Yu, Shan; Chan, Franky L.			Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription	ONCOGENE			English	Article							RADICAL PROSTATECTOMY; GENE-EXPRESSION; SELF-RENEWAL; THERAPEUTIC TARGET; CELL-PROLIFERATION; STEM-CELLS; TUMOR; PROGRESSION; AMPLIFICATION; SURVIVAL	The metastatic castration-resistant prostate cancer (CRPC) is a lethal form of prostate cancer, in which the expression of androgen receptor (AR) is highly heterogeneous. Indeed, lower AR expression and attenuated AR signature activity is shown in CRPC tissues, especially in the subset of neuroendocrine prostate cancer (NEPC) and prostate cancer stem-like cells (PCSCs). However, the significance of AR downregulation in androgen insensitivity and de-differentiation of tumor cells in CRPC is poorly understood and much neglected. Our previous study shows that the orphan nuclear receptor TLX (NR2E1), which is upregulated in prostate cancer, plays an oncogenic role in prostate carcinogenesis by suppressing oncogene-induced senescence. In the present study, we further established that TLX exhibited an increased expression in metastatic CRPC. Further analyses showed that overexpression of TLX could confer resistance to androgen deprivation and anti-androgen in androgen-dependent prostate cancer cells in vitro and in vivo, whereas knockdown of endogenous TLX could potentiate the sensitivity to androgen deprivation and anti-androgen in prostate cancer cells. Our study revealed that the TLX-induced resistance to androgen deprivation and anti-androgen was mediated through its direct suppression of AR gene transcription and signaling in both androgen-stimulated and - unstimulated prostate cancer cells. We also characterized that TLX could bind directly to AR promoter and repress AR transcription by recruitment of histone modifiers, including HDAC1, HDAC3, and LSD1. Together, our present study shows, for the first time, that TLX can contribute to androgen insensitivity in CRPC via repression of AR gene transcription and signaling, and also implicates that targeting the druggable TLX may have a potential therapeutic significance in CRPC management, particularly in NEPC and PCSCs.	[Jia, Lin; Wu, Dinglan; Wang, Yuliang; You, Wenxing; Wang, Zhu; Xiao, Lijia; Cai, Ganhui; Xu, Zhenyu; Zou, Chang; Yu, Shan; Chan, Franky L.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Jia, Lin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, Dinglan] Southern Med Univ, Shenzhen Key Lab Viral Oncol, Clin Innovat & Res Ctr, Shenzhen Hosp, Shenzhen 518110, Peoples R China; [Wang, Fei] Hosp Hainan Prov, Dept Urol, Haikou 570311, Hainan, Peoples R China; [Teoh, Jeremy Yuen-Chun; Ng, Chi-Fai] Chinese Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; University of Hong Kong; Southern Medical University - China; Chinese University of Hong Kong	Wu, DL; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.; Wu, DL (corresponding author), Southern Med Univ, Shenzhen Key Lab Viral Oncol, Clin Innovat & Res Ctr, Shenzhen Hosp, Shenzhen 518110, Peoples R China.	teenawu@gmail.com; franky-chan@cuhk.edu.hk	Zou, Chang/AAS-3356-2021; Teoh, Jeremy Yuen Chun/H-5184-2016; Chan, Franky L./M-1043-2018; Ng, Chi-Fai/E-5134-2011; Chi-fai, NG/AAV-8270-2021	Zou, Chang/0000-0002-2003-7834; Teoh, Jeremy Yuen Chun/0000-0002-9361-2342; Chan, Franky L./0000-0003-0567-2052; Ng, Chi-Fai/0000-0002-1723-9646; Jia, Lin/0000-0002-5501-5029; Wang, Zhu/0000-0002-5457-3731; Wu, Dinglan/0000-0002-5057-9626	National Natural Science Foundation of China [81502570, 81760461]; Research Grants Council of Hong Kong [461012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grants Council of Hong Kong(Hong Kong Research Grants Council)	This work was supported by research grants from the National Natural Science Foundation of China (project number 81502570) (to D.W.), General Research Fund (project number 461012) from the Research Grants Council of Hong Kong (to F.L.C.), and National Natural Science Foundation of China (project number 81760461) (to F.W.). We thank Dr. Vanacker J.M. for the ARE-Luc and Dr. Poletti A. for the pGL3-AR2.4 plasmid, Drs. Kenneth Pienta, Shutung Liao, and Helmet Klocker for the prostatic cell lines.	Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Brown RSD, 2002, J PATHOL, V198, P237, DOI 10.1002/path.1206; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai G, 2017, ONCOGENE, V36, P546, DOI 10.1038/onc.2016.227; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chavali PL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.449; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Corso-Diaz X, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3173-5; Cui Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10637; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fleischmann A, 2011, PROSTATE, V71, P453, DOI 10.1002/pros.21259; Islam MM, 2015, BBA-GENE REGUL MECH, V1849, P210, DOI 10.1016/j.bbagrm.2014.06.001; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Katsogiannou M, 2015, CANCER TREAT REV, V41, P588, DOI 10.1016/j.ctrv.2015.05.003; Knuuttila M, 2014, AM J PATHOL, V184, P2163, DOI 10.1016/j.ajpath.2014.04.010; Koivisto P, 1997, CANCER RES, V57, P314; KOKONTIS J, 1994, CANCER RES, V54, P1566; Komiya A, 2013, MOL CLIN ONCOL, V1, P257, DOI 10.3892/mco.2013.69; Li R, 2004, AM J SURG PATHOL, V28, P928, DOI 10.1097/00000478-200407000-00013; Lin ML, 2015, ONCOTARGET, V6, P21685, DOI 10.18632/oncotarget.3942; Linja MJ, 2001, CANCER RES, V61, P3550; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; MASAI M, 1990, PROSTATE, V17, P293, DOI 10.1002/pros.2990170405; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; O'Leary JD, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12357; Palmberg C, 1997, EUR UROL, V31, P216; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Park HJ, 2010, MOL CELLS, V30, P403, DOI 10.1007/s10059-010-0122-z; PERTSCHUK LP, 1995, LAB INVEST, V73, P302; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Rosner IL, 2007, UROLOGY, V70, DOI 10.1016/j.urology.2007.09.010; Segawa N, 2001, PATHOL INT, V51, P452, DOI 10.1046/j.1440-1827.2001.01226.x; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Takeda H, 1996, CANCER, V77, P934, DOI 10.1002/(SICI)1097-0142(19960301)77:5<934::AID-CNCR20>3.3.CO;2-Q; Tamburrino L, 2012, STEROIDS, V77, P996, DOI 10.1016/j.steroids.2012.01.008; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teyssier C, 2008, NUCLEIC ACIDS RES, V36, P5350, DOI 10.1093/nar/gkn520; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Vismara G, 2009, NEUROBIOL DIS, V33, P395, DOI 10.1016/j.nbd.2008.11.007; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Wise D, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5054; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576; Zhu Z, 2014, CELL STEM CELL, V15, P185, DOI 10.1016/j.stem.2014.04.007; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329; Zou YH, 2012, MOL CELL BIOL, V32, P4811, DOI 10.1128/MCB.01122-12	66	18	20	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3340	3355		10.1038/s41388-018-0198-z	http://dx.doi.org/10.1038/s41388-018-0198-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29555975	Green Published, hybrid			2022-12-28	WOS:000436411300002
J	Zhu, ZC; Liu, JW; Li, K; Zheng, J; Xiong, ZQ				Zhu, Zhi-Chuan; Liu, Ji-Wei; Li, Kui; Zheng, Jing; Xiong, Zhi-Qi			KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells	ONCOGENE			English	Article							IMPORTIN-BETA; NUCLEAR IMPORT; MYELOMA CELLS; RECEPTOR; TRANSPORT; DEATH; PROLIFERATION; KPN-BETA-1; PHOSPHORYLATION; INDUCTION	The nuclear import receptor karyopherin beta 1 (KPNB1) is involved in the nuclear import of most proteins and in the regulation of multiple mitotic events. Upregulation of KPNB1 has been observed in cancers including glioblastoma. Depletion of KPNB1 induces mitotic arrest and apoptosis in cancer cells, but the underlying mechanism is not clearly elucidated. Here, we found that downregulation and functional inhibition of KPNB1 in glioblastoma cells induced growth arrest and apoptosis without apparent mitotic arrest. KPNB1 inhibition upregulated Puma and Noxa and freed Mcl-1-sequestered Bax and Bak, leading to mitochondrial outer membrane permeabilization (MOMP) and apoptosis. Moreover, combination of Bcl-xL inhibitors and KPNB1 inhibition enhanced apoptosis in glioblastoma cells. KPNB1 inhibition promoted cytosolic retention of its cargo and impaired cellular proteostasis, resulting in elevated polyubiquitination, formation of aggresome-like-induced structure (ALIS), and unfolded protein response (UPR). Ubiquitination elevation and UPR activation in KPNB1-deficient cells were reversed by KPNB1 overexpression or inhibitors of protein synthesis but aggravated by inhibitors of autophagylysosome or proteasome, indicating that rebalance of cytosolic/nuclear protein distribution and alleviation of protein overload favor proteostasis and cell survival. Chronic activation of eIF2 alpha/ATF4 cascade of UPR was responsible for the upregulation of Puma and Noxa, apoptosis and ABT-263 sensitivity. Taken together, our findings demonstrate that KPNB1 is required for proteostasis maintenance and its inhibition induces apoptosis in glioblastoma cells through UPR-mediated deregulation of Bcl-2 family members.	[Zhu, Zhi-Chuan; Li, Kui; Xiong, Zhi-Qi] Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techn, State Key Lab Neurosci, Shanghai 200031, Peoples R China; [Liu, Ji-Wei; Zheng, Jing] East China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China; [Xiong, Zhi-Qi] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Xiong, Zhi-Qi] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China	Chinese Academy of Sciences; East China University of Science & Technology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; ShanghaiTech University	Xiong, ZQ (corresponding author), Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techn, State Key Lab Neurosci, Shanghai 200031, Peoples R China.; Xiong, ZQ (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Xiong, ZQ (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.	xiongzhiqi@ion.ac.cn	Zhu, Zhichuan/GYV-0605-2022	Zhu, Zhichuan/0000-0003-0327-9978	National Natural Science Foundation of China [31021063, 91332203, 31490591]; Chinese Academy of Sciences [XDB02020007, QYZDJ-SSW-SMC010]; Ministry of Science and Technology [2016YFA0501002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by grants from National Natural Science Foundation of China (31021063, 91332203, and 31490591), Chinese Academy of Sciences (XDB02020007, QYZDJ-SSW-SMC010), and Ministry of Science and Technology (2016YFA0501002).	Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008-5472.CAN-12-1118; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Cory S, 2016, TRENDS CANCER, V2, P443, DOI 10.1016/j.trecan.2016.07.001; Dai HM, 2018, CELL DEATH DIFFER, V25, P282, DOI 10.1038/cdd.2017.156; Dai HM, 2014, J BIOL CHEM, V289, P89, DOI 10.1074/jbc.M113.505701; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Dikovskaya D, 2010, J CELL SCI, V123, P736, DOI 10.1242/jcs.060806; Ding WX, 2007, APOPTOSIS, V12, P2233, DOI 10.1007/s10495-007-0142-0; El Fajoui Z, 2011, GASTROENTEROLOGY, V141, P663, DOI 10.1053/j.gastro.2011.04.055; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gomes DA, 2008, J BIOL CHEM, V283, P4344, DOI 10.1074/jbc.M706550200; Han CC, 2013, CELL SIGNAL, V25, P144, DOI 10.1016/j.cellsig.2012.09.023; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; He S, 2016, J CANCER RES CLIN, V142, P561, DOI 10.1007/s00432-015-2057-4; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Liang PZ, 2013, TRAFFIC, V14, P1132, DOI 10.1111/tra.12097; Lieu KG, 2014, J CELL BIOL, V205, P301, DOI 10.1083/jcb.201304055; Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lopez H, 2010, J BIOL CHEM, V285, P15016, DOI 10.1074/jbc.M109.086231; Lu XL, 2010, J BIOL CHEM, V285, P33281, DOI 10.1074/jbc.M110.102368; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Mingot JM, 2009, J CELL SCI, V122, P1452, DOI 10.1242/jcs.041749; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Polier G, 2015, INT J CANCER, V136, P688, DOI 10.1002/ijc.29009; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Quadroni M, 2015, J PROTEOMICS, V120, P215, DOI 10.1016/j.jprot.2015.02.020; Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141; Rodriguez D, 2011, BBA-MOL CELL RES, V1813, P564, DOI 10.1016/j.bbamcr.2010.11.012; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Shao DC, 2015, EUR J PHARMACOL, V758, P89, DOI 10.1016/j.ejphar.2015.03.069; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Szczepny A, 2014, BIOCHEM J, V461, P469, DOI 10.1042/BJ20130709; Uvarov AV, 2008, BBA-MOL CELL RES, V1783, P1237, DOI 10.1016/j.bbamcr.2008.03.004; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204; Vogler Meike, 2014, Adv Med, V2014, P943648, DOI 10.1155/2014/943648; Wong E, 2012, CURR BIOL, V22, pR966; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang LL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0559-1; Yang WD, 2006, J CELL BIOL, V174, P951, DOI 10.1083/jcb.200605053; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5; Zhang PY, 2014, J PATHOL, V232, P308, DOI 10.1002/path.4294; Zhu ZC, 2013, J NEURO-ONCOL, V112, P17, DOI 10.1007/s11060-012-1032-z	54	22	23	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2936	2952		10.1038/s41388-018-0180-9	http://dx.doi.org/10.1038/s41388-018-0180-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29520102	Green Published, hybrid			2022-12-28	WOS:000433936300003
J	Celik, H; Sciandra, M; Flashner, B; Gelmez, E; Kayrakilogiu, N; Allegakoen, DV; Petro, JR; Conn, EJ; Hour, S; Han, J; Oktay, L; Tiwari, PB; Hayran, M; Harris, BT; Manara, MC; Toretsky, JA; Scotlandi, K; Uren, A				Celik, Haydar; Sciandra, Marika; Flashner, Bess; Gelmez, Elif; Kayrakilogiu, Neslihan; Allegakoen, David V.; Petro, Jeff R.; Conn, Erin J.; Hour, Sarah; Han, Jenny; Oktay, Lalehan; Tiwari, Purushottam B.; Hayran, Mutlu; Harris, Brent T.; Manara, Maria Cristina; Toretsky, Jeffrey A.; Scotlandi, Katia; Uren, Aykut			Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99	ONCOGENE			English	Article							MIC2 EXPRESSION; CELL; TUMORS; GENE; OSTEOSARCOMA; ENGAGEMENT; MIGRATION; CANCER; FAMILY; IDENTIFICATION	Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.	[Celik, Haydar; Flashner, Bess; Gelmez, Elif; Kayrakilogiu, Neslihan; Allegakoen, David V.; Petro, Jeff R.; Conn, Erin J.; Hour, Sarah; Han, Jenny; Oktay, Lalehan; Tiwari, Purushottam B.; Toretsky, Jeffrey A.; Uren, Aykut] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; [Sciandra, Marika; Manara, Maria Cristina; Scotlandi, Katia] Rizzoli Orthopaed Inst, Expt Oncol Lab, CRS Dev Biomol Therapies, Bologna, Italy; [Sciandra, Marika; Manara, Maria Cristina; Scotlandi, Katia] Rizzoli Orthopaed Inst, RIT Dept, STB, PROMETEO Lab, Bologna, Italy; [Hayran, Mutlu] Hacettepe Univ, Canc Inst, Dept Prevent Oncol, Ankara, Turkey; [Harris, Brent T.] Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; Hacettepe University; Georgetown University	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.; Scotlandi, K (corresponding author), Rizzoli Orthopaed Inst, Expt Oncol Lab, CRS Dev Biomol Therapies, Bologna, Italy.; Scotlandi, K (corresponding author), Rizzoli Orthopaed Inst, RIT Dept, STB, PROMETEO Lab, Bologna, Italy.	katia.scotlandi@ior.it; au26@georgetown.edu	Sciandra, Marika/C-8724-2018; Manara, Maria Cristina/K-3366-2018; Scotlandi, Katia/J-9009-2016	Sciandra, Marika/0000-0001-7147-6960; Manara, Maria Cristina/0000-0001-5686-720X; Scotlandi, Katia/0000-0001-6114-9499; Celik, Haydar/0000-0003-4314-8438	Children's Cancer Foundation; Hyundai Hope on Wheels; Alan B. Slifka Foundation; Italian Association for Cancer Research [AIRC_IG14049]; National Cancer Institute [P30CA51008]	Children's Cancer Foundation; Hyundai Hope on Wheels; Alan B. Slifka Foundation; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the funds from the Children's Cancer Foundation (to A. Uren), Hyundai Hope on Wheels (to A. Uren), the Alan B. Slifka Foundation (to A. Uren and K. Scotlandi) and the Italian Association for Cancer Research (AIRC_IG14049 to K. Scotlandi). The authors thank the Animal Models Shared Resource, Tissue Culture Shared Resource, Histopathology and Tissue Shared Resource and the Biacore Molecular Interaction Shared Resource at the Lombardi Comprehensive Cancer Center (Georgetown University), which are supported by a grant P30CA51008 from the National Cancer Institute.	AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bixel G, 2004, BLOOD, V104, P3205, DOI 10.1182/blood-2004-03-1184; Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; CCEDILELIK H, 2015, MOL CELL BIOL, V35, P3145, DOI DOI 10.1128/MCB.00332-15; Choi G, 2007, EXP MOL MED, V39, P746, DOI 10.1038/emm.2007.81; Chung SS, 2014, BLOOD, V124, P3760; Chung SS, 2013, BLOOD, V122; Chung SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2025; Cox CV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165210; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; ELLIS NA, 1994, NAT GENET, V8, P285, DOI 10.1038/ng1194-285; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Gellini M, 2013, CURR PHARM BIOTECHNO, V14, P449, DOI 10.2174/1389201011314040011; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Gollnest T, 2016, ANGEW CHEM INT EDIT, V55, P5255, DOI 10.1002/anie.201511808; Gollnest T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9716; Guerzoni C, 2015, CLIN CANCER RES, V21, P146, DOI 10.1158/1078-0432.CCR-14-0492; Halliday BE, 1998, DIAGN CYTOPATHOL, V19, P410, DOI 10.1002/(SICI)1097-0339(199812)19:6<410::AID-DC2>3.0.CO;2-Z; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Husak Z, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.164; Husak Z, 2010, J LEUKOCYTE BIOL, V88, P405, DOI 10.1189/jlb.0210097; KAWASAKI H, 1993, BLOOD, V81, P597; Khoury JD, 2005, ADV ANAT PATHOL, V12, P212, DOI 10.1097/01.pap.0000175114.55541.52; Kim HJ, 2004, IMMUNOL LETT, V95, P155, DOI 10.1016/j.imlet.2004.07.001; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kovar H, 2016, ONCOTARGET, V7, P8613, DOI 10.18632/oncotarget.6937; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553; Lee CS, 1996, PEDIATR PATHOL LAB M, V16, P379, DOI 10.1080/15513819609168678; Longhi A, 2012, CANCER-AM CANCER SOC, V118, P5050, DOI 10.1002/cncr.27493; Lucas DR, 2001, AM J CLIN PATHOL, V115, P11; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Mi-Kyung L, 2008, J MICROBIOL BIOTECHN, V18, P472; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Moricoli D, 2016, APPL MICROBIOL BIOT, V100, P3949, DOI 10.1007/s00253-015-7226-5; PERLMAN EJ, 1994, HUM PATHOL, V25, P304, DOI 10.1016/0046-8177(94)90203-8; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2006, EUR J CANCER, V42, P91, DOI 10.1016/j.ejca.2005.09.015; Sigal DS, 2010, BLOOD, V116, P2884, DOI 10.1182/blood-2010-02-246140; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Suh YH, 2003, GENE, V307, P63, DOI 10.1016/S0378-1119(03)00401-3; Ventura S, 2016, ONCOGENE, V35, P3944, DOI 10.1038/onc.2015.463; Watson RL, 2015, J EXP MED, V212, P1021, DOI 10.1084/jem.20150354; WEIDNER N, 1994, AM J SURG PATHOL, V18, P486, DOI 10.1097/00000478-199405000-00008; Winger RC, 2016, J IMMUNOL, V196, P1443, DOI 10.4049/jimmunol.1501634; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	59	15	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2181	2196		10.1038/s41388-017-0080-4	http://dx.doi.org/10.1038/s41388-017-0080-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29382926				2022-12-28	WOS:000430589000008
J	NavaneethaKrishnan, S; Rosales, JL; Lee, KY				NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young			Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; OXIDATIVE STRESS; NEURONAL APOPTOSIS; REPERFUSION INJURY; DNA-DAMAGE; DRP1; PHOSPHORYLATION; FISSION; PROTEIN; FRAGMENTATION	Cdk5, which plays a role in the development and progression of many human cancers, localizes in the mitochondria, a key determinant of apoptotic cell death. Cdk5 is upregulated in breast cancer cells but it was shown that Cdk5 loss increases chemotherapy-induced apoptosis. However, the molecular mechanism by which Cdk5 loss promotes cell death remains unclear. Here, we investigate the possibility that Cdk5 loss activates the intrinsic apoptotic pathway in breast cancer cells. We demonstrate that Cdk5-deficient breast cancer cells exhibit increased mitochondrial depolarization, mitochondrial ROS levels, and mitochondrial fragmentation that is associated with an increase in both intracellular Ca2+ level and calcineurin activity, and DRP1 S637 dephosphorylation. These events accompany increased apoptosis, indicating that Cdk5 loss promotes mitochondria-mediated apoptosis. To define this apoptotic pathway, we utilized various inhibitors of mitochondrial function. Apoptosis is completely prevented by mPTP inhibition, almost fully inhibited by blocking ROS and unaffected by inhibition of mitochondrial fission, suggesting that apoptosis in breast cancer cells due to Cdk5 loss occurs via a novel mPTP-dependent mechanism that acts primarily through ROS increase.	[NavaneethaKrishnan, Saranya; Lee, Ki-Young] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB, Canada; [Rosales, Jesusa L.] Univ Calgary, Snyder Inst Chron Dis, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB, Canada.	kylee@ucalgary.ca		Rosales, Jesusa/0000-0002-2543-3801	CIHR [MOP-123400]; NSERC [RGPIN/312985-2011]; Alberta Cancer Foundation	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Cancer Foundation	We thank Novartis Pharma AG and Dr. BC Lee for providing SfA and HeLa mitoDSRed2 cells, respectively. We also thank Drs. Timothy Shutt, Karl Riabowol, Susan Lees-Miller, and Derek McKay for their critical reviews of the manuscript. This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/312985-2011) to K-YL and an Alberta Cancer Foundation graduate studentship to SN.	Abdullah C, 2011, CELL CYCLE, V10, P977, DOI 10.4161/cc.10.6.15079; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; Bernardi P, 2015, PHYSIOL REV, V95, P1111, DOI 10.1152/physrev.00001.2015; Bernardi P, 2015, J MOL CELL CARDIOL, V78, P100, DOI 10.1016/j.yjmcc.2014.09.023; Bolin C, 2012, CELL MOL LIFE SCI, V69, P951, DOI 10.1007/s00018-011-0811-6; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Cho B, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.36; Cho SG, 2010, AM J PHYSIOL-RENAL, V299, pF199, DOI 10.1152/ajprenal.00716.2009; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elwi AN, 2012, INT J BIOCHEM CELL B, V44, P1366, DOI 10.1016/j.biocel.2012.05.004; Feldmann G, 2010, CANCER RES, V70, P4460, DOI 10.1158/0008-5472.CAN-09-1107; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fitzgerald JC, 2012, CELL DEATH DIFFER, V19, P257, DOI 10.1038/cdd.2011.90; Goodyear S, 2007, EXP MOL PATHOL, V82, P25, DOI 10.1016/j.yexmp.2006.09.002; Halestrap AP, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00234; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Iqbal S, 2014, AM J PHYSIOL-CELL PH, V306, pC1176, DOI 10.1152/ajpcell.00017.2014; Jahani-Asl A, 2015, HUM MOL GENET, V24, P4573, DOI 10.1093/hmg/ddv188; Jena NR, 2012, J BIOSCIENCES, V37, P503, DOI 10.1007/s12038-012-9218-2; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Levacque Z, 2012, CELL CYCLE, V11, P4093, DOI 10.4161/cc.21886; Liang Q, 2013, SCI REP-UK, V3, DOI 10.1038/srep02932; Liu JL, 2011, MED ONCOL, V28, P673, DOI 10.1007/s12032-010-9510-7; Meuer K, 2007, CELL DEATH DIFFER, V14, P651, DOI 10.1038/sj.cdd.4402087; Mnatsakanyan N, 2017, J BIOENERG BIOMEMBR, V49, P13, DOI 10.1007/s10863-016-9652-1; Morciano G, 2015, J MOL CELL CARDIOL, V78, P142, DOI 10.1016/j.yjmcc.2014.08.015; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Rosales JL, 2006, BIOESSAYS, V28, P1023, DOI 10.1002/bies.20473; Rosdah AA, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.235; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Sun KH, 2008, J NEUROCHEM, V107, P265, DOI 10.1111/j.1471-4159.2008.05616.x; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Turner C, 2003, CELL DEATH DIFFER, V10, P302, DOI 10.1038/sj.cdd.4401170; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0019879; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Wu SN, 2011, FEBS J, V278, P941, DOI 10.1111/j.1742-4658.2011.08010.x; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Zhang SY, 2015, 2015 IEEE WORKSHOP ON ENVIRONMENTAL, ENERGY AND STRUCTURAL MONITORING SYSTEMS (EESMS), P1, DOI [10.1109/EESMS.2015.7175842, 10.1109/INTMAG.2015.7156970]; Zhu YX, 2011, BLOOD, V117, P3847, DOI 10.1182/blood-2010-08-304022	57	39	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1788	1804		10.1038/s41388-017-0103-1	http://dx.doi.org/10.1038/s41388-017-0103-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348461	hybrid, Green Published			2022-12-28	WOS:000428632600008
J	Kha, ML; Hesse, L; Deisinger, F; Sipos, B; Rocken, C; Arlt, A; Sebens, S; Helm, O; Schafer, H				Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Sipos, Bence; Roecken, Christoph; Arlt, Alexander; Sebens, Susanne; Helm, Ole; Schaefer, Heiner			The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant Delta Zip2	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; NUCLEAR FACTOR; GENE ATF3; CANCER; APOPTOSIS; PATHWAY; PROLIFERATION; CARCINOMA; ONCOGENE; GROWTH	Pancreatic ductal adenocarcinoma (PDAC) exhibits one of the worst survival rates of all cancers. While death rates show declining trends in the majority of cancers, PDAC registers rising rates. Based on the recently described crosstalk between TGF-beta 1 and Nrf2 in the PDAC development, the involvement of ATF3 and its splice variant Delta Zip2 in TGF-beta 1- and Nrf2-driven pancreatic tumorigenesis was investigated. As demonstrated here, PDAC (Panc1, T3M4) cells or premalignant H6c7 pancreatic ductal epithelial cells differentially express Delta Zip2- and ATF3, relating to stronger Nrf2 activity seen in Panc1 cells and TGF-beta 1 activity in T3M4 or H6c7 cells, respectively. Treatment with the electrophile/oxidative stress inducer tBHQ or the cytostatic drug gemcitabine strongly elevated Delta Zip2 expression in a Nrf2-dependent fashion. The differential expression of ATF3 and Delta Zip2 in response to Nrf2 and TGF-beta 1 relates to differential ATF3-gene promoter usage, giving rise of distinct splice variants. Nrf2-dependent Delta Zip2 expression confers resistance against gemcitabine-induced apoptosis, only partially relating to interference with ATF3 and its proapoptotic activity, e.g., through CHOP-expression. In fact, Delta Zip2 autonomously activates expression of cIAP anti-apoptotic proteins. Moreover, Delta Zip2 favors and ATF3 suppresses growth and clonal expansion of PDAC cells, again partially independent of each other. Using a Panc1 tumor xenograft model in SCID-beige mice, the opposite activities of ATF3 and Delta Zip2 on tumor-growth and chemoresistance were verified in vivo. Immunohistochemical analyses confirmed Delta Zip2 and Nrf2 coexpression in cancerous and PanIN structures of human PDAC and chronic pancreatitis tissues, respectively, which to some extent was reciprocal to ATF3 expression. It is concluded that depending on selective ATF3-gene promoter usage by Nrf2, the Delta Zip2 expression is induced in response to electrophile/oxidative (here through tBHQ) and xenobiotic (here through gemcitabine) stress, providing apoptosis protection and growth advantages to pancreatic ductal epithelial cells. This condition may substantially add to pancreatic carcinogenesis driven by chronic inflammation.	[Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Schaefer, Heiner] Univ Kiel, Lab Mol Gastroenterol & Tumor Biol, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Sebens, Susanne; Helm, Ole; Schaefer, Heiner] UKSH, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Sipos, Bence] Univ Hosp Tubingen, Dept Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Roecken, Christoph] Univ Kiel, Inst Pathol, Campus Kiel,Bldg 14,Arnold Heller Str 3, Kiel, Germany; [Roecken, Christoph] UKSH, Campus Kiel,Bldg 14,Arnold Heller Str 3, Kiel, Germany; [Roecken, Christoph; Sebens, Susanne] UKSH, Biomat Bank, Comprehens Canc Ctr Kiel, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Arlt, Alexander] UKSH, Lab Gastrointestinal Signal Transduct, Dept Internal Med 1, Campus Kiel,Bldg 6,Arnold Heller Str 3, D-24105 Kiel, Germany; [Sebens, Susanne; Helm, Ole] Univ Kiel, Grp Inflammatory Carcinogenesis, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel	Schafer, H (corresponding author), Univ Kiel, Lab Mol Gastroenterol & Tumor Biol, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.; Schafer, H (corresponding author), UKSH, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Röcken, Christoph/A-9239-2010; Arlt, Alexander/G-7308-2019	Röcken, Christoph/0000-0002-6989-8002; Arlt, Alexander/0000-0002-6160-1059	Medical Faculty of the CAU Kiel; Cluster of Excellence "Inflammation at Interfaces"	Medical Faculty of the CAU Kiel; Cluster of Excellence "Inflammation at Interfaces"	Financial support by the Medical Faculty of the CAU Kiel (to HS and OH) and the Cluster of Excellence "Inflammation at Interfaces" (to HS, AA, and SS) is greatly acknowledged.	Arfmann-Knubel S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132978; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Buganim Y, 2011, CARCINOGENESIS, V32, P1749, DOI 10.1093/carcin/bgr203; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Disis ML, 2010, J CLIN ONCOL, V28, P4531, DOI 10.1200/JCO.2009.27.2146; Distler M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474905; Dziunycz PJ, 2014, J INVEST DERMATOL, V134, P1998, DOI 10.1038/jid.2014.77; Erkan M, 2013, PANCREATOLOGY, V13, P106, DOI 10.1016/j.pan.2013.01.008; Esakky P, 2015, J MOL CELL BIOL, V7, P73, DOI 10.1093/jmcb/mju049; Evans A, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00270; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041; Geismann C, 2014, ONCOTARGETS THER, V7, P1497, DOI 10.2147/OTT.S36624; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Genrich G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2191-7; Hai T, 1999, GENE EXPRESSION, V7, P321; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hawkins KE, 2016, CELL REP, V14, P1883, DOI 10.1016/j.celrep.2016.02.003; Hayes AJ, 2015, INT J BIOCHEM CELL B, V65, P288, DOI 10.1016/j.biocel.2015.06.017; Helm O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094357; Hiss DC, 2009, EXPERT OPIN DRUG DIS, V4, P799, DOI 10.1517/17460440903052559; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hua B, 2006, J BIOL CHEM, V281, P1620, DOI 10.1074/jbc.M508471200; Hunt D, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00007; Inman KS, 2014, WORLD J GASTROENTERO, V20, P11160, DOI 10.3748/wjg.v20.i32.11160; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang XJ, 2016, ANTICANCER RES, V36, P509; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406; La Rosa S, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00041; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Lohr M, 2001, CANCER RES, V61, P550; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Muerkoster SS, 2008, INT J CANCER, V123, P1751, DOI 10.1002/ijc.23703; Murakami S, 2015, FREE RADICAL BIO MED, V88, P168, DOI 10.1016/j.freeradbiomed.2015.06.030; Nilsson M, 1997, CELL GROWTH DIFFER, V8, P913; O'Brien A, 2012, ANTICANCER RES, V32, P2679; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Pandol S, 2009, CLIN GASTROENTEROL H, V7, pS44, DOI 10.1016/j.cgh.2009.07.039; Reichert M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9298535; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sato A, 2014, FEBS J, V281, P1892, DOI 10.1111/febs.12752; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sipos B, 2009, PANCREATOLOGY, V9, P45, DOI 10.1159/000178874; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Weng SY, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0442-3; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yin X, 2010, J CELL SCI, V123, P3558, DOI 10.1242/jcs.064915	64	8	8	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1461	1476		10.1038/s41388-018-0518-3	http://dx.doi.org/10.1038/s41388-018-0518-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30302023				2022-12-28	WOS:000459945800007
J	Zhang, HL; Wang, YL; Dou, JZ; Guo, YM; He, JF; Li, L; Liu, XJ; Chen, R; Deng, R; Huang, J; Xie, RY; Zhao, X; Yu, JX				Zhang, Hailong; Wang, Yanli; Dou, Jinzhuo; Guo, Yanmin; He, Jianfeng; Li, Lian; Liu, Xiaojia; Chen, Ran; Deng, Rong; Huang, Jian; Xie, Ruiyu; Zhao, Xian; Yu, Jianxiu			Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis	ONCOGENE			English	Article							RNA-INTERFERENCE; MIR-17-SIMILAR-TO-92 CLUSTER; MICRORNA BIOGENESIS; PHOSPHORYLATION; ARGONAUTE; DICER; COMPLEX; BINDING; METASTASIS; HYPOXIA	Argonaute2 (AGO2) is an effector of small RNA mediated gene silencing. Increasing evidence show that post-translational modifications of AGO2 can change miRNA activity at specific or global levels. Among the six mature miRNAs that are encoded by miR-17-92, miR-19b1 is the most powerful to exert the oncogenic properties of the entire cluster. Here we identify that AGO2 can be acetylated by P300/CBP and deacetylated by HDAC7, and that acetylation occurs at three sites K720, K493, and K355. Mutation of K493R/K720R, but not K355R at AGO2, inhibits miR-19b biogenesis. We demonstrate that acetylation of AGO2 specifically increases its recruiting pre-miR-19b1 to form the miPDC (miRNA precursor deposit complex), thereby to enhance miR-19b maturation. The motif UGUGUG in the terminal-loop of pre-miR-19b1, as a specific processing feature that is recognized and bound by acetylated AGO2, is essential for the assembly of miRISC (miRNA-induced silencing complex) loading complex. Analyses on public clinical data, xenograft mouse models, and IHC and ISH staining of lung cancer tissues, further confirm that the high levels of both AGO2 acetylation and miR-19b correlate with poor prognosis in lung cancer patients. Our finding reveals a novel function of AGO2 acetylation in increasing oncogenic miR-19b biogenesis and suggests that modulation of AGO2 acetylation has potential clinical implications.	[Zhang, Hailong; Wang, Yanli; Dou, Jinzhuo; Guo, Yanmin; He, Jianfeng; Li, Lian; Liu, Xiaojia; Chen, Ran; Deng, Rong; Huang, Jian; Zhao, Xian; Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China; [Xie, Ruiyu] Univ Macau, Fac Hlth Sci, Macau 999078, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Macau	Zhao, X; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China.	Xianzhao1985@sjtu.edu.cn; Jianxiu.Yu@gmail.com	Huang, Jian/ABF-8355-2021	Xie, Ruiyu/0000-0003-0518-2897	National Natural Science Foundation of China [31671345, 81472571, 81630075, 81602251, 81702837, 81702532, 81721004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China [31671345, 81472571, 81630075, 81602251, 81702837, 81702532, 81721004]	Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031; Bridge KS, 2017, CELL REP, V20, P173, DOI 10.1016/j.celrep.2017.06.027; Bronevetsky Y, 2013, J EXP MED, V210, P417, DOI 10.1084/jem.20111717; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9899; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809; Dahm GM, 2012, JOVE-J VIS EXP, DOI 10.3791/3851; de Pontual L, 2011, NAT GENET, V43, P1026, DOI 10.1038/ng.915; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Fan Y, 2014, RNA, V20, P765, DOI 10.1261/rna.043026.113; Golden RJ, 2017, NATURE, V542, P197, DOI 10.1038/nature21025; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Horman SR, 2013, MOL CELL, V50, P356, DOI 10.1016/j.molcel.2013.03.015; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Huberdeau MQ, 2017, EMBO J, V36, P2088, DOI 10.15252/embj.201696386; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Josa-Prado F, 2015, BIOCHEM BIOPH RES CO, V464, P1066, DOI 10.1016/j.bbrc.2015.07.073; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Leung AKL, 2011, MOL CELL, V42, P489, DOI 10.1016/j.molcel.2011.04.015; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.458; Liu X, 2012, IMMUNOL LETT, V143, P208, DOI 10.1016/j.imlet.2012.02.014; Liu XH, 2014, MOL CELL, V55, P868, DOI 10.1016/j.molcel.2014.07.017; Liu XH, 2012, MOL CELL, V46, P507, DOI 10.1016/j.molcel.2012.03.010; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Nowak JS, 2017, RNA, V23, P317, DOI 10.1261/rna.059196.116; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Qi HH, 2008, NATURE, V455, P421, DOI 10.1038/nature07186; Rybak A, 2009, NAT CELL BIOL, V11, P1411, DOI 10.1038/ncb1987; Sahin U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102957; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Sun HL, 2016, CANCER CELL, V30, P723, DOI 10.1016/j.ccell.2016.10.001; Tan GS, 2009, NUCLEIC ACIDS RES, V37, P7533, DOI 10.1093/nar/gkp812; Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang HW, 2009, NAT STRUCT MOL BIOL, V16, P1148, DOI 10.1038/nsmb.1673; Weinmann L, 2009, CELL, V136, P496, DOI 10.1016/j.cell.2008.12.023; Wu C, 2011, MOL CELL BIOL, V31, P4760, DOI 10.1128/MCB.05776-11; Yang JS, 2010, P NATL ACAD SCI USA, V107, P15163, DOI 10.1073/pnas.1006432107; Yoda M, 2013, CELL REP, V5, P715, DOI 10.1016/j.celrep.2013.09.029; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Zeng Y, 2008, BIOCHEM J, V413, P429, DOI 10.1042/BJ20080599; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhao X, 2016, ONCOTARGET, V7, P33136, DOI 10.18632/oncotarget.8887	57	39	40	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1410	1431		10.1038/s41388-018-0530-7	http://dx.doi.org/10.1038/s41388-018-0530-7			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305728	Green Published, hybrid			2022-12-28	WOS:000459945800004
J	Turner, JA; Bemis, JGT; Bagby, SM; Capasso, A; Yacob, BW; Chimed, TS; Van Gulick, R; Lee, H; Tobin, R; Tentler, JJ; Pitts, T; McCarter, M; Robinson, WA; Couts, KL				Turner, Jacqueline A.; Bemis, Judson G. T.; Bagby, Stacey M.; Capasso, Anna; Yacob, Betelehem W.; Chimed, Tugs-Saikhan; Van Gulick, Robert; Lee, Hannah; Tobin, Richard; Tentler, John J.; Pitts, Todd; McCarter, Martin; Robinson, William A.; Couts, Kasey L.			BRAF fusions identified in melanomas have variable treatment responses and phenotypes	ONCOGENE			English	Article							RAF INHIBITOR RESISTANCE; TARGETED THERAPY; GENE FUSIONS; B-RAF; ACTIVATION; DIMERIZATION; MUTATIONS; PATHWAY; TUMORS	Oncogenic BRAF fusions have emerged as an alternate mechanism for BRAF activation in melanomas and other cancers. A number of BRAF fusions with different 5' gene partners and BRAF exon breakpoints have been described, but the effects of different partners and breakpoints on cancer phenotypes and treatment responses has not been well characterized. Targeted RNA sequencing was used to screen 60 melanoma patient-derived xenograft (PDX) models for BRAF fusions. We identified three unique BRAF fusions, including a novel SEPT3-BRAF fusion, occurring in four tumors (4/60, 6.7%), all of which were "pan-negative" (lacking other common mutations) (4/18, 22.2%). The BRAF fusion PDX models showed variable growth rates and responses to MAPK inhibitors in vivo. Overexpression of BRAF fusions identified in our study, as well as other BRAF fusions previously identified in melanomas, resulted in a high degree of variability in 2D proliferation and 3D invasion between the different fusions. While exogenously expressed BRAF fusions all responded to MAPK inhibition in vitro, we observed potential differences in signaling and feedback mechanisms. In summary, BRAF fusions are actionable therapeutic targets, however there are significant differences in phenotypes, treatment responses, and signaling which may be clinically relevant.	[Turner, Jacqueline A.; Bemis, Judson G. T.; Bagby, Stacey M.; Capasso, Anna; Yacob, Betelehem W.; Chimed, Tugs-Saikhan; Van Gulick, Robert; Lee, Hannah; Tentler, John J.; Pitts, Todd; Robinson, William A.; Couts, Kasey L.] Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Lee, Hannah] Univ Colorado Denver, Dept Med, Internal Med Residency Training Program, Aurora, CO USA; [Tobin, Richard; McCarter, Martin] Univ Colorado Denver, Dept Surg, Div Surg Oncol, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Couts, KL (corresponding author), Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.	kasey.couts@ucdenver.edu		Turner, Jacqueline A./0000-0002-6638-1956; Robinson, William/0000-0003-1875-9691	Melanoma Scientific Advisory Board at the University of Colorado; Amy Davis Foundation; Moore Family Foundation; Heidi Horner Foundation; Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant [P30CA046934]; NIH/N CATS CCTSI Grant [UL1 TR001082]; Cancer League of Colorado	Melanoma Scientific Advisory Board at the University of Colorado; Amy Davis Foundation; Moore Family Foundation; Heidi Horner Foundation; Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant; NIH/N CATS CCTSI Grant; Cancer League of Colorado	We thank the patients and their families for donating tissue to the International Melanoma Biorepository and Research Laboratory at the University of Colorado Cancer Center. We thank the Melanoma Scientific Advisory Board at the University of Colorado for their support. The work presented here was supported in part by the Amy Davis Foundation, the Moore Family Foundation, and the Heidi Horner Foundation. Additionally, funding was also provided by the Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant P30CA046934, NIH/N CATS CCTSI Grant UL1 TR001082, and Cancer League of Colorado.	Alatrash G, 2013, EXPERT OPIN DRUG SAF, V12, P631, DOI 10.1517/14740338.2013.795944; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bagby S, 2016, JOVE-J VIS EXP, V115, P54393; Baitei EY, 2009, J PATHOL, V217, P707, DOI 10.1002/path.2496; Baiter M, 2015, DERMATOLOGY, V231, P127, DOI 10.1159/000381849; Botton T, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12148; Brummer T, 2006, ONCOGENE, V25, P6262, DOI 10.1038/sj.onc.1209640; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Couts KL, 2018, MOL CANCER THER, V17, P222, DOI 10.1158/1535-7163.MCT-17-0472; Feitelson MA, 2015, SEMIN CANCER BIOL, V35, pS25, DOI 10.1016/j.semcancer.2015.02.006; Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200; Fouad YA, 2017, AM J CANCER RES, V7, P1016; Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Hennig A, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0128-z; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Jain P, 2017, ONCOTARGET, V8, P84697, DOI 10.18632/oncotarget.20949; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Klempner SJ, 2016, CANCER DISCOV, V6, P594, DOI 10.1158/2159-8290.CD-15-1192; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Li E, 2012, BBA-BIOMEMBRANES, V1818, P183, DOI 10.1016/j.bbamem.2011.08.031; Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240; Lu HY, 2017, CANCER RES, V77, P3502, DOI 10.1158/0008-5472.CAN-16-2745; Mar VJ, 2015, BRIT J DERMATOL, V173, P76, DOI 10.1111/bjd.13756; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; Ortore MG, 2015, BIOPHYS J, V108, P2896, DOI 10.1016/j.bpj.2015.05.015; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scolnick JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128916; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Turner J, 2017, PIGM CELL MELANOMA R, V30, P53, DOI 10.1111/pcmr.12560; UEKI K, 1994, J BIOL CHEM, V269, P15756; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Wang L, 2017, J MOL DIAGN, V19, P387, DOI 10.1016/j.jmoldx.2016.11.005; Weiss RH, 1998, AM J PHYSIOL-CELL PH, V274, pC1521, DOI 10.1152/ajpcell.1998.274.6.C1521	40	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1296	1308		10.1038/s41388-018-0514-7	http://dx.doi.org/10.1038/s41388-018-0514-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254212				2022-12-28	WOS:000459249800011
J	Li, H; Tian, ZF; Qu, YP; Yang, Q; Guan, HX; Shi, BY; Ji, MJ; Hou, P				Li, Heng; Tian, Zhufang; Qu, Yiping; Yang, Qi; Guan, Haixia; Shi, Bingyin; Ji, Meiju; Hou, Peng			SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis	ONCOGENE			English	Article							CELL-LINES; CANCER; NICOTINAMIDE; EXPRESSION; CARCINOMA; APOPTOSIS; SURVIVAL; TARGET; MTOR; S6K1	SIRT7 is an NAD(+)-dependent histone/non-histone deacetylase, which is highly expressed in different types of cancer including thyroid cancer; however, its biological function in thyroid cancer is still undiscovered. In this study, we found that SIRT7 expression was elevated in papillary thyroid cancers (PTCs), and demonstrated that SIRT7 knockdown dramatically inhibited the proliferation, colony formation, migration and invasion of thyroid cancer cells, and induced thyroid cancer cell cycle arrest and apoptosis. Conversely, SIRT7 re-expression markedly enhanced thyroid cancer cell growth, invasiveness and tumorigenic potential in nude mice. Further studies revealed that SIRT7 exerted an oncogenic function in thyroid tumorigenesis by phosphorylation of Akt and p70S6K1. Mechanistically, SIRT7 binds to the promoter of deleted in breast cancer-1 (DBC1), an endogenous inhibitor of SIRT1, and represses its transcription via deacetylation of H3K18Ac. This results in enhanced interactions between SIRT1 and Akt or p70S6K1, thereby promoting deacetylation and subsequent phosphorylation of Akt and p70S6K1 through a SIRT1-dependent manner. Altogether, our results show that DBC1 is a downstream target of SIRT7, and first uncover that SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via the modulation of DBC1/SIRT1 axis.	[Li, Heng; Qu, Yiping; Yang, Qi; Shi, Bingyin; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Li, Heng; Tian, Zhufang] Xian Cent Hosp, Dept Endocrinol, Xian 710003, Shaanxi, Peoples R China; [Guan, Haixia] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang 110001, Liaoning, Peoples R China; [Shi, Bingyin; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China; [Ji, Meiju] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; China Medical University; Xi'an Jiaotong University; Xi'an Jiaotong University	Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.; Ji, MJ (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China.	mjji0409@163.com; phou@xjtu.edu.cn			National Natural Science Foundation of China [81372217, 81572627, 81672645]; China International Medical Foundation [2016-N-07-12]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China International Medical Foundation	We would like to thank Drs. Haixia Guan (The First Affiliated Hospital of China Medical University, Shenyang, China) and Lei Ye (Ruijin Hospital, Shanghai, China) for kindly providing human thyroid cancer cell lines. This work was supported by the National Natural Science Foundation of China (no. 81372217, 81572627 and 81672645), and the China International Medical Foundation (no. 2016-N-07-12).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burns WR, 2010, SEMIN ONCOL, V37, P557, DOI 10.1053/j.seminoncol.2010.10.008; Chalkiadaki A, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc3985; Chen SF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10734; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; de Nigris F, 2002, BRIT J CANCER, V86, P917, DOI 10.1038/sj.bjc.6600156; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Frye R, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600635; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Hong SK, 2014, J BIOL CHEM, V289, P13132, DOI 10.1074/jbc.M113.520734; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kang H, 2011, MOL CELL, V44, P203, DOI 10.1016/j.molcel.2011.07.038; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Petrulea MS, 2015, CANCER TREAT REV, V41, P707, DOI 10.1016/j.ctrv.2015.06.005; Qu N, 2017, INT J ONCOL, V50, P1683, DOI 10.3892/ijo.2017.3951; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shackelford R, 2013, ANTICANCER RES, V33, P3047; Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.346; Shi J, 2015, ONCOTARGET, V6, P14344, DOI 10.18632/oncotarget.3852; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Toker A, 2008, MOL CELL, V31, P6, DOI 10.1016/j.molcel.2008.06.007; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yu HY, 2014, CLIN CANCER RES, V20, P3434, DOI 10.1158/1078-0432.CCR-13-2952; Yu J, 2017, CELL REP, V18, P1229, DOI 10.1016/j.celrep.2017.01.009; Zhang PY, 2016, NUCLEIC ACIDS RES, V44, P3629, DOI 10.1093/nar/gkv1504; Zhang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09787; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	41	29	32	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					345	359		10.1038/s41388-018-0434-6	http://dx.doi.org/10.1038/s41388-018-0434-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093629				2022-12-28	WOS:000455851200004
J	Hamaidi, M; Coquard, C; Danilin, S; Dormoy, V; Beraud, C; Rothhut, S; Barthelmebs, M; Benkirane-Jessel, N; Lindner, V; Lang, H; Massfelder, T				Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Beraud, Claire; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Lindner, Veronique; Lang, Herve; Massfelder, Thierry			The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma	ONCOGENE			English	Article							MOUSE; LHX1; PATHWAY; DIFFERENTIATION; REQUIREMENT; EXPRESSION; GROWTH; LDB1	Metastatic clear cell renal cell carcinoma (CCC) remains incurable despite advances in the development of anti-angiogenic targeted therapies and the emergence of immune checkpoint inhibitors. We have previously shown that the sonic hedgehog-Gli signaling pathway is oncogenic in CCC allowing us to identify the developmental Lim1 transcription factor as a Gli target and as a new oncogene in CCC regulating cell proliferation and apoptosis, and promoting tumor growth. In this previous study, preliminary in vitro results also suggested that Lim1 may be implicated in metastatic spread. Here we investigated the potential pro-metastatic role of Lim1 in advanced CCC (1) in vitro using a panel of CCC cell lines expressing or not the von Hippel-Lindau (VHL) tumor suppressor gene either naturally or by gene transfer and (2) ex vivo in 30 CCC metastatic tissues, including lymph nodes, lung, skin, bone, and adrenal metastases, and (3) in vivo, using a metastatic model by intravenous injection of siRNA-transfected cells into Balb/c nude. Our in vitro results reveal that Lim1 knockdown time-dependently decreased CCC cell motility, migration, invasion, and clonogenicity by up to 50% regardless of their VHL status. Investigating the molecular machinery involved in these processes, we identified a large panel of Lim1 targets known to be involved in cell adhesion (paxillin and fibronectin), epithelial-mesenchymal transition (Twist1/2 and snail), invasion (MMP1/2/3/8/9), and metastatic progression (CXCR4, SDF-1, and ANG-1). Importantly, Lim1 was found constitutively expressed in all metastatic tissues. The H-score in metastatic tissues being significantly superior to the score in the corresponding primary tumor tissues (P value = 0.009). Furthermore, we showed that Lim1 silencing decreases pulmonary metastasis development in terms of number and size in the in vivo metastatic model of human CCC. Taken together, these experiments strengthen the potential therapeutic value of Lim1 targeting as a promising novel approach for treating metastatic human CCC.	[Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Massfelder, Thierry] INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France; [Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Massfelder, Thierry] Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France; [Beraud, Claire] UROLEAD SAS, Sch Med, F-67085 Strasbourg, France; [Benkirane-Jessel, Nadia] INSERM, UMR S1260, Regenerat Nanomed Lab, F-67085 Strasbourg, France; [Lindner, Veronique] Hop Univ Strasbourg, Dept Pathol, Hop Strasbourg Hautepierre, F-67200 Strasbourg, France; [Lang, Herve] Hop Univ Strasbourg, Dept Urol, Nouvel Hop Civil, F-67200 Strasbourg, France; [Danilin, Sabrina] Firalis, F-68330 Huningue, France; [Dormoy, Valerian] URCA, INSERM UMR S1250, CHU Maison Blanche, 45 Rue Cognacq Jay, F-51092 Reims, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; CHU Strasbourg; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Reims; Universite de Reims Champagne-Ardenne	Massfelder, T (corresponding author), INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France.; Massfelder, T (corresponding author), Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France.	massfeld@unistra.fr	Dormoy, Valerian/P-5109-2016; Massfelder, Thierry/I-1260-2016; Benkirane-Jessel, Nadia/H-6438-2016	Dormoy, Valerian/0000-0003-1725-371X; 	INSERM; University of Strasbourg; Ligue Contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Strasbourg; Ligue Contre le Cancer(Ligue nationale contre le cancer)	This study was sponsored by INSERM (recipient TM), the University of Strasbourg (recipient TM), and the Ligue Contre le Cancer (recipient TM). The authors thank Martine MUCKENSTURM, Fabienne REYMANN, and Angelique WERCK, from the Department of Pathology, University Hospital, Strasbourg, for their technical assistance in immunohistochemistry.	BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beksac AT, 2017, UROL ONCOL, pS1078; Beraud C, 2015, INT J CANCER, V137, P1549, DOI 10.1002/ijc.29522; Cheah SS, 2000, GENESIS, V27, P12, DOI 10.1002/1526-968X(200005)27:1<12::AID-GENE30>3.3.CO;2-O; Cirio MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018858; Costello I, 2015, GENE DEV, V29, P2108, DOI 10.1101/gad.268979.115; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Dormoy V, 2011, ONCOGENE, V30, P1753, DOI 10.1038/onc.2010.557; Dormoy V, 2012, ANTICANCER RES, V32, P3609; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Escudier B, 2014, J CLIN ONCOL, V32, P1412, DOI 10.1200/JCO.2013.50.8267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao Y, 2017, CANCER RES, V77, P330, DOI 10.1158/0008-5472.CAN-16-0348; Guertl B, 2011, PATHOBIOLOGY, V78, P210, DOI 10.1159/000326769; Huang CC, 2014, DEV BIOL, V389, P124, DOI 10.1016/j.ydbio.2014.01.025; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Ledig S, 2012, HUM REPROD, V27, P2872, DOI 10.1093/humrep/des206; Li H, 2016, ONCOTARGET, V7, P80415, DOI 10.18632/oncotarget.11246; Li JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0681-0; Lin TC, 2015, J PATHOL, V237, P50, DOI 10.1002/path.4552; Lin YW, 2016, J PINEAL RES, V60, P277, DOI 10.1111/jpi.12308; Liu LQ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711951; Mehta K, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0457-4; Mikami S, 2016, PATHOL INT, V66, P481, DOI 10.1111/pin.12433; Mumert M, 2012, CANCER RES, V72, P4944, DOI 10.1158/0008-5472.CAN-12-1629; Neuberg P, 2018, NANOSCALE, V10, P1587, DOI 10.1039/c7nr09202d; Posadas EM, 2017, NAT REV NEPHROL, V13, P496, DOI 10.1038/nrneph.2017.82; Qu LS, 2016, ONCOL LETT, V11, P624, DOI 10.3892/ol.2015.3958; Ruan HL, 2017, INT J ONCOL, V51, P336, DOI 10.3892/ijo.2017.4010; Sato N, 2003, CANCER RES, V63, P3735; Scelo G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15724; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Tong Wei-Gang, 2010, Epigenetics, V5, P499; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varis A, 2002, CANCER RES, V62, P2625; Wang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01084-w; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Yang HL, 2017, ONCOL LETT, V13, P4755, DOI 10.3892/ol.2017.6084; Ye L, 2012, HISTOCHEM CELL BIOL, V137, P527, DOI 10.1007/s00418-011-0909-9; Yerokhin VA, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.233002; Zhao Y, 2007, P NATL ACAD SCI USA, V104, P13182, DOI 10.1073/pnas.0705464104; Zhao ZH, 2017, ONCOL RES, V25, P773, DOI 10.3727/096504016X14774889687280; Zhu JD, 2017, ONCOTARGET, V8, P51559, DOI 10.18632/oncotarget.18086	48	7	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					60	72		10.1038/s41388-018-0413-y	http://dx.doi.org/10.1038/s41388-018-0413-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076415	Green Submitted			2022-12-28	WOS:000454775900005
J	Chen, A; Sceneay, J; Godde, N; Kinwel, T; Ham, S; Thompson, EW; Humbert, PO; Moller, A				Chen, Anna; Sceneay, Jaclyn; Godde, Nathan; Kinwel, Tanja; Ham, Sunyoung; Thompson, Erik W.; Humbert, Patrick O.; Moller, Andreas			Intermittent hypoxia induces a metastatic phenotype in breast cancer	ONCOGENE			English	Article							SUPPRESSOR-CELLS; SIGNALING PATHWAYS; GENE-EXPRESSION; DOWN-REGULATION; TUMOR-CELLS; MECHANISMS; ANGIOGENESIS; PROGRESSION; AUTOPHAGY; PROMOTES	Hypoxia arises frequently in solid tumors and is a poor prognostic factor as it promotes tumor cell proliferation, invasion, angiogenesis, therapy resistance, and metastasis. Notably, there are two described forms of hypoxia present in a growing tumor: chronic hypoxia, caused by abnormal tumor vasculature, and intermittent hypoxia, caused by transient perfusion facilitated by tumor-supplying blood vessels. Here, we demonstrate that intermittent hypoxia, but not chronic hypoxia, endows breast cancer cells with greater metastatic potential. Using an immunocompetent and syngeneic murine model of breast cancer, we show that intermittent hypoxia enhances metastatic seeding and outgrowth in lungs in vivo. Furthermore, exposing mammary tumor cells to intermittent hypoxia promoted clonal diversity, upregulated metastasis-associated gene expression, induced a pro-tumorigenic secretory profile, increased stem-like cell marker expression, and gave rise to tumor-initiating cells at a relatively higher frequency. This work demonstrates that intermittent hypoxia, but not chronic hypoxia, induces a number of genetic, molecular, biochemical, and cellular changes that facilitate tumor cell survival, colonization, and the creation of a permissive microenvironment and thus enhances metastatic growth.	[Chen, Anna; Godde, Nathan; Kinwel, Tanja; Humbert, Patrick O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia; [Chen, Anna; Kinwel, Tanja; Humbert, Patrick O.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; [Chen, Anna; Sceneay, Jaclyn; Ham, Sunyoung; Moller, Andreas] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld 4006, Australia; [Godde, Nathan; Kinwel, Tanja; Humbert, Patrick O.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Godde, Nathan; Humbert, Patrick O.] Univ Melbourne, Sir Peter MaCallum Dept Oncol, Parkville, Vic 3010, Australia; [Godde, Nathan] CSIRO, Australian Anim Hlth Lab, Pathol & Pathogenesis Grp, Diagnost Surveillance & Response, Geelong, Vic 3220, Australia; [Thompson, Erik W.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4000, Australia; [Thompson, Erik W.] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4000, Australia; [Thompson, Erik W.] Univ Melbourne, St Vincents Hosp, Dept Surg, East Melbourne 3002, Australia; [Humbert, Patrick O.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; [Sceneay, Jaclyn] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Peter Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical Research Institute; La Trobe University; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Melbourne; University of Melbourne; Harvard University; Brigham & Women's Hospital	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.; Moller, A (corresponding author), QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld 4006, Australia.; Humbert, PO (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Sir Peter MaCallum Dept Oncol, Parkville, Vic 3010, Australia.; Humbert, PO (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	p.humbert@latrobe.edu.au; andreas.moller@qimrberghofer.edu.au	Möller, Andreas/O-1063-2015; Humbert, Patrick O/L-4264-2016; Thompson, Erik/GPK-2067-2022; Thompson, Erik W/A-1425-2009	Möller, Andreas/0000-0002-8618-6998; Humbert, Patrick O/0000-0002-1366-6691; Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Godde, Nathan/0000-0002-3413-407X	National Health and Medical Research Council of Australia [APP1068510, APP1079133]; Cancer Council Queensland [APP1045620]; National Breast Cancer Foundation (Australia) [ECF-11-09, NC-13-26]; APA scholarship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); National Breast Cancer Foundation (Australia); APA scholarship	The authors thank Carmen Yong for help with flow cytometry and IV injections, and the groups of POH and AM for proof-reading the manuscript. This work was supported by funding from a project grant from the National Health and Medical Research Council of Australia (APP1068510 to AM). POH was supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia (APP1079133). AM was supported by Cancer Council Queensland (APP1045620), and National Breast Cancer Foundation (Australia) fellowship and grant (ECF-11-09, NC-13-26). AC was supported by an APA scholarship.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alqawi O, 2007, FREE RADICAL RES, V41, P788, DOI 10.1080/10715760701361531; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bayer C, 2012, STRAHLENTHER ONKOL, V188, P616, DOI 10.1007/s00066-012-0085-4; Bhaskara VK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030905; Boidot R, 2014, ONCOTARGET, V5, P6947, DOI 10.18632/oncotarget.2285; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Cairns RA, 2001, CANCER RES, V61, P8903; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan N, 2008, CANCER RES, V68, P605, DOI 10.1158/0008-5472.CAN-07-5472; Chen A, 2015, ONCOTARGET, V6, P862, DOI 10.18632/oncotarget.2696; Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078-0432.CCR-04-1235; Daneau G, 2010, CLIN CANCER RES, V16, P410, DOI 10.1158/1078-0432.CCR-09-0583; Fang YY, 2015, CELL BIOL INT, V39, P891, DOI 10.1002/cbin.10463; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gupta R, 2011, INT J ONCOL, V38, P733, DOI 10.3892/ijo.2010.883; Gutsche K, 2016, FREE RADICAL BIO MED, V101, P129, DOI 10.1016/j.freeradbiomed.2016.10.002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hsieh CH, 2012, MOL IMAGING BIOL, V14, P489, DOI 10.1007/s11307-011-0516-0; Hsieh CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023945; Hsieh CH, 2010, ONCOL REP, V24, P1629, DOI 10.3892/or_00001027; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussein D, 2006, MOL CANCER THER, V5, P2241, DOI 10.1158/1535-7163.MCT-06-0145; Kalliomaki TM, 2009, CANCER LETT, V282, P98, DOI 10.1016/j.canlet.2009.03.009; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Liu YL, 2010, J CELL BIOCHEM, V111, P554, DOI 10.1002/jcb.22739; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinive P, 2006, CANCER RES, V66, P11736, DOI 10.1158/0008-5472.CAN-06-2056; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015; Miao ZF, 2014, TUMOR BIOL, V35, P6801, DOI 10.1007/s13277-014-1928-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moller A, 2009, ONCOGENE, V28, P289, DOI 10.1038/onc.2008.382; Mujcic H, 2013, CLIN CANCER RES, V19, P6126, DOI 10.1158/1078-0432.CCR-13-0526; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Rofstad EK, 2010, INT J CANCER, V127, P1535, DOI 10.1002/ijc.25176; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sceneay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066388; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Wong CSF, 2012, CANCER RES, V72, P1694, DOI 10.1158/0008-5472.CAN-11-3310; Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298; Zolzer F, 2002, INT J RADIAT ONCOL, V54, P910, DOI 10.1016/S0360-3016(02)02963-2	60	72	73	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4214	4225		10.1038/s41388-018-0259-3	http://dx.doi.org/10.1038/s41388-018-0259-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713057				2022-12-28	WOS:000440566100002
J	Lee, HK; Lee, EW; Seo, J; Jeong, M; Lee, SH; Kim, SY; Jho, EH; Choi, CH; Chung, JY; Song, J				Lee, Hae-Kyung; Lee, Eun-Woo; Seo, Jinho; Jeong, Manhyung; Lee, Seon-Hyeong; Kim, Soo-Youl; Jho, Eek-Hoon; Choi, Chel Hun; Chung, Joon-Yong; Song, Jaewhan			Ubiquitylation and degradation of adenomatous polyposis coli by MKRN1 enhances Wnt/beta-catenin signaling	ONCOGENE			English	Article							TUMOR-SUPPRESSOR APC; BETA-CATENIN; WNT PATHWAY; COLORECTAL-CANCER; PLASMA-MEMBRANE; WILMS-TUMOR; GENE; AXIN; PHOSPHORYLATION; UBIQUITIN	The adenomatous polyposis coli (APC) protein has a tumor-suppressor function by acting as a negative regulator of the Wnt signaling pathway. While its role as a tumor suppressor is well-defined, the post-translational modifications that regulate APC stability are not fully understood. Here we showed that MKRN1, an E3 ligase, could directly interact with and ubiquitylate APC, promoting its proteasomal degradation. In contrast, an E3 ligase-defective MKRN1 mutant was no longer capable of regulating APC, indicating that its E3 ligase activity is required for APC regulation by MKRN1. Strengthening these results, MKRN1 ablation resulted in reduced beta-catenin activity and decreased expression of Wnt target genes. The ability of the Wnt-dependent pathway to induce cancer cell proliferation, migration, and invasion was impaired by MKRN1 depletion, but restored by simultaneous APC knockdown. Taken together, these results demonstrate that MKRN1 functions as a novel E3 ligase of APC that positively regulates Wnt/beta-catenin-mediated biological processes.	[Lee, Hae-Kyung; Seo, Jinho; Jeong, Manhyung; Song, Jaewhan] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, 50 Yonsei Ro, Seoul 03722, South Korea; [Lee, Eun-Woo] KRIBB, Metab Regulat Res Ctr, Daejeon 34141, South Korea; [Lee, Seon-Hyeong; Kim, Soo-Youl] Natl Canc Ctr, Div Canc Biol, Tumor Microenvironm Res Branch, Goyang 10408, Gyeonggi Do, South Korea; [Jho, Eek-Hoon] Univ Seoul, Dept Life Sci, 90 Jeonnong Dong, Seoul 02592, South Korea; [Choi, Chel Hun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul 135710, South Korea; [Chung, Joon-Yong] NCI, Expt Pathol Lab, Lab Pathol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Cancer Center - Korea (NCC); University of Seoul; Sungkyunkwan University (SKKU); Samsung Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, 50 Yonsei Ro, Seoul 03722, South Korea.	jso678@yonsei.ac.kr	Chung, Joon-Yong/J-9177-2017; Lee, Eun-Woo/AAP-9603-2020	Chung, Joon-Yong/0000-0001-5041-5982; Song, Jaewhan/0000-0001-8152-9210; Lee, Hae-Kyung/0000-0001-6076-481X; Lee, Eun-Woo/0000-0002-5156-0003; Jho, Eek-hoon/0000-0003-2414-6234	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1A3A2066581]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	We thank Prof. KY Choi (Yonsei University) for providing L929, L929-hWnt3a, and HEK293-TOP-FLASH stable cell lines. This research was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A3A2066581) to J Song.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bastakoty D, 2016, FASEB J, V30, P3271, DOI 10.1096/fj.201600502R; Berndt JD, 2013, SCIENCE, V339, P1388, DOI 10.1126/science.1236641; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x; Cassar PA, 2015, EMBO REP, V16, P1334, DOI 10.15252/embr.201540974; Choi J, 2004, J BIOL CHEM, V279, P49188, DOI 10.1074/jbc.M404655200; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Tran H, 2013, J BIOL CHEM, V288, P3753, DOI 10.1074/jbc.M112.415240; Tran H, 2012, J BIOL CHEM, V287, P28552, DOI 10.1074/jbc.M112.387878; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kim JH, 2014, CELL DEATH DIFFER, V21, P594, DOI 10.1038/cdd.2013.181; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kim W, 2013, ONCOGENE, V32, P3390, DOI 10.1038/onc.2012.373; Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lee EW, 2009, EMBO J, V28, P2100, DOI 10.1038/emboj.2009.164; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morishita EC, 2011, STRUCTURE, V19, P1496, DOI 10.1016/j.str.2011.07.013; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 2015, NATURE, V519, P163, DOI 10.1038/nature14208; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Saito-Diaz K, 2013, GROWTH FACTORS, V31, P1, DOI 10.3109/08977194.2012.752737; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Tauriello DVF, 2010, CELL CYCLE, V9, P3700, DOI 10.4161/cc.9.18.13204; Tong J, 2013, STRUCTURE, V21, P1203, DOI 10.1016/j.str.2013.05.007; Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208; Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Zhang ZY, 2012, CELL RES, V22, P372, DOI 10.1038/cr.2011.119; Zimmerman ZF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008086	68	12	13	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4273	4286		10.1038/s41388-018-0267-3	http://dx.doi.org/10.1038/s41388-018-0267-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713058				2022-12-28	WOS:000440566100006
J	Pentimalli, F; Forte, IM; Esposito, L; Indovina, P; Iannuzzi, CA; Alfano, L; Costa, C; Barone, D; Rocco, G; Giordano, A				Pentimalli, Francesca; Forte, Iris M.; Esposito, Luca; Indovina, Paola; Iannuzzi, Carmelina A.; Alfano, Luigi; Costa, Caterina; Barone, Daniela; Rocco, Gaetano; Giordano, Antonio			RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA FAMILY; PRB2/P130 EXPRESSION; GENE-EXPRESSION; CDK INHIBITORS; CYCLE; PHOSPHORYLATION; KINASE; RB; ACTIVATION	The retinoblastoma (RB) protein family includes RB1/p105, RBL1/p107, and RBL2/p130, which are key factors in cell-cycle regulation and stand at the crossroads of multiple pathways dictating cell fate decisions. The role of RB proteins in apoptosis is controversial because they can inhibit or promote apoptosis depending on the context, on the apoptotic stimuli and on their intrinsic status, impacting on the response to antitumoral treatments. Here we identified RBL2/p130 as a direct substrate of the AKT kinase, a key antiapoptotic factor hyperactive in multiple cancer types. We showed that RBL2/p130 and AKT1 physically interact and AKT phosphorylates RBL2/p130 Ser941, located in the pocket domain, but not when this residue is mutated into Ala. We found that pharmacological inhibition of AKT, through the highly selective AKT inhibitor VIII (AKTiVIII), impairs RBL2/p130 Ser941 phosphorylation and increases RBL2/p130 stability, mRNA expression and nuclear levels in both lung cancer and mesothelioma cell lines, mirroring the more extensively studied effects on the p27 cell-cycle inhibitor. Consistently, AKT inhibition reduced cell viability, induced cell accumulation in G0/G1, and triggered apoptosis, which proved to be largely dependent on RBL2/p130 itself, as shown upon RBL2/p130 silencing. AKT inhibition induced RBL2/p130-dependent apoptosis also in HEK-293 cells, in which re-expression of a short hairpin-resistant RBL2/p130 was able to rescue AKTiVIII-induced apoptosis upon RBL2/p130 silencing. Our data also showed that the combination of AKT and cyclin-dependent kinases (CDK) inhibitors, which converge on the re-activation of RBL2/p130 antitumoral potential, could be a promising anticancer strategy.	[Pentimalli, Francesca; Forte, Iris M.; Esposito, Luca; Iannuzzi, Carmelina A.; Alfano, Luigi; Costa, Caterina; Barone, Daniela] Fdn G Pascale, Ist Nazl Tumori IRCCS, Oncol Res Ctr Mercogliano CROM, I-80131 Naples, Italy; [Indovina, Paola; Giordano, Antonio] Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; [Iannuzzi, Carmelina A.; Barone, Daniela; Giordano, Antonio] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy; [Rocco, Gaetano] Fdn G Pascale, Div Thorac Surg, Dept Thorac Surg & Oncol, Ist Nazl Tumori, I-80131 Naples, Italy; [Rocco, Gaetano] IRCCS, I-80131 Naples, Italy	IRCCS Fondazione Pascale; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Pentimalli, F (corresponding author), Fdn G Pascale, Ist Nazl Tumori IRCCS, Oncol Res Ctr Mercogliano CROM, I-80131 Naples, Italy.; Giordano, A (corresponding author), Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA.; Giordano, A (corresponding author), Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy.	f.pentimalli@istitutotumori.na.it; president@shro.org	Alfano, Luigi/B-8330-2015; Forte, Iris Maria/K-7588-2016; Costa, Caterina/N-1742-2019; Barone, Daniela/N-1024-2015; Pentimalli, Francesca/K-4936-2014; Iannuzzi, CarmelinaAntonella/K-3131-2018; Giordano, Antonio/AAU-1201-2020; Costa, Caterina/ABE-2452-2020; Rocco, Gaetano/K-4801-2016	Alfano, Luigi/0000-0002-4516-9956; Forte, Iris Maria/0000-0001-9490-5844; Costa, Caterina/0000-0003-0909-7366; Barone, Daniela/0000-0002-5543-7686; Pentimalli, Francesca/0000-0003-4740-6801; Iannuzzi, CarmelinaAntonella/0000-0002-4445-9687; Giordano, Antonio/0000-0002-5959-016X; Indovina, Paola/0000-0001-8416-435X; Rocco, Gaetano/0000-0003-4150-8604	AIRC-Associazione Italiana per la Ricerca sul Cancro [IG 2014-15690]; Italian Ministry of Health; Sbarro Health Research Organization [phosphoRBL2/p130S941]	AIRC-Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Sbarro Health Research Organization	This work was supported by the AIRC-Associazione Italiana per la Ricerca sul Cancro, IG 2014-15690 to AG and by the Italian Ministry of Health. We are grateful to the Sbarro Health Research Organization (www.shro.org) for its support and for providing the custom phosphoRBL2/p130S941 antibody, and to the Commonwealth of Pennsylvania. We are grateful to our intern students Flora Magnotti, Michela Napolitano, Caterina Miro and Sonia Sodano for technical help. We are grateful to Flavio Rizzolio for sharing RBL2/p130 silencing vectors and to Enrico Bucci for helpful discussion. AG is also Director of the Cell Cycle and Cancer Research Line at CROM, Istituto Nazionale Tumori; Naples. FP is also Adjunct Associate professor at Temple University, Department of Biology, Philadelphia, PA, USA.	Abate AA, 2013, EXPERT OPIN INV DRUG, V22, P895, DOI 10.1517/13543784.2013.798641; Alessio N, 2013, CELL MOL LIFE SCI, V70, P1637, DOI 10.1007/s00018-012-1224-x; Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Busacca S, 2010, AM J RESP CELL MOL, V42, P312, DOI 10.1165/rcmb.2009-0060OC; Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017; Caputi M, 2002, CLIN CANCER RES, V8, P3850; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cirillo D, 2011, CURR MED CHEM, V18, P2854, DOI 10.2174/092986711796150496; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; David O, 2004, CLIN CANCER RES, V10, P6865, DOI 10.1158/1078-0432.CCR-04-0174; De Falco G, 2006, ONCOGENE, V25, P5333, DOI 10.1038/sj.onc.1209614; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Di Marzo D, 2014, CELL CYCLE, V13, P652, DOI 10.4161/cc.27546; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Ecker K, 2009, NAT CELL BIOL, V11, P377, DOI [10.1038/ncb1859, 10.1038/ncb0409-377]; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Helmbold H, 2012, J CELL PHYSIOL, V227, P508, DOI 10.1002/jcp.22786; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Howard CM, 2000, CANCER RES, V60, P2737; Indovina P, 2012, ONCOGENE, V31, P929, DOI 10.1038/onc.2011.286; Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286; Indovina P, 2013, J CELL PHYSIOL, V228, P525, DOI 10.1002/jcp.24170; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2010, CLIN CANCER RES, V16, P1094, DOI 10.1158/1078-0432.CCR-09-0787; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; Liu PD, 2014, CELL CYCLE, V13, P2162, DOI 10.4161/cc.29584; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logie L, 2007, DIABETES, V56, P2218, DOI 10.2337/db07-0343; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Masciullo V, 2008, CLIN CANCER RES, V14, P4775, DOI 10.1158/1078-0432.CCR-07-4055; MAYOL X, 1993, ONCOGENE, V8, P2561; Meuillet EJ, 2011, CURR MED CHEM, V18, P2727; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pentimalli F, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-LB-080; Pentimalli F, 2010, CANCER DRUG DISCOV D, P109, DOI 10.1007/978-1-60761-178-3_8; Pucci B, 2002, ONCOGENE, V21, P5897, DOI 10.1038/sj.onc.1205750; Qiu ZX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081451; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rizzolio F, 2012, CELL DEATH DIFFER, V19, P1152, DOI 10.1038/cdd.2011.202; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Yang H, 2006, ONCOGENE, V25, P4585, DOI 10.1038/sj.onc.1209481; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010; Zhou S, 2014, BRIT J CANCER, V110, P2479, DOI 10.1038/bjc.2014.220	61	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3657	3671		10.1038/s41388-018-0214-3	http://dx.doi.org/10.1038/s41388-018-0214-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29606701				2022-12-28	WOS:000437975200004
J	Tang, QL; Lu, JC; Zou, CY; Shao, Y; Chen, Y; Narala, S; Fang, H; Xu, HY; Wang, J; Shen, JN; Khokha, R				Tang, Qinglian; Lu, Jinchang; Zou, Changye; Shao, Yang; Chen, Yan; Narala, Swami; Fang, Hui; Xu, Huaiyuan; Wang, Jin; Shen, Jingnan; Khokha, Rama			CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; TYPHIMURIUM A1-R REGRESSES; CADHERIN EXPRESSION; PEDIATRIC OSTEOSARCOMA; OSTEOBLAST LINEAGE; LUNG METASTASIS; TUMOR-GROWTH; C-JUN; CELLS; CANCER	The era of cancer genomics now provides an opportunity to discover novel determinants of osteosarcoma (OS), the most common primary bone cancer in children and adolescents known for its poor prognosis due to lung metastasis. Here, we identify CDH4 amplification in 43.6% of human osteosarcoma using array CGH and demonstrate its critical role in osteosarcoma development and progression. Gain or loss-of-function of CDH4, which encodes R-cadherin, causally impacts multiple features of human OS cells including cell migration and invasion, osteogenic differentiation, and stemness. CDH4 overexpression activates c-Jun via the JNK pathway, while CDH4 knockdown suppresses both tumor xenograft growth and lung colonization. In OS patient specimens, high CDH4 expression associates with lung metastases and poor prognosis. Collectively, our bioinformatics, functional, molecular, and clinical analyses uncover an oncogenic function of CDH4 in osteosarcoma and its relationship with patient outcome.	[Tang, Qinglian; Lu, Jinchang; Shao, Yang; Chen, Yan; Narala, Swami; Fang, Hui; Khokha, Rama] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 0A3, Canada; [Tang, Qinglian; Lu, Jinchang; Zou, Changye; Xu, Huaiyuan; Wang, Jin; Shen, Jingnan] Sun Yat Sen Univ, Dept Orthoped Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Sun Yat Sen University	Khokha, R (corresponding author), Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 0A3, Canada.; Shen, JN (corresponding author), Sun Yat Sen Univ, Dept Orthoped Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.	shenjingnan@126.com; rama.khokha@utoronto.ca			Canadian Institutes of Health Research (CIHR); Canadian Cancer Society Research Institute (CCSRI); International Science & Technology Cooperation Program of Guangzhou [201704030008]; Graduate Student Overseas Study Program of China Scholarship Council; National Natural Science Foundation of China [81502324]; National Postdoctoral Program for Innovative Talents [BX201600196]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); International Science & Technology Cooperation Program of Guangzhou; Graduate Student Overseas Study Program of China Scholarship Council; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Postdoctoral Program for Innovative Talents	This study is supported by funding from the Canadian Institutes of Health Research (CIHR) and the Canadian Cancer Society Research Institute (CCSRI) to RK, and International Science & Technology Cooperation Program of Guangzhou to JS (201704030008). Q.T. and J.L. are supported by Graduate Student Overseas Study Program of China Scholarship Council. Q.T. is also supported by National Natural Science Foundation of China (81502324), and J.L. is supported by National Postdoctoral Program for Innovative Talents (BX201600196).	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Biermann J Sybil, 2007, J Natl Compr Canc Netw, V5, P420; Bjornland K, 2005, J SURG RES, V127, P151, DOI 10.1016/j.jss.2004.12.016; Both J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030907; Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Fromigue O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200; Gustems M, 2014, NUCLEIC ACIDS RES, V42, P3059, DOI 10.1093/nar/gkt1323; Gvozdenovic A, 2013, J BONE MINER RES, V28, P838, DOI 10.1002/jbmr.1817; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Igarashi K, 2017, CELL CYCLE, V16, P1164, DOI 10.1080/15384101.2017.1317417; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashima T, 1999, AM J PATHOL, V155, P1549, DOI 10.1016/S0002-9440(10)65471-5; Kawaguchi J, 2001, J BONE MINER RES, V16, P260, DOI 10.1359/jbmr.2001.16.2.260; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Kitajima H, 2013, CANCER MED-US, V2, P267, DOI 10.1002/cam4.67; Kresse SH, 2009, GENE CHROMOSOME CANC, V48, P679, DOI 10.1002/gcc.20675; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Lorenz S, 2016, ONCOTARGET, V7, P5273, DOI 10.18632/oncotarget.6567; Lu J, 2017, ONCOGENE, V36, P231, DOI 10.1038/onc.2016.194; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006; Martin Jeff W., 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Murakami T, 2017, ONCOTARGET, V8, P8035, DOI 10.18632/oncotarget.14040; Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Pohlig F, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1315-6; Poos K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123082; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; Smida J, 2017, INT J CANCER, V141, P816, DOI 10.1002/ijc.30778; Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang GY, 2011, ASIAN PAC J CANCER P, V12, P2075	45	23	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3617	3630		10.1038/s41388-018-0231-2	http://dx.doi.org/10.1038/s41388-018-0231-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29610525				2022-12-28	WOS:000437975200001
J	Cajal, SRY; Castellvi, J; Hummer, S; Peg, V; Pelletier, J; Sonenberg, N				Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente; Pelletier, Jerry; Sonenberg, Nahum			Beyond molecular tumor heterogeneity: protein synthesis takes control	ONCOGENE			English	Review							INITIATION-FACTOR 4E; PHOSPHORYLATED 4E-BINDING PROTEIN-1; BREAST-CANCER; EUKARYOTIC TRANSLATION; BINDING-PROTEIN; POOR-PROGNOSIS; 4E-BP1 PHOSPHORYLATION; EIF4E EXPRESSION; MAMMALIAN TARGET; CLONAL EVOLUTION	One of the daunting challenges facing modern medicine lies in the understanding and treatment of tumor heterogeneity. Most tumors show intra-tumor heterogeneity at both genomic and proteomic levels, with marked impacts on the responses of therapeutic targets. Therapeutic target-related gene expression pathways are affected by hypoxia and cellular stress. However, the finding that targets such as eukaryotic initiation factor (eIF) 4E (and its phosphorylated form, p-eIF4E) are generally homogenously expressed throughout tumors, regardless of the presence of hypoxia or other cellular stress conditions, opens the exciting possibility that malignancies could be treated with therapies that combine targeting of eIF4E phosphorylation with immune checkpoint inhibitors or chemotherapy.	[Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente] Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Ramon y Cajal, Santiago; Castellvi, Josep; Peg, Vicente] Vall dHebron Hosp, Pathol Dept, Barcelona 08035, Spain; [Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente] Spanish Biomed Res Network Ctr Oncol CIBERONC, Madrid, Spain; [Pelletier, Jerry; Sonenberg, Nahum] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Pelletier, Jerry; Sonenberg, Nahum] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; McGill University; McGill University	Cajal, SRY (corresponding author), Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	sramon@vhebron.net	Hümmer, Stefan/J-9861-2013; Peg, Vicente/E-9160-2018; Ramon y Cajal, Santiago/H-4955-2016; Castellvi, Josep/C-5092-2014; Peg., Vicente/AAC-9447-2020	Hümmer, Stefan/0000-0002-8184-3872; Peg, Vicente/0000-0002-5203-6166; Ramon y Cajal, Santiago/0000-0002-3867-1390; Castellvi, Josep/0000-0001-5745-9996; Peg., Vicente/0000-0002-5203-6166	Fondo de Investigaciones Sanitarias [P1170185, PI 14/01320]; Redes Tematicas de Investigacion Cooperativa en Salud (RTICC) [RD 12/0036/0057]; Generalitat de Catalunya (AGAUR) [1131]; CIBERONC	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Redes Tematicas de Investigacion Cooperativa en Salud (RTICC); Generalitat de Catalunya (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); CIBERONC	SRYC acknowledges support from Fondo de Investigaciones Sanitarias (P1170185 and PI 14/01320), Redes Tematicas de Investigacion Cooperativa en Salud (RTICC, RD 12/0036/0057), Generalitat de Catalunya (AGAUR, 2014, 1131), and CIBERONC 2017.	Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Banerji CRS, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004115; Benavente S, 2009, INT J RADIAT ONCOL, V75, P1316, DOI 10.1016/j.ijrobp.2009.01.004; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Buckley NE, 2016, SCI REP-UK, V6, DOI 10.1038/srep23383; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campbell L, 2015, AM J CANCER RES, V5, P2838; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Castellvi J, 2009, HUM PATHOL, V40, P1418, DOI 10.1016/j.humpath.2008.12.019; Cencic R, 2011, J VIROL, V85, P6381, DOI 10.1128/JVI.00078-11; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chao MW, 2015, ONCOTARGET, V6, P24092, DOI 10.18632/oncotarget.4483; Chao YK, 2012, J SURG ONCOL, V105, P288, DOI 10.1002/jso.22097; Chen LM, 2012, ONCOTARGET, V3, P869, DOI 10.18632/oncotarget.598; Chen Y, 2017, NEOPLASMA, V64, P787, DOI 10.4149/neo_2017_518; Chen YT, 2017, PATHOL RES PRACT, V213, P490, DOI 10.1016/j.prp.2017.02.004; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Dai XF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06566; Darb-Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432-008-0529-5; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Di Gregorio A, 2016, DEV CELL, V38, P621, DOI 10.1016/j.devcel.2016.08.012; Diab S, 2014, CHEMMEDCHEM, V9, P962, DOI 10.1002/cmdc.201300552; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dreas A, 2017, CURR MED CHEM, V24, P3025, DOI 10.2174/0929867324666170203123427; Faes S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1726078; Fan WB, 2017, J NEURO-ONCOL, V131, P485, DOI 10.1007/s11060-016-2327-2; Fang Z, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0940-5; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Ghosh B, 2009, ACS CHEM BIOL, V4, P367, DOI 10.1021/cb9000475; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Han M, 2014, J INT MED RES, V42, P976, DOI 10.1177/0300060514527912; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heikkinen T, 2013, BREAST CANCER RES TR, V141, P79, DOI 10.1007/s10549-013-2671-2; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hu AX, 2014, TUMORI, V100, P541, DOI 10.1700/1660.18176; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Jiang XM, 2016, J CANCER RES CLIN, V142, P2309, DOI 10.1007/s00432-016-2232-2; Jiao XD, 2013, HEPATO-GASTROENTEROL, V60, P921, DOI 10.5754/hge12865; Karlsson E, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3557; Khosravi S, 2015, J INVEST DERMATOL, V135, P1358, DOI 10.1038/jid.2014.552; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Korkolopoulou P, 2012, HISTOPATHOLOGY, V61, P293, DOI 10.1111/j.1365-2559.2012.04236.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kuznetsov G, 2009, MOL CANCER THER, V8, P1250, DOI 10.1158/1535-7163.MCT-08-1026; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HW, 2015, INT J CLIN EXP PATHO, V8, P3955; Lee HW, 2015, PATHOL RES PRACT, V211, P298, DOI 10.1016/j.prp.2014.12.015; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li ZQ, 2017, ONCOTARGET, V8, P2906, DOI 10.18632/oncotarget.13772; Martinez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123352; Martinez-Saez E, 2016, CANCER MED-US, V5, P2501, DOI 10.1002/cam4.817; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Nishikawa M., 2015, UROL ONCOL, V33, pe9, DOI DOI 10.1016/J.UR0L0NC.2014.12.006; Nishikawa M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0792-4; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pelletier J, 2015, CANCER RES, V75, P250, DOI 10.1158/0008-5472.CAN-14-2789; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Pons B, 2011, INT J ONCOL, V39, P1337, DOI 10.3892/ijo.2011.1118; Qu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23594; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramalingam S, 2014, ONCOTARGET, V5, P530, DOI 10.18632/oncotarget.1528; Cajal SRY, 2014, CLIN TRANSL ONCOL, V16, P937, DOI 10.1007/s12094-014-1203-9; Cajal SRY, 2017, BBA-REV CANCER, V1868, P484, DOI 10.1016/j.bbcan.2017.09.004; Rodon J, 2012, NAT REV CLIN ONCOL, V9, P359, DOI 10.1038/nrclinonc.2012.48; Roh MS, 2015, VIRCHOWS ARCH, V467, P667, DOI 10.1007/s00428-015-1860-2; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Rybinski B, 2016, ONCOTARGET, V7, P72322, DOI 10.18632/oncotarget.11875; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Seki N, 2010, LUNG CANCER, V70, P329, DOI 10.1016/j.lungcan.2010.03.006; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Singh DK, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.22; Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028; Svitkin YV, 2001, RNA, V7, P1743; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2011, WIRES RNA, V2, P277, DOI 10.1002/wrna.52; Tsumuraya T, 2011, BIOCHEM PHARMACOL, V81, P713, DOI 10.1016/j.bcp.2010.12.025; Velasquez C, 2016, P NATL ACAD SCI USA, V113, P8466, DOI 10.1073/pnas.1607768113; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Wang R, 2009, LUNG CANCER, V66, P237, DOI 10.1016/j.lungcan.2009.02.001; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webster KR, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-596; Webster RM, 2016, NAT REV DRUG DISCOV, V15, P81, DOI 10.1038/nrd.2016.3; Xu J, 2013, CHEMMEDCHEM, V8, P1483, DOI 10.1002/cmdc.201300231; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yeh CJ, 2011, VIRCHOWS ARCH, V458, P171, DOI 10.1007/s00428-010-0994-5; Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549-011-1475-5; Yu H, 2017, AM J HEMATOL, V92, pE11, DOI 10.1002/ajh.24594; Zheng JY, 2014, ENVIRON RES LETT, V9, DOI 10.1088/1748-9326/9/7/074006; Zochowska M, 2015, NANOMED-NANOTECHNOL, V11, P67, DOI 10.1016/j.nano.2014.07.009	117	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2490	2501		10.1038/s41388-018-0152-0	http://dx.doi.org/10.1038/s41388-018-0152-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29463861	Green Published, hybrid			2022-12-28	WOS:000431873400003
J	Roudnicky, F; Yoon, SY; Poghosyan, S; Schwager, S; Poyet, C; Vella, G; Bachmann, SB; Karaman, S; Shin, JW; Otto, VI; Detmar, M				Roudnicky, Filip; Yoon, Sun Young; Poghosyan, Susanna; Schwager, Simon; Poyet, Cedric; Vella, Giorgia; Bachmann, Samia B.; Karaman, Sinem; Shin, Jay W.; Otto, Vivianne I.; Detmar, Michael			Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels	ONCOGENE			English	Article							ENDOTHELIAL-CELL PROLIFERATION; INVASIVE BLADDER-CANCER; TUMOR-GROWTH; VEGF-A; ENDOGENOUS INHIBITOR; EXPRESSION DATA; TYPE-1 REPEATS; MICE; IDENTIFICATION; SKIN	Thrombospondin-2 (TSP2) is an anti-angiogenic matricellular protein that inhibits tumor growth and angiogenesis. Tumor-associated blood vascular endothelial cells (BECs) were isolated from human invasive bladder cancers and from matched normal bladder tissue by immuno-laser capture microdissection. Exon expression profiling analyses revealed a particularly high expression of a short TSP2 transcript containing only the last 9 (3') exons of the full-length TSP2 transcript. Using 5' and 3' RACE (rapid amplification of cDNA ends) and Sanger sequencing, we confirmed the existence of the shorter transcript of TSP2 (sTSP2) and determined its sequence which completely lacked the anti-angiogenic thrombospondin type 1 repeats domain. The largest open reading frame predicted within the transcript comprises 209 amino acids and matches almost completely the C-terminal lectin domain of full-length TSP2. We produced recombinant sTSP2 and found that unlike the full-length TSP2, sTSP2 did not inhibit vascular endothelial growth factor-A-induced proliferation of cultured human BECs, but in contrast when combined with TSP2 blocked the inhibitory effects of TSP2 on BEC proliferation. In vivo studies with stably transfected A431 squamous cell carcinoma cells revealed that full-length TSP2, but not sTSP2, inhibited tumor growth and angiogenesis. This study reveals that the transcriptional program of tumor stromal cells can change to transcribe a new version of an endogenous angiogenesis inhibitor that has lost its anti-angiogenic activity.	[Roudnicky, Filip; Yoon, Sun Young; Poghosyan, Susanna; Schwager, Simon; Vella, Giorgia; Bachmann, Samia B.; Karaman, Sinem; Otto, Vivianne I.; Detmar, Michael] ETH, Inst Pharmaceut Sci, Zurich, Switzerland; [Poyet, Cedric] Univ Zurich Hosp, Dept Urol, Zurich, Switzerland; [Shin, Jay W.] RIKEN Ctr Life Sci Technol, Div Genom Technol, Yokohama, Kanagawa, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; RIKEN	Detmar, M (corresponding author), ETH, Inst Pharmaceut Sci, Zurich, Switzerland.	michael.detmar@pharma.ethz.ch	Karaman, Sinem/C-4428-2017	Karaman, Sinem/0000-0002-0719-1773; Roudnicky, Filip/0000-0001-7156-2383; Otto, Vivianne/0000-0002-1157-0186	Swiss National Science Foundation [310030B_147087]; Advanced European Research Council Grant LYVICAM; Krebsliga Schweiz; Krebsliga Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Advanced European Research Council Grant LYVICAM; Krebsliga Schweiz; Krebsliga Zurich	This work was supported by Swiss National Science Foundation grant 310030B_147087, Advanced European Research Council Grant LYVICAM, Krebsliga Schweiz and Krebsliga Zurich (to MD).	Armstrong LC, 2002, MOL BIOL CELL, V13, P1893, DOI 10.1091/mbc.E01-09-0066; Balar AV, 2013, J CLIN ONCOL, V31, P724, DOI 10.1200/JCO.2012.42.5215; Bengtsson M, 2008, AROMA AFFYMETRIX GEN; Borgia B, 2010, CANCER RES, V70, P309, DOI 10.1158/0008-5472.CAN-09-2939; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Carlson CB, 2008, CELL MOL LIFE SCI, V65, P672, DOI 10.1007/s00018-007-7484-1; Carnemolla B, 2002, BLOOD, V99, P1659, DOI 10.1182/blood.V99.5.1659; Castronovo V, 2006, MOL CELL PROTEOMICS, V5, P2083, DOI 10.1074/mcp.M600164-MCP200; Cline MS, 2005, BIOINFORMATICS, V21, pI107, DOI 10.1093/bioinformatics/bti1010; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Dieterich LC, 2012, J PATHOL, V228, P378, DOI 10.1002/path.4072; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Emig D, 2010, NUCLEIC ACIDS RES, V38, pW755, DOI 10.1093/nar/gkq405; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Francois P, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3246; Freeman LA, 2013, METHODS MOL BIOL, V1027, P3, DOI 10.1007/978-1-60327-369-5_1; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Huggenberger R, 2010, J EXP MED, V207, P2255, DOI 10.1084/jem.20100559; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Kunstfeld R, 2014, J DERMATOL SCI, V74, P106, DOI 10.1016/j.jdermsci.2014.01.002; Kyriakides TR, 1999, J INVEST DERMATOL, V113, P782, DOI 10.1046/j.1523-1747.1999.00755.x; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1999, P NATL ACAD SCI USA, V96, P4449, DOI 10.1073/pnas.96.8.4449; Laajala E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-7-r77; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Noh YH, 2003, J INVEST DERMATOL, V121, P1536, DOI 10.1046/j.1523-1747.2003.12643.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Purdom E, 2008, BIOINFORMATICS, V24, P1707, DOI 10.1093/bioinformatics/btn284; Ren B, 2009, CANCER RES, V69, P3856, DOI 10.1158/0008-5472.CAN-08-2940; Rodrigo-Domingo M, 2014, BRIEF BIOINFORM, V15, P519, DOI 10.1093/bib/bbt011; Roudnicky F, 2017, J PATHOL, V242, P193, DOI 10.1002/path.4892; Roudnicky F, 2013, CANCER RES, V73, P1097, DOI 10.1158/0008-5472.CAN-12-1855; Rybak JN, 2007, CANCER RES, V67, P10948, DOI 10.1158/0008-5472.CAN-07-1436; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Srinivasan K, 2005, METHODS, V37, P345, DOI 10.1016/j.ymeth.2005.09.007; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Streit M, 2002, CANCER RES, V62, P2004; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Yang XP, 2016, CELL, V164, P805, DOI 10.1016/j.cell.2016.01.029; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6	60	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2573	2585		10.1038/s41388-018-0129-z	http://dx.doi.org/10.1038/s41388-018-0129-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467494	Green Published, hybrid			2022-12-28	WOS:000431873400009
J	Takahashi, K; Ehata, S; Koinuma, D; Morishita, Y; Soda, M; Mano, H; Miyazono, K				Takahashi, Kei; Ehata, Shogo; Koinuma, Daizo; Morishita, Yasuyuki; Soda, Manabu; Mano, Hiroyuki; Miyazono, Kohei			Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells	ONCOGENE			English	Article							DISTANT METASTASIS; NESTIN; EXPRESSION; PROLIFERATION; FIBROBLASTS; MARKER; GROWTH; PROGRESSION; PROGNOSIS; EVOLUTION	Tumor microenvironment plays a pivotal role in cancer progression; however, little is known regarding how differences in the microenvironment affect characteristics of cancer cells. Here, we investigated the effects of tumor microenvironment on cancer cells by using mouse tumor models. After three cycles of inoculation and extraction of human pancreatic cancer cells, including SUIT-2 and Panc-1 cells, from tumors, distinct cancer cell lines were established: 3P cells from the pancreas obtained using the orthotopic tumor model and 3sc cells from subcutaneous tissue obtained using the subcutaneous tumor model. On re-inoculation of these cells, the 3sc cells and, more prominently, the 3P cells, exhibited higher tumorigenic activity than the parental cells. The 3P cells specifically exhibited low E-cadherin expression and high invasiveness, suggesting that they were endowed with the highest malignant characteristics. RNA-sequence analysis demonstrated that distinct signaling pathways were activated in each cell line and that the 3P cells acquired a cancer stem cell-like phenotype. Among cancer stem cell-related genes, those specifically expressed in the 3P cells, including NES, may be potential new targets for cancer therapy. The mechanisms underlying the development of highly malignant cancer cell lines were investigated. Individual cell clones within the parental cells varied in tumor-forming ability, indicating the presence of cellular heterogeneity. Moreover, the tumor-forming ability and the gene expression profile of each cell clone were altered after serial orthotopic inoculations. The present study thus suggests that both selection and education processes by tumor microenvironment are involved in the development of highly malignant cancer cells.	[Takahashi, Kei; Ehata, Shogo; Koinuma, Daizo; Morishita, Yasuyuki; Miyazono, Kohei] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan; [Soda, Manabu; Mano, Hiroyuki] Univ Tokyo, Dept Cellular Signaling, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122; Ehata, Shogo/0000-0002-6740-9391; Takahashi-Yamashiro, Kei/0000-0002-7925-6636	Grand for Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) [16ck0106193h0001]; KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002]; KAKENHI from the Japan Society for the Promotion of Science (JSPS), [15K08393, 25-10991]; Yasuda Medical Foundation; Cell Science Research Foundation; Tokyo Society of Medical Sciences; Grants-in-Aid for Scientific Research [15H05774, 17H06326] Funding Source: KAKEN	Grand for Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); KAKENHI from the Japan Society for the Promotion of Science (JSPS),(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Yasuda Medical Foundation; Cell Science Research Foundation(Cell Science Research Foundation, Japan); Tokyo Society of Medical Sciences; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Yoko Katsuno, Dr. Yuichiro Yokoyama, and Dr. Yukari Hoshino (The University of Tokyo) for their technical assistance, and Hiroyuki Miyoshi (Keio University) for providing the lentiviral vectors. This work was supported by a Grand for Practical Research for Innovative Cancer Control (16ck0106193h0001) from the Japan Agency for Medical Research and Development (AMED; K.M.), a KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas, Integrative Research on Cancer Microenvironment Network (22112002) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT; K.M.), a KAKENHI Grant-in-Aid for Scientific Research (C; 15K08393; S.E.) and Research Fellowship for Young Scientists (25-10991; K.T.) from the Japan Society for the Promotion of Science (JSPS), Specific Research Grants from Yasuda Medical Foundation (K.M.), The Cell Science Research Foundation (S.E.), and The Tokyo Society of Medical Sciences (S.E.).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arase M, 2014, CANCER SCI, V105, P974, DOI 10.1111/cas.12454; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Eguchi D, 2013, SURGERY, V154, P573, DOI 10.1016/j.surg.2013.03.010; Ehrmann J, 2005, J CLIN PATHOL, V58, P222, DOI 10.1136/jcp.2004.021238; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hippo Y, 2001, CANCER RES, V61, P889; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Liu CG, 2010, CANCER SCI, V101, P815, DOI 10.1111/j.1349-7006.2009.01422.x; Ma J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.293; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Matsuda Y, 2016, PANCREAS, V45, P93, DOI 10.1097/MPA.0000000000000427; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Neradil J, 2015, CANCER SCI, V106, P803, DOI 10.1111/cas.12691; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Perera RM, 2015, CANCER DISCOV, V5, P1247, DOI 10.1158/2159-8290.CD-15-0671; Piras F, 2010, ONCOL REP, V23, P17, DOI 10.3892/or_00000601; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ryan DP, 2014, NEW ENGL J MED, V371, P2140, DOI 10.1056/NEJMc1412266; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Strojnik T, 2007, SURG NEUROL, V68, P133, DOI 10.1016/j.surneu.2006.10.050; Takahashi K, 2015, CANCER SCI, V106, P867, DOI 10.1111/cas.12685; Takeda K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14607; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112; Zhao ZW, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0408-8	41	47	50	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2757	2772		10.1038/s41388-018-0144-0	http://dx.doi.org/10.1038/s41388-018-0144-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511349	hybrid, Green Published			2022-12-28	WOS:000432929800001
J	Zhao, YH; Hu, XD; Wei, L; Song, D; Wang, JJ; You, LF; Saiyin, H; Li, ZJ; Yu, WB; Yu, L; Ding, J; Wu, JX				Zhao, Yahui; Hu, Xiaoding; Wei, Li; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Li, Zhaojie; Yu, Wenbo; Yu, Long; Ding, Jin; Wu, Jiaxue			PARP10 suppresses tumor metastasis through regulation of Aurora A activity	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA METASTASIS; ADP-RIBOSYLTRANSFERASE ARTD10; MESENCHYMAL TRANSITION; CANCER-THERAPY; KINASE; CELLS; POLY(ADP-RIBOSE); RIBOSYLATION; MIGRATION; TARGETS	ADP-ribosylation, including poly-ADP-ribosylation (PARylation) and mono-ADP-ribosylation (MARylation), is a multifunctional post-translational modification catalyzed by intracellular ADP-ribosyltransferases (ARTDs or PARPs). Although PARylation has been investigated most thoroughly, the function of MARylation is currently largely undefined. Here, we provide evidences that deficiency of PARP10, a mono-ADP-ribosyltransferase, markedly increased the migration and invasion of tumor cells through regulation of epithelial-mesenchymal transition (EMT), and PARP10 inhibited tumor metastasis in vivo, which was dependent on its enzyme activity. Mechanistically, we found that PARP10 interacted with and mono-ADP-ribosylated Aurora A, and inhibited its kinase activity, thereby regulating its downstream signaling. Moreover, the expression level of PARP10 was downregulated in intrahepatic metastatic hepatocellular carcinoma (HCC) compared with its corresponding primary HCC and adjacent non-tumorous tissues. Taken together, our results indicated that PARP10 has an important role in tumor metastasis suppression via negatively regulation of Aurora A activity.	[Zhao, Yahui; Hu, Xiaoding; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Yu, Wenbo; Yu, Long; Wu, Jiaxue] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China; [Zhao, Yahui; Hu, Xiaoding; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Yu, Wenbo; Yu, Long; Wu, Jiaxue] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Wei, Li] 401 Hosp PLA, Dept Oncol, Qingdao, Peoples R China; [Li, Zhaojie] Shanghai Appl Prot Technol Co Ltd, Shanghai, Peoples R China; [Ding, Jin] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Int Cooperat Lab Signal Transduct, Shanghai, Peoples R China	Fudan University; Fudan University; Naval Medical University	Wu, JX (corresponding author), Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China.; Wu, JX (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.	jiaxue@fudan.edu.cn	wang, juanjuan/GYV-5540-2022	Wang, Juanjuan/0000-0001-5477-8860; Hu, xiaoding/0000-0002-3144-1859	national key research and development plan [2016YFC0902401]; National Natural Science Foundation of China [81272250, 81472619]; National Key Sci-Tech Special Project of China [2013ZX10002010-08]	national key research and development plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Sci-Tech Special Project of China	This work was supported by national key research and development plan (2016YFC0902401 to JW); the National Natural Science Foundation of China (81272250 and 81472619 to JW) and the National Key Sci-Tech Special Project of China (2013ZX10002010-08 to JW).	Chen T, 2017, NATURE COMMUN, V8, P1; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Feijs KLH, 2013, NAT REV MOL CELL BIO, V14, P443, DOI 10.1038/nrm3601; Feijs KLH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-5; Forst AH, 2013, STRUCTURE, V21, P462, DOI 10.1016/j.str.2012.12.019; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Herzog N, 2013, FEBS J, V280, P1330, DOI 10.1111/febs.12124; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Hu X, 2017, ONCOGENE, V36, P4047, DOI 10.1038/onc.2017.10; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kaufmann M, 2015, CURR TOP MICROBIOL, V384, P167, DOI 10.1007/82_2014_379; Kleine H, 2008, MOL CELL, V32, P57, DOI 10.1016/j.molcel.2008.08.009; Kleine H, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-28; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Nicolae CM, 2014, J BIOL CHEM, V289, P13627, DOI 10.1074/jbc.M114.556340; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Verheugd P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2672; Vyas S, 2014, NAT REV CANCER, V14, P502, DOI 10.1038/nrc3748; Wang JJ, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.34; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang XX, 2012, MOL CANCER RES, V10, P588, DOI 10.1158/1541-7786.MCR-11-0416; Wu D, 2016, HEPATOLOGY, V64, P1148, DOI 10.1002/hep.28708; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Yu M, 2005, ONCOGENE, V24, P1982, DOI 10.1038/sj.onc.1208410; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180	33	28	29	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2921	2935		10.1038/s41388-018-0168-5	http://dx.doi.org/10.1038/s41388-018-0168-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515234				2022-12-28	WOS:000433936300002
J	Munoz-Galvan, S; Lucena-Cacace, A; Perez, M; Otero-Albiol, D; Gomez-Cambronero, J; Carnero, A				Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Gomez-Cambronero, Julian; Carnero, Amancio			Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment	ONCOGENE			English	Article							PHOSPHOLIPASE D2 PLD2; NUCLEOTIDE EXCHANGE; CANCER-CELLS; ACTIVATION; FIBROBLASTS; INVASION; GROWTH; IDENTIFICATION; TRANSFORMATION; TUMORIGENESIS	Cancer cells are in continuous communication with the surrounding microenvironment and this communication can affect tumor evolution. In this work, we show that phospholipase D2 (PLD2) was overexpressed in colon tumors and is secreted by cancer cells, inducing senescence in neighboring fibroblasts. This occurs through its lipase domain. Senescence induced by its product, phosphatidic acid, leads to a senescence-associated secretory phenotype (SASP) able to increase the stem properties of cancer cells. This increase in stemness occurs by Wnt pathway activacion. This closes a feedback loop in which senescence acts as a crosspoint for the generation of CSCs mediated by phospholipid metabolism. We also demonstrate the connexion of both phenomena in mouse models in vivo showing that a high PLD2 expression increased stemness and tumorigenesis. Thus, the patients with colon cancer show high levels of PLD2 and SASP factor genes expression correlating with Wnt pathway activation. Therefore, we demonstrate that tumor cell-secreted PLD2 contributes to tumor development by modifying the microenvironment, making it a possible therapeutic target for cancer treatment. This mechanism may also explain the high levels of Wnt pathway activation in colon cancer.	[Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Carnero, Amancio] Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, CSIC,IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain; [Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Carnero, Amancio] Inst Salud Carlos III, CIBER CANC, Madrid, Spain; [Gomez-Cambronero, Julian] Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III; University System of Ohio; Wright State University Dayton	Carnero, A (corresponding author), Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, CSIC,IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain.; Carnero, A (corresponding author), Inst Salud Carlos III, CIBER CANC, Madrid, Spain.	acarnero-ibis@us.es	Muñoz-Galván, Sandra/K-5827-2015	Carnero, Amancio/0000-0003-4357-3979; Lucena-Cacace, Antonio/0000-0002-1181-2683; Gomez-Cambronero, Julian/0000-0002-7581-9227; Munoz-Galvan, Sandra/0000-0003-0579-325X	ISCIII-Red de Biobancos [PT13/0010/0056]; ISCIII [CD16/00230]; Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII [Fis: PI15/00045]; CIBER de Cancer [CD16/12/00275]; FEDER from Regional Development European Funds (European Union); Consejeria de Ciencia e Innovacion [CTS-1848]; Consejeria de Salud of the Junta de Andalucia [PI-0397-2017]; Fundacion BBVA; AECC Foundation; NIH [HL056653-14]	ISCIII-Red de Biobancos; ISCIII(Instituto de Salud Carlos III); Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII; CIBER de Cancer; FEDER from Regional Development European Funds (European Union); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); Fundacion BBVA(BBVA Foundation); AECC Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the donors, the HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study, Carolina Castilla for the assistance with IHC assays and Carmen Saez for histological analyses. SM-G was supported by a Sara Borrell grant from ISCIII (CD16/00230). AC lab was supported by grants from the Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII (Fis: PI15/00045), and CIBER de Cancer (CD16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion (CTS-1848), and Consejeria de Salud of the Junta de Andalucia (PI-0397-2017). This work was also supported by Fundacion BBVA. Especial thanks to the AECC Foundation for supporting this work. JG-C is supported by Grant HL056653-14 from the NIH.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Ferrer I, 2016, ONCOGENE, V35, P2777, DOI 10.1038/onc.2015.341; Foster DA, 2003, MOL CANCER RES, V1, P789; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gomez-Cambronero J, 2014, J BIOL CHEM, V289, P22557, DOI 10.1074/jbc.R114.574152; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207; Henkels KM, 2011, J MOL BIOL, V408, P850, DOI 10.1016/j.jmb.2011.03.017; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Jeon H, 2011, CELL SIGNAL, V23, P1320, DOI 10.1016/j.cellsig.2011.03.014; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012109; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lee YH, 2014, FEBS LETT, V588, P3251, DOI 10.1016/j.febslet.2014.07.009; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Mahankali M, 2012, J BIOL CHEM, V287, P41417, DOI 10.1074/jbc.M112.383596; Mahankali M, 2011, P NATL ACAD SCI USA, V108, P19617, DOI 10.1073/pnas.1114692108; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nakamura T, 1997, CANCER RES, V57, P3305; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimoto H, 2003, ONCOL RES, V14, P31, DOI 10.3727/000000003108748586; Park JB, 2012, NAT REV CANCER, V12, P782, DOI 10.1038/nrc3379; Perez M, 2016, ONCOTARGET, V7, P33111, DOI 10.18632/oncotarget.8880; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito M, 2007, ONCOL REP, V18, P1329; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	53	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1309	1323		10.1038/s41388-018-0527-2	http://dx.doi.org/10.1038/s41388-018-0527-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30305726				2022-12-28	WOS:000459249800012
J	Lin, YP; Wu, JI; Tseng, CW; Chen, HJ; Wang, LH				Lin, Yi-Pei; Wu, Jun-I; Tseng, Chien-Wei; Chen, Huei-Jane; Wang, Lu-Hai			Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation	ONCOGENE			English	Article							PROTEIN-KINASE-C; SIGNALING PATHWAYS; CELL-MIGRATION; ANGIOTENSIN-II; GAP-JUNCTIONS; EXPRESSION; INVASION; CONNEXIN-43; GROWTH; RECEPTOR	Most lung cancer patients are diagnosed late with metastasis, which is the major cause of cancer-related death and recurrent tumors that often exhibit chemoresistance. In the present study, we initially identified gap junction beta-4 protein (Gjb4) to be overexpressed in highly metastatic cancer cells selected by their enhanced binding to serum components. Overexpression or knockdown of Gjb4 increased or decreased lung metastasis of syngeneic mice, respectively. We found that Gjb4 expression was higher in lung tumors than normal tissues (p = 0.0026), and Gjb4 levels in blood buffy coat samples showed significant performance in diagnosing stage I-III (p = 0.002814) and stage IV (p < 0.0001) lung cancer. Moreover, high Gjb4 expression levels were correlated with poor prognosis (p = 1.4e-4) and recurrence (p = 1.9e-12). Using syngeneic mouse model, we observed that Gjb4 was able to promote tumor growth. High molecular weight serum fraction containing the major growth factor component IGF1 was able to induce Gjb4 via PKC pathway. Gjb4 activated Src signaling via MET, and overexpression of Gjb4 enhanced sphere-forming ability and anchorage-independent growth, which were reversed by inhibition of Src. In addition, we demonstrated that Gjb4-mediated Src activation enhanced chemoresistance of cancer cells toward gemcitabine and etoposide. The combination of Gjb4 knockdown, gemcitabine, and dasatinib further enhanced the inhibition of cancer cell viability. Together, our study has identified Gjb4 as a potential novel diagnostic and prognostic biomarker for lung cancer. Targeting Gjb4 may be exploited as a modality for improving lung cancer therapy.	[Lin, Yi-Pei; Wu, Jun-I; Tseng, Chien-Wei; Chen, Huei-Jane; Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Lin, Yi-Pei; Wang, Lu-Hai] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei, Taiwan; [Wu, Jun-I; Wang, Lu-Hai] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Tseng, Chien-Wei] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University; National Central University; China Medical University Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan.; Wang, LH (corresponding author), Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei, Taiwan.; Wang, LH (corresponding author), Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan.; Wang, LH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	lu-hai.wang@nhri.org.tw			National Health Research Institutes, Taiwan [06A1-MGPP09-014]; Ministry of Education, Taiwan [CMRC-CHM-7]; Ministry of Science and Technology, Taiwan [MOST 104-2320-B-039-055-MY3, MOST 104-2320-B-039-054-MY3, MOST 106-2320-B-039-059-]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Education, Taiwan(Ministry of Education, Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the National Health Research Institutes, Taiwan (06A1-MGPP09-014), the Ministry of Education, Taiwan (CMRC-CHM-7), and the Ministry of Science and Technology, Taiwan (MOST 104-2320-B-039-055-MY3, MOST 104-2320-B-039-054-MY3 and MOST 106-2320-B-039-059-). We thank Core Laboratory of Microarray, Cell Sorting, Pathology, Confocal Microscopy as well as Proteomics and chemistry of National Health Research Institutes (NHRI) for experiments involving exon array analysis, cell sorting, H&E staining, Immunohistochemistry, confocal microscopy and mass spectrometry, respectively. We thank Dr. Yi Rong Chen of IMGM, NHRI, Taiwan for the gift of H1650 human lung cancer cell line. We also thank Dr. Chin Fu Hsiao of Division of Biostatistics and Bioinformatics of NHRI, Taiwan for the clinical samples from lung cancer tissue bank. We thank Dr. Sheng-Chieh Lin for the assistance of manuscript preparation.	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Banerjee Debarshi, 2016, Int J Cell Biol, V2016, P9025905, DOI 10.1155/2016/9025905; Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chu CH, 2008, J ENDOCRINOL, V197, P381, DOI 10.1677/JOE-07-0619; Common JEA, 2005, J INVEST DERMATOL, V125, P920, DOI 10.1111/j.0022-202X.2005.23919.x; Dorey K, 2010, DEVELOPMENT, V137, P3731, DOI 10.1242/dev.037689; Duggan MA, 2016, AM J SURG PATHOL, V40, pE94, DOI 10.1097/PAS.0000000000000749; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Ezumi K, 2008, CLIN CANCER RES, V14, P677, DOI 10.1158/1078-0432.CCR-07-1184; Feliciano P., 2012, NAT GENET, V44, P840; Ganapathy V, 2015, J CONTROL RELEASE, V219, P215, DOI 10.1016/j.jconrel.2015.09.042; Gavalas NG, 2013, INT J MOL SCI, V14, P15885, DOI 10.3390/ijms140815885; Geimonen E, 1996, J BIOL CHEM, V271, P23667, DOI 10.1074/jbc.271.39.23667; George TJ, 2014, ONCOLOGIST, V19, P211, DOI 10.1634/theoncologist.2013-0410; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Giuffrida ML, 2010, REV NEUROSCIENCE, V21, P83; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Guan PP, 2015, ONCOTARGET, V6, P9140, DOI 10.18632/oncotarget.3274; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han YH, 2009, ONCOL REP, V22, P215, DOI 10.3892/or_00000427; Hedberg KK, 2000, EXP CELL RES, V257, P67, DOI 10.1006/excr.2000.4873; Huang GY, 2015, CELL MOL LIFE SCI, V72, P1741, DOI 10.1007/s00018-015-1833-2; Huang LM, 2014, ONCOTARGETS THER, V7, DOI 10.2147/OTT.S67251; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jia GH, 2007, J SURG RES, V142, P137, DOI 10.1016/j.jss.2006.11.007; Kalemkerian GP, 2016, LANCET ONCOL, V17, P1033, DOI 10.1016/S1470-2045(16)30160-7; Kloverpris S, 2013, BIOCHEM J, V449, P209, DOI 10.1042/BJ20120801; Kotini M, 2015, DEV BIOL, V401, P143, DOI 10.1016/j.ydbio.2014.12.023; Kyo N, 2008, ONCOL REP, V19, P627; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Leto SM, 2014, J MOL MED, V92, P709, DOI 10.1007/s00109-014-1161-2; Li X, 2012, NEOPLASMA, V59, P500, DOI 10.4149/neo_2012_064; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LONGATI P, 1994, ONCOGENE, V9, P49; Lopez-Bigas N, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9023; Losa D, 2011, EXPERT OPIN THER TAR, V15, P989, DOI 10.1517/14728222.2011.584875; Manegold Christian, 2004, Expert Rev Anticancer Ther, V4, P345, DOI 10.1586/14737140.4.3.345; Matta C, 2014, CELL SIGNAL, V26, P979, DOI 10.1016/j.cellsig.2014.01.011; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; Miyata T, 2015, PERS MED U, V4, P40, DOI [10.1016/j.pmu.2015.03.007, DOI 10.1016/J.PMU.2015.03.007]; Montuenga Luis M, 2009, Eur J Cancer, V45 Suppl 1, P377, DOI 10.1016/S0959-8049(09)70055-3; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Munoz JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.111; Murphy SF, 2016, CANCER RES, V76, P139, DOI 10.1158/0008-5472.CAN-15-1286; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555-016-9618-0; Reck M, 2005, LUNG CANCER-J IASLC, V48, P409, DOI 10.1016/j.lungcan.2004.11.013; Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003; Shigyo M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12055; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Steinberg M, 2007, CLIN THER, V29, P2289, DOI 10.1016/j.clinthera.2007.11.005; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; TAPPER H, 1995, J CELL PHYSIOL, V163, P137, DOI 10.1002/jcp.1041630116; Teleki I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112541; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Touyz RM, 2000, PHARMACOL REV, V52, P639; Tung SL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.25; Uramoto H, 2014, TRANSL LUNG CANCER R, V3, P242, DOI 10.3978/j.issn.2218-6751.2013.12.05; van Oosterwijk JG, 2013, BRIT J CANCER, V109, P1214, DOI 10.1038/bjc.2013.451; Wan YT, 2017, EXP THER MED, V13, P3067, DOI 10.3892/etm.2017.4356; Wang SY, 2009, METHODS MOL BIOL, V568, P151, DOI 10.1007/978-1-59745-280-9_9; Yeh YM, 2013, INT J CANCER, V133, P867, DOI 10.1002/ijc.28086; Zaghloul M., 2015, TROP MED SURG, V3, pe122, DOI [10.4172/2329-9088.1000 e122, DOI 10.4172/2329-9088.1000E122]; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang W, 2003, J NEUROSURG, V99, P1039, DOI 10.3171/jns.2003.99.6.1039; Zhao JH, 2016, PHARMACOL THERAPEUT, V160, P145, DOI 10.1016/j.pharmthera.2016.02.008	74	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					822	837		10.1038/s41388-018-0471-1	http://dx.doi.org/10.1038/s41388-018-0471-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177841				2022-12-28	WOS:000458006300005
J	Best, SA; Harapas, CR; Kersbergen, A; Rathi, V; Asselin-Labat, ML; Sutherland, KD				Best, Sarah A.; Harapas, Cassandra R.; Kersbergen, Ariena; Rathi, Vivek; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.			FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium	ONCOGENE			English	Article							CELL LUNG-CANCER; MEDIATED GENE-TRANSFER; MOUSE MODEL; STEM-CELLS; TUMOR-SUPPRESSOR; OF-ORIGIN; IN-VIVO; ADENOCARCINOMA; IDENTIFICATION; CARCINOMA	Structural rearrangements of the genome can drive lung tumorigenesis through the generation of fusion genes with oncogenic properties. Advanced genomic approaches have identified the presence of a genetic fusion between fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil 3 (TACC3) in non-small cell lung cancer (NSCLC), providing a novel target for FGFR inhibition. To interrogate the functional consequences of the FGFR3-TACC3 fusion in the transformation of lung epithelial cells, we generated a novel transgenic mouse model that expresses FGFR3-TACC3 concomitant with loss of the p53 tumor suppressor gene. Intranasal delivery of an Ad5-CMV-Cre virus promoted seromucinous glandular transformation of olfactory cells lining the nasal cavities of FGFR3-TACC3 (LSL-F3T3) mice, which was further accelerated upon loss of p53 (LSL-F3T3/p53). Surprisingly, lung tumors failed to develop in intranasally infected LSL-F3T3 and LSL-F3T3/p53 mice. In line with these observations, we demonstrated that intranasal delivery of Ad5-CMV-Cre induces widespread Cre-mediated recombination in the olfactory epithelium. Intra-tracheal delivery of Ad5-CMV-Cre into the lungs of LSL-F3T3 and LSL-F3T3/p53 mice, however, resulted in the development of lung adenocarcinomas. Taken together, these findings provide in vivo evidence for an oncogenic function of FGFR3-TACC3 in respiratory epithelium.	[Best, Sarah A.; Harapas, Cassandra R.; Kersbergen, Ariena; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia; [Best, Sarah A.; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; [Rathi, Vivek] Univ Melbourne, St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia	Walter & Eliza Hall Institute; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Sutherland, KD (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.; Sutherland, KD (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.	sutherland.k@wehi.edu.au	Rathi, Vivek/AAD-5983-2021	Best, Sarah/0000-0002-4232-9432; Sutherland, Kate/0000-0002-7453-3366	Worldwide Cancer Research Project Grant [14-0433]; Victorian Cancer Agency (VCA) Early Career Seed Grant [ECSG16001]; Viertel Foundation Senior Medical Research Fellowship; Peter and Julie Alston Centenary Fellowship	Worldwide Cancer Research Project Grant; Victorian Cancer Agency (VCA) Early Career Seed Grant; Viertel Foundation Senior Medical Research Fellowship; Peter and Julie Alston Centenary Fellowship	We are grateful to C. Alvarado, L. Scott, H. Johnson, K. Birchall, and L. Mackiewicz for animal husbandry, E. Tsui and C. Tsui in the WEHI Histology Facility for expert support and P. Maltezos for preparation of the nasal cavity graphic image. The authors thank T. Wilson, J. Mighall, and J. Pasquet for technical support and W. Alexander for useful discussions and critically reading the manuscript. This work was supported in part by a Worldwide Cancer Research Project Grant [14-0433]. SAB is supported by a Victorian Cancer Agency (VCA) Early Career Seed Grant (ECSG16001); M-LA-L is supported by a Viertel Foundation Senior Medical Research Fellowship; KDS is supported by the Peter and Julie Alston Centenary Fellowship. This work was made possible through Victorian Government Operational Infrastructure Support and Australian Government.	[Anonymous], 2016, CANC FACTS FIG 2016; Arimoto Y, 2002, ACTA OTO-LARYNGOL, V122, P627, DOI 10.1080/000164802320396303; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006; Best SA, 2018, METHODS MOL BIOL, V1725, P15, DOI 10.1007/978-1-4939-7568-6_2; Best SA, 2017, J INVEST DERMATOL, V137, P506, DOI 10.1016/j.jid.2016.09.027; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Capelletti M, 2014, CLIN CANCER RES, V20, P6551, DOI 10.1158/1078-0432.CCR-14-1337; Carneiro BA, 2015, GYNECOL ONCOL REP, V13, P53, DOI 10.1016/j.gore.2015.06.005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Z, 2010, CANCER RES, V70, P9827, DOI 10.1158/0008-5472.CAN-10-1671; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Daly C, 2017, ONCOGENE, V36, P471, DOI 10.1038/onc.2016.216; Damjanovic Daniela, 2008, Genet Vaccines Ther, V6, P5, DOI 10.1186/1479-0556-6-5; Doi K, 2005, ANN OTO RHINOL LARYN, V114, P629, DOI 10.1177/000348940511400808; Duggan CD, 2007, NAT NEUROSCI, V10, P673, DOI 10.1038/nn0607-673; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hatch TF, 1964, PULM DEP RET INH AER; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Johnson VJ, 2007, J IMMUNOL, V179, P1864, DOI 10.4049/jimmunol.179.3.1864; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kwon MC, 2013, MOL ONCOL, V7, P165, DOI 10.1016/j.molonc.2013.02.010; Leong HS, 2013, CANCER RES, V73, P1591, DOI 10.1158/0008-5472.CAN-12-3019; Leung CT, 2007, NAT NEUROSCI, V10, P720, DOI 10.1038/nn1882; Majewski IJ, 2013, J PATHOL, V230, P270, DOI 10.1002/path.4209; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nelson KN, 2016, MOL CANCER RES, V14, P458, DOI 10.1158/1541-7786.MCR-15-0497; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Weeden CE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000731; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yin YJ, 2013, CANCER RES, V73, P5730, DOI 10.1158/0008-5472.CAN-13-0495; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhao HQ, 1996, J NEUROBIOL, V30, P521, DOI 10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5	58	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6096	6104		10.1038/s41388-018-0399-5	http://dx.doi.org/10.1038/s41388-018-0399-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991799	Green Accepted			2022-12-28	WOS:000450175900007
J	Phoomak, C; Silsirivanit, A; Park, D; Sawanyawisuth, K; Vaeteewoottacharn, K; Wongkham, C; Lam, EWF; Pairojkul, C; Lebrilla, CB; Wongkham, S				Phoomak, Chatchai; Silsirivanit, Atit; Park, Dayoung; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Lam, Eric W. -F.; Pairojkul, Chawalit; Lebrilla, Carlito B.; Wongkham, Sopit			O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1	ONCOGENE			English	Article							ABERRANT GLYCOSYLATION; N-ACETYLGLUCOSAMINE; CANCER; CELLS; TRANSCRIPTION; EXPRESSION; OLIGOSACCHARIDES; AGGRESSIVENESS; RELEVANCE; INVASION	The leading cause of death in cancer patients is metastasis, for which an effective treatment is still necessary. During metastasis, cancer cells aberrantly express several glycans that are correlated with poor patient outcome. This study was aimed toward exploring the effects of O-GlcNAcylation on membranous N-glycans that are associated with the progression of cholangiocarcinoma (CCA). Global O-GlcNAcylation in CCA cells was depleted using specific siRNA against O-GlcNAc transferase (OGT), which transfers GlcNAc to the acceptor proteins. Using an HPLC-Chip/Time-of-Flight (Chip/ TOF) MS system, the N-glycans associated with O-GlcNAcylation were identified by comparing the membranous N-glycans of siOGT-treated cells with those of scramble siRNA-treated cells. In parallel, the membranous N-glycans of the parental cells (KKU-213 and KKU-214) were compared with those of the highly metastatic cells (KKU-213L5 and KKU-214L5). Together, these data revealed that high mannose (Hex(9)HexNAc(2)) and biantennary complex (Hex(5)HexNAc(4)Fuc(1)NeuAc(1)) N-linked glycans correlated positively with metastasis. We subsequently demonstrate that suppression of O-GlcNAcylation decreased the expression of these two N-glycans, suggesting that O-GlcNAcylation mediates their levels in CCA. In addition, the ability of highly metastatic cells to migrate and invade was reduced by the presence of Pisum Sativum Agglutinin (PSA), a mannose-specific lectin, further indicating the association of high mannose type N-glycans with CCA metastasis. The molecular mechanism of O-GlcNAc-mediated progression of CCA was shown to proceed via a series of signaling events, involving the activation of Akt/Erk (i), an increase in FOXO3 phosphorylation (ii), which results in the reduction of MAN1A1 expression (iii) and thus the accumulation of Hex(9)HexNAc(2) N-glycans (iv). This study demonstrates for the first time the association between O-GlcNAcylation, high mannose type N-glycans, and the progression of CCA metastasis, suggesting a novel therapeutic target for treatment of metastatic CCA.	[Phoomak, Chatchai; Silsirivanit, Atit; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Wongkham, Sopit] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand; [Phoomak, Chatchai; Silsirivanit, Atit; Sawanyawisuth, Kanlayanee; Vaeteewoottacharn, Kulthida; Wongkham, Chaisiri; Pairojkul, Chawalit; Wongkham, Sopit] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand; [Park, Dayoung; Lebrilla, Carlito B.] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; [Park, Dayoung] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA; [Lam, Eric W. -F.] Imperial Coll London, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London W12 0NN, England; [Pairojkul, Chawalit] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand	Khon Kaen University; Khon Kaen University; University of California System; University of California Davis; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Imperial College London; Khon Kaen University	Wongkham, S (corresponding author), Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand.; Wongkham, S (corresponding author), Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand.; Lebrilla, CB (corresponding author), Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.	cblebrilla@ucdavis.edu; sopit@kku.ac.th	Silsirivanit, Atit/AAN-1728-2020; Lebrilla, Carlito Bangeles/ABE-6369-2020; Lam, Eric W-F/AAW-8566-2020; Sawanyawisuth, Kanlayanee/AAU-8424-2020; Park, Diane Dayoung/N-5390-2019; Vaeteewoottacharn, Kulthida/GSE-1017-2022; Wongkham, Sopit/ABB-6966-2021; Park, Dayoung/V-7537-2017	Lam, Eric W-F/0000-0003-1274-3576; Sawanyawisuth, Kanlayanee/0000-0003-2260-6372; Park, Diane Dayoung/0000-0003-4983-4340; Vaeteewoottacharn, Kulthida/0000-0001-6557-9680; Park, Dayoung/0000-0003-4983-4340; Lebrilla, Carlito/0000-0001-7190-5323; Silsirivanit, Atit/0000-0002-5777-3843; Phoomak, Chatchai/0000-0002-3808-8816	Thailand Research Fund; Medical Research Council-UK [DBG5980004]; National Research University; Khon Kaen University [NRU592010]; Research Affairs and Graduate School, Khon Kaen University, Thailand [59151]; National Institutes of Health (USA) [R01GM049077]; MRC [MR/N012097/1]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Cancer Research UK Imperial Centre; Imperial ECMC; NIHR Imperial BRC; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049077] Funding Source: NIH RePORTER	Thailand Research Fund(Thailand Research Fund (TRF)); Medical Research Council-UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research University; Khon Kaen University; Research Affairs and Graduate School, Khon Kaen University, Thailand; National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; Imperial ECMC; NIHR Imperial BRC; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was co-supported by the Thailand Research Fund and Medical Research Council-UK (Newton Fund) project no. DBG5980004, and National Research University grant, Khon Kaen University (NRU592010), a scholarship under the Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University, Thailand (59151) and National Institutes of Health (USA) R01GM049077. EW-FL work is supported by MRC (MR/N012097/1), CRUK (A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC.	Anderson CD, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-1-43; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380; Christie DR, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-3; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; de Leoz MLA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002717; de Queirozl RM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00132; Ghazarian H, 2011, ACTA HISTOCHEM, V113, P236, DOI 10.1016/j.acthis.2010.02.004; Handerson T, 2005, CLIN CANCER RES, V11, P2969, DOI 10.1158/1078-0432.CCR-04-2211; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Heath JM, 2014, CIRC RES, V114, P1094, DOI 10.1161/CIRCRESAHA.114.302968; Higashi M, 1999, HEPATOLOGY, V30, P1347, DOI 10.1002/hep.510300609; Indramanee S, 2012, ASIAN PAC J CANCER P, V13, P119, DOI 10.7314/APJCP.2012.13.KKSuppl.119; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; Kannagi R, 2008, BBA-GEN SUBJECTS, V1780, P525, DOI 10.1016/j.bbagen.2007.10.007; Kronewitter SR, 2009, PROTEOMICS, V9, P2986, DOI 10.1002/pmic.200800760; Li X, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00033; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Litynska A, 2006, BIOCHIMIE, V88, P527, DOI 10.1016/j.biochi.2005.10.012; Liu TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107941; Liu YB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0522-0; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Matsuda A, 2015, ANAL CHEM, V87, P7274, DOI 10.1021/acs.analchem.5b01329; Milde-Langosch K, 2014, BREAST CANCER RES TR, V145, P295, DOI 10.1007/s10549-014-2949-z; Morishima S, 2003, J ENDOCRINOL, V176, P285, DOI 10.1677/joe.0.1760285; Park D, 2016, MOL CELL PROTEOMICS, V15, P3653, DOI 10.1074/mcp.M116.063206; Park HM, 2015, CARBOHYD RES, V413, P5, DOI 10.1016/j.carres.2015.04.019; Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389; Phoomak C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43842; Phoomak C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27853; Phoomak C, 2012, ASIAN PAC J CANCER P, V13, P101, DOI 10.7314/APJCP.2012.13.KKSuppl.101; Pilobello KT, 2007, P NATL ACAD SCI USA, V104, P11534, DOI 10.1073/pnas.0704954104; Powers TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106255; Saentaweesuk W, 2018, ONCOL RES, V26, P605, DOI 10.3727/096504017X15009778205068; Silsirivanit A, 2011, CANCER-AM CANCER SOC, V117, P3393, DOI 10.1002/cncr.25912; Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3; Stanley P., 2009, ESSENTIALS GLYCOBIOL; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Takahashi M, 2009, CARBOHYD RES, V344, P1387, DOI 10.1016/j.carres.2009.04.031; Tao SC, 2008, GLYCOBIOLOGY, V18, P761, DOI 10.1093/glycob/cwn063; Tolek A, 2012, EXP BIOL MED, V237, P1142, DOI 10.1258/ebm.2012.012215; Uthaisar K, 2016, ONCOL REP, V36, P1435, DOI 10.3892/or.2016.4974; Uttaravichien T, 1999, J Hepatobiliary Pancreat Surg, V6, P128, DOI 10.1007/s005340050095; Varki A, 2009, ESSENTIALS GLYCOBIOL, P617; Varki A., 2009, ESSENTIALS GLYCOBIOL, P601; Vojta A, 2016, BBA-GEN SUBJECTS, V1860, P1776, DOI 10.1016/j.bbagen.2016.01.002; Yan FX, 2016, BIOMED PHARMACOTHER, V84, P1538, DOI 10.1016/j.biopha.2016.11.027; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; Zhang P, 2015, ONCOTARGETS THER, V8, P3305, DOI 10.2147/OTT.S82845; Zhang XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087978; Zhao YX, 2007, INDIAN J BIOCHEM BIO, V44, P145; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1	54	19	19	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5648	5665		10.1038/s41388-018-0366-1	http://dx.doi.org/10.1038/s41388-018-0366-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29915392	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000447619100005
J	Liu, J; Zhang, Z; Li, XW; Chen, J; Wang, GD; Tian, ZH; Qian, MR; Chen, ZQ; Guo, H; Tang, GB; Huang, WJ; Tian, DA; Wang, DW; Nie, YZ; Fan, DM; Wu, KC; Xia, LM				Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Tian, Dean; Wang, Daowen; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin			Forkhead box Cl promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; TO-MESENCHYMAL TRANSITION; INDICATES POOR-PROGNOSIS; TUMOR-METASTASIS; FOXC1; CARCINOMA; GENE; OVEREXPRESSION; INHIBITION; MUTATION	Metastatic colorectal cancer (CRC) is one of the most common causes of cancer death worldwide; however, the molecular mechanism underlying CRC metastasis remains unknown. Using an integrated approach, we identified forkhead box C1 (FOXC1) as a novel regulator of CRC metastasis. Elevated expression of FOXC1 is significantly correlated with metastasis, recurrence and reduced survival. FOXC1 overexpression promotes CRC invasion and lung metastasis, whereas FOXC1 knockdown has the opposite effect. In addition, FOXC1 directly binds its target genes integrin ea (ITGA7) and fibroblast growth factor receptor 4 (FGFR4) and activates their expression. Genetic epistasis analysis confirmed that ITGA7 and FGFR4 act downstream of FOXC1. Furthermore, pharmaceutical inhibition of FGFR4 can reverse CRC metastasis mediated by FOXC1 overexpression. These results suggest that FOXC1 is a prognostic biomarker in CRC patients and targeting the FGFR4 signaling pathway may provide a promising strategy for the treatment of FOXC1-driven CRC metastasis.	[Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Huang, Wenjie; Tian, Dean; Wang, Daowen; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430030, Hubei, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Huazhong University of Science & Technology	Wu, KC; Xia, LM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Wu, KC; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430030, Hubei, Peoples R China.	kaicwu@fmmu.edu.cn; xialimin@fmmu.edu.cn			National Natural Science Foundation of China [81522031, 81772623, 81627807, 81421003]; National Center for Clinical Research of Digestive Diseases [2015BAI13B07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Center for Clinical Research of Digestive Diseases	This study was supported by the National Natural Science Foundation of China (Nos. 81522031, 81772623, 81627807, and 81421003) and the National Center for Clinical Research of Digestive Diseases (2015BAI13B07).	Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Benayoun BA, 2011, TRENDS GENET, V27, P224, DOI 10.1016/j.tig.2011.03.003; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286; Haas TL, 2017, CELL STEM CELL, V21, P35, DOI 10.1016/j.stem.2017.04.009; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Han BC, 2018, ONCOGENE, V37, P1399, DOI 10.1038/s41388-017-0021-2; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Honkanen RA, 2003, AM J OPHTHALMOL, V135, P368, DOI 10.1016/S0002-9394(02)02061-5; Huang L, 2017, AM J TRANSL RES, V9, P1297; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, P1; Li CS, 2014, BIOMARKERS, V19, P81, DOI 10.3109/1354750X.2013.876555; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; MCNUTT NS, 1981, LAB INVEST, V44, P309; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Mortemousque B, 2004, ARCH OPHTHALMOL-CHIC, V122, P1527, DOI 10.1001/archopht.122.10.1527; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Packer LM, 2015, CANCER DISCOV, V5, P355, DOI 10.1158/2159-8290.CD-15-0246; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Su Y, 2014, INT J MOL MED, V34, P842, DOI 10.3892/ijmm.2014.1819; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turkington RC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.10; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang L, 2013, TUMOR BIOL, V34, P853, DOI 10.1007/s13277-012-0617-7; Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005; Xia LM, 2014, HEPATOLOGY, V59, P958, DOI 10.1002/hep.26735; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	38	37	38	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5477	5491		10.1038/s41388-018-0355-4	http://dx.doi.org/10.1038/s41388-018-0355-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29884889				2022-12-28	WOS:000446991200001
J	Miess, H; Dankworth, B; Gouw, AM; Rosenfeldt, M; Schmitz, W; Jiang, M; Saunders, B; Howell, M; Downward, J; Felsher, DW; Peck, B; Schulze, A				Miess, Heike; Dankworth, Beatrice; Gouw, Arvin M.; Rosenfeldt, Mathias; Schmitz, Werner; Jiang, Ming; Saunders, Becky; Howell, Michael; Downward, Julian; Felsher, Dean W.; Peck, Barrie; Schulze, Almut			The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma	ONCOGENE			English	Article							GLUTAMINE-METABOLISM; TUMOR SUPPRESSION; OXIDATIVE STRESS; C-MYC; CANCER; HYPOXIA; DEATH; PROLIFERATION; PROGRESSION; EXPRESSION	Metabolic reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Here we investigated metabolic dependencies in a panel of ccRCC cell lines using nutrient depletion, functional RNAi screening and inhibitor treatment. We found that ccRCC cells are highly sensitive to the depletion of glutamine or cystine, two amino acids required for glutathione (GSH) synthesis. Moreover, silencing of enzymes of the GSH biosynthesis pathway or glutathione peroxidases, which depend on GSH for the removal of cellular hydroperoxides, selectively reduced viability of ccRCC cells but did not affect the growth of non-malignant renal epithelial cells. Inhibition of GSH synthesis triggered ferroptosis, an iron-dependent form of cell death associated with enhanced lipid peroxidation. VHL is a major tumour suppressor in ccRCC and loss of VHL leads to stabilisation of hypoxia inducible factors HIF-1 alpha and HIF-2 alpha. Restoration of functional VHL via exogenous expression of pVHL reverted ccRCC cells to an oxidative metabolism and rendered them insensitive to the induction of ferroptosis. VHL reconstituted cells also exhibited reduced lipid storage and higher expression of genes associated with oxidiative phosphorylation and fatty acid metabolism. Importantly, inhibition of beta-oxidation or mitochondrial ATP-synthesis restored ferroptosis sensitivity in VHL reconstituted cells. We also found that inhibition of GSH synthesis blocked tumour growth in a MYC-dependent mouse model of renal cancer. Together, our data suggest that reduced fatty acid metabolism due to inhibition of beta-oxidation renders renal cancer cells highly dependent on the GSH/GPX pathway to prevent lipid peroxidation and ferroptotic cell death.	[Miess, Heike; Peck, Barrie; Schulze, Almut] Canc Res UK London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England; [Miess, Heike] Francis Crick Inst, Oncogene Biol Lab, 1 Midland Rd London, London NW1 1AT, England; [Dankworth, Beatrice; Schmitz, Werner; Schulze, Almut] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; [Gouw, Arvin M.; Felsher, Dean W.] Stanford Univ, Div Med Oncol, Sch Med, Stanford, CA 94305 USA; [Rosenfeldt, Mathias] Univ Hosp Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany; [Jiang, Ming; Saunders, Becky; Howell, Michael] Francis Crick Inst, High Throughput Screening, 1 Midland Rd London, London NW1 1AT, England; [Downward, Julian; Peck, Barrie] Inst Canc Res, Div Canc Biol, 237 Fulham Rd, London SW7 3RP, England; [Schulze, Almut] Comprehens Canc Ctr Mainfranken, Josef Schneider Str 6, D-97080 Wurzburg, Germany	Cancer Research UK; Francis Crick Institute; University of Wurzburg; Stanford University; University of Wurzburg; Francis Crick Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Wurzburg	Schulze, A (corresponding author), Canc Res UK London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.; Schulze, A (corresponding author), Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.; Schulze, A (corresponding author), Comprehens Canc Ctr Mainfranken, Josef Schneider Str 6, D-97080 Wurzburg, Germany.	almut.schulze@uni-wuerzburg.de	Schulze, Almut/AAX-8257-2020; Rosenfeldt, Mathias/ABE-4736-2022	Schulze, Almut/0000-0002-8199-6422; Rosenfeldt, Mathias/0000-0001-7650-8458; Peck, Barrie/0000-0002-6687-8495; Howell, Michael/0000-0003-0912-0079; Downward, Julian/0000-0002-2331-4729; Gouw, Arvin/0000-0002-9552-635X	Cancer Research UK; German Research Foundation [FOR2314]; German Cancer Aid [111917]; NATIONAL CANCER INSTITUTE [T32CA196585] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); German Research Foundation(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the LRI research services for technical support. We also thank Prof. William Kaelin (Dana Faber Cancer Institute, Boston) for providing isogenic renal cancer cell lines. This study was funded by Cancer Research UK, the German Research Foundation (FOR2314) and the German Cancer Aid (111917).	AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Bierl C, 2004, J BIOL CHEM, V279, P26839, DOI 10.1074/jbc.M401907200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drabkin HA, 2012, CURR OPIN PHARMACOL, V12, P742, DOI 10.1016/j.coph.2012.08.002; Faronato M, 2007, HISTOL HISTOPATHOL, V22, P1109, DOI 10.14670/HH-22.1109; Gatto F, 2015, SCI REP-UK, V5, DOI 10.1038/srep10738; Gatto F, 2014, P NATL ACAD SCI USA, V111, pE866, DOI 10.1073/pnas.1319196111; GEBHARD RL, 1987, J LIPID RES, V28, P1177; Gerlinger M, 2012, J PATHOL, V227, P146, DOI 10.1002/path.4006; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Malo N, 2006, NAT BIOTECHNOL, V24, P167, DOI 10.1038/nbt1186; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Perroud B, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-64; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Radmark O, 2015, BBA-MOL CELL BIOL L, V1851, P331, DOI 10.1016/j.bbalip.2014.08.012; Saito K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28932; Semenza GL, 2007, J BIOENERG BIOMEMBR, V39, P231, DOI 10.1007/s10863-007-9081-2; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Singer EA, 2013, CURR OPIN ONCOL, V25, P273, DOI 10.1097/CCO.0b013e32835fc857; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Tang SW, 2009, CANCER LETT, V273, P35, DOI 10.1016/j.canlet.2008.07.038; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Warner GJ, 2000, J BIOL CHEM, V275, P28110; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152	56	146	152	4	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5435	5450		10.1038/s41388-018-0315-z	http://dx.doi.org/10.1038/s41388-018-0315-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29872221	Green Accepted, Green Submitted			2022-12-28	WOS:000446312900005
J	Cheng, Y; Ren, X; Yuan, Y; Shan, Y; Li, L; Chen, X; Zhang, L; Takahashi, Y; Yang, JW; Han, B; Liao, J; Li, Y; Harvey, H; Ryazanov, A; Robertson, GP; Wan, G; Liu, D; Chen, AF; Tao, Y; Yang, JM				Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J-M			eEF-2 kinase is a critical regulator of Warbrug effect through controlling PP2A-A synthesis (vol 35, pg 6293, 2016)	ONCOGENE			English	Correction									[Cheng, Y.; Li, L.; Chen, X.] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Li, Y.; Robertson, G. P.; Wan, G.; Yang, J-M] Penn State Univ, Coll Med, Dept Pharmacol, Penn State Hershey Canc Inst, Hershey, PA 17033 USA; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Robertson, G. P.; Wan, G.; Yang, J-M] Milton S Hershey Med Ctr, Hershey, PA 17033 USA; [Yuan, Y.; Liu, D.] Washington State Univ, Dept Pharmaceut Sci, Coll Pharm, Spokane, WA USA; [Han, B.] Penn State Univ, Coll Med, Dept Pathol, Penn State Hershey Canc Inst, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Div Biostat & Bioinformat, Hershey, PA USA; [Harvey, H.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Med, Hershey, PA USA; [Ryazanov, A.] Rutgers State Univ, Dept Pharmacol, Robert wood Jonson Med Sch, Piscataway, NJ USA; [Chen, A. F.] Cent S Univ, Xiangya Hosp 3, Coll Pharm, Ctr Vasc & Translat Med, Changsha, Hunan, Peoples R China; [Tao, Y.] Cent S Univ, Canc Res Inst, Sch Basic Med, Changsha, Hunan, Peoples R China; [Tao, Y.] Cent S Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China	Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Central South University; Central South University; Central South University	Cheng, Y (corresponding author), Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China.; Cheng, Y (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Penn State Hershey Canc Inst, Hershey, PA 17033 USA.; Cheng, Y (corresponding author), Milton S Hershey Med Ctr, Hershey, PA 17033 USA.	chengyan0677@163.com; juy16@psu.edu						Cheng Y, 2016, ONCOGENE, V35, P6293, DOI 10.1038/onc.2016.166	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4633	4634		10.1038/s41388-018-0322-0	http://dx.doi.org/10.1038/s41388-018-0322-0			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29973686	Bronze			2022-12-28	WOS:000441736700011
J	Madhav, A; Andres, A; Duong, F; Mishra, R; Haldar, S; Liu, ZQ; Angara, B; Gottlieb, R; Zumsteg, ZS; Bhowmick, NA				Madhav, Anisha; Andres, Allen; Duong, Frank; Mishra, Rajeev; Haldar, Subhash; Liu, Zhenqiu; Angara, Bryan; Gottlieb, Roberta; Zumsteg, Zachary S.; Bhowmick, Neil A.			Antagonizing CD105 enhances radiation sensitivity in prostate cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CELLS IN-VITRO; ENDOGLIN CD105; TGF-BETA; PANCREATIC-CANCER; ENERGY-METABOLISM; GASTRIC-CANCER; PHASE-I; THERAPY; RADIOSENSITIVITY	Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for nearly 30-50% of patients undergoing radiotherapy. A better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome. Here we identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-beta signaling. Antagonizing CD 105-dependent BMP signaling with a partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with irradiation. In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD 105/ BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and PGC-1 alpha activation. Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone. However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells. This suggested DNA damage repair was not the sole determinant of CD 105 radio-resistance. As cancer cells undergo an energy deficit following irradiation, due to the demands of DNA and organelle repair, we examined SIRT1's role on p53 and PGC-1 alpha with respect to glycolysis and mitochondrial biogenesis, respectively. Consequently, blocking the CD105-SIRT1 axis was found to deplete the ATP stores of irradiated cells and cause G2 cell cycle arrest. Xenograft models supported these findings that combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value = 10(-9)). We identified a novel synthetic lethality strategy of combining radiation and CD 105 targeting to address the DNA repair and metabolic addiction induced by irradiation in p53-functional prostate cancers.	[Madhav, Anisha; Andres, Allen; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Duong, Frank; Mishra, Rajeev; Haldar, Subhash; Liu, Zhenqiu; Angara, Bryan; Gottlieb, Roberta; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Zumsteg, Zachary S.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA; [Bhowmick, Neil A.] Greater Los Angeles Vet Adm, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Greater Los Angeles Vet Adm, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Bhowmick, Neil/AAA-7302-2019	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; Haldar, Subhash/0000-0002-1230-1770; Gottlieb, Roberta/0000-0002-1432-006X	Department of Defense [PC161016]; Department of Veterans Affairs [I01BX0011040]; National Cancer Institute (NIH) [CA108646, CA098912]; NATIONAL CANCER INSTITUTE [P01CA098912, R01CA108646] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001040] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by grants from the Department of Defense (PC161016 to AM), Department of Veterans Affairs (I01BX0011040 to NAB), and the National Cancer Institute (NIH, CA108646 and CA098912 to NAB). The metabolic analysis was possible because of help from the Cedars-Sinai Medical Center Metabolism and Mitochondrial Research Core. We also thank Tracon Pharmaceuticals for providing the CD105 antagonist, TRC105.	Andres AM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89303; Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Borno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041; Bouquet F, 2011, CLIN CANCER RES, V17, P6754, DOI 10.1158/1078-0432.CCR-11-0544; Canto C, 2012, PHARMACOL REV, V64, P166, DOI 10.1124/pr.110.003905; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Chen L, 2016, CELL CYCLE, V15, P840, DOI 10.1080/15384101.2016.1151582; Deckbar D, 2011, CRIT REV BIOCHEM MOL, V46, P271, DOI 10.3109/10409238.2011.575764; Ewan KB, 2002, CANCER RES, V62, P5627; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Hoeferlin L Alexis, 2011, Genes Cancer, V2, P889, DOI 10.1177/1947601911432495; Jonker L, 2014, MICROCIRCULATION, V21, P93, DOI 10.1111/micc.12099; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Koyama Y, 2010, EXP THER MED, V1, P627, DOI 10.3892/etm_00000098; Kumar S, 2014, ONCOGENE, V33, P3970, DOI 10.1038/onc.2013.386; Lee NY, 2008, J BIOL CHEM, V283, P32527, DOI 10.1074/jbc.M803059200; Lin Zhenghong, 2013, Genes Cancer, V4, P97, DOI 10.1177/1947601912475079; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Miao ZF, 2016, HUM PATHOL, V51, P114, DOI 10.1016/j.humpath.2015.12.023; Moeller BJ, 2004, CELL CYCLE, V3, P1107; Moon DH, 2017, UROL ONCOL-SEMIN ORI, V35, P59, DOI 10.1016/j.urolonc.2016.06.002; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Munoz-Fontela C, 2011, CELL CYCLE, V10, P3701, DOI 10.4161/cc.10.21.17899; Pal K, 2014, MOL CANCER THER, V13, P2264, DOI 10.1158/1535-7163.MCT-14-0291; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Rukstalis Daniel B, 2002, Rev Urol, V4 Suppl 2, pS12; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Shipley WU, 2017, NEW ENGL J MED, V376, P417, DOI 10.1056/NEJMoa1607529; Smith SJ, 2012, ACTA NEUROPATHOL, V124, P99, DOI 10.1007/s00401-012-0952-1; Vo MN, 2010, BREAST CANCER RES TR, V119, P767, DOI 10.1007/s10549-008-0261-5; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Winter Jordan M, 2006, HPB (Oxford), V8, P324, DOI 10.1080/13651820600804203; Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033; Yamoah K, 2015, INT J RADIAT ONCOL, V93, P737, DOI 10.1016/j.ijrobp.2015.07.2284; YOUNG VR, 1977, CANCER RES, V37, P2336; Zhang J, 2015, CANCER LETT, V363, P108, DOI 10.1016/j.canlet.2015.04.015; Zhong J, 2013, RADIOTHER ONCOL, V106, P390, DOI 10.1016/j.radonc.2013.02.013; Ziebarth AJ, 2013, CLIN CANCER RES, V19, P170, DOI 10.1158/1078-0432.CCR-12-1045; Zumsteg ZS, 2016, CLIN CANCER RES, V22, P2009, DOI 10.1158/1078-0432.CCR-15-2245; Zumsteg ZS, 2015, J UROLOGY, V194, P1624, DOI 10.1016/j.juro.2015.06.100	46	15	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4385	4397		10.1038/s41388-018-0278-0	http://dx.doi.org/10.1038/s41388-018-0278-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29717261	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000441144300004
J	Weeden, CE; Ah-Cann, C; Holik, AZ; Pasquet, J; Garnier, JM; Merino, D; Lessene, G; Asselin-Labat, ML				Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Pasquet, Julie; Garnier, Jean-Marc; Merino, Delphine; Lessene, Guillaume; Asselin-Labat, Marie-Liesse			Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition	ONCOGENE			English	Article							GENETIC ALTERATIONS; KINASE INHIBITOR; FAMILY PROTEINS; DOWN-REGULATION; CANCER; ABT-737; RESISTANCE; PREDICT; NVP-BGJ398; OVERCOME	Genetic alterations in the fibroblast growth factor receptors (FGFRs) have been described in multiple solid tumours including bladder cancer, head and neck and lung squamous cell carcinoma (SqCC). However, recent clinical trials showed limited efficacy of FGFR-targeted therapy in lung SqCC, suggesting combination therapy may be necessary to improve patient outcomes. Here we demonstrate that FGFR therapy primes SqCC for cell death by increasing the expression of the pro-apoptotic protein BIM. We therefore hypothesised that combining BH3-mimetics, potent inhibitors of pro-survival proteins, with FGFR-targeted therapy may enhance the killing of SqCC cells. Using patient-derived xenografts and specific inhibitors of BCL-2, BCL-XL, and MCL-1, we identified a greater reliance of lung SqCC cells on BCL-XL and MCL-1 compared to BCL-2 for survival. However, neither BCL-XL nor MCL-1 inhibitors alone provided a survival benefit in combination FGFR therapy in vivo. Only triple BCL-XL, MCL-1, and FGFR inhibition resulted in tumour volume regression and prolonged survival in vivo, demonstrating the ability of BCL-XL and MCL-1 proteins to compensate for each other in lung SqCC. Our work therefore provides a rationale for the inhibition of MCL-1, BCL-XL, and FGFR1 to maximize therapeutic response in FGFR1 -expressing lung SqCC.	[Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Pasquet, Julie; Asselin-Labat, Marie-Liesse] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic, Australia; [Weeden, Clare E.; Ah-Cann, Casey; Holik, Aliaksei Z.; Garnier, Jean-Marc; Lessene, Guillaume; Asselin-Labat, Marie-Liesse] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Garnier, Jean-Marc; Lessene, Guillaume] Walter & Eliza Hall Inst Med Res, ACRF Chem Biol Div, Parkville, Vic, Australia; [Merino, Delphine] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Merino, Delphine] La Trobe Univ, Sch Canc Med, Melbourne, Vic, Australia; [Merino, Delphine] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Lessene, Guillaume] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne; Walter & Eliza Hall Institute; La Trobe University; Olivia Newton-John Cancer Research Institute; La Trobe University; Walter & Eliza Hall Institute; University of Melbourne	Asselin-Labat, ML (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic, Australia.; Asselin-Labat, ML (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.	labat@wehi.edu.au	Holik, Aliaksei Z/H-5828-2015; Holik, Aliaksei/GYA-2218-2022; Merino, Delphine/L-9159-2017	Holik, Aliaksei Z/0000-0002-3555-8587; Merino, Delphine/0000-0002-8075-6275; Ah-Cann, Casey/0000-0001-9210-3776; Weeden, Clare/0000-0002-1561-1416	Viertel Foundation Senior Medical Researcher Fellowship; Australian Postgraduate Award; Cancer Therapeutics CRC top-up scholarship; Deep Manchanda Lung Foundation Australia Early Career Fellowship; Lung Foundation Australia PhD Scholarship; NBCF Early Career Fellowship; NHMRC Project grant [1101378]; Servier; Cancer Therapeutics CRC; Harry Secomb Foundation; Ian Potter Foundation; Leukemia and Lymphoma Society; Australian Cancer Research Foundation; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC IRIISS; Victorian Cancer Agency	Viertel Foundation Senior Medical Researcher Fellowship; Australian Postgraduate Award(Australian Government); Cancer Therapeutics CRC top-up scholarship(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Deep Manchanda Lung Foundation Australia Early Career Fellowship; Lung Foundation Australia PhD Scholarship; NBCF Early Career Fellowship; NHMRC Project grant(National Health and Medical Research Council (NHMRC) of Australia); Servier(Servier); Cancer Therapeutics CRC(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Harry Secomb Foundation; Ian Potter Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Cancer Research Foundation; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency	M-LA-L is supported by a Viertel Foundation Senior Medical Researcher Fellowship. CEW is supported by an Australian Postgraduate Award, a Cancer Therapeutics CRC top-up scholarship, and a Deep Manchanda Lung Foundation Australia Early Career Fellowship. CA is supported by a Lung Foundation Australia PhD Scholarship. DM is supported by an NBCF Early Career Fellowship and NHMRC Project grant (1101378). This work was made possible through financial support from Servier, grants from the Victorian Cancer Agency, the Cancer Therapeutics CRC, the Harry Secomb Foundation, the Ian Potter Foundation, the Leukemia and Lymphoma Society, the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Fan WW, 2011, CANCER RES, V71, P4494, DOI 10.1158/0008-5472.CAN-10-2668; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Gardner EE, 2014, CANCER RES, V74, P2846, DOI 10.1158/0008-5472.CAN-13-3460; Gong JN, 2016, BLOOD, V128, P1834, DOI 10.1182/blood-2016-03-704908; Greenberg EF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.355; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lam LT, 2017, MOL CANCER THER, V16, P1511, DOI 10.1158/1535-7163.MCT-16-0459; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Merino D, 2009, APOPTOSIS, V14, P570, DOI 10.1007/s10495-008-0308-4; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; PRICHARD MN, 1991, ANTIMICROB AGENTS CH, V35, P1060, DOI 10.1128/AAC.35.6.1060; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thiagarajan PS, 2016, ONCOTARGET, V7, P82013, DOI 10.18632/oncotarget.13307; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Weeden CE, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.49; Weeden CE, 2017, MOL CANCER THER, V16, P1610, DOI 10.1158/1535-7163.MCT-17-0174; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wykosky J, 2015, CANCER RES, V75, P394, DOI 10.1158/0008-5472.CAN-14-2004; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Ye MX, 2017, CANCER RES, V77, P3527, DOI 10.1158/0008-5472.CAN-16-3470; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zeuner A, 2014, CELL DEATH DIFFER, V21, P1877, DOI 10.1038/cdd.2014.105	47	59	60	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4475	4488		10.1038/s41388-018-0268-2	http://dx.doi.org/10.1038/s41388-018-0268-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743589				2022-12-28	WOS:000441144300010
J	Dankner, M; Rose, AAN; Rajkumar, S; Siegel, PM; Watson, IR				Dankner, Matthew; Rose, April A. N.; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.			Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations	ONCOGENE			English	Review							MEK INHIBITOR TRAMETINIB; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; DABRAFENIB PLUS TRAMETINIB; WILD-TYPE; OPEN-LABEL; B-RAF; MAPK PATHWAY; MUTANT MELANOMA; DOSE-ESCALATION	The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation. Non-V600 BRAF mutants are found in many cancers, and are more prevalent than V600 mutations in certain tumor types. For example, between 50-80% of BRAF mutations in non-small cell lung cancer and 22-30% in colorectal cancer encode for non-V600 mutants. As next generation sequencing becomes increasingly used in clinical practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient's tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment. From recent studies, a new classification system is emerging for BRAF mutations based on biochemical and signaling mechanisms associated with these mutants. Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class III mutations are kinase impaired but increase signaling through the MAPK pathway due to enhanced RAS binding and subsequent CRAF activation. These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development. Herein, we discuss pre-clinical and clinical findings that may lead to improved treatments for all classes of BRAF mutant cancers.	[Dankner, Matthew; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Dankner, Matthew; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Rose, April A. N.] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada; [Rajkumar, Shivshankari; Watson, Ian R.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; University of Toronto; McGill University	Watson, IR (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada.; Watson, IR (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	ian.watson2@mcgill.ca	Rose, April/AAR-8222-2020; ravegnini, gloria/K-1330-2016	Rose, April/0000-0002-9845-4603; ravegnini, gloria/0000-0002-7774-402X; Dankner, Matthew/0000-0003-4869-5895; Watson, Ian/0000-0002-6025-3080	Canadian Institutes of Health Research (CIHR); Brain Tumor Foundation of Canada; David Cornfield Melanoma Fund Award; US Department of Defense (US DOD) [CA140389]; Melanoma Research Alliance (MRA) [412429]; V Foundation [V2016-023]; Canadian Institute of Health Research (CIHR) [PJT-152975]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Brain Tumor Foundation of Canada; David Cornfield Melanoma Fund Award; US Department of Defense (US DOD)(United States Department of Defense); Melanoma Research Alliance (MRA); V Foundation; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	MD acknowledges MD/PhD training support from the Canadian Institutes of Health Research (CIHR) and the Brain Tumor Foundation of Canada. AANR acknowledges receipt of a David Cornfield Melanoma Fund Award. PMS acknowledges research support from the US Department of Defense (US DOD - CA140389), IRW is funded by grants from the Melanoma Research Alliance (MRA - Grant #412429), the V Foundation (Grant #V2016-023), and the Canadian Institute of Health Research (CIHR - Grant # PJT-152975). PMS is a William Dawson Scholar of McGill University and IRW is a Canada Research Chair.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andreadi C, 2012, GENE DEV, V26, P1945, DOI 10.1101/gad.193458.112; [Anonymous], 2018, CANCER DISCOV, V8, P4, DOI [10.1158/2159-8290.CD-NB2017-163, DOI 10.1158/2159-8290.CD-NB2017-163]; [Anonymous], 2016, SOC MEL RES 13 INT C; Bahadoran P, 2013, J CLIN ONCOL, V31, pE324, DOI 10.1200/JCO.2012.46.1061; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Bendell JC, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3502; Berghoff AS, 2014, CURR OPIN NEUROL, V27, P689, DOI 10.1097/WCO.0000000000000146; Bowyer SE, 2014, MELANOMA RES, V24, P504, DOI 10.1097/CMR.0000000000000099; Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv310; Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868; Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8; Burger MC, 2017, ONCOL REP, V38, P3291, DOI 10.3892/or.2017.6013; Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657; Carrera C, 2015, JAMA DERMATOL, V151, P544, DOI 10.1001/jamadermatol.2014.4115; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Falchook GS, 2015, THYROID, V25, P71, DOI 10.1089/thy.2014.0123; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, CANCER-AM CANCER SOC, V116, P4902, DOI 10.1002/cncr.25261; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Gallo S, 2018, MELANOMA RES, V28, P143, DOI 10.1097/CMR.0000000000000417; Gardini AC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2463-2; Garman B, 2017, CELL REP, V21, P1936, DOI 10.1016/j.celrep.2017.10.052; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625; Gautschi O, 2013, LUNG CANCER, V82, P365, DOI 10.1016/j.lungcan.2013.08.012; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Grilley-Olson JE, 2016, INVEST NEW DRUG, V34, P740, DOI 10.1007/s10637-016-0377-0; Haase O, 2016, HAUTARZT, V67, P648, DOI 10.1007/s00105-016-3785-3; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hallmeyer S, 2017, MELANOMA RES, V27, P585, DOI 10.1097/CMR.0000000000000398; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Huijberts S, 2017, ANN ONCOL          S, V28, pv158, DOI [10.1093/annonc/mdx393, DOI 10.1093/ANNONC/MDX393]; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Johnson DB, 2018, PIGM CELL MELANOMA R, V31, P432, DOI 10.1111/pcmr.12674; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394; Joshi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118210; Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024; Kim DW, 2016, CANCER, V123, P1372; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966; Kopetz S., 2010, J CLIN ONCOL S15S, V28; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Krepler C, 2017, CELL REP, V21, P1953, DOI 10.1016/j.celrep.2017.10.021; Kulkarni A, 2017, CLIN CANCER RES, V23, P5631, DOI 10.1158/1078-0432.CCR-16-0758; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Lavoie H, 2013, NAT CHEM BIOL, V9, P428, DOI [10.1038/NCHEMBIO.1257, 10.1038/nchembio.1257]; Le K, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12092; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Marconcini R, 2017, EXP HEMATOL ONCOL, V6, DOI 10.1186/s40164-017-0067-4; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; Miller WH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3057; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Nowroozi S, 2013, J CLIN ONCOL, V31; Okimoto RA, 2016, P NATL ACAD SCI USA, V113, P13456, DOI 10.1073/pnas.1610456113; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Preusser M, 2016, EXPERT OPIN INV DRUG, V25, P7, DOI 10.1517/13543784.2016.1110143; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rasco DW, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14102; Reddy SM, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0531-z; Richtig G, 2016, CASE REP ONCOL, V9, P543, DOI 10.1159/000449125; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rose AANDM, 2017, AACR NCI EORTC INT C; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Santarpia L, 2009, HUM PATHOL, V40, P827, DOI 10.1016/j.humpath.2008.11.003; Sereno M, 2015, ANTI-CANCER DRUG, V26, P1004, DOI 10.1097/CAD.0000000000000277; Shinozaki E, 2017, BRIT J CANCER, V117, P1450, DOI 10.1038/bjc.2017.308; Siroy AE, 2015, J INVEST DERMATOL, V135, P508, DOI 10.1038/jid.2014.366; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun Y, 2017, NEURO-ONCOLOGY, V19, P774, DOI 10.1093/neuonc/now261; Tejpar S, 2010, ONCOLOGIST, V15, P390, DOI 10.1634/theoncologist.2009-0233; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	144	185	189	8	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3183	3199		10.1038/s41388-018-0171-x	http://dx.doi.org/10.1038/s41388-018-0171-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29540830				2022-12-28	WOS:000435526600001
J	Yao, K; Lee, SY; Peng, C; Lim, DY; Yamamoto, H; Ryu, J; Lim, TG; Chen, HY; Jin, GG; Zhao, ZJ; Han, YP; Ma, WY; Bode, AM; Dong, ZG				Yao, Ke; Lee, Sung-Young; Peng, Cong; Lim, Do Young; Yamamoto, Hiroyuki; Ryu, Joohyun; Lim, Tae-Gyu; Chen, Hanyong; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang			RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation	ONCOGENE			English	Article							INNATE IMMUNITY; UBIQUITIN; ACTIVATION; RECEPTOR; KINASES; FAMILY; RESPONSES; DOMAIN; CELLS	Inflammation is a complex biological host reaction to tissue damage, infection and trauma. Extensive study of the inflammatory response has led to the identification of several protein kinases that are essential for signaling and could be potential therapeutic targets. The RSK family of kinases has multiple cellular functions. In our study, we found that RSK2 is a mediator for inflammation signaling and interacts with TRAF6. In vitro kinase assay results indicated that RSK2 strongly phosphorylates TRAF6 at serines 46, 47 and 48. Ectopic overexpression of TRAF6 or knocking down RSK2 expression confirmed that RSK2 is a positive regulator of TRAF6 K63 ubiquitination. TRAF6 is also required for RSK2 ubiquitination. TRAF6 bridges the TNF receptor superfamily and intracellular signaling for the induction of proinflammatory cytokines. We developed a colon inflammation model using RSK2 wild type (WT) and knockout (KO) mice. As expected, F4/80 and CD3 infiltration were significantly upregulated in WT mice compared to RSK2 KO mice. Furthermore, inflammation signaling, including Ikk alpha/beta, p38 and JNKs, was dramatically upregulated in WT mice. Colon tissue immunoprecipitation results further confirmed that TRAF6 K63 ubiquitination was lower in RSK2 KO mice. Overall, these results indicate that phosphorylation of TRAF6 (S46, 47, 48) by RSK2 is required for TRAF6 K63 ubiquitination and inflammation signaling.	[Yao, Ke; Lee, Sung-Young; Peng, Cong; Lim, Do Young; Yamamoto, Hiroyuki; Ryu, Joohyun; Lim, Tae-Gyu; Chen, Hanyong; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Yao, Ke; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou, Henan, Peoples R China; [Peng, Cong] Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China; [Zhao, Zhenjiang] Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China	University of Minnesota System; Central South University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou, Henan, Peoples R China.	zgdong@hi.umn.edu	Lim, Tae-Gyu/AAO-8475-2020	Lim, Tae-Gyu/0000-0001-6930-9565	Hormel Foundation; National Institutes of Health [CA166011, CA187027, CA196639]; NSF of Henan Province China [162300410337]; NATIONAL CANCER INSTITUTE [R01CA196639, R01CA166011, R01CA187027] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF of Henan Province China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Simin Zhao and Todd Schuster for supporting experiments, Nicki Brickman and Dr. Tia Rai for assistance in submitting our manuscript (The Hormel Institute, University of Minnesota). This work was funded by The Hormel Foundation, National Institutes of Health grants CA166011, CA187027, CA196639 and NSF of Henan Province China No. 162300410337.	Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bekes M, 2009, CELL, V137, P604, DOI 10.1016/j.cell.2009.04.052; Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2007, J BIOL CHEM, V282, P8380, DOI 10.1074/jbc.M611322200; Cho YY, 2009, CANCER RES, V69, P4398, DOI 10.1158/0008-5472.CAN-08-4959; Choo Yeun Su, 2009, J Vis Exp, DOI 10.3791/1293; Corn JE, 2014, NAT STRUCT MOL BIOL, V21, P297, DOI 10.1038/nsmb.2808; Davidson LA, 2015, CANCER RES, V75, P5392, DOI 10.1158/0008-5472.CAN-15-1706; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Huang GH, 2009, CYTOKINE, V48, P161, DOI 10.1016/j.cyto.2009.08.002; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jiao S, 2015, NAT IMMUNOL, V16, P246, DOI 10.1038/ni.3097; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Liu AG, 2012, J BIOL CHEM, V287, P16132, DOI 10.1074/jbc.M111.310102; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Malakhova M, 2008, NAT STRUCT MOL BIOL, V15, P112, DOI 10.1038/nsmb1347; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Wang YB, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000253; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e; Zhang XF, 2013, CELL RES, V23, P366, DOI 10.1038/cr.2013.21; Zhao W, 2012, J IMMUNOL, V188, P2567, DOI 10.4049/jimmunol.1103255; Zhou FF, 2012, J BIOL CHEM, V287, P11002, DOI 10.1074/jbc.M111.328187; Zhu F, 2011, CANCER RES, V71, P393, DOI 10.1158/0008-5472.CAN-10-2012; Zinngrebe J, 2014, EMBO REP, V15, P28, DOI 10.1002/embr.201338025	47	11	12	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3501	3513		10.1038/s41388-018-0167-6	http://dx.doi.org/10.1038/s41388-018-0167-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563609	Green Accepted			2022-12-28	WOS:000436412500003
J	Mancini, R; Noto, A; Pisanu, ME; De Vitis, C; Maugeri-Sacca, M; Ciliberto, G				Mancini, Rita; Noto, Alessia; Pisanu, Maria Elena; De Vitis, Claudia; Maugeri-Sacca, Marcello; Ciliberto, Gennaro			Metabolic features of cancer stem cells: the emerging role of lipid metabolism	ONCOGENE			English	Review							CHOLESTERYL ESTER ACCUMULATION; BREAST-CANCER; OXIDATIVE-PHOSPHORYLATION; LACTIC-ACID; PROSPECTIVE WINDOW; INITIATING CELLS; AMINO-ACID; METFORMIN; IDENTIFICATION; LEUKEMIA	Cancer stem cells (CSCs) are an uncommon subset of tumor cells capable of self-renewal, differentiating, and recreating the parental tumor when transplanted into the murine background. Over the past two decades, efforts toward understanding CSC biology culminated into identifying a set of signaling pathways sustaining "stemness". Nevertheless, while metabolic rewiring is nowadays considered a hallmark of cancer, no consensus has been reached on the metabolic features underlying the plastic nature of CSCs, which are capable of residing in a dormant state, and able to rapidly proliferate when the need to repopulate the tumor mass arises. An emerging concept in the field of CSC metabolism is that these cells are extremely reliant on the activity of enzymes involved in lipid metabolism, such as stearoyl-CoA desaturase 1 (SCD1) and 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR). Indeed, SCD1 and HMG-CoAR have been described as key factors for the correct function of a number of concatenated pathways involved in CSC fate decision, such as Hippo and Wnt. In the present review, we describe metabolic futures of CSCs with a special focus on lipid metabolism, which until now represents an underappreciated force in maintaining CSCs and an attractive therapeutic target.	[Mancini, Rita; Noto, Alessia; Pisanu, Maria Elena; De Vitis, Claudia] Sapienza Univ Rome, Dept Clin & Mol Med, I-00161 Rome, Italy; [Maugeri-Sacca, Marcello] Regina Elena Inst Canc Res, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy; [Ciliberto, Gennaro] Regina Elena Inst Canc Res, Sci Direct, Via Elio Chianesi 53, I-00144 Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Maugeri-Sacca, M (corresponding author), Regina Elena Inst Canc Res, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy.; Ciliberto, G (corresponding author), Regina Elena Inst Canc Res, Sci Direct, Via Elio Chianesi 53, I-00144 Rome, Italy.	marcello.maugerisacca@ifo.gov.it; gennaro.ciliberto@ifo.gov.it	Ciliberto, Gennaro/J-4131-2017; Pisanu, Maria Elena/AAC-9143-2019; Maugeri-Saccà, Marcello/K-2350-2014; De Vitis, Claudia/K-4726-2016	Ciliberto, Gennaro/0000-0003-2851-8605; Maugeri-Saccà, Marcello/0000-0003-2287-9581; De Vitis, Claudia/0000-0001-8899-2347; pisanu, maria elena/0000-0002-0029-3523	Italian Association for Cancer Research (AIRC) [IG17009, IG15216]; Fondo di Ricerca di Ateneo [C26A142LZ8]; POR FESR Lazio; Fondazione Veronesi fellowship	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondo di Ricerca di Ateneo; POR FESR Lazio; Fondazione Veronesi fellowship(Fondazione Umberto Veronesi)	We thank Tania Merlino for editorial assistance. This work was supported by Italian Association for Cancer Research (AIRC) grant IG17009 to RM, and grant IG15216 to GC, and by Fondo di Ricerca di Ateneo 2014 (C26A142LZ8) and POR FESR Lazio 2007/2013 to RM. MEP is supported by a Fondazione Veronesi fellowship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6; Bonanni B, 2012, J CLIN ONCOL, V30, P2593, DOI 10.1200/JCO.2011.39.3769; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cai J, 2015, GENE DEV, V29, P1493, DOI 10.1101/gad.264515.115; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castro LFC, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-132; Cazzaniga M, 2013, BRIT J CANCER, V109, P2792, DOI 10.1038/bjc.2013.657; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; DeCensi A, 2014, BREAST CANCER RES TR, V148, P81, DOI 10.1007/s10549-014-3141-1; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dowling RJO, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0540-0; EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501; El Helou R, 2017, CELL REP, V18, P2256, DOI 10.1016/j.celrep.2017.02.016; Emmink BL, 2013, J PROTEOMICS, V91, P84, DOI 10.1016/j.jprot.2013.06.027; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Freitas DP, 2014, INT J CANCER, V134, P1270, DOI 10.1002/ijc.28478; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Gazi E, 2007, J LIPID RES, V48, P1846, DOI 10.1194/jlr.M700131-JLR200; Giarnieri E, 2013, J CELL PHYSIOL, V228, P1720, DOI 10.1002/jcp.24300; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hadad SM, 2015, BREAST CANCER RES TR, V150, P149, DOI 10.1007/s10549-015-3307-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hjelmeland AB, 2011, CELL DEATH DIFFER, V18, P829, DOI 10.1038/cdd.2010.150; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Kalinsky K, 2014, CANCER INVEST, V32, P150, DOI 10.3109/07357907.2014.889706; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lobello N, 2016, ONCOTARGET, V7, P62019, DOI 10.18632/oncotarget.11495; Ma MKF, 2017, J HEPATOL, V67, P979, DOI 10.1016/j.jhep.2017.06.015; Mancini R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021320; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MARQUEZ J, 1989, ARCH BIOCHEM BIOPHYS, V268, P667, DOI 10.1016/0003-9861(89)90335-4; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Maugeri-Sacca M, 2016, CRIT REV ONCOL HEMAT, V106, P132, DOI 10.1016/j.critrevonc.2016.08.004; Mitra R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-540; Mollinedo Faustino, 2015, Adv Biol Regul, V57, P130, DOI 10.1016/j.jbior.2014.10.003; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Niraula S, 2012, BREAST CANCER RES TR, V135, P821, DOI 10.1007/s10549-012-2223-1; Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Peck B, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0146-8; Peiris-Pages M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0712-6; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pisanu ME, 2017, CANCER LETT, V406, P93, DOI 10.1016/j.canlet.2017.07.027; Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; RIVERA S, 1988, BIOCHEM J, V249, P443, DOI 10.1042/bj2490443; Rocheteau P, 2012, CELL, V148, P112, DOI 10.1016/j.cell.2011.11.049; Rodriguez-Colman MJ, 2017, NATURE, V543, P424, DOI 10.1038/nature21673; Rothberg JM, 2013, NEOPLASIA, V15, P1111, DOI 10.1593/neo.13946; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; SAUER LA, 1982, CANCER RES, V42, P4090; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Sugihara E, 2013, INT J CANCER, V132, P1249, DOI 10.1002/ijc.27961; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang XX, 2017, CANCER RES, V77, P4947, DOI 10.1158/0008-5472.CAN-17-0114; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zhang JQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0704-x; Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935; Zhuang LY, 2005, J CLIN INVEST, V115, P959	121	72	73	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2367	2378		10.1038/s41388-018-0141-3	http://dx.doi.org/10.1038/s41388-018-0141-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29445137				2022-12-28	WOS:000431386000002
J	Zhu, Y; Lu, L; Qiao, C; Shan, Y; Li, HP; Qian, SX; Hong, M; Zhao, HH; Li, JY; Yang, ZF; Chen, YY				Zhu, Yu; Lu, Luo; Qiao, Chun; Shan, Yi; Li, Huapeng; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Yang, Zhongfa; Chen, Yaoyu			Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; IMATINIB-RESISTANCE; STEM-CELLS; IN-VITRO; THERAPY; GLYCOLYSIS; EXPRESSION; CANCER; PU.1	Resistance to the BCR-ABL tyrosine kinase inhibitor (TKI) remains a challenge for curing the disease in chronic myeloid leukemia (CML) patients as leukemia cells may survive through BCR-ABL kinase activity-independent signal pathways. To gain insight into BCR-ABL kinase activity-independent mechanisms, we performed an initial bioinformatics screen and followed by a quantitative PCR screen of genes that were elevated in CML samples. A total of 33 candidate genes were identified to be highly expressed in TKIs resistant patients. Among those genes, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), controlling the limiting step of glycolysis, was found to be strongly associated with TKIs resistance. PFKFB3 knockdown or pharmacological inhibition of its kinase activity markedly enhanced the sensitivity of CML cells to TKIs. Furthermore, pharmacological inhibition of PFKFB3 inhibited CML cells growth and significantly prolonged the survival of both allograft and xenograft CML mice. ChIP-seq data analysis combined with subsequent knockdown experiment showed that the Ets transcription factor PU.1 regulated the elevated expression of PFKFB3 in TKIs-resistant CML cells. Therefore, our results showed that targeting PFKFB3 sensitizes CML cells to TKIs and PFKFB3 may be a potential BCR-ABL kinase activity-independent mechanism in CML.	[Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China; [Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, Yu; Shan, Yi; Li, Huapeng; Yang, Zhongfa] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Massachusetts System; University of Massachusetts Worcester	Zhu, Y; Chen, YY (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China.; Zhu, Y; Chen, YY (corresponding author), Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, Y; Chen, YY (corresponding author), Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, Y (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA.	zhuyu@jsph.org.cn; Yaoyu.chen@njmu.edu.cn	Li, Jing/GYU-5036-2022; LI, JIAN/GRY-2197-2022; li, jian/GSE-0245-2022		National Natural Science Foundation of the People's Republic of China [81070437, 81270614, 81300379, 81570134, 81570141, 81522001, 81200362]; National Public Health Grand Research Foundation [201202017]; Priority Academic Program Development of Jiangsu Higher Education Institute [JX10231801]; Key Project of Jiangsu Province Health Agency [K201107]	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); National Public Health Grand Research Foundation; Priority Academic Program Development of Jiangsu Higher Education Institute; Key Project of Jiangsu Province Health Agency	This work was supported by the National Natural Science Foundation of the People's Republic of China (Nos. 81070437, 81270614, 81300379, 81570134, 81570141, 81522001, 81200362), National Public Health Grand Research Foundation (No. 201202017), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801) and Key Project of Jiangsu Province Health Agency (K201107).	Antony-Debre I, 2017, J CLIN INVEST, V127, P4297, DOI 10.1172/JCI92504; Bar-Natan Michal, 2012, JAKSTAT, V1, P55, DOI 10.4161/jkst.20006; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Cang SD, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-15; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chen YY, 2014, J CLIN INVEST, V124, P3847, DOI 10.1172/JCI66129; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Chen Z, 2017, LEUKEMIA, V31, P585, DOI 10.1038/leu.2016.231; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035; Cruys B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12240; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Eadie LN, 2017, LEUKEMIA, V31, P75, DOI 10.1038/leu.2016.179; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Gotlib J, 2017, BLOOD, V129, P838, DOI 10.1182/blood-2016-08-693630; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Han SH, 2017, LEUKEMIA, V31, P1532, DOI 10.1038/leu.2017.72; Holyoake TL, 2017, BLOOD, V129, P1595, DOI 10.1182/blood-2016-09-696013; Lee CR, 2016, FEBS LETT, V590, P358, DOI 10.1002/1873-3468.12057; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Moon SH, 2013, CELL CYCLE, V12, P867, DOI 10.4161/cc.23911; Oaxaca DM, 2016, TUMOR BIOL, V37, P12643, DOI 10.1007/s13277-016-5179-7; Ohzono T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4735; Okabe S, 2008, CLIN CANCER RES, V14, P6181, DOI 10.1158/1078-0432.CCR-08-0461; Pene-Dumitrescu T, 2010, J BIOL CHEM, V285, P21446, DOI 10.1074/jbc.M109.090043; Qian SX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0360-4; Quentmeier H, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-6; RAY D, 1990, ONCOGENE, V5, P663; Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778; Rosti G, 2017, NAT REV CLIN ONCOL, V14, P141, DOI 10.1038/nrclinonc.2016.139; Schutz C, 2017, LEUKEMIA, V31, P829, DOI 10.1038/leu.2017.9; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Sweet K, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-54; Wagle M, 2016, LEUKEMIA, V30, P1493, DOI 10.1038/leu.2016.51; Yalcin A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.292; Yalcin A, 2017, BIOCHEM BIOPH RES CO, V484, P687, DOI 10.1016/j.bbrc.2017.01.178; Yamada Osamu, 2013, JAKSTAT, V2, pe25256, DOI 10.4161/jkst.25256; Yang Z, 2014, AUTOPHAGY, V10, P382, DOI 10.4161/auto.27345; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhou H, 2017, LEUKEMIA, V31, P2065, DOI 10.1038/leu.2017.87	44	16	16	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2837	2849		10.1038/s41388-018-0157-8	http://dx.doi.org/10.1038/s41388-018-0157-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511345				2022-12-28	WOS:000432929800006
J	Tessari, A; Parbhoo, K; Pawlikowski, M; Fassan, M; Rulli, E; Foray, C; Fabbri, A; Embrione, V; Ganzinelli, M; Capece, M; Campbell, MJ; Broggini, M; La Perle, K; Farina, G; Cole, S; Marabese, M; Hernandez, M; Amann, JM; Pruneri, G; Carbone, DP; Garassino, MC; Croce, CM; Palmieri, D; Coppola, V				Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Fassan, Matteo; Rulli, Eliana; Foray, Claudia; Fabbri, Alessandra; Embrione, Valerio; Ganzinelli, Monica; Capece, Marina; Campbell, Moray J.; Broggini, Massimo; La Perle, Krista; Farina, Gabriella; Cole, Sara; Marabese, Mirko; Hernandez, Marianna; Amann, Joseph M.; Pruneri, Giancarlo; Carbone, David P.; Garassino, Marina C.; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo			RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; DOUBLE-EDGED-SWORD; LUNG-CANCER; CHEMOTHERAPY; CISPLATIN; THERAPY; EXPRESSION; TUMORS; RESISTANCE; STABILITY	Although limited by severe side effects and development of resistance platinum-based therapies still represent the most common first-line treatment for non-small cell lung cancer (NSCLC). However a crucial need in the clinical management of NSCLC is represented by the identification of cases sensitive to DNA damage response (DDR)-targeting drugs such as cisplatin or PARP inhibitors. Here we provide a molecular rationale for the stratification of NSCLC patients potentially benefitting from platinum compounds based on the expression levels of RANBP9 a recently identified player of the cellular DDR. RANBP9 was found overexpressed by immunohistochemistry (IHC) in NSCLC compared to normal adjacent tissues (NATs) (n = 147). Moreover a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio ((RANBP9 high vs low) )1.73, 95% CI 1.15-2.59, p = 0.0084 Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003]. Accordingly RANBP9 KO cells showed higher sensitivity to cisplatin in comparison with WT controls both in vitro and in vivo models. NSCLC RANBP9 KO cells were also more sensitive than control cells to the PARP inhibitor olaparib alone and in combination with cisplatin due to defective ATM-dependent and hyper-activated PARP-dependent DDR. The current investigation paves the way to prospective studies to assess the clinical value of RANBP9 protein levels as prognostic and predictive biomarker of response to DDR-targeting drugs leading to the development of new tools for the management of NSCLC patients.	[Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Foray, Claudia; Embrione, Valerio; Capece, Marina; Hernandez, Marianna; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo] Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Foray, Claudia; Embrione, Valerio; Capece, Marina; La Perle, Krista; Hernandez, Marianna; Amann, Joseph M.; Carbone, David P.; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo] Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA; [Fassan, Matteo] Univ Padua, Surg Pathol Unit, Dept Med DIMED, Padua, Italy; [Rulli, Eliana; Broggini, Massimo; Marabese, Mirko] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Milan, Italy; [Fabbri, Alessandra] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Milan, Italy; [Ganzinelli, Monica; Garassino, Marina C.] Ist Nazl Tumori, Fdn IRCCS, Dept Med Oncol, Thorac Oncol Unit, Milan, Italy; [Campbell, Moray J.] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA; [La Perle, Krista] Ohio State Univ, Coll Vet Med, Dept Vet Biosci & Comparat Pathol & Mouse Phenoty, Columbus, OH 43210 USA; [Farina, Gabriella] Osped Fatebenefratelli & Oftalm, Dept Oncol, Milan, Italy; [Cole, Sara] Ohio State Univ, Campus Microscopy & Imaging Facil, Columbus, OH 43210 USA; [Amann, Joseph M.; Carbone, David P.] Ohio State Univ, Dept Internal Med, Coll Med, James Thorac Ctr, Columbus, OH 43210 USA; [Pruneri, Giancarlo] Ist Nazl Tumori, Fdn IRCCS, Div Pathol, Milan, Italy	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Padua; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Coppola, V (corresponding author), Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA.; Coppola, V (corresponding author), Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA.	vincenzo.coppola@osumc.edu	Coppola, Vincenzo/D-5352-2014; Embrione, Valerio/AAB-3897-2019; Cole, Sara L/GYQ-5700-2022; Marabese, Mirko/AAA-6876-2019; Foray, Claudia/AAU-5895-2021; broggini, massimo/AAA-6460-2020; Ganzinelli, Monica/K-4548-2016; Pruneri, Giancarlo/AAC-7767-2022; Campbell, Moray/ABF-1264-2021; La Perle, Krista Marie DuBray/B-3099-2015; Fassan, Matteo/F-5152-2012; Rulli, Eliana/K-3211-2018	Coppola, Vincenzo/0000-0001-6163-1779; Embrione, Valerio/0000-0003-0184-3862; Marabese, Mirko/0000-0001-9379-0301; Ganzinelli, Monica/0000-0002-0526-0835; Pruneri, Giancarlo/0000-0002-7963-7172; Campbell, Moray/0000-0002-3355-0928; Fassan, Matteo/0000-0001-6515-5482; Palmieri, Dario/0000-0002-0797-4268; Foray, Claudia/0000-0003-0384-5765; Parbhoo, Kareesma/0000-0002-4806-9571; Rulli, Eliana/0000-0003-1058-4137	Pelotonia Fellowship for Cancer Research; College of Medicine of the Ohio State University; Office of Research of the Ohio State University; Comprehensive Cancer Center of the Ohio State University; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	Pelotonia Fellowship for Cancer Research; College of Medicine of the Ohio State University; Office of Research of the Ohio State University; Comprehensive Cancer Center of the Ohio State University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Authors are thankful to Dr. R. Shakya and the Target Validation Shared Resource, the Campus Microscopy & Imaging Facility, the Analytical Cytometry Shared Resource, the Comparative Pathology and Mouse Phenotyping Shared Resource, the Genetically Engineered Mouse Modeling Core, and N. Single and L. Monovich of the Biospecimen Services Shared Resource of the Ohio State University-Comprehensive Cancer Center. A.T. and M.P. are recipients of a Pelotonia Fellowship for Cancer Research. This work was supported by start-up funds to V.C. from the College of Medicine, Office of Research, and Comprehensive Cancer Center of the Ohio State University.	Arafa HMM, 2006, TOXICOLOGY, V222, P103, DOI 10.1016/j.tox.2006.02.007; Atabakhsh E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047803; Atabakhsh E, 2009, MOL CANCER RES, V7, P1962, DOI 10.1158/1541-7786.MCR-09-0098; Ballestrero A, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1296-3; Bonanno L, 2013, TRANSL LUNG CANCER R, V2, P160, DOI 10.3978/j.issn.2218-6751.2013.03.07; Brouwers Elke E M, 2008, BMC Clin Pharmacol, V8, P7, DOI 10.1186/1472-6904-8-7; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chaudhary UB, 2003, DRUGS, V63, P1565, DOI 10.2165/00003495-200363150-00004; Chen MK, 2016, AM J CANCER RES, V6, P827; Drottar M, 2006, LARYNGOSCOPE, V116, P292, DOI 10.1097/01.mlg.0000197630.85208.36; Eustermann S, 2015, MOL CELL, V60, P742, DOI 10.1016/j.molcel.2015.10.032; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Ghosal G, 2013, TRANSL CANCER RES, V2, P107, DOI 10.3978/j.issn.2218-676X.2013.04.01; Hatzopoulos S, 1999, ANN NY ACAD SCI, V884, P211, DOI 10.1111/j.1749-6632.1999.tb08643.x; Hoernes TP, 2016, RNA BIOL, V13, P760, DOI 10.1080/15476286.2016.1203504; Horibe S, 2015, LIFE SCI, V124, P31, DOI 10.1016/j.lfs.2015.01.011; Jin HO, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.63; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Kris MG, 2017, J CLIN ONCOL; Kuribayashi K, 2016, J CANCER RES THER, V12, P528, DOI 10.4103/0973-1482.174185; Lee SM, 2017, J CLIN ONCOL, V35, P402, DOI 10.1200/JCO.2016.68.1841; Leung AWY, 2017, CLIN CANCER RES, V23, P6555, DOI 10.1158/1078-0432.CCR-17-0700; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Palmieri D, 2016, ONCOTARGET, V7, P18371, DOI 10.18632/oncotarget.7813; Pawlowska E, 2015, INT J MOL SCI, V16, P27535, DOI 10.3390/ijms161126049; Pisters KMW, 2007, J CLIN ONCOL, V25, P5506, DOI 10.1200/JCO.2007.14.1226; Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3; Quinn JE, 2003, CANCER RES, V63, P6221; Reinhold WC, 2017, TRENDS CANCER, V3, P2, DOI 10.1016/j.trecan.2016.11.002; Rosell R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001129; Salemi LM, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170081; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Sears CR, 2016, DNA REPAIR, V40, P35, DOI 10.1016/j.dnarep.2016.02.004; Shao S, 2016, ANTICANCER RES, V36, P1295; Shukuya T, 2016, J THORAC ONCOL, V11, P976, DOI 10.1016/j.jtho.2016.02.015; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Socinski MA, 2018, J THORAC ONCOL, V13, P165, DOI 10.1016/j.jtho.2017.11.111; Suresh B, 2012, DRUG DISCOV TODAY, V17, P379, DOI 10.1016/j.drudis.2011.10.030; Suresh B, 2010, J BIOL CHEM, V285, P35340, DOI 10.1074/jbc.M110.156836; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761; Xiong Y, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0905-6; Yard BD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11428; Zhao ZH, 2017, ANTICANCER RES, V37, P4389, DOI 10.21873/anticanres.11833; Zhu LL, 2016, J BIOL REG HOMEOS AG, V30, P103	54	9	9	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6463	6476		10.1038/s41388-018-0424-8	http://dx.doi.org/10.1038/s41388-018-0424-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30076413	Green Accepted			2022-12-28	WOS:000452989100006
J	Di Modugno, F; Spada, S; Palermo, B; Visca, P; Iapicca, P; Di Carlo, A; Antoniani, B; Sperduti, I; Di Benedetto, A; Terrenato, I; Mottolese, M; Gandolfi, F; Facciolo, F; Chen, EI; Schwartz, MA; Santoni, A; Bissell, MJ; Nistico, P				Di Modugno, Francesca; Spada, Sheila; Palermo, Belinda; Visca, Paolo; Iapicca, Pierluigi; Di Carlo, Anna; Antoniani, Barbara; Sperduti, Isabella; Di Benedetto, Anna; Terrenato, Irene; Mottolese, Marcella; Gandolfi, Francesco; Facciolo, Francesco; Chen, Emily I.; Schwartz, Martin A.; Santoni, Angela; Bissell, Mina J.; Nistico, Paola			hMENA isoforms impact NSCLC patient outcome through fibronectin/beta 1 integrin axis	ONCOGENE			English	Article							BREAST-CANCER CELLS; EXTRACELLULAR-MATRIX; BETA(1) INTEGRIN; LUNG-CANCER; ACTIN DYNAMICS; BARBED END; TRANSENDOTHELIAL MIGRATION; 3-DIMENSIONAL CULTURE; ENA/VASP PROTEINS; SRF ACTIVITY	We demonstrated previously that the splicing of the actin regulator, hMENA, generates two alternatively expressed isoforms, hMENA(11a) and hMENA Delta v6, which have opposite functions in cell invasiveness. Their mechanisms of action have remained unclear. Here we report two major findings: (i) hMENA regulates beta 1 integrin expression. This was shown by depleting total hMENA, which led to loss of nuclear expression of serum response factor (SRF)-coactivator myocardin-related transcription factor 1 (MRTF-A), leading to an increase in the G-actin/F-actin ratio crucial for MRTF-A localization. This in turn inhibited SRF activity and the expression of its target gene beta 1 integrin. (ii) hMENA(11a) reduces and hMENA Delta v6 increases beta 1 integrin activation and signaling. Moreover, exogenous expression of hMENA(11a) in hMENA Delta v6-positive cancer cells dramatically reduces secretion of extracellular matrix (ECM) components, including beta 1 integrin ligands and metalloproteinases. On the other hand, overexpression of the pro-invasive hMENA.v6 increases fibronectin production. In primary tumors high hMENA(11a) correlates with low stromal fibronectin and a favorable clinical outcome of early node-negative non-small-cell lung cancer patients. These data provide new insights into the roles of hMENA(11a) and hMENA Delta v6 in the druggable beta 1 integrin-ECM signaling axis and allow stratification of patient risk, guiding their clinical management.	[Di Modugno, Francesca; Spada, Sheila; Palermo, Belinda; Iapicca, Pierluigi; Di Carlo, Anna; Nistico, Paola] IRCCS Regina Elena Natl Canc Inst, Tumor Immunol & Immunotherapy Unit, Rome, Italy; [Spada, Sheila; Santoni, Angela] Univ Sapienza, Dept Mol Med, Rome, Italy; [Visca, Paolo; Antoniani, Barbara; Di Benedetto, Anna; Mottolese, Marcella] IRCCS Regina Elena Natl Canc Inst, Pathol Lab, Rome, Italy; [Sperduti, Isabella; Terrenato, Irene] IRCCS Regina Elena Natl Canc Inst, Biostat Sci Direct, Rome, Italy; [Gandolfi, Francesco] Univ Sapienza, Dept Phys, Rome, Italy; [Facciolo, Francesco] IRCCS Regina Elena Natl Canc Inst, Thorac Surg Unit, Rome, Italy; [Chen, Emily I.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Pharmacol, New York, NY USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Internal Med, New Haven, CT 06511 USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Cell Biol, New Haven, CT 06511 USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Biomed Engn, New Haven, CT 06511 USA; [Bissell, Mina J.] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Sapienza University Rome; Sapienza University Rome; Columbia University; Yale University; Yale University; Yale University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Nistico, P (corresponding author), IRCCS Regina Elena Natl Canc Inst, Tumor Immunol & Immunotherapy Unit, Rome, Italy.	paola.nistico@ifo.gov.it	Di Modugno, Francesca/ABH-9406-2020; Sperduti, Isabella/K-8902-2016; Terrenato, Irene/B-1308-2017; Spada, Sheila/AAN-1520-2020; Di Carlo, Anna/AAY-4368-2021; Nistico, Paola/B-2862-2018	Di Modugno, Francesca/0000-0003-1427-1883; Sperduti, Isabella/0000-0001-5115-3099; Terrenato, Irene/0000-0002-0187-9323; Di Carlo, Anna/0000-0002-6037-6160; Facciolo, Francesco/0000-0002-7137-8946; Nistico, Paola/0000-0003-4409-2261; Di Benedetto, Anna/0000-0002-9853-8671; Palermo, Belinda/0000-0001-6293-0113; iapicca, pierluigi/0000-0002-7995-2391	Italian Association for Cancer Research AIRC: 5x1000 [12182, IG 15224]; NCI [R37CA064786, U54CA143836]; Department of Defense Breast Cancer Research Program [W81XWH0810736]; Breast Cancer Research Foundation; NIH [RO1 GM47214]; NATIONAL CANCER INSTITUTE [R37CA064786, U54CA143836, R01CA064786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	Italian Association for Cancer Research AIRC: 5x1000(Fondazione AIRC per la ricerca sul cancro); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	PN is supported by the Italian Association for Cancer Research AIRC: 5x1000, 12182, and IG 15224. M.J.B. is supported by the NCI (awards R37CA064786 and U54CA143836-Bay Area Physical Sciences Oncology Center), the Department of Defense Breast Cancer Research Program (award W81XWH0810736), and by a grant from the Breast Cancer Research Foundation. MAS is supported by NIH, RO1 GM47214.	AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; Bae YK, 2013, HUM PATHOL, V44, P2028, DOI 10.1016/j.humpath.2013.03.006; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bear JE, 2009, J CELL SCI, V122, P1947, DOI 10.1242/jcs.038125; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Bria E, 2014, ONCOTARGET, V5, P11054, DOI 10.18632/oncotarget.2609; Caccavari F, 2010, CELL ADHES MIGR, V4, P124, DOI 10.4161/cam.4.1.10976; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Di Modugno F, 2004, INT J CANCER, V109, P909, DOI 10.1002/ijc.20094; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Modugno F, 2018, P NATL ACAD SCI USA, V115, P3132, DOI 10.1073/pnas.1715998115; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gertler F, 2011, TRENDS CELL BIOL, V21, P81, DOI 10.1016/j.tcb.2010.10.001; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Han JY, 2003, LUNG CANCER-J IASLC, V41, P65, DOI 10.1016/S0169-5002(03)00146-6; Hansen SD, 2010, J CELL BIOL, V191, P571, DOI 10.1083/jcb.201003014; HOWLETT AR, 1995, J CELL SCI, V108, P1945; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kuhnel K, 2004, P NATL ACAD SCI USA, V101, P17027, DOI 10.1073/pnas.0403069101; Li J, 2017, P NATL ACAD SCI USA, V114, P4685, DOI 10.1073/pnas.1704171114; Margadant C, 2011, CURR OPIN CELL BIOL, V23, P607, DOI 10.1016/j.ceb.2011.08.005; Melchionna R, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1221556; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Nam JM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3454; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Rotty JD, 2015, DEV CELL, V32, P54, DOI 10.1016/j.devcel.2014.10.026; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Su Y, 2016, P NATL ACAD SCI USA, V113, pE3872, DOI 10.1073/pnas.1605074113; Trono P, 2016, ONCOGENE, V35, P887, DOI 10.1038/onc.2015.143; Vidaki M, 2017, NEURON, V95, P608, DOI 10.1016/j.neuron.2017.06.048; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Worth DC, 2010, J CELL BIOL, V189, P369, DOI 10.1083/jcb.200912014; Xu R, 2009, CANCER METAST REV, V28, P167, DOI 10.1007/s10555-008-9178-z; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	56	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5605	5617		10.1038/s41388-018-0364-3	http://dx.doi.org/10.1038/s41388-018-0364-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907768	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000447619100002
J	Boboila, S; Lopez, G; Yu, JY; Banerjee, D; Kadenhe-Chiweshe, A; Connolly, EP; Kandel, JJ; Rajbhandari, P; Silva, JM; Califano, A; Yamashiro, DJ				Boboila, Shuobo; Lopez, Gonzalo; Yu, Jiyang; Banerjee, Debarshi; Kadenhe-Chiweshe, Angela; Connolly, Eileen P.; Kandel, Jessica J.; Rajbhandari, Presha; Silva, Jose M.; Califano, Andrea; Yamashiro, Darrell J.			Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; THERAPEUTIC TARGETS; EXPRESSION; AP4; METASTASIS; NETWORK; GENES; IDENTIFICATION; PROGRESSION; ASSOCIATION	Despite the identification of MYCN amplification as an adverse prognostic marker in neuroblastoma, MYCN inhibitors have yet to be developed. Here, by integrating evidence from a whole-genome shRNA library screen and the computational inference of master regulator proteins, we identify transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma, providing a novel synthetic lethal target. We demonstrate that TFAP4 is a direct target of MYCN in neuroblastoma cells, and that its expression and activity strongly negatively correlate with neuroblastoma patient survival. Silencing TFAP4 selectively inhibits MYCN-amplified neuroblastoma cell growth both in vitro and in vivo, in xenograft mouse models. Mechanistically, silencing TFAP4 induces neuroblastoma differentiation, as evidenced by increased neurite outgrowth and upregulation of neuronal markers. Taken together, our results demonstrate that TFAP4 is a key regulator of MYCN-amplified neuroblastoma and may represent a valuable novel therapeutic target.	[Boboila, Shuobo; Banerjee, Debarshi; Yamashiro, Darrell J.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA; [Boboila, Shuobo; Yamashiro, Darrell J.] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA; [Boboila, Shuobo; Connolly, Eileen P.] Columbia Univ, Dept Radiat Oncol, Med Ctr, New York, NY 10032 USA; [Lopez, Gonzalo; Yu, Jiyang; Rajbhandari, Presha; Califano, Andrea] Columbia Univ, Dept Syst Biol, Med Ctr, New York, NY 10032 USA; [Lopez, Gonzalo] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Banerjee, Debarshi; Kadenhe-Chiweshe, Angela; Yamashiro, Darrell J.] Columbia Univ, Dept Surg, Med Ctr, New York, NY 10032 USA; [Kandel, Jessica J.] Univ Chicago Med & Biol Sci, Dept Surg, Sect Pediat Surg, Chicago, IL 60637 USA; [Rajbhandari, Presha] Columbia Univ, Dept Biol Sci, New York, NY 10025 USA; [Silva, Jose M.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Lopez, Gonzalo] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Lopez, Gonzalo] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Yu, Jiyang] St Jude Childrens Res Hosp, Dept Computat Biol, Kay Res & Care Ctr, IA6053,262 Danny Thomas Pl,Mail Stop 1135, Memphis, TN 38105 USA	Columbia University; Columbia University; Columbia University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; St Jude Children's Research Hospital	Yamashiro, DJ (corresponding author), Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA.; Yamashiro, DJ (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA.; Califano, A (corresponding author), Columbia Univ, Dept Syst Biol, Med Ctr, New York, NY 10032 USA.; Yamashiro, DJ (corresponding author), Columbia Univ, Dept Surg, Med Ctr, New York, NY 10032 USA.	ac2248@cumc.columbia.edu; dy39@cumc.columbia.edu	Connolly, Eileen/AAX-9112-2021; banerjee, debarshi/AAF-5704-2020	Lopez, Gonzalo/0000-0002-5092-1284; Yamashiro, Darrell/0000-0002-1250-0235; Connolly, Eileen/0000-0001-6558-1932; Califano, Andrea/0000-0003-4742-3679	Alex's Lemonade Stand Foundation; Hyundai Hope on Wheels; Cancer Target Discovery and Development Consortium; National Cancer Institute (NCI) Outstanding Investigator Award [R35CA197745-02];  [NIH-1S10OD021764];  [NIH-1S10OD012351]; NATIONAL CANCER INSTITUTE [U01CA217858, R35CA197745] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD012351, S10OD021764] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Hyundai Hope on Wheels; Cancer Target Discovery and Development Consortium; National Cancer Institute (NCI) Outstanding Investigator Award; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from Alex's Lemonade Stand Foundation (DJY), Hyundai Hope on Wheels (DJY), The Cancer Target Discovery and Development Consortium (AC, GL, JS), the National Cancer Institute (NCI) Outstanding Investigator Award (R35CA197745-02) (AC). The computational analyses were supported by instrumentation grants NIH-1S10OD021764 and NIH-1S10OD012351. The results published here are, in part, based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative managed by the NCI. We thank Dr. Jose Silva, Icahn School of Medicine at Mount Sinai, for the generous gift of whole-genome shRNA library. We thank Dr. Garrett Brodeur, Children's Hospital of Philadelphia, for the SHEP21N engineered neuroblastoma cell line. We thank Dr. C. Patrick Reynolds, Texas Tech University, for the CHLA-255 neuroblastoma cell line.	Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Califano A, 2017, NAT REV CANCER, V17, P116, DOI 10.1038/nrc.2016.124; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chong CM, 2016, MOL BIOSYST, V12, P2713, DOI 10.1039/c6mb00343e; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; D'Annibale S, 2014, J BIOL CHEM, V289, P7730, DOI 10.1074/jbc.M114.549535; Dart AE, 2013, EUR J CELL BIOL, V92, P129, DOI 10.1016/j.ejcb.2013.03.002; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Egawa T, 2011, P NATL ACAD SCI USA, V108, P14873, DOI 10.1073/pnas.1112293108; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hong SJ, 2008, NEUROCHEM RES, V33, P1821, DOI 10.1007/s11064-008-9639-3; Hsu CL, 2016, ONCOTARGET, V7, P36293, DOI 10.18632/oncotarget.9202; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jackstadt R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.282; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kesanakurti D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.182; Keshelava N, 2005, METH MOLEC MED, V110, P139; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kim MY, 2006, P NATL ACAD SCI USA, V103, P13074, DOI 10.1073/pnas.0601915103; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Loh SHY, 2008, CELL DEATH DIFFER, V15, P283, DOI 10.1038/sj.cdd.4402258; Lutz W, 1996, ONCOGENE, V13, P803; Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7; Matthay KK, 2012, CLIN CANCER RES, V18, P2740, DOI 10.1158/1078-0432.CCR-11-1939; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Rajbhandari P, 2018, CANCER DISCOV, V8, P582, DOI 10.1158/2159-8290.CD-16-0861; Rodriguez-Barrueco R, 2015, GENE DEV, V29, P1631, DOI 10.1101/gad.262642.115; Schofield AV, 2013, CRIT REV BIOCHEM MOL, V48, P301, DOI 10.3109/10409238.2013.786671; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian YM, 2011, DEV BIOL, V353, P206, DOI 10.1016/j.ydbio.2011.02.026; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Xue CY, 2016, ONCOTARGET, V7, P54937, DOI 10.18632/oncotarget.10709; Yu Jiyang, 2013, Methods Mol Biol, V980, P371, DOI 10.1007/978-1-62703-287-2_22; Zhou J, 2003, WORLD J GASTROENTERO, V9, P9, DOI 10.3748/wjg.v9.i1.9; Zhou ZX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-944	50	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5451	5465		10.1038/s41388-018-0326-9	http://dx.doi.org/10.1038/s41388-018-0326-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29880876	hybrid, Green Published			2022-12-28	WOS:000446312900006
J	Tomoshige, K; Guo, MZ; Tsuchiya, T; Fukazawa, T; Fink-Baldauf, IM; Stuart, WD; Naomoto, Y; Nagayasu, T; Maeda, Y				Tomoshige, Koichi; Guo, Minzhe; Tsuchiya, Tomoshi; Fukazawa, Takuya; Fink-Baldauf, Iris M.; Stuart, William D.; Naomoto, Yoshio; Nagayasu, Takeshi; Maeda, Yutaka			An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo	ONCOGENE			English	Article							TRANSFORMING-GROWTH-FACTOR; FACTOR-ALPHA; TRANSGENIC MICE; CONDITIONAL EXPRESSION; KINASE INHIBITORS; EPITHELIAL-CELLS; FACTOR RECEPTOR; STEM-CELLS; TGF-ALPHA; MUTATIONS	EGFR ligands (e.g., EGF and TGFA) have been shown to be clinically associated with poor survival in lung cancer. Since TGFA itself initiates autochthonous tumors in liver, breast, and pancreas but not in the lung in transgenic mice in vivo, it would appear that an EGFR ligand may not initiate but rather promote lung cancer. However, it has not been proven in vivo whether lung cancer is promoted by an EGFR ligand. Using transgenic mouse models conditionally expressing EGFR(L858R) or Kras(G12D) with TGFA (an EGFR ligand) in lung epithelium, we determined that TGFA promoted the growth of EGFR(L858R)-lung tumors in airway regions but not that of Kras(G12D)-lung tumors. Analysis of TCGA datasets identified Delta Np63 and AGR2 as potential key tumor-promoting regulators, which were highly induced in the TGFA-induced EGFR(L858R)-lung tumors. The expression of AGR2 was positively correlated with the expression of TGFA in human EGFR-mutant lung adenocarcinomas. The expression of TGFA in human EGFR-mutant lung adenocarcinomas but not in the EGFR wild-type lung adenocarcinoma was associated with poor survival. These results suggest that targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors.	[Tomoshige, Koichi; Guo, Minzhe; Fink-Baldauf, Iris M.; Stuart, William D.; Maeda, Yutaka] Cincinnati Childrens Hosp Med Ctr, Div Neonatol Perinatal & Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Tomoshige, Koichi; Guo, Minzhe; Fink-Baldauf, Iris M.; Stuart, William D.; Maeda, Yutaka] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Tsuchiya, Tomoshi; Nagayasu, Takeshi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, Nagasaki 8528501, Japan; [Fukazawa, Takuya; Naomoto, Yoshio] Kawasaki Med Sch, Dept Gen Surg, Okayama 7010192, Japan; [Tomoshige, Koichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oncol, Nagasaki 8528501, Japan; [Tomoshige, Koichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, Nagasaki 8528501, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Nagasaki University; Kawasaki Medical School; Nagasaki University; Nagasaki University	Maeda, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Neonatol Perinatal & Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA.; Maeda, Y (corresponding author), Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA.	yutaka.maeda@cchmc.org	Fukazawa, Takuya/GLR-7099-2022; Guo, Minzhe/Y-3982-2018	Tomoshige, Koichi/0000-0002-0712-2989; GUO, MINZHE/0000-0002-5502-9172; Tsuchiya, Tomoshi/0000-0002-8419-1478	American Lung Association [RG309608]; CF-RDP Pilot & Feasibility Grant; Cincinnati Children's Hospital Medical Center; Rotary Foundation Global Grant; AMED; Ministry of Education, Science and Culture, Japan	American Lung Association; CF-RDP Pilot & Feasibility Grant; Cincinnati Children's Hospital Medical Center; Rotary Foundation Global Grant; AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by the American Lung Association (RG309608), Trustee Award Grant, CF-RDP Pilot & Feasibility Grant, Cincinnati Children's Hospital Medical Center (YM), the Rotary Foundation Global Grant (KT), AMED (TF), and the Ministry of Education, Science and Culture, Japan (TT, TF, YN, and TN)	Ceteci F, 2011, NEOPLASIA, V13, P1005, DOI 10.1593/neo.11652; Chen Z, 2010, CANCER RES, V70, P9827, DOI 10.1158/0008-5472.CAN-10-1671; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dave V, 2008, AM J RESP CELL MOL, V38, P337, DOI 10.1165/rcmb.2007-0182OC; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Giannou AD, 2017, EMBO MOL MED, V9, P672, DOI 10.15252/emmm.201606978; Green JA, 2017, J EXP MED, V214, P3565, DOI 10.1084/jem.20170356; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hardie WD, 2004, AM J PHYSIOL-LUNG C, V286, pL741, DOI 10.1152/ajplung.00208.2003; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Huang QL, 2016, MOL CANCER THER, V15, P2521, DOI 10.1158/1535-7163.MCT-16-0258; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Liu J, 2015, CELL REP, V10, P1599, DOI 10.1016/j.celrep.2015.02.014; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Perera SA, 2009, P NATL ACAD SCI USA, V106, P474, DOI 10.1073/pnas.0808930106; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Rodriguez PC, 2016, CLIN CANCER RES, V22, P3782, DOI 10.1158/1078-0432.CCR-15-0855; Rusch V, 1997, CLIN CANCER RES, V3, P515; Saito M, 2016, CANCER SCI, V107, P713, DOI 10.1111/cas.12941; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schneider MR, 2005, ENDOCRINOLOGY, V146, P5237, DOI 10.1210/en.2005-0418; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777; TATEISHI M, 1991, BRIT J CANCER, V63, P130, DOI 10.1038/bjc.1991.26; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xu CX, 2015, MOL CANCER THER, V14, P2382, DOI 10.1158/1535-7163.MCT-15-0077; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yoh K, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00051; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao R, 2014, DEV CELL, V30, P151, DOI 10.1016/j.devcel.2014.06.004; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	56	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3894	3908		10.1038/s41388-018-0240-1	http://dx.doi.org/10.1038/s41388-018-0240-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662194				2022-12-28	WOS:000438465600010
J	Nicolae, CM; O'Connor, MJ; Constantin, D; Moldovan, GL				Nicolae, Claudia M.; O'Connor, Michael J.; Constantin, Daniel; Moldovan, George-Lucian			NF kappa B regulates p21 expression and controls DNA damage-induced leukemic differentiation	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; HL-60 CELLS; GENE; ACTIVATION; MUTATIONS; EVOLUTION; APOPTOSIS; SURVIVAL; DISEASE	DNA damage exposure is a major modifier of cell fate in both normal and cancer tissues. In response to DNA damage, myeloid leukemia cells activate a poorly understood terminal differentiation process. Here, we show that the NF kappa B pathway directly activates expression of the proliferation inhibitor p21 in response to DNA damage in myeloid leukemia cells. In order to understand the role of this unexpected regulatory event, we ablated the NF kappa B binding site we identified in the p21 promoter, using CRISPR/Cas9-mediated genome editing. We found that NF kappa B-mediated p21 activation controls DNA damage-induced myeloid differentiation. Our results uncover a p53-independent pathway for p21 activation involved in controlling hematopoietic cell fate.	[Nicolae, Claudia M.; O'Connor, Michael J.; Constantin, Daniel; Moldovan, George-Lucian] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.	glm29@psu.edu		Nicolae, Claudia/0000-0003-4933-5496; George-Lucian, Moldovan/0000-0003-3825-149X	Department of Defense [CA140303]; St. Baldrick Foundation	Department of Defense(United States Department of Defense); St. Baldrick Foundation	We would like to thank Wafik el-Deiry, Sinisa Dovat, David Claxton, Gregory Yochum, Sergei Grigoryev, James Broach, and the Penn State Flow Cytometry Core for materials, advice, and support. This work was supported by the Department of Defense (award CA140303) and the St. Baldrick Foundation.	Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Bruserud O, 2000, Oncologist, V5, P454, DOI 10.1634/theoncologist.5-6-454; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Figarola JL, 2012, INVEST NEW DRUG, V30, P1413, DOI 10.1007/s10637-011-9711-8; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Grove CS, 2014, DIS MODEL MECH, V7, P941, DOI 10.1242/dmm.015974; Gupta D, 2014, CURR PROTOC IMMUNOL, V104; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Lee S, 2001, P NATL ACAD SCI USA, V98, P3340, DOI 10.1073/pnas.051013798; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Melo Monica B, 2002, Hematology, V7, P13, DOI 10.1080/10245330290020090; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Price JG, 2015, NAT IMMUNOL, V16, P1060, DOI 10.1038/ni.3270; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Sherman MH, 2011, TRENDS CELL BIOL, V21, P312, DOI 10.1016/j.tcb.2011.01.004; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Tilstra JS, 2011, AGING DIS, V2, P449; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	30	12	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3647	3656		10.1038/s41388-018-0219-y	http://dx.doi.org/10.1038/s41388-018-0219-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622796				2022-12-28	WOS:000437975200003
J	Kullmann, L; Krahn, MP				Kullmann, Lars; Krahn, Michael P.			Controlling the master-upstream regulation of the tumor suppressor LKB1	ONCOGENE			English	Review							PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; LKB1-AMPK SIGNALING PATHWAY; HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; ENERGY-METABOLISM; AMPK ACTIVATION; BREAST-CANCER; LUNG-CANCER; IN-VIVO	The tumor suppressor LKB1 is an essential serine/threonine kinase, which regulates various cellular processes such as cell metabolism, cell proliferation, cell polarity, and cell migration. Germline mutations in the STK11 gene (encoding LKB1) are the cause of the Peutz-Jeghers syndrome, which is characterized by benign polyps in the intestine and a higher risk for the patients to develop intestinal and extraintestinal tumors. Moreover, mutations and misregulation of LKB1 have been reported to occur in most types of tumors and are among the most common aberrations in lung cancer. LKB1 activates several downstream kinases of the AMPK family by direct phosphorylation in the T-loop. In particular the activation of AMPK upon energetic stress has been intensively analyzed in various diseases, including cancer to induce a metabolic switch from anabolism towards catabolism to regulate energy homeostasis and cell survival. In contrast, the regulation of LKB1 itself has long been only poorly understood. Only in the last years, several proteins and posttranslational modifications of LKB1 have been analyzed to control its localization, activity and recognition of substrates. Here, we summarize the current knowledge about the upstream regulation of LKB1, which is important for the understanding of the pathogenesis of many types of tumors.	[Kullmann, Lars; Krahn, Michael P.] Univ Hosp Munster, Internal Med D, Domagkstr 3a, D-48149 Munster, Germany	University of Munster	Krahn, MP (corresponding author), Univ Hosp Munster, Internal Med D, Domagkstr 3a, D-48149 Munster, Germany.	Michael.Krahn@ukmuenster.de	Krahn, Michael/AAD-4476-2022	Krahn, Michael/0000-0001-7718-9890	German Research Foundation (DFG) [SFB1348-A5]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG, SFB1348-A5).	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Amin N, 2009, P NATL ACAD SCI USA, V106, P8941, DOI 10.1073/pnas.0812469106; Avtanski DB, 2015, ONCOTARGET, V6, P29947, DOI 10.18632/oncotarget.4937; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bai B, 2016, ONCOTARGET, V7, P39065, DOI 10.18632/oncotarget.9687; Bai Y, 2012, FEBS LETT, V586, P1111, DOI 10.1016/j.febslet.2012.03.018; Barbier-Torres L, 2015, ONCOTARGET, V6, P2509, DOI 10.18632/oncotarget.3191; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Bright NJ, 2008, J BIOL CHEM, V283, P14946, DOI 10.1074/jbc.M710381200; Bultot L, 2009, FEBS LETT, V583, P25, DOI 10.1016/j.febslet.2008.11.022; Busch AM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-211; Calamaras TD, 2015, FREE RADICAL BIO MED, V82, P137, DOI 10.1016/j.freeradbiomed.2015.01.007; Calamaras TD, 2012, J BIOL CHEM, V287, P42400, DOI 10.1074/jbc.M112.385831; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Casimiro MC, 2017, CANCER RES, V77, P3391, DOI 10.1158/0008-5472.CAN-16-0425; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chen J, 2017, ELIFE, V6, DOI 10.7554/eLife.31268; Cidlinsky N, 2016, CELL ONCOL, V39, P389, DOI 10.1007/s13402-016-0290-8; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Courchet J, 2013, CELL, V153, P1510, DOI 10.1016/j.cell.2013.05.021; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Dogliotti G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15747; Dolinsky VW, 2009, CIRCULATION, V119, P1643, DOI 10.1161/CIRCULATIONAHA.108.787440; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; Fogarty S, 2009, J BIOL CHEM, V284, P77, DOI 10.1074/jbc.M806152200; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gaude H, 2012, ONCOGENE, V31, P1582, DOI 10.1038/onc.2011.342; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; George SHL, 2016, ONCOGENE, V35, P59, DOI 10.1038/onc.2015.62; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Granot Z, 2009, CELL METAB, V10, P296, DOI 10.1016/j.cmet.2009.08.010; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Houde VP, 2014, BIOCHEM J, V458, P41, DOI 10.1042/BJ20131324; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Huo YL, 2014, NAT CELL BIOL, V16, P526, DOI 10.1038/ncb2969; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Konen J, 2016, MOL BIOL CELL, V27, P1069, DOI 10.1091/mbc.E15-08-0569; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Lai DM, 2012, CELL REPROGRAM, V14, P164, DOI 10.1089/cell.2011.0068; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Li TY, 2017, BIOCHEM BIOPH RES CO, V482, P1037, DOI 10.1016/j.bbrc.2016.11.154; Liu L, 2012, AM J TRANSL RES, V4, P175; Liu ZY, 2015, J BIOL CHEM, V290, P19011, DOI 10.1074/jbc.M115.649210; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mali VR, 2014, FREE RADICAL RES, V48, P251, DOI 10.3109/10715762.2013.864761; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; McGarrity TJ, 2000, AM J GASTROENTEROL, V95, P596; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; O'Farrell F, 2017, NAT CELL BIOL, V19, P1412, DOI 10.1038/ncb3631; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Sebbagh M, 2009, CURR BIOL, V19, P37, DOI 10.1016/j.cub.2008.11.033; Sengupta S, 2017, ONCOGENE, V36, P5709, DOI 10.1038/onc.2017.164; Seo MS, 2015, TOXICOL APPL PHARM, V284, P113, DOI 10.1016/j.taap.2015.02.020; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Shen YAA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5991; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Song P, 2008, J BIOL CHEM, V283, P12446, DOI 10.1074/jbc.M708208200; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tanaka T, 1999, CANCER RES, V59, P2041; Tang XQ, 2017, CIRCULATION, V136, P2051, DOI 10.1161/CIRCULATIONAHA.117.028728; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Tortelote GG, 2017, CELL SIGNAL, V40, P30, DOI 10.1016/j.cellsig.2017.08.008; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Walz HA, 2010, J BIOL CHEM, V285, P14101, DOI 10.1074/jbc.M110.110536; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Wilkinson S, 2017, SCI REP-UK, V7, DOI 10.1038/srep40929; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xie Z, 2008, CIRCULATION, V117, P952, DOI 10.1161/CIRCULATIONAHA.107.744490; Xie ZL, 2009, MOL CELL BIOL, V29, P3582, DOI 10.1128/MCB.01417-08; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yang WL, 2010, ONCOGENE, V29, P4493, DOI 10.1038/onc.2010.190; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang CS, 2017, NATURE, V548, P112, DOI 10.1038/nature23275; Zhang CS, 2014, CELL METAB, V20, P526, DOI 10.1016/j.cmet.2014.06.014; Zhang WC, 2014, CIRCULATION, V129, P1428, DOI 10.1161/CIRCULATIONAHA.113.004146; Zhang YL, 2013, CELL METAB, V18, P546, DOI 10.1016/j.cmet.2013.09.005; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng X, 2018, ONCOGENE, V37, P502, DOI 10.1038/onc.2017.354; Zhu H, 2013, J BIOL CHEM, V288, P16495, DOI 10.1074/jbc.M112.443580; Zu Y, 2010, CIRC RES, V106, P1384, DOI 10.1161/CIRCRESAHA.109.215483	121	31	32	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3045	3057		10.1038/s41388-018-0145-z	http://dx.doi.org/10.1038/s41388-018-0145-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540834				2022-12-28	WOS:000434641400001
J	Cheng, Y; Gao, XH; Li, XJ; Cao, QH; Zhao, DD; Zhou, JR; Wu, HX; Wang, Y; You, LJ; Yang, HB; He, YL; Li, YR; Bian, JS; Zhu, QY; Birnbaumer, L; Yang, Y				Cheng, Yan; Gao, Xing-Hua; Li, Xian-Jing; Cao, Qiu-Hua; Zhao, Dan-Dan; Zhou, Jin-Rong; Wu, Hong-Xi; Wang, Yun; You, Lin-Jun; Yang, Hong-Bao; He, Yun-Long; Li, Yong-Ren; Bian, Jin-Song; Zhu, Qing-Yi; Birnbaumer, Lutz; Yang, Yong			Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway	ONCOGENE			English	Article							TUMOR-GROWTH; CHRONIC STRESS; MILD STRESS; RECEPTOR; MODEL; PROGRESSION; ACTIVATION; ONCOLOGY; MICE; PHOSPHORYLATION	Depression drives cancer progression and induces poor clinical outcome. However, the mechanisms underlying depression and cancer outcomes are unclear. In this work, we investigated 98 prostate cancer patients and found that patients with high score of psychological depression were correlated with tumor invasion and metastasis. We found focal adhesion kinase (FAK) was increased in cancer patients with metastatic features and high score of depression. FAK knockdown completely blocked depression-promoted tumor invasion in orthotopic transplantation tumors. In Hi-myc mice and a murine model of depression, sympathetic activation was detected in the prostate tissue. Further we showed that FAK activation was dependent on a cAMP-PKA signaling pathway. Our results demonstrated that the activation of a sympathetic-FAK signaling pathway in prostate cancer patients with high degrees of depression facilitates tumor invasion. We suggest that blocking beta 2AR with propranolol or inhibiting FAK activation with PF562 271 may be novel strategies for depressed patients with invasive prostate cancer.	[Cheng, Yan; Gao, Xing-Hua; Li, Xian-Jing; Cao, Qiu-Hua; Zhao, Dan-Dan; Wu, Hong-Xi; Wang, Yun; You, Lin-Jun; Yang, Hong-Bao; He, Yun-Long; Li, Yong-Ren; Yang, Yong] China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 211198, Jiangsu, Peoples R China; [Zhou, Jin-Rong] Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Nutr Metab Lab, Boston, MA 02138 USA; [Bian, Jin-Song] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117597, Singapore; [Zhu, Qing-Yi] Jiangsu Prov Hosp Tradit Chinese Med, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China; [Birnbaumer, Lutz] NIEHS, Neurobiol Lab, Durham, NC 27709 USA; [Birnbaumer, Lutz] BOMED Catholic Univ Argentina, Biomed Res Inst, C1107AAZ, Buenos Aires, DF, Argentina	China Pharmaceutical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National University of Singapore; Nanjing University of Chinese Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yang, Y (corresponding author), China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 211198, Jiangsu, Peoples R China.; Birnbaumer, L (corresponding author), NIEHS, Neurobiol Lab, Durham, NC 27709 USA.; Birnbaumer, L (corresponding author), BOMED Catholic Univ Argentina, Biomed Res Inst, C1107AAZ, Buenos Aires, DF, Argentina.	birnbau1@gmail.com; yy@cpu.edu.cn		Bian, Jinsong/0000-0002-7741-598X	Intramural Research Program of the NIH [Z01-ES101684]; 111 Project [111-2-07]; National Science Foundation of China [91529304, 81673468, 81603132, 81403020]; Natural Science Foundation of Jiangsu Province [BK20160753]; China Postdoctoral Science Foundation [2016M591965]	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 111 Project(Ministry of Education, China - 111 Project); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Mrs. Ning Su for IHC studies, Mrs. Jian-hua Ding for HPLC studies, and Dr. Wen-tao Liu for gelatin zymography experiments and helpful suggestions. This study was supported by grants from Intramural Research Program of the NIH (Z01-ES101684 to LB), The 111 Project (No. 111-2-07), National Science Foundation of China (91529304, 81673468 to YY, 81603132 to XG and 81403020 to LY), Natural Science Foundation of Jiangsu Province (No. BK20160753 to XG), and China Postdoctoral Science Foundation (No. 2016M591965 to XG).	Agudelo LZ, 2014, CELL, V159, P33, DOI 10.1016/j.cell.2014.07.051; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038; BATKIN S, 1970, P NATL ACAD SCI USA, V67, P1521, DOI 10.1073/pnas.67.3.1521; Batty GD, 2017, BMJ-BRIT MED J, V356, P108; Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641; de la Taille A, 2000, EUR UROL, V38, P79, DOI 10.1159/000020256; Dimitrov S, 2010, J IMMUNOL, V184, P503, DOI 10.4049/jimmunol.0902189; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Feng Y, 2016, PSYCHIAT RES, V243, P92, DOI 10.1016/j.psychres.2016.06.021; Furukawa TA, 2010, J PSYCHOSOM RES, V68, P581, DOI 10.1016/j.jpsychores.2009.05.003; Gaston SM, 2005, NAT MED, V11, P95, DOI 10.1038/nm1169; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Harryman WL, 2016, BBA-REV CANCER, V1866, P221, DOI 10.1016/j.bbcan.2016.09.005; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Hill MN, 2012, NEUROSCI BIOBEHAV R, V36, P2085, DOI 10.1016/j.neubiorev.2012.07.001; Incio J, 2016, CANCER DISCOV, V6, P852, DOI 10.1158/2159-8290.CD-15-1177; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; KATZ RJ, 1982, PHARMACOL BIOCHEM BE, V16, P965, DOI 10.1016/0091-3057(82)90053-3; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kupfer DJ, 2012, LANCET, V379, P1045, DOI 10.1016/S0140-6736(11)60602-8; Law NC, 2017, ENDOCRINOLOGY, V158, P2043, DOI 10.1210/en.2017-00163; Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634; Li XJ, 2015, P NATL ACAD SCI USA, V112, P4731, DOI 10.1073/pnas.1503779112; Lopez-Calderero I, 2017, ACTAS UROL ESP, V41, P368, DOI 10.1016/j.acuro.2016.12.006; Lu DH, 2016, CLIN CANCER RES, V22, P765, DOI 10.1158/1078-0432.CCR-15-0101; Ma XJ, 2012, J BIOL CHEM, V287, P18925, DOI 10.1074/jbc.M112.352260; Madden KS, 2017, DEV COMP IMMUNOL, V66, P92, DOI 10.1016/j.dci.2016.04.015; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Malik R, 2015, TRENDS BIOTECHNOL, V33, P230, DOI 10.1016/j.tibtech.2015.01.004; Mao J, 2016, CANCER LETT, V380, P134, DOI 10.1016/j.canlet.2016.06.020; Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Mehta RD, 2015, CA-CANCER J CLIN, V65, P299, DOI 10.3322/caac.21285; Mo F, 2017, EUR UROL; Nader GPF, 2016, NAT CELL BIOL, V18, P491, DOI 10.1038/ncb3333; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Piiper A, 2003, BIOCHEM BIOPH RES CO, V301, P848, DOI 10.1016/S0006-291X(03)00055-X; Prasad SM, 2014, J CLIN ONCOL, V32, P2471, DOI 10.1200/JCO.2013.51.1048; Qin JF, 2015, BMB REP, V48, P295, DOI 10.5483/BMBRep.2015.48.5.008; Slack-Davis JK, 2009, MOL CANCER THER, V8, P2470, DOI 10.1158/1535-7163.MCT-09-0262; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; Sullivan DR, 2016, J CLIN ONCOL, V34, P3984, DOI 10.1200/JCO.2016.66.8459; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Uehara A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34012; Venkatesh H, 2017, TRENDS CANCER, V3, P89, DOI 10.1016/j.trecan.2016.12.008; Venkitaraman R, 2015, EUR UROL, V67, P673, DOI 10.1016/j.eururo.2014.10.004; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569	55	33	36	4	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2953	2966		10.1038/s41388-018-0177-4	http://dx.doi.org/10.1038/s41388-018-0177-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515233	Green Accepted			2022-12-28	WOS:000433936300004
J	Chen, ZR; Lin, SB; Li, JL; Ni, W; Guo, RF; Lu, JR; Kaye, FJ; Wu, LZ				Chen, Zirong; Lin, Shuibin; Li, Jian-Liang; Ni, Wei; Guo, Ruifeng; Lu, Jianrong; Kaye, Frederic J.; Wu, Lizi			CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells	ONCOGENE			English	Article							LONG NONCODING RNAS; SIGNALING PATHWAY; GENE-EXPRESSION; SALIVARY; CANCER; TRANSLOCATION; ONCOGENE; PROLIFERATION; TRANSCRIPTOME; ACTIVATION	Mucoepidermoid carcinoma (MEC) arises in many glandular tissues and contributes to the most common malignant salivary gland cancers. MEC is specifically associated with a unique t(11; 19) translocation and the resulting CRTC1-MAML2 fusion is a major oncogenic driver for MEC initiation and maintenance. However, the molecular basis underlying the CRTC1-MAML2 oncogenic functions remains elusive. Through gene expression profiling analysis, we observed that LINC00473, a long non-coding RNA (lncRNA), was the top down-regulated target in CRTC1-MAML2-depleted human MEC cells. LncRNAs belong to a new class of non-coding RNAs with emerging roles in tumorigenesis and progression, but remain poorly characterized. In this study, we investigated the role of LINC00473 in mediating CRTC1-MAML2 oncogenic activity in human MEC. We found that LINC00473 transcription was significantly induced in human CRTC1-MAML2-positive MEC cell lines and primary MEC tumors, and was tightly correlated with the CRTC1-MAML2 RNA level. LINC00473 induction was dependent on the ability of CRTC1-MAML2 to activate CREB-mediated transcription. Depletion of LINC00473 significantly reduced the proliferation and survival of human MEC cells in vitro and blocked the in vivo tumor growth in a human MEC xenograft model. RNA in situ hybridization analysis demonstrated a predominantly nuclear localization pattern for LINC00473 in human MEC cells. Furthermore, gene expression profiling revealed that LINC00473 depletion resulted in differential expression of genes important in cancer cell growth and survival. LINC00473 likely regulates gene expression in part through its ability to bind to a cAMP signaling pathway component NONO, enhancing the ability of CRTC1-MAML2 to activate CREB-mediated transcription. Our overall results demonstrate that LINC00473 is a downstream target and an important mediator of the CRTC1-MAML2 oncoprotein. Therefore, LINC00473 acts as a promising biomarker and therapeutic target for human CRTC1-MAML2-positive MECs.	[Chen, Zirong; Ni, Wei; Wu, Lizi] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA; [Chen, Zirong; Ni, Wei; Lu, Jianrong; Kaye, Frederic J.; Wu, Lizi] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32611 USA; [Lin, Shuibin] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou, Guangdong, Peoples R China; [Li, Jian-Liang] Sanford Burnham Prebys Med Discovery Inst Lake No, Orlando, FL USA; [Ni, Wei; Wu, Lizi] Univ Florida, UF Genet Inst, Gainesville, FL 32611 USA; [Guo, Ruifeng] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Lu, Jianrong] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Kaye, Frederic J.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Sun Yat Sen University; Sanford Burnham Prebys Medical Discovery Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, LZ (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.; Wu, LZ (corresponding author), Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32611 USA.; Wu, LZ (corresponding author), Univ Florida, UF Genet Inst, Gainesville, FL 32611 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; Guo, Ruifeng/AAK-2072-2020; Li, Jian-Liang/AAE-9315-2019; Lu, Jianrong/F-5240-2013	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; Lu, Jianrong/0000-0002-4969-6040; Wu, Lizi/0000-0002-0076-2617	NIH National Institute of Dental and Craniofacial Research [R01DE023641]; NIH National Cancer Institute [R21CA187730]; NATIONAL CANCER INSTITUTE [R21CA187730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023641] Funding Source: NIH RePORTER	NIH National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by the NIH National Institute of Dental and Craniofacial Research (R01DE023641) and the NIH National Cancer Institute (R21CA187730).	Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Amelio AL, 2014, P NATL ACAD SCI USA, V111, pE3260, DOI 10.1073/pnas.1319176111; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bell D, 2012, CURR ONCOL REP, V14, P166, DOI 10.1007/s11912-012-0220-5; Birkeland AC, 2017, ORAL ONCOL, V68, P5, DOI 10.1016/j.oraloncology.2017.02.025; Cabanski CR, 2015, RNA BIOL, V12, P628, DOI 10.1080/15476286.2015.1038012; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Chen J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1827-3; Chen Z, 2014, ONCOGENE, V33, P3869, DOI 10.1038/onc.2013.348; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Dickson Iain, 2016, Nat Rev Gastroenterol Hepatol, V13, P122, DOI 10.1038/nrgastro.2016.21; Dinh TA, 2017, SCI REP-UK, V7, DOI 10.1038/srep44653; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Eveson JW, 2011, PERIODONTOL 2000, V57, P150, DOI 10.1111/j.1600-0757.2011.00385.x; Fehr A, 2008, GENE CHROMOSOME CANC, V47, P203, DOI 10.1002/gcc.20522; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Kubo T, 2009, INT J CANCER, V124, P1778, DOI 10.1002/ijc.24150; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Liang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22744; Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296; Noda H, 2013, CANCER SCI, V104, P85, DOI 10.1111/cas.12039; NORDKVIST A, 1994, CANCER GENET CYTOGEN, V74, P77, DOI 10.1016/0165-4608(94)90001-9; Reitmair A, 2012, PHYSIOL GENOMICS, V44, P152, DOI 10.1152/physiolgenomics.00089.2011; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Saade RE, 2016, JAMA OTOLARYNGOL, V142, P234, DOI 10.1001/jamaoto.2015.3270; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang LN, 2014, J INTEGR MED-JIM, V12, P20, DOI 10.1016/S2095-4964(14)60003-0; Warner KA, 2013, ORAL ONCOL, V49, P1059, DOI 10.1016/j.oraloncology.2013.08.004; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wu YH, 2014, TUMOR BIOL, V35, P11887, DOI 10.1007/s13277-014-2453-4; Zhen S, 2017, ONCOTARGET, V8, P9634, DOI 10.18632/oncotarget.14176	41	35	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1885	1895		10.1038/s41388-017-0104-0	http://dx.doi.org/10.1038/s41388-017-0104-0			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353885	Green Accepted			2022-12-28	WOS:000429303300006
J	Ghannam-Shahbari, D; Jacob, E; Kakun, RR; Wasserman, T; Korsensky, L; Sternfeld, O; Kagan, J; Bublik, DR; Aviel-Ronen, S; Levanon, K; Sabo, E; Larisch, S; Oren, M; Hershkovitz, D; Perets, R				Ghannam-Shahbari, Dima; Jacob, Eyal; Kakun, Reli Rachel; Wasserman, Tanya; Korsensky, Lina; Sternfeld, Ofir; Kagan, Juliana; Bublik, Debora Rosa; Aviel-Ronen, Sarit; Levanon, Keren; Sabo, Edmond; Larisch, Sarit; Oren, Moshe; Hershkovitz, Dov; Perets, Ruth			PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma	ONCOGENE			English	Article							CELL-CYCLE ARREST; FALLOPIAN-TUBE; TUMOR SUPPRESSION; THYROID-HORMONE; CANCER; P53; EXPRESSION; P21; PROTEIN; MUTANT	High grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer and it is now widely accepted that this disease often originates from the fallopian tube epithelium. PAX8 is a fallopian tube lineage marker with an essential role in embryonal female genital tract development. In the adult fallopian tube, PAX8 is expressed in the fallopian tube secretory epithelial cell (FTSEC) and its expression is maintained through the process of FTSEC transformation to HGSC. We now report that PAX8 has a pro-proliferative and anti-apoptotic role in HGSC. The tumor suppressor gene TP53 is mutated in close to 100% of HGSC; in the majority of cases, these are missense mutations that endow the mutant p53 protein with potential gain of function (GOF) oncogenic activities. We show that PAX8 positively regulates the expression of TP53 in HGSC and the pro-proliferative role of PAX8 is mediated by the GOF activity of mutant p53. Surprisingly, mutant p53 transcriptionally activates the expression of p21, which localizes to the cytoplasm of HGSC cells where it plays a noncanonical, pro-proliferative role. Together, our findings illustrate how TP53 mutations in HGSC subvert a normal regulatory pathway into a driver of tumor progression.	[Ghannam-Shahbari, Dima; Jacob, Eyal; Kakun, Reli Rachel; Wasserman, Tanya; Korsensky, Lina; Sternfeld, Ofir; Perets, Ruth] Technion Israel Inst Technol, Clin Res Inst Rambam, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel; [Kagan, Juliana; Larisch, Sarit] Univ Haifa, Dept Biol, Cell Death Res Lab, Fac Sci, Haifa, Israel; [Bublik, Debora Rosa; Oren, Moshe] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Aviel-Ronen, Sarit] Sheba Med Ctr, Dept Pathol, Talpiot Med Leadership Program, Ramat Gan, Israel; [Levanon, Keren] Sheba Med Ctr, Sheba Canc Res Ctr, Talpiot Med Leadership Program, Ramat Gan, Israel; [Levanon, Keren] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Sabo, Edmond] Technion Israel Inst Technol, Dept Pathol, Rambam Hlth Care Campus, Haifa, Israel; [Hershkovitz, Dov] Tel Aviv Univ, Dept Pathol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Ramat Aviv, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; University of Haifa; Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Perets, R (corresponding author), Technion Israel Inst Technol, Clin Res Inst Rambam, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel.	Ru_Perets@rambam.health.gov.il		Hershkovitz, Dov/0000-0002-7954-4486; Oren, Moshe/0000-0003-4311-7172; Levanon, Keren/0000-0002-5122-064X	The Israel Science Foundation [1901/13]; Israel Cancer Research Fund; The European Commission [PCIG13-GA-2013-618174]; Israel Cancer Association [20150894, 20170117]; The women's health grant at Rambam; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Science Foundation [822/12]; Hymen Milgrom Trust	The Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; The European Commission(European CommissionEuropean Commission Joint Research Centre); Israel Cancer Association; The women's health grant at Rambam; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Science Foundation(Israel Science Foundation); Hymen Milgrom Trust	The work presented here was funded by The Israel Science Foundation (1901/13), Israel Cancer Research Fund, The European Commission (PCIG13-GA-2013-618174), Israel Cancer Association (20150894, 20170117), The women's health grant at Rambam (all to R.P.), Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to M.O.), Israel Science Foundation (822/12) (to S.L.), The Hymen Milgrom Trust (to S.L.). We would like to thank Prof. Ronny Drapkin (University of Pennsylvania) for FT237 immortalized FTSEC line and Prof. Reuven Agami (AVL, Nederland Cancer Institute) for retroviral p21 shRNA construct.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Al-Hujaily EM, 2015, CANCER PREV RES, V8, P1163, DOI 10.1158/1940-6207.CAPR-15-0121-T; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Au AYM, 2006, ENDOCRINOLOGY, V147, P367, DOI 10.1210/en.2005-0147; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Bijron JG, 2013, AM J SURG PATHOL, V37, P1123, DOI 10.1097/PAS.0b013e318282da7f; Blake JA, 2014, DEVELOPMENT, V141, P737, DOI 10.1242/dev.091785; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Brachova P, 2013, INT J MOL SCI, V14, P19257, DOI 10.3390/ijms140919257; Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chan DW, 2017, ONCOGENE, V36, P1404, DOI 10.1038/onc.2016.307; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Doberstein K, 2011, CARCINOGENESIS, V32, P262, DOI 10.1093/carcin/bgq249; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; HARPER JW, 1993, CELL, V75, P805; Hua G, 2016, ONCOGENE, V35, P2247, DOI 10.1038/onc.2015.288; Iwanicki MP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86829; Kar SP, 2017, BRIT J CANCER, V116, P524, DOI 10.1038/bjc.2016.426; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mhawech-Fauceglia P, 2012, GYNECOL ONCOL, V127, P198, DOI 10.1016/j.ygyno.2012.06.012; Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P140, DOI 10.1097/PAP.0b013e318253465d; Oren O, 2017, STEM CELL REV REP, V13, P17, DOI 10.1007/s12015-016-9691-3; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Perets R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046467; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Tong GX, 2011, DIAGN CYTOPATHOL, V39, P567, DOI 10.1002/dc.21426; Tung CS, 2009, MODERN PATHOL, V22, P1243, DOI 10.1038/modpathol.2009.92; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wistuba J, 2007, J ENDOCRINOL, V192, P99, DOI 10.1677/JOE-06-0054; Xia X, 2015, EUR J GYNAECOL ONCOL, V36, P662; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	60	32	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2213	2224		10.1038/s41388-017-0040-z	http://dx.doi.org/10.1038/s41388-017-0040-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29379162				2022-12-28	WOS:000431100200001
J	Konno, H; Yamauchi, S; Berglund, A; Putney, RM; Mule, JJ; Barber, GN				Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders; Putney, Ryan M.; Mule, James J.; Barber, Glen N.			Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production	ONCOGENE			English	Article							CYCLIC GMP-AMP; INNATE IMMUNE RECOGNITION; INFECTION; SYNTHASE; CGAS	The production of cytokines in response to DNA-damage events may be an important host defense response to help prevent the escape of pre-cancerous cells. The innate immune pathways involved in these events are known to be regulated by cellular molecules such as stimulator of interferon genes (STING), which controls type I interferon and pro-inflammatory cytokine production in response to the presence of microbial DNA or cytosolic DNA that has escaped from the nucleus. STING signaling has been shown to be defective in a variety of cancers, such as colon cancer and melanoma, actions that may enable damaged cells to escape the immunosurveillance system. Here, we report through examination of databases that STING signaling may be commonly suppressed in a greater variety of tumors due to loss-of-function mutation or epigenetic silencing of the STING/cGAS promoter regions. In comparison, RNA activated innate immune pathways controlled by RIGI/ MDA5 were significantly less affected. Examination of reported missense STING variants confirmed that many exhibited a loss-of-function phenotype and could not activate cytokine production following exposure to cytosolic DNA or DNAdamage events. Our data imply that the STING signaling pathway may be recurrently suppressed by a number of mechanisms in a considerable variety of malignant disease and be a requirement for cellular transformation.	[Konno, Hiroyasu; Yamauchi, Shota; Barber, Glen N.] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Berglund, Anders; Putney, Ryan M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA; [Mule, James J.] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol, Tampa, FL USA; [Mule, James J.] H Lee Moffitt Canc Ctr & Res Inst, Immunol Programs, Tampa, FL USA	University of Miami; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Barber, GN (corresponding author), Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA.	gbarber@med.miami.edu		Berglund, Anders/0000-0002-0393-3530	NCI [R01CA194404]; NCI-NIH [1R01 CA148995, 1R01 CA184845, P30 CA076292, P50 CA168536]; Cindy and Jon Gruden Fund; Chris Sullivan Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [P50CA168536, R01CA184845, R01CA148995, P30CA076292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079336] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cindy and Jon Gruden Fund; Chris Sullivan Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from NCI (R01CA194404) (G.N. Barber) and NCI-NIH (1R01 CA148995, 1R01 CA184845, P30 CA076292, P50 CA168536), Cindy and Jon Gruden Fund, Chris Sullivan Fund, and Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (J. J. Mule). We thank the staff of the Moffitt Cancer Center Cancer Informatics and Collaborative Data Services.	Ahn J, 2015, ONCOGENE, V34, P5302, DOI 10.1038/onc.2014.457; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kolodkin-Gal D, 2009, GENE THER, V16, P905, DOI 10.1038/gt.2009.44; Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049; Kranzusch PJ, 2014, CELL, V158, P1011, DOI 10.1016/j.cell.2014.07.028; Li X, 2013, IMMUNITY, V39, P1019, DOI 10.1016/j.immuni.2013.10.019; Ma YJ, 2012, J VIROL, V86, P2188, DOI 10.1128/JVI.05376-11; Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003; Song SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep39858; Spitzer M, 2014, NAT METHODS, V11, P121, DOI 10.1038/nmeth.2811; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114; Zhang X, 2014, CELL REP, V6, P421, DOI 10.1016/j.celrep.2014.01.003	31	92	94	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2037	2051		10.1038/s41388-017-0120-0	http://dx.doi.org/10.1038/s41388-017-0120-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367762	Green Accepted			2022-12-28	WOS:000429899400007
J	McLean, K; Tan, LJ; Bolland, DE; Coffman, LG; Peterson, LF; Talpaz, M; Neamati, N; Buckanovich, RJ				McLean, Karen; Tan, Lijun; Bolland, Danielle E.; Coffman, Lan G.; Peterson, Luke F.; Talpaz, Moshe; Neamati, Nouri; Buckanovich, Ronald J.			Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth	ONCOGENE			English	Article							STEM-CELLS; PROGNOSTIC-SIGNIFICANCE; CARCINOMA; TUMORIGENESIS; METASTASIS; EXPRESSION; RESISTANCE; MODEL; LINE	Ovarian carcinoma-associated mesenchymal stem cells (CA-MSC) produce not only high levels of interleukin-6 (IL6) but also the related cytokine leukemia inhibitory factor (LIF). IL6-mediated activation of STAT3 is implicated as a critical therapeutic target for cancer therapy. Less is known about the role of LIF, which can similarly activate STAT3, in ovarian cancer. We therefore sought to evaluate the tumorigenic effects of CA-MSC paracrine LIF signaling and the redundancy of IL6 and LIF in activating ovarian cancer STAT3 mediated cancer growth. As expected, we found that both IL6 and LIF induce STAT3 phosphorylation in tumor cells. In addition, both IL6 and LIF increased the percentage of ALDH+ ovarian cancer stem-like cells (CSC). Supporting redundancy of function by the two cytokines, CA-MSC induced STAT3 phosphorylation and increased cancer cell "stemness". This effect was not inhibited by LIF or IL6 blocking antibodies alone, but was prevented by dual IL6/LIF blockade or JAK2 inhibition. Similarly, small hairpin RNA (shRNA)-mediated reduction of IL6 or LIF in CA-MSC partially decreased but could not completely abrograte the ability of CA-MSC to induce STAT3 phosphorylation and stemness. Importantly, the in vivo pro-tumorigenic effect of CA-MSC is abrogated by dual blockade with the JAK2 inhibitor ruxolitinib to a much greater extent than treatment with anti-IL6 or anti-LIF antibody alone. Ruxolitinib treatment also improves survival in the immunocompetent ovarian cancer mouse model system with ID8 tumor cells plus MSC. Ruxolitinib-treated tumors in both the immunocompromised and immunocompetent animal models demonstrate decreased phospho-STAT3, indicating on-target activity. In conclusion, CA-MSC activate ovarian cancer cell STAT3 signaling via IL6 and LIF and increase tumor cell stemness. This functional redundancy suggests that therapeutic targeting of a single cytokine may be less effective than strategies such as dual inhibitor therapy or targeting shared downstream factors of the JAK/STAT pathway.	[McLean, Karen; Tan, Lijun; Bolland, Danielle E.] Univ Michigan, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA; [Coffman, Lan G.; Buckanovich, Ronald J.] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh, PA USA; [Peterson, Luke F.; Talpaz, Moshe] Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Neamati, Nouri] Coll Pharm, Dept Med Chem, North Campus Res Complex, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Michigan System; University of Michigan	McLean, K (corresponding author), Univ Michigan, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA.	karenmcl@umich.edu	Coffman, Lan/AAP-7600-2021	Coffman, Lan/0000-0002-3753-1652; Talpaz, Moshe/0000-0003-3361-3981	Women's Reproductive Health Research (WRHR) Career Development Program Award [K12 HD065257]; Department of Defense Ovarian Cancer Academy Early-Career Investigator Award [DOD W81XWH-15-0194]; Goldberg Family; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD065257] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA211362] Funding Source: NIH RePORTER	Women's Reproductive Health Research (WRHR) Career Development Program Award; Department of Defense Ovarian Cancer Academy Early-Career Investigator Award; Goldberg Family; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors would like to thank Yusong Gong for her technical assistance in the beginning stages of this project. Funding for this work has been provided in part by the Women's Reproductive Health Research (WRHR) Career Development Program Award to KM (National Institutes of Health, K12 HD065257), the Department of Defense Ovarian Cancer Academy Early-Career Investigator Award to KM (DOD W81XWH-15-0194), and the generous support of the Goldberg Family.	American Cancer Society, SURV RAT OV CANC STA; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Burgos-Ojeda D, 2013, CANCER RES, V73, P3555, DOI 10.1158/0008-5472.CAN-12-2845; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Coffman LG, 2016, ONCOTARGET, V7, P6916, DOI 10.18632/oncotarget.6870; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Ding DC, 2016, J CANCER, V7, P1815, DOI 10.7150/jca.16116; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Kenny HA, 2011, CANCER DISCOV, V1, P100, DOI 10.1158/2159-8290.CD-11-0117; Kim B, 2017, CANCER RES TREAT, V49, P338, DOI 10.4143/crt.2016.175; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lane D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-210; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Musrap N, 2012, MOL CANCER RES, V10, P1254, DOI 10.1158/1541-7786.MCR-12-0353; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pardanani A, 2007, LEUKEMIA, V21, P1658, DOI 10.1038/sj.leu.2404750; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; SCAMBIA G, 1995, BRIT J CANCER, V71, P354, DOI 10.1038/bjc.1995.71; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Xu SL, 2013, MOL CANCER THER, V12, P937, DOI 10.1158/1535-7163.MCT-12-1082; Ye F, 2008, HISTOPATHOLOGY, V53, P224, DOI 10.1111/j.1365-2559.2008.03068.x; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhou T, 2014, LEUKEMIA, V28, P471, DOI 10.1038/leu.2013.299	30	38	39	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1576	1584		10.1038/s41388-018-0523-6	http://dx.doi.org/10.1038/s41388-018-0523-6			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305729	Green Accepted			2022-12-28	WOS:000459945800015
J	Na'ara, S; Amit, M; Gil, Z				Na'ara, Shorook; Amit, Moran; Gil, Ziv			L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression	ONCOGENE			English	Article							PRESENILIN/GAMMA-SECRETASE; DUCTAL ADENOCARCINOMA; MOLECULE L1; ADHESION; ACTIVATION; CARCINOMA; NERVE; DISSEMINATION; CONTRIBUTES; MIGRATION	Pancreas cancer cells have a tendency to invade along nerves. Such cancerous nerve invasion (CNI) is associated with poor outcome; however, the exact mechanism that drives cancer cells to disseminate along nerves is unknown. Immunohistochemical analysis of human pancreatic ductal adenocarcinoma (PDAC) specimens showed overexpression of the L1 cell adhesion molecule (L1CAM) in cancer cells and in adjacent Schwann cells (SC) in invaded nerves. By modeling the neural microenvironment, we found that L1CAM secreted from SCs acts as a strong chemoattractant to cancer cells, through activation of MAP kinase signaling. L1CAM also upregulated expression of metalloproteinase-2 (MMP-2) and MMP-9 by PDAC cells, through STAT3 activation. Using a transgenic Pdx-1-Cre/KrasG12D /p53R172H (KPC) mouse model, we show that treatment with anti-L1CAM Ab significantly reduces CNI in vivo. We provide evidence of a paracrine response between SCs and cancer cells in the neural niche, which promotes cancer invasion via L1CAM secretion.	[Na'ara, Shorook; Amit, Moran; Gil, Ziv] Rambam Healthcare Campus, Lab Appl Canc Res, Head & Neck Ctr, Dept Otolaryngol Head & Neck Surg,Clin Res Inst, Haifa, Israel; [Gil, Ziv] Technion Israel Inst Technol, Rappaport Inst Med & Res, Technion Integrated Canc Ctr, Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gil, Z (corresponding author), Rambam Healthcare Campus, Lab Appl Canc Res, Head & Neck Ctr, Dept Otolaryngol Head & Neck Surg,Clin Res Inst, Haifa, Israel.; Gil, Z (corresponding author), Technion Israel Inst Technol, Rappaport Inst Med & Res, Technion Integrated Canc Ctr, Haifa, Israel.	ziv@baseofskull.org			Israeli Science Foundation; Binational US-Israel Science Foundation; ICRF grant (Jacki and Bruce Barron cancer research scholars' program); ICRF grant (Barbara S Goodman research grant); Israel Cancer Association	Israeli Science Foundation(Israel Science Foundation); Binational US-Israel Science Foundation(US-Israel Binational Science Foundation); ICRF grant (Jacki and Bruce Barron cancer research scholars' program); ICRF grant (Barbara S Goodman research grant); Israel Cancer Association	Cindy Cohen is thanked for her editorial assistance. Nofar Rada is thanked for her artistic work. This study was supported by grants from the Israeli Science Foundation, Binational US-Israel Science Foundation, ICRF grant (Jacki and Bruce Barron cancer research scholars' program and Barbara S Goodman research grant) and Israel Cancer Association.	Abiatari I, 2009, INT J ONCOL, V35, P1111, DOI 10.3892/ijo_00000426; Amit M, 2017, ONCOGENE, V36, P3232, DOI 10.1038/onc.2016.483; Amit M, 2016, NAT REV CANCER, V16, P399, DOI 10.1038/nrc.2016.38; Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Bapat AA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165586; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; CARTER RL, 1983, J CLIN PATHOL, V36, P269, DOI 10.1136/jcp.36.3.269; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; Colombo F, 2014, P NATL ACAD SCI USA, V111, P16943, DOI 10.1073/pnas.1406097111; Dai H, 2007, HUM PATHOL, V38, P299, DOI 10.1016/j.humpath.2006.08.002; Deborde S, 2016, J CLIN INVEST, V126, P1538, DOI 10.1172/JCI82658; Demir IE, 2014, J NATL CANC I, V106; Demir IE, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00097; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Gavert N, 2008, EXPERT OPIN BIOL TH, V8, P1749, DOI 10.1517/14712598.8.11.1749 ; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Guo K, 2013, MOL CANCER THER, V12, P264, DOI 10.1158/1535-7163.MCT-12-0809; Hauser S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018989; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Huang XH, 2013, BRAIN RES, V1530, P13, DOI 10.1016/j.brainres.2013.07.043; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; Lahoud MJ, 2016, WORLD J GASTRO ONCOL, V8, P599, DOI 10.4251/wjgo.v8.i8.599; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Na'ara S, 2016, JOVE-J VIS EXP, DOI 10.3791/52990; Riedle S, 2009, BIOCHEM J, V420, P391, DOI 10.1042/BJ20081625; Roh J, 2015, ORAL ONCOL, V51, P16, DOI 10.1016/j.oraloncology.2014.10.004; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Schafer MKE, 2010, CELL MOL LIFE SCI, V67, P2425, DOI 10.1007/s00018-010-0339-1; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Stopczynski RE, 2014, CANCER RES, V74, P1718, DOI 10.1158/0008-5472.CAN-13-2050; Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483; Takahashi T, 1997, J SURG ONCOL, V65, P164, DOI 10.1002/(SICI)1096-9098(199707)65:3<164::AID-JSO4>3.0.CO;2-4; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Webber C, 2010, EXP NEUROL, V223, P51, DOI 10.1016/j.expneurol.2009.05.037; Weinspach D, 2014, CLIN EXP METASTAS, V31, P87, DOI 10.1007/s10585-013-9613-6	42	39	39	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					596	608		10.1038/s41388-018-0458-y	http://dx.doi.org/10.1038/s41388-018-0458-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30171263				2022-12-28	WOS:000456589800010
J	Patel, Y; Soni, M; Awgulewitsch, A; Kern, MJ; Liu, S; Shah, N; Singh, UP; Chen, H				Patel, Y.; Soni, M.; Awgulewitsch, A.; Kern, M. J.; Liu, S.; Shah, N.; Singh, U. P.; Chen, H.			Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis	ONCOGENE			English	Article							STEM-CELLS; BREAST-CANCER; GLAND; MAINTENANCE; QUIESCENT	Although it has been demonstrated that transformed progenitor cell population can contribute to tumor initiation, factors contributing to this malignant transformation are poorly known. Using in vitro and xenograft-based models, previous studies demonstrated that miR-489 acts as a tumor suppressor miRNA by targeting various oncogenic pathways. It has been demonstrated that miR-489 directly targets HER2 and inhibits the HER2 signaling pathway; however, its role in mammary gland development and HER2-induced tumor initiation hasn't been studied. To dissect the role of miR-489, we sorted different populations of mammary epithelial cells and determined that miR-489 was highly expressed in mammary stem cells. MMTV-miR-489 mice that overexpressed miR-489 in mammary epithelial cells were developed and these mice exhibited an inhibition of mammary gland development in early ages with a specific impact on highly proliferative cells. Double transgenic MMTV-Her2-miR489 mice were then generated to observe how miR-489 overexpression affects HER2-induced tumorigenesis. miR-489 overexpression delayed HER2-induced tumor initiation significantly. Moreover, miR-489 overexpression inhibited tumor growth and lung metastasis. miR-489 overexpression reduced mammary progenitor cell population significantly in preneoplastic mammary glands of MMTV-Her2 mice which showed a putative transformed population in HER2-induced tumorigenesis. The miR-489 overexpression reduced CD49f(hi)CD61(hi) populations in tumors that have stem-like properties, and miR-489 overexpression altered the HER2 signaling pathway in mammary tumors. Altogether, these data indicate that the inhibition of HER2-induced tumorigenesis by miR-489 overexpression was due to altering progenitor cell populations while decreasing tumor growth and metastasis via influencing tumor promoting genes DEK and SHP2.	[Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Transgen & Genome Editing Core, Charleston, SC 29425 USA; [Kern, M. J.] Med Univ South Carolina, Gene Funct Core, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Singh, U. P.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA.; Chen, H (corresponding author), Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.	hchen@biol.sc.edu	chen, hexin/F-1714-2011	Chen, Hexin/0000-0001-9300-0859; Singh, Udai/0000-0002-7048-4325	NIH [4R01 CA178386-04, 4P30 GM103342-05]; USC ASPIRE-1 grant; USC SPARC graduate research grant; NATIONAL CANCER INSTITUTE [R01CA178386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103342] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USC ASPIRE-1 grant; USC SPARC graduate research grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the Gene Function and Transgenic and Genome Editing (TGE) Cores of the Medical University of South Carolina (MUSC) for their assistance with the generation of transgenic MMTV-miR-489 mice. This work was supported by the NIH grants (4R01 CA178386-04 and 4P30 GM103342-05) and the USC ASPIRE-1 grant to H.C., and the USC SPARC graduate research grant to M.S.	Boras-Granic K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0487-6; Cai S, 2017, CELL STEM CELL, V20, P247, DOI 10.1016/j.stem.2016.11.007; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chang THT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3593; Chen H, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0754-0; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; Cho Andrew, 2009, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1911s42; Elsarraj HS, 2013, J CELL SCI, V126, P2446, DOI 10.1242/jcs.119214; Fu NY, 2017, NAT CELL BIOL, V19, P164, DOI 10.1038/ncb3471; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiang L, 2014, FEBS LETT, V588, P2009, DOI 10.1016/j.febslet.2014.04.024; Ke J, 2015, ONCOTARGET, V6, P3709, DOI 10.18632/oncotarget.2888; Kikkawa N, 2010, BRIT J CANCER, V103, P877, DOI 10.1038/sj.bjc.6605811; Kim JC, 2016, CANCER RES, V76, P6424, DOI 10.1158/0008-5472.CAN-16-1571; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Martinez-Ruiz H, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf5402; Patel Y, 2016, ONCOTARGET, V7, P18295, DOI 10.18632/oncotarget.7577; Phua YW, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0593-0; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Rodriguez-Barrueco R, 2017, GENE DEV, V31, P553, DOI 10.1101/gad.292318.116; Soady KJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0539-6; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2009, J PATHOL, V217, P229, DOI 10.1002/path.2457; Tiede BJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008035; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Yallowitz AR, 2014, CELL DEATH DIFFER, V21, P645, DOI 10.1038/cdd.2013.199; Yoo KH, 2014, DEV BIOL, V395, P245, DOI 10.1016/j.ydbio.2014.09.012; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	34	13	13	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					445	453		10.1038/s41388-018-0439-1	http://dx.doi.org/10.1038/s41388-018-0439-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30104710	Green Accepted			2022-12-28	WOS:000455851200010
J	Klein, ME; Dickson, MA; Antonescu, C; Qin, LX; Dooley, SJ; Barlas, A; Manova, K; Schwartz, GK; Crago, AM; Singer, S; Koff, A; Tap, WD				Klein, Mary E.; Dickson, Mark A.; Antonescu, Cristina; Qin, Li-Xuan; Dooley, Scott J.; Barlas, Afsar; Manova, Katia; Schwartz, Gary K.; Crago, Aimee M.; Singer, Samuel; Koff, Andrew; Tap, William D.			PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence	ONCOGENE			English	Article							BREAST-CANCER; DEDIFFERENTIATED LIPOSARCOMA; TUMOR-GROWTH; PALBOCICLIB; COMPLEXES; CDK6; SUPPRESSION; PROGRESSION; SURVIVAL; SARCOMA	CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein. The downregulation of MDM2 following treatment with CDK4/6 inhibitors also induces many cultured tumor cell lines derived from different types of malignancies to progress from quiescence into senescence. Here we used cultured human cell lines and defined a role for PDLIM7 and CDH18, regulating MDM2 protein in CDK4/6 inhibitor-treated cells. Materials from our previous phase II trials with palbociclib were then used to demonstrate that expression of CDH18 protein was associated with response, measured as both progression-free survival and overall survival. This supports the hypothesis that the biologic transition from quiescence to senescence has clinical relevance for this class of drugs.	[Klein, Mary E.; Koff, Andrew] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10065 USA; [Klein, Mary E.; Koff, Andrew] Mem Sloan Kettering Canc Ctr, Programs Mol, 1275 York Ave, New York, NY 10065 USA; [Dickson, Mark A.; Tap, William D.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA; [Dickson, Mark A.; Tap, William D.] Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA; [Antonescu, Cristina] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Qin, Li-Xuan] Mem Sloan Kettering Canc Ctr, Dept Epidemiol, 1275 York Ave, New York, NY 10065 USA; [Qin, Li-Xuan] Mem Sloan Kettering Canc Ctr, Dept Biostat, 1275 York Ave, New York, NY 10065 USA; [Dooley, Scott J.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Ctr Adv Retinal & Ocular Therapeut, Philadelphia, PA 19104 USA; [Barlas, Afsar; Manova, Katia] Mem Sloan Kettering Canc Ctr, Dev Biol, 1275 York Ave, New York, NY 10065 USA; [Schwartz, Gary K.] Columbia Univ, Med Ctr, Div Hematol & Oncol, Herbert Irving Pavil 9th Floor, New York, NY 10032 USA; [Crago, Aimee M.; Singer, Samuel] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA; [Crago, Aimee M.; Singer, Samuel] Weill Cornell Med Coll, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Columbia University; Memorial Sloan Kettering Cancer Center; Cornell University	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Louis V Gerstner Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10065 USA.; Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol, 1275 York Ave, New York, NY 10065 USA.	koffa@mskcc.org			NIH/NCI Cancer Center Support Grant [P30 CA008748]; NCI Soft Tissue Sarcoma SPORE [CA140146]; Maloris Foundation; Linn Fund from Cycle For Survival; Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE [P50CA217694, P30CA008748, P50CA140146] Funding Source: NIH RePORTER	NIH/NCI Cancer Center Support Grant; NCI Soft Tissue Sarcoma SPORE; Maloris Foundation; Linn Fund from Cycle For Survival; Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Annalee Tai for technical assistance, Maura Dickler for discussions on the clinical impact of palbociclib in breast cancer, and Marta Kovatcheva, Caroline Gleason, Andrew Schade (Eli Lilly and Company), Michael Overholtzer and others in our laboratories for discussions during the course of these studies. The research was funded in part through NIH/NCI Cancer Center Support Grant P30 CA008748 and the NCI Soft Tissue Sarcoma SPORE CA140146 (AK, WDT, MD, GKS). Additional funding was provided by the Maloris Foundation, The Linn Fund from Cycle For Survival, and a Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America to AK.	Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; Bollard J, 2017, GUT, V66, P1286, DOI 10.1136/gutjnl-2016-312268; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Dickson MA, 2016, JAMA ONCOL, V2, P937, DOI 10.1001/jamaoncol.2016.0264; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Guschin DY, 2010, METHODS MOL BIOL, V649, P247, DOI 10.1007/978-1-60761-753-2_15; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Kanojia D, 2015, ONCOTARGET, V6, P42429, DOI 10.18632/oncotarget.6464; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kovatcheva M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00540-5; Kovatcheva M, 2015, ONCOTARGET, V6, P8226, DOI 10.18632/oncotarget.3364; Krcmery J, 2010, BIOESSAYS, V32, P100, DOI 10.1002/bies.200900148; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Shapiro GI, 2017, CANCER CELL, V32, P721, DOI 10.1016/j.ccell.2017.11.013; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tan MCB, 2016, ANN SURG, V263, P593, DOI 10.1097/SLA.0000000000001149; Urban AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164042; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931	38	22	23	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5066	5078		10.1038/s41388-018-0332-y	http://dx.doi.org/10.1038/s41388-018-0332-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789718	Green Published, hybrid			2022-12-28	WOS:000444405300003
J	Seo, J; Lee, EW; Shin, J; Seong, D; Nam, YW; Jeong, M; Lee, SH; Lee, C; Song, J				Seo, Jinho; Lee, Eun-Woo; Shin, Jihye; Seong, Daehyeon; Nam, Young Woo; Jeong, Manhyung; Lee, Seon-Hyeong; Lee, Cheolju; Song, Jaewhan			K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death	ONCOGENE			English	Article							UBIQUITIN LIGASE CHIP; CONTAINING PROTEIN; APOPTOSIS; FAS; PHOSPHORYLATION; KINASE; DOMAIN; CASPASE-8; RECEPTOR; CHAINS	Fas-associated death domain (FADD) is an adaptor protein recruiting complexes of caspase 8 to death ligand receptors to induce extrinsic apoptotic cell death in response to a TNF superfamily member. Although, formation of the complex of FADD and caspase 8 upon death stimuli has been studied in detail, posttranslational modifications fine-tuning these processes have yet to be identified. Here we revealed that K6-linked polyubiquitylation of FADD on lysines 149 and 153 mediated by C terminus HSC70-interacting protein (CHIP) plays an important role in preventing formation of the death inducing signaling complex (DISC), thus leading to the suppression of cell death. Cells depleted of CHIP showed higher sensitivity toward death ligands such as FasL and TRAIL, leading to upregulation of DISC formation composed of a death receptor, FADD, and caspase 8. CHIP was able to bind to FADD, induce K6-linked polyubiquitylation of FADD, and suppress DISC formation. By mass spectrometry, lysines 149 and 153 of FADD were found to be responsible for CHIP-mediated FADD ubiquitylation. FADD mutated at these sites was capable of more potent cell death induction as compared with the wild type and was no longer suppressed by CHIP. On the other hand, CHIP deficient in E3 ligase activity was not capable of suppressing FADD function and of FADD ubiquitylation. CHIP depletion in ME-180 cells induced significant sensitization of these cells toward TRAIL in xenograft analyses. These results imply that K6-linked ubiquitylation of FADD by CHIP is a crucial checkpoint in cytokine-dependent extrinsic apoptosis.	[Seo, Jinho; Seong, Daehyeon; Nam, Young Woo; Jeong, Manhyung; Song, Jaewhan] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea; [Lee, Eun-Woo] KRIBB, Metab Regulat Res Ctr, Daejeon 34141, South Korea; [Shin, Jihye; Lee, Cheolju] Korea Inst Sci & Technol, Ctr Theragnosis, 5 Hwarang Ro 14 Gil, Seoul 02792, South Korea; [Lee, Seon-Hyeong] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Goyang 10408, South Korea	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Institute of Science & Technology (KIST); National Cancer Center - Korea (NCC)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea.	jso678@yonsei.ac.kr	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003	Ministry of Science, ICT, and Future Planning [2015R1A3A2066581]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2017R1A6A3A11035262]; BK21 Plus project of the National Research Foundation of Korea Grant	Ministry of Science, ICT, and Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of Korea); BK21 Plus project of the National Research Foundation of Korea Grant(National Research Foundation of Korea)	This research was supported by a grant from the Ministry of Science, ICT, and Future Planning (2015R1A3A2066581) (Jaewhan S.) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) Funded by the Ministry of Education (2017R1A6A3A11035262) (Jinho S.). Additionally, this research was partly supported by the BK21 Plus project of the National Research Foundation of Korea Grant (Jinho S., D.S., M.J., and Y.W. N.), and C.L. acknowledges institutional support by KIST.	Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Alappat EC, 2003, J BIOL CHEM, V278, P41585, DOI 10.1074/jbc.C300385200; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Durcan TM, 2014, EMBO J, V33, P2473, DOI 10.15252/embj.201489729; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fulda S, 2000, CANCER RES, V60, P3947; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hospenthal MK, 2013, NAT STRUCT MOL BIOL, V20, P555, DOI 10.1038/nsmb.2547; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Jeong M, 2017, ONCOGENE, V36, P458, DOI 10.1038/onc.2016.215; Kalia LV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014695; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim C, 2016, CELL DEATH DIFFER, V23, P333, DOI 10.1038/cdd.2015.103; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Mert U, 2017, CELL MOL LIFE SCI, V74, P245, DOI 10.1007/s00018-016-2321-z; Morgan MJ, 2009, J IMMUNOL, V183, P3278, DOI 10.4049/jimmunol.0803428; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Paul I, 2015, INT J BIOCHEM CELL B, V58, P37, DOI 10.1016/j.biocel.2014.10.027; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaglione KM, 2011, MOL CELL, V43, P599, DOI 10.1016/j.molcel.2011.05.036; Scott FL, 2009, NATURE, V457, P1019, DOI 10.1038/nature07606; Seo J, 2016, NAT CELL BIOL, V18, P291, DOI 10.1038/ncb3314; Shimamoto S, 2013, J BIOL CHEM, V288, P7158, DOI 10.1074/jbc.M112.436758; Srivastava D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wang LW, 2010, NAT STRUCT MOL BIOL, V17, P1324, DOI 10.1038/nsmb.1920; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899	48	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4994	5006		10.1038/s41388-018-0323-z	http://dx.doi.org/10.1038/s41388-018-0323-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795330				2022-12-28	WOS:000443823600007
J	Gala, K; Li, Q; Sinha, A; Razavi, P; Dorso, M; Sanchez-Vega, F; Chung, YR; Hendrickson, R; Hsieh, JJ; Berger, M; Schultz, N; Pastore, A; Abdel-Wahab, O; Chandarlapaty, S				Gala, Kinisha; Li, Qing; Sinha, Amit; Razavi, Pedram; Dorso, Madeline; Sanchez-Vega, Francisco; Chung, Young Rock; Hendrickson, Ronald; Hsieh, James J.; Berger, Michael; Schultz, Nikolaus; Pastore, Alessandro; Abdel-Wahab, Omar; Chandarlapaty, Sarat			KMT2C mediates the estrogen dependence of breast cancer through regulation of ER alpha enhancer function	ONCOGENE			English	Article							ACTIVATING SIGNAL COINTEGRATOR-2; METHYLTRANSFERASE MLL3; GENE-EXPRESSION; CRUCIAL ROLES; DNA-BINDING; RECEPTOR; COMPLEX; TUMORS; BRAF(V600E); MACROPHAGE	Estrogen receptor alpha (ER alpha) is a ligand-activated nuclear receptor that directs proliferation and differentiation in selected cancer cell types including mammary-derived carcinomas. These master-regulatory functions of ER alpha require trans-acting elements such as the pioneer factor FOXA1 to establish a genomic landscape conducive to ER alpha control. Here, we identify the H3K4 methyltransferase KMT2C as necessary for hormone-driven ER alpha activity and breast cancer proliferation. KMT2C knockdown suppresses estrogen-dependent gene expression and causes H3K4me1 and H3K27ac loss selectively at ER alpha enhancers. Correspondingly, KMT2C loss impairs estrogen-driven breast cancer proliferation but has no effect on ER- breast cells. Whereas KMT2C loss disrupts estrogen-driven proliferation, it conversely promotes tumor outgrowth under hormone-depleted conditions. In accordance, KMT2C is one of the most frequently mutated genes in ER-positive breast cancer with KMT2C deletion correlating with significantly shorter progression-free survival on anti-estrogen therapy. From a therapeutic standpoint, KMT2C-depleted cells that develop hormone-independence retain their dependence on ER alpha, displaying ongoing sensitivity to ER alpha antagonists. We conclude that KMT2C is a key regulator of ER alpha activity whose loss uncouples breast cancer proliferation from hormone abundance.	[Gala, Kinisha; Chandarlapaty, Sarat] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA; [Gala, Kinisha; Li, Qing; Razavi, Pedram; Dorso, Madeline; Chung, Young Rock; Berger, Michael; Abdel-Wahab, Omar; Chandarlapaty, Sarat] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Sinha, Amit] Basepair Inc, New York, NY USA; [Sanchez-Vega, Francisco; Hsieh, James J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Hendrickson, Ronald] Mem Sloan Kettering Canc Ctr, Microchem & Prote Core Facil, 1275 York Ave, New York, NY 10021 USA; [Schultz, Nikolaus; Pastore, Alessandro] Mem Sloan Kettering Canc Ctr, Computat Biol Program, 1275 York Ave, New York, NY 10021 USA; [Chandarlapaty, Sarat] Weill Cornell Med Coll, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Washington University (WUSTL); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Chandarlapaty, S (corresponding author), Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.; Chandarlapaty, S (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Chandarlapaty, S (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	chandars@mskcc.org	Schultz, Nikolaus/ABE-6347-2020	Razavi, Pedram/0000-0003-4236-0576; Sanchez-Vega, Francisco/0000-0002-2990-4893; Chung, Young Rock/0000-0001-5752-8322	Anna Fuller Foundation; Cancer Couch Foundation; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; Susan G. Komen Foundation; Geoffrey Beene Cancer Research Center; Grayer Fellowship; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Anna Fuller Foundation; Cancer Couch Foundation; NCI Cancer Center Support Grant (CCSG); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Geoffrey Beene Cancer Research Center; Grayer Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank P. Chi for plasmids and cells, C. Sawyers for plasmids, M. Jasin and S. Lowe for mice and S. Monette for assistance with mouse pathology. We would like to thank J. Reis-Filho, W. Toy, Z. Li, A. Smith, R. Levine, N. Rosen and P. Chi for their helpful discussions. This work was funded by generous support of the Anna Fuller Foundation, the Cancer Couch Foundation, and the NCI Cancer Center Support Grant (CCSG, P30 CA08748). SC is funded by the Susan G. Komen Foundation. KG is funded by the Geoffrey Beene Cancer Research Center and a Grayer Fellowship. AP is a Mildred-Scheel Postdoctoral Research Fellow of the Deutsche Krebshilfe e.V.	Ananthanarayanan M, 2011, AM J PHYSIOL-GASTR L, V300, pG771, DOI 10.1152/ajpgi.00499.2010; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Flockhart RJ, 2012, GENOME RES, V22, P1006, DOI 10.1101/gr.140061.112; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Guo XY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0328-y; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Kaikkonen MU, 2013, MOL CELL, V51, P310, DOI 10.1016/j.molcel.2013.07.010; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002; Kim DH, 2015, HEPATOLOGY, V61, P1012, DOI 10.1002/hep.27578; Kim DH, 2009, MOL ENDOCRINOL, V23, P1556, DOI 10.1210/me.2009-0099; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503; Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012; Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Razavi P, 2016, CANC RES; Richart L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1152346; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Sato K, 2016, CLIN BREAST CANCER, V17, pe135; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110; Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Won HH, 2013, JOVE-J VIS EXP, V80, P50710; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang Z, 2016, CELL REP, V16, P3146, DOI 10.1016/j.celrep.2016.08.048; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	60	65	67	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4692	4710		10.1038/s41388-018-0273-5	http://dx.doi.org/10.1038/s41388-018-0273-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755131	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000442514400005
J	Chang, JW; Kuo, WH; Lin, CM; Chen, WL; Chan, SH; Chiu, MF; Chang, IS; Jiang, SS; Tsai, FY; Chen, CH; Huang, PH; Chang, KJ; Lin, KT; Lin, SC; Wang, MY; Uen, YH; Tu, CW; Hou, MF; Tsai, SF; Shen, CY; Tung, SL; Wang, LH				Chang, Jer-Wei; Kuo, Wen-Hung; Lin, Chiao-Mei; Chen, Wen-Ling; Chan, Shih-Hsuan; Chiu, Meng-Fan; Chang, I-Shou; Jiang, Shih-Sheng; Tsai, Fang-Yu; Chen, Chung-Hsing; Huang, Pei-Hsin; Chang, King-Jen; Lin, Kai-Ti; Lin, Sheng-Chieh; Wang, Ming-Yang; Uen, Yih-Huei; Tu, Chi-Wen; Hou, Ming-Feng; Tsai, Shih-Feng; Shen, Chen-Yang; Tung, Shiao-Lin; Wang, Lu-Hai			Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway	ONCOGENE			English	Article							YOUNG AGE; PROTEIN; ACTIN; DIAGNOSIS; PROGNOSIS; PATTERNS; IDENTIFICATION; PROGRESSION; ABNORMALITY; FEATURES	The early onset breast cancer patients (age <= 40) often display higher incidence of axillary lymph node metastasis, and poorer five-year survival than the late-onset patients. To identify the genes and molecules associated with poor prognosis of early onset breast cancer, we examined gene expression profiles from paired breast normal/tumor tissues, and coupled with Gene Ontology and public data base analysis. Our data showed that the expression of GAS7b gene was lower in the early onset breast cancer patients as compared to the elder patients. We found that GAS7 was associated with CYFIP1 and WAVE2 complex to suppress breast cancer metastasis via blocking CYFIP1 and Rac1 protein interaction, actin polymerization, and beta 1-integrin/FAK/Src signaling. We further demonstrated that p53 directly regulated GAS7 gene expression, which was inversely correlated with p53 mutations in breast cancer specimens. Our study uncover a novel regulatory mechanism of p53 in early onset breast cancer progression through GAS7-CYFIP1-mediated signaling pathways.	[Chang, Jer-Wei; Lin, Chiao-Mei; Chen, Wen-Ling; Chan, Shih-Hsuan; Chiu, Meng-Fan; Tsai, Shih-Feng; Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Kuo, Wen-Hung; Chang, King-Jen; Wang, Ming-Yang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Chan, Shih-Hsuan] Natl Tsing Hua Univ, Inst Mol Med, Coll Life Sci, Hsinchu, Taiwan; [Chan, Shih-Hsuan] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan; [Chang, I-Shou; Jiang, Shih-Sheng; Tsai, Fang-Yu; Chen, Chung-Hsing] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Huang, Pei-Hsin] Natl Taiwan Univ, Dept Pathol, Coll Med, Taipei, Taiwan; [Chang, King-Jen] Taiwan Adventist Hosp, Taipei, Taiwan; [Lin, Kai-Ti] Natl Tsing Hua Univ, Inst Biotechnol, Coll Life Sci, Hsinchu, Taiwan; [Lin, Sheng-Chieh; Wang, Lu-Hai] China Med Univ, Coll Chinese Med, Taichung, Taiwan; [Uen, Yih-Huei] Asia Univ Hosp, Dept Surg, Taichung, Taiwan; [Tu, Chi-Wen] Ditmanson Med Fdn, Dept Gen Surg, Chia Yi Christian Hosp, Chiayi, Taiwan; [Hou, Ming-Feng] Kaohsiung Med Univ, Dept Surg, Coll Med, Kaohsiung, Taiwan; [Hou, Ming-Feng] Kaohsiung Municipal Hsiaokang Hosp, Dept Surg, Kaohsiung, Taiwan; [Hou, Ming-Feng] Kaohsiung Med Univ Hosp, Div Breast Surg, Kaohsiung, Taiwan; [Shen, Chen-Yang] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Tung, Shiao-Lin] Ton Yen Gen Hosp, Dept Hematol & Oncol, Hsinchu, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; China Medical University Taiwan; National Health Research Institutes - Taiwan; National Taiwan University; National Tsing Hua University; China Medical University Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Academia Sinica - Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan.; Wang, LH (corresponding author), China Med Univ, Coll Chinese Med, Taichung, Taiwan.	luhaiwang@mail.cmu.edu.tw	Jiang, Shih Sheng/J-9671-2019; Chan, Shih-Hsuan/AAD-4317-2021; Shen, CY/F-6271-2010; Chan, Shih-Hsuan/AAW-6857-2020; Lin, Kai-Ti/B-3840-2016	Jiang, Shih Sheng/0000-0003-1909-437X; Lin, Kai-Ti/0000-0001-8656-5755; KUO, WEN-HUNG/0000-0002-9881-4605; Tung, Shiao-Lin/0000-0002-6241-6293; Chen, Chung-Hsing/0000-0002-1205-7368; Hou, Ming-Feng/0000-0001-6030-9702; Chan, Shih-Hsuan/0000-0002-8703-5139; Chang, King jen/0000-0001-9811-3422	Advance Medical Plan from Ministry of Health and Welfare, Taiwan [107-0324-01-19-03];  [CA-105-SP-01];  [MOHW105-TDU-B-212-112017]	Advance Medical Plan from Ministry of Health and Welfare, Taiwan; ; 	This work was supported by grants (CA-105-SP-01 and MOHW105-TDU-B-212-112017) and Advance Medical Plan (107-0324-01-19-03) from Ministry of Health and Welfare, Taiwan.	ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; Anders CK, 2011, J CLIN ONCOL, V29, pE18, DOI 10.1200/JCO.2010.28.9199; Anders CK, 2009, SEMIN ONCOL, V36, P237, DOI 10.1053/j.seminoncol.2009.03.001; Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; BONNIER P, 1995, INT J CANCER, V62, P138, DOI 10.1002/ijc.2910620205; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Chao CCK, 2005, J NEUROSCI RES, V81, P153, DOI 10.1002/jnr.20552; Chen FM, 2004, CANCER LETT, V207, P59, DOI 10.1016/j.canlet.2003.12.005; Cheng SH, 2000, BREAST CANCER RES TR, V63, P213, DOI 10.1023/A:1006468514396; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; El Saghir NS, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-194; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jong YJ, 2004, CANCER GENET CYTOGEN, V148, P55, DOI 10.1016/S0165-4608(03)00205-X; Ju YT, 1998, P NATL ACAD SCI USA, V95, P11423, DOI 10.1073/pnas.95.19.11423; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuo WH, 2006, BREAST CANCER RES TR, V99, P221, DOI 10.1007/s10549-006-9194-z; Kurisu S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-226; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Liu SX, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0144-2; Lortie K, 2005, BRAIN RES, V1036, P27, DOI 10.1016/j.brainres.2004.12.024; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Melhem-Bertrandt A, 2012, CANCER-AM CANCER SOC, V118, P908, DOI 10.1002/cncr.26377; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; Saengsawang W, 2012, CURR BIOL, V22, P494, DOI 10.1016/j.cub.2012.01.038; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; She BR, 2002, EXP CELL RES, V273, P34, DOI 10.1006/excr.2001.5435; Shen YC, 2005, CANCER EPIDEM BIOMAR, V14, P1986, DOI 10.1158/1055-9965.EPI-04-0932; Tseng RC, 2008, LUNG CANCER, V59, P332, DOI 10.1016/j.lungcan.2007.08.038; Tseng RC, 2015, ONCOTARGET, V6, P44207, DOI 10.18632/oncotarget.6229; Xu GW, 2005, INT J CANCER, V116, P187, DOI 10.1002/ijc.21071; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; You JJ, 2010, J BIOL CHEM, V285, P11652, DOI 10.1074/jbc.M109.051094; Zhou P, 2004, CANCER-AM CANCER SOC, V101, P1264, DOI 10.1002/cncr.20523	42	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4137	4150		10.1038/s41388-018-0253-9	http://dx.doi.org/10.1038/s41388-018-0253-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706651	Green Published, hybrid			2022-12-28	WOS:000439847000007
J	Toosi, BM; El Zawily, A; Truitt, L; Shannon, M; Allonby, O; Babu, M; DeCoteau, J; Mousseau, D; Ali, M; Freywald, T; Gall, A; Vizeacoumar, FS; Kirzinger, MW; Geyer, CR; Anderson, DH; Kim, T; Welm, AL; Siegel, P; Vizeacoumar, FJ; Kusalik, A; Freywald, A				Toosi, Behzad M.; El Zawily, Amr; Truitt, Luke; Shannon, Matthew; Allonby, Odette; Babu, Mohan; DeCoteau, John; Mousseau, Darrell; Ali, Mohsin; Freywald, Tanya; Gall, Amanda; Vizeacoumar, Frederick S.; Kirzinger, Morgan W.; Geyer, C. Ronald; Anderson, Deborah H.; Kim, TaeHyung; Welm, Alana L.; Siegel, Peter; Vizeacoumar, Franco J.; Kusalik, Anthony; Freywald, Andrew			EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; MAMMARY STEM-CELLS; METASTATIC COLONIZATION; CARCINOMA CELLS; EXPRESSION; IDENTIFICATION; HETEROGENEITY; TRANSITION; MECHANISMS; PLASTICITY	Triple-negative breast cancer (TNBC) tumours that lack expression of oestrogen, and progesterone receptors, and do not overexpress the HER2 receptor represent the most aggressive breast cancer subtype, which is characterised by the resistance to therapy in frequently relapsing tumours and a high rate of patient mortality. This is likely due to the resistance of slowly proliferating tumour-initiating cells (TICs), and understanding molecular mechanisms that control TICs behaviour is crucial for the development of effective therapeutic approaches. Here, we present our novel findings, indicating that an intrinsically catalytically inactive member of the Eph group of receptor tyrosine kinases, EPHB6, partially suppresses the epithelial-mesenchymal transition in TNBC cells, while also promoting expansion of TICs. Our work reveals that EPHB6 interacts with the GRB2 adapter protein and that its effect on enhancing cell proliferation is mediated by the activation of the RAS-ERK pathway, which allows it to elevate the expression of the TIC-related transcription factor, OCT4. Consistent with this, suppression of either ERK or OCT4 activities blocks EPHB6-induced pro-proliferative responses. In line with its ability to trigger propagation of TICs, EPHB6 accelerates tumour growth, potentiates tumour initiation and increases TIC populations in xenograft models of TNBC. Remarkably, EPHB6 also suppresses tumour drug resistance to DNA-damaging therapy, probably by forcing TICs into a more proliferative, drug-sensitive state. In agreement, patients with higher EPHB6 expression in their tumours have a better chance for recurrence-free survival. These observations describe an entirely new mechanism that governs TNBC and suggest that it may be beneficial to enhance EPHB6 action concurrent with applying a conventional DNA-damaging treatment, as it would decrease drug resistance and improve tumour elimination.	[Toosi, Behzad M.; El Zawily, Amr; Truitt, Luke; Allonby, Odette; DeCoteau, John; Ali, Mohsin; Freywald, Tanya; Vizeacoumar, Frederick S.; Geyer, C. Ronald; Freywald, Andrew] Univ Saskatchewan, Coll Med, Dept Pathol & Lab Med, Royal Univ Hosp, Room 2841,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada; [El Zawily, Amr] Damanhour Univ, Fac Sci, Damanhour 22516, Egypt; [Shannon, Matthew; Kirzinger, Morgan W.; Kusalik, Anthony] Univ Saskatchewan, Dept Comp Sci, 176 Thorvaldsen Bldg,110 Sci Pl, Saskatoon, SK S7N 5C9, Canada; [Babu, Mohan] Univ Regina, Dept Chem & Biochem, Fac Sci, Res & Innovat Ctr, Room 232, Regina, SK S4S 0A2, Canada; [Mousseau, Darrell] Univ Saskatchewan, Dept Psychiat, Coll Med, Cell Signaling Lab, GB41 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Gall, Amanda] Univ Saskatchewan, Dept Biochem, Coll Med, Room 2D01 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Anderson, Deborah H.; Vizeacoumar, Franco J.] Univ Saskatchewan, Saskatchewan Canc Agcy, 4D30-2 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada; [Kim, TaeHyung] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Kim, TaeHyung] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3E1, Canada; [Welm, Alana L.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA; [Siegel, Peter] McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada	University of Saskatchewan; Egyptian Knowledge Bank (EKB); Damanhour University; University of Saskatchewan; University of Regina; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Toronto; University of Toronto; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; McGill University	Freywald, A (corresponding author), Univ Saskatchewan, Coll Med, Dept Pathol & Lab Med, Royal Univ Hosp, Room 2841,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.; Kusalik, A (corresponding author), Univ Saskatchewan, Dept Comp Sci, 176 Thorvaldsen Bldg,110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.	kusalik@cs.usask.ca; andrew.freywald@usask.ca	Vizeacoumar, Franco/GLS-7161-2022; Mohan, Babu P./I-7362-2019; Ali, Mohsin/GRY-0476-2022	Vizeacoumar, Frederick/0000-0002-4676-2911	Canadian Breast Cancer Foundation (CBCF) [C7003]	Canadian Breast Cancer Foundation (CBCF)	We thank Chelsea Cunningham for her help with qPCR experiments and Farhad Maleki for assistance with cluster validity analysis. This work was supported by Canadian Breast Cancer Foundation (CBCF) grant # C7003.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bailey CM, 2014, MOL CANCER RES, V12, P1303, DOI 10.1158/1541-7786.MCR-13-0673; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bhushan L, 2014, CANCER GENOM PROTEOM, V11, P239; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen J, 2015, CYTOKINE GROWTH F R, V26, P1, DOI 10.1016/j.cytogfr.2014.05.001; Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; DeVeale B, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003957; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Duggal Rohit, 2013, J Stem Cells, V8, P135, DOI jsc.2014.8.3/4.135; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; El Zawily AM, 2016, ONCOTARGET, V7, P77865, DOI 10.18632/oncotarget.12838; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fox BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI 10.1016/j.bbrc.2005.11.174; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Fox BP, 2009, ONCOGENE, V23, P23; Funasaka T, 2009, CANCER RES, V69, P5349, DOI 10.1158/0008-5472.CAN-09-0488; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goke J, 2013, MOL CELL, V50, P844, DOI 10.1016/j.molcel.2013.04.030; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gu Y, 2016, J CLIN PATHOL, V69, P448, DOI 10.1136/jclinpath-2015-203160; Hafner C, 2003, INT J ONCOL, V23, P1553; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kidd ME, 2014, AM J RESP CELL MOL, V50, P1, DOI 10.1165/rcmb.2013-0314TR; Kleffel S, 2013, ADV EXP MED BIOL, V734, P145, DOI 10.1007/978-1-4614-1445-2_8; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kurpios NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058151; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Li J, 2007, DIFFERENTIATION, V75, P299, DOI 10.1111/j.1432-0436.2006.00143.x; Liersch-Lohn B, 2016, INT J CANCER, V138, P1220, DOI 10.1002/ijc.29865; Lisabeth EM, 2013, COLD SPRING HARB PER, V5; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mateo-Lozano S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43702; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Mohamed ER, 2015, ONCOL LETT, V9, P1672, DOI 10.3892/ol.2015.2925; Morrison BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049752; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Mustacchi G, 2015, DRUG DES DEV THER, V9, P4303, DOI 10.2147/DDDT.S86105; Nishi M, 2014, ONCOGENE, V33, P643, DOI 10.1038/onc.2012.614; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Stratford AL, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001535; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Tang XX, 2000, MED PEDIATR ONCOL, V35, P656, DOI 10.1002/1096-911X(20001201)35:6<656::AID-MPO37>3.0.CO;2-A; Truitt L, 2011, BIOCHEM CELL BIOL, V89, P115, DOI [10.1139/O10-145, 10.1139/o10-145]; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Vizeacoumar FJ, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.54; Yu J, 2010, CLIN CANCER RES, V16, P2275, DOI 10.1158/1078-0432.CCR-09-2000; Yu J, 2009, INT J ONCOL, V35, P175, DOI 10.3892/ijo_00000326	64	19	20	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4073	4093		10.1038/s41388-018-0228-x	http://dx.doi.org/10.1038/s41388-018-0228-x			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29700392	Green Published, hybrid			2022-12-28	WOS:000439847000003
J	Zhang, YY; Tabataba, H; Liu, XY; Wang, JY; Yan, XG; Farrelly, M; Jiang, CC; Guo, ST; Liu, T; Kao, HY; Thorne, RF; Zhang, XD; Jin, L				Zhang, Yuan Yuan; Tabataba, Hessam; Liu, Xiao Ying; Wang, Jia Yu; Yan, Xu Guang; Farrelly, Margaret; Jiang, Chen Chen; Guo, Su Tang; Liu, Tao; Kao, Hung-Ying; Thorne, Rick F.; Zhang, Xu Dong; Jin, Lei			ACTN4 regulates the stability of RIPK1 in melanoma	ONCOGENE			English	Article							ALPHA-ACTININ 4; NF-KAPPA-B; COPY NUMBER INCREASE; GENE AMPLIFICATION; CELL MOTILITY; STAGE-I; CANCER; KINASE; CROSSROADS; ALPHA-ACTININ-4	The actin crosslinking protein alpha-actinin-4 (ACTN4) is emerging as an important contributor to the pathogenesis of cancer. This has largely been attributed to its role in regulating cytoskeleton organization and its involvement in transcriptional regulation of gene expression. Here we report a novel function of ACTN4 as a scaffold necessary for stabilization of receptor-interacting protein kinase 1 (RIPK1) that we have recently found to be an oncogenic driver in melanoma. ACTN4 bound to RIPK1 and cellular inhibitor of apoptosis protein 1 (cIAP1) with its actin-binding domain at the N-terminus and the CaM-like domain at the C-terminus, respectively. This facilitated the physical association between RIPK1 and cIAP1 and was critical for stabilization of RIPK1 that in turn activated NF-kappa B. Functional investigations showed that silencing of ACTN4 suppressed melanoma cell proliferation and retarded melanoma xenograft growth. In contrast, overexpression of ACTN4 promoted melanocyte and melanoma cell proliferation and moreover, prompted melanocyte anchorage-independent growth. Of note, the expression of ACTN4 was transcriptionally activated by NF-kappa B. Taken together, our findings identify ACTN4 as an oncogenic regulator through driving a feedforward signaling axis of ACTN4-RIPK1-NF-kappa B, with potential implications for targeting ACTN4 in the treatment of melanoma.	[Zhang, Yuan Yuan; Liu, Xiao Ying; Jiang, Chen Chen; Jin, Lei] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Tabataba, Hessam; Wang, Jia Yu; Yan, Xu Guang; Farrelly, Margaret; Guo, Su Tang; Zhang, Xu Dong] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Liu, Xiao Ying] Anhui Med Univ, Sch Life Sci, Hefei 230000, Anhui, Peoples R China; [Jiang, Chen Chen; Zhang, Xu Dong; Jin, Lei] Hunter Med Res Inst, Canc Res Program, New Lambton, NSW 2305, Australia; [Guo, Su Tang] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan 030013, Shanxi, Peoples R China; [Liu, Tao] Univ New South Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW 2750, Australia; [Kao, Hung-Ying] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Thorne, Rick F.] Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia	University of Newcastle; University of Newcastle; Anhui Medical University; Hunter Medical Research Institute; University of Newcastle; Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Case Western Reserve University; University of Newcastle	Jin, L (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.; Zhang, XD (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.; Zhang, XD; Jin, L (corresponding author), Hunter Med Res Inst, Canc Res Program, New Lambton, NSW 2305, Australia.	Xu.Zhang@newcastle.edu.au; Lei.Jin@newcastle.edu.au	ZHANG, YUANYUAN/Q-3332-2019; Jin, Lei/J-1896-2019; Liu, Tao/A-3922-2015; Wang, jiayu/ABB-6772-2020; Jin, Lei/K-2315-2019; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	ZHANG, YUANYUAN/0000-0001-5851-5128; Jin, Lei/0000-0001-7187-9671; Tabatabaee, Hessam/0000-0001-8912-1746; Zhang, Xu Dong/0000-0001-9457-8003; Liu, Tao/0000-0001-6244-7316; Thorne, Rick/0000-0001-7882-7081	National Health and Medical Research Council (NHMRC) [APP1083496, APP1099947]; Natural Science Foundation of China (NSFC) [81772908]; Cancer Institute NSW Fellowships	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Cancer Institute NSW Fellowships	This work was supported by the National Health and Medical Research Council (NHMRC) (APP1083496 and APP1099947) and the Natural Science Foundation of China (NSFC) (81772908). L.J. and C.C.J. are recipients of Cancer Institute NSW Fellowships.	Agarwal N, 2013, ONCOGENE, V32, P462, DOI 10.1038/onc.2012.69; Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Babakov V N, 2004, Tsitologiia, V46, P1064; Babakov VN, 2008, EXP CELL RES, V314, P1030, DOI 10.1016/j.yexcr.2007.12.001; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Blackwell K, 2013, MOL CELL BIOL, V33, P1901, DOI 10.1128/MCB.01416-12; Broderick MJF, 2002, J STRUCT BIOL, V137, P184, DOI 10.1006/jsbi.2002.4465; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Dong L, 2014, ONCOGENE, V33, P4756, DOI 10.1038/onc.2013.420; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao YF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1295-9; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0031-0; Hsu KS, 2013, VITAM HORM, V93, P323, DOI 10.1016/B978-0-12-416673-8.00005-8; Hu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.441; Jin L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1035690; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kakuya T, 2017, INT J ORAL MAX SURG, V46, P968, DOI 10.1016/j.ijom.2017.03.001; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kumeta M, 2010, J CELL SCI, V123, P1020, DOI 10.1242/jcs.059568; Liu XY, 2015, CANCER RES, V75, P1736, DOI 10.1158/0008-5472.CAN-14-2199; Luan Q, 2015, AUTOPHAGY, V11, P975, DOI 10.1080/15548627.2015.1049800; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Noro R, 2013, ANN ONCOL, V24, P2594, DOI 10.1093/annonc/mdt293; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Oikonomou KG, 2011, AUTOIMMUN REV, V10, P389, DOI 10.1016/j.autrev.2010.12.009; Shao HS, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.579185; Shao HS, 2013, INT J BIOCHEM CELL B, V45, P1051, DOI 10.1016/j.biocel.2013.02.015; Shao HS, 2010, J BIOL CHEM, V285, P2591, DOI 10.1074/jbc.M109.035790; Sjoblom B, 2008, CELL MOL LIFE SCI, V65, P2688, DOI 10.1007/s00018-008-8080-8; Tay KH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.79; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Watabe Y, 2014, CANCER MED-US, V3, P613, DOI 10.1002/cam4.214; Watanabe T, 2015, BRIT J CANCER, V112, P704, DOI 10.1038/bjc.2014.623; Yamamoto S, 2012, HISTOPATHOLOGY, V60, P1073, DOI 10.1111/j.1365-2559.2011.04163.x; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Zhao X, 2015, J BIOL CHEM, V290, P338, DOI 10.1074/jbc.M114.597260	48	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4033	4045		10.1038/s41388-018-0260-x	http://dx.doi.org/10.1038/s41388-018-0260-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29706658				2022-12-28	WOS:000439101300009
J	Ozes, AR; Pulliam, N; Ertosun, MG; Yilmaz, O; Tang, J; Copuroglu, E; Matei, D; Ozes, ON; Nephew, KP				Ozes, Ali R.; Pulliam, Nick; Ertosun, Mustafa G.; Yilmaz, Ozlem; Tang, Jessica; Copuroglu, Ece; Matei, Daniela; Ozes, Osman N.; Nephew, Kenneth P.			Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; ZESTE HOMOLOG 2; PKA PHOSPHORYLATES; PROSTATE-CANCER; TARGETING EZH2; STEM-CELLS; IN-VITRO; PROLIFERATION; COMPLEX; GENE	Polycomb repressive complex 2 (PRC2) member enhancer of zeste homolog 2 (EZH2) trimethylates histone H3 lysine 27 (H3K27me3), alters chromatin structure and contributes to epigenetic regulation of gene expression in normal and disease processes. Phosphorylation of EZH2 augmented EZH2 oncogenic activity in cancer but observations have been limited to threonine 350 (T350) and serine 21 (S21) residues by cyclin-dependent kinase 1 and protein kinase B, respectively. In addition, phosphorylation of the evolutionarily conserved T372 motif of EZH2 by p38 resulted in EZH2 interaction with Ying Yang 1 and promoted muscle stem cell differentiation. In the present study, we used epithelial ovarian cancer (OC) cells as a model to demonstrate that phosphorylation of EZH2 at T372 by protein kinase A (PKA) induced a dominant-negative EZH2 phenotype, inhibited OC cell proliferation and migration in vitro and decreased ovarian xenograft tumor growth in vivo. Phosphorylation of T372 by PKA enhanced the interaction between EZH2 and signal transducer and activator of transcription 3 (STAT3), and STAT3 binding to pT372-EZH2 reduced cellular levels of pSTAT3 and downregulated interleukin 6 receptor expression in OC. Furthermore, PKA-mediated pT372-EZH2 decreased ATP levels and altered mitochondrial gene expression, resulting in mitochondrial dysfunction and reduced OC cell growth. These findings demonstrate that PKA-mediated T372 phosphorylation reduces oncogenic EZH2 activity and reveal a novel role for pT372 in regulating EZH2 in OC and possibly other cancers.	[Ozes, Ali R.; Pulliam, Nick; Nephew, Kenneth P.] Indiana Univ, Mol & Cellular Biochem Dept, Bloomington, IN 47405 USA; [Ozes, Ali R.; Pulliam, Nick; Tang, Jessica; Nephew, Kenneth P.] Indiana Univ, Sch Med Med Sci, Bloomington, IN 47405 USA; [Ertosun, Mustafa G.; Yilmaz, Ozlem; Copuroglu, Ece; Ozes, Osman N.] Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey; [Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Akdeniz University; Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ, Mol & Cellular Biochem Dept, Bloomington, IN 47405 USA.; Nephew, KP (corresponding author), Indiana Univ, Sch Med Med Sci, Bloomington, IN 47405 USA.; Ozes, ON (corresponding author), Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey.; Nephew, KP (corresponding author), Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.; Nephew, KP (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.	oozes@akdeniz.edu.tr; knephew@indiana.edu	Copuroglu, F.Ece/AAG-1925-2020	Matei, Daniela/0000-0003-2169-5035	National Cancer Institute [CA13001, CA182832]; V Foundation for Cancer Research Translational Grant; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University); NATIONAL CANCER INSTITUTE [R01CA182832] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V Foundation for Cancer Research Translational Grant; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Fang Fang and Jay Pilrose for assistance with animal studies, Dr. Scott Michaels, Dr. Doug Rusch and Aaron Buechlein (Center for Genomics and Bioinformatics, Indiana University) for RNA-seq data analysis, Dr. Haojie Huang for EZH2-pGEX-4T-1 vectors (University of Minnesota) and Dr. Jian Jian (UC Davis) for PGL2-3 x -SIEGAS STAT3 reporter plasmid. We thank Dr. Heather O'Hagan and Dr. Peter Hollenorst (Medical Sciences, Indiana University School of Medicine) for critically reading the manuscript and offering valuable suggestions. This work was made possible by funding from the National Cancer Institute (Awards CA13001 and CA182832), The V Foundation for Cancer Research Translational Grant, Walther Cancer Foundation (Indianapolis, IN) and the Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University).	Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575; Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Cardenas H, 2016, ONCOTARGET, V7, P84453, DOI 10.18632/oncotarget.11497; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chen S, 2013, J IMMUNOL, V191, P2614, DOI 10.4049/jimmunol.1203143; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Copeland RA, 2013, ONCOGENE, V32, P939, DOI 10.1038/onc.2012.552; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Djouder N, 2010, EMBO J, V29, P469, DOI 10.1038/emboj.2009.339; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Garcia-Bermudez J, 2015, CELL REP, V12, P2143, DOI 10.1016/j.celrep.2015.08.052; Garipov A, 2013, MOL CANCER RES, V11, P360, DOI 10.1158/1541-7786.MCR-12-0661; Gibaja V, 2016, ONCOGENE, V35, P558, DOI 10.1038/onc.2015.114; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Liu T, 2014, TUMOR BIOL, V35, P7239, DOI 10.1007/s13277-014-1950-9; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Ozes AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00966-3; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Papa S, 2012, FEBS LETT, V586, P568, DOI 10.1016/j.febslet.2011.09.019; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022; Wee ZN, 2014, CELL REP, V8, P204, DOI 10.1016/j.celrep.2014.05.045; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649	42	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3589	3600		10.1038/s41388-018-0218-z	http://dx.doi.org/10.1038/s41388-018-0218-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29576612	Green Accepted, Green Submitted			2022-12-28	WOS:000436412500009
J	Zhou, HH; Liu, YS; Zhu, R; Ding, F; Cao, XF; Lin, DX; Liu, ZH				Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Cao, Xiufeng; Lin, Dongxin; Liu, Zhihua			OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; BREAST-CANCER; POOR-PROGNOSIS; DEGRADATION; INVASION; EMT; DEUBIQUITINATION; PROGRESSION; ENZYME	Snail is a key regulator of epithelial-mesenchymal transition (EMT) and plays an important role in tumor progression and metastasis. Snail is rapidly degraded in the cells and its protein level is critically controlled. Although several E3 ligases regulating Snail degradation have been defined, the deubiquitinases (DUBs) responsible for Snail deubiquitination are less studied. We identified ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (OTUB1) as a DUB that stabilizes Snail through preventing its ubiquitination and proteasomal degradation. Functionally, OTUB1 facilitates metastasis of esophageal squamous cell carcinoma (ESCC) through promoting Snail protein stability. Moreover, OTUB1 is highly expressed in ESCC and higher expression of OTUB1 predicts poor prognosis. These findings suggest that OTUB1 is an essential regulator of Snail and plays a critical role in facilitating esophageal cancer progression.	[Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Lin, Dongxin; Liu, Zhihua] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, State Key Lab Mol Oncol, Beijing, Peoples R China; [Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Lin, Dongxin; Liu, Zhihua] Peking Union Med Coll, Beijing, Peoples R China; [Zhou, Honghong; Lin, Dongxin] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Etiol & Carcinogenesis, Beijing, Peoples R China; [Cao, Xiufeng] Nanjing Med Univ, Nanjing Hosp 1, Dept Surg Oncol, Nanjing, Jiangsu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Nanjing Medical University	Liu, ZH (corresponding author), Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, State Key Lab Mol Oncol, Beijing, Peoples R China.; Liu, ZH (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	liuzh@cicams.ac.cn	Liu, Yongshuo/GRX-6416-2022; Liu, Yongshuo/AGZ-8274-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139; Lin, Dongxin/0000-0002-8723-8868	National Key R&D Program of China [2016YFC1302100]; National Science Foundation of China [81420108025]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D Program of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Key R&D Program of China (2016YFC1302100), National Science Foundation of China (81420108025), and CAMS Initiative for Innovative Medicine (2016-I2M-1-001). We thank Dr. Shimada Y. (Kyoto University, Kyoto, Japan) for kindly providing the ESCC cell lines.	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Edelmann MJ, 2010, FEBS J, V277, P2515, DOI 10.1111/j.1742-4658.2010.07665.x; Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318; Guzik P, 2013, CLIN AUTON RES, V23, P91, DOI 10.1007/s10286-013-0188-8; Herhaus L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3519; Iglesias-Gato D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0280-2; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971; Li YH, 2014, J BIOL CHEM, V289, P5097, DOI 10.1074/jbc.M113.533109; Lin YW, 2017, ONCOTARGET, V8, P75127, DOI 10.18632/oncotarget.20561; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Liu X, 2014, PATHOL RES PRACT, V210, P770, DOI 10.1016/j.prp.2014.05.008; Luo AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096610; Matysiak M, 2017, ARCH GYNECOL OBSTET, V295, P817, DOI 10.1007/s00404-017-4304-1; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Wang M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-225; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Wang YQ, 2016, ONCOTARGET, V7, P36681, DOI 10.18632/oncotarget.9160; Weng WW, 2016, AM J TRANSL RES, V8, P2234; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258	37	53	56	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3356	3368		10.1038/s41388-018-0224-1	http://dx.doi.org/10.1038/s41388-018-0224-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559747				2022-12-28	WOS:000436411300003
